PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hedstrom, P				Hedstrom, P			Sociology - Experimental macro sociology: Predicting the next best seller	SCIENCE			English	Editorial Material									Univ Oxford Nuffield Coll, Oxford OX1 1NF, England	University of Oxford	Hedstrom, P (corresponding author), Univ Oxford Nuffield Coll, New Rd, Oxford OX1 1NF, England.	peter.hedstrom@nuffield.oxford.ac.uk						Coleman J., 1994, FDN SOCIAL THEORY; Harding DJ, 2003, AM J SOCIOL, V109, P676, DOI 10.1086/379217; Hedstrom P, 2005, DISSECTING SOCIAL PR; Manski CF, 2000, J ECON PERSPECT, V14, P115, DOI 10.1257/jep.14.3.115; Raudenbush SW, 1999, SOCIOL METHODOL, V29, P1, DOI 10.1111/0081-1750.00059; Salganik MJ, 2006, SCIENCE, V311, P854, DOI 10.1126/science.1121066	6	16	16	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					786	787		10.1126/science.1124707	http://dx.doi.org/10.1126/science.1124707			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	012XT	16469907				2022-12-28	WOS:000235374900027
J	Summerscales, OT; Cloke, FGN; Hitchcock, PB; Green, JC; Hazari, N				Summerscales, OT; Cloke, FGN; Hitchcock, PB; Green, JC; Hazari, N			Reductive cyclotrimerization of carbon monoxide to the deltate dianion by an organometallic uranium complex	SCIENCE			English	Article								Despite the long history of the Fischer-Tropsch reaction, carbon monoxide has proven remarkably resistant to selective homologation under mild conditions. Here, we find that an organouranium(III) complex induces efficient reductive trimerization of carbon monoxide at room temperature and pressure. The result is a triangular, cyclic C3O32-, or deltate, dianion held between two uranium(IV) units. The bonding within the C3O32- unit and its coordination to the two U centers have been analyzed by x-ray diffraction and density functional theory computational studies, which show a stabilizing C-C agostic interaction between the C-3 core and one U center. Solution nuclear magnetic resonance studies reveal a rapid equilibration of the deltate unit between the U centers.	Univ Sussex, Sch Life Sci, Dept Chem, Brighton BN1 9QJ, E Sussex, England; Univ Oxford, Inorgan Chem Lab, Oxford OX1 3QR, England	University of Sussex; University of Oxford	Cloke, FGN (corresponding author), Univ Sussex, Sch Life Sci, Dept Chem, Brighton BN1 9QJ, E Sussex, England.	f.g.cloke@sussex.ac.uk	Summerscales, Owen/E-6877-2012; Green, Jennifer/F-2195-2018	Green, Jennifer/0000-0002-2933-2303				BUCHNER W, 1963, HELV CHIM ACTA, V46, P2111, DOI 10.1002/hlca.19630460629; Castro-Rodriguez I, 2005, J AM CHEM SOC, V127, P11242, DOI 10.1021/ja053497r; Castro-Rodriguez I, 2004, SCIENCE, V305, P1757, DOI 10.1126/science.1102602; Cloke FGN, 2004, ORGANOMETALLICS, V23, P832, DOI 10.1021/om0305824; Cloke FGN, 2002, J AM CHEM SOC, V124, P9352, DOI 10.1021/ja027000e; COLUCCIA S, 1981, J CHEM SOC FARAD T 1, V77, P1063, DOI 10.1039/f19817701063; CORNILS B, 1996, APPL HOMOGENOUS CATA; EGGERDING D, 1976, J AM CHEM SOC, V98, P3641, DOI 10.1021/ja00428a043; Evans WJ, 2003, J AM CHEM SOC, V125, P14264, DOI 10.1021/ja037647e; EVANS WJ, 1985, J AM CHEM SOC, V107, P3728, DOI 10.1021/ja00298a060; Gmelin L., 1825, ANN PHYS CHEM, V80, P31; LEDNOR PW, 1983, J CHEM SOC CHEM COMM, P284, DOI 10.1039/c39830000284; ROFERDEPOORTER CK, 1981, CHEM REV, V81, P447, DOI 10.1021/cr00045a002; SCHAKE AR, 1993, ORGANOMETALLICS, V12, P1497, DOI 10.1021/om00029a004; Schleyer PV, 2000, J ORG CHEM, V65, P426, DOI 10.1021/jo991267n; SEITZ G, 1992, CHEM REV, V92, P1227, DOI 10.1021/cr00014a004; SILVESTRI G, 1978, ELECTROCHIM ACTA, V23, P413, DOI 10.1016/0013-4686(78)87039-X; SPIRLET MR, 1990, ACTA CRYSTALLOGR C, V46, P2318, DOI 10.1107/S0108270190005054; WEST R, 1979, J AM CHEM SOC, V101, P1710, DOI 10.1021/ja00501a010	19	228	233	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					829	831		10.1126/science.1121784	http://dx.doi.org/10.1126/science.1121784			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	012XT	16469921				2022-12-28	WOS:000235374900042
J	Aharonian, F; Akhperjanian, AG; Bazer-Bachi, AR; Beilicke, M; Benbow, W; Berge, D; Bernlohr, K; Boisson, C; Bolz, O; Borrel, V; Braun, I; Breitling, F; Brown, AM; Chadwick, PM; Chounet, LM; Cornils, R; Costamante, L; Degrange, B; Dickinson, HJ; Djannati-Atai, A; Drury, LO; Dubus, G; Emmanoulopoulos, D; Espigat, P; Feinstein, F; Fontaine, G; Fuchs, Y; Funk, S; Gallant, YA; Giebels, B; Gillessen, S; Glicenstein, JF; Goret, P; Hadjichristidis, C; Hauser, D; Hauser, M; Heinzelmann, G; Henri, G; Hermann, G; Hinton, JA; Hofmann, W; Holleran, M; Horns, D; Jacholkowska, A; de Jager, OC; Khelifi, B; Klages, S; Komin, N; Konopelko, A; Latham, IJ; Le Gallou, R; Lemiere, A; Lemoine-Goumard, M; Leroy, N; Lohse, T; Marcowith, A; Martin, JM; Martineau-Huynh, O; Masterson, C; McComb, TJL; de Naurois, M; Nolan, SJ; Noutsos, A; Orford, KJ; Osborne, JL; Ouchrif, M; Panter, M; Pelletier, G; Pita, S; Puhlhofer, G; Punch, M; Raubenheimer, BC; Raue, M; Raux, J; Rayner, SM; Reimer, A; Reimer, O; Ripken, J; Rob, L; Rolland, L; Rowell, G; Sahakian, V; Sauge, L; Schlenker, S; Schlickeiser, R; Schuster, C; Schwanke, U; Siewert, M; Sol, H; Spangler, D; Steenkamp, R; Stegmann, C; Tavernet, JP; Terrier, R; Theoret, CG; Tluczykont, M; van Eldik, C; Vasileiadis, G; Venter, C; Vincent, P; Volk, HJ; Wagner, SJ				Aharonian, F; Akhperjanian, AG; Bazer-Bachi, AR; Beilicke, M; Benbow, W; Berge, D; Bernlohr, K; Boisson, C; Bolz, O; Borrel, V; Braun, I; Breitling, F; Brown, AM; Chadwick, PM; Chounet, LM; Cornils, R; Costamante, L; Degrange, B; Dickinson, HJ; Djannati-Atai, A; Drury, LO; Dubus, G; Emmanoulopoulos, D; Espigat, P; Feinstein, F; Fontaine, G; Fuchs, Y; Funk, S; Gallant, YA; Giebels, B; Gillessen, S; Glicenstein, JF; Goret, P; Hadjichristidis, C; Hauser, D; Hauser, M; Heinzelmann, G; Henri, G; Hermann, G; Hinton, JA; Hofmann, W; Holleran, M; Horns, D; Jacholkowska, A; de Jager, OC; Khelifi, B; Klages, S; Komin, N; Konopelko, A; Latham, IJ; Le Gallou, R; Lemiere, A; Lemoine-Goumard, M; Leroy, N; Lohse, T; Marcowith, A; Martin, JM; Martineau-Huynh, O; Masterson, C; McComb, TJL; de Naurois, M; Nolan, SJ; Noutsos, A; Orford, KJ; Osborne, JL; Ouchrif, M; Panter, M; Pelletier, G; Pita, S; Puhlhofer, G; Punch, M; Raubenheimer, BC; Raue, M; Raux, J; Rayner, SM; Reimer, A; Reimer, O; Ripken, J; Rob, L; Rolland, L; Rowell, G; Sahakian, V; Sauge, L; Schlenker, S; Schlickeiser, R; Schuster, C; Schwanke, U; Siewert, M; Sol, H; Spangler, D; Steenkamp, R; Stegmann, C; Tavernet, JP; Terrier, R; Theoret, CG; Tluczykont, M; van Eldik, C; Vasileiadis, G; Venter, C; Vincent, P; Volk, HJ; Wagner, SJ			Discovery of very-high-energy gamma-rays from the Galactic Centre ridge	NATURE			English	Article							MOLECULAR CLOUDS; CENTER REGION; ACCELERATION; DIRECTION; EMISSION; SHELL; MASS	The source of Galactic cosmic rays ( with energies up to 10(15) eV) remains unclear, although it is widely believed that they originate in the shock waves of expanding supernova remnants(1,2). At present the best way to investigate their acceleration and propagation is by observing the gamma-rays produced when cosmic rays interact with interstellar gas(3). Here we report observations of an extended region of very-high-energy (> 10(11) eV) gamma-ray emission correlated spatially with a complex of giant molecular clouds in the central 200 parsecs of the Milky Way. The hardness of the gamma-ray spectrum and the conditions in those molecular clouds indicate that the cosmic rays giving rise to the gamma-rays are likely to be protons and nuclei rather than electrons. The energy associated with the cosmic rays could have come from a single supernova explosion around 10(4) years ago.	Max Planck Inst Kernphys, D-69029 Heidelberg, Germany; Yerevan Phys Inst, Yerevan 375036, Armenia; UPS, CNRS, Ctr Etud Spatiale Rayonnements, F-31029 Toulouse 4, France; Univ Hamburg, Inst Expt Phys, D-22761 Hamburg, Germany; Humboldt Univ, Inst Phys, D-12489 Berlin, Germany; Observ Paris, CNRS, UMR 8102, LUTH,Sect Meudon, F-92195 Meudon, France; Univ Durham, Dept Phys, Durham DH1 3LE, England; Ecole Polytech, CNRS, IN2P3, Lab Leprince Ringuet, F-91128 Palaiseau, France; APC, F-75231 Paris 05, France; Univ Paris 06, CEA, Observ Paris, CNRS,UMR 7164, F-75252 Paris 05, France; Dublin Inst Adv Studies, Dublin 2, Ireland; Landessternwarte Konigstuhl, D-69117 Heidelberg, Germany; Univ Montpellier 2, CNRS, IN2P3, Lab Phys Theoret & Astroparticules, F-34095 Montpellier 5, France; Univ Grenoble 1, CNRS, INSU, Lab AStrophys Grenoble, F-38041 Grenoble 9, France; Ctr Etud Saclay, CEA, DAPNIA, DSM, F-91191 Gif Sur Yvette, France; NW Univ, Unit Space Phys, ZA-2520 Potchefstroom, South Africa; Univ Paris 06, CNRS, IN2P3, Lab Phys Nucl & Hautes Energies, F-75252 Paris 5, France; Univ Paris 07, CNRS, IN2P3, Lab Phys Nucl & Hautes Energies, F-75252 Paris 5, France; Ruhr Univ Bochum, Inst Theoret Phys, Lehrstuhl Weltraum & Astrophys 4, D-44780 Bochum, Germany; Charles Univ Prague, Inst Nucl & Particle Phys, Prague 18000 8, Czech Republic; Univ Namibia, Windhoek, Namibia	Max Planck Society; Yerevan Physics Institute; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Hamburg; Humboldt University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Universite Paris Cite; Durham University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); Institut Polytechnique de Paris; UDICE-French Research Universities; PSL Research University Paris; Universite Paris Cite; Observatoire de Paris; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; PSL Research University Paris; Universite Paris Cite; Observatoire de Paris; CEA; Sorbonne Universite; Dublin Institute for Advanced Studies; Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Universite Paris Saclay; North West University - South Africa; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Ruhr University Bochum; Charles University Prague; University of Namibia	Hinton, JA (corresponding author), Max Planck Inst Kernphys, POB 103980, D-69029 Heidelberg, Germany.	jim.hinton@mpi-hd.mpg.de	Djannati-Atai, Arache/ABA-9249-2021; van Eldik, Christopher/C-3901-2013; Marcowith, Alexandre/ABH-1254-2020; Venter, Christo/E-6884-2011; Horns, Dieter/ABE-9516-2020; Drury, Luke O'C/B-1916-2017; Funk, Stefan/AAI-1568-2021; Horns, Dieter/C-9727-2011; Berge, David/P-2179-2017; Braun, Isabel V/C-9373-2012; Funk, Stefan/B-7629-2015; Hadjichristidis, Christos/G-7284-2012; Pühlhofer, Gerd/Q-2336-2018; Reimer, Olaf/A-3117-2013; Fontaine, Gerard/D-6420-2014; Reimer, Anita/K-5822-2015; Komin, Nukri/J-6781-2015	van Eldik, Christopher/0000-0001-9669-645X; Marcowith, Alexandre/0000-0002-3971-0910; Venter, Christo/0000-0002-2666-4812; Horns, Dieter/0000-0003-1945-0119; Drury, Luke O'C/0000-0002-9257-2270; Funk, Stefan/0000-0002-2012-0080; Berge, David/0000-0002-2918-1824; Braun, Isabel V/0000-0002-9389-0502; Funk, Stefan/0000-0002-2012-0080; Hadjichristidis, Christos/0000-0002-5933-0755; Reimer, Olaf/0000-0001-6953-1385; Fontaine, Gerard/0000-0002-6443-5025; Reimer, Anita/0000-0001-8604-7077; Brown, Anthony/0000-0003-0259-3148; Hermann, German/0000-0002-4595-1032; Khelifi, Bruno/0000-0001-6876-5577; Punch, Michael/0000-0002-4710-2165; Rowell, Gavin/0000-0002-9516-1581; Chadwick, Paula/0000-0002-1468-2685; Komin, Nukri/0000-0003-3280-0582; Martineau-Huynh, Olivier/0000-0001-5334-8244				Aharonian F, 2005, SCIENCE, V307, P1938, DOI 10.1126/science.1108643; Aharonian F, 2004, ASTRON ASTROPHYS, V425, pL13, DOI 10.1051/0004-6361:200400055; AHARONIAN F, 2005, IN PRESS ASTROPHYS J; AHARONIAN F, 2005, IN PRESS SPACE SCI R; Aharonian FA, 2005, ASTRON ASTROPHYS, V442, pL25, DOI 10.1051/0004-6361:200500180; Aharonian FA, 2005, ASTRON ASTROPHYS, V437, pL7, DOI 10.1051/0004-6361:200500130; Aharonian FA, 2004, NATURE, V432, P75, DOI 10.1038/nature02960; Aharonian FA, 2001, SPACE SCI REV, V99, P187, DOI 10.1023/A:1013845015364; BELANGER G, 2005, IN PRESS ASTROPHYS J; Crocker RM, 2005, ASTROPHYS J, V622, P892, DOI 10.1086/427972; Crutcher RM, 1999, ASTROPHYS J, V520, P706, DOI 10.1086/307483; Dahmen G, 1998, ASTRON ASTROPHYS, V331, P959; Ginzburg V.L., 1990, ASTROPHYSICS COSMIC; Hillas AM, 2005, J PHYS G NUCL PARTIC, V31, pR95, DOI 10.1088/0954-3899/31/5/R02; HOFMANN W, 2003, P 28 ICRC TSUK, P2811; Hunter SD, 1997, ASTROPHYS J, V481, P205, DOI 10.1086/304012; Kosack K, 2004, ASTROPHYS J, V608, pL97, DOI 10.1086/422469; LIS DC, 1989, ASTROPHYS J, V337, P704, DOI 10.1086/167141; Maeda Y, 2002, ASTROPHYS J, V570, P671, DOI 10.1086/339773; Mattox JR, 2001, ASTROPHYS J SUPPL S, V135, P155, DOI 10.1086/321782; Morris M, 1996, ANNU REV ASTRON ASTR, V34, P645, DOI 10.1146/annurev.astro.34.1.645; Oka T, 1998, ASTROPHYS J SUPPL S, V118, P455, DOI 10.1086/313138; Pierce-Price D, 2000, ASTROPHYS J, V545, pL121, DOI 10.1086/317884; ROCKEFELLER G, 2005, UNPUB ASTROPHYS J; Tsuboi M, 1999, ASTROPHYS J SUPPL S, V120, P1, DOI 10.1086/313165; Tsuchiya K, 2004, ASTROPHYS J, V606, pL115, DOI 10.1086/421292	26	402	407	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					695	698		10.1038/nature04467	http://dx.doi.org/10.1038/nature04467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467831	Green Submitted, Green Accepted			2022-12-28	WOS:000235193100037
J	Barluenga, M; Stolting, KN; Salzburger, W; Muschick, M; Meyer, A				Barluenga, M; Stolting, KN; Salzburger, W; Muschick, M; Meyer, A			Sympatric speciation in Nicaraguan crater lake cichlid fish	NATURE			English	Article							SEXUAL SELECTION; CICHLASOMA-CITRINELLUM; SPECIES COMPLEX; DIVERGENCE; EVOLUTION	Sympatric speciation, the formation of species in the absence of geographical barriers, remains one of the most contentious concepts in evolutionary biology. Although speciation under sympatric conditions seems theoretically possible(1-5), empirical studies are scarce and only a few credible examples of sympatric speciation exist(6). Here we present a convincing case of sympatric speciation in the Midas cichlid species complex (Amphilophus sp.) in a young and small volcanic crater lake in Nicaragua. Our study includes phylogeographic, population-genetic ( based on mitochondrial DNA, microsatellites and amplified fragment length polymorphisms), morphometric and ecological analyses. We find, first, that crater Lake Apoyo was seeded only once by the ancestral high-bodied benthic species Amphilophus citrinellus, the most common cichlid species in the area; second, that a new elongated limnetic species ( Amphilophus zaliosus) evolved in Lake Apoyo from the ancestral species ( A. citrinellus) within less than similar to 10,000 yr; third, that the two species in Lake Apoyo are reproductively isolated; and fourth, that the two species are eco-morphologically distinct.	Univ Konstanz, Lehrstuhl Zool & Evolut Biol, Dept Biol, D-78457 Constance, Germany; Univ Konstanz, Ctr Jr Res Fellows, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Meyer, A (corresponding author), Univ Konstanz, Lehrstuhl Zool & Evolut Biol, Dept Biol, Univ Str 10, D-78457 Constance, Germany.	Axel.Meyer@uni-konstanz.de	Meyer, Axel/C-9826-2009; Salzburger, Walter/G-1598-2011; Barluenga, Marta/ABA-4194-2020; Muschick, Moritz/B-9843-2012	Meyer, Axel/0000-0002-0888-8193; Salzburger, Walter/0000-0002-9988-1674; Barluenga, Marta/0000-0003-1514-0586; Muschick, Moritz/0000-0002-7782-7503; Stolting, Kai N./0000-0003-3498-3343				[Anonymous], 1861, ORIGIN SPECIES MEANS; Arnegard ME, 2004, EVOLUTION, V58, P222, DOI 10.1111/j.0014-3820.2004.tb01640.x; Barlow G.W., 1976, P333; Barluenga M, 2004, MOL ECOL, V13, P2061, DOI 10.1111/j.1365-294X.2004.02211.x; BAYLIS JR, 1976, BEHAVIOUR, V59, P59, DOI 10.1163/156853976X00460; BICE DC, 1985, GEOL SOC AM BULL, V96, P553, DOI 10.1130/0016-7606(1985)96<553:QVSOMN>2.0.CO;2; Coyne J.A., 2004, SPECIATION; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Fryer G, 1972, CICHLID FISHES GREAT; GAVRILETS S, 2004, MONOGRAPHS POPULATIO, V41; Gislason D, 1999, CAN J FISH AQUAT SCI, V56, P2229, DOI 10.1139/cjfas-56-12-2229; HAMMER O, 2004, PALAEONTOL ELECTRON, V4; Higashi M, 1999, NATURE, V402, P523, DOI 10.1038/990087; KAWECKI TJ, 2004, ADAPTIVE SPECIATION; Kirkpatrick M, 2004, P ROY SOC B-BIOL SCI, V271, P687, DOI 10.1098/rspb.2003.2645; Klingenberg CP, 2003, BIOL J LINN SOC, V80, P397, DOI 10.1046/j.1095-8312.2003.00246.x; Kocher TD, 2004, NAT REV GENET, V5, P288, DOI 10.1038/nrg1316; Kondrashov AS, 1999, NATURE, V400, P351, DOI 10.1038/22514; LEVINS RICHARD, 1968; McKaye K.R., 2002, CUADERNOS INVESTIGAC, V12, P19; MEYER A, 1989, OECOLOGIA, V80, P431, DOI 10.1007/BF00379047; Rohlf FJ, 2018, TPSDIG; Schliewen U, 2001, MOL ECOL, V10, P1471, DOI 10.1046/j.1365-294X.2001.01276.x; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; SCHLUTER D, 1993, TRENDS ECOL EVOL, V8, P197, DOI 10.1016/0169-5347(93)90098-A; Seehausen O, 1999, ECOL LETT, V2, P262; Van Oppen MJH, 1998, MOL ECOL, V7, P991, DOI 10.1046/j.1365-294x.1998.00417.x; Weiblen GD, 2002, MOL ECOL, V11, P1573, DOI 10.1046/j.1365-294X.2002.01529.x; [No title captured]	29	493	511	5	305	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					719	723		10.1038/nature04325	http://dx.doi.org/10.1038/nature04325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467837	Green Published			2022-12-28	WOS:000235193100043
J	Kang, SK				Kang, SK			Radiation recall reaction after antimicrobial therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Naval Med Ctr San Diego, San Diego, CA 92134 USA	United States Department of Defense; United States Navy; Naval Medical Center San Diego	Kang, SK (corresponding author), Naval Med Ctr San Diego, San Diego, CA 92134 USA.								0	21	21	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					622	622		10.1056/NEJMicm041058	http://dx.doi.org/10.1056/NEJMicm041058			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467549				2022-12-28	WOS:000235177500011
J	Rowley, DB; Currie, BS				Rowley, DB; Currie, BS			Palaeo-altimetry of the late Eocene to Miocene Lunpola basin, central Tibet	NATURE			English	Article							INDIA-ASIA COLLISION; STABLE ISOTOPES; SOUTHERN TIBET; PLATEAU; PALEOALTIMETRY; PALEOELEVATION; HIMALAYA; DEFORMATION; TOPOGRAPHY; INITIATION	The elevation history of the Tibetan plateau provides direct insight into the tectonic processes associated with continent - continent collisions. Here we present oxygen-isotope-based estimates of the palaeo-altimetry of late Eocene and younger deposits of the Lunpola basin in the centre of the plateau, which indicate that the surface of Tibet has been at an elevation of more than 4 kilometres for at least the past 35 million years. We conclude that crustal, but not mantle, thickening models, combined with plate-kinematic solutions of India - Asia convergence, are compatible with palaeoelevation estimates across the Tibetan plateau.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Miami Univ, Dept Geol, Oxford, OH 45056 USA	University of Chicago; University System of Ohio; Miami University	Rowley, DB (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	drowley@uchicago.edu		Currie, Brian/0000-0002-5759-3914; Rowley, David/0000-0001-9767-9029				ARGAND E, 1924, 13 INT GEOL C COLL R, V1, P171; Beaumont C, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002809; BEAUMONT C, 1992, THRUST TECTONICS, P1; BERGGREN WA, 1995, TIME SCALES GLOBAL S, P129; Bureau of Geology and Mineral Resources of Xizang Autonomous Region, 1993, REG GEOL XIZ TIB AUT; Currie BS, 2005, GEOLOGY, V33, P181, DOI 10.1130/G21170.1; Cyr AJ, 2005, J GEOL, V113, P517, DOI 10.1086/431907; DANSGAARD W, 1964, TELLUS, V16, P436; DEWEY JF, 1973, J GEOL, V81, P683, DOI 10.1086/627920; ENGLAND P, 1986, J GEOPHYS RES-SOLID, V91, P3664, DOI 10.1029/JB091iB03p03664; Friedman I., 1977, US GEOLOGICAL SURVEY, V776, P1, DOI [10.3133/pp440KK, DOI 10.1017/CB09781107415324.004]; Garzione CN, 2000, GEOLOGY, V28, P339, DOI 10.1130/0091-7613(2000)28<339:HTOTTP>2.0.CO;2; Garzione CN, 2000, EARTH PLANET SC LETT, V183, P215, DOI 10.1016/S0012-821X(00)00252-1; Garzione CN, 2004, PALAEOGEOGR PALAEOCL, V212, P119, DOI 10.1016/j.palaeo.2004.05.020; Graham SA, 2005, AM J SCI, V305, P101, DOI 10.2475/ajs.305.2.101; Houseman G., 1996, TECTONIC EVOLUTION A, P3; LEPICHON X, 1992, TECTONICS, V11, P1085, DOI 10.1029/92TC01566; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; Rowley DB, 1996, EARTH PLANET SC LETT, V145, P1, DOI 10.1016/S0012-821X(96)00201-4; Rowley DB, 2001, EARTH PLANET SC LETT, V188, P253, DOI 10.1016/S0012-821X(01)00324-7; Royden LH, 1997, SCIENCE, V276, P788, DOI 10.1126/science.276.5313.788; Rozanski K., 1993, CLIMATE CHANGE CONTI, V78, P1, DOI DOI 10.1029/GM078P0001; Spicer RA, 2003, NATURE, V421, P622, DOI 10.1038/nature01356; TAPPONNIER P, 1982, GEOLOGY, V10, P611, DOI 10.1130/0091-7613(1982)10<611:PETIAN>2.0.CO;2; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978; Tian L, 2001, J GEOPHYS RES-ATMOS, V106, P28081, DOI 10.1029/2001JD900186; Xia J., 1983, CONTRIBUTION GEOLOGY, P243; Xu Z. Y., 1985, CONTRIBUTION GEOLOGY, V17, P391; Xu ZY., 1980, OIL GAS GEOL, V1, P153; Zhai G. M., 1990, PETROLEUM GEOLOGY CH, V14; Zhu B, 2005, J GEOL, V113, P265, DOI 10.1086/428805	31	605	711	6	183	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					677	681		10.1038/nature04506	http://dx.doi.org/10.1038/nature04506			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467830				2022-12-28	WOS:000235193100034
J	Peile, E				Peile, E			Commentary: Integrated learning	BRITISH MEDICAL JOURNAL			English	Editorial Material							CURRICULUM		Univ Warwick, Warwick Med Sch, Div Med, Coventry CV4 7AL, W Midlands, England	University of Warwick	Peile, E (corresponding author), Univ Warwick, Warwick Med Sch, Div Med, Coventry CV4 7AL, W Midlands, England.	ed.peile@warwick.ac.uk						DOLMANS DHJM, 1993, ACAD MED, V68, P207, DOI 10.1097/00001888-199303000-00013; Eshach H, 2003, ACAD MED, V78, P491, DOI 10.1097/00001888-200305000-00011; McPherson S, 2006, BRIT MED J, V332, P276, DOI 10.1136/bmj.332.7536.276; Schmidt HG, 1996, ACAD MED, V71, P658, DOI 10.1097/00001888-199606000-00021; Tamblyn R, 2005, BMJ-BRIT MED J, V331, P1002, DOI 10.1136/bmj.38636.582546.7C; Whitcomb ME, 2002, ACAD MED, V77, P1067, DOI 10.1097/00001888-200211000-00001	6	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					278	278		10.1136/bmj.332.7536.278	http://dx.doi.org/10.1136/bmj.332.7536.278			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455726	Green Published			2022-12-28	WOS:000235259000021
J	Rajan, R; Clement, JP; Bhalla, US				Rajan, R; Clement, JP; Bhalla, US			Rats smell in stereo	SCIENCE			English	Article							CHEMOTAXIS; MECHANISMS; OLFACTION	It has been hypothesized that rats and other mammals can use stereo cues to localize odor sources, but there is limited behavioral evidence to support this hypothesis. We found that rats trained on an odor-localization task can localize odors accurately in one or two sniffs. Bilateral sampling was essential for accurate odor localization, with internasal. intensity and timing differences as directional cues. If the stimulus arrived at the correct point of the respiration cycle, internasal. timing differences as short as 50 milliseconds sufficed. Neuronal recordings show that bulbar neurons responded differentially to stimuli from the left and stimuli from the right.	Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); University of Agricultural Sciences Bangalore	Bhalla, US (corresponding author), Univ Agr Sci Bangalore, Natl Ctr Biol Sci, Gandhi Krishi Vignan Kendra Campus,Bellary Rd, Bangalore 560065, Karnataka, India.	bhalla@ncbs.res.in	Clement, James/Q-5628-2019	Clement, James/0000-0001-7625-6430				Atema J, 1996, BIOL BULL, V191, P129, DOI 10.2307/1543074; FORD N, 1986, CHEM SIGNALS VERTEBR; JOHNSEN PB, 1980, J COMP PHYSIOL, V140, P95, DOI 10.1007/BF00606301; KOBAL G, 1989, EXPERIENTIA, V45, P130, DOI 10.1007/BF01954845; Konishi M, 2003, ANNU REV NEUROSCI, V26, P31, DOI 10.1146/annurev.neuro.26.041002.131123; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MEANS LW, 1971, J COMP PHYSIOL PSYCH, V76, P160, DOI 10.1037/h0031058; Neimark MA, 2003, J NEUROSCI, V23, P6499; Porter J, 2005, NEURON, V47, P581, DOI 10.1016/j.neuron.2005.06.028; Radil T, 1998, ANN NY ACAD SCI, V855, P641, DOI 10.1111/j.1749-6632.1998.tb10638.x; SILVER WL, 1982, PHYSIOL BEHAV, V28, P927, DOI 10.1016/0031-9384(82)90216-5; Uchida N, 2003, NAT NEUROSCI, V6, P1224, DOI 10.1038/nn1142; Vickers NJ, 2000, BIOL BULL, V198, P203, DOI 10.2307/1542524; VONBEKESY G, 1964, J APPL PHYSIOL, V19, P369, DOI 10.1152/jappl.1964.19.3.369; Wallace DG, 2002, BEHAV BRAIN RES, V131, P185, DOI 10.1016/S0166-4328(01)00384-9; Welker W. I., 1964, Behaviour, V22, P223, DOI 10.1163/156853964X00030; Wilson DA, 1999, PHYSIOL BEHAV, V66, P41, DOI 10.1016/S0031-9384(98)00269-8; Wilson DA, 1997, J NEUROPHYSIOL, V78, P160, DOI 10.1152/jn.1997.78.1.160	18	137	139	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2006	311	5761					666	670		10.1126/science.1122096	http://dx.doi.org/10.1126/science.1122096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456082				2022-12-28	WOS:000235257400050
J	Juweid, ME; Cheson, BD				Juweid, ME; Cheson, BD			Current concepts - Positron-emission tomography and assessment of cancer therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NON-HODGKINS-LYMPHOMA; CELL LUNG-CANCER; HEAD-AND-NECK; FDG-PET; BREAST-CANCER; PREOPERATIVE CHEMOTHERAPY; F-18 FLUORODEOXYGLUCOSE; COLORECTAL-CANCER; LIVER METASTASES; PROGNOSTIC VALUE		Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; Georgetown Univ Hosp, Div Hematol Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	University of Iowa; University of Iowa; Georgetown University	Juweid, ME (corresponding author), Univ Iowa, Dept Radiol, JPP 3859,200 Hawkins Dr, Iowa City, IA 52242 USA.	malik-juweid@uiowa.edu						Ahmad A, 1999, BRIT J CANCER, V79, P478, DOI 10.1038/sj.bjc.6690074; Allen-Auerbach M, 2004, MOL IMAGING BIOL, V6, P411, DOI 10.1016/j.mibio.2004.08.004; Antoch G, 2004, J CLIN ONCOL, V22, P4357, DOI 10.1200/JCO.2004.08.120; Arulampalam T H, 2001, Lancet Oncol, V2, P172, DOI 10.1016/S1470-2045(00)00259-X; Bender H, 1999, HYBRIDOMA, V18, P87, DOI 10.1089/hyb.1999.18.87; Berger M, 2003, AM J ROENTGENOL, V181, P359, DOI 10.2214/ajr.181.2.1810359; Bos R, 2002, J CLIN ONCOL, V20, P379, DOI 10.1200/JCO.20.2.379; Brun E, 2002, HEAD NECK-J SCI SPEC, V24, P127, DOI 10.1002/hed.10037.abs; Bury T, 1999, EUR RESPIR J, V14, P1376; CANELLOS GP, 1988, J CLIN ONCOL, V6, P931, DOI 10.1200/JCO.1988.6.6.931; Conti PS, 1996, NUCL MED BIOL, V23, P717, DOI 10.1016/0969-8051(96)00074-1; Effert PJ, 1996, J UROLOGY, V155, P994, DOI 10.1016/S0022-5347(01)66366-3; Elstrom R, 2003, BLOOD, V101, P3875, DOI 10.1182/blood-2002-09-2778; Even-Sapir E, 2004, RADIOLOGY, V232, P815, DOI 10.1148/radiol.2323031065; Findlay M, 1996, J CLIN ONCOL, V14, P700, DOI 10.1200/JCO.1996.14.3.700; Flamen P, 2000, J THORAC CARDIOV SUR, V120, P1085, DOI 10.1067/mtc.2000.110464; Flanagan FL, 1998, ANN SURG, V227, P319, DOI 10.1097/00000658-199803000-00001; Fuster D, 2004, J NUCL MED, V45, P1323; GALLAGHER BM, 1978, J NUCL MED, V19, P1154; Gambhir SS, 2001, J NUCL MED, V42, p1S; Goerres GW, 2004, J NUCL MED, V45, p66S; Greven KM, 2001, HEAD NECK-J SCI SPEC, V23, P942, DOI 10.1002/hed.1136; GRIERSON JR, 1989, J NUCL MED, V30, P343; Grigsby PW, 2004, J CLIN ONCOL, V22, P2167, DOI 10.1200/JCO.2004.09.035; Hathaway PB, 1999, RADIOLOGY, V210, P807, DOI 10.1148/radiology.210.3.r99mr43807; INOUE T, 1995, J NUCL MED, V36, P788; Israel O, 2004, J NUCL MED, V45, P2045; Jerusalem G, 1999, BLOOD, V94, P429, DOI 10.1182/blood.V94.2.429.414k26_429_433; Juweid ME, 2005, J CLIN ONCOL, V23, P4577, DOI 10.1200/JCO.2005.01.904; Juweid ME, 2005, J CLIN ONCOL, V23, P4652, DOI 10.1200/JCO.2005.01.891; Kato H, 2004, BRIT J SURG, V91, P1004, DOI 10.1002/bjs.4595; Keidar Z, 2004, J NUCL MED, V45, P1640; Kim TS, 2001, WORLD J SURG, V25, P829, DOI 10.1007/s002680020095; Kostakoglu L, 2002, J NUCL MED, V43, P1018; Lapela M, 2000, EUR J CANCER, V36, P858, DOI 10.1016/S0959-8049(00)00037-X; Lardinois D, 2003, NEW ENGL J MED, V348, P2500, DOI 10.1056/NEJMoa022136; Libutti SK, 2001, ANN SURG ONCOL, V8, P779, DOI 10.1245/aso.2001.8.10.779; Lowe VJ, 2000, J CLIN ONCOL, V18, P651, DOI 10.1200/JCO.2000.18.3.651; Moon DH, 1998, J NUCL MED, V39, P431; Ott K, 2003, J CLIN ONCOL, V21, P4604, DOI 10.1200/JCO.2003.06.574; PATZ EF, 1994, RADIOLOGY, V191, P379, DOI 10.1148/radiology.191.2.8153309; Porceddu SV, 2005, HEAD NECK-J SCI SPEC, V27, P175, DOI 10.1002/hed.20130; Romer W, 1998, BLOOD, V91, P4464; Schaefer NG, 2004, RADIOLOGY, V232, P823, DOI 10.1148/radiol.2323030985; Schelling M, 2000, J CLIN ONCOL, V18, P1689, DOI 10.1200/JCO.2000.18.8.1689; Schluter B, 2001, J NUCL MED, V42, P71; Schwimmer J, 2000, Q J NUCL MED, V44, P153; Selzner MK, 2004, ANN SURG, V240, P1027, DOI 10.1097/01.sla.0000146145.69835.c5; Smith IC, 2000, J CLIN ONCOL, V18, P1676, DOI 10.1200/JCO.2000.18.8.1676; Spaepen K, 2001, J CLIN ONCOL, V19, P414, DOI 10.1200/JCO.2001.19.2.414; Spaepen K, 2002, ANN ONCOL, V13, P1356, DOI 10.1093/annonc/mdf256; Valk P. E., 1997, Journal of Nuclear Medicine, V38, p90P; Valk PE, 1999, ARCH SURG-CHICAGO, V134, P503, DOI 10.1001/archsurg.134.5.503; von Schulthess GK, 2004, MOL IMAGING BIOL, V6, P183, DOI 10.1016/j.mibio.2004.05.001; WAHL RL, 1993, J CLIN ONCOL, V11, P2101, DOI 10.1200/JCO.1993.11.11.2101; Wang WP, 1999, J CLIN ENDOCR METAB, V84, P2291, DOI 10.1210/jc.84.7.2291; Weber WA, 2003, J CLIN ONCOL, V21, P2651, DOI 10.1200/JCO.2003.12.004; Weber WA, 2001, J CLIN ONCOL, V19, P3058, DOI 10.1200/JCO.2001.19.12.3058; Yao M, 2004, INT J RADIAT ONCOL, V60, P1410, DOI 10.1016/j.ijrobp.2004.05.058	59	548	582	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					496	507		10.1056/NEJMra050276	http://dx.doi.org/10.1056/NEJMra050276			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452561				2022-12-28	WOS:000235019400009
J	Thomson, MC; Doblas-Reyes, FJ; Mason, SJ; Hagedorn, R; Connor, SJ; Phindela, T; Morse, AP; Palmer, TN				Thomson, MC; Doblas-Reyes, FJ; Mason, SJ; Hagedorn, R; Connor, SJ; Phindela, T; Morse, AP; Palmer, TN			Malaria early warnings based on seasonal climate forecasts from multi-model ensembles	NATURE			English	Article							SPACE-TIME CLIMATE; VARIABILITY; RAINFALL	The control of epidemic malaria is a priority for the international health community and specific targets for the early detection and effective control of epidemics have been agreed(1). Interannual climate variability is an important determinant of epidemics in parts of Africa(2) where climate drives both mosquito vector dynamics and parasite development rates(3). Hence, skilful seasonal climate forecasts may provide early warning of changes of risk in epidemic-prone regions. Here we discuss the development of a system to forecast probabilities of anomalously high and low malaria incidence with dynamically based, seasonal-timescale, multi-model ensemble predictions of climate, using leading global coupled ocean - atmosphere climate models developed in Europe. This forecast system is successfully applied to the prediction of malaria risk in Botswana, where links between malaria and climate variability are well established(4), adding up to four months lead time over malaria warnings issued with observed precipitation and having a comparably high level of probabilistic prediction skill. In years in which the forecast probability distribution is different from that of climatology, malaria decision-makers can use this information for improved resource allocation.	European Ctr Medium Range Weather Forecasts, Reading RG2 9AX, Berks, England; Columbia Univ, Earth Inst, Int Res Inst Climate & Soc, Palisades, NY 10964 USA; Minist Hlth, Epidemiol & Dis Control Unit, Natl Malaria Control Programme, Gaborone, Botswana; Univ Liverpool, Dept Geog, Liverpool L69 7ZT, Merseyside, England	European Centre for Medium-Range Weather Forecasts (ECMWF); Columbia University; University of Liverpool	Palmer, TN (corresponding author), European Ctr Medium Range Weather Forecasts, Shinfield Pk, Reading RG2 9AX, Berks, England.	tim.palmer@ecmwf.int	Doblas-Reyes, Francisco J./C-1228-2016; Mason, Simon/AAH-5699-2020	Doblas-Reyes, Francisco J./0000-0002-6622-4280; Morse, Andrew/0000-0002-0413-2065; Palmer, Tim/0000-0002-7121-2196	Natural Environment Research Council [NE/B505538/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		BRINKMANN U, 1991, TROP MED PARASITOL, V42, P204; CANE M.A., 1994, NATURE, V16, P3059; Coelho CAS, 2004, J CLIMATE, V17, P1504, DOI 10.1175/1520-0442(2004)017<1504:FCACAS>2.0.CO;2; DaSilva J, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-37; Goddard L, 2001, INT J CLIMATOL, V21, P1111, DOI 10.1002/joc.636; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Hagedorn R, 2005, TELLUS A, V57, P219, DOI 10.1111/j.1600-0870.2005.00103.x; JOLLIFFE IT, 2003, PRACTITIONERS GUIDE, P1; Mason S.J., 2000, DROUGHT GLOBAL ASSES, V1, P113; Mason SJ, 2002, Q J ROY METEOR SOC, V128, P2145, DOI 10.1256/003590002320603584; NAJERA JA, 1998, WHOMAL981084, P1; New M, 1999, J CLIMATE, V12, P829, DOI 10.1175/1520-0442(1999)012<0829:RTCSTC>2.0.CO;2; New M, 2000, J CLIMATE, V13, P2217, DOI 10.1175/1520-0442(2000)013<2217:RTCSTC>2.0.CO;2; Palmer TN, 2005, ANNU REV EARTH PL SC, V33, P163, DOI 10.1146/annurev.earth.33.092203.122552; Palmer TN, 2004, B AM METEOROL SOC, V85, P853, DOI 10.1175/BAMS-85-6-853; Richardson DS, 2000, Q J ROY METEOR SOC, V126, P649, DOI 10.1002/qj.49712656313; Stockdale TN, 1998, NATURE, V392, P370, DOI 10.1038/32861; Thomson MC, 2005, AM J TROP MED HYG, V73, P214, DOI 10.4269/ajtmh.2005.73.214; Thomson MC, 1996, ANN TROP MED PARASIT, V90, P243, DOI 10.1080/00034983.1996.11813050; UPPALA S, 2004, ECMWF NEWSLETTER, P2; *WHO, 2001, WHO GLOB STRAT CONT, P1; *WHOUNICEF, 2005, WHOHTMMAL20051102 WH, P1; Worrall E, 2004, AM J TROP MED HYG, V71, P136, DOI 10.4269/ajtmh.2004.71.136; Xie PP, 1998, J CLIMATE, V11, P137, DOI 10.1175/1520-0442(1998)011<0137:GMPEFS>2.0.CO;2	24	338	345	1	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					576	579		10.1038/nature04503	http://dx.doi.org/10.1038/nature04503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452977	Green Published			2022-12-28	WOS:000235033900038
J	Kerr, T; Stoltz, JA; Tyndall, M; Li, K; Zhang, R; Montaner, J; Wood, E				Kerr, T; Stoltz, JA; Tyndall, M; Li, K; Zhang, R; Montaner, J; Wood, E			Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study	BRITISH MEDICAL JOURNAL			English	Article							VANCOUVER; COHORT; ROOMS; CANADA	Problem Illicit use of injected drugs is linked with high rates of HIV infection and fatal overdose, as well as community concerns about public drug use. Supervised injecting facilities have been proposed as a potential solution, but fears have been raised that they might encourage drug use. Design A before and after study Participants and setting 871 injecting drug users recruited from the community in Vancouver, Canada. Key measures for improvement Rates of relapse into injected drug use among former users and of stopping drug use among current users. Strategies for change Local health authorities established die Vancouver supervised injecting facility to provide injecting drug users with sterile injecting equipment, intervention in the event of overdose, primary health care, and referral to external health and social services. Effects of change Analysis of periods before and after the facility's opening showed no substantial increase in the rate of relapse into injected drug use (17% v 20%) and no substantial decrease in the Late of stopping injected drug use (17% v 15%). Lessons learnt Recently reported benefits of supervised injecting facilities on drug, users' high risk behaviours and on public order do not seem to have been offset by negative community impacts.	St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan	Kerr, T (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	tkerr@cfenet.ubc.ca	Montaner, Julio/K-7621-2012	Tyndall, Mark/0000-0003-4450-5679				BULA F, 2002, VANCOUVER SUN A 1121, P1; Coffin PO, 2003, ADDICTION, V98, P739, DOI 10.1046/j.1360-0443.2003.00376.x; Des Jarlais DC, 2000, AIDS, V14, pS41, DOI 10.1097/00002030-200006001-00006; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; Doherty MC, 1997, AM J EPIDEMIOL, V145, P730, DOI 10.1093/aje/145.8.730; Gandey A, 2003, CAN MED ASSOC J, V169, P1063; Hedlund J, 2000, Inj Prev, V6, P82, DOI 10.1136/ip.6.2.82; Hedrich D, 2004, EUROPEAN REPORT DRUG; International Narcotics Control Board, 2003, REP INT NARC CONTR B; Kerr T, 2005, LANCET, V366, P316, DOI 10.1016/S0140-6736(05)66475-6; Kerr T, 2005, J PUBLIC HEALTH-UK, V27, P62, DOI 10.1093/pubmed/fdh189; Kimber J, 2003, DRUG ALCOHOL REV, V22, P227, DOI 10.1080/095952301000116951; MARTINUK S, 2002, PROVINCE VANC A 1120, P20; MENSCH BS, 1988, PUBLIC OPIN QUART, V52, P100, DOI 10.1086/269084; Strang J, 2004, BRIT MED J, V328, P102, DOI 10.1136/bmj.328.7431.102; Tyndall MW, 2001, J ACQ IMMUN DEF SYND, V28, P351, DOI 10.1097/00126334-200112010-00008; Wood E, 2004, CAN MED ASSOC J, V171, P731, DOI 10.1503/cmaj.1040774; Wood E, 2004, CAN MED ASSOC J, V170, P1551, DOI 10.1503/cmaj.1031928; Wood E, 2004, LANCET INFECT DIS, V4, P301, DOI 10.1016/S1473-3099(04)01006-0; Wood E, 2001, CAN MED ASSOC J, V165, P405; Wright NMJ, 2004, BRIT MED J, V328, P100, DOI 10.1136/bmj.328.7431.100; Yamey G, 2000, BRIT MED J, V320, P667	22	82	82	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 28	2006	332	7535					220	222		10.1136/bmj.332.7535.220	http://dx.doi.org/10.1136/bmj.332.7535.220			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16439401	Green Published			2022-12-28	WOS:000235086900021
J	Menzel, R; Leboulle, G; Eisenhardt, D				Menzel, R; Leboulle, G; Eisenhardt, D			Small brains, bright minds	CELL			English	Editorial Material							APIS-MELLIFERA; HONEYBEE BRAIN; MEMORY; BEHAVIOR; NEURONS; BEES	Learning, memory, and social behavior are innate properties of the honeybee that are essential for the survival of each individual as well as for the survival of the hive. The small, accessible brain of the honeybee and the availability of the complete sequence of its genome make this social insect an ideal model for studying the connection between learning, memory, and social behavior.	Free Univ Berlin, Dept Biol Chem & Pharm, D-14195 Berlin, Germany	Free University of Berlin	Menzel, R (corresponding author), Free Univ Berlin, Dept Biol Chem & Pharm, D-14195 Berlin, Germany.	menzel@neurobiologie.fu-berlin.de						Amdam GV, 2004, P NATL ACAD SCI USA, V101, P11350, DOI 10.1073/pnas.0403073101; Farooqui T, 2003, J NEUROSCI, V23, P5370; Farris SM, 2001, J NEUROSCI, V21, P6395, DOI 10.1523/JNEUROSCI.21-16-06395.2001; Fiala A, 1999, J NEUROSCI, V19, P10125; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; Kunieda T, 2004, BIOCHEM BIOPH RES CO, V318, P25, DOI 10.1016/j.bbrc.2004.03.178; Menzel R, 2001, LEARN MEMORY, V8, P53, DOI 10.1101/lm.38801; Menzel R, 2005, J EXP BIOL, V208, P4317, DOI 10.1242/jeb.01908; Menzel R, 2005, P NATL ACAD SCI USA, V102, P3040, DOI 10.1073/pnas.0408550102; Menzel R, 2001, TRENDS COGN SCI, V5, P62, DOI 10.1016/S1364-6613(00)01601-6; Muller U, 2002, ZOOLOGY, V105, P313, DOI 10.1078/0944-2006-00075; Riley JR, 2005, NATURE, V435, P205, DOI 10.1038/nature03526; Robinson GE, 2005, NAT REV GENET, V6, P257, DOI 10.1038/nrg1575; Robinson KO, 2000, INSECT MOL BIOL, V9, P625, DOI 10.1046/j.1365-2583.2000.00225.x; Stollhoff N, 2005, J NEUROSCI, V25, P4485, DOI 10.1523/JNEUROSCI.0117-05.2005; von Frisch K., 1967, DANCE LANGUAGE ORIEN	16	77	81	2	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 27	2006	124	2					237	239		10.1016/j.cell.2006.01.011	http://dx.doi.org/10.1016/j.cell.2006.01.011			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439194	hybrid			2022-12-28	WOS:000235068500007
J	Brockmann, D; Hufnagel, L; Geisel, T				Brockmann, D; Hufnagel, L; Geisel, T			The scaling laws of human travel	NATURE			English	Article							RANDOM-WALKS; DISPERSAL; EPIDEMICS; DYNAMICS; PATTERNS	The dynamic spatial redistribution of individuals is a key driving force of various spatiotemporal phenomena on geographical scales. It can synchronize populations of interacting species, stabilize them, and diversify gene pools(1-3). Human travel, for example, is responsible for the geographical spread of human infectious disease(4-9). In the light of increasing international trade, intensified human mobility and the imminent threat of an influenza A epidemic(10), the knowledge of dynamical and statistical properties of human travel is of fundamental importance. Despite its crucial role, a quantitative assessment of these properties on geographical scales remains elusive, and the assumption that humans disperse diffusively still prevails in models. Here we report on a solid and quantitative assessment of human travelling statistics by analysing the circulation of bank notes in the United States. Using a comprehensive data set of over a million individual displacements, we find that dispersal is anomalous in two ways. First, the distribution of travelling distances decays as a power law, indicating that trajectories of bank notes are reminiscent of scale-free random walks known as Levy flights. Second, the probability of remaining in a small, spatially confined region for a time T is dominated by algebraically long tails that attenuate the superdiffusive spread. We show that human travelling behaviour can be described mathematically on many spatiotemporal scales by a two-parameter continuous-time random walk model to a surprising accuracy, and conclude that human travel on geographical scales is an ambivalent and effectively superdiffusive process.	Max Planck Inst Dynam & Self Org, D-37073 Gottingen, Germany; Univ Gottingen, Dept Phys, D-37073 Gottingen, Germany; Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA; Bernstein Ctr Computat Neurosci, D-37073 Gottingen, Germany	Max Planck Society; University of Gottingen; University of California System; University of California Santa Barbara	Brockmann, D (corresponding author), Max Planck Inst Dynam & Self Org, Bunsenstr 10, D-37073 Gottingen, Germany.	brockmann@ds.mpg.de	Brockmann, Dirk A/B-7342-2009; Brockmann, Dirk/A-1931-2014	Geisel, Theo/0000-0002-5681-2708				Brockmann D, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.170601; Bullock JM, 2002, DISPERSAL ECOLOGY, P279; Gardiner C. W., 1985, HDB STOCHASTIC METHO, V3; Grassly NC, 2005, NATURE, V433, P417, DOI 10.1038/nature03072; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; Hudson P., 2002, ECOLOGY WILDLIFE DIS; Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; Klafter J, 1996, PHYS TODAY, V49, P33, DOI 10.1063/1.881487; Kot M, 1996, ECOLOGY, V77, P2027, DOI 10.2307/2265698; Levin SA, 2003, ANNU REV ECOL EVOL S, V34, P575, DOI 10.1146/annurev.ecolsys.34.011802.132428; Metzler R, 2000, PHYS REP, V339, P1, DOI 10.1016/S0370-1573(00)00070-3; MONTROLL EW, 1965, J MATH PHYS, V6, P167, DOI 10.1063/1.1704269; Murray J. D., 1993, MATH BIOL, DOI [10.1007/b98869, DOI 10.1007/B98869]; Nathan R, 2002, NATURE, V418, P409, DOI 10.1038/nature00844; Nathan Ran, 2001, Trends in Ecology and Evolution, V16, P481, DOI 10.1016/S0169-5347(01)02272-8; Nichols J., 2001, DISPERSAL; Nicholson KG, 1998, TXB INFLUENZA, P219; Ramos-Fernandez G, 2004, BEHAV ECOL SOCIOBIOL, V55, P223, DOI 10.1007/s00265-003-0700-6; Shlesinger M., 1995, LEVY FLIGHTS RELATED, Ved, DOI [10.1007/3-540-59222-9, DOI 10.1007/3-540-59222-9]; SHLESINGER MF, 1982, J STAT PHYS, V27, P499, DOI 10.1007/BF01011089; Viswanathan GM, 1996, NATURE, V381, P413, DOI 10.1038/381413a0; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350	23	1410	1464	19	358	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					462	465		10.1038/nature04292	http://dx.doi.org/10.1038/nature04292			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437114	Green Submitted			2022-12-28	WOS:000234859200044
J	Noda, T; Sagara, H; Yen, A; Takada, A; Kida, H; Cheng, RH; Kawaoka, Y				Noda, T; Sagara, H; Yen, A; Takada, A; Kida, H; Cheng, RH; Kawaoka, Y			Architecture of ribonucleoprotein complexes in influenza A virus particles	NATURE			English	Article							RNA SEGMENTS; PACKAGING SIGNALS; NONCODING REGIONS; VIRIONS; PB2	In viruses, as in eukaryotes, elaborate mechanisms have evolved to protect the genome and to ensure its timely replication and reliable transmission to progeny. Influenza A viruses are enveloped, spherical or filamentous structures, ranging from 80 to 120 nm in diameter(1). Inside each envelope is a viral genome consisting of eight single-stranded negative- sense RNA segments of 890 to 2,341 nucleotides each(1). These segments are associated with nucleoprotein and three polymerase subunits, designated PA, PB1 and PB2; the resultant ribonucleoprotein complexes (RNPs) resemble a twisted rod ( 10 - 15 nm in width and 30 - 120 nm in length) that is folded back and coiled on itself(2-4). Late in viral infection, newly synthesized RNPs are transported from the nucleus to the plasma membrane, where they are incorporated into progeny virions capable of infecting other cells. Here we show, by transmission electron microscopy of serially sectioned virions, that the RNPs of influenza A virus are organized in a distinct pattern ( seven segments of different lengths surrounding a central segment). The individual RNPs are suspended from the interior of the viral envelope at the distal end of the budding virion and are oriented perpendicular to the budding tip. This finding argues against random incorporation of RNPs into virions(5), supporting instead a model in which each segment contains specific incorporation signals that enable the RNPs to be recruited and packaged as a complete set(6-12). A selective mechanism of RNP incorporation into virions and the unique organization of the eight RNP segments may be crucial to maintaining the integrity of the viral genome during repeated cycles of replication.	Univ Tokyo, Inst Med Sci, Internal Res Ctr Infect Dis, Minato Ku, Tokyo 1088639, Japan; Hokkaido Univ, Grad Sch Vet Med, Dept Dis Control, Microbiol Lab,Kita Ku, Sapporo, Hokkaido 0600818, Japan; Japan SCi & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Div Virol, Tokyo 1088639, Japan; Univ Tokyo, Dept Basic Med Sci, Fine Morphol Lab, Minato Ku, Tokyo 1088639, Japan; Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, Tokyo 1088639, Japan; Univ Calif Davis, Davis, CA 95616 USA; Univ Wisconsin, Sch Vet Med, Dept Pathol Sci, Madison, WI 53706 USA	University of Tokyo; Hokkaido University; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; Karolinska Institutet; University of Tokyo; University of California System; University of California Davis; University of Wisconsin System; University of Wisconsin Madison	Kawaoka, Y (corresponding author), Univ Tokyo, Inst Med Sci, Internal Res Ctr Infect Dis, Minato Ku, Tokyo 1088639, Japan.	Kawaoka@ims.u-tokyo.ac.jp	Takada, Ayato/A-6679-2012; Sagara, Hiroshi/GRX-7740-2022; Kida, Hiroshi/F-7244-2012; Cheng, Holland/A-8973-2008	Sagara, Hiroshi/0000-0001-8456-8362; 				Afonso EDS, 2005, VIROLOGY, V341, P34, DOI 10.1016/j.virol.2005.06.040; BENDAYAN M, 1984, BIOL CELL, V52, P129; BENDAYAN M, 1983, J HISTOCHEM CYTOCHEM, V31, P101, DOI 10.1177/31.1.6187796; COMPANS RW, 1972, J VIROL, V10, P795, DOI 10.1128/JVI.10.4.795-800.1972; Duhaut SD, 1996, VIROLOGY, V216, P326, DOI 10.1006/viro.1996.0068; ENAMI M, 1991, VIROLOGY, V185, P291, DOI 10.1016/0042-6822(91)90776-8; Fujii K, 2005, J VIROL, V79, P3766, DOI 10.1128/JVI.79.6.3766-3774.2005; Fujii Y, 2003, P NATL ACAD SCI USA, V100, P2002, DOI 10.1073/pnas.0437772100; HEGGENESS MH, 1982, VIROLOGY, V118, P466, DOI 10.1016/0042-6822(82)90367-1; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; Lamb R.A., 2001, FIELDS VIROLOGY, P1487; Liang YY, 2005, J VIROL, V79, P10348, DOI 10.1128/JVI.79.16.10348-10355.2005; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Noda T, 2002, J VIROL, V76, P4855, DOI 10.1128/JVI.76.10.4855-4865.2002; Odagiri T, 1997, J VIROL, V71, P2138, DOI 10.1128/JVI.71.3.2138-2145.1997; Oxford J. S., 1987, ORTHOMYXOVIRIDAE ANI, P213; SCHULZE IT, 1970, VIROLOGY, V42, P890, DOI 10.1016/0042-6822(70)90338-7; Watanabe T, 2003, J VIROL, V77, P10575, DOI 10.1128/JVI.77.19.10575-10583.2003	18	296	326	4	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					490	492		10.1038/nature04378	http://dx.doi.org/10.1038/nature04378			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437116				2022-12-28	WOS:000234859200050
J	Reich, PB; Tjoelker, MG; Machado, JL; Oleksyn, J				Reich, PB; Tjoelker, MG; Machado, JL; Oleksyn, J			Universal scaling of respiratory metabolism, size and nitrogen in plants	NATURE			English	Article							CYPRESS CHAMAECYPARIS-OBTUSA; TREE SIZE; ABOVEGROUND RESPIRATION; GENERAL-MODEL; BIOLOGY; TEMPERATURE; ECOSYSTEMS; ORGANISMS; ALLOMETRY; PATTERNS	The scaling of respiratory metabolism to body size in animals is considered to be a fundamental law of nature(1-11), and there is substantial evidence for an approximate 3/4-power relation. Studies suggest that plant respiratory metabolism also scales as the 3/4-power of mass(12-14), and that higher plant and animal scaling follow similar rules owing to the predominance of fractal-like transport networks and associated allometric scaling(8-14). Here, however, using data obtained from about 500 laboratory and field-grown plants from 43 species and four experiments, we show that whole-plant respiration rate scales approximately isometrically ( scaling exponent approximate to 1) with total plant mass in individual experiments and has no common relation across all data. Moreover, consistent with theories about biochemically based physiological scaling(15-18), isometric scaling of whole-plant respiration rate to total nitrogen content is observed within and across all data sets, with a single relation common to all data. This isometric scaling is unaffected by growth conditions including variation in light, nitrogen availability, temperature and atmospheric CO2 concentration, and is similar within or among species or functional groups. These findings suggest that plants and animals follow different metabolic scaling relations, driven by distinct mechanisms.	Univ Minnesota, Dept Forest Resources, St Paul, MN 55108 USA; Texas A&M Univ, Dept Forest Sci, College Stn, TX 77843 USA; Swarthmore Coll, Dept Biol, Swarthmore, PA 19081 USA; Polish Acad Sci, Inst Dendrol, PL-62035 Kornik, Poland	University of Minnesota System; University of Minnesota Twin Cities; Texas A&M University System; Texas A&M University College Station; Swarthmore College; Polish Academy of Sciences	Reich, PB (corresponding author), Univ Minnesota, Dept Forest Resources, St Paul, MN 55108 USA.	preich@umn.edu	Machado, Jose-Luis/W-1229-2019; Oleksyn, Jacek/AAR-2351-2020; Oleksyn, Jacek/I-4539-2012; Tjoelker, Mark G/M-2413-2016	Machado, Jose-Luis/0000-0002-6047-3665; Tjoelker, Mark G/0000-0003-4607-5238; Reich, Peter/0000-0003-4424-662X; Oleksyn, Jacek/0000-0002-6576-3258				Atkin OK, 2003, TRENDS PLANT SCI, V8, P343, DOI 10.1016/S1360-1385(03)00136-5; Banavar JR, 2002, P NATL ACAD SCI USA, V99, P10506, DOI 10.1073/pnas.162216899; Banavar JR, 1999, NATURE, V399, P130, DOI 10.1038/20144; Brown JH, 2004, ECOLOGY, V85, P1771, DOI 10.1890/03-9000; Calder WA., 1984, SIZE FUNCTION LIFE H; Dodds PS, 2001, J THEOR BIOL, V209, P9, DOI 10.1006/jtbi.2000.2238; Enquist BJ, 2002, TREE PHYSIOL, V22, P1045, DOI 10.1093/treephys/22.15-16.1045; Enquist BJ, 1998, NATURE, V395, P163, DOI 10.1038/25977; Enquist BJ, 2003, NATURE, V423, P639, DOI 10.1038/nature01671; Enquist BJ, 2002, SCIENCE, V295, P1517, DOI 10.1126/science.1066360; Gillooly JF, 2001, SCIENCE, V293, P2248, DOI 10.1126/science.1061967; KLEIBER MAX, 1932, HILGARDIA, V6, P315; Kozlowski J, 2004, FUNCT ECOL, V18, P283, DOI 10.1111/j.0269-8463.2004.00830.x; McCulloh KA, 2005, TREE PHYSIOL, V25, P257, DOI 10.1093/treephys/25.3.257; Meinzer FC, 2005, FUNCT ECOL, V19, P558, DOI 10.1111/j.1365-2435.2005.01017.x; Niklas KJ, 2002, AM NAT, V159, P482, DOI 10.1086/339459; Niklas KJ, 2001, P NATL ACAD SCI USA, V98, P2922, DOI 10.1073/pnas.041590298; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; Reich PB, 1998, OECOLOGIA, V114, P471, DOI 10.1007/s004420050471; Reich PB, 2001, TRENDS ECOL EVOL, V16, P674, DOI 10.1016/S0169-5347(01)02306-0; Riisgard HU, 1998, ECOL LETT, V1, P71; RYAN MG, 1995, PLANT CELL ENVIRON, V18, P765, DOI 10.1111/j.1365-3040.1995.tb00579.x; Savage VM, 2004, FUNCT ECOL, V18, P257, DOI 10.1111/j.0269-8463.2004.00856.x; West GB, 1999, NATURE, V400, P664, DOI 10.1038/23251; West GB, 1999, SCIENCE, V284, P1677, DOI 10.1126/science.284.5420.1677; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; White CR, 2003, P NATL ACAD SCI USA, V100, P4046, DOI 10.1073/pnas.0436428100; Wright IJ, 2004, NATURE, V428, P821, DOI 10.1038/nature02403; Yokota T, 1998, TREE PHYSIOL, V18, P37; YOKOTA T, 1994, TREE PHYSIOL, V14, P467, DOI 10.1093/treephys/14.5.467	30	364	444	1	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					457	461		10.1038/nature04282	http://dx.doi.org/10.1038/nature04282			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437113	Green Published			2022-12-28	WOS:000234859200043
J	Sheth, SS				Sheth, SS			Missing female births in India	LANCET			English	Editorial Material							PRETERM BIRTH; FETAL SEX		Breach Candy Hosp, Bombay, Maharashtra, India		Sheth, SS (corresponding author), Breach Candy Hosp, Bombay, Maharashtra, India.	silsal@bom2.vsnl.net.in						*CENS IND, 2002, CENS IND 2001 IND DA; Chan CLW, 2002, J ASSIST REPROD GEN, V19, P426, DOI 10.1023/A:1016815807703; CHAUDHURI M, 2003, GREAT INDIAN DREAM, P229; FATHALLA MF, 1994, INT J GYNECOL OBSTET, V46, P101, DOI 10.1016/0020-7292(94)90224-0; *FED OBST GYN SOC, 2002, FOGSI NEWS MUMBAI, P18; Grace J, 2004, BJOG-INT J OBSTET GY, V111, P1165, DOI 10.1111/j.1471-0528.2004.00440.x; Heyzer Noeline, 2004, WOMEN WAR PEACE MOBI; Human Fertilisation Embryology Authority United Kingdom, 2003, SEX SEL OPT REG; Ingemarsson I, 2003, BJOG-INT J OBSTET GY, V110, P34, DOI 10.1016/S1470-0328(03)00022-3; Jha P, 2006, LANCET, V367, P211, DOI 10.1016/S0140-6736(06)67930-0; Jongbloet PH, 2005, AM J OBSTET GYNECOL, V193, P302, DOI 10.1016/j.ajog.2005.01.079; Renzetti CM, 2005, LANCET, V365, P1009; Sen A, 2003, BMJ-BRIT MED J, V327, P1297, DOI 10.1136/bmj.327.7427.1297; United Nations Population Fund, 2001, SEX SEL AB FERT DECL; Varghese J, 2005, ANAL TRENDS SEX RATI; Zeitlin J, 2004, AM J OBSTET GYNECOL, V190, P1322, DOI 10.1016/j.ajog.2003.10.703; Zeng Y, 1992, China Popul Today, V9, P3	17	22	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					185	186		10.1016/S0140-6736(06)67931-2	http://dx.doi.org/10.1016/S0140-6736(06)67931-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005GM	16427471				2022-12-28	WOS:000234810600004
J	Janssens, S; Dubois, C; Bogaert, J; Theunissen, K; Deroose, C; Desmet, W; Kolantzi, M; Herbots, L; Sinnaeve, P; Dens, J; Maertens, J; Rademakers, F; Dymarkowski, S; Gheysens, O; Van Cleemput, J; Bormans, G; Nuyts, J; Belmans, A; Mortelmans, L; Boogaerts, M; Van de Werf, F				Janssens, S; Dubois, C; Bogaert, J; Theunissen, K; Deroose, C; Desmet, W; Kolantzi, M; Herbots, L; Sinnaeve, P; Dens, J; Maertens, J; Rademakers, F; Dymarkowski, S; Gheysens, O; Van Cleemput, J; Bormans, G; Nuyts, J; Belmans, A; Mortelmans, L; Boogaerts, M; Van de Werf, F			Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial	LANCET			English	Article							LEFT-VENTRICULAR FUNCTION; MICROVASCULAR OBSTRUCTION; REGENERATION ENHANCEMENT; ISCHEMIC MYOCARDIUM; PROGENITOR CELLS; HEART FUNCTION; TOPCARE-AMI; TRANSPLANTATION; REPAIR; ANGIOGENESIS	Background The benefit of reperfusion therapies for ST-elevation acute myocardial infarction (STEMI) is limited by post-infarction left-ventricular (LV) dysfunction. Our aim was to investigate the effect of autologous bone marrow-derived stem cell (BMSC) transfer in the infarct-related artery on LV function and structure. Methods We did a randomised, double-blind, placebo-controlled study in 67 patients from whom we harvested bone marrow 1 day after successful percutaneous coronary intervention for STEML We assigned patients optimum medical treatment and infusion of placebo (n=34) or BMSC (n=33). Our primary endpoint was the increase in LV ejection fraction and our secondary endpoints were change in infarct size and regional LV function at 4 months' follow-up, all assessed by MRI. We assessed changes in myocardial perfusion and oxidative metabolism with serial 1-[(11)C]acetate PET. Analyses were per protocol. This study is registered with clinicaltrials.gov, number NCT00264316. Findings Mean global LV ejection fraction 4 days after percutaneous coronary intervention was 46.9% (SD 8.2) in controls and 48.5% (7.2) in BMSC patients, and increased after 4 months to 49.1% (10.7) and 51.8% (8.8; OR for treatment effect 1.036, 95% Cl 0.961-1.118, p=0.36). Compared with placebo infusion, BMSC transfer was associated with a significant reduction in myocardial infarct size (BM S C treatment effect 28%, p=0.036) and a better recovery of regional systolic function. Myocardial perfusion and metabolism increased similarly in both groups. We noted no complications associated with BMSC transfer and all but one patient in the BMSC group completed the 4 months' follow-up. Interpretation intracoronary transfer of autologous bone marrow cells within 24 h of optimum reperfusion therapy does not augment recovery of global LV function after myocardial infarction, but could favourably affect infarct remodelling.	Univ Louvain, Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium; Univ Louvain, Univ Hosp Gasthuisberg, Dept Radiol, B-3000 Louvain, Belgium; Univ Louvain, Univ Hosp Gasthuisberg, Dept Nucl Med, B-3000 Louvain, Belgium; Univ Louvain, Univ Hosp Gasthuisberg, Dept Haematol, B-3000 Louvain, Belgium; Univ Louvain, Interunvi Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Stem Cell Inst Leuven, Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven	Janssens, S (corresponding author), Univ Louvain, Univ Hosp Gasthuisberg, Dept Cardiol, Herestr 49, B-3000 Louvain, Belgium.	Stefan.Janssens@uz.kuleuven.ac.be	Rademakers, Frank E/B-5622-2013; Deroose, Christophe/AAG-7385-2020; bogaert, jan g/E-6181-2012	Rademakers, Frank E/0000-0002-7786-4179; Deroose, Christophe/0000-0002-6080-1577; Van de Werf, Frans/0000-0001-9479-7767; Nuyts, Johan/0000-0003-1923-6198; Sinnaeve, Peter/0000-0003-4716-5892				Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Bartunek J, 2005, CIRCULATION, V112, pI178, DOI 10.1161/CIRCULATIONAHA.104.522292; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Cerqueira MD, 2002, CIRCULATION, V105, P539, DOI 10.1161/hc0402.102975; Choi CJ, 2004, J CARDIOVASC MAGN R, V6, P917, DOI 10.1081/JCMR-20036206; Cluitmans FHM, 1997, ANN HEMATOL, V75, P27, DOI 10.1007/s002770050308; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Dymarkowski S, 2002, INVEST RADIOL, V37, P77, DOI 10.1097/00004424-200202000-00005; Fernandez-Aviles F, 2004, CIRC RES, V95, P742, DOI 10.1161/01.RES.0000144798.54040.ed; Fuchs S, 2003, J AM COLL CARDIOL, V41, P1721, DOI 10.1016/S0735-1097(03)00328-0; GARCIADORADO D, 1993, CARDIOVASC RES, V27, P1462, DOI 10.1093/cvr/27.8.1462; Gerber BL, 2000, CIRCULATION, V101, P2734, DOI 10.1161/01.CIR.101.23.2734; Gibbons RJ, 2004, J AM COLL CARDIOL, V44, P1533, DOI 10.1016/j.jacc.2004.06.071; Gibson CM, 1996, CIRCULATION, V93, P879, DOI 10.1161/01.CIR.93.5.879; Heil M, 2004, CIRC RES, V94, P573, DOI 10.1161/01.RES.0000124603.46777.EB; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kim RJ, 2000, NEW ENGL J MED, V343, P1445, DOI 10.1056/NEJM200011163432003; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; LUNDE K, 2005, PLEN SCI SESS AM HEA; Maes AF, 2001, J AM COLL CARDIOL, V37, P30, DOI 10.1016/S0735-1097(00)01088-3; Mathur A, 2004, LANCET, V364, P183, DOI 10.1016/S0140-6736(04)16632-4; MEYER GP, 2004, CIRCULATION, V110, pA1145; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ottervanger JP, 2001, EUR HEART J, V22, P785, DOI 10.1053/euhj.2000.2316; Paroli M, 2004, CLIN IMMUNOL, V112, P78, DOI 10.1016/j.clim.2004.03.021; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Rochitte CE, 1998, CIRCULATION, V98, P1006, DOI 10.1161/01.CIR.98.10.1006; Schachinger V, 2004, J AM COLL CARDIOL, V44, P1690, DOI 10.1016/j.jacc.2004.08.014; SCHACHINGER V, 2005, PLEN SCI SESS AM HEA; Silva GV, 2005, CIRCULATION, V111, P150, DOI 10.1161/01.CIR.0000151812.86142.45; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Tomita S, 2002, J THORAC CARDIOV SUR, V123, P1132, DOI 10.1067/mtc.2002.120716; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Wollert KC, 2005, CIRC RES, V96, P151, DOI 10.1161/01.RES.0000155333.69009.63; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326	43	995	1083	1	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 14	2006	367	9505					113	121		10.1016/S0140-6736(05)67861-0	http://dx.doi.org/10.1016/S0140-6736(05)67861-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413875				2022-12-28	WOS:000234655500026
J	Paterick, TE; Paterick, TJ; Fletcher, GF; Maron, BJ				Paterick, TE; Paterick, TJ; Fletcher, GF; Maron, BJ			Medical and legal issues in the cardiovascular evaluation of competitive athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; SUDDEN CARDIAC DEATH; YOUNG-ADULTS; CARDIOMYOPATHY; DISEASE; PREVENTION; RECOMMENDATIONS; PARTICIPATION; CARDIOLOGY; ANOMALIES	Healthy-appearing competitive athletes may harbor unsuspected cardiovascular disease with the potential to cause sudden death. This fact raises issues of physician responsibility in preparticipation screening and eligibility/ disqualification decisions. A number of medical-legal cases now represent a framework for screening and eligibility decision making in high school and college athletes. Physicians screening competitive athletes should strictly adhere to recommendations from the American Heart Association. Precedent exists for disqualifying athletes with heart disease from competition to prevent unnecessary exposure to risk of injury or death. By virtue of the court decision in Larkin v Archdiocese of Cincinnati, high school students with heart disease have no compelling right to participate in interscholastic sports without medical clearance. In Knapp v Northwestern University, an appellate court ruled that college athletes can be medically disqualified from sports and supported the use of national association medical guidelines by team physicians in formulating eligibility/disqualification decisions. This medical-legal analysis provides guidelines for physicians participating in medical evaluations of competitive athletes by clarifying the standard of care, potential pitfalls, and the evolving liability associated with this clinical practice.	Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN 55407 USA; Mayo Clin, Div Cardiovasc Med, Jacksonville, FL 32224 USA; Univ Richmond, Richmond, VA 23173 USA	Minneapolis Heart Institute Foundation; Mayo Clinic; University of Richmond	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, 920 E 28th St,Suite 60, Minneapolis, MN 55407 USA.	hcm.maron@mhif.org						ANDERSON D, 1993, NY TIMES        0729, pB1; BAKER WH, 1993, DICK L REV, V97, P656; Basso C, 2000, J AM COLL CARDIOL, V35, P1493, DOI 10.1016/S0735-1097(00)00566-0; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; COHEN AJ, 1989, ANN THORAC SURG, V47, P630, DOI 10.1016/0003-4975(89)90454-2; Corrado D, 2005, EUR HEART J, V26, P516, DOI 10.1093/eurheartj/ehi108; Corrado D, 2003, CIRCULATION, V108, P3084, DOI 10.1161/01.CIR.0000103130.33451.D2; Corrado D, 2003, J AM COLL CARDIOL, V42, P1959, DOI 10.1016/j.jacc.2003.03.002; Glover DW, 1998, JAMA-J AM MED ASSOC, V279, P1817, DOI 10.1001/jama.279.22.1817; Harris KM, 2005, J AM COLL CARDIOL, V45, p180A; Jones CJ, 1992, BUFF L REV, V113, P114; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; MARON BJ, 1994, J AM COLL CARDIOL, V24, P848, DOI 10.1016/0735-1097(94)90837-0; Maron BJ, 2005, J AM COLL CARDIOL, V45, P1318, DOI 10.1016/j.jacc.2005.02.006; Maron BJ, 2005, EUR HEART J, V26, P428, DOI 10.1093/eurheartj/ehi154; Maron BJ, 1998, NEW ENGL J MED, V339, P1632, DOI 10.1056/NEJM199811263392211; Maron BJ, 1998, ANN INTERN MED, V129, P379, DOI 10.7326/0003-4819-129-5-199809010-00006; Maron BJ, 2004, CIRCULATION, V109, P2807, DOI 10.1161/01.CIR.0000128363.85581.E1; Maron BJ, 2003, J AM COLL CARDIOL, V41, P974, DOI 10.1016/S0735-1097(02)02976-5; MARON BJ, 1985, J AM COLL CARDIOL, V6, P1189; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Mitten MJ, 2005, J AM COLL CARDIOL, V45, P1373, DOI 10.1016/j.jacc.2005.02.019; MITTEN MJ, 1993, U PITT LAW REV, V55, P129; Movahed MR, 2002, CIRCULATION, V106, P352; Pfister GC, 2000, JAMA-J AM MED ASSOC, V283, P1597, DOI 10.1001/jama.283.12.1597; POST JC, 1995, CIRCULATION, V92, P3163, DOI 10.1161/01.CIR.92.11.3163; *PROF DIV, 2005, PREP PHYS EX, P1; ULMER RA, 1996, MED MALPRACTICE LIB, P89; Vinereanu D, 2001, AM J CARDIOL, V88, P53, DOI 10.1016/S0002-9149(01)01585-5; 1993, NY TIMES        0728, pB7; 1992, NY TIMES        0331, pB13	36	47	48	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					3011	3018		10.1001/jama.294.23.3011	http://dx.doi.org/10.1001/jama.294.23.3011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414949				2022-12-28	WOS:000234087700028
J	Saigal, S; Stoskopf, B; Streiner, D; Boyle, M; Pinelli, J; Paneth, N; Goddeeris, J				Saigal, S; Stoskopf, B; Streiner, D; Boyle, M; Pinelli, J; Paneth, N; Goddeeris, J			Transition of extremely low-birth-weight infants from adolescence to young adulthood - Comparison with normal birth-weight controls	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; DEVELOPMENTAL-DISABILITY; CHILDREN BORN; 1000 GRAMS; SCHOOL PERFORMANCE; PRETERM; OUTCOMES; HEALTH; AGE; PSYCHOPATHOLOGY	Context Traditionally, educational attainment, getting a job, living independently, getting married, and parenthood have been considered as markers of successful transition to adulthood. Objective To describe and compare the achievement and the age at attainment of the above markers between extremely low-birth-weight (ELBW) and normal birth-weight (NBW) young adults. Design, Setting, and Participants A prospective, longitudinal, population-based study in central-west Ontario, Canada, of 166 ELBW participants who weighed 501 to 1000 g at birth (1977-1982) and 145 sociodemographically comparable NBW participants assessed at young adulthood (22-25 years). Interviewers masked to participant status administered validated questionnaires via face-to-face interviews between January 1, 2002, and April 30, 2004. Main Outcome Measures Markers of successful transition to adulthood, including educational attainment, student and/or worker role, independent living, getting married, and parenthood. Results At young adulthood, 149 (90%) of 166 ELBW participants and 133 (92%) of 145 NBW participants completed the assessments at mean (SD) age of 23.3 (1.2) years and 23.6 (1.1) years, respectively. We included participants with neurosensory impairments (ELBW vs NBW: 40 [27%] vs 3 [2%]) and 7 proxy respondents. The proportion who graduated from high school was similar (82% vs 87%, P=.21). Overall, no statistically significant differences were observed in the education achieved to date. A substantial proportion of both groups were still pursuing postsecondary education (47 [32%] vs 44 [33%]). No significant differences were observed in employment/school status; 71 (48%) ELBW vs 76 (57%) NBW young adults were permanently employed (P=.09). In a subanalysis, a higher proportion of ELBW young adults were neither employed nor in school (39 [26%] vs 20 [15%], P=.02 by Holm's correction); these differences did not persist when participants with disabilities were excluded. No significant differences were found in the proportion living independently ( 63 [42%] vs 70 [53%], P=.19), married/cohabitating (34 [23%] vs 33 [25%], P=.69), or who were parents ( 16 [11%] vs 19 [14%], P=.36). The age at attainment of the above markers was similar for both cohorts. Conclusion Our study results indicate that a significant majority of former ELBW infants have overcome their earlier difficulties to become functional young adults.	McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Psychiat & Neurosci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Sch Nursing, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada; Michigan State Univ, Dept Epidemiol & Human Dev, E Lansing, MI 48824 USA; Michigan State Univ, Dept Econ, E Lansing, MI 48824 USA	McMaster University; McMaster University; McMaster University; University of Toronto; Michigan State University; Michigan State University	Saigal, S (corresponding author), McMaster Univ, Dept Pediat, 1200 Main St W,Room 4G40, Hamilton, ON L8N 3Z5, Canada.	saigal@mcmaster.ca	Streiner, David/E-6563-2011	Streiner, David/0000-0003-0610-6271	NICHD NIH HHS [1 R01 HD40219] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040219] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson P, 2003, JAMA-J AM MED ASSOC, V289, P3264, DOI 10.1001/jama.289.24.3264; ARNETT J, 1994, J YOUTH ADOLESCENCE, V23, P1; Arnett JJ, 1998, HUM DEV, V41, P295, DOI 10.1159/000022591; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Beaujot Roderic, 2004, DELAYED LIFE TRANSIT; Bjerager M, 1995, ACTA PAEDIATR, V84, P1339, DOI 10.1111/j.1651-2227.1995.tb13565.x; Botting N, 1998, DEV MED CHILD NEUROL, V40, P652; BOYLE MH, 1987, ARCH GEN PSYCHIAT, V44, P826; Caspi A, 1998, AM SOCIOL REV, V63, P424, DOI 10.2307/2657557; Cooke RWI, 2004, ARCH DIS CHILD, V89, P201, DOI 10.1136/adc.2003.030197; Dinesen SJ, 2001, ARCH DIS CHILD-FETAL, V85, pF165, DOI 10.1136/fn.85.3.F165; Doyle LW, 2001, ARCH DIS CHILD-FETAL, V85, pF159, DOI 10.1136/fn.85.3.F159; Ericson A, 1998, ARCH DIS CHILD-FETAL, V78, pF171, DOI 10.1136/fn.78.3.F171; FURSTENBERG F, ADOLESCENCE ADULTHOO; Goldscheider F., 1999, UNDERSTANDING FAMILI, V17; Grunau RE, 2004, PEDIATRICS, V114, pE725, DOI 10.1542/peds.2004-0932; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; Hack M, 2002, NEW ENGL J MED, V346, P149, DOI 10.1056/NEJMoa010856; Hallum A, 1995, Curr Probl Pediatr, V25, P12, DOI 10.1016/S0045-9380(06)80013-7; Harrison H, 2002, NEW ENGL J MED, V347, P141; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; HOLM S, 1979, SCAND J STAT, V6, P65; Johnson A, 2003, ARCH DIS CHILD-FETAL, V88, P190; LAMBERT M, 2004, PUBLICATION HUMAN RE; Lefebvre F, 2005, ACTA PAEDIATR, V94, P733, DOI 10.1080/08035250510025987; Lorenz JM, 1998, ARCH PEDIAT ADOL MED, V152, P425, DOI 10.1001/archpedi.152.5.425; Luciana M, 2003, DEV PSYCHOPATHOL, V15, P1017, DOI 10.1017/S095457940300049X; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; MAUGHAN B, 1990, SUCCESSFUL AGING PER, P296; MELLON S, 1994, DEV DISABIL B, V22, P27; Pharoah POD, 2003, ARCH DIS CHILD, V88, P295, DOI 10.1136/adc.88.4.295; PILLING DS, 2002, J PREV ASSESS REHABI, V18, P75; RUMBAUT R, YOUNG ADULTS US PROF; RUTTER M, 1989, J CHILD PSYCHOL PSYC, V30, P23, DOI 10.1111/j.1469-7610.1989.tb00768.x; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Saigal S, 2000, PEDIATRICS, V105, P325, DOI 10.1542/peds.105.2.325; SAIGAL S, 1990, J PEDIATR-US, V116, P409, DOI 10.1016/S0022-3476(05)82835-5; Saigal S, 2003, PEDIATRICS, V111, P969, DOI 10.1542/peds.111.5.969; SAIGAL S, 1989, J PEDIATR-US, V114, P839, DOI 10.1016/S0022-3476(89)80150-7; Saigal S, 2002, PEDIATRICS, V109, P429, DOI 10.1542/peds.109.3.429; STRAX TE, 1991, PEDIATR ANN, V20, P507, DOI 10.3928/0090-4481-19910901-10; SZATMARI P, 1993, DEV PSYCHOPATHOL, V5, P345, DOI 10.1017/S0954579400004454; *US BUR CENS, 1995, CURR POP REP P, V20; Walther FJ, 2000, EARLY HUM DEV, V59, P175, DOI 10.1016/S0378-3782(00)00094-3; Werner E.E., 2001, JOURNEYS CHILDHOOD M; WERNER EE, 1993, DEV PSYCHOPATHOL, V5, P503, DOI 10.1017/S095457940000612X; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; ZEMAN K, 2004, PUBLICATION HUMAN RE	49	159	165	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					667	675		10.1001/jama.295.6.667	http://dx.doi.org/10.1001/jama.295.6.667			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	010DX	16467235				2022-12-28	WOS:000235168200026
J	Poulet, JFA; Hedwig, B				Poulet, JFA; Hedwig, B			The cellular basis of a corollary discharge	SCIENCE			English	Article							PRESYNAPTIC INHIBITION; STRIDULATING CRICKET; GRYLLUS-BIMACULATUS; MOTOR CONTROL; NEURONS; VERTEBRATE; PATHWAYS; INTERNEURONS; LOCOMOTION; MECHANISM	How do animals discriminate self-generated from external stimuli during behavior and prevent desensitization of their sensory pathways? A fundamental concept in neuroscience states that neural signals, termed corollary discharges or efference copies, are forwarded from motor to sensory areas. Neurons mediating these signals have proved difficult to identify. We show that a single, multisegmental interneuron is responsible for the pre- and postsynaptic inhibition of auditory neurons in singing crickets (Gryllus bimaculatus). Therefore, this neuron represents a corollary discharge interneuron that provides a neuronal basis for the central control of sensory responses.	Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Sensory Proc, CH-1015 Lausanne, Switzerland; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Cambridge	Poulet, JFA (corresponding author), Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Sensory Proc, CH-1015 Lausanne, Switzerland.	james.poulet@epfl.ch		Poulet, James/0000-0003-0296-5415	Biotechnology and Biological Sciences Research Council [S19133] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BELL C, 1995, J COMP PHYSIOL A, V177, P449, DOI 10.1007/BF00187481; BELL CC, 1989, J NEUROSCI, V9, P1029; BELL CC, 1981, SCIENCE, V214, P450, DOI 10.1126/science.7291985; Blakemore SJ, 1998, NAT NEUROSCI, V1, P635, DOI 10.1038/2870; Clarac F, 1996, EXP BRAIN RES, V112, P163; Cullen KE, 2004, CURR OPIN NEUROBIOL, V14, P698, DOI 10.1016/j.conb.2004.10.002; DAMBACH M, 1983, NATURWISSENSCHAFTEN, V70, P417, DOI 10.1007/BF01047183; HENNIG RM, 1990, J COMP PHYSIOL A, V167, P629; KIRK MD, 1984, SCIENCE, V225, P854, DOI 10.1126/science.6474158; Li WC, 2002, J NEUROSCI, V22, P10924; MICHEL K, 1974, Z MORPHOL TIERE, V77, P285, DOI 10.1007/BF00298805; NOLEN TG, 1984, SCIENCE, V226, P992, DOI 10.1126/science.6505681; PEARSON KG, 1993, ANNU REV NEUROSCI, V16, P265, DOI 10.1146/annurev.ne.16.030193.001405; Poulet JFA, 2003, J NEUROSCI, V23, P4717; Poulet JFA, 2003, J NEUROPHYSIOL, V89, P1528, DOI 10.1152/jn.0846.2002; Poulet JFA, 2002, NATURE, V418, P872, DOI 10.1038/nature00919; Poulet JFA, 2001, J EXP BIOL, V204, P1281; Rosen SC, 2000, J NEUROPHYSIOL, V83, P1621, DOI 10.1152/jn.2000.83.3.1621; Roy JE, 2004, J NEUROSCI, V24, P2102, DOI 10.1523/JNEUROSCI.3988-03.2004; Rudomin P, 1999, EXP BRAIN RES, V129, P1, DOI 10.1007/s002210050933; Schildberger K., 1989, P423; SILLAR KT, 1988, NATURE, V331, P262, DOI 10.1038/331262a0; SILLAR KT, 1986, J NEUROPHYSIOL, V55, P678, DOI 10.1152/jn.1986.55.4.678; Sommer MA, 2002, SCIENCE, V296, P1480, DOI 10.1126/science.1069590; SPERRY RW, 1950, J COMP PHYSIOL PSYCH, V43, P482, DOI 10.1037/h0055479; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503; Weeg MS, 2005, J NEUROSCI, V25, P5967, DOI 10.1523/JNEUROSCI.0019-05.2005; ZARETSKY M, 1979, NATURE, V280, P583, DOI 10.1038/280583a0	28	119	123	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2006	311	5760					518	522		10.1126/science.1120847	http://dx.doi.org/10.1126/science.1120847			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439660				2022-12-28	WOS:000235071400045
J	Sheng, HW; Luo, WK; Alamgir, FM; Bai, JM; Ma, E				Sheng, HW; Luo, WK; Alamgir, FM; Bai, JM; Ma, E			Atomic packing and short-to-medium-range order in metallic glasses	NATURE			English	Article							TOTAL-ENERGY CALCULATIONS; STRUCTURAL MODEL; MOLECULAR-DYNAMICS; SIMPLE LIQUIDS; ARRANGEMENTS; PRINCIPLES; GEOMETRY; SYMMETRY; CLUSTERS; DEFECTS	Unlike the well-defined long-range order that characterizes crystalline metals, the atomic arrangements in amorphous alloys remain mysterious at present. Despite intense research activity on metallic glasses and relentless pursuit of their structural description, the details of how the atoms are packed in amorphous metals are generally far less understood than for the case of network-forming glasses. Here we use a combination of state-of-the-art experimental and computational techniques to resolve the atomic-level structure of amorphous alloys. By analysing a range of model binary systems that involve different chemistry and atomic size ratios, we elucidate the different types of short-range order as well as the nature of the medium-range order. Our findings provide a reality check for the atomic structural models proposed over the years, and have implications for understanding the nature, forming ability and properties of metallic glasses.	Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA; Oak Ridge Natl Lab, High Temp Mat Lab, Oak Ridge, TN 37831 USA	Johns Hopkins University; National Institute of Standards & Technology (NIST) - USA; United States Department of Energy (DOE); Oak Ridge National Laboratory	Sheng, HW (corresponding author), Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.	hwsheng@jhu.edu; ema@jhu.edu	Ma, En/A-3232-2010; Sheng, Howard/B-2033-2013; Bai, Jianming/O-5005-2015	Bai, Jianming/0000-0002-0575-2987; Alamgir, Faisal/0000-0002-0894-8096; Sheng, Howard/0000-0002-6134-0354				Allen M. P., 1989, COMPUTER SIMULATION, DOI DOI 10.1093/OSO/9780198803195.001.0001; Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; BERNAL JD, 1960, NATURE, V185, P68, DOI 10.1038/185068a0; BERNAL JD, 1964, PROC R SOC LON SER-A, V280, P299, DOI 10.1098/rspa.1964.0147; BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953; Borodin VA, 1999, PHILOS MAG A, V79, P1887, DOI 10.1080/01418619908210398; Borodin VA, 2001, PHILOS MAG A, V81, P2427, DOI 10.1080/01418610110039177; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CLARKE AS, 1993, PHYS REV E, V47, P3975, DOI 10.1103/PhysRevE.47.3975; Doye JPK, 1996, J PHYS B-AT MOL OPT, V29, P4859, DOI 10.1088/0953-4075/29/21/002; DUBOIS JM, 1985, PROC R SOC LON SER-A, V402, P323, DOI 10.1098/rspa.1985.0121; EGAMI T, 1984, J NON-CRYST SOLIDS, V64, P113, DOI 10.1016/0022-3093(84)90210-2; Elliott SR, 1990, PHYS AMORPHOUS MAT, V2nd, P139; FINNEY JL, 1970, PROC R SOC LON SER-A, V319, P479, DOI [10.1098/rspa.1970.0189, 10.1098/rspa.1970.0190]; FINNEY JL, 1977, NATURE, V266, P309, DOI 10.1038/266309a0; FRANK FC, 1958, ACTA CRYSTALLOGR, V11, P184, DOI 10.1107/S0365110X58000487; Gaskell PH, 2005, J NON-CRYST SOLIDS, V351, P1003, DOI 10.1016/j.jnoncrysol.2005.01.011; GASKELL PH, 1979, J NON-CRYST SOLIDS, V32, P207, DOI 10.1016/0022-3093(79)90073-5; GASKELL PH, 1978, NATURE, V276, P484, DOI 10.1038/276484a0; Gaskell PH, 1985, AMORPHOUS METALS, P35; Greer A. L., 1995, INTERMETALLIC COMPOU, V1, P731; GREER AL, 1995, SCIENCE, V267, P1947, DOI 10.1126/science.267.5206.1947; HAFNER J, 1980, PHYS REV B, V21, P406, DOI 10.1103/PhysRevB.21.406; JONSSON H, 1988, PHYS REV LETT, V60, P2295, DOI 10.1103/PhysRevLett.60.2295; Kelton KF, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.195504; KOB W, 1995, PHYS REV E, V51, P4626, DOI 10.1103/PhysRevE.51.4626; Kramer MJ, 2005, J NON-CRYST SOLIDS, V351, P1586, DOI 10.1016/j.jnoncrysol.2005.03.042; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0; LAMPARTER P, 1995, PHYS SCRIPTA, VT57, P45, DOI 10.1088/0031-8949/1995/T57/008; LAMPARTER P, 1995, PHYS SCRIPTA, VT57, P72, DOI 10.1088/0031-8949/1995/T57/011; Luo WK, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.145502; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; McGreevy RL, 2001, J PHYS-CONDENS MAT, V13, pR877, DOI 10.1088/0953-8984/13/46/201; Miracle DB, 2004, NAT MATER, V3, P697, DOI 10.1038/nmat1219; Miracle DB, 2003, PHILOS MAG, V83, P2409, DOI 10.1080/1478643031000098828; NELSON DR, 1983, PHYS REV B, V28, P5515, DOI 10.1103/PhysRevB.28.5515; O'Keeffe M, 1981, STRUCTURE BONDING CR; OHKOBU T, 2003, PHYS REV B, V67; Pauling L, 1929, J AM CHEM SOC, V51, P1010, DOI 10.1021/ja01379a006; PAYNE MC, 1992, REV MOD PHYS, V64, P1045, DOI 10.1103/RevModPhys.64.1045; QI DW, 1991, PHYS REV B, V44, P884, DOI 10.1103/PhysRevB.44.884; STILLINGER FH, 1984, SCIENCE, V225, P983, DOI 10.1126/science.225.4666.983; WANG Y, 1991, PHYS REV B, V44, P13298, DOI 10.1103/PhysRevB.44.13298; WATSON RE, 1991, PHYS REV B, V43, P11642, DOI 10.1103/PhysRevB.43.11642; Zandi R, 2004, P NATL ACAD SCI USA, V101, P15556, DOI 10.1073/pnas.0405844101	47	1534	1572	31	851	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					419	425		10.1038/nature04421	http://dx.doi.org/10.1038/nature04421			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437105				2022-12-28	WOS:000234859200035
J	Kesselheim, AS; Avorn, J				Kesselheim, AS; Avorn, J			Biomedical patents and the public's health - Is there a role for eminent domain?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACCESS; DRUGS		Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kesselheim, AS (corresponding author), Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Attaran A, 2001, JAMA-J AM MED ASSOC, V286, P1886, DOI 10.1001/jama.286.15.1886; Avorn J, 2005, NEW ENGL J MED, V352, P2573, DOI 10.1056/NEJMp058075; Avorn J, 2004, POWERFUL MED BENEFIT; BRADSHER K, 2005, NY TIMES        0422, pC1; DASH PR, 2005, INDIA TIMES     0215; DUGGER CW, 2001, NY TIMES        1116, pW1; *FTC, 2003, PROM INN PROP BAL CO; Guell RC, 1997, HEALTH ECON, V6, P179, DOI 10.1002/(SICI)1099-1050(199703)6:2<179::AID-HEC254>3.0.CO;2-5; HARRIS G, 2001, WALL STREET J   1121, pA16; Kesselheim AS, 2005, J GEN INTERN MED, V20, P139; Kesselheim AS, 2005, JAMA-J AM MED ASSOC, V293, P850, DOI 10.1001/jama.293.7.850; Levey Annette C., 1999, BERKELEY TECH LJ, V14, P1095; LOVE J, 2004, NIH M NORV RIT MARCH; Malakoff D, 2004, SCIENCE, V305, P926; MANN T, 2005, DAY             1016, pA1; MCGRORY M, 1995, WASHINGTON POST 1128, pA2; Mojtabai R, 2003, HEALTH AFFAIR, V22, P220, DOI 10.1377/hlthaff.22.4.220; NADER R, 2001, COMMUNICATION   1018; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Petersen Lody, 2001, NY TIMES, pA1; POLLACK A, 2005, NY TIMES        1027, pA16; Pollack Andrew, 2001, NY TIMES        0420, pA6; Resnik David B., 2002, American Journal of Bioethics, V2, P29, DOI 10.1162/152651602760250084; RIORDAN T, 1999, NY TIMES        0510, pC13; Schull M, 2000, BRIT MED J, V321, P833; VEDANTAN C, 2001, WASHINGTON POST 1020, pA4	26	20	20	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					434	437		10.1001/jama.295.4.434	http://dx.doi.org/10.1001/jama.295.4.434			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005QJ	16434634				2022-12-28	WOS:000234838600024
J	Burroughs, AK; Sabin, CA; Rolles, K; Delvart, V; Karam, V; Buckels, J; O'Grady, JG; Castaing, D; Klempnauer, J; Jamieson, N; Neuhaus, P; Lerut, J; de Goyet, JD; Pollard, S; Salizzoni, M; Rogiers, X; Muhlbacher, F; Valdecasas, JCG; Broelsch, C; Jaeck, D; Berenguer, J; Gonzalez, EM; Adam, R				Burroughs, AK; Sabin, CA; Rolles, K; Delvart, V; Karam, V; Buckels, J; O'Grady, JG; Castaing, D; Klempnauer, J; Jamieson, N; Neuhaus, P; Lerut, J; de Goyet, JD; Pollard, S; Salizzoni, M; Rogiers, X; Muhlbacher, F; Valdecasas, JCG; Broelsch, C; Jaeck, D; Berenguer, J; Gonzalez, EM; Adam, R		European Liver Transplant Assoc	3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome	LANCET			English	Article							FULMINANT HEPATIC-FAILURE; MELD SCORE; SURVIVAL; EXPERIENCE; REGISTRY; GRAFT	Background Mortality after liver transplantation depends on heterogeneous recipient and donor factors. Our aim was to assess risk of death and to develop models to help predict mortality after liver transplantation. Methods We analysed data from 34 664 first adult liver transplants from the European Liver Transplant Registry to identify factors associated with mortality at 3-months (n=21 605 in training dataset) and 12-months (n=18 852 in training dataset) after transplantation. We used multivariable logistic regression models to generate mortality scores for each individual, and assessed model discrimination and calibration on an independent validation dataset (n=9489 for 3-month model and n=8313 for 12-month model). Findings 2540 of 21 605 (12%) individuals in the 3-month training sample had died by 3 months. Compared with those transplanted in 2000-03, those transplanted earlier had a higher risk of death. increased mortality at 3-months post- transplantation was associated with acute liver failure (adjusted odds ratio 1.61), donor age older than 60 years (1.16), compatible (1.22) or incompatible (2.07) donor-recipient blood group, older recipient age (1.12 per 5 years), split or reduced graft (1.96), total ischaemia time of longer than 13 h (1.38), and low United Network for Organ Sharing score (score 1: 2.43; score 2: 1.67). However, cirrhosis with hepatocellular carcinoma, alcohol cirrhosis, hepatitis C or primary biliary cirrhosis, donor age 40 years or younger, or less, hepatitis B, and larger size of transplant Centre (>= 70 transplants per year) were associated with improved early outcomes. The 3-month mortality score discriminated well between those who did and did not die in the validation sample (C statistic=0.688). We noted similar findings for 12-month mortality, although deaths were generally underestimated at this timepoint. Interpretation The 3-month and 12-month mortality models can be effectively used to assess outcomes both within and between centres. Furthermore, the models provide a means of assessing the risk of post-transplantation mortality, giving clinicians important data on which to base strategic decisions about transplant policy in particular individuals or groups.	UCL Royal Free Hampstead NHS Trust, London NW3 2QG, England; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England; Hop Paul Brousse, Villejuif, France; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; Kings Coll Hosp London, London, England; Hannover Med Sch, Hannover, Germany; Addenbrookes Hosp, Cambridge, England; Charite Univ Klinikum Berlin, Berlin, Germany; Clin Univ St Luc, B-1200 Brussels, Belgium; St James & Seacroft Univ Hosp, Leeds, W Yorkshire, England; Ctr Trapianti Fegato, Turin, Italy; Univ Krankenhaus Eppendorf, Hamburg, Germany; Klin Abt Transplantat, Vienna, Austria; Hosp Clin Barcelona, Barcelona, Spain; CUK GHs Essen, Essen, Germany; Hop Hautepierre, Strasbourg, France; Hosp Univ L Fe, Valencia, Spain; Hosp 12 Octubre, E-28041 Madrid, Spain	University of London; University College London; University of London; University College London; UCL Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; University of Birmingham; King's College Hospital NHS Foundation Trust; King's College Hospital; Hannover Medical School; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Saint James's University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Barcelona; Hospital Clinic de Barcelona; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Hospital Universitario 12 de Octubre	Burroughs, AK (corresponding author), UCL Royal Free Hampstead NHS Trust, London NW3 2QG, England.	andrew.burroughs@royalfree.nhs.uk	Lerut, Jan PM/B-9571-2016; Sabin, Caroline/C-2464-2008; Burroughs, Andrew K/C-5645-2009; Goyet, Jean de Ville de/A-1708-2014; Goyet, Jean de Ville de/I-6913-2019	Lerut, Jan PM/0000-0002-4718-9950; Sabin, Caroline/0000-0001-5173-2760; Burroughs, Andrew K/0000-0001-6527-457X; Goyet, Jean de Ville de/0000-0001-7681-6178; Goyet, Jean de Ville de/0000-0001-7681-6178; Karam, Vincent/0000-0002-7391-0190; Salizzoni, Mauro/0000-0002-5480-8705				Adam P, 2003, LIVER TRANSPLANT, V9, P1231, DOI 10.1016/j.lts.2003.09.018; Adam R, 2005, J HEPATOL, V42, P33, DOI 10.1016/j.jhep.2004.11.006; ADAM R, 1992, LANCET, V340, P1373, DOI 10.1016/0140-6736(92)92559-X; Adam R, 2000, LANCET, V356, P621, DOI 10.1016/S0140-6736(00)02603-9; ASCHER NL, 1993, ARCH SURG-CHICAGO, V128, P677; Belle S H, 1995, Liver Transpl Surg, V1, P347, DOI 10.1002/lt.500010602; Bilbao I, 2003, CLIN TRANSPLANT, V17, P401, DOI 10.1034/j.1399-0012.2003.00068.x; Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; CLAVIEN PA, 1994, ANN SURG, V220, P109, DOI 10.1097/00000658-199408000-00002; Farmer DG, 2003, ANN SURG, V237, P666, DOI 10.1097/00000658-200305000-00009; Ghobrial RM, 2002, ANN SURG, V236, P315, DOI 10.1097/00000658-200209000-00008; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hosmer DW, 1997, STAT MED, V16, P965; Jacob M, 2004, LIVER TRANSPLANT, V10, P903, DOI 10.1002/lt.20169; KALAYOGLU M, 1988, LANCET, V1, P617; Karam V, 2003, TRANSPLANTATION, V75, P2167, DOI 10.1097/01.TP.0000080271.20145.07; Lin HM, 1998, JAMA-J AM MED ASSOC, V280, P1153, DOI 10.1001/jama.280.13.1153; Marino IR, 1998, LIVER TRANSPLANT SUR, V4, pS115; Northup PG, 2004, AM J TRANSPLANT, V4, P1643, DOI 10.1111/j.1600-6143.2004.00593.x; Rela M, 1998, ANN SURG, V227, P282, DOI 10.1097/00000658-199802000-00019; Roques F, 2003, EUR HEART J, V24, P881, DOI 10.1016/S0195-668X(02)00799-6; Thuluvath PJ, 2003, LIVER TRANSPLANT, V9, P527, DOI 10.1053/jlts.2003.50089	22	260	265	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					225	232		10.1016/S0140-6736(06)68033-1	http://dx.doi.org/10.1016/S0140-6736(06)68033-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427491	Green Submitted			2022-12-28	WOS:000234810600027
J	Chernajovsky, Y; Layward, L; Lemoine, N				Chernajovsky, Y; Layward, L; Lemoine, N			Controversy - Fighting cancer with oncolytic viruses	BRITISH MEDICAL JOURNAL			English	Article							VACCINIA VIRUS; PHASE-I; CELLS; EXPRESSION; INTERLEUKIN-4; POXVIRUSES; MOUSEPOX; LACKING; TUMORS; GENES		Univ London Queen Mary Coll, Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Bone & Joint Res Unit, London EC1M 6BQ, England; Help Aged, Res Ageing, London, England; Univ London Queen Mary Coll, Barts & London Queen Marys Sch Med & Dent, Canc Res UK Clin Ctr, Inst Canc, London EC1M 6BQ, England	University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London	Chernajovsky, Y (corresponding author), Univ London Queen Mary Coll, Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Bone & Joint Res Unit, London EC1M 6BQ, England.	y.chernajovsky@qmul.ac.uk						ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; Alexander D J, 1974, Avian Pathol, V3, P269, DOI 10.1080/03079457409353840; Anderson BD, 2004, CANCER RES, V64, P4919, DOI 10.1158/0008-5472.CAN-04-0884; Breen EC, 2001, CELL IMMUNOL, V212, P118, DOI 10.1006/cimm.2001.1852; Cortes PL, 2004, AVIAN DIS, V48, P50, DOI 10.1637/7050; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; GOODING LR, 1992, CELL, V71, P5; Guo ZS, 2005, CANCER RES, V65, P9991, DOI 10.1158/0008-5472.CAN-05-1630; Hermiston TW, 2002, CANCER GENE THER, V9, P1022, DOI 10.1038/sj.cgt.7700542; Ichikawa T, 2001, CANCER RES, V61, P5336; Jackson RJ, 2001, J VIROL, V75, P1205, DOI 10.1128/JVI.75.3.1205-1210.2001; Kaufman HL, 2005, J CLIN INVEST, V115, P1903, DOI 10.1172/JCI24624; Lin E, 2004, CANCER GENE THER, V11, P643, DOI 10.1038/sj.cgt.7700733; Lorence RM, 2003, CURR OPIN MOL THER, V5, P618; Mokros T, 2002, J BIOL CHEM, V277, P45122, DOI 10.1074/jbc.M208214200; Myers R, 2005, CANCER GENE THER, V12, P593, DOI 10.1038/sj.cgt.7700823; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042; Raftery MJ, 2004, J IMMUNOL, V173, P3383, DOI 10.4049/jimmunol.173.5.3383; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Robbins SJ, 2005, ANTIVIR RES, V66, P1, DOI 10.1016/j.antiviral.2004.12.003; Russell SJ, 2002, CANCER GENE THER, V9, P961, DOI 10.1038/sj.cgt.7700535; Sabourdy F, 2004, J GEN VIROL, V85, P3597, DOI 10.1099/vir.0.80311-0; Shen YQ, 2005, MOL THER, V11, P180, DOI 10.1016/j.ymthe.2004.10.015; Thorne SH, 2005, CURR GENE THER, V5, P429, DOI 10.2174/1566523054546215; Wang YH, 2005, CANCER RES, V65, P1523, DOI 10.1158/0008-5472.CAN-04-3113; Yunus AS, 1999, ARCH VIROL, V144, P1977, DOI 10.1007/s007050050719	29	26	40	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					170	172		10.1136/bmj.332.7534.170	http://dx.doi.org/10.1136/bmj.332.7534.170			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424499	Green Published			2022-12-28	WOS:000234905800030
J	van Wijck, AJM; Opstelten, W; Moons, KGM; van Essen, GA; Stolker, RJ; Kalkman, CJ; Verheij, TJM				van Wijck, AJM; Opstelten, W; Moons, KGM; van Essen, GA; Stolker, RJ; Kalkman, CJ; Verheij, TJM			The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial	LANCET			English	Article							ACUTE HERPES-ZOSTER; ACYCLOVIR; PAIN; COMPLICATIONS; PREDNISOLONE; MANAGEMENT; INJECTIONS	Background Postherpetic neuralgia is the most frequent complication of herpes zoster. Treatment of this neuropathic pain syndrome is difficult and often disappointing. We assessed the effectiveness of a single epidural injection of steroids and local anaesthetics for prevention of postherpetic neuralgia in older patients with herpes zoster. Methods We randomly assigned 598 patients older than 50 years, with acute herpes zoster (rash <7 days) below dermatome C6, to receive either standard therapy (oral antivirals and analgesics) or standard therapy with one additional epidural injection of 80 mg methylprednisolone acetate and 10 mg bupivacaine. The primary endpoint was the proportion of patients with zoster-associated pain 1 month after inclusion. Analyses were by intention-to-treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN32866390. Findings At 1 month, 137 (48%) patients in the epidural group reported pain compared with 164 (58%) in the control group (relative risk [RR] 0.83, 95% Cl 0.71-0.97, p=0.02). After 3 months these values were 58 (21%) and 63 (24%) respectively (0.89, 0.65-1.21, p=0.47) and, at 6 months, 39 (15%) and 44 (17%; 0.85, 0.57-1.13, p=0.43). We detected no subgroups in which the relative risk for pain 1 month after inclusion substantially differed from the overall estimate. No patient had major adverse events related to epidural injection. Interpretation A single epidural injection of steroids and local anaesthetics in the acute phase of herpes zoster has a modest effect in reducing zoster-associated pain for 1 month. This treatment is not effective for prevention of long-term postherpetic neuralgia.	Univ Med Ctr Utrecht, Pain Clin, Dept Anaesthesiol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; Catharina Hosp, Dept Anaesthesiol, Eindhoven, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Catharina Hospital	van Wijck, AJM (corresponding author), Univ Med Ctr Utrecht, Pain Clin, Dept Anaesthesiol, POB 85500, NL-3508 GA Utrecht, Netherlands.	a.vanwijck@umcutrecht.nl	Kalkman, Cor/O-3215-2019	Kalkman, Cor/0000-0002-8372-6960				Abram SE, 1996, REGION ANESTH, V21, P149; Alper BS, 2000, J FAM PRACTICE, V49, P255; Alper BS, 2002, J FAM PRACTICE, V51, P121; Cluff R, 2002, ANESTH ANALG, V95, P403, DOI 10.1097/00000539-200208000-00031; Coplan PM, 2004, J PAIN, V5, P344, DOI 10.1016/j.jpain.2004.06.001; Cousins M.J, 1998, NEURAL BLOCKADE CLIN; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; Fitzgibbon DR, 2004, ANESTHESIOLOGY, V100, P98, DOI 10.1097/00000542-200401000-00018; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; Jackson JL, 1997, ARCH INTERN MED, V157, P909, DOI 10.1001/archinte.157.8.909; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; Kumar V, 2004, REGION ANESTH PAIN M, V29, P454, DOI 10.1016/j.rapm.2004.04.010; LANCASTER T, 1995, BRIT J GEN PRACT, V45, P39; Liu SS, 2001, REGION ANESTH PAIN M, V26, P143, DOI 10.1053/rapm.2001.21743; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Opstelten W, 2002, FAM PRACT, V19, P471, DOI 10.1093/fampra/19.5.471; Opstelten W, 2004, PAIN, V107, P202, DOI 10.1016/j.pain.2003.10.021; Opstelten W, 2004, ANAESTHESIA, V59, P213, DOI 10.1111/j.1365-2044.2004.03702.x; Opstelten Wim, 2004, BMC Anesthesiol, V4, P2, DOI 10.1186/1471-2253-4-2; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pasqualucci A, 2000, ACTA ANAESTH SCAND, V44, P910, DOI 10.1034/j.1399-6576.2000.440803.x; PERKINS HM, 1978, ARCH SURG-CHICAGO, V113, P253; ROWBOTHAM MC, 1994, SEMIN NEUROL, V14, P247, DOI 10.1055/s-2008-1041083; ROWBOTHAM MC, 2001, HERPES ZOSTER POSTHE, P183; RUTGERS MJ, 1988, BRIT J CLIN PRACT, V42, P412; VANWIJCK A, 2003, NTTP, V22, P18; Whitley RJ, 1999, J INFECT DIS, V179, P9, DOI 10.1086/314562; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; WINNIE AP, 1993, REGION ANESTH, V18, P277; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304	31	134	137	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					219	224		10.1016/S0140-6736(06)68032-X	http://dx.doi.org/10.1016/S0140-6736(06)68032-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427490				2022-12-28	WOS:000234810600026
J	McKee, MG; Layman, JM; Cashion, MP; Long, TE				McKee, MG; Layman, JM; Cashion, MP; Long, TE			Phospholipid nonwoven electrospun membranes	SCIENCE			English	Article							FIBER FORMATION; SURFACE-MORPHOLOGY; MOLECULAR-WEIGHT; POLYMER; NANOFIBERS; MONOLAYER; MICELLES; BEHAVIOR	Nonwoven fibrous membranes were formed from electrospinning lecithin solutions in a single processing step. As the concentration of lecithin increased, the micellar morphology evolved from spherical to cylindrical, and at higher concentrations the cylindrical micelles overlapped and entangled in a fashion similar to polymers in semi-dilute or concentrated solutions. At concentrations above the onset of entanglements of the wormlike micelles, electrospun fibers were fabricated with diameters on the order of 1 to 5 micrometers. The electrospun phospholipid fibers offer the potential for direct fabrication of biologically based, high-surface-area membranes without the use of multiple synthetic steps, complicated electrospinning designs, or postprocessing surface treatments.	Virginia Tech, Dept Chem, MII, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	Long, TE (corresponding author), Virginia Tech, Dept Chem, MII, Blacksburg, VA 24061 USA.	telong@vt.edu						Bai SJ, 2002, J POLYM SCI POL PHYS, V40, P1760, DOI 10.1002/polb.10229; CAPPELAERE E, 1995, COLLOID SURFACE A, V104, P353, DOI 10.1016/0927-7757(95)03332-2; Casper CL, 2004, MACROMOLECULES, V37, P573, DOI 10.1021/ma0351975; CHAPMAN D, 1993, LANGMUIR, V9, P39, DOI 10.1021/la00025a012; Cirkel PA, 1998, LANGMUIR, V14, P7095, DOI 10.1021/la971326x; Deitzel JM, 2001, POLYMER, V42, P261, DOI 10.1016/S0032-3861(01)00336-6; FENDLER JH, 1984, SCIENCE, V223, P888, DOI 10.1126/science.223.4639.888; Fong H, 1999, POLYMER, V40, P4585, DOI 10.1016/S0032-3861(99)00068-3; Fridrikh SV, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.144502; Gupta P, 2005, POLYMER, V46, P4799, DOI 10.1016/j.polymer.2005.04.021; He P, 2005, BIOMACROMOLECULES, V6, P2455, DOI 10.1021/bm050338r; Kanamaru M, 2002, POLYMER, V43, P3925, DOI 10.1016/S0032-3861(02)00218-5; Kim HK, 2005, BIOMATERIALS, V26, P3435, DOI 10.1016/j.biomaterials.2004.09.066; Kim K, 2004, LANGMUIR, V20, P5396, DOI 10.1021/la049959g; Korematsu A, 2002, BIOMATERIALS, V23, P263, DOI 10.1016/S0142-9612(01)00104-1; Lee KH, 2003, POLYMER, V44, P4029, DOI 10.1016/S0032-3861(03)00345-8; Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719; Magid LJ, 1998, J PHYS CHEM B, V102, P4064, DOI 10.1021/jp9730961; McKee MG, 2004, POLYMER, V45, P8705, DOI 10.1016/j.polymer.2004.10.049; McKee MG, 2004, MACROMOLECULES, V37, P1760, DOI 10.1021/ma035689h; McKee MG, 2005, MACROMOLECULES, V38, P6015, DOI 10.1021/ma050667b; Megelski S, 2002, MACROMOLECULES, V35, P8456, DOI 10.1021/ma020444a; Mezzasalma SA, 2000, LANGMUIR, V16, P10564, DOI 10.1021/la000860t; Morimoto N, 2002, BIOMATERIALS, V23, P4881, DOI 10.1016/S0142-9612(02)00246-6; NAKAI S, 1978, MAKROMOL CHEM, V179, P2349; Pratt C. W., 2004, ESSENTIAL BIOCH, V3rd; Regalado EJ, 1999, MACROMOLECULES, V32, P8580, DOI 10.1021/ma990999e; Reneker DH, 1996, NANOTECHNOLOGY, V7, P216, DOI 10.1088/0957-4484/7/3/009; Rubinstein M, 2001, MACROMOLECULES, V34, P1058, DOI 10.1021/ma0013049; SCHURTENBERGER P, 1990, J PHYS CHEM-US, V94, P3695, DOI 10.1021/j100372a062; SHCHIPUNOV YA, 1995, MAT SCI ENG C-BIOMIM, V3, P43, DOI 10.1016/0928-4931(95)00102-6; Shenoy SL, 2005, POLYMER, V46, P3372, DOI 10.1016/j.polymer.2005.03.011; Ye SH, 2003, BIOMATERIALS, V24, P4143, DOI 10.1016/S0142-9612(03)00296-5	33	239	254	4	224	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					353	355		10.1126/science.1119790	http://dx.doi.org/10.1126/science.1119790			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424332				2022-12-28	WOS:000234938500036
J	Schmeler, KM; Lynch, HT; Chen, LM; Munsell, MF; Soliman, PT; Clark, MB; Daniels, MS; White, KG; Boyd-Rogers, SG; Conrad, PG; Yang, KY; Rubin, MM; Sun, CC; Slomovitz, BM; Gershenson, DM; Lu, KH				Schmeler, KM; Lynch, HT; Chen, LM; Munsell, MF; Soliman, PT; Clark, MB; Daniels, MS; White, KG; Boyd-Rogers, SG; Conrad, PG; Yang, KY; Rubin, MM; Sun, CC; Slomovitz, BM; Gershenson, DM; Lu, KH			Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; MUTATION CARRIERS; WOMEN; HYSTERECTOMY; CARCINOMA; HOMOLOG; OOPHORECTOMY; ESTROGEN; TRIAL	BACKGROUND: Women with the Lynch syndrome (hereditary nonpolyposis colorectal cancer) have a 40 to 60 percent lifetime risk of endometrial cancer and a 10 to 12 percent lifetime risk of ovarian cancer. The benefit of prophylactic gynecologic surgery for women with this syndrome has been uncertain. We designed this study to determine the reduction in the risk of gynecologic cancers associated with prophylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome. METHODS: Three hundred fifteen women with documented germ-line mutations associated with the Lynch syndrome were identified. Women who had undergone prophylactic hysterectomy (61 women) and women who had undergone prophylactic bilateral salpingo-oophorectomy (47 women) were matched with mutation-positive women who had not undergone the procedure in question (210 women for the analysis of endometrial cancer and 223 for the analysis of ovarian cancer). Women who had undergone prophylactic surgery and their matched controls were followed from the date of the surgery until the occurrence of cancer or until the data were censored at the time of the last follow-up visit. RESULTS: There were no occurrences of endometrial, ovarian, or primary peritoneal cancer among the women who had undergone prophylactic surgery. Endometrial cancer was diagnosed in 69 women in the control group (33 percent), for an incidence density of 0.045 per woman-year, yielding a prevented fraction (the proportion of potential new cancers prevented) of 100 percent (95 percent confidence interval, 90 to 100 percent). Ovarian cancer was diagnosed in 12 women in the control group (5 percent), for an incidence density of 0.005 per woman-year, yielding a prevented fraction of 100 percent (95 percent confidence interval, -62 to 100 percent). CONCLUSIONS: These findings suggest that prophylactic hysterectomy with bilateral salpingo-oophorectomy is an effective strategy for preventing endometrial and ovarian cancer in women with the Lynch syndrome.	Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77230 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77230 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Genet, Houston, TX 77230 USA; Creighton Univ, Dept Prevent Med, Omaha, NE 68178 USA; Univ Calif San Francisco, Dept Gynecol Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Creighton University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lu, KH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, POB 301439,Unit 1362, Houston, TX 77230 USA.	khlu@mdanderson.org	Slomovitz, Brian/AAB-3247-2022; Slomoivtz, Brian/AAB-3226-2022	Daniels, Molly/0000-0002-5093-5539	DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005127] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-05127] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bertagnolli MM, 2005, J CLIN ONCOL, V23, P324, DOI 10.1200/JCO.2005.08.096; Boks DES, 2002, INT J CANCER, V102, P198, DOI 10.1002/ijc.10667; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Chung L, 2003, OBSTET GYNECOL, V102, P1152, DOI 10.1016/S0029-7844(03)00699-9; Dove-Edwin I, 2002, CANCER, V94, P1708, DOI 10.1002/cncr.10380; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, P167; GOODNO JA, 1995, AM J OBSTET GYNECOL, V172, P1817, DOI 10.1016/0002-9378(95)91417-X; Graziottin A, 2004, MENOPAUSE, V11, P766, DOI 10.1097/01.GME.0000139926.02689.A1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Kolodner RD, 1999, CANCER RES, V59, P5068; Kovac SR, 2000, OBSTET GYNECOL, V95, P787, DOI 10.1016/S0029-7844(99)00641-9; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lu KH, 2005, OBSTET GYNECOL, V105, P569, DOI 10.1097/01.AOG.0000154885.44002.ae; Lynch HT, 1999, CANCER, V86, P2457, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2457::AID-CNCR2>3.0.CO;2-I; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Prior JC, 1997, J BONE MINER RES, V12, P1851, DOI 10.1359/jbmr.1997.12.11.1851; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rijcken FEM, 2003, GYNECOL ONCOL, V91, P74, DOI 10.1016/S0090-8258(03)00371-8; Scully R. E., 1998, ATLAS TUMOR PATHOL, P125; SPEROFF L, 1999, CLIN GYNECOLOGIC END, P662; Vasen HFA, 2001, J CLIN ONCOL, V19, P4074, DOI 10.1200/JCO.2001.19.20.4074; Watson P, 2001, GYNECOL ONCOL, V82, P223, DOI 10.1006/gyno.2001.6279; Weber AM, 1996, NEW ENGL J MED, V335, P1406	29	515	533	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					261	269		10.1056/NEJMoa052627	http://dx.doi.org/10.1056/NEJMoa052627			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421367				2022-12-28	WOS:000234661100006
J	Alford, DP; Compton, P; Samet, JH				Alford, DP; Compton, P; Samet, JH			Acute pain management for patients receiving maintenance methadone or buprenorphine therapy	ANNALS OF INTERNAL MEDICINE			English	Review							INTRAVENOUS-DRUG-USERS; CLINICAL-PHARMACOLOGY; OPIOID-USE; HYPERALGESIA; TOLERANCE; OPIATE; ANALGESIA; HEROIN; DEPENDENCE; ADDICTION	More patients with opioid addiction are receiving opioid agonist therapy (OAT) with methadone and buprenorphine. As a result, physicians will more frequently encounter patients receiving OAT who develop acutely painful conditions, requiring effective treatment strategies. Undertreatment of acute pain is suboptimal medical treatment, and patients receiving long-term OAT are at particular risk. This paper acknowledges the complex interplay among addictive disease, OAT, and acute pain management and describes 4 common misconceptions resulting in suboptimal treatment of acute pain. Clinical recommendations for providing analgesia for patients with acute pain who are receiving OAT are presented. Although challenging, acute pain in patients receiving this type of therapy can effectively be managed.	Boston Univ, Med Ctr, CARE Unit, Boston, MA 02118 USA; Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA	Boston University; University of California System; University of California Los Angeles	Alford, DP (corresponding author), Boston Univ, Med Ctr, CARE Unit, 91 E Concord St,Suite 200, Boston, MA 02118 USA.			Samet, Jeffrey/0000-0002-0897-3400; Alford, Daniel/0000-0002-6250-8390	NIDA NIH HHS [R25-DA-13582, R25 DA013582] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R25DA013582] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 1998, JAMA, V280, P1936; [Anonymous], 2003, MED LETT DRUGS THER, V45, P13; Ball J.C., 2012, EFFECTIVENESS METHAD; BOTNEY M, 1983, ANN NEUROL, V13, P160, DOI 10.1002/ana.410130209; BOYLE RK, 1991, ANAESTH INTENS CARE, V19, P276, DOI 10.1177/0310057X9101900227; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; Center for Substance Abuse Treatment, 2004, DHHS PUBL; Clark HW, 2003, NEW ENGL J MED, V349, P928, DOI 10.1056/NEJMp038126; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Collett BJ, 1998, BRIT J ANAESTH, V81, P58, DOI 10.1093/bja/81.1.58; COMPTON MA, 1994, J PAIN SYMPTOM MANAG, V9, P462, DOI 10.1016/0885-3924(94)90203-8; Compton P, 2001, DRUG ALCOHOL DEPEN, V63, P139, DOI 10.1016/S0376-8716(00)00200-3; Compton P, 1998, J PAIN SYMPTOM MANAG, V16, P21, DOI 10.1016/S0885-3924(98)00035-9; Compton P, 2000, J PAIN SYMPTOM MANAG, V20, P237, DOI 10.1016/S0885-3924(00)00191-3; COMPTON P, 2003, PRINCIPLES ADDICTION, P1385; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; *CTR SUBST AB TREA, 1993, DHHS PUBL SMA; DEVILLERS JP, 1995, BRAIN RES, V700, P173, DOI 10.1016/0006-8993(95)00948-P; Devulder J, 1996, PAIN, V64, P589, DOI 10.1016/0304-3959(95)00187-5; Devulder J, 1997, J NEUROSURG ANESTH, V9, P146, DOI 10.1097/00008506-199704000-00007; DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304; Doverty M, 2001, PAIN, V93, P155, DOI 10.1016/S0304-3959(01)00306-2; Doverty M, 2001, PAIN, V90, P91, DOI 10.1016/S0304-3959(00)00391-2; Dunbar SA, 1998, J PHARMACOL EXP THER, V284, P678; EDGE WG, 1979, ANAESTHESIA, V34, P463, DOI 10.1111/j.1365-2044.1979.tb06325.x; Eriator II, 1998, CURR REV PAIN, V2, P193; Evers GCM, 1997, SUPPORT CARE CANCER, V5, P457, DOI 10.1007/s005200050114; *FED STAT MED BOAR, 2003, MOD GUID US CONTR SU; Fiellin DA, 2002, NEW ENGL J MED, V347, P817, DOI 10.1056/NEJMcp013579; Fiellin DA, 2002, ANN INTERN MED, V137, P688, DOI 10.7326/0003-4819-137-8-200210150-00014; Fishman SM, 2002, PAIN MED, V3, P339, DOI 10.1046/j.1526-4637.2002.02047.x; FULTZ JM, 1975, ANN INTERN MED, V82, P815, DOI 10.7326/0003-4819-82-6-815; Gardner E.L., 1997, SUBSTANCE ABUSE COMP, P51; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; GRILLY DM, 1986, PSYCHOPHARMACOLOGY, V88, P500; Gutstein HB, 2001, GOODMAN GILMANS PHAR, P569; Haddox JD, 1997, CLIN J PAIN, V13, P6; HANKS GW, 1981, ANAESTHESIA, V36, P37, DOI 10.1111/j.1365-2044.1981.tb08596.x; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; HO A, 1979, P SOC EXP BIOL MED, V162, P392; HOFFMAN M, 1991, CANCER, V68, P1121, DOI 10.1002/1097-0142(19910901)68:5<1121::AID-CNCR2820680539>3.0.CO;2-1; Houtsmuller EJ, 1998, J PHARMACOL EXP THER, V285, P387; *I MED, 1995, FED REG METH TREATM, P21; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Jasinski DR, 1997, ACTA ANAESTH SCAND, V41, P184, DOI 10.1111/j.1399-6576.1997.tb04635.x; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; Johnson RE, 2003, DRUG ALCOHOL DEPEN, V70, pS59, DOI 10.1016/S0376-8716(03)00060-7; *JOINT COMM ACCR H, 1999, COMPR ACCR MAN HOSP; *JOINT COMM ACCR H, 1999, JOINT COMM FOC PAIN; JONES BE, 1975, PSYCHOPHARMACOLOGIA, V41, P7, DOI 10.1007/BF00421297; KANTOR TG, 1980, DRUG ALCOHOL DEPEN, V6, P163, DOI 10.1016/0376-8716(80)90455-X; Karasz A, 2004, J PAIN SYMPTOM MANAG, V28, P517, DOI 10.1016/j.jpainsymman.2004.02.025; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Krantz MJ, 2004, ARCH INTERN MED, V164, P277, DOI 10.1001/archinte.164.3.277; LANDER J, 1990, BRIT J ADDICT, V85, P803; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1999, NEUROSCIENCE, V89, P631, DOI 10.1016/S0306-4522(98)00652-6; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; Manfredi PL, 2001, J PAIN SYMPTOM MANAG, V21, P169, DOI 10.1016/S0885-3924(00)00252-9; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; Martin J E, 1965, Br J Soc Clin Psychol, V4, P224; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; McCance-Katz EF, 2004, HARVARD REV PSYCHIAT, V12, P321, DOI 10.1080/10673220490905688; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; Merrill J, 2002, J GEN INTERN MED, V17, P361; Merrill J, 2002, J GEN INTERN MED, V17, P327, DOI 10.1046/j.1525-1497.2002.10625.x; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; Mitra S, 2004, ANESTHESIOLOGY, V101, P212, DOI 10.1097/00000542-200407000-00032; MOA G, 1990, ACTA ANAESTH SCAND, V34, P68, DOI 10.1111/j.1399-6576.1990.tb03044.x; MORGAN J P, 1985, Advances in Alcohol and Substance Abuse, V5, P163; O'Connor PG, 2000, ANN INTERN MED, V133, P40, DOI 10.7326/0003-4819-133-1-200007040-00008; OBRIEN CP, 2001, GOODMAN GILMANS PHAR, P621; OCONNOR PG, 1994, AM J MED, V96, P551, DOI 10.1016/0002-9343(94)90096-5; Paige D, 1994, AJPM, V4, P101; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; Portenoy RK, 1997, JAMA-J AM MED ASSOC, V278, P592, DOI 10.1001/jama.278.7.592; Prater Christopher D., 2002, Prim Care Companion J Clin Psychiatry, V4, P125; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Savage Seddon R., 1995, P373; Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7; Savage SR, 1999, MED CLIN N AM, V83, P761, DOI 10.1016/S0025-7125(05)70133-4; SAVAGE SR, 1993, J PAIN SYMPTOM MANAG, V8, P265, DOI 10.1016/0885-3924(93)90155-O; Schall U, 1996, PHARMACOPSYCHIATRY, V29, P176, DOI 10.1055/s-2007-979567; Schnoll SH, 2003, AM J ADDICTION, V12, pS27, DOI 10.1080/10550490390210218; Scimeca MM, 2000, MT SINAI J MED, V67, P412; Streltzer J, 2001, Curr Psychiatry Rep, V3, P489, DOI 10.1007/s11920-001-0043-9; TILSON HA, 1973, PSYCHOPHARMACOLOGIA, V28, P287, DOI 10.1007/BF00429309; Vukmir RB, 2004, AM J DRUG ALCOHOL AB, V30, P551, DOI 10.1081/ADA-200032294; Walsh SL, 2003, DRUG ALCOHOL DEPEN, V70, pS13, DOI 10.1016/S0376-8716(03)00056-5; WALSH TD, 1981, PAIN S, V1, P39; WEISSMAN DE, 1989, PAIN, V36, P363, DOI 10.1016/0304-3959(89)90097-3; White JM, 2004, ADDICT BEHAV, V29, P1311, DOI 10.1016/j.addbeh.2004.06.007; Zacny JP, 1996, DRUG ALCOHOL DEPEN, V42, P133, DOI 10.1016/0376-8716(96)01274-4	103	262	266	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					127	134		10.7326/0003-4819-144-2-200601170-00010	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	004AX	16418412	Green Accepted			2022-12-28	WOS:000234725500009
J	West, R; Sohal, T				West, R; Sohal, T			"Catastrophic" pathways to smoking cessation: findings from national survey	BRITISH MEDICAL JOURNAL			English	Article							MODEL	Objective To assess the extent to which the prevailing model of smoking cessation (that smokers typically prepare their attempts to stop smoking in advance and that doing so increases their chances of success) is correct. Design Cross sectional household survey. Setting England. Participants 918 smokers who reported having made at least one quit attempt and 996 ex-smokers aged 16 and over. Main outcome measures Whether the most recent quit attempt was planned in advance and whether quit attempts made at least six months before resulted in at least six months' abstinence. Results 48.6% of smokers reported that their most recent quit attempt was put into effect immediately the decision to quit was made. Unplanned quit attempts were more likely to succeed for at least six months: among respondents who had made a quit attempt between six months and five years previously the odds of success were 2.6 times higher (95% confidence interval 1.9 to 3.6) in unplanned attempts than in planned attempts; in quit attempts made 6-12 months previously the corresponding figure was 2.5 (1.4 to 4.7). The differences remained after controlling for age, sex, and socioeconomic group. Conclusions A model of the process of change based on "catastrophe theory" is proposed, in which smokers have varying levels of motivational "tension" to stop and then "triggers" in the environment result in a switch in motivational state. If that switch involves immediate renunciation of cigarettes, this can signal a more complete transformation than if it involves a plan to quit at some future point.	UCL, London WC1E 6BT, England; BMRB Social Res, London W5 2BP, England	University of London; University College London	West, R (corresponding author), UCL, Mortimer St, London WC1E 6BT, England.	robert.west@ucl.ac.uk	West, Robert/B-5414-2009; West, Robert/B-5414-2009	West, Robert/0000-0002-0291-5760; West, Robert/0000-0001-6398-0921				Brown C., 1995, CHAOS CATASTROPHE TH; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; LADER D, 2005, SMOKING RELATED ATTI; LARABIE L, IN PRESS TOB CONTROL; *NICE, 2002, 38 NICE; *OFF NAT STAT, 2005, GEN HOUS SURV 2003; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; West R, 2005, ADDICTION, V100, P1036, DOI 10.1111/j.1360-0443.2005.01139.x; West R., 2006, THEORY ADDICTION	9	215	217	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 25	2006	332	7539					458	460		10.1136/bmj.38723.573866.AE	http://dx.doi.org/10.1136/bmj.38723.573866.AE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16443610	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000235792900017
J	Bent, S; Kane, C; Shinohara, K; Neuhaus, J; Hudes, ES; Goldberg, H; Avins, AL				Bent, S; Kane, C; Shinohara, K; Neuhaus, J; Hudes, ES; Goldberg, H; Avins, AL			Saw palmetto for benign prostatic hyperplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; SERENOA-REPENS; FINASTERIDE; EFFICACY; MEN; DOXAZOSIN; EXTRACT; TRIAL	BACKGROUND: Saw palmetto is used by over 2 million men in the United States for the treatment of benign prostatic hyperplasia and is commonly recommended as an alternative to drugs approved by the Food and Drug Administration. METHODS: In this double-blind trial, we randomly assigned 225 men over the age of 49 years who had moderate-to-severe symptoms of benign prostatic hyperplasia to one year of treatment with saw palmetto extract (160 mg twice a day) or placebo. The primary outcome measures were changes in the scores on the American Urological Association Symptom Index (AUASI) and the maximal urinary flow rate. Secondary outcome measures included changes in prostate size, residual urinary volume after voiding, quality of life, laboratory values, and the rate of reported adverse effects. RESULTS: There was no significant difference between the saw palmetto and placebo groups in the change in AUASI scores (mean difference, 0.04 point; 95 percent confidence interval, -0.93 to 1.01), maximal urinary flow rate (mean difference, 0.43 ml per minute; 95 percent confidence interval, -0.52 to 1.38), prostate size, residual volume after voiding, quality of life, or serum prostate-specific antigen levels during the one-year study. The incidence of side effects was similar in the two groups. CONCLUSIONS: In this study, saw palmetto did not improve symptoms or objective measures of benign prostatic hyperplasia.	San Francisco VA Med Ctr, Dept Med, Gen Internal Med Sect, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, Urol Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, Osher Ctr Integrat Med, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Family Practice, San Francisco, CA 94143 USA; Kaiser Permanente No Calif, Oakland, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Bent, S (corresponding author), San Francisco VA Med Ctr, Dept Med, Gen Internal Med Sect, 111-A1,4150 Clement St, San Francisco, CA 94121 USA.	bent@itsa.ucsf.edu			NCCIH NIH HHS [1 K08 ATO1338-01] Funding Source: Medline; NIDDK NIH HHS [1 R01 DK56199-01] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K08AT001338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056199] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM UR ASS ED RES, 2003, AM UR ASS GUID MAN B; Barnes Patricia M, 2004, Adv Data, P1; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; Bauer H W, 1999, MMW Fortschr Med, V141, P62; Boccafoschi C, 1983, UROLOGIA, V50, P1257; Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; BRAECKMAN J, 1997, EUR J CLIN RES, V9, P247; CARBIN BE, 1990, BRIT J UROL, V66, P639, DOI 10.1111/j.1464-410X.1990.tb07199.x; CHAMPAULT G, 1984, BRIT J CLIN PHARMACO, V18, P461, DOI 10.1111/j.1365-2125.1984.tb02491.x; CUKIER J, 1985, CR THER PHARM CLIN, V4, P15; DESCOTES JL, 1995, CLIN DRUG INVEST, V9, P291, DOI 10.2165/00044011-199509050-00007; Emili E, 1983, UROLOGIA, V50, P1042; *EXP COMM, 2002, DSB DIET S BOT, V28, P425; FOWLER FJ, 1993, EUR UROL, V24, P24; FUGHBERMAN A, 2003, 5 MINUTE HERB DIET S; GABRIC V, 1987, THERAPIEWOCHE, V37, P1775; Gerber GS, 2001, UROLOGY, V58, P960, DOI 10.1016/S0090-4295(01)01442-X; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; LOBELENZ J, 1992, THERAPEUTIKON, V6, P34; Lowe FC, 1996, UROLOGY, V48, P12, DOI 10.1016/S0090-4295(96)00077-5; MANDRESSI A, 1983, UROLOGIA, V50, P752; Marks LS, 2000, J UROLOGY, V163, P1451, DOI 10.1016/S0022-5347(05)67641-0; Mattei F. M., 1990, TW UROL NEPHROL, V2, P346; McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; McCulloch C. E., 2001, GEN LINEAR MIXED MOD; Metzker H, 1996, UROLOGE B, V36, P292, DOI DOI 10.1007/S001310050033; Niederprum H J, 1994, Phytomedicine, V1, P127, DOI 10.1016/S0944-7113(11)80030-9; Roehrborn CG, 1996, UROLOGY, V48, P406, DOI 10.1016/S0090-4295(96)00208-7; Rotblatt M, 2002, EVIDENCE BASED HERBA; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Ryan P, 2000, RALLOC STATA MODULE; SMITH HR, 1986, BRIT J UROL, V58, P36, DOI 10.1111/j.1464-410X.1986.tb05424.x; *STAT CORP, 2003, STAT STAT SOFTW; Tasca A, 1985, Minerva Urol Nefrol, V37, P87; ULBRICHT CE, 2005, NATURAL STANDARD HER, P651; Ware JE, 1993, SF36 HLTH SURVEY MAN; Willetts KE, 2003, BJU INT, V92, P267, DOI 10.1046/j.1464-410X.2003.04316.x; Wilt T, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001423	39	246	257	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					557	566		10.1056/NEJMoa053085	http://dx.doi.org/10.1056/NEJMoa053085			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467543	Green Published			2022-12-28	WOS:000235177500005
J	Davis, MH; Ponnamperuma, GG				Davis, MH; Ponnamperuma, GG			Medical education research at the crossroads	LANCET			English	Editorial Material							HEALTH-SERVICES RESEARCH		Ctr Med Educ, Dundee DD2 1LR, Scotland	University of Dundee	Davis, MH (corresponding author), Ctr Med Educ, Dundee DD2 1LR, Scotland.	m.h.davis@dundee.ac.uk		Ponnamperuma, Gominda/0000-0003-0023-6550				[Anonymous], 2003, EDUC RESEARCHER, DOI [DOI 10.3102/0013189X032009003, DOI 10.3102/0013189X03]; GOLDSTEIN BP, 1994, ACAD MED, V69, P625; Harden RM, 1999, MED TEACH, V21, P553, DOI 10.1080/01421599978960; *I MED, 2003, AC HLTH CTR LEAD CHA; Morrison J, 2005, MED EDUC, V39, P542, DOI 10.1111/j.1365-2929.2005.02186.x; Reed DA, 2005, JAMA-J AM MED ASSOC, V294, P1052, DOI 10.1001/jama.294.9.1052; Regehr G, 2004, ACAD MED, V79, P939, DOI 10.1097/00001888-200410000-00008; *RES ASS EX, 2005, RAE 2008 GUID PAN; Searle J, 2005, MED EDUC, V39, P544, DOI 10.1111/j.1365-2929.2005.02185.x; Shea JA, 2001, MED EDUC, V35, P319, DOI 10.1046/j.1365-2923.2001.00913.x; Torgerson CJ, 2002, MED EDUC, V36, P1002, DOI 10.1046/j.1365-2923.2002.01335.x; Wartman SA, 2004, ACAD MED, V79, P910, DOI 10.1097/00001888-200410000-00003; Watt GCM, 2005, MED EDUC, V39, P555, DOI 10.1111/j.1365-2929.2005.02188.x	13	14	16	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					377	378		10.1016/S0140-6736(06)68116-6	http://dx.doi.org/10.1016/S0140-6736(06)68116-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458747				2022-12-28	WOS:000235139400008
J	Hunkeler, EM; Katon, W; Tang, LQ; Williams, JW; Kroenke, K; Lin, EHB; Harpole, LH; Arean, P; Levine, S; Grypma, LM; Hargreaves, WA; Unutzer, J				Hunkeler, EM; Katon, W; Tang, LQ; Williams, JW; Kroenke, K; Lin, EHB; Harpole, LH; Arean, P; Levine, S; Grypma, LM; Hargreaves, WA; Unutzer, J			Long term outcomes from the MPACT randomised trial for depressed elderly patients in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISSEMINATING QUALITY IMPROVEMENT; MENTAL-HEALTH-SERVICES; LATE-LIFE; MANAGEMENT; DISORDERS; EFFICACY; ANXIETY; ADULTS; IMPACT	Objective To determine the long term effectiveness of collaborative care management for depression in late life. Design Two arm, randomised, clinical trial; intervention one year and follow-up two years. Setting 18 primary care clinics in eight US healthcare organisations. Patients 1801 primary care patients aged 60 and older with major depression, dysthymia, or both. Intervention Patients were randomly assigned to a 12 month collaborative care intervention (IMPACT) or usual care for depression. Teams including a depression care manager, primary care doctor, and psychiatrist offered education, behavioural activation, antidepressants, a brief, behaviour based psychotherapy (problem solving treatment), and relapse prevention geared to each patient's needs and preferences. Main outcome measures Interviewers, blinded to treatment assignment, conducted interviews in person at baseline and by telephone at each subsequent follow-up. They measured depression (SCL-20), overall functional impairment and quality of life (SF-12), physical functioning (PCS-12), depression treatment, and satisfaction with care. Results IMPACT patients fared significantly (P < 0.05) better than controls regarding continuation of antidepressant treatment, depressive symptoms, remission of depression, physical functioning, quality of life, self efficacy, and satisfaction with care at 18 and 24 months. One year after IMPACT resources were withdrawn, a significant difference in SCL-20 scores (0.23, P < 0.0001) favouring IMPACT patients remained. Conclusions Tailored collaborative care actively engages older adults in treatment for depression and delivers substantial and persistent long term benefits. Benefits include less depression, better physical functioning, and an enhanced quality of life. The IMPACT model may show the way to less depression and healthier lives for older adults.	Kaiser Permanente, Div Res, Oakland, CA 94612 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Hlth Serv Res Ctr, Los Angeles, CA 90024 USA; Duke Univ, Med Ctr, Durham, NC 27705 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; GlaxoSmithKline Inc, Global Hlth Outcomes, Res Triangle Pk, NC 27709 USA; Univ Calif San Francisco, Langley Porter Psychiat Inst, Dept Psychiat, San Francisco, CA 94143 USA; SCAN Hlth Plan, Long Beach, CA 90801 USA; Kaiser Permanente, La Mesa, CA 91942 USA; Univ Calif San Francisco, Oakland, CA 94612 USA; Univ Washington, Dept Psychiat, Seattle, WA 98195 USA	Kaiser Permanente; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Group Health Cooperative; GlaxoSmithKline; University of California System; University of California San Francisco; Kaiser Permanente; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	Hunkeler, EM (corresponding author), Kaiser Permanente, Div Res, 2000 Broadway,2nd Floor, Oakland, CA 94612 USA.	emh@dor.kaiscr.org	Unutzer, Jurgen/N-4048-2018; Williams, John/AAM-4572-2020; anand, amit/A-7222-2009; Arean, Patricia/GLR-1550-2022; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558; Kroenke, Kurt/0000-0002-0114-4669				Bartels SJ, 2004, AM J PSYCHIAT, V161, P1455, DOI 10.1176/appi.ajp.161.8.1455; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Callahan CM, 2002, MED CARE, V40, P771, DOI 10.1097/00005650-200209000-00007; First M.B., 2014, STRUCTURED CLIN INTE; GOLDSTROM ID, 1987, J GERONTOL, V42, P147, DOI 10.1093/geronj/42.2.147; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; LAVORI PW, 1995, STAT MED, V14, P1913, DOI 10.1002/sim.4780141707; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Lyness JM, 1999, J GEN INTERN MED, V14, P249, DOI 10.1046/j.1525-1497.1999.00326.x; OXMAN TE, 1990, PSYCHOSOMATICS, V31, P174, DOI 10.1016/S0033-3182(90)72191-3; *PRES NEW FREED CO, 2005, DHHS PUB SMA; Rost K, 2002, BMJ-BRIT MED J, V325, P934, DOI 10.1136/bmj.325.7370.934; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Schulberg HC, 1996, ARCH GEN PSYCHIAT, V53, P913; Sherbourne CD, 2001, ARCH GEN PSYCHIAT, V58, P696, DOI 10.1001/archpsyc.58.7.696; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Tang LQ, 2005, STAT MED, V24, P2111, DOI 10.1002/sim.2099; Unutzer J, 1999, MILBANK Q, V77, P225, DOI 10.1111/1468-0009.00132; Unutzer J, 2001, MED CARE, V39, P785, DOI 10.1097/00005650-200108000-00005; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	24	234	242	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2006	332	7536					259	262		10.1136/bmj.38683.710255.BE	http://dx.doi.org/10.1136/bmj.38683.710255.BE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16428253	Green Published, Bronze			2022-12-28	WOS:000235259000013
J	Serruys, PW; Kutryk, MJB; Ong, ATL				Serruys, PW; Kutryk, MJB; Ong, ATL			Drug therapy - Coronary-artery stents	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SIROLIMUS-ELUTING STENTS; ACUTE MYOCARDIAL-INFARCTION; UNPROTECTED LEFT MAIN; AORTOCORONARY BYPASS GRAFTS; RANDOMIZED CONTROLLED-TRIAL; BALLOON-EXPANDABLE-STENT; SLOW-RELEASE; DOUBLE-BLIND; BARE-METAL; FOLLOW-UP		Erasmus MC, Thoraxctr, Dept Intervent Cardiol, NL-3015 GD Rotterdam, Netherlands; Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada	Erasmus University Rotterdam; Erasmus MC; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Serruys, PW (corresponding author), Erasmus MC, Thoraxctr, Dept Intervent Cardiol, NL-3015 GD Rotterdam, Netherlands.							AGOSTONI P, IN PRESS AM HEART J; Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; Aoki J, 2005, J AM COLL CARDIOL, V45, P1574, DOI 10.1016/j.jacc.2005.01.048; Baim DS, 2002, CIRCULATION, V105, P1285, DOI 10.1161/01.CIR.0000012783.63093.0C; Bertrand ME, 2000, CIRCULATION, V102, P624, DOI 10.1161/01.CIR.102.6.624; Brophy JM, 2003, ANN INTERN MED, V138, P777, DOI 10.7326/0003-4819-138-10-200305200-00005; Carter AJ, 2004, CARDIOVASC RES, V63, P617, DOI 10.1016/j.cardiores.2004.04.029; Chieffo A, 2005, CIRCULATION, V111, P791, DOI 10.1161/01.CIR.0000155256.88940.F8; Colombo A, 2003, CIRCULATION, V108, P788, DOI 10.1161/01.CIR.0000086926.62288.A6; Colombo A, 2004, CIRCULATION, V109, P1244, DOI 10.1161/01.CIR.0000118474.71662.E3; Colombo A, 2001, J AM COLL CARDIOL, V38, P1427, DOI 10.1016/S0735-1097(01)01557-1; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DEFEYTER PJ, 1994, AM HEART J, V127, P643, DOI 10.1016/0002-8703(94)90675-0; Degertekin M, 2003, J AM COLL CARDIOL, V41, P184, DOI 10.1016/S0735-1097(02)02704-3; Dibra A, 2005, NEW ENGL J MED, V353, P663, DOI 10.1056/NEJMoa044372; DOTTER CT, 1964, CIRCULATION, V30, P654, DOI 10.1161/01.CIR.30.5.654; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Gawaz M, 1996, CIRCULATION, V94, P279, DOI 10.1161/01.CIR.94.3.279; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; Grube E, 2004, CIRCULATION, V109, P2168, DOI 10.1161/01.CIR.0000128850.84227.FD; Grube E, 2003, CIRCULATION, V107, P38, DOI 10.1161/01.CIR.0000047700.58683.A1; Grube Eberhard, 2005, EuroIntervention, V1, P53; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; Guagliumi G, 2003, CIRCULATION, V107, P1340, DOI 10.1161/01.CIR.0000062700.42060.6F; Gupta Vishal, 2004, J Invasive Cardiol, V16, P304; Hausleiter J, 2002, J AM COLL CARDIOL, V40, P882, DOI 10.1016/S0735-1097(02)02043-0; Heublein B, 2003, HEART, V89, P651, DOI 10.1136/heart.89.6.651; Holmes DR, 2002, CIRCULATION, V106, P1243, DOI 10.1161/01.CIR.0000028335.31300.DA; Hoye A, 2004, J AM COLL CARDIOL, V43, P1954, DOI 10.1016/j.jacc.2004.01.045; Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126; Kaiser C, 2005, LANCET, V366, P921, DOI 10.1016/S0140-6736(05)67221-2; Kastrati A, 2000, CIRCULATION, V101, P2478, DOI 10.1161/01.CIR.101.21.2478; Kastrati A, 2005, JAMA-J AM MED ASSOC, V293, P165, DOI 10.1001/jama.293.2.165; Kay IP, 2001, CIRCULATION, V103, P14; Kobayashi Y, 1999, J AM COLL CARDIOL, V34, P651, DOI 10.1016/S0735-1097(99)00303-4; LABINAZ M, 1995, J INTERV CARDIOL, V8, P395, DOI 10.1111/j.1540-8183.1995.tb00565.x; Lefevre T, 2001, J Interv Cardiol, V14, P573, DOI 10.1111/j.1540-8183.2001.tb00375.x; Lemos PA, 2004, J AM COLL CARDIOL, V43, P704, DOI 10.1016/j.jacc.2003.12.022; Lemos PA, 2004, CIRCULATION, V109, P190, DOI 10.1161/01.CIR.0000109138.84579.FA; Mauri L, 2005, AM J CARDIOL, V95, P1140, DOI 10.1016/j.amjcard.2005.01.039; McFadden EP, 2004, LANCET, V364, P1519, DOI 10.1016/S0140-6736(04)17275-9; Meredith Ian T, 2005, EuroIntervention, V1, P157; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; MORICE MC, 2005, AM COLL CARD 54 ANN; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Nordmann AJ, 2004, AM J MED, V116, P253, DOI 10.1016/j.amjmed.2003.08.035; ONG AT, IN PRESS AM HEART J; ONG AT, IN PRESS J AM COLL C; Ong ATL, 2005, J AM COLL CARDIOL, V45, P2088, DOI 10.1016/j.jacc.2005.02.086; Ong ATL, 2005, J AM COLL CARDIOL, V45, P947, DOI 10.1016/j.jacc.2004.09.079; PALMAZ JC, 1985, RADIOLOGY, V156, P73, DOI 10.1148/radiology.156.1.3159043; Park SJ, 1998, J AM COLL CARDIOL, V31, P37, DOI 10.1016/S0735-1097(97)00425-7; Regar E, 2001, BRIT MED BULL, V59, P227, DOI 10.1093/bmb/59.1.227; Rensing BJ, 2001, EUR HEART J, V22, P2125, DOI 10.1053/euhj.2001.2892; Rogue M, 2000, ATHEROSCLEROSIS, V153, P315, DOI 10.1016/S0021-9150(00)00421-4; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; Saia F, 2004, CATHETER CARDIO INTE, V62, P283, DOI 10.1002/ccd.20068; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Schampaert E, 2004, J AM COLL CARDIOL, V43, P1110, DOI 10.1016/j.jacc.2004.01.024; SCHATZ RA, 1987, CIRCULATION, V76, P450, DOI 10.1161/01.CIR.76.2.450; Schofer J, 2003, LANCET, V362, P1093, DOI 10.1016/S0140-6736(03)14462-5; Serruys P, 1998, LANCET, V352, P1478; Serruys Patrick W, 2005, EuroIntervention, V1, P147; Serruys Patrick W, 2005, EuroIntervention, V1, P58; Serruys PW, 2005, J AM COLL CARDIOL, V46, P575, DOI 10.1016/j.jacc.2004.12.082; Serruys PW, 2002, J AM COLL CARDIOL, V39, P393, DOI 10.1016/S0735-1097(01)01760-0; Serruys PW, 2002, CIRCULATION, V106, P798, DOI 10.1161/01.CIR.0000025585.63486.59; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; Silvestri M, 2000, J AM COLL CARDIOL, V35, P1543, DOI 10.1016/S0735-1097(00)00588-X; Sousa JE, 2005, CIRCULATION, V111, P2326, DOI 10.1161/01.CIR.0000164271.01172.1A; Stankovic G, 2003, CIRCULATION, V108, P37, DOI 10.1161/01.CIR.0000079106.71097.1C; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2003, CIRCULATION, V108, P548, DOI 10.1161/01.CIR.0000080894.51311.0A; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Suryapranata H, 1998, CIRCULATION, V97, P2502, DOI 10.1161/01.CIR.97.25.2502; Tamai H, 2000, CIRCULATION, V102, P399; Tanabe K, 2003, CIRCULATION, V107, P559, DOI 10.1161/01.CIR.0000048184.96491.8A; Tsuji Takafumi, 2003, Int J Cardiovasc Intervent, V5, P13; Valgimigli M, 2005, CIRCULATION, V111, P1383, DOI 10.1161/01.CIR.0000158486.20865.8B; Virmani R, 2004, CIRCULATION, V109, P701, DOI 10.1161/01.CIR.0000116202.41966.D4; Vogt F, 2004, EUR HEART J, V25, P1330, DOI 10.1016/j.ehj.2004.06.010; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; WIJNS W, 2005, AM COLL CARD 54 ANN; Windecker S, 2005, NEW ENGL J MED, V353, P653, DOI 10.1056/NEJMoa051175; Windecker S, 2005, CIRCULATION, V111, P2617, DOI 10.1161/CIRCULATIONAHA.104.486647; Yamashita T, 2000, J AM COLL CARDIOL, V35, P1145, DOI 10.1016/S0735-1097(00)00534-9	91	508	561	1	57	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					483	495		10.1056/NEJMra051091	http://dx.doi.org/10.1056/NEJMra051091			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452560				2022-12-28	WOS:000235019400008
J	Burt, RK; Traynor, A; Statkute, L; Barr, WG; Rosa, R; Schroeder, J; Verda, L; Krosnjar, N; Quigley, K; Yaung, K; Villa, M; Takahashi, M; Jovanovic, B; Oyama, Y				Burt, RK; Traynor, A; Statkute, L; Barr, WG; Rosa, R; Schroeder, J; Verda, L; Krosnjar, N; Quigley, K; Yaung, K; Villa, M; Takahashi, M; Jovanovic, B; Oyama, Y			Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLONY-STIMULATING FACTOR; HIGH-DOSE CHEMOTHERAPY; AUTOIMMUNE-DISEASES; ANTIPHOSPHOLIPID SYNDROME; CLINICAL-TRIALS; MORTALITY; NEPHRITIS; NEUTROPENIA; INDUCTION; THERAPIES	Context Manifestations of systemic lupus erythematosus (SLE) may in most patients be ameliorated with medications that suppress the immune system. Nevertheless, there remains a subset of SLE patients for whom current strategies are insufficient to control disease. Objective To assess the safety of intense immunosuppression and autologous hematopoietic stem cell support in patients with severe and treatment-refractory SLE. Design, Setting, and Participants A single-arm trial of 50 patients with SLE refractory to standard immunosuppressive therapies and either organ- or life-threatening visceral involvement. Patients were enrolled from April 1997 through January 2005 in an autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) study at a single US medical center. Interventions Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m(2)) and granulocyte colony-stimulating factor (5 mu g/kg per day), enriched ex vivo by CD34(+) immunoselection, cryopreserved, and reinfused after treatment with cyclophosphamide (200 mg/kg) and equine antithymocyte globulin (90 mg/kg). Main Outcome Measures The primary end point was survival, both overall and disease-free. Secondary end points included SLE Disease Activity Index (SLEDAI), serology (antinuclear antibody [ANA] and anti-double-stranded (ds) DNA), complement C3 and C4, and changes in renal and pulmonary organ function assessed before treatment and at 6 months, 12 months, and then yearly for 5 years. Results Fifty patients were enrolled and underwent stem cell mobilization. Two patients died after mobilization, one from disseminated mucormycosis and another from active lupus after postponing the transplantation for 4 months. Forty-eight patients underwent nonmyeloablative HSCT. Treatment-related mortality was 2% (1/50). By intention to treat, treatment-related mortality was 4% (2/50). With a mean follow-up of 29 months (range, 6 months to 7.5 years) for patients undergoing HSCT, overall 5-year survival was 84%, and probability of disease-free survival at 5 years following HSCT was 50%. Secondary analysis demonstrated stabilization of renal function and significant improvement in SLEDAI score, ANA, anti-ds DNA, complement, and carbon monoxide diffusion lung capacity adjusted for hemoglobin. Conclusions In treatment-refractory SLE, autologous nonmyeloablative HSCT results in amelioration of disease activity, improvement in serologic markers, and either stabilization or reversal of organ dysfunction. These data are nonrandomized and thus preliminary, providing the foundation and justification for a definitive randomized trial.	Northwestern Univ, Feinberg Sch Med, Div Immunotherapy, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Div Nephrol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Burt, RK (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Immunotherapy, 750 N Lake Shore Dr, Chicago, IL 60611 USA.	rburt@northwestern.edu		Burt, Richard K/0000-0002-0922-4145; Quigley, Kathleen/0000-0002-6344-3904				ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1265; Anolik JH, 2004, ARTHRITIS RHEUM-US, V50, P3580, DOI 10.1002/art.20592; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; Bansal VK, 1997, AM J KIDNEY DIS, V29, P193, DOI 10.1016/S0272-6386(97)90029-9; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Burt RK, 2004, SPRINGER SEMIN IMMUN, V26, P57, DOI 10.1007/s00281-004-0162-6; Burt RK, 2002, BLOOD, V99, P768, DOI 10.1182/blood.V99.3.768; Burt RK, 1998, BLOOD, V92, P3505, DOI 10.1182/blood.V92.10.3505.422k48_3505_3514; Cervera R, 1999, MEDICINE, V78, P167, DOI 10.1097/00005792-199905000-00003; Chan TM, 2000, NEW ENGL J MED, V343, P1156, DOI 10.1056/NEJM200010193431604; Cohen Y, 2003, CURR PHARM DESIGN, V9, P279, DOI 10.2174/1381612033392134; Dubey S, 2003, ANN HEMATOL, V82, P496, DOI 10.1007/s00277-003-0645-x; Eisenberg R, 2003, ARTHRITIS RES THER, V5, P157, DOI 10.1186/ar759; ESDAILE JM, 1994, SPRINGER SEMIN IMMUN, V16, P337; Euler HH, 1997, J RHEUMATOL, V24, P2153; Goldblatt F, 2005, CLIN EXP IMMUNOL, V140, P205, DOI 10.1111/j.1365-2249.2005.02795.x; Gottenberg JE, 2001, ARTHRITIS RHEUM, V44, P2458, DOI 10.1002/1529-0131(200110)44:10<2458::AID-ART420>3.0.CO;2-B; IKEHARA S, 1985, P NATL ACAD SCI USA, V82, P2483, DOI 10.1073/pnas.82.8.2483; Jayne D, 2004, LUPUS, V13, P168, DOI 10.1191/0961203304lu525oa; Kang I, 2003, CURR OPIN RHEUMATOL, V15, P528, DOI 10.1097/00002281-200309000-00002; Leandro MJ, 2002, ARTHRITIS RHEUM-US, V46, P2673, DOI 10.1002/art.10541; Liang MH, 2004, ARTHRITIS RHEUM-US, V50, P3418, DOI 10.1002/art.20628; Loberiza FR, 2005, BLOOD, V105, P2979, DOI 10.1182/blood-2004-10-3863; Marmont AM, 1998, HAEMATOLOGICA, V83, P733; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; Salzberger B, 1997, BLOOD, V90, P2502; Snowden JA, 1997, BRIT J HAEMATOL, V99, P9, DOI 10.1046/j.1365-2141.1997.3273144.x; Statkute L, 2005, BLOOD, V106, P2700, DOI 10.1182/blood-2005-01-0330; Takada K, 2001, LUPUS, V10, P154, DOI 10.1191/096120301671376017; Traynor AE, 2000, LANCET, V356, P701, DOI 10.1016/S0140-6736(00)02627-1; Traynor AE, 2002, ARTHRITIS RHEUM, V46, P2917, DOI 10.1002/art.10594; Willis F, 2001, BRIT J HAEMATOL, V114, P891, DOI 10.1046/j.1365-2141.2001.03039.x; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; Young N, 1984, Prog Clin Biol Res, V148, P221; Zavala F, 1999, J IMMUNOL, V163, P5125	35	205	228	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					527	535		10.1001/jama.295.5.527	http://dx.doi.org/10.1001/jama.295.5.527			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007SP	16449618				2022-12-28	WOS:000234990300020
J	Ghosh, P; Garzione, CN; Eiler, JM				Ghosh, P; Garzione, CN; Eiler, JM			Rapid uplift of the Altiplano revealed through C-13-O-18 bonds in paleosol carbonates	SCIENCE			English	Article							ISOTOPIC COMPOSITION; ROCKY-MOUNTAINS; NORTHERN CHILE; CENTRAL ANDES; LATE MIOCENE; ALTITUDE; CLIMATE; OXYGEN; PALEOALTIMETRY; HIMALAYA	The elevation of Earth's surface is among the most difficuit environmental variables to reconstruct from the geological record. Here we describe an approach to paleoaltimetry based on independent and simultaneous determinations of soil temperatures and the oxygen isotope compositions of soil waters, constrained by measurements of abundances of C-13-O-18 bonds in soil carbonates. We use this approach to show that the Altiplano plateau in the Bolivian Andes rose at an average rate of 1.03 +/- 0.12 millimeters per year between similar to 10.3 and similar to 6.7 million years ago. This rate is consistent with the removal of dense lower crust and/or lithospheric mantle as the cause of elevation gain.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA	California Institute of Technology; University of Rochester	Ghosh, P (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.			Ghosh, Prosenjit/0000-0001-7828-577X				AFFECK H, IN PRESS GEOCHIM COS; ALPERS CN, 1988, GEOL SOC AM BULL, V100, P1640, DOI 10.1130/0016-7606(1988)100<1640:MMCCIT>2.3.CO;2; BIRD P, 1978, J GEOPHYS RES, V83, P4975, DOI 10.1029/JB083iB10p04975; Cerling T., 1993, AM GEOPHYS UNION GEO, V78, P217; Chamberlain CP, 1999, CHEM GEOL, V155, P279, DOI 10.1016/S0009-2541(98)00165-X; Dettman DL, 2000, GEOLOGY, V28, P243, DOI 10.1130/0091-7613(2000)028<0243:OIEFHA>2.3.CO;2; DRUMMOND CN, 1993, PALAEOGEOGR PALAEOCL, V101, P67, DOI 10.1016/0031-0182(93)90152-9; Echavarria L, 2003, AAPG BULL, V87, P965, DOI 10.1306/01200300196; Eiler JM, 2004, GEOCHIM COSMOCHIM AC, V68, P4767, DOI 10.1016/j.gca.2004.05.035; ENGLAND P, 1989, J GEOPHYS RES-SOLID, V94, P17561, DOI 10.1029/JB094iB12p17561; Forest CE, 1999, GEOL SOC AM BULL, V111, P497, DOI 10.1130/0016-7606(1999)111<0497:PIAPAB>2.3.CO;2; Garreaud R, 2003, PALAEOGEOGR PALAEOCL, V194, P5, DOI 10.1016/S0031-0182(03)00269-4; Garzione CN, 2000, EARTH PLANET SC LETT, V183, P215, DOI 10.1016/S0012-821X(00)00252-1; Garzione CN, 2006, EARTH PLANET SC LETT, V241, P543, DOI 10.1016/j.epsl.2005.11.026; Gat J.R., 2001, INT HYDROLOGICAL PRO; GHOSH P, IN PRESS GEOCHIM COS; Gonfiantini R, 2001, CHEM GEOL, V181, P147, DOI 10.1016/S0009-2541(01)00279-0; Gosse JC, 2001, QUATERNARY SCI REV, V20, P1475, DOI 10.1016/S0277-3791(00)00171-2; GREGORY KM, 1992, GEOLOGY, V20, P581, DOI 10.1130/0091-7613(1992)020<0581:TSOPEC>2.3.CO;2; Gregory-Wodzicki KM, 1998, J S AM EARTH SCI, V11, P533, DOI 10.1016/S0895-9811(98)00031-5; Gregory-Wodzicki KM, 2000, GEOL SOC AM BULL, V112, P1091, DOI 10.1130/0016-7606(2000)112<1091:UHOTCA>2.0.CO;2; Hoke GD, 2004, GEOLOGY, V32, P605, DOI 10.1130/G20601.1; Horton BK, 1999, TECTONICS, V18, P1292, DOI 10.1029/1999TC900051; KAY RW, 1991, GEOL RUNDSCH, V80, P259, DOI 10.1007/BF01829365; Kim ST, 1997, GEOCHIM COSMOCHIM AC, V61, P3461, DOI 10.1016/S0016-7037(97)00169-5; Lamb S, 1997, TECTONICS, V16, P623, DOI 10.1029/97TC00495; Liu BL, 1996, PALAEOGEOGR PALAEOCL, V124, P233, DOI 10.1016/0031-0182(95)00093-3; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; McElwain JC, 2004, GEOLOGY, V32, P1017, DOI 10.1130/G20915.1; Poage MA, 2001, AM J SCI, V301, P1, DOI 10.2475/ajs.301.1.1; Rowley DB, 2001, EARTH PLANET SC LETT, V188, P253, DOI 10.1016/S0012-821X(01)00324-7; Sahagian DL, 2002, J GEOL, V110, P671, DOI 10.1086/342627; SAVIN SM, 1975, GEOL SOC AM BULL, V86, P1499, DOI 10.1130/0016-7606(1975)86<1499:TMP>2.0.CO;2; Smith A. G., 1981, PHANEROZOIC PALEOCON; SWART PK, 1991, CHEM GEOL, V86, P89, DOI 10.1016/0168-9622(91)90055-2; Wang ZG, 2004, GEOCHIM COSMOCHIM AC, V68, P4779, DOI 10.1016/j.gca.2004.05.039; WOLFE JA, 1995, ANNU REV EARTH PL SC, V23, P119, DOI 10.1146/annurev.earth.23.1.119; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	38	303	321	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2006	311	5760					511	515		10.1126/science.1119365	http://dx.doi.org/10.1126/science.1119365			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439658				2022-12-28	WOS:000235071400043
J	Poage, MA; Chamberlain, CP				Poage, MA; Chamberlain, CP			Rising mountain ranges	SCIENCE			English	Editorial Material							PALEOELEVATION; MIOCENE		Indiana Univ Penn, Dept Geosci, Indiana, PA 15705 USA; Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA	Pennsylvania State System of Higher Education (PASSHE); Indiana University of Pennsylvania; Stanford University	Poage, MA (corresponding author), Indiana Univ Penn, Dept Geosci, Indiana, PA 15705 USA.	mpoage@iup.edu; chamb@pangea.stanford.edu						Chamberlain CP, 1999, CHEM GEOL, V155, P279, DOI 10.1016/S0009-2541(98)00165-X; Fricke HC, 2003, GEOL SOC AM BULL, V115, P1088, DOI 10.1130/B25249.1; Garzione CN, 2000, GEOLOGY, V28, P339, DOI 10.1130/0091-7613(2000)28<339:HTOTTP>2.0.CO;2; Ghosh P, 2006, SCIENCE, V311, P511, DOI 10.1126/science.1119365; GHOSH P, IN PRESS GEOCHIM COS; Mulch A, 2004, GEOLOGY, V32, P525, DOI 10.1130/G20394.1; Rowley DB, 2001, EARTH PLANET SC LETT, V188, P253, DOI 10.1016/S0012-821X(01)00324-7; SAHAGIAN DL, 1994, NATURE, V372, P449, DOI 10.1038/372449a0; Wolfe JA, 1997, SCIENCE, V276, P1672, DOI 10.1126/science.276.5319.1672	9	7	8	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					478	479		10.1126/science.1123215	http://dx.doi.org/10.1126/science.1123215			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439651				2022-12-28	WOS:000235071400033
J	Henry, CR; Satran, D; Lindgren, B; Adkinson, C; Nicholson, CI; Henry, TD				Henry, CR; Satran, D; Lindgren, B; Adkinson, C; Nicholson, CI; Henry, TD			Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC TROPONIN-T; STAGE RENAL-DISEASE; HYPERBARIC-OXYGEN; PROGNOSTIC VALUE; VITAL STATUS; INTOXICATION; SEQUELAE; ISCHEMIA; SURVIVAL; RISK	Context Carbon monoxide (CO) poisoning is a common cause of toxicological morbidity and mortality. Myocardial injury is a frequent consequence of moderate to severe CO poisoning. While the in-hospital mortality for these patients is low, the long-term outcome of myocardial injury in this setting is unknown. Objective To determine the association between myocardial injury and long-term mortality in patients following moderate to severe CO poisoning. Design, Setting, and Participants Prospective cohort study of 230 consecutive adult patients treated for moderate to severe CO poisoning with hyperbaric oxygen and admitted to the Hennepin County Medical Center, a regional center for treatment of CO poisoning, between January 1, 1994, and January 1, 2002. Follow-up was through November 11, 2005. Main Outcome Measure All-cause mortality. Results Myocardial injury (cardiac troponin I level >= 0.7 ng/mL or creatine kinase-MB level >= 5.0 ng/mL and/or diagnostic electrocardiogram changes) occurred in 85 (37%) of 230 patients. At a median follow-up of 7.6 years (range: in-hospital only to 11.8 years), there were 54 deaths (24%). Twelve of those deaths (5%) occurred in the hospital as a result of a combination of burn injury and anoxic brain injury (n=8) or cardiac arrest and anoxic brain injury (n=4). Among the 85 patients who sustained myocardial injury from CO poisoning, 32 (38%) eventually died compared with 22 (15%) of 145 patients who did not sustain myocardial injury (adjusted hazard ratio, 2.1; 95% confidence interval, 1.2-3.7; P=.009). Conclusion Myocardial injury occurs frequently in patients hospitalized for moderate to severe CO poisoning and is a significant predictor of mortality.	Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA; Hennepin Cty Med Ctr, Dept Internal Med, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Minneapolis Heart Institute Foundation; Hennepin County Medical Center; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Medical College of Wisconsin	Henry, TD (corresponding author), Minneapolis Heart Inst Fdn, 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.	henry003@umn.edu		/0000-0003-4011-3758				Alonso JR, 2003, PHARMACOL TOXICOL, V93, P142, DOI 10.1034/j.1600-0773.2003.930306.x; Annane D, 2001, INTENS CARE MED, V27, P1776, DOI 10.1007/s00134-001-1127-z; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 2002, CIRCULATION, V106, P2941, DOI 10.1161/01.CIR.0000041254.30637.34; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; BRUNO A, 1993, ACTA NEUROL SCAND, V87, P205; *CDCP, WONDER COMPR MORT DA; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; Deschamps D, 2003, OCCUP ENVIRON MED, V60, P212, DOI 10.1136/oem.60.3.212; Dierkes J, 2000, CIRCULATION, V102, P1964, DOI 10.1161/01.CIR.102.16.1964; Ernst A, 1998, NEW ENGL J MED, V339, P1603, DOI 10.1056/NEJM199811263392206; Giannitsis E, 2000, CIRCULATION, V102, P211, DOI 10.1161/01.CIR.102.2.211; GORMAN DF, 1992, ANAESTH INTENS CARE, V20, P311, DOI 10.1177/0310057X9202000306; Hsiao Cheng-Lung, 2004, Acta Neurol Taiwan, V13, P64; James P, 2000, BRIT MED J, V320, P1502, DOI 10.1136/bmj.320.7248.1502; Khan NA, 2005, CIRCULATION, V112, P3088, DOI 10.1161/CIRCULATIONAHA.105.560128; Landesberg G, 2003, J AM COLL CARDIOL, V42, P1547, DOI 10.1016/j.jacc.2003.05.001; Landesberg G, 2005, CRIT CARE MED, V33, P1281, DOI 10.1097/01.CCM.0000166607.22550.87; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; MIN SK, 1986, ACTA PSYCHIAT SCAND, V73, P80, DOI 10.1111/j.1600-0447.1986.tb02671.x; Mott JA, 2002, JAMA-J AM MED ASSOC, V288, P988, DOI 10.1001/jama.288.8.988; Newman TB, 1997, J AM MED INFORM ASSN, V4, P233, DOI 10.1136/jamia.1997.0040233; Parkinson RB, 2002, NEUROLOGY, V58, P1525, DOI 10.1212/WNL.58.10.1525; Pavese N, 1999, ITAL J NEUROL SCI, V20, P171, DOI 10.1007/s100720050028; Raskin N, 1940, J NERV MENT DIS, V92, P640, DOI 10.1097/00005053-194011000-00008; Roohi F, 2001, CLIN NEUROL NEUROSUR, V103, P92, DOI 10.1016/S0303-8467(01)00119-6; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Satran D, 2005, J AM COLL CARDIOL, V45, P1513, DOI 10.1016/j.jacc.2005.01.044; SAWADA Y, 1980, LANCET, V1, P783; Shillito FH, 1936, J AMER MED ASSOC, V106, P669; SMITH JS, 1973, BRIT MED J, V1, P318, DOI 10.1136/bmj.1.5849.318; SMITH JS, 1970, POSTGRAD MED J, V46, P65, DOI 10.1136/pgmj.46.532.65; Spies C, 1998, CHEST, V113, P1055, DOI 10.1378/chest.113.4.1055; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; VIEREGGE P, 1989, J NEUROL, V236, P478, DOI 10.1007/BF00328511; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Weaver LK, 1999, CRIT CARE CLIN, V15, P297, DOI 10.1016/S0749-0704(05)70056-7; World Health Organisation, 1977, INT CLASS DIS 9 REV; World Health Organization, 1992, INT STAT CLASS DIS 1	40	202	212	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					398	402		10.1001/jama.295.4.398	http://dx.doi.org/10.1001/jama.295.4.398			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005QJ	16434630	Bronze			2022-12-28	WOS:000234838600020
J	Baron, R; Wasner, G				Baron, R; Wasner, G			Prevent on and treatment of postherpetic neuralgia	LANCET			English	Editorial Material							HERPES-ZOSTER; DOUBLE-BLIND; PAIN; AMITRIPTYLINE; GABAPENTIN; VARICELLA		Univ Klinikum Schleswig Holstein, Dept Neurol, Div Neurol Pain Res & Therapy, D-24105 Kiel, Germany; Univ New S Wales, Prince Wales Med Res Inst, Sydney, NSW, Australia	University of Kiel; Schleswig Holstein University Hospital; Prince Wales Medical Research Institute; University of New South Wales Sydney	Baron, R (corresponding author), Univ Klinikum Schleswig Holstein, Dept Neurol, Div Neurol Pain Res & Therapy, D-24105 Kiel, Germany.	r.baron@neurologie.uni-kiel.de	Baron, Ralf/E-4298-2010					BARON R, IN PRESS NAT CLIN PR; Bowsher D, 1997, J PAIN SYMPTOM MANAG, V13, P327, DOI 10.1016/S0885-3924(97)00077-8; Edmunds WJ, 2002, J INFECTION, V44, P211, DOI 10.1053/jinf.2002.0988; Fields HL, 1998, NEUROBIOL DIS, V5, P209, DOI 10.1006/nbdi.1998.0204; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580; Hempenstall K, 2005, PLOS MED, V2, P628, DOI 10.1371/journal.pmed.0020164; Jung BF, 2004, NEUROLOGY, V62, P1545, DOI 10.1212/01.WNL.0000123261.00004.29; Kotani N, 2000, NEW ENGL J MED, V343, P1514, DOI 10.1056/NEJM200011233432102; Kuraishi Y, 2004, LIFE SCI, V74, P2619, DOI 10.1016/j.lfs.2004.01.005; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Thomas SL, 2002, LANCET, V360, P678, DOI 10.1016/S0140-6736(02)09837-9; van Wijck AJM, 2006, LANCET, V367, P219, DOI 10.1016/S0140-6736(06)68032-X; Wasner G, 2005, J NEUROL, V252, P677, DOI 10.1007/s00415-005-0717-z; Wassilew SW, 2005, J EUR ACAD DERMATOL, V19, P47, DOI 10.1111/j.1468-3083.2004.01119.x	15	35	40	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					186	188		10.1016/S0140-6736(06)68010-0	http://dx.doi.org/10.1016/S0140-6736(06)68010-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427472				2022-12-28	WOS:000234810600005
J	Dehaene, S; Izard, V; Pica, P; Spelke, E				Dehaene, S; Izard, V; Pica, P; Spelke, E			Core knowledge of geometry in an Amazonian indigene group	SCIENCE			English	Article							LANGUAGE	Does geometry constitute a core set of intuitions present in all humans, regardless of their language or schooling? We used two nonverbal tests to probe the conceptual primitives of geometry in the Munduruku, an isolated Amazonian indigene group. Munduruku children and adults spontaneously made use of basic geometric concepts such as points, tines, parallelism, or right angles to detect intruders in simple pictures, and they used distance, angle, and sense relationships in geometrical maps to locate hidden objects. Our results provide evidence for geometrical intuitions in the absence of schooling, experience with graphic symbols or maps, or a rich language of geometrical terms.	Commissariat Energie Atom, Serv Hosp Frederic Joliot, INSERM CEA Cognit Neuroimaging Unit, F-91401 Orsay, France; Coll France, F-75231 Paris 05, France; CNRS, Unite Mixte Rech Formal Struct & Language 7023, Paris, France; Univ Paris 08, Paris, France; Harvard Univ, Dept Psychol, Cambridge, MA 02139 USA	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Universite Paris-VIII; Harvard University	Dehaene, S (corresponding author), Commissariat Energie Atom, Serv Hosp Frederic Joliot, INSERM CEA Cognit Neuroimaging Unit, F-91401 Orsay, France.	dehaene@shfj.cea.fr	Pica, Pierre/H-9523-2012; Pica, Pierre/N-1342-2019	Pica, Pierre/0000-0001-9452-5446; Pica, Pierre/0000-0001-9452-5446				Berthoz A., 2000, BRAINS SENSE MOVEMEN; Boi L., 1995, PROBLEME MATH ESPACE; CHENG K, 1990, PSYCHON B REV, V12, P1; Dehaene S., 1997, NUMBER SENSE; DELOACHE JS, 1987, SCIENCE, V238, P1556, DOI 10.1126/science.2446392; EUCLID, 2002, ELEMENTS; FRANCO L, 1977, NEUROPSYCHOLOGIA, V15, P107, DOI 10.1016/0028-3932(77)90120-8; Gallistel C. R., 1990, ORG LEARNING; Hermer L, 1996, COGNITION, V61, P195, DOI 10.1016/S0010-0277(96)00714-7; Hespos SJ, 2004, NATURE, V430, P453, DOI 10.1038/nature02634; Kant I., 1920, CRITIQUE PURE REASON; Keller O., 2004, ORIGINES GEOMETRIE P; Lawson R.W, 1952, RELATIVITY SPECIAL G; Levinson S, 2003, LANGUAGE, V79, P485, DOI 10.1353/lan.2003.0174; Levinson S. C., 2003, SPACE LANGUAGE COGNI; Li P, 2002, COGNITION, V83, P265, DOI 10.1016/S0010-0277(02)00009-4; Majid A, 2004, TRENDS COGN SCI, V8, P108, DOI 10.1016/j.tics.2004.01.003; MARZOLF DP, 1994, CHILD DEV, V65, P1; Newcombe N., 2000, MAKING SPACE; Piaget J., 1960, CHILDS CONCEPTION GE; Pica P, 2004, SCIENCE, V306, P499, DOI 10.1126/science.1102085; Poincare H, 1902, SCI HYPOTHESE; RIEMANN B, 1873, NATURE, V8, P183; Shepard RN, 2001, BEHAV BRAIN SCI, V24, P581, DOI 10.1017/S0140525X01000012	24	190	196	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2006	311	5759					381	384		10.1126/science.1121739	http://dx.doi.org/10.1126/science.1121739			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	007AE	16424341	Green Submitted			2022-12-28	WOS:000234938500045
J	Forget, F; Haberle, RM; Montmessin, F; Levrard, B; Heads, JW				Forget, F; Haberle, RM; Montmessin, F; Levrard, B; Heads, JW			Formation of glaciers on Mars by atmospheric precipitation at high obliquity	SCIENCE			English	Article							DEBRIS APRONS; ICE; CIRCULATION; LATITUDES; DEPOSITS; GULLIES; SURFACE; FLOWS; SNOW	Surface conditions on Mars are currently cold and dry, with water ice unstable on the surface except near the poles. However, geologically recent glacierlike landforms have been identified in the tropics and the midlatitudes of Mars. The ice has been proposed to originate from either a subsurface reservoir or the atmosphere. We present high-resolution climate simulations performed with a model designed to simulate the present-day Mars water cycle but assuming a 45 degrees obliquity as experienced by Mars a few million years ago. The model predicts ice accumulation in regions where glacier landforms are observed, on the western flanks of the great volcanoes and in the eastern Hellas region. This agreement points to an atmospheric origin for the ice and reveals how precipitation could have formed glaciers on Mars.	Univ Paris 06, Inst Pierre Simon Laplace, Meteorol Dynam Lab, F-75252 Paris 05, France; NASA, Div Space Sci, Ames Res Ctr, Moffett Field, CA 94035 USA; Univ Paris 06, Inst Pierre Simon Laplace, Serv Aeron, F-75252 Paris 05, France; Inst Mecan Celeste, F-75014 Paris, France; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Brown University	Forget, F (corresponding author), Univ Paris 06, Inst Pierre Simon Laplace, Meteorol Dynam Lab, Boite Postale 99, F-75252 Paris 05, France.	forget@lmd.jussieu.fr		Montmessin, Franck/0000-0002-4187-1457				Christensen PR, 2003, NATURE, V422, P45, DOI 10.1038/nature01436; Clancy R. T., 2003, Journal of Geophysical Research, V108, P2, DOI 10.1029/2003JE002058; Costard F, 2002, SCIENCE, V295, P110, DOI 10.1126/science.1064419; Forget F, 1999, J GEOPHYS RES-PLANET, V104, P24155, DOI 10.1029/1999JE001025; Haberle RA, 2003, ICARUS, V161, P66, DOI 10.1016/S0019-1035(02)00017-9; Hartmann WK, 2003, ICARUS, V162, P259, DOI 10.1016/S0019-1035(02)00065-9; Hauber E, 2005, NATURE, V434, P356, DOI 10.1038/nature03423; Head JW, 2005, NATURE, V434, P346, DOI 10.1038/nature03359; Head JW, 2003, GEOLOGY, V31, P641, DOI 10.1130/0091-7613(2003)031<0641:CMGOMW>2.0.CO;2; JAKOSKY BM, 1985, NATURE, V315, P559, DOI 10.1038/315559a0; Laskar J, 2004, ICARUS, V170, P343, DOI 10.1016/j.icarus.2004.04.005; Levrard B, 2004, NATURE, V431, P1072, DOI 10.1038/nature03055; LUCCHITTA BK, 1981, ICARUS, V45, P264, DOI 10.1016/0019-1035(81)90035-X; LUCCHITTA BK, 1984, J GEOPHYS RES S, V89, P409, DOI DOI 10.1029/JB089IS02P0B409; Mangold N, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001885; MILKOVICH SM, IN PRESS ICARUS; Mischna MA, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002051; Montmessin F, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2004JE002284; MONTMESSIN F, 2004, P LUNAR PLANET SCI C, V35, P1312; Neukum G, 2004, NATURE, V432, P971, DOI 10.1038/nature03231; Newman CE, 2005, ICARUS, V174, P135, DOI 10.1016/j.icarus.2004.10.023; Pierce TL, 2003, ICARUS, V163, P46, DOI 10.1016/S0019-1035(03)00046-0; Richardson MI, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001536; Shean DE, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2004JE002360; SQUYRES SW, 1979, J GEOPHYS RES, V84, P8087, DOI 10.1029/JB084iB14p08087; Thomas P., 1992, MARS, P767	26	314	315	5	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					368	371		10.1126/science.1120335	http://dx.doi.org/10.1126/science.1120335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424337				2022-12-28	WOS:000234938500041
J	Zhang, JF; Kaasik, K; Blackburn, MR; Lee, CC				Zhang, JF; Kaasik, K; Blackburn, MR; Lee, CC			Constant darkness is a circadian metabolic signal in mammals	NATURE			English	Article							RAT; HIBERNATION; 5'-NUCLEOTIDASE; 5-NUCLEOTIDASE; ADENOSINE; TISSUES; TORPOR; ACID	Environmental light is the 'zeitgeber' (time-giver) of circadian behaviour(1). Constant darkness is considered a 'free-running' circadian state. Mammals encounter constant darkness during hibernation(2). Ablation of the master clock synchronizer, the suprachiasmatic nucleus, abolishes torpor, a hibernation-like state, implicating the circadian clock in this phenomenon(2,3). Here we report a mechanism by which constant darkness regulates the gene expression of fat catabolic enzymes in mice. Genes for murine procolipase (mClps) and pancreatic lipase-related protein 2 (mPlrp2) are activated in a circadian manner in peripheral organs during 12 h dark: 12 h dark (DD) but not light-dark (LD) cycles. This mechanism is deregulated in circadian-deficient mPer1(-/-)/mPer2(m/m) mice. We identified circadian-regulated 5'-AMP, which is elevated in the blood of DD mice, as a key mediator of this response. Synthetic 5'-AMP induced torpor and mClps expression in LD animals. Torpor induced by metabolic stress was associated with elevated 5'-AMP levels in DD mice. Levels of glucose and non-esterified fatty acid in the blood are reversed in DD and LD mice. Induction of mClps expression by 5'-AMP in LD mice was reciprocally linked to blood glucose levels. Our findings uncover a circadian metabolic rhythm in mammals.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Tartu, Inst Mol & Cell Biol, Dept Biotechnol, EE-51010 Tartu, Estonia	University of Texas System; University of Texas Health Science Center Houston; University of Tartu	Lee, CC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	cheng.c.lee@uth.tmc.edu		Blackburn, Michael/0000-0002-1394-9966				AHLERSOVA E, 1982, PHYSIOL BOHEMOSLOV, V31, P57; Alila-Johansson A, 2004, COMP BIOCHEM PHYS A, V138, P119, DOI 10.1016/j.cbpb.2004.02.021; ARCH JRS, 1978, BIOCHEM J, V174, P965, DOI 10.1042/bj1740965; ASCHOFF J, 1960, COLD SPRING HARB SYM, V25, P11, DOI 10.1101/SQB.1960.025.01.004; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; D'Agostino D, 2002, J BIOL CHEM, V277, P7170, DOI 10.1074/jbc.M108328200; ERLANSONALBERTSSON C, 1988, REGUL PEPTIDES, V22, P325, DOI 10.1016/0167-0115(88)90109-7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GarciaFuentes L, 1996, J BIOL CHEM, V271, P27569, DOI 10.1074/jbc.271.44.27569; Gavrilova O, 1999, P NATL ACAD SCI USA, V96, P14623, DOI 10.1073/pnas.96.25.14623; Heldmaier G, 2004, RESP PHYSIOL NEUROBI, V141, P317, DOI 10.1016/j.resp.2004.03.014; Heller HC, 2004, ANNU REV PHYSIOL, V66, P275, DOI 10.1146/annurev.physiol.66.032102.115313; Kaasik K, 2004, NATURE, V430, P467, DOI 10.1038/nature02724; Kaushik VK, 2001, AM J PHYSIOL-ENDOC M, V281, pE335, DOI 10.1152/ajpendo.2001.281.2.E335; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; LeBlanc PJ, 2001, J COMP PHYSIOL B, V171, P327, DOI 10.1007/s003600100180; Lehninger A.L., 1977, BIOCH MOL BASIS CELL, P623; Lindsley JE, 2004, COMP BIOCHEM PHYS B, V139, P543, DOI 10.1016/j.cbpc.2004.06.014; Lowe ME, 1997, J NUTR, V127, P549, DOI 10.1093/jn/127.4.549; Lowe ME, 1998, METHODS MOL BIOL LIP, P59; OGATA S, 1990, BIOCHEMISTRY-US, V29, P7923, DOI 10.1021/bi00486a021; Overton JM, 2004, PHYSIOL BEHAV, V81, P749, DOI 10.1016/j.physbeh.2004.04.025; Ruby NF, 1996, P NATL ACAD SCI USA, V93, P9864, DOI 10.1073/pnas.93.18.9864; STOYNEV A G, 1983, Acta Physiologica et Pharmacologica Bulgarica, V9, P58; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; Thorn JA, 1996, GEN PHARMACOL, V27, P613, DOI 10.1016/0306-3623(95)02053-5; VONMAYERSBACH H, 1979, CELL MOL BIOL, V24, P73; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	29	160	170	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					340	343		10.1038/nature04368	http://dx.doi.org/10.1038/nature04368			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421573				2022-12-28	WOS:000234682100046
J	Davey, E; Barratt, A; Irwig, L; Chan, SF; Macaskill, P; Mannes, P; Saville, AM				Davey, E; Barratt, A; Irwig, L; Chan, SF; Macaskill, P; Mannes, P; Saville, AM			Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review	LANCET			English	Article							THIN-LAYER PREPARATIONS; PAP TEST; PAPANICOLAOU SMEARS; FOLLOW-UP; AUTOCYTE PREP; SCREENING POPULATION; DIAGNOSTIC-ACCURACY; PREPARATION DEVICE; CLINICAL-PRACTICE; RANDOMIZED-TRIAL	Background Liquid-based cytology is reported to increase the sensitivity of cervical cytology and the proportion of slides that are satisfactory for assessment, in comparison with conventional cytology. Although some countries have changed to liquid-based cytology for cervical screening, controversy remains. We reviewed the published work to assess the performance of liquid-based cytology relative to conventional cytology in primary studies assessed to be of low, medium, or high methodological quality. Methods 56 primary studies were reviewed and assessed with strict methodological criteria. Liquid-based cytology and conventional cytology were compared in terms of the percentage of slides classified as unsatisfactory, the percentage of slides classified in each cytology category, and the accuracy of detection of high-grade disease. Data were examined for studies overall and in strata to examine the effect of study quality on results. Findings The median difference in the percentage of unsatisfactory slides between liquid-based cytology and conventional cytology was 0.17%. Only one small study was a randomised controlled trial. The classification of high-grade squamous epithelial lesion varied according to study quality (p=0.04), with conventional cytology classifying more slides in this category than did liquid-based cytology in high-quality studies (n=3) only. In medium-quality (n=30) and high-quality studies, liquid-based cytology classified more slides as atypical squamous cells of unknown significance than did conventional cytology when compared with low-quality studies (n=17; p=0.05). Only four studies provided sufficient verified data to allow estimation of sensitivity and specificity and comparison of test accuracy. Interpretation We saw no evidence that liquid-based cytology reduced the proportion of unsatisfactory slides, or detected more high-grade lesions in high-quality studies, than conventional cytology. This review does not lend support to claims of better performance by liquid-based cytology. Large randomised controlled trials are needed.	Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia; Victorian Cytol Serv, Carlton, Vic, Australia	University of Sydney	Davey, E (corresponding author), Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Edward Ford Bldg,A27, Sydney, NSW 2006, Australia.	daveye@health.usyd.edu.au	Barratt, Alexandra/A-7349-2011	Barratt, Alexandra/0000-0002-2561-3319; Macaskill, Petra/0000-0001-5879-6193				Abulafia O, 2003, GYNECOL ONCOL, V90, P137, DOI 10.1016/S0090-8258(03)00176-8; APONTECIPRIANI SL, 1995, ACTA CYTOL, V39, P623; ARBYN M, 2004, 15 INT C CYT CHIL AP; *AUSTR GOV DEP HLT, BOW CANC SCREEN PROG; AWEN C, 1994, DIAGN CYTOPATHOL, V11, P33, DOI 10.1002/dc.2840110109; Baker JJ, 2002, DIAGN CYTOPATHOL, V27, P185, DOI 10.1002/dc.10158; Bergeron C, 2003, ACTA CYTOL, V47, P753, DOI 10.1159/000326601; Bergeron C, 2001, ACTA CYTOL, V45, P519, DOI 10.1159/000327858; Bernstein SJ, 2001, AM J OBSTET GYNECOL, V185, P308, DOI 10.1067/mob.2001.116736; Biscotti CV, 2002, J REPROD MED, V47, P9; Bishop JW, 1998, ACTA CYTOL, V42, P189, DOI 10.1159/000331545; Bishop JW, 1997, ACTA CYTOL, V41, P15, DOI 10.1159/000332299; Bolick DR, 1998, ACTA CYTOL, V42, P209, DOI 10.1159/000331548; Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; BUR M, 1995, ACTA CYTOL, V39, P631; Carpenter AB, 1999, CANCER CYTOPATHOL, V87, P105, DOI 10.1002/(SICI)1097-0142(19990625)87:3<105::AID-CNCR2>3.0.CO;2-Z; Cheung ANY, 2003, CANCER CYTOPATHOL, V99, P331, DOI 10.1002/cncr.11786; Corkill M, 1998, J Low Genit Tract Dis, V2, P12, DOI 10.1097/00128360-199801000-00003; Coste J, 2003, BMJ-BRIT MED J, V326, P733, DOI 10.1136/bmj.326.7392.733; Diaz-Rosario LA, 1999, ARCH PATHOL LAB MED, V123, P817; Dupree WB, 1998, CANCER CYTOPATHOL, V84, P202, DOI 10.1002/(SICI)1097-0142(19980825)84:4<202::AID-CNCR4>3.0.CO;2-O; Egger M, 2001, SYSTEMATIC REV HLTH; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Ferenczy A, 1996, ACTA CYTOL, V40, P1136; Ferris DG, 2000, J FAM PRACTICE, V49, P1005; Franco EL, 2001, CAN MED ASSOC J, V164, P1017; GEYER JW, 1993, DIAGN CYTOPATHOL, V9, P417, DOI 10.1002/dc.2840090409; Guidos BJ, 1999, DIAGN CYTOPATHOL, V20, P70, DOI 10.1002/(SICI)1097-0339(199902)20:2<70::AID-DC5>3.0.CO;2-E; Hatch Kenneth D, 2004, J Low Genit Tract Dis, V8, P308, DOI 10.1097/00128360-200410000-00009; Hessling JJ, 2001, J REPROD MED, V46, P880; Howell LP, 1998, ACTA CYTOL, V42, P171, DOI 10.1159/000331542; Hunink MGM, 2002, RADIOLOGY, V222, P604, DOI 10.1148/radiol.2223010335; HUTCHINSON ML, 1991, AM J CLIN PATHOL, V96, P300, DOI 10.1093/ajcp/96.3.300; HUTCHINSON ML, 1992, ACTA CYTOL, V36, P499; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; Klinkhamer PJJM, 2003, CANCER CYTOPATHOL, V99, P263, DOI 10.1002/cncr.11673; Laverty CR, 1997, ANAL QUANT CYTOL, V19, P239; LAVERTY CRA, 1995, CYTOPATHOLOGY, V6, P140, DOI 10.1111/j.1365-2303.1995.tb00466.x; Lee KR, 1997, OBSTET GYNECOL, V90, P278, DOI 10.1016/S0029-7844(97)00228-7; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Luthra UK, 2002, ACTA CYTOL, V46, P303, DOI 10.1159/000326726; Malle D, 2003, ACTA CYTOL, V47, P129, DOI 10.1159/000326492; Marino JF, 2001, J REPROD MED, V46, P353; McGoogan E, 1996, ACTA CYTOL, V40, P107; Minge L, 2000, J REPROD MED, V45, P179; Monsonego J, 2001, BRIT J CANCER, V84, P360, DOI 10.1054/bjoc.2000.1588; Moseley RP, 2002, CYTOPATHOLOGY, V13, P71, DOI 10.1046/j.1365-2303.2002.00394.x; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; *NAT I CLIN EXC, GUID US LIQ BAS CYT; NOORANI HZ, 2003, LIQUID BASED CYTOLOG; Obwegeser JH, 2001, ACTA CYTOL, V45, P709, DOI 10.1159/000328292; Papillo JL, 1998, ACTA CYTOL, V42, P203, DOI 10.1159/000331547; Park IA, 2001, ACTA CYTOL, V45, P525, DOI 10.1159/000327859; Ring M, 2002, CYTOPATHOLOGY, V13, P152, DOI 10.1046/j.1365-2303.2002.00408.x; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; SHEETS EE, 1995, J GYNECOL TECH, V1, P27; Sherman ME, 1998, MODERN PATHOL, V11, P837; Solomon D, 2003, AM J OBSTET GYNECOL, V188, P1383, DOI 10.1067/mob.2003.457; Sprenger E, 1996, ACTA CYTOL, V40, P81; Stevens MW, 1998, DIAGN CYTOPATHOL, V18, P236, DOI 10.1002/(SICI)1097-0339(199803)18:3<236::AID-DC15>3.0.CO;2-L; Sulik SM, 2001, J FAM PRACTICE, V50, P1040; Takahashi M, 1997, ACTA CYTOL, V41, P1785; Tench W, 2000, J REPROD MED, V45, P912; Tezuka F, 1996, ACTA CYTOL, V40, P513; Vassilakos P, 2000, J REPROD MED, V45, P11; Vassilakos P, 1996, ACTA CYTOL, V40, P496; Walter SD, 1999, J CLIN EPIDEMIOL, V52, P943, DOI 10.1016/S0895-4356(99)00086-4; Wang TY, 1999, J FORMOS MED ASSOC, V98, P500; Weintraub J, 2000, DIAGN CYTOPATHOL, V22, P52, DOI 10.1002/(SICI)1097-0339(200001)22:1<52::AID-DC14>3.0.CO;2-#; Weynand B, 2003, ACTA CYTOL, V47, P149, DOI 10.1159/000326495; Whiting P, 2004, ANN INTERN MED, V140, P189, DOI 10.7326/0003-4819-140-3-200402030-00010; Wilbur DC, 1997, ACTA CYTOL, V41, P24, DOI 10.1159/000332300; WILBUR DC, 1994, AM J CLIN PATHOL, V101, P209, DOI 10.1093/ajcp/101.2.209; Wilbur DC, 1996, DIAGN CYTOPATHOL, V14, P201, DOI 10.1002/(SICI)1097-0339(199604)14:3<201::AID-DC2>3.3.CO;2-2; Yeoh G. P. S., 1999, Hong Kong Medical Journal, V5, P233	75	185	208	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2006	367	9505					122	132		10.1016/S0140-6736(06)67961-0	http://dx.doi.org/10.1016/S0140-6736(06)67961-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413876				2022-12-28	WOS:000234655500027
J	Heneghan, C; Alonso-Coello, P; Garcia-Alamino, JM; Perera, R; Meats, E; Glasziou, P				Heneghan, C; Alonso-Coello, P; Garcia-Alamino, JM; Perera, R; Meats, E; Glasziou, P			Self-monitoring of oral anticoagulation: a systematic review and meta-analysis	LANCET			English	Article							NONRHEUMATIC ATRIAL-FIBRILLATION; RANDOMIZED CONTROLLED-TRIAL; WARFARIN THERAPY; CLINICAL-TRIALS; STROKE PREVENTION; OLDER PATIENTS; DOSE WARFARIN; LOW-INTENSITY; MANAGEMENT; TRANSLATE	Background Near-patient testing has made self-monitoring of anticoagulation with warfarin feasible, and several trials have suggested that such monitoring might be equal to or better than standard monitoring. We did a systematic review and meta-analysis of all randomised controlled trials that assessed the effects of self-monitoring or self-management (self-testing and self-dosage) of anticoagulation compared with standard monitoring. Methods We searched the Cochrane Register of Controlled Trials, MEDLINE, EMBASE to April 2005, and contacted manufacturers and authors of relevant studies. Outcomes analysed were: major haemorrhage, thromboembolic events, death, tests in range, minor haemorrhage, frequency of testing, and feasibility of self-monitoring. Findings We identified 14 randomised trials of self-monitoring: pooled estimates showed significant reductions in thromboembolic events (odds ratio 0.45, 95% Cl 0.30-0.68), all-cause mortality (0.61, 0.38-0.98), and major haemorrhage (0.65, 0.42-0.99). Trials of combined self-monitoring and self-adjusted therapy showed significant reductions in thromboembolic events (0.27, 0.12-0.59) and death (0.37, 0.16-0.85), but not major haemorrhage (0.93, 0.42-2.05). No difference was noted in minor haemorrhage. 11 trials reported improvements in the mean proportion of international normalisation ratios in range. Interpretation Self-management improves the quality of oral anticoagulation. Patients capable of self-monitoring and self-adjusting therapy have fewer thromboembolic events and lower mortality than those who self-monitor alone. However, self-monitoring is not feasible for all patients, and requires identification and education of suitable candidates.	Univ Oxford, Dept Primary Hlth Care, Ctr Evidence Based Med, Oxford OX3 7LF, England; Hosp Sant Pau, Iberoamer Cochrane Ctr, Dept Clin Epidemiol & Publ Hlth, Barcelona, Spain	University of Oxford; Hospital of Santa Creu i Sant Pau	Heneghan, C (corresponding author), Univ Oxford, Dept Primary Hlth Care, Ctr Evidence Based Med, Rosemary Rue Bldg, Oxford OX3 7LF, England.	carl.heneghan@dphpc.ox.ac.uk	Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X; Perera, Rafael/0000-0003-2418-2091				Ansell J, 2005, INT J CARDIOL, V99, P37, DOI 10.1016/j.ijcard.2003.11.008; Ansell JE, 1999, JAMA-J AM MED ASSOC, V281, P182, DOI 10.1001/jama.281.2.182; Ansell JE, 1996, AM HEART J, V132, P1095, DOI 10.1016/S0002-8703(96)90040-X; BERNARDO A, 1992, THROMBOSIS EMBOLISM, P325; Beyth RJ, 2000, ANN INTERN MED, V133, P687, DOI 10.7326/0003-4819-133-9-200011070-00010; Blackshear JL, 1996, LANCET, V348, P633; Buckingham TA, 2002, CLIN CARDIOL, V25, P447, DOI 10.1002/clc.4960251003; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Cromheecke ME, 2000, LANCET, V356, P97, DOI 10.1016/S0140-6736(00)02470-3; Dickersin K, 2002, EVAL HEALTH PROF, V25, P38, DOI 10.1177/0163278702025001004; Douketis J D, 2001, Am J Cardiovasc Drugs, V1, P245, DOI 10.2165/00129784-200101040-00003; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; Fitzmaurice DA, 2001, BRIT MED J, V323, P985, DOI 10.1136/bmj.323.7319.985; Gadisseur APA, 2003, ARCH INTERN MED, V163, P2639, DOI 10.1001/archinte.163.21.2639; Gardiner C, 2005, BRIT J HAEMATOL, V128, P242, DOI 10.1111/j.1365-2141.2004.05300.x; Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HOBBS F, 1996, BRIT MED J, V312, P577; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Horstkotte, 1998, J Thromb Thrombolysis, V5 Suppl 1, P19, DOI 10.1023/A:1013228718768; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Khan TI, 2004, BRIT J HAEMATOL, V126, P557, DOI 10.1111/j.1365-2141.2004.05074.x; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Kortke H, 2001, ANN THORAC SURG, V72, P44, DOI 10.1016/S0003-4975(01)02656-X; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Menendez-Jandula B, 2005, ANN INTERN MED, V142, P1, DOI 10.7326/0003-4819-142-1-200501040-00006; Odegaard Kaja Johannson, 2004, Tidsskr Nor Laegeforen, V124, P2900; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Sawicki PT, 2003, J INTERN MED, V254, P515, DOI 10.1046/j.1365-2796.2003.01215.x; Serra ODM, 2005, MED CLIN-BARCELONA, V124, P321, DOI 10.1157/13072418; Sidhu P, 2001, ANN THORAC SURG, V72, P1523, DOI 10.1016/S0003-4975(01)03049-1; Siebenhofer A, 2004, THROMB HAEMOSTASIS, V91, P225, DOI 10.1160/TH03-09-0598; Sunderji R, 2004, CAN J CARDIOL, V20, P1117; Taborski U, 1999, SEMIN THROMB HEMOST, V25, P43, DOI 10.1055/s-2007-996423; Voller H, 2001, EUR HEART J SUPPL, V3, pQ44, DOI 10.1016/S1520-765X(01)90042-2; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730	42	308	320	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					404	411		10.1016/S0140-6736(06)68139-7	http://dx.doi.org/10.1016/S0140-6736(06)68139-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458764				2022-12-28	WOS:000235139400029
J	Schmitz, D; Wiesing, U				Schmitz, D; Wiesing, U			Ethics - Just a family medical history?	BRITISH MEDICAL JOURNAL			English	Editorial Material							HUNTINGTONS-DISEASE		Univ Tubingen, Inst Eth & Hist Med, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schmitz, D (corresponding author), Univ Tubingen, Inst Eth & Hist Med, D-72076 Tubingen, Germany.	dagmar.schmitz@uni-tuebingen.de						Andorno R, 2004, J MED ETHICS, V30, P435, DOI 10.1136/jme.2002.001578; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P123; *BUND GES SOZ SICH, 2004, DISK SENTW GES GEN U; *BUND SCHW EIDG, 2004, BUND GEN UNT BEIM ME, P5483; Burgermeister J, 2003, BRIT MED J, V327, P827, DOI 10.1136/bmj.327.7419.827-a; *EUR GROUP ETH SCI, 2003, OPINION, V18, P4; Godard B, 2003, EUR J HUM GENET, V11, pS123, DOI 10.1038/sj.ejhg.5201117; *HUM RIGHTS WATCH, 2002, INV EX N KOR PEOPL R, P20; Rothstein MA, 2001, GENET MED, V3, P354, DOI 10.1097/00125817-200109000-00005; TOLMEIN O, 2003, FRANKFURTER ALL 0925; *VERW DARMST, 2004, 47004 I E VERW DARMS, P7; WENT L, 1994, J MED GENET, V31, P555	12	4	4	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					297	299		10.1136/bmj.332.7536.297	http://dx.doi.org/10.1136/bmj.332.7536.297			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455734	Green Published			2022-12-28	WOS:000235259000028
J	Rehmann, H; Das, J; Knipscheer, P; Wittinghofer, A; Bos, JL				Rehmann, H; Das, J; Knipscheer, P; Wittinghofer, A; Bos, JL			Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state	NATURE			English	Article							CAMP-BINDING DOMAINS; REGULATORY SUBUNIT; RAS-GTP; ACTIVATION; RAP1; FAMILY; GEF; SOS	Epac proteins ( exchange proteins directly activated by cAMP) are guanine-nucleotide-exchange factors ( GEFs) for the small GTP-binding proteins Rap1 and Rap2 that are directly regulated by the second messenger cyclic AMP(1,2) and function in the control of diverse cellular processes, including cell adhesion and insulin secretion(3). Here we report the three-dimensional structure of full-length Epac2, a 110-kDa protein that contains an amino-terminal regulatory region with two cyclic-nucleotide-binding domains and a carboxy-terminal catalytic region. The structure was solved in the absence of cAMP and shows the auto-inhibited state of Epac. The regulatory region is positioned with respect to the catalytic region by a rigid, tripartite beta-sheet-like structure we refer to as the 'switchboard' and an ionic interaction we call the 'ionic latch'. As a consequence of this arrangement, the access of Rap to the catalytic site is sterically blocked. Mutational analysis suggests a model for cAMP-induced Epac activation with rigid body movement of the regulatory region, the features of which are universally conserved in cAMP-regulated proteins.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; Netherlands Cancer Institute; Max Planck Society	Bos, JL (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	J.L.Bos@med.uu.nl						Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Canaves JM, 2002, J MOL EVOL, V54, P17, DOI 10.1007/s00239-001-0013-1; Clayton GM, 2004, CELL, V119, P615, DOI 10.1016/j.cell.2004.10.030; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rehmann H, 2003, J BIOL CHEM, V278, P23508, DOI 10.1074/jbc.M301680200; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rehmann H, 2003, J BIOL CHEM, V278, P38548, DOI 10.1074/jbc.M306292200; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922	20	162	164	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					625	628		10.1038/nature04468	http://dx.doi.org/10.1038/nature04468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452984				2022-12-28	WOS:000235033900049
J	Larsson, J; Scadden, D				Larsson, J; Scadden, D			Nervous activity in a stem cell niche	CELL			English	Editorial Material							HEMATOPOIETIC STEM; BONE-MARROW; MOBILIZATION	In this issue of Cell, Katayama et al. (2006) report a new regulatory axis for the mobilization of hematopoietic stem cells that links these cells to the nervous system and bone in an unanticipated way. The new findings suggest that the nervous system, which has the inherent ability to integrate information from throughout the organism, may govern the local relationship between stem cells and their niches.	Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA; Harvard Univ, Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University	Scadden, D (corresponding author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.	scadden.david@mgh.harvard.edu						Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Frenette PS, 2000, BLOOD, V96, P2460, DOI 10.1182/blood.V96.7.2460.h8002460_2460_2468; KATAYAMA Y, 2006, CELL; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Papayannopoulou T, 2004, BLOOD, V103, P1580, DOI 10.1182/blood-2003-05-1595; Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood-2004-01-0272; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	11	19	19	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					253	255		10.1016/j.cell.2006.01.006	http://dx.doi.org/10.1016/j.cell.2006.01.006			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439198	Bronze			2022-12-28	WOS:000235068500011
J	Hirschmann, M				Hirschmann, M			Earth science - A wet mantle conductor?	NATURE			English	Editorial Material							ELECTRICAL-CONDUCTIVITY; TRANSITION-ZONE		Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Hirschmann, M (corresponding author), Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA.	marc.m.hirschmann-1@umn.edu	Hirschmann, marc m/B-9455-2016	Hirschmann, marc m/0000-0003-1213-6645				Bercovici D, 2003, NATURE, V425, P39, DOI 10.1038/nature01918; Huang XG, 2005, NATURE, V434, P746, DOI 10.1038/nature03426; JAMBON A, 1994, REV MINERAL, V30, P479; McCammon C, 2005, SCIENCE, V308, P807, DOI 10.1126/science.1110532; MICHAEL P, 1995, EARTH PLANET SC LETT, V131, P301, DOI 10.1016/0012-821X(95)00023-6; ONEILL HSC, 1993, GEOPH MONOG SERIES, V74, P73; Saal AE, 2002, NATURE, V419, P451, DOI 10.1038/nature01073; Utada H, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016092	8	4	4	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					E3	E3		10.1038/nature04528	http://dx.doi.org/10.1038/nature04528			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437063	Bronze			2022-12-28	WOS:000234859200032
J	Fergusson, DM; Poulton, R; Smith, PF; Boden, JM				Fergusson, DM; Poulton, R; Smith, PF; Boden, JM			Drugs - Cannabis and psychosis	BRITISH MEDICAL JOURNAL			English	Editorial Material							EVOKED DOPAMINE RELEASE; ADULT PSYCHOSIS; YOUNG-PEOPLE; SCHIZOPHRENIA; SYMPTOMS; RISK; DELTA-9-TETRAHYDROCANNABINOL; POPULATION; RATS		Univ Otago, Christchurch Sch Med & Hlth Sci, Christchurch, New Zealand; Univ Otago, Dunedin Sch Med, Dunedin, New Zealand; Univ Otago, Otago Sch Med Sci, Dunedin, New Zealand	University of Otago; University of Otago; University of Otago	Fergusson, DM (corresponding author), Univ Otago, Christchurch Sch Med & Hlth Sci, POB 4345, Christchurch, New Zealand.	david.fergusson@chmeds.ac.nz	Boden, Joe/C-3316-2009	Boden, Joe/0000-0003-1502-1608; Fergusson, David/0000-0002-8117-017X				ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; Arendt M, 2005, BRIT J PSYCHIAT, V187, P510, DOI 10.1192/bjp.187.6.510; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212; Cadogan AK, 1997, J NEUROCHEM, V69, P1131; Caspi A, 2005, BIOL PSYCHIAT, V57, P1117, DOI 10.1016/j.biopsych.2005.01.026; Cheer JF, 2004, J NEUROSCI, V24, P4393, DOI 10.1523/JNEUROSCI.0529-04.2004; D'Souza DC, 2005, BIOL PSYCHIAT, V57, P594, DOI 10.1016/j.biopsych.2004.12.006; D'Souza DC, 2004, NEUROPSYCHOPHARMACOL, V29, P1558, DOI 10.1038/sj.npp.1300496; Degenhardt L, 2003, DRUG ALCOHOL DEPEN, V71, P37, DOI 10.1016/S0376-8716(03)00064-4; Fergusson DM, 2005, ADDICTION, V100, P354, DOI 10.1111/j.1360-0443.2005.01001.x; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Gorriti MA, 1999, EUR J PHARMACOL, V365, P133, DOI 10.1016/S0014-2999(98)00851-6; Hall W, 2003, CANNABIS USE DEPENDE; Henquet C, 2005, BMJ-BRIT MED J, V330, P11, DOI 10.1136/bmj.38267.664086.63; Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030; Kathmann M, 1999, N-S ARCH PHARMACOL, V359, P466, DOI 10.1007/PL00005377; Macleod J, 2004, LANCET, V363, P1579, DOI 10.1016/S0140-6736(04)16200-4; Miller P, 2001, SOC PSYCH PSYCH EPID, V36, P338, DOI 10.1007/s001270170038; Semple DM, 2005, J PSYCHOPHARMACOL, V19, P187, DOI 10.1177/0269881105049040; Steffens M, 2004, BRIT J PHARMACOL, V141, P1193, DOI 10.1038/sj.bjp.0705706; Tamminga CA, 2005, MOL PSYCHIATR, V10, P27, DOI 10.1038/sj.mp.4001563; van Os J, 2002, AM J EPIDEMIOL, V156, P319, DOI 10.1093/aje/kwf043; 2005, ADDICTION, V100, P722	23	118	121	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					172	175		10.1136/bmj.332.7534.172	http://dx.doi.org/10.1136/bmj.332.7534.172			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	006OC	16424500	Green Published			2022-12-28	WOS:000234905800031
J	Lee, YP; Wu, YJ; Lees, RM; Xu, LH; Hougen, JT				Lee, YP; Wu, YJ; Lees, RM; Xu, LH; Hougen, JT			Internal rotation and spin conversion of CH3OH in solid para-hydrogen	SCIENCE			English	Article							HIGH-RESOLUTION SPECTROSCOPY; INFRARED MATRIX-ISOLATION; PARAHYDROGEN; METHANOL; SPECTRA; TORSION; ASSIGNMENTS; CH3-ROCKING; CLUSTERS	The quantum solid para-hydrogen (p-H-2) has recently proven useful in matrix isolation spectroscopy. Spectral lines of compounds embedded in this host are unusually narrow, and several species have been reported to rotate in p-H-2. We found that a p-H-2 matrix inhibits rotation of isolated methanol (CH3OH) but still allows internal rotation about the C-O bond, with splittings of the E/A torsional doublet in internal rotation-coupled vibrational modes that are qualitatively consistent with those for CH3OH in the gaseous phase. This simplified high-resolution spectrum further revealed the slow conversion of nuclear spin symmetry from species E to species A in the host matrix, offering potential insight into nuclear spin conversion in astrophysical sources.	Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 30010, Taiwan; Natl Chiao Tung Univ, Inst Mol Sci, Hsinchu 30010, Taiwan; Acad Sinica, Inst Atom & Mol Sci, Taipei 10617, Taiwan; Natl Tsing Hua Univ, Dept Chem, Hsinchu 30013, Taiwan; Univ New Brunswick, Dept Phys Sci, Ctr Laser Atom & Mol Sci, St John, NB E2L 4L5, Canada; Natl Inst Stand & Technol, Opt Technol Div, Gaithersburg, MD 20899 USA	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Tsing Hua University; University of New Brunswick; National Institute of Standards & Technology (NIST) - USA	Lee, YP (corresponding author), Natl Chiao Tung Univ, Dept Appl Chem, 1001 Ta Hsueh Rd, Hsinchu 30010, Taiwan.	yplee@mail.nctu.edu.tw	Xu, Li-Hong/J-5095-2015; Lee, Yuan-Pern/F-7938-2012	Lee, Yuan-Pern/0000-0001-6418-7378; Lees, Ronald/0000-0002-7937-2856				FRAYER FH, 1968, J CHEM PHYS, V48, P781, DOI 10.1063/1.1668712; HOPKINS HP, 1968, J CHEM PHYS, V48, P2959, DOI 10.1063/1.1669559; KLEINER I, 1991, J MOL SPECTROSC, V147, P155, DOI 10.1016/0022-2852(91)90176-B; Lees RM, 2004, J MOL SPECTROSC, V228, P528, DOI 10.1016/j.jms.2004.06.004; Lees RM, 2000, PHYS REV LETT, V84, P3815, DOI 10.1103/PhysRevLett.84.3815; MOMOSE T, 1995, J CHEM PHYS, V103, P1400, DOI 10.1063/1.469763; Momose T, 1998, B CHEM SOC JPN, V71, P1, DOI 10.1246/bcsj.71.1; Momose T, 1997, J CHEM PHYS, V107, P7707, DOI 10.1063/1.475085; Moruzzi G., 1995, MICROWAVE INFRARED L; OKA T, 1993, ANNU REV PHYS CHEM, V44, P299, DOI 10.1146/annurev.physchem.44.1.299; REDINGTON RL, 1963, J CHEM PHYS, V39, P1276, DOI 10.1063/1.1734427; Tam S, 1999, J CHEM PHYS, V111, P4191, DOI 10.1063/1.479717; Taylor BN, 1994, NIST GUIDELINES EVAL; Temsamani MA, 2003, J MOL SPECTROSC, V218, P220, DOI 10.1016/S0022-2852(02)00087-5; WANG X, UNPUB; Wang XL, 1998, J CHEM PHYS, V109, P10795, DOI 10.1063/1.477777; Wu YJ, 2004, J CHEM PHYS, V120, P1168, DOI 10.1063/1.1639151; Xu LH, 2004, J MOL SPECTROSC, V228, P453, DOI 10.1016/j.jms.2004.05.017; Xu LH, 1997, J MOL SPECTROSC, V185, P158, DOI 10.1006/jmsp.1997.7367; Yoshioka K, 2003, J CHEM PHYS, V119, P4731, DOI 10.1063/1.1595089	20	80	81	3	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2006	311	5759					365	368		10.1126/science.1121300	http://dx.doi.org/10.1126/science.1121300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424336				2022-12-28	WOS:000234938500040
J	Yager, JD; Davidson, NE				Yager, JD; Davidson, NE			Mechanisms of disease: Estrogen carcinogenesis in breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CATECHOL-O-METHYLTRANSFERASE; HORMONE REPLACEMENT THERAPY; OXIDATIVE DNA-DAMAGE; HAMSTER EMBRYO CELLS; RECEPTOR-ALPHA; GENE-EXPRESSION; PLASMA-MEMBRANE; SUBCELLULAR-DISTRIBUTION; MAMMARY CARCINOGENESIS; POSTMENOPAUSAL WOMEN		Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Yager, JD (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Rm 1033,615 N Wolfe St, Baltimore, MD 21205 USA.	jyager@jhsph.edu			NCI NIH HHS [CA88843, CA77550, CA36701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036701, P50CA088843, R01CA077550] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Cammarata PR, 2004, EXP EYE RES, V78, P861, DOI 10.1016/j.exer.2003.09.027; Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75; Cavalieri EL, 2001, CHEM RES TOXICOL, V14, P1041, DOI 10.1021/tx010042g; Chakravarti D, 2001, ONCOGENE, V20, P7945, DOI 10.1038/sj.onc.1204969; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Chen JQ, 2004, ANN NY ACAD SCI, V1028, P258, DOI 10.1196/annals.1322.030; Chen JQ, 2004, J CELL BIOCHEM, V93, P358, DOI 10.1002/jcb.20178; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Collaborative Group on Hormonal Factors in Breast Cancer, 1997, LANCET, V350, P1484; Coombes RC, 2004, NEW ENGL J MED, V351, P2461; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Dawling S, 2003, CANCER RES, V63, P3127; Demonacos CV, 1996, STEROIDS, V61, P226, DOI 10.1016/0039-128X(96)00019-0; Devanesan P, 2001, CARCINOGENESIS, V22, P489, DOI 10.1093/carcin/22.3.489; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Druckmann R, 2003, MATURITAS, V46, pS59, DOI 10.1016/j.maturitas.2003.09.020; Fournier A, 2005, INT J CANCER, V114, P448, DOI 10.1002/ijc.20710; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Gambacciani M, 2003, GYNECOL ENDOCRINOL, V17, P359, DOI 10.1080/09513590312331290248; Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250; Govind AP, 2003, MOL CELL BIOCHEM, V253, P233, DOI 10.1023/A:1026068017309; Harvell DME, 2000, P NATL ACAD SCI USA, V97, P2779, DOI 10.1073/pnas.050569097; Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776; Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559; Hoogenboom LAP, 2001, APMIS, V109, P101, DOI 10.1034/j.1600-0463.2001.d01-110.x; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Hulley SB, 2004, JAMA-J AM MED ASSOC, V291, P1769, DOI 10.1001/jama.291.14.1769; International Agency for Research on Cancer, 1999, IARC SCI PUBL; Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95; Kaaks R, 2005, JNCI-J NATL CANCER I, V97, P755, DOI 10.1093/jnci/dji132; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Key TJ, 2003, J NATL CANCER I, V95, P1218, DOI 10.1093/jnci/djg022; Kong LY, 2000, INT J ONCOL, V17, P1141; Lavigne JA, 1997, CANCER RES, V57, P5493; Lavigne JA, 2001, CANCER RES, V61, P7488; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860; Lewis JS, 2005, J STEROID BIOCHEM, V94, P131, DOI 10.1016/j.jsbmb.2004.12.032; Li KM, 2004, CARCINOGENESIS, V25, P289, DOI 10.1093/carcin/bgg191; Li Y, 2004, CHEM RES TOXICOL, V17, P512, DOI 10.1021/tx0342464; LI YB, 1994, CARCINOGENESIS, V15, P1421, DOI 10.1093/carcin/15.7.1421; Liao JK, 2003, BIOCHEM SOC T, V31, P66, DOI 10.1042/bst0310066; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319; Micheli A, 2004, INT J CANCER, V112, P312, DOI 10.1002/ijc.20403; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336; Mitrunen K, 2003, MUTAT RES-REV MUTAT, V544, P9, DOI 10.1016/S1383-5742(03)00016-4; Miyoshi Y, 2003, BIOMED PHARMACOTHER, V57, P471, DOI 10.1016/j.biopha.2003.09.008; Mobley JA, 1999, CHEM RES TOXICOL, V12, P270, DOI 10.1021/tx980128i; Monje P, 2001, J CELL BIOCHEM, V82, P467, DOI 10.1002/jcb.1182; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Newbold RR, 2000, CANCER RES, V60, P235; NOTEBOOM WD, 1965, ARCH BIOCHEM BIOPHYS, V111, P559, DOI 10.1016/0003-9861(65)90235-3; NUTTER LM, 1994, CHEM RES TOXICOL, V7, P609, DOI 10.1021/tx00041a004; NUTTER LM, 1991, J BIOL CHEM, V266, P16380; NUTTER LM, 1994, CHEM RES TOXICOL, V7, P23, DOI 10.1021/tx00037a004; Olsson H, 2003, MATURITAS, V46, P87, DOI 10.1016/j.maturitas.2003.09.001; Onland-Moret NC, 2003, BRIT J CANCER, V88, P1394, DOI 10.1038/sj.bjc.6600890; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Park SK, 2004, BREAST CANCER RES TR, V88, P55, DOI 10.1007/s10549-004-0745-x; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Philips BJ, 2004, BIOCHEMISTRY-US, V43, P6698, DOI 10.1021/bi036154j; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Samuni AM, 2003, P NATL ACAD SCI USA, V100, P5390, DOI 10.1073/pnas.0930078100; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; SANTEN RJ, 2003, WILLIAMS TXB ENDOCRI, P1797; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schairer C, 2000, JAMA-J AM MED ASSOC, V284, P2597; Schumacher G, 2001, J CANCER RES CLIN, V127, P405, DOI 10.1007/s004320000233; Schumacher G, 1999, CLIN CANCER RES, V5, P493; SCHUTZE N, 1993, J STEROID BIOCHEM, V46, P781, DOI 10.1016/0960-0760(93)90319-R; SCHUTZE N, 1994, J STEROID BIOCHEM, V48, P453, DOI 10.1016/0960-0760(94)90193-7; Seacat AM, 1997, ARCH BIOCHEM BIOPHYS, V347, P45, DOI 10.1006/abbi.1997.0323; Sekeris C E, 1990, In Vivo, V4, P317; Shull JD, 1997, CARCINOGENESIS, V18, P1595, DOI 10.1093/carcin/18.8.1595; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Speroff L, 2003, MATURITAS, V46, P1, DOI 10.1016/j.maturitas.2003.08.001; Stoica GE, 2003, ONCOGENE, V22, P7998, DOI 10.1038/sj.onc.1206769; Tsutsui T, 2000, CARCINOGENESIS, V21, P735, DOI 10.1093/carcin/21.4.735; Tsutsui T, 2000, INT J CANCER, V86, P8, DOI 10.1002/(SICI)1097-0215(20000401)86:1<8::AID-IJC2>3.0.CO;2-V; TSUTSUI T, 1987, CARCINOGENESIS, V8, P1715, DOI 10.1093/carcin/8.11.1715; Turan VK, 2004, J ENDOCRINOL, V183, P91, DOI 10.1677/joe.1.05802; VANLANDEGHEM AAJ, 1985, CANCER RES, V45, P2900; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Williams JA, 2000, CANCER RES, V60, P4667; Yager J D, 2000, J Natl Cancer Inst Monogr, P67; Yager JD, 1996, ANNU REV PHARMACOL, V36, P203, DOI 10.1146/annurev.pa.36.040196.001223; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yang XH, 2003, CANCER RES, V63, P2425; Yao JQ, 2003, CHEM RES TOXICOL, V16, P668, DOI 10.1021/tx0340549; Yao JQ, 2002, CHEM RES TOXICOL, V15, P935, DOI 10.1021/tx020018i; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Yue W, 2003, J STEROID BIOCHEM, V86, P477, DOI 10.1016/S0960-0760(03)00377-7; Zhang WH, 2003, FEBS LETT, V546, P17, DOI 10.1016/S0014-5793(03)00436-8; Zhu BT, 1998, CANCER RES, V58, P2269; 1996, CONTRACEPTION S3, V54, pS1; 2003, LANCET, V362, P1160	118	1276	1321	1	145	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					270	282		10.1056/NEJMra050776	http://dx.doi.org/10.1056/NEJMra050776			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421368				2022-12-28	WOS:000234661100007
J	Ratzka, P; Schlachetzki, JCM; Bahr, M; Nau, R				Ratzka, P; Schlachetzki, JCM; Bahr, M; Nau, R			Varicella zoster virus cerebellitis in a 66-year-old patient without herpes zoster	LANCET			English	Editorial Material									Univ Gottingen, Dept Neurol, D-37099 Gottingen, Germany	University of Gottingen	Ratzka, P (corresponding author), Univ Gottingen, Dept Neurol, Robert Koch Str 40, D-37099 Gottingen, Germany.	peter@ratzka-online.de	Baehr, Mathias/K-2188-2014; Nau, Roland/F-8234-2015	Schlachetzki, Johannes/0000-0002-7801-9743				CONNOLLY AM, 1994, ANN NEUROL, V35, P673, DOI 10.1002/ana.410350607; Gilden DH, 2000, NEW ENGL J MED, V342, P635, DOI 10.1056/NEJM200003023420906; Nau R, 1998, NEUROLOGY, V51, P914, DOI 10.1212/WNL.51.3.914; Osaki Y, 1995, NEUROLOGY, V45, P2293; POWELL KF, 1995, J NEUROL NEUROSUR PS, V59, P198, DOI 10.1136/jnnp.59.2.198	5	25	25	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					182	182		10.1016/S0140-6736(06)67967-1	http://dx.doi.org/10.1016/S0140-6736(06)67967-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413882				2022-12-28	WOS:000234655500033
J	Kelly, DF; Pollard, AJ; Moxon, ER				Kelly, DF; Pollard, AJ; Moxon, ER			Immunological memory - The role of B cells in long-term protection against invasive bacterial pathogens	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLUENZAE TYPE-B; C CONJUGATE VACCINE; ACELLULAR PERTUSSIS; ANTIBODY; HIB; IMMUNIZATION; DISEASE; INFANTS; MARKER; POLYSACCHARIDE	Protein-polysaccharide conjugate vaccines that protect against Haemophilus influenzae type b (Hib), serogroup C Neisseria meningitidis, and multiple capsular serotypes of Streptococcus pneumoniae have had a major impact on invasive bacterial disease in childhood when incorporated into routine infant immunization schedules. However, effectiveness data from the United Kingdom suggest that primary infant immunization alone may not be associated with long-term protection. Both immunological priming and antibody persistence are important aspects of long-term protection induced by these vaccines. An improved understanding of the immunobiology of the B-cell response to these vaccines may direct development of immunization strategies that provide sustained protection.	Univ Oxford, Dept Paediat, Oxford, England	University of Oxford	Kelly, DF (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Paediat, Level 4, Oxford OX3 9DU, England.	dominic.kelly@paediatrics.ox.ac.uk	Kelly, Dominic F/C-5498-2011	Kelly, Dominic/0000-0002-6063-8896				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; Ala'Aldeen DAA, 2000, J CLIN MICROBIOL, V38, P2311; Anderson P, 2000, PEDIATR INFECT DIS J, V19, P589, DOI 10.1097/00006454-200007000-00001; ANDERSON P, 1987, J PEDIATR-US, V111, P644, DOI 10.1016/S0022-3476(87)80237-8; ANDERSON PW, 1986, J IMMUNOL, V137, P1181; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Borrow R, 2001, VACCINE, V19, P3043, DOI 10.1016/S0264-410X(01)00050-0; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; Eskola J, 1999, LANCET, V354, P2063, DOI 10.1016/S0140-6736(99)04377-9; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; Goldblatt D, 1998, J INFECT DIS, V177, P1112, DOI 10.1086/517407; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; Gourley TS, 2004, SEMIN IMMUNOL, V16, P323, DOI 10.1016/j.smim.2004.08.013; Heath PT, 2000, JAMA-J AM MED ASSOC, V284, P2334, DOI 10.1001/jama.284.18.2334; Heath PT, 2003, BMJ-BRIT MED J, V326, P1158, DOI 10.1136/bmj.326.7400.1158; Hougs L, 1999, J IMMUNOL, V162, P224; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Leyendeckers H, 1999, EUR J IMMUNOL, V29, P1406, DOI 10.1002/(SICI)1521-4141(199904)29:04<1406::AID-IMMU1406>3.0.CO;2-P; Lucas AH, 2001, INFECT IMMUN, V69, P853, DOI 10.1128/IAI.69.2.853-864.2001; Lucas AH, 2001, PEDIATR INFECT DIS J, V20, P235, DOI 10.1097/00006454-200103000-00002; MacLennan I C, 1997, Semin Immunol, V9, P229, DOI 10.1006/smim.1997.0078; MacLennan JM, 2000, JAMA-J AM MED ASSOC, V283, P2795, DOI 10.1001/jama.283.21.2795; Makela PH, 2003, VACCINE, V22, P287, DOI 10.1016/S0264-410X(03)00524-3; McVernon J, 2003, LANCET, V361, P1521, DOI 10.1016/S0140-6736(03)13171-6; McVernon J, 2003, ARCH DIS CHILD, V88, P379, DOI 10.1136/adc.88.5.379; Nanan R, 2001, VACCINE, V20, P498, DOI 10.1016/S0264-410X(01)00328-0; Pichichero ME, 1999, J INFECT DIS, V180, P1390, DOI 10.1086/314989; Richmond P, 2001, J INFECT DIS, V183, P160, DOI 10.1086/317646; Tangye SG, 2003, J IMMUNOL, V170, P686, DOI 10.4049/jimmunol.170.2.686; Traggiai E, 2003, VACCINE, V21, pS35, DOI 10.1016/S0264-410X(03)00198-1; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Trotter CL, 2003, LANCET, V361, P1523, DOI 10.1016/S0140-6736(03)13172-8	34	68	76	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					3019	3023		10.1001/jama.294.23.3019	http://dx.doi.org/10.1001/jama.294.23.3019			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414950				2022-12-28	WOS:000234087700029
J	Obenauer, JC; Denson, J; Mehta, PK; Su, XP; Mukatira, S; Finkelstein, DB; Xu, XQ; Wang, JH; Ma, J; Fan, YP; Rakestraw, KM; Webster, RG; Hoffmann, E; Krauss, S; Zheng, J; Zhang, ZW; Naeve, CW				Obenauer, JC; Denson, J; Mehta, PK; Su, XP; Mukatira, S; Finkelstein, DB; Xu, XQ; Wang, JH; Ma, J; Fan, YP; Rakestraw, KM; Webster, RG; Hoffmann, E; Krauss, S; Zheng, J; Zhang, ZW; Naeve, CW			Large-scale sequence analysis of avian influenza isolates	SCIENCE			English	Article							NS1 PROTEIN; PDZ DOMAINS; GENE; VIRUSES; CELLS; RECOGNITION; RESPONSES	The spread of H5N1 avian influenza viruses (AIVs) from China to Europe has raised global concern about their potential to infect humans and cause a pandemic. In spite of their substantial threat to human health, remarkably little AIV whole-genome information is available. We report here a preliminary analysis of the first large-scale sequencing of AIVs, including 2196 AIV genes and 169 complete genomes. We combine this new information with public AIV data to identify new gene alleles, persistent genotypes, compensatory mutations, and a potential virulence determinant.	St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Naeve, CW (corresponding author), St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, 332 N Lauderdale St, Memphis, TN 38105 USA.	clayton.naeve@stjude.org		Zheng, Jie/0000-0001-6524-6800	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061739, R01GM069916] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIAID NIH HHS [AI95357] Funding Source: Medline; NIGMS NIH HHS [R01 GM061739, R01 GM069916] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Enserink M, 2005, SCIENCE, V310, P209, DOI 10.1126/science.310.5746.209; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Geiss GK, 2002, P NATL ACAD SCI USA, V99, P10736, DOI 10.1073/pnas.112338099; Horimoto T, 2005, NAT REV MICROBIOL, V3, P591, DOI 10.1038/nrmicro1208; Kawaoka Y, 1998, VIRUS RES, V55, P143, DOI 10.1016/S0168-1702(98)00038-0; Krug RM, 2003, VIROLOGY, V309, P181, DOI 10.1016/S0042-6822(03)00119-3; Lipatov AS, 2005, J GEN VIROL, V86, P1121, DOI 10.1099/vir.0.80663-0; Liu J, 2005, SCIENCE, V309, P1206, DOI 10.1126/science.1115273; MAHY BWJ, 1983, GENETICS INFLUENZA V, P192; Richterich P, 1998, GENOME RES, V8, P251, DOI 10.1101/gr.8.3.251; Schultz-Cherry S, 2001, J VIROL, V75, P7875, DOI 10.1128/JVI.75.17.7875-7881.2001; Seo SH, 2004, VIRUS RES, V103, P107, DOI 10.1016/j.virusres.2004.02.022; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wuthrich K, 2000, NAT STRUCT BIOL, V7, P188, DOI 10.1038/73278; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	19	474	728	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2006	311	5767					1576	1580		10.1126/science.1121586	http://dx.doi.org/10.1126/science.1121586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BK	16439620				2022-12-28	WOS:000236029500036
J	Sazanov, LA; Hinchliffe, P				Sazanov, LA; Hinchliffe, P			Structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus	SCIENCE			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; BOVINE HEART-MITOCHONDRIA; IRON-SULFUR CLUSTERS; NITRATE REDUCTASE-A; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 49-KDA SUBUNIT; QUINONE OXIDOREDUCTASE; ELECTRON-TRANSFER; AQUIFEX-AEOLICUS	Respiratory complex I plays a central role in cellular energy production in bacteria and mitochondria. Its dysfunction is implicated in many human neurodegenerative diseases, as well as in aging. The crystal structure of the hydrophilic domain ( peripheral arm) of complex I from Thermus thermophilus has been solved at 3.3 angstrom resolution. This subcomplex consists of eight subunits and contains all the redox centers of the enzyme, including nine iron-sulfur clusters. The primary electron acceptor, flavin-mononucleotide, is within electron transfer distance of cluster N3, leading to the main redox pathway, and of the distal cluster N1a, a possible antioxidant. The structure reveals new aspects of the mechanism and evolution of the enzyme. The terminal cluster N2 is coordinated, uniquely, by two consecutive cysteines. The novel subunit Nqo15 has a similar fold to the mitochondrial iron chaperone frataxin, and it may be involved in iron-sulfur cluster regeneration in the complex.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Sazanov, LA (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	sazanov@mrc-dunn.cam.ac.uk	Sazanov, Leonid A/ABF-2125-2021	Sazanov, Leonid A/0000-0002-0977-7989; Hinchliffe, Philip/0000-0001-8611-4743	MRC [MC_U105674180] Funding Source: UKRI; Medical Research Council [MC_U105674180] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Chen YR, 2005, J BIOL CHEM, V280, P37339, DOI 10.1074/jbc.M503936200; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Finel M, 1998, BBA-BIOENERGETICS, V1364, P112, DOI 10.1016/S0005-2728(98)00022-X; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Fritz G, 2002, P NATL ACAD SCI USA, V99, P1836, DOI 10.1073/pnas.042664399; Grgic L, 2004, J BIOL CHEM, V279, P21193, DOI 10.1074/jbc.M313180200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Grivennikova VG, 2003, BBA-BIOENERGETICS, V1607, P79, DOI 10.1016/j.bbabio.2003.09.001; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Hinchliffe P, 2005, SCIENCE, V309, P771, DOI 10.1126/science.1113988; HINCHLIFFE P, UNPUB; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Holt PJ, 2003, J BIOL CHEM, V278, P43114, DOI 10.1074/jbc.M308247200; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; KOTLYAR AB, 1990, FEBS LETT, V264, P17, DOI 10.1016/0014-5793(90)80753-6; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Mamedova AA, 2004, J BIOL CHEM, V279, P23830, DOI 10.1074/jbc.M401539200; MORGAN D, UNPUB; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakamaru-Ogiso E, 2005, J BIOL CHEM, V280, P301, DOI 10.1074/jbc.M410377200; Oh JI, 1998, J BIOL CHEM, V273, P26349, DOI 10.1074/jbc.273.41.26349; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Rothery RA, 2004, BIOCHEMISTRY-US, V43, P5324, DOI 10.1021/bi049938l; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; SLED VD, 1994, BIOCHEMISTRY-US, V33, P10069, DOI 10.1021/bi00199a034; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yano T, 2005, BIOCHEMISTRY-US, V44, P1744, DOI 10.1021/bi048132i; Yano T, 2003, J BIOL CHEM, V278, P15514, DOI 10.1074/jbc.M212275200; Yeh AP, 2000, J MOL BIOL, V300, P587, DOI 10.1006/jmbi.2000.3871; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200	51	619	646	3	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1430	1436		10.1126/science.1123809	http://dx.doi.org/10.1126/science.1123809			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16469879				2022-12-28	WOS:000236029400040
J	Bright, RA; Shay, DK; Shu, B; Cox, NJ; Klimov, AI				Bright, RA; Shay, DK; Shu, B; Cox, NJ; Klimov, AI			Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURAMINIDASE INHIBITORS; H3N2 VIRUSES; AMANTADINE; RIMANTADINE; SUSCEPTIBILITY; PROPHYLAXIS; EMERGENCE	Context The adamantanes, amantadine and rimantadine, have been used as first-choice antiviral drugs against community outbreaks of influenza A viruses for many years. Rates of viruses resistant to these drugs have been increasing globally. Rapid surveillance for the emergence and spread of resistant viruses has become critical for appropriate treatment of patients. Objective To investigate the frequency of adamantane-resistant influenza A viruses circulating in the United States during the initial months of the 2005-2006 influenza season. Design and Setting Influenza isolates collected from 26 states from October 1 through December 31, 2005, and submitted to the US Centers for Disease Control and Prevention were tested for drug resistance as part of ongoing surveillance. Isolates were submitted from World Health Organization collaborating laboratories and National Respiratory and Enteric Virus Surveillance System laboratories. Main Outcome Measures Using pyrosequencing and confirmatory assays, we identified viruses containing mutations within the M2 gene that are known to confer resistance to both amantadine and rimantadine. Results A total of 209 influenza A(H3N2) viruses isolated from patients in 26 states were screened, of which 193 (92.3%) contained a change at amino acid 31 (serine to asparagine [S31N]) in the M2 gene known to be correlated with adamantane resistance. Two of 8 influenza A(H1N1) viruses contained the same mutation. Drug-resistant viruses were distributed across the United States. Conclusions The high proportion of influenza A viruses currently circulating in the United States demonstrating adamantane resistance highlights the clinical importance of rapid surveillance for antiviral resistance. Our results indicate that these drugs should not be used for the treatment or prophylaxis of influenza in the United States until susceptibility to adamantanes has been reestablished among circulating influenza A isolates.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Influenza Branch, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Bright, RA (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Influenza Branch, 1600 Clifton Rd NE,Mailstop G16, Atlanta, GA 30333 USA.			Shay, David/0000-0001-9619-4820				BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; Boivin G, 2002, CLIN INFECT DIS, V34, pE23, DOI 10.1086/338870; Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P44; DEGELAU J, 1992, ARCH INTERN MED, V152, P390, DOI 10.1001/archinte.152.2.390; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; Englund JA, 1998, CLIN INFECT DIS, V26, P1418, DOI 10.1086/516358; FOX JP, 1982, AM J EPIDEMIOL, V116, P228, DOI 10.1093/oxfordjournals.aje.a113408; GLEZEN WP, 1978, NEW ENGL J MED, V298, P587, DOI 10.1056/NEJM197803162981103; HAY AJ, 1986, J ANTIMICROB CHEMOTH, V18, P19, DOI 10.1093/jac/18.Supplement_B.19; HAYDEN FG, 1991, ANTIMICROB AGENTS CH, V35, P1741, DOI 10.1128/AAC.35.9.1741; HAYDEN FG, 1992, CURR TOP MICROBIOL, V176, P119; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; HOUCK P, 1995, ARCH INTERN MED, V155, P533, DOI 10.1001/archinte.155.5.533; Hurt AC, 2004, ANTIVIR RES, V62, P37, DOI 10.1016/j.antiviral.2003.11.008; Hurt Aeron C, 2003, Commun Dis Intell Q Rep, V27, P542; Mungall BA, 2004, VIRUS RES, V103, P195, DOI 10.1016/j.virusres.2004.02.033; OXFORD JS, 1984, VIRAL CHEMOTHERAPY, V1, P169; *PUBL HLTH AG CAN, INT REC US AM INFL; REUMAN PD, 1989, ANTIVIR RES, V11, P27, DOI 10.1016/0166-3542(89)90018-1; Shiraishi K, 2003, J INFECT DIS, V188, P57, DOI 10.1086/375799; SWEET C, 1991, J INFECT DIS, V164, P969, DOI 10.1093/infdis/164.5.969; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Tominack R L, 1987, Infect Dis Clin North Am, V1, P459; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; YOUNKIN SW, 1983, ANTIMICROB AGENTS CH, V23, P577, DOI 10.1128/AAC.23.4.577; Ziegler T, 1999, J INFECT DIS, V180, P935, DOI 10.1086/314994	27	517	581	1	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2006	295	8					891	894		10.1001/jama.295.8.joc60020	http://dx.doi.org/10.1001/jama.295.8.joc60020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	014DO	16456087	Bronze			2022-12-28	WOS:000235459200021
J	Moore, ZS; Seward, JF; Lane, JM				Moore, ZS; Seward, JF; Lane, JM			Smallpox	LANCET			English	Review							VACCINE PROTECTS MICE; REAL-TIME PCR; INTRAFAMILIAL TRANSMISSION; VARIOLA MAJOR; POSTEXPOSURE VACCINATION; LABORATORY DIAGNOSIS; VIRUS-INFECTIONS; DNA; RESPONSES; CIDOFOVIR	The WHO declared smallpox eradicated in 1980. However, concern over its potential use by terrorists or in biowarfare has led to striking growth in research related to this much-feared disease. Modern molecular techniques and new animal models are advancing our understanding of smallpox and its interaction with the host immune system. Rapid progress is likewise being made in smallpox laboratory diagnostics, smallpox vaccines, and antiviral medications. WHO and several nations are developing stockpiles of smallpox vaccine for use in the event the disease is reintroduced. National and international public-health agencies have also drawn up plans to help with early detection of and response to a smallpox outbreak. These plans hinge on physicians' ability to recognise the clinical features of smallpox and to distinguish it from other illnesses characterised by rashes.	Emory Univ, Sch Med, Div Pediat Infect Dis, Atlanta, GA 30322 USA; Ctr Dis Control & Prevent, Viral Vaccine Prevent Dis Branch, Natl Immunizat Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Smallpox Eradicat Program, Atlanta, GA USA	Emory University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Moore, ZS (corresponding author), Emory Univ, Sch Med, Div Pediat Infect Dis, 2015 Uppergate Dr NE, Atlanta, GA 30322 USA.	zack_moore@oz.ped.emory.edu						Alibek K, 2004, INT J INFECT DIS, V8, pS3, DOI 10.1016/j.ijid.2004.09.004; Alibek Ken., 1999, BIOHAZARD; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Arness MK, 2004, AM J EPIDEMIOL, V160, P642, DOI 10.1093/aje/kwh269; *AUSTR GOV DEP HLT, GUID SMALLP OUTBR PR; Barquet N, 1997, ANN INTERN MED, V127, P635, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00010; Basu R N, 1979, Indian J Public Health, V23, P123; Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100; Besser JM, 2003, J LAB CLIN MED, V142, P246, DOI 10.1016/S0022-2143(03)00146-X; Bonilla-Guerrero R, 2003, J LAB CLIN MED, V142, P252, DOI 10.1016/S0022-2143(03)00143-4; Bray M, 2004, J ANTIMICROB CHEMOTH, V54, P1, DOI 10.1093/jac/dkh286; Bray M, 2004, CLIN INFECT DIS, V38, P882, DOI 10.1086/381976; Bray M, 2000, J INFECT DIS, V181, P10, DOI 10.1086/315190; Breman JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMra020025; Buller RM, 2004, VIROLOGY, V318, P474, DOI 10.1016/j.virol.2003.11.015; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; Cassimatis DC, 2004, J AM COLL CARDIOL, V43, P1503, DOI 10.1016/j.jacc.2003.11.053; *CDCP, SMALLP VACC VACC CON; *CDCP, CLIN ALG EV RASH ILL; *CDCP, AC GEN VES PUST RASH; Centers for Disease Control and Prevention, MED MAN SMALLP VACC; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P492; Centers for Disease Control and Prevention (CDC), 2003, MMWR-MORBID MORTAL W, V23, P537; Centers for Disease Control Prevention, SMALLP RESP PLAN GUI; Chen RT, 2003, LANCET, V362, P1345, DOI 10.1016/S0140-6736(03)14674-0; CHO CT, 1973, BACTERIOL REV, V37, P1; CONYBEARE E. T., 1950, Monthly Bull. Ministry of Health & Pub. Health Lab. Service (directed by Med. Res. Council)., V9, P56; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; Cummings JF, 2004, CLIN INFECT DIS, V38, P456, DOI 10.1086/381101; De Clercq E, 2004, REV MED VIROL, V14, P289, DOI 10.1002/rmv.439; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; DIXON C.W, 1962, SMALLPOX; DOWNIE AW, 1965, B WORLD HEALTH ORGAN, V33, P615; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; Eichner M, 2003, AM J EPIDEMIOL, V158, P717, DOI 10.1093/aje/kwg225; EMPIG C, 2004, NAT FDN INF DIS 7 AN, P47; Esteban DJ, 2004, J GEN VIROL, V85, P1291, DOI 10.1099/vir.0.79902-0; FOEGE WH, 1971, AM J EPIDEMIOL, V94, P311, DOI 10.1093/oxfordjournals.aje.a121325; FOEGE WH, 1975, B WORLD HEALTH ORGAN, V52, P209; Fogg C, 2004, J VIROL, V78, P10230, DOI 10.1128/JVI.78.19.10230-10237.2004; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Fulginiti VA, 2003, CLIN INFECT DIS, V37, P251, DOI 10.1086/375825; Fulginiti VA, 2003, CLIN INFECT DIS, V37, P241, DOI 10.1086/375824; GELB DL, 1990, FIELDS VIROLOGY; Gellman B., 2002, WASHINGTON POST 0120, pA1; Gouvras G, 2004, INT J INFECT DIS, V8, pS21, DOI 10.1016/j.ijid.2004.09.003; Greenberg RN, 2005, LANCET, V365, P398, DOI 10.1016/S0140-6736(05)70234-8; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Hanrahan JA, 2003, NEW ENGL J MED, V348, P467; HARPER GJ, 1961, J HYG-CAMBRIDGE, V59, P479, DOI 10.1017/S0022172400039176; Harrison SC, 2004, P NATL ACAD SCI USA, V101, P11178, DOI 10.1073/pnas.0403600101; HEINER GG, 1971, AM J EPIDEMIOL, V94, P316, DOI 10.1093/oxfordjournals.aje.a121326; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HENDERSON DA, 2004, VACCINES; Hepburn MJ, 2004, AM J INFECT CONTROL, V32, P126, DOI 10.1016/j.ajic.2003.08.006; Heymann DL, 2004, INT J INFECT DIS, V8, pS15, DOI 10.1016/j.ijid.2004.09.005; Hooper JW, 2004, J VIROL, V78, P4433, DOI 10.1128/JVI.78.9.4433-4443.2004; Hooper JW, 2003, VIROLOGY, V306, P181, DOI 10.1016/S0042-6822(02)00038-7; Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096; Hopkins D. R., 1983, PRINCES PEASANTS SMA; HOPKINS DR, 1971, AM J EPIDEMIOL, V94, P341, DOI 10.1093/oxfordjournals.aje.a121328; Jackson RJ, 2001, J VIROL, V75, P1205, DOI 10.1128/JVI.75.3.1205-1210.2001; Jahrling PB, 2004, P NATL ACAD SCI USA, V101, P15196, DOI 10.1073/pnas.0405954101; Jezek Z, 1978, Indian J Public Health, V22, P107; JEZEK Z, 1987, B WORLD HEALTH ORGAN, V65, P425; Jezek Z, 1988, HUMAN MONKEYPOX; Jezek Z., 1988, MONOGRAPHS VIROLOGY, V17; Kennedy JS, 2004, J INFECT DIS, V190, P1286, DOI 10.1086/423848; Kern ER, 2003, ANTIVIR RES, V57, P35, DOI 10.1016/S0166-3542(02)00198-5; Kidokoro M, 2005, P NATL ACAD SCI USA, V102, P4152, DOI 10.1073/pnas.0406671102; Kim M, 2004, J BIOL CHEM, V279, P25838, DOI 10.1074/jbc.M400343200; KOPLAN JP, 1979, J INFECT DIS, V140, P440, DOI 10.1093/infdis/140.3.440; Kulesh DA, 2004, J CLIN MICROBIOL, V42, P601, DOI 10.1128/JCM.42.2.601-609.2004; Lane HC, 2001, NAT MED, V7, P1271, DOI 10.1038/nm1201-1271; Lane J Michael, 2003, Semin Pediatr Infect Dis, V14, P189, DOI 10.1016/S1045-1870(03)00032-3; Lane JM, 2003, ANN INTERN MED, V138, P488, DOI 10.7326/0003-4819-138-6-200303180-00014; MACK TM, 1970, J INFECT DIS, V122, P479, DOI 10.1093/infdis/122.6.479; MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161; MACK TM, 1972, AM J EPIDEMIOL, V95, P157, DOI 10.1093/oxfordjournals.aje.a121380; Madeley CR, 2003, LANCET, V361, P97, DOI 10.1016/S0140-6736(03)12241-6; Martin DB, 2002, MIL MED, V167, P546; Massoudi MS, 2003, J INFECT DIS, V188, P973, DOI 10.1086/378357; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; McCurdy LH, 2004, CLIN INFECT DIS, V38, P1749, DOI 10.1086/421266; Monath TP, 2004, INT J INFECT DIS, V8, pS31, DOI 10.1016/j.ijid.2004.09.002; Moore ZS, 2004, CLIN INFECT DIS, V39, P1810, DOI 10.1086/426026; Mortimer PP, 2003, CLIN INFECT DIS, V36, P622, DOI 10.1086/374054; MUKHERJEE MK, 1974, B WORLD HEALTH ORGAN, V51, P219; Nitsche A, 2004, J CLIN MICROBIOL, V42, P1207, DOI 10.1128/JCM.42.3.1207-1213.2004; NOBLE J, 1970, AM J TROP MED HYG, V19, P1020, DOI 10.4269/ajtmh.1970.19.1020; Olson VA, 2004, J CLIN MICROBIOL, V42, P1940, DOI 10.1128/JCM.42.5.1940-1946.2004; Painter GR, 2004, TRENDS BIOTECHNOL, V22, P423, DOI 10.1016/j.tibtech.2004.06.008; Pastoret PP, 2003, COMP IMMUNOL MICROB, V26, P343, DOI 10.1016/S0147-9571(03)00019-5; Poland GA, 2005, VACCINE, V23, P2078, DOI 10.1016/j.vaccine.2005.01.012; *PUBL HLTH AG CAN, INT EM RESP OUTBR SM; Pulford D, 2004, J VIROL METHODS, V117, P81, DOI 10.1016/j.jviromet.2004.01.001; Quenelle DC, 2004, ANTIMICROB AGENTS CH, V48, P404, DOI 10.1128/AAC.48.2.404-412.2004; Quenelle DC, 2003, ANTIMICROB AGENTS CH, V47, P3275, DOI 10.1128/AAC.47.10.3275-3280.2003; RAO AR, 1968, INDIAN J MED RES, V56, P1826; Rao AR, 1972, SMALLPOX; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; RICKETTS TF, 1908, DIAGNOSIS SMALLPOX; ROPP SL, 1995, J CLIN MICROBIOL, V33, P2069, DOI 10.1128/JCM.33.8.2069-2076.1995; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; Rubins KH, 2004, P NATL ACAD SCI USA, V101, P15190, DOI 10.1073/pnas.0405759101; SANDHU DS, 2004, VACCINES; SARKAR JK, 1973, B WORLD HEALTH ORGAN, V48, P523; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Seregin SV, 1996, FEBS LETT, V382, P79, DOI 10.1016/0014-5793(96)00069-5; Seward JF, 2004, CLIN INFECT DIS, V39, P1477, DOI 10.1086/425500; Shchelkunov SN, 2000, VIROLOGY, V266, P361, DOI 10.1006/viro.1999.0086; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; Smee DF, 2003, ANTIVIR RES, V57, P41, DOI 10.1016/S0166-3542(02)00199-7; Smee DF, 2002, ANTIMICROB AGENTS CH, V46, P1329, DOI 10.1128/AAC.46.5.1329-1335.2002; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5; Talbot TR, 2004, JAMA-J AM MED ASSOC, V292, P1205, DOI 10.1001/jama.292.10.1205; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; THOMAS G, 1974, J HYG-CAMBRIDGE, V73, P1, DOI 10.1017/S0022172400023767; *UK DEP HLTH, GUID SMALLP RESP MAN; WADE N, 2005, NY TIMES NY     0112, pA5; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; *WHO, 2004, GLOB SMALLP VACC RES; *WHO, 2002, IMM VACC BIOL SMALLP; Woods R, 2004, BIOSECUR BIOTERROR, V2, P157, DOI 10.1089/15387130460759209; World Health Organization, 1980, GLOB ER SMALLP FIN R; Wyatt LS, 2004, P NATL ACAD SCI USA, V101, P4590, DOI 10.1073/pnas.0401165101; Yang HL, 2005, J CLIN INVEST, V115, P379, DOI 10.1172/jc1200523200; Zanders JP, 2004, INT J INFECT DIS, V8, pS9, DOI 10.1016/j.ijid.2004.09.006	131	67	71	4	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					425	435		10.1016/S0140-6736(06)68143-9	http://dx.doi.org/10.1016/S0140-6736(06)68143-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458769				2022-12-28	WOS:000235139400034
J	Jiang, W; Chang, J; Jakana, J; Weigele, P; King, J; Chiu, W				Jiang, W; Chang, J; Jakana, J; Weigele, P; King, J; Chiu, W			Structure of epsilon15 bacteriophage reveals genome organization and DNA packaging/injection apparatus	NATURE			English	Article							PARTICLE RECONSTRUCTION; MATURATION TRANSITION; ANGSTROM RESOLUTION; COMMON ANCESTRY; VISUALIZATION; MICROSCOPY; VERTEX; MOTOR; T7; T4	The critical viral components for packaging DNA, recognizing and binding to host cells, and injecting the condensed DNA into the host are organized at a single vertex of many icosahedral viruses. These component structures do not share icosahedral symmetry and cannot be resolved using a conventional icosahedral averaging method. Here we report the structure of the entire infectious Salmonella bacteriophage epsilon15 ( ref. 1) determined from single-particle cryo-electron microscopy, without icosahedral averaging. This structure displays not only the icosahedral shell of 60 hexamers and 11 pentamers, but also the non-icosahedral components at one pentameric vertex. The densities at this vertex can be identified as the 12-subunit portal complex sandwiched between an internal cylindrical core and an external tail hub connecting to six projecting trimeric tailspikes. The viral genome is packed as coaxial coils in at least three outer layers with similar to 90 terminal nucleotides extending through the protein core and the portal complex and poised for injection. The shell protein from icosahedral reconstruction at higher resolution exhibits a similar fold to that of other double-stranded DNA viruses including herpesvirus(2-6), suggesting a common ancestor among these diverse viruses. The image reconstruction approach should be applicable to studying other biological nanomachines with components of mixed symmetries.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Baylor College of Medicine; Baylor College of Medicine; Massachusetts Institute of Technology (MIT)	Chiu, W (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA.	wah@bcm.edu	jiang, wen/GYI-9662-2022; Weigele, Peter/AIE-8230-2022	Weigele, Peter/0000-0003-3696-4541; Jiang, Wen/0000-0002-1292-2411	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070557] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR002250] Funding Source: Medline; NIAID NIH HHS [R01 AI038469] Funding Source: Medline; NIGMS NIH HHS [R01 GM070557] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agirrezabala X, 2005, J MOL BIOL, V347, P895, DOI 10.1016/j.jmb.2005.02.005; [Anonymous], PHAGES; Arsuaga J, 2002, BIOPHYS CHEM, V101, P475, DOI 10.1016/S0301-4622(02)00197-7; Baker ML, 2005, J VIROL, V79, P14967, DOI 10.1128/JVI.79.23.14967-14970.2005; BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; Booth CR, 2004, J STRUCT BIOL, V147, P116, DOI 10.1016/j.jsb.2004.02.004; CARAZO JM, 1986, J ULTRA MOL STRUCT R, V94, P105, DOI 10.1016/0889-1605(86)90056-X; Cerritelli ME, 1997, CELL, V91, P271, DOI 10.1016/S0092-8674(00)80409-2; Cerritelli ME, 2003, J MOL BIOL, V327, P1, DOI 10.1016/S0022-2836(03)00117-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EARNSHAW WC, 1978, CELL, V14, P559, DOI 10.1016/0092-8674(78)90242-8; Fokine A, 2005, P NATL ACAD SCI USA, V102, P7163, DOI 10.1073/pnas.0502164102; Jiang W, 2003, NAT STRUCT BIOL, V10, P131, DOI 10.1038/nsb891; Jiang W, 2001, J STRUCT BIOL, V136, P214, DOI 10.1006/jsbi.2002.4439; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Lurz R, 2001, J MOL BIOL, V310, P1027, DOI 10.1006/jmbi.2001.4800; MCCONNELL M, 1979, VIROLOGY, V94, P10, DOI 10.1016/0042-6822(79)90434-3; Molineux IJ, 2001, MOL MICROBIOL, V40, P1, DOI 10.1046/j.1365-2958.2001.02357.x; Morais MC, 2005, MOL CELL, V18, P149, DOI 10.1016/j.molcel.2005.03.013; Orlova EV, 2003, EMBO J, V22, P1255, DOI 10.1093/emboj/cdg123; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Tang L, 2005, EMBO J, V24, P2087, DOI 10.1038/sj.emboj.7600695; Tavares P, 1996, J MOL BIOL, V264, P954, DOI 10.1006/jmbi.1996.0689; Wikoff WR, 2000, SCIENCE, V289, P2129, DOI 10.1126/science.289.5487.2129; Zhang ZX, 2000, J MOL BIOL, V297, P615, DOI 10.1006/jmbi.2000.3601	28	240	250	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					612	616		10.1038/nature04487	http://dx.doi.org/10.1038/nature04487			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452981	Green Accepted			2022-12-28	WOS:000235033900046
J	Macilwain, C				Macilwain, C			Ticking the right boxes	NATURE			English	News Item																			0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2006	439	7076					533	533		10.1038/439533a	http://dx.doi.org/10.1038/439533a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452953	Bronze			2022-12-28	WOS:000235033900016
J	Zenkin, N; Naryshkina, T; Kuznedelov, K; Severinov, K				Zenkin, N; Naryshkina, T; Kuznedelov, K; Severinov, K			The mechanism of DNA replication primer synthesis by RNA polymerase	NATURE			English	Article							ESCHERICHIA-COLI; TRANSCRIPTION ELONGATION; SINGLE-STRAND; INITIATION; PROMOTER; HYBRID	RNA primers for DNA replication are usually synthesized by specialized enzymes, the primases(1). However, some replication systems have evolved to use cellular DNA-dependent RNA polymerase for primer synthesis(1,2). The main requirement for the replication primer, an exposed RNA 3' end annealed to the DNA template, is not compatible with known conformations of the transcription elongation complex(3), raising a question of how the priming is achieved. Here we show that a previously unrecognized kind of transcription complex is formed during RNA polymerase-catalysed synthesis of the M13 bacteriophage replication primer. The complex contains an overextended RNA - DNA hybrid bound in the RNA-polymerase trough that is normally occupied by downstream double-stranded DNA, thus leaving the 3' end of the RNA available for interaction with DNA polymerase. Transcription complexes with similar topology may prime the replication of other bacterial mobile elements and may regulate transcription elongation under conditions that favour the formation of an extended RNA - DNA hybrid.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Russian Academy of Sciences	Zenkin, N (corresponding author), Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA.	nicserzen@mail.ru; severik@waksman.rutgers.edu	Severinov, Konstantin/C-8545-2016	Zenkin, Nikolay/0000-0003-2212-9545				GEIDER K, 1974, J BIOL CHEM, V249, P3999; Horiuchi K, 1997, GENES CELLS, V2, P425, DOI 10.1046/j.1365-2443.1997.1360334.x; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Kornberg A., 1992, DNA REPLICATION; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Kramer MG, 1997, EMBO J, V16, P5784, DOI 10.1093/emboj/16.18.5784; Kramer MG, 1999, MOL MICROBIOL, V33, P466, DOI 10.1046/j.1365-2958.1999.01471.x; Kuznedelov K, 2002, EMBO J, V21, P1369, DOI 10.1093/emboj/21.6.1369; Masai H, 1997, CELL, V89, P897, DOI 10.1016/S0092-8674(00)80275-5; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; Mustaev A, 2003, METHOD ENZYMOL, V371, P191; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Zenkin N, 2004, P NATL ACAD SCI USA, V101, P4396, DOI 10.1073/pnas.0400886101	15	38	38	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					617	620		10.1038/nature04337	http://dx.doi.org/10.1038/nature04337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452982				2022-12-28	WOS:000235033900047
J	Steneck, RS				Steneck, RS			Staying connected in a turbulent world	SCIENCE			English	Editorial Material							FISHERY MANAGEMENT; MARINE RESERVES; CORAL-REEFS		Univ Maine, Darling Marine Ctr, Sch Marine Sci, Walpole, ME 04573 USA	University of Maine System; University of Maine Orono	Steneck, RS (corresponding author), Univ Maine, Darling Marine Ctr, Sch Marine Sci, Walpole, ME 04573 USA.	steneck@maine.edu						Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; Birkeland C, 2005, TRENDS ECOL EVOL, V20, P356, DOI 10.1016/j.tree.2005.03.015; Connell JH, 1997, CORAL REEFS S, V16, P101; Cowen RK, 2000, SCIENCE, V287, P857, DOI 10.1126/science.287.5454.857; Cowen RK, 2006, SCIENCE, V311, P522, DOI 10.1126/science.1122039; COWEN RK, 2005, SCIENCE         1215; Gardner TA, 2003, SCIENCE, V301, P958, DOI 10.1126/science.1086050; Hughes TP, 2005, TRENDS ECOL EVOL, V20, P380, DOI 10.1016/j.tree.2005.03.022; Jones GP, 2004, P NATL ACAD SCI USA, V101, P8251, DOI 10.1073/pnas.0401277101; Pandolfi JM, 2005, SCIENCE, V307, P1725, DOI 10.1126/science.1104258; Pikitch EK, 2004, SCIENCE, V305, P346, DOI 10.1126/science.1098222; POLUNIN NVC, 1993, MAR ECOL PROG SER, V100, P167, DOI 10.3354/meps100167; Roberts CM, 1997, SCIENCE, V278, P1454, DOI 10.1126/science.278.5342.1454; Sale PF, 2005, TRENDS ECOL EVOL, V20, P74, DOI 10.1016/j.tree.2004.11.007; SAMMARCO PW, 1988, SCIENCE, V239, P1422, DOI 10.1126/science.239.4846.1422	15	26	28	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2006	311	5760					480	481		10.1126/science.1123541	http://dx.doi.org/10.1126/science.1123541			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439653				2022-12-28	WOS:000235071400035
J	Fasel, R; Parschau, M; Ernst, KH				Fasel, R; Parschau, M; Ernst, KH			Amplification of chirality in two-dimensional enantiomorphous lattices	NATURE			English	Article							PHASE-TRANSITION; ENANTIOMERS; MOLECULES; SEPARATION	The concept of chirality dates back to 1848, when Pasteur manually separated left-handed from right-handed sodium ammonium tartrate crystals(1). Crystallization is still an important means for separating chiral molecules into their two different mirror-image isomers (enantiomers)(2), yet remains poorly understood(3). For example, there are no firm rules to predict whether a particular pair of chiral partners will follow the behaviour of the vast majority of chiral molecules and crystallize together as racemic crystals(4), or as separate enantiomers. A somewhat simpler and more tractable version of this phenomenon is crystallization in two dimensions, such as the formation of surface structures by adsorbed molecules. The relatively simple spatial molecular arrangement of these systems makes it easier to study the effects of specific chiral interactions(5); moreover, chiral assembly and recognition processes can be observed directly and with molecular resolution using scanning tunnelling microscopy(6-9). The enantioseparation of chiral molecules in two dimensions is expected to occur more readily because planar confinement excludes some bulk crystal symmetry elements and enhances chiral interactions(10,11); however, many surface structures have been found to be racemic(12-18). Here we show that the chiral hydrocarbon heptahelicene on a Cu(111) surface does not undergo two-dimensional spontaneous resolution into enantiomers(19), but still shows enantiomorphism on a mesoscopic length scale that is readily amplified. That is, we observe formation of racemic heptahelicene domains with non-superimposable mirror-like lattice structures, with a small excess of one of the heptahelicene enantiomers suppressing the formation of one domain type. Similar to the induction of homochirality in achiral enantiomorphous monolayers(20) by a chiral modifier, a small enantiomeric excess suffices to ensure that the entire molecular monolayer consists of domains having only one of two possible, non-superimposable, mirror-like lattice structures.	Swiss Fed Labs Mat Testing & Res, Empa, CH-8600 Dubendorf, Switzerland	Swiss Federal Institutes of Technology Domain; Swiss Federal Laboratories for Materials Science & Technology (EMPA)	Ernst, KH (corresponding author), Swiss Fed Labs Mat Testing & Res, Empa, Uberlandstr 129, CH-8600 Dubendorf, Switzerland.	karl-heinz.ernst@empa.ch	Ernst, Karl-Heinz/O-6128-2015; Fasel, Roman/B-5396-2011; Fasel, Roman/M-9992-2019; Ernst, Karl-Heinz/GZA-3468-2022	Ernst, Karl-Heinz/0000-0002-2077-4922; Fasel, Roman/0000-0002-1553-6487; Fasel, Roman/0000-0002-1553-6487; 				Addadi L, 2001, NATURE, V411, P753, DOI 10.1038/35081227; Barlow SM, 2003, SURF SCI REP, V50, P201, DOI [10.1016/S0167-5729(03)00015-3, 10.1016/s0167-5729(03)00015-3]; Bohringer M, 2000, ANGEW CHEM INT EDIT, V39, P792, DOI 10.1002/(SICI)1521-3773(20000218)39:4<792::AID-ANIE792>3.0.CO;2-2; Cai YG, 2005, J PHYS CHEM B, V109, P4514, DOI 10.1021/jp0466587; Cai YU, 2003, J AM CHEM SOC, V125, P1655, DOI 10.1021/ja0285619; Chen Q, 2003, NAT MATER, V2, P324, DOI 10.1038/nmat878; De Feyter S, 2003, CHEM SOC REV, V32, P139, DOI 10.1039/b206566p; De Feyter S, 2001, ANGEW CHEM INT EDIT, V40, P3217, DOI 10.1002/1521-3773(20010903)40:17<3217::AID-ANIE3217>3.0.CO;2-Y; Green MM, 1999, ANGEW CHEM INT EDIT, V38, P3139; Jacques J., 1981, ENANTIOMERS RACEMATE; Kuhnle A, 2002, NATURE, V415, P891, DOI 10.1038/415891a; Kuzmenko I, 1998, CHIRALITY, V10, P415, DOI 10.1002/(SICI)1520-636X(1998)10:5<415::AID-CHIR7>3.0.CO;2-4; MADDOX J, 1989, NATURE, V341, P101, DOI 10.1038/341101a0; OrtegaLorenzo M., 2000, NATURE, V404, P376; Parschau M, 2004, J AM CHEM SOC, V126, P15398, DOI 10.1021/ja044136z; Pasteur L., 1848, ANN CHIM PHYS, V24, P442; Perez-Garcia L, 2002, CHEM SOC REV, V31, P342, DOI 10.1039/b201099m; Romer S, 2005, CHEM-EUR J, V11, P4149, DOI 10.1002/chem.200400962; SHELDON RA, 1993, CHIROTECHNOLOGY IND, P173; Vidal F, 2005, J AM CHEM SOC, V127, P10101, DOI 10.1021/ja0525049; Wie Y., 2004, J AM CHEM SOC, V126, P5318	23	342	342	4	256	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					449	452		10.1038/nature04419	http://dx.doi.org/10.1038/nature04419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437111				2022-12-28	WOS:000234859200041
J	Jha, P; Kumar, R; Vasa, P; Dhingra, N; Thiruchelvam, D; Moineddin, R				Jha, P; Kumar, R; Vasa, P; Dhingra, N; Thiruchelvam, D; Moineddin, R			Low male-to-female sex ratio of children born in India: national survey of 1.1 million households	LANCET			English	Article							MISSING WOMEN; INFANTS; TIME	Background Fewer girls than boys are born in India. Various hypotheses have been proposed to explain this low sex ratio. Our aim was to ascertain the contribution of prenatal sex determination and selective abortion as measured by previous birth sex. Methods We analysed data obtained for the Special Fertility and Mortality Survey undertaken in 1998. Ever-married women living in 1.1 million households in 6671 nationally-representative units were asked questions about their fertility history and children born in 1997. Findings For the 133 738 births studied for 1997, the adjusted sex ratio for the second birth when the preceding child was a girl was 759 per 1000 males (99% Cl 731-787). The adjusted sex ratio for the third child was 719 (675-762) if the previous two children were girls. By contrast, adjusted sex ratios for second or third births if the previous children were boys were about equal (1102 and 1176, respectively). Mothers with grade 10 or higher education had a significantly lower adjusted sex ratio (683, 610-756) than did illiterate mothers (869, 820-917). Stillbirths and neonatal deaths were more commonly male, and the numbers of stillbirths were fewer than the numbers of missing births, suggesting that female infanticide does not account for the difference. Interpretation Prenatal sex determination followed by selective abortion of female fetuses is the most plausible explanation for the low sex ratio at birth in India. Women most clearly at risk are those who already have one or two female children. Based on conservative assumptions, the practice accounts for about 0.5 million missing female births yearly, translating over the past 2 decades into the abortion of some 10 million female fetuses.	Univ Toronto, St Michaels Hosp, Ctr Global Hlth Res, Toronto, ON M5C 1N8, Canada; Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON M5C 1N8, Canada; Postgrad Inst Med Educ & Res, Sch Publ Hlth, Chandigarh 160012, India	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Jha, P (corresponding author), Univ Toronto, St Michaels Hosp, Ctr Global Hlth Res, 70 Richmond St E,2nd Floor, Toronto, ON M5C 1N8, Canada.	prabhat.jha@utoronto.ca			FOGARTY INTERNATIONAL CENTER [R01TW005991] Funding Source: NIH RePORTER; FIC NIH HHS [R01 TW05991-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		[Anonymous], 2019, NATL FAMILY HLTH SUR; [Anonymous], 2005, SPEC FERT MORT SURV; Babu NP, 1998, J FAM WELFARE, V44, P45; BOOTH BE, 1994, BRIT MED J, V309, P1259, DOI 10.1136/bmj.309.6964.1259; Census of India, 2001, PROV POP TOT; Chan CLW, 2002, J ASSIST REPROD GEN, V19, P426, DOI 10.1023/A:1016815807703; Chaturvedi S, 2001, TROP DOCT, V31, P204, DOI 10.1177/004947550103100407; Dickinson HO, 1997, OCCUP ENVIRON MED, V54, P868, DOI 10.1136/oem.54.12.868; DREW JS, 1986, HUM BIOL, V58, P115; Fukuda M, 2002, LANCET, V359, P1407, DOI 10.1016/S0140-6736(02)08362-9; Ganatra B.R., 2001, ASIA PACIFIC POPULAT, V16, P109; GEORGE S, 1998, SEARCH B, V12, P18; George SM, 2002, REPROD HEALTH MATTER, V10, P190, DOI 10.1016/S0968-8080(02)00034-4; Grant VJ, 2003, HUM BIOL, V75, P917, DOI 10.1353/hub.2004.0005; HATTI N, 2004, 93 LUND PAP EC HIST; James WH, 1996, J THEOR BIOL, V180, P271, DOI 10.1006/jtbi.1996.0102; Jha P, 2006, PLOS MED, V3, P191, DOI 10.1371/journal.pmed.0030018; Khanna SK, 1997, SOC SCI MED, V44, P171, DOI 10.1016/S0277-9536(96)00144-X; Klasen S, 2003, FEM ECON, V9, P263, DOI 10.1080/1354570022000077999; MCCURRY J, 2004, GUARDIAN        0903; Miller R. G., 1981, SURVIVAL ANAL; MUTHARYAPPA R, 1997, 3 NAT FAM HLTH SURV; NORBERG K, DADS CADS PARENTAL C; *REG GEN IND, 2002, SAMPL REG SYST STAT; Rodgers JL., 2001, CHANCE MAG, V14, P8, DOI DOI 10.1080/09332480.2001.10542293; Sen A, 2003, BMJ-BRIT MED J, V327, P1297, DOI 10.1136/bmj.327.7427.1297; Smits LJM, 2005, BRIT MED J, V331, P1437, DOI 10.1136/bmj.331.7530.1437; Teitelbaum M S, 1970, J Biosoc Sci Suppl, V2, P61; *UN POP DIV, 2003, DEM YB SYST; *UNFPA, 2001, SEX SEL AB FERT DECL; WILLIAMS RJ, 1992, SOC BIOL, V39, P285; Zeng Y, 1992, China Popul Today, V9, P3; 2005, TIMES INDIA     0715, P1	33	230	233	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					211	218		10.1016/S0140-6736(06)67930-0	http://dx.doi.org/10.1016/S0140-6736(06)67930-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005GM	16427489				2022-12-28	WOS:000234810600025
J	Davis, BT; Thiim, M; Zukerberg, LR				Davis, BT; Thiim, M; Zukerberg, LR			A 31-year-old, HIV-positive man with rectal pain - Lymphogranuloma venereum proctitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHLAMYDIA-TRACHOMATIS; MEN; SEX		Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Davis, BT (corresponding author), Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.							Blank S, 2005, LANCET, V365, P1607, DOI 10.1016/S0140-6736(05)66490-2; DELAMONTE SM, 1985, HUM PATHOL, V16, P1025, DOI 10.1016/S0046-8177(85)80280-X; DEMETS A, 1998, CHLAMYDIA TRACHOMATI; Ina K, 2003, J GASTROENTEROL, V38, P111, DOI 10.1007/s005350300019; Klausner JD, 2004, CLIN INFECT DIS, V38, P300, DOI 10.1086/380838; Nieuwenhuis RF, 2004, CLIN INFECT DIS, V39, P996, DOI 10.1086/423966; PALMER L, 1986, PLASMID, V16, P52, DOI 10.1016/0147-619X(86)90079-X; PETERSON EM, 1988, J CLIN MICROBIOL, V26, P625, DOI 10.1128/JCM.26.4.625-629.1988; Spaargaren J, 2005, EMERG INFECT DIS, V11, P1090; 2004, MMWR MORB MORTAL WKL, V53, P985	10	11	11	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					284	289		10.1056/NEJMcpc059038	http://dx.doi.org/10.1056/NEJMcpc059038			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421370				2022-12-28	WOS:000234661100010
J	Adrain, C; Martin, SJ				Adrain, C; Martin, SJ			Cell biology - Double knockout blow for caspases	SCIENCE			English	Editorial Material							CYTOCHROME-C; APOPTOSIS; ACTIVATION; BRAIN; DEATH; MICE		Univ Dublin Trinity Coll, Smurfit Inst Genet, Dublin 2, Ireland	Trinity College Dublin	Adrain, C (corresponding author), Univ Dublin Trinity Coll, Smurfit Inst Genet, Dublin 2, Ireland.	martinsj@tcd.ie	Adrain, Colin/I-6259-2013	Adrain, Colin/0000-0001-7597-4393				Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Potts MB, 2005, J CELL BIOL, V171, P925, DOI 10.1083/jcb.200504082; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	10	12	12	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					785	786		10.1126/science.1124154	http://dx.doi.org/10.1126/science.1124154			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469906				2022-12-28	WOS:000235374900026
J	Keenan, N; Dhillo, WS; Williams, GR; Todd, JF				Keenan, N; Dhillo, WS; Williams, GR; Todd, JF			Unexpected shortness of breath in a patient with Cushing's syndrome	LANCET			English	Editorial Material							ADRENOCORTICOTROPIN; INFECTIONS		Hammersmith Hosp, Endocrine Unit, Imperial Coll Fac Med, London W12 0NN, England	Imperial College London	Todd, JF (corresponding author), Hammersmith Hosp, Endocrine Unit, Imperial Coll Fac Med, London W12 0NN, England.	jeannie.todd@imperial.ac.uk	Keenan, Niall/AAG-3376-2020	Dhillo, Waljit/0000-0001-5950-4316; Keenan, Niall/0000-0002-0841-6989				Aron DC, 1997, J CLIN ENDOCR METAB, V82, P1780, DOI 10.1210/jc.82.6.1780; FRENKEL JK, 1966, LAB INVEST, V15, P1559; GRAHAM BS, 1984, ANN INTERN MED, V101, P334, DOI 10.7326/0003-4819-101-3-334; Kim DS, 2000, EXP CLIN ENDOCR DIAB, V108, P146, DOI 10.1055/s-2000-5810; Sarlis NJ, 2000, J CLIN ENDOCR METAB, V85, P42, DOI 10.1210/jc.85.1.42	5	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					446	446		10.1016/S0140-6736(06)68146-4	http://dx.doi.org/10.1016/S0140-6736(06)68146-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458772				2022-12-28	WOS:000235139400037
J	Donati, JF; Forveille, T; Cameron, AC; Barnes, JR; Delfosse, X; Jardine, MM; Valenti, JA				Donati, JF; Forveille, T; Cameron, AC; Barnes, JR; Delfosse, X; Jardine, MM; Valenti, JA			The large-scale axisymmetric magnetic topology of a very-low-mass fully convective star	SCIENCE			English	Article							T-TAURI STARS; ACTIVE STARS; M-DWARFS; SOLAR DYNAMO; ROTATION; FIELD; RECONSTRUCTION; GENERATION	Understanding how cool stars produce magnetic fields within their interiors is crucial for predicting the impact of such fields, such as the activity cycle of the Sun. In this respect, studying fully convective stars enables us to investigate the role of convective zones in magnetic field generation. We produced a magnetic map of a rapidly rotating, very-low-mass, fully convective dwarf through tomographic imaging from time series of spectropolarimetric data. Our results, which demonstrate that fully convective stars are able to trigger axisymmetric large-scale poloidal fields without differential rotation, challenge existing theoretical models of field generation in cool stars.	Observ Midi Pyrenees, Lab AStrophys Toulouse Tarbes, F-31400 Toulouse, France; Canada France Hawaii Telescope Corp, Kamuela, HI 96743 USA; Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; Univ Grenoble 1, Observ Grenoble, Astrophys Lab, F-38041 Grenoble, France; Space Telescope Sci Inst, Baltimore, MD 21218 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Canada France Hawaii Telescope; University of St Andrews; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Space Telescope Science Institute	Donati, JF (corresponding author), Observ Midi Pyrenees, Lab AStrophys Toulouse Tarbes, 14 Ave Exxxx Belin, F-31400 Toulouse, France.	jean-francois.donati@ast.obs-mip.fr		Valenti, Jeff/0000-0003-3305-6281; Cameron, Andrew/0000-0002-8863-7828; Jardine, Moira/0000-0002-1466-5236	STFC [PP/D000890/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/D000890/1] Funding Source: researchfish	STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Barnes JR, 2005, MON NOT R ASTRON SOC, V357, pL1, DOI 10.1111/j.1745-3933.2005.08587.x; BROWN SF, 1991, ASTRON ASTROPHYS, V250, P463; Brun AS, 2005, ASTROPHYS J, V629, P461, DOI 10.1086/430430; CAMERON AC, 1992, LECT NOTE PHYS, V397, P33; Chabrier G, 1997, ASTRON ASTROPHYS, V327, P1039; CHABRIER G, ASTRON ASTROPHYS; Delfosse X, 2000, ASTRON ASTROPHYS, V364, P217; Delfosse X, 1998, ASTRON ASTROPHYS, V331, P581; DOBLER W, IN PRESS ASTROPHYS J; Donati J.-F, 2001, LECT NOTE PHYS, V573, P207; Donati JF, 2003, ASTR SOC P, V307, P41; Donati JF, 2003, MON NOT R ASTRON SOC, V345, P1145, DOI 10.1046/j.1365-2966.2003.07031.x; Donati JF, 2003, MON NOT R ASTRON SOC, V345, P1187, DOI 10.1046/j.1365-2966.2003.07101.x; Donati JF, 1997, ASTRON ASTROPHYS, V326, P1135; Donati JF, 1997, MON NOT R ASTRON SOC, V291, P658, DOI 10.1093/mnras/291.4.658; DZIEMBOWSKI WA, 1989, ASTROPHYS J, V337, pL53, DOI 10.1086/185377; JohnsKrull CM, 1996, ASTROPHYS J, V459, pL95, DOI 10.1086/309954; Krause F., 1980, MEAN FIELD MAGNETOHY; Kuker M, 1999, ASTRON ASTROPHYS, V346, P922; Kuker M, 1997, ASTRON ASTROPHYS, V328, P253; Moss D, 1995, GEOPHYS ASTRO FLUID, V80, P229, DOI 10.1080/03091929508228956; PARKER EN, 1993, ASTROPHYS J, V408, P707, DOI 10.1086/172631; Robrade J, 2005, ASTRON ASTROPHYS, V435, P1073, DOI 10.1051/0004-6361:20041941; RUDIGER G, 1994, ASTRON ASTROPHYS, V281, P46; RUDIGER G, 1995, ASTRON ASTROPHYS, V296, P557; SAAR SH, 1985, ASTROPHYS J, V299, pL47, DOI 10.1086/184578; SCHUSSLER M, 1975, ASTRON ASTROPHYS, V38, P263; Segransan D, 2003, ASTRON ASTROPHYS, V397, pL5, DOI 10.1051/0004-6361:20021714; SEMEL M, 1989, ASTRON ASTROPHYS, V225, P456; VOGT SS, 1987, ASTROPHYS J, V321, P496, DOI 10.1086/165647	30	181	181	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					633	635		10.1126/science.1121102	http://dx.doi.org/10.1126/science.1121102			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456073	Green Submitted			2022-12-28	WOS:000235257400039
J	Wakeford, R				Wakeford, R			Commentary: Criteria, competencies, and confidence tricks	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Cambridge, Cambridge CB1 2EW, England	University of Cambridge	Wakeford, R (corresponding author), Univ Cambridge, Hughes Hall, Cambridge CB1 2EW, England.	richardwakeford@hotmail.com						Baker R, 2006, BMJ-BRIT MED J, V332, P230, DOI 10.1136/bmj.332.7535.230; Bloom B. S., 1956, CLASSIFICATION ED GO; Eraut M, 2000, BRIT J EDUC PSYCHOL, V70, P113, DOI 10.1348/000709900158001; Mager RF, 1962, PREPARING INSTRUCTIO	4	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 28	2006	332	7535					233	233		10.1136/bmj.332.7535.233	http://dx.doi.org/10.1136/bmj.332.7535.233			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16439406	Green Published			2022-12-28	WOS:000235086900025
J	Buck, D; Malivert, L; de Chasseval, P; Barraud, A; Fondaneche, MC; Sanal, O; Plebani, A; Stephan, JL; Hufnagel, M; le Deist, F; Fischer, A; Durandy, A; de Villartay, JP; Revy, P				Buck, D; Malivert, L; de Chasseval, P; Barraud, A; Fondaneche, MC; Sanal, O; Plebani, A; Stephan, JL; Hufnagel, M; le Deist, F; Fischer, A; Durandy, A; de Villartay, JP; Revy, P			Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly	CELL			English	Article							DNA-LIGASE-IV; NIJMEGEN BREAKAGE SYNDROME; DEPENDENT PROTEIN-KINASE; V(D)J RECOMBINATION; SACCHAROMYCES-CEREVISIAE; HYPOMORPHIC MUTATIONS; ANIMAL-MODELS; REPAIR; ARTEMIS; CELLS	DNA double-strand breaks (DSBs) occur at random upon genotoxic stresses and represent obligatory intermediates during physiological DNA rearrangement events such as the V(D)J recombination in the immune system. DSBs, which are among the most toxic DNA lesions, are preferentially repaired by the nonhomologous end-joining (NHEJ) pathway in higher eukaryotes. Failure to properly repair DSBs results in genetic instability, developmental delay, and various forms of immunodeficiency. Here we describe five patients with growth retardation, microcephaly, and immunodeficiency characterized by a profound T+B lymphocytopenia. An increased cellular sensitivity to ionizing radiation, a defective V(D)J recombination, and an impaired DNA-end ligation process both in vivo and in vitro are indicative of a general DNA repair defect in these patients. All five patients carry mutations in the Cernunnos gene, which was identified through cDNA functional complementation cloning. Cernunnos/XLF represents a novel DNA repair factor essential for the NHEJ pathway.	Hop Necker Enfants Malad, INSERM, Unite Dev Normal & Pathol Syst Immunitaire, U768, F-75015 Paris, France; Univ Paris 05, Fac Med Rene Descartes, F-75005 Paris, France; Hacettepe Univ, Div Immunol, Ankara, Turkey; Univ Brescia, Pediat Clin, I-25121 Brescia, Italy; Univ Brescia, Ist Med Mol Angelo Nocivelli, I-25121 Brescia, Italy; CHU St Etienne, Unite Hematol & Oncol Pediat, St Etienne, France; Univ Hosp Schleswig Holstein, Childrens Hosp, Dept Gen Pediat, Kiel, Germany; Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Hacettepe University; University of Brescia; University of Brescia; CHU de St Etienne; University of Kiel; Schleswig Holstein University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	de Villartay, JP (corresponding author), Hop Necker Enfants Malad, INSERM, Unite Dev Normal & Pathol Syst Immunitaire, U768, F-75015 Paris, France.	devillar@necker.fr	de Villartay, jean pierre/H-9353-2017; Durandy, Anne/H-7475-2017; Revy, Patrick/H-8137-2017; Plebani, Alessandro/C-8593-2011	de Villartay, jean pierre/0000-0001-5987-0463; Durandy, Anne/0000-0001-7706-8466; Malivert, Laurent/0000-0002-0944-6573				Abner CW, 2004, DNA REPAIR, V3, P1141, DOI 10.1016/j.dnarep.2004.03.009; Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Badie C, 1997, CANCER RES, V57, P4600; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bassing CH, 2004, CELL CYCLE, V3, P149; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; de Villartay JP, 2003, NAT REV IMMUNOL, V3, P962, DOI 10.1038/nri1247; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Diggle CP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng083; DISANTO JP, 1994, P NATL ACAD SCI USA, V91, P9466, DOI 10.1073/pnas.91.20.9466; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Durandy A, 2005, IMMUNOL REV, V203, P67, DOI 10.1111/j.0105-2896.2005.00222.x; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Revy P, 2005, ADV IMMUNOL, V87, P237, DOI 10.1016/S0065-2776(05)87007-5; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Robbins PB, 1998, P NATL ACAD SCI USA, V95, P10182, DOI 10.1073/pnas.95.17.10182; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Smith J, 2003, NUCLEIC ACIDS RES, V31, P2157, DOI 10.1093/nar/gkg317; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7	46	539	549	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					287	299		10.1016/j.cell.2005.12.030	http://dx.doi.org/10.1016/j.cell.2005.12.030			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439204	Bronze			2022-12-28	WOS:000235068500018
J	Scherf, A				Scherf, A			A greedy promoter controls malarial var-iations	CELL			English	Editorial Material							ANTIGENIC VARIATION; PLASMODIUM-FALCIPARUM; GENES	Immune evasion by the malaria parasite Plasmodium falciparum is mediated by the mutually exclusive expression of a single member of the var family of genes, which encode variant surface antigens. In a recent paper in Nature, Voss et al. (2005) demonstrate that a construct carrying a transcriptionally active var promoter is sufficient to promote allelic exclusion of the parasite's endogenous var gene.	Inst Pasteur, CNRS, URA 2581, Unite Biol Interact HOte Parasite, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Scherf, A (corresponding author), Inst Pasteur, CNRS, URA 2581, Unite Biol Interact HOte Parasite, Paris, France.	ascherf@pasteur.fr	Scherf, Artur/A-9674-2014	Scherf, Artur/0000-0003-2411-3328				Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Gannoun-Zaki L, 2005, EUKARYOT CELL, V4, P490, DOI 10.1128/EC.4.2.490-492.2005; Horrocks P, 2004, P NATL ACAD SCI USA, V101, P11129, DOI 10.1073/pnas.0402347101; Ralph SA, 2005, CURR OPIN MICROBIOL, V8, P434, DOI 10.1016/j.mib.2005.06.007; Ralph SA, 2005, P NATL ACAD SCI USA, V102, P5414, DOI 10.1073/pnas.0408883102; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; VOSS TS, 2005, IN PRESS NATURE	12	8	11	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 27	2006	124	2					251	253		10.1016/j.cell.2006.01.004	http://dx.doi.org/10.1016/j.cell.2006.01.004			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439197	Bronze			2022-12-28	WOS:000235068500010
J	Hsu, HJ; Liang, MR; Chen, CT; Chung, BC				Hsu, HJ; Liang, MR; Chen, CT; Chung, BC			Pregnenolone stabilizes microtubules and promotes zebrafish embryonic cell movement	NATURE			English	Article							YOLK SYNCYTIAL LAYER; EXPRESSION; VERTEBRATE; GENES; ORGANIZATION; DYNAMICS; MICE	Embryonic cell movement is essential for morphogenesis and the establishment of body shapes(1,2), but little is known about its mechanism. Here we report that pregnenolone, which is produced from cholesterol by the steroidogenic enzyme Cyp11a1 ( cholesterol side-chain cleavage enzyme, P450scc)(3), functions in promoting cell migration during epiboly. Epiboly is a process in which embryonic cells spread from the animal pole to cover the underlying yolk. During epiboly, cyp11a1 is expressed in an extra-embryonic yolk syncytial layer(4). Reducing cyp11a1 expression in zebrafish using antisense morpholino oligonucleotides did not perturb cell fates, but caused epibolic delay. This epibolic defect was partially rescued by the injection of cyp11a1 RNA or the supplementation of pregnenolone. We show that the epibolic delay is accompanied by a decrease in the level of polymerized microtubules, and that pregnenolone can rescue this microtubule defect. Our results indicate that pregnenolone preserves microtubule abundance and promotes cell movement during epiboly.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11490, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 10617, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Taiwan University	Chung, BC (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mbchung@sinica.edu.tw	Hsu, Hwei-Jan/AAD-1518-2022	Hsu, Hwei-Jan/0000-0001-7892-2310; Chung, Bon-chu/0000-0002-8612-0219				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Arensburg J, 1999, ENDOCRINOLOGY, V140, P5220, DOI 10.1210/en.140.11.5220; Babin PJ, 1997, P NATL ACAD SCI USA, V94, P8622, DOI 10.1073/pnas.94.16.8622; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Chen SR, 2000, DEVELOPMENT, V127, P4681; Chiang EFL, 2001, DEV BIOL, V231, P149, DOI 10.1006/dbio.2000.0129; D'Amico LA, 2001, DEV DYNAM, V222, P611, DOI 10.1002/dvdy.1216; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; GARD DL, 1991, DEV BIOL, V143, P346, DOI 10.1016/0012-1606(91)90085-H; Grigoryev DN, 1999, ANAL BIOCHEM, V267, P319, DOI 10.1006/abio.1998.2993; Hsu Hwei-Jan, 2002, Gene Expression Patterns, V2, P219, DOI 10.1016/S1567-133X(02)00059-5; Hu MC, 2002, MOL ENDOCRINOL, V16, P1943, DOI 10.1210/me.2002-0055; Jesuthasan S, 1997, CURR BIOL, V7, P31, DOI 10.1016/S0960-9822(06)00025-X; Kozlova T, 2003, SCIENCE, V301, P1911, DOI 10.1126/science.1087419; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Locascio A, 2001, CURR OPIN GENET DEV, V11, P464, DOI 10.1016/S0959-437X(00)00218-5; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Morris NR, 2003, CURR OPIN CELL BIOL, V15, P54, DOI 10.1016/S0955-0674(02)00004-2; Murakami K, 2000, P NATL ACAD SCI USA, V97, P3579, DOI 10.1073/pnas.97.7.3579; Myers DC, 2002, TRENDS GENET, V18, P447, DOI 10.1016/S0168-9525(02)02725-7; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Sharma MK, 2004, COMP BIOCHEM PHYS B, V138, P391, DOI 10.1016/j.cbpc.2004.05.009; SOLNICAKREZEL L, 1994, DEVELOPMENT, V120, P2443; STRAHLE U, 1993, DEVELOPMENT, V119, P909; Venihaki M, 2000, P NATL ACAD SCI USA, V97, P7336, DOI 10.1073/pnas.97.13.7336; Watanabe T, 2005, TRENDS CELL BIOL, V15, P76, DOI 10.1016/j.tcb.2004.12.006; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669	28	76	81	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					480	483		10.1038/nature04436	http://dx.doi.org/10.1038/nature04436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437115	Green Published			2022-12-28	WOS:000234859200048
J	Schwoerer, H; Pfotenhauer, S; Jackel, O; Amthor, KU; Liesfeld, B; Ziegler, W; Sauerbrey, R; Ledingham, KWD; Esirkepov, T				Schwoerer, H; Pfotenhauer, S; Jackel, O; Amthor, KU; Liesfeld, B; Ziegler, W; Sauerbrey, R; Ledingham, KWD; Esirkepov, T			Laser-plasma acceleration of quasi-monoenergetic protons from microstructured targets	NATURE			English	Article							HIGH-INTENSITY LASER; ELECTRON ACCELERATION; ION ACCELERATORS; BEAMS; FEASIBILITY; GENERATION; THERAPY; SOLIDS; PULSE	Particle acceleration based on high intensity laser systems ( a process known as laser - plasma acceleration) has achieved high quality particle beams that compare favourably with conventional acceleration techniques in terms of emittance, brightness and pulse duration(1-4). A long-term difficulty associated with laser - plasma acceleration - the very broad, exponential energy spectrum of the emitted particles - has been overcome recently for electron beams(5-7). Here we report analogous results for ions, specifically the production of quasi-monoenergetic proton beams using laser - plasma accelerators. Reliable and reproducible laser-accelerated ion beams were achieved by intense laser irradiation of solid microstructured targets. This proof-of-principle experiment serves to illuminate the role of laser-generated plasmas as feasible particle sources. Scalability studies show that, owing to their compact size and reasonable cost, such table-top laser systems with high repetition rates could contribute to the development of new generations of particle injectors that may be suitable for medical proton therapy(8-10).	Univ Jena, Inst Opt & Quantenelektron, D-07743 Jena, Germany; Univ Strathclyde, Dept Phys, Glasgow G4 0NG, Lanark, Scotland; AWE Plc, Reading RG7 4PR, Berks, England; JAERI, Kansai Res Estab, Kyoto 6190215, Japan; Moscow Inst Phys & Technol, Dolgoprudnyi 141700, Russia	Friedrich Schiller University of Jena; University of Strathclyde; Japan Atomic Energy Agency; Moscow Institute of Physics & Technology	Schwoerer, H (corresponding author), Univ Jena, Inst Opt & Quantenelektron, D-07743 Jena, Germany.	schwoerer@ioq.uni-jena.de		Esirkepov, Timur/0000-0002-9027-0703; , Oliver/0000-0002-6056-9747				Allen M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.265004; Bulanov SV, 2004, AIP CONF PROC, V740, P414, DOI 10.1063/1.1843524; Bulanov SV, 2002, PLASMA PHYS REP+, V28, P453, DOI 10.1134/1.1478534; Clark EL, 2000, PHYS REV LETT, V85, P1654, DOI 10.1103/PhysRevLett.85.1654; Cowan TE, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.204801; Damato B, 2005, INT J RADIAT ONCOL, V62, P1405, DOI 10.1016/j.ijrobp.2005.01.016; ESIRKEPOV T, 2005, UNPUB PHYS REV LETT; Esirkepov TZ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.175003; Faure J, 2004, NATURE, V431, P541, DOI 10.1038/nature02963; Geddes CGR, 2004, NATURE, V431, P538, DOI 10.1038/nature02900; GITOMER SJ, 1986, PHYS FLUIDS, V29, P2679, DOI 10.1063/1.865510; Hegelich M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.085002; Hein J, 2004, APPL PHYS B-LASERS O, V79, P419, DOI 10.1007/s00340-004-1586-3; Kaluza M, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.045003; Ledingham KWD, 2003, SCIENCE, V300, P1107, DOI 10.1126/science.1080552; Maksimchuk A, 2000, PHYS REV LETT, V84, P4108, DOI 10.1103/PhysRevLett.84.4108; Malka V, 2002, SCIENCE, V298, P1596, DOI 10.1126/science.1076782; Mangles SPD, 2004, NATURE, V431, P535, DOI 10.1038/nature02939; Matsukado K, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.215001; MODENA A, 1995, NATURE, V377, P606, DOI 10.1038/377606a0; Schreiber J, 2004, APPL PHYS B-LASERS O, V79, P1041, DOI 10.1007/s00340-004-1665-5; Snavely RA, 2000, PHYS REV LETT, V85, P2945, DOI 10.1103/PhysRevLett.85.2945; Spencer I, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.046402; Tajima T, 2002, PHYS REV SPEC TOP-AC, V5, DOI 10.1103/PhysRevSTAB.5.031301; Wilks SC, 2001, PHYS PLASMAS, V8, P542, DOI 10.1063/1.1333697	25	633	670	0	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2006	439	7075					445	448		10.1038/nature04492	http://dx.doi.org/10.1038/nature04492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437110				2022-12-28	WOS:000234859200040
J	MacLean, CH; Newberry, SJ; Mojica, WA; Khanna, P; Issa, AM; Suttorp, MJ; Lim, YW; Traina, SB; Hilton, L; Garland, R; Morton, SC				MacLean, CH; Newberry, SJ; Mojica, WA; Khanna, P; Issa, AM; Suttorp, MJ; Lim, YW; Traina, SB; Hilton, L; Garland, R; Morton, SC			Effects of omega-3 fatty acids on cancer risk - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DIETARY-FAT INTAKE; BREAST-CANCER; PROSTATE-CANCER; COLON-CANCER; LUNG-CANCER; COLORECTAL-CANCER; ENTERAL IMMUNONUTRITION; METHODOLOGICAL QUALITY; NETHERLANDS-COHORT; PANCREATIC-CANCER	Context Omega-3 fatty acids are purported to reduce the risk of cancer. Studies have reported mixed results. Objective To synthesize published and unpublished evidence to determine estimates of the effect of omega-3 fatty acids on cancer risk in prospective cohort studies. Data Sources Articles published from 1966 to October 2005 identified through MEDLINE, PREMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and CAB Health; unpublished literature sought through letters to experts in the neutraceutical industry. Study Selection A total of 38 articles with a description of effects of consumption of omega-3 fatty acids on tumor incidence, prospective cohort study design, human study population; and description of effect of omega-3 among groups with different levels of exposure in the cohort were included. Two reviewers independently reviewed articles using structured abstraction forms; disagreements were resolved by consensus. Data Extraction Two reviewers independently abstracted detailed data about the incidence of cancer, the type of cancer, the number and characteristics of the patients, details on the exposure to omega-3 fatty acids, and the elapsed time between the intervention and outcome measurements. Data about the methodological quality of the study were also abstracted. Data Synthesis Across 20 cohorts from 7 countries for 11 different types of cancer and using up to 6 different ways to categorize omega-3 fatty acid consumption, 65 estimates of the association between omega-3 fatty acid consumption were reported. Among these, only 8 were statistically significant. The high degree of heterogeneity across these studies precluded pooling of data. For breast cancer 1 significant estimate was for increased risk (incidence risk ratio [RR], 1.47; 95% confidence interval [CI], 1.10-1.98) and 3 were for decreased risk (RR, 0.68-0.72); 7 other estimates did not show a significant association. For colorectal cancer, there was 1 estimate of decreased risk (RR, 0.49; 95% Cl, 0.27-0.89) and 17 estimates without association. For lung cancer one of the significant associations was for increased cancer risk (IRR, 3.0; 95% Cl, 1.2-7.3), the other was for decreased risk (RR, 0.32; 95% Cl, 0.13-0.76), and 4 other estimates were not significant. For prostate cancer, there was 1 estimate of decreased risk (RR, 0.43; 95% Cl, 0.22-0.83) and 1 of increased risk (RR, 1.98; 95% Cl, 1.34-2.93) for advanced prostate cancer; 15 other estimates did not show a significant association. The study that assessed skin cancer found an increased risk (RR, 1.13; 95% CI, 1.01-1.27). No significant associations between omega-3 fatty acid consumption and cancer incidence were found for aerodigestive cancer, bladder cancer, lymphoma, ovarian cancer, pancreatic cancer, or stomach cancer. Conclusions A large body of literature spanning numerous cohorts from many countries and with different demographic characteristics does not provide evidence to suggest a significant association between omega-3 fatty acids and cancer incidence. Dietary supplementation with omega-3 fatty acids is unlikely to prevent cancer.	So Calif Evidence Based Practice Ctr, Santa Monica, CA USA; Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA; Wright State Univ, Sch Med, Dayton, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University System of Ohio; Wright State University Dayton	MacLean, CH (corresponding author), RAND Corp, 1776 Main St,M4W, Santa Monica, CA 90407 USA.	maclean@rand.org			PHS HHS [290-02-0003] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Augustsson K, 2003, CANCER EPIDEM BIOMAR, V12, P64; Avula C. P. R., 2000, Recent Research Developments in Lipids, V4, P303; BARONZIO G, 1994, ANTICANCER RES, V14, P1145; Bertone ER, 2002, AM J EPIDEMIOL, V156, P22, DOI 10.1093/aje/kwf008; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; Braga M, 1999, ARCH SURG-CHICAGO, V134, P428, DOI 10.1001/archsurg.134.4.428; Braga M, 2002, SURGERY, V132, P805, DOI 10.1067/msy.2002.128350; Braga M, 2002, ARCH SURG-CHICAGO, V137, P174, DOI 10.1001/archsurg.137.2.174; BRAGA M, 1995, INFUSIONSTHERAPIE, V22, P280; Chiu BCH, 1996, JAMA-J AM MED ASSOC, V275, P1315, DOI 10.1001/jama.275.17.1315; Cho EY, 2003, JNCI-J NATL CANCER I, V95, P1079, DOI 10.1093/jnci/95.14.1079; Chyou P H, 1993, Ann Epidemiol, V3, P211; CHYOU PH, 1995, INT J CANCER, V60, P616, DOI 10.1002/ijc.2910600508; DALY JM, 1992, SURGERY, V112, P56; DALY JM, 1995, ANN SURG, V221, P327, DOI 10.1097/00000658-199504000-00002; Di Carlo V, 1999, DIGEST SURG, V16, P320, DOI 10.1159/000018742; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Fay MP, 1997, CANCER RES, V57, P3979; Gago-Dominguez M, 2003, BRIT J CANCER, V89, P1686, DOI 10.1038/sj.bjc.6601340; Gianotti L, 1997, ARCH SURG-CHICAGO, V132, P1222, DOI 10.1001/archsurg.1997.01430350072012; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GOLDBOHM RA, 1994, CANCER RES, V54, P718; Holmes MD, 2003, INT J CANCER, V104, P221, DOI 10.1002/ijc.10910; Holmes MD, 1999, JAMA-J AM MED ASSOC, V281, P914, DOI 10.1001/jama.281.10.914; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johnson IT, 2002, FOOD CHEM TOXICOL, V40, P1171, DOI 10.1016/S0278-6915(02)00051-0; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; Kenler AS, 1996, ANN SURG, V223, P316, DOI 10.1097/00000658-199603000-00013; Key TJ, 1999, BRIT J CANCER, V81, P1248, DOI 10.1038/sj.bjc.6690837; KVALE G, 1983, INT J CANCER, V31, P397, DOI 10.1002/ijc.2910310402; Larsson SC, 2005, CANCER EPIDEM BIOMAR, V14, P1024, DOI 10.1158/1055-9965.EPI-04-0795; Larsson SC, 2005, INT J CANCER, V113, P829, DOI 10.1002/ijc.20658; LE ML, 1994, EPIDEMIOLOGY, V5, P276; Leitzmann MF, 2004, AM J CLIN NUTR, V80, P204; Lin J, 2004, AM J EPIDEMIOL, V160, P1011, DOI 10.1093/aje/kwh319; McCarter MD, 1998, JPEN-PARENTER ENTER, V22, P206, DOI 10.1177/0148607198022004206; Michaud DS, 2003, AM J EPIDEMIOL, V157, P1115, DOI 10.1093/aje/kwg098; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; Ngoan LT, 2002, BRIT J CANCER, V87, P37, DOI 10.1038/sj.bjc.6600415; Oh K, 2005, CANCER EPIDEM BIOMAR, V14, P835, DOI 10.1158/1055-9965.EPI-04-0545; Ozasa K, 2001, JPN J CANCER RES, V92, P1259, DOI 10.1111/j.1349-7006.2001.tb02148.x; Saunders LD, 2003, WESTERN J NURS RES, V25, P223, DOI 10.1177/0193945902250039; Schilling J, 1996, NUTRITION, V12, P423, DOI 10.1016/S0899-9007(96)00096-2; Schuurman AG, 1999, CANCER, V86, P1019, DOI 10.1002/(SICI)1097-0142(19990915)86:6&lt;1019::AID-CNCR18&gt;3.0.CO;2-H; Senkal M, 1999, ARCH SURG-CHICAGO, V134, P1309, DOI 10.1001/archsurg.134.12.1309; Senkal M, 1997, CRIT CARE MED, V25, P1489, DOI 10.1097/00003246-199709000-00015; Stolzenberg-Solomon RZ, 2002, AM J EPIDEMIOL, V155, P783, DOI 10.1093/aje/155.9.783; Stripp C, 2003, J NUTR, V133, P3664, DOI 10.1093/jn/133.11.3664; Swails WS, 1997, JPEN-PARENTER ENTER, V21, P266, DOI 10.1177/0148607197021005266; Takezaki T, 2003, NUTR CANCER, V45, P160, DOI 10.1207/S15327914NC4502_04; Terry P, 2001, LANCET, V357, P1764, DOI 10.1016/S0140-6736(00)04889-3; Terry P, 2001, CANCER EPIDEM BIOMAR, V10, P913; Troyer D, 1996, NUTR RES, V16, P1959, DOI 10.1016/S0271-5317(96)00219-9; van Dam RM, 2000, AM J CLIN NUTR, V71, P135; VATTEN LJ, 1990, INT J CANCER, V46, P12, DOI 10.1002/ijc.2910460105; Veierod MB, 1997, EUR J CANCER PREV, V6, P540, DOI 10.1097/00008469-199712000-00009; Voorrips LE, 2002, AM J CLIN NUTR, V76, P873, DOI 10.1093/ajcn/76.4.873; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P1751, DOI 10.1093/jnci/91.20.1751	60	354	370	0	57	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					403	415		10.1001/jama.295.4.403	http://dx.doi.org/10.1001/jama.295.4.403			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005QJ	16434631	Green Published			2022-12-28	WOS:000234838600021
J	Stratta, P; Soragna, G; Morellini, V; Gai, M; Motto, D; Lazzarich, E; Brustia, M; Quaglia, M; Canavese, C				Stratta, P; Soragna, G; Morellini, V; Gai, M; Motto, D; Lazzarich, E; Brustia, M; Quaglia, M; Canavese, C			The patient whose hypocalcaemia worsened after prompt intravenous calcium replacement therapy	LANCET			English	Editorial Material									Amedeo Avogadro Univ, Osped Maggiore Carita, Dept Nephrourol, I-28100 Novara, Italy; Univ Turin, Dept Internal Med, Nephrol Sect, Molinette Mauriziano Hosp, I-10126 Turin, Italy	Azienda Ospedaliera Maggiore della Carita di Novara; University of Eastern Piedmont Amedeo Avogadro; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Stratta, P (corresponding author), Amedeo Avogadro Univ, Osped Maggiore Carita, Dept Nephrourol, Corso Mazzini 18, I-28100 Novara, Italy.	strattanefro@hotmail.com	Quaglia, Marco/ABH-7159-2020	Quaglia, Marco/0000-0001-9423-9255					0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					273	273		10.1016/S0140-6736(06)68038-0	http://dx.doi.org/10.1016/S0140-6736(06)68038-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427497				2022-12-28	WOS:000234810600033
J	Uchida, M; Onose, Y; Matsui, Y; Tokura, Y				Uchida, M; Onose, Y; Matsui, Y; Tokura, Y			Real-space observation of helical spin order	SCIENCE			English	Article							WEAK FERROMAGNETISM; MAGNETIC-STRUCTURES; DENSITY-WAVE; MNSI; PHASE; SPINTRONICS; FEGE	Helical spin order in magnetic materials has been investigated only in reciprocal space. We visualized the helical spin order and dynamics in a metal silicide in real space by means of Lorentz electron microscopy. The real space of the helical spin order proves to be much richer than that expected from the averaged structure; it exhibits a variety of magnetic defects similar to atomic dislocations in the crystal lattice. The application of magnetic fields allows us to directly observe the deformation processes of the helical spin order accompanied by nucleation, movement, and annihilation of the magnetic defects.	Japan Sci & Technol Agcy, ERATO, Spin Superstruct Project, Tsukuba, Ibaraki 3058562, Japan; NIMS, Adv Mat Lab, Tsukuba, Ibaraki 3050044, Japan; Natl Inst Adv Ind Sci & Technol, CERC, Tsukuba, Ibaraki 3058562, Japan; Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan	Japan Science & Technology Agency (JST); National Institute for Materials Science; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Uchida, M (corresponding author), Japan Sci & Technol Agcy, ERATO, Spin Superstruct Project, Tsukuba, Ibaraki 3058562, Japan.	uchida.masaya@aist.go.jp	Onose, Yoshinori/F-1977-2010; Tokura, Yoshinori/C-7352-2009; MATSUI, Yoshio/H-2685-2011	Onose, Yoshinori/0000-0002-8398-2956; Tokura, Yoshinori/0000-0002-2732-4983; MATSUI, Yoshio/0000-0003-2044-3450				[Anonymous], 2007, PRINCIPLES CONDENSED; Bajt S, 2000, ULTRAMICROSCOPY, V83, P67, DOI 10.1016/S0304-3991(99)00174-6; BAK P, 1980, J PHYS C SOLID STATE, V13, pL881, DOI 10.1088/0022-3719/13/31/002; BEILLE J, 1983, SOLID STATE COMMUN, V47, P399, DOI 10.1016/0038-1098(83)90928-6; DZYALOSHINSKY I, 1958, J PHYS CHEM SOLIDS, V4, P241, DOI 10.1016/0022-3697(58)90076-3; FAWCETT E, 1988, REV MOD PHYS, V60, P209, DOI 10.1103/RevModPhys.60.209; Fiebig M, 1998, J APPL PHYS, V83, P6560, DOI 10.1063/1.367579; Hubert A, 1998, MAGNETIC DOMAINS; ISHIKAWA Y, 1976, SOLID STATE COMMUN, V19, P525, DOI 10.1016/0038-1098(76)90057-0; ISHIMOTO K, 1995, PHYSICA B, V213, P381, DOI 10.1016/0921-4526(95)00163-4; KITTEL C, 1995, INTRO SOLID STATE PH; LEBECH B, 1989, J PHYS-CONDENS MAT, V1, P6105, DOI 10.1088/0953-8984/1/35/010; LI YY, 1956, PHYS REV, V101, P1450, DOI 10.1103/PhysRev.101.1450; Manyala N, 2000, NATURE, V404, P581, DOI 10.1038/35007030; MORIYA T, 1960, PHYS REV, V120, P91, DOI 10.1103/PhysRev.120.91; NAGAMIYA T, 1967, SOLID STATE PHYS; NAKANISHI O, 1980, SOLID STATE COMMUN, V35, P995, DOI 10.1016/0038-1098(80)91004-2; Pfleiderer C, 2004, NATURE, V427, P227, DOI 10.1038/nature02232; SHIRANE G, 1983, PHYS REV B, V28, P6251, DOI 10.1103/PhysRevB.28.6251; Uchida M, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1887816; Uchida M., UNPUB; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; YOSHIMORI A, 1959, J PHYS SOC JPN, V14, P807, DOI 10.1143/JPSJ.14.807; Zutic I, 2004, REV MOD PHYS, V76, P323, DOI 10.1103/RevModPhys.76.323	24	213	213	3	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2006	311	5759					359	361		10.1126/science.1120639	http://dx.doi.org/10.1126/science.1120639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424334				2022-12-28	WOS:000234938500038
J	Elkins, MR; Robinson, M; Rose, BR; Harbour, C; Moriarty, CP; Marks, GB; Belousova, EG; Xuan, W; Bye, PTP				Elkins, MR; Robinson, M; Rose, BR; Harbour, C; Moriarty, CP; Marks, GB; Belousova, EG; Xuan, W; Bye, PTP		NHSCF Study Grp	A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUCOCILIARY CLEARANCE; PULMONARY-FUNCTION; DISEASE; SPUTUM; LUNG; PATHOGENESIS; BACTERIA; DNASE; CARE	BACKGROUND: Inhaled hypertonic saline acutely increases mucociliary clearance and, in short-term trials, improves lung function in people with cystic fibrosis. We tested the safety and efficacy of inhaled hypertonic saline in a long-term trial. METHODS: In this double-blind, parallel-group trial, 164 patients with stable cystic fibrosis who were at least six years old were randomly assigned to inhale 4 ml of either 7 percent hypertonic saline or 0.9 percent (control) saline twice daily for 48 weeks, with quinine sulfate (0.25 mg per milliliter) added to each solution to mask the taste. A bronchodilator was given before each dose, and other standard therapies were continued during the trial. RESULTS: The primary outcome measure, the rate of change (slope) in lung function (reflected by the forced vital capacity [FVC], forced expiratory volume in one second [FEV(sub 1)], and forced expiratory flow at 25 to 75 percent of FVC [FEF(sub 25-75)]) during the 48 weeks of treatment, did not differ significantly between groups (P=0.79). However, the absolute difference in lung function between groups was significant (P=0.03) when averaged across all post-randomization visits in the 48-week treatment period. As compared with the control group, the hypertonic-saline group had significantly higher FVC (by 82 ml; 95 percent confidence interval, 12 to 153) and FEV(sub 1) (by 68 ml; 95 percent confidence interval, 3 to 132) values, but similar FEF(sub 25-75) values. The hypertonic-saline group also had significantly fewer pulmonary exacerbations (relative reduction, 56 percent; P=0.02) and a significantly higher percentage of patients without exacerbations (76 percent, as compared with 62 percent in the control group; P=0.03). Hypertonic saline was not associated with worsening bacterial infection or inflammation. CONCLUSIONS: Hypertonic saline preceded by a bronchodilator is an inexpensive, safe, and effective additional therapy for patients with cystic fibrosis.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Univ Sydney, Dept Microbiol & Infect Dis, Sydney, NSW 2006, Australia; Woolcock Inst Med Res, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; Woolcock Institute of Medical Research	Bye, PTP (corresponding author), Royal Prince Alfred Hosp, Dept Resp Med, Level 11 E Block,Missenden Rd, Camperdown, NSW 2050, Australia.	peterb@med.usyd.edu.au	Wainwright, Claire E/G-4218-2013; Marks, Guy B./F-5058-2013; Elkins, Mark/C-3240-2012	Wainwright, Claire E/0000-0001-8389-3809; Marks, Guy B./0000-0002-8976-8053; Elkins, Mark/0000-0002-2052-7366; mcdonald, vanessa/0000-0001-9890-3408				Ballmann Manfred, 2002, J Cyst Fibros, V1, P35, DOI 10.1016/S1569-1993(01)00009-1; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Cobos N, 2000, EUR J PEDIATR, V159, P176, DOI 10.1007/s004310050046; *CYST FIBR FDN, 1994, CLIN PRACT GUID CONC, P5; De Rse V, 2002, EUR RESPIR J, V19, P333, DOI 10.1183/09031936.02.00229202; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; King M, 1997, AM J RESP CRIT CARE, V156, P173, DOI 10.1164/ajrccm.156.1.9512074; Koehler DR, 2004, AM J RESP CELL MOL, V31, P377, DOI 10.1165/rcmb.2004-0124TR; Liou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MORRIS JF, 1976, WESTERN J MED, V125, P110; Pocock S, 1996, CLIN TRIALS PRACTICA; POLGAR G, 1971, PULMONARY FUNCTION T, P254; Quittner AL, 2000, J PEDIATR PSYCHOL, V25, P403, DOI 10.1093/jpepsy/25.6.403; Ramsey BW, 1999, NEW ENGL J MED, V340, P23, DOI 10.1056/NEJM199901073400104; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749; SAS Institute, 1997, SAS STAT SOFTW CHANG; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Smith JJ, 1996, CELL, V87, pU25; Suri R, 2002, THORAX, V57, P841, DOI 10.1136/thorax.57.10.841; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; Wolter JM, 1999, CLIN DIAGN LAB IMMUN, V6, P260, DOI 10.1128/CDLI.6.2.260-265.1999; WONG K, 1984, J MED MICROBIOL, V17, P113, DOI 10.1099/00222615-17-2-113	32	601	637	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					229	240		10.1056/NEJMoa043900	http://dx.doi.org/10.1056/NEJMoa043900			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421364	Bronze			2022-12-28	WOS:000234661100003
J	Fitzgibbons, RJ; Giobbie-Hurder, A; Gibbs, JO; Dunlop, DD; Reda, DJ; McCarthy, M; Neumayer, LA; Barkun, JST; Hoehn, JL; Murphy, JT; Sarosi, GA; Syme, WC; Thompson, JS; Wang, J; Jonasson, O				Fitzgibbons, RJ; Giobbie-Hurder, A; Gibbs, JO; Dunlop, DD; Reda, DJ; McCarthy, M; Neumayer, LA; Barkun, JST; Hoehn, JL; Murphy, JT; Sarosi, GA; Syme, WC; Thompson, JS; Wang, J; Jonasson, O			Watchful waiting vs repair of inguinal hernia in minimally symptomatic men - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MESH REPAIR	Context Many men with inguinal hernia have minimal symptoms. Whether deferring surgical repair is a safe and acceptable option has not been assessed. Objective To compare pain and the physical component score (PCS) of the Short Form-36 Version 2 survey at 2 years in men with minimally symptomatic inguinal hernias treated with watchful waiting or surgical repair. Design, Setting, and Participants Randomized trial conducted January 1, 1999, through December 31, 2004, at 5 North American centers and enrolling 720 men (364 watchful waiting, 356 surgical repair) followed up for 2 to 4.5 years. Interventions Watchful-waiting patients were followed up at 6 months and annually and watched for hernia symptoms; repair patients received standard open tension-free repair and were followed up at 3 and 6 months and annually. Main Outcome Measures Pain and discomfort interfering with usual activities at 2 years and change in PCS from baseline to 2 years. Secondary outcomes were complications, patient-reported pain, functional status, activity levels, and satisfaction with care. Results Primary intention-to-treat outcomes were similar at 2 years for watchful waiting vs surgical repair: pain limiting activities (5.1% vs 2.2%, respectively; P=.52); PCS (improvement over baseline, 0.29 points vs 0.13 points; P=.79). Twenty-three percent of patients assigned to watchful waiting crossed over to receive surgical repair (increase in hernia-related pain was the most common reason offered); 17% assigned to receive repair crossed over to watchful waiting. Self-reported pain in watchful-waiting patients crossing over improved after repair. Occurrence of postoperative hernia-related complications was similar in patients who received repair as assigned and in watchful-waiting patients who crossed over. One watchful-waiting patient (0.3%) experienced acute hernia incarceration without strangulation within 2 years; a second had acute incarceration with bowel obstruction at 4 years, with a frequency of 1.8/1000 patient-years inclusive of patients followed up for as long as 4.5 years. Conclusions Watchful waiting is an acceptable option for men with minimally symptomatic inguinal hernias. Delaying surgical repair until symptoms increase is safe because acute hernia incarcerations occur rarely.	Univ Illinois, Dept Surg, Chicago, IL 60607 USA; Creighton Univ, Dept Surg, Omaha, NE 68178 USA; Omaha VA Med Ctr, Dept Surg, Omaha, NE USA; VA Cooperat Studies Program Coordinating Ctr, Hines, IL USA; Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA; Salt Lake City VA Hlth Care Syst, Salt Lake City, UT USA; Univ Utah, Dept Surg, Salt Lake City, UT USA; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; Marshfield Clin Dept Surg, Marshfield, WI USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Dallas VA Med Ctr, Dept Surg, Dallas, TX USA; Lovelace Clin Dept Surg, Albuquerque, NM USA; Univ Nebraska, Dept Surg, Omaha, NE 68182 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Creighton University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; Northwestern University; Northwestern University; Utah System of Higher Education; University of Utah; McGill University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Nebraska System	Jonasson, O (corresponding author), Univ Illinois, Dept Surg, 1514 W Jackson Blvd, Chicago, IL 60607 USA.	ojonasson@ameritech.net	Giobbie-Hurder, Anita/AAU-6193-2021; Sarosi, George/M-2977-2019; , Robert/A-2904-2019	, Domenic/0000-0003-1831-4270; , Robert/0000-0002-3652-7686	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009860] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS 09860] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AMID PK, 1995, SURG TODAY, V25, P619, DOI 10.1007/BF00311436; Bay-Nielsen M, 2004, BRIT J SURG, V91, P362, DOI 10.1002/bjs.4437; BERGER P, 1896, EXTR 9 C FRANC CHIR; Cunningham J, 1996, ANN SURG, V224, P598, DOI 10.1097/00000658-199611000-00003; Fitzgibbons RJ, 2003, J AM COLL SURGEONS, V196, P737, DOI 10.1016/S1072-7515(03)00003-6; Hochberg Y., 1987, MULTIPLE COMP PROCED; Lee E, 2013, STAT METHODS SURVIVA; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; Malek S, 2004, INT J CLIN PRACT, V58, P207, DOI 10.1111/j.1368-5031.2004.0097.x; McCarthy M, 2005, J AM COLL SURGEONS, V201, P245, DOI 10.1016/j.jamcollsurg.2005.03.034; McCarthy M, 2005, J AM COLL SURGEONS, V201, P171, DOI 10.1016/j.jamcollsurg.2005.03.035; Neumayer L, 2004, NEW ENGL J MED, V350, P1819, DOI 10.1056/NEJMoa040093; NEUTRA R, 1981, J CHRON DIS, V34, P561, DOI 10.1016/0021-9681(81)90018-7; NYHUS LM, 1993, SURGERY, V114, P1; Oberschmidt O, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P65; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; Ware J. E., 1993, SF 36 PHYS MENTAL HL; Ware JE, 1993, SF36 HLTH SURVEY MAN	19	269	276	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2006	295	3					285	292		10.1001/jama.295.3.285	http://dx.doi.org/10.1001/jama.295.3.285			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003LU	16418463	Bronze			2022-12-28	WOS:000234684500021
J	Alter, DA; Chong, A; Austin, PC; Mustard, C; Iron, K; Williams, JI; Morgan, CD; Tu, JV; Irvine, J; Naylor, CD				Alter, DA; Chong, A; Austin, PC; Mustard, C; Iron, K; Williams, JI; Morgan, CD; Tu, JV; Irvine, J; Naylor, CD		SESAMI Study Grp	Socioeconomic status and mortality after acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE RISK-FACTORS; CARDIOVASCULAR-DISEASE; REGIONAL-VARIATIONS; CARDIAC PROCEDURES; FACTORS EXPLAIN; HEART-DISEASE; SOCIAL-CLASS; HEALTH; CARE; INCOME	Background: Gradients that link socioeconomic status and cardiovascular mortality have been observed in many populations, including those of countries that provide publicly funded comprehensive medical coverage. The intermediary causes of such gradients remain poorly elucidated. Objective: To examine the relationships among socioeconomic status, other health factors, and 2-year mortality rates after acute myocardial infarction (MI). Design: Prospective cohort study. Setting: Ontario, Canada. Patients: 3407 patients who were hospitalized for acute MI in 53 large-volume hospitals in Canada from December 1999 to February 2003. Measurements: The authors obtained self-reported measures of income and education and developed profiles of the patients' pre-hospitalization cardiac risks and comorbid conditions. To create these profiles, the authors used the patients' self-reports and retrospectively linked no less than 12 years' worth of previous hospitalization data. Mortality rates 2 years after acute MI were examined with and without sequential risk adjustment for age, sex, ethnicity, social support, cardiovascular history and risk, comorbid conditions, and selected in-hospital process factors. Results: Income was strongly and inversely correlated with 2-year mortality rate (crude hazard ratio for high-income vs. low-income tertile, 0.45 [95% Cl, 0.35 to 0.57); P < 0.001). However, after adjustment for age and preexisting cardiovascular events or conventional vascular risk factors, the effect of income was greatly attenuated (adjusted hazard ratio for high-income vs. low-income tertile, 0.77 [CI, 0.54 to 1.10]; P = 0.150). Noncardiovascular comorbid conditions and in-hospital process factors had negligible explanatory effect. Limitations: Previous cardiovascular risks were ascertained through self-report or retrospectively through the longitudinal tracking of the hospitals' administrative databases. The study began with a cohort of patients who had an index cardiac event rather than with asymptomatic individuals. Conclusions: Age, past cardiovascular events, and current vascular risk factors accounted for most of the income-mortality gradient after acute MI. This observation suggests that the "wealth-health gradient" in cardiovascular mortality may be partially ameliorated by more rigorous management of known risk factors among less affluent persons.	York Univ, Inst Clin Evaluat Sci, Sunnybrook Womens Coll Hlth Sci Ctr, Inst Work & Hlth, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada	Institute for Work & Health; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; York University - Canada; University of Toronto	Alter, DA (corresponding author), York Univ, Inst Clin Evaluat Sci, Sunnybrook Womens Coll Hlth Sci Ctr, Inst Work & Hlth, 2075 Bayview Ave,G106, Toronto, ON M4N 3M5, Canada.	david.alter@ices.on.ca	Irvine, M. Jane/F-5442-2011	Austin, Peter/0000-0003-3337-233X; Tu, Jack/0000-0003-0111-722X				Abubakar Ibrahim, 2004, BMC Cardiovasc Disord, V4, P14, DOI 10.1186/1471-2261-4-14; Alter DA, 2004, JAMA-J AM MED ASSOC, V291, P1100, DOI 10.1001/jama.291.9.1100; Alter DA, 2004, CAN J CARDIOL, V20, P1219; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Anderson RT, 1997, EPIDEMIOLOGY, V8, P42, DOI 10.1097/00001648-199701000-00007; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Capewell S, 2001, LANCET, V358, P1213, DOI 10.1016/S0140-6736(01)06343-7; Chang CL, 2002, J CLIN EPIDEMIOL, V55, P749, DOI 10.1016/S0895-4356(02)00414-6; Choiniere R, 2000, CAN MED ASSOC J, V162, pS13; Connolly VM, 1996, DIABETES CARE, V19, P419, DOI 10.2337/diacare.19.5.419; Deswal A, 2004, J AM COLL CARDIOL, V43, P778, DOI 10.1016/j.jacc.2003.10.033; Evans R. G., 1994, WHY ARE SOME PEOPLE, P3; Filate WA, 2003, CAN J CARDIOL, V19, P1241; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fox J., 1991, SAGE U PAPER SERIES; Frances CD, 1999, ARCH INTERN MED, V159, P1429, DOI 10.1001/archinte.159.13.1429; Goldman N, 2001, ANN NY ACAD SCI, V954, P118; GUADAGNOLI E, 1995, SOC SCI MED, V40, P1399, DOI 10.1016/0277-9536(94)00266-V; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Hemingway H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/bmj.318.7196.1460; HERLITZ J, 1994, CORONARY ARTERY DIS, V5, P51; HOUSE JS, 1994, J HEALTH SOC BEHAV, V35, P213, DOI 10.2307/2137277; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Lynch JW, 1996, AM J EPIDEMIOL, V144, P934, DOI 10.1093/oxfordjournals.aje.a008863; Marmot M, 2002, HEALTH AFFAIR, V21, P31, DOI 10.1377/hlthaff.21.2.31; MARMOT M, 1996, HLTH SOCIAL ORG, P42; MARMOT MG, 1983, J PSYCHOSOM RES, V27, P377, DOI 10.1016/0022-3999(83)90069-7; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; Millar W J, 1993, Health Rep, V5, P143; Mookadam F, 2004, ARCH INTERN MED, V164, P1514, DOI 10.1001/archinte.164.14.1514; Mulatu MS, 2002, J HEALTH SOC BEHAV, V43, P22, DOI 10.2307/3090243; Mustard CA, 1997, SOC SCI MED, V45, P383, DOI 10.1016/S0277-9536(96)00354-1; Pilote L, 2003, AM HEART J, V146, P1030, DOI 10.1016/S0002-8703(03)00448-4; POCOCK SJ, 1987, LANCET, V2, P197; Rao S, 2003, J AM COLL CARDIOL, V41, P1948, DOI 10.1016/S0735-1097(03)00402-9; Roos NP, 1997, MILBANK Q, V75, P89, DOI 10.1111/1468-0009.00045; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; Shen JJ, 2001, HEALTH SERV RES, V36, P711; *STAT CAN, 1996, NAT POP HLTH SURV DO; Stronks K, 2002, SCAND J PUBLIC HEALT, V30, P20, DOI 10.1080/140349402760232625; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; Tu JV, 2004, NEW ENGL J MED, V350, P1414, DOI 10.1056/NEJMsa031697; Tu JV, 2001, JAMA-J AM MED ASSOC, V285, P3116, DOI 10.1001/jama.285.24.3116; Wolfson M, 1999, BRIT MED J, V319, P953, DOI 10.1136/bmj.319.7215.953; WOLFSON M, 1993, J GERONTOL, V48, pS167, DOI 10.1093/geronj/48.4.S167; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	47	132	141	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					82	93		10.7326/0003-4819-144-2-200601170-00005	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00005			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	004AX	16418407				2022-12-28	WOS:000234725500004
J	Hanisch, LJ; Mao, JJ; Kodransky, M; Coyne, JC				Hanisch, LJ; Mao, JJ; Kodransky, M; Coyne, JC			Endogenous opioids and hot flushes still hypothetical	LANCET			English	Editorial Material							MENOPAUSAL FLUSHES; POSTMENOPAUSAL WOMEN; BETA-ENDORPHIN; NALOXONE; SECRETION; FLASHES		Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Family Practice & Community Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Hanisch, LJ (corresponding author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.	hanisch@mail.med.upenn.edu	Hanisch, Laura/A-2222-2008					CAGNACCI A, 1991, MATURITAS, V13, P283, DOI 10.1016/0378-5122(91)90237-K; CASPER RF, 1985, CLIN ENDOCRINOL, V22, P293, DOI 10.1111/j.1365-2265.1985.tb03243.x; COHEN MR, 1983, ARCH GEN PSYCHIAT, V40, P613; DEFAZIO J, 1984, J CLIN ENDOCR METAB, V58, P578, DOI 10.1210/jcem-58-3-578; Freeman EW, 2005, MENOPAUSE, V12, P258, DOI 10.1097/01.GME.0000142440.49698.B7; GENAZZANI AR, 1984, AM J OBSTET GYNECOL, V149, P775, DOI 10.1016/0002-9378(84)90121-2; GUILLEMIN R, 1977, SCIENCE, V197, P1367, DOI 10.1126/science.197601; JEFFCOATE WJ, 1978, LANCET, V2, P119; LESLIE RDG, 1979, LANCET, V1, P341; LIGHTMAN SL, 1981, BRIT J OBSTET GYNAEC, V88, P919, DOI 10.1111/j.1471-0528.1981.tb02229.x; Nedstrand E, 2005, CLIMACTERIC, V8, P243, DOI 10.1080/13697130500118050; SIMPKINS JW, 1983, LIFE SCI, V32, P1957, DOI 10.1016/0024-3205(83)90047-4; TEPPER R, 1987, OBSTET GYNECOL, V70, P150; TULANDI T, 1985, AM J OBSTET GYNECOL, V151, P277, DOI 10.1016/0002-9378(85)90026-2	14	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2006	367	9505					92	93		10.1016/S0140-6736(06)67940-3	http://dx.doi.org/10.1016/S0140-6736(06)67940-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413859				2022-12-28	WOS:000234655500007
J	Sazawal, S; Black, RE; Ramsan, M; Chwaya, HM; Stoltzfus, RJ; Dutta, A; Dhingra, U; Kabole, I; Deb, S; Othman, MK; Kabole, FM				Sazawal, S; Black, RE; Ramsan, M; Chwaya, HM; Stoltzfus, RJ; Dutta, A; Dhingra, U; Kabole, I; Deb, S; Othman, MK; Kabole, FM			Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial	LANCET			English	Article							INTERMITTENT TREATMENT; PLASMODIUM-FALCIPARUM; NITRIC-OXIDE; ORAL IRON; ANEMIA; DEFICIENCY; INFANTS; CHELATION; INFECTION; IMMUNITY	Background Anaemia caused by iron deficiency is common in children younger than age 5 years in eastern Africa. However, there is concern that universal supplementation of children with iron and folic acid in areas of high malaria transmission might be harmful. Methods We did a randomised, placebo-controlled trial, of children aged 1-35 months and living in Pemba, Zanzibar. We assigned children to daily oral supplementation with: iron (12.5 mg) and folic acid (50 mu g; n=7950), iron, folic acid, and zinc (n=8120), or placebo (n=8006); children aged 1-11 months received half the dose. Our primary endpoints were all-cause mortality and admission to hospital. Analyses were by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59549825. Findings The iron and folic acid-containing groups of the trial were stopped early on Aug 19, 2003, on the recommendation of the data and safety monitoring board. To this date, 24 076 children contributed a follow-up of 25 524 child-years. Those who received iron and folic acid with or without zinc were 12% (95% Cl 2-23, p=0.02) more likely to die or need treatment in hospital for an adverse event and 11% (1-23%, p=0.03) more likely to be admitted to hospital; there were also 15% (- 7 to 41, p=0.19) more deaths in these groups. Interpretation Routine supplementation with iron and folic acid in preschool children in a population with high rates of malaria can result in an increased risk of severe illness and death. In the presence of an active programme to detect and treat malaria and other infections, iron-deficient and anaemic children can benefit from supplementation. However, supplementation of those who are not iron deficient might be harmful. As such, current guidelines for universal supplementation with iron and folic acid should be revised.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Publ Hlth Lab Ivo de Carneri, Pemba, Zanzibar, Tanzania; Govt Zanzibar, Minist Hlth & Social Welf, Zanzibar, Tanzania; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Cornell University	Black, RE (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	rblack@jhsph.edu	Girelli, Domenico/B-1183-2008	Girelli, Domenico/0000-0001-9684-1899; Black, Robert/0000-0001-9926-7984				ADAM Z, 1996, THESIS U LONDON; ANKER M, 1999, WHOCDSCSRIR994, P78; BATES CJ, 1987, T ROY SOC TROP MED H, V81, P286, DOI 10.1016/0035-9203(87)90244-6; Berger J, 2000, EUR J CLIN NUTR, V54, P29, DOI 10.1038/sj.ejcn.1600888; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Brunet LR, 2001, INT IMMUNOPHARMACOL, V1, P1457, DOI 10.1016/S1567-5769(01)00090-X; Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986; Dewey KG, 2002, J NUTR, V132, P3249, DOI 10.1093/jn/132.11.3249; FAIRWEATHERTAIT SJ, 1989, J NUTR, V119, P599, DOI 10.1093/jn/119.4.599; FANNATI F, 1995, J HEPATOL, V22, P4449; Gera T, 2002, BMJ-BRIT MED J, V325, P1142, DOI 10.1136/bmj.325.7373.1142; GORDEUK VR, 1992, BLOOD, V79, P308; Grantham-McGregor S, 2001, J NUTR, V131, p649S, DOI 10.1093/jn/131.2.649S; Hoen B, 1999, AM J KIDNEY DIS, V34, pS30, DOI 10.1053/ajkd.1999.v34.aajkd0344b0030; IDJRADINATA P, 1994, LANCET, V343, P1252, DOI 10.1016/S0140-6736(94)92151-2; Massaga JJ, 2003, LANCET, V361, P1853, DOI 10.1016/S0140-6736(03)13504-0; Mebrahtu T, 2004, J NUTR, V134, P3037, DOI 10.1093/jn/134.11.3037; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; MURRAY MJ, 1978, BRIT MED J, V2, P1113, DOI 10.1136/bmj.2.6145.1113; Nyakeriga AM, 2004, J INFECT DIS, V190, P439, DOI 10.1086/422331; Oppenheimer SJ, 2001, J NUTR, V131, p616S, DOI 10.1093/jn/131.2.616S; PAYNE D, 1988, B WORLD HEALTH ORGAN, V66, P621; Rigamonti C, 2002, EUR J CLIN INVEST, V32, P28, DOI 10.1046/j.1365-2362.2002.0320s1028.x; Romeo AM, 2001, J BIOL CHEM, V276, P24301, DOI 10.1074/jbc.M010806200; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17, DOI 10.1080/02724936.1989.11748589; Stoltzfus R, 2001, BRIT MED J, V323, P1, DOI DOI 10.1136/BMJ.323.7326.1389; Stoltzfus RJ, 1998, GUIDELINES USE IRON, P1; Therneau TM, 1997, STAT MED, V16, P2029, DOI 10.1002/(SICI)1097-0258(19970930)16:18<2029::AID-SIM637>3.0.CO;2-H; Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4; *UN ACC, 2000, 4 UN ACC SCN; VANASBECK BS, 1982, BRIT MED J, V284, P542, DOI 10.1136/bmj.284.6315.542; vandenHombergh J, 1996, J TROP PEDIATRICS, V42, P220, DOI 10.1093/tropej/42.4.220; vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7; Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0; Wang P, 1999, MOL MICROBIOL, V32, P1254, DOI 10.1046/j.1365-2958.1999.01437.x; Weinberg ED, 1999, J EUKARYOT MICROBIOL, V46, P231, DOI 10.1111/j.1550-7408.1999.tb05119.x; [No title captured]	38	692	703	2	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					133	143		10.1016/S0140-6736(06)67962-2	http://dx.doi.org/10.1016/S0140-6736(06)67962-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413877				2022-12-28	WOS:000234655500028
J	Chekulaeva, M; Hentze, MW; Ephrussi, A				Chekulaeva, M; Hentze, MW; Ephrussi, A			Bruno acts as a dual repressor of oskar translation, promoting mRNA oligomerization and formation of silencing particles	CELL			English	Article							POLE CELL-FORMATION; BINDING-PROTEIN; DOSAGE COMPENSATION; INITIATION-FACTORS; SEX-LETHAL; DROSOPHILA; LOCALIZATION; RIBOSOMES; REQUIRE; RECRUITMENT	Prior to reaching the posterior pole of the Drosophila oocyte, oskar mRNA is translationally silenced by Bruno binding to BREs in the 3' untranslated region. The elF4E binding protein Cup interacts with Bruno and inhibits Oskar translation. Validating current models, we directly demonstrate the mechanism proposed for Cup-mediated repression: inhibition of small ribosomal subunit recruitment to Oskar mRNA. However, 43S complex recruitment remains inhibited in the absence of functional Cup, uncovering a second Bruno-dependent silencing mechanism. This mechanism involves mRNA oligomerization and formation of large (50S-80S) silencing particles that cannot be accessed by ribosomes. Bruno-dependent mRNA oligomerization into silencing particles emerges as a mode of translational control that may be particularly suited to coupling with mRNA transport.	European Mol Biol Lab, Dev Biol Unit, D-69117 Heidelberg, Germany; European Mol Biol Lab, Gene Express Unit, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Chekulaeva, M (corresponding author), European Mol Biol Lab, Dev Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	hentze@embl.de; ephrussi@embl.de	Hentze, Matthias W/V-3980-2017; Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020; Chekulayeva, Marina/AAK-4853-2020	Hentze, Matthias W/0000-0002-4023-7876; Ephrussi, Anne/0000-0002-5061-4620; 				Baron-Benhamou Julie, 2004, Methods Mol Biol, V257, P135, DOI 10.1385/1-59259-750-5:135; Beckmann K, 2005, CELL, V122, P529, DOI 10.1016/j.cell.2005.06.011; Braat AK, 2004, DEV CELL, V7, P125, DOI 10.1016/j.devcel.2004.06.009; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Castagnetti S, 2000, DEVELOPMENT, V127, P1063; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Czaplinski K, 2005, DEV CELL, V8, P505, DOI 10.1016/j.devcel.2005.01.012; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Lee JH, 2002, P NATL ACAD SCI USA, V99, P16689, DOI 10.1073/pnas.262569399; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lie YS, 1999, DEVELOPMENT, V126, P4989; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; Nakamura A, 2004, DEV CELL, V6, P69, DOI 10.1016/S1534-5807(03)00400-3; Nakamura A, 2001, DEVELOPMENT, V128, P3233; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Preiss T, 2003, BIOESSAYS, V25, P1201, DOI 10.1002/bies.10362; RONGO C, 1995, DEVELOPMENT, V121, P2737; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; Teixeira D, 2005, RNA, V11, P371, DOI 10.1261/rna.7258505; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; Wagner C, 2001, J MOL BIOL, V313, P511, DOI 10.1006/jmbi.2001.5057; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wilhelm JE, 2003, J CELL BIOL, V163, P1197, DOI 10.1083/jcb.200309088	37	157	159	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					521	533		10.1016/j.cell.2006.01.031	http://dx.doi.org/10.1016/j.cell.2006.01.031			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469699	Bronze			2022-12-28	WOS:000235464000015
J	Pichersky, E; Noel, JP; Dudareva, N				Pichersky, E; Noel, JP; Dudareva, N			Biosynthesis of plant volatiles: Nature's diversity and ingenuity	SCIENCE			English	Review							ACID CARBOXYL METHYLTRANSFERASE; O-METHYLTRANSFERASES; GLANDULAR TRICHOMES; KEY ENZYME; EMISSION; IDENTIFICATION; LEAVES; SYNTHASES; FLOWERS; GENES	Plant volatiles (PVs) are lipophilic molecules with high vapor pressure that serve various ecological roles. The synthesis of PVs involves the removal of hydrophilic moieties and oxidation/hydroxylation, reduction, methylation, and acylation reactions. Some PV biosynthetic enzymes produce multiple products from a single substrate or act on multiple substrates. Genes for PV biosynthesis evolve by duplication of genes that direct other aspects of plant metabolism; these duplicated genes then diverge from each other over time. Changes in the preferred substrate or resultant product of PV enzymes may occur through minimal changes of critical residues. Convergent evolution is often responsible for the ability of distally related species to synthesize the same volatile.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Salk Inst Biol Studies, Jack H Skirball Ctr Chem Biol & Proteom, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; Salk Institute; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Pichersky, E (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 n Univ St, Ann Arbor, MI 48109 USA.	lelx@umich.edu	Dudareva, Natalia/S-8710-2017; Noel, Joseph P/A-9459-2009	Dudareva, Natalia/0000-0003-0777-7763; 	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Bate NJ, 1998, PHYSIOL PLANTARUM, V104, P97, DOI 10.1034/j.1399-3054.1998.1040113.x; Boatright J, 2004, PLANT PHYSIOL, V135, P1993, DOI 10.1104/pp.104.045468; Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; BorejszaWysocki W, 1996, PLANT PHYSIOL, V110, P791, DOI 10.1104/pp.110.3.791; Bouwmeester HJ, 1998, PLANT PHYSIOL, V117, P901, DOI 10.1104/pp.117.3.901; Bouwmeester HJ, 1999, PHYTOCHEMISTRY, V50, P243, DOI 10.1016/S0031-9422(98)00516-0; Buchanan B.B., 2000, BIOCH MOL BIOL PLANT; D'Auria JC, 2002, PLANT PHYSIOL, V130, P466, DOI 10.1104/pp.006460; Dudareva N, 2004, PLANT PHYSIOL, V135, P1893, DOI 10.1104/pp.104.049981; Franceschi VR, 2005, NEW PHYTOL, V167, P353, DOI 10.1111/j.1469-8137.2005.01436.x; Frey M, 2000, P NATL ACAD SCI USA, V97, P14801, DOI 10.1073/pnas.260499897; Fridman E, 2005, PLANT CELL, V17, P1252, DOI 10.1105/tpc.104.029736; Gang DR, 2002, PLANT CELL, V14, P505, DOI 10.1105/tpc.010327; Gang DR, 2001, PLANT PHYSIOL, V125, P539, DOI 10.1104/pp.125.2.539; Gershenzon J, 2000, PLANT PHYSIOL, V122, P205, DOI 10.1104/pp.122.1.205; Goff SA, 2006, SCIENCE, V311, P815, DOI 10.1126/science.1112614; Goodwin SM, 2003, PHYSIOL PLANTARUM, V117, P435, DOI 10.1034/j.1399-3054.2003.00047.x; Hayashi S, 2004, TETRAHEDRON, V60, P7005, DOI 10.1016/j.tet.2003.10.130; Helsper JPFG, 1998, PLANTA, V207, P88, DOI 10.1007/s004250050459; Howe GA, 2002, CURR OPIN PLANT BIOL, V5, P230, DOI 10.1016/S1369-5266(02)00250-9; KNUDSEN JT, 1993, PHYTOCHEMISTRY, V33, P253, DOI 10.1016/0031-9422(93)85502-I; Kollner TG, 2004, PLANT CELL, V16, P1115, DOI 10.1105/tpc.019877; Kolosova N, 2001, PLANT PHYSIOL, V126, P956, DOI 10.1104/pp.126.3.956; Lavid N, 2002, PLANT PHYSIOL, V129, P1899, DOI 10.1104/pp.005330; Lewinsohn E, 1998, ANN BOT-LONDON, V81, P35, DOI 10.1006/anbo.1997.0525; Negre F, 2003, PLANT CELL, V15, P2992, DOI 10.1105/tpc.016766; Pichersky E, 2002, CURR OPIN PLANT BIOL, V5, P237, DOI 10.1016/S1369-5266(02)00251-0; Pichersky E, 2000, TRENDS PLANT SCI, V5, P439, DOI 10.1016/S1360-1385(00)01741-6; Pott MB, 2004, PLANT PHYSIOL, V135, P1946, DOI 10.1104/pp.104.041806; Schuler MA, 2003, ANNU REV PLANT BIOL, V54, P629, DOI 10.1146/annurev.arplant.54.031902.134840; Schwab W, 2003, PHYTOCHEMISTRY, V62, P837, DOI 10.1016/S0031-9422(02)00723-9; Seo HS, 2001, P NATL ACAD SCI USA, V98, P4788, DOI 10.1073/pnas.081557298; Shalit M, 2003, PLANT PHYSIOL, V131, P1868, DOI 10.1104/pp.102.018572; Simkin AJ, 2004, PLANT J, V40, P882, DOI 10.1111/j.1365-313X.2004.02263.x; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; Staudt M, 1998, PLANT CELL ENVIRON, V21, P385, DOI 10.1046/j.1365-3040.1998.00288.x; Tadmor Y, 2002, J AGR FOOD CHEM, V50, P2005, DOI 10.1021/jf011237x; Tholl D, 2005, PLANT J, V42, P757, DOI 10.1111/j.1365-313X.2005.02417.x; Turner GW, 2000, PLANT PHYSIOL, V124, P655, DOI 10.1104/pp.124.2.655; van der Hoeven RS, 2000, PLANT CELL, V12, P2283, DOI 10.1105/tpc.12.11.2283; Verdonk JC, 2005, PLANT CELL, V17, P1612, DOI 10.1105/tpc.104.028837; Wang JH, 1999, ARCH BIOCHEM BIOPHYS, V368, P172, DOI 10.1006/abbi.1999.1304; Watanabe S, 2001, BIOSCI BIOTECH BIOCH, V65, P442, DOI 10.1271/bbb.65.442; Wu SQ, 2004, PLANT PHYSIOL, V135, P95, DOI 10.1104/pp.103.037051	44	558	608	7	214	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					808	811		10.1126/science.1118510	http://dx.doi.org/10.1126/science.1118510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469917	Green Accepted			2022-12-28	WOS:000235374900036
J	Pokidysheva, E; Zhang, Y; Battisti, AJ; Bator-Kelly, CM; Chipman, PR; Xiao, CA; Gregorio, GG; Hendrickson, WA; Kuhn, RJ; Rossmann, MG				Pokidysheva, E; Zhang, Y; Battisti, AJ; Bator-Kelly, CM; Chipman, PR; Xiao, CA; Gregorio, GG; Hendrickson, WA; Kuhn, RJ; Rossmann, MG			Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN	CELL			English	Article							LIGAND-BINDING; ENVELOPE GLYCOPROTEIN; CELLULAR RECEPTOR; STRUCTURAL BASIS; DENDRITIC CELLS; INFECTION; VISUALIZATION; POLYOMAVIRUS; ORGANIZATION; ENHANCEMENT	Dengue virus (DENV) is a significant human pathogen that causes millions of infections and results in about 24,000 deaths each year. Dendritic cell-specific ICAM3 grabbing nonintegrin (DC-SIGN), abundant in immature dendritic cells, was previously reported as being an ancillary receptor interacting with the surface of DENV. The structure of DENV in complex with the carbohydrate recognition domain (CRD) of DC-SIGN was determined by cryo-electron microscopy at 25 angstrom resolution. One CRD monomer was found to bind to two glycosylation sites at Asn67 of two neighboring glycoproteins in each icosahedral asymmetric unit, leaving the third Asn67 residue vacant. The vacancy at the third Asn67 site is a result of the nonequivalence of the glycoprotein environments, leaving space for the primary receptor binding to domain III of E. The use of carbohydrate moieties for receptor binding sites suggests a mechanism for avoiding immune surveillance.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Columbia University; Howard Hughes Medical Institute	Pokidysheva, E (corresponding author), Purdue Univ, Dept Biol Sci, Lilly Hall,915 W State St, W Lafayette, IN 47907 USA.	mr@purdue.edu	Xiao, Chuan/B-2130-2010; Kuhn, Richard/AAR-2722-2021	Xiao, Chuan/0000-0001-6599-8762; Kuhn, Richard/0000-0003-4148-1026; Chipman, Paul/0000-0003-3652-4087; Gregorio, Gabriel Glenn/0000-0001-8677-133X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055672] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 55672, AI40895] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker TS, 1999, MICROBIOL MOL BIOL R, V63, P862, DOI 10.1128/MMBR.63.4.862-922.1999; Bernhard OK, 2004, J BIOL CHEM, V279, P51828, DOI 10.1074/jbc.M402741200; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Bhardwaj S, 2001, J VIROL, V75, P4002, DOI 10.1128/JVI.75.8.4002-4007.2001; Bhella D, 2004, J BIOL CHEM, V279, P8325, DOI 10.1074/jbc.M311334200; Burmeister WP, 2004, J VIROL, V78, P7727, DOI 10.1128/JVI.78.14.7727-7736.2004; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Conway JF, 1999, J STRUCT BIOL, V128, P106, DOI 10.1006/jsbi.1999.4168; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599; JOHNSON AJ, 1994, VIROLOGY, V203, P241, DOI 10.1006/viro.1994.1481; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; ROSSMANN MG, 1994, PROTEIN SCI, V3, P1712, DOI 10.1002/pro.5560031010; Rossmann MG, 2001, J STRUCT BIOL, V136, P190, DOI 10.1006/jsbi.2002.4435; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; Rossmann MG, 2002, TRENDS MICROBIOL, V10, P324, DOI 10.1016/S0966-842X(02)02383-1; Snyder GA, 2005, J MOL BIOL, V347, P979, DOI 10.1016/j.jmb.2005.01.063; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; Su SV, 2004, J BIOL CHEM, V279, P19122, DOI 10.1074/jbc.M400184200; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Verdaguer N, 2004, NAT STRUCT MOL BIOL, V11, P429, DOI 10.1038/nsmb753; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553; Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990; Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019; Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270	44	229	239	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					485	493		10.1016/j.cell.2005.11.042	http://dx.doi.org/10.1016/j.cell.2005.11.042			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469696	Bronze			2022-12-28	WOS:000235464000012
J	Cyranoski, D				Cyranoski, D			No end in sight for stem-cell odyssey	NATURE			English	News Item								Advanced Cell Technology was founded in 1994 and has led the field in cloning and stem cell research for more than a decade. However, following the revelation that Korean researcher Woo Suk Hwang lied about successfully cloning a human embryo, Advanced Cell Technology need to tread cautiously when it comes to future research. Funding for therapeutic cloning research has dried up as a result of the controversy, as has the supply of human eggs.										Cibelli J.B., 2001, J REGEN MED, V2, P25, DOI [10.1089/152489001753262168, DOI 10.1089/152489001753262168]; Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/clo.2004.6.217; Weissman IL, 2006, NATURE, V439, P145, DOI 10.1038/439145a	3	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					658	659		10.1038/439658a	http://dx.doi.org/10.1038/439658a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467811				2022-12-28	WOS:000235193100019
J	Monson, RK; Lipson, DL; Burns, SP; Turnipseed, AA; Delany, AC; Williams, MW; Schmidt, SK				Monson, RK; Lipson, DL; Burns, SP; Turnipseed, AA; Delany, AC; Williams, MW; Schmidt, SK			Winter forest soil respiration controlled by climate and microbial community composition	NATURE			English	Article							TURBULENT FLUX MEASUREMENTS; TEMPERATURE-DEPENDENCE; HIGH-ELEVATION; AIR-FLOWS; CO2; N2O; CH4; SNOWPACK	Most terrestrial carbon sequestration at mid-latitudes in the Northern Hemisphere occurs in seasonal, montane forest ecosystems(1). Winter respiratory carbon dioxide losses from these ecosystems are high, and over half of the carbon assimilated by photosynthesis in the summer can be lost the following winter(2,3). The amount of winter carbon dioxide loss is potentially susceptible to changes in the depth of the snowpack; a shallower snowpack has less insulation potential, causing colder soil temperatures and potentially lower soil respiration rates. Recent climate analyses have shown widespread declines in the winter snowpack of mountain ecosystems in the western USA and Europe that are coupled to positive temperature anomalies(4-6). Here we study the effect of changes in snow cover on soil carbon cycling within the context of natural climate variation. We use a six-year record of net ecosystem carbon dioxide exchange in a subalpine forest to show that years with a reduced winter snowpack are accompanied by significantly lower rates of soil respiration. Furthermore, we show that the cause of the high sensitivity of soil respiration rate to changes in snow depth is a unique soil microbial community that exhibits exponential growth and high rates of substrate utilization at the cold temperatures that exist beneath the snow. Our observations suggest that a warmer climate may change soil carbon sequestration rates in forest ecosystems owing to changes in the depth of the insulating snow cover.	Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; Univ Colorado, Ctr Interdisciplinary Res Environm Sci, Boulder, CO 80309 USA; Univ Colorado, Dept Geog, Boulder, CO 80309 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Natl Ctr Atmospher Res, Boulder, CO 80305 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; California State University System; San Diego State University; National Center Atmospheric Research (NCAR) - USA	Monson, RK (corresponding author), Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA.	Russell.Monson@colorado.edu	Burns, Sean P/A-9352-2008; Schmidt, Steven K/G-2771-2010	Burns, Sean P/0000-0002-6258-1838; Schmidt, Steven K/0000-0002-9175-2085				[Anonymous], 2002, EOS T; Brooks PD, 2005, GLOBAL CHANGE BIOL, V11, P231, DOI 10.1111/j.1365-2486.2004.00877.x; Brooks PD, 1997, OECOLOGIA, V110, P403, DOI 10.1007/s004420050175; Burnett AW, 2003, J CLIMATE, V16, P3535, DOI [10.1175/1520-0442(2003)016<3535:IGLSDT>2.0.CO;2, 10.1175/1520-0442(2003)016&lt;3535:IGLSDT&gt;2.0.CO;2]; Decker KLM, 2003, SOIL SCI SOC AM J, V67, P1234, DOI 10.2136/sssaj2003.1234; Fitzhugh RD, 2003, SOIL SCI SOC AM J, V67, P1897, DOI 10.2136/sssaj2003.1897; Groffman PM, 2001, BIOGEOCHEMISTRY, V56, P135, DOI 10.1023/A:1013039830323; Hubbard RM, 2005, BIOGEOCHEMISTRY, V73, P93, DOI 10.1007/s10533-004-1990-0; Katterer T, 1998, BIOL FERT SOILS, V27, P258, DOI 10.1007/s003740050430; Laternser M, 2003, INT J CLIMATOL, V23, P733, DOI 10.1002/joc.912; Lipson DA, 2004, APPL ENVIRON MICROB, V70, P2867, DOI 10.1128/AEM.70.5.2867-2879.2004; Lipson DA, 1999, ECOLOGY, V80, P1623; LLOYD J, 1994, FUNCT ECOL, V8, P315, DOI 10.2307/2389824; Martin AP, 2002, APPL ENVIRON MICROB, V68, P3673, DOI 10.1128/AEM.68.8.3673-3682.2002; Massman WJ, 1997, J GEOPHYS RES-ATMOS, V102, P18851, DOI 10.1029/97JD00844; Mast MA, 1998, GLOBAL BIOGEOCHEM CY, V12, P607, DOI 10.1029/98GB02313; Mikan CJ, 2002, SOIL BIOL BIOCHEM, V34, P1785, DOI 10.1016/S0038-0717(02)00168-2; Monson RK, 2005, OECOLOGIA, V146, P130, DOI 10.1007/s00442-005-0169-2; Monson RK, 2002, GLOBAL CHANGE BIOL, V8, P459, DOI 10.1046/j.1365-2486.2002.00480.x; Mote PW, 2005, B AM METEOROL SOC, V86, P39, DOI 10.1175/BAMS-86-1-39; PATTERSON DE, 1981, CAN GEOTECH J, V18, P131, DOI 10.1139/t81-012; Scherrer SC, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020255; SCHMIDT SK, 1992, FEMS MICROBIOL ECOL, V101, P197, DOI 10.1016/0378-1097(92)90816-7; Scott-Denton LE, 2003, SOIL BIOL BIOCHEM, V35, P525, DOI 10.1016/S0038-0717(03)00007-5; SOMMERFELD RA, 1993, NATURE, V361, P140, DOI 10.1038/361140a0; Swanson AL, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021809; Turnipseed AA, 2004, AGR FOREST METEOROL, V125, P187, DOI 10.1016/j.agrformet.2004.04.007; Turnipseed AA, 2003, AGR FOREST METEOROL, V119, P1, DOI 10.1016/S0168-1923(03)00136-9; Valentini R, 2000, NATURE, V404, P861, DOI 10.1038/35009084; Williams MW, 1996, WATER RESOUR RES, V32, P3161, DOI 10.1029/96WR02240	30	395	452	15	313	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					711	714		10.1038/nature04555	http://dx.doi.org/10.1038/nature04555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467835				2022-12-28	WOS:000235193100041
J	Steinbrook, R				Steinbrook, R			Facing the diabetes epidemic - Mandatory reporting of glycosylated hemoglobin values in New York City	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4; Frieden TR, 2004, AM J PUBLIC HEALTH, V94, P2059, DOI 10.2105/AJPH.94.12.2059; MacLean Charles D, 2004, Clin Trials, V1, P532, DOI 10.1191/1740774504cn051oa; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Saydah SH, 2004, JAMA-J AM MED ASSOC, V291, P335, DOI 10.1001/jama.291.3.335	5	68	68	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					545	548		10.1056/NEJMp068008	http://dx.doi.org/10.1056/NEJMp068008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467539				2022-12-28	WOS:000235177500001
J	Di Toro, G; Hirose, T; Nielsen, S; Pennacchioni, G; Shimamoto, T				Di Toro, G; Hirose, T; Nielsen, S; Pennacchioni, G; Shimamoto, T			Natural and experimental evidence of melt lubrication of faults during earthquakes	SCIENCE			English	Article							STRESS; SLIP; FRICTION; PSEUDOTACHYLYTES	Melt produced by friction during earthquakes may act either as a coseismic fault lubricant or as a viscous brake. Here we estimate the dynamic shear resistance (tau(f)) in the presence of friction-induced melts from both exhumed faults and high-velocity (1.28 meters per second) frictional experiments. Exhumed faults within granitoids (tonalites) indicate low tau(f) at 10 kilometers in depth. Friction experiments on tonalite samples show that tau(f) depends weakly on normal stress. Extrapolation of experimental data yields tau(f) values consistent with the field estimates and well below the Byerlee strength. We conclude that friction-induced melts can lubricate faults at intermediate crustal depths.	Univ Padua, Dipartimento Geol Paleontol & Geofis, I-35137 Padua, Italy; Kyoto Univ, Grad Sch Sci, Div Earth & Planetary Sci, Kyoto 6068502, Japan; RISSC Ist Nazl Geofis & Vulcanol, Res Unit, I-00143 Rome, Italy	University of Padua; Kyoto University	Di Toro, G (corresponding author), Univ Padua, Dipartimento Geol Paleontol & Geofis, I-35137 Padua, Italy.	giulio.ditoro@unipd.it	Nielsen, Stefan B/F-6210-2011; pennacchioni, giorgio/L-9471-2019	Nielsen, Stefan B/0000-0002-9214-2932; pennacchioni, giorgio/0000-0002-5956-5327; Hirose, Takehiro/0000-0002-5397-3346				Bouchon M, 1997, J GEOPHYS RES-SOL EA, V102, P11731, DOI 10.1029/97JB00623; Brodsky EE, 2001, J GEOPHYS RES-SOL EA, V106, P16357, DOI 10.1029/2001JB000430; BRUNE JN, 1969, J GEOPHYS RES, V74, P3821, DOI 10.1029/JB074i015p03821; BYERLEE J, 1978, PURE APPL GEOPHYS, V116, P615, DOI 10.1007/BF00876528; Di Toro G, 2005, TECTONOPHYSICS, V402, P55, DOI 10.1016/j.tecto.2004.12.036; Di Toro G, 2005, TECTONOPHYSICS, V402, P3, DOI 10.1016/j.tecto.2004.10.014; Di Toro G, 2004, J STRUCT GEOL, V26, P1783, DOI 10.1016/j.jsg.2004.03.001; Di Toro G, 2004, NATURE, V427, P436, DOI 10.1038/nature02249; Fialko Y, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2005JB003869; Guatteri M, 1998, B SEISMOL SOC AM, V88, P777; HEATON TH, 1990, PHYS EARTH PLANET IN, V64, P1, DOI 10.1016/0031-9201(90)90002-F; Hirose T, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003207; Kanamori H., 2000, GEOPHYS MONOGR AM GE, V120, P147; Koizumi Y, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020642; OHTOMO Y, 1994, STRUCT GEOL, V39, P135; PITTARELLO L, 2005, EOS T AGU, V86; Scholz C.H., 2002, MECH EARTHQUAKES FAU, DOI 10.1017/CBO9780511818516; SIBSON RH, 1975, GEOPHYS J ROY ASTR S, V43, P775, DOI 10.1111/j.1365-246X.1975.tb06195.x; SIBSON RH, 1973, NATURE-PHYS SCI, V243, P66, DOI 10.1038/physci243066a0; SIBSON RH, 1974, NATURE, V249, P542, DOI 10.1038/249542a0; Spray JG, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022293; SPRAY JG, 1993, J GEOPHYS RES-SOL EA, V98, P8053, DOI 10.1029/93JB00020; Tsutsumi A, 1997, GEOPHYS RES LETT, V24, P699, DOI 10.1029/97GL00503; ZHANG G, 1998, B SEISMOL SOC AM, V58, P1466	24	274	275	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					647	649		10.1126/science.1121012	http://dx.doi.org/10.1126/science.1121012			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456076				2022-12-28	WOS:000235257400044
J	Heyns, AD; Benjamin, RJ; Swanevelder, JPR; Laycock, ME; Pappalardo, BL; Crookes, RL; Wright, DJ; Busch, MP				Heyns, AD; Benjamin, RJ; Swanevelder, JPR; Laycock, ME; Pappalardo, BL; Crookes, RL; Wright, DJ; Busch, MP			Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMITTED VIRAL-INFECTIONS; FACING DONOR RECRUITMENT; RISK-FACTORS; UNITED-STATES; PERIOD MODEL; ZIMBABWE; EPIDEMIOLOGY; TRANSMISSION; PREVENTION	Context The South African National Blood Service collects more than 700000 units of blood annually from a population in which 11.4% is infected with human immunodeficiency virus 1 (HIV-1). The prevalence of HIV-1 in blood donations increased to 0.26% (1:385) in 1998, indicating that a significant number of window-period infective units were entering the blood supply (risk 3.4/100 000). Objectives To determine whether the implementation of anew donor selection policy and educational program introduced in 1999 was associated with reductions in the incidence and prevalence of HIV-1 in blood donations and the reduced transmission risk. Design We compared the prevalence of HIV-1 in 880534 blood donations collected from 1999 through 2000 with the 791639 blood donations collected from 2001 through 2002. We estimated the incidence of HIV-1 in 93 378 (1999-2000) and 67 231 (2001-2002) first-time donations and the residual risk for all donations in 2001-2002 using the less-sensitive enzyme-linked immunoassay and incidence-window period model. Setting All blood donors in the Inland region of the South African National Blood Service were analyzed. Intervention Donor clinics in high HIV prevalence areas were closed. Programs targeting repeat donors and youth were initiated and HIV risk behavior education programs were developed. Structured donor interviews and an enhanced donor self-exclusion questionnaire were institutionalized. Results The prevalence of HIV-1 in blood donations declined from 0.17% in 1999-2000 to 0.08% in 2001-2002 after the implementation of the new donor selection and education policy. The number of high-risk donations collected decreased from 2.6% to 1.7% (P<.001), and the likelihood of these donations being infected decreased from 4.8% to 3.25%. The likelihood of first-time donors being recently infected with HIV-1 decreased from 18% to 14% (P=.07) and respective incidence of high-risk donations collected decreased from 2.6% to 1.7%. Donations from the majority black population declined from 6.6% to 4.2% (P<.001). Analysis of HIV-1 incidence in 20012002 suggests a residual risk of collecting a window period infectious unit of 2.6/ 100 000. Conclusion The implementation of enhanced education and selection policies in South Africa was associated with decreased prevalence of HIV-1 in blood donations.	S African Natl Blood Serv, ZA-1715 Weltevreden Pk, South Africa; Harvard Univ, Joint Program Transfus Med, Boston, MA 02115 USA; Amer Red Cross Blood Serv, Dedham, MA USA; Blood Syst Res Inst, San Francisco, CA USA; Westat Corp, Rockville, MD USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Harvard University; American Red Cross; Vitalant; Vitalant Research Institute; Westat; University of California System; University of California San Francisco	Heyns, AD (corresponding author), S African Natl Blood Serv, Private Bag X14, ZA-1715 Weltevreden Pk, South Africa.	aheyns@inl.sanbs.org.za						Bateman C, 2005, SAMJ S AFR MED J, V95, P202; Busch MP, 2005, TRANSFUSION, V45, P254, DOI 10.1111/j.1537-2995.2004.04215.x; Connolly C, 2004, SAMJ S AFR MED J, V94, P776; de Coning D, 2004, VOX SANG, V87, P168, DOI 10.1111/j.1741-6892.2004.00478.x; deConing D, 2002, VOX SANG, V83, P237, DOI 10.1111/j.1423-0410.2002.tb05310.x; Dodd RY, 2002, TRANSFUSION, V42, P975, DOI 10.1046/j.1537-2995.2002.00174.x; Fang CT, 2003, VOX SANG, V85, P9, DOI 10.1046/j.1423-0410.2003.00311.x; Field SP, 2004, VOX SANG, V87, P19, DOI 10.1111/j.1741-6892.2004.00447.x; Glynn SA, 2000, JAMA-J AM MED ASSOC, V284, P229, DOI 10.1001/jama.284.2.229; Glynn SA, 2002, TRANSFUSION, V42, P966, DOI 10.1046/j.1537-2995.2002.00200.x; HEYNS A, 2005, SAFE BLOOD SUPPLIES; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Kaplan JB, 2003, JAMA-J AM MED ASSOC, V289, P2709, DOI 10.1001/jama.289.20.2709; Kleinman S, 1997, TRANSFUS MED REV, V11, P155, DOI 10.1053/tmrv.1997.0110155; KUSTNER HGV, 1994, S AFR MED J, V84, P195; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; MCFARLAND W, 1995, J ACQ IMMUN DEF SYND, V9, P183; McFarland W, 1998, TRANSFUSION, V38, P279, DOI 10.1046/j.1537-2995.1998.38398222872.x; McFarland W, 1997, VOX SANG, V72, P85, DOI 10.1046/j.1423-0410.1997.7220085.x; McFarland W, 1997, AIDS, V11, pS97; MILLER RG, 1981, DELTA METHOD; Mvere D, 1996, LANCET, V347, P902, DOI 10.1016/S0140-6736(96)91382-3; *NAT DEP HLTH, NAT HIV SYPH ANT SER; Okware S, 2001, B WORLD HEALTH ORGAN, V79, P1113; *S AFR NAT BLOOD S, HAEM ANN REP BLOOD T; *S AFR NAT BLOOD S, DON SELF EXCL QUEST; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Statistics South Africa, 2005, MID POP EST S AFR 20; Stramer SL, 2000, TRANSFUSION, V40, P1165, DOI 10.1046/j.1537-2995.2000.40101165.x; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; *UNAIDS WHO, AIDS EP UPD 2003; *WHO, AID MEM NAT BLOOD PR	32	41	44	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					519	526		10.1001/jama.295.5.519	http://dx.doi.org/10.1001/jama.295.5.519			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007SP	16449617	Bronze			2022-12-28	WOS:000234990300019
J	Wills, C; Harms, KE; Condit, R; King, D; Thompson, J; He, FL; Muller-Landau, HC; Ashton, P; Losos, E; Comita, L; Hubbell, S; LaFrankie, J; Bunyavejchewin, S; Dattaraja, HS; Davies, S; Esufali, S; Foster, R; Gunatilleke, N; Gunatilleke, S; Hall, P; Itoh, A; John, R; Kiratiprayoon, S; de Lao, SL; Massa, M; Nath, C; Noor, MNS; Kassim, AR; Sukumar, R; Suresh, HS; Sun, IF; Tan, S; Yamakura, T; Zimmerman, E				Wills, C; Harms, KE; Condit, R; King, D; Thompson, J; He, FL; Muller-Landau, HC; Ashton, P; Losos, E; Comita, L; Hubbell, S; LaFrankie, J; Bunyavejchewin, S; Dattaraja, HS; Davies, S; Esufali, S; Foster, R; Gunatilleke, N; Gunatilleke, S; Hall, P; Itoh, A; John, R; Kiratiprayoon, S; de Lao, SL; Massa, M; Nath, C; Noor, MNS; Kassim, AR; Sukumar, R; Suresh, HS; Sun, IF; Tan, S; Yamakura, T; Zimmerman, E			Nonrandom processes maintain diversity in tropical forests	SCIENCE			English	Article							POPULATION REGULATION; DENSITY-DEPENDENCE; NEOTROPICAL FOREST; SPATIAL-PATTERNS; SOIL PATHOGENS; RAIN-FORESTS; TREE; PRODUCTIVITY; MAINTENANCE; MORTALITY	An ecological community's species diversity tends to erode through time as a result of stochastic extinction, competitive exclusion, and unstable host-enemy dynamics. This erosion of diversity can be prevented over the short term if recruits are highly diverse as a result of preferential recruitment of rare species or, alternatively, if rare species survive preferentially, which increases diversity as the ages of the individuals increase. Here, we present census data from seven New and Old World tropical forest dynamics plots that all show the latter pattern. Within local areas, the trees that survived were as a group more diverse than those that were recruited or those that died. The larger (and therefore on average older) survivors were more diverse within local areas than the smaller survivors. When species were rare in a local area, they had a higher survival rate than when they were common, resulting in enrichment for rare species and increasing diversity with age and size class in these complex ecosystems.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; Smithsonian Trop Res Inst, Unit 0948, APO, AA 34002 USA; Harvard Univ, Herbaria, Arnold Arboretum Asia Program, Ctr Trop Forest Sci, Cambridge, MA 02138 USA; Univ Puerto Rico, Inst Trop Ecosyst Studies, San Juan, PR 00931 USA; Univ Alberta, Dept Renewable Resources, Edmonton, AB T6G 2H1, Canada; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Smithsonian Trop Res Inst, Ctr Trop Forest Sci, Washington, DC 20560 USA; Univ Georgia, Dept Plant Sci, Athens, GA 30602 USA; Nanyang Technol Univ, Natl Inst Educ, Arnold Arboretum Asia Program, Ctr Trop Forest Sci, Singapore 637616, Singapore; Thai Natl Pk Wildlife & Plant Conservat Dept, Bangkok 10900, Thailand; Indian Inst Sci, Ctr Ecol Sci, Bangalore 560012, Karnataka, India; Univ Peradeniya, Fac Sci, Dept Bot, Peradeniya 20400, Sri Lanka; Field Museum Nat Hist, Dept Bot, Chicago, IL 60605 USA; Florida State Univ, Dept Biol, Tallahassee, FL 32309 USA; Osaka City Univ, Fac Sci, Plant Ecol Lab, Sumiyoshi Ku, Osaka 558, Japan; Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; Thammasat Univ Rangsit, Fac Sci & Technol, Klongluang 12121, Patumtani, Thailand; Forest Res Inst Malaysia, Forest Environm Div, Kuala Lumpur 52109, Malaysia; Tunghai Univ, Ctr Trop Ecol & Biodivers, Taipei 407, Taiwan; Sarawak Forest Dept, Forest Res Ctr, Kuching 93250, Sarawak, Malaysia	University of California System; University of California San Diego; Louisiana State University System; Louisiana State University; Smithsonian Institution; Smithsonian Tropical Research Institute; Harvard University; University of Puerto Rico; University of Puerto Rico Rio Piedras; University of Alberta; University of Minnesota System; University of Minnesota Twin Cities; Smithsonian Institution; Smithsonian Tropical Research Institute; University System of Georgia; University of Georgia; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National Institute of Education (NIE) Singapore; Indian Institute of Science (IISC) - Bangalore; University of Peradeniya; Field Museum of Natural History (Chicago); State University System of Florida; Florida State University; Osaka Metropolitan University; University of Illinois System; University of Illinois Urbana-Champaign; Thammasat University; Institute Penyelidikan Perhutanan Malaysia; Tunghai University; Jabatan Hutan Sarawak; Pusat Penyelidikan Hutan	Wills, C (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	cwills@ucsd.edu	Thompson, Jill/K-2200-2012; Bunyavejchewin, Sarayudh/P-1529-2017; Raman, Sukumar/C-9809-2013	Thompson, Jill/0000-0002-4370-2593; Bunyavejchewin, Sarayudh/0000-0002-1976-5041; Comita, Liza/0000-0002-9169-1331; Muller-Landau, Helene C./0000-0002-3526-9021				AUGSPURGER CK, 1983, J ECOL, V71, P759, DOI 10.2307/2259591; Bruno JF, 2003, TRENDS ECOL EVOL, V18, P119, DOI 10.1016/S0169-5347(02)00045-9; Chesson P, 2000, THEOR POPUL BIOL, V58, P211, DOI 10.1006/tpbi.2000.1486; CONNELL J H, 1971, P298; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Feeny P., 1975, COEVOLUTION ANIMALS, P3, DOI DOI 10.1111/J.1472-4642.2007.00422.X; Harms KE, 2000, NATURE, V404, P493, DOI 10.1038/35006630; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Hood LA, 2004, J ECOL, V92, P816, DOI 10.1111/j.0022-0477.2004.00917.x; Hubbell Stephen P., 2001, V32, pi; HURTT GC, 1995, J THEOR BIOL, V176, P1, DOI 10.1006/jtbi.1995.0170; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; Laurance WF, 2002, CONSERV BIOL, V16, P605, DOI 10.1046/j.1523-1739.2002.01025.x; Mills KE, 1998, ECOLOGY, V79, P1595, DOI 10.1890/0012-9658(1998)079[1595:MODWPC]2.0.CO;2; Noble IR, 1997, SCIENCE, V277, P522, DOI 10.1126/science.277.5325.522; Packer A, 2000, NATURE, V404, P278, DOI 10.1038/35005072; Peters HA, 2003, ECOL LETT, V6, P757, DOI 10.1046/j.1461-0248.2003.00492.x; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; Rhoades D.F., 1976, RECENT ADV PHYTOCHEM, P168, DOI DOI 10.1007/978-1-4684-2646-5_4; SHELLY TE, 1985, OECOLOGIA, V67, P57, DOI 10.1007/BF00378452; Silman MR, 2003, ECOLOGY, V84, P431, DOI 10.1890/0012-9658(2003)084[0431:PROADR]2.0.CO;2; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391; Volkov I, 2005, NATURE, V438, P658, DOI 10.1038/nature04030; Wills C, 1997, P NATL ACAD SCI USA, V94, P1252, DOI 10.1073/pnas.94.4.1252; Wills C, 1999, P ROY SOC B-BIOL SCI, V266, P1445, DOI 10.1098/rspb.1999.0799; Wills C, 1996, NEW SCI, V149, P38; WILLS C, 1995, IMMUNOL REV, V143, P263, DOI 10.1111/j.1600-065X.1995.tb00679.x; Wright SJ, 2005, TRENDS ECOL EVOL, V20, P553, DOI 10.1016/j.tree.2005.07.009	28	139	153	3	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					527	531		10.1126/science.1117715	http://dx.doi.org/10.1126/science.1117715			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439661	Green Submitted			2022-12-28	WOS:000235071400047
J	Redig, AJ				Redig, AJ			Jigsaw	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												a-redig@md.northwestern.edu							0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					363	364		10.1001/jama.295.4.363	http://dx.doi.org/10.1001/jama.295.4.363			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005QJ	16434620				2022-12-28	WOS:000234838600001
J	Simmons, SL; Bazylinski, DA; Edwards, KJ				Simmons, SL; Bazylinski, DA; Edwards, KJ			South-seeking magnetotactic bacteria in the Northern Hemisphere	SCIENCE			English	Article							SULFATE-REDUCING BACTERIUM; MAGNETIC SPIRILLUM; SEDIMENTS	Magnetotactic bacteria contain membrane-bound intracellular iron crystals (magnetosomes) and respond to magnetic fields. Polar magnetotactic bacteria in vertical chemical gradients are thought to respond to high oxygen levels by swimming downward into areas with tow or no oxygen (toward geomagnetic north in the Northern Hemisphere and geomagnetic south in the Southern Hemisphere). We identified populations of polar magnetotactic bacteria in the Northern Hemisphere that respond to high oxygen levels by swimming toward geomagnetic south, the opposite of all previously reported magnetotactic behavior. The percentage of magnetotactic bacteria with south polarity in the environment is positively correlated with higher redox potential. The coexistence of magnetotactic bacteria with opposing polarities in the same redox environment conflicts with current models of the adaptive value of magnetotaxis.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Geomicrobiol Grp, Woods Hole, MA 02543 USA; Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, MIT WHOI Joint Program Oceanog, Woods Hole, MA 02543 USA; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Woods Hole Oceanographic Institution; Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution; Iowa State University	Edwards, KJ (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Geomicrobiol Grp, MS 52, Woods Hole, MA 02543 USA.	katrina@whoi.edu						BAZYLINSKI DA, 1995, APPL ENVIRON MICROB, V61, P3232, DOI 10.1128/AEM.61.9.3232-3239.1995; BLAKEMORE R, 1975, SCIENCE, V190, P377, DOI 10.1126/science.170679; BLAKEMORE RP, 1982, ANNU REV MICROBIOL, V36, P217, DOI 10.1146/annurev.mi.36.100182.001245; BLAKEMORE RP, 1979, J BACTERIOL, V140, P720, DOI 10.1128/JB.140.2.720-729.1979; BLAKEMORE RP, 1980, NATURE, V286, P384, DOI 10.1038/286384a0; DELONG EF, 1993, SCIENCE, V259, P803, DOI 10.1126/science.259.5096.803; Frankel RB, 1997, BIOPHYS J, V73, P994, DOI 10.1016/S0006-3495(97)78132-3; Kalmijn AJ., 1978, ANIMAL MIGRATION NAV, P354; KAWAGUCHI R, 1995, FEMS MICROBIOL LETT, V126, P277, DOI 10.1016/0378-1097(95)00023-X; KIRSCHVINK JL, 1980, J EXP BIOL, V86, P345; Lie TJ, 1999, APPL ENVIRON MICROB, V65, P3328; MOENCH TT, 1978, ARCH MICROBIOL, V119, P203, DOI 10.1007/BF00964274; PETERMANN H, 1993, EARTH PLANET SC LETT, V117, P223, DOI 10.1016/0012-821X(93)90128-V; Sakaguchi T, 2002, INT J SYST EVOL MICR, V52, P215, DOI 10.1099/00207713-52-1-215; Simmons SL, 2004, APPL ENVIRON MICROB, V70, P6230, DOI 10.1128/AEM.70.10.6230-6239.2004; SIMMONS SL, UNPUB; SPORMANN AM, 1984, FEMS MICROBIOL LETT, V22, P171; SPRING S, 1992, SYST APPL MICROBIOL, V15, P116, DOI 10.1016/S0723-2020(11)80147-5; SPRING S, 1993, APPL ENVIRON MICROB, V59, P2397, DOI 10.1128/AEM.59.8.2397-2403.1993; STOLZ JF, 1986, NATURE, V321, P849, DOI 10.1038/321849a0	20	84	91	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					371	374		10.1126/science.1122843	http://dx.doi.org/10.1126/science.1122843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424338				2022-12-28	WOS:000234938500042
J	Gavin, AC; Aloy, P; Grandi, P; Krause, R; Boesche, M; Marzioch, M; Rau, C; Jensen, LJ; Bastuck, S; Dumpelfeld, B; Edelmann, A; Heurtier, MA; Hoffman, V; Hoefert, C; Klein, K; Hudak, M; Michon, AM; Schelder, M; Schirle, M; Remor, M; Rudi, T; Hooper, S; Bauer, A; Bouwmeester, T; Casari, G; Drewes, G; Neubauer, G; Rick, JM; Kuster, B; Bork, P; Russell, RB; Superti-Furga, G				Gavin, AC; Aloy, P; Grandi, P; Krause, R; Boesche, M; Marzioch, M; Rau, C; Jensen, LJ; Bastuck, S; Dumpelfeld, B; Edelmann, A; Heurtier, MA; Hoffman, V; Hoefert, C; Klein, K; Hudak, M; Michon, AM; Schelder, M; Schirle, M; Remor, M; Rudi, T; Hooper, S; Bauer, A; Bouwmeester, T; Casari, G; Drewes, G; Neubauer, G; Rick, JM; Kuster, B; Bork, P; Russell, RB; Superti-Furga, G			Proteome survey reveals modularity of the yeast cell machinery	NATURE			English	Article							CAP-BINDING COMPLEX; SACCHAROMYCES-CEREVISIAE; GLOBAL ANALYSIS; IDENTIFICATION; PURIFICATION; ANNOTATION; METABOLISM; NETWORKS; PROTEINS; NUCLEAR	Protein complexes are key molecular entities that integrate multiple gene products to perform cellular functions. Here we report the first genome-wide screen for complexes in an organism, budding yeast, using affinity purification and mass spectrometry. Through systematic tagging of open reading frames (ORFs), the majority of complexes were purified several times, suggesting screen saturation. The richness of the data set enabled a de novo characterization of the composition and organization of the cellular machinery. The ensemble of cellular proteins partitions into 491 complexes, of which 257 are novel, that differentially combine with additional attachment proteins or protein modules to enable a diversification of potential functions. Support for this modular organization of the proteome comes from integration with available data on expression, localization, function, evolutionary conservation, protein structure and binary interactions. This study provides the largest collection of physically determined eukaryotic cellular machines so far and a platform for biological data integration and modelling.	Cellzome AG, D-69117 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; MPI IB, MPI MG, D-10117 Berlin, Germany; Austrian Acad Sci, Ctr Mol Med, A-1090 Vienna, Austria	GlaxoSmithKline; Cellzome GmbH; European Molecular Biology Laboratory (EMBL); Austrian Academy of Sciences	Russell, RB (corresponding author), Cellzome AG, Meyerhofstr 1, D-69117 Heidelberg, Germany.	russell@embl-heidelberg.de	Russell, Robert/GWU-6389-2022; Kuster, Bernhard/Q-6031-2016; Aloy, Patrick/AAB-3538-2019; Superti-Furga, Giulio/AAE-5681-2019; Bork, Peer/F-1813-2013; Superti-Furga, Giulio/F-4755-2015; Jensen, Lars Juhl/C-6492-2008; Russell, Rob/AAH-9145-2019	Russell, Robert/0000-0002-7213-1398; Kuster, Bernhard/0000-0002-9094-1677; Bork, Peer/0000-0002-2627-833X; Superti-Furga, Giulio/0000-0002-0570-1768; Jensen, Lars Juhl/0000-0001-7885-715X; Russell, Rob/0000-0002-1905-4717; Drewes, Gerard/0000-0003-0575-6766; Krause, Roland/0000-0001-9938-7126; Aloy, Patrick/0000-0002-3557-0236; Gavin, Anne-Claude/0000-0003-4917-2340				Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Aloy P, 2004, SCIENCE, V303, P2026, DOI 10.1126/science.1092645; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; de Lichtenberg U, 2005, SCIENCE, V307, P724, DOI 10.1126/science.1105103; Dezso Z, 2003, GENOME RES, V13, P2450, DOI 10.1101/gr.1073603; Dudley AM, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100004; Edwards AM, 2002, TRENDS GENET, V18, P529, DOI 10.1016/S0168-9525(02)02763-4; Fortes P, 2000, MOL CELL, V6, P191, DOI 10.1016/S1097-2765(00)00020-4; Friesen H, 2005, GENETICS, V170, P555, DOI 10.1534/genetics.104.040063; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hood L, 2004, SCIENCE, V306, P640, DOI 10.1126/science.1104635; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kao LR, 1996, MOL CELL BIOL, V16, P168; Kelley R, 2005, NAT BIOTECHNOL, V23, P561, DOI 10.1038/nbt1096; Kemmeren P, 2002, MOL CELL, V9, P1133, DOI 10.1016/S1097-2765(02)00531-2; Kraynack BA, 2005, MOL BIOL CELL, V16, P3963, DOI 10.1091/mbc.E05-01-0056; Kumar A, 2002, NAT BIOTECHNOL, V20, P58, DOI 10.1038/nbt0102-58; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Mewes HW, 2004, NUCLEIC ACIDS RES, V32, pD41, DOI 10.1093/nar/gkh092; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROSS J, 1988, J GEN MICROBIOL, V134, P1131; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Said MR, 2004, P NATL ACAD SCI USA, V101, P18006, DOI 10.1073/pnas.0405996101; Sehnke PC, 2000, SCI STKE 2000, V56, P1, DOI [10.1126/stke.2000.56.pe1, DOI 10.1126/STKE.2000.56.PE1]; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Shi YJ, 2004, TRENDS GENET, V20, P445, DOI 10.1016/j.tig.2004.07.004; Subramanian S, 2004, MOL BIOL CELL, V15, P2593, DOI 10.1091/mbc.E03-10-0767; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Winstall E, 2000, J BIOL CHEM, V275, P21817, DOI 10.1074/jbc.M002412200	43	1967	2046	3	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	2006	440	7084					631	636		10.1038/nature04532	http://dx.doi.org/10.1038/nature04532			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	026OY	16429126				2022-12-28	WOS:000236350400035
J	Poustie, VJ; Russell, JE; Watling, RM; Ashby, D; Smyth, RL				Poustie, VJ; Russell, JE; Watling, RM; Ashby, D; Smyth, RL		CALICO Trial Collaborative Grp	Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PULMONARY-FUNCTION; NUTRITIONAL-STATUS; DIETARY-INTAKE; LUNG-FUNCTION; GROWTH	Objective To determine whether oral protein energy supplements, used long term in children with cystic fibrosis Who are moderately malnourished, improve nutritional and other outcomes. Design Multicentre randomised controlled trial. Setting Seven specialist paediatric cystic fibrosis centres and their associated shared care clinics and seven smaller paediatric cystic fibrosis clinics. Participants 102 children with cystic fibrosis, aged between 2 and 15 years, who were moderately malnourished. Interventions Oral protein energy supplements in addition to usual dietary advice compared with dietary advice alone, for 12 months. Main outcome measure Change in body mass index centile over one year. Results Use of supplements was not associated with a change in body mass index centile (mean difference 2.99 centile points, 95% confidence interval - 2.70 to 8.68) or other nutritional and spirometric outcomes in this group of children. Conclusions Long term use of oral protein energy supplements did not result in an improvement in nutritional status or other clinical outcomes in children with cystic fibrosis who were moderately malnourished. Oral protein energy Supplements should not be regarded as an essential part of the management of this group of children. Trial registration ISRCTNT: 95744468.	Univ Liverpool, Royal Liverpool Childrens Hosp, Div Child Hlth, Liverpool L12 2AP, Merseyside, England; Royal Liverpool Childrens Hosp, Dept Nutr & Dietet, Liverpool L7 7DG, Merseyside, England; Univ London, Queen Mary, Wolfson Inst Prevent Med, London WC1E 7HU, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of London; Queen Mary University London	Smyth, RL (corresponding author), Univ Liverpool, Royal Liverpool Childrens Hosp, Div Child Hlth, Liverpool L12 2AP, Merseyside, England.	r.l.smyth@liv.ac.uk						Ball SD, 2005, J AM DIET ASSOC, V105, P78, DOI 10.1016/j.jada.2004.10.008; Boucher GP, 1997, AM J PHYS MED REHAB, V76, P311, DOI 10.1097/00002060-199707000-00010; Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4&lt;407::AID-SIM742&gt;3.0.CO;2-L; *COMM MED ASP FOOD, 1991, DIET REF FOOD EN NUT; Committee on Medical Aspects of Food Policy, 1991, DIET REF VAL FOOD EN; DODGE JA, 1988, J PEDIAT GASTROENTER, V7, P8; Dorlochter Ludger, 2002, J Cyst Fibros, V1, P131, DOI 10.1016/S1569-1993(02)00076-0; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Kawchak DA, 1996, J PEDIATR-US, V129, P119, DOI 10.1016/S0022-3476(96)70198-1; Konstan MW, 2003, J PEDIATR-US, V142, P624, DOI 10.1067/mpd.2003.152; MacDonald A, 1996, ARCH DIS CHILD, V74, P81, DOI 10.1136/adc.74.1.81; Peterson ML, 2003, PEDIATRICS, V112, P588, DOI 10.1542/peds.112.3.588; POUSTIE VJ, 2000, COCHRANE DB SYST REV; POUSTIE VJ, 1998, P 22 EUR CYST FIBR C, P98; Powers SW, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.5.e75; Sinaasappel M, 2002, J Cyst Fibros, V1, P51, DOI 10.1016/S1569-1993(02)00032-2; SMYTH R, 2000, COCHRANE DB SYST REV; STEAD RJ, 1987, THORAX, V42, P533, DOI 10.1136/thx.42.7.533; Steinkamp G, 2002, THORAX, V57, P596, DOI 10.1136/thorax.57.7.596; Westerterp KR, 2002, CURR OPIN CLIN NUTR, V5, P489, DOI 10.1097/00075197-200209000-00006; Zemel BS, 2000, J PEDIATR-US, V137, P374, DOI 10.1067/mpd.2000.107891; 2001, MANUAL DIETETIC PRAC	22	57	58	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 18	2006	332	7542					632	635		10.1136/bmj.38737.600880.AE	http://dx.doi.org/10.1136/bmj.38737.600880.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CQ	16467348	Green Published, Bronze			2022-12-28	WOS:000236314700014
J	Breitkreutz, A; Tyers, M				Breitkreutz, A; Tyers, M			Cell signaling - A sophisticated scaffold wields a new trick	SCIENCE			English	Editorial Material							MAP KINASE PATHWAYS; SACCHAROMYCES-CEREVISIAE; YEAST; ACTIVATION; SPECIFICITY; AUTOPHOSPHORYLATION; NETWORK; COMPLEX		Campbell Family Inst Breast Canc Res, Toronto, ON M5G 1L7, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Breitkreutz, A (corresponding author), Campbell Family Inst Breast Canc Res, Toronto Med Discovery Tower, Toronto, ON M5G 1L7, Canada.	abreitkr@uhnres.utoronto.ca; tyers@mshri.on.ca	Tyers, Michael/ABE-3194-2021					Bhattacharyya RP, 2006, SCIENCE, V311, P822, DOI 10.1126/science.1120941; Breitkreutz A, 2001, CURR BIOL, V11, P1266, DOI 10.1016/S0960-9822(01)00370-0; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; CHOI KY, 1994, CELL, V78, P499; Colman-Lerner A, 2005, NATURE, V437, P699, DOI 10.1038/nature03998; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Harris K, 2001, CURR BIOL, V11, P1815, DOI 10.1016/S0960-9822(01)00567-X; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Lochhead PA, 2005, CELL, V121, P925, DOI 10.1016/j.cell.2005.03.034; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Remenyi A, 2005, MOL CELL, V20, P951, DOI 10.1016/j.molcel.2005.10.030; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; van Drogen F, 2001, NAT CELL BIOL, V3, P1051, DOI 10.1038/ncb1201-1051; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870	21	4	4	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					789	790		10.1126/science.1124620	http://dx.doi.org/10.1126/science.1124620			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469909				2022-12-28	WOS:000235374900029
J	Okazaki, T; Honjo, T				Okazaki, T; Honjo, T			Rejuvenating exhausted T cells during chronic viral infection	CELL			English	Editorial Material							DENDRITIC CELLS; PD-1; PERSISTENCE; EXPRESSION; LIVER	In a recent paper in Nature, Barber et al. (2005) show that the immunoreceptor PD-1 is upregulated by "exhausted" T cells during the chronic phase of viral infection in mice. Remarkably, blocking the interaction between PD-1 and its ligand, PD-L1, reactivates these T cells and reduces viral load.	Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Century COE Format 21st, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Okazaki, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Okazaki, Taku/0000-0003-4790-1925				BARBER DL, 2005, NATURE; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Isogawa M, 2005, IMMUNITY, V23, P53, DOI 10.1016/j.immuni.2005.05.005; Iwai YH, 2003, J EXP MED, V198, P39, DOI 10.1084/jem.20022235; Kirchberger S, 2005, J IMMUNOL, V175, P1145, DOI 10.4049/jimmunol.175.2.1145; Okazaki T, 2002, CURR OPIN IMMUNOL, V14, P779, DOI 10.1016/S0952-7915(02)00398-9; Probst HC, 2005, NAT IMMUNOL, V6, P280, DOI 10.1038/ni1165; Prokunina L, 2004, HUM MOL GENET, V13, pR143, DOI 10.1093/hmg/ddh076; Sevilla N, 2000, J EXP MED, V192, P1249, DOI 10.1084/jem.192.9.1249; Wang J, 2005, P NATL ACAD SCI USA, V102, P11823, DOI 10.1073/pnas.0505497102; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	11	31	34	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					459	461		10.1016/j.cell.2006.01.022	http://dx.doi.org/10.1016/j.cell.2006.01.022			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469690	Bronze			2022-12-28	WOS:000235464000006
J	Sowers, T				Sowers, T			Late quaternary atmospheric CH4 isotope record suggests marine clathrates are stable	SCIENCE			English	Article							METHANE; HYDROGEN; CARBON; CLIMATE; WATER; PRECIPITATION; FRACTIONATION; OXIDATION; MODEL	one explanation for the abrupt increases in atmospheric CH4, that occurred repeatedly during the Last glacial cycle involves clathrate destabalization events. Because marine clathrates have a distinct deuterium/hydrogen (D/H) isotope ratio, any such destabilization event should cause the D/H ratio of atmospheric CH4 (delta D-CH4) to increase. Analyses of air trapped in the ice from the second Greenland ice sheet project show stable and/or decreasing delta D-CH4 values during the end of the Younger and Older Dryas periods and one stadial period, suggesting that marine clathrates were stable during these abrupt warming episodes. Elevated glacial delta D-CH4 values may be the result of a lower ratio of net to gross wetland CH4 emissions and an increase in petroleum-based emissions.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Penn State Univ, Earth & Environm Syst Inst, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Sowers, T (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	sowers@geosc.psu.edu						BALABANE M, 1987, ORG GEOCHEM, V11, P115, DOI 10.1016/0146-6380(87)90033-7; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; CHAPPELLAZ J, 1990, NATURE, V345, P127, DOI 10.1038/345127a0; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; Charles CD, 2001, CLIM DYNAM, V17, P489, DOI 10.1007/s003820000126; Chikaraishi Y, 2003, PHYTOCHEMISTRY, V63, P361, DOI 10.1016/S0031-9422(02)00749-5; Collatz GJ, 1998, OECOLOGIA, V114, P441, DOI 10.1007/s004420050468; EPSTEIN S, 1976, EARTH PLANET SC LETT, V30, P241, DOI 10.1016/0012-821X(76)90251-X; Gierczak T, 1997, J PHYS CHEM A, V101, P3125, DOI 10.1021/jp963892r; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Jouzel J, 2000, QUATERNARY SCI REV, V19, P363, DOI 10.1016/S0277-3791(99)00069-4; Kennett JP, 2003, METHANE HYDRATES QUA; Luyendyk B, 2005, MAR PETROL GEOL, V22, P591, DOI 10.1016/j.marpetgeo.2004.08.005; MARTINERIE P, 1995, J GEOPHYS RES-ATMOS, V100, P14291, DOI 10.1029/95JD00826; Milkov AV, 2005, ORG GEOCHEM, V36, P681, DOI 10.1016/j.orggeochem.2005.01.010; Moosavi SC, 1998, J GEOPHYS RES-ATMOS, V103, P29093, DOI 10.1029/97JD03519; Quay P, 1999, GLOBAL BIOGEOCHEM CY, V13, P445, DOI 10.1029/1998GB900006; REEBURGH WS, 2004, ATMOSPHERE, V4, P65; Rice AL, 2001, ANAL CHEM, V73, P4104, DOI 10.1021/ac0155106; Sachse D, 2004, GEOCHIM COSMOCHIM AC, V68, P4877, DOI 10.1016/j.gca.2004.06.004; Schrag DP, 2002, QUATERNARY SCI REV, V21, P331, DOI 10.1016/S0277-3791(01)00110-X; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Snover AK, 2000, GLOBAL BIOGEOCHEM CY, V14, P25, DOI 10.1029/1999GB900089; Snover AK, 2000, GLOBAL BIOGEOCHEM CY, V14, P11, DOI 10.1029/1999GB900075; Spahni R, 2005, SCIENCE, V310, P1317, DOI 10.1126/science.1120132; Thonicke K, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002278; Valentine DL, 2004, GEOCHIM COSMOCHIM AC, V68, P1571, DOI 10.1016/j.gca.2003.10.012; Waldron S, 1999, GEOCHIM COSMOCHIM AC, V63, P2237, DOI 10.1016/S0016-7037(99)00192-1; Whiticar MJ, 1999, CHEM GEOL, V161, P291, DOI 10.1016/S0009-2541(99)00092-3; WHITICAR MJ, 1986, GEOCHIM COSMOCHIM AC, V50, P693, DOI 10.1016/0016-7037(86)90346-7	30	130	135	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					838	840		10.1126/science.1121235	http://dx.doi.org/10.1126/science.1121235			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469923				2022-12-28	WOS:000235374900045
J	Brumfiel, G				Brumfiel, G			The scientific balance of power	NATURE			English	News Item																			0	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					646	647		10.1038/439646a	http://dx.doi.org/10.1038/439646a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467807				2022-12-28	WOS:000235193100014
J	Erbse, A; Schmidt, R; Bornemann, T; Schneider-Mergener, J; Mogk, A; Zahn, R; Dougan, DA; Bukau, B				Erbse, A; Schmidt, R; Bornemann, T; Schneider-Mergener, J; Mogk, A; Zahn, R; Dougan, DA; Bukau, B			ClpS is an essential component of the N-end rule pathway in Escherichia coli	NATURE			English	Article							METHIONINE AMINOPEPTIDASE; SUBSTRATE-SPECIFICITY; PEPTIDE LIBRARIES; DEGRADATION; PROTEIN; APOPTOSIS; CHAPERONE; CELLS	The N-end rule states that the half-life of a protein is determined by the nature of its amino-terminal residue(1). Eukaryotes and prokaryotes use N-terminal destabilizing residues as a signal to target proteins for degradation by the N-end rule pathway. In eukaryotes an E3 ligase, N-recognin, recognizes N-end rule substrates and mediates their ubiquitination and degradation by the proteasome(1,2). In Escherichia coli, N-end rule substrates are degraded by the AAA+ chaperone ClpA in complex with the ClpP peptidase (ClpAP)(3). Little is known of the molecular mechanism by which N-end rule substrates are initially selected for proteolysis. Here we report that the ClpAP-specific adaptor, ClpS, is essential for degradation of N-end rule substrates by ClpAP in bacteria. ClpS binds directly to N-terminal destabilizing residues through its substrate-binding site distal to the ClpS - ClpA interface(4), and targets these substrates to ClpAP for degradation. Degradation by the N-end rule pathway is more complex than anticipated and several other features are involved, including a net positive charge near the Nterminus and an unstructured region between the N-terminal signal and the folded protein substrate. Through interaction with this signal, ClpS converts the ClpAP machine into a protease with exquisitely defined specificity, ideally suited to regulatory proteolysis.	Univ Heidelberg, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Humboldt Univ, Univ Klinikum Charite, D-10098 Berlin, Germany; La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia	Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; La Trobe University	Bukau, B (corresponding author), Univ Heidelberg, Zentrum Mol Biol Heidelberg, INF 282, D-69120 Heidelberg, Germany.	bukau@zmbh.uni-heidelberg.de	dougan, david/B-3359-2010	dougan, david/0000-0001-9313-1904; Bukau, Bernd/0000-0003-0521-7199; ERBSE, ANNETTE/0000-0003-0950-3707				BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; Kramer A, 1998, METH MOL B, V87, P25; Levy F, 1999, EUR J BIOCHEM, V259, P244, DOI 10.1046/j.1432-1327.1999.00024.x; Lupas AN, 2003, J STRUCT BIOL, V141, P77, DOI 10.1016/S1047-8477(02)00582-8; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869	19	172	176	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					753	756		10.1038/nature04412	http://dx.doi.org/10.1038/nature04412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467841				2022-12-28	WOS:000235193100051
J	O'Connor, RJ; Cummings, KM; Giovino, GA; McNeill, A; Kozlowski, LT				O'Connor, RJ; Cummings, KM; Giovino, GA; McNeill, A; Kozlowski, LT			How did UK cigarette makers reduce tar to 10 mg or less?	BRITISH MEDICAL JOURNAL			English	Letter									Roswell Pk Canc Inst, Dept Hlth Behav, Buffalo, NY 14263 USA; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA	Roswell Park Cancer Institute; University of London; University College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	O'Connor, RJ (corresponding author), Roswell Pk Canc Inst, Dept Hlth Behav, Buffalo, NY 14263 USA.	Richard.Oconnor@roswellpark.org	O'Connor, Richard/A-6961-2009	McNeill, Ann/0000-0002-6223-4000	NATIONAL CANCER INSTITUTE [P50CA111236] Funding Source: NIH RePORTER; NCI NIH HHS [1 P50 CA111236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2001, RISKS ASS SMOK CIG L; *COMM EUR PARL COU, 2005, 1 REP APPL TOB PROD; Kozlowski LT, 1998, TOB CONTROL, V7, P369, DOI 10.1136/tc.7.4.369; KOZLOWSKI LT, 2002, TOBACCO CONTROL S1, V11, P40; *LGC TEDD, 1999, TAR NIC CARB MON YIE	5	18	19	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					302	302		10.1136/bmj.332.7536.302	http://dx.doi.org/10.1136/bmj.332.7536.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455737	Green Published			2022-12-28	WOS:000235259000030
J	Basri, G				Basri, G			Astronomy - Big fields on small stars	SCIENCE			English	Editorial Material									Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Basri, G (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	basri@berkeley.edu	Basri, Gibor B/Y-4048-2018					Donati JF, 2006, SCIENCE, V311, P633, DOI 10.1126/science.1121102; LINSKY JL, 1996, STELLAR SURFACE STRU, V176	2	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2006	311	5761					618	619		10.1126/science.1122815	http://dx.doi.org/10.1126/science.1122815			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456068				2022-12-28	WOS:000235257400033
J	Honer, WG; Thornton, AE; Chen, EYH; Chan, RCK; Wong, JOY; Bergmann, A; Falkai, P; Pomarol-Clotet, E; McKenna, PJ; Stip, E; Williams, R; MacEwan, GW; Wasan, K; Procyshyn, R; Leung, SP; Wong, JOY; Rodriguez, JP; Lalonde, P; Stip, E; Pomarol-Clotet, E; McKenna, PJ; MacEwan, GW; Chen, EYH; Chan, RCK; Flynn, SW; Altman, S; Honer, WG; Thornton, AE; Procyshyn, R; Huckin, S; Au, T; Boudreau, A; Humphries, B; Williams, R; Wasan, K; Bergmann, A; Falkai, P; Wobrock, T; Wollny, H				Honer, WG; Thornton, AE; Chen, EYH; Chan, RCK; Wong, JOY; Bergmann, A; Falkai, P; Pomarol-Clotet, E; McKenna, PJ; Stip, E; Williams, R; MacEwan, GW; Wasan, K; Procyshyn, R; Leung, SP; Wong, JOY; Rodriguez, JP; Lalonde, P; Stip, E; Pomarol-Clotet, E; McKenna, PJ; MacEwan, GW; Chen, EYH; Chan, RCK; Flynn, SW; Altman, S; Honer, WG; Thornton, AE; Procyshyn, R; Huckin, S; Au, T; Boudreau, A; Humphries, B; Williams, R; Wasan, K; Bergmann, A; Falkai, P; Wobrock, T; Wollny, H		CARE Study Grp	Clozapine alone versus clozapine and risperidone with refractory schizophrenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; ANTIPSYCHOTIC POLYPHARMACY; HOSPITALIZED-PATIENTS; THERAPY; METAANALYSIS; OLANZAPINE; EFFICACY; PATTERNS; SCALE; RISKS	BACKGROUND: The treatment of schizophrenia with multiple antipsychotic drugs is common, but the benefits and risks are not known. METHODS: In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to receive eight weeks of daily augmentation with 3 mg of risperidone or with placebo. This course of treatment was followed by an optional 18 weeks of augmentation with risperidone. The primary outcome was reduction in the total score for severity of symptoms on the Positive and Negative Syndrome Scale (PANSS). The secondary outcomes included cognitive functioning. RESULTS: A total of 68 patients were randomly assigned to treatment. In the double-blind phase, the mean total score for the severity of symptoms decreased from baseline to eight weeks in both the risperidone and the placebo groups. There was no statistically significant difference in symptomatic benefit between augmentation with risperidone and placebo: 9 of 34 patients receiving placebo and 6 of 34 receiving risperidone responded to treatment (P=0.38). The mean difference in the change in PANSS scores from baseline to eight weeks between those receiving risperidone and those receiving placebo was 0.1 (95 percent confidence interval, -7.3 to 7.0). The verbal working-memory index showed a small decline in the risperidone group and a small improvement in the placebo group (P=0.02 for the comparison between the two groups in the change from baseline). The increase in fasting blood glucose levels was mildly greater in the risperidone group than in the placebo group (16.2 vs. 1.8 mg per deciliter [0.90 vs. 0.10 mmol per liter], P=0.04). The incidence and severity of other side effects did not differ between the two groups. CONCLUSIONS: In this short-term study, the addition of risperidone to clozapine did not improve symptoms in patients with severe schizophrenia.	Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; Univ British Columbia, Div Pharmaceut & Biopharmaceut, Vancouver, BC, Canada; Simon Fraser Univ, Dept Psychol, Burnaby, BC V5A 1S6, Canada; Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; Sun Yat Sen Univ, Dept Psychol, Guangzhou, Peoples R China; Castle Peak Hosp, Hong Kong, Hong Kong, Peoples R China; Univ Saarland, Dept Psychiat, D-6650 Homburg, Germany; Univ Cambridge, Dept Psychiat, Cambridge, England; Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada; Riverview Hosp, Port Coquitlam, BC, Canada	University of British Columbia; University of British Columbia; Simon Fraser University; University of Hong Kong; Sun Yat Sen University; Saarland University; University of Cambridge; Universite de Montreal	Honer, WG (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Ctr Complex Disorders, Res Pavil,828 W 10th Ave,Suite 211, Vancouver, BC V5Z 1L8, Canada.	honer@interchange.ubc.ca	Falkai, Peter/E-3273-2017; Chan, Raymond CK/B-6717-2009; Procyshyn, Ric/AAE-5499-2019	Falkai, Peter/0000-0003-2873-8667; Chan, Raymond CK/0000-0002-3414-450X; McKenna, Peter/0000-0001-5474-1144; Thornton, Allen/0000-0002-9942-0122; Chen, Eric/0000-0002-5247-3593; Procyshyn, Ric/0000-0002-4348-0855; Pomarol-Clotet, Edith/0000-0002-8159-8563				BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Centorrino F, 2004, AM J PSYCHIAT, V161, P700, DOI 10.1176/appi.ajp.161.4.700; Chakos M, 2001, AM J PSYCHIAT, V158, P518, DOI 10.1176/appi.ajp.158.4.518; CHOUINARD G, 1980, CAN J NEUROL SCI, V7, P233; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Faries D, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-26; Freedman R, 2003, NEW ENGL J MED, V349, P1738, DOI 10.1056/NEJMra035458; Freudenreich O, 2002, ACTA PSYCHIAT SCAND, V106, P323, DOI 10.1034/j.1600-0447.2002.01331.x; GUY W, 1976, 76338 ADM DEP HLTH E; Henderson DC, 1996, J CLIN PSYCHIAT, V57, P395; Henderson DC, 2001, J CLIN PSYCHIAT, V62, P605, DOI 10.4088/JCP.v62n0805; Josiassen RC, 2005, AM J PSYCHIAT, V162, P130, DOI 10.1176/appi.ajp.162.1.130; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Kapur S, 1999, AM J PSYCHIAT, V156, P286; KAY SR, 1988, PSYCHIAT RES, V23, P99, DOI 10.1016/0165-1781(88)90038-8; Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Newcomer JW, 2004, J CLIN PSYCHIAT, V65, P36; Paton C, 2003, J PSYCHOPHARMACOL, V17, P223, DOI 10.1177/0269881103017002012; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Pickar D, 2003, AM J PSYCHIAT, V160, P1133, DOI 10.1176/appi.ajp.160.6.1133; Procyshyn RM, 2004, PHARMACOPSYCHIATRY, V37, P12, DOI 10.1055/s-2004-815469; *PSYCH CORP, 1997, WAIS III WMS III TEC; Reeves SJ, 2005, NEUROIMAGE, V28, P216, DOI 10.1016/j.neuroimage.2005.05.034; Rosenheck R, 1997, NEW ENGL J MED, V337, P809, DOI 10.1056/NEJM199709183371202; Sernyak MJ, 2004, J CLIN PSYCHIAT, V65, P1597, DOI 10.4088/JCP.v65n1203; Sherwood M, 2005, INT J NEUROPSYCHOPH, V9, P1; Stahl SM, 2004, INT J NEUROPSYCHOPH, V7, P113, DOI 10.1017/S1461145704004146; Stern RG, 1997, BIOL PSYCHIAT, V42, P138, DOI 10.1016/S0006-3223(96)00295-8; Tapp A, 2003, PSYCHIAT SERV, V54, P55, DOI 10.1176/appi.ps.54.1.55; Taylor CG, 2001, SCHIZOPHR RES, V48, P156, DOI 10.1016/S0920-9964(00)00104-3; Taylor D, 2004, BRIT J PSYCHIAT, V185, P152, DOI 10.1192/bjp.185.2.152; THORNTON AE, IN PRESS J PSYCHOPHA; Waddington JL, 1998, BRIT J PSYCHIAT, V173, P325, DOI 10.1192/bjp.173.4.325; Wang M, 2004, SCIENCE, V303, P853, DOI 10.1126/science.1091162; Woodward ND, 2005, INT J NEUROPSYCHOPH, V8, P457, DOI 10.1017/S146114570500516X; Yagcioglu AEA, 2005, J CLIN PSYCHIAT, V66, P63, DOI 10.4088/JCP.v66n0109	38	196	214	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					472	482		10.1056/NEJMoa053222	http://dx.doi.org/10.1056/NEJMoa053222			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452559	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000235019400007
J	Van den Berghe, G; Wilmer, A; Hermans, G; Meersseman, W; Wouters, PJ; Milants, I; Van Wijngaerden, E; Bobbaers, H; Bouillon, R				Van den Berghe, G; Wilmer, A; Hermans, G; Meersseman, W; Wouters, PJ; Milants, I; Van Wijngaerden, E; Bobbaers, H; Bouillon, R			Intensive insulin therapy in the medical ICU	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERVENTION SCORING SYSTEM; BLOOD-GLUCOSE CONTROL; CRITICALLY-ILL; MYOCARDIAL-INFARCTION; STRESS HYPERGLYCEMIA; MORTALITY; PROTECTS; CULTURES	BACKGROUND: Intensive insulin therapy reduces morbidity and mortality in patients in surgical intensive care units (ICUs), but its role in patients in medical ICUs is unknown. METHODS: In a prospective, randomized, controlled study of adult patients admitted to our medical ICU, we studied patients who were considered to need intensive care for at least three days. On admission, patients were randomly assigned to strict normalization of blood glucose levels (80 to 110 mg per deciliter [4.4 to 6.1 mmol per liter]) with the use of insulin infusion or to conventional therapy (insulin administered when the blood glucose level exceeded 215 mg per deciliter [12 mmol per liter], with the infusion tapered when the level fell below 180 mg per deciliter [10 mmol per liter]). There was a history of diabetes in 16.9 percent of the patients. RESULTS: In the intention-to-treat analysis of 1200 patients, intensive insulin therapy reduced blood glucose levels but did not significantly reduce in-hospital mortality (40.0 percent in the conventional-treatment group vs. 37.3 percent in the intensive-treatment group, P=0.33). However, morbidity was significantly reduced by the prevention of newly acquired kidney injury, accelerated weaning from mechanical ventilation, and accelerated discharge from the ICU and the hospital. Although length of stay in the ICU could not be predicted on admission, among 433 patients who stayed in the ICU for less than three days, mortality was greater among those receiving intensive insulin therapy. In contrast, among 767 patients who stayed in the ICU for three or more days, in-hospital mortality in the 386 who received intensive insulin therapy was reduced from 52.5 to 43.0 percent (P=0.009) and morbidity was also reduced. CONCLUSIONS: Intensive insulin therapy significantly reduced morbidity but not mortality among all patients in the medical ICU. Although the risk of subsequent death and disease was reduced in patients treated for three or more days, these patients could not be identified before therapy. Further studies are needed to confirm these preliminary data.	Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dept Med Intens Care Med, B-3000 Louvain, Belgium; Catholic Univ Louvain, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; KU Leuven; Universite Catholique Louvain	Van den Berghe, G (corresponding author), Catholic Univ Louvain, Dept Intens Care Med, B-3000 Louvain, Belgium.	greta.vandenberghe@med.kuleuven.be	Van Wijngaerden, Eric/AAB-9187-2021; Van den Berghe, Greet/J-6788-2018; Hermans, Greet M/E-6234-2018; Wilmer, Alexander/H-7784-2018	Van Wijngaerden, Eric/0000-0001-8926-099X; Van den Berghe, Greet/0000-0002-5320-1362; Hermans, Greet M/0000-0001-5340-1500; Wilmer, Alexander/0000-0002-4176-3608				Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Cely CM, 2004, CHEST, V126, P879, DOI 10.1378/chest.126.3.879; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Clement S, 2004, DIABETES CARE, V27, P1255; Clement S, 2004, DIABETES CARE, V27, P856; Evans TW, 2001, NEW ENGL J MED, V345, P1417, DOI 10.1056/NEJM200111083451910; Furnary AP, 2003, J THORAC CARDIOV SUR, V125, P1007, DOI 10.1067/mtc.2003.181; Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; Malmberg K, 2005, EUR HEART J, V26, P650, DOI 10.1093/eurheartj/ehi199; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; MIZOCK BA, 1995, AM J MED, V98, P75, DOI 10.1016/S0002-9343(99)80083-7; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4; Weekers F, 2003, ENDOCRINOLOGY, V144, P5329, DOI 10.1210/en.2003-0697; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; Weinstein MP, 1998, J CLIN MICROBIOL, V36, P2089, DOI 10.1128/JCM.36.7.2089-2092.1998	28	2377	2454	1	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					449	461		10.1056/NEJMoa052521	http://dx.doi.org/10.1056/NEJMoa052521			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452557				2022-12-28	WOS:000235019400005
J	Grunebaum, E; Mazzolari, E; Porta, F; Dallera, D; Atkinson, A; Reid, B; Notarangelo, LD; Roifman, CM				Grunebaum, E; Mazzolari, E; Porta, F; Dallera, D; Atkinson, A; Reid, B; Notarangelo, LD; Roifman, CM			Bone marrow transplantation for severe combined immune deficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; STEM-CELL TRANSPLANTATION; VERSUS-HOST-DISEASE; UNRELATED-DONOR; SINGLE-CENTER; EUROPEAN EXPERIENCE; RECONSTITUTION; CHILDREN; GRAFT; SURVIVAL	Context Bone marrow transplantation (BMT) using stem cells obtained from a family-related, HLA-identical donor (RID) is the optimal treatment for patients with severe combined immune deficiency (SCID). in the absence of an RID, HLA-mismatched related donors (MMRDs) are often used. However, compared with RIDS, use of MMRDs for BMT is associated with reduced survival and inferior long-term immune reconstitution. Use of HLA-matched unrelated donors (MUDs) represents another potential alternative for BMT. Objective To compare outcomes and immune reconstitution in a large cohort of patients with SCID who received RID, MUD, or MMRD BMT. Design, Setting, and Patients Retrospective study of medical records from 94 infants diagnosed as having SCID who received BMT between 1990 and 2004 at 1 Canadian and 1 Italian pediatric referral center. Thirteen, 41, and 40 patients received RID, MUD, and MMRD BMT, respectively. Main Outcome Measures Survival and graft failure, along with incidence of graft-vs-host disease, infections, and other complications; immune reconstitution was assessed in children who survived for more than 2 years after BMT. Results Survival after RID BMT was highest. Twelve (92.3%) of 13 patients who received RID BMT, 33 (80.5%) of 41 who received MUD BMT, and 21 (52.5%) of 40 patients who received MMRD BMT survived. Compared with MMRD BMT, survival was significantly higher with RID (P = .008) or with MUD (P = .03). Graft failures and need for repeat BMT were more common in patients receiving MMRD BMT than in those who underwent MUD BMT. Long-term reconstitution of a full T-cell repertoire was achieved more frequently following MUD BMT (94.7%) than after MMRD BMT (61.1%) (P = .02). Acute graft-vs-host disease was documented in 73.1% of patients following MUD BMT but in only 45% after MMRD BMT (P = .009). Conversely, interstitial pneumonitis was observed more frequently after MMRD BMT (14 [35.0%] of 40) than after MUD BMT (3 [7.3%] of 41; P = .002). Conclusion Our study suggests that in the absence of a relative with identical HLA, MUD BMT may provide better engraftment, immune reconstitution, and survival for patients with SCID than MMRD BMT.	Hosp Sick Children, Res Inst, Dept Paediat,Div Immunol Allergy, Infect Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Univ Brescia, Spedali Civili, Dept Pediat, Pediat Bone Marrow Transplantat Unit, Brescia, Italy; Univ Brescia, Spedali Civili, Angelo Nocivelli Inst Mol Med, Brescia, Italy	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia	Roifman, CM (corresponding author), Hosp Sick Children, Res Inst, Dept Paediat,Div Immunol Allergy, Infect Immun Injury & Repair Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262	Telethon [GAT0203] Funding Source: Medline	Telethon(Fondazione Telethon)		Amrolia PJ, 2003, BLOOD, V102, P2292, DOI 10.1182/blood-2002-11-3516; Anasetti C, 2001, CURR OPIN HEMATOL, V8, P337, DOI 10.1097/00062752-200111000-00004; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Ball LM, 2005, BONE MARROW TRANSPL, V35, pS35, DOI 10.1038/sj.bmt.1704842; Barker JN, 2002, BIOL BLOOD MARROW TR, V8, P257, DOI 10.1053/bbmt.2002.v8.pm12064362; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Buckley RH, 2000, IMMUNOL RES, V22, P237, DOI 10.1385/IR:22:2-3:237; Caillat-Zucman S, 2004, BONE MARROW TRANSPL, V33, P1089, DOI 10.1038/sj.bmt.1704510; Candusso M., 2000, Haematologica, V85, P58; Cavazzana-Calvo M, 2002, SEMIN HEMATOL, V39, P32, DOI 10.1053/shem.2002.29251; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Dalal I, 2000, BONE MARROW TRANSPL, V25, P613, DOI 10.1038/sj.bmt.1702215; Drobyski WR, 2002, BLOOD, V99, P806, DOI 10.1182/blood.V99.3.806; FILIPOVICH AH, 1992, BLOOD, V80, P270; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Haddad E, 1998, BLOOD, V91, P3646; Huang H, 2005, FRONT BIOSCI-LANDMRK, V10, P1024, DOI 10.2741/1596; Laffort C, 2004, LANCET, V363, P2051, DOI 10.1016/S0140-6736(04)16457-X; Lanfranchi A., 2000, Haematologica, V85, P41; Martin P, 2003, BONE MARROW TRANSPL, V32, P881, DOI 10.1038/sj.bmt.1704239; Mazzolari E, 2005, BONE MARROW TRANSPL, V36, P107, DOI 10.1038/sj.bmt.1705017; NAVARI RM, 1984, AM J MED, V76, P564, DOI 10.1016/0002-9343(84)90274-2; Notorangelo LD, 2001, HUM MUTAT, V18, P255; OREILLY RJ, 1977, NEW ENGL J MED, V297, P1311, DOI 10.1056/NEJM197712152972403; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; Slatter MA, 2003, BONE MARROW TRANSPL, V32, P225, DOI 10.1038/sj.bmt.1704109; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111; STORB R, 1974, BLOOD, V44, P57, DOI 10.1182/blood.V44.1.57.57; STRONCEK D, 1993, TRANSFUSION, V33, P567, DOI 10.1046/j.1537-2995.1993.33793325052.x; Tiercy JM, 2000, BONE MARROW TRANSPL, V26, P437, DOI 10.1038/sj.bmt.1702529; Veys P, 2003, BRIT J HAEMATOL, V123, P193, DOI 10.1046/j.1365-2141.2003.04655.x; Yang YL, 2005, J FORMOS MED ASSOC, V104, P448; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	39	165	167	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					508	518		10.1001/jama.295.5.508	http://dx.doi.org/10.1001/jama.295.5.508			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007SP	16449616	Bronze			2022-12-28	WOS:000234990300018
J	Chowdhury, ME; Ronsmans, C; Killewo, J; Anwar, I; Gausia, K; Das-Gupta, S; Blum, LS; Dieltiens, G; Marshall, T; Saha, S; Borghi, J				Chowdhury, ME; Ronsmans, C; Killewo, J; Anwar, I; Gausia, K; Das-Gupta, S; Blum, LS; Dieltiens, G; Marshall, T; Saha, S; Borghi, J			Equity in use of home-based or facility-based skilled obstetric care in rural Bangladesh: an observational study	LANCET			English	Article							BIRTH ATTENDANTS; MATERNITY-CARE; CHILD HEALTH; MORTALITY; DELIVERY; DHAKA	Background Few studies have assessed whether the poorest people in developing countries benefit from giving birth at home rather than in a facility. We analysed whether socioeconomic status results in differences in the use of professional midwives at home and in a basic obstetric facility in a rural area of Bangladesh, where obstetric care was free of charge. Methods We routinely obtained data from Matlab, Bangladesh between 1987 and 2001. We compared the benefits of home-based and facility-based obstetric care using a multinomial logistic and binomial log link regression, controlling for multiple confounders. Findings Whether or not a midwife was used at home or in a facility differed significantly with wealth (adjusted odds ratio comparing the wealthiest and poorest quintiles 1.94 [95% CI 1.69-2.24] for home-based care, and 2.05 [1.72-2.43] for facility-based care). The gap between rich and poor widened after the introduction of facility-based care in 1996. The risk ratio (RR) between the wealthiest and poorest quintiles was 1.91 (adjusted RR 1.49 [95% CI 1.16-1.91] when most births with a midwife took place at home compared with 2.71 (1.66 [1.41-1.96]) at the peak of facility-based care. Interpretation In this area of Bangladesh, a shift from home-based to facility-based basic obstetric care is feasible but might lead to increased inequities in access to health care. However, there is also evidence of substantial inequities in home births. Before developing countries reinforce home-based births with a skilled attendant, research is needed to compare the feasibility, cost, effectiveness, acceptability, and implications for health-care equity in both approaches.	Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England; ICDDR B, Ctr Hlth & Populat Res, Dhaka, Bangladesh; Muhimbili Univ, Coll Hlth Sci, Dar Es Salaam, Tanzania; Inst Trop Med, B-2000 Antwerp, Belgium	University of London; London School of Hygiene & Tropical Medicine; International Centre for Diarrhoeal Disease Research (ICDDR); Institute of Tropical Medicine (ITM)	Ronsmans, C (corresponding author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.	carine.ronsmans@lshtm.ac.uk	; Gausia, Kaniz/G-8803-2013	Borghi, Josephine/0000-0002-0482-5451; Gausia, Kaniz/0000-0003-2499-1403				Afsana K, 2001, REPROD HEALTH MATTER, V9, P79, DOI 10.1016/S0968-8080(01)90094-1; Blanchet Therese, 1984, MEANINGS RITUALS BIR; Borghi J, 2003, HEALTH POLICY PLANN, V18, P383, DOI 10.1093/heapol/czg046; BORGHI J, 2004, 3 INT C HLTH EC MAN; Culyer AJ, 2001, J MED ETHICS, V27, P275, DOI 10.1136/jme.27.4.275; DEBROUWERE V, 1998, BESOINS OBSTET NONCO; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; FAUVEAU V, 1991, LANCET, V338, P1183, DOI 10.1016/0140-6736(91)92041-Y; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; GEEFHUYSEN CJ, 1999, SAFE MOTHERHOOD INIT, P62; Graham WJ, 2004, LANCET, V363, P23, DOI 10.1016/S0140-6736(03)15165-3; Gwatkin DR, 2004, LANCET, V364, P1273, DOI 10.1016/S0140-6736(04)17145-6; GWATKIN DR, 2000, SOCIOECONOMIC DIFFER; Hodgkin D, 1996, HEALTH ECON, V5, P333, DOI 10.1002/(SICI)1099-1050(199607)5:4<333::AID-HEC202>3.0.CO;2-K; Houweling TA, 2003, INT J EQUITY HEALTH, V2, P1; HUQUE ZA, 1999, SAFE MOTHERHOOD INIT, P53; *ICDDR B CTR HLTH, 2002, HLTH DEM SURV SYST M, V33; Kowalewski Marga, 2002, Afr J Reprod Health, V6, P65, DOI 10.2307/3583147; Kunst A. E., 2001, STUDIES HLTH SERV OR, V17, P297; Murakami I, 2003, LANCET, V362, P1940, DOI 10.1016/S0140-6736(03)14983-5; Nahar S, 1998, HEALTH POLICY PLANN, V13, P417, DOI 10.1093/heapol/13.4.417; *NIPORT ORC MACR J, 2003, BANGL MAT HLTH SERV; OLSEN O, 1998, COCHRANE DB SYST REV, V3; Paul BK, 2002, SOC SCI MED, V54, P1755, DOI 10.1016/S0277-9536(01)00148-4; Raghupathy S, 1996, SOC SCI MED, V43, P459, DOI 10.1016/0277-9536(95)00411-4; Ronsmans C, 1997, LANCET, V350, P1810, DOI 10.1016/S0140-6736(97)08012-4; Routh S, 2001, B WORLD HEALTH ORGAN, V79, P142; VANGINNEKEN J, 1998, SPECIAL PUBLICATION, V72; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; World Health Organization (WHO), 2004, MAK PREGN SAF CRIT R	30	83	83	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					327	332		10.1016/S0140-6736(06)68070-7	http://dx.doi.org/10.1016/S0140-6736(06)68070-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	009AX	16443040				2022-12-28	WOS:000235084600029
J	Yao, DC; Taguchi, T; Matsumura, T; Pestell, R; Edelstein, D; Giardino, I; Suske, G; Ahmed, N; Thornalley, PJ; Sarthy, VP; Hammes, HP; Brownlee, M				Yao, DC; Taguchi, T; Matsumura, T; Pestell, R; Edelstein, D; Giardino, I; Suske, G; Ahmed, N; Thornalley, PJ; Sarthy, VP; Hammes, HP; Brownlee, M			RETRACTED: Methylglyoxal modification of rnSin3A links glycolysis to angiopoietin-2 transcription (Retracted Article. See vol 128, pg 625, 2007)	CELL			English	Article; Retracted Publication							3 MAJOR PATHWAYS; GLYOXALASE-I; DIABETIC-RETINOPATHY; ADVANCED GLYCATION; O-GLYCOSYLATION; POSTTRANSLATIONAL MODIFICATION; HYPERGLYCEMIC DAMAGE; CANCER-CHEMOTHERAPY; ENDOTHELIAL-CELLS; SP1	Methylglyoxal is a highly reactive dicarbonyl degradation product formed from triose phosphates during glycolysis. Methylglyoxal forms stable adducts primarily with arginine residues of intracellular proteins. The biologic role of this covalent modification in regulating cell function is not known. Here, we report that in retinal Muller cells, increased glycolytic flux causes increased methylglyoxal modification of the corepressor mSin3A. Methylglyoxal modification of mSin3A results in increased recruitment of O-GlcNAc transferase to an mSin3A-Sp3 complex, with consequent increased modification of Sp3 by O-linked N-acetylglucosamine. This modification of Sp3 causes decreased binding of the repressor complex to a glucose-responsive GC box in the angiopoietin-2 promoter, resulting in increased Ang-2 expression. A similar mechanism involving methylglyoxal-modification of other coregulator proteins may play a role in the pathobiology of a variety of conditions associated with changes in methylglyoxal concentration, including cancer and diabetic vascular disease.	Yeshiva Univ Albert Einstein Coll Med, JDRF Int Ctr Diabet Complicat Res, Bronx, NY 10461 USA; Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20057 USA; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, Chicago, IL 60093 USA; Univ Mannheim, Med Klin 5, D-68167 Mannheim, Germany	Yeshiva University; Albert Einstein College of Medicine; Georgetown University; Philipps University Marburg; University of Essex; Northwestern University; Feinberg School of Medicine; Ruprecht Karls University Heidelberg; University of Mannheim	Brownlee, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, JDRF Int Ctr Diabet Complicat Res, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	brownlee@aecom.yu.edu	Hammes, Hans-Peter/S-3719-2019	Thornalley, Paul/0000-0001-7659-443X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, R01DK033861, R56DK033861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021654] Funding Source: NIH RePORTER; NIA NIH HHS [AG 021654] Funding Source: Medline; NIDDK NIH HHS [DK 20541, DK 33861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalou S, 2003, BIOCHEM SOC T, V31, P1394; Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200; Ahmed N, 2003, BIOCHEM SOC T, V31, P1417; Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Beisswenger PJ, 2003, BIOCHEM SOC T, V31, P1358; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chakraborty S, 2001, J CELL BIOCHEM, V82, P310, DOI 10.1002/jcb.1165; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Creighton DJ, 2003, BIOCHEM SOC T, V31, P1378; Crowley PB, 2005, PROTEINS, V59, P231, DOI 10.1002/prot.20417; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; Fingerman IM, 2004, CELL, V117, P690, DOI 10.1016/j.cell.2004.05.021; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; Iozef R, 2003, FEBS LETT, V554, P284, DOI 10.1016/S0014-5793(03)01146-3; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lu F, 2003, J VIROL, V77, P11425, DOI 10.1128/JVI.77.21.11425-11435.2003; Maeta K, 2004, MOL CELL BIOL, V24, P8753, DOI 10.1128/MCB.24.19.8753-8764.2004; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Sakamoto H, 2001, CLIN CANCER RES, V7, P2513; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1372, DOI 10.1042/BST0311372; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; Van Herreweghe F, 2002, P NATL ACAD SCI USA, V99, P949, DOI 10.1073/pnas.012432399; Venkatraman J, 2001, CHEM BIOL, V8, P611, DOI 10.1016/S1074-5521(01)00036-9; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005; Zhanel George G, 2002, Expert Opin Pharmacother, V3, P277; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	58	63	68	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					275	286		10.1016/j.cell.2005.11.024	http://dx.doi.org/10.1016/j.cell.2005.11.024			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16413606	Bronze			2022-12-28	WOS:000235068500017
J	Lee, CM; Szabo, A; Shrieve, DC; Macdonald, OK; Gaffney, DK				Lee, CM; Szabo, A; Shrieve, DC; Macdonald, OK; Gaffney, DK			Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GYNECOLOGIC-ONCOLOGY-GROUP; PROGNOSTIC FACTORS; EXTERNAL IRRADIATION; RANDOMIZED-TRIAL; CARCINOMA; CANCER; RADIOTHERAPY; SURGERY; DOXORUBICIN; SURVIVAL	Context The benefit of adjuvant radiation therapy (RT) in stage I endometrial adenocarcinoma remains controversial despite several phase 3 trials. Objective To evaluate the frequency and effect of adjuvant RT on overall and relative survival within a large US population database. Design, Setting, and Population A retrospective analysis that used data from the Surveillance, Epidemiology, and End Results program of the US National Cancer Institute from January 1, 1988, to December 31, 2001. A total of 21249 patients with American Joint Committee on Cancer stage IA-C node-negative endometrial adenocarcinoma comprised the study population. Main Outcome Measures Overall survival curves were constructed using Kaplan-Meier method and compared via stratified log-rank test within T stage/grade combinations, adjusted for age. Relative survival was performed to assess the effects of age, race, stage, grade, whether nodes were examined, and whether adjuvant RT was administered. Results Of 21249 women, 4080 received adjuvant RT (19.2%) and 17169 did not receive adjuvant RT (80.8%). The mean age at diagnosis was 63.2 years (range, 14-99 years). Adjuvant RT significantly improved overall survival for patients with stage IC/ grade 1 (P<.001) and stage IC/grades 3 and 4 (P<.001). Cox proportional hazards regression analysis revealed a statistically detectable association of adjuvant RT with improved relative survival in patients with stage IC/grade 1 and stage IC/grades 3 and 4 (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.31-0.63; P<.001; and HR, 0.72; 95% Cl, 0.57-0.92; P=.009; respectively). A separate analysis of those patients with a surgical lymph node examination at the time of total abdominal hysterectomy and bilateral salpingo-oophorectomy revealed similar estimates (HR, 0.59; 95% Cl, 0.39-0.90; P = .01; and HR, 0.73; 95% Cl, 0.55-0.96; P = .02; respectively). Conclusions As the largest reported population analysis to date of adjuvant RT in early stage endometrial adenocarcinoma, our study reveals a statistically significant association between improved overall and relative survival and adjuvant RT in stage IC disease (grades 1 and 3-4). Future work is needed to continue to delineate clinical and biological factors, which can guide treatment decisions and account for disparities in outcome between varied subsets of patients.	Huntsman Canc Hosp, Dept Radiat Oncol, Salt Lake City, UT 84112 USA; Univ Utah, Med Ctr, Salt Lake City, UT USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA; Huntsman Canc Inst, Biostat Shared Resource, Salt Lake City, UT USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute	Lee, CM (corresponding author), Huntsman Canc Hosp, Dept Radiat Oncol, 1950 Circle Hope, Salt Lake City, UT 84112 USA.		Szabo, Aniko/F-9656-2012	Szabo, Aniko/0000-0002-8129-0614; Lee, Christopher/0000-0003-1887-119X	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA042014-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Aapro MS, 2003, ANN ONCOL, V14, P441, DOI 10.1093/annonc/mdg112; ANDERSEN PK, 1985, BIOMETRICS, V41, P921, DOI 10.2307/2530964; CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8; Creutzberg CL, 2004, J CLIN ONCOL, V22, P1234, DOI 10.1200/JCO.2004.08.159; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Creutzberg CL, 2003, GYNECOL ONCOL, V89, P201, DOI 10.1016/S0090-8258(03)00126-4; Greven KM, 1997, INT J RADIAT ONCOL, V39, P413, DOI 10.1016/S0360-3016(97)00323-4; Irwin C, 1998, GYNECOL ONCOL, V70, P247, DOI 10.1006/gyno.1998.5064; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; KUCERA H, 1990, GYNECOL ONCOL, V38, P99, DOI 10.1016/0090-8258(90)90018-G; MEERWALDT JH, 1990, INT J RADIAT ONCOL, V18, P299, DOI 10.1016/0360-3016(90)90093-Y; MORROW CP, 1991, GYNECOL ONCOL, V40, P55, DOI 10.1016/0090-8258(91)90086-K; MORROW CP, 1990, GYNECOL ONCOL, V36, P166, DOI 10.1016/0090-8258(90)90166-I; *NCI CANC CONTR PO, EC SURV; Piercy C., 1990, INT CLASSIFICATION D, V2; PIVER MS, 1990, CANCER, V66, P1133, DOI 10.1002/1097-0142(19900915)66:6<1133::AID-CNCR2820660610>3.0.CO;2-H; *R FDN STAT COMP, 2005, R PROJ STAT COMP R V; *SEER, 2002, SEER STAT VERS 4 2; *SEER, DAT QUAL; *SEER PROGR PUBL U, DCCPS SURV RES PROGR	21	100	102	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					389	397		10.1001/jama.295.4.389	http://dx.doi.org/10.1001/jama.295.4.389			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005QJ	16434629	Bronze			2022-12-28	WOS:000234838600019
J	Guo, XF; Small, JP; Klare, JE; Wang, YL; Purewal, MS; Tam, IW; Hong, BH; Caldwell, R; Huang, LM; O'Brien, S; Yan, JM; Breslow, R; Wind, SJ; Hone, J; Kim, P; Nuckolls, C				Guo, XF; Small, JP; Klare, JE; Wang, YL; Purewal, MS; Tam, IW; Hong, BH; Caldwell, R; Huang, LM; O'Brien, S; Yan, JM; Breslow, R; Wind, SJ; Hone, J; Kim, P; Nuckolls, C			Covalently bridging gaps in single-walled carbon nanotubes with conducting molecules	SCIENCE			English	Article							TRANSISTORS; FLUCTUATION; ELECTRODES; JUNCTIONS; CONTACTS	Molecular electronics is often limited by the poorly defined nature of the contact between the molecules and the metal surface. We describe a method to wire molecules into gaps in single-waited carbon nanotubes (SWNTs). Precise oxidative cutting of a SWNT produces carboxylic acid-terminated electrodes separated by gaps of <= 10 nanometers. These point contacts react with molecules derivatized with amines to form molecular bridges held in place by amide linkages. These chemical contacts are robust and allow a wide variety of molecules to be tested electrically. In addition to testing molecular wires, we show how to install functionality in the molecular backbone that allows the conductance of the single-molecule bridges to switch with pH.	Columbia Univ, Dept Phys, New York, NY 10027 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA; Columbia Univ, Dept Mech Engn, New York, NY 10027 USA; Columbia Univ, Dept Appl Phys Appl Math, New York, NY 10027 USA; Columbia Univ, Ctr Elect Mol Nanostruct, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Kim, P (corresponding author), Columbia Univ, Dept Phys, 538 W 120th St, New York, NY 10027 USA.	pkim@phys.columbia.edu; cn37@columbia.edu	OBrien, Stephen/O-8814-2019; Kim, Philip/N-1886-2013; O'Brien, Stephen/D-7682-2013; Hong, Byung Hee/J-4464-2013; Huang, Limin/J-6211-2014; Hone, James C/E-1879-2011; bartelsdoe, ludwig/F-8008-2011	OBrien, Stephen/0000-0001-7531-8900; Kim, Philip/0000-0002-8255-0086; O'Brien, Stephen/0000-0001-7531-8900; Hong, Byung Hee/0000-0001-8355-8875; Huang, Limin/0000-0003-3053-0160; Hone, James C/0000-0002-8084-3301; 				Appenzeller J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.226802; Artukovic E, 2005, NANO LETT, V5, P757, DOI 10.1021/nl050254o; Basch H, 2005, NANO LETT, V5, P1668, DOI 10.1021/nl050702s; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Chiu PW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.246802; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Dai HJ, 2002, ACCOUNTS CHEM RES, V35, P1035, DOI 10.1021/ar0101640; Dettlaff-Weglikowska U, 2002, CURR APPL PHYS, V2, P497, DOI 10.1016/S1567-1739(02)00164-5; Gu Z, 2002, NANO LETT, V2, P1009, DOI 10.1021/nl025675+; Houck AA, 2005, NANO LETT, V5, P1685, DOI 10.1021/nl050799i; Huang LM, 2004, J PHYS CHEM B, V108, P16451, DOI 10.1021/jp0474125; Klare JE, 2004, LANGMUIR, V20, P10068, DOI 10.1021/la0479152; Klinke C, 2005, NANO LETT, V5, P555, DOI 10.1021/nl048055c; MacDiarmid AG, 2001, ANGEW CHEM INT EDIT, V40, P2581, DOI 10.1002/1521-3773(20010716)40:14<2581::AID-ANIE2581>3.0.CO;2-2; Mayor M, 2004, ANGEW CHEM INT EDIT, V43, P2882, DOI 10.1002/anie.200301733; Mayor M, 2003, ANGEW CHEM INT EDIT, V42, P5834, DOI 10.1002/anie.200352179; Niyogi S, 2002, ACCOUNTS CHEM RES, V35, P1105, DOI 10.1021/ar010155r; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; Qi PF, 2004, J AM CHEM SOC, V126, P11774, DOI 10.1021/ja045900k; Ramachandran GK, 2003, SCIENCE, V300, P1413, DOI 10.1126/science.1083825; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Salomon A, 2003, ADV MATER, V15, P1881, DOI 10.1002/adma.200306091; Siaj M, 2005, SCIENCE, V309, P588, DOI 10.1126/science.1113667; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Tsukagoshi K, 2004, APPL PHYS LETT, V85, P1021, DOI 10.1063/1.1779345; Tulevski GS, 2005, SCIENCE, V309, P591, DOI 10.1126/science.1112767; Williams E., 1981, LINGUIST REV, V1, P81, DOI [10.1515/tlir.1981.1.1.81, DOI 10.1515/TLIR.1981.1.1.81]; Zhitenev NB, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.186805; Ziegler KJ, 2005, NANOTECHNOLOGY, V16, pS539, DOI 10.1088/0957-4484/16/7/031	29	401	427	12	260	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					356	359		10.1126/science.1120986	http://dx.doi.org/10.1126/science.1120986			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424333				2022-12-28	WOS:000234938500037
J	Zupanc, GKH				Zupanc, GKH			Theodore H. Bullock (1915-2005) - Trailblazer in neurobiology. Obituary	NATURE			English	Biographical-Item									Int Univ Bremen, Sch Sci & Engn, D-28725 Bremen, Germany	Jacobs University	Zupanc, GKH (corresponding author), Int Univ Bremen, Sch Sci & Engn, POB 750 561, D-28725 Bremen, Germany.	g.zupanc@iu-bremen.de						BULLOCK TH, PUBLICATION LIST	1	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					280	280		10.1038/439280a	http://dx.doi.org/10.1038/439280a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421559	Bronze			2022-12-28	WOS:000234682100031
J	De Francesco, V; Margiotta, M; Zullo, A; Hassan, C; Trolani, L; Burattini, O; Stella, F; Di Leo, A; Russo, F; Marangi, S; Monno, R; Stoppino, V; Morini, S; Panella, C; Ierardi, E				De Francesco, V; Margiotta, M; Zullo, A; Hassan, C; Trolani, L; Burattini, O; Stella, F; Di Leo, A; Russo, F; Marangi, S; Monno, R; Stoppino, V; Morini, S; Panella, C; Ierardi, E			Clarithromycin-resistant genotypes and eradication of Helicobacter pylori	ANNALS OF INTERNAL MEDICINE			English	Article							RIBOSOMAL-RNA GENE; ANTIBIOTIC-RESISTANCE; POINT MUTATIONS; TRIPLE THERAPY; RISK-FACTORS; PROBE ASSAY; PCR; PREVALENCE; INFECTION; OLIGONUCLEOTIDES	Background: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance. Objective: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resistance. Design: Post hoc subgroup study from a multicenter, randomized trial. Setting: Two hospitals in-central and southern Italy between January and December 2001. Patients: 156 patients with H. pylori infection. Measurements: Real-time polymerase chain reaction for assessing clarithromycin resistance; histology, rapid urease test, and C-13-urea breath test at entry and after 4 to 6 weeks. Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin) in 75 patients or a 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days) in 81 patients. All drugs were given twice daily. Results: Helicobacter pylori infection was eradicated in 11 of 23 patients (48%) with the A2143G mutation and in 14 of 15 patients (93%) with either A2142G or A2142C strains (difference, 45 percentage points [95% Cl, 15 to 65 percentage points]; P = 0.004). The sequential regimen achieved a higher cure rate than triple therapy in A2143G mutate strains (difference, 49 percentage points [Cl, 8 to 72 percentage points]; P = 0.024) Limitations: The post hoc substudy design may require further confirmation. Other limitations are the accessibility to the tool and the cost of investigations (EURO70 per patient). Conclusions: The A2143G mutation seemed to be associated with a very low eradication rate. The sequential regimen achieved a higher cure rate than standard therapy even in patients with these strains.	Univ Foggia, Osped Riuniti, Dept Med Sci, Gastroenterol Sect, I-71100 Foggia, Italy; Univ Bari, I-70121 Bari, Italy; Osped Nuovo Regina Margherita, Rome, Italy; San Giacomo Hosp, Rome, Italy; IRCCS De Bellis, Castellana Grotte, Italy	University of Foggia; Universita degli Studi di Bari Aldo Moro; Poliambulatorio Nuovo Regina Margherita; IRCCS Saverio de Bellis	Ierardi, E (corresponding author), Univ Foggia, Osped Riuniti, Dept Med Sci, Gastroenterol Sect, Viale L Pinto, I-71100 Foggia, Italy.	e.ierardi@virgilio.it	Zullo, Angelo/AAV-7092-2020; Russo, Francesco/H-1738-2016; hassan, cesare/H-2844-2012; Zullo, Angelo/I-8809-2018; Ierardi, Enzo/AAI-1598-2020	Russo, Francesco/0000-0003-0538-6072; hassan, cesare/0000-0001-7167-1459; Zullo, Angelo/0000-0003-2329-8105; Ierardi, Enzo/0000-0001-7275-5080; Di Leo, Alfredo/0000-0003-2026-1200; Monno, Rosa/0000-0002-5789-4194				Afonina I, 1997, NUCLEIC ACIDS RES, V25, P2657, DOI 10.1093/nar/25.13.2657; Broutet N, 2003, ALIMENT PHARM THER, V17, P99, DOI 10.1046/j.1365-2036.2003.01396.x; De Francesco V, 2004, DIGEST LIVER DIS, V36, P322, DOI 10.1016/j.dld.2003.12.015; De Francesco V, 2004, ALIMENT PHARM THER, V19, P407, DOI 10.1046/j.1365-2036.2004.01818.x; De Francesco V, 2001, DIGEST LIVER DIS, V33, P676, DOI 10.1016/S1590-8658(01)80044-X; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047; Howden CW, 1998, AM J GASTROENTEROL, V93, P2330, DOI 10.1111/j.1572-0241.1998.00684.x; Kaneko F, 2004, ALIMENT PHARM THER, V20, P62, DOI 10.1111/j.1365-2036.2004.01993.x; Kim KS, 2002, J KOREAN MED SCI, V17, P599, DOI 10.3346/jkms.2002.17.5.599; Kutyavin IV, 1997, NUCLEIC ACIDS RES, V25, P3718, DOI 10.1093/nar/25.18.3718; LEE LG, 1993, NUCLEIC ACIDS RES, V21, P3761, DOI 10.1093/nar/21.16.3761; Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x; Marais A, 1999, GUT, V44, P463, DOI 10.1136/gut.44.4.463; Masaoka T, 2004, ALIMENT PHARM THER, V20, P68, DOI 10.1111/j.1365-2036.2004.01994.x; Megraud F, 2004, GUT, V53, P1374, DOI 10.1136/gut.2003.022111; Oleastro M, 2003, J CLIN MICROBIOL, V41, P397, DOI 10.1128/JCM.41.1.397-402.2003; Owen RJ, 2002, GUT, V50, P285, DOI 10.1136/gut.50.3.285; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Perri F, 2001, ALIMENT PHARM THER, V15, P1023, DOI 10.1046/j.1365-2036.2001.01006.x; Pilotto A, 2000, DIGEST LIVER DIS, V32, P763, DOI 10.1016/S1590-8658(00)80352-7; Roberts MC, 2004, MOL BIOTECHNOL, V28, P47, DOI 10.1385/MB:28:1:47; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Savarino V, 2000, ALIMENT PHARM THER, V14, P893; Stone GG, 1997, ANTIMICROB AGENTS CH, V41, P712, DOI 10.1128/AAC.41.3.712; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Toracchio S, 2003, DIGEST LIVER DIS, V35, P541, DOI 10.1016/S1590-8658(03)00265-2; Toracchio S, 2004, HELICOBACTER, V9, P396, DOI 10.1111/j.1083-4389.2004.00267.x; van Doorn LJ, 2001, ANTIMICROB AGENTS CH, V45, P1500, DOI 10.1128/AAC.45.5.1500-1504.2001; Versalovic J, 1997, J ANTIMICROB CHEMOTH, V40, P283, DOI 10.1093/jac/40.2.283; Wada T, 2004, J CLIN MICROBIOL, V42, P5277, DOI 10.1128/JCM.42.11.5277-5285.2004; Webber MA, 2003, J ANTIMICROB CHEMOTH, V51, P9, DOI 10.1093/jac/dkg050; Zullo A, 2003, DIGEST LIVER DIS, V35, P357, DOI 10.1016/S1590-8658(03)00081-1; Zullo A, 2003, ALIMENT PHARM THER, V17, P719, DOI 10.1046/j.1365-2036.2003.01461.x; Zullo A, 2000, ALIMENT PHARM THER, V14, P715	35	158	165	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					94	100		10.7326/0003-4819-144-2-200601170-00006	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	004AX	16418408				2022-12-28	WOS:000234725500005
J	[Anonymous]				[Anonymous]			Health and the environment after Hurricane Katrina	ANNALS OF INTERNAL MEDICINE			English	News Item														Wilson, Jennifer/0000-0003-4025-3136					0	18	18	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					153	153		10.7326/0003-4819-144-2-200601170-00029	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00029			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	004AX	16418428				2022-12-28	WOS:000234725500026
J	Obwegeser, J; Schneider, V				Obwegeser, J; Schneider, V			Thin-layer cervical cytology: a new meta-analysis	LANCET			English	Editorial Material							HIGH-RISK POPULATIONS; LIQUID-BASED CYTOLOGY				Obwegeser, J (corresponding author), Gfrennstr 39, CH-8603 Schwerzenbach, Switzerland.	zylabob@swissonline.ch		Schneider, Volker PE/0000-0003-1212-7263				*AG NAT ACCR EV SA, 2002, COND TEN DEV PAT AYA; BROADSTOCK M, 2000, EFFECTIVENESS COST E; Davey E, 2006, LANCET, V367, P122, DOI 10.1016/S0140-6736(06)67961-0; Henstock E., 2002, EVALUATION HPV LBC C; KARNON J, 2003, LIQUID BASED CYTOLOG; Lee KR, 1997, OBSTET GYNECOL, V90, P278, DOI 10.1016/S0029-7844(97)00228-7; MCCRORY DC, 1999, AHCPR PUBLICATION; Medical Services Advisory Committee, 2002, 12A MSAC; NOORANI H, 2003, 40 CAN COORD OFF HLT; Obwegeser JH, 2001, ACTA CYTOL, V45, P709, DOI 10.1159/000328292; Ring M, 2002, CYTOPATHOLOGY, V13, P152, DOI 10.1046/j.1365-2303.2002.00408.x; Schneider V, 2003, CYTOPATHOLOGY, V14, P41, DOI 10.1046/j.1365-2303.2003.12052.x; SIEBERT U, 2003, DUNNSCHICHTPRAPARATI	13	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					88	89		10.1016/S0140-6736(06)67938-5	http://dx.doi.org/10.1016/S0140-6736(06)67938-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413857				2022-12-28	WOS:000234655500005
J	Johansen, D; Friis, K; Skovenborg, E; Gronbaek, M				Johansen, D; Friis, K; Skovenborg, E; Gronbaek, M			Food buying habits of people who buy wine or beer: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; ALCOHOLIC BEVERAGE PREFERENCE; CONSUMPTION; MORTALITY; RISK; DIET; DRINKING; SPIRITS; LIQUOR	Objective To investigate whether people who buy wine buy healthier food items than those who buy beer. Design Cross sectional study. Setting Supermarkets in Denmark. Data Information on number, type of item, and total charge from 3.5 million transactions over a period of six months. Results Wine buyers bought more olives, fruit and vegetables, poultry, cooking oil, and low fat cheese, milk, and meat than beer buyers. Beer buyers bought more ready cooked dishes, sugar, cold cuts, chips, pork, butter or margarine, sausages, lamb, and soft drinks than wine buyers. Conclusions Wine buyers made more purchases of healthy food items than people who buy beer.	Natl Inst Publ Hlth, DK-1399 Copenhagen K, Denmark		Gronbaek, M (corresponding author), Natl Inst Publ Hlth, Oster Farimagsgade 5A, DK-1399 Copenhagen K, Denmark.	mg@niph.dk		Gronbaek, Morten Klocker/0000-0002-8473-6474				Barefoot JC, 2002, AM J CLIN NUTR, V76, P466, DOI 10.1093/ajcn/76.2.466; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; Corrao G, 1999, ADDICTION, V94, P1551, DOI 10.1046/j.1360-0443.1999.9410155111.x; Ekholm O, 2004, EUR J CLIN NUTR, V58, P60, DOI 10.1038/sj.ejcn.1601746; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; Gaziano JM, 1998, NOVART FDN SYMP, V216, P86; Gronbaek M, 1996, EUR J CLIN NUTR, V50, P487; Gronbaek M, 1999, J EPIDEMIOL COMMUN H, V53, P721, DOI 10.1136/jech.53.11.721; Gronbaek M, 2000, ANN INTERN MED, V133, P411, DOI 10.7326/0003-4819-133-6-200009190-00008; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Kesse E, 2001, AM J CLIN NUTR, V74, P322; Klatsky AL, 2003, AM J EPIDEMIOL, V158, P585, DOI 10.1093/aje/kwg184; KLATSKY AL, 1990, BRIT J ADDICT, V85, P1279; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; Mortensen EL, 2001, ARCH INTERN MED, V161, P1844, DOI 10.1001/archinte.161.15.1844; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Ruidavets JB, 2004, EUR HEART J, V25, P1153, DOI 10.1016/j.ehj.2003.12.022; Tjonneland A, 1999, AM J CLIN NUTR, V69, P49; Trevisan M, 2004, ADDICTION, V99, P313, DOI 10.1111/j.1360-0443.2003.00630.x; Wannamethee SG, 1999, AM J PUBLIC HEALTH, V89, P685, DOI 10.2105/AJPH.89.5.685	24	91	93	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					519	521		10.1136/bmj.38694.568981.80	http://dx.doi.org/10.1136/bmj.38694.568981.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	023WB	16428251	Green Published, Bronze			2022-12-28	WOS:000236155800015
J	Hannon, JB; Kodambaka, S; Ross, FM; Tromp, RM				Hannon, JB; Kodambaka, S; Ross, FM; Tromp, RM			The influence of the surface migration of gold on the growth of silicon nanowires	NATURE			English	Article							SEMICONDUCTOR NANOWIRES; BUILDING-BLOCKS; HETEROSTRUCTURES; MECHANISM; LOGIC	Interest in nanowires continues to grow, fuelled in part by applications in nanotechnology(1-5). The ability to engineer nanowire properties makes them especially promising in nanoelectronics(6-9). Most silicon nanowires are grown using the vapour liquid - solid (VLS) mechanism, in which the nanowire grows from a gold/silicon catalyst droplet during silicon chemical vapour deposition(10-13). Despite over 40 years of study, many aspects of VLS growth are not well understood. For example, in the conventional picture the catalyst droplet does not change during growth, and the nanowire sidewalls consist of clean silicon facets(10-13). Here we demonstrate that these assumptions are false for silicon nanowires grown on Si( 111) under conditions where all of the experimental parameters ( surface structure, gas cleanliness, and background contaminants) are carefully controlled. We show that gold diffusion during growth determines the length, shape, and sidewall properties of the nanowires. Gold from the catalyst droplets wets the nanowire sidewalls, eventually consuming the droplets and terminating VLS growth. Gold diffusion from the smaller droplets to the larger ones (Ostwald ripening) leads to nanowire diameters that change during growth. These results show that the silicon nanowire growth is fundamentally limited by gold diffusion: smooth, arbitrarily long nanowires cannot be grown without eliminating gold migration.	IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Hannon, JB (corresponding author), IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA.	jbhannon@us.ibm.com	Ross, Frances/P-8919-2015	Ross, Frances/0000-0003-0838-9770				Bjork MT, 2002, APPL PHYS LETT, V80, P1058, DOI 10.1063/1.1447312; Bjork MT, 2002, NANO LETT, V2, P87, DOI 10.1021/nl010099n; Cui Y, 2003, NANO LETT, V3, P149, DOI 10.1021/nl025875l; Duan XF, 2002, NANO LETT, V2, P487, DOI 10.1021/nl025532n; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; GIVARGIZOV EI, 1975, J CRYST GROWTH, V31, P20, DOI 10.1016/0022-0248(75)90105-0; Gudiksen MS, 2002, NATURE, V415, P617, DOI 10.1038/415617a; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Kolb FM, 2004, J ELECTROCHEM SOC, V151, pG472, DOI 10.1149/1.1759365; Lauhon LJ, 2002, NATURE, V420, P57, DOI 10.1038/nature01141; Law M, 2004, ANNU REV MATER RES, V34, P83, DOI 10.1146/annurev.matsci.34.040203.112300; Lee ST, 2000, MAT SCI ENG A-STRUCT, V286, P16, DOI 10.1016/S0921-5093(00)00658-4; Nagao T, 1998, PHYS REV B, V57, P10100, DOI 10.1103/PhysRevB.57.10100; STOLWIJK NA, 1983, PHYSICA B & C, V116, P335, DOI 10.1016/0378-4363(83)90271-1; TROMP RM, 1991, ULTRAMICROSCOPY, V36, P99, DOI 10.1016/0304-3991(91)90141-R; WAGNER RS, 1964, APPL PHYS LETT, V4, P89, DOI 10.1063/1.1753975; WAGNER RS, 1970, WHISKER TECHNOLOGY, P47; Wu Y, 2004, NANO LETT, V4, P433, DOI 10.1021/nl035162i; YAGI K, 1993, SURF SCI REP, V17, P305, DOI 10.1016/0167-5729(93)90002-7; Zhang HM, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.035314	20	782	791	11	441	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					69	71		10.1038/nature04574	http://dx.doi.org/10.1038/nature04574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16452928				2022-12-28	WOS:000235685700040
J	Baldwin, IT; Halitschke, R; Paschold, A; von Dahl, CC; Preston, CA				Baldwin, IT; Halitschke, R; Paschold, A; von Dahl, CC; Preston, CA			Volatile signaling in plant-plant interactions: "Talking trees" in the genomics era	SCIENCE			English	Review							INDUCED RESISTANCE; METHYL JASMONATE; HYDROPEROXIDE LYASE; ETHYLENE; HERBIVORY; COMMUNICATION; EMISSION; TOBACCO; SAGEBRUSH; RESPONSES	Plants may "eavesdrop" on volatile organic compounds WOO released by herbivore-attacked neighbors to activate defenses before being attacked themselves. Transcriptome and signal cascade analyses of VOC-exposed plants suggest that plants eavesdrop to prime direct and indirect defenses and to hone competitive abilities. Advances in research on VOC biosynthesis and perception have facilitated the production of plants that are genetically "deaf" to particular VOC5 or "mute" in elements of their volatile vocabulary. Such plants, together with advances in VOC analytical instrumentation, will allow researchers to determine whether fluency enhances the fitness of plants in natural communities.	Max Planck Inst Chem Ecol, Dept Mol Ecol, D-07745 Jena, Germany; Cornell Univ, Ithaca, NY 14853 USA; US Anim & Plant Hlth Inspect Serv, Biotechnol Regulatory Serv, USDA, Riverdale, MD 20737 USA	Max Planck Society; Cornell University; United States Department of Agriculture (USDA)	Baldwin, IT (corresponding author), Max Planck Inst Chem Ecol, Dept Mol Ecol, Hans Knoll Str 8, D-07745 Jena, Germany.	baldwin@ice.mpg.de	Halitschke, Rayko/AAY-2365-2020; Baldwin, Ian T/K-1809-2013	Halitschke, Rayko/0000-0002-1109-8782; Baldwin, Ian/0000-0001-5371-2974				Almeras E, 2003, PLANT J, V34, P202, DOI 10.1046/j.1365-313X.2003.01718.x; Arimura G, 2000, NATURE, V406, P512, DOI 10.1038/35020072; Arimura G, 2002, PLANT J, V29, P87, DOI 10.1046/j.1365-313x.2002.01198.x; Arimura G, 2001, BIOCHEM SYST ECOL, V29, P1049, DOI 10.1016/S0305-1978(01)00049-7; Baldwin IT, 2002, CURR OPIN PLANT BIOL, V5, P351, DOI 10.1016/S1369-5266(02)00263-7; Baldwin IT, 1998, P NATL ACAD SCI USA, V95, P8113, DOI 10.1073/pnas.95.14.8113; Ballare CL, 1999, TRENDS PLANT SCI, V4, P97, DOI 10.1016/S1360-1385(99)01383-7; Bate NJ, 1998, PLANT J, V16, P561, DOI 10.1046/j.1365-313x.1998.00324.x; Choh Y, 2004, J CHEM ECOL, V30, P1305, DOI 10.1023/B:JOEC.0000037741.13402.19; Dicke M, 2003, TRENDS PLANT SCI, V8, P403, DOI 10.1016/S1360-1385(03)00183-3; Dong XN, 2004, CURR OPIN PLANT BIOL, V7, P547, DOI 10.1016/j.pbi.2004.07.005; Engelberth J, 2004, P NATL ACAD SCI USA, V101, P1781, DOI 10.1073/pnas.0308037100; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; Halitschke R, 2004, PLANT J, V40, P35, DOI 10.1111/j.1365-313X.2004.02185.x; Halitschke R, 2003, PLANT J, V36, P794, DOI 10.1046/j.1365-313X.2003.01921.x; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; Heil M, 2002, TRENDS PLANT SCI, V7, P61, DOI 10.1016/S1360-1385(01)02186-0; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Jimenez-Martinez ES, 2004, ENVIRON ENTOMOL, V33, P1207, DOI 10.1603/0046-225X-33.5.1207; Karban R, 2000, OECOLOGIA, V125, P66, DOI 10.1007/PL00008892; Karban R, 2004, ECOLOGY, V85, P1846, DOI 10.1890/03-0593; Karban R, 2002, ECOLOGY, V83, P1209, DOI 10.1890/0012-9658(2002)083[1209:TFCOIE]2.0.CO;2; Kesselmeier J, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001813; KESSLER A, IN PRESS OECOLOGIA; Kost C, 2005, BASIC APPL ECOL, V6, P237, DOI 10.1016/j.baae.2004.11.002; Niinemets U, 2004, TRENDS PLANT SCI, V9, P180, DOI 10.1016/j.tplants.2004.02.006; Ninkovic V, 2003, J EXP BOT, V54, P1931, DOI 10.1093/jxb/erg192; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; Pare PW, 1997, PLANT PHYSIOL, V114, P1161, DOI 10.1104/pp.114.4.1161; PASCHOLD A, IN PRESS PLANT J; Pierik R, 2004, PLANT J, V38, P310, DOI 10.1111/j.1365-313X.2004.02044.x; Pierik R, 2003, PLANT CELL ENVIRON, V26, P1229, DOI 10.1046/j.1365-3040.2003.01045.x; Preston CA, 2004, J CHEM ECOL, V30, P2193, DOI 10.1023/B:JOEC.0000048783.64264.2a; Preston CA, 2001, BIOCHEM SYST ECOL, V29, P1007, DOI 10.1016/S0305-1978(01)00047-3; Rasmann S, 2005, NATURE, V434, P732, DOI 10.1038/nature03451; Ruther J, 2005, J CHEM ECOL, V31, P2217, DOI 10.1007/s10886-005-6413-8; Shulaev V, 1997, NATURE, V385, P718, DOI 10.1038/385718a0; Thaler JS, 2002, ECOL LETT, V5, P764, DOI 10.1046/j.1461-0248.2002.00388.x; Thistle HW, 2004, FOREST SCI, V50, P610; Tscharntke T, 2001, BIOCHEM SYST ECOL, V29, P1025, DOI 10.1016/S0305-1978(01)00048-5; Vancanneyt G, 2001, P NATL ACAD SCI USA, V98, P8139, DOI 10.1073/pnas.141079498; WIGNALL B, 1993, SHRUBS TREES SW DESE, P19	42	566	627	15	433	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					812	815		10.1126/science.1118446	http://dx.doi.org/10.1126/science.1118446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469918				2022-12-28	WOS:000235374900037
J	Reilly, BM; Evans, AT				Reilly, BM; Evans, AT			Translating clinical research into clinical practice: Impact of using prediction rules to make decisions	ANNALS OF INTERNAL MEDICINE			English	Article							OTTAWA ANKLE RULES; ACUTE CHEST-PAIN; COST-EFFECTIVENESS ANALYSIS; ACUTE CARDIAC ISCHEMIA; DEEP-VEIN THROMBOSIS; SHORT-TERM PROGNOSIS; TIMI RISK SCORE; ST-ELEVATION MI; C-SPINE RULE; MYOCARDIAL-INFARCTION	Clinical prediction rules, sometimes called clinical decision rules, have proliferated in recent years. However, very few have undergone formal impact analysis, the standard of evidence to assess their impact on patient care. Without impact analysis, clinicians cannot know whether using a prediction rule will be beneficial or harmful. This paper reviews standards of evidence for developing and evaluating prediction rules; important differences between prediction rules and decision rules; how to assess the potential clinical impact of a prediction rule before translating it into a decision rule; methodologic issues critical to successful impact analysis, including defining outcome measures and estimating sample size; the importance of close collaboration between clinical investigators and practicing clinicians before, during, and after impact analysis; and the need to measure both efficacy and effectiveness when analyzing a decision rule's clinical impact. These considerations should inform future development, evaluation, and use of all clinical prediction or decision rules.	Cook Cty Stroger Hosp, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County; Rush University	Reilly, BM (corresponding author), Cook Cty Stroger Hosp, Adm Bldg,Room 1528,1900 W Polk St, Chicago, IL 60612 USA.	breilly@cchil.org						Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Arozullah AM, 2001, ANN INTERN MED, V135, P847, DOI 10.7326/0003-4819-135-10-200111200-00005; Bailey WC, 2002, JAMA-J AM MED ASSOC, V287, P996, DOI 10.1001/jama.287.8.996; Benavente O, 2001, NEW ENGL J MED, V345, P1084, DOI 10.1056/NEJMoa002994; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; BRAND DA, 1982, NEW ENGL J MED, V306, P333, DOI 10.1056/NEJM198202113060604; Brindle P, 2003, BMJ-BRIT MED J, V327, P1267, DOI 10.1136/bmj.327.7426.1267; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Cadarette SM, 2001, JAMA-J AM MED ASSOC, V286, P57, DOI 10.1001/jama.286.1.57; Cameron C, 1999, CAN MED ASSOC J, V160, P1165; Casalino LP, 1999, NEW ENGL J MED, V341, P1147, DOI 10.1056/NEJM199910073411511; Casey BM, 2001, NEW ENGL J MED, V344, P467, DOI 10.1056/NEJM200102153440701; Collins S, 2000, JAMA-J AM MED ASSOC, V284, P621, DOI 10.1001/jama.284.5.621; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; Daly K, 2001, BRIT MED J, V322, P1274, DOI 10.1136/bmj.322.7297.1274; Durairaj L, 2001, AM J MED, V110, P7, DOI 10.1016/S0002-9343(00)00640-9; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P3342, DOI 10.1001/jama.267.24.3342; English DR, 2003, BRIT MED J, V327, P375, DOI 10.1136/bmj.327.7411.375; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GENUIS SJ, 2004, BRIT MED J, V329, P179; Gilbert K, 2000, ANN INTERN MED, V133, P356, DOI 10.7326/0003-4819-133-5-200009050-00011; Goldman L, 2003, ANN INTERN MED, V139, P987, DOI 10.7326/0003-4819-139-12-200312160-00008; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; Hasbun R, 2003, JAMA-J AM MED ASSOC, V289, P1933, DOI 10.1001/jama.289.15.1933; Hasbun R, 2001, NEW ENGL J MED, V345, P1727, DOI 10.1056/NEJMoa010399; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Hurwitz B, 2004, BMJ-BRIT MED J, V329, P1024, DOI 10.1136/bmj.329.7473.1024; Imperiale TF, 2003, ANN INTERN MED, V139, P959, DOI 10.7326/0003-4819-139-12-200312160-00005; James BC, 2001, NEW ENGL J MED, V345, P991, DOI 10.1056/NEJM200109273451311; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LUCCHESI GM, 1995, ANN EMERG MED, V26, P1, DOI 10.1016/S0196-0644(95)70229-6; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Mehr DR, 2001, JAMA-J AM MED ASSOC, V286, P2427, DOI 10.1001/jama.286.19.2427; Michie S, 2004, BRIT MED J, V328, P343, DOI 10.1136/bmj.328.7435.343; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056/NEJM200001133420203; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P1356, DOI 10.1001/jama.286.11.1356; Nielsen OW, 2000, BRIT MED J, V320, P220, DOI 10.1136/bmj.320.7229.220; Ozuah PO, 2001, JAMA-J AM MED ASSOC, V285, P451, DOI 10.1001/jama.285.4.451; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; Ramachandran S, 2000, BRIT MED J, V320, P676, DOI 10.1136/bmj.320.7236.676; Reilly B, 1999, AM J MED, V106, P285, DOI 10.1016/S0002-9343(99)00024-8; Reilly BM, 2002, JAMA-J AM MED ASSOC, V288, P342, DOI 10.1001/jama.288.3.342; Reilly BM, 2002, AM J MED, V112, P95, DOI 10.1016/S0002-9343(01)01054-3; Rutter D., 2002, CHANGING HLTH BEHAV; Schoonhoven L, 2002, BMJ-BRIT MED J, V325, P797, DOI 10.1136/bmj.325.7368.797; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; Stiell IG, 2003, NEW ENGL J MED, V349, P2510, DOI 10.1056/NEJMoa031375; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; van Walraven C, 2001, JAMA-J AM MED ASSOC, V285, P1602, DOI 10.1001/jama.285.12.1602; Verma S, 1997, AM J ROENTGENOL, V169, P825, DOI 10.2214/ajr.169.3.9275906; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; Wang TJ, 2003, JAMA-J AM MED ASSOC, V290, P1049, DOI 10.1001/jama.290.8.1049; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Weber JE, 2003, NEW ENGL J MED, V348, P510, DOI 10.1056/NEJMoa022206; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010	74	510	518	1	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					201	209		10.7326/0003-4819-144-3-200602070-00009	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008XS	16461965				2022-12-28	WOS:000235074800007
J	Kashikar-Zuck, S				Kashikar-Zuck, S			Treatment of children with unexplained chronic pain	LANCET			English	Editorial Material							PRIMARY FIBROMYALGIA SYNDROME; RANDOMIZED CONTROLLED-TRIALS; FUNCTIONAL DISABILITY; PEDIATRIC PAIN; INTERVENTION; METAANALYSIS; DEPRESSION; THERAPY		Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Kashikar-Zuck, S (corresponding author), Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA.	Susmita.Kashikar-Zuck@cchmc.org						Chambers CT, 2003, PROG PAIN RES MANAG, V26, P99; Eccleston C, 2002, PAIN, V99, P157, DOI 10.1016/S0304-3959(02)00072-6; Gatchel RJ, 1996, PSYCHOL APPROACHES P; Kashikar-Zuck S, 2005, J RHEUMATOL, V32, P1594; Kashikar-Zuck S, 2001, CLIN J PAIN, V17, P341, DOI 10.1097/00002508-200112000-00009; Kashikar-Zuck S, 2002, J PAIN, V3, P412, DOI 10.1054/jpai.2002.126786; Konijnenberg AY, 2005, ARCH DIS CHILD, V90, P680, DOI 10.1136/adc.2004.056820; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Perquin CW, 2001, PAIN, V94, P205, DOI 10.1016/S0304-3959(01)00355-4; Robins PM, 2005, J PEDIATR PSYCHOL, V30, P397, DOI 10.1093/jpepsy/jsi063	10	24	24	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					380	382		10.1016/S0140-6736(06)68118-X	http://dx.doi.org/10.1016/S0140-6736(06)68118-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458749				2022-12-28	WOS:000235139400010
J	Edouard, L; Bernstein, S				Edouard, L; Bernstein, S			Seeking equity in maternal health	LANCET			English	Editorial Material							BIRTH ATTENDANTS; OBSTETRIC CARE; MORTALITY; BANGLADESH; COST		UN Populat Fund, New York, NY 10017 USA	United Nations Population Fund	Edouard, L (corresponding author), UN Populat Fund, New York, NY 10017 USA.	edouard@unfpa.org						Afsana K, 2004, REPROD HEALTH MATTER, V12, P171, DOI 10.1016/S0968-8080(04)24142-8; Chowdhury ME, 2006, LANCET, V367, P327, DOI 10.1016/S0140-6736(06)68070-7; Gertler P., 2000, FINAL REPORT IMPACT; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Jokhio AH, 2005, NEW ENGL J MED, V352, P2091, DOI 10.1056/NEJMsa042830; Moser KA, 2005, BRIT MED J, V331, P1180, DOI 10.1136/bmj.38659.588125.79; Paul BK, 2002, SOC SCI MED, V54, P1755, DOI 10.1016/S0277-9536(01)00148-4; Prata N, 2005, INT J GYNECOL OBSTET, V90, P51, DOI 10.1016/j.ijgo.2005.03.007; UN Millennium Project, 2005, WHOS GOT POW TRANSF; van Roosmalen J, 2005, TROP MED INT HEALTH, V10, P393, DOI 10.1111/j.1365-3156.2005.01411.x; *WHO, 2004, RE HLTH STRAT ACC PR; Xiong X, 2003, INT J GYNECOL OBSTET, V83, P159, DOI [10.1016/S0020-7292(03)00214-5, 10.1016/s0020-7292(03)00214-5]	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					279	281		10.1016/S0140-6736(06)68047-1	http://dx.doi.org/10.1016/S0140-6736(06)68047-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443022				2022-12-28	WOS:000235084600006
J	Ahnesorg, P; Smith, P; Jackson, SP				Ahnesorg, P; Smith, P; Jackson, SP			XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining	CELL			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; POLYNUCLEOTIDE KINASE; TARGETED DISRUPTION; CRYSTAL-STRUCTURE; PROTEIN XRCC4; GENE-PRODUCT; MECHANISM; CELLS; PK	DNA nonhomologous end-joining (NHEJ) is a predominant pathway of DNA double-strand break repair in mammalian cells, and defects in it cause radiosensitivity at the cellular and whole-organism levels. Central to NHEJ is the protein complex containing DNA Ligase IV and XRCC4. By searching for additional XRCC4-interacting factors, we identified a previously uncharacterized 33 kDa protein, XRCC4-like factor (XLF, also named Cernunnos), that has weak sequence homology with XRCC4 and is predicted to display structural similarity to XRCC4. We show that XLF directly interacts with the XRCC4-Ligase IV complex in vitro and in vivo and that siRNA-mediated downregulation of XLF in human cell lines leads to radiosensitivity and impaired NHEJ. Furthermore, we establish that NHEJ-deficient 2BN cells derived from a radiosensitive and immune-deficient patient lack XLF due to an inactivating frameshift mutation in its gene, and that reintroduction of wild-type XLF into such cells corrects their radiosensitivity and NHEJ defects. XLF thus constitutes a novel core component of the mammalian NHEJ apparatus.	Univ Cambridge, Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QN, England	University of Cambridge; University of Cambridge	Jackson, SP (corresponding author), Univ Cambridge, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	s.jackson@gurdon.cam.ac.uk	Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 				Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hefferin ML, 2005, DNA REPAIR, V4, P639, DOI 10.1016/j.dnarep.2004.12.005; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koch CA, 2004, EMBO J, V23, P3874, DOI 10.1038/sj.emboj.7600375; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lou ZK, 2004, J BIOL CHEM, V279, P46359, DOI 10.1074/jbc.C400375200; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; Modesti M, 2001, GENOME BIOL, V2; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003	57	561	576	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					301	313		10.1016/j.cell.2005.12.031	http://dx.doi.org/10.1016/j.cell.2005.12.031			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439205	Bronze			2022-12-28	WOS:000235068500019
J	Halloran, J				Halloran, J			Making better ceramic composites with ice	SCIENCE			English	Editorial Material							FRACTURE		Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Halloran, J (corresponding author), Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.	peterjon@umich.edu	Halloran, John W/G-9210-2011	Halloran, John/0000-0002-1913-6886				CURREY JD, 1976, J MATER SCI, V11, P1615, DOI 10.1007/BF00737517; Deville S, 2006, SCIENCE, V311, P515, DOI 10.1126/science.1120937; GARVIE RC, 1975, NATURE, V258, P703, DOI 10.1038/258703a0; Green DJ, 1998, INTRO MECH PROPERTIE, P218; Griffith A.A., 1921, PHILOS T R SOC A, V221, P163, DOI 10.1098/rsta.1921.0006; HEUER AH, 1987, J AM CERAM SOC, V70, P689, DOI 10.1111/j.1151-2916.1987.tb04865.x; Kamat S, 2000, NATURE, V405, P1036, DOI 10.1038/35016535; KENDALL K, 1989, NATURE, V339, P130, DOI 10.1038/339130a0; Kovar D, 1997, J AM CERAM SOC, V80, P2471, DOI 10.1111/j.1151-2916.1997.tb03148.x; Lawn P.R, 1993, CAMBRIDGE SOLID STAT, Vsecond; Mayer G, 2005, SCIENCE, V310, P1144, DOI 10.1126/science.1116994; Sofie SW, 2001, J AM CERAM SOC, V84, P1459; Tang ZY, 2003, NAT MATER, V2, P413, DOI 10.1038/nmat906	13	26	32	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					479	480		10.1126/science.1123220	http://dx.doi.org/10.1126/science.1123220			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439652				2022-12-28	WOS:000235071400034
J	Sanchez-Alvarado, A				Sanchez-Alvarado, A			Planarian regeneration: Its end is its beginning	CELL			English	Editorial Material							STEM-CELLS; SCHMIDTEA-MEDITERRANEA	Why does regeneration take place in some animals but not others? Increased understanding of gene function is required to dissect the genetics, cell biology, and physiological aspects that make regeneration possible. An unlikely model animal, the planarian Schmidtea mediterranea, is proving valuable in this endeavor.	Univ Utah, Sch Med, Dept Neurobiol & Anat, Howard Hughes Med Inst, Salt Lake City, UT 84103 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Sanchez-Alvarado, A (corresponding author), Univ Utah, Sch Med, Dept Neurobiol & Anat, Howard Hughes Med Inst, Salt Lake City, UT 84103 USA.	sanchez@neuro.utah.edu		Sanchez Alvarado, Alejandro/0000-0002-1966-6959				Alvarado AS, 2000, BIOESSAYS, V22, P578, DOI 10.1002/(SICI)1521-1878(200006)22:6<578::AID-BIES11>3.0.CO;2-#; Alvarado AS, 2003, CURR OPIN GENET DEV, V13, P438, DOI 10.1016/S0959-437X(03)00082-0; Alvarado AS, 2002, DEVELOPMENT, V129, P5659, DOI 10.1242/dev.00167; Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Brockes JP, 2001, J ANAT, V199, P3; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Cebria F, 2002, NATURE, V419, P620, DOI 10.1038/nature01042; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Morgan T.H., 1901, REGENERATION; Nechiporuk A, 2003, DEV BIOL, V258, P291, DOI 10.1016/S0012-1606(03)00129-5; Newmark PA, 2000, DEV BIOL, V220, P142, DOI 10.1006/dbio.2000.9645; Newmark PA, 2002, NAT REV GENET, V3, P210, DOI 10.1038/nrg759; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Reddien PW, 2005, SCIENCE, V310, P1327, DOI 10.1126/science.1116110; Reddien PW, 2005, DEV CELL, V8, P635, DOI 10.1016/j.devcel.2005.02.014; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P725, DOI 10.1146/annurev.cellbio.20.010403.095114; Stanhope MJ, 2001, NATURE, V411, P940, DOI 10.1038/35082058	17	88	92	4	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					241	245		10.1016/j.cell.2006.01.012	http://dx.doi.org/10.1016/j.cell.2006.01.012			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439195	Bronze			2022-12-28	WOS:000235068500008
J	Beaulieu, JP; Bennett, DP; Fouque, P; Williams, A; Dominik, M; Jorgensen, UG; Kubas, D; Cassan, A; Coutures, C; Greenhill, J; Hill, K; Menzies, J; Sackett, PD; Albrow, M; Brillant, S; Caldwell, JAR; Calitz, JJ; Cook, KH; Corrales, E; Desort, M; Dieters, S; Dominis, D; Donatowicz, J; Hoffman, M; Kane, S; Marquette, JB; Martin, R; Meintjes, P; Pollard, K; Sahu, K; Vinter, C; Wambsganss, J; Woller, K; Horne, K; Steele, I; Bramich, DM; Burgdorf, M; Snodgrass, C; Bode, M; Udalski, A; Szymanski, MK; Kubiak, M; Wieckowski, T; Pietrzynski, G; Soszynski, I; Szewczyk, O; Wyrzykowski, L; Paczynski, B; Abe, F; Bond, IA; Britton, TR; Gilmore, AC; Hearnshaw, JB; Itow, Y; Kamiya, K; Kilmartin, PM; Korpela, AV; Masuda, K; Matsubara, Y; Motomura, M; Muraki, Y; Nakamura, S; Okada, C; Ohnishi, K; Rattenbury, NJ; Sako, T; Sato, S; Sasaki, M; Sekiguchi, T; Sullivan, DJ; Tristram, PJ; Yock, PCM; Yoshioka, T				Beaulieu, JP; Bennett, DP; Fouque, P; Williams, A; Dominik, M; Jorgensen, UG; Kubas, D; Cassan, A; Coutures, C; Greenhill, J; Hill, K; Menzies, J; Sackett, PD; Albrow, M; Brillant, S; Caldwell, JAR; Calitz, JJ; Cook, KH; Corrales, E; Desort, M; Dieters, S; Dominis, D; Donatowicz, J; Hoffman, M; Kane, S; Marquette, JB; Martin, R; Meintjes, P; Pollard, K; Sahu, K; Vinter, C; Wambsganss, J; Woller, K; Horne, K; Steele, I; Bramich, DM; Burgdorf, M; Snodgrass, C; Bode, M; Udalski, A; Szymanski, MK; Kubiak, M; Wieckowski, T; Pietrzynski, G; Soszynski, I; Szewczyk, O; Wyrzykowski, L; Paczynski, B; Abe, F; Bond, IA; Britton, TR; Gilmore, AC; Hearnshaw, JB; Itow, Y; Kamiya, K; Kilmartin, PM; Korpela, AV; Masuda, K; Matsubara, Y; Motomura, M; Muraki, Y; Nakamura, S; Okada, C; Ohnishi, K; Rattenbury, NJ; Sako, T; Sato, S; Sasaki, M; Sekiguchi, T; Sullivan, DJ; Tristram, PJ; Yock, PCM; Yoshioka, T			Discovery of a cool planet of 5.5 Earth masses through gravitational microlensing	NATURE			English	Article							INTERFEROMETRY; SYSTEMS; SEARCH; MODEL	In the favoured core-accretion model of formation of planetary systems, solid planetesimals accumulate to build up planetary cores, which then accrete nebular gas if they are sufficiently massive. Around M-dwarf stars ( the most common stars in our Galaxy), this model favours the formation of Earth-mass (M+) to Neptune-mass planets with orbital radii of 1 to 10 astronomical units (AU), which is consistent with the small number of gas giant planets known to orbit M-dwarf host stars(1-4). More than 170 extrasolar planets have been discovered with a wide range of masses and orbital periods, but planets of Neptune's mass or less have not hitherto been detected at separations of more than 0.15 AU from normal stars. Here we report the discovery of a 5.5(-2.7)(+5.5)M(+) planetary companion at a separation of 2.6(-0.6)(+1.5) AU from a 0.22(-0.11)(+0.21)M(.) M-dwarf star, where M-. refers to a solar mass. (We propose to name it OGLE-2005-BLG-390Lb, indicating a planetary mass companion to the lens star of the microlensing event.) The mass is lower than that of GJ876d (ref. 5), although the error bars overlap. Our detection suggests that such cool, sub-Neptune-mass planets may be more common than gas giant planets, as predicted by the core accretion theory.	Univ Paris 06, CNRS, UMR 7095, Inst Astrophys Paris, F-75014 Paris, France; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Univ Toulouse 3, Observ Midi Pyrenees, Astrophys Lab, UMR 5572, F-31400 Toulouse, France; Perth Observ, Perth, WA 6076, Australia; Univ St Andrews, Sch Phys & Astron, Scottish Univ Phys Alliance, St Andrews KY16 9SS, Fife, Scotland; Astron Observ, Niels Bohr Inst, DK-2100 Copenhagen O, Denmark; European So Observ, Santiago 19, Chile; CEA, DAPNIA, SPP Saclay, F-91191 Gif Sur Yvette, France; Univ Tasmania, Sch Math & Phys, Hobart, Tas 7001, Australia; S African Astron Observ, ZA-7935 Cape Town, South Africa; Australian Natl Univ, Mt Stromlo Observ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia; Univ Canterbury, Dept Phys & Astron, Christchurch 8020, New Zealand; McDonald Observ, Ft Davis, TX 79734 USA; Univ Orange Free State, Dept Phys, Boyden Observ, ZA-9300 Bloemfontein, South Africa; Lawrence Livermore Natl Lab, IGPP, Livermore, CA 94551 USA; Univ Potsdam, Inst Phys, D-14469 Potsdam, Germany; Astrophys Inst Potsdam, D-14482 Potsdam, Germany; Vienna Univ Technol, A-1040 Vienna, Austria; Univ Florida, Dept Astron, Gainesville, FL 32611 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Heidelberg Univ, Zentrum Astron, ARI, D-69120 Heidelberg, Germany; Liverpool John Moores Univ, Astrophys Res Inst, Birkenhead CH41 1LD, Merseyside, England; Queens Univ Belfast, Dept Phys, Astron & Planetary Sci Div, Belfast, Antrim, North Ireland; Observ Astron Uniwersytetu Warszawskiego, PL-00478 Warsaw, Poland; Univ Concepcion, Concepcion, Chile; Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England; Princeton Univ Observ, Princeton, NJ 08544 USA; Nagoya Univ, Solar Terr Environm Lab, Nagoya, Aichi 464860, Japan; Massey Univ, Inst Informat & Math Sci, Auckland, New Zealand; Univ Auckland, Dept Phys, Auckland, New Zealand; Univ Victoria, Sch Chem & Phys Sci, Wellington, New Zealand; Nagoya Univ, Fac Sci, Dept Astrophys, Nagoya, Aichi 464860, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; University of Notre Dame; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of St Andrews; University of Copenhagen; Niels Bohr Institute; European Southern Observatory; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Tasmania; National Research Foundation - South Africa; South African Astronomical Observatory; Australian National University; University of Canterbury; University of Texas System; University of Texas Austin; University of the Free State; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Potsdam; Technische Universitat Wien; State University System of Florida; University of Florida; Space Telescope Science Institute; Ruprecht Karls University Heidelberg; Liverpool John Moores University; Queens University Belfast; University of Warsaw; Universidad de Concepcion; University of Manchester; Jodrell Bank Centre for Astrophysics; Princeton University; Nagoya University; Massey University; University of Auckland; Victoria University Wellington; Nagoya University	Beaulieu, JP (corresponding author), Univ Paris 06, CNRS, UMR 7095, Inst Astrophys Paris, F-75014 Paris, France.	beaulieu@iap.fr; bennett@nd.edu	Bennett, David/O-2136-2013; Prester, Dijana Dominis/O-5014-2018; Rattenbury, Nicholas James/ABB-2102-2021; Kane, Stephen/B-4798-2013; Dominik, Martin/AAA-9501-2020; Szymański, Michał K/H-6951-2018; Greenhill, John G/C-8367-2013; Szymański, Michał Krzysztof/X-5627-2019; Williams, Andrew J/K-2931-2013; Burgdorf, Martin/H-5576-2019	Bennett, David/0000-0001-8043-8413; Prester, Dijana Dominis/0000-0002-9880-5039; Rattenbury, Nicholas James/0000-0001-5069-319X; Dominik, Martin/0000-0002-3202-0343; Szymański, Michał K/0000-0002-0548-8995; Szymański, Michał Krzysztof/0000-0002-0548-8995; Williams, Andrew J/0000-0001-9080-0105; Fouque, Pascal/0000-0002-1436-7351; Udalski, Andrzej/0000-0001-5207-5619; Brillant, Stephane/0000-0001-8217-8686; Snodgrass, Colin/0000-0001-9328-2905; Yock, Philip/0000-0001-9716-7752; Wyrzykowski, Lukasz/0000-0002-9658-6151; Albrow, Michael/0000-0003-3316-4012; Pietrzynski, Grzegorz/0000-0002-9443-4138; Soszynski, Igor/0000-0002-7777-0842; Marquette, Jean-Baptiste/0000-0002-7901-7213; Sahu, Kailash/0000-0001-6008-1955; Burgdorf, Martin/0000-0002-5854-4217; Beaulieu, Jean-Philippe/0000-0003-0014-3354	STFC [PP/D000890/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/D000890/1] Funding Source: researchfish	STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Abe F, 2004, SCIENCE, V305, P1264, DOI 10.1126/science.1100714; Alard C, 2000, ASTRON ASTROPHYS SUP, V144, P363, DOI 10.1051/aas:2000214; Albrow M, 1998, ASTROPHYS J, V509, P687, DOI 10.1086/306513; Beaulieu JP, 2005, EAS PUBLICATIONS, V14, P297, DOI 10.1051/eas:2005047; Bennett DP, 2002, ASTROPHYS J, V574, P985, DOI 10.1086/340977; Bennett DP, 2004, ASTR SOC P, V321, P59; Bennett DP, 1996, ASTROPHYS J, V472, P660, DOI 10.1086/178096; Claret A, 1995, ASTRON ASTROPHYS SUP, V114, P247; Gaudi BS, 1998, ASTROPHYS J, V506, P533, DOI 10.1086/306256; Gaudi BS, 2002, ASTROPHYS J, V566, P463, DOI 10.1086/337987; GOULD A, 1992, ASTROPHYS J, V396, P104, DOI 10.1086/171700; Griest K, 1998, ASTROPHYS J, V500, P37, DOI 10.1086/305729; Ida S, 2004, ASTROPHYS J, V616, P567, DOI 10.1086/424830; Kervella P, 2004, ASTRON ASTROPHYS, V428, P587, DOI 10.1051/0004-6361:20041416; Laughlin G, 2004, ASTROPHYS J, V612, pL73, DOI 10.1086/424384; Mao S., 1991, APJ, V374, pL37; Mayor M, 2004, ASTRON ASTROPHYS, V415, P391, DOI 10.1051/0004-6361:20034250; Moutou C, 2005, ASTRON ASTROPHYS, V437, P355, DOI 10.1051/0004-6361:20042334; Sozzetti A, 2002, PUBL ASTRON SOC PAC, V114, P1173, DOI 10.1086/343823; Udalski A, 2005, ASTROPHYS J, V628, pL109, DOI 10.1086/432795; Vogt SS, 2005, ASTROPHYS J, V632, P638, DOI 10.1086/432901; Wambsganss J, 1997, MON NOT R ASTRON SOC, V284, P172, DOI 10.1093/mnras/284.1.172; WETHERILL GW, 1980, ANNU REV ASTRON ASTR, V18, P77, DOI 10.1146/annurev.aa.18.090180.000453; [No title captured]; [No title captured]	26	477	482	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					437	440		10.1038/nature04441	http://dx.doi.org/10.1038/nature04441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437108	Green Submitted, Bronze			2022-12-28	WOS:000234859200038
J	Snyder, EY; Loring, JF				Snyder, EY; Loring, JF			Beyond fraud - Stem-cell research continues	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Burnham Inst Med Res, Program Stem Cells & Regenerat Dev & Regenerat Ce, Stem Cell Resource, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Snyder, EY (corresponding author), Burnham Inst Med Res, Program Stem Cells & Regenerat Dev & Regenerat Ce, Stem Cell Resource, La Jolla, CA 92037 USA.		Loring, Jeanne F/A-1620-2011	Loring, Jeanne F/0000-0001-6226-9767				DRUKKER M, IN PRESS STEM CELLS; Hwang WS, 2005, SCIENCE, V308, P1777, DOI 10.1126/science.1112286; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Institute of Medicine and National Research Council, 2007, GUID HUM EMBR STEM C, DOI [10.17226/11870, DOI 10.17226/11153]; MEISSNER A, 2005, NATURE          1016	5	29	31	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					321	324		10.1056/NEJMp058323	http://dx.doi.org/10.1056/NEJMp058323			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005VY	16436761				2022-12-28	WOS:000234854000001
J	Bchir, A; Bhutta, Z; Binka, F; Black, R; Bradshaw, D; Garnett, G; Hayashi, K; Jha, P; Peto, R; Sawyer, C; Schwartlander, B; Walker, N; Wolfson, M; Yach, D; Zaba, B				Bchir, A; Bhutta, Z; Binka, F; Black, R; Bradshaw, D; Garnett, G; Hayashi, K; Jha, P; Peto, R; Sawyer, C; Schwartlander, B; Walker, N; Wolfson, M; Yach, D; Zaba, B			Better health statistics are possible	LANCET			English	Editorial Material									Global Alliance Vaccine & Immunizat, Geneva, Switzerland; Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan; Univ Ghana, Sch Publ Hlth, Legon, Ghana; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; MRC, Tygerberg, South Africa; Univ London Imperial Coll Sci & Technol, Fac Med, Dept Infect Dis, London, England; Natl Inst Publ Hlth, Wako, Saitama, Japan; Univ Toronto, Toronto, ON, Canada; Univ Oxford, Clin Trial Serv Unit, Oxford, England; UN, Populat Div, New York, NY 10017 USA; Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland; UNICEF, New York, NY USA; STAT Canada, Ottawa, ON, Canada; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; London Sch Hyg & Trop Med, Ctr Populat Studies, London WC1, England	Aga Khan University; University of Ghana; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Imperial College London; National Institute of Public Health - Japan; University of Toronto; University of Oxford; UNICEF; Statistics Canada; Yale University; University of London; London School of Hygiene & Tropical Medicine	Yach, D (corresponding author), Global Alliance Vaccine & Immunizat, Geneva, Switzerland.	derek.yach@yale.edu	Garnett, Geoffrey P/A-9312-2008	Black, Robert/0000-0001-9926-7984				Horton R, 2005, LANCET, V366, P179, DOI 10.1016/S0140-6736(05)66883-3; Jamison DT, 1998, LANCET, V351, P514, DOI 10.1016/S0140-6736(97)11451-9; Stansfield S, 2005, B WORLD HEALTH ORGAN, V83, P562; *WHO, 2005, 1 CONS HIGH LEV ADV; 2005, LANCET, V365, P1983	5	15	15	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					190	193		10.1016/S0140-6736(06)68011-2	http://dx.doi.org/10.1016/S0140-6736(06)68011-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427474				2022-12-28	WOS:000234810600007
J	Kapoor, TM; Lampson, MA; Hergert, P; Cameron, L; Cimini, D; Salmon, ED; McEwen, BF; Khodjakov, A				Kapoor, TM; Lampson, MA; Hergert, P; Cameron, L; Cimini, D; Salmon, ED; McEwen, BF; Khodjakov, A			Chromosomes can congress to the metaphase plate before biorientation	SCIENCE			English	Article							NEWT LUNG-CELLS; CENP-E; MICROTUBULE CAPTURE; MITOTIC CHECKPOINT; ANAPHASE ONSET; PROTEIN-E; KINETOCHORE; SPINDLE; MECHANISMS; ATTACHMENT	The stable propagation of genetic material during cell division depends on the congression of chromosomes to the spindle equator before the cell initiates anaphase. It is generally assumed that congression requires that chromosomes are connected to the opposite poles of the bipolar spindle ("bioriented"). In mammalian cells, we found that chromosomes can congress before becoming bioriented. By combining the use of reversible chemical inhibitors, live-cell light microscopy, and correlative electron microscopy, we found that monooriented chromosomes could glide toward the spindle equator alongside kinetochore fibers attached to other already bioriented chromosomes. This congression mechanism depended on the kinetochore-associated, plus end-directed microtubule motor CENP-E (kinesin-7).	Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Div Mol Med, Albany, NY 12201 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	Rockefeller University; Marine Biological Laboratory - Woods Hole; State University of New York (SUNY) System; Wadsworth Center; University of North Carolina; University of North Carolina Chapel Hill	Khodjakov, A (corresponding author), Rockefeller Univ, Lab Chem & Cell Biol, 1230 York Ave, New York, NY 10021 USA.	khodj@wadsworth.org	Cimini, Daniela/A-3039-2016	Cimini, Daniela/0000-0002-4082-4894	NIGMS NIH HHS [R01 GM024364, R01 GM065933, R37 GM024364, GM65933, R01 GM059363, GM06627, GM59363, GM24364] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059363, R37GM024364, R01GM065933, R01GM024364] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cimini D, 2004, CURR BIOL, V14, P2149, DOI 10.1016/j.cub.2004.11.029; EUTENEUER U, 1981, J CELL BIOL, V89, P338, DOI 10.1083/jcb.89.2.338; Hauf S, 2004, CELL, V119, P317, DOI 10.1016/j.cell.2004.10.014; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Khodjakov A, 1996, J CELL BIOL, V135, P315, DOI 10.1083/jcb.135.2.315; Khodjakov A, 1997, J CELL BIOL, V136, P229, DOI 10.1083/jcb.136.2.229; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; MURRAY AW, 1994, CURR BIOL, V4, P38, DOI 10.1016/S0960-9822(00)00007-5; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Waters JC, 1996, J CELL SCI, V109, P2823; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435	25	316	321	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					388	391		10.1126/science.1122142	http://dx.doi.org/10.1126/science.1122142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424343	Green Submitted, Green Accepted			2022-12-28	WOS:000234938500047
J	Brazeau, MD; Ahlberg, PE				Brazeau, MD; Ahlberg, PE			Tetrapod-like middle ear architecture in a Devonian fish	NATURE			English	Article							EARLY EVOLUTION; STAPES; BRAINCASE; SKATE	Few fossils show the incipient stages of complex morphological transformations(1). For example, the earliest stages in the remodelling of the spiracular tract and suspensorium (jaw suspension) of osteolepiform fishes(2-4) into the middle ear of tetrapods have remained elusive(3). The most primitive known tetrapods show a middle ear architecture that is very different from osteolepiforms such as Eusthenopteron(3), with little indication of how this transformation took place. Here we present an analysis of tetrapod middle ear origins that is based on a detailed study of Panderichthys, the immediate sister taxon of tetrapods. We show that the spiracular region is radically transformed from osteolepiforms and represents the earliest stages in the origin of the tetrapod middle ear architecture. The posterior palatoquadrate of Panderichthys is completely tetrapod-like and defines a similarly tetrapod-like spiracular tract. The hyomandibula has lost its distal portion, representing a previously unrecognized advance towards a stapes-like morphology. This spiracular specialization suggests that the middle ear of early tetrapods evolved initially as part of a spiracular breathing apparatus(5,6).	Uppsala Univ, Evolutionary Biol Ctr, Dept Physiol & Dev Biol, Subdept Evolutionary Organismal Biol, SE-75236 Uppsala, Sweden	Uppsala University	Brazeau, MD (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Physiol & Dev Biol, Subdept Evolutionary Organismal Biol, Norbyv 18A, SE-75236 Uppsala, Sweden.	martin.brazeau@ebc.uu.se	Brazeau, Martin D/AAU-5390-2020; Ahlberg, Per/E-8086-2013; Brazeau, Martin D/B-6971-2009	Brazeau, Martin D/0000-0001-6566-2820; Brazeau, Martin/0000-0002-0650-1282; Ahlberg, Per/0000-0001-9054-2900				AHLBERG PE, 1994, PHILOS T ROY SOC B, V343, P303, DOI 10.1098/rstb.1994.0027; Ahlberg PE, 1998, NATURE, V395, P792, DOI 10.1038/27421; AHLBERG PE, 1991, ZOOL J LINN SOC-LOND, V103, P241, DOI 10.1111/j.1096-3642.1991.tb00905.x; Ahlberg PE, 1996, NATURE, V381, P61, DOI 10.1038/381061a0; Carroll R. L., 1980, TERRESTRIAL ENV ORIG, P293; Carroll RL, 1997, PATTERNS PROCESSES V; Clack J.A., 1994, Meddelelser om Gronland Geoscience, V31, P1; Clack JA, 2003, NATURE, V425, P65, DOI 10.1038/nature01904; Clack JA, 1998, ZOOL J LINN SOC-LOND, V122, P61, DOI 10.1006/zjls.1997.0114; CLACK JA, 1994, NATURE, V369, P392, DOI 10.1038/369392a0; Clack JA, 2002, J NEUROBIOL, V53, P251, DOI 10.1002/neu.10129; CLACK JA, 1989, NATURE, V342, P425, DOI 10.1038/342425a0; Clack JA., 2012, GAINING GROUND ORIGI; Gardiner B.G., 1984, Bulletin of the British Museum (Natural History) Geology, V37, P173; JARVIK E, 1972, Meddelelser om Gronland, V187, P1; Jarvik E., 1980, BASIC STRUCTURE EVOL; JARVIK ERIK, 1954, K SVENSKA VETENSKAPSAKAD HANDL, V5, P1; Lebedev Oleg A., 1995, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V17, P287; Long J.A., 1997, Records of the Western Australian Museum Supplement, V53, P1; PANCHEN AL, 1985, PHILOS T ROY SOC B, V309, P505, DOI 10.1098/rstb.1985.0095; Rand HW, 1907, AM NAT, V41, P287, DOI 10.1086/278771; ROSEN D E, 1981, Bulletin of the American Museum of Natural History, V167, P159; SMITHSON TR, 1982, ZOOL J LINN SOC-LOND, V74, P93, DOI 10.1111/j.1096-3642.1982.tb01142.x; Summers AP, 2001, J EXP BIOL, V204, P1577; Vorobyeva E., 1991, P68; Westoll TS, 1943, BIOL REV CAMB PHILOS, V18, P78, DOI 10.1111/j.1469-185X.1943.tb00289.x	26	66	70	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					318	321		10.1038/nature04196	http://dx.doi.org/10.1038/nature04196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421569				2022-12-28	WOS:000234682100041
J	Ebmeier, KP; Donaghey, C; Steele, JD				Ebmeier, KP; Donaghey, C; Steele, JD			Recent developments and current controversies in depression	LANCET			English	Review							TRANSCRANIAL MAGNETIC STIMULATION; SEROTONIN REUPTAKE INHIBITORS; FACTOR GENETIC-POLYMORPHISM; RANDOMIZED CONTROLLED-TRIAL; LEFT PREFRONTAL ACTIVATION; PROBLEM-SOLVING TREATMENT; DEEP BRAIN-STIMULATION; STRESSFUL LIFE EVENTS; SEIZURE THERAPY MST; MAJOR DEPRESSION	In this review of the last 5 years' developments in research into depression we focus on recent advances and current controversies. We cover epidemiology and basic science as well as the treatment of depression in adults in all its forms. Depression in childhood and adolescence, as well as in old age has been covered in recent Seminars in The Lancet. Depression in adulthood remains a very common and under-treated condition, resulting in a high degree of disability. Increasingly detailed knowledge about impairment of information processing in depression is being supplemented by quantitative studies of the brain processes underlying these impairments. Most patients improve with present treatments. The mechanisms of action of antidepressants are not fully understood; the hypothesis that reversing hippocampal cell loss in depression may be their active principle is a fascinating new development. Moral panic about the claim that antidepressant serotonin reuptake inhibitors cause patients to commit suicide and become addicted to their medication may have disconcerted the public and members of the medical profession. We will try to describe the considerable effort that has gone into collecting evidence to enlighten this debate.	Univ Edinburgh, Div Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland; Univ Aberdeen, Dept Mental Hlth, Royal Cornhill Hosp, Aberdeen, Scotland	University of Edinburgh; University of Aberdeen	Ebmeier, KP (corresponding author), Univ Edinburgh, Div Psychiat, Kennedy Tower,Morningside Pk, Edinburgh EH10 5HF, Midlothian, Scotland.	k.ebmeier@ed.ac.uk	Ebmeier, Klaus Peter/B-4789-2008; Steele, J Douglas/A-8972-2017; Steele, Douglas/AAB-9889-2019	Ebmeier, Klaus Peter/0000-0002-5190-7038; Steele, J Douglas/0000-0002-9822-8753; Steele, Douglas/0000-0002-9822-8753				Aben I, 2003, J NEUROL NEUROSUR PS, V74, P581, DOI 10.1136/jnnp.74.5.581; Airaksinen E, 2004, PSYCHOL MED, V34, P83, DOI 10.1017/S0033291703008559; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; *APA, 2000, PRACT GUID TREATM PA; Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Avery DH, 1999, J NERV MENT DIS, V187, P114, DOI 10.1097/00005053-199902000-00009; Baev KV, 2002, PROG NEURO-PSYCHOPH, V26, P771, DOI 10.1016/S0278-5846(02)00201-4; Barkham M, 2001, BRIT MED BULL, V57, P115, DOI 10.1093/bmb/57.1.115; Barret JE, 2001, J FAM PRACTICE, V50, P405; Beck AT, 1987, COGNITIVE THERAPY DE; Berman RM, 2000, BIOL PSYCHIAT, V47, P332, DOI 10.1016/S0006-3223(99)00243-7; Bostwick JM, 2000, AM J PSYCHIAT, V157, P1925, DOI 10.1176/appi.ajp.157.12.1925; Boutros NN, 2002, PSYCHIAT RES, V113, P245, DOI 10.1016/S0165-1781(02)00267-6; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Browne G, 2002, J AFFECT DISORDERS, V68, P317, DOI 10.1016/S0165-0327(01)00343-3; Burt T, 2002, INT J NEUROPSYCHOPH, V5, P73, DOI 10.1017/S1461145702002791; Campbell S, 2004, J PSYCHIATR NEUROSCI, V29, P417; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; Carney S, 2003, LANCET, V361, P799; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; *COMM EN COMM, 2004, FDAS ROL PROT PUBL H; *CRAG WORK GROUP, 1996, NEUR MENT DIS; Cuijpers P, 2002, J AFFECT DISORDERS, V72, P227, DOI 10.1016/S0165-0327(01)00413-X; D'Zurilla TJ, 1998, J CLIN PSYCHOL, V54, P1091, DOI 10.1002/(SICI)1097-4679(199812)54:8<1091::AID-JCLP9>3.0.CO;2-J; Damasio A.R., 2005, DESCARTES ERROR EMOT; Davidoff F, 2001, LANCET, V358, P854, DOI 10.1016/S0140-6736(01)06035-4; Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7; de Jonghe F, 2004, BRIT J PSYCHIAT, V185, P37, DOI 10.1192/bjp.185.1.37; Dougherty DD, 2003, J NEUROSURG, V99, P1010, DOI 10.3171/jns.2003.99.6.1010; Dowrick C, 2000, BMJ-BRIT MED J, V321, P1450, DOI 10.1136/bmj.321.7274.1450; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; DREVETS WC, 2000, PROGR BRAIN RES; Du LS, 2004, NEUROREPORT, V15, P2097, DOI 10.1097/00001756-200409150-00020; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Dunlap WP, 1996, PSYCHOL METHODS, V1, P170, DOI 10.1037/1082-989X.1.2.170; Dwork AJ, 2004, AM J PSYCHIAT, V161, P576, DOI 10.1176/appi.ajp.161.3.576; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Ebert D, 1996, BIOL PSYCHIAT, V39, P1044, DOI 10.1016/0006-3223(95)00320-7; EBMEIER KP, 2002, BIOL PSYCHIAT; Elliott R, 2002, ARCH GEN PSYCHIAT, V59, P597, DOI 10.1001/archpsyc.59.7.597; Eschweiler GW, 2000, PSYCHIAT RES-NEUROIM, V99, P161, DOI 10.1016/S0925-4927(00)00062-7; Fallgatter AJ, 2004, NEUROPSYCHOPHARMACOL, V29, P1506, DOI 10.1038/sj.npp.1300409; Fava GA, 2004, PSYCHOTHER PSYCHOSOM, V73, P1, DOI 10.1159/000074433; Fergusson D, 2005, BMJ-BRIT MED J, V330, P396, DOI 10.1136/bmj.330.7488.396; Fitzgerald PB, 2003, ARCH GEN PSYCHIAT, V60, P1002, DOI 10.1001/archpsyc.60.9.1002; Fossati P, 2004, J PSYCHIATR RES, V38, P137, DOI 10.1016/j.jpsychires.2003.08.002; Fossati P, 2002, J AFFECT DISORDERS, V68, P261, DOI 10.1016/S0165-0327(00)00362-1; Frank E, 2000, J CLIN PSYCHIAT, V61, P51, DOI 10.4088/JCP.v61n0112; Frank E, 2002, GEN HOSP PSYCHIAT, V24, P12, DOI 10.1016/S0163-8343(01)00173-6; Frank E, 1999, ANNU REV MED, V50, P453; Frodl T, 2004, ARCH GEN PSYCHIAT, V61, P177, DOI 10.1001/archpsyc.61.2.177; Fuchs E, 2004, EUR NEUROPSYCHOPHARM, V14, pS481, DOI 10.1016/j.euroneuro.2004.09.002; Fuchs E, 2004, BEHAV PHARMACOL, V15, P315, DOI 10.1097/00008877-200409000-00003; Fuster J., 2015, PREFRONTAL CORTEX, V5th; Garcia-Toro M, 2001, J NEUROL NEUROSUR PS, V71, P546, DOI 10.1136/jnnp.71.4.546; Gehring WJ, 2000, PSYCHOL SCI, V11, P1, DOI 10.1111/1467-9280.00206; George MS, 1997, AM J PSYCHIAT, V154, P1752, DOI 10.1176/ajp.154.12.1752; George MS, 2000, BIOL PSYCHIAT, V48, P962, DOI 10.1016/S0006-3223(00)01048-9; Gibbons RD, 2005, ARCH GEN PSYCHIAT, V62, P165, DOI 10.1001/archpsyc.62.2.165; Gillespie NA, 2005, PSYCHOL MED, V35, P101, DOI 10.1017/S0033291704002727; Gloaguen V, 1998, J AFFECT DISORDERS, V49, P59, DOI 10.1016/S0165-0327(97)00199-7; Goodwin FK, 1990, MANIC DEPRESSIVE ILL, P227; Gray JA, 2000, NEUROPSYCHOLOGY ANXI; Greenberg RM, 2005, AM J GERIAT PSYCHIAT, V13, P268; Groves DA, 2005, NEUROSCI BIOBEHAV R, V29, P493, DOI 10.1016/j.neubiorev.2005.01.004; Grunebaum MF, 2004, J CLIN PSYCHIAT, V65, P1456, DOI 10.4088/JCP.v65n1103; Gunnell D, 2005, BMJ-BRIT MED J, V330, P385, DOI 10.1136/bmj.330.7488.385; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; Hajcak G, 2003, BIOL PSYCHOL, V64, P77, DOI 10.1016/S0301-0511(03)00103-0; Hamalainen J, 2004, J AFFECT DISORDERS, V79, P105, DOI 10.1016/S0165-0327(02)00342-7; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Harvey PO, 2004, J PSYCHIATR RES, V38, P567, DOI 10.1016/j.jpsychires.2004.03.003; Hausmann A, 2004, J NEUROL NEUROSUR PS, V75, P320; HEATH RG, 1976, BIOL PSYCHIAT, V11, P463; Hensley PL, 2004, DEPRESS ANXIETY, V20, P1, DOI 10.1002/da.20022; Herwig U, 2003, J PSYCHIATR RES, V37, P267, DOI 10.1016/S0022-3956(03)00042-6; Herxheimer A, 2004, CAN MED ASSOC J, V170, P487; Holroyd CB, 2004, NAT NEUROSCI, V7, P497, DOI 10.1038/nn1238; Holroyd CB, 2003, TRENDS NEUROSCI, V26, P402, DOI 10.1016/S0166-2236(03)00175-9; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; HOLROYD CB, 2004, COGNITIVE NEUROSCIEN; Holtzheimer PE, 2004, DEPRESS ANXIETY, V19, P24, DOI 10.1002/da.10147; Hong CJ, 2003, NEUROPSYCHOBIOLOGY, V48, P186, DOI 10.1159/000074636; Hoppner J, 2003, EUR ARCH PSY CLIN N, V253, P103, DOI 10.1007/s00406-003-0416-7; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; ILSLEY JE, 1995, J AFFECT DISORDERS, V35, P1, DOI 10.1016/0165-0327(95)00032-I; Isacsson G, 2005, ACTA PSYCHIAT SCAND, V111, P286, DOI 10.1111/j.1600-0447.2004.00504.x; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; Jorge RE, 2004, BIOL PSYCHIAT, V55, P398, DOI 10.1016/j.biopsych.2003.08.017; Kauffmann CD, 2004, DEPRESS ANXIETY, V19, P59, DOI 10.1002/da.10144; Keck ME, 2002, NEUROPHARMACOLOGY, V43, P101, DOI 10.1016/S0028-3908(02)00069-2; Kendler KS, 2005, ARCH GEN PSYCHIAT, V62, P529, DOI 10.1001/archpsyc.62.5.529; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kimbrell TA, 1999, BIOL PSYCHIAT, V46, P1603, DOI 10.1016/S0006-3223(99)00195-X; KING M, 2000, HEALTH TECHNOL ASSES, V4; Kirchheiner J, 2004, MOL PSYCHIATR, V9, P442, DOI 10.1038/sj.mp.4001494; Klein E, 1999, ARCH GEN PSYCHIAT, V56, P315, DOI 10.1001/archpsyc.56.4.315; Klerman GL, 1984, INTERPERSONAL PSYCHO; Koerselman F, 2004, J CLIN PSYCHIAT, V65, P1323, DOI 10.4088/JCP.v65n1005; Kosel M, 2003, NEUROPSYCHOPHARMACOL, V28, P2045, DOI 10.1038/sj.npp.1300293; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Kumari V, 2003, BIOL PSYCHIAT, V54, P777, DOI 10.1016/S0006-3223(02)01785-7; Lisanby SH, 2000, ARCH GEN PSYCHIAT, V57, P581, DOI 10.1001/archpsyc.57.6.581; Lisanby SH, 2003, SUPPL CLIN NEUROPHYS, V56, P81; Lisanby SH, 2003, NEUROPSYCHOPHARMACOL, V28, P1852, DOI 10.1038/sj.npp.1300229; Lisanby SH, 2001, BIOL PSYCHIAT, V49, p81S; Loo C, 1999, AM J PSYCHIAT, V156, P946, DOI 10.1176/ajp.156.6.946; Loo CK, 2003, PSYCHOL MED, V33, P33, DOI 10.1017/S0033291702006839; Luu P, 2003, PSYCHOL SCI, V14, P47, DOI 10.1111/1467-9280.01417; Luu P, 2000, J EXP PSYCHOL GEN, V129, P43, DOI 10.1037//0096-3445.129.1.43; Luu P., 2004, COGNITIVE NEUROSCIEN; Manes F, 2001, INT PSYCHOGERIATR, V13, P225, DOI 10.1017/S1041610201007608; Martinez C, 2005, BRIT MED J, V330, P389, DOI 10.1136/bmj.330.7488.389; Matthews K, 2003, BRIT J PSYCHIAT, V182, P404, DOI 10.1192/bjp.182.5.404; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; MAYBERG HS, 2003, IMAGING NEUROSCIENCE, P193; McEwen BS, 2004, EUR NEUROPSYCHOPHARM, V14, pS497, DOI 10.1016/j.euroneuro.2004.09.008; Mosimann UP, 2004, PSYCHIAT RES, V126, P123, DOI 10.1016/j.psychres.2003.10.006; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; Nahas Z, 2003, BIPOLAR DISORD, V5, P40, DOI 10.1034/j.1399-5618.2003.00011.x; National Institute for Clinical Excellence (NICE), 2004, 23 NICE, V23; Nelson JC, 2000, J CLIN PSYCHIAT, V61, P13; NEWCOMBE R, 1975, BRIT J PSYCHIAT, V126, P478, DOI 10.1192/bjp.126.5.478; Nezu AM, 2004, BEHAV THER, V35, P1, DOI 10.1016/S0005-7894(04)80002-9; Nezu AM, 2001, J PSYCHOTHER INTEGR, V11, P187, DOI [10.1023/A:1016653407338, DOI 10.1023/A:1016653407338]; *NICE, 2003, 59 NICE; Nutt DJ, 2003, J PSYCHOPHARMACOL, V17, P355, DOI 10.1177/0269881103174019; Nuttin B, 1999, LANCET, V354, P1526, DOI 10.1016/S0140-6736(99)02376-4; Okada G, 2003, NEUROPSYCHOBIOLOGY, V47, P21, DOI 10.1159/000068871; Ormel J, 2004, ARCH GEN PSYCHIAT, V61, P387, DOI 10.1001/archpsyc.61.4.387; OWENS DC, 2004, COMPANION PSYCHIAT S; Padberg F, 1999, PSYCHIAT RES, V88, P163, DOI 10.1016/S0165-1781(99)00092-X; Padberg F, 2002, NEUROPSYCHOPHARMACOL, V27, P638; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Paulus W, 2005, NEURON, V45, P181, DOI 10.1016/j.neuron.2005.01.008; Paykel ES, 2005, PSYCHOL MED, V35, P59, DOI 10.1017/S003329170400282X; Paykel ES, 1999, ARCH GEN PSYCHIAT, V56, P829, DOI 10.1001/archpsyc.56.9.829; Perlis RH, 2002, J CLIN PSYCHOPHARM, V22, P474, DOI 10.1097/00004714-200210000-00006; Pier MPBI, 2004, J AFFECT DISORDERS, V83, P109, DOI 10.1016/j.jad.2004.05.002; Pochon JB, 2002, P NATL ACAD SCI USA, V99, P5669, DOI 10.1073/pnas.082111099; Porter RJ, 2003, BRIT J PSYCHIAT, V182, P214, DOI 10.1192/bjp.182.3.214; Poulet E, 2004, EUR PSYCHIAT, V19, P382, DOI 10.1016/j.eurpsy.2004.06.021; Reid IC, 2001, BRIT J PSYCHIAT, V178, P299, DOI 10.1192/bjp.178.4.299; Reynolds CF, 1999, JAMA-J AM MED ASSOC, V281, P39, DOI 10.1001/jama.281.1.39; ROLLS ET, 1999, BRAIN EMOTION; Rose EJ, 2006, NEUROIMAGE, V29, P203, DOI 10.1016/j.neuroimage.2005.07.002; Ruchsow M, 2006, J PSYCHIATR RES, V40, P37, DOI 10.1016/j.jpsychires.2005.02.002; Ruchsow M, 2004, PSYCHOPHYSIOLOGY, V41, P833, DOI 10.1111/j.1469-8986.2004.00237.x; Sackeim HA, 2001, JAMA-J AM MED ASSOC, V285, P1299, DOI 10.1001/jama.285.10.1299; Sackett D. L., 1998, EVIDENCE BASED MED P; Sanz EJ, 2005, LANCET, V365, P482, DOI 10.1016/S0140-6736(05)17865-9; Schulze TG, 2000, AM J MED GENET, V96, P801, DOI 10.1002/1096-8628(20001204)96:6<801::AID-AJMG21>3.3.CO;2-W; Schumacher J, 2005, BIOL PSYCHIAT, V58, P307, DOI 10.1016/j.biopsych.2005.04.006; Scott J, 2001, BRIT MED BULL, V57, P101, DOI 10.1093/bmb/57.1.101; Shah PJ, 2002, BRIT J PSYCHIAT, V180, P434, DOI 10.1192/bjp.180.5.434; Shah PJ, 1998, BRIT J PSYCHIAT, V172, P527, DOI 10.1192/bjp.172.6.527; Shajahan PM, 2002, PROG NEURO-PSYCHOPH, V26, P945, DOI 10.1016/S0278-5846(02)00210-5; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Siegle GJ, 2002, BIOL PSYCHIAT, V51, P693, DOI 10.1016/S0006-3223(02)01314-8; Smits KM, 2004, MOL PSYCHIATR, V9, P433, DOI 10.1038/sj.mp.4001488; Sobin C, 1997, AM J PSYCHIAT, V154, P4; Spijker J, 2004, ACTA PSYCHIAT SCAND, V110, P208, DOI 10.1111/j.1600-0447.2004.00335.x; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Steele JD, 2005, CURR MED IMAGING, V1, P157, DOI 10.2174/1573405054038708; Steele JD, 2004, NEUROIMAGE, V23, P269, DOI 10.1016/j.neuroimage.2004.04.023; Steele JD, 2004, NEUROIMAGE, V21, P868, DOI 10.1016/j.neuroimage.2003.09.066; STEELE JD, 2004, EDINBURGH COMPANION; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Stikhina NY, 1999, ZH NEVROPATOL PSIKH, V99, P26; Strafella AP, 2003, BRAIN, V126, P2609, DOI 10.1093/brain/awg268; Sturm V, 2003, J CHEM NEUROANAT, V26, P293, DOI 10.1016/j.jchemneu.2003.09.003; Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI 10.1176/appi.ajp.157.10.1552; Surguladze S, 2005, BIOL PSYCHIAT, V57, P201, DOI 10.1016/j.biopsych.2004.10.028; Sweeney JA, 2000, BIOL PSYCHIAT, V48, P674, DOI 10.1016/S0006-3223(00)00910-0; Szegedi A, 2005, PHARMACOGENOMICS J, V5, P49, DOI 10.1038/sj.tpj.6500289; Taylor WD, 2005, ARCH GEN PSYCHIAT, V62, P537, DOI 10.1001/archpsyc.62.5.537; Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037//0022-006X.68.4.615; Thase ME, 2000, J AFFECT DISORDERS, V57, P63, DOI 10.1016/S0165-0327(99)00066-X; Thase ME, 2000, J CLIN PSYCHIAT, V61, P466, DOI 10.4088/JCP.v61n0702; Tsai Shih-Jen, 2003, Current Pharmacogenomics, V1, P1, DOI 10.2174/1570160033378312; Tsai SJ, 2003, AM J MED GENET B, V123B, P19, DOI 10.1002/ajmg.b.20026; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; Walsh MT, 2001, ACTA PSYCHIAT SCAND, V104, P84, DOI 10.1034/j.1600-0447.2001.00357.x; Wampold BE, 2002, J AFFECT DISORDERS, V68, P159, DOI 10.1016/S0165-0327(00)00287-1; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Weller I.V.D., 2004, REPORT COMMITTEE SAF; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1; Wohlfarth T, 2004, LANCET, V364, P659, DOI 10.1016/S0140-6736(04)16880-3; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Yerevanian BI, 2004, ACTA PSYCHIAT SCAND, V110, P452, DOI 10.1111/j.1600-0447.2004.00437.x; Zhang XD, 2005, NEURON, V45, P11, DOI 10.1016/j.neuron.2004.12.014	195	280	306	1	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					153	167		10.1016/S0140-6736(06)67964-6	http://dx.doi.org/10.1016/S0140-6736(06)67964-6			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	003BB	16413879				2022-12-28	WOS:000234655500030
J	Penn, MS				Penn, MS			Stem-cell therapy after acute myocardial infarction: the focus should be on those at risk	LANCET			English	Editorial Material							REGENERATION; TRIAL		Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44122 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44122 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Penn, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44122 USA.	pennm@ccf.org						Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Schachinger V, 2004, J AM COLL CARDIOL, V44, P1690, DOI 10.1016/j.jacc.2004.08.014; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9	8	29	30	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2006	367	9505					87	88		10.1016/S0140-6736(05)67895-6	http://dx.doi.org/10.1016/S0140-6736(05)67895-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413856				2022-12-28	WOS:000234655500004
J	Gidalevitz, T; Ben-Zvi, A; Ho, KH; Brignull, HR; Morimoto, RI				Gidalevitz, T; Ben-Zvi, A; Ho, KH; Brignull, HR; Morimoto, RI			Progressive disruption of cellular protein folding in models of polyglutamine diseases	SCIENCE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; CAENORHABDITIS-ELEGANS; HUNTINGTONS-DISEASE; AGGREGATION; PROTEASOME; MUTATION; LOCALIZATION; PATHOGENESIS; DEGRADATION; SUPPRESSION		Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Rice Inst Biomed Res, Evanston, IL 60208 USA	Northwestern University	Morimoto, RI (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Rice Inst Biomed Res, 2153 Sheridan Rd, Evanston, IL 60208 USA.	r-morimoto@northwestern.edu	Gidalevitz, Tali/C-9217-2009; BEN-ZVI, ANAT/F-1674-2012; Longo, Kenneth A/A-5631-2010	Gidalevitz, Tali/0000-0002-9178-6648; BEN-ZVI, ANAT/0000-0003-2477-6519; 	NHLBI NIH HHS [T32 HL076139] Funding Source: Medline; NIA NIH HHS [R37 AG026647] Funding Source: Medline; NIGMS NIH HHS [F32 GM075583-01, T32 GM08061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL076139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061, F32GM075583] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BRIGNULL HR, UNPUB; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Clark SG, 1997, P NATL ACAD SCI USA, V94, P10438, DOI 10.1073/pnas.94.19.10438; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Eisenmann DM, 1997, GENETICS, V146, P553; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; GENGYOANDO K, 1991, J MOL BIOL, V219, P429, DOI 10.1016/0022-2836(91)90184-8; GIDALEVITZ, UNPUB; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Li K, 1997, J NEUROPATHOL EXP NE, V56, P125; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; Pedersen CB, 2003, J BIOL CHEM, V278, P47449, DOI 10.1074/jbc.M309514200; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101	31	477	491	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1471	1474		10.1126/science.1124514	http://dx.doi.org/10.1126/science.1124514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16469881				2022-12-28	WOS:000236029400052
J	Ancelin, ML; Artero, S; Portet, F; Dupuy, AM; Touchon, J; Ritchie, K				Ancelin, ML; Artero, S; Portet, F; Dupuy, AM; Touchon, J; Ritchie, K			Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POPULATION; MEMORY; RISK; CLASSIFICATION; PERFORMANCE; SCOPOLAMINE; PREVALENCE	Objective To assess the potential of anticholinergic drugs as a cause of non-degenerative mild cognitive impairment in elderly people. Design Longitudinal cohort study. Setting 63 randomly selected general practices in the Montpellier region of southern France. Participants 372 people aged > 60 years without dementia at recruitment. Main outcome measures Anticholinergic burden from drug use, cognitive examination, and neurological assessment. Results 9.2% of subjects continuously used anticholinergic drugs during the year before cognitive assessment. Compared with non-users, they had poorer performance on reaction time, attention, delayed non-verbal memory, narrative recall, visuospatial construction, and language tasks but not on tasks of reasoning, immediate and delayed recall of wordlists, and implicit memory. Eighty per cent of the continuous users were classified as having mild cognitive impairment compared with 35% of non-users, and anticholinergic drug use was a strong predictor of mild cognitive impairment (odds ratio 5.12, P = 0.001). No difference was found between users and non-users in risk of developing dementia at follow-up after eight years. Conclusions Elderly people taking anticholinergic drugs had significant deficits in cognitive functioning and were highly likely to be classified as mildly cognitively impaired, although not at increased risk for dementia. Doctors should assess current use of anticholinergic drugs in elderly people with mild cognitive impairment before considering administration of acetylcholinesterase inhibitors.	Hop Colombiere, INSERM, E361, F-34093 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Ritchie, K (corresponding author), Hop Colombiere, INSERM, E361, Pav 42,39 Ave Flahault,BP 34493, F-34093 Montpellier 5, France.	ritchie@montp.inserm.fr	Artero, Sylvaine/AAE-6059-2020; Ancelin, Marie-Laure/F-3079-2013; Ritchie, Karen/G-3571-2013; Ancelin, Marie-Laure/L-1198-2019	Ancelin, Marie-Laure/0000-0002-1149-4320; Ritchie, Karen/0000-0002-0688-8982; Ancelin, Marie-Laure/0000-0002-1149-4320; dupuy, anne marie/0000-0001-6538-3944; Artero, Sylvaine/0000-0002-1671-226X				Aizenberg D, 2002, INT PSYCHOGERIATR, V14, P307, DOI 10.1017/S1041610202008505; BLAZER DG, 1983, J GERONTOL, V38, P31, DOI 10.1093/geronj/38.1.31; Doniger S, 2002, J COMPUT BIOL, V9, P849, DOI 10.1089/10665270260518317; DRACHMAN DA, 1980, NEUROBIOL AGING, V1, P39, DOI 10.1016/0197-4580(80)90022-6; FEINBERG M, 1993, DRUG AGING, V3, P335, DOI 10.2165/00002512-199303040-00004; Fisk JD, 2003, NEUROLOGY, V61, P1179, DOI 10.1212/01.WNL.0000089238.07771.C7; FLICKER C, 1992, PSYCHOPHARMACOLOGY, V107, P437, DOI 10.1007/BF02245172; FLICKER C, 1990, PSYCHOPHARMACOLOGY, V100, P243, DOI 10.1007/BF02244414; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; Mintzer J, 2000, J ROY SOC MED, V93, P457, DOI 10.1177/014107680009300903; Moore AR, 1999, DRUG AGING, V15, P15, DOI 10.2165/00002512-199915010-00002; Mulsant BH, 2003, ARCH GEN PSYCHIAT, V60, P198, DOI 10.1001/archpsyc.60.2.198; Pekkonen E, 2005, NEUROIMAGE, V27, P387, DOI 10.1016/j.neuroimage.2005.04.018; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Remillard Alfred J., 1996, Pharmacoepidemiology and Drug Safety, V5, P155, DOI 10.1002/(SICI)1099-1557(199605)5:3<155::AID-PDS196>3.0.CO;2-D; Richie K, 2004, DIALOGUES CLIN NEURO, V6, P333; Ritchie K, 2001, NEUROLOGY, V56, P37, DOI 10.1212/WNL.56.1.37; RITCHIE K, 1993, INT J GERIATR PSYCH, V8, P899, DOI 10.1002/gps.930081104; RITCHIE K, 1993, INT J GERIATR PSYCH, V8, P969, DOI 10.1002/gps.930081203; Sippl Wolfgang, 2002, Current Medicinal Chemistry - Central Nervous System Agents, V2, P211, DOI 10.2174/1568015023357996; Sperling R, 2002, P NATL ACAD SCI USA, V99, P455, DOI 10.1073/pnas.012467899; Tervo S, 2004, DEMENT GERIATR COGN, V17, P196, DOI 10.1159/000076356; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; TOLLEFSON GD, 1991, J NEUROPSYCH CLIN N, V3, P314; TUNE L, 1992, AM J PSYCHIAT, V149, P1393; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x	26	390	407	1	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					455	458		10.1136/bmj.38740.439664.DE	http://dx.doi.org/10.1136/bmj.38740.439664.DE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16452102	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000235792900016
J	Laage, D; Hynes, JT				Laage, D; Hynes, JT			A molecular jump mechanism of water reorientation	SCIENCE			English	Article							HYDROGEN-BOND DYNAMICS; LIQUID WATER; INFRARED-SPECTROSCOPY; D2O; SIMULATION; HYDRATION; MOTIONS; MODELS; PROTON; H2O	Despite long study, a molecular picture of the mechanism of water reorientation is still lacking. Using numerical simulations, we find support for a pathway in which the rotating water molecule breaks a hydrogen bond (H-bond) with an overcoordinated first-shell neighbor to form an H-bond with an undercoordinated second-shell neighbor. The H-bond cleavage and the molecular reorientation occur concertedly and not successively as usually considered. This water reorientation mechanism involves large-amplitude angular jumps, rather than the commonly accepted sequence of small diffusive steps, and therefore calls for reinterpretation of many experimental data wherein water rotational relaxation is assumed to be diffusive.	Ecole Normale Super, CNRS, UMR Pasteur 8640, Dept Chim, F-75231 Paris, France; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; University of Colorado System; University of Colorado Boulder	Laage, D (corresponding author), Ecole Normale Super, CNRS, UMR Pasteur 8640, Dept Chim, 24 Rue Lhomond, F-75231 Paris, France.	damien.laage@ens.fr; hynes@chimie.ens.fr	Laage, Damien/C-6859-2008	Laage, Damien/0000-0001-5706-9939				AGMON N, 1995, CHEM PHYS LETT, V244, P456, DOI 10.1016/0009-2614(95)00905-J; Ando K, 1999, ADV CHEM PHYS, V110, P381, DOI 10.1002/9780470141694.ch6; ANDO K, 1995, J MOL LIQ, V64, P25, DOI 10.1016/0167-7322(95)92818-V; Bagchi B, 2005, CHEM REV, V105, P3197, DOI 10.1021/cr020661+; BUCKUP T, COMMUNICATION; Chen S. H., 1986, ADV CHEM PHYS, V64, P1; Csajka FS, 1998, J CHEM PHYS, V109, P1125, DOI 10.1063/1.476656; Eaves JD, 2005, P NATL ACAD SCI USA, V102, P13019, DOI 10.1073/pnas.0505125102; Eisenberg D. S., 2005, STRUCTURE PROPERTIES; Fecko CJ, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1839179; Fecko CJ, 2003, SCIENCE, V301, P1698, DOI 10.1126/science.1087251; Gallot G, 2002, J CHEM PHYS, V117, P11301, DOI 10.1063/1.1522378; IVANOV EN, 1964, SOV PHYS JETP-USSR, V18, P1041; Keutsch FN, 2001, P NATL ACAD SCI USA, V98, P10533, DOI 10.1073/pnas.191266498; Lawrence CP, 2003, J CHEM PHYS, V118, P264, DOI 10.1063/1.1525802; Luzar A, 1996, NATURE, V379, P55, DOI 10.1038/379055a0; MADDEN P, 1984, ADV CHEM PHYS, V56, P467, DOI 10.1002/9780470142806.ch5; Marx D, 1999, NATURE, V397, P601, DOI 10.1038/17579; OHMINE I, 1993, CHEM REV, V93, P2545, DOI 10.1021/cr00023a011; Rey R, 2002, J PHYS CHEM A, V106, P11993, DOI 10.1021/jp026419o; Rezus YLA, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2009729; Ronne C, 1999, PHYS REV LETT, V82, P2888, DOI 10.1103/PhysRevLett.82.2888; SCIORTINO F, 1991, NATURE, V354, P218, DOI 10.1038/354218a0; SVISHCHEV IM, 1994, J PHYS CHEM-US, V98, P728, DOI 10.1021/j100054a002; SZABO A, 1984, J CHEM PHYS, V81, P150, DOI 10.1063/1.447378; Tan HS, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1883605; van der Spoel D, 1998, J CHEM PHYS, V108, P10220, DOI 10.1063/1.476482; WALLQVIST A, 1993, J PHYS CHEM-US, V97, P13841, DOI 10.1021/j100153a066; Winkler K, 2000, J CHEM PHYS, V113, P4674, DOI 10.1063/1.1288690; Woutersen S, 1997, SCIENCE, V278, P658, DOI 10.1126/science.278.5338.658	30	872	874	7	258	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					832	835		10.1126/science.1122154	http://dx.doi.org/10.1126/science.1122154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16439623				2022-12-28	WOS:000235374900043
J	Gruchalla, RS; Pirmohamed, M				Gruchalla, RS; Pirmohamed, M			Antibiotic allergy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE DRUG-REACTIONS; HYPERSENSITIVITY REACTIONS; PENICILLIN ALLERGY; SULFONAMIDE ANTIBIOTICS; HOSPITALIZED-PATIENTS; CYSTIC-FIBROSIS; DESENSITIZATION; SULFAMETHOXAZOLE; PERSPECTIVE; MECHANISMS	A 55-year-old woman presents to the hospital with cellulitis. She reports a history of urticaria 30 years earlier associated with taking penicillin for a respiratory tract infection. Should cephalosporins be avoided? More generally, how should patients with a history of allergy to antibiotics be evaluated and treated?	Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Liverpool	Gruchalla, RS (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	rebecca.gruchalla@utsouthwestern.edu	Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266				ADKINSON NF, 2003, MIDDLETONS ALLERGY P, P1679, DOI DOI 10.1016/J.JCLINEPI.2005.08.012; [Anonymous], 1999, Ann Allergy Asthma Immunol, V83, P665; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; Brackett CC, 2004, PHARMACOTHERAPY, V24, P856, DOI 10.1592/phco.24.9.856.36106; Burrows JA, 2003, RESPIROLOGY, V8, P359, DOI 10.1046/j.1440-1843.2003.00461.x; CARR A, 1993, AIDS, V7, P65, DOI 10.1097/00002030-199301000-00010; Empedrad R, 2003, J ALLERGY CLIN IMMUN, V112, P629, DOI 10.1067/mai.2003.1690; Farrell J, 2003, J PHARMACOL EXP THER, V306, P229, DOI 10.1124/jpet.103.050112; Fiszenson-Albala F, 2003, BRIT J DERMATOL, V149, P1018, DOI 10.1111/j.1365-2133.2003.05584.x; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; Gruchalla RS, 2000, LANCET, V356, P1505, DOI 10.1016/S0140-6736(00)02885-3; GRUCHALLA RS, 2001, LANCET, V357, P724; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; Knowles S, 2001, DRUG SAFETY, V24, P239, DOI 10.2165/00002018-200124040-00001; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee CE, 2000, ARCH INTERN MED, V160, P2819, DOI 10.1001/archinte.160.18.2819; Levy M, 1997, DRUG SAFETY, V16, P1, DOI 10.2165/00002018-199716010-00001; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; LIN RY, 1992, ARCH INTERN MED, V152, P930, DOI 10.1001/archinte.152.5.930; LITT JZ, 2004, LITTS DRUG ERUPTION; LUND BMA, 1975, SCAND J INFECT DIS, V7, P21, DOI 10.3109/inf.1975.7.issue-1.04; Macy E, 2004, IMMUNOL ALLERGY CLIN, V24, P533, DOI 10.1016/j.iac.2004.03.002; Macy E, 2003, J ALLERGY CLIN IMMUN, V111, P1111, DOI 10.1067/mai.2003.1385; Malakar S, 2001, ARCH DERMATOL, V137, P100; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; Messaad D, 2004, ANN INTERN MED, V140, P1001, DOI 10.7326/0003-4819-140-12-200406150-00009; Mori K, 2000, J PHARM PHARMACOL, V52, P577, DOI 10.1211/0022357001774228; NACLERIO R, 1983, J ALLERGY CLIN IMMUN, V71, P294, DOI 10.1016/0091-6749(83)90083-0; NAZARETH I, 1972, Scandinavian Journal of Infectious Diseases, V4, P229, DOI 10.3109/inf.1972.4.issue-3.09; O'Donohue J, 2000, GUT, V47, P717, DOI 10.1136/gut.47.5.717; Ordoqui E, 1997, ALLERGY, V52, P1102, DOI 10.1111/j.1398-9995.1997.tb00182.x; Park BE, 1998, CHEM RES TOXICOL, V11, P969, DOI 10.1021/tx980058f; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; PIRMOHAMED M, 1994, DRUG SAFETY, V11, P114, DOI 10.2165/00002018-199411020-00006; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; Pirmohamed M, 2001, CURR OPIN ALLERGY CL, V1, P311, DOI 10.1097/00130832-200108000-00006; PULLEN H, 1967, LANCET, V2, P1176; Pumphrey RSH, 1999, LANCET, V353, P1157, DOI 10.1016/S0140-6736(99)00449-3; Rich JD, 1997, ANN ALLERG ASTHMA IM, V79, P409, DOI 10.1016/S1081-1206(10)63034-7; Romano A, 1998, ANN ALLERG ASTHMA IM, V80, P433, DOI 10.1016/S1081-1206(10)62997-3; RUDOLPH AH, 1973, JAMA-J AM MED ASSOC, V223, P499, DOI 10.1001/jama.223.5.499; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2000, ANN ALLERG ASTHMA IM, V85, P195, DOI 10.1016/S1081-1206(10)62466-0; Solensky R, 2004, IMMUNOL ALLERGY CLIN, V24, P425, DOI 10.1016/j.iac.2004.03.008; Strom BL, 2003, NEW ENGL J MED, V349, P1628, DOI 10.1056/NEJMoa022963; Sullivan JR, 2001, ARCH DERMATOL, V137, P357; Turvey SE, 2004, ANN ALLERG ASTHMA IM, V92, P426, DOI 10.1016/S1081-1206(10)61778-4; VANDERVEN AJAM, 1991, LANCET, V338, P431, DOI 10.1016/0140-6736(91)91046-W; Veien M, 2000, ANESTHESIOLOGY, V92, P1074, DOI 10.1097/00000542-200004000-00026; Warr WA, 2000, CHIM OGGI, V18, P9; Weltzien HU, 1998, J INVEST DERMATOL, V110, P203, DOI 10.1046/j.1523-1747.1998.00122.x; Wills R, 1998, J PAEDIATR CHILD H, V34, P325, DOI 10.1046/j.1440-1754.1998.00197.x	56	141	148	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					601	609		10.1056/NEJMcp043986	http://dx.doi.org/10.1056/NEJMcp043986			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467547				2022-12-28	WOS:000235177500009
J	Daly, CA; De Stavola, B; Fox, KM				Daly, CA; De Stavola, B; Fox, KM		Euro Heart Survey Investigators	Predicting prognosis in stable angina - results from the Euro heart survey of stable angina: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY-DISEASE; RISK; EXERCISE; TRIAL; PREVALENCE; FRAMINGHAM; MORTALITY; SURVIVAL; PECTORIS; EVENTS	Objectives To investigate the prognosis associated With stable angina in a contemporary population as seen in clinical practice, to identify the key prognostic features, and from this to construct a simple score to assist risk prediction. Design Prospective observational cohort study. Setting Pan-European survey in 156 outpatient cardiology clinics. Participants 3031 patients were included on the basis of a new clinical diagnosis by a cardiologist of stable angina with follow-up at one year. Main outcome measure Death or non-fatal myocardial infarction. Results The rate of death and non-fatal myocardial infarction in the first year was 2.3 per 100 patient years; the rate was 3.9 per 100 patient years in the subgroup (n = 994) with angiographic confirmation of coronary disease. The clinical and investigative factors most predictive of adverse outcome were comorbidity, diabetes, shorter duration of symptoms, increasing severity of symptoms, abnormal ventricular function, resting electrocardiographic changes, or not having any stress test done. Results of non-invasive stress tests did not significantly predict outcome in the population Who had tests done. A score Was constructed using the parameters predictive of outcome to estimate the probability of death or myocardial infarction within one year of presentation with stable angina. Conclusions A score based on the presence of simple, objective clinical and investigative variables makes it possible to discriminate effectively between very low risk mid very high risk patients and to estimate die probability of death or non-fatal myocardial infarction over one year.	Royal Brompton Hosp, London SW3 6NP, England; London Sch Hyg & Trop Med, London, England	Royal Brompton Hospital; University of London; London School of Hygiene & Tropical Medicine	Daly, CA (corresponding author), Royal Brompton Hosp, London SW3 6NP, England.	caroline.daly@imperial.ac.uk	Verheugt, F.W.A./H-8105-2014	De Stavola, Bianca Lucia/0000-0001-7853-0528; Daly, Caroline/0000-0002-8259-3561				Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Brindle P, 2003, BMJ-BRIT MED J, V327, P1267, DOI 10.1136/bmj.327.7426.1267; Califf RM, 1996, J AM COLL CARDIOL, V27, P1007, DOI 10.1016/0735-1097(96)87733-3; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; Collett D, 1994, MODELLING SURVIVAL D; Cosin J, 1999, EUR J EPIDEMIOL, V15, P323, DOI 10.1023/A:1007542700074; Daly CA, 2005, EUR HEART J, V26, P996, DOI 10.1093/eurheartj/ehi171; Dargie HJ, 2002, LANCET, V359, P1269, DOI 10.1016/s0140-6736(02)08265-x; Empana JP, 2003, EUR HEART J, V24, P1903, DOI 10.1016/j.ehj.2003.09.002; Ford ES, 2000, AM HEART J, V139, P371, DOI 10.1067/mhj.2000.102907; Fox KM, 2003, LANCET, V362, P782; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Henderson RA, 2003, J AM COLL CARDIOL, V42, P1161, DOI 10.1016/S0735-1097(03)00951-3; Hense HW, 2003, BMJ-BRIT MED J, V327, P1238, DOI 10.1136/bmj.327.7426.1238; HENSE HW, 2003, BMJ-BRIT MED J, V29, P1238; HULTGREN HN, 1984, AM J CARDIOL, V54, P988, DOI 10.1016/S0002-9149(84)80131-9; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MOCK MB, 1982, CIRCULATION, V66, P562, DOI 10.1161/01.CIR.66.3.562; Prakash M, 2001, CHEST, V120, P1003, DOI 10.1378/chest.120.3.1003; PRYOR DB, 1991, AM J MED, V90, P553; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; Sachdev M, 2004, J AM COLL CARDIOL, V43, P576, DOI 10.1016/j.jacc.2003.10.031; Yamada H, 1997, PROG CARDIOVASC DIS, V39, P457, DOI 10.1016/S0033-0620(97)80040-0	25	155	163	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2006	332	7536					262	265		10.1136/bmj.38695.605440.AE	http://dx.doi.org/10.1136/bmj.38695.605440.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16415069	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000235259000014
J	Lin, HQ; Van Wagner, E; Freeman, BD; Toy, LG; Gupta, RP				Lin, HQ; Van Wagner, E; Freeman, BD; Toy, LG; Gupta, RP			Plasticization-enhanced hydrogen purification using polymeric membranes	SCIENCE			English	Article							GAS SEPARATION MEMBRANE; HIGH-SELECTIVITY; GLASSY-POLYMERS; CROSS-LINKING; PERMEABILITY; CO2; NANOCOMPOSITE; PERMEATION; MIXTURES	Polymer membranes are attractive for molecular-scale separations such as hydrogen purification because of inherently low energy requirements. However, membrane materials with outstanding hydrogen separation performance in feed streams containing high-pressure carbon,dioxide and impurities such as hydrogen sulfide and water are not available. We report highly permeable, reverse-selective membrane materials for hydrogen purification, as exemplified by molecularly engineered, highly branched, cross-linked poly(ethylene oxide). in contrast to the performance of conventional materials, we demonstrate that plasticization can be harnessed to improve separation performance.	Univ Texas, Ctr Energy & Environm Resources, Austin, TX 78758 USA; Univ Texas, Dept Chem Engn, Austin, TX 78758 USA; Membrane Technol & Res, Menlo Pk, CA 94025 USA; Res Triangle Inst, Ctr Energy Technol, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Research Triangle Institute	Freeman, BD (corresponding author), Univ Texas, Ctr Energy & Environm Resources, Austin, TX 78758 USA.	freeman@che.utexas.edu	Lin, Haiqing/K-3181-2013; Freeman, Benny/G-5405-2016	Lin, Haiqing/0000-0001-8042-154X; Freeman, Benny/0000-0003-2779-7788				Baker R. W., 2004, MEMBRANE TECHNOLOGY, DOI DOI 10.1002/0470020393; Barrer RM, 1937, NATURE, V140, P106, DOI 10.1038/140106b0; Blume I., 1990, US Patent, Patent No. [4963165, 4,963,165]; Bos A, 2001, AICHE J, V47, P1088, DOI 10.1002/aic.690470515; Chen H, 2000, IND ENG CHEM RES, V39, P2447, DOI 10.1021/ie9908736; CHIOU JS, 1985, J APPL POLYM SCI, V30, P2633, DOI 10.1002/app.1985.070300626; CHOW TS, 1980, MACROMOLECULES, V13, P362, DOI 10.1021/ma60074a029; Cussler E. L., 1994, POLYM GAS SEPARATION, P273; de Vos RM, 1998, SCIENCE, V279, P1710, DOI 10.1126/science.279.5357.1710; Freeman BD, 1999, MACROMOLECULES, V32, P375, DOI 10.1021/ma9814548; Gupta RP, 2000, IND ENG CHEM RES, V39, P610, DOI 10.1021/ie990533k; HEILMAN W, 1956, IND ENG CHEM, V48, P821, DOI 10.1021/ie50556a046; HENIS JMS, 1983, SCIENCE, V220, P11, DOI 10.1126/science.220.4592.11; Hsieh PY, 1963, J APPL POLYM SCI, V7, P1743, DOI [10.1002/app.1963.070070515, DOI 10.1002/APP.1963.070070515]; Ismail AF, 2002, SEP PURIF TECHNOL, V27, P173, DOI 10.1016/S1383-5866(01)00211-8; Kohl A.L., 1997, GAS PURIFICATION, V5th; Kovvali AS, 2000, J AM CHEM SOC, V122, P7594, DOI 10.1021/ja0013071; Lai ZP, 2003, SCIENCE, V300, P456, DOI 10.1126/science.1082169; Lin H, 2004, J MEMBRANE SCI, V239, P105, DOI 10.1016/j.memsci.2003.08.031; Lin H, UNPUB; Lin HQ, 2005, MACROMOLECULES, V38, P8381, DOI 10.1021/ma0510136; Lin HQ, 2005, J MOL STRUCT, V739, P57, DOI 10.1016/j.molstruc.2004.07.045; Merkel TC, 2002, SCIENCE, V296, P519, DOI 10.1126/science.1069580; Pinnau I, 2004, J MEMBRANE SCI, V244, P227, DOI 10.1016/j.memsci.2004.06.055; Quinn R, 1997, J MEMBRANE SCI, V131, P49, DOI 10.1016/S0376-7388(97)00024-0; ROBESON LM, 1991, J MEMBRANE SCI, V62, P165, DOI 10.1016/0376-7388(91)80060-J; Shiflett MB, 1999, SCIENCE, V285, P1902, DOI 10.1126/science.285.5435.1902; Staudt-Bickel C, 1999, J MEMBRANE SCI, V155, P145, DOI 10.1016/S0376-7388(98)00306-8; Teramoto M, 2004, J MEMBRANE SCI, V234, P83, DOI 10.1016/j.memsci.2003.12.023; WHITE LS, 1995, J MEMBRANE SCI, V103, P73, DOI 10.1016/0376-7388(94)00313-N; Yamaguchi A, 2004, NAT MATER, V3, P337, DOI 10.1038/nmat1107	31	522	545	17	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2006	311	5761					639	642		10.1126/science.1118079	http://dx.doi.org/10.1126/science.1118079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456074				2022-12-28	WOS:000235257400041
J	Stainier, D				Stainier, D			No stem cell is an islet (yet)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DIFFERENTIATION; ENDODERM		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Stainier, D (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			Stainier, Didier/0000-0002-0382-0026				D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060; Stainier DYR, 2002, GENE DEV, V16, P893, DOI 10.1101/gad.974902; Yasunaga M, 2005, NAT BIOTECHNOL, V23, P1542, DOI 10.1038/nbt1167	5	6	11	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					521	523		10.1056/NEJMcibr055048	http://dx.doi.org/10.1056/NEJMcibr055048			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452566				2022-12-28	WOS:000235019400014
J	Khan, NA; Rahim, SA; Anand, SS; Simel, DL; Panju, A				Khan, NA; Rahim, SA; Anand, SS; Simel, DL; Panju, A			Does the clinical examination predict lower extremity peripheral arterial disease?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANKLE-BRACHIAL INDEX; INTERMITTENT CLAUDICATION; PULSE PALPATION; PHYSICAL-EXAMINATION; VASCULAR-DISEASE; NATIONAL-HEALTH; BLOOD-PRESSURE; LEG SYMPTOMS; PREVALENCE; FLOW	Context Lower extremity peripheral arterial disease (PAD) is common and associated with significant increases in morbidity and mortality. Physicians typically depend on the clinical examination to identify patients who need further diagnostic testing. Objective To systematically review the accuracy and precision of the clinical examination for PAD. Data Sources, Study Selection, and Data Extraction MEDLINE (January 1966 to March 2005) and Cochrane databases were searched for articles on the diagnosis of PAD based on physical examination published in the English language. Included studies compared an element of the history or physical examination with a reference standard of ankle-brachial index, duplex sonography, or angiogram. Seventeen of the 51 potential articles identified met inclusion criteria. Two of the authors independently extracted data, performed quality review, and used consensus to resolve any discrepancies. Data Synthesis For asymptomatic patients, the most useful clinical findings to diagnose PAD are the presence of claudication (likelihood ratio [LR], 3.30; 95% confidence interval [CI], 2.30-4.80), femoral bruit (LR, 4.80; 95% CI, 2.40-9.50), or any pulse abnormality (LR, 3.10; 95% CI, 1.40-6.60). While none of the clinical examination features help to lower the likelihood of any degree of PAD, the absence of claudication or the presence of normal pulses decreases the likelihood of moderate to severe disease. When considering patients who are symptomatic with leg complaints, the most useful clinical findings are the presence of cool skin (LR, 5.90; 95% CI, 4.10-8.60), the presence of at least 1 bruit (LR, 5.60; 95% CI, 4.70-6.70), or any palpable pulse abnormality (LR, 4.70; 95% CI, 2.20-9.90). The absence of any bruits (iliac, femoral, or popliteal) (LR, 0.39; 95% CI, 0.34-0.45) or pulse abnormality (LR, 0.38; 95% Cl, 0.23-0.64) reduces the likelihood of PAD. Combinations of physical examination findings do not increase the likelihood of PAD beyond that of individual clinical findings. However, when combinations of clinical findings are all normal, the likelihood of disease is lower than when individual symptoms or signs are normal. A PAD scoring system, which includes auscultation of arterial components by handheld Doppler, provides greater diagnostic accuracy. Conclusions Clinical examination findings must be used in the context of the pretest probability because they are not independently sufficient to include or exclude a diagnosis of PAD with certainty. The PAD screening score using the hand-held Doppler has the greatest diagnostic accuracy.	Univ British Columbia, Dept Med, Vancouver, BC, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Duke Univ, Dept Med, Durham, NC USA; Durham Vet Affairs Med Ctr, Durham, NC USA	University of British Columbia; McMaster University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Khan, NA (corresponding author), Univ British Columbia, St Pauls Hosp, 1081 Burrard St,620 B, Vancouver, BC V6Z 1Y6, Canada.	nakhan@shaw.ca						BARNHORST DA, 1968, NEW ENGL J MED, V278, P264, DOI 10.1056/NEJM196802012780508; BAXTER GM, 1993, CLIN RADIOL, V47, P91, DOI 10.1016/S0009-9260(05)81179-1; Belch JJF, 2003, ARCH INTERN MED, V163, P884, DOI 10.1001/archinte.163.8.884; BICKLEY LS, 1999, BATES GUIDE PHYS EXA; Boyko EJ, 1997, J CLIN EPIDEMIOL, V50, P659, DOI 10.1016/S0895-4356(97)00005-X; Braunwald E., 2001, HEART DIS TXB CARDIO; BREARLEY S, 1992, ANN ROY COLL SURG, V74, P169; CARTER SA, 1981, JAMA-J AM MED ASSOC, V246, P1682, DOI 10.1001/jama.246.15.1682; CHRISTENSEN JH, 1989, J INTERN MED, V226, P95, DOI 10.1111/j.1365-2796.1989.tb01361.x; Criqui M H, 1997, Vasc Med, V2, P221; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DEGOWAN R, 1987, DEGOWAN DEGOWANS BED, P415; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Doobay AV, 2005, ARTERIOSCL THROM VAS, V25, P1463, DOI 10.1161/01.ATV.0000168911.78624.b7; Dormandy J A, 1991, Eur J Vasc Surg, V5, P131, DOI 10.1016/S0950-821X(05)80676-0; Elhadd TA, 1999, PRACT DIABETES INT, V16, P163, DOI DOI 10.1002/PDI.1960160605; Farkouh M. E., 1994, Journal of General Internal Medicine, V9, P28; FARKOUH ME, 2002, INT J ANGIOL, V11, P41, DOI DOI 10.1007/S00547-001-0052-X; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; Gardner AW, 1998, ANGIOLOGY, V49, P723; Gregg EW, 2004, DIABETES CARE, V27, P1591, DOI 10.2337/diacare.27.7.1591; HIATT WR, 1990, J CLIN EPIDEMIOL, V43, P597, DOI 10.1016/0895-4356(90)90164-K; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; INSALL RL, 1989, J ROY SOC MED, V82, P729, DOI 10.1177/014107688908201209; Jeelani NUO, 2000, EUR J VASC ENDOVASC, V20, P25, DOI 10.1053/ejvs.2000.1141; JELNES R, 1986, BRIT MED J, V293, P1137, DOI 10.1136/bmj.293.6555.1137; Kazmers A, 1996, AM SURGEON, V62, P315; LAWSON IR, 1980, J AM GERIATR SOC, V28, P300, DOI 10.1111/j.1532-5415.1980.tb00619.x; Lundin M, 1999, WORLD J SURG, V23, P252, DOI 10.1007/PL00013177; Marcon G, 1991, Qual Assur Health Care, V3, P115; McDermott MM, 1999, ARCH INTERN MED, V159, P387; McDermott MM, 2003, J GEN INTERN MED, V18, P461, DOI 10.1046/j.1525-1497.2003.20527.x; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2004, JAMA-J AM MED ASSOC, V292, P453, DOI 10.1001/jama.292.4.453; McGee SR, 1998, ARCH INTERN MED, V158, P1357, DOI 10.1001/archinte.158.12.1357; MEADE TW, 1968, BRIT HEART J, V30, P661; Meijer WT, 1998, ARTERIOSCL THROM VAS, V18, P185, DOI 10.1161/01.ATV.18.2.185; MILNE J S, 1972, Age and Ageing, V1, P146, DOI 10.1093/ageing/1.3.146; Moffatt C, 1995, J Wound Care, V4, P134; Mohler ER, 2004, VASC MED, V9, P253, DOI 10.1191/1358863x04vm559oa; Mowlavi A, 2002, POSTGRAD MED J, V78, P746, DOI 10.1136/pmj.78.926.746; Murabito JM, 1997, CIRCULATION, V96, P44; Myers K A, 1987, Eur J Vasc Surg, V1, P245, DOI 10.1016/S0950-821X(87)80075-0; Newman AB, 2001, J CLIN EPIDEMIOL, V54, P294, DOI 10.1016/S0895-4356(00)00308-5; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; NICHOLSON ML, 1993, EUR J VASCULAR SURG, V7, P59, DOI 10.1016/S0950-821X(05)80545-6; O'Flynn I, 1993, J Vasc Nurs, V11, P71; ORIENT JM, 2000, SAPIRAS ART SCI BEDS, P379; OURIEL K, 1982, SURGERY, V91, P686; Regensteiner JG, 2002, AM J MED, V112, P49, DOI 10.1016/S0002-9343(01)01034-8; Resnick HE, 2004, CIRCULATION, V109, P733, DOI 10.1161/01.CIR.0000112642.63927.54; ROBERTSON GSM, 1990, ANN ROY COLL SURG, V72, P99; Sacks D, 2002, J VASC INTERV RADIOL, V13, P353, DOI 10.1016/S1051-0443(07)61735-7; Selvin E, 2004, CIRCULATION, V110, P738, DOI 10.1161/01.CIR.0000137913.26087.F0; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; *SOC VASC MED BIOL, 1999, MARK CARD RISK; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; Stoffers HEJH, 1997, MED DECIS MAKING, V17, P61, DOI 10.1177/0272989X9701700107; SUMNER DS, 1969, SURGERY, V65, P763; TAN M H, 1982, SMJ Singapore Medical Journal, V23, P194; TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1; Welch Harold J., 1997, Comprehensive Therapy, V23, P534; WOODS B O, 1991, Cardiology Clinics, V9, P413; YOUNG DF, 1977, CIRC RES, V41, P99, DOI 10.1161/01.RES.41.1.99	65	183	191	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					536	546		10.1001/jama.295.5.536	http://dx.doi.org/10.1001/jama.295.5.536			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007SP	16449619				2022-12-28	WOS:000234990300021
J	Opie, LH; Commerford, PJ; Gersh, BJ; Pfeffer, MA				Opie, LH; Commerford, PJ; Gersh, BJ; Pfeffer, MA			Controversies in Cardiology 4 - Controversies in ventricular remodelling	LANCET			English	Review							NECROSIS-FACTOR-ALPHA; STAGE HEART-FAILURE; FUNCTIONAL MITRAL REGURGITATION; AORTIC-VALVE-REPLACEMENT; IDIOPATHIC DILATED CARDIOMYOPATHY; MATRIX-METALLOPROTEINASE ACTIVITY; ANTERIOR MYOCARDIAL-INFARCTION; PRESSURE-OVERLOAD HYPERTROPHY; CARDIAC STEM-CELLS; ANGIOTENSIN-II	Ventricular remodelling describes structural changes in the left ventricle in response to chronic alterations in loading conditions, with three major patterns: concentric remodelling, when a pressure load leads to growth in cardiomyocyte thickness; eccentric hypertrophy, when a volume load produces myocyte lengthening; and myocardial infarction, an amalgam of patterns in which stretched and dilated infarcted tissue increases left-ventricular volume with a combined volume and pressure load on non-infarcted areas. Whether left-ventricular hypertrophy is adaptive or maladaptive is controversial, as suggested by patterns of signalling pathways, transgenic models, and clinical findings in aortic stenosis. The transition from apparently compensated hypertrophy to the failing heart indicates a changing balance between metalloproteinases and their inhibitors, effects of reactive oxygen species, and death-promoting and profibrotic neurohumoral responses. These processes are evasive therapeutic targets. Here, we discuss potential novel therapies for these disorders, including: sildenafil, an unexpected option for anti-transition therapy; surgery for increased sphericity caused by chronic volume overload of mitral regurgitation; an antifibrotic peptide to inhibit the fibrogenic effects of transforming growth factor beta; mechanical intervention in advanced heart failure; and stem-cell therapy.	Univ Cape Town, Fac Hlth Sci, Hatter Inst Heart Res, Cape Heart Ctr,Observ, ZA-7925 Cape Town, South Africa; Univ Cape Town, Fac Hlth Sci, Dept Med, Cape Heart Ctr,Observ, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, Cardiac Clin, Dept Med, ZA-7925 Cape Town, South Africa; Univ Cape Town, ZA-7925 Cape Town, South Africa; Mayo Clin, Mayo Coll Med, Rochester, MN USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA	University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town; Mayo Clinic; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Opie, LH (corresponding author), Univ Cape Town, Fac Hlth Sci, Hatter Inst Heart Res, Cape Heart Ctr,Observ, ZA-7925 Cape Town, South Africa.	Opie@capeheart.uct.ac.za						Aikawa Y, 2001, AM HEART J, V141, P234, DOI 10.1067/mhj.2001.112237; Antonini-Canterin F, 2003, HYPERTENSION, V41, P1268, DOI 10.1161/01.HYP.0000070029.30058.59; ANVERSA P, 1985, AM J PHYSIOL, V248, pH876, DOI 10.1152/ajpheart.1985.248.6.H876; AURIGEMMA GP, 1994, AM J CARDIOL, V74, P794, DOI 10.1016/0002-9149(94)90437-5; BACH DS, 1995, AM HEART J, V129, P1165, DOI 10.1016/0002-8703(95)90399-2; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Banfi C, 2005, EUR HEART J, V26, P481, DOI 10.1093/eurheartj/ehi073; Barlucchi L, 2001, CIRC RES, V88, P298, DOI 10.1161/01.RES.88.3.298; Beeri R, 2005, J AM COLL CARDIOL, V45, p362A; Blom AS, 2005, CIRCULATION, V112, P1274, DOI 10.1161/CIRCULATIONAHA.104.499202; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; Borlaug BA, 2005, CIRCULATION, V112, P2642, DOI 10.1161/CIRCULATIONAHA.105.540500; Bradham WS, 2002, CARDIOVASC RES, V53, P822, DOI 10.1016/S0008-6363(01)00503-X; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; CARABELLO B, 2003, EVIDENCE BASED CARDI, P758; Carabello BA, 2004, J AM COLL CARDIOL, V44, P376, DOI 10.1016/j.jacc.2004.03.061; Chaudhry PA, 2000, ANN THORAC SURG, V70, P1275, DOI 10.1016/S0003-4975(00)01755-0; Chen JQ, 2005, CIRCULATION, V111, P1800, DOI 10.1161/01.CIR.0000160936.91849.9F; Chen XW, 2005, CIRC RES, V97, P1009, DOI 10.1161/01.RES.0000189270.72915.D1; Chen XW, 2002, CIRC RES, V91, P517, DOI 10.1161/01.RES.0000033988.13062.7C; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Dawn B, 2005, P NATL ACAD SCI USA, V102, P3766, DOI 10.1073/pnas.0405957102; Dib N, 2005, CIRCULATION, V112, P1748, DOI 10.1161/CIRCULATIONAHA.105.547810; Dimmeler S, 2005, J CLIN INVEST, V115, P572, DOI 10.1172/JCI200524283; Dipla K, 1998, CIRCULATION, V97, P2316, DOI 10.1161/01.CIR.97.23.2316; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; EICHHORN P, 1982, CIRCULATION, V65, P1395, DOI 10.1161/01.CIR.65.7.1395; Enriquez-Sarano M, 2005, NEW ENGL J MED, V352, P875, DOI 10.1056/NEJMoa041451; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; Guazzi M, 2004, J AM COLL CARDIOL, V44, P2339, DOI 10.1016/j.jacc.2004.09.041; GunjaSmith Z, 1996, AM J PATHOL, V148, P1639; Hayashi M, 2003, CIRCULATION, V107, P2559, DOI 10.1161/01.CIR.0000068340.96506.0F; Heerdt PM, 2000, CIRCULATION, V102, P2713, DOI 10.1161/01.CIR.102.22.2713; Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7; Hein S, 2002, CIRCULATION, V106, P1302, DOI 10.1161/01.CIR.0000031760.65615.3B; Heymans S, 2005, CIRCULATION, V112, P1136, DOI 10.1161/CIRCULATIONAHA.104.516963; Hirata K, 2005, AM J CARDIOL, V96, P1436, DOI 10.1016/j.amjcard.2005.06.091; Howes AL, 2003, J BIOL CHEM, V278, P40343, DOI 10.1074/jbc.M305964200; Ichinose F, 2004, AM J PHYSIOL-HEART C, V286, pH1070, DOI 10.1152/ajpheart.00940.2003; Ikeuchi M, 2004, CARDIOVASC RES, V64, P526, DOI 10.1016/j.cardiores.2004.07.017; Inagaki K, 2002, J MOL CELL CARDIOL, V34, P1377, DOI 10.1006/jmcc.2002.2089; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Janssens S, 2006, LANCET, V367, P113, DOI 10.1016/S0140-6736(05)67861-0; Kapadia SR, 2000, J AM COLL CARDIOL, V36, P208, DOI 10.1016/S0735-1097(00)00721-X; Kapadia SR, 1997, CIRC RES, V81, P187, DOI 10.1161/01.RES.81.2.187; Katada J, 2005, CIRCULATION, V111, P2157, DOI 10.1161/01.CIR.0000163562.82134.8E; Katz AM, 1998, CIRCULATION, V98, P623, DOI 10.1161/01.CIR.98.7.623; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; Khan SS, 2000, ANN THORAC SURG, V69, P531, DOI 10.1016/S0003-4975(99)01389-2; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Klotz S, 2005, J AM COLL CARDIOL, V45, P668, DOI 10.1016/j.jacc.2004.11.042; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6; KONO T, 1992, J AM COLL CARDIOL, V20, P1594, DOI 10.1016/0735-1097(92)90455-V; KRAYENBUEHL HP, 1989, CIRCULATION, V79, P744, DOI 10.1161/01.CIR.79.4.744; Kupari M, 2005, EUR HEART J, V26, P1790, DOI 10.1093/eurheartj/ehi290; Kuster GM, 2005, CIRCULATION, V111, P420, DOI 10.1161/01.CIR.0000153800.09920.40; Kuwahara F, 2004, HYPERTENSION, V43, P739, DOI 10.1161/01.HYP.0000118584.33350.7d; Lal A, 2005, J MOL CELL CARDIOL, V39, P521, DOI 10.1016/j.yjmcc.2005.05.002; Lamb HJ, 2002, J AM COLL CARDIOL, V40, P2182, DOI 10.1016/S0735-1097(02)02604-9; Leri A, 2005, PHYSIOL REV, V85, P1373, DOI 10.1152/physrev.00013.2005; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Li YY, 2001, CIRCULATION, V104, P1147, DOI 10.1161/hc3501.095215; Lund O, 1997, EUR HEART J, V18, P1977; Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536; Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249; Martin J, 2005, CLIN EXP PHARMACOL P, V32, P697, DOI 10.1111/j.1440-1681.2005.04256.x; Matsui T, 2005, J MOL CELL CARDIOL, V38, P63, DOI 10.1016/j.yjmcc.2004.11.005; MATSUMOTOIDA M, 2000, AM J PHYSIOL-HEART C, V290, pH709; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; MEERSON FZ, 1962, CIRC RES, V10, P250, DOI 10.1161/01.RES.10.3.250; Mehra MR, 2005, J AM COLL CARDIOL, V45, P388, DOI 10.1016/j.jacc.2004.11.007; Mehta RH, 2000, AM J CARDIOL, V86, P1193, DOI 10.1016/S0002-9149(00)01201-7; MITCHELL GF, 1992, J AM COLL CARDIOL, V19, P1136, DOI 10.1016/0735-1097(92)90314-D; Modesti PA, 2000, AM J PHYSIOL-HEART C, V279, pH976, DOI 10.1152/ajpheart.2000.279.3.H976; Modesti PA, 2002, J MOL CELL CARDIOL, V34, P1491, DOI 10.1006/jmcc.2002.2095; Mori T, 2004, CARDIOVASC RES, V61, P771, DOI 10.1016/j.cardiores.2003.12.005; MULIERI LA, 1993, CIRCULATION, V88, P2700, DOI 10.1161/01.CIR.88.6.2700; Norton GR, 2002, J AM COLL CARDIOL, V39, P664, DOI 10.1016/S0735-1097(01)01792-2; OLIVETTI G, 1990, CIRC RES, V67, P23, DOI 10.1161/01.RES.67.1.23; OPIE L, 2004, HEART PHYSL; Oral H, 2003, CIRCULATION, V107, P831, DOI 10.1161/01.CIR.0000049745.38594.6D; Otsuji Y, 1997, CIRCULATION, V96, P1999, DOI 10.1161/01.CIR.96.6.1999; Otto CM, 2001, NEW ENGL J MED, V345, P740, DOI 10.1056/NEJMcp003331; Palmieri EA, 2002, AM J PHYSIOL-HEART C, V282, pH926, DOI 10.1152/ajpheart.00436.2001; Peng HM, 2005, CIRCULATION, V112, P2436, DOI 10.1161/CIRCULATIONAHA.104.528695; PERLOFF JK, 1972, CIRCULATION, V46, P227, DOI 10.1161/01.CIR.46.2.227; Perry GJ, 2002, J AM COLL CARDIOL, V39, P1374, DOI 10.1016/S0735-1097(02)01763-1; Peters J, 2002, CIRC RES, V90, P1135, DOI 10.1161/01.RES.0000019242.51541.99; Peterson JT, 2000, CARDIOVASC RES, V46, P307, DOI 10.1016/S0008-6363(00)00029-8; Peterson JT, 2001, CIRCULATION, V103, P2303; PFEFFER JM, 1985, CIRC RES, V57, P84, DOI 10.1161/01.RES.57.1.84; PFEFFER JM, 1991, AM J CARDIOL, V68, pD17; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; Polyakova V, 2004, J AM COLL CARDIOL, V44, P1609, DOI 10.1016/j.jacc.2004.07.023; Reddy HK, 2004, MOL CELL BIOCHEM, V264, P183, DOI 10.1023/B:MCBI.0000044387.04670.81; Reiken S, 2003, CIRCULATION, V107, P2459, DOI 10.1161/01.CIR.0000068316.53218.49; Rihal CS, 2006, NAT CLIN PRACT CARD, V3, P588, DOI 10.1038/ncpcardio0685; Ruetten H, 2005, CARDIOVASC RES, V66, P444, DOI 10.1016/j.cardiores.2005.01.021; SABBAH HN, 1993, AM J CARDIOL, V72, P1074, DOI 10.1016/0002-9149(93)90865-A; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Serneri GGN, 2001, CIRC RES, V88, P961, DOI 10.1161/hh0901.089882; Shah PK, 2005, CIRCULATION, V112, P1245, DOI 10.1161/CIRCULATIONAHA.105.554725; SILVERMAN ME, 1968, AM HEART J, V76, P399, DOI 10.1016/0002-8703(68)90237-8; Sivasubramanian N, 2001, CIRCULATION, V104, P826, DOI 10.1161/hc3401.093154; Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, pC53, DOI 10.1152/ajpcell.2001.280.1.C53; Solomon SD, 2001, ANN INTERN MED, V134, P451, DOI 10.7326/0003-4819-134-6-200103200-00009; SPANN JF, 1980, CIRCULATION, V62, P576, DOI 10.1161/01.CIR.62.3.576; STARLING MR, 1995, CIRCULATION, V92, P811, DOI 10.1161/01.CIR.92.4.811; Sugden PH, 2001, CIRCULATION, V103, P1375, DOI 10.1161/01.CIR.103.10.1375; Sundstrom J, 2004, CIRCULATION, V109, P2850, DOI 10.1161/01.CIR.0000129318.79570.84; Sutton MS, 1997, CIRCULATION, V96, P3294; Takimoto E, 2005, NAT MED, V11, P214, DOI 10.1038/nm1175; Takimoto E, 2005, J CLIN INVEST, V115, P1221, DOI 10.1172/JCI200521968; Terracciano CMN, 2004, CIRCULATION, V109, P2263, DOI 10.1161/01.CIR.0000129233.51320.92; Terracciano CMN, 2003, EUR HEART J, V24, P1329, DOI 10.1016/S0195-668X(03)00242-2; Tsoporis JN, 2005, CIRCULATION, V111, P598, DOI 10.1161/01.CIR.0000154554.65287.F5; Uozumi H, 2001, J BIOL CHEM, V276, P23115, DOI 10.1074/jbc.M100814200; URABE Y, 1992, CIRC RES, V70, P131, DOI 10.1161/01.RES.70.1.131; VILLARI B, 1995, CIRCULATION, V91, P2353, DOI 10.1161/01.CIR.91.9.2353; Vinten-Johansen J, 2005, CIRCULATION, V112, P2085, DOI 10.1161/CIRCULATIONAHA.105.569798; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Woodiwiss AJ, 2001, CIRCULATION, V103, P155; Wu AH, 2005, J AM COLL CARDIOL, V45, P381, DOI 10.1016/j.jacc.2004.09.073; Yu CM, 2003, AM J CARDIOL, V91, P684, DOI 10.1016/S0002-9149(02)03404-5; Yu CM, 2002, CIRCULATION, V105, P1195, DOI 10.1161/hc1002.105185; Zimmerman SD, 2004, AM J PHYSIOL-HEART C, V287, pH2697, DOI 10.1152/ajpheart.00160.2004	131	595	618	0	49	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					356	367		10.1016/S0140-6736(06)68074-4	http://dx.doi.org/10.1016/S0140-6736(06)68074-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443044				2022-12-28	WOS:000235084600033
J	Pfund, C; Pribbenow, CM; Branchaw, J; Lauffer, SM; Handelsman, J				Pfund, C; Pribbenow, CM; Branchaw, J; Lauffer, SM; Handelsman, J			Professional skills - The merits of training mentors	SCIENCE			English	Editorial Material							EXPERIENCES; EDUCATION; GRADUATE		Univ Wisconsin, Wisconsin Program Sci Teaching, Dept Plant Pathol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Integrat Res Teaching & Learning, Madison, WI 53706 USA; Univ Wisconsin, Women Sci & Engn Leadership Inst, Madison, WI 53706 USA; Univ Wisconsin, Ctr Biol Educ, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Handelsman, J (corresponding author), Univ Wisconsin, Wisconsin Program Sci Teaching, Dept Plant Pathol, Madison, WI 53706 USA.	joh@plantpath.wisc.edu						Astin A. W., 1993, WHAT MATTERS COLL 4; Handelsman J, 2004, SCIENCE, V304, P521, DOI 10.1126/science.1096022; Handelsman J, 2005, ENTERING MENTORING S; Hathaway RS, 2002, J COLL STUDENT DEV, V43, P614; HEARN JC, 1987, RES HIGH EDUC, V27, P119, DOI 10.1007/BF00992365; Kardash CM, 2000, J EDUC PSYCHOL, V92, P191, DOI 10.1037//0022-0663.92.1.191; Lopatto David, 2004, Cell Biol Educ, V3, P270, DOI 10.1187/cbe.04-07-0045; Nagda BA, 1998, REV HIGH EDUC, V22, P55; Pascarella E.T, 1991, COLL AFFECTS STUDENT; Seymour E, 2004, SCI EDUC, V88, P493, DOI 10.1002/sce.10131	10	145	147	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					473	474		10.1126/science.1123806	http://dx.doi.org/10.1126/science.1123806			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439648				2022-12-28	WOS:000235071400030
J	Bagai, A; Thavendiranathan, P; Detsky, AS				Bagai, A; Thavendiranathan, P; Detsky, AS			Does this patient have hearing impairment?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; TUNING FORK; HANDICAP INVENTORY; WHISPERED VOICE; SCREENING-TEST; PRIMARY-CARE; ACCURACY; PREVALENCE; TESTS; RELIABILITY	Context Hearing impairment is prevalent among the elderly population but commonly underdiagnosed. Objective To review the accuracy and precision of bedside clinical maneuvers for diagnosing hearing impairment. Data Sources MEDLINE and EMBASE databases (1966 to April 2005) were searched for English-language articles related to screening for hearing impairment. Study Selection Original studies on the accuracy or precision of screening questions and tests were included. Articles that used unaccepted reference standards or contained insufficient data were excluded. Medical Subject Headings or keywords used in the search included hearing loss, hearing handicap, hearing tests, tuning fork, deafness, physical, examination, sensitivity, specificity, audiometry, tuning fork tests, Rinne, Weber, audioscope, Hearing Handicap Inventory for the Elderly-Screening version, whispered voice test, sensorineural, and conductive. Data Extraction One author screened all potential articles and 2 authors independently abstracted data. Differences were resolved by consensus. Each included study (n=24) was assigned a methodological grade. Data Synthesis A yes response when asking individuals whether they have hearing impairment has a summary likelihood ratio (LR) of 2.5 (95% confidence interval [CI], 1.7-3.6); a no response has an LR of 0.13 (95% CI, 0.09-0.19). A score of 8 or greater on the screening version of the Hearing Handicap Inventory for the Elderly (HHIE-S) has an LR of 3.8 (95% CI, 3.0-4.8); a score less than 8 has an LR of 0.38 (95% CI, 0.29-0.51). An abnormal Weber tuning fork test response has an LR of 1.6 (95% CI, 1.0-2.3); a normal response has an LR of 0.70 (95% CI, 0.48-1.0). An abnormal Rinne tuning fork test response has LRs ranging from 2.7 to 62; a normal response has LRs from 0.01 to 0.85. Inability to perceive a whispered voice has an LR of 6.1 (95% CI, 4.5-8.4); normal perception has an LR of 0.03 (95% CI, 0-0.24). Not passing the audioscope test has an LR of 2.4 (95% CI, 1.4-4.1); passing has an LR of 0.07 (95% CI, 0.03-0.17). Conclusions Elderly individuals who acknowledge they have hearing impairment require audiometry, while those who reply no should be screened with the whispered-voice test. Individuals who perceive the whispered voice require no further testing, while those unable to perceive the voice require audiometry. The Weber and Rinne tests should not be used for general screening.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, Room 427,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	allan.detsky@uhn.on.ca		Thavendiranathan, Paaladinesh/0000-0002-6497-1098				Abyad A, 2004, GERIATRICS TODAY, V7, P43; [Anonymous], 1994, Vital Health Stat 10, P1; BICKLEY LS, 1999, BATES GUIDE PHYS EXA; BIENVENUE GR, 1985, EAR HEARING, V6, P251, DOI 10.1097/00003446-198509000-00005; British Society of Audiology, 1987, BRIT J AUDIOL, V21, P229; BROWNING GG, 1989, J LARYNGOL OTOL, V103, P7, DOI 10.1017/S0022215100107923; Burkey JM, 1998, AM J OTOL, V19, P59; CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x; CHANDLER JAMES R., 1964, LARYNGOSCOPE, V74, P22; CHOLE RA, 1988, ARCH OTOLARYNGOL, V114, P399; CIURLIAGUY E, 1993, GERONTOLOGIST, V33, P644, DOI 10.1093/geront/33.5.644; Clark J G, 1981, ASHA, V23, P493; CLARK K, 1991, AM J EPIDEMIOL, V134, P704, DOI 10.1093/oxfordjournals.aje.a116147; CROWLEY H, 1966, ARCHIV OTOLARYNGOL, V84, P406; Dalton DS, 2003, GERONTOLOGIST, V43, P661, DOI 10.1093/geront/43.5.661; DOYLE PJ, 1984, J OTOLARYNGOL, V13, P83; Eekhof JAH, 1996, BRIT J GEN PRACT, V46, P473; FLEMING KC, 1995, MAYO CLIN PROC, V70, P890; FRANK T, 1987, EAR HEARING, V8, P180, DOI 10.1097/00003446-198706000-00009; GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001; GELFAND SA, 1977, ACTA OTO-LARYNGOL, V83, P480, DOI 10.3109/00016487709128875; GOLABEK W, 1979, CLIN OTOLARYNGOL, V4, P421, DOI 10.1111/j.1365-2273.1979.tb01775.x; Goldstein D P, 1984, ASHA, V26, P24; Goldstein D. P., 1984, ASHA, V26, P38; Griffin D H, 1984, Md State Med J, V33, P285; HERBST KG, 1980, BMJ-BRIT MED J, V281, P903, DOI 10.1136/bmj.281.6245.903; HINCHCLIFFE R, 1961, J Laryngol Otol, V75, P201, DOI 10.1017/S0022215100057698; Jackson CL., 1959, DIS NOSE THROAT EAR; JOHNSTON DF, 1992, CLIN OTOLARYNGOL, V17, P322, DOI 10.1111/j.1365-2273.1992.tb01005.x; LICHTENSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V259, P2875, DOI 10.1001/jama.259.19.2875; LICHTENSTEIN MJ, 1988, EAR HEARING, V9, P208, DOI 10.1097/00003446-198808000-00006; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MARTIN F, 1972, CLIN AUDIOMETRY MASK; MCBRIDE WS, 1994, AM J MED SCI, V307, P40, DOI 10.1097/00000441-199401000-00007; McDowell A, 1981, Vital Health Stat 1, P1; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; MULROW CD, 1990, J AM GERIATR SOC, V38, P45, DOI 10.1111/j.1532-5415.1990.tb01595.x; Nondahl DM, 1998, AUDIOLOGY, V37, P295; Okamoto M, 2004, INT J AUDIOL, V43, P54, DOI 10.1080/14992020400050008; PARVING A, 1991, AUDIOLOGY, V30, P61; Pirozzo S, 2003, BRIT MED J, V327, P967, DOI 10.1136/bmj.327.7421.967; RAHKO T, 1985, ANN OTO RHINOL LARYN, V94, P140, DOI 10.1177/000348948509400208; Reuben DB, 1998, J AM GERIATR SOC, V46, P1008, DOI 10.1111/j.1532-5415.1998.tb02758.x; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SALOMON G, 1986, DAN MED BULL, V33, P1; Sindhusake D, 2001, INT J EPIDEMIOL, V30, P1371, DOI 10.1093/ije/30.6.1371; STANKIEWICZ JA, 1979, LARYNGOSCOPE, V89, P1956; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; SWAN IRC, 1985, J ROY COLL GEN PRACT, V35, P197; UHLMANN RF, 1989, J GEN INTERN MED, V4, P90, DOI 10.1007/BF02602346; *US DEP COMM, 1997, STAT ABSTR US; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; Ventry I M, 1983, ASHA, V25, P37; VENTRY IM, 1982, EAR HEARING, V3, P128, DOI 10.1097/00003446-198205000-00006; VOEKS SK, 1993, J FAM PRACTICE, V36, P54; WEINSTEIN BE, 1982, J SPEECH HEAR RES, V25, P593, DOI 10.1044/jshr.2504.593; WEINSTEIN BE, 1986, EAR HEARING, V7, P295, DOI 10.1097/00003446-198610000-00002; Wiley T L, 2000, J Am Acad Audiol, V11, P67; Wu H. Y., 2004, SMJ Singapore Medical Journal, V45, P79; Yueh B, 2003, JAMA-J AM MED ASSOC, V289, P1976, DOI 10.1001/jama.289.15.1976	60	111	123	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					416	428		10.1001/jama.295.4.416	http://dx.doi.org/10.1001/jama.295.4.416			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005QJ	16434632				2022-12-28	WOS:000234838600022
J	Hall, W				Hall, W			Is cannabis use psychotogenic?	LANCET			English	Editorial Material							PSYCHOTIC SYMPTOMS; YOUNG-PEOPLE; SWEDISH CONSCRIPTS; ADULT PSYCHOSIS; RISK-FACTOR; SCHIZOPHRENIA; POPULATION; COHORT; ONSET		Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia	University of Queensland	Hall, W (corresponding author), Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia.		Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; Arendt M, 2005, BRIT J PSYCHIAT, V187, P510, DOI 10.1192/bjp.187.6.510; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212; Arseneault L, 2004, MARIJUANA MADNESS PS, P101; Caspi A, 2005, BIOL PSYCHIAT, V57, P1117, DOI 10.1016/j.biopsych.2005.01.026; Degenhardt L, 2003, DRUG ALCOHOL DEPEN, V71, P37, DOI 10.1016/S0376-8716(03)00064-4; DSouza DC, 2004, MARIJUANA MADNESS PS, P142; Ferdinand RF, 2005, ADDICTION, V100, P612, DOI 10.1111/j.1360-0443.2005.01070.x; Fergusson DM, 2003, PSYCHOL MED, V33, P15, DOI 10.1017/S0033291702006402; Hall W, 1998, DRUG ALCOHOL REV, V17, P433, DOI 10.1080/09595239800187271; Henquet C, 2005, BMJ-BRIT MED J, V330, P11, DOI 10.1136/bmj.38267.664086.63; HENQUET C, 2005, SCHIZOPHR B, V31, P60812; Leweke FM, 2004, CNS DRUGS, V18, P895, DOI 10.2165/00023210-200418130-00005; Macleod J, 2004, LANCET, V363, P1579, DOI 10.1016/S0140-6736(04)16200-4; Mirken B, 2005, ADDICTION, V100, P714, DOI 10.1111/j.1360-0443.2005.01117.x; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Semple DM, 2005, J PSYCHOPHARMACOL, V19, P187, DOI 10.1177/0269881105049040; Smit F, 2004, ADDICTION, V99, P425, DOI 10.1111/j.1360-0443.2004.00683.x; van Os J, 2002, AM J EPIDEMIOL, V156, P319, DOI 10.1093/aje/kwf043; Veen ND, 2004, AM J PSYCHIAT, V161, P501, DOI 10.1176/appi.ajp.161.3.501; Verdoux H, 2002, EUR PSYCHIAT, V17, p180S; Zammit S, 2002, BRIT MED J, V325, P1199, DOI 10.1136/bmj.325.7374.1199	22	42	42	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					193	195		10.1016/S0140-6736(06)68012-4	http://dx.doi.org/10.1016/S0140-6736(06)68012-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005GM	16427475				2022-12-28	WOS:000234810600008
J	McVary, KT				McVary, KT			Non-steroidal anti-inflammatory drugs and urinary retention	LANCET			English	Editorial Material							BENIGN PROSTATIC HYPERPLASIA; CLINICAL PROGRESSION; IMPACT; RISK; MEN		Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	McVary, KT (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.	k-mcvary@northwestern.edu						Araki T, 2004, ACTA MED OKAYAMA, V58, P45; Gannon K, 2004, J HEALTH PSYCHOL, V9, P411, DOI 10.1177/1359105304042350; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; Pickard R, 1998, BRIT J UROL, V81, P712; Roehrborn CG, 2005, J UROLOGY, V173, P346, DOI 10.1016/S0022-5347(18)35422-3; Thomas K, 2005, BJU INT, V95, P72, DOI 10.1111/j.1464-410X.2004.05254.x; Verhamme KMC, 2005, ARCH INTERN MED, V165, P1547, DOI 10.1001/archinte.165.13.1547	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					195	196		10.1016/S0140-6736(06)68013-6	http://dx.doi.org/10.1016/S0140-6736(06)68013-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427476				2022-12-28	WOS:000234810600009
J	Smaglik, P				Smaglik, P			For he on honeydew hath fed ... ... and drunk the milk of Paradise	NATURE			English	Editorial Material																			0	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					368	368		10.1038/439368a	http://dx.doi.org/10.1038/439368a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16468117	Bronze			2022-12-28	WOS:000234682100051
J	O'Connell, KA; Wood, JJ; Wise, RP; Lozier, JN; Braun, MM				O'Connell, KA; Wood, JJ; Wise, RP; Lozier, JN; Braun, MM			Thromboembolic adverse events after use of recombinant human coagulation factor VIIa	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED FACTOR-VII; DOSE FACTOR VIIA; DEPENDENT COAGULATION; HEMOPHILIA BLOOD; MECHANISM	Context The US Food and Drug Administration (FDA) licensed recombinant human coagulation factor VIIa (rFVIIa) on March 25, 1999, for bleeding in patients with hemophilia A or B and inhibitors to factors VIII or IX Use in patients without hemophilia has been increasing since licensure. Objective To review serious thromboembolic adverse events (AEs) reported to the FDA's Adverse Event Reporting System (AERS). Design, Setting, and Patients The AERS database was reviewed from March 25, 1999, through December 31, 2004, for thromboembolic AE reports with rFVIIa. The AERS database includes US and non-US spontaneous AE reports from both approved (specific indications for patients with hemophilia) and unlabeled uses. It also includes serious AEs in patients enrolled in postlicensure clinical trials who received rFVIIa. Manufacturer reporting to FDA is mandatory, but primary notification from clinicians and others to FDA or manufacturers is voluntary for spontaneous reports; therefore, AERS underrepresents actual event occurrences. Main Outcome Measure Reported thromboembolic events occurring in patients administered rFVIIa. Results A total of 431 AE reports for rFVIIa were found, of which 168 reports described 185 thromboembolic events. Seventeen events occurred in patients with hemophilia and 59 occurred in patients enrolled in postlicensure trials. Unlabeled indications accounted for 151 of the reports, most with active bleeding (n=115). Reported AEs were thromboembolic cerebrovascular accident (n=39), acute myocardial infarction (n=34), other arterial thromboses (n=26), pulmonary embolism (n=32), other venous thromboses (including deep vein thrombosis) (n=42), and clotted devices (n=10). In 36 (72%) of 50 reported deaths, the probable cause of death was the thromboembolic event. In 144 patients with timing information, 73 events (52%) occurred in, the first 24 hours after the last dose (30 events within 2 hours). Sixty-four reports (38%) noted concomitant use of hemostatic agents. Most reports lacked sufficient information to evaluate potential dosage associations. Conclusions Most reported thromboembolic AEs followed the use of rFVIIa for unlabeled indications and occurred in arterial and venous systems, often resulting in serious morbidity and mortality. Analysis of the relationship between AEs and rFVIIa is hindered by concomitant medications, preexisting medical conditions, confounding by indication, and inherent limitations of passive surveillance. Randomized controlled trials are needed to establish the safety and efficacy of rFVIIa in patients without hemophilia.	US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA; US FDA, Div Hematol, Off Blood Res & Review, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	O'Connell, KA (corresponding author), US FDA, Div Epidemiol HFM224, Ctr Biol Evaluat & Res, 1401 Rockville Pike, Rockville, MD 20852 USA.	oconnellk@cber.fda.gov						[Anonymous], 2005, NOVOSEVEN PACK INS; Butenas S, 2002, BLOOD, V99, P923, DOI 10.1182/blood.V99.3.923; Ghorashian S, 2004, BLOOD REV, V18, P245, DOI 10.1016/j.blre.2003.12.003; Hoffman M, 1998, BLOOD COAGUL FIBRIN, V9, pS61; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958, DOI 10.1055/s-0037-1615947; Hoffman M, 2002, BLOOD, V100, P364, DOI 10.1182/blood-2002-03-0736; Mann KG, 2002, BLOOD, V100, P365; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Monroe DM, 1997, BRIT J HAEMATOL, V99, P542, DOI 10.1046/j.1365-2141.1997.4463256.x; *US FDA, CLIN IMP ADV EV REP; Weber J.C.P., 1984, ADV INFLAMMAT RES, V6, P1; World Health Organization, 1977, INT CLASS DIS	12	493	510	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2006	295	3					293	298		10.1001/jama.295.3.293	http://dx.doi.org/10.1001/jama.295.3.293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003LU	16418464				2022-12-28	WOS:000234684500022
J	Herbig, U; Ferreira, M; Condel, L; Carey, D; Sedivy, JM				Herbig, U; Ferreira, M; Condel, L; Carey, D; Sedivy, JM			Cellular senescence in aging primates	SCIENCE			English	Article							TELOMERES		Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02903 USA; SW Fdn Biomed Res, Dept Comparat Med, San Antonio, TX 78245 USA	Brown University; Texas Biomedical Research Institute	Sedivy, JM (corresponding author), Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02903 USA.	john_sedivy@brown.edu			NATIONAL CANCER INSTITUTE [F32CA099388] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR013986, P20RR015578] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016694] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA099388] Funding Source: Medline; NCRR NIH HHS [P20 RR015578, P51 RR013986] Funding Source: Medline; NHLBI NIH HHS [P01 HL028972] Funding Source: Medline; NIA NIH HHS [R01 AG016694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baerlocher GM, 2003, J LEUKOCYTE BIOL, V73, P289, DOI 10.1189/jlb.0702361; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Cristofalo VJ, 2005, EXP GERONTOL, V40, P836, DOI 10.1016/j.exger.2005.08.005; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	6	749	779	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1257	1257		10.1126/science.1122446	http://dx.doi.org/10.1126/science.1122446			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16456035				2022-12-28	WOS:000235870400032
J	Davidson, EH; Erwin, DH				Davidson, EH; Erwin, DH			Gene regulatory networks and the evolution of animal body plans	SCIENCE			English	Review							TRANSCRIPTIONAL NETWORK; MOLECULAR CLOCK; DROSOPHILA; EXPRESSION; ULTRABITHORAX; INSIGHTS; SPECIFICATION; ENDODERM; PROTEINS; EMBRYOS	Development of the animal body plan is controlled by large gene regulatory networks (GRNs), and hence evolution of body plans must depend upon change in the architecture of developmental GRNs. However, these networks are composed of diverse components that evolve at different rates and in different ways. Because of the hierarchical organization of developmental GRNs, some kinds of change affect terminal properties of the body plan such as occur in speciation, whereas others affect major aspects of body plan morphology. A notable feature of the paleontological record of animal evolution is the establishment by the Early Cambrian of virtually all phylum-level body plans. We identify a class of GRN component, the "kernels" of the network, which, because of their developmental rote and their particular internal structure, are most impervious to change. Conservation of phyletic body plans may have been due to the retention since pre-Cambrian time of GRN kernels, which underlie development of major body parts.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20013 USA; Santa Fe Inst, Santa Fe, NM 87501 USA	California Institute of Technology; Smithsonian Institution; Smithsonian National Museum of Natural History; The Santa Fe Institute	Davidson, EH (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	davidson@caltech.edu	Erwin, Douglas H/A-9668-2009	Erwin, Douglas/0000-0003-2518-5614	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD037105] Funding Source: NIH RePORTER; NICHD NIH HHS [HD37105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Afouda BA, 2005, DEVELOPMENT, V132, P763, DOI 10.1242/dev.01647; Alberch P., 1982, EVOL DEV, P312; Arendt D, 1999, DEVELOPMENT, V126, P2309; Aris-Brosou S, 2002, SYST BIOL, V51, P703, DOI 10.1080/10635150290102375; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Avise J.C., 2000, PHYLOGEOGRAPHY HIST; Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Bolouri H, 2002, DEV BIOL, V246, P2, DOI 10.1006/dbio.2002.0617; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHEN J. Y., 2004, DAWN ANIMAL WORLD; Condon D, 2005, SCIENCE, V308, P95, DOI 10.1126/science.1107765; Cornell RA, 2000, CURR OPIN NEUROBIOL, V10, P63, DOI 10.1016/S0959-4388(99)00049-5; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; DAVIDSON EH, 2001, GENE REGULATORY SYST; Douzery EJP, 2004, P NATL ACAD SCI USA, V101, P15386, DOI 10.1073/pnas.0403984101; ERWIN DH, 1987, EVOLUTION, V41, P1177, DOI 10.1111/j.1558-5646.1987.tb02459.x; Erwin DH, 2002, DEVELOPMENT, V129, P3021; Galant R, 2002, DEVELOPMENT, V129, P3115; Hersh BM, 2005, DEVELOPMENT, V132, P1567, DOI 10.1242/dev.01737; Hinman VF, 2003, P NATL ACAD SCI USA, V100, P13356, DOI 10.1073/pnas.2235868100; Hirth F, 2003, DEVELOPMENT, V130, P2365, DOI 10.1242/dev.00438; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Inoue T, 2005, P NATL ACAD SCI USA, V102, P4972, DOI 10.1073/pnas.0408122102; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Koide T, 2005, P NATL ACAD SCI USA, V102, P4943, DOI 10.1073/pnas.0408125102; Levine M, 2005, P NATL ACAD SCI USA, V102, P4936, DOI 10.1073/pnas.0408031102; Lichtneckert R, 2005, HEREDITY, V94, P465, DOI 10.1038/sj.hdy.6800664; Longabaugh WJR, 2005, DEV BIOL, V283, P1, DOI 10.1016/j.ydbio.2005.04.023; Lowe CJ, 2003, CELL, V113, P853, DOI 10.1016/S0092-8674(03)00469-0; Maduro MF, 2002, DEV BIOL, V246, P68, DOI 10.1006/dbio.2002.0655; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Meulemans D, 2004, DEV CELL, V7, P291, DOI 10.1016/j.devcel.2004.08.007; Ochoa-Espinosa A, 2005, P NATL ACAD SCI USA, V102, P4960, DOI 10.1073/pnas.0500373102; Oliveri P, 2004, CURR OPIN GENET DEV, V14, P351, DOI 10.1016/j.gde.2004.06.004; Peterson KJ, 2004, P NATL ACAD SCI USA, V101, P6536, DOI 10.1073/pnas.0401670101; Punzo C, 2002, DEVELOPMENT, V129, P625; Reim I, 2005, DEVELOPMENT, V132, P4911, DOI 10.1242/dev.02077; Reim I, 2005, MECH DEVELOP, V122, P1056, DOI 10.1016/j.mod.2005.04.006; Rothenberg EV, 2003, INFEC DIS S, P61; SCHWENK K, 1994, ZOOL-ANAL COMPLEX SY, V98, P251; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Shivdasani RA, 2002, DEV BIOL, V249, P191, DOI 10.1006/dbio.2002.0765; Silver SJ, 2005, DEVELOPMENT, V132, P3, DOI 10.1242/dev.01539; Singh H, 2005, P NATL ACAD SCI USA, V102, P4949, DOI 10.1073/pnas.0500480102; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tokuoka M, 2004, DEV BIOL, V274, P211, DOI 10.1016/j.ydbio.2004.07.007; Tomoyasu Y, 2005, NATURE, V433, P643, DOI 10.1038/nature03272; VALENTINE JW, 2004, ORIGIN PHYLA; Wada H, 1997, DEV BIOL, V187, P240, DOI 10.1006/dbio.1997.8626; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Wellik DM, 2003, SCIENCE, V301, P363, DOI 10.1126/science.1085672; Zhu XY, 2004, CURR OPIN GENET DEV, V14, P567, DOI 10.1016/j.gde.2004.08.006	55	769	797	7	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					796	800		10.1126/science.1113832	http://dx.doi.org/10.1126/science.1113832			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469913				2022-12-28	WOS:000235374900032
J	McGrath, PT; Iniesta, AA; Ryan, KR; Shapiro, L; McAdams, HH				McGrath, PT; Iniesta, AA; Ryan, KR; Shapiro, L; McAdams, HH			A dynamically localized protease complex and a polar specificity factor control a cell cycle master regulator	CELL			English	Article							CAULOBACTER MCPA CHEMORECEPTOR; SIGNAL-TRANSDUCTION PROTEIN; BACTERIAL CHEMORECEPTOR; RESPONSE REGULATOR; ESCHERICHIA-COLI; HISTIDINE KINASE; DNA-REPLICATION; CLPXP PROTEASE; CRESCENTUS; PROTEOLYSIS	Regulated proteolysis is essential for cell cycle progression in both prokaryotes and eukaryotes. We show here that the ClpXP protease, responsible for the degradation of multiple bacterial proteins, is dynamically localized to specific cellular positions in Caulobacter where it degrades colocalized proteins. The CtrA cell cycle master regulator, that must be cleared from the Caulobacter cell to allow the initiation of chromosome replication, interacts with the ClpXP protease at the cell pole where it is degraded. We have identified a novel, conserved protein, RcdA, that forms a complex with CtrA and ClpX in the cell. RcdA is required for CtrA polar localization and degradation by ClpXP. The localization pattern of RcdA is coincident with and dependent upon ClpX localization. Thus, a dynamically localized ClpXP proteolysis complex in concert with a cytoplasmic factor provides temporal and spatial specificity to protein degradation during a bacterial cell cycle.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	Stanford University; Stanford University; University of California System; University of California Berkeley	McGrath, PT (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	shapiro@stanford.edu	Iniesta, Antonio A/G-7798-2015	Iniesta, Antonio A/0000-0002-7629-1057	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032506, R37GM032506] Funding Source: NIH RePORTER; NHGRI NIH HHS [T32 HG00044] Funding Source: Medline; NIGMS NIH HHS [GM32506] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ades SE, 2004, CURR BIOL, V14, pR924, DOI 10.1016/j.cub.2004.10.015; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Alley MRK, 2001, MOL MICROBIOL, V40, P1335, DOI 10.1046/j.1365-2958.2001.02476.x; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BlondeletRouault MH, 1997, GENE, V190, P315, DOI 10.1016/S0378-1119(97)00014-0; Chen JC, 2005, MOL MICROBIOL, V55, P1085, DOI 10.1111/j.1365-2958.2004.04443.x; Crosson S, 2004, CELL CYCLE, V3, P1252, DOI 10.4161/cc.3.10.1181; Din N, 1998, MOL MICROBIOL, V27, P1051, DOI 10.1046/j.1365-2958.1998.00752.x; Domian IJ, 1999, P NATL ACAD SCI USA, V96, P6648, DOI 10.1073/pnas.96.12.6648; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; EDWARDS P, 1991, J BACTERIOL, V173, P5568, DOI 10.1128/jb.173.17.5568-5572.1991; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Holtzendorff J, 2004, SCIENCE, V304, P983, DOI 10.1126/science.1095191; Hung DY, 2002, P NATL ACAD SCI USA, V99, P13160, DOI 10.1073/pnas.202495099; Jacobs C, 2003, MOL MICROBIOL, V47, P1279, DOI 10.1046/j.1365-2958.2003.03379.x; Jacobs C, 1999, CELL, V97, P111, DOI 10.1016/S0092-8674(00)80719-9; Jenal U, 1998, EMBO J, V17, P5658, DOI 10.1093/emboj/17.19.5658; Judd EM, 2003, P NATL ACAD SCI USA, V100, P8235, DOI 10.1073/pnas.1433105100; Kelly AJ, 1998, GENE DEV, V12, P880, DOI 10.1101/gad.12.6.880; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Laub MT, 2002, P NATL ACAD SCI USA, V99, P4632, DOI 10.1073/pnas.062065699; Martin ME, 2004, MOL MICROBIOL, V54, P60, DOI 10.1111/j.1365-2958.2004.04251.x; Matroule JY, 2004, CELL, V118, P579, DOI 10.1016/j.cell.2004.08.019; Msadek T, 1998, MOL MICROBIOL, V27, P899, DOI 10.1046/j.1365-2958.1998.00735.x; Osteras M, 1999, J BACTERIOL, V181, P3039; Potocka I, 2002, J BACTERIOL, V184, P6635, DOI 10.1128/JB.184.23.6635-6642.2002; Quon KC, 1998, P NATL ACAD SCI USA, V95, P120, DOI 10.1073/pnas.95.1.120; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; Reisenauer A, 2002, EMBO J, V21, P4969, DOI 10.1093/emboj/cdf490; Ryan KR, 2004, P NATL ACAD SCI USA, V101, P7415, DOI 10.1073/pnas.0402153101; Ryan KR, 2002, J MOL BIOL, V324, P443, DOI 10.1016/S0022-2836(02)01042-2; Skerker JM, 2004, NAT REV MICROBIOL, V2, P325, DOI 10.1038/nrmicro864; Skerker JM, 2000, EMBO J, V19, P3223, DOI 10.1093/emboj/19.13.3223; Tsai JW, 2001, J BACTERIOL, V183, P5001, DOI 10.1128/JB.183.17.5001-5007.2001; Viollier PH, 2004, CURR OPIN MICROBIOL, V7, P572, DOI 10.1016/j.mib.2004.10.005; Viollier PH, 2002, P NATL ACAD SCI USA, V99, P13831, DOI 10.1073/pnas.182411999; Weart RB, 2005, MOL MICROBIOL, V57, P238, DOI 10.1111/j.1365-2958.2005.04673.x	41	135	137	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					535	547		10.1016/j.cell.2005.12.033	http://dx.doi.org/10.1016/j.cell.2005.12.033			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469700	Bronze			2022-12-28	WOS:000235464000016
J	Armitage, M				Armitage, M			Advanced-care practitioners - friend or foe?	LANCET			English	Editorial Material									Royal Coll Physicians, London NW1 4LE, England	Royal College of Physicians	Armitage, M (corresponding author), Royal Coll Physicians, Regents Pk, London NW1 4LE, England.	mary.armitage@rcplondon.ac.uk						Cawley James F, 2003, J Health Serv Res Policy, V8, P65, DOI 10.1258/135581903321466012; *DEP HLTH, 2005, AN PRACT CURR FRAM; *DEP HLTH, 2005, COMP CURR FRAM MED C; *DEP HLTH, 2005, CURR FRAM SURG CAR P; General Medical Council, 2001, GOOD MED PRACT; *HLTH SERV MAN CTR, 2005, EV US TRAIN PHYS ASS; *ROYAL COLL PHYS, 2003, SKILLM HOSP DOCT NEW; Stewart A, 2005, CLIN MED, V5, P344, DOI 10.7861/clinmedicine.5-4-344	8	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					375	377		10.1016/S0140-6736(06)68115-4	http://dx.doi.org/10.1016/S0140-6736(06)68115-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458746				2022-12-28	WOS:000235139400007
J	Janes, SEJ; Meagher, A; Frizelle, FA				Janes, SEJ; Meagher, A; Frizelle, FA			Management of diverticulitis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HOSPITAL ADMISSIONS; ELECTIVE SURGERY; DISEASE; COLON; MULTICENTER; PERITONITIS; RESECTION; EFFICACY; RISK		Christchurch Hosp, Dept Surg, Colorectal Unit, Christchurch, New Zealand; St Vincents Hosp, Dept Colorectal Surg, Darlinghurst, NSW 2010, Australia	Christchurch Hospital New Zealand; St Vincents Hospital Sydney	Frizelle, FA (corresponding author), Christchurch Hosp, Dept Surg, Colorectal Unit, POB 4345, Christchurch, New Zealand.	frank.frizelle@chmeds.ac.nz	Meagher, Alan/ABG-4105-2021	Meagher, Alan/0000-0003-4666-9845				ALDOORI WH, 1994, AM J CLIN NUTR, V60, P757, DOI 10.1093/ajcn/60.5.757; American Gastroenterological Association, 2001, BURD GASTR DIS; ARFWIDSSON S, 1964, ACTA CHIR SCAND    S, V342, P1; BACON HE, 1960, ARCH SURG-CHICAGO, V80, P646; BENN PL, 1986, AM J SURG, V151, P269, DOI 10.1016/0002-9610(86)90085-1; BRODRIBB AJM, 1977, LANCET, V1, P664; Bruzzi JF, 2003, EUR RADIOL, V13, P2264, DOI 10.1007/s00330-003-2012-7; Di Mario F, 2005, DIGEST DIS SCI, V50, P581, DOI 10.1007/s10620-005-2478-z; Ferzoco LB, 1998, NEW ENGL J MED, V338, P1521, DOI 10.1056/NEJM199805213382107; Golder M, 2003, LANCET, V361, P1945, DOI 10.1016/S0140-6736(03)13583-0; HAGLUND U, 1979, ANN CHIR GYNAECOL FE, V68, P41; Hart AR, 2000, EUR J GASTROEN HEPAT, V12, P661, DOI 10.1097/00042737-200012060-00016; Hinchey E J, 1978, Adv Surg, V12, P85; Janes S, 2005, BRIT J SURG, V92, P133, DOI 10.1002/bjs.4873; Kang JY, 2003, ALIMENT PHARM THER, V17, P1189, DOI 10.1046/j.1365-2036.2003.01551.x; KORUTH NM, 1985, BRIT J SURG, V72, P708, DOI 10.1002/bjs.1800720911; KRUKOWSKI ZH, 1984, BRIT J SURG, V71, P921, DOI 10.1002/bjs.1800711202; KYLE J, 1975, BRIT J SURG, V62, P537, DOI 10.1002/bjs.1800620709; LEIGH JE, 1962, AM J SURG, V103, P51, DOI 10.1016/0002-9610(62)90012-0; Lorimer JW, 1997, CAN J SURG, V40, P445; Makela J, 2002, DIS COLON RECTUM, V45, P955, DOI 10.1007/s10350-004-6335-5; MARSH J, 1975, SOUTHERN MED J, V68, P133, DOI 10.1097/00007611-197502000-00003; MING SC, 1998, PATHOLOGY GASTROINTE, P801; Mizuki A, 2005, ALIMENT PHARM THER, V21, P889, DOI 10.1111/j.1365-2036.2005.02422.x; Morris CR, 2003, GUT, V52, P1734, DOI 10.1136/gut.52.12.1734; Morris CR, 2003, BRIT J SURG, V90, P1267, DOI 10.1002/bjs.4221; NYLAMO E, 1990, ANN CHIR GYNAECOL FE, V79, P139; ORNSTEIN MH, 1981, BRIT MED J, V282, P1353, DOI 10.1136/bmj.282.6273.1353; OTTE JJ, 1986, AM J GASTROENTEROL, V81, P529; PAINTER NS, 1971, BMJ-BRIT MED J, V2, P450, DOI 10.1136/bmj.2.5759.450; PAPI C, 1995, ALIMENT PHARM THERAP, V9, P33; RYAN P, 1983, DIS COLON RECTUM, V26, P12, DOI 10.1007/BF02554670; Salem L, 2004, J AM COLL SURGEONS, V199, P904, DOI 10.1016/j.jamcollsurg.2004.07.029; SARIN S, 1994, ANN ROY COLL SURG, V76, P117; Simpson J, 2003, EUR J GASTROEN HEPAT, V15, P1005, DOI 10.1097/00042737-200309000-00011; STABILE BE, 1990, AM J SURG, V159, P99, DOI 10.1016/S0002-9610(05)80613-0; Stollman N, 2004, LANCET, V363, P631, DOI 10.1016/S0140-6736(04)15597-9; TRESPI E, 1999, MINERVA GASTROENTERO, V45, P245; WHITEWAY J, 1985, GUT, V26, P258, DOI 10.1136/gut.26.3.258; Williams R, 1995, DIVERTICULAR DIS COL, V5th; Young-Fadok TM, 2000, CURR PROB SURG, V37, P462; Zeitoun G, 2000, BRIT J SURG, V87, P1366, DOI 10.1046/j.1365-2168.2000.01552.x	42	43	44	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2006	332	7536					271	275		10.1136/bmj.332.7536.271	http://dx.doi.org/10.1136/bmj.332.7536.271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455722	Green Published			2022-12-28	WOS:000235259000017
J	McPherson, S; Rees, CJ				McPherson, S; Rees, CJ			An alcoholic patient who continues to drink: case outcome	BRITISH MEDICAL JOURNAL			English	Editorial Material									S Tyneside Healthcare NHS Fdn Trust, Dept Gastroenterol, S Shields NE34 0PL, England		Rees, CJ (corresponding author), S Tyneside Healthcare NHS Fdn Trust, Dept Gastroenterol, S Shields NE34 0PL, England.	Colin.rees@sthct.nhs.uk		McPherson, Stuart/0000-0002-5638-2453				Chick J, 2000, ALCOHOL ALCOHOLISM, V35, P176, DOI 10.1093/alcalc/35.2.176; Comar KM, 2003, GASTROENTEROL CLIN N, V32, P1079, DOI 10.1016/S0889-8553(03)00099-2	2	6	6	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					276	276		10.1136/bmj.332.7536.276	http://dx.doi.org/10.1136/bmj.332.7536.276			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	011HN	16455723	Green Published			2022-12-28	WOS:000235259000018
J	Lee, JB; Hite, RK; Hamdan, SM; Xie, XS; Richardson, CC; van Oijen, AM				Lee, JB; Hite, RK; Hamdan, SM; Xie, XS; Richardson, CC; van Oijen, AM			DNA primase acts as a molecular brake in DNA replication	NATURE			English	Article							LAGGING-STRAND SYNTHESIS; GENE 4 HELICASE/PRIMASE; BACTERIOPHAGE T7; SINGLE-MOLECULE; POLYMERASE; PROTEIN; MECHANISM; BINDING; PROCESSIVITY; KINETICS	A hallmark feature of DNA replication is the coordination between the continuous polymerization of nucleotides on the leading strand and the discontinuous synthesis of DNA on the lagging strand(1). This synchronization requires a precisely timed series of enzymatic steps that control the synthesis of an RNA primer, the recycling of the lagging-strand DNA polymerase, and the production of an Okazaki fragment. Primases synthesize RNA primers at a rate that is orders of magnitude lower(2-4) than the rate of DNA synthesis by the DNA polymerases at the fork. Furthermore, the recycling of the lagging-strand DNA polymerase from a finished Okazaki fragment to a new primer is inherently slower than the rate of nucleotide polymerization(5). Different models have been put forward to explain how these slow enzymatic steps can take place at the lagging strand without losing coordination with the continuous and fast leading-strand synthesis(6-8). Nonetheless, a clear picture remains elusive. Here we use single-molecule techniques to study the kinetics of a multiprotein replication complex from bacteriophage T7 and to characterize the effect of primase activity on fork progression. We observe the synthesis of primers on the lagging strand to cause transient pausing of the highly processive leading-strand synthesis. In the presence of both leading- and lagging-strand synthesis, we observe the formation and release of a replication loop on the lagging strand. Before loop formation, the primase acts as a molecular brake and transiently halts progression of the replication fork. This observation suggests a mechanism that prevents leading- strand synthesis from outpacing lagging-strand synthesis during the slow enzymatic steps on the lagging strand.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Grad Program Biol & Biomed Sci, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University	van Oijen, AM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	antoine_van_oijen@hms.harvard.edu	van Oijen, Antoine/I-3167-2014; Lee, Jong-Bong/AAH-4669-2020	van Oijen, Antoine/0000-0002-1794-5161; Hamdan, Samir/0000-0001-5192-1852				Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418; Alberts B, 2003, NATURE, V421, P431, DOI 10.1038/nature01407; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bustamante C, 2000, CURR OPIN STRUC BIOL, V10, P279, DOI 10.1016/S0959-440X(00)00085-3; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 1999, J BIOL CHEM, V274, P35899, DOI 10.1074/jbc.274.50.35899; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102; He ZG, 2004, J BIOL CHEM, V279, P22190, DOI 10.1074/jbc.M401100200; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; KOLODNER R, 1978, J BIOL CHEM, V253, P574; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Maier B, 2000, P NATL ACAD SCI USA, V97, P12002, DOI 10.1073/pnas.97.22.12002; Mitkova AV, 2003, J BIOL CHEM, V278, P52253, DOI 10.1074/jbc.M308956200; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; Swart JR, 1995, BIOCHEMISTRY-US, V34, P16097, DOI 10.1021/bi00049a025; TABOR S, 1987, J BIOL CHEM, V262, P16212; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; Yang JS, 2005, J BIOL CHEM, V280, P25416, DOI 10.1074/jbc.M501847200	30	215	222	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					621	624		10.1038/nature04317	http://dx.doi.org/10.1038/nature04317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452983	Green Submitted, Green Published			2022-12-28	WOS:000235033900048
J	Pearse, AM; Swift, K				Pearse, AM; Swift, K			Transmission of devil facial-tumour disease - An uncanny similarity in the karyotype of these malignant tumours means that they could be infective.	NATURE			English	Editorial Material							DONOR		Dept Primary Ind Water & Environm, Kings Meadows, Tas 7249, Australia		Pearse, AM (corresponding author), Dept Primary Ind Water & Environm, POB 46, Kings Meadows, Tas 7249, Australia.	anne-maree.pearse@dpiwe.tas.gov.au						Das U, 2000, VET RES COMMUN, V24, P545, DOI 10.1023/A:1006491918910; FORBES GB, 1981, J CLIN PATHOL, V34, P109, DOI 10.1136/jcp.34.2.109; HAMEDE R, 2004, THESIS U TASMANIA HO; HAWKINS CE, UNPUB BIOL CONS; Jones ME, 2004, MOL ECOL, V13, P2197, DOI 10.1111/j.1365-294X.2004.02239.x; Kauffman HM, 2002, TRANSPLANTATION, V74, P358, DOI 10.1097/00007890-200208150-00011; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; MURRAY M, 1969, RES VET SCI, V10, P565; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	10	298	309	4	118	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2006	439	7076					549	549		10.1038/439549a	http://dx.doi.org/10.1038/439549a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452970				2022-12-28	WOS:000235033900031
J	Leavell, NR; Muggli, ME; Hurt, RD; Repace, J				Leavell, NR; Muggli, ME; Hurt, RD; Repace, J			Public health - Blowing smoke: British American Tobacco's air filtration scheme	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SECONDHAND SMOKE; BAN	As Westminster MPs prepare for a free vote on a complete smoking ban in public places, researchers question the efficacy of a technique meant to clear the air of tobacco sruoke-heavily promoted by tobacco companies as an alternative to legislation.	Mayo Clin, Nicotine Dependence Ctr, Rochester, MN 55905 USA; Mayo Clin, Nicotine Res Program, Rochester, MN 55905 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Mayo Clinic; Mayo Clinic; Tufts University	Hurt, RD (corresponding author), Mayo Clin, Nicotine Dependence Ctr, 200 1st St SW, Rochester, MN 55905 USA.	rhurt@mayo.edu		Repace, james/0000-0002-7104-900X	NCI NIH HHS [R01 CA90791] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090791] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ACT SMOK HLTH, 2004, SMOK WORKPL PUBL PLA; Barnoya J, 2002, TOB CONTROL, V11, P305, DOI 10.1136/tc.11.4.305; BARNOYA J, 2005, EUR J PUBLIC HL 0802; *BRIT AM TOB, 1995, 70097753 BRIT AM TOB; *BRIT AM TOB, 1995, 7000977347737 BRIT A; *BRIT AM TOB, 7000977307731 BRIT A; *BRIT AM TOB BAT, ETS TASK FORC M NEUC; *BRIT AM TOB CO, UKS PUBL PLAC CHART; *BRIT MED ASS, 2004, SMOK WORKPL PUBL PLA; BRYAN H, 1996, 700431643165 BRIT AM; BRYAN N, 1996, 700473166 BRIT AM TO; *DEP HLTH HUM SERV, 1986, HLTH CONS INV SMOK R; Department of Health, 1998, SMOK KILLS WHIT PAP; Department of Health, 2004, CHOOS HLTH MAK HLTH; Drope J, 2004, TOB CONTROL, V13, P41, DOI 10.1136/tc.2003.004101; Eisner MD, 1998, JAMA-J AM MED ASSOC, V280, P1909, DOI 10.1001/jama.280.22.1909; Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; GRAHAM L, 2000, 322054154944 BRIT AM; *IR OFF TOB CONTR, CURR TRENDS CIG SMOK; LINCHAN K, 1992, 2047916006013 BRIT A; McKee M, 2004, J PUBLIC HEALTH-UK, V26, P325, DOI 10.1093/pubmed/fdh187; Muggli ME, 2003, NICOTINE TOB RES, V5, P303, DOI 10.1080/1462220031000094169; QUEK D, 1996, 700596762 BRIT AM T; Repace J, 2004, J OCCUP ENVIRON MED, V46, P887, DOI 10.1097/01.jom.0000141644.69355.52; REPACE J, 2003, KILLER LOOSE ACTION; SAX NI, 1961, DANGEROUS PROPERTIES; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; SIMS D, 1997, 900030342900030343 B; TURNER A, 1996, 7004732393255 BRIT A; VASUDEVAN B, 1994, 4036643714374 BRIT A; VASUDEVAN B, 1994, 6001079247926 BRIT A; WARREN N, 1994, 4036644044427 BRIT A; WARREN N, 1994, 6001080498053 BRIT A; WARREN N, 2000, 325192311 BRIT AM TO; WARREN N, 1995, 600108255 BRIT AM TO; WARREN N, 1996, 7001224102412 BRIT A; WARREN N, 1995, 6001080938094 BRIT A; WARREN N, 1996, 800027387 BRIT AM TO; WARREN N, 700098392 BRIT AM TO; WARREN N, 1966, 800273307331 BRIT AM; WARREN N, 1994, 4036984088410 BRIT A; Woodall AA, 2005, BRIT MED J, V331, P488, DOI 10.1136/bmj.38576.467292.EB; 2000, 3250529302938 BRIT A	43	12	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2006	332	7535					227	229		10.1136/bmj.332.7535.227	http://dx.doi.org/10.1136/bmj.332.7535.227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	009BU	16439404	Green Published			2022-12-28	WOS:000235086900023
J	Pang, T; Gray, M; Evans, T				Pang, T; Gray, M; Evans, T			A 15th grand challenge for global public health	LANCET			English	Editorial Material							SYSTEMS		WHO, CH-1211 Geneva, Switzerland; Natl Hlth Serv, UK Natl Screening Comm, Oxford, England	World Health Organization; NHS Blood & Transplant (NHSBT)	Pang, T (corresponding author), WHO, CH-1211 Geneva, Switzerland.	pangt@who.int						Birn AE, 2005, LANCET, V366, P514, DOI 10.1016/S0140-6736(05)66479-3; Cohen J, 2005, SCIENCE, V309, P33; PABLOSMENDEZ A, 2005, B WORLD HEALTH ORGAN, V84, P723; Pang T, 2003, NATURE, V426, P383, DOI 10.1038/426383a; Tamburlini G, 2005, LANCET, V366, P1357, DOI 10.1016/S0140-6736(05)67563-0; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Varmus H, 2003, SCIENCE, V302, P398, DOI 10.1126/science.1091769; World Health Organization, 2004, WORLD REP KNOWL BETT	8	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					284	286		10.1016/S0140-6736(06)68050-1	http://dx.doi.org/10.1016/S0140-6736(06)68050-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443025				2022-12-28	WOS:000235084600009
J	Ramasamy, R; Yan, SF; Schmidt, AM				Ramasamy, R; Yan, SF; Schmidt, AM			Methylglyoxal comes of AGE	CELL			English	Editorial Material							GLYCATION END-PRODUCTS; GLYOXALASE-I; OVEREXPRESSION	The posttranslational modification of proteins by methylglyoxal, a highly reactive compound derived from glycolysis, may contribute to aging, diabetes, and other disorders. In this issue of Cell, Brownlee and colleagues (Yao et al., 2006) demonstrate a specific mechanism by which methylglyoxal modifies a transcriptional corepressor to enhance gene expression.	Columbia Univ, Med Ctr, Dept Surg, New York, NY 10032 USA	Columbia University	Schmidt, AM (corresponding author), Columbia Univ, Med Ctr, Dept Surg, New York, NY 10032 USA.	ams11@columbia.edu		Ramasamy, Ravichandran/0000-0002-3666-3346				Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Poggioli S, 2002, EXP GERONTOL, V37, P1207, DOI 10.1016/S0531-5565(02)00145-6; Price CL, 2004, DIABETES, V53, P1452, DOI 10.2337/diabetes.53.6.1452; Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053; Sakamoto H, 2002, J BIOL CHEM, V277, P45770, DOI 10.1074/jbc.M207485200; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Thornalley PJ, 1996, BIOCHEM PHARMACOL, V51, P1365, DOI 10.1016/0006-2952(96)00059-7; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1372, DOI 10.1042/BST0311372; YAO D, 2006, CELL	10	116	121	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					258	260		10.1016/j.cell.2006.01.002	http://dx.doi.org/10.1016/j.cell.2006.01.002			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439200	Bronze			2022-12-28	WOS:000235068500013
J	Iversen, A; Liddell, K; Fear, N; Hotopf, M; Wessely, S				Iversen, A; Liddell, K; Fear, N; Hotopf, M; Wessely, S			Epidemiology - Consent, confidentiality, and the Data Protection Act	BRITISH MEDICAL JOURNAL			English	Editorial Material							GULF-WAR VETERANS; MENTAL-HEALTH; FOLLOW-UP; COHORT		Kings Coll London, Inst Psychiat, Kings Ctr Mil Hlth Res, London WC2R 2LS, England; Univ Cambridge, Fac Law, Cambridge, England; Kings Coll London, Acad Ctr Def Mental Hlth, London WC2R 2LS, England	University of London; King's College London; University of Cambridge; University of London; King's College London	Iversen, A (corresponding author), Weston Educ Ctr, Dept Psychol Med, London SE5 9RJ, England.	A.lversen@iop.kcl.ac.uk	Wessely, Simon C/A-8713-2008; Iversen, Amy/D-1112-2011; Fear, Nicola/A-1917-2012; Hotopf, Matthew/E-4971-2010	Fear, Nicola/0000-0002-5792-2925; Hotopf, Matthew/0000-0002-3980-4466; Wessely, Simon Charles/0000-0002-6743-9929				Coleman MP, 2003, CLIN MED, V3, P219, DOI 10.7861/clinmedicine.3-3-219; Eaker S, 1998, AM J EPIDEMIOL, V147, P74; Hotopf M, 2003, BRIT MED J, V327, P1370, DOI 10.1136/bmj.327.7428.1370; Hotopf M, 2003, PSYCHOL MED, V33, P155, DOI 10.1017/S0033291702006840; Ismail K, 2002, BMJ-BRIT MED J, V325, P576, DOI 10.1136/bmj.325.7364.576; Iversen A, 2005, BRIT J PSYCHIAT, V186, P480, DOI 10.1192/bjp.186.6.480; Jousilahti P, 2005, J EPIDEMIOL COMMUN H, V59, P310, DOI 10.1136/jech.2004.024349; Macfarlane GJ, 2003, BRIT MED J, V327, P1373, DOI 10.1136/bmj.327.7428.1373; Muir-Gray J.A., 1999, LANCET, V354, P1550; Prince M., 2003, PRACTICAL PSYCHIAT E; Strobl J, 2000, BMJ-BRIT MED J, V321, P890, DOI 10.1136/bmj.321.7265.890; Tyrer P, 2003, J MED ETHICS, V29, P238, DOI 10.1136/jme.29.4.238; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; WOOD AM, IN PRESS J R STAT SO	14	62	62	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					165	169		10.1136/bmj.332.7534.165	http://dx.doi.org/10.1136/bmj.332.7534.165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424496	Green Published			2022-12-28	WOS:000234905800028
J	Jeffery, CS; Tout, CA; Lattanzio, JC				Jeffery, CS; Tout, CA; Lattanzio, JC			Nucleosynthesis in binary stars	SCIENCE			English	Editorial Material									Armagh Observ, Armagh BT6 9DG, North Ireland; Univ Cambridge, Inst Astron, Cambridge CB2 1TN, England; Monash Univ, Sch Math Sci, Ctr Stellar & Planetary Astrophys, Clayton, Vic 3800, Australia	University of Cambridge; Monash University	Jeffery, CS (corresponding author), Armagh Observ, Coll Hill, Armagh BT6 9DG, North Ireland.	john.lattanzio@sci.monash.edu.au	Tout, Christopher/AAE-6975-2021; Jeffery, Simon/AAD-6318-2021	Jeffery, Simon/0000-0003-1759-0302; Tout, Christopher/0000-0002-1556-9449; Lattanzio, John/0000-0003-2952-859X				DEARBORN DS, IN PRESS ASTROPHYS J; IZZARD R, 2004, THESIS CAMBRIDGE U; *LOR CTR, 2005, LOR WORKSH NUCL BIN; Lucatello S, 2005, ASTROPHYS J, V625, P825, DOI 10.1086/428104; Lugaro M, 2003, ASTROPHYS J, V593, P486, DOI 10.1086/376442; Tout CA, 1999, IAU SYMP, P447	6	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2006	311	5759					345	346		10.1126/science.1115848	http://dx.doi.org/10.1126/science.1115848			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424330				2022-12-28	WOS:000234938500033
J	Salzman, C; Delbanco				Salzman, C; Delbanco			A 60-year-old woman who has felt sad for much of her life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Combined Longwood Psychiatry Grand Rounds	JAN 04, 2005	Beth Israel Deaconess Med Ctr, Boston, MA		Beth Israel Deaconess Med Ctr		TREATMENT-RESISTANT DEPRESSION; ANTIDEPRESSANT RESPONSE; MEDICAL COMORBIDITY; MAJOR DEPRESSION; MANAGEMENT; DISEASE; ILLNESS; ASSOCIATION; NONRESPONSE; FLUOXETINE		Massachusetts Mental Hlth Ctr, Dept Psychiat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard Medical School	Salzman, C (corresponding author), Massachusetts Mental Hlth Ctr, Dept Psychiat, 25 Shattuck St, Boston, MA 02115 USA.	carl-salzman@hms.harvard.edu						Alexapoulos GS, 2005, LANCET, V365, P1961, DOI 10.1016/S0140-6736(05)66665-2; Alexopoulos GS, 2003, J AM GERIATR SOC, V51, P1178, DOI 10.1046/j.1532-5415.2003.51373.x; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, V4th; Baldwin RC, 1997, J AFFECT DISORDERS, V46, P163, DOI 10.1016/S0165-0327(97)00143-2; Bauer M, 2003, CAN J PSYCHIAT, V48, P440, DOI 10.1177/070674370304800703; Bosworth HB, 2002, AM J GERIAT PSYCHIAT, V10, P551, DOI 10.1176/appi.ajgp.10.5.551; BROWN WA, 1992, PSYCHOPHARMACOL BULL, V28, P253; Castaneda R, 1996, J CLIN PSYCHIAT, V57, P207; Corey-Lisle PK, 2004, ARCH INTERN MED, V164, P1197, DOI 10.1001/archinte.164.11.1197; Evans M, 1997, INT J GERIATR PSYCH, V12, P817, DOI 10.1002/(SICI)1099-1166(199708)12:8<817::AID-GPS645>3.0.CO;2-4; Fagiolini A, 2003, BIOL PSYCHIAT, V53, P640, DOI 10.1016/S0006-3223(02)01670-0; Fava M, 2003, BIOL PSYCHIAT, V53, P649, DOI 10.1016/S0006-3223(03)00231-2; Fava M, 2003, J CLIN PSYCHIAT, V64, P24; Fava M, 2000, J CLIN PSYCHIAT, V61, P10; FIGIEL GS, 1991, NEUROBIOL AGING, V12, P245, DOI 10.1016/0197-4580(91)90104-R; FINK M, 1991, ADV NEUROPSYCHIATRY, V2, P87; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fujikawa T, 1996, STROKE, V27, P2040, DOI 10.1161/01.STR.27.11.2040; Goodnick P J, 2001, Ann Clin Psychiatry, V13, P31, DOI 10.3109/10401230109147127; Greden John F., 2001, Journal of Clinical Psychiatry, V62, P26; Hirschfeld RMA, 1998, J CLIN PSYCHIAT, V59, P669, DOI 10.4088/JCP.v59n1205; Iosifescu DV, 2004, PSYCHOSOMATICS, V45, P419, DOI 10.1176/appi.psy.45.5.419; Iosifescu DV, 2003, AM J PSYCHIAT, V160, P2122, DOI 10.1176/appi.ajp.160.12.2122; Joffe RT, 1996, J CLIN PSYCHIAT, V57, P114; KATZIR G, 2005, CLIN GERIATRIC PSYCH, P212; KEITNER GI, 1991, AM J PSYCHIAT, V148, P345; Kornstein SG, 2001, J CLIN PSYCHIAT, V62, P11; Lesperance F, 2000, J PSYCHOSOM RES, V48, P379, DOI 10.1016/S0022-3999(99)00102-6; Manning JS, 2003, J CLIN PSYCHIAT, V64, P24; Miller MD, 2002, AM J GERIAT PSYCHIAT, V10, P592, DOI 10.1176/appi.ajgp.10.5.592; Musselman DL, 2003, BIOL PSYCHIAT, V54, P317, DOI 10.1016/S0006-3223(03)00569-9; Nelson JC, 2003, J CLIN PSYCHIAT, V64, P5; Newman JR, 2000, J AFFECT DISORDERS, V57, P241, DOI 10.1016/S0165-0327(99)00046-4; Oslin DW, 2002, J AM GERIATR SOC, V50, P823, DOI 10.1046/j.1532-5415.2002.50206.x; Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714; Papakostas GI, 2003, PSYCHIAT RES, V118, P183, DOI 10.1016/S0165-1781(03)00067-2; Papakostas GI, 2003, PSYCHIAT RES, V118, P39, DOI 10.1016/S0165-1781(03)00063-5; Robinson RG, 2003, BIOL PSYCHIAT, V54, P376, DOI 10.1016/S0006-3223(03)00423-2; Roose SP, 1998, AM J PSYCHIAT, V155, P660, DOI 10.1176/ajp.155.5.660; ROTHSCHILD AJ, 1993, J CLIN PSYCHIAT, V54, P338; Rothschild AJ, 2003, BIOL PSYCHIAT, V53, P680, DOI 10.1016/S0006-3223(02)01747-X; Rothschild AJ, 2003, J CLIN PSYCHIAT, V64, P390, DOI 10.4088/JCP.v64n0405; SALZMAN C, 1990, COMBINATION PSYCHIAT, P152; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; Small GW, 1996, J AM GERIATR SOC, V44, P1220, DOI 10.1111/j.1532-5415.1996.tb01373.x; SPIKER DG, 1985, AM J PSYCHIAT, V142, P430; Thase ME, 1996, PSYCHIAT CLIN N AM, V19, P287, DOI 10.1016/S0193-953X(05)70289-6; Van Praag HM, 2002, NEUROTOX RES, V4, P531, DOI 10.1080/1029842021000022115; Wei WH, 2005, AM J PSYCHIAT, V162, P711, DOI 10.1176/appi.ajp.162.4.711; Worthington J, 1996, PSYCHOSOMATICS, V37, P518, DOI 10.1016/S0033-3182(96)71515-3; Yu YWY, 2002, MOL PSYCHIATR, V7, P1115, DOI 10.1038/sj.mp.4001141; Zajecka JM, 2003, J CLIN PSYCHIAT, V64, P7	52	4	4	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2006	295	3					318	323		10.1001/jama.295.3.318	http://dx.doi.org/10.1001/jama.295.3.318			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	003LU	16418468				2022-12-28	WOS:000234684500026
J	Barondess, JA				Barondess, JA			On the preservation of health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARDIOVASCULAR-DISEASE; HEART-DISEASE; UNITED-STATES; DEATH; LIFE; MORTALITY; GROWTH		New York Acad Med, New York, NY 10029 USA	New York Academy of Medicine	Barondess, JA (corresponding author), New York Acad Med, 1216 5th Ave, New York, NY 10029 USA.	jbarondess@nyam.org						Berenson GS, 2002, AM J CARDIOL, V90, p3L, DOI 10.1016/S0002-9149(02)02953-3; Brent DA, 2002, NEW ENGL J MED, V347, P667, DOI 10.1056/NEJMcp012249; *CDC WOND, DAT 2010 HLTH PEOPL; *CDCP, 2005, MMWR-MORBID MORTAL W, V54, P826; *CDCP, 2004, NAT DIAB FACT SHEET; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; Day INM, 2004, J CLIN ENDOCR METAB, V89, P5569, DOI 10.1210/jc.2004-0152; ENOS WF, 1955, JAMA-J AM MED ASSOC, V158, P912, DOI 10.1001/jama.1955.02960110018005; Forsen TJ, 2004, ANN MED, V36, P389, DOI 10.1080/07853890410028438; Fraser GE, 2001, ARCH INTERN MED, V161, P1645, DOI 10.1001/archinte.161.13.1645; Fried Linda., 2005, HDB URBAN HLTH POPUL; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Gaziano JM, 1998, NEW ENGL J MED, V338, P1690, DOI 10.1056/NEJM199806043382310; Gregg EW, 2003, JAMA-J AM MED ASSOC, V289, P2379, DOI 10.1001/jama.289.18.2379; JUDSON JJ, 1971, J AMER MED ASSOC, V216, P1185; Kajantie E, 2005, INT J EPIDEMIOL, V34, P655, DOI 10.1093/ije/dyi048; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; National Center for Health Statistics, 2004, HLTH US 2004; National Institute on Drug Abuse, 2003, DRUG US RAC ETHN MIN; Pamuk ER, 2004, AM J PUBLIC HEALTH, V94, P378, DOI 10.2105/AJPH.94.3.378; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; Singhal A, 2004, LANCET, V363, P1642, DOI 10.1016/S0140-6736(04)16210-7; STRONG JP, 1969, J ATHEROSCLER RES, V9, P251, DOI 10.1016/S0368-1319(69)80020-7; *US CANC STAT WORK, 2004, US CANC STAT 2001 IN; *US DEP HHS, 2000, HLTH PEOPL 2010 IMPR	26	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					3024	3026		10.1001/jama.294.23.3024	http://dx.doi.org/10.1001/jama.294.23.3024			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414951				2022-12-28	WOS:000234087700030
J	Carnethon, MR; Gulati, M; Greenland, P				Carnethon, MR; Gulati, M; Greenland, P			Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-FITNESS; EXERCISE CAPACITY; RISK-FACTORS; AEROBIC EXERCISE; CANCER-MORTALITY; UNITED-STATES; MEN; HEALTHY; AGE	Context Population surveys indicate that physical activity levels are low in the United States. One consequence of inactivity, low cardiorespiratory fitness, is an established risk factor for cardiovascular disease (CVD) morbidity and mortality, but the prevalence of cardiorespiratory fitness has not been quantified in representative US population samples. Objectives To describe the prevalence of low fitness in the US population aged 12 through 49 years and to relate low fitness to CVD risk factors in this population. Design, Setting, and Participants Inception cohort study using data from the cross-sectional nationally representative National Health and Nutrition Examination Survey 1999-2002. Participants were adolescents (aged 12-19 years; n=3110) and adults (aged 20-49 years; n=2205) free from previously diagnosed CVD who underwent submaximal graded exercise treadmill testing to achieve at least 75% to 90% of their age-predicted maximum heart rate. Maximal oxygen consumption ((V) over dot o(2)max) was estimated by measuring the heart rate response to reference levels of submaximal work. Main Outcome Measures Low fitness defined using percentile cut points of estimated ((V) over dot(2)max from existing external referent populations; anthropometric and other CVD risk factors measured according to standard methods. Results Low fitness was identified in 33.6% of adolescents (approximately 7.5 million US adolescents) and 13.9% of adults (approximately 8.5 million US adults); the prevalence was similar in adolescent females (34.4%) and males (32.9%) (P=.40) but was higher in adult females (16.2%) than in males (11.8%) (P=.03). Non-Hispanic blacks and Mexican Americans were less fit than non-Hispanic whites. In all age-sex groups, body mass index and waist circumference were inversely associated with fitness-, age- and race-adjusted odds ratios of overweight or obesity (body mass index >= 25) ranged from 2.1 to 3.7 (P<.01 for all), comparing persons with low fitness with those with moderate or high fitness. Total cholesterol levels and systolic blood pressure were higher and levels of high-density lipoprotein cholesterol were lower among participants with low vs high fitness. Conclusion Low fitness in adolescents and adults is common in the US population and is associated with an increased prevalence of CVD risk factors.	Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Cardiol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Carnethon, MR (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.	carnethon@northwestern.edu	Gulati, Martha/AAB-7722-2022; Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL073249] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc10-S062, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062]; American College of Sports Medicine, 2000, ACSMS GUID EX TEST P; [Anonymous], 1995, DIABETES, V44, P968; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Carnethon MR, 2003, JAMA-J AM MED ASSOC, V290, P3092, DOI 10.1001/jama.290.23.3092; Caspersen CJ, 2000, MED SCI SPORT EXER, V32, P1601; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P764; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cook S, 2003, ARCH PEDIAT ADOL MED, V157, P821, DOI 10.1001/archpedi.157.8.821; CURETON KJ, 1990, RES Q EXERCISE SPORT, V61, P7, DOI 10.1080/02701367.1990.10607473; Diabetes Prevention Program Research Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; Duncan GE, 2005, MED SCI SPORT EXER, V37, P1324, DOI 10.1249/01.mss.0000174893.74326.11; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Evenson KR, 2003, MED SCI SPORT EXER, V35, P270, DOI 10.1249/01.MSS.0000053511.02356.72; Ferreira I, 2002, EUR J CLIN INVEST, V32, P723, DOI 10.1046/j.1365-2362.2002.01066.x; FLUCKIGER R, 1984, DIABETES, V33, P73, DOI 10.2337/diabetes.33.1.73; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GOULD BJ, 1984, ANN CLIN BIOCHEM, V21, P16, DOI 10.1177/000456328402100103; Gulati M, 2003, CIRCULATION, V108, P1554, DOI 10.1161/01.CIR.0000091080.57509.E9; Gulati M, 2005, NEW ENGL J MED, V353, P468, DOI 10.1056/NEJMoa044154; Gustat J, 2002, J CLIN EPIDEMIOL, V55, P997, DOI 10.1016/S0895-4356(02)00427-4; *I AER RES, 1994, FITNESSGRAM TEST ADM; JACKSON AS, 1990, MED SCI SPORT EXER, V22, P863, DOI 10.1249/00005768-199012000-00021; Laaksonen DE, 2000, MED SCI SPORT EXER, V32, P1541, DOI 10.1097/00005768-200009000-00003; Laaksonen DE, 2002, DIABETES CARE, V25, P1612, DOI 10.2337/diacare.25.9.1612; Lee CD, 2002, MED SCI SPORT EXER, V34, P735; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; MORRIS CK, 1993, J AM COLL CARDIOL, V22, P175, DOI 10.1016/0735-1097(93)90832-L; *NAT CTR HLTH STAT, 2004, NHANES 1999 2000 DAT; *NAT CTR HLTH STAT, 2004, NHANES CARD FITN PRO; *NAT CTR HLTH STAT, 2004, AN GUID; OLSHANSKY SJ, 2000, NEW ENGL J MED, V352, P1138; Raitakari OT, 1997, MED SCI SPORT EXER, V29, P1055, DOI 10.1097/00005768-199708000-00011; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; Tanaka H, 2001, J AM COLL CARDIOL, V37, P153, DOI 10.1016/S0735-1097(00)01054-8; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Wei M, 1999, JAMA-J AM MED ASSOC, V282, P1547, DOI 10.1001/jama.282.16.1547; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	43	263	273	1	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					2981	2988		10.1001/jama.294.23.2981	http://dx.doi.org/10.1001/jama.294.23.2981			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414945	Bronze			2022-12-28	WOS:000234087700024
J	Stover, J; Bertozzi, S; Gutierrez, JP; Walker, N; Stanecki, KA; Greener, R; Gouws, E; Hankins, C; Garnett, GP; Salomon, JA; Boerma, JT; De Lay, P; Ghys, PD				Stover, J; Bertozzi, S; Gutierrez, JP; Walker, N; Stanecki, KA; Greener, R; Gouws, E; Hankins, C; Garnett, GP; Salomon, JA; Boerma, JT; De Lay, P; Ghys, PD			The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries	SCIENCE			English	Article							HIV PREVENTION; AIDS		Joint UN Programme HIV AIDS UNAIDS, CH-1211 Geneva, Switzerland; Futures Grp Constella, Glastonbury, CT 06033 USA; Natl Inst Publ Hlth, Cuernavaca 62508, Morelos, Mexico; Ctr Invest & Docencia Econ, Mexico City 01210, DF, Mexico; UN Childrens Fund UNICEF, New York, NY 10017 USA; Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; Harvard Univ, Cambridge, MA 02138 USA; WHO, CH-1211 Geneva 27, Switzerland	UNAIDS; Instituto Nacional de Salud Publica; Centro de Investigacion y Docencia Economicas A.C. (CIDE); UNICEF; Imperial College London; Harvard University; World Health Organization	Ghys, PD (corresponding author), Joint UN Programme HIV AIDS UNAIDS, CH-1211 Geneva, Switzerland.	ghysp@unaids.org	Gutierrez, Juan Pablo/A-4253-2010; Salomon, Joshua A/D-3898-2009; Salomon, Joshua/S-1929-2019; Garnett, Geoffrey P/A-9312-2008	Gutierrez, Juan Pablo/0000-0002-0557-5562; Salomon, Joshua A/0000-0003-3929-5515; Salomon, Joshua/0000-0003-3929-5515; Bertozzi, Stefano M/0000-0002-1723-7085; Hankins, Catherine/0000-0002-1642-8592				Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; BERTOZZI S, IN PRESS DIS CONTROL; Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Pisani E, 2003, BRIT MED J, V326, P1384, DOI 10.1136/bmj.326.7403.1384; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Stover J, 2002, LANCET, V360, P73, DOI 10.1016/S0140-6736(02)09339-X; Stover J, 2003, ADDING FAMILY PLANNI; *UNAIDS, 2005, RES NEEDS EXP RESP A; *USAID, 2004, COV SEL SERV HIV AID	11	82	88	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 10	2006	311	5766					1474	1476		10.1126/science.1121176	http://dx.doi.org/10.1126/science.1121176			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16456039				2022-12-28	WOS:000236029400053
J	Illes, J; Kirschen, MP; Edwards, E; Stanford, LR; Bandettini, P; Cho, MK; Ford, PJ; Glover, GH; Kulynych, J; Macklin, R; Michael, DB; Wolf, SM				Illes, J; Kirschen, MP; Edwards, E; Stanford, LR; Bandettini, P; Cho, MK; Ford, PJ; Glover, GH; Kulynych, J; Macklin, R; Michael, DB; Wolf, SM		Working Grp Incidental Findings	Ethics - Incidental findings in brain imaging research	SCIENCE			English	Editorial Material									Stanford Univ, Ctr Biomed Eth, Palo Alto, CA 94304 USA; Stanford Univ, Dept Radiol, Palo Alto, CA 94304 USA; Stanford Univ, Program Neurosci, Palo Alto, CA 94304 USA; Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA; Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA; Natl Inst Drug Abuse, NIH, Bethesda, MD 20892 USA; NIMH, NIH, Bethesda, MD 20892 USA; Cleveland Clin Fdn, Dept Bioeth, Cleveland, OH 44195 USA; Johns Hopkins Hosp & Hlth Syst, Legal Dept, Washington, DC 20005 USA; Albert Einstein Coll Med, Dept Bioeth, Bronx, NY 10461 USA; Michigan Head & Spine Inst, Southfield, MI 48075 USA; Univ Minnesota, Sch Law, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA	Stanford University; Stanford University; Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Cleveland Clinic Foundation; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Illes, J (corresponding author), Stanford Univ, Ctr Biomed Eth, Palo Alto, CA 94304 USA.	illes@stanford.edu	Kam, Grace/F-5364-2012; Bandettini, Peter A./F-5871-2012		NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG003389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045831] Funding Source: NIH RePORTER; NHGRI NIH HHS [P50 HG003389-02, P50 HG003389-01, P50 HG003389] Funding Source: Medline; NINDS NIH HHS [R01 NS045831] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*CENTR BRAIN TUM R, 1997, PRIM BRAIN TUM US 19; CLAYTON EW, 1997, GENETIC SECRETS PROT, P126; Illes J, 2004, J MAGN RESON IMAGING, V20, P743, DOI 10.1002/jmri.20180; Illes J, 2004, NEUROLOGY, V62, P888, DOI 10.1212/01.WNL.0000118531.90418.89; Illes J, 2002, BRAIN COGNITION, V50, P358, DOI 10.1016/S0278-2626(02)00532-8; Katzman GL, 1999, JAMA-J AM MED ASSOC, V282, P36, DOI 10.1001/jama.282.1.36; Kim BS, 2002, AM J NEURORADIOL, V23, P1674; Kirschen MP, 2006, J MAGN RESON IMAGING, V23, P205, DOI 10.1002/jmri.20499; QUAID KA, 1993, AM J CARDIOL, V72, pD64, DOI 10.1016/0002-9149(93)90013-3; Shalowitz DI, 2005, JAMA-J AM MED ASSOC, V294, P737, DOI 10.1001/jama.294.6.737; Weber F, 2006, J NEUROL SCI, V240, P81, DOI 10.1016/j.jns.2005.09.008	11	184	186	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					783	784		10.1126/science.1124665	http://dx.doi.org/10.1126/science.1124665			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469905	Green Accepted			2022-12-28	WOS:000235374900025
J	Nel, A; Xia, T; Madler, L; Li, N				Nel, A; Xia, T; Madler, L; Li, N			Toxic potential of materials at the nanolevel	SCIENCE			English	Review							INDUCE OXIDATIVE STRESS; WALL CARBON NANOTUBES; PULMONARY TOXICITY; INHALED ULTRAFINE; AIR-POLLUTION; PARTICLES; EXPOSURE; NANOTOXICOLOGY; TRANSLOCATION; NANOPARTICLES	Nanomaterials are engineered structures with at least one dimension of 100 nanometers or less. These materials are increasingly being used for commercial purposes such as filters, opacifiers, catalysts, semiconductors, cosmetics, microelectronics, and drug carriers. Materials in this size range may approach the length scale at which some specific physical or chemical interactions with their environment can occur. As a result, their properties differ substantially from those bulk materials of the same composition, allowing them to perform exceptional feats of conductivity, reactivity, and optical sensitivity. Possible undesirable results of these capabilities are harmful interactions with biological systems and the environment, with the potential to generate toxicity. The establishment of principles and test procedures to ensure safe manufacture and use of nanomaterials in the marketplace is urgently required and achievable.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Calif NANOSyst Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Nel, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.	anel@mednet.ucla.edu	Xiao, Jian/GYU-4351-2022; xia, tian/C-3158-2013; Mädler, Lutz/N-3068-2019; Nel, Andre E/J-2808-2012; Mädler, Lutz/F-2982-2013	xia, tian/0000-0003-0123-1305; Mädler, Lutz/0000-0002-7073-0733; Mädler, Lutz/0000-0002-7073-0733	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010553, R01ES013432, R01ES012053] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI50495] Funding Source: Medline; NIEHS NIH HHS [R01 ES013432, R01 ES12053, R0-1 ES10553] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beckett WS, 2005, AM J RESP CRIT CARE, V171, P1129, DOI 10.1164/rccm.200406-837OC; Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brown JS, 2002, AM J RESP CRIT CARE, V166, P1240, DOI 10.1164/rccm.200205-399OC; Chen BX, 1998, P NATL ACAD SCI USA, V95, P10809, DOI 10.1073/pnas.95.18.10809; Chen HHC, 1998, TOXICOL PATHOL, V26, P143, DOI 10.1177/019262339802600117; Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875; Donaldson K, 2004, OCCUP ENVIRON MED, V61, P727, DOI 10.1136/oem.2004.013243; Donaldson K, 2002, INHAL TOXICOL, V14, P5, DOI 10.1080/089583701753338613; Donaldson K, 2001, OCCUP ENVIRON MED, V58, P211, DOI 10.1136/oem.58.3.211; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Geller MD, 2002, AEROSOL SCI TECH, V36, P748, DOI 10.1080/02786820290038447; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649; Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Monteiro-Riviere NA, 2005, TOXICOL LETT, V155, P377, DOI 10.1016/j.toxlet.2004.11.004; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Oberdorster C, 2005, PART FIBRE TOXICOL, V2, DOI 10.1186/1743-8977-2-8; Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597; Patton JS, 1996, ADV DRUG DELIVER REV, V19, P3, DOI 10.1016/0169-409X(95)00113-L; Raynal I, 2004, INVEST RADIOL, V39, P56, DOI 10.1097/01.rli.0000101027.57021.28; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Service RF, 2004, SCIENCE, V304, P1732, DOI 10.1126/science.304.5678.1732; Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/713853956; SHVEDOVA AA, 2005, AM J PHYSIOL, V289, P1698; Somasundaran P, 2004, J COSMET SCI, V55, pS1; The Royal Society, 2004, NAN NAN OPP UNC; Tinkle SS, 2003, ENVIRON HEALTH PERSP, V111, P1202, DOI 10.1289/ehp.5999; Vertegel AA, 2004, LANGMUIR, V20, P6800, DOI 10.1021/la0497200; Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; YAMAGO S, 1995, CHEM BIOL, V2, P385, DOI 10.1016/1074-5521(95)90219-8	39	6588	6992	80	3444	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					622	627		10.1126/science.1114397	http://dx.doi.org/10.1126/science.1114397			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456071				2022-12-28	WOS:000235257400036
J	Haiman, CA; Stram, DO; Wilkens, LR; Pike, MC; Kolonel, LN; Henderson, BE; Le Marchand, L				Haiman, CA; Stram, DO; Wilkens, LR; Pike, MC; Kolonel, LN; Henderson, BE; Le Marchand, L			Ethnic and racial differences in the smoking-related risk of lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM COTININE LEVELS; CIGARETTE-SMOKING; JAPANESE MEN; SMOKERS; WHITE; WOMEN; CARCINOMA; AMERICANS; NUTRITION; HAWAII	BACKGROUND There is remarkable variation in the incidence of lung cancer among ethnic and racial groups in the United States. METHODS We investigated differences in the risk of lung cancer associated with cigarette smoking among 183,813 African-American, Japanese-American, Latino, Native Hawaiian, and white men and women in the Multiethnic Cohort Study. Our analysis included 1979 cases of incident lung cancer identified prospectively over an eight-year period, between baseline (1993 through 1996) and 2001. RESULTS The risk of lung cancer among ethnic and racial groups was modified by the number of cigarettes smoked per day. Among participants who smoked no more than 30 cigarettes per day, African Americans and Native Hawaiians had significantly greater risks of lung cancer than did the other groups. Among those who smoked no more than 10 and those who smoked 11 to 20 cigarettes per day, relative risks ranged from 0.21 to 0.39 (P<0.001) among Japanese Americans and Latinos and from 0.45 to 0.57 (P<0.001) among whites, as compared with African Americans. However, at levels exceeding 30 cigarettes per day, these differences were not significant. Differences in risk associated with smoking were observed among both men and women and for all histologic types of lung cancer. CONCLUSIONS Among cigarette smokers, African Americans and Native Hawaiians are more susceptible to lung cancer than whites, Japanese Americans, and Latinos.	Univ So Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA; Univ Hawaii, Canc Res Ctr Hawaii, Canc Epidemiol Program, Honolulu, HI 96813 USA	University of Southern California; Cancer Research Center of Hawaii; University of Hawaii System	Haiman, CA (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, 1441 Eastlake Ave,Rm 4441, Los Angeles, CA 90089 USA.	haiman@usc.edu			NCI NIH HHS [CA 54281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA054281, R01CA054281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; Carpenter CL, 1999, ANN EPIDEMIOL, V9, P114, DOI 10.1016/S1047-2797(98)00042-8; Clark PI, 1996, ANN EPIDEMIOL, V6, P483, DOI 10.1016/S1047-2797(96)00049-X; Department of Health and Human Services PHS, 1998, TOB US US RAC ETHN M; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; Gadgeel SM, 2001, CHEST, V120, P55, DOI 10.1378/chest.120.1.55; HARRIS RE, 1993, INT J EPIDEMIOL, V22, P592, DOI 10.1093/ije/22.4.592; HINDS MW, 1981, INT J CANCER, V27, P297, DOI 10.1002/ijc.2910270307; HUMBLE CG, 1985, AM J PUBLIC HEALTH, V75, P145, DOI 10.2105/AJPH.75.2.145; Kolonel L, 1979, Natl Cancer Inst Monogr, P81; Kolonel LN, 2000, AM J EPIDEMIOL, V151, P346, DOI 10.1093/oxfordjournals.aje.a010213; LEMARCHAND L, 1992, CANCER EPIDEM BIOMAR, V1, P103; Menck H R, 1982, Natl Cancer Inst Monogr, V62, P101; Perez-Stable EJ, 1998, JAMA-J AM MED ASSOC, V280, P152, DOI 10.1001/jama.280.2.152; Richiardi L, 2004, CANCER CAUSE CONTROL, V15, P285, DOI 10.1023/B:CACO.0000024223.91059.ed; Schwartz AG, 1997, CANCER, V79, P45, DOI 10.1002/(SICI)1097-0142(19970101)79:1<45::AID-CNCR7>3.0.CO;2-L; Smith-Warner SA, 2003, INT J CANCER, V107, P1001, DOI 10.1002/ijc.11490; Sobue T, 2002, INT J CANCER, V99, P245, DOI 10.1002/ijc.10308; Stellman SD, 2003, ANN EPIDEMIOL, V13, P294, DOI 10.1016/S1047-2797(02)00420-9; Stellman SD, 2001, CANCER EPIDEM BIOMAR, V10, P1193; WAGENKNECHT LE, 1990, AM J PUBLIC HEALTH, V80, P1053, DOI 10.2105/AJPH.80.9.1053; Wills TA, 1997, AM J PUBLIC HEALTH, V87, P56, DOI 10.2105/AJPH.87.1.56; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	24	536	543	0	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					333	342		10.1056/NEJMoa033250	http://dx.doi.org/10.1056/NEJMoa033250			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436765				2022-12-28	WOS:000234854000005
J	MacKenzie, EJ; Rivara, FP; Jurkovich, GJ; Nathens, AB; Frey, KP; Egleston, BL; Salkever, DS; Scharfstein, DO				MacKenzie, EJ; Rivara, FP; Jurkovich, GJ; Nathens, AB; Frey, KP; Egleston, BL; Salkever, DS; Scharfstein, DO			A national evaluation of the effect of trauma-center care on mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INJURY SEVERITY SCORE; UNITED-STATES; SURVIVAL; SYSTEM; VALIDATION; OUTCOMES	BACKGROUND Hospitals have difficulty justifying the expense of maintaining trauma centers without strong evidence of their effectiveness. To address this gap, we examined differences in mortality between level 1 trauma centers and hospitals without a trauma center (non-trauma centers). METHODS Mortality outcomes were compared among patients treated in 18 hospitals with a level 1 trauma center and 51 hospitals non-trauma centers located in 14 states. Patients 18 to 84 years old with a moderate-to-severe injury were eligible. Complete data were obtained for 1104 patients who died in the hospital and 4087 patients who were discharged alive. We used propensity-score weighting to adjust for observable differences between patients treated at trauma centers and those treated at non-trauma centers. RESULTS After adjustment for differences in the case mix, the in-hospital mortality rate was significantly lower at trauma centers than at non-trauma centers (7.6 percent vs. 9.5 percent; relative risk, 0.80; 95 percent confidence interval, 0.66 to 0.98), as was the one-year mortality rate (10.4 percent vs. 13.8 percent; relative risk, 0.75; 95 percent confidence interval, 0.60 to 0.95). The effects of treatment at a trauma center varied according to the severity of injury, with evidence to suggest that differences in mortality rates were primarily confined to patients with more severe injuries. CONCLUSIONS Our findings show that the risk of death is significantly lower when care is provided in a trauma center than in a non-trauma center and argue for continued efforts at regionalization.	Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD 21205 USA; Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Washington; University of Washington Seattle	MacKenzie, EJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, 624 N Broadway,Rm 554, Baltimore, MD 21205 USA.	emackenz@jhsph.edu	Egleston, Brian L./P-1000-2019	Egleston, Brian L./0000-0002-1633-799X	NIA NIH HHS [R01/AG20361] Funding Source: Medline; ODCDC CDC HHS [R49/CCR316840] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); ODCDC CDC HHS		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; *COMM TRAUM, 1998, RES OPT CAR INJ PAT; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Hannan EL, 2004, J TRAUMA, V56, P1297, DOI 10.1097/01.TA.0000075350.66739.53; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Jurkovich GJ, 1999, J TRAUMA, V47, pS46, DOI 10.1097/00005373-199909001-00011; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MacKenzie EJ, 2003, JAMA-J AM MED ASSOC, V289, P1515, DOI 10.1001/jama.289.12.1515; MacKenzie EJ, 1999, J TRAUMA, V47, pS34, DOI 10.1097/00005373-199909001-00008; Mann NC, 2001, J TRAUMA, V50, P1111, DOI 10.1097/00005373-200106000-00022; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; Meredith JW, 2003, J TRAUMA, V55, P924, DOI 10.1097/01.TA.0000085645.62482.87; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; *NAT CTR HLTH STAT, 2000, 030078 NAT CTR HLTH; Nathens AB, 2004, J TRAUMA, V56, P173, DOI 10.1097/01.TA.0000056159.65396.7C; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Potter F., 1990, P SECT SURV RES METH, P225; Raghunathan T.E., 2001, SURV METHODOL, V27, P85; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Sacco WJ, 1999, J TRAUMA, V47, P441, DOI 10.1097/00005373-199909000-00001; Taheri PA, 2004, AM J SURG, V187, P7, DOI 10.1016/j.amjsurg.2003.06.002; TAN Z, 2004, 48 J HOPK U DEP BIOS; Tepas JJ, 2000, J TRAUMA, V48, P581, DOI 10.1097/00005373-200004000-00001	34	1720	1743	0	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					366	378		10.1056/NEJMsa052049	http://dx.doi.org/10.1056/NEJMsa052049			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436768	Bronze			2022-12-28	WOS:000234854000008
J	Remuzzi, G; Cravedi, P; Perna, A; Dimitrov, BD; Turturro, M; Locatelli, G; Rigotti, P; Baldan, N; Beatini, M; Valente, U; Scalamogna, M; Ruggenenti, P				Remuzzi, G; Cravedi, P; Perna, A; Dimitrov, BD; Turturro, M; Locatelli, G; Rigotti, P; Baldan, N; Beatini, M; Valente, U; Scalamogna, M; Ruggenenti, P		Dual Kidney Transplant Grp	Long-term outcome of renal transplantation from older donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KIDNEY-TRANSPLANTATION; MULTIVARIATE ANALYSES; GRAFT FUNCTION; UNITED-STATES; AGE; SURVIVAL; ALLOGRAFTS; RECIPIENTS; FAILURE; SINGLE	BACKGROUND Long-term survival of kidney grafts from older donors is inferior to that of grafts from younger donors. We sought to determine whether selecting older kidneys according to their histologic characteristics before implantation would positively influence long-term outcome. METHODS In a prospective cohort study, we assessed outcomes among 62 patients who received one or two histologically evaluated kidneys from donors older than 60 years of age. These outcomes were compared with outcomes among 248 matched recipients of single kidney grafts that had not been histologically evaluated and were either from donors 60 years of age or younger (124 positive-reference recipients who, according to available data, were expected to have an optimal outcome) or from those older than 60 years (124 negative-reference recipients, expected to have a worse outcome). The primary end point was graft survival. RESULTS During a median period of 23 months, 4 recipients (6 percent) of histologically evaluated kidneys progressed to dialysis, as compared with 7 positive-reference recipients (6 percent) and 29 negative-reference recipients (23 percent). Graft survival in recipients of histologically evaluated kidneys did not differ significantly from that of grafts in positive-reference recipients but was superior to that of grafts in negative-reference recipients (hazard ratio for graft failure in the negative-reference recipients relative to the recipients of histologically evaluated kidneys, 3.68; 95 percent confidence interval, 1.29 to 10.52; P=0.02). The performance of preimplantation histologic evaluation predicted better survival both in the whole study group (P=0.02) and among recipients of kidneys from older donors (P=0.01). CONCLUSIONS The long-term survival of single or dual kidney grafts from donors older than 60 years of age is excellent, provided that the grafts are evaluated histologically before implantation. This approach may help to expand the donor-organ pool for kidney transplantation.	Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy; Osped Riuniti Bergamo, Azienda Osped, I-24100 Bergamo, Italy; Univ Padua, Azienda Osped Giustinianeo, Padua, Italy; Osped San Martino Genova, Genoa, Italy; Osped Maggiore Policlin, Ist Ricovero & Cura Carattere Sci, Ctr Interreg Riferimento Nord Italia Transplant, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo; University of Padua; University of Genoa; IRCCS AOU San Martino IST; IRCCS Ca Granda Ospedale Maggiore Policlinico	Ruggenenti, P (corresponding author), Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24125 Bergamo, Italy.	manuelap@marionegri.it	Baldan, Nicola/AAH-9515-2019; Perna, Annalisa/AAC-1323-2020; Cravedi, Paolo/AAA-1390-2019; Remuzzi, Giuseppe/V-9766-2017; Dimitrov, Borislav/A-1246-2010	Baldan, Nicola/0000-0003-4725-8167; Perna, Annalisa/0000-0002-9257-0283; Cravedi, Paolo/0000-0001-7837-0923; Remuzzi, Giuseppe/0000-0002-6194-3446; RIGOTTI, PAOLO/0000-0002-8895-935X; Dimitrov, Borislav/0000-0002-5896-2072				Basar H, 1999, TRANSPLANTATION, V67, P1191, DOI 10.1097/00007890-199904270-00019; BRENNER BM, 1992, J AM SOC NEPHROL, V3, P1038; BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; Bunnapradist S, 2003, J AM SOC NEPHROL, V14, P1031, DOI 10.1097/01.ASN.0000054494.85680.1C; Cardillo M, 2000, Ann Ist Super Sanita, V36, P151; Cecka J M, 1997, Clin Transpl, P1; COFAN F, 1995, TRANSPLANT P, V27, P2248; *END STAG REN DAT, 2003, ANN REP; GAY J, CLIN EPIDEMIOLOGY EV; Harper Ann M, 2002, Clin Transpl, P79; HARRISON J H, 1956, Surg Forum, V6, P432; Karpinski J, 1999, TRANSPLANTATION, V67, P1162, DOI 10.1097/00007890-199904270-00013; LLOVERAS J, 1993, TRANSPLANT P, V25, P3175; MACKENZIE HS, 1995, KIDNEY INT, V48, pS38; Marcen R, 2003, TRANSPL P, V35, P1679, DOI 10.1016/S0041-1345(03)00617-1; Moreso F, 1999, NEPHROL DIAL TRANSPL, V14, P930, DOI 10.1093/ndt/14.4.930; Ojo AO, 1998, TRANSPLANTATION, V66, P1651, DOI 10.1097/00007890-199812270-00014; Perico N, 2003, AM J NEPHROL, V23, P245, DOI 10.1159/000072055; PIRANI CL, 1975, KIDNEY PATHOLOGY DEC; Rao PS, 2005, NEPHROL DIAL TRANSPL, V20, P387, DOI 10.1093/ndt/gfh595; Remuzzi G, 1998, J AM SOC NEPHROL, V9, P1321; Remuzzi G, 2000, TRANSPLANTATION, V69, P2000, DOI 10.1097/00007890-200005270-00002; Remuzzi G, 1999, J AM SOC NEPHROL, V10, P2591; Salvadori M, 2003, TRANSPL P, V35, P2863, DOI 10.1016/j.transproceed.2003.10.070; Terasaki PI, 1997, CLIN TRANSPLANT, V11, P366; Tullius SG, 2000, J AM SOC NEPHROL, V11, P1317, DOI 10.1681/ASN.V1171317; *UN NETW ORG SHAR, 1999, ANN REP 1999 UNOS RE; *UN NETW ORG SHAR, 2004, ANN REP; VIANELLO A, 1993, NEPHRON, V65, P541, DOI 10.1159/000187561; [No title captured]	30	367	383	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					343	352		10.1056/NEJMoa052891	http://dx.doi.org/10.1056/NEJMoa052891			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436766	Green Published			2022-12-28	WOS:000234854000006
J	Webber, SA; Naftel, DC; Fricker, FJ; Olesnevich, P; Blume, ED; Addonizio, L; Kirklin, JK; Canter, CE				Webber, SA; Naftel, DC; Fricker, FJ; Olesnevich, P; Blume, ED; Addonizio, L; Kirklin, JK; Canter, CE		Pediat Heart Transplant Study	Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study	LANCET			English	Article							CHILDREN; CHEMOTHERAPY; RITUXIMAB; SURVIVAL	Background Post-transplant lymphoproliferative disorders (PTLD) are an important cause of morbidity and mortality after organ transplantation. We sought to better define the prevalence, pathology, current therapeutic approaches, and outcomes of PTLD in a large group of children who had received heart transplants. Methods We assessed data on patients followed up at 19 centres in the Pediatric Heart Transplant Study (PHTS) from 1993 to 2002. Probability of freedom from PTLD was assessed along with details of presentation, pathology, treatment, and outcomes. Risk factors for survival and event-free survival were investigated. Findings Of 1184 primary transplant recipients, 56 (5%) developed PTLD. Probability of freedom from PTLD was 98% at 1 year, 94% at 3 years, and 92% at 5 years. Mean time to PTLD was 23.8 months. Most common sites of disease were gastrointestinal tract (n=22, 39%) and respiratory system (n=14, 25%). Histology was polymorphic in 35 (65%) and monomorphic in 19 (35%). 47 of 48 cases were of B-cell origin, 39 of 45 (87%) were Epstein-Barr virus positive. Probability of survival was 75% at 1 year, 68% at 3 years, and 67% at 5 years after diagnosis. Death from graft loss was as frequent as death from PTLD. Interpretation About 5% of paediatric heart-transplant recipients develop PTLD, almost always of B-cell lineage and driven by Epstein-Barr virus. Although many achieve satisfactory outcomes, mortality remains substantial with death due to progressive disease and allograft loss. Advances in management should focus on strategies to protect the allograft as well as improved therapies for PTLD.	Childrens Hosp, Dept Pediat, Div Cardiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Florida, Shands Hosp, Gainesville, FL USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Childrens Hosp New York, New York, NY USA; Columbia Univ, New York, NY USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; Washington Univ, St Louis, MO USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of Florida; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Columbia University; St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham	Webber, SA (corresponding author), Childrens Hosp, Dept Pediat, Div Cardiol, Pittsburgh, PA 15213 USA.	steve.webber@chp.edu						Auffermann-Gretzinger S, 2002, BLOOD, V99, P1442, DOI 10.1182/blood.V99.4.1442; BLACKSTONE EH, 1986, J AM STAT ASSOC, V81, P615, DOI 10.2307/2288989; Boyle GJ, 1997, J PEDIATR-US, V131, P309, DOI 10.1016/S0022-3476(97)70173-2; Capello D, 2003, BLOOD, V102, P3775, DOI 10.1182/blood-2003-05-1683; Cesarman E, 1998, BLOOD, V92, P2294, DOI 10.1182/blood.V92.7.2294.2294_2294_2302; Chadburn A, 1998, CANCER, V82, P1978; GREEN M, 1999, CURR OPIN ORGAN TRAN, V4, P292; Green M, 2003, PEDIAT SOLID ORGAN T, P471; Gross Thomas G, 2002, Recent Results Cancer Res, V159, P96; Harris NL, 1997, SEMIN DIAGN PATHOL, V14, P8; Harris NL, 2001, WHO CLASSIFICATION T, P264; Hayashi RJ, 2001, J PEDIAT HEMATOL ONC, V23, P14, DOI 10.1097/00043426-200101000-00005; Nalesnik MA, 1998, SPRINGER SEMIN IMMUN, V20, P325, DOI 10.1007/BF00838047; Orjuela M, 2003, CLIN CANCER RES, V9, p3945S; Paessler M, 2002, LAB INVEST, V82, P1599, DOI 10.1097/01.LAB.0000036873.16297.A5; Ranganathan S, 2004, PEDIATR DEVEL PATHOL, V7, P348, DOI 10.1007/s10024-003-1115-0; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shaddy RE, 1996, CIRCULATION, V94, P69; Smets F, 2002, TRANSPLANTATION, V73, P1603, DOI 10.1097/00007890-200205270-00014; Webber S, 2004, BLOOD, V104, p213A, DOI 10.1182/blood.V104.11.746.746; Webber S A, 1999, Pediatr Transplant, V3, P95	21	166	169	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					233	239		10.1016/S0140-6736(06)67933-6	http://dx.doi.org/10.1016/S0140-6736(06)67933-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427492				2022-12-28	WOS:000234810600028
J	Huang, JY; Chen, S; Wang, ZQ; Kempa, K; Wang, YM; Jo, SH; Chen, G; Dresselhaus, MS; Ren, ZF				Huang, JY; Chen, S; Wang, ZQ; Kempa, K; Wang, YM; Jo, SH; Chen, G; Dresselhaus, MS; Ren, ZF			Superplastic carbon nanotubes - Conditions have been discovered that allow extensive deformation of rigid single-walled nanotubes.	NATURE			English	Editorial Material							STRENGTH; ROUTE		Boston Coll, Dept Phys, Boston, MA 02467 USA; Lawrence Livermore Natl Lab, Nanoscale Synth & Characterizat Lab, Livermore, CA 94550 USA; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; MIT, Dept Phys Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Boston College; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Huang, JY (corresponding author), Boston Coll, Dept Phys, Boston, MA 02467 USA.	huangje@bc.edu	Chen, Gang/J-1325-2014; Chen, Shuo/H-2491-2011; Huang, Jianyu/AAZ-2474-2020; Huang, Jianyu/C-5183-2008; Ren, Zhifeng/B-4275-2014; Chen, Shuo/HCH-3354-2022; Wang, Yinmin (Morris)/F-2249-2010	Chen, Gang/0000-0002-3968-8530; Chen, Shuo/0000-0002-7145-1269; Huang, Jianyu/0000-0002-8424-5368; Wang, Yinmin (MORRIS)/0000-0003-0393-5154; Wang, Yinmin (Morris)/0000-0002-7161-2034				Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Calvert P, 1999, NATURE, V399, P210, DOI 10.1038/20326; Huang JY, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.236802; Nardelli MB, 1998, PHYS REV LETT, V81, P4656, DOI 10.1103/PhysRevLett.81.4656; Nardelli MB, 1998, PHYS REV B, V57, pR4277, DOI 10.1103/PhysRevB.57.R4277; Orlikowski D, 1999, PHYS REV LETT, V83, P4132, DOI 10.1103/PhysRevLett.83.4132; Walters DA, 1999, APPL PHYS LETT, V74, P3803, DOI 10.1063/1.124185; Yu MF, 2000, PHYS REV LETT, V84, P5552, DOI 10.1103/PhysRevLett.84.5552; Yu MF, 2000, SCIENCE, V287, P637, DOI 10.1126/science.287.5453.637; Zhan GD, 2003, NAT MATER, V2, P38, DOI 10.1038/nmat793; Zhao QZ, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.144105	11	299	309	3	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					281	281		10.1038/439281a	http://dx.doi.org/10.1038/439281a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421560	Bronze			2022-12-28	WOS:000234682100032
J	Moukhametzianov, R; Klare, JP; Efremov, R; Baeken, C; Goppner, A; Labahn, J; Engelhard, M; Buldt, G; Gordeliy, VI				Moukhametzianov, R; Klare, JP; Efremov, R; Baeken, C; Goppner, A; Labahn, J; Engelhard, M; Buldt, G; Gordeliy, VI			Development of the signal in sensory rhodopsin and its transfer to the cognate transducer	NATURE			English	Article							NATRONOBACTERIUM-PHARAONIS; TRANSIENT MOVEMENT; STRUCTURAL-CHANGES; HELIX F; PHOTOCYCLE; PHOBORHODOPSIN; RECEPTOR; TEMPERATURE; DIFFRACTION; INSIGHTS	The microbial phototaxis receptor sensory rhodopsin II ( NpSRII, also named phoborhodopsin) mediates the photophobic response of the haloarchaeon Natronomonas pharaonis(1,2) by modulating the swimming behaviour of the bacterium(3). After excitation by blue-green light NpSRII triggers, by means of a tightly bound transducer protein ( NpHtrII), a signal transduction chain homologous with the two-component system of eubacterial chemotaxis(4). Two molecules of NpSRII and two molecules of NpHtrII form a 2: 2 complex in membranes as shown by electron paramagnetic resonance(5) and X-ray structure analysis(6). Here we present X-ray structures of the photocycle intermediates K and late M (M-2) explaining the evolution of the signal in the receptor after retinal isomerization and the transfer of the signal to the transducer in the complex. The formation of late M has been correlated with the formation of the signalling state(2,7). The observed structural rearrangements allow us to propose the following mechanism for the light-induced activation of the signalling complex. On excitation by light, retinal isomerization leads in the K state to a rearrangement of a water cluster that partly disconnects two helices of the receptor. In the transition to late M the changes in the hydrogen bond network proceed further. Thus, in late M state an altered tertiary structure establishes the signalling state of the receptor. The transducer responds to the activation of the receptor by a clockwise rotation of about 158 of helix TM2 and a displacement of this helix by 0.9 angstrom at the cytoplasmic surface.	Forschungszentrum Julich, Inst Struct Biol IBI2, D-52425 Julich, Germany; MIPT, Ctr Biophys & Phys Chem Supramol Struct, Dolgoprudnyi 141700, Russia; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Helmholtz Association; Research Center Julich; Moscow Institute of Physics & Technology; Max Planck Society	Engelhard, M (corresponding author), Forschungszentrum Julich, Inst Struct Biol IBI2, Postfach 1913, D-52425 Julich, Germany.	martin.engelhard@mpi-dortmund.mpg.de	Klare, Johann P./C-1428-2009; Baeken, Chris/D-6790-2013; Baeken, Chris/E-2074-2013; Büldt, Georg/H-9509-2014; Buldt, Georg/K-5345-2013; Gordeliy, Valentin I/J-3636-2013; Efremov, Rouslan/P-9085-2015; Labahn, Jörg/G-9593-2013	Klare, Johann P./0000-0002-5761-5968; Gordeliy, Valentin I/0000-0001-5782-5896; Efremov, Rouslan/0000-0001-7516-8658; Labahn, Jörg/0000-0002-0648-8145				Balashov SP, 2000, BIOPHYS J, V78, P3150, DOI 10.1016/S0006-3495(00)76851-2; Bergo VB, 2005, J BIOL CHEM, V280, P28365, DOI 10.1074/jbc.M505555200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chizhov I, 1998, BIOPHYS J, V75, P999, DOI 10.1016/S0006-3495(98)77588-5; Edman K, 2002, STRUCTURE, V10, P473, DOI 10.1016/S0969-2126(02)00736-0; Engelhard M, 1996, FEBS LETT, V395, P195, DOI 10.1016/0014-5793(96)01041-1; Furutani Y, 2002, BIOPHYS J, V83, P3482, DOI 10.1016/S0006-3495(02)75347-2; Gordeliy Valentin I, 2003, Methods Mol Biol, V228, P305, DOI 10.1385/1-59259-400-X:305; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; HIRAYAMA J, 1992, BIOCHEMISTRY-US, V31, P2093, DOI 10.1021/bi00122a029; Klare JP, 2004, FEBS LETT, V564, P219, DOI 10.1016/S0014-5793(04)00193-0; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Rudolph J, 1996, J MOL BIOL, V258, P548, DOI 10.1006/jmbi.1996.0267; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; SCHARF B, 1994, FEBS LETT, V340, P114, DOI 10.1016/0014-5793(94)80183-5; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; Spudich JL, 1998, MOL MICROBIOL, V28, P1051, DOI 10.1046/j.1365-2958.1998.00859.x; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Wegener AA, 2001, EMBO J, V20, P5312, DOI 10.1093/emboj/20.19.5312; YAN B, 1991, BIOCHEMISTRY-US, V30, P10686, DOI 10.1021/bi00108a012; Yoshida H, 2004, PHOTOCH PHOTOBIO SCI, V3, P537, DOI 10.1039/b315454h	27	141	144	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 2	2006	440	7080					115	119		10.1038/nature04520	http://dx.doi.org/10.1038/nature04520			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017HW	16452929				2022-12-28	WOS:000235685700051
J	Yoon, SJ; Yi, SK; Lee, YW				Yoon, SJ; Yi, SK; Lee, YW			Explaining the color distributions of globular cluster systems in elliptical galaxies	SCIENCE			English	Article							HORIZONTAL-BRANCH STARS; INNER GALAXY; LICK INDEXES; LARGE-SAMPLE; MILKY-WAY; NGC-4472; M87; SPECTROSCOPY; POPULATIONS; KINEMATICS	The colors of globular clusters in most large elliptical galaxies are bimodal. This is generally taken as evidence for the presence of two cluster subpopulations that have different geneses. However, here we find that, because of the nonlinear nature of the metallicity-to-color transformation, a coeval group of old clusters with a unimodal metallicity spread can exhibit color bimodality. The models of cluster colors indicate that horizontal-branch stars are the main drivers behind the empirical nonlinearity. We show that the scenario gives simple and cohesive explanations for all the key observations and could simplify theories of elliptical galaxy formation.	Yonsei Univ, Dept Astron, Seoul 120749, South Korea; Yonsei Univ, Ctr Space Astrophys, Seoul 120749, South Korea; Univ Oxford, Oxford OX1 3RH, England	Yonsei University; Yonsei University; University of Oxford	Yoon, SJ (corresponding author), Yonsei Univ, Dept Astron, Seoul 120749, South Korea.	sjyoon@galaxy.yonsei.ac.kr	Yi, Sukyoung/AAO-7826-2020	Lee, Young-Wook/0000-0002-2210-1238				Bruzual G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/j.1365-8711.2003.06897.x; Cohen JG, 1998, ASTROPHYS J, V496, P808, DOI 10.1086/305429; Cote P, 1999, ASTRON J, V118, P406, DOI 10.1086/300930; Cote P, 2003, ASTROPHYS J, V591, P850, DOI 10.1086/375488; Cote P, 2001, ASTROPHYS J, V559, P828, DOI 10.1086/322347; Dinescu DI, 2003, ASTRON J, V125, P1373, DOI 10.1086/367801; Dirsch B, 2003, ASTRON J, V125, P1908, DOI 10.1086/368238; Fioc M, 1997, ASTRON ASTROPHYS, V326, P950; Forbes DA, 1997, ASTRON J, V113, P887, DOI 10.1086/118308; Forbes DA, 2004, MON NOT R ASTRON SOC, V355, P608, DOI 10.1111/j.1365-2966.2004.08333.x; Gebhardt K, 1999, ASTRON J, V118, P1526, DOI 10.1086/301059; Geisler D, 1996, ASTRON J, V111, P1529, DOI 10.1086/117894; Harris WE, 1996, ASTRON J, V112, P1487, DOI 10.1086/118116; Kundu A, 2001, ASTRON J, V121, P2950, DOI 10.1086/321073; Kundu A, 1999, ASTROPHYS J, V513, P733, DOI 10.1086/306865; Larsen SS, 2001, ASTRON J, V121, P2974, DOI 10.1086/321081; Lee HC, 2002, ASTRON J, V124, P2664, DOI 10.1086/344066; LEE YW, 1994, ASTROPHYS J, V423, P248, DOI 10.1086/173803; Lee YW, 2005, ASTROPHYS J, V621, pL57, DOI 10.1086/428944; LEE YW, 1994, ASTROPHYS J, V430, pL113, DOI 10.1086/187451; PENG E, IN PRESS ASTROPHYS J; Puzia TH, 2004, ASTRON ASTROPHYS, V415, P123, DOI 10.1051/0004-6361:20031448; Puzia TH, 2002, ASTRON ASTROPHYS, V395, P45, DOI 10.1051/0004-6361:20021283; RICH MR, 1997, APJ, V484, pL25; Richtler T, 2004, ASTRON J, V127, P2094, DOI 10.1086/382721; STRADER J, IN PRESS ASTRON J; Thomas D, 2003, MON NOT R ASTRON SOC, V339, P897, DOI 10.1046/j.1365-8711.2003.06248.x; West MJ, 2004, NATURE, V427, P31, DOI 10.1038/nature02235; Yoon SJ, 2002, SCIENCE, V297, P578, DOI 10.1126/science.1073090; Zepf SE, 2000, ASTRON J, V120, P2928, DOI 10.1086/316850	31	131	132	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	2006	311	5764					1129	1132		10.1126/science.1122294	http://dx.doi.org/10.1126/science.1122294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16424297				2022-12-28	WOS:000235688100042
J	Scott, EC				Scott, EC			Creationism and evolution: It's the American way	CELL			English	Editorial Material								The recent ruling in the Kitzmiller v. Dover court case that intelligent design is a form of religion and cannot be taught alongside evolution in science classes in US public schools garnered worldwide attention. But why is the antievolution movement so powerful in the United States?	Natl Ctr Sci Educ Inc, Oakland, CA 94609 USA		Scott, EC (corresponding author), Natl Ctr Sci Educ Inc, Oakland, CA 94609 USA.	scott@ncseweb.org		Scott, Eugenie Carol/0000-0003-3795-8207				Gross P. R., 2005, STATE STATE SCI STAN; HAMILTON D, 2004, DARWIN GOES BAKC SCH; National Research Council, 1996, NAT COMM SCI ED STAN; Scott EC, 2005, EVOLUTION VS CREATIO	4	6	7	0	13	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 10	2006	124	3					449	451		10.1016/j.cell.2006.01.028	http://dx.doi.org/10.1016/j.cell.2006.01.028			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469687	Bronze			2022-12-28	WOS:000235464000002
J	del Zoppo, GJ				del Zoppo, GJ			Focus on research - Stroke and neurovascular protection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92093 USA	Scripps Research Institute	del Zoppo, GJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92093 USA.							Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234, DOI 10.1152/ajpheart.1992.263.4.H1234; Mabuchi T, 2005, J CEREBR BLOOD F MET, V25, P257, DOI 10.1038/sj.jcbfm.9600027	3	174	183	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					553	555		10.1056/NEJMp058312	http://dx.doi.org/10.1056/NEJMp058312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467542				2022-12-28	WOS:000235177500004
J	Saur, J; Mauk, BH; Mitchell, DG; Krupp, N; Khurana, KK; Livi, S; Krimigis, M; Newell, PT; Williams, DJ; Brandt, PC; Lagg, A; Roussos, E; Dougherty, MK				Saur, J; Mauk, BH; Mitchell, DG; Krupp, N; Khurana, KK; Livi, S; Krimigis, M; Newell, PT; Williams, DJ; Brandt, PC; Lagg, A; Roussos, E; Dougherty, MK			Anti-planetward auroral electron beams at Saturn	NATURE			English	Article							CURRENT REGION; FIELD; EMISSIONS; DYNAMICS	Strong discrete aurorae on Earth are excited by electrons, which are accelerated along magnetic field lines towards the planet(1). Surprisingly, electrons accelerated in the opposite direction have been recently observed(2-6). The mechanisms and significance of this anti-earthward acceleration are highly uncertain because only earthward acceleration was traditionally considered, and observations remain limited. It is also unclear whether upward acceleration of the electrons is a necessary part of the auroral process or simply a special feature of Earth's complex space environment. Here we report anti-planetward acceleration of electron beams in Saturn's magnetosphere along field lines that statistically map into regions of aurora. The energy spectrum of these beams is qualitatively similar to the ones observed at Earth, and the energy fluxes in the observed beams are comparable with the energies required to excite Saturn's aurora. These beams, along with the observations at Earth(2-6) and the barely understood electron beams in Jupiter's magnetosphere(7,8), demonstrate that anti-planetward acceleration is a universal feature of aurorae. The energy contained in the beams shows that upward acceleration is an essential part of the overall auroral process.	Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; Max Planck Inst Sonnensyst Forsch, D-37191 Katlenburg Lindau, Germany; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2AZ, England	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Max Planck Society; University of California System; University of California Los Angeles; Imperial College London	Saur, J (corresponding author), Univ Cologne, Inst Geophys & Meteorol, Albertus Magnus Pl, D-50923 Cologne, Germany.	saur@geo.uni-koeln.de	Mauk, Barry H/E-8420-2017; Saur, Joachim/V-6780-2019; Brandt, Pontus C/N-1218-2016; Korpi-Lagg, Andreas/W-8166-2019; Mitchell, Donald G/H-4601-2016; Roussos, Elias/H-2249-2011	Mauk, Barry H/0000-0001-9789-3797; Saur, Joachim/0000-0003-1413-1231; Brandt, Pontus C/0000-0002-4644-0306; Korpi-Lagg, Andreas/0000-0003-1459-7074; Mitchell, Donald G/0000-0003-1960-2119; Khurana, Krishan/0000-0002-2856-1171; Roussos, Elias/0000-0002-5699-0678				Andersson L, 2002, PHYS PLASMAS, V9, P3600, DOI 10.1063/1.1490134; [Anonymous], 2003, AURORAL PLASMA PHYS; [Anonymous], 1991, AURORAL PHYS; Bhardwaj A, 2000, REV GEOPHYS, V38, P295, DOI 10.1029/1998RG000046; Carlson CW, 1998, GEOPHYS RES LETT, V25, P2017, DOI 10.1029/98GL00851; Clarke JT, 2005, NATURE, V433, P717, DOI 10.1038/nature03331; Clarke JT, 2002, NATURE, V415, P997, DOI 10.1038/415997a; Cowley SWH, 2005, J GEOPHYS RES-SPACE, V110, DOI 10.1029/2004JA010796; Cowley SWH, 2004, ANN GEOPHYS-GERMANY, V22, P1379, DOI 10.5194/angeo-22-1379-2004; Crary FJ, 2005, NATURE, V433, P720, DOI 10.1038/nature03333; Dougherty MK, 2004, SPACE SCI REV, V114, P331, DOI 10.1007/s11214-004-1432-2; Ergun RE, 1998, GEOPHYS RES LETT, V25, P2025, DOI 10.1029/98GL00635; FELDSTEIN YI, 1985, REV GEOPHYS, V23, P217, DOI 10.1029/RG023i003p00217; Frank LA, 2002, J GEOPHYS RES-SPACE, V107, DOI 10.1029/2001JA000077; Gerard JC, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2004JA010513; Grodent D, 2005, J GEOPHYS RES-SPACE, V110, DOI 10.1029/2004JA010983; Gurnett DA, 2005, SCIENCE, V307, P1255, DOI 10.1126/science.1105356; KHURANA KK, 2005, GEOPH RES ABSTR, V7; KLUMPAR DM, 1988, GEOPHYS RES LETT, V15, P1295, DOI 10.1029/GL015i011p01295; KLUMPAR DM, 1990, SPI C P REPRINT SERI, V9, P265; Krimigis SM, 2004, SPACE SCI REV, V114, P233, DOI 10.1007/s11214-004-1410-8; Krimigis SM, 2005, SCIENCE, V307, P1270, DOI 10.1126/science.1105978; Kurth WS, 2005, NATURE, V433, P722, DOI 10.1038/nature03334; Marklund GT, 2001, NATURE, V414, P724, DOI 10.1038/414724a; Prange R, 2004, NATURE, V432, P78, DOI 10.1038/nature02986; Temerin M, 1998, GEOPHYS RES LETT, V25, P2365, DOI 10.1029/98GL01865; Tomas AT, 2004, J GEOPHYS RES-SPACE, V109, DOI 10.1029/2004JA010405; Williams DJ, 1997, J GEOPHYS RES-SPACE, V102, P24283, DOI 10.1029/97JA02260; Williams DJ, 1999, J GEOPHYS RES-SPACE, V104, P14739, DOI 10.1029/1999JA900115	29	38	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					699	702		10.1038/nature04401	http://dx.doi.org/10.1038/nature04401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467832				2022-12-28	WOS:000235193100038
J	Hanson, LC; Ersek, M				Hanson, LC; Ersek, M			Meeting palliative care needs in post-acute care settings - "To help them live until they die"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; HOSPICE ENROLLMENT; QUALITY-IMPROVEMENT; PAIN MANAGEMENT; END; FACILITIES; HOSPITALIZATION; PREFERENCES		Univ N Carolina, Div Geriatr Med, Pain & Symptom Care Program, Chapel Hill, NC 27599 USA; Univ Washington, Sch Nursing, Swedish Med Ctr, Pain & Palliat Care Res Dept, Seattle, WA 98195 USA; Univ Washington, Sch Nursing, Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; Swedish Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hanson, LC (corresponding author), Univ N Carolina, Div Geriatr Med, Pain & Symptom Care Program, CB 7550, Chapel Hill, NC 27599 USA.	lhanson@med.unc.edu		Ersek, Mary/0000-0002-0520-311X; Hanson, Laura/0000-0001-5120-6058				Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; Baier RR, 2004, J AM GERIATR SOC, V52, P1988, DOI 10.1111/j.1532-5415.2004.52553.x; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Bradley EH, 1998, J AM GERIATR SOC, V46, P1235, DOI 10.1111/j.1532-5415.1998.tb04539.x; Brock D B, 1998, Hosp J, V13, P49; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Castle N G, 1997, Hosp J, V12, P59; Castle NG, 2005, MED CARE, V43, P616, DOI 10.1097/01.mlr.0000163661.67170.b9; Chan J, 2002, GERONTOLOGIST, V42, P301; Dixon Sharon, 2002, Am J Hosp Palliat Care, V19, P187, DOI 10.1177/104990910201900310; Ersek Mary, 2005, J Palliat Med, V8, P556, DOI 10.1089/jpm.2005.8.556; Ersek Mary, 2003, J Palliat Med, V6, P45, DOI 10.1089/10966210360510118; FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007; Fried TR, 1999, ANN INTERN MED, V131, P109, DOI 10.7326/0003-4819-131-2-199907200-00006; Gillick M, 1999, J AM GERIATR SOC, V47, P227, DOI 10.1111/j.1532-5415.1999.tb04582.x; Hanson Laura C, 2002, J Palliat Med, V5, P117; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hanson LC, 2005, J PALLIAT MED, V8, P1207, DOI 10.1089/jpm.2005.8.1207; HENDERSON ML, 2003, IMPROVING NURSING HO; Hickman SE, 2004, J AM GERIATR SOC, V52, P1424, DOI 10.1111/j.1532-5415.2004.52402.x; Horner JK, 2005, J PAIN SYMPTOM MANAG, V30, P271, DOI 10.1016/j.jpainsymman.2005.03.014; Keay Timothy J, 2003, J Palliat Med, V6, P205, DOI 10.1089/109662103764978452; Kovach CR, 1996, AM J ALZHEIMERS DIS, V11, P7, DOI DOI 10.1177/153331759601100402; Levin JR, 1999, J AM GERIATR SOC, V47, P82, DOI 10.1111/j.1532-5415.1999.tb01905.x; LINN MW, 1989, INT J AGING HUM DEV, V28, P305, DOI 10.2190/JA0E-9T0Y-H2K8-QBV6; Maccabee Joyce, 1994, Palliative Medicine, V8, P211, DOI 10.1177/026921639400800304; Marcantonio ER, 2005, J AM GERIATR SOC, V53, P963, DOI 10.1111/j.1532-5415.2005.53305.x; Mattimore TJ, 1997, J AM GERIATR SOC, V45, P818, DOI 10.1111/j.1532-5415.1997.tb01508.x; Miller SC, 2004, J PAIN SYMPTOM MANAG, V28, P537, DOI 10.1016/j.jpainsymman.2004.10.007; Miller SC, 2004, J AM GERIATR SOC, V52, P1284, DOI 10.1111/j.1532-5415.2004.52357.x; Miller SC, 2003, J PAIN SYMPTOM MANAG, V26, P791, DOI 10.1016/S0885-3924(03)00284-7; Miller SC, 2001, AM J MED, V111, P38, DOI 10.1016/S0002-9343(01)00747-1; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Morrison RS, 2005, J AM GERIATR SOC, V53, P290, DOI 10.1111/j.1532-5415.2005.53116.x; Murtaugh CM, 2002, MED CARE, V40, P227; OMORI DM, 1991, ARCH INTERN MED, V151, P1562, DOI 10.1001/archinte.151.8.1562; Petrisek AC, 1999, GERONTOLOGIST, V39, P279, DOI 10.1093/geront/39.3.279; Reynolds Kimberly, 2002, J Palliat Med, V5, P895, DOI 10.1089/10966210260499087; Sloane PD, 2003, J AM GERIATR SOC, V51, P1587, DOI 10.1046/j.1532-5415.2003.51511.x; Tarzian Anita J, 2004, J Am Med Dir Assoc, V5, P82, DOI 10.1097/01.JAM.0000110648.46882.B3; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, FACTS DYING; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; VOLICER L, 1994, J AM GERIATR SOC, V42, P597, DOI 10.1111/j.1532-5415.1994.tb06856.x; Weissman DE, 2000, J PAIN SYMPTOM MANAG, V20, P35, DOI 10.1016/S0885-3924(00)00168-8; Wilson S A, 1998, J Palliat Med, V1, P21, DOI 10.1089/jpm.1998.1.21; Wilson SA, 1996, GERIATR NURS, V17, P6, DOI 10.1016/S0197-4572(96)80004-8; Zerzan J, 2000, JAMA-J AM MED ASSOC, V284, P2489, DOI 10.1001/jama.284.19.2489; Zimmerman Sheryl, 2003, J Am Med Dir Assoc, V4, P23, DOI 10.1016/S1525-8610(04)70260-1	50	30	30	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					681	+		10.1001/jama.295.6.681	http://dx.doi.org/10.1001/jama.295.6.681			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467237				2022-12-28	WOS:000235168200028
J	Walton, S; Bedford, H; Dezateux, C				Walton, S; Bedford, H; Dezateux, C		Millennium Cohort Study Child Hlth	Use of personal child health records in the UK: findings from the millennium cohort study	BRITISH MEDICAL JOURNAL			English	Article								Objectives The personal child health record (PCHR) is a record of a child's growth, development, and uptake of preventive health services, designed to enhance communication between parents and health professionals. We examined its use throughout the United Kingdom with respect to recording children's weight and measures of social disadvantage and infant health. Design Cross sectional survey within a cohort study. Setting UK. Participants Mothers of 18 503 children born between 2000 and 2002, living in the UK at 9 months of age. Main outcome measures Proportion of mothers able to produce their child's PCHR; proportion of PCHRs consulted containing record of child's last weight; effective use of the PCHR (defined as production, consultation, and child's last weight recorded). Results In all, 16 917 (93%) mothers produced their child's PCHR and 15 138 (85%) mothers showed effective use of their child's PCHR. Last weight was recorded in 97% of PCHRs consulted. Effective use was less in children previously admitted to hospital, and, in association with factors reflecting social disadvantage, including residence in disadvantaged communities, young maternal age, large family size (four or more children; incidence rate ratio 0.87; 95% confidence interval 0.83 to 0.91), mid lone parent status (0.88; 0.86 to 0.91). Conclusions Use of the PCHR is lower by women living in disadvantaged circumstances, but overall the record is retained and used by a high proportion of all mothers throughout the UK in their child's first year of life. PCHR use is endorsed in the National Service Framework for Children and has potential benefits which extend beyond the direct care of individual children.	Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London	Walton, S (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	S.Walton@ich.ucl.ac.uk	Dezateux, Carol/A-3416-2009	Dezateux, Carol/0000-0001-9787-6276				*CTR LONG STUD, 2005, MILL COH STUD; Department of Health, 2004, COR DOC NAT SERV FRA; Hall DMB, 2003, HLTH ALL CHILDREN; Plewis I, 2004, MILLENNIUM COHORT ST; *ROYAL COLL PAED C, 2004, NAT STAND PCHR	5	22	23	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					269	270		10.1136/bmj.332.7536.269	http://dx.doi.org/10.1136/bmj.332.7536.269			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455721	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000235259000016
J	Bacles, CFE; Lowe, AJ; Ennos, RA				Bacles, CFE; Lowe, AJ; Ennos, RA			Effective seed dispersal across a fragmented landscape	SCIENCE			English	Article									Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland; Ctr Ecol & Hydrol, Penicuik EH26 0QB, Midlothian, Scotland; Univ Queensland, Sch Integrat Biol, Brisbane, Qld 4072, Australia	University of Edinburgh; UK Centre for Ecology & Hydrology (UKCEH); University of Queensland	Ennos, RA (corresponding author), Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland.	rennos@ed.ac.uk	Bacles, Cecile FE/D-3093-2010	Bacles, Cecile FE/0000-0002-1061-1898; Lowe, Andrew/0000-0003-1139-2516	Natural Environment Research Council [CEH010021, ceh010010] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Aldrich PR, 1998, SCIENCE, V281, P103, DOI 10.1126/science.281.5373.103; Bacles CFE, 2005, EVOLUTION, V59, P979, DOI 10.1111/j.0014-3820.2005.tb01037.x; Lowe AJ, 2005, HEREDITY, V95, P255, DOI 10.1038/sj.hdy.6800725; Nathan R, 2005, P NATL ACAD SCI USA, V102, P8251, DOI 10.1073/pnas.0503048102; Pearson RG, 2005, BIOL CONSERV, V123, P389, DOI 10.1016/j.biocon.2004.12.006; Schnabel A, 1998, MOL ECOL, V7, P819, DOI 10.1046/j.1365-294x.1998.00397.x	6	187	189	0	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					628	628		10.1126/science.1121543	http://dx.doi.org/10.1126/science.1121543			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456072				2022-12-28	WOS:000235257400037
J	Hayes, R; Weiss, H				Hayes, R; Weiss, H			Epidemiology - Understanding HIV epidemic trends in Africa	SCIENCE			English	Editorial Material							INFECTION; BEHAVIOR; DECLINE; RISK		Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Hayes, R (corresponding author), Univ London London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.	richard.hayes@lshtm.ac.uk	weiss, helen/ABC-7823-2021	weiss, helen/0000-0003-3547-7936; Hayes, Richard/0000-0002-1729-9892				ANDERSON R M, 1991; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Buve A, 2001, AIDS, V15, pS127, DOI 10.1097/00002030-200108004-00014; Gregson S, 2006, SCIENCE, V311, P664, DOI 10.1126/science.1121054; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166; STOVER J, 2006, SCIENCE         0202, DOI DOI 10.1126/1121176; *UNAIDS, 2005, AIDS EP UPD DEC 2005; Wawer M., 2005, 12 C RETR OPP INF BO	9	22	28	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					620	621		10.1126/science.1124072	http://dx.doi.org/10.1126/science.1124072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	011GY	16456070				2022-12-28	WOS:000235257400035
J	Zhang, Q; Sun, XY; Watt, ED; Al-Hashimi, HM				Zhang, Q; Sun, XY; Watt, ED; Al-Hashimi, HM			Resolving the motional modes that code for RNA adaptation	SCIENCE			English	Article							HIV-1 TAR RNA; NMR RELAXATION; PROTEIN RECOGNITION; INDUCED FIT; CONFORMATION; DYNAMICS; REVEALS; BULGE; MACROMOLECULES; STABILIZATION	Using a domain elongation strategy, we decoupled internal motions in RNA from overall rotational diffusion. This allowed us to site-specifically resolve a manifold of motional modes in two regulatory RNAs from HIV-1 with the use of nuclear magnetic resonance spin relaxation methods. Base and sugar librations vary on a picosecond time scale and occur within helical domains that move collectively at diffusion-limited nanosecond time scales. Pivot points are short; functionally important, and highly mobile internal loops. These spontaneous changes in RNA conformation correlate quantitatively with those that follow adaptive recognition of diverse targets. Thus, ligands may stabilize existing RNA conformations rather than inducing new ones.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Al-Hashimi, HM (corresponding author), Univ Michigan, Dept Chem, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	hashimi@umich.edu	Zhang, Qi/B-5869-2014; Zhang, Qi/E-1722-2011; Zhang, Qi/F-3323-2010; Watt, Eric D/K-9819-2015	Zhang, Qi/0000-0003-1754-4058; Watt, Eric D/0000-0002-1211-0229	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066975] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI066975-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; Baram D, 2005, FEBS LETT, V579, P948, DOI 10.1016/j.febslet.2004.11.063; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; Dingley AJ, 1999, J AM CHEM SOC, V121, P6019, DOI 10.1021/ja9908321; Doudna JA, 2005, NAT STRUCT MOL BIOL, V12, P395, DOI 10.1038/nsmb932; Du ZH, 2002, CHEM BIOL, V9, P707, DOI 10.1016/S1074-5521(02)00151-5; Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200; Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820; Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819; Lawrence DC, 2003, J MOL BIOL, V326, P529, DOI 10.1016/S0022-2836(02)01305-0; Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y; Lilley David M J, 2004, Methods Mol Biol, V252, P77; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; Murchie AIH, 2004, J MOL BIOL, V336, P625, DOI 10.1016/j.jmb.2003.12.028; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Pitt SW, 2004, J MOL BIOL, V338, P7, DOI 10.1016/j.jmb.2004.02.031; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Schroeder R, 2004, NAT REV MOL CELL BIO, V5, P908, DOI 10.1038/nrm1497; Tugarinov V, 2001, J AM CHEM SOC, V123, P3055, DOI 10.1021/ja003803v; Vallurupalli P, 2005, J AM CHEM SOC, V127, P6893, DOI 10.1021/ja0427799; Vugmeyster L, 2003, J AM CHEM SOC, V125, P8400, DOI 10.1021/ja029480f; Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575	27	190	193	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					653	656		10.1126/science.1119488	http://dx.doi.org/10.1126/science.1119488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456078				2022-12-28	WOS:000235257400046
J	Duchaine, TF; Wohlschlegel, JA; Kennedy, S; Bei, YX; Conte, D; Pang, KM; Brownell, DR; Harding, S; Mitani, S; Ruvkun, G; Yates, JR; Mello, CC				Duchaine, TF; Wohlschlegel, JA; Kennedy, S; Bei, YX; Conte, D; Pang, KM; Brownell, DR; Harding, S; Mitani, S; Ruvkun, G; Yates, JR; Mello, CC			Functional proteomics reveals the biochemical niche of C-elegans DCR-1 in multiple small-RNA-mediated pathways	CELL			English	Article							PROTEIN IDENTIFICATION TECHNOLOGY; DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; SHOTGUN PROTEOMICS; FISSION YEAST; DICER; PHOSPHATASE; MICRORNAS; COMPLEXES	In plants, animals, and fungi, members of the Dicer family of RNase III-related enzymes process double-stranded RNA (dsRNA) to initiate small-RNA-mediated gene-silencing mechanisms. To learn how C. elegans Dicer, DCR-1, functions in multiple distinct silencing mechanisms, we used a mass-spectrometry-based proteomics approach to identify DCR-1-interacting proteins. We then generated and characterized deletion alleles for the corresponding genes. The interactors are required for production of three species of small RNA, including (1) small interfering RNAs (siRNAs), derived from exogenous dsRNA triggers (exo-siRNAs); (2) siRNAs derived from endogenous triggers (endo-siRNAs); and (3) developmental regulatory microRNAs (miRNAs). One interactor, the conserved RNA-phosphatase homolog PIR-1, is required for the processing of a putative amplified DCR-1 substrate. Interactors required for endo-siRNA production include ERI-1 and RRF-3, whose loss of function enhances RNAi Our findings provide a first glimpse at the complex biochemical niche of Dicer and suggest that competition exists between DCR-1-mediated small-RNA pathways.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53701 USA; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Scripps Research Institute; University of Wisconsin System; University of Wisconsin Madison; Tokyo Women's Medical University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Mello, CC (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	craig.mello@umassmed.edu	pang, Ka Ming Ming/AAW-4059-2021; Duchaine, Thomas/U-2399-2019; pang, ka ming/H-4082-2011	pang, ka ming/0000-0001-7262-3918; Kennedy, Scott/0000-0002-7974-8155; Duchaine, Thomas/0000-0002-3454-1839	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058800] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58800] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ambros Victor, 2004, Methods Mol Biol, V265, P131; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BRENNER S, 1974, GENETICS, V77, P71; Cheng Y, 2004, J MOL BIOL, V343, P305, DOI 10.1016/j.jmb.2004.08.055; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Dominski Z, 2003, MOL CELL, V12, P295, DOI 10.1016/S1097-2765(03)00278-8; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukagawa T, 2004, NAT CELL BIOL, V6, P784, DOI 10.1038/ncb1155; Gengyo-Ando K, 2000, BIOCHEM BIOPH RES CO, V269, P64, DOI 10.1006/bbrc.2000.2260; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Praitis V, 2001, GENETICS, V157, P1217; Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yuan Y, 1998, J BIOL CHEM, V273, P20347, DOI 10.1074/jbc.273.32.20347	42	293	322	0	31	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 27	2006	124	2					343	354		10.1016/j.cell.2005.11.036	http://dx.doi.org/10.1016/j.cell.2005.11.036			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439208	Bronze			2022-12-28	WOS:000235068500022
J	Farrell, AE; Plevin, RJ; Turner, BT; Jones, AD; O'Hare, M; Kammen, DM				Farrell, AE; Plevin, RJ; Turner, BT; Jones, AD; O'Hare, M; Kammen, DM			Ethanol can contribute to energy and environmental goals	SCIENCE			English	Article								To study the potential effects of increased biofuel use, we evaluated six representative analyses of fuel ethanol. Studies that reported negative net energy incorrectly ignored coproducts and used some obsolete data. All studies indicated that current corn ethanol technologies are much less petroteum-intensive than gasoline but have greenhouse gas emissions similar to those of gasoline. However, many important environmental effects of biofuel production are poorly understood. New metrics that measure specific resource inputs are developed, but further research into environmental metrics is needed. Nonetheless, it is already clear that large-scale use of ethanol for fuel will almost certainly require cellulosic technology.	Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Goldman Sch Publ Policy, Berkeley, CA 94720 USA; Univ Calif Berkeley, Renewable & Appropriate Energy Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Farrell, AE (corresponding author), Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA.	aef@berkeley.edu	Jones, Andrew D/M-4363-2013; Jones, Andrew/AHH-1227-2022; Plevin, Richard/G-6428-2010	Jones, Andrew D/0000-0002-1913-7870; Jones, Andrew/0000-0002-1913-7870; Plevin, Richard/0000-0003-3919-0836; O'Hare, Michael/0000-0002-3288-9065				CHAMBERS RS, 1979, SCIENCE, V206, P789, DOI 10.1126/science.206.4420.789; Cleveland CJ, 2005, ENERGY, V30, P769, DOI 10.1016/j.energy.2004.05.023; DAVIS SC, 2004, ORNL6973; De Oliveira MED, 2005, BIOSCIENCE, V55, P593, DOI 10.1641/0006-3568(2005)055[0593:EAFECD]2.0.CO;2; DELUCCHI MA, 2004, UCDITSRR0445; GRABOSKI MS, 2002, FOSSIL ENERGY USE MA; Kerr RA, 2005, SCIENCE, V309, P101, DOI 10.1126/science.309.5731.101; Kim S, 2005, BIOMASS BIOENERG, V29, P426, DOI 10.1016/j.biombioe.2005.06.004; Kim S, 2002, INT J LIFE CYCLE ASS, V7, P237, DOI 10.1007/BF02978879; Lave LB, 2001, ISSUES SCI TECHNOL, V18, P73; Patzek TW, 2004, CRIT REV PLANT SCI, V23, P519, DOI 10.1080/07352680490886905; Perlack R.D., 2005, ORNLTM200666; Pimentel D., 2005, NAT RESOUR RES, V14, P65, DOI [DOI 10.1007/S11053-005-4679-8, 10.1007/s11053-005-4679-8]; Shapouri H, 2003, T ASAE, V46, P959, DOI 10.13031/2013.13951; SHAPOURI H, 2004, 2001 NET ENERGY BALA; Tegtmeier E. M., 2004, International Journal of Agricultural Sustainability, V2, P1, DOI 10.1080/14735903.2004.9684563; *U MO FOOD AGR POL, 2005, 1005 U MISS FOOD AGR; Wang M., 2001, ANLESDTM163; Wirth TE, 2003, FOREIGN AFF, V82, P132, DOI 10.2307/20033654	19	1873	1971	13	656	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					506	508		10.1126/science.1121416	http://dx.doi.org/10.1126/science.1121416			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439656				2022-12-28	WOS:000235071400041
J	Ragauskas, AJ; Williams, CK; Davison, BH; Britovsek, G; Cairney, J; Eckert, CA; Frederick, WJ; Hallett, JP; Leak, DJ; Liotta, CL; Mielenz, JR; Murphy, R; Templer, R; Tschaplinski, T				Ragauskas, AJ; Williams, CK; Davison, BH; Britovsek, G; Cairney, J; Eckert, CA; Frederick, WJ; Hallett, JP; Leak, DJ; Liotta, CL; Mielenz, JR; Murphy, R; Templer, R; Tschaplinski, T			The path forward for biofuels and biomaterials	SCIENCE			English	Review							LIQUID; XYLOSE; WATER; ACID	Biomass represents an abundant carbon-neutral renewable resource for the production of bioenergy and biomaterials, and its enhanced use would address several societal needs. Advances in genetics, biotechnology, process chemistry, and engineering are leading to a new manufacturing concept for converting renewable biomass to valuable fuels and products, generally referred to as the biorefinery. The integration of agroenergy crops and biorefinery manufacturing technologies offers the potential for the development of sustainable biopower and biomaterials that will lead to a new manufacturing paradigm.	Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA; Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Div Biol, London SW7 2AZ, England; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37831 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Imperial College London; Imperial College London; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory	Ragauskas, AJ (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.	arthur.ragauskas@chemistry.gatech.edu	Ragauskas, Art/J-7486-2016; Williams, Charlotte/A-2503-2013; Davison, Brian/D-7617-2013; Britovsek, George/J-8014-2016; Hallett, Jason P./A-3281-2012; Tschaplinski, Timothy/D-6382-2018	Ragauskas, Art/0000-0002-3536-554X; Davison, Brian/0000-0002-7408-3609; Britovsek, George/0000-0001-9321-4814; Hallett, Jason P./0000-0003-3431-2371; Tschaplinski, Timothy/0000-0002-9540-6622; MURPHY, Richard/0000-0002-3063-515X; Templer, Richard/0000-0002-9911-8011; Williams, Charlotte/0000-0002-0734-1575				Akiya N, 2002, CHEM REV, V102, P2725, DOI 10.1021/cr000668w; Auras R, 2004, MACROMOL BIOSCI, V4, P835, DOI 10.1002/mabi.200400043; Berndes G, 2001, BIOMASS BIOENERG, V20, P371, DOI 10.1016/S0961-9534(01)00002-2; BOATENG AA, IN PRESS J ANAL APPL; Boudet AM, 2003, TRENDS PLANT SCI, V8, P576, DOI 10.1016/j.tplants.2003.10.001; Bredwell MD, 1999, BIOTECHNOL PROGR, V15, P834, DOI 10.1021/bp990108m; Britt PF, 2000, J ORG CHEM, V65, P1376, DOI 10.1021/jo991479k; Chakar FS, 2004, IND CROP PROD, V20, P131, DOI 10.1016/j.indcrop.2004.04.016; Chamblee TS, 2004, GREEN CHEM, V6, P382, DOI 10.1039/b400393d; Chum H.L., 2003, ADV SOLAR ENERGY, V15, P83; Eckert CA, 2004, J PHYS CHEM B, V108, P18108, DOI 10.1021/jp0487612; Fitzpatrick S.W., 1996, WO patent, Patent No. 9640609; Good AG, 2004, TRENDS PLANT SCI, V9, P597, DOI 10.1016/j.tplants.2004.10.008; Helle SS, 2004, BIORESOURCE TECHNOL, V92, P163, DOI 10.1016/j.biortech.2003.08.011; Hoffert MI, 2002, SCIENCE, V298, P981, DOI 10.1126/science.1072357; Huber GW, 2005, SCIENCE, V308, P1446, DOI 10.1126/science.1111166; Jing ZP, 2004, NEW PHYTOL, V164, P137, DOI 10.1111/j.1469-8137.2004.01173.x; Kamm B, 2004, APPL MICROBIOL BIOT, V64, P137, DOI 10.1007/s00253-003-1537-7; Lawford HG, 2002, APPL BIOCHEM BIOTECH, V98, P429, DOI 10.1385/ABAB:98-100:1-9:429; Li L, 2003, P NATL ACAD SCI USA, V100, P4939, DOI 10.1073/pnas.0831166100; Lichtenthaler FW, 2002, ACCOUNTS CHEM RES, V35, P728, DOI 10.1021/ar010071i; Lovins A.B., 2004, WINNING OIL ENDGAME, P1; Morandini P., 2005, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V5, P103, DOI 10.2174/1568013053586441; Mosier N, 2005, BIORESOURCE TECHNOL, V96, P673, DOI 10.1016/j.biortech.2004.06.025; Nolen SA, 2003, GREEN CHEM, V5, P663, DOI 10.1039/b308499j; Pacala S, 2004, SCIENCE, V305, P968, DOI 10.1126/science.1100103; Parikka M, 2004, BIOMASS BIOENERG, V27, P613, DOI 10.1016/j.biombioe.2003.07.005; Perlack R.D., 2005, BIOMASS FEEDSTOCK BI; Rishi AS, 2001, J PLANT BIOCHEM BIOT, V10, P1; Ritter S, 2004, CHEM ENG NEWS, V82, P4, DOI 10.1021/cen-v082n027.p004; SHABTAI JS, 2003, Patent No. 972461; Sricharoenchaikul V, 2002, IND ENG CHEM RES, V41, P5640, DOI 10.1021/ie020207w; Van Camp W, 2005, CURR OPIN BIOTECH, V16, P147, DOI 10.1016/j.copbio.2005.03.002; van Wyk JPH, 2001, TRENDS BIOTECHNOL, V19, P172, DOI 10.1016/S0167-7799(01)01601-8; Vinocur B, 2005, CURR OPIN BIOTECH, V16, P123, DOI 10.1016/j.copbio.2005.02.001; Werpy T., 2004, TOP VALUE ADDED CHEM, VI; Zhang YHP, 2005, P NATL ACAD SCI USA, V102, P7321, DOI 10.1073/pnas.0408734102; 2005, 27 S BIOT FUELS CHEM	38	4327	4588	84	3240	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					484	489		10.1126/science.1114736	http://dx.doi.org/10.1126/science.1114736			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439654				2022-12-28	WOS:000235071400036
J	Tawfik, DS				Tawfik, DS			Loop grafting and the origins of enzyme species	SCIENCE			English	Editorial Material							EVOLUTION; SUPERFAMILY; DESIGN		Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tawfik, DS (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tawfik@weizmann.ac.il						Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Bogarad LD, 1999, P NATL ACAD SCI USA, V96, P2591, DOI 10.1073/pnas.96.6.2591; Brannigan JA, 2002, NAT REV MOL CELL BIO, V3, P964, DOI 10.1038/nrm975; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Park HS, 2006, SCIENCE, V311, P535, DOI 10.1126/science.1118953; PRIES F, 1994, J BIOL CHEM, V269, P17490; Roodveldt C, 2005, BIOCHEMISTRY-US, V44, P12728, DOI 10.1021/bi051021e; Schmidt DMZ, 2003, BIOCHEMISTRY-US, V42, P8387, DOI 10.1021/bi034769a; Service RF, 2005, SCIENCE, V307, P1555, DOI 10.1126/science.307.5715.1555	12	55	55	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2006	311	5760					475	476		10.1126/science.1123883	http://dx.doi.org/10.1126/science.1123883			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439649				2022-12-28	WOS:000235071400031
J	Gittenberger, E; Groenenberg, DSJ; Kokshoorn, B; Preece, RC				Gittenberger, E; Groenenberg, DSJ; Kokshoorn, B; Preece, RC			Molecular trails from hitch-hiking snails	NATURE			English	Editorial Material									Natl Museum Nat Hist Naturalis, NL-2300 RA Leiden, Netherlands; Leiden Univ, Inst Biol, NL-2300 RA Leiden, Netherlands; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	Naturalis Biodiversity Center; Leiden University; Leiden University - Excl LUMC; University of Cambridge	Gittenberger, E (corresponding author), Natl Museum Nat Hist Naturalis, POB 9517, NL-2300 RA Leiden, Netherlands.	rcp1001@cam.ac.uk		Kokshoorn, Bas/0000-0003-1927-854X				BACKHUYS W, 1975, LAND FRESHWATER MOLL; BOETTGER O, 1878, BERICHT THATIGKEIT O, V17, P18; Cockerell TDA, 1921, NATURE, V108, P496, DOI 10.1038/108496d0; Darwin C., 1877, ORIGIN SPECIES; GHEERAERTS M, 1567, WARACHTIGHE FABULEN; GITTENBERGER E, UNPUB J CONCH; GRAy J. E., 1824, ZOOLOGICAL J, V1, P62; NORDSIECK H, 1978, Archiv fuer Molluskenkunde, V109, P67; Nordsieck H., 1979, ARCH MOLLUSKENKD, V109, P249; Odhner N. Hj., 1960, Proceedings of the Malacological Society of London, V34, P168; Preece RC, 2003, J MOLLUS STUD, V69, P329, DOI 10.1093/mollus/69.4.329; Rees W. J., 1965, Proceedings of the Malacological Society of London, V36, P269; Schileyko A.A., 1999, Ruthenica Supplement, V2, P437	13	111	119	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					409	409		10.1038/439409a	http://dx.doi.org/10.1038/439409a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437103	Bronze			2022-12-28	WOS:000234859200031
J	Singer, T; Seymour, B; O'Doherty, JP; Stephan, KE; Dolan, RJ; Frith, CD				Singer, T; Seymour, B; O'Doherty, JP; Stephan, KE; Dolan, RJ; Frith, CD			Empathic neural responses are modulated by the perceived fairness of others	NATURE			English	Article							MOTIVATION; STRIATUM; REWARD; ROLES; PAIN	The neural processes underlying empathy are a subject of intense interest within the social neurosciences(1-3). However, very little is known about how brain empathic responses are modulated by the affective link between individuals. We show here that empathic responses are modulated by learned preferences, a result consistent with economic models of social preferences(4-7). We engaged male and female volunteers in an economic game, in which two confederates played fairly or unfairly, and then measured brain activity with functional magnetic resonance imaging while these same volunteers observed the confederates receiving pain. Both sexes exhibited empathy-related activation in pain-related brain areas (fronto-insular and anterior cingulate cortices) towards fair players. However, these empathy-related responses were significantly reduced in males when observing an unfair person receiving pain. This effect was accompanied by increased activation in reward-related areas, correlated with an expressed desire for revenge. We conclude that in men ( at least) empathic responses are shaped by valuation of other people's social behaviour, such that they empathize with fair opponents while favouring the physical punishment of unfair opponents, a finding that echoes recent evidence for altruistic punishment.	UCL, Wellcome Dept Imaging Neurosci, London WC1N 3AR, England; UCL, Inst Cognit Neurosci, London WC1N 3AR, England; CALTECH, Div Humanities & Social Sci, Pasadena, CA 91125 USA	University of London; University College London; University of London; University College London; California Institute of Technology	Singer, T (corresponding author), UCL, Wellcome Dept Imaging Neurosci, London WC1N 3AR, England.	t.singer@fil.ion.ucl.ac.uk	Girault, Johann/B-2430-2012; O'Doherty, John P/F-1204-2013; Frith, Chris D/A-2171-2009	Frith, Chris D/0000-0002-8665-0690; Dolan, Ray/0000-0001-9356-761X; Seymour, Ben/0000-0003-1724-5832; Stephan, Klaas Enno/0000-0002-8594-9092	Wellcome Trust [078865] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERG J, 1995, GAME ECON BEHAV, V10, P122, DOI 10.1006/game.1995.1027; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; Camerer C.F., 2011, BEHAV GAME THEORY EX, DOI 10.1257/jep.9.2.209; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Craig AD, 2004, TRENDS COGN SCI, V8, P239, DOI 10.1016/j.tics.2004.04.004; Davis M. H., 1980, JSAS CATALOG SELECTE, V10, P1, DOI DOI 10.1037/0022-3514.44.1.113; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Gallese V, 2004, TRENDS COGN SCI, V8, P396, DOI 10.1016/j.tics.2004.07.002; Jackson PL, 2005, NEUROIMAGE, V24, P771, DOI 10.1016/j.neuroimage.2004.09.006; Josephs O, 1997, HUM BRAIN MAPP, V5, P243, DOI 10.1002/(SICI)1097-0193(1997)5:4<243::AID-HBM7>3.0.CO;2-3; Keysers C, 2004, NEURON, V42, P335, DOI 10.1016/S0896-6273(04)00156-4; Levine DK, 1998, REV ECON DYNAM, V1, P593; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; Morrison I, 2004, COGN AFFECT BEHAV NE, V4, P270, DOI 10.3758/CABN.4.2.270; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; Penny W.D., 2004, HUMAN BRAIN FUNCTION, P843; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; RABIN M, 1993, AM ECON REV, V83, P1281; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2004, NEURON, V41, P653, DOI 10.1016/S0896-6273(04)00014-5; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2	29	1017	1053	10	351	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					466	469		10.1038/nature04271	http://dx.doi.org/10.1038/nature04271			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	005XH	16421576	Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000234859200045
J	Conen, AE; Schoenenberger, RA				Conen, AE; Schoenenberger, RA			A pain in the back	LANCET			English	Editorial Material									Buergerspital, CH-4500 Solothurn, Switzerland		Conen, AE (corresponding author), Buergerspital, CH-4500 Solothurn, Switzerland.	conen_anna@gmx.net							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					240	240		10.1016/S0140-6736(06)68034-3	http://dx.doi.org/10.1016/S0140-6736(06)68034-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427493	Bronze			2022-12-28	WOS:000234810600029
J	Nattel, S; Opie, LH				Nattel, S; Opie, LH			Controversies in cardiology 3 - Controversies in atrial fibrillation	LANCET			English	Article							CORONARY-ARTERY-BYPASS; PULMONARY VEIN ISOLATION; STROKE PREVENTION; RHYTHM-CONTROL; FOLLOW-UP; ELECTRICAL CARDIOVERSION; SINUS RHYTHM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CIRCUMFERENTIAL ABLATION; CONTRACTILE DYSFUNCTION	Atrial fibrillation is the most common sustained cardiac arrhythmia, and contributes greatly to cardiovascular morbidity and mortality. Many aspects of the management of atrial fibrillation remain controversial. We address nine specific controversies in atrial fibrillation management, briefly focusing on the relations between mechanisms and therapy, the roles of rhythm and rate control, the definition of optimum rate control, the need for early cardioversion to prevent remodelling, the comparison of electrical with pharmacological cardioversion, the selection of patients for long-term oral anticoagulation, the roles of novel long-term anticoagulation approaches and ablation therapy, and the potential usefulness of upstream therapy targeting substrate development. The background of every controversy is reviewed and our opinions expressed. Here, we hope to inform physicians about the most important controversies in this specialty and stimulate investigators to address unresolved issues.	Univ Montreal, Dept Med, Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Res Ctr, Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Univ Cape Town, Hatter Inst, ZA-7925 Cape Town, South Africa	Universite de Montreal; Universite de Montreal; University of Cape Town	Nattel, S (corresponding author), Univ Montreal, Dept Med, Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.	stanley.nattel@icm-mhi.org		Nattel, Stanley/0000-0002-5565-3311				Agner E, 2002, AM HEART J, V144, P597, DOI 10.1067/mhj.2002.125326; Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690; Albers GW, 2003, LANCET, V362, P1691; Bath PMW, 2005, EUR HEART J SUPPL, V7, pC12, DOI 10.1093/eurheartj/sui015; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; Boriani G, 2003, DRUGS, V63, P1489, DOI 10.2165/00003495-200363140-00005; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; Bruins P, 1997, CIRCULATION, V96, P3542; Calo L, 2005, J AM COLL CARDIOL, V45, P1723, DOI 10.1016/j.jacc.2005.02.079; Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2; Cleland JGF, 2005, EUR J HEART FAIL, V7, P1070, DOI 10.1016/j.ejheart.2005.09.006; Conway DSG, 2003, CIRCULATION, V107, P3141, DOI 10.1161/01.CIR.0000077912.12202.FC; Cooper HA, 2004, AM J CARDIOL, V93, P1247, DOI 10.1016/j.amjcard.2004.01.069; Corley SD, 2004, CIRCULATION, V109, P1509, DOI 10.1161/01.CIR.0000121736.16643.11; Courtemanche M, 1999, CARDIOVASC RES, V42, P477, DOI 10.1016/S0008-6363(99)00034-6; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; de Denus S, 2005, ARCH INTERN MED, V165, P258, DOI 10.1001/archinte.165.3.258; Diener HC, 1997, J NEUROL SCI, V153, P112; Donnan GA, 2004, LANCET NEUROL, V3, P305, DOI 10.1016/S1474-4422(04)00738-0; Duytschaever A, 2005, CARDIOVASC RES, V67, P69, DOI 10.1016/j.cardiores.2005.02.019; Emmerich J, 2005, EUR HEART J SUPPL, V7, pC28, DOI 10.1093/eurheartj/sui017; FLEGEL KM, 1995, ANN INTERN MED, V122, P867, DOI 10.7326/0003-4819-122-11-199506010-00010; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Fynn SP, 2002, J CARDIOVASC ELECTR, V13, P135, DOI 10.1046/j.1540-8167.2002.00135.x; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685; GOLDMAN MJ, 1960, PROG CARDIOVASC DIS, V2, P465, DOI 10.1016/S0033-0620(60)80005-9; Gossage AM, 1913, Q J MED, V6, P435; Hagens VE, 2005, HEART RHYTHM, V2, P19, DOI 10.1016/j.hrthm.2004.09.028; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Healey JS, 2005, J AM COLL CARDIOL, V45, P1832, DOI 10.1016/j.jacc.2004.11.070; Heppell RM, 1997, HEART, V77, P407, DOI 10.1136/hrt.77.5.407; Hesketh JC, 2005, CURR PHARM DESIGN, V11, P1959, DOI 10.2174/1381612054021051; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Hsu LF, 2004, NEW ENGL J MED, V351, P2373, DOI 10.1056/NEJMoa041018; Jais P, 2002, CARDIOVASC RES, V54, P337, DOI 10.1016/S0008-6363(02)00263-8; Khan IA, 2003, INT J CARDIOL, V92, P113, DOI 10.1016/S0167-5273(03)00107-4; Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901; Kumagai K, 2003, J AM COLL CARDIOL, V41, P2197, DOI 10.1016/S0735-1097(03)00464-9; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lemola K, 2005, J AM COLL CARDIOL, V46, P1060, DOI 10.1016/j.jacc.2005.05.069; Leung JM, 2004, EUR HEART J, V25, P1836, DOI 10.1016/j.ehj.2004.07.014; Levine MN, 2004, CHEST, V126, p287S, DOI 10.1378/chest.126.3_suppl.287S; Li DS, 1999, CIRCULATION, V100, P87, DOI 10.1161/01.CIR.100.1.87; Li DS, 2001, CIRCULATION, V104, P2608, DOI 10.1161/hc4601.099402; Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760; LOWN B, 1967, BRIT HEART J, V29, P469; Man-Son-Hing M, 2003, ARCH INTERN MED, V163, P1580, DOI 10.1001/archinte.163.13.1580; MARYRABINE L, 1983, CIRC RES, V52, P188, DOI 10.1161/01.RES.52.2.188; McNamara RL, 2003, ANN INTERN MED, V139, P1018, DOI 10.7326/0003-4819-139-12-200312160-00012; Miller PSJ, 2005, EUR HEART J SUPPL, V7, pC41, DOI 10.1093/eurheartj/sui019; Mittal Suneet, 2003, Card Electrophysiol Rev, V7, P285, DOI 10.1023/B:CEPR.0000012397.29446.16; Nattel S, 1998, CARDIOVASC RES, V37, P567, DOI 10.1016/S0008-6363(97)00293-9; Nattel S, 2002, DRUGS, V62, P2377, DOI 10.2165/00003495-200262160-00005; Nattel S, 2002, CARDIOVASC RES, V54, P347, DOI 10.1016/S0008-6363(01)00562-4; Nattel S, 2002, NATURE, V415, P219, DOI 10.1038/415219a; Olshansky B, 2004, J AM COLL CARDIOL, V43, P1201, DOI 10.1016/j.jacc.2003.11.032; Opolski G, 2004, CHEST, V126, P476, DOI 10.1378/chest.126.2.476; Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712; Page RL, 2003, CIRCULATION, V107, P1141, DOI 10.1161/01.CIR.0000051455.44919.73; Pappone C, 2004, CIRCULATION, V109, P327, DOI 10.1161/01.CIR.0000112641.16340.C7; Pedersen OD, 1999, CIRCULATION, V100, P376, DOI 10.1161/01.CIR.100.4.376; PETERSEN P, 1990, STROKE, V21, P4, DOI 10.1161/01.STR.21.1.4; Raanani E, 2001, EUR J CARDIO-THORAC, V19, P438, DOI 10.1016/S1010-7940(01)00576-0; Rockson SG, 2004, J AM COLL CARDIOL, V43, P929, DOI 10.1016/j.jacc.2003.11.028; Roy D, 2000, NEW ENGL J MED, V342, P913, DOI 10.1056/NEJM200003303421302; Schotten U, 2003, CIRCULATION, V107, P1433, DOI 10.1161/01.CIR.0000055314.10801.4F; Shinagawa K, 2003, CIRCULATION, V107, P1440, DOI 10.1161/01.CIR.0000055316.35552.74; Singer DE, 2004, CHEST, V126, p429S, DOI 10.1378/chest.126.3_suppl.429S; Singh BN, 2005, NEW ENGL J MED, V352, P1861, DOI 10.1056/NEJMoa041705; Snow V, 2003, ANN INTERN MED, V139, P1009, DOI 10.7326/0003-4819-139-12-200312160-00011; Solomon Allen J, 2003, Card Electrophysiol Rev, V7, P172, DOI 10.1023/A:1027475819539; Stamou SC, 2001, STROKE, V32, P1508, DOI 10.1161/01.STR.32.7.1508; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; Sun H, 2001, CARDIOVASC RES, V49, P751, DOI 10.1016/S0008-6363(00)00294-7; Sun H, 1998, CIRCULATION, V98, P719, DOI 10.1161/01.CIR.98.7.719; TAYLOR GJ, 1987, AM J CARDIOL, V60, P905, DOI 10.1016/0002-9149(87)91045-9; Tieleman RG, 2005, HEART RHYTHM, V2, P223, DOI 10.1016/j.hrthm.2004.11.014; Timmermans C, 2000, J AM COLL CARDIOL, V35, P1428, DOI 10.1016/S0735-1097(00)00579-9; Tse HF, 2000, AM J CARDIOL, V86, P1023, DOI 10.1016/S0002-9149(00)01143-7; Tse HF, 1999, J CARDIOVASC ELECTR, V10, P1200, DOI 10.1111/j.1540-8167.1999.tb00296.x; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; VANGELDER IC, 2004, HEART RHYTHM S, V1, pS34; Vasishta S, 2001, ARCH GERONTOL GERIAT, V33, P219, DOI 10.1016/S0167-4943(01)00184-4; Verma A, 2005, CIRCULATION, V112, P627, DOI 10.1161/CIRCULATIONAHA.104.533190; Vermes E, 2003, CIRCULATION, V107, P2926, DOI 10.1161/01.CIR.0000072793.81076.D4; Voller H, 2005, EUR HEART J SUPPL, V7, pE4, DOI 10.1093/eurheartj/sui029; Wachtell K, 2005, J AM COLL CARDIOL, V45, P712, DOI 10.1016/j.jacc.2004.10.068; Wazni OM, 2005, JAMA-J AM MED ASSOC, V293, P2634, DOI 10.1001/jama.293.21.2634; Wazowska-Kaplon B, 2004, INT J CARDIOL, V96, P171, DOI 10.1016/ijcard.2003.05.033; Weigner MJ, 1997, ANN INTERN MED, V126, P615, DOI 10.7326/0003-4819-126-8-199704150-00005; Weigner MJ, 2001, AM J MED, V110, P694, DOI 10.1016/S0002-9343(01)00716-1; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Yue LX, 1997, CIRC RES, V81, P512, DOI 10.1161/01.RES.81.4.512	98	131	135	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					262	272		10.1016/S0140-6736(06)68037-9	http://dx.doi.org/10.1016/S0140-6736(06)68037-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427496				2022-12-28	WOS:000234810600032
J	Nori, F; Tonomura, A				Nori, F; Tonomura, A			Helical spin order on the move	SCIENCE			English	Editorial Material									Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA; RIKEN, Frontier Res Syst, Wako, Saitama 3510198, Japan; Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan	University of Michigan System; University of Michigan; RIKEN; Hitachi Limited	Nori, F (corresponding author), Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA.	nori@umich.edu; tonomura@harl.hitachi.co.jp	Nori, Franco/B-1222-2009	Nori, Franco/0000-0003-3682-7432				CHAPMAN JN, 1984, J PHYS D APPL PHYS, V17, P623, DOI 10.1088/0022-3727/17/4/003; LAI GM, 1994, J APPL PHYS, V75, P4593, DOI 10.1063/1.355955; Tonomura A, 2001, NATURE, V412, P620, DOI 10.1038/35088021; TONOMURA A, 1988, QUANTUM WORLD UNVEIL; Uchida M, 2006, SCIENCE, V311, P359, DOI 10.1126/science.1120639; YOSHIMORI A, 1959, J PHYS SOC JPN, V14, P807, DOI 10.1143/JPSJ.14.807	6	5	5	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					344	345		10.1126/science.1122627	http://dx.doi.org/10.1126/science.1122627			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424329				2022-12-28	WOS:000234938500032
J	Valderrama, F; Cordeiro, JV; Schleich, S; Frischknecht, F; Way, M				Valderrama, F; Cordeiro, JV; Schleich, S; Frischknecht, F; Way, M			Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling	SCIENCE			English	Article							HOST-RANGE; MIGRATION; ANKARA; MORPHOGENESIS; PROPAGATION; ADHESION; INVASION; INSIGHTS; KINASES; MVA	RhoA signaling plays a critical, role in many cellular processes, including cell migration. Here we show that the vaccinia F11L protein interacts directly with RhoA, inhibiting its signaling by blocking the interaction with its downstream effectors Rho-associated kinase (ROCK) and mDia. RNA interference-mediated depletion of F11L during infection resulted in an absence of vaccinia-induced cell motility and inhibition of viral morphogenesis. Disruption of the RhoA binding site in F11L, which resembles that of ROCK, led to an identical phenotype. Thus, inhibition of RhoA signaling is required for both vaccinia morphogenesis and virus-induced cell motility.	Canc Res UK, London Res Inst, Lincolns Inn Fields Labs, Cell Motil Lab, London WC2A 3PX, England	Cancer Research UK	Way, M (corresponding author), Canc Res UK, London Res Inst, Lincolns Inn Fields Labs, Cell Motil Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	michael.way@cancer.org.uk	Valderrama, Ferran/E-8017-2011; Cordeiro, Joao V/M-6122-2013	Cordeiro, Joao V/0000-0003-4605-1615; Frischknecht, Friedrich/0000-0002-8332-6668; Way, Michael/0000-0001-7207-2722				Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Carroll MW, 1997, VIROLOGY, V238, P198, DOI 10.1006/viro.1997.8845; Drexler I, 1998, J GEN VIROL, V79, P347, DOI 10.1099/0022-1317-79-2-347; Dvorsky R, 2004, J BIOL CHEM, V279, P7098, DOI 10.1074/jbc.M311911200; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gallego-Gomez JC, 2003, J VIROL, V77, P10606, DOI 10.1128/JVI.77.19.10606-10622.2003; Kato SEM, 2004, J VIROL METHODS, V115, P31, DOI 10.1016/j.jviromet.2003.09.011; Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sancho MC, 2002, J VIROL, V76, P8318, DOI 10.1128/JVI.76.16.8318-8334.2002; Sanderson CM, 1998, J VIROL, V72, P1235, DOI 10.1128/JVI.72.2.1235-1243.1998; Sanderson CM, 1998, J VIROL, V72, P9924, DOI 10.1128/JVI.72.12.9924-9933.1998; Smith A, 2003, J CELL SCI, V116, P3123, DOI 10.1242/jcs.00606; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Wyatt LS, 1998, VIROLOGY, V251, P334, DOI 10.1006/viro.1998.9397	18	91	93	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					377	381		10.1126/science.1122411	http://dx.doi.org/10.1126/science.1122411			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424340				2022-12-28	WOS:000234938500044
J	Schratt, GM; Tuebing, F; Nigh, EA; Kane, CG; Sabatini, ME; Kiebler, M; Greenberg, ME				Schratt, GM; Tuebing, F; Nigh, EA; Kane, CG; Sabatini, ME; Kiebler, M; Greenberg, ME			A brain-specific microRNA regulates dendritic spine development	NATURE			English	Article							LOCAL PROTEIN-SYNTHESIS; HIPPOCAMPAL-NEURONS; SYNAPTIC PLASTICITY; TRANSLATION; EXPRESSION; BDNF; DIFFERENTIATION; IDENTIFICATION; POTENTIATION; MECHANISMS	MicroRNAs are small, non-coding RNAs that control the translation of target messenger RNAs, thereby regulating critical aspects of plant and animal development. In the mammalian nervous system, the spatiotemporal control of mRNA translation has an important role in synaptic development and plasticity. Although a number of microRNAs have been isolated from the mammalian brain, neither the specific microRNAs that regulate synapse function nor their target mRNAs have been identified. Here we show that a brain-specific microRNA, miR-134, is localized to the synaptodendritic compartment of rat hippocampal neurons and negatively regulates the size of dendritic spines-postsynaptic sites of excitatory synaptic transmission. This effect is mediated by miR-134 inhibition of the translation of an mRNA encoding a protein kinase, Limk1, that controls spine development. Exposure of neurons to extracellular stimuli such as brain-derived neurotrophic factor relieves miR-134 inhibition of Limk1 translation and in this way may contribute to synaptic development, maturation and/or plasticity.	Childrens Hosp, Neurobiol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Med Univ Vienna, Ctr Brain Res, Div Neuronal Cell Biol, A-1090 Vienna, Austria	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Medical University of Vienna	Greenberg, ME (corresponding author), Childrens Hosp, Neurobiol Program, 300 Longwood Ave, Boston, MA 02115 USA.	Michael.Greenberg@childrens.harvard.edu		Kiebler, Michael/0000-0002-8850-6297				Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Eberwine J, 2001, P NATL ACAD SCI USA, V98, P7080, DOI 10.1073/pnas.121146698; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; GOETZE B, 2003, SCI STKE, pPL12; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Ji YY, 2005, NAT NEUROSCI, V8, P164, DOI 10.1038/nn1381; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Nagerl UV, 2004, NEURON, V44, P759, DOI 10.1016/j.neuron.2004.11.016; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; RAO A, 1991, J NEUROSCI, V11, P2881; Rusinov V, 2005, NUCLEIC ACIDS RES, V33, pW696, DOI 10.1093/nar/gki364; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Zhang XH, 2002, NEURON, V36, P675, DOI 10.1016/S0896-6273(02)01023-1; Zito K, 2004, NEURON, V44, P321, DOI 10.1016/j.neuron.2004.09.022	43	1339	1469	1	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					283	289		10.1038/nature04367	http://dx.doi.org/10.1038/nature04367			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421561				2022-12-28	WOS:000234682100033
J	van Bommel, EFH; Hendriksz, TR; Huiskes, AWLC; Zeegers, AGM				van Bommel, EFH; Hendriksz, TR; Huiskes, AWLC; Zeegers, AGM			Brief communication: Tamoxifen therapy for nonmalignant retroperitoneal fibrosis	ANNALS OF INTERNAL MEDICINE			English	Article							FOLLOW-UP; IN-VIVO; AUTOIMMUNITY; SCINTIGRAPHY	Background: Anecdotal case reports suggest tamoxifen as a possible treatment for retroperitoneal fibrosis, but a systematic assessment of its effect is not available. Objective: To describe the course and outcomes of patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen. Design: Prospective, consecutive series. Setting: Single tertiary care referral center. Patients: 19 patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen from April 1998 through April 2005. Intervention: Tamoxifen, 20 mg orally twice daily. Measurements: Clinical improvement, laboratory variables, and follow-up computed tomography (CT) and gallium scan findings. Results: Fifteen patients reported substantial resolution of symptoms after a median treatment duration of 2.5 weeks. Erythrocyte sedimentation rate and C-reactive protein also improved. Gallium scanning at follow-up showed incomplete disappearance of pathologic gallium-67 activity. Repeated CT scanning showed slow but steady mass regression in 14 of 15 clinical responders. Five patients failed treatment, including 1 patient who improved clinically. Disease recurred in 1 patient who responded to reintroduction of tamoxifen. One patient developed reversible hepatitis. Limitations: This small observational study did not have a control group. Conclusion: Tamoxifen may be a viable therapeutic option in the treatment of retroperitoneal fibrosis.	Albert Schweitzer Hosp, Dept Internal Med, NL-3300 AK Dordrecht, Netherlands	Albert Schweitzer Ziekenhuis	van Bommel, EFH (corresponding author), Albert Schweitzer Hosp, Dept Internal Med, POB 444, NL-3300 AK Dordrecht, Netherlands.	e.f.h.vanbommel@asz.nl						Al Rabi N, 2002, SCAND J UROL NEPHROL, V36, P391; Al-Musawi D, 1998, BRIT J UROL, V82, P442; Al-Salman J, 2002, SOUTHERN MED J, V95, P947, DOI 10.1097/00007611-200208000-00038; BENSON JR, 1993, LANCET, V341, P836, DOI 10.1016/0140-6736(93)90618-Q; Bourouma R, 1997, NEPHROL DIAL TRANSPL, V12, P2407, DOI 10.1093/ndt/12.11.2407; BROOKS AP, 1987, CLIN RADIOL, V38, P597, DOI 10.1016/S0009-9260(87)80334-3; Chau D, 1998, ANN PLAS SURG, V40, P490, DOI 10.1097/00000637-199805000-00008; CHAUVEAU D, 1995, J AM SOC NEPHROL, V6, P460; CLARK CP, 1991, SURGERY, V109, P502; Cotsamire D, 1991, ARTHRITIS RHEUM, V34, pR34; Cutolo M, 2004, LUPUS, V13, P635, DOI 10.1191/0961203304lu1094oa; Dedeoglu F, 2001, J RHEUMATOL, V28, P1693; Devevey J M, 1996, Prog Urol, V6, P578; Frankart L, 1997, POSTGRAD MED J, V73, P653, DOI 10.1136/pgmj.73.864.653; Garvin S, 2003, CANCER RES, V63, P8742; HARREBY M, 1994, SCAND J UROL NEPHROL, V28, P237, DOI 10.3109/00365599409181272; HIGGINS PM, 1988, BRIT J SURG, V75, P573, DOI 10.1002/bjs.1800750625; Hillebrand M, 1996, NUKLEARMED, V35, P25; JACOBSON AF, 1991, J NUCL MED, V32, P521; Kardar AH, 2002, J UROLOGY, V168, P550, DOI 10.1016/S0022-5347(05)64677-0; Kuhn MA, 2002, J SURG RES, V103, P146, DOI 10.1006/jsre.2001.6350; LOFFELD RJLF, 1993, LANCET, V341, P382, DOI 10.1016/0140-6736(93)90195-M; Marcolongo R, 2004, AM J MED, V116, P194, DOI 10.1016/j.amjmed.2003.08.033; McMurray RW, 2001, INT IMMUNOPHARMACOL, V1, P995, DOI 10.1016/S1567-5769(01)00045-5; McNamara DA, 2001, EUR J SURG ONCOL, V27, P714, DOI 10.1053/ejso.2001.1177; OWENS LV, 1995, AM SURGEON, V61, P842; Ozener C, 1997, NEPHROL DIAL TRANSPL, V12, P2166, DOI 10.1093/ndt/12.10.2166; Puce Roberto, 2000, Archivos Espanoles de Urologia, V53, P184; Seabold JE, 1997, J NUCL MED, V38, P994; SPILLANE RM, 1995, AM J ROENTGENOL, V164, P515, DOI 10.2214/ajr.164.2.7840016; TALATI SJ, 1995, CLIN NUCL MED, V20, P995, DOI 10.1097/00003072-199511000-00012; Tan MO, 2003, UROL INT, V71, P426, DOI 10.1159/000074099; Tonietto G, 1997, EUR J SURG, V163, P231; van Bommel EFH, 2002, NETH J MED, V60, P231; VANBOMMEL EFH, 1991, NETH J MED, V39, P338; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405	36	111	112	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					101	106		10.7326/0003-4819-144-2-200601170-00007	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	004AX	16418409				2022-12-28	WOS:000234725500006
J	Gleckler, PJ; Wigley, TML; Santer, BD; Gregory, JM; AchutaRao, K; Taylor, KE				Gleckler, PJ; Wigley, TML; Santer, BD; Gregory, JM; AchutaRao, K; Taylor, KE			Krakatoa's signature persists in the ocean	NATURE			English	Editorial Material									Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Univ Reading, Dept Meteorol, Reading RG6 6BB, Berks, England; Met Off Hadley Ctr, Exeter EX1 3PB, Devon, England	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Center Atmospheric Research (NCAR) - USA; University of Reading; Met Office - UK; Hadley Centre	Gleckler, PJ (corresponding author), Lawrence Livermore Natl Lab, Program Climate Model Diag & Intercomparison, Livermore, CA 94550 USA.	pgleckler@llnl.gov	Santer, Benjamin D/F-9781-2011; Gleckler, Peter/H-4762-2012; Gregory, Jonathan/J-2939-2016; Wigley, Tom M.L./B-4705-2008; Santer, Ben/ABA-1099-2021; Taylor, Karl E/F-7290-2011	Gleckler, Peter/0000-0003-2816-6224; Gregory, Jonathan/0000-0003-1296-8644; Taylor, Karl E/0000-0002-6491-2135				Barnett TP, 2005, SCIENCE, V309, P284, DOI 10.1126/science.1112418; Church JA, 2005, NATURE, V438, P74, DOI 10.1038/nature04237; Delworth TL, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024457; Levitus S, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021592; RAO KMA, IN PRESS J GEOPHYS R; Robock A, 2000, REV GEOPHYS, V38, P191, DOI 10.1029/1998RG000054	6	74	76	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					675	675		10.1038/439675a	http://dx.doi.org/10.1038/439675a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467829	Bronze, Green Published			2022-12-28	WOS:000235193100033
J	Savulescu, J				Savulescu, J			Ethics - Conscientious objection in medicine	BRITISH MEDICAL JOURNAL			English	Editorial Material							LATE TERMINATION; PREGNANCY; INTERESTS; ABORTION		Univ Oxford, Oxford Uehiro Ctr Pract Eth, Oxford OX1 1PT, England	University of Oxford	Savulescu, J (corresponding author), Univ Oxford, Oxford Uehiro Ctr Pract Eth, Oxford OX1 1PT, England.	julian.savulescu@philosophy.ox.ac.uk						*AR NEWS, SQUADS ENF ANT LAW; *ASS PRESS PAK, BAN CIG ADDS EXT PRI; BROCK DW, 1990, NEW ENGL J MED, V322, P1595, DOI 10.1056/NEJM199005313222209; *CAN PRESS, MAN SENT SYR SMOK PU; Charo RA, 2005, NEW ENGL J MED, V352, P2471, DOI 10.1056/NEJMp058112; COLLETT TS, 2004, PROTECTING HLTH CARE; *DAWN GROUP NEWSP, GOVT FORC IMPL BAN S; *DAWN GROUP NEWSP, RAWALPINDI BAN SMOK; de Crespigny LJ, 2004, MED J AUSTRALIA, V181, P201; GREEN JM, 1993, LANCET, V342, P1179, DOI 10.1016/0140-6736(93)92164-O; Harris J., 1985, VALUE LIFE; HOPE T, 1993, BRIT MED J, V306, P379, DOI 10.1136/bmj.306.6874.379; *LAKS NET, SUT PLANS SMOK BAN P; LILFORD RJ, 1993, LANCET, V342, P499, DOI 10.1016/0140-6736(93)91627-X; Maziak W, 2002, INT J TUBERC LUNG D, V6, P183; *MIDDL E ONL, IR BANS SMOK PUBL PL; *REUT, BANGL BAN SMOK PUBL; Savulescu J, 1995, J MED ETHICS, V21, P327, DOI 10.1136/jme.21.6.327; Savulescu J, 1998, J MED ETHICS, V24, P382, DOI 10.1136/jme.24.6.382; Savulescu J, 2001, J MED ETHICS, V27, P165, DOI 10.1136/jme.27.3.165; AL AHRAM WEEKLY; BANGLADESH J	22	276	286	0	23	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					294	297		10.1136/bmj.332.7536.294	http://dx.doi.org/10.1136/bmj.332.7536.294			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	011HN	16455733	Green Published			2022-12-28	WOS:000235259000027
J	Thompson, MJ; Ninis, N; Perera, R; Mayon-White, R; Phillips, C; Bailey, L; Harnden, A; Mant, D; Levin, M				Thompson, MJ; Ninis, N; Perera, R; Mayon-White, R; Phillips, C; Bailey, L; Harnden, A; Mant, D; Levin, M			Clinical recognition of meningococcal disease in children and adolescents	LANCET			English	Article							BACTERIAL-MENINGITIS; HEALTH-CARE; MANAGEMENT; FEATURES; DELIVERY; ADULTS	Background Meningococcal disease is a rapidly progressive childhood infection of global importance. To our knowledge, no systematic quantitative research exists into the occurrence of symptoms before admission to hospital. Methods Data were obtained from questionnaires answered by parents and from primary-care records for the course of illness before admission to hospital in 448 children (103 fatal, 345 non-fatal), aged 16 years or younger, with meningococcal disease. In 373 cases, diagnosis was confirmed with microbiological techniques. The rest of the children were included because they had a purpuric rash, and either meningitis or evidence of septicaemic shock. Results were standardised to UK case-fatality rates. Findings The time-window for clinical diagnosis was narrow. Most children had only non-specific symptoms in the first 4-6 h, but were close to death by 24 h. Only 165 (51%) children were sent to hospital after the first consultation. The classic features of haemorrhagic rash, meningism, and impaired consciousness developed late (median onset 13-22 h). By contrast, 72% of children had early symptoms of sepsis (leg pains, cold hands and feet, abnormal skin colour) that first developed at a median time of 8 h, much earlier than the median time to hospital admission of 19 h. Interpretation Classic clinical features of meningococcal disease appear late in the illness. Recognising early symptoms of sepsis could increase the proportion of children identified by primary-care clinicians and shorten the time to hospital admission. The framework within which meningococcal disease is diagnosed should be changed to emphasise identification of these early symptoms by parents and clinicians.	Univ Oxford, Dept Primary Hlth Care, Oxford, England; Univ London Imperial Coll Sci & Technol, Fac Med, Dept Paediat, London, England	University of Oxford; Imperial College London	Thompson, MJ (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford, England.		Mant, David CA/C-7763-2009	Perera, Rafael/0000-0003-2418-2091; Levin, Michael/0000-0003-2767-6919	Medical Research Council [G0000340] Funding Source: Medline; MRC [G0000340] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BRANDTZAEG P, 2003, OXFORD TXB MED, P478; Davison K L, 2002, Commun Dis Public Health, V5, P205; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Goldacre MJ, 2003, BRIT MED J, V327, P596, DOI 10.1136/bmj.327.7415.596; Granier S, 1998, BRIT J GEN PRACT, V48, P1167; Harrison LH, 1999, JAMA-J AM MED ASSOC, V281, P1906, DOI 10.1001/jama.281.20.1906; *HLTH PROT AG, 2002, ENH SURV MEN DIS; Inkelis SH, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e3; Nadel S, 1998, J ACCID EMERG MED, V15, P298; Ninis N, 2005, BRIT MED J, V330, P1475, DOI 10.1136/bmj.330.7506.1475; Ragunathan L, 2000, J INFECTION, V40, P74, DOI 10.1053/jinf.1999.0595; Ramsay M, 1997, COMMUN DIS REP CDR R, V7, pR49; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; Rosenstein NE, 1999, J INFECT DIS, V180, P1894, DOI 10.1086/315158; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; SORENSEN HT, 1992, J CLIN EPIDEMIOL, V45, P1289; STUART JM, 1997, C D R REV, V7, P3; TARLOW MJ, 1992, LANCET, V340, P1481, DOI 10.1016/0140-6736(92)92678-9; Tikhomirov Eugene, 1997, World Health Statistics Quarterly, V50, P170; van de Beek D, 2004, NEW ENGL J MED, V351, P1849, DOI 10.1056/NEJMoa040845; van Deuren M, 2000, CLIN MICROBIOL REV, V13, P144, DOI 10.1128/CMR.13.1.144-166.2000	21	306	315	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					397	403		10.1016/S0140-6736(06)67932-4	http://dx.doi.org/10.1016/S0140-6736(06)67932-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458763				2022-12-28	WOS:000235139400028
J	Huai, Q; Mazar, AP; Kuo, A; Parry, GC; Shaw, DE; Callahan, J; Li, YD; Yuan, C; Bian, CB; Chen, LQ; Furie, B; Furie, BC; Cines, DB; Huang, MD				Huai, Q; Mazar, AP; Kuo, A; Parry, GC; Shaw, DE; Callahan, J; Li, YD; Yuan, C; Bian, CB; Chen, LQ; Furie, B; Furie, BC; Cines, DB; Huang, MD			Structure of human urokinase plasminogen activator in complex with its receptor	SCIENCE			English	Article							BINDING; UPAR; METASTASIS; INHIBITION; RESIDUES; INVASION; SYSTEM; GROWTH	The urokinase plasminogen activator binds to its cellular receptor with high affinity and initiates signaling cascades that are implicated in pathological processes including tumor growth, metastasis, and inflammation. We report the crystal structure at 1.9 angstroms of the urokinase receptor complexed with the urokinase amino-terminal fragment and an antibody against the receptor. The three domains of urokinase receptor form a concave shape with a central cone-shaped cavity where the urokinase fragment inserts. The structure provides insight into the flexibility of the urokinase receptor that enables its interaction with a wide variety of ligands and a basis for the design of urokinase-urokinase receptor antagonists.	Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Div Hemostasis & Thrombosis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Attenuon LLC, San Diego, CA 92121 USA; Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Peoples R China; Univ Alabama, Struct Biol Lab, Dept Chem, Grad Program Biotechnol, Huntsville, AL 35899 USA; Univ Alabama, Struct Biol Lab, Dept Chem, Grad Program Chem, Huntsville, AL 35899 USA; Univ Alabama, Struct Biol Lab, Dept Chem, Grad Program Mat Sci, Huntsville, AL 35899 USA; DE Shaw Res & Dev, New York, NY 10036 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Pennsylvania; Chinese Academy of Sciences; Fujian Institute of Research on the Structure of Matter, CAS; University of Alabama System; University of Alabama Huntsville; University of Alabama System; University of Alabama Huntsville; University of Alabama System; University of Alabama Huntsville; D. E. Shaw Research	Huang, MD (corresponding author), Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Div Hemostasis & Thrombosis, Boston, MA 02215 USA.	mhuang@fjirsm.ac.cn	Huang, Mingdong/J-4278-2017	Huang, Mingdong/0000-0003-0085-9141	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086584] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL086584-01, R01 HL086584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Behrendt N, 2004, BIOL CHEM, V385, P103, DOI 10.1515/BC.2004.031; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P4847, DOI 10.1021/bi00182a013; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Magdolen V, 1996, EUR J BIOCHEM, V237, P743, DOI 10.1111/j.1432-1033.1996.0743p.x; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; Myohanen H, 2004, CELL MOL LIFE SCI, V61, P2840, DOI 10.1007/s00018-004-4230-9; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006; QUATTRONE A, 1995, ANTI-CANCER DRUG DES, V10, P97; Quax PHA, 1998, ARTERIOSCL THROM VAS, V18, P693, DOI 10.1161/01.ATV.18.5.693; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; Stephens RW, 1997, CLIN CHEM, V43, P1868; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	22	244	262	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2006	311	5761					656	659		10.1126/science.1121143	http://dx.doi.org/10.1126/science.1121143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456079				2022-12-28	WOS:000235257400047
J	Bard, F; Casano, L; Mallabiabarrena, A; Wallace, E; Saito, K; Kitayama, H; Guizzunti, G; Hu, Y; Wendler, F; DasGupta, R; Perrimon, N; Malhotra, V				Bard, F; Casano, L; Mallabiabarrena, A; Wallace, E; Saito, K; Kitayama, H; Guizzunti, G; Hu, Y; Wendler, F; DasGupta, R; Perrimon, N; Malhotra, V			Functional genomics reveals genes involved in protein secretion and Golgi organization	NATURE			English	Article							MITOSIS; TRANSPORT; MECHANISM; NUCLEAR; GROWTH; CELLS	Yeast genetics and in vitro biochemical analysis have identified numerous genes involved in protein secretion(1,2). As compared with yeast, however, the metazoan secretory pathway is more complex and many mechanisms that regulate organization of the Golgi apparatus remain poorly characterized. We performed a genome-wide RNA-mediated interference screen in a Drosophila cell line to identify genes required for constitutive protein secretion. We then classified the genes on the basis of the effect of their depletion on organization of the Golgi membranes. Here we show that depletion of class A genes redistributes Golgi membranes into the endoplasmic reticulum, depletion of class B genes leads to Golgi fragmentation, depletion of class C genes leads to aggregation of Golgi membranes, and depletion of class D genes causes no obvious change. Of the 20 new gene products characterized so far, several localize to the Golgi membranes and the endoplasmic reticulum.	Univ Calif San Diego, Dept Cell & Dev Biol, La Jolla, CA 92093 USA; Natl Inst Med Res, London NW7 1AA, England; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	University of California System; University of California San Diego; MRC National Institute for Medical Research; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Malhotra, V (corresponding author), Univ Calif San Diego, Dept Cell & Dev Biol, La Jolla, CA 92093 USA.	malhotra@biomail.ucsd.edu	BARD, Frederic/G-9914-2011; Malhotra, Vivek/O-9811-2014	BARD, Frederic/0000-0002-3783-4805; Malhotra, Vivek/0000-0001-6198-7943; Perrimon, Norbert/0000-0001-7542-472X; Saito, Kota/0000-0003-2478-2687; Dasgupta, Ramanuj/0000-0001-9015-3729				Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Chua JJE, 2004, VIRUS RES, V102, P151, DOI 10.1016/j.virusres.2004.01.025; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; De Langhe S, 2002, INT J MOL MED, V9, P451; Dilcher M, 2003, EMBO J, V22, P3664, DOI 10.1093/emboj/cdg339; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; Eggert US, 2004, PLOS BIOL, V2, P2135, DOI 10.1371/journal.pbio.0020379; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; Sharp DJ, 2002, CURR BIOL, V12, pR585, DOI 10.1016/S0960-9822(02)01098-9; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Snaith HA, 1996, J CELL SCI, V109, P3001; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; Uhlmann F, 2003, BIOCHEM SOC SYMP, V70, P243, DOI 10.1042/bss0700243	18	258	274	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					604	607		10.1038/nature04377	http://dx.doi.org/10.1038/nature04377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452979				2022-12-28	WOS:000235033900044
J	Davidson, B; Christiaen, L				Davidson, B; Christiaen, L			Linking chordate gene networks to cellular behavior in ascidians	CELL			English	Editorial Material							CIONA-INTESTINALIS; MESSENGER-RNAS; NOTOCHORD; SPECIFICATION; EMBRYOS; DIFFERENTIATION; POLARITY; CORTEX	Embryos of simple chordates called ascidians (sea squirts) have few cells, develop rapidly, and are transparent, enabling the in vivo fluorescent imaging of labeled cell lineages. Ascidians are also simple genetically, with limited redundancy and compact regulatory regions. This cellular and genetic simplicity is now being exploited to link comprehensive gene networks to the cellular events underlying morphogenesis.	Univ Calif Berkeley, Div Genet & Dev, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Davidson, B (corresponding author), Univ Calif Berkeley, Div Genet & Dev, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA.	bandl@berkeley.edu		Christiaen, Lionel/0000-0001-5930-5667; Davidson, Brad/0000-0001-5082-7872				Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; Davidson B, 2005, DEVELOPMENT, V132, P4811, DOI 10.1242/dev.02051; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Imai KS, 2004, DEVELOPMENT, V131, P4047, DOI 10.1242/dev.01270; Jiang D, 2005, CURR BIOL, V15, P79; Munro EM, 2002, DEVELOPMENT, V129, P13; Munro EM, 2002, DEVELOPMENT, V129, P1; Nakamura Y, 2005, DEVELOPMENT, V132, P4731, DOI 10.1242/dev.02049; Nishida H, 2005, DEV DYNAM, V233, P1177, DOI 10.1002/dvdy.20469; Nishida H, 2001, NATURE, V409, P724, DOI 10.1038/35055568; Prodon F, 2005, J CELL SCI, V118, P2393, DOI 10.1242/jcs.02366; Rhee JM, 2005, GENESIS, V43, P136, DOI 10.1002/gene.20164; Sardet C, 2005, BIOL CELL, V97, P35; Takahashi H, 1999, GENE DEV, V13, P1519, DOI 10.1101/gad.13.12.1519; Yagi K, 2005, DEV BIOL, V282, P535, DOI 10.1016/j.ydbio.2005.03.029	15	14	14	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					247	250		10.1016/j.cell.2006.01.013	http://dx.doi.org/10.1016/j.cell.2006.01.013			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439196	Bronze			2022-12-28	WOS:000235068500009
J	Ludlam, CA; Powderly, WG; Bozzette, S; Diamond, M; Koerper, MA; Kulkarni, K; Ritchie, B; Siegel, J; Simmonds, P; Stanley, S; Tapper, ML; von Depka, M				Ludlam, CA; Powderly, WG; Bozzette, S; Diamond, M; Koerper, MA; Kulkarni, K; Ritchie, B; Siegel, J; Simmonds, P; Stanley, S; Tapper, ML; von Depka, M			Clinical perspectives of emerging pathogens in bleeding disorders	LANCET			English	Review							CREUTZFELDT-JAKOB-DISEASE; WEST-NILE-VIRUS; POLYMERASE-CHAIN-REACTION; ALPHA-2A PLUS RIBAVIRIN; CHRONIC HEPATITIS-C; CANINE-PARVOVIRUS; BLOOD-TRANSFUSION; ENTEROVIRUS 71; HOST-RANGE; BK VIRUS	As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe in terms of many known infectious agents, including hepatitis B and C viruses, HIV, and human T-cell lymphotropic virus. However, emerging pathogens could pose future threats, particularly those with blood-borne stages that are resistant to viral-inactivation steps in the manufacturing process, such as non-lipid-coated viruses. As outlined in this Review, better understanding of infectious diseases allows challenges from newly described agents of potential concern in the future to be anticipated, but the processes of zoonotic transmission and genetic selection or modification ensure that plasma-derived products will continue to be subject to infectious concerns. Manufacturers of plasma-derived CFC have addressed the issue of emerging infectious agents by developing recombinant products that limit the need for human plasma during production. Such recombinant products have extended the safety profile of their predecessors by ensuring that all reagents used for cell culture, purification steps, and stabilisation and storage buffers are completely independent of human plasma.	Univ Edinburgh, Edinburgh, Midlothian, Scotland; Univ Coll Dublin, Dublin 2, Ireland; Univ Calif San Diego, San Diego, CA 92103 USA; Washington Univ, St Louis, MO USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Michigan State Univ, E Lansing, MI 48824 USA; Univ Alberta, Edmonton, AB, Canada; Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA; Lenox Hill Hosp, New York, NY 10021 USA; Hannover Med Sch, Hannover, Germany	University of Edinburgh; University College Dublin; University of California System; University of California San Diego; Washington University (WUSTL); University of California System; University of California San Francisco; Michigan State University; University of Alberta; Jefferson University; Northwell Health; Hannover Medical School	Ludlam, CA (corresponding author), Royal Infirm, Dept Clin & Lab Haematol, Edinburgh EH16 4SA, Midlothian, Scotland.	Christopher.Ludlam@ed.ac.uk		Powderly, William/0000-0001-7808-3086; Ritchie, Bruce/0000-0003-4754-1050; Simmonds, Peter/0000-0002-7964-4700	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057160] Funding Source: NIH RePORTER; NIAID NIH HHS [U54AI057160] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baatz G, 1992, Tierarztl Prax, V20, P69; BASTIANELLO SS, 1981, J S AFR VET ASSOC, V52, P105; Behzad-Behbahani A, 2004, J CLIN VIROL, V29, P224, DOI 10.1016/S1386-6532(03)00155-0; Berger JR, 1999, SEMIN NEUROL, V19, P193, DOI 10.1055/s-2008-1040837; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; Busch MP, 2003, JAMA-J AM MED ASSOC, V289, P959, DOI 10.1001/jama.289.8.959; Butler D, 2004, NATURE, V429, P7, DOI 10.1038/429007b; *CDCP, DIV VECT BORN INF DI; Chamberland ME, 2002, CLIN INFECT DIS, V34, P797, DOI 10.1086/338787; Chan YF, 2004, EMERG INFECT DIS, V10, P1468; Chang LY, 2004, JAMA-J AM MED ASSOC, V291, P222, DOI 10.1001/jama.291.2.222; Chang LY, 1999, PEDIATR INFECT DIS J, V18, P1092, DOI 10.1097/00006454-199912000-00013; Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432; Chung RT, 2004, NEW ENGL J MED, V351, P451, DOI 10.1056/NEJMoa032653; Croul S, 2003, J NEUROVIROL, V9, P173, DOI 10.1080/13550280390194055; Diamondstone LS, 2002, HAEMOPHILIA, V8, P660, DOI 10.1046/j.1365-2516.2002.00651.x; Dobson A, 2001, PHILOS T R SOC B, V356, P1001, DOI 10.1098/rstb.2001.0900; Dodd RY, 2004, ANNU REV MED, V55, P191, DOI 10.1146/annurev.med.55.091902.103831; Dolei A, 2000, J GEN VIROL, V81, P1967, DOI 10.1099/0022-1317-81-8-1967; Enserink M, 2004, SCIENCE, V303, P1121; Fenaux M, 2000, J CLIN MICROBIOL, V38, P2494, DOI 10.1128/JCM.38.7.2494-2503.2000; GROWE G, 1995, CAN MED ASSOC J, V153, P19; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; HILGARTNER MW, 1991, SEMIN HEMATOL, V28, P6; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill FGH, 2004, AIDS, V18, P525, DOI [10.1097/01.aids.0000104368.21567.3c, 10.1097/00002030-200402200-00020]; Hino S, 2002, REV MED VIROL, V12, P151, DOI 10.1002/rmv.351; Hoots WK, 2001, TRANSFUS MED REV, V15, P1, DOI 10.1053/tm.2001.25375; Huang CC, 1999, NEW ENGL J MED, V341, P936, DOI 10.1056/NEJM199909233411302; Huhn GD, 2003, AM FAM PHYSICIAN, V68, P653; Ikeda Y, 2002, EMERG INFECT DIS, V8, P341, DOI 10.3201/eid0804.010228; JASON J, 1985, JAMA-J AM MED ASSOC, V253, P3409; Komar Nicholas, 2003, Adv Virus Res, V61, P185; Komatsu H, 1999, PEDIATR NEUROL, V20, P17, DOI 10.1016/S0887-8994(98)00087-3; Lee DC, 2001, TRANSFUSION, V41, P449, DOI 10.1046/j.1537-2995.2001.41040449.x; Li CC, 2002, SCAND J INFECT DIS, V34, P104, DOI 10.1080/00365540110077119; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Ludlam CA, 2006, BRIT J HAEMATOL, V132, P13, DOI 10.1111/j.1365-2141.2005.05796.x; MacGregor I, 2001, TRANSFUSION, V41, P1453, DOI 10.1046/j.1537-2995.2001.41111453.x; Maggi F, 2003, J VIROL, V77, P2418, DOI 10.1128/JVI.77.4.2418-2425.2003; Mairuhu ATA, 2004, EUR J CLIN MICROBIOL, V23, P425, DOI 10.1007/s10096-004-1145-1; Makris M, 2001, HAEMOPHILIA, V7, P339, DOI 10.1046/j.1365-2516.2001.00527.x; MEEGAN JM, 1979, VET REC, V105, P124, DOI 10.1136/vr.105.6.124; MOCHIZUKI M, 1993, VET MICROBIOL, V38, P1, DOI 10.1016/0378-1135(93)90070-N; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; Mylonakis E, 2001, TRANSPLANTATION, V72, P1587, DOI 10.1097/00007890-200111270-00001; *NAT HEM FDN, 2003, 151 NAT HEM FDN; Parrish CR, 1999, VET MICROBIOL, V69, P29, DOI 10.1016/S0378-1135(99)00084-X; Patience C, 1998, CURR OPIN IMMUNOL, V10, P539, DOI 10.1016/S0952-7915(98)80220-3; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Pereira CAD, 2000, VET MICROBIOL, V75, P127, DOI 10.1016/S0378-1135(00)00214-5; Pomper GJ, 2003, CURR OPIN HEMATOL, V10, P412, DOI 10.1097/00062752-200311000-00003; POON MC, 1983, ANN INTERN MED, V98, P287, DOI 10.7326/0003-4819-98-3-287; Reiter P, 2003, EMERG INFECT DIS, V9, P86; Ritchie BC, 2003, TRANSFUS APHER SCI, V29, P269, DOI 10.1016/j.transci.2003.08.010; Rockstroh JK, 2004, LANCET INFECT DIS, V4, P437, DOI 10.1016/S1473-3099(04)01059-X; ROTHSCHILD C, 2003, J THROMB HAEMOST S, V1; SALAS R, 1991, LANCET, V338, P1033, DOI 10.1016/0140-6736(91)91899-6; Scaramozzino N, 2001, J CLIN MICROBIOL, V39, P1922, DOI 10.1128/JCM.39.5.1922-1927.2001; Seth P, 2003, J NEUROVIROL, V9, P236, DOI 10.1080/13550280390194019; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Solomon T, 2004, ARCH VIROL, P161; Solomon T, 2004, NEW ENGL J MED, V351, P370, DOI 10.1056/NEJMra030476; Solomon T, 2003, BMJ-BRIT MED J, V326, P865, DOI 10.1136/bmj.326.7394.865; Solomon T, 2001, J INFECTION, V42, P104, DOI 10.1053/jinf.2001.0802; Solomon T, 2002, CURR TOP MICROBIOL, V267, P171; Soucie JM, 2000, BLOOD, V96, P437; Takeuchi Y, 1998, J VIROL, V72, P9986, DOI 10.1128/JVI.72.12.9986-9991.1998; Thio Chloe L, 2004, AIDS Read, V14, P122; Thio CL, 2004, AIDS READ, V14, P133; Thio CL, 2004, AIDS READ, V14, P136; Tiroumourougane SV, 2002, POSTGRAD MED J, V78, P205, DOI 10.1136/pmj.78.918.205; Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842; TRUYEN U, 1992, J VIROL, V66, P5399, DOI 10.1128/JVI.66.9.5399-5408.1992; *UN ENV PROGR, 2004, GEO YB; United Kingdom Haemophilia Centre, 2003, HAEMOPHILIA, V9, P1; Vandamme AM, 1996, J GEN VIROL, V77, P1089, DOI 10.1099/0022-1317-77-5-1089; Vats A, 2003, TRANSPLANTATION, V75, P105, DOI 10.1097/00007890-200301150-00020; Vorberg I, 2004, J INFECT DIS, V189, P431, DOI 10.1086/381166; Weiss RA, 2004, NAT MED, V10, pS70, DOI 10.1038/nm1150; Welch J, 2003, TRANSFUSION, V43, P1060, DOI 10.1046/j.1537-2995.2003.00463.x; Westbury HA, 2000, REV SCI TECH OIE, V19, P151, DOI 10.20506/rst.19.1.1203; *WHO, STRENGTH IMPL GLOB S; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	84	46	47	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					252	261		10.1016/S0140-6736(06)68036-7	http://dx.doi.org/10.1016/S0140-6736(06)68036-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427495	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000234810600031
J	Mukha, I; Roeckl, E; Batist, L; Blazhev, A; Doring, J; Grawe, H; Grigorenko, L; Huyse, M; Janas, Z; Kirchner, R; La Commara, M; Mazzocchi, C; Tabor, SL; Van Duppen, P				Mukha, I; Roeckl, E; Batist, L; Blazhev, A; Doring, J; Grawe, H; Grigorenko, L; Huyse, M; Janas, Z; Kirchner, R; La Commara, M; Mazzocchi, C; Tabor, SL; Van Duppen, P			Proton-proton correlations observed in two-proton radioactivity of Ag-94	NATURE			English	Article							DECAY; EMISSION; ISOTOPES; NUCLEI; FE-45; STATE	The stability and spontaneous decay of naturally occurring atomic nuclei have been much studied ever since Becquerel discovered natural radioactivity in 1896. In 1960, proton-rich nuclei with an odd or an even atomic number Z were predicted(1) to decay through one- and two-proton radioactivity, respectively. The experimental observation of one- proton radioactivity was first reported(2) in 1982, and two-proton radioactivity has now also been detected by experimentally studying the decay properties of Fe-45 (refs 3, 4) and Zn-54 (ref. 5). Here we report proton-proton correlations observed during the radioactive decay of a spinning long-lived state of the lightest known isotope of silver(6), Ag-94, which is known to undergo one- proton decay(7). We infer from these correlations that the long-lived state must also decay through simultaneous two-proton emission, making Ag-94 the first nucleus to exhibit one-as well as two-proton radioactivity. We attribute the two-proton emission behaviour and the unexpectedly large probability for this decay mechanism to a very large deformation of the parent nucleus into a prolate (cigar-like) shape, which facilitates emission of protons either from the same or from opposite ends of the 'cigar'.	Gesell Schwerionenforsch mbH, D-64291 Darmstadt, Germany; Katholieke Univ Leuven, Inst Kern & Stralingsfys, B-3001 Louvain, Belgium; IV Kurchatov Atom Energy Inst, RU-123184 Moscow, Russia; St Petersburg Nucl Phys Inst, RU-188350 Gatchina, Russia; Univ Sofia, BG-1164 Sofia, Bulgaria; Joint Inst Nucl Res Dubna, Flerov Lab Nucl React, RU-141980 Dubna, Russia; Univ Warsaw, PL-00681 Warsaw, Poland; Univ Naples Federico 2, I-80126 Naples, Italy; Ist Nazl Fis Nucl, I-80126 Naples, Italy; Florida State Univ, Tallahassee, FL 32306 USA	Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research; KU Leuven; National Research Centre - Kurchatov Institute; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; University of Sofia; Joint Institute for Nuclear Research - Russia; University of Warsaw; University of Naples Federico II; Istituto Nazionale di Fisica Nucleare (INFN); State University System of Florida; Florida State University	Mukha, I (corresponding author), Univ Seville, ES-41080 Seville, Spain.	I.Mukha@gsi.de	Huyse, Mark/ABC-7645-2020	Mazzocchi, Chiara/0000-0003-2503-5413; Janas, Zenon/0000-0001-8621-0954; Mukha, Ivan/0000-0003-3072-5670; Van Duppen, Piet/0000-0002-5053-7370				Audi G, 2003, NUCL PHYS A, V729, P337, DOI 10.1016/j.nuclphysa.2003.11.003; Blank B, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.232501; BOCHKAREV OV, 1989, NUCL PHYS A, V505, P215, DOI 10.1016/0375-9474(89)90371-0; BOCHKAREV OV, 1990, SOV J NUCL PHYS+, V52, P964; CABLE MD, 1983, PHYS REV LETT, V50, P404, DOI 10.1103/PhysRevLett.50.404; CERNY J, 1977, ANNU REV NUCL PART S, V27, P333, DOI 10.1146/annurev.ns.27.120177.002001; Chromik MJ, 2002, PHYS REV C, V66, DOI 10.1103/PhysRevC.66.024313; del Campo JG, 2001, PHYS REV LETT, V86, P43, DOI 10.1103/PhysRevLett.86.43; Giovinazzo J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.102501; GOLDANSKY VI, 1960, NUCL PHYS, V19, P482, DOI 10.1016/0029-5582(60)90258-3; Grigorenko LV, 2000, PHYS REV LETT, V85, P22, DOI 10.1103/PhysRevLett.85.22; Grigorenko LV, 2003, PHYS REV C, V68, DOI 10.1103/PhysRevC.68.054005; Grigorenko LV, 2003, NUCL PHYS A, V714, P425, DOI 10.1016/S0375-9474(02)01374-X; Grigorenko LV, 2001, PHYS REV C, V64, DOI 10.1103/PhysRevC.64.054002; HOFMANN S, 1982, Z PHYS A-HADRON NUCL, V305, P111, DOI 10.1007/BF01415018; Kast D, 1997, Z PHYS A-HADRON NUCL, V356, P363, DOI 10.1007/s002180050190; KIRCHNER R, 1992, NUCL INSTRUM METH B, V70, P186, DOI 10.1016/0168-583X(92)95930-P; KRYGER RA, 1995, PHYS REV LETT, V74, P860, DOI 10.1103/PhysRevLett.74.860; La Commara M, 2002, NUCL PHYS A, V708, P167, DOI 10.1016/S0375-9474(02)01024-2; LANE AM, 1958, REV MOD PHYS, V30, P257, DOI 10.1103/RevModPhys.30.257; Mukha I, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.022501; Mukha I, 2004, PHYS REV C, V70, DOI 10.1103/PhysRevC.70.044311; OHLSEN GG, 1965, NUCL INSTRUM METHODS, V37, P240, DOI 10.1016/0029-554X(65)90368-X; Pfutzner M, 2002, EUR PHYS J A, V14, P279, DOI 10.1140/epja/i2002-10033-9; PHILLIPS RJN, 1960, NUCL PHYS, V21, P686, DOI 10.1016/0029-5582(60)90087-0; Plettner C, 2004, NUCL PHYS A, V733, P20, DOI 10.1016/j.nuclphysa.2003.12.014; Roeckl E, 2003, NUCL INSTRUM METH B, V204, P53, DOI 10.1016/S0168-583X(02)01890-6; SCHMIDT K, 1994, Z PHYS A-HADRON NUCL, V350, P99, DOI 10.1007/BF01290677; TWIN PJ, 1986, PHYS REV LETT, V57, P811, DOI 10.1103/PhysRevLett.57.811; Zerguerras T, 2004, EUR PHYS J A, V20, P389, DOI 10.1140/epja/i2003-10176-1	30	123	132	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					298	302		10.1038/nature04453	http://dx.doi.org/10.1038/nature04453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421564				2022-12-28	WOS:000234682100036
J	English, M; Snow, RW				English, M; Snow, RW			Iron and folic acid supplementation and malaria risk	LANCET			English	Editorial Material							ROUTINE PROPHYLACTIC SUPPLEMENTATION; CHILDREN; TRANSMISSION; MORTALITY; AFRICA		Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Programme, Nairobi, Kenya	Kenya Medical Research Institute	English, M (corresponding author), Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Programme, Nairobi, Kenya.	menglish@wtnairobi.mimcom.net	Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; English, Michael/0000-0002-7427-0826				[Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Carter JY, 2005, AM J TROP MED HYG, V73, P166, DOI 10.4269/ajtmh.2005.73.166; Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3; MURRAY MJ, 1978, BRIT MED J, V2, P1113, DOI 10.1136/bmj.2.6145.1113; Oppenheimer SJ, 2001, J NUTR, V131, p616S, DOI 10.1093/jn/131.2.616S; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; Schellenberg JRMA, 2004, LANCET, V364, P1583, DOI 10.1016/S0140-6736(04)17311-X; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4	11	29	30	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					90	91		10.1016/S0140-6736(06)67939-7	http://dx.doi.org/10.1016/S0140-6736(06)67939-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413858				2022-12-28	WOS:000234655500006
J	Vento, S; Cainelli, F; Temesgen, Z				Vento, S; Cainelli, F; Temesgen, Z			Interleukin-2 therapy and CD4+T cells in HIV-1 infection	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; T-CELLS; EXPANSION; TRIAL		Univ Verona, Dept Pathol, Infect Dis Sect, I-37138 Verona, Italy; Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA	University of Verona; Mayo Clinic	Vento, S (corresponding author), Univ Verona, Dept Pathol, Infect Dis Sect, I-37138 Verona, Italy.	ventosandro@yahoo.it	Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062; Cainelli, Francesca/0000-0003-1838-3946				De Paoli P, 2001, CLIN EXP IMMUNOL, V125, P440, DOI 10.1046/j.1365-2249.2001.01615.x; Douek Daniel C., 2003, AIDS Reviews, V5, P172; Emery S, 2000, J INFECT DIS, V182, P428, DOI 10.1086/315736; Hengge UR, 1998, AIDS, V12, pF225, DOI 10.1097/00002030-199817000-00003; Kovacs JA, 2005, J CLIN INVEST, V115, P2139, DOI 10.1172/JCI23196; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; Levy Y, 1999, LANCET, V353, P1923, DOI 10.1016/S0140-6736(98)07345-0; Sereti I, 2004, BLOOD, V104, P775, DOI 10.1182/blood-2003-12-4355; Sereti I, 2005, J CLIN INVEST, V115, P1839, DOI 10.1172/JCI24307; Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804	10	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					93	95		10.1016/S0140-6736(06)67941-5	http://dx.doi.org/10.1016/S0140-6736(06)67941-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413860				2022-12-28	WOS:000234655500008
J	Gomes, B; Higginson, IJ				Gomes, B; Higginson, IJ			Factors influencing death at home in terminally ill patients with cancer: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PALLIATIVE-CARE; SOUTH-AUSTRALIA; HOSPICE CARE; PATIENTS DIE; BACK-PAIN; PLACE; LIFE; DETERMINANTS; END; PREDICTORS	Objectives To determine the relative influence of different factors on place of death in patients with cancer. Data sources Four electronic databases-Medline (1966-2004), PsycINFO (1972-2004), CINAHL (1982-2004), and ASSIA (1987-2004); previous contacts with key experts; hand search of six relevant journals. Review methods We generated a conceptual model, against which studies were analysed. Included studies had original data on risk factors for place of death among patients, > 80% of whom had cancer. Strength of evidence was assigned according to the quantity and quality of studies and consistency of findings. Odds ratios for home death were plotted for factors with high strength evidence. Results 58 studies were included, with over 1.5 million patients from 13 countries. There was high strength evidence for the effect of 17 factors on place of death, of which six were strongly associated with home death: patients' low functional status (odds ratios range 2.29-11.1), their preferences (2.19-8.38), home care (1.37-5.1) and its intensity (1.06-8.65), living with relatives (1.78-7.85), and extended family support (2.28-5.47). The risk factors covered all groups of the model: related to illness, the individual and the environment (healthcare input and social support), the latter found to be the most important. Conclusions The network of factors that influence where patients with cancer die is complicated. Future policies and clinical practice should focus on ways of empowering families and public education, as well as intensifying home care, risk assessment, and training practitioners in end of life care.	Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Fdn, London SE5 9RJ, England	University of London; King's College London	Gomes, B (corresponding author), Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Fdn, London SE5 9RJ, England.	barbara.gomes_da_silva@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313; Gomes, Barbara/0000-0001-8149-1806				ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], GOLD STANDARDS FRAME; [Anonymous], 2005, MORT STAT; Auchincloss AH, 2001, J AGING HEALTH, V13, P329, DOI 10.1177/089826430101300302; BASS DM, 1985, OMEGA-J DEATH DYING, V16, P51; BASS DM, 1984, DEATH EDUC, V8, P199, DOI 10.1080/07481188408252460; Brazil Kevin, 2002, BMC Palliat Care, V1, P2, DOI 10.1186/1472-684X-1-2; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; Bruera E, 2003, J PAIN SYMPTOM MANAG, V26, P637, DOI 10.1016/S0885-3924(03)00204-5; Bruera E, 2002, J CLIN ONCOL, V20, P2127, DOI 10.1200/JCO.2002.08.138; Burge F, 2003, CAN MED ASSOC J, V168, P265; Burge Frederick, 2003, J Palliat Med, V6, P911, DOI 10.1089/109662103322654794; Cantwell P, 2000, J PALLIATIVE CARE, V16, P23, DOI 10.1177/082585970001600105; CATALANFERNANDEZ JG, 1991, MED CARE, V29, P841, DOI 10.1097/00005650-199109000-00005; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; Chow E, 2001, CLIN ONCOL-UK, V13, P209, DOI 10.1007/s001740170078; Costantini M, 2000, PUBLIC HEALTH, V114, P15, DOI 10.1016/S0033-3506(00)00302-4; Costantini Massimo, 1993, Palliative Medicine, V7, P323; Dansky KH, 2001, TELEMED J E-HEALTH, V7, P225, DOI 10.1089/153056201316970920; DeConno F, 1996, EUR J CANCER, V32A, P1142, DOI 10.1016/0959-8049(96)00036-6; Ebell MH, 2004, J AM BOARD FAM PRACT, V17, P59, DOI 10.3122/jabfm.17.1.59; Ellershaw JE, 2003, CARE DYING PATHWAY E; Ferreira PH, 2002, J CLIN EPIDEMIOL, V55, P1126, DOI 10.1016/S0895-4356(02)00498-5; Flynn A, 1979, J Community Health, V5, P126, DOI 10.1007/BF01324014; Fukui S, 2004, CANCER-AM CANCER SOC, V101, P421, DOI 10.1002/cncr.20383; Fukui S, 2003, PALLIATIVE MED, V17, P445, DOI 10.1191/0269216303pm782oa; Gallo WT, 2001, J AM GERIATR SOC, V49, P771, DOI 10.1046/j.1532-5415.2001.49154.x; Gomes B, 2004, J ROY SOC MED, V97, P413, DOI 10.1258/jrsm.97.9.413; Gott M, 2004, PALLIATIVE MED, V18, P460, DOI 10.1191/0269216304pm889oa; Grande GE, 2003, J PALLIAT CARE, V19, P263, DOI 10.1177/082585970301900408; Grande GE, 1998, SOC SCI MED, V47, P565, DOI 10.1016/S0277-9536(98)00115-4; Gyllenhammar E, 2003, SUPPORT CARE CANCER, V11, P560, DOI 10.1007/s00520-003-0487-z; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; Higginson IJ, 1999, J PUBLIC HEALTH MED, V21, P22, DOI 10.1093/pubmed/21.1.22; Higginson IJ, 2002, J CLIN ONCOL, V20, P3674, DOI 10.1200/JCO.2002.11.008; Hinton John, 1994, Palliative Medicine, V8, P197, DOI 10.1177/026921639400800303; Hoogendoorn WE, 2000, SPINE, V25, P2114, DOI 10.1097/00007632-200008150-00017; Hunt R, 1996, PALLIATIVE MED, V10, P5, DOI 10.1177/026921639601000103; HUNT R, 1993, AUST NZ J MED, V23, P245, DOI 10.1111/j.1445-5994.1993.tb01725.x; Izquierdo-Porrera AM, 2001, J PAIN SYMPTOM MANAG, V21, P481, DOI 10.1016/S0885-3924(01)00283-4; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Karlsen S, 1998, PALLIATIVE MED, V12, P279, DOI 10.1191/026921698673427657; KHAN K, 2001, UNDERTAKING SYSTEMAT; Koffman Jonathan, 2004, J Palliat Med, V7, P628, DOI 10.1089/jpm.2004.7.628; MACADAM M, 2004, HOME HLTH CARE MANAG, V16, P393; MANN WJ, 1993, CANCER, V71, P2876, DOI 10.1002/1097-0142(19930501)71:9<2876::AID-CNCR2820710932>3.0.CO;2-V; Martineau I, 2003, J APPL SOC PSYCHOL, V33, P1973, DOI 10.1111/j.1559-1816.2003.tb02089.x; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; MCCUSKER J, 1988, PUBLIC HLTH REP, V98, P170; MOINPOUR CM, 1989, AM J PUBLIC HEALTH, V79, P1549, DOI 10.2105/AJPH.79.11.1549; Moos RH., 1977, COPING PHYS ILLNESS; MOR V, 1983, J HEALTH SOC BEHAV, V24, P375, DOI 10.2307/2136403; Munday DF, 2003, PALLIATIVE MED, V17, P308, DOI 10.1191/0269216303pm771oa; Murray MA, 2003, J PALLIATIVE CARE, V19, P176, DOI 10.1177/082585970301900305; Murray SA, 2004, BMJ-BRIT MED J, V329, P1056, DOI 10.1136/bmj.329.7474.1056; Pemberton Chris, 2003, Int J Palliat Nurs, V9, P439; RODER D, 1987, MED J AUSTRALIA, V147, P11, DOI 10.5694/j.1326-5377.1987.tb133227.x; Sachpazidis I, 2002, Biomed Tech (Berl), V47 Suppl 1 Pt 2, P970, DOI 10.1515/bmte.2002.47.s1b.970; STOREY L, 2003, CANC NURS PRACT, V2, P33; Takahashi T, 2001, INT J MED INFORM, V61, P131, DOI 10.1016/S1386-5056(01)00135-6; Tang ST, 2000, CANCER NURS, V23, P367, DOI 10.1097/00002820-200010000-00007; Tang ST, 2003, CANCER NURS, V26, P245, DOI 10.1097/00002820-200306000-00012; Tang ST, 2001, CANCER INVEST, V19, P165, DOI 10.1081/CNV-100000151; Tang ST, 2002, CANCER NURS, V25, P158, DOI 10.1097/00002820-200204000-00013; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Weitzen S, 2003, MED CARE, V41, P323, DOI 10.1097/00005650-200302000-00013; West S, 2002, Evid Rep Technol Assess (Summ), P1; World Health Organization, PALL CAR SOL FACTS; Young NL, 2004, TELEMED J E-HEALTH, V10, P45, DOI 10.1089/153056204773644571	69	646	651	1	66	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					515	518A		10.1136/bmj.38740.614954.55	http://dx.doi.org/10.1136/bmj.38740.614954.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	023WB	16467346	Bronze, Green Published			2022-12-28	WOS:000236155800014
J	Sutton, M; McLean, G				Sutton, M; McLean, G			Determinants of primary medical care quality measured under the new UK contract: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ENGLISH GENERAL-PRACTICE; OF-CARE	Objective To identify factors associated with the quality of primary medical care incentivised under the new UK general medical services contract. Design Cross sectional study. Setting NHS Ayrshire and Arran area, Scotland. Participants 60 general practices. Main outcome measures Quality scores reflecting the total points achieved on the 10 clinical domains and holistic care. Univariate and multivariate regression analyses were used to relate quality scores to measures of population characteristics, urban-rural location, general practitioner characteristics, clinical team size and composition, practice characteristics, and income from other sources. Results Deprivation was associated with higher scores. Quality scores increased with the size of the clinical team. Practices with higher income from other sources had lower quality scores. Practices that were accredited, had training status, or contained younger general practitioners had higher quality scores, but these effects were explained by other associated factors. 53% of the variation in quality scores was explained by a multivariate model, which included measures of deprivation, clinical team size and composition, and financial incentives. Conclusions Population characteristics showed little association with the quality of primary medical care incentivised under the UK general medical services contract. Larger clinical teams delivered higher quality clinical care, but the nurse-doctor composition of the clinical team did not influence quality Practices that were more likely to respond to financial incentives because of previous behaviour or lower income from other sources recorded higher quality. If generalisable, the results suggest that initiatives to improve primary medical care quality should focus on the structure and resourcing of providers.	Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland; Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland	University of Aberdeen; University of Glasgow	Sutton, M (corresponding author), Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland.	m.sutton@abdn.ac.uk		Sutton, Matt/0000-0002-6635-2127	Chief Scientist Office [HERU1] Funding Source: Medline	Chief Scientist Office		Campbell SM, 2005, BMJ-BRIT MED J, V331, P1121, DOI 10.1136/bmj.38632.611123.AE; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819; McElduff P, 2004, QUAL SAF HEALTH CARE, V13, P191, DOI 10.1136/qshc.2003.007401; Roland M, 2004, NEW ENGL J MED, V351, P1448, DOI 10.1056/NEJMhpr041294	5	39	39	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 18	2006	332	7538					389	390		10.1136/bmj.38742.554468.55	http://dx.doi.org/10.1136/bmj.38742.554468.55			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16467345	Green Published, Bronze			2022-12-28	WOS:000235686000015
J	Arnaud, P; Feil, R				Arnaud, P; Feil, R			MEDEA takes control of its own imprinting	CELL			English	Editorial Material							REPRESSIVE HISTONE METHYLATION; PROTEIN; ENDOSPERM; DOMAIN; GENE	Genomic imprinting is an essential epigenetic process that controls the size of seeds in flowering plants. In Arabidopsis, DEMETER activates the maternal copy of the imprinted MEDEA Polycomb gene. In this issue of Cell, Gehring et al. (2006) demonstrate that this activation involves DNA demethylation of MEDEA by DEMETER. Remarkably, they also find that silencing of the paternal MEDEA allele is independent of DNA methylation and is controlled by maternal expression of MEDEA itself.	CNRS, Inst Mol Genet, UMR 5535, F-34090 Montpellier, France; Univ Montpellier 2, F-34090 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Arnaud, P (corresponding author), CNRS, Inst Mol Genet, UMR 5535, 1919 Route Mende, F-34090 Montpellier, France.	robert.feil@igmm.cnrs.fr	Arnaud, Philippe/O-9507-2015; Feil, Robert P/D-2087-2013	Arnaud, Philippe/0000-0002-7937-8764; Feil, Robert P/0000-0002-5671-5860				Autran D, 2005, CURR OPIN PLANT BIOL, V8, P19, DOI 10.1016/j.pbi.2004.11.011; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Choi YH, 2002, CELL, V110, P33, DOI 10.1016/S0092-8674(02)00807-3; Constancia M, 2004, NATURE, V432, P53, DOI 10.1038/432053a; Gehring M, 2006, CELL, V124, P495, DOI 10.1016/j.cell.2005.12.034; Kinoshita T, 1999, PLANT CELL, V11, P1945, DOI 10.1105/tpc.11.10.1945; Kinoshita T, 2004, SCIENCE, V303, P521, DOI 10.1126/science.1089835; Kohler C, 2005, NAT GENET, V37, P28, DOI 10.1038/ng1495; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Umlauf D, 2004, NAT GENET, V36, P1296, DOI 10.1038/ng1467	11	12	14	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					468	470		10.1016/j.cell.2006.01.020	http://dx.doi.org/10.1016/j.cell.2006.01.020			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469694	Bronze			2022-12-28	WOS:000235464000010
J	Chao, XJ; Muff, TJ; Park, SY; Zhang, S; Pollard, AM; Ordal, GW; Bilwes, AM; Crane, BR				Chao, XJ; Muff, TJ; Park, SY; Zhang, S; Pollard, AM; Ordal, GW; Bilwes, AM; Crane, BR			A receptor-modifying deamidase in complex with a signaling phosphatase reveals reciprocal regulation	CELL			English	Article							BACILLUS-SUBTILIS; CHEMOTAXIS PROTEINS; CHEY-P; METHYLATION; BEHAVIOR; PROGRAM; FAMILY; DOMAIN; MCPB	Signal transduction underlying bacterial chemotaxis involves excitatory phosphorylation and feedback control through deamidation and methylation of sensory receptors. The structure of a complex between the signal-terminating phosphatase, CheC, and the receptor-modifying deamidase, CheD, reveals how CheC mimics receptor substrates to inhibit CheD and how CheD stimulates CheC phosphatase activity. CheD resembles other cysteine deamidases from bacterial pathogens that inactivate host Rho-GTPases. CheD not only deamidates receptor glutamine residues contained within a conserved structural motif but also hydrolyzes glutamyl-methyl-esters at select regulatory positions. Substituting Gln into the receptor motif of CheC turns the inhibitor into a CheD substrate. Phospho-CheY, the intracellular signal and CheC target, stabilizes the CheC: CheD complex and reduces availability of CheD. A point mutation that dissociates CheC from CheD impairs chemotaxis in vivo. Thus, CheC incorporates an element of an upstream receptor to influence both its own effect on receptor output and that of its binding partner, CheD.	Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Proteom & Mass Spectrometry Core Facil, Ithaca, NY 14853 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	Cornell University; University of Illinois System; University of Illinois Urbana-Champaign	Chao, XJ (corresponding author), Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.	bc69@cornell.edu		Bilwes Crane, Alexandrine/0000-0001-9922-0692	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066775, R01GM054365, R56GM054365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM066775, GM054365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buetow L, 2001, NAT STRUCT BIOL, V8, P584, DOI 10.1038/89610; Charon NW, 2002, ANNU REV GENET, V36, P47, DOI 10.1146/annurev.genet.36.041602.134359; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Flatau G, 2000, BIOCHEM BIOPH RES CO, V267, P588, DOI 10.1006/bbrc.1999.1904; Foynes S, 2000, INFECT IMMUN, V68, P2016, DOI 10.1128/IAI.68.4.2016-2023.2000; Hoffmann C, 2005, REV PHYSIOL BIOCH P, V152, P49, DOI 10.1007/s10254-004-0026-4; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; Kirby JR, 1999, J BIOL CHEM, V274, P11092, DOI 10.1074/jbc.274.16.11092; Kirby JR, 2001, MOL MICROBIOL, V42, P573, DOI 10.1046/j.1365-2958.2001.02581.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kristich CJ, 2004, J BACTERIOL, V186, P5950, DOI 10.1128/JB.186.17.5950-5955.2004; Kristich CJ, 2002, J BIOL CHEM, V277, P25356, DOI 10.1074/jbc.M201334200; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Park SY, 2004, MOL CELL, V16, P563, DOI 10.1016/j.molcel.2004.10.018; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pepperkok R, 2000, J CELL BIOL, V148, P715, DOI 10.1083/jcb.148.4.715; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; ROSARIO MML, 1995, BIOCHEMISTRY-US, V34, P3823, DOI 10.1021/bi00011a040; Saulmon MM, 2004, MICROBIOL-SGM, V150, P581, DOI 10.1099/mic.0.26463-0; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Szurmant H, 2004, J BIOL CHEM, V279, P21787, DOI 10.1074/jbc.M311497200; Szurmant H, 2003, J BIOL CHEM, V278, P48611, DOI 10.1074/jbc.M306180200; Wadhams GH, 2004, NAT REV MOL CELL BIO, V5, P1024, DOI 10.1038/nrm1524; WEST AH, 1995, J MOL BIOL, V250, P276, DOI 10.1006/jmbi.1995.0376; Zimmer MA, 2000, J BIOL CHEM, V275, P24264, DOI 10.1074/jbc.M004001200	32	57	62	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					561	571		10.1016/j.cell.2005.11.046	http://dx.doi.org/10.1016/j.cell.2005.11.046			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469702	Bronze			2022-12-28	WOS:000235464000018
J	Berlin, L				Berlin, L			Communicating radiology results	LANCET			English	Editorial Material									Rush N Shore Med Ctr, Dept Radiol, Skokie, IL 60076 USA	Rush University	Berlin, L (corresponding author), Rush N Shore Med Ctr, Dept Radiol, Skokie, IL 60076 USA.	lberlin@rsh.net						American College of Radiology, 2005, PRACT GUID TECHN STA; Friedrich MJ, 2005, JAMA-J AM MED ASSOC, V294, P781, DOI 10.1001/jama.294.7.781; Garvey CH, 2006, LANCET, V367, P443, DOI 10.1016/S0140-6736(06)68145-2; JORDAN H, 2000, NO SUCH THING BAD DA, P153; KOLATA G, 2005, NY TIMES        0820; Kushner David C, 2005, J Am Coll Radiol, V2, P15, DOI 10.1016/j.jacr.2004.08.005; MACDONALD N, XRAY DELAYS CITED CA; Murphy J F A, 2004, Ir Med J, V97, P292; Poon EG, 2004, ARCH INTERN MED, V164, P2223, DOI 10.1001/archinte.164.20.2223; Shalowitz DI, 2005, JAMA-J AM MED ASSOC, V294, P737, DOI 10.1001/jama.294.6.737	10	19	19	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					373	375		10.1016/S0140-6736(06)68114-2	http://dx.doi.org/10.1016/S0140-6736(06)68114-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458745				2022-12-28	WOS:000235139400006
J	Garvey, CH; Connolly, S				Garvey, CH; Connolly, S			Radiology reporting - where does the radiologist's duty end?	LANCET			English	Editorial Material							MALPRACTICE; COMMUNICATION		Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Garvey, CH (corresponding author), Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England.	conall.garvey@rlbuht.nhs.uk						American College of Radiology, 2005, PRACT GUID TECHN STA; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; Berlin L, 2003, AM J ROENTGENOL, V181, P375, DOI 10.2214/ajr.181.2.1810375; Berlin L, 2002, AM J ROENTGENOL, V178, P809, DOI 10.2214/ajr.178.4.1780809; Brenner RJ, 1998, AM J ROENTGENOL, V171, P19, DOI 10.2214/ajr.171.1.9648756; *DEP HLTH, 2004, MAN CANC MEAS 1E 205; *EUR ASS RAD, RISK MAN RAD EUR; European Association of Radiologists, GOOD PRACT GUID EUR; KLINE TJ, 1992, RADIOLOGY, V184, P131, DOI 10.1148/radiology.184.1.1609068; Physician Insurers Association of America and American College of Radiology, 1997, PRACT STAND CLAIMS S; ROBERTSON CL, 1989, RADIOLOGY, V172, P443, DOI 10.1148/radiology.172.2.2748825; *ROYAL COLL RAD, 2004, TEL GUID DOC CLIN RA; *ROYAL COLL RAD, 2002, RISK MAN CLIN RAD	13	24	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					443	445		10.1016/S0140-6736(06)68145-2	http://dx.doi.org/10.1016/S0140-6736(06)68145-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458771				2022-12-28	WOS:000235139400036
J	Haynes, J; Haynes, R				Haynes, J; Haynes, R			10-minute consultation - Proteinuria	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford, Dept Primary Hlth Care, Inst Hlth Sci, Oxford OX3 7LF, England; Churchill Hosp, Oxford Kidney Unit, Oxford, England	University of Oxford; University of Oxford	Haynes, J (corresponding author), Univ Oxford, Dept Primary Hlth Care, Inst Hlth Sci, Oxford OX3 7LF, England.	jaynehaynes@onetel.com		Haynes, Richard/0000-0002-1179-0023					0	4	4	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					284	284		10.1136/bmj.332.7536.284	http://dx.doi.org/10.1136/bmj.332.7536.284			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455729	Green Published			2022-12-28	WOS:000235259000024
J	Lane, JA; Murray, LJ; Noble, S; Egger, M; Harvey, IM; Donovan, JL; Nair, P; Harvey, RF				Lane, JA; Murray, LJ; Noble, S; Egger, M; Harvey, IM; Donovan, JL; Nair, P; Harvey, RF			Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ECONOMIC-EVALUATION; NONULCER DYSPEPSIA; POPULATION; THERAPY; QUESTIONNAIRE; INFECTION; COMMUNITY; SYMPTOMS; RATES	Objective To determine the impact of a community based Helicobacter pylori screening and eradication programme on the incidence of dyspepsia, resource use, and quality of life, including a cost consequences analysis. Design H pylori screening programme followed by randomised placebo controlled trial of eradication. Setting Seven general practices in southwest England. Participants 10 537 unselected people aged 20-59),cars were screened for H pylori infection (C-13 urea breath test); 1558 of the 1636 participants who tested positive were randomised to H pylori eradication treatment or placebo, and 1539 (99%) were followed up for two years. Intervention Ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for two weeks or placebo. Main outcome measures Primary care consultation rates for dyspepsia (defined as epigastric pain) two years after randomisation, with secondary outcomes of dyspepsia symptoms, resource use, NHS costs, and quality of life. Results In the eradication group, 35% fewer participants consulted for dyspepsia over two years compared with the placebo group (55/787 v 78/771; odds ratio 0.65, 95% confidence interval 0.46 to 0.94; P = 0.021; number needed to treat 30) and 29% fewer participants had regular symptoms (odds ratio 0.71, 0.56 to 0.90; P = 0.05). NHS costs were 84.70 pound (74.90 pound to 93.91) pound greater per participant in the eradication group over two years, of which 83.40 pound ($146; El 2 1) was the cost of eradication treatment. No difference in quality of life existed between the two groups. Conclusions Community screening and eradication of H pylori is feasible in the general population and led to significant reductions in the number of people who consulted for dyspepsia and had symptoms two years after treatment. These benefits have to be balanced against the costs of eradication treatment, so a targeted eradication strategy in dyspeptic patients may be preferable.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT9 5EE, Antrim, North Ireland; Univ Bern, Inst Social & Preventat Med, CH-3012 Bern, Switzerland; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Peterborough Dist Gen Hosp, Peterborough Hosp Trust, Peterborough PE3 6DA, England; Frenchay Hosp, N Bristol Healthcare Trust, Bristol BS16 1LE, Avon, England	University of Bristol; Queens University Belfast; University of Bern; University of East Anglia	Lane, JA (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	Athene.lane@bristol.ac.uk		Egger, Matthias/0000-0001-7462-5132; Noble, Sian/0000-0002-8011-0722				Asante M, 1999, EUR J GASTROEN HEPAT, V11, P851, DOI 10.1097/00042737-199908000-00007; ASANTE MA, 1999, EUR J GASTROEN HEPAT, V11, pS51; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; *BRIT MED ASS, 2004, BRIT NAT FORM; *BRIT MED ASS, 2001, BRIT NAT FORMULARY; CHIA N, 2005, ALIMENT PHARM THER, V19, P349; Chiba N, 2004, ALIMENT PHARM THER, V19, P349, DOI 10.1111/j.1365-2036.2004.01865.x; Chiba N, 2002, BRIT MED J, V324, P1012, DOI 10.1136/bmj.324.7344.1012; CHIBA N, 2002, BMJ-BRIT MED J, V321, P1012; Coast J, 2004, BRIT MED J, V329, P1233, DOI 10.1136/bmj.329.7476.1233; COAST J, 2001, BMJ-BRIT MED J, V320, P1233; DELANEY BC, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001961; El-Serag HB, 2003, ALIMENT PHARM THER, V18, P387, DOI 10.1046/j.1365-2036.2003.01706.x; Forman D, 2000, BRIT MED J, V320, P1682, DOI 10.1136/bmj.320.7251.1682; Harvey RF, 2004, BMJ-BRIT MED J, V328, P1417, DOI 10.1136/bmj.38082.626725.EE; HEATLEY RV, 1987, LANCET, V2, P779; Hobbs FDR, 1996, FAM PRACT, V13, P225, DOI 10.1093/fampra/13.3.225; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; KENNEDY T, 1995, SCAND J PRIM HEALTH, V13, P243, DOI 10.3109/02813439508996770; Laine L, 2001, ANN INTERN MED, V134, P361, DOI 10.7326/0003-4819-134-5-200103060-00008; Lane JA, 2002, CONTROL CLIN TRIALS, V23, P321, DOI 10.1016/S0197-2456(01)00208-2; LASSEN A, 2005, BMJ-BRIT MED J, V327, P603; Mason J, 2002, ALIMENT PHARM THER, V16, P559, DOI 10.1046/j.1365-2036.2002.01204.x; Moayyedi P, 2000, LANCET, V355, P1665, DOI 10.1016/S0140-6736(00)02236-4; Moayyedi P, 2003, AM J GASTROENTEROL, V98, P2621, DOI [10.1016/j.amjgastroenterol.2003.07.003, 10.1111/j.1572-0241.2003.08724.x]; Moayyedi P, 2000, BRIT MED J, V321, P659, DOI 10.1136/bmj.321.7262.659; NETTEN A, 2002, UNIT COSTS HLTH NORM; NETTEN A, 2002, UNIT COSTS HLTH SOCI; Rosengren H, 1996, BRIT J GEN PRACT, V46, P177; ROSENGREN H, 1996, BR J GEN MED, V16, P177; Stone MA, 1998, EUR J GASTROEN HEPAT, V10, P957, DOI 10.1097/00042737-199811000-00010; Talley NJ, 2002, ALIMENT PHARM THER, V16, P95, DOI 10.1046/j.1365-2036.16.s4.12.x; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Tytgat GNJ, 2000, ALIMENT PHARM THERAP, V14, P55, DOI 10.1046/j.1365-2036.2000.03101.x; Wildner-Christensen M, 2003, GASTROENTEROLOGY, V125, P372, DOI 10.1016/S0016-5085(03)00897-7	35	38	38	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2006	332	7535					199	202		10.1136/bmj.38702.662546.55	http://dx.doi.org/10.1136/bmj.38702.662546.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16428249	Green Published			2022-12-28	WOS:000235086900015
J	Gan, JH; Tropea, JE; Austin, BP; Court, DL; Waugh, DS; Ji, XH				Gan, JH; Tropea, JE; Austin, BP; Court, DL; Waugh, DS; Ji, XH			Structural insight into the mechanism of double-stranded RNA processing by ribonuclease III	CELL			English	Article							ESCHERICHIA-COLI; BINDING DOMAIN; DSRNA-BINDING; SUBSTRATE RECOGNITION; BACTERIOPHAGE-LAMBDA; GENE-EXPRESSION; NUCLEASE DOMAIN; PROTEIN; CLEAVAGE; INTERFERENCE	Members of the ribonuclease III (RNase III) family are double-stranded RNA (dsRNA) specific endoribonucleases characterized by a signature motif in their active centers and a two-base 3' overhang in their products. While Dicer, which produces small interfering RNAs, is currently the focus of intense interest, the structurally simpler bacterial RNase III serves as a paradigm for the entire family. Here, we present the crystal structure of an RNase III-product complex, the first catalytic complex observed for the family. A 7 residue linker within the protein facilitates induced fit in protein-RNA recognition. A pattern of protein-RNA interactions, defined by four RNA binding motifs in RNase III and three protein-interacting boxes in dsRNA, is responsible for substrate specificity, while conserved amino acid residues and divalent cations are responsible for scissile-bond cleavage. The structure reveals a wealth of information about the mechanism of RNA hydrolysis that can be extrapolated to other RNase III family members.	NCI, Canc Res Ctr, NIH, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ji, XH (corresponding author), NCI, Canc Res Ctr, NIH, Ft Detrick, MD 21702 USA.	jix@ncifcrf.gov	Ji, Xinhua/C-9664-2012	Ji, Xinhua/0000-0001-6942-1514	NATIONAL CANCER INSTITUTE [ZIABC010326, ZIABC010336, Z01BC010336, Z01BC010326] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akey DL, 2005, PROTEIN SCI, V14, P2744, DOI 10.1110/ps.051665905; [Anonymous], EUKARYOTIC MRNA PROC; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blaszczyk J, 2004, STRUCTURE, V12, P457, DOI 10.1016/j.str.2004.02.004; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calin-Jageman I, 2003, NUCLEIC ACIDS RES, V31, P2381, DOI 10.1093/nar/gkg329; Campbell FE, 2002, J MOL BIOL, V317, P21, DOI 10.1006/jmbi.2002.5413; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Chang KY, 2005, FEBS J, V272, P2109, DOI 10.1111/j.1742-4658.2005.04652.x; Conrad C, 2002, INT J BIOCHEM CELL B, V34, P116, DOI 10.1016/S1357-2725(01)00112-1; Conrad C, 2001, FEBS LETT, V509, P53, DOI 10.1016/S0014-5793(01)03142-8; Court D. L., 1993, CONTROL MESSENGER RN, P71; Dasgupta S, 1998, MOL MICROBIOL, V28, P629, DOI 10.1046/j.1365-2958.1998.00828.x; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; DUNN JJ, 1982, ENZYMES, P485; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; Gan JH, 2005, STRUCTURE, V13, P1435, DOI 10.1016/j.str.2005.06.014; GUARNEROS G, 1988, CURR TOP MICROBIOL, V136, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INADA T, 1995, BIOCHIMIE, V77, P294, DOI 10.1016/0300-9084(96)88139-9; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamontagne B, 2003, J MOL BIOL, V327, P985, DOI 10.1016/S0022-2836(03)00231-6; Lamontagne B, 2001, Curr Issues Mol Biol, V3, P71; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li HL, 1996, EMBO J, V15, P1421, DOI 10.1002/j.1460-2075.1996.tb00484.x; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicholson AW, 1999, FEMS MICROBIOL REV, V23, P371, DOI 10.1016/S0168-6445(99)00013-3; Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0; Nowotny M, 2005, CELL, V121, P1005, DOI 10.1016/j.cell.2005.04.024; OPPENHEIM AB, 1993, PROG NUCLEIC ACID RE, V46, P37, DOI 10.1016/S0079-6603(08)61017-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REED RJ, 2000, ACTA CRYSTALLOGR D, V57, P1373; ROBERTSON HD, 1982, CELL, V30, P669, DOI 10.1016/0092-8674(82)90270-7; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; ROBERTSON HD, 1975, J BIOL CHEM, V250, P3050; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Steiniger-White M, 2004, CURR OPIN STRUC BIOL, V14, P50, DOI 10.1016/j.sbi.2004.01.008; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sun W, 2005, NUCLEIC ACIDS RES, V33, P807, DOI 10.1093/nar/gki197; Sun WM, 2004, BIOCHEMISTRY-US, V43, P13054, DOI 10.1021/bi049258i; Sun WM, 2001, BIOCHEMISTRY-US, V40, P5102, DOI 10.1021/bi010022d; Sun WM, 2001, BIOCHEMISTRY-US, V40, P14976, DOI 10.1021/bi011570u; Tian B, 2004, NAT REV MOL CELL BIO, V5, P1013, DOI 10.1038/nrm1528; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhang KJ, 1997, P NATL ACAD SCI USA, V94, P13437, DOI 10.1073/pnas.94.25.13437	54	182	188	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					355	366		10.1016/j.cell.2005.11.034	http://dx.doi.org/10.1016/j.cell.2005.11.034			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439209	Bronze			2022-12-28	WOS:000235068500023
J	Steinbrook, R				Steinbrook, R			Egg donation and human embryonic stem-cell research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*AM SOC REPR MED E, 2004, FERTIL STERIL S1, V82, pS240; Hwang WS, 2005, SCIENCE, V308, P1777, DOI 10.1126/science.1112286; Magnus D, 2005, SCIENCE, V308, P1747, DOI 10.1126/science.1114454; Practice Committe of the American Society for Reproductive Medicine, 2003, Fertil Steril, V80, P1309; Steinbock B, 2004, MT SINAI J MED, V71, P255	5	53	54	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					324	326		10.1056/NEJMp058313	http://dx.doi.org/10.1056/NEJMp058313			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436762				2022-12-28	WOS:000234854000002
J	Rosenbaum, S				Rosenbaum, S			US health policy in the aftermath of Hurricane Katrina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Hlth Policy, Washington, DC 20006 USA	George Washington University	Rosenbaum, S (corresponding author), George Washington Univ, Sch Publ Hlth, Hirsch Hlth Law & Policy Program, 2021 K St NW 800, Washington, DC 20006 USA.	sarar@gwu.edu						ALTER J, 2005, NEWSWEEK        0919; *COUNC HLTH CAR EC, 2005, WILL STAT HLTH CAR, P1; GRAHAM J, 2005, CHICAGO TRIBUNE 1229; Haslanger K, 2003, HEALTH AFFAIR, V22, P252, DOI 10.1377/hlthaff.22.1.252; LEMANN N, 2005, NEW YORKER       SEP, P34; MORIN R, 2005, WASHINGTON POST 0916, P1; Rosenbaum S, 2002, NEW ENGL J MED, V346, P635, DOI 10.1056/NEJM200202213460825; SANGER D, 2005, NY TIMES        0917; Wynia MK, 2004, AM J PUBLIC HEALTH, V94, P1096, DOI 10.2105/AJPH.94.7.1096	9	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					437	440		10.1001/jama.295.4.437	http://dx.doi.org/10.1001/jama.295.4.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005QJ	16434635				2022-12-28	WOS:000234838600025
J	Liou, JC; Johnson, NL				Liou, JC; Johnson, NL			Planetary science - Risks in space from orbiting debris	SCIENCE			English	Editorial Material									NASA, Lyndon B Johnson Space Ctr, Engn Sci Contract Grp, ERC, Houston, TX 77058 USA; NASA, Lyndon B Johnson Space Ctr, Orbital Debris Program Off, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER	Liou, JC (corresponding author), NASA, Lyndon B Johnson Space Ctr, Engn Sci Contract Grp, ERC, Mail Code JE104,2224 Bay Area Blvd,Box 7, Houston, TX 77058 USA.	jer-chyi.liou1@jsc.nasa.gov						ANSELMO L, 1997, ESA, P339; Inter-Agency Space Debris Coordination Committee, 2002, IADC0201; Johnson NL, 2001, ADV SPACE RES, V28, P1377, DOI 10.1016/S0273-1177(01)00423-9; JOHNSON NL, 2004, SC62530 NASA JOHNS S; JOHNSTON AE, 1986, SOIL USE MANAGE, V2, P3, DOI 10.1111/j.1475-2743.1986.tb00669.x; Kessler D. J., 1991, ADV SPACE RES, V11, P63, DOI 10.1016/0273-1177(91)90543-S; KESSLER DJ, 2001, ESA, P265; KESSLER DJ, 2000, JSC28949 NASA JOHNS; KRISKO PH, 2001, ESA, P273; Liou JC, 2004, ADV SPACE RES, V34, P981, DOI 10.1016/j.asr.2003.02.027; LIOU JC, IN PRESS ADV SPACE R, DOI DOI 10.1016/J.ASR.2005.06.021; ROSSI A, 1994, J GEOPHYS RES-PLANET, V99, P23195, DOI 10.1029/94JE02320; SU SY, 1993, ADV SPACE RES-SERIES, V13, P221, DOI 10.1016/0273-1177(93)90594-2; *UN COMM PEAC US O, 1999, TECHN REP SPAC DEBR; *US NAT SERV TECHN, 1995, INT REP ORB DEBR; 2005, ORBITAL DEBRIS Q NEW, V9, P10; 2005, ORBITAL DEBRIS Q NEW, V9, P1	17	199	217	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					340	341		10.1126/science.1121337	http://dx.doi.org/10.1126/science.1121337			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424326				2022-12-28	WOS:000234938500029
J	Tomasz, A				Tomasz, A			Weapons of microbial drug resistance abound in soil flora	SCIENCE			English	Editorial Material							VANCOMYCIN RESISTANCE		Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA	Rockefeller University	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10021 USA.	tomasz@rockefeller.edu	Tomasz, Alexander/B-9939-2011	Tomasz, Alexander/0000-0003-1520-1983				Berdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; de Sousa MA, 2004, FEMS IMMUNOL MED MIC, V40, P101, DOI 10.1016/S0928-8244(03)00370-5; Demain AL, 2000, ADV BIOCHEM ENG BIOT, V69, P1; Hong HJ, 2002, MOL MICROBIOL, V44, P1199, DOI 10.1046/j.1365-2958.2002.02960.x; MCALEESE F, IN PRESS J BACTERIOL; Severin A, 2004, J BIOL CHEM, V279, P3398, DOI 10.1074/jbc.M309593200; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; Witte W, 1995, MICROB DRUG RESIST, V1, P259, DOI 10.1089/mdr.1995.1.259	12	16	20	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					342	343		10.1126/science.1123982	http://dx.doi.org/10.1126/science.1123982			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424327				2022-12-28	WOS:000234938500030
J	Farley, KA; Vokrouhlicky, D; Bottke, WF; Nesvorny, D				Farley, KA; Vokrouhlicky, D; Bottke, WF; Nesvorny, D			A late Miocene dust shower from the break-up of an asteroid in the main belt	NATURE			English	Article							INTERPLANETARY DUST; EXTRATERRESTRIAL HE-3; ACCRETION RATE; PERIODICITY; EVOLUTION; HELIUM; ORIGIN; COMET	Throughout the history of the Solar System, Earth has been bombarded by interplanetary dust particles (IDPs), which are asteroid and comet fragments of diameter similar to 1-1,000 mu m. The IDP flux is believed to be in quasi-steady state: particles created by episodic main belt collisions or cometary fragmentation replace those removed by comminution, dynamical ejection, and planetary or solar impact. Because IDPs are rich in He-3, seafloor sediment He-3 concentrations provide a unique means of probing the major events that have affected the IDP flux and its source bodies over geological timescales(1-4). Here we report that collisional disruption of the >150-km-diameter asteroid that created the Veritas family 8.3 +/- 0.5 Myr ago(5) also produced a transient increase in the flux of interplanetary dust-derived He-3. The increase began at 8.2 +/- 0.1 Myr ago, reached a maximum of similar to 4 times pre-event levels, and dissipated over similar to 1.5 Myr. The terrestrial IDP accretion rate was overwhelmingly dominated by Veritas family fragments during the late Miocene. No other event of this magnitude over the past similar to 10(8) yr has been deduced from main belt asteroid orbits. One remarkably similar event is present in the He-3 record 35 Myr ago, but its origin by comet shower(1) or asteroid collision(6) remains uncertain.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Charles Univ Prague, Inst Astron, CR-18000 Prague 8, Czech Republic; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA	California Institute of Technology; Charles University Prague	Farley, KA (corresponding author), CALTECH, Div Geol & Planetary Sci, MS 170-25, Pasadena, CA 91125 USA.	farley@gps.caltech.edu	Vokrouhlický, David/Q-4359-2017; Farley, Kenneth/AAE-7735-2020	Vokrouhlický, David/0000-0002-6034-5452; Farley, Kenneth/0000-0002-7846-7546				BOGARD DD, 1995, METEORITICS, V30, P244, DOI 10.1111/j.1945-5100.1995.tb01124.x; Bottke WF, 2005, ICARUS, V175, P111, DOI 10.1016/j.icarus.2004.10.026; Bottke WF, 2002, ICARUS, V156, P399, DOI 10.1006/icar.2001.6788; Bottke WF, 2005, IAU COLLOQ, V197, P357, DOI 10.1017/S1743921304008865; Burbine T. H., 2002, ASTEROIDS, VIII, P653, DOI DOI 10.2307/J.CTV1V7ZDN4.50; BURNS JA, 1979, ICARUS, V40, P1, DOI 10.1016/0019-1035(79)90050-2; CURRY WB, 1995, ODP INIT REP LEG, V154, P1; Dermott SF, 2001, ASTR AST LI, P569; FARLEY KA, 1995, NATURE, V376, P153, DOI 10.1038/376153a0; Farley KA, 1997, GEOCHIM COSMOCHIM AC, V61, P2309, DOI 10.1016/S0016-7037(97)00068-9; Farley KA, 1998, SCIENCE, V280, P1250, DOI 10.1126/science.280.5367.1250; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; GRAF T, 1995, J GEOPHYS RES-PLANET, V100, P21247, DOI 10.1029/95JE01903; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; Gupta AK, 2004, GEOLOGY, V32, P753, DOI 10.1130/G20662.1; Kortenkamp SJ, 1998, SCIENCE, V280, P874, DOI 10.1126/science.280.5365.874; Low F. J., 1984, APJ, V278, pL19; Marcantonio F, 1996, NATURE, V383, P705, DOI 10.1038/383705a0; Morbidelli A, 1999, ICARUS, V139, P295, DOI 10.1006/icar.1999.6097; Mukhopadhyay S, 2001, GEOCHIM COSMOCHIM AC, V65, P653, DOI 10.1016/S0016-7037(00)00555-X; Muller RA, 1997, SCIENCE, V277, P215, DOI 10.1126/science.277.5323.215; Nesvorny D, 2003, ASTROPHYS J, V591, P486, DOI 10.1086/374807; NESVORNY D, UNPUB ICARUS; NOLAN MC, 1989, METEORITICS, V24, P310; Patterson DB, 1998, GEOCHIM COSMOCHIM AC, V62, P3669, DOI 10.1016/S0016-7037(98)00263-4; SHACKLETON NJ, 1997, P ODP SCI RES, V154, P1; Tagle R, 2004, SCIENCE, V305, P492, DOI 10.1126/science.1098481; TAKAYANAGI M, 1987, J GEOPHYS RES-SOLID, V92, P12531, DOI 10.1029/JB092iB12p12531	28	71	71	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					295	297		10.1038/nature04391	http://dx.doi.org/10.1038/nature04391			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421563				2022-12-28	WOS:000234682100035
J	Waldor, MK				Waldor, MK			Disarming pathogens - A new approach for antibiotic development	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tufts Univ, Sch Med, Dept Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts University; Tufts University	Waldor, MK (corresponding author), Tufts Univ, Sch Med, Dept Microbiol, Boston, MA 02111 USA.			Waldor, Matthew/0000-0003-1843-7000				Hung DT, 2005, SCIENCE, V310, P670, DOI 10.1126/science.1116739	1	18	20	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					296	297		10.1056/NEJMcibr054591	http://dx.doi.org/10.1056/NEJMcibr054591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421373				2022-12-28	WOS:000234661100013
J	Kaplan, NM; Opie, LH				Kaplan, NM; Opie, LH			Controversies in cardiology 2 - Controversies in hypertension	LANCET			English	Article							ANGIOTENSIN RECEPTOR BLOCKERS; MODEST SALT REDUCTION; SERUM URIC-ACID; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; LIFE-STYLE; RISK-FACTORS; CARDIOVASCULAR EVENTS; EUROPEAN COUNTRIES; BETA-BLOCKERS	Hypertension remains the most common risk factor for cardiovascular morbidity and mortality. Its incidence is rising in both ageing and obese populations, but its control remains inadequate worldwide. We address several persisting controversies that may interfere with appropriate management of hypertension. They include: the reasons behind the increasing incidence of hypertension and the possible ways to slow the process, especially by lifestyle changes; the need for overall cardiovascular risk assessment; the major issues in the decision to institute drug therapy and the choice of drugs; and the importance of screening for various identifiable causes. We provide the background for these controversies, followed by some opinions on how to guide practitioners to offer more effective management of hypertension.	Univ Cape Town, Sch Med, Hatter Inst Heart Res, Cape Heart Ctr, ZA-7925 Cape Town, South Africa; Univ Texas, SW Med Ctr, Dallas, TX USA; Univ Cape Town, Sch Med, Dept Med, ZA-7925 Cape Town, South Africa	University of Cape Town; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Cape Town	Opie, LH (corresponding author), Univ Cape Town, Sch Med, Hatter Inst Heart Res, Cape Heart Ctr, ZA-7925 Cape Town, South Africa.	norman.kaplan@utsouthwestern.edu						Adami G, 2005, AM J HYPERTENS, V18, P780, DOI 10.1016/j.amjhyper.2004.12.013; Angeli F, 2004, AM J HYPERTENS, V17, P817, DOI 10.1016/j.amjhyper.2004.06.002; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Aucott L, 2005, HYPERTENSION, V45, P1035, DOI 10.1161/01.HYP.0000165680.59733.d4; Baguet JP, 2005, J HYPERTENS, V23, P521, DOI 10.1097/01.hjh.0000160207.58781.4e; Bakris GL, 2005, HYPERTENSION, V46, P1309, DOI 10.1161/01.HYP.0000190585.54734.48; Barzon L, 2002, EUR J ENDOCRINOL, V146, P61, DOI 10.1530/eje.0.1460061; Bourne LT, 2002, PUBLIC HEALTH NUTR, V5, P157, DOI 10.1079/PHN2001288; Butler D, 2004, NATURE, V428, P252, DOI 10.1038/428252a; Carlberg B, 2004, LANCET, V364, P1684, DOI 10.1016/S0140-6736(04)17355-8; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Doulton TWR, 2005, HYPERTENSION, V45, P880, DOI 10.1161/01.HYP.0000161880.59963.da; Ezzati M, 2005, PLOS MED, V2, P404, DOI 10.1371/journal.pmed.0020133; Fesler P, 2005, KIDNEY INT, V67, P1974, DOI 10.1111/j.1523-1755.2005.00297.x; Fox KM, 2003, LANCET, V362, P782; Freel EM, 2004, J AM SOC NEPHROL, V15, P1993, DOI 10.1097/01.ASN.0000132473.50966.14; Hamrahian AH, 2005, J CLIN ENDOCR METAB, V90, P871, DOI 10.1210/jc.2004-1627; He F, 2002, J HUM HYPERTENS, V16, P761, DOI 10.1038/sj.jhh.1001459; He FJ, 2005, HYPERTENSION, V46, P66, DOI 10.1161/01.HYP.0000171474.84969.7a; Jackson R, 2005, LANCET, V365, P434, DOI 10.1016/S0140-6736(05)17833-7; Johnson RJ, 2003, HYPERTENSION, V41, P1183, DOI 10.1161/01.HYP.0000069700.62727.C5; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lewis EJ, 2005, BMJ-BRIT MED J, V330, P1269, DOI 10.1136/bmj.330.7502.1269-a; Lindholm LH, 2005, LANCET, V366, P1545, DOI 10.1016/S0140-6736(05)67573-3; MACMAHON SW, 1985, LANCET, V1, P1233; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; Masuo K, 2003, HYPERTENSION, V42, P474, DOI 10.1161/01.HYP.0000091371.53502.D3; McMurray J, 2005, BRIT MED J, V330, P1269, DOI 10.1136/bmj.330.7502.1269; Nicolson DJ, 2004, J HYPERTENS, V22, P2043, DOI 10.1097/00004872-200411000-00001; OPIE L, 2004, HEART PHYSL; Opie LH, 2005, BRIT MED J, V330, P1270, DOI 10.1136/bmj.330.7502.1270; Opie LH, 2004, J HYPERTENS, V22, P1453, DOI 10.1097/01.hjh.0000133732.24501.9e; ORDUNEZGARCIA P, CARDIOVASCULAR HLTH; Reyes AJ, 2003, CARDIOVASC DRUG THER, V17, P397, DOI 10.1023/B:CARD.0000015855.02485.e3; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Sawka AM, 2003, J CLIN ENDOCR METAB, V88, P553, DOI 10.1210/jc.2002-021251; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Staessen JA, 2003, J HYPERTENS, V21, P1055, DOI 10.1097/00004872-200306000-00002; Strippoli GFM, 2004, BMJ-BRIT MED J, V329, P828, DOI 10.1136/bmj.38237.585000.7C; Svetkey LP, 2005, J HUM HYPERTENS, V19, P21, DOI 10.1038/sj.jhh.1001770; Textor SC, 2004, J AM SOC NEPHROL, V15, P1974, DOI 10.1097/01.ASN.0000133699.97353.24; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; TIMIO M, 1988, HYPERTENSION, V12, P457, DOI 10.1161/01.HYP.12.4.457; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Turnbull F, 2005, ARCH INTERN MED, V165, P1410; Turnbull F, 2003, LANCET, V362, P1527; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Vasan RS, 2001, NEW ENGL J MED, V345, P1291, DOI 10.1056/NEJMoa003417; Vasbinder GBC, 2004, ANN INTERN MED, V141, P674, DOI 10.7326/0003-4819-141-9-200411020-00007; Verma S, 2004, BMJ-BRIT MED J, V329, P1248, DOI 10.1136/bmj.329.7477.1248; Viazzi F, 2005, HYPERTENSION, V45, P991, DOI 10.1161/01.HYP.0000161184.10873.ea; Wang JG, 2005, HYPERTENSION, V45, P907, DOI 10.1161/01.HYP.0000165020.14745.79; Whelton PK, 2004, J HUM HYPERTENS, V18, P545, DOI 10.1038/sj.jhh.1001701; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; Williams B, 2005, J AM COLL CARDIOL, V45, P813, DOI 10.1016/j.jacc.2004.10.069; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Wolf-Maier K, 2004, HYPERTENSION, V43, P10, DOI 10.1161/01.HYP.0000103630.72812.10; Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Yusuf S, 2000, NEW ENGL J MED, V342, P145	67	104	108	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					168	176		10.1016/S0140-6736(06)67965-8	http://dx.doi.org/10.1016/S0140-6736(06)67965-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413880				2022-12-28	WOS:000234655500031
J	Sharp, D				Sharp, D			Long-term effects of sarin	LANCET			English	Editorial Material							POSTTRAUMATIC-STRESS-DISORDER; VICTIMS; AGENTS		The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Abou-Donia MB, 2003, ARCH ENVIRON HEALTH, V58, P484, DOI 10.3200/AEOH.58.8.484-497; Bide RW, 2005, J APPL TOXICOL, V25, P393, DOI 10.1002/jat.1074; *CDCP, 2004, EM PREP RESP FACTS; EVANS R, 2004, GUARDIAN        1116; GASSED ER, 2000, BRIT CHEM WARFARE EX; *I MED, 2004, GULF WAR HLTH UPD LI; Lee H A, 2004, J R Army Med Corps, V150, P14; Li Q, 2004, TOXICOLOGY, V201, P209, DOI 10.1016/j.tox.2004.04.014; *MED RES COUNC, 2004, PORT UPD FEBR; *MIN DEF, PORT VOL COMM COLD U; *MIN DEF, 2005, REV MOD DEM KHAM MAR; *MIN DEF, 2002, HIST SURV PORT SERV; *MIN DEF, GULF VET ILLN ANN BR; *MIN DEF, 2001, PORT VOL BRIEF HIST; OHBU S, 1997, SOUTH MED J, V90, P687; Ohtani T, 2004, PSYCHIAT CLIN NEUROS, V58, P624, DOI 10.1111/j.1440-1819.2004.01313.x; Page WF, 2003, MIL MED, V168, P239, DOI 10.1093/milmed/168.3.239; Pappworth M., 1967, HUMAN GUINEA PIGS; Smith TC, 2003, AM J EPIDEMIOL, V158, P457, DOI 10.1093/aje/kwg178; Thompson KR, 1990, HARVARD HOSP ITS VOL; Tochigi M, 2005, NEUROSCI RES, V52, P129, DOI 10.1016/j.neures.2005.03.012; World Health Organization, 2004, PUBL HLTH RESP BIOL; 2004, LORDS HANSARD   1221; 1967, LANCET, V2, P1144	24	9	18	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2006	367	9505					95	97		10.1016/S0140-6736(06)67942-7	http://dx.doi.org/10.1016/S0140-6736(06)67942-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413861				2022-12-28	WOS:000234655500009
J	Thompson, IM; Tangen, CM; Goodman, PJ; Probstfield, JL; Moinpour, CM; Coltman, CA				Thompson, IM; Tangen, CM; Goodman, PJ; Probstfield, JL; Moinpour, CM; Coltman, CA			Erectile dysfunction and subsequent cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; MYOCARDIAL-INFARCTION; INTERNATIONAL INDEX; HEART-DISEASE; 52 COUNTRIES; MEN; PREVALENCE; ASSOCIATION; INTERHEART; PREVENTION	Context The risk factors for cardiovascular disease and erectile dysfunction are similar Objective To examine the association of erectile dysfunction and subsequent cardiovascular disease. Design, Setting, and Participants Men aged 55 years or older who were randomized to the placebo group (n=9457) in the Prostate Cancer Prevention Trial at 221 US centers were evaluated every 3 months for cardiovascular disease and erectile dysfunction between 1994 and 2003. Proportional hazards regression models were used to evaluate the association of erectile dysfunction and cardiovascular disease. In an adjusted model, covariates included age, body mass index, blood pressure, serum lipids, diabetes, family history of myocardial infarction, race, smoking history, physical activity, and quality of life. Main Outcome Measures Erectile dysfunction and cardiovascular disease. Results Of the 9457 men randomized to placebo, 8063 (85%) had no cardiovascular disease at study entry; of these men, 3816 (47%) had erectile dysfunction at study entry. Among the 4247 men without erectile dysfunction at study entry, 2420 men (57%) reported incident erectile dysfunction after 5 years. After adjustment, incident erectile dysfunction was associated with a hazard ratio of 1.25 (95% confidence interval [CI], 1.02-1.53; P=.04) for subsequent cardiovascular events during study follow-up. For men with either incident or prevalent erectile dysfunction, the hazard ratio was 1.45 (95% Cl, 1.25-1.69; P<.001). For subsequent cardiovascular events, the unadjusted risk of an incident cardiovascular event was 0.015 per person-year among men without erectile dysfunction at study entry and was 0.024 per person-year for men with erectile dysfunction at study entry. This association was in the range of risk associated with current smoking or a family history of myocardial infarction. Conclusions Erectile dysfunction is a harbinger of cardiovascular clinical events in some men. Erectile dysfunction should prompt investigation and intervention for cardiovascular risk factors.	Univ Texas, Hlth Sci Ctr, Dept Urol, San Antonio, TX 78229 USA; SW Oncol Grp, San Antonio, TX USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Washington, Seattle, WA 98195 USA	University of Texas System; University of Texas Health San Antonio; Southwest Oncology Group; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Thompson, IM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Urol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	thompsoni@uthscsa.edu			NCI NIH HHS [CA 86402, CA 35178, CA 37429, CA 45808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA035178, U01CA086402, U10CA037429, U10CA045808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Heart Association, 2003, HEART DIS STROK STAT; Bai Q, 2004, ASIAN J ANDROL, V6, P343; Blumentals W A, 2003, Aging Male, V6, P217, DOI 10.1080/13685530312331309752; Collins R, 2003, LANCET, V361, P2005; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DeBusk R, 2000, AM J CARDIOL, V86, P175, DOI 10.1016/S0002-9149(00)00896-1; DeBusk RF, 2003, JAMA-J AM MED ASSOC, V290, P3129, DOI 10.1001/jama.290.23.3129; Derby CA, 2000, INT J IMPOT RES, V12, P197, DOI 10.1038/sj.ijir.3900542; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Fung MM, 2004, J AM COLL CARDIOL, V43, P1405, DOI 10.1016/j.jacc.2003.11.041; Gazzaruso C, 2004, CIRCULATION, V110, P22, DOI 10.1161/01.CIR.0000133278.81226.C9; Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1; Katz DL, 2004, MED CLIN N AM, V88, P1295, DOI 10.1016/j.mcna.2004.02.003; Le NA, 2004, CURR OPIN LIPIDOL, V15, P227, DOI 10.1097/00041433-200404000-00018; Liu PY, 2003, ENDOCR REV, V24, P313, DOI 10.1210/er.2003-0005; Mittleman MA, 2003, INT J CLIN PRACT, V57, P597; Moinpour CM, 2000, J CLIN ONCOL, V18, P1942, DOI 10.1200/JCO.2000.18.9.1942; Montorsi F, 2003, EUR UROL, V44, P360, DOI 10.1016/S0302-2838(03)00305-1; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; Ponholzer A, 2005, EUR UROL, V47, P80, DOI 10.1016/j.eururo.2004.08.017; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0; SHERBOURNE CD, 1991, MEASURING FUNCTIONIN, P194; Speel TGW, 2003, EUR UROL, V44, P366, DOI 10.1016/S0302-2838(03)00304-X; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Turnbull F, 2003, LANCET, V362, P1527; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zusman RM, 1999, AM J CARDIOL, V83, p35C	31	619	631	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					2996	3002		10.1001/jama.294.23.2996	http://dx.doi.org/10.1001/jama.294.23.2996			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414947	Bronze			2022-12-28	WOS:000234087700026
J	Shi, N; Ye, S; Alam, A; Chen, LP; Jiang, YX				Shi, N; Ye, S; Alam, A; Chen, LP; Jiang, YX			Atomic structure of a Na+- and K+-conducting channel	NATURE			English	Article							GMP-ACTIVATED CHANNEL; POTASSIUM CHANNELS; DIVALENT-CATIONS; EXCISED PATCHES; ION CHANNELS; SELECTIVITY; PERMEATION; BLOCKAGE	Ion selectivity is one of the basic properties that define an ion channel. Most tetrameric cation channels, which include the K+, Ca2+, Na+ and cyclic nucleotide-gated channels, probably share a similar overall architecture in their ion-conduction pore, but the structural details that determine ion selection are different. Although K+ channel selectivity has been well studied from a structural perspective(1,2), little is known about the structure of other cation channels. Here we present crystal structures of the NaK channel from Bacillus cereus, a non-selective tetrameric cation channel, in its Na+- and K+-bound states at 2.4 angstrom and 2.8 angstrom resolution, respectively. The NaK channel shares high sequence homology and a similar overall structure with the bacterial KcsA K+ channel, but its selectivity filter adopts a different architecture. Unlike a K+ channel selectivity filter, which contains four equivalent K+-binding sites, the selectivity filter of the NaK channel preserves the two cation-binding sites equivalent to sites 3 and 4 of a K+ channel, whereas the region corresponding to sites 1 and 2 of a K+ channel becomes a vestibule in which ions can diffuse but not bind specifically. Functional analysis using an Rb-86 flux assay shows that the NaK channel can conduct both Na+ and K+ ions. We conclude that the sequence of the NaK selectivity filter resembles that of a cyclic nucleotide-gated channel and its structure may represent that of a cyclic nucleotide-gated channel pore.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jiang, YX (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.	youxing.jiang@utsouthwestern.edu		Alam, Amer/0000-0001-9580-4949	NIGMS NIH HHS [R01 GM079179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1980, BIOPHYS J, V30, P473, DOI 10.1016/S0006-3495(80)85108-3; ARMSTRONG CM, 1982, J GEN PHYSIOL, V80, P663, DOI 10.1085/jgp.80.5.663; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FRINGS S, 1995, NEURON, V15, P169, DOI 10.1016/0896-6273(95)90074-8; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; Noskov SY, 2004, NATURE, V431, P830, DOI 10.1038/nature02943; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; STERN JH, 1987, SCIENCE, V236, P1674, DOI 10.1126/science.3037695; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112; ZUFALL F, 1994, ANNU REV BIOPH BIOM, V23, P577, DOI 10.1146/annurev.bb.23.060194.003045	27	190	194	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2006	440	7083					570	574		10.1038/nature04508	http://dx.doi.org/10.1038/nature04508			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024DV	16467789				2022-12-28	WOS:000236176100064
J	Westermann, S; Wang, HW; Avila-Sakar, A; Drubin, DG; Nogales, E; Barnes, G				Westermann, S; Wang, HW; Avila-Sakar, A; Drubin, DG; Nogales, E; Barnes, G			The Dam1 kinetochore ring complex moves processively on depolymerizing microtubule ends	NATURE			English	Article							BUDDING YEAST KINETOCHORE; SPINDLE MICROTUBULES; FORCE PRODUCTION; FISSION YEAST; DASH COMPLEX; ATTACHMENT; DYNAMICS; ARCHITECTURE; MICROSCOPY; INTERFACE	Chromosomes interact through their kinetochores with microtubule plus ends and they are segregated to the spindle poles as the kinetochore microtubules shorten during anaphase A of mitosis. The molecular natures and identities of coupling proteins that allow microtubule depolymerization to pull chromosomes to poles during anaphase have long remained elusive(1). In budding yeast, the ten-protein Dam1 complex is a critical microtubule-binding component of the kinetochore(2) that oligomerizes into a 50-nm ring around a microtubule in vitro(3,4). Here we show, with the use of a real-time, two-colour fluorescence microscopy assay, that the ring complex moves processively for several micrometres at the ends of depolymerizing microtubules without detaching from the lattice. Electron microscopic analysis of 'end-on views' revealed a 16-fold symmetry of the kinetochore rings. This out-of-register arrangement with respect to the 13-fold microtubule symmetry is consistent with a sliding mechanism based on an electrostatically coupled ring-microtubule interface. The Dam1 ring complex is a molecular device that can translate the force generated by microtubule depolymerization into movement along the lattice to facilitate chromosome segregation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Barnes, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	gbarnes@socrates.berkeley.edu		Westermann, Stefan/0000-0001-6921-9113				Cheeseman IM, 2001, J CELL BIOL, V155, P1137, DOI 10.1083/jcb.200109063; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; Cheeseman IM, 2001, J CELL BIOL, V152, P197, DOI 10.1083/jcb.152.1.197; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Grishchuk EL, 2005, NATURE, V438, P384, DOI 10.1038/nature04132; HILL TL, 1985, P NATL ACAD SCI USA, V82, P4404, DOI 10.1073/pnas.82.13.4404; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; Liu XK, 2005, EMBO J, V24, P2919, DOI 10.1038/sj.emboj.7600762; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; Maddox PS, 2000, NAT CELL BIOL, V2, P36, DOI 10.1038/71357; Mahadevan L, 2005, NATURE, V435, P895, DOI 10.1038/435895a; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Miranda JJL, 2005, NAT STRUCT MOL BIOL, V12, P138, DOI 10.1038/nsmb896; Molodtsov MI, 2005, P NATL ACAD SCI USA, V102, P4353, DOI 10.1073/pnas.0501142102; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005; Sanchez-Perez I, 2005, EMBO J, V24, P2931, DOI 10.1038/sj.emboj.7600761; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Tanaka K, 2005, NATURE, V434, P987, DOI 10.1038/nature03483; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; Wang HW, 2005, NATURE, V435, P911, DOI 10.1038/nature03606; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Westermann S, 2005, MOL CELL, V17, P277, DOI 10.1016/j.molcel.2004.12.019	30	216	236	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	2006	440	7083					565	569		10.1038/nature04409	http://dx.doi.org/10.1038/nature04409			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	024DV	16415853				2022-12-28	WOS:000236176100063
J	Dewan, PK; Lal, SS; Lonnroth, K; Wares, F; Uplekar, M; Sahu, S; Granich, R; Chauhan, LS				Dewan, PK; Lal, SS; Lonnroth, K; Wares, F; Uplekar, M; Sahu, S; Granich, R; Chauhan, LS			Improving tuberculosis control through public-private collaboration in India: literature review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MIX; PARTNERSHIP; DOCTORS; DOTS	Objective To review the characteristics of public-private mix projects in India and their effect on case notification and treatment outcomes for tuberculosis. Design Literature review. Data sources Review of surveillance records from Indian tuberculosis programme project, evaluation reports, and medical literature for public-private mix projects in India. Data extraction Project characteristics, tuberculosis case notification of new patients with sputum smear results positive for acid fast bacilli, and treatment outcome. Data synthesis Of 24 identified public-private mix projects, data were available from 14 (58% involving private practitioners, corporations, and non-governmental organisations. In all reviewed projects, the public sector tuberculosis programme provided training and supervision of private providers. Among the five projects with available data on historical controls, case notification rates were higher after implementation of a public-private mix project. Among seven projects involving private practitioners, 2796 of 12 147 (23%) new, patients positive for acid fast bacilli were attributed to private providers. Corporate based and non-governmental organisations served as the main source for tuberculosis programme services in seven project areas, detecting 9967 new patients positive for acid fast bacilli. In nine of 12 projects with data on treatment outcomes, private providers exceeded the programme target of 85% treatment success for new patients positive for acid fast bacilli. Conclusions Public-private mix activities were associated with increased case notification, while maintaining acceptable treatment outcomes. Collaborations between public and private providers of health care hold considerable potential to improve tuberculosis control in India.	Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, Atlanta, GA 30333 USA; Off World Hlth Org Representat India, New Delhi, India; WHO, TB Strategy & Operat, Stop TB Dept, CH-1211 Geneva, Switzerland; Minist Hlth & Family Welf, Cent TB Div, Directorate Gen Hlth Serv, Publ Private Mix Subgrp, New Delhi, India	Centers for Disease Control & Prevention - USA; World Health Organization; World Health Organization	Dewan, PK (corresponding author), Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA.	phd8@cdc.gov	Lonnroth, Knut/H-5470-2017; Lönnroth, Knut/L-2339-2014	Lonnroth, Knut/0000-0001-6944-0256; Lönnroth, Knut/0000-0001-5054-8240				Ambe G, 2005, INT J TUBERC LUNG D, V9, P562; Arora VK, 2004, INDIAN J CHEST DIS, V46, P1; FLOYD K, 2004, WHOHTMTB2001337; FLOYD K, 2004, WHOHTMTB2004337; *GOV IND, 2002, INV PRIV PRACT REV N; *GOV IND, 1998, INV NONG ORG REV NAT; *GOV IND, 2003, REC 2 M NAT TASK FOR; *GOV IND, 2003, MAN PED TB REV NAT T; Hopewell PC, 2005, JAMA-J AM MED ASSOC, V293, P2790, DOI 10.1001/jama.293.22.2790; KLEIN SJ, 1993, PUBLIC HLTH MANAG PR, V1, P1; Kumar MKA, 2005, INT J TUBERC LUNG D, V9, P870; Lonnroth K, 2004, B WORLD HEALTH ORGAN, V82, P580; Mantala MJ, 2003, TUBERCULOSIS, V83, P173, DOI 10.1016/S1472-9792(02)00067-7; Murthy KJR, 2001, INT J TUBERC LUNG D, V5, P354; Newell JN, 2004, B WORLD HEALTH ORGAN, V82, P92; Prasad R, 2002, INT J TUBERC LUNG D, V6, P895; QUV HT, 2003, INT J TUBERC LUNG D, V7, P464; Rangan SG, 2004, INT J TUBERC LUNG D, V8, P552; Tonsing Jamie, 2003, J Indian Med Assoc, V101, P164; Uplekar M, 1998, INT J TUBERC LUNG D, V2, P324; UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A; *WHO, 1997, WHOTB97223; *WHO, 2005, WHOHTMTB2005349; WHO, 2004, WHOHTMTB2004338; World Health Organization, 2003, TREATM TUB GUID NAT	25	104	108	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					574	577		10.1136/bmj.38738.473252.7C	http://dx.doi.org/10.1136/bmj.38738.473252.7C			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16467347	Green Published, Bronze			2022-12-28	WOS:000236314400014
J	Cassell, JA; Mercer, CH; Sutcliffe, L; Petersen, I; Islam, A; Brook, MG; Ross, JD; Kinghorn, GR; Simms, I; Hughes, G; Majeed, A; Stephenson, JM; Johnson, AM; Hayward, AC				Cassell, JA; Mercer, CH; Sutcliffe, L; Petersen, I; Islam, A; Brook, MG; Ross, JD; Kinghorn, GR; Simms, I; Hughes, G; Majeed, A; Stephenson, JM; Johnson, AM; Hayward, AC			Trends in sexually transmitted infections in general practice 1990-2000: population based study using data from the UK general practice research database	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To describe the contribution of primary care to the diagnosis and management of sexually transmitted infections in the United Kingdom, 1990-2000, in the context of increasing incidence of infections in genitourinary medicine clinics. Design Population based Study. Setting UK primary care. Participants Patients registered in the UK general practice research database. Main outcome measures Incidence of diagnosed sexually transmitted infections in primary care and estimation of the proportion of major such infections diagnosed in primary care. Results An estimated 23.0% of chlamydia cases in women but only 5.3% in men were diagnosed and treated in primary care during 1998-2000, along with 49.2% cases of non-specific urethritis and urethral discharge in men and 5.7% cases of gonorrhoea in women and 2.9% in men. Rates of diagnosis in primary care rose Substantially in the late 1990s. Conclusions A substantial and increasing number of sexually transmitted infections are diagnosed and treated in primary care in the United Kingdom, with sex ratios differing from those in genitourinary medicine clinics. Large numbers of men are treated in primary care for presumptive sexually transmitted infections.	UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 3PF, England; UCL Royal Free & Univ Coll Med Sch, Ctr Sexual Hlth & HIV Res, London WC1E 6AU, England; Cent Middlesex Hosp, Patrick Clements Clin, London NW10 7NS, England; Whittall St Clin, Birmingham B4 6DH, W Midlands, England; Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Hlth Protect Agcy, Ctr Communicable Dis Surveillance, Ctr Infect, London NW9 5EQ, England; Med & Healthcare Regulatory Agcy, Gen Practice Res Database Div, Res Serv, London SW8 5NQ, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; Imperial College London; University of Sheffield; Health Protection Agency	Cassell, JA (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 3PF, England.	j.cassell@pcpc.ucl.ac.uk	Simms, Ian/AAA-8740-2019; Kinghorn, George/AAO-1425-2021; Hayward, Andrew C/C-3268-2013; Petersen, Irene/I-2751-2012; Petersen, Irene/C-5702-2009; Simms, Ian/P-1454-2019	Hayward, Andrew C/0000-0002-3549-6232; Petersen, Irene/0000-0002-0037-7524; Simms, Ian/0000-0003-4519-5684; Kinghorn, George/0000-0001-6608-5076; Majeed, Azeem/0000-0002-2357-9858; Cassell, Jackie/0000-0003-0777-0385; Johnson, Anne/0000-0003-1330-7100; Mercer, Catherine/0000-0002-4220-5034; Ross, Jonathan/0000-0002-4193-6919; Hughes, Gwenda/0000-0003-2090-7702	National Institute for Health Research [PAS/01/05/PDA/048] Funding Source: researchfish; Medical Research Council [G0601726, G0200565] Funding Source: Medline; Department of Health [PAS/01/05/PDA/048] Funding Source: Medline; MRC [G0200565] Funding Source: UKRI	National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Department of Health, 2001, NAT STRAT SEX HLTH H; Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6; Health Protection Agency, 2004, FOC PREV HIV OTH SEX; Majeed Azeem, 2004, Health Stat Q, P5; *PHLS DHSS PS SCOT, 2000, TRENDS SEX TRANSM IN	5	56	57	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					332	334		10.1136/bmj.38726.404120.7C	http://dx.doi.org/10.1136/bmj.38726.404120.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16439371	Green Published, Bronze			2022-12-28	WOS:000235376400016
J	Prentice, RL; Caan, B; Chlebowski, RT; Patterson, R; Kuller, LH; Ockene, JK; Margolis, KL; Limacher, MC; Manson, JE; Parker, LM; Paskett, E; Phillips, L; Robbins, J; Rossouw, JE; Sarto, GE; Shikany, JM; Stefanick, ML; Thomson, CA; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Wassertheil-Smoller, S; Whitlock, E; Yano, K; Adams-Campbell, L; Anderson, GL; Assaf, AR; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Ford, L; Gass, M; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Kotchen, JM; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Henderson, MM				Prentice, RL; Caan, B; Chlebowski, RT; Patterson, R; Kuller, LH; Ockene, JK; Margolis, KL; Limacher, MC; Manson, JE; Parker, LM; Paskett, E; Phillips, L; Robbins, J; Rossouw, JE; Sarto, GE; Shikany, JM; Stefanick, ML; Thomson, CA; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Wassertheil-Smoller, S; Whitlock, E; Yano, K; Adams-Campbell, L; Anderson, GL; Assaf, AR; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Ford, L; Gass, M; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Kotchen, JM; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Henderson, MM			Low-fat dietary pattern and risk of invasive breast cancer - The women's health initiative randomized controlled dietary modification trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADJUVANT CHEMOTHERAPY; DISEASE PREVENTION; SERUM ESTROGEN; GRAIN INTAKE; INTERVENTION; METAANALYSIS; WHOLE; FEASIBILITY; TRASTUZUMAB; VEGETABLES	Context The hypothesis that a low-fat dietary pattern can reduce breast cancer risk has existed for decades but has never been tested in a controlled intervention trial. Objective To assess the effects of undertaking a low-fat dietary pattern on breast cancer incidence. Design and Setting A randomized, controlled, primary prevention trial conducted at 40 US clinical centers from 1993 to 2005. Participants A total of 48 835 postmenopausal women, aged 50 to 79 years, without prior breast cancer, including 18.6% of minority race/ethnicity, were enrolled. Interventions Women were randomly assigned to the dietary modification intervention group (40% [n = 19 541]) or the comparison group (60% [n = 29 294]). The intervention was designed to promote dietary change with the goals of reducing intake of total fat to 20% of energy and increasing consumption of vegetables and fruit to at least 5 servings daily and grains to at least 6 servings daily. Comparison group participants were not asked to make dietary changes. Main Outcome Measure Invasive breast cancer incidence. Results Dietary fat intake was significantly lower in the dietary modification intervention group compared with the comparison group. The difference between groups in change from baseline for percentage of energy from fat varied from 10.7% at year 1 to 8.1% at year 6. Vegetable and fruit consumption was higher in the intervention group by at least 1 serving per day and a smaller, more transient difference was found for grain consumption. The number of women who developed invasive breast cancer (annualized incidence rate) over the 8.1-year average follow-up period was 655 (0.42%) in the intervention group and 1072 (0.45%) in the comparison group (hazard ratio, 0.91; 95% confidence interval, 0.83-1.01 for the comparison between the 2 groups). Secondary analyses suggest a lower hazard ratio among adherent women, provide greater evidence of risk reduction among women having a high-fat diet at baseline, and suggest a dietary effect that varies by hormone receptor characteristics of the tumor. Conclusions Among postmenopausal women, a low-fat dietary pattern did not result in a statistically significant reduction in invasive breast cancer risk over an 8.1-year average follow-up period. However, the nonsignificant trends observed suggesting reduced risk associated with a low-fat dietary pattern indicate that longer, planned, nonintervention follow-up may yield a more definitive comparison.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Kaiser Permanente, Div Res, Oakland, CA USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Univ Minnesota, Minneapolis, MN USA; Univ Florida, Gainesville, FL USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Miami, Miami, FL 33152 USA; Ohio State Univ, Columbus, OH 43210 USA; Emory Univ, Atlanta, GA 30322 USA; Univ Calif Davis, Sacramento, CA 95817 USA; NHLBI, Bethesda, MD 20892 USA; Univ Wisconsin, Madison, WI USA; Univ Alabama Birmingham, Birmingham, AL USA; Stanford Prevent Res Ctr, Stanford, CA USA; Univ Arizona, Tucson, AZ USA; Northwestern Univ, Chicago, IL 60611 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; SUNY Buffalo, Buffalo, NY 14260 USA; Univ Iowa, Iowa City, IA USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Pacific Hlth Res Inst, Honolulu, HI USA; MedStar Res Inst, Washington, DC USA; Howard Univ, Washington, DC 20059 USA; Brown Univ, Providence, RI 02912 USA; Univ Washington, Seattle, WA 98195 USA; Rush Univ, Med Ctr, Chicago, IL 60612 USA; Univ Nevada, Reno, NV 89557 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; NCI, Bethesda, MD 20892 USA; Univ Cincinnati, Cincinnati, OH USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Detroit, MI USA; Hutzel Hosp, Detroit, MI 48201 USA; George Washington Univ, Washington, DC USA; Univ Calif Irvine, Irvine, CA 92717 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA	Fred Hutchinson Cancer Center; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester; University of Minnesota System; University of Minnesota Twin Cities; State University System of Florida; University of Florida; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Miami; University System of Ohio; Ohio State University; Emory University; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham; Stanford University; University of Arizona; Northwestern University; Wake Forest University; Wake Forest Baptist Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Iowa; Yeshiva University; Albert Einstein College of Medicine; Kaiser Permanente; Pacific Health Research & Education Institute; Howard University; Brown University; University of Washington; University of Washington Seattle; Rush University; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Ohio; University of Cincinnati; Baylor College of Medicine; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; George Washington University; University of California System; University of California Irvine; University of Tennessee System; University of Tennessee Health Science Center; Medical College of Wisconsin; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center	Prentice, RL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,M3-A410,POB 19024, Seattle, WA 98109 USA.	rprentice@whi.org	Wactawski-Wende, Jean/AGH-5457-2022	Wactawski-Wende, Jean/0000-0003-3096-9595; Hays-Grudo, Jennifer/0000-0002-8107-1243; Margolis, Karen/0000-0003-1862-7402; Caan, Bette/0000-0002-5803-310X				Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bingham SA, 2003, LANCET, V362, P212, DOI 10.1016/S0140-6736(03)13913-X; Boyd NF, 2003, BRIT J CANCER, V89, P1672, DOI 10.1038/sj.bjc.6601314; Chatenoud L, 1998, INT J CANCER, V77, P24, DOI 10.1002/(SICI)1097-0215(19980703)77:1&lt;24::AID-IJC5&gt;3.0.CO;2-1; Chlebowski RT, 2005, J CLIN ONCOL, V23, p3S; Coates RJ, 1999, AM J EPIDEMIOL, V149, P1104, DOI 10.1093/oxfordjournals.aje.a009764; COX DR, 1972, J R STAT SOC B, V34, P187; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; Day NE, 2001, INT J EPIDEMIOL, V30, P309, DOI 10.1093/ije/30.2.309; Freedman L, 1996, CONTROL CLIN TRIALS, V17, P509, DOI 10.1016/S0197-2456(96)00016-5; FREEDMAN LS, 1990, CANCER RES, V50, P5710; Fung TT, 2005, INT J CANCER, V116, P116, DOI 10.1002/ijc.20999; Gandini S, 2000, EUR J CANCER, V36, P636, DOI 10.1016/S0959-8049(00)00022-8; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; HEITMANN BL, 1995, BRIT MED J, V311, P986; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; INSULL W, 1990, ARCH INTERN MED, V150, P421, DOI 10.1001/archinte.150.2.421; Jacobs DR, 1998, NUTR CANCER, V30, P85, DOI 10.1080/01635589809514647; Kalbfleisch JD, 2002, STAT ANAL FAILURE TI, P255; Kipnis V, 2001, AM J EPIDEMIOL, V153, P394, DOI 10.1093/aje/153.4.394; Lawlor DA, 2004, CANCER CAUSE CONTROL, V15, P267, DOI 10.1023/B:CACO.0000024225.14618.a8; Nicodemus KK, 2001, CANCER CAUSE CONTROL, V12, P917, DOI 10.1023/A:1013746719385; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Patterson RE, 2004, J AM DIET ASSOC, V104, P654, DOI 10.1016/j.jada.2004.01.014; Patterson RE, 2003, J AM DIET ASSOC, V103, P454, DOI 10.1053/jada.2003.50068; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206; PRENTICE R, 1990, J NATL CANCER I, V82, P129, DOI 10.1093/jnci/82.2.129; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Rock CL, 2004, J CLIN ONCOL, V22, P2379, DOI 10.1200/JCO.2004.09.025; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; ROSE DP, 1993, BREAST CANCER RES TR, V27, P253, DOI 10.1007/BF00665695; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769; Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092; Tinker Lesley Fels, 1996, P510; Toniolo P, 2000, INT J CANCER, V88, P828, DOI 10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8; [US Department of Health and Human Services and US Department of Agriculture US Department of Health and Human Services and US Department of Agriculture], 1990, NUTR YOUR HLTH DIET; *WORK IARC GROUP E, 2003, IARC HDB CANC PREV, V8; *WORLD CAN RES FUN, 1997, FOOD NUTR PREV CANC; Wu AH, 1999, J NATL CANCER I, V91, P529, DOI 10.1093/jnci/91.6.529	51	549	566	1	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					629	642		10.1001/jama.295.6.629	http://dx.doi.org/10.1001/jama.295.6.629			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467232	Bronze			2022-12-28	WOS:000235168200023
J	Schmitt, A; Gilden, DJ; Saint, S; Moseley, RH				Schmitt, A; Gilden, DJ; Saint, S; Moseley, RH			Empirically incorrect	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EXTRAHEPATIC HODGKINS-DISEASE; INTRAHEPATIC CHOLESTASIS; DIAGNOSIS; LYMPHOMA		Legacy Emanuel & Legacy Good Samaritan Hosp, Dept Med, Portland, OR USA; Ann Arbor Vet Affairs Med Ctr, Dept Med, Ann Arbor, MI USA; Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Ann Arbor, MI USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schmitt, A (corresponding author), Legacy Emanuel Hosp & Hlth Ctr, 2801 N Gantenbein Ave,Suite 4100, Portland, OR 97227 USA.	aschmitt@lhs.org	Saint, Sanjay/AAF-5126-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BIRRER MJ, 1987, SEMIN LIVER DIS, V7, P269, DOI 10.1055/s-2008-1040582; Crosbie OM, 1997, HEPATOLOGY, V26, P5; HUBSCHER SG, 1993, HEPATOLOGY, V17, P70, DOI 10.1016/0270-9139(93)90194-R; JANSEN PLM, 1994, NETH J MED, V44, P99; LIEBERMAN DA, 1986, J CLIN GASTROENTEROL, V8, P304, DOI 10.1097/00004836-198606000-00022; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; WARNER AS, 1994, AM J GASTROENTEROL, V89, P940	7	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					509	514		10.1056/NEJMcps051762	http://dx.doi.org/10.1056/NEJMcps051762			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452563				2022-12-28	WOS:000235019400011
J	Hankey, GJ; Norman, PE; Eikelboom, JW				Hankey, GJ; Norman, PE; Eikelboom, JW			Medical treatment of peripheral arterial disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ANKLE-BRACHIAL INDEX; MODIFIABLE RISK-FACTORS; LOW-DOSE ASPIRIN; INTERMITTENT CLAUDICATION; OCCLUSIVE DISEASE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; PRESSURE INDEX; THERAPEUTIC ANGIOGENESIS; SMOKING-CESSATION	Context Peripheral arterial disease (PAD) affects approximately 20% of adults older than 55 years and is a powerful predictor of myocardial infarction, stroke, and death due to vascular causes. The goals of treatment are to prevent future major coronary and cerebrovascular events and improve leg symptoms. Objective To review the best evidence for medical treatment of PAD. Evidence Acquisition MEDLINE and the Cochrane database were searched from 1990 to November 2005 for randomized trials and meta-analyses of medical treatments for PAD. References from these articles were also searched. Search terms included, singly and in combination: peripheral arterial disease, peripheral artery disease, PAD, randomized controlled trial, controlled trial, randomized, and meta-analysis. Particular attention was directed toward randomized controlled trials and meta-analyses of clinically relevant medical treatments for PAD. Outcome measures included leg symptoms (intermittent claudication and walking distance), death, and major coronary and cerebrovascular events. Evidence Synthesis Symptoms of leg claudication, walking distance, and quality of life can be improved by smoking cessation (physician advice, nicotine replacement therapy, and bupropion), a structured exercise program, statin drugs, cilostazol, and angiotensin-converting enzyme inhibitors. The risk of major coronary and cerebrovascular events can be reduced through lowering blood pressure with angiotensin-converting enzyme inhibitors and other anti hypertensive drugs, use of statin drugs, antiplatelet therapy with aspirin or clopidogrel, and probably by stopping smoking. Conclusion The substantial and increasing burden of PAD, and its local and systemic complications, can be reduced by lifestyle modification (smoking cessation, exercise) and medical therapies (nicotine replacement therapy, bupropion, antihypertensive drugs, statins, and antiplatelet drugs).	Univ Western Australia, Sch Med & Pharmcol, Perth, WA 6009, Australia; Univ Western Australia, Royal Perth Hosp, Dept Neurol, Perth, WA 6009, Australia; Univ Western Australia, Sch Surg & Pathol, Nedlands, WA 6009, Australia; McMaster Univ, Dept Med, Hamilton, ON, Canada	University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia; McMaster University	Eikelboom, JW (corresponding author), McMaster Univ, Hamilton Gen Hosp McMaster Clin, Dept Med, 237 Barton St E, Hamilton, ON L9K 1H8, Canada.	eikelbj@mcmaster.ca	Norman, Paul E/C-5485-2013; Hankey, Graeme J/H-4968-2014; Eikelboom, John/AAG-6117-2019	Norman, Paul E/0000-0003-3406-0506; Hankey, Graeme J/0000-0002-6044-7328; Eikelboom, John/0000-0003-4126-1285				Adler AI, 2002, DIABETES CARE, V25, P894, DOI 10.2337/diacare.25.5.894; Anand S, 2006, AM HEART J, V151, P1, DOI 10.1016/j.ahj.2005.03.021; Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; Aquino R, 2001, J VASC SURG, V34, P962, DOI 10.1067/mva.2001.119749; Aronow WS, 2003, AM J CARDIOL, V92, P711, DOI 10.1016/S0002-9149(03)00833-6; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; BALSANO F, 1989, J LAB CLIN MED, V114, P84; BERGQVIST D, 1995, EUR J VASC ENDOVASC, V10, P69, DOI 10.1016/S1078-5884(05)80200-X; Bhatt DL, 2004, AM HEART J, V148, P263, DOI 10.1016/j.ahj.2004.03.028; BOISSEL JP, 1989, THROMB HAEMOSTASIS, V62, P681; Brevetti G, 1999, J AM COLL CARDIOL, V34, P1618, DOI 10.1016/S0735-1097(99)00373-3; Caruana MF, 2005, EUR J VASC ENDOVASC, V29, P443, DOI 10.1016/j.ejvs.2005.01.015; Catalano M, 1993, Eur J Med, V2, P11; Clark N, 2003, DIABETES CARE, V26, P3333; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins TC, 2004, AM J MED, V117, P93, DOI 10.1016/j.amjmed.2003.12.042; Cosmi B, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DAGENAIS GR, 1991, CLIN INVEST MED, V14, P93; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Diehm C, 2004, ATHEROSCLEROSIS, V172, P95, DOI 10.1016/S0021-9150(03)00204-1; Diehm C, 2002, VASA-J VASCULAR DIS, V31, P241, DOI 10.1024/0301-1526.31.4.241; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Doobay AV, 2005, ARTERIOSCL THROM VAS, V25, P1463, DOI 10.1161/01.ATV.0000168911.78624.b7; DORFFLERMELLY J, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000535; Dormandy J, 1999, Semin Vasc Surg, V12, P123; EAGLE KA, 1994, J AM COLL CARDIOL, V23, P1091, DOI 10.1016/0735-1097(94)90596-7; EBSKOV LB, 1994, BRIT J SURG, V81, P1600, DOI 10.1002/bjs.1800811111; Engel S, 2003, NEW ENGL J MED, V348, P2294; Faglia E, 2005, DIABETIC MED, V22, P1310, DOI 10.1111/j.1464-5491.2005.01612.x; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; Fowler B, 2002, AUST NZ J PUBL HEAL, V26, P219, DOI 10.1111/j.1467-842X.2002.tb00677.x; GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Girolami B, 1999, ARCH INTERN MED, V159, P337, DOI 10.1001/archinte.159.4.337; GOLDHABER SZ, 1992, LANCET, V340, P143, DOI 10.1016/0140-6736(92)93216-A; Hankey GJ, 2003, STROKE, V34, P354, DOI 10.1161/01.STR.0000054261.97525.4B; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HESS H, 1985, LANCET, V1, P415; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; Hobbs SD, 2003, EUR J VASC ENDOVASC, V26, P341, DOI 10.1016/S1078-5884(03)00356-3; Hooi JD, 2004, J CLIN EPIDEMIOL, V57, P294, DOI 10.1016/j.jclinepi.2003.09.003; Hooi JD, 2002, MED DECIS MAKING, V22, P99, DOI 10.1177/02729890222062991; Hooi JD, 2001, AM J EPIDEMIOL, V153, P666, DOI 10.1093/aje/153.7.666; Hooi JD, 1999, BRIT J GEN PRACT, V49, P49; Horsch S, 2004, INT J CLIN PHARM TH, V42, P63; Jepson R. G., 1997, COCHRANE DB SYST REV, DOI [10. 1002/14651858. CD000095, DOI 10.1002/14651858.CD000095]; JONASON T, 1987, ACTA MED SCAND, V221, P253; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; KORNITZER M, 1995, ANGIOLOGY, V46, P211, DOI 10.1177/000331979504600304; Lancaster T., 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000165.pub2, DOI 10.1002/14651858.CD000165.PUB2, 10.1002/14651858.CD000165.pub2.AMBIGUOUS]; Lawes CMM, 2004, STROKE, V35, P1024, DOI 10.1161/01.STR.0000126208.14181.DD; Lederman RJ, 2002, LANCET, V359, P2053, DOI 10.1016/S0140-6736(02)08937-7; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Leng GC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000990; Lindholm LH, 2005, LANCET, V366, P1545, DOI 10.1016/S0140-6736(05)67573-3; Lip GYH, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003186.pub3; Majumdar SR, 2004, J AM COLL CARDIOL, V43, P1738, DOI 10.1016/j.jacc.2003.12.043; McDermott MM, 1999, ARCH INTERN MED, V159, P387; McDermott MM, 2003, CIRCULATION, V107, P757, DOI 10.1161/01.CIR.0000050380.64025.07; MCDERMOTT MM, 1994, J GEN INTERN MED, V9, P445, DOI 10.1007/BF02599061; Mehler PS, 2003, CIRCULATION, V107, P753, DOI 10.1161/01.CIR.0000049640.46039.52; Meijer WT, 1998, ARTERIOSCL THROM VAS, V18, P185, DOI 10.1161/01.ATV.18.2.185; Mohler ER, 2003, CIRCULATION, V108, P1481, DOI 10.1161/01.CIR.0000090686.57897.F5; Mondillo S, 2003, AM J MED, V114, P359, DOI 10.1016/S0002-9343(03)00010-X; NEWMAN AB, 1991, J CLIN EPIDEMIOL, V44, P15, DOI 10.1016/0895-4356(91)90196-G; Newman AB, 1997, J AM GERIATR SOC, V45, P1472, DOI 10.1111/j.1532-5415.1997.tb03198.x; NEWMAN AB, 1993, JAMA-J AM MED ASSOC, V270, P487, DOI 10.1001/jama.270.4.487; Newman AB, 1999, ARTERIOSCL THROM VAS, V19, P538, DOI 10.1161/01.ATV.19.3.538; Novo S, 1996, INT ANGIOL, V15, P169; O'Hare AM, 2004, CIRCULATION, V109, P320, DOI 10.1161/01.CIR.0000114519.75433.DD; Patrono C, 2005, NEW ENGL J MED, V353, P2373, DOI 10.1056/NEJMra052717; Pedersen TR, 1998, AM J CARDIOL, V81, P333, DOI 10.1016/S0002-9149(97)00904-1; Pittler MH, 2000, AM J MED, V108, P276, DOI 10.1016/S0002-9343(99)00454-4; PRICE JF, 2001, COCHRANE DB SYST REV, P188, DOI DOI 10.1002/14651858; RADACK K, 1991, ARCH INTERN MED, V151, P1769, DOI 10.1001/archinte.151.9.1769; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1; Smith S C Jr, 2000, Circulation, V101, P111; Solomon CG, 2003, NEW ENGL J MED, V348, P457, DOI 10.1056/NEJMe020172; SOLOMON SA, 1991, BRIT MED J, V303, P1100, DOI 10.1136/bmj.303.6810.1100; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stewart KJ, 2002, NEW ENGL J MED, V347, P1941, DOI 10.1056/NEJMra021135; Stoffers HEJH, 1996, INT J EPIDEMIOL, V25, P282, DOI 10.1093/ije/25.2.282; TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Thompson PD, 2002, AM J CARDIOL, V90, P1314, DOI 10.1016/S0002-9149(02)02869-2; Turnbull F, 2003, LANCET, V362, P1527; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UKPDS GROUP, 1998, LANCET, V352, P1557; Villarruz MV, 2002, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD002785, DOI 10.1002/14651858.CD002785, DOI 10.1002/14651858]; VOGT MT, 1993, JAMA-J AM MED ASSOC, V270, P465, DOI 10.1001/jama.270.4.465; WIDMER LK, 1985, INT ANGIOL, V4, P289; Willigendael EM, 2004, J VASC SURG, V40, P1158, DOI 10.1016/j.jvs.2004.08.049; Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Yusuf S, 2000, NEW ENGL J MED, V342, P145	100	216	241	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					547	553		10.1001/jama.295.5.547	http://dx.doi.org/10.1001/jama.295.5.547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007SP	16449620				2022-12-28	WOS:000234990300022
J	Bisgaard, H; Szefler, S				Bisgaard, H; Szefler, S			Long-acting beta(2) agonists and paediatric asthma	LANCET			English	Editorial Material							DRUG-USE; CHILDREN; LABEL		Copenhagen Univ Hosp, Danish Paediat Asthma Ctr, DK-2900 Copenhagen, Denmark; Natl Jewish Med Res Ctr, Denver, CO USA	University of Copenhagen; National Jewish Health	Bisgaard, H (corresponding author), Copenhagen Univ Hosp, Danish Paediat Asthma Ctr, DK-2900 Copenhagen, Denmark.	Bisgaard@copsac.dk	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592				Bisgaard H, 2000, PEDIATR PULM, V29, P221, DOI 10.1002/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.3.CO;2-G; Bisgaard H, 2003, PEDIATR PULM, V36, P391, DOI 10.1002/ppul.10381; Chalumeau M, 2000, ARCH DIS CHILD, V83, P502, DOI 10.1136/adc.83.6.502; CHOWDHURY BA, 2005, COMMUNICATION   0615; Conroy S, 2000, BRIT MED J, V320, P79, DOI 10.1136/bmj.320.7227.79; *DAN MED AG, DAN MED REG; *EUR COMM, 2004, PROP REG EUR PARL CO; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; *NIH NAT HEART LUN, 2002, GLOB IN ASTHM GLOB S; *PAED FORM COMM, 2005, BNF CHILDR, P159; Rogers A, 2002, LANCET, V359, P862, DOI 10.1016/S0140-6736(02)07987-4; *US FOOD DRUG ADM, 2000, GUID IND REC COMPL P; *US FOOD DRUG ADM, 1998, PULM ALL END ADV COM; 2004, LANCET, V364, P732; 2003, FDA SAFETY INFORMATI	15	48	50	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					286	288		10.1016/S0140-6736(06)68051-3	http://dx.doi.org/10.1016/S0140-6736(06)68051-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443026				2022-12-28	WOS:000235084600010
J	Steffen, LM				Steffen, LM			Eat your fruit and vegetables	LANCET			English	Editorial Material							BLOOD-PRESSURE; CONSUMPTION; STROKE; RISK; MORTALITY; ADULTS; TRIAL; FOOD		Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA	University of Minnesota System; University of Minnesota Twin Cities	Steffen, LM (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.	steffen@epi.umn.edu		Steffen, Lyn M/0000-0002-4053-6729				Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Bazzano LA, 2002, STROKE, V33, P1183, DOI 10.1161/01.STR.0000014607.90464.88; Commission of the European, 2005, GREEN PAP PROM HLTH; FOERSTER SB, 1995, AM J PREV MED, V11, P124, DOI 10.1016/S0749-3797(18)30488-4; He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0; *I MED NAT AC SCI, 2005, FOOD MARK CHILDR YOU; Jacobs DR, 2003, AM J CLIN NUTR, V78, p508S, DOI 10.1093/ajcn/78.3.508S; John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6; KOTZ K, 1994, J AM DIET ASSOC, V94, P1296, DOI 10.1016/0002-8223(94)92463-5; Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230; Li RW, 2000, AM J PUBLIC HEALTH, V90, P777, DOI 10.2105/AJPH.90.5.777; Ness AR, 2005, HEART, V91, P894, DOI 10.1136/hrt.2004.043489; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; New SA, 2000, AM J CLIN NUTR, V71, P142; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Steffen LM, 2005, AM J CLIN NUTR, V82, P1169, DOI 10.1093/ajcn/82.6.1169; *USDA US DEP HHS, MYP STEPS HEALTH YOU; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	18	27	31	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					278	279		10.1016/S0140-6736(06)68046-X	http://dx.doi.org/10.1016/S0140-6736(06)68046-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443021				2022-12-28	WOS:000235084600005
J	Behrensmeyer, AK				Behrensmeyer, AK			Climate change and human evolution	SCIENCE			English	Editorial Material							AFRICAN CLIMATE; HOMININ EVOLUTION; VEGETATION; RECORDS; ORIGIN; HOMO		Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA	Smithsonian Institution; Smithsonian National Museum of Natural History	Behrensmeyer, AK (corresponding author), Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA.	behrensa@si.edu						Bobe R, 2004, PALAEOGEOGR PALAEOCL, V207, P399, DOI 10.1016/j.palaeo.2003.09.033; Bobe R, 2002, J HUM EVOL, V42, P475, DOI 10.1006/jhev.2001.0535; Bonnefille R, 2004, P NATL ACAD SCI USA, V101, P12125, DOI 10.1073/pnas.0401709101; CAMPISANO CJ, 2004, PALEOANTHROPOLOGY, pA34; Cohen AS, 2000, J PALEOLIMNOL, V24, P231, DOI 10.1023/A:1008158902422; deMenocal PB, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P262; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; DeMenocal PB, 2004, EARTH PLANET SC LETT, V220, P3, DOI 10.1016/S0012-821X(04)00003-2; DEMENOCAL PB, 1999, HOMINID EVOLUTION CL, V1, P23; Feakins SJ, 2005, GEOLOGY, V33, P977, DOI 10.1130/G21814.1; Feibel CS, 1999, HUMAN EVOLUT SER, P276; FEIBEL CS, 1997, GSA TODAY, V7, P1; HILL A, 2003, GEOLOGICAL SOC AM AN, V736; LAPORTE LF, 1983, S AFR J SCI, V79, P96; LEPRE CJ, 2005, PALEOANTHROPOLOGY, pA38; Levin NE, 2004, EARTH PLANET SC LETT, V219, P93, DOI 10.1016/S0012-821X(03)00707-6; Lisiecki LE, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2005PA001164; *NAT RES COUNC COM, 2005, GEOL REC EC DYN UND; Owen R.B, 2002, SEPM SPECIAL PUBLICA, V73, P233, DOI DOI 10.2110/pec.02.73.0233; Potts R, 1998, YEARB PHYS ANTHROPOL, V41, P93; POTTS R, IN PRESS HOMINID ENV; Potts R, 1996, HUMANITYS DESCENT CO; QUINN RL, 2004, EOS T AGU S, V85; SERLING TE, 1992, PALAEOGEOGR PALAEOCL, V97, P241; Shackleton NJ, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P242; STANLEY SM, 1992, PALEOBIOLOGY, V18, P237, DOI 10.1017/S0094837300010836; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; Trauth MH, 2005, SCIENCE, V309, P2051, DOI 10.1126/science.1112964; Trauth MH, 2003, EARTH PLANET SC LETT, V206, P297, DOI 10.1016/S0012-821X(02)01105-6; Vrba ES, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P24; Wynn JG, 2004, AM J PHYS ANTHROPOL, V123, P106, DOI 10.1002/ajpa.10317; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	32	118	124	16	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					476	478		10.1126/science.1116051	http://dx.doi.org/10.1126/science.1116051			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	008WM	16439650				2022-12-28	WOS:000235071400032
J	Biek, R; Drummond, AJ; Poss, M				Biek, R; Drummond, AJ; Poss, M			A virus reveals population structure and recent demographic history of its carnivore host	SCIENCE			English	Article							FELINE IMMUNODEFICIENCY VIRUS; HUMAN MIGRATIONS; DIVERGENCE; EPIDEMIC; ANCESTOR; STRAINS; COUGARS	Directly transmitted parasites often provide substantial information about the temporal and spatial characteristics of host-to-host contact. Here, we demonstrate that a fast-evolving virus (feline immunodeficiency virus, FIV) can reveal details of the contemporary population structure and recent demographic history of its natural wildlife host (Puma concolor) that were not apparent from host genetic data and would be impossible to obtain by other means. We suggest that rapidly evolving pathogens may provide a complementary tool for studying population dynamics of their hosts in "shallow" time.	Univ Montana, Wildlife Biol Program, Missoula, MT 59812 USA; Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; Univ Auckland, Dept Comp Sci, Auckland 1, New Zealand	University of Montana System; University of Montana; University of Montana System; University of Montana; University of Auckland	Biek, R (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.	rbiek@emory.edu	Drummond, Alexei J/A-3209-2010; Biek, Roman/AAT-8109-2020	Drummond, Alexei J/0000-0003-4454-2576; Biek, Roman/0000-0003-3471-5357				Anderson CR, 2004, J MAMMAL, V85, P1207, DOI 10.1644/BEL-111.1; Biek R, 2003, J VIROL, V77, P9578, DOI 10.1128/JVI.77.17.9578-9589.2003; BIEK R, 2004, THESIS U MONTANA; Carpenter MA, 1996, J VIROL, V70, P6682, DOI 10.1128/JVI.70.10.6682-6693.1996; Drummond AJ, 2003, TRENDS ECOL EVOL, V18, P481, DOI 10.1016/S0169-5347(03)00216-7; Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/mss075; DRUMMOND AJ, 2003, BEAST VERSION 1 2; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Holmes EC, 2004, MOL ECOL, V13, P745, DOI 10.1046/j.1365-294X.2003.02051.x; JALKOTZY MG, 1992, MANAGEMENT PLAN COUG; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; LANGLEY RJ, 1994, VIROLOGY, V202, P853, DOI 10.1006/viro.1994.1407; Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100; LOGAN K.A., 2001, DESERT PUMA EVOLUTIO; Lukashov VV, 2002, J MOL EVOL, V54, P680, DOI 10.1007/s00239-001-0070-5; Martins EP, 2004, COMPUTER PROGRAMS ST; Nowak R.M., 1976, COUGAR US CANADA; OLMSTED RA, 1992, J VIROL, V66, P6008, DOI 10.1128/JVI.66.10.6008-6018.1992; Riley, 1998, THESIS CORNELL U; Sinclair EA, 2001, ANIM CONSERV, V4, P257, DOI 10.1017/S1367943001001305; Sugimoto C, 1997, P NATL ACAD SCI USA, V94, P9191, DOI 10.1073/pnas.94.17.9191; Troyer JL, 2005, J VIROL, V79, P8282, DOI 10.1128/JVI.79.13.8282-8294.2005; Whiteman NK, 2005, ANIM CONSERV, V8, P175, DOI 10.1017/S1367943005001915; Wirth T, 2005, MOL ECOL, V14, P3289, DOI 10.1111/j.1365-294X.2005.02687.x; ONLINE MAP CREATOR	25	121	123	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					538	541		10.1126/science.1121360	http://dx.doi.org/10.1126/science.1121360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439664				2022-12-28	WOS:000235071400050
J	Hunter, D				Hunter, D			Focus on research - First, gather the data	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Hunter, D (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.								0	37	49	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					329	331		10.1056/NEJMp058235	http://dx.doi.org/10.1056/NEJMp058235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436764				2022-12-28	WOS:000234854000004
J	Dyachok, O; Isakov, Y; Sagetorp, J; Tengholm, A				Dyachok, O; Isakov, Y; Sagetorp, J; Tengholm, A			Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells	NATURE			English	Article							GLUCAGON-LIKE PEPTIDE-1; PROTEIN-KINASE-A; PANCREATIC-ISLETS; NUCLEOTIDE PHOSPHODIESTERASES; ADENYLYL CYCLASES; CYTOPLASMIC CA2+; CAMP; GLUCOSE; EXOCYTOSIS; RECEPTORS	Cyclic AMP is a ubiquitous second messenger that transduces signals from a variety of cell surface receptors to regulate diverse cellular functions, including secretion, metabolism and gene transcription. In pancreatic beta-cells, cAMP potentiates Ca2+-dependent exocytosis(1-3) and mediates the stimulation of insulin release exerted by the hormones glucagon and glucagon-like peptide-1 (GLP-1) (refs 4-6). Whereas Ca2+ signals have been extensively characterized and shown to involve oscillations important for the temporal control of insulin secretion(4,7,8), the kinetics of receptor-triggered cAMP signals is unknown. Here we introduce a new ratiometric evanescent-wave-microscopy approach to measure cAMP concentration beneath the plasma membrane, and show that insulin-secreting beta-cells respond to glucagon and GLP-1 with marked cAMP oscillations. Simultaneous measurements of intracellular Ca2+ concentration revealed that the two messengers are interlinked and reinforce each other. Moreover, cAMP oscillations are capable of inducing rapid on-off Ca2+ responses, but only sustained elevation of cAMP concentration induces nuclear translocation of the catalytic subunit of the cAMP-dependent protein kinase. Our results establish a new signalling mode for cAMP and indicate that temporal encoding of cAMP signals might constitute a basis for differential regulation of downstream cellular targets.	Uppsala Univ, BMC, Dept Med Cell Biol, SE-75123 Uppsala, Sweden; Kiev T Shevchenko Natl Univ, Dept Biophys, UA-01033 Kiev, Ukraine	Uppsala University; Ministry of Education & Science of Ukraine; Taras Shevchenko National University Kiev	Tengholm, A (corresponding author), Uppsala Univ, BMC, Dept Med Cell Biol, Box 571, SE-75123 Uppsala, Sweden.	anders.tengholm@medcellbiol.uu.se	Dyachok, Oleg/B-5935-2017	Dyachok, Oleg/0000-0003-1825-9793				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; Cooper DMF, 2003, BIOCHEM J, V375, P517, DOI 10.1042/BJ20031061; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Delmeire D, 2003, DIABETOLOGIA, V46, P1383, DOI 10.1007/s00125-003-1203-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dyachok O, 2004, J BIOL CHEM, V279, P45455, DOI 10.1074/jbc.M407673200; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; GILON P, 1993, J BIOL CHEM, V268, P22265; Gorbunova YV, 2002, NATURE, V418, P93, DOI 10.1038/nature00835; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Gromada J, 2004, BASIC CLIN PHARMACOL, V95, P252, DOI 10.1111/j.1742-7843.2004.t01-1-pto950502.x; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; List JF, 2004, AM J PHYSIOL-ENDOC M, V286, pE875, DOI 10.1152/ajpendo.00007.2004; Ma XS, 2005, MOL ENDOCRINOL, V19, P198, DOI 10.1210/me.2004-0059; Maeda M, 2004, SCIENCE, V304, P875, DOI 10.1126/science.1094647; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Porksen N, 1998, DIABETES, V47, P45, DOI 10.2337/diabetes.47.1.45; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Pyne NJ, 2003, DIABETOLOGIA, V46, P1179, DOI 10.1007/s00125-003-1176-7; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; Rich TC, 2002, ANN BIOMED ENG, V30, P1088, DOI 10.1114/1.1511242; Ritzel R, 2001, DIABETES, V50, P776, DOI 10.2337/diabetes.50.4.776; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; [No title captured]	29	202	207	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					349	352		10.1038/nature04410	http://dx.doi.org/10.1038/nature04410			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421574				2022-12-28	WOS:000234682100048
J	Nusbaum, C; Mikkelsen, TS; Zody, MC; Asakawa, S; Taudien, S; Garber, M; Kodira, CD; Schueler, MG; Shimizu, A; Whittaker, CA; Chang, JL; Cuomo, CA; Dewar, K; FitzGerald, MG; Yang, XP; Allen, NR; Anderson, S; Asakawa, T; Blechschmidt, K; Bloom, T; Borowsky, ML; Butler, J; Cook, A; Corum, B; DeArellano, K; DeCaprio, D; Dooley, KT; Dorris, L; Engels, R; Glockner, G; Hafez, N; Hagopian, DS; Hall, JL; Ishikawa, SK; Jaffe, DB; Kamat, A; Kudoh, J; Lehmann, R; Lokitsang, T; Macdonald, P; Major, JE; Matthews, CD; Mauceli, E; Menzel, U; Mihalev, AH; Minoshima, S; Murayama, Y; Naylor, JW; Nicol, R; Nguyen, C; O'Leary, SB; O'Neill, K; Parker, SCJ; Polley, A; Raymond, CK; Reichwald, K; Rodriguez, J; Sasaki, T; Schilhabel, M; Siddiqui, R; Smith, CL; Sneddon, TP; Talamas, JA; Tenzin, P; Topham, K; Venkataraman, V; Wen, GP; Yamazaki, S; Young, SK; Zeng, QD; Zimmer, AR; Rosenthal, A; Birren, BW; Platzer, M; Shimizu, N; Lander, ES				Nusbaum, C; Mikkelsen, TS; Zody, MC; Asakawa, S; Taudien, S; Garber, M; Kodira, CD; Schueler, MG; Shimizu, A; Whittaker, CA; Chang, JL; Cuomo, CA; Dewar, K; FitzGerald, MG; Yang, XP; Allen, NR; Anderson, S; Asakawa, T; Blechschmidt, K; Bloom, T; Borowsky, ML; Butler, J; Cook, A; Corum, B; DeArellano, K; DeCaprio, D; Dooley, KT; Dorris, L; Engels, R; Glockner, G; Hafez, N; Hagopian, DS; Hall, JL; Ishikawa, SK; Jaffe, DB; Kamat, A; Kudoh, J; Lehmann, R; Lokitsang, T; Macdonald, P; Major, JE; Matthews, CD; Mauceli, E; Menzel, U; Mihalev, AH; Minoshima, S; Murayama, Y; Naylor, JW; Nicol, R; Nguyen, C; O'Leary, SB; O'Neill, K; Parker, SCJ; Polley, A; Raymond, CK; Reichwald, K; Rodriguez, J; Sasaki, T; Schilhabel, M; Siddiqui, R; Smith, CL; Sneddon, TP; Talamas, JA; Tenzin, P; Topham, K; Venkataraman, V; Wen, GP; Yamazaki, S; Young, SK; Zeng, QD; Zimmer, AR; Rosenthal, A; Birren, BW; Platzer, M; Shimizu, N; Lander, ES			DNA sequence and analysis of human chromosome 8	NATURE			English	Article							GENOME SEQUENCE; MICROCEPHALIN; ANNOTATION; DEFENSINS; MUTATION; HISTORY; MAP	The International Human Genome Sequencing Consortium (IHGSC) recently completed a sequence of the human genome(1). As part of this project, we have focused on chromosome 8. Although some chromosomes exhibit extreme characteristics in terms of length, gene content, repeat content and fraction segmentally duplicated, chromosome 8 is distinctly typical in character, being very close to the genome median in each of these aspects. This work describes a finished sequence and gene catalogue for the chromosome, which represents just over 5% of the euchromatic human genome. A unique feature of the chromosome is a vast region of similar to 15 megabases on distal 8p that appears to have a strikingly high mutation rate, which has accelerated in the hominids relative to other sequenced mammals. This fast-evolving region contains a number of genes related to innate immunity and the nervous system, including loci that appear to be under positive selection(2)-these include the major defensin (DEF) gene cluster(3,4) and MCPH1(5,6), a gene that may have contributed to the evolution of expanded brain size in the great apes. The data from chromosome 8 should allow a better understanding of both normal and disease biology and genome evolution.	MIT, Broad Inst, Cambridge, MA 02141 USA; Harvard Univ, Cambridge, MA 02141 USA; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan; Inst Mol Biotechnol, D-07745 Jena, Germany; NHGRI, NIH, Bethesda, MD 20982 USA; UCL, Dept Biol, Galton Lab, HGNC, London NW1 2HE, England	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Keio University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of London; University College London	Nusbaum, C (corresponding author), MIT, Broad Inst, 320 Charles St, Cambridge, MA 02141 USA.	chad@broad.mit.edu; shimizu@dmb.med.keio.ac.jp	Glöckner, Gernot/A-7800-2010; Zeng, Qiandong/AAF-3305-2019; Cuomo, Christina/L-2222-2019; Sasaki, Takashi/AAD-1461-2019; Mikkelsen, Tarjei S/A-1306-2007; Parker, Stephen/ABF-1063-2021; Rodriguez, Joseph/I-9277-2014	Glöckner, Gernot/0000-0002-9061-1061; Cuomo, Christina/0000-0002-5778-960X; Mikkelsen, Tarjei S/0000-0002-8133-3135; Rodriguez, Joseph/0000-0002-6017-1376; Whittaker, Charles/0000-0002-2400-0094; Nicol, Robert/0000-0003-1932-1392; DeCaprio, Dave/0000-0001-8931-9461; Sasaki, Takashi/0000-0002-6275-046X; Sneddon, Tam Paterson/0000-0003-1137-8992; Engels, Reinhard/0000-0003-0921-0736	Medical Research Council [G0000107] Funding Source: Medline; MRC [G0000107] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083; Ashurst JL, 2005, NUCLEIC ACIDS RES, V33, pD459, DOI 10.1093/nar/gki135; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Deloukas P, 2004, NATURE, V429, P375, DOI 10.1038/nature02462; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Evans PD, 2005, SCIENCE, V309, P1717, DOI 10.1126/science.1113722; Evans PD, 2004, HUM MOL GENET, V13, P1139, DOI 10.1093/hmg/ddh126; GE Y, 1992, GENOMICS, V13, P585, DOI 10.1016/0888-7543(92)90128-F; Giglio S, 2001, AM J HUM GENET, V68, P874, DOI 10.1086/319506; Grimwood J, 2004, NATURE, V428, P529, DOI 10.1038/nature02399; Hellmann I, 2005, GENOME RES, V15, P1222, DOI 10.1101/gr.3461105; Hillier LW, 2005, NATURE, V434, P724, DOI 10.1038/nature03466; Hollox EJ, 2003, AM J HUM GENET, V73, P591, DOI 10.1086/378157; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Mars WM, 1995, J BIOL CHEM, V270, P30371, DOI 10.1074/jbc.270.51.30371; Martin J, 2004, NATURE, V432, P988, DOI 10.1038/nature03187; Maxwell AI, 2003, MOL IMMUNOL, V40, P413, DOI 10.1016/S0161-5890(03)00160-3; Nusbaum C, 2005, NATURE, V437, P551, DOI 10.1038/nature03983; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Reich DE, 2002, NAT GENET, V32, P135, DOI 10.1038/ng947; Ross MT, 2005, NATURE, V434, P325, DOI 10.1038/nature03440; Schmutz J, 2004, NATURE, V429, P365, DOI 10.1038/nature02390; Shimokawa O, 2004, AM J MED GENET A, V128A, P133, DOI 10.1002/ajmg.a.30063; Taudien S, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-92; Vallender EJ, 2004, HUM MOL GENET, V13, pR245, DOI 10.1093/hmg/ddh253; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wyckoff GJ, 2005, TRENDS GENET, V21, P381, DOI 10.1016/j.tig.2005.05.005; Xiao YJ, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-56	32	84	503	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					331	335		10.1038/nature04406	http://dx.doi.org/10.1038/nature04406			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421571	Bronze			2022-12-28	WOS:000234682100044
J	Berger, JS; Roncaglioni, MC; Avanzini, F; Pangrazzi, I; Tognoni, G; Brown, DL				Berger, JS; Roncaglioni, MC; Avanzini, F; Pangrazzi, I; Tognoni, G; Brown, DL			Aspirin for the primary prevention of cardiovascular events in women and men - A sex-specific meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-DOSE ASPIRIN; DISEASE; INHIBITION; DIFFERENCE; REDUCTION; CORONARY; UPDATE; RISK	Context Aspirin therapy reduces the risk of cardiovascular disease in adults who are at increased risk. However, it is unclear if women derive the same benefit as men. Objective To determine if the benefits and risks of aspirin treatment in the primary prevention of cardiovascular disease vary by sex. Data Sources and Study Selection MEDLINE and the Cochrane Central Register of Controlled Trials databases (1966 to March 2005), bibliographies of retrieved trials, and reports presented at major scientific meetings. Eligible studies were prospective, randomized controlled trials of aspirin therapy in participants without cardiovascular disease that reported data on myocardial infarction (MI), stroke, and cardiovascular mortality. Six trials with a total of 95 456 individuals were identified; 3 trials included only men, 1 included only women, and 2 included both sexes. Data Extraction Studies were reviewed to determine the number of patients randomized, mean duration of follow-up, and end points (a composite of cardiovascular events [nonfatal MI, nonfatal stroke, and cardiovascular mortality], each of these individual components separately, and major bleeding). Data Synthesis Among 51342 women, there were 1285 major cardiovascular events: 625 strokes, 469 MIs, and 364 cardiovascular deaths. Aspirin therapy was associated with a significant 12% reduction in cardiovascular events (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.79-,0.99; P=.03) and a 17% reduction in stroke (OR, 0.83; 95% CI, 0.70-0.97; P=.02), which was a reflection of reduced rates of ischemic stroke (OR, 0.76; 95% CI, 0.63-0.93; P=.008). There was no significant effect on MI or cardiovascular mortality. Among 44 114 men, there were 2047 major cardiovascular events: 597 strokes, 1023 MIS, and 776 cardiovascular deaths. Aspirin therapy was associated with a significant 14% reduction in cardiovascular events (OR, 0.86; 95% CI, 0.78-0.94; P=.01) and a 32% reduction in MI (OR, 0.68; 95% CI, 0.54-0.86; P=.001). There was no significant effect on stroke or cardiovascular mortality. Aspirin treatment increased the risk of bleeding in women (OR, 1.68; 95% CI, 1.13-2.52; P=.01) and in men (OR, 1.72; 95% CI, 1.35-2.20; P<.001). Conclusions For women and men, aspirin therapy reduced the risk of a composite of cardiovascular events due to its effect on reducing the risk of ischemic stroke in women and MI in men. Aspirin significantly increased the risk of bleeding to a similar degree among women and men.	SUNY Stony Brook, Hlth Sci Ctr T16 080, Sch Med, Div Cardiovasc Med, Stony Brook, NY 11794 USA; Duke Univ, Dept Cardiovasc Med, Durham, NC USA; Ist Ric Farmacol Mario Negri, Dept Cardiovasc Med, Milan, Italy	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Duke University; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Brown, DL (corresponding author), SUNY Stony Brook, Hlth Sci Ctr T16 080, Sch Med, Div Cardiovasc Med, Stony Brook, NY 11794 USA.	david.brown@stonybrook.edu	roncaglioni, maria carla/AAB-1875-2020	roncaglioni, maria carla/0000-0002-2029-7847; Berger, Jeffrey/0000-0001-8216-4647; Avanzini, Fausto/0000-0002-4029-2891				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Berg AO, 2002, ANN INTERN MED, V136, P157, DOI 10.7326/0003-4819-136-2-200201150-00015; Eidelman RS, 2003, ARCH INTERN MED, V163, P2006, DOI 10.1001/archinte.163.17.2006; ESCOLAR G, 1986, THROMB RES, V44, P837, DOI 10.1016/0049-3848(86)90029-0; Gum PA, 2001, AM J CARDIOL, V88, P230, DOI 10.1016/S0002-9149(01)01631-9; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HARRISON MJG, 1983, THROMB HAEMOSTASIS, V50, P773; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Ikonomidis I, 1999, CIRCULATION, V100, P793, DOI 10.1161/01.CIR.100.8.793; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; Meade TW, 1998, LANCET, V351, P233; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P2908, DOI 10.1001/jama.293.23.2908; Mosca L, 2004, J AM COLL CARDIOL, V43, P900, DOI 10.1016/j.jacc.2004.02.001; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; Patrono C, 2004, CHEST, V126, p234S, DOI 10.1378/chest.126.3_suppl.234S; PATRONO C, 1985, CIRCULATION, V72, P1177, DOI 10.1161/01.CIR.72.6.1177; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Ridker P M, 1996, J Cardiovasc Risk, V3, P209, DOI 10.1097/00043798-199604000-00013; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SPRANGER M, 1989, STROKE, V20, P34, DOI 10.1161/01.STR.20.1.34; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; WEKSLER BB, 1983, NEW ENGL J MED, V308, P800, DOI 10.1056/NEJM198304073081402; Wood D, 1998, EUR HEART J, V19, P1434	28	582	616	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2006	295	3					306	313		10.1001/jama.295.3.306	http://dx.doi.org/10.1001/jama.295.3.306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003LU	16418466				2022-12-28	WOS:000234684500024
J	Grossman, HB; Soloway, M; Messing, E; Katz, G; Stein, B; Kassabian, V; Shen, Y				Grossman, HB; Soloway, M; Messing, E; Katz, G; Stein, B; Kassabian, V; Shen, Y			Surveillance for recurrent bladder cancer using a point-of-care proteomic assay	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; URINE CYTOLOGY; 5-AMINOLEVULINIC ACID; RADICAL CYSTECTOMY; DIAGNOSTIC-VALUE; MUSCLE INVASION; MESSENGER-RNA; GOLD STANDARD; TELOMERASE	Context At least 50% of patients with a history of bladder cancer have recurrences, so rigorous surveillance is necessary. Cystoscopy is standard but can fail to detect some bladder cancers, so a urine test is frequently part of the evaluation. Objective To investigate whether a point-of-care proteomic test that measures the nuclear matrix protein NMP22 in voided urine could improve detection of recurrence during monitoring of patients with a history of bladder cancer. Design, Setting, and Patients From September 2001 to February 2002, 23 academic, private practice, and hospital facilities in 9 US states prospectively enrolled 668 consecutive patients with a history of bladder cancer in this cross-sectional study. Patients provided a voided urine sample for analysis of NMP22 protein and cytology prior to cystoscopy. Main Outcome Measures Diagnosis of bladder cancer recurrence, based on cystoscopy with biopsy, was accepted as the reference standard. The performance of the NMP22 test was compared with voided urine cytology as an aid to detection. Testing for the NMP22 tumor marker was conducted in a blinded manner. Results Bladder cancer was diagnosed in 103 patients. Cystoscopy alone identified 91.3% of the cancers (94/103; 95% confidence interval [CI], 84.1%-95.9%). The combination of cystoscopy with the NMP22 assay detected 99.0% of the malignancies (102/103; 95% CI, 94.7%-100%; P=.005). The NMP22 assay detected 8 of 9 cancers that were not visualized during initial cystoscopy, including 7 that were high-grade. The sensitivity and specificity of the NMP22 test alone were 49.5% (51/103; 95% CI, 39.5%-59.5%) and 87.3% (493/565; 95% CI, 84.2%-89.9%), respectively, Voided cytology detected only 3 of the malignancies missed during initial cystoscopy and did not significantly increase the sensitivity of cystoscopy (94.2%; 95% CI, 87.7%-97.8%; P=.08). Conclusion The noninvasive point-of-care assay for elevated urinary NMP22 protein can increase the ability to detect recurrent bladder cancer, with test results available during the patient visit.	Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Miami, Sch Med, Miami, FL USA; Univ Rochester, Med Ctr, Rochester, NY 14642 USA; Lakeshore Urol, Manitowoc, WI USA; Lake City Vet Adm Hosp, Lake City, FL USA; Rhode Isl Hosp, Providence, RI USA; Georgia Urol, Atlanta, GA USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Miami; University of Rochester; Lifespan Health Rhode Island; Rhode Island Hospital	Grossman, HB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd,Unit 1373, Houston, TX 77030 USA.	HBGrossman@mdanderson.org		Shen, Yu/0000-0002-3899-7868				*AM JOINT COMM CAN, 1997, CANC STAG MAN; BADALAMENT RA, 1987, CANCER, V60, P1423, DOI 10.1002/1097-0142(19871001)60:7<1423::AID-CNCR2820600702>3.0.CO;2-6; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; Botteman MF, 2003, PHARMACOECONOMICS, V21, P1315, DOI 10.1007/BF03262330; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; Chang SS, 2003, J UROLOGY, V170, P1085, DOI 10.1097/01.ju.0000086828.26001.ca; de Kok JB, 2000, CLIN CHEM, V46, P2003; Durkalski VL, 2003, STAT MED, V22, P2417, DOI 10.1002/sim.1438; FARROW GM, 1990, J OCCUP ENVIRON MED, V32, P817, DOI 10.1097/00043764-199009000-00012; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; Frimberger D, 2000, Semin Urol Oncol, V18, P264; Grossman HB, 2005, JAMA-J AM MED ASSOC, V293, P810, DOI 10.1001/jama.293.7.810; Halling KC, 2002, J UROLOGY, V167, P2001, DOI 10.1016/S0022-5347(05)65072-0; Halling KC, 2000, J UROLOGY, V164, P1768, DOI 10.1016/S0022-5347(05)67104-2; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; HOLMANG S, 1995, J UROLOGY, V153, P1823, DOI 10.1016/S0022-5347(01)67321-X; HUDSON MA, 1995, J UROLOGY, V153, P564, DOI 10.1016/S0022-5347(01)67650-X; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jocham D, 2005, J UROLOGY, V174, P862, DOI 10.1097/01.ju.0000169257.19841.2a; Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5; MARIANI AJ, 1989, J UROLOGY, V141, P350, DOI 10.1016/S0022-5347(17)40763-4; MATZKIN H, 1992, UROLOGY, V39, P201, DOI 10.1016/0090-4295(92)90288-8; May M, 2004, SCAND J UROL NEPHROL, V38, P231, DOI 10.1080/00365590410029141; Mian C, 2003, CYTOPATHOLOGY, V14, P338, DOI 10.1046/j.0956-5507.2003.00094.x; Mian C, 1999, J UROLOGY, V161, P1486, DOI 10.1016/S0022-5347(05)68934-3; MURPHY WM, 1981, J UROLOGY, V126, P320, DOI 10.1016/S0022-5347(17)54505-X; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; Pfister C, 2003, J UROLOGY, V169, P921, DOI 10.1097/01.ju.0000048983.83079.4c; RIFE CC, 1979, UROL CLIN N AM, V6, P599; Sachs MD, 2005, J UROLOGY, V173, P246, DOI 10.1016/S0022-5347(18)35068-7; Sanchez-Ortiz RF, 2003, J UROLOGY, V169, P110, DOI 10.1016/S0022-5347(05)64047-5; Sanchini MA, 2005, JAMA-J AM MED ASSOC, V294, P2052, DOI 10.1001/jama.294.16.2052; Sarosdy MF, 2002, J UROLOGY, V168, P1950, DOI 10.1016/S0022-5347(05)64270-X; Schneeweiss S, 1999, J UROLOGY, V161, P1116, DOI 10.1016/S0022-5347(01)61605-7; Zaak D, 2001, UROLOGY, V57, P690, DOI 10.1016/S0090-4295(00)01053-0; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111	37	206	215	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2006	295	3					299	305		10.1001/jama.295.3.299	http://dx.doi.org/10.1001/jama.295.3.299			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003LU	16418465				2022-12-28	WOS:000234684500023
J	Lee, G; Abdi, K; Jiang, Y; Michaely, P; Bennett, V; Marszalek, PE				Lee, G; Abdi, K; Jiang, Y; Michaely, P; Bennett, V; Marszalek, PE			Nanospring behaviour of ankyrin repeats	NATURE			English	Article							PROTEIN; SPECTROSCOPY; MICROSCOPY; SPECTRIN; HEARING; CHANNEL	Ankyrin repeats are an amino-acid motif believed to function in protein recognition; they are present in tandem copies in diverse proteins in nearly all phyla(1). Ankyrin repeats contain antiparallel alpha-helices that can stack to form a superhelical spiral(2). Visual inspection of the extrapolated structure of 24 ankyrin-R repeats(2) indicates the possibility of spring-like behaviour of the putative superhelix. Moreover, stacks of 17-29 ankyrin repeats in the cytoplasmic domains of transient receptor potential (TRP) channels have been identified as candidates for a spring that gates mechanoreceptors in hair cells as well as in Drosophila bristles(3-5). Here we report that tandem ankyrin repeats exhibit tertiary-structure-based elasticity and behave as a linear and fully reversible spring in single-molecule measurements by atomic force microscopy. We also observe an unexpected ability of unfolded repeats to generate force during refolding, and report the first direct measurement of the refolding force of a protein domain. Thus, we show that one of the most common amino-acid motifs has spring properties that could be important in mechanotransduction and in the design of nanodevices.	Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA; Duke Univ, Ctr Biol Inspired Mat & Mat Syst, Durham, NC 27708 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27708 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bennett, V (corresponding author), Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA.	benne012@mc.duke.edu; pemar@duke.edu	Jiang, Yong/A-4173-2008	Jiang, Yong/0000-0002-5815-1480; Lee, Gwangrog/0000-0002-1720-8524				Ashmore J, 2004, NATURE, V432, P685, DOI 10.1038/432685a; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Best RB, 2003, ANAL CHIM ACTA, V479, P87, DOI 10.1016/S0003-2670(02)01572-6; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Cecconi C, 2005, SCIENCE, V309, P2057, DOI 10.1126/science.1116702; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Corey DP, 2004, NATURE, V428, P901, DOI 10.1038/428901a; Fernandez JM, 2004, SCIENCE, V303, P1674, DOI 10.1126/science.1092497; Fisher TE, 2000, NAT STRUCT BIOL, V7, P719; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Howard J, 2004, CURR BIOL, V14, pR224, DOI 10.1016/j.cub.2004.02.050; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; Mello CC, 2004, P NATL ACAD SCI USA, V101, P14102, DOI 10.1073/pnas.0403386101; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Oberhauser AF, 2002, J MOL BIOL, V319, P433, DOI 10.1016/S0022-2836(02)00306-6; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Schmid EL, 1997, ANAL CHEM, V69, P1979, DOI 10.1021/ac9700033; Schmitt L, 2000, BIOPHYS J, V78, P3275, DOI 10.1016/S0006-3495(00)76863-9; Schwaiger I, 2005, EMBO REP, V6, P46, DOI 10.1038/sj.embor.7400317; Schwaiger I, 2002, NAT MATER, V1, P232, DOI 10.1038/nmat776; Sotomayor M, 2005, STRUCTURE, V13, P669, DOI 10.1016/j.str.2005.03.001; Tang KS, 2003, STRUCTURE, V11, P67, DOI 10.1016/S0969-2126(02)00929-2; Williams PM, 2003, NATURE, V422, P446, DOI 10.1038/nature01517	28	283	299	3	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	2006	440	7081					246	249		10.1038/nature04437	http://dx.doi.org/10.1038/nature04437			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019MC	16415852	Bronze			2022-12-28	WOS:000235839500054
J	Rodriguez-Viciana, P; Tetsu, O; Tidyman, WE; Estep, AL; Conger, BA; Cruz, MS; McCormick, F; Rauen, KA				Rodriguez-Viciana, P; Tetsu, O; Tidyman, WE; Estep, AL; Conger, BA; Cruz, MS; McCormick, F; Rauen, KA			Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome	SCIENCE			English	Article							SIGNALING PATHWAY; COSTELLO-SYNDROME; KINASE KINASE; MICE; CELLS; MEK1; RAF; DIFFERENTIATION; PROTOONCOGENES; TRANSFORMATION	Cardio-facio-cutaneous (CFC) syndrome is a sporadic developmental disorder involving characteristic craniofacial features, cardiac defects, ectodermal abnormalities, and developmental delay. We demonstrate that heterogeneous de novo missense mutations in three genes within the mitogen-activated protein kinase (MAPK) pathway cause CFC syndrome. The majority of cases (18 out of 23) are caused by mutations in BRAF, a gene frequently mutated in cancer. Of the 11 mutations identified, two result in amino acid substitutions that occur in tumors, but most are unique and suggest previously unknown mechanisms of B-Raf activation. Furthermore, three of five individuals without BRAF mutations had missense mutations in either MEK1 or MEK2, downstream effectors of B-Raf. Our findings highlight the involvement of the MAPK pathway in human development and will provide a molecular diagnosis of CFC syndrome.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94115 USA; CFC Int, Vestal, NY 13850 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rauen, KA (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA.	rauen@cc.ucsf.edu		Tetsu, Osamu/0000-0003-1820-7539	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD048502] Funding Source: NIH RePORTER; NICHD NIH HHS [HD048502] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Bansal A, 1997, ONCOGENE, V14, P1231, DOI 10.1038/sj.onc.1200947; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Estep AL, 2006, AM J MED GENET A, V140A, P8, DOI 10.1002/ajmg.a.31078; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gong XH, 2001, INVEST OPHTH VIS SCI, V42, P539; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; REYNOLDS JF, 1986, AM J MED GENET, V25, P413, DOI 10.1002/ajmg.1320250303; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; SOLIT DB, 2005, NATURE          1106; STORM SM, 1990, ONCOGENE, V5, P345; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2	20	424	456	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2006	311	5765					1287	1290		10.1126/science.1124642	http://dx.doi.org/10.1126/science.1124642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	019XB	16439621				2022-12-28	WOS:000235870400042
J	Lund, ST; Bohlmann, J				Lund, ST; Bohlmann, J			The molecular basis for wine grape quality - A volatile subject	SCIENCE			English	Editorial Material							SAUVIGNON BLANC GRAPES; FUNCTIONAL-CHARACTERIZATION; IDENTIFICATION; EXPRESSION; SYNTHASE; BERRY	Volatile organic compounds are important flavor components of finished wines. In addition to winemaking practices, which shape wine quality, cultivation of the grape berries in the vineyard each season affects the production of volatile organic compounds as well as other chemical components that ultimately contribute to our perception of flavor in finished wines. By studying how berry flavor components are determined by the interplay of vine genotypes, the environment, and cultivation practices at the molecular level, scientists will develop advanced tools and knowledge that will aid viticulturalists in consistently producing balanced, flavorful berries for wine production.	Univ British Columbia, Wine Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia	Lund, ST (corresponding author), Univ British Columbia, Wine Res Ctr, 241-2205 E Mall, Vancouver, BC V6T 1Z4, Canada.	stlund@interchange.ubc.ca						Campo E, 2005, J AGR FOOD CHEM, V53, P5682, DOI 10.1021/jf047870a; Canal- Llauberes R. M., 1993, WINE MICROBIOLOGY BI, P477; COOMBE BG, 1992, AM J ENOL VITICULT, V43, P101; des Gachons CP, 2000, J AGR FOOD CHEM, V48, P3387, DOI 10.1021/jf990979b; Girard B, 2002, AM J ENOL VITICULT, V53, P99; JACKSON DI, 1993, AM J ENOL VITICULT, V44, P409; Kotseridis Y, 1999, J CHROMATOGR A, V849, P245, DOI 10.1016/S0021-9673(99)00540-3; LACEY MJ, 1991, AM J ENOL VITICULT, V42, P103; Lucker J, 2004, PHYTOCHEMISTRY, V65, P2649, DOI 10.1016/j.phytochem.2004.08.017; Martin DM, 2004, PHYTOCHEMISTRY, V65, P1223, DOI 10.1016/j.phytochem.2004.03.018; Mathieu S, 2005, J EXP BOT, V56, P2721, DOI 10.1093/jxb/eri265; van Leeuwen C, 2004, AM J ENOL VITICULT, V55, P207; Wang J, 2005, PLANT J, V44, P606, DOI 10.1111/j.1365-313X.2005.02552.x; WATSON B, 2003, OREGON VITICULTURE, P235	14	134	143	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					804	805		10.1126/science.1118962	http://dx.doi.org/10.1126/science.1118962			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469915				2022-12-28	WOS:000235374900034
J	Wullschleger, S; Loewith, R; Hall, MN				Wullschleger, S; Loewith, R; Hall, MN			TOR signaling in growth and metabolism	CELL			English	Review							MAMMALIAN TARGET; TUMOR-SUPPRESSOR; TUBEROUS-SCLEROSIS; CELL-GROWTH; AMINO-ACIDS; S6 KINASE; RAPAMYCIN MTOR; ACTIN CYTOSKELETON; GENE-TRANSCRIPTION; BINDING PARTNER	The target of rapamycin (TOR) is a conserved Ser/Thr kinase that regulates cell growth and metabolism in response to environmental cues. Here, highlighting contributions from studies in model organisms, we review mammalian TOR complexes and the signaling branches they mediate. TOR is part of two distinct multiprotein complexes, TOR complex 1 (TORC1), which is sensitive to rapamycin, and TORC2, which is not. The physiological consequences of mammalian TORC1 dysregulation suggest that inhibitors of mammalian TOR may be useful in the treatment of cancer, cardiovascular disease, autoimmunity, and metabolic disorders.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	University of Basel; University of Geneva	Wullschleger, S (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.	m.hall@unibas.ch	Loewith, Robbie J/S-6289-2016	Loewith, Robbie J/0000-0002-2482-603X; Hall, Michael N/0000-0002-2998-0757; Wullschleger, Stephan/0000-0002-5521-2276				Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Ballif BA, 2005, P NATL ACAD SCI USA, V102, P667, DOI 10.1073/pnas.0409143102; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Basso AD, 2005, J BIOL CHEM, V280, P31101, DOI 10.1074/jbc.M503763200; Bateman JM, 2004, CELL, V119, P87, DOI 10.1016/j.cell.2004.08.028; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Crespo JL, 2005, PLANT PHYSIOL, V139, P1736, DOI 10.1104/pp.105.070847; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dancey JE, 2005, EXPERT OPIN INV DRUG, V14, P313, DOI 10.1517/13543784.14.3.313; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GERSHLICK AH, 2005, HEART S3, V91, P24; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Humphrey EL, 2004, CHEM BIOL, V11, P295, DOI 10.1016/j.chembiol.2004.03.001; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2004, DIABETES, V53, P2748, DOI 10.2337/diabetes.53.11.2748; Kristof AS, 2003, J BIOL CHEM, V278, P33637, DOI 10.1074/jbc.M301053200; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Loewith Robbie, 2004, VVolume 42, P139; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Martin PM, 2001, DEV BIOL, V240, P182, DOI 10.1006/dbio.2001.0461; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schawalder SB, 2004, NATURE, V432, P1058, DOI 10.1038/nature03200; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sigal A, 2000, CANCER RES, V60, P6788; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Teleman AA, 2005, DEV CELL, V9, P271, DOI 10.1016/j.devcel.2005.07.004; Thomas G., 2004, TOR TARGET RAPAMYCIN; Tischmeyer W, 2003, EUR J NEUROSCI, V18, P942, DOI 10.1046/j.1460-9568.2003.02820.x; Tremblay F, 2005, CURR OPIN CLIN NUTR, V8, P457, DOI 10.1097/01.mco.0000172589.55434.03; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wade JT, 2004, NATURE, V432, P1054, DOI 10.1038/nature03175; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Young DA, 2005, CURR OPIN PHARMACOL, V5, P418, DOI 10.1016/j.coph.2005.03.004; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	117	4210	4426	19	688	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					471	484		10.1016/j.cell.2006.01.016	http://dx.doi.org/10.1016/j.cell.2006.01.016			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469695	Bronze, Green Published			2022-12-28	WOS:000235464000011
J	Renner, FU; Stierle, A; Dosch, H; Kolb, DM; Lee, TL; Zegenhagen, J				Renner, FU; Stierle, A; Dosch, H; Kolb, DM; Lee, TL; Zegenhagen, J			Initial corrosion observed on the atomic scale	NATURE			English	Article							X-RAY-DIFFRACTION; SELECTIVE DISSOLUTION; EVOLUTION; ALLOYS	Corrosion destroys more than three per cent of the world's GDP(1). Recently, the electrochemical decomposition of metal alloys has been more productively harnessed to produce porous materials with diverse technological potential(2,3). High-resolution insight into structure formation during electrocorrosion is a prerequisite for an atomistic understanding and control of such electrochemical surface processes. Here we report atomic-scale observations of the initial stages of corrosion of a Cu3Au(111) single crystal alloy within a sulphuric acid solution. We monitor, by in situ X-ray diffraction with picometre-scale resolution, the structure and chemical composition of the electrolyte/alloy interface as the material decomposes. We reveal the microscopic structural changes associated with a general passivation phenomenon of which the origin has been hitherto unclear. We observe the formation of a gold-enriched single-crystal layer that is two to three monolayers thick, and has an unexpected inverted (CBA-) stacking sequence. At higher potentials, we find that this protective passivation layer dewets and pure gold islands are formed; such structures form the templates for the growth of nanoporous metals(2). Our experiments are carried out on a model single-crystal system. However, the insights should equally apply within a crystalline grain of an associated polycrystalline electrode fabricated from many other alloys exhibiting a large difference in the standard potential of their constituents(4), such as stainless steel ( see ref. 5 for example) or alloys used for marine applications, such as CuZn or CuAl.	Max Planck Inst Met Res, D-70569 Stuttgart, Germany; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Ulm, Abt Elektrochem, D-89081 Ulm, Germany	Max Planck Society; European Synchrotron Radiation Facility (ESRF); Ulm University	Renner, FU (corresponding author), Max Planck Inst Met Res, Heisenbergstr 3, D-70569 Stuttgart, Germany.	renner@esrf.fr	Stierle, Andreas/Q-2679-2018; Renner, Frank U/G-1655-2014	Stierle, Andreas/0000-0002-0303-6282; Renner, Frank U/0000-0003-0425-393X				Al-Kharafi FM, 2004, J APPL ELECTROCHEM, V34, P47, DOI 10.1023/B:JACH.0000005616.41240.d0; CHEN SJ, 1993, SURF SCI, V292, P289, DOI 10.1016/0039-6028(93)90334-G; ECKSTEIN GA, 2001, THESIS ERLANGEN; Erlebacher J, 2004, J ELECTROCHEM SOC, V151, pC614, DOI 10.1149/1.1784820; Erlebacher J, 2001, NATURE, V410, P450, DOI 10.1038/35068529; FLEISCHMANN M, 1987, J ELECTROANAL CHEM, V229, P125, DOI 10.1016/0022-0728(87)85135-5; FORTY AJ, 1979, NATURE, V282, P597, DOI 10.1038/282597a0; FORTY AJ, 1981, PHILOS MAG A, V43, P171, DOI 10.1080/01418618108239399; GERISCHER H, 1962, KORROSION, V14, P59; KABIUS B, 1986, SURFACES INHIBITION, P562; Kaiser H., 2003, ENCY ELECTROCHEMISTR, V4, P156; LI R, 1992, PHYS REV LETT, V68, P1168, DOI 10.1103/PhysRevLett.68.1168; MOFFAT TP, 1991, J ELECTROCHEM SOC, V138, P3224, DOI 10.1149/1.2085396; OPPENHEIM IC, 1991, SCIENCE, V254, P687, DOI 10.1126/science.254.5032.687; Pickering H.W., 1963, NACE, V19, p373t; PICKERING HW, 1970, J ELECTROCHEM SOC, V117, P8, DOI 10.1149/1.2407450; PICKERING HW, 1983, CORROS SCI, V23, P1107, DOI 10.1016/0010-938X(83)90092-6; ROBINSON IK, 1992, REP PROG PHYS, V55, P599, DOI 10.1088/0034-4885/55/5/002; Stierle A, 2004, REV SCI INSTRUM, V75, P5302, DOI 10.1063/1.1819552; Stratmann M, 2001, NATURE, V410, P420, DOI 10.1038/35068652; Vlieg E, 2000, J APPL CRYSTALLOGR, V33, P401, DOI 10.1107/S0021889899013655; Weissmuller J, 2003, SCIENCE, V300, P312, DOI 10.1126/science.1081024; WILLIAMS DE, 1991, NATURE, V350, P216, DOI 10.1038/350216a0; Zegenhagen J, 1996, SURF SCI, V352, P346, DOI 10.1016/0039-6028(95)01158-7; ZOUBOV N, 1963, ATLAS EQULIBRES ELEC, pCH14; [No title captured]	26	198	203	10	253	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					707	710		10.1038/nature04465	http://dx.doi.org/10.1038/nature04465			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467834				2022-12-28	WOS:000235193100040
J	Roy, PM; Meyer, G; Vielle, B; Le Gall, C; Verschuren, F; Carpentier, F; Leveau, P; Furber, A				Roy, PM; Meyer, G; Vielle, B; Le Gall, C; Verschuren, F; Carpentier, F; Leveau, P; Furber, A		EMDEPU Study Grp	Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article							VENOUS THROMBOEMBOLISM; COMPUTED-TOMOGRAPHY; PREDICTION	Background: International guidelines include several strategies for diagnosing pulmonary embolism with confidence, but little is known about how these guidelines are implemented in routine practice. Objective: To evaluate the appropriateness of diagnostic management of suspected pulmonary embolism and the relationship between diagnostic criteria and outcome. Design: Prospective cohort study with a 3-month follow-up. Setting: 116 emergency departments in France and 1 in Belgium. Patients: 1529 consecutive outpatients with suspected pulmonary embolism. Measurements: Appropriateness of diagnostic criteria according to international guidelines; incidence of thromboembolic events during follow-up. Results: Diagnostic management was inappropriate in 662 (43%) patients: 36 of 429 (8%) patients with confirmed pulmonary embolism and 626 of 1100 (57%) patients in whom pulmonary embolism was ruled out. independent risk factors for inappropriate management were age older than 75 years (adjusted odds ratio, 2.27 [95% Cl, 1.48 to 3.47]), known heart failure (odds ratio, 1.53 [Cl, 1.11 to 2.12]), chronic lung disease (odds ratio, 1.39 [Cl, 1.00 to 1.94]), current or recent pregnancy (odds ratio, 5.92 [Cl, 1.81 to 19.30]), currently receiving anticoagulant treatment (odds ratio, 4.57 [Cl, 2.51 to 8.31]), and the lack of a written diagnostic algorithm and clinical probability scoring in the emergency department (odds ratio, 2.54 [Cl, 1.51 to 4.28]). Among patients who did not receive anticoagulant treatment, 44 had a thromboembolic event during follow-up: 5 of 418 (1.2%) patients who received appropriate management and 39 of 506 (7.7%) patients who received inappropriate management (absolute risk difference, 6.5 percentage points [Cl, 4.0 to 9.1 percentage points]; P < 0.001). Inappropriateness was independently associated with thromboembolism occurrence (adjusted odds ratio, 4.29 [Cl, 1.45 to 12.70]). Limitations: This was an observational study without evaluation of the risk for overdiagnosis. Conclusions: Diagnostic management that does not adhere to guidelines is frequent and harmful in patients with suspected pulmonary embolism. Several risk factors for inappropriateness constitute useful findings for subsequent interventions.	CHU Angers, Serv Accueil & Traitement Urgences, F-49033 Angers 01, France; Hop Europeen Georges Pompidou, Paris, France; Ctr Hosp Gen, Argenteuil, France; Clin Univ St Luc, B-1200 Brussels, Belgium; CHU Grenoble, F-38043 Grenoble, France; Ctr Hosp Nord Deux Sevres, Thouars, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Roy, PM (corresponding author), CHU Angers, Serv Accueil & Traitement Urgences, 4 Rue Larrey, F-49033 Angers 01, France.	PMRoy@chu-angers.fr	Roy, Pierre-Marie/AAA-7737-2022					BARRITT DW, 1960, LANCET, V1, P1309; Campbell IA, 2003, THORAX, V58, P470; Chagnon I, 2002, AM J MED, V113, P269, DOI 10.1016/S0002-9343(02)01212-3; Chunilal SD, 2003, JAMA-J AM MED ASSOC, V290, P2849, DOI 10.1001/jama.290.21.2849; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Fedullo PF, 2003, NEW ENGL J MED, V349, P1247, DOI 10.1056/NEJMcp035442; Fesmire FM, 2003, ANN EMERG MED, V41, P257, DOI 10.1067/mem.2003.40; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Kearon C, 2003, CAN MED ASSOC J, V168, P183; Kline JA, 2000, ANN EMERG MED, V35, P168, DOI 10.1016/S0196-0644(00)70137-5; Kruip MJHA, 2003, ANN INTERN MED, V138, P941, DOI 10.7326/0003-4819-138-12-200306170-00005; Linkins LA, 2003, ANN INTERN MED, V139, P893, DOI 10.7326/0003-4819-139-11-200312020-00007; Miller AC, 2003, THORAX, V58, P463, DOI 10.1136/thorax.58.6.463; Mountain David, 2003, Emerg Med (Fremantle), V15, P250, DOI 10.1046/j.1442-2026.2003.00444.x; Musset D, 2002, LANCET, V360, P1914, DOI 10.1016/S0140-6736(02)11914-3; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Perrier A, 2004, AM J MED, V116, P291, DOI 10.1016/j.amjmed.2003.09.041; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; Pineda LA, 2001, CHEST, V120, P791, DOI 10.1378/chest.120.3.791; Schoepf UJ, 2004, CIRCULATION, V109, P2160, DOI 10.1161/01.CIR.0000128813.04325.08; STEIN PD, 1991, CHEST, V100, P598, DOI 10.1378/chest.100.3.598; Torbicki A, 2000, EUR HEART J, V21, P1301; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010	23	227	232	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					157	164		10.7326/0003-4819-144-3-200602070-00003	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008XS	16461959				2022-12-28	WOS:000235074800001
J	Halloran, ME; Longini, IM				Halloran, ME; Longini, IM			Public health - Community studies for vaccinating schoolchildren against influenza	SCIENCE			English	Editorial Material							CAIV-T; CHILDREN; TRIVALENT; EFFICACY; POPULATION		Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98109 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Halloran, ME (corresponding author), Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98109 USA.	betz@u.washington.edu						Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Francis T, 1955, AM J PUBLIC HEALTH N, V45, P1; HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004; Halloran ME, 2003, AM J EPIDEMIOL, V158, P305, DOI 10.1093/aje/kwg163; Halloran ME, 2001, AM J EPIDEMIOL, V154, P391, DOI 10.1093/aje/154.5.391; JORDAN R, 2005, IN PRESS VACCINE, DOI DOI 10.1016/J.VACCINE.2005.09.017; Longini IM, 2005, AM J EPIDEMIOL, V161, P303, DOI 10.1093/aje/kwi053; MONTO AS, 1969, B WORLD HEALTH ORGAN, V41, P537; NEUSTADT RE, 2005, SWINE FLU AFFAIR DEC; Patel R, 2005, J THEOR BIOL, V234, P201, DOI 10.1016/j.jtbi.2004.11.032; Piedra PA, 2005, VACCINE, V23, P1540, DOI 10.1016/j.vaccine.2004.09.025; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; RUDENKO LG, 1993, J INFECT DIS, V168, P881, DOI 10.1093/infdis/168.4.881; Weycker D, 2005, VACCINE, V23, P1284, DOI 10.1016/j.vaccine.2004.08.044	14	57	59	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					615	616		10.1126/science.1122143	http://dx.doi.org/10.1126/science.1122143			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	011GY	16456066				2022-12-28	WOS:000235257400031
J	De Cock, KM; Bunnell, R; Mermin, J				De Cock, KM; Bunnell, R; Mermin, J			Unfinished business - Expanding HIV testing in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Mermin, Jonathan/J-9847-2012					[Anonymous], 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]; *CBS MOH ORC MACR, 2004, KEN DEM HLTH SURV 20, P227; Downing RG, 1998, J ACQ IMMUN DEF SYND, V18, P384, DOI 10.1097/00042560-199808010-00011; World Health Organization (WHO), 2003, RIGHT KNOW NEW APPR	4	96	97	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					440	442		10.1056/NEJMp058327	http://dx.doi.org/10.1056/NEJMp058327			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	008DC	16452554	Green Published			2022-12-28	WOS:000235019400002
J	Smith, IE; Chua, S				Smith, IE; Chua, S			ABC of breast diseases - Medical treatment of early breast cancer. IV: neoadjuvant treatment	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Marsden Hosp, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Smith, IE (corresponding author), Royal Marsden Hosp, London SW3 6JJ, England.								0	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 28	2006	332	7535					223	224		10.1136/bmj.332.7535.223	http://dx.doi.org/10.1136/bmj.332.7535.223			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16439402	Green Published			2022-12-28	WOS:000235086900022
J	Park, HS; Nam, SH; Lee, JK; Yoon, CN; Mannervik, B; Benkovic, SJ; Kim, HS				Park, HS; Nam, SH; Lee, JK; Yoon, CN; Mannervik, B; Benkovic, SJ; Kim, HS			Design and evolution of new catalytic activity with an existing protein scaffold	SCIENCE			English	Article							METALLO-BETA-LACTAMASE; BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; GLYOXALASE-II; BINDING; SITE; INHIBITOR; MECHANISM; COMPLEX; ENZYME	The design of enzymes with new functions and properties has long been a goal in protein engineering. Here, we report a strategy to change the catalytic activity of an existing protein scaffold. This was achieved by simultaneous incorporation and adjustment of functional elements through insertion, deletion, and substitution of several active site loops, followed by point mutations to fine-tune the activity. Using this approach, we were able to introduce beta-lactamase activity into the alpha beta/beta alpha metallohydrolase scaffold of glyoxalase II. The resulting enzyme, evMBL8 (evolved metallo beta-lactamase 8), completely lost its original activity and, instead, catalyzed the hydrolysis of cefotaxime with a (k(cat)/K-m)(app) of 1.8 x 10(2) (mole/titer)(-1) second(-1), thus increasing resistance to Escherichia coli growth on cefotaxime by a factor of about 100.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Inst Sci & Technol, Bioanal & Biotransformat Res Ctr, Seoul 130650, South Korea; Uppsala Univ, Biomed Ctr, Dept Biochem, SE-75123 Uppsala, Sweden; Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Korea Advanced Institute of Science & Technology (KAIST); Korea Institute of Science & Technology (KIST); Uppsala University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Kim, HS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusung Dong, Taejon 305701, South Korea.	hskim76@kaist.ac.kr	Park, Hee-Sung/C-2042-2011; Kim, Hak-Sung/C-1929-2011					Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Arnold FH, 2001, NATURE, V409, P253, DOI 10.1038/35051731; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; Cheon YH, 2004, BIOCHEMISTRY-US, V43, P7413, DOI 10.1021/bi036330o; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Joerger AC, 2003, P NATL ACAD SCI USA, V100, P5694, DOI 10.1073/pnas.0531477100; Leopoldseder S, 2004, J MOL BIOL, V337, P871, DOI 10.1016/j.jmb.2004.01.062; Park HS, 2004, METHOD ENZYMOL, V388, P187; Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; Tang LX, 2005, BIOCHEMISTRY-US, V44, P6609, DOI 10.1021/bi047613z; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524; Zang TM, 2001, J BIOL CHEM, V276, P4788, DOI 10.1074/jbc.M005090200	18	196	213	6	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					535	538		10.1126/science.1118953	http://dx.doi.org/10.1126/science.1118953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439663				2022-12-28	WOS:000235071400049
J	Dietrich, WE; Perron, JT				Dietrich, WE; Perron, JT			The search for a topographic signature of life	NATURE			English	Review							SEDIMENT-TRANSPORT; SOIL PRODUCTION; LANDSCAPE; EVOLUTION; MODEL; EROSION; VEGETATION; WIND; PROFILES; GEOMICROBIOLOGY	Landscapes are shaped by the uplift, deformation and breakdown of bedrock and the erosion, transport and deposition of sediment. Life is important in all of these processes. Over short timescales, the impact of life is quite apparent: rock weathering, soil formation and erosion, slope stability and river dynamics are directly influenced by biotic processes that mediate chemical reactions, dilate soil, disrupt the ground surface and add strength with a weave of roots. Over geologic time, biotic effects are less obvious but equally important: biota affect climate, and climatic conditions dictate the mechanisms and rates of erosion that control topographic evolution. Apart from the obvious influence of humans, does the resulting landscape bear an unmistakable stamp of life? The influence of life on topography is a topic that has remained largely unexplored. Erosion laws that explicitly include biotic effects are needed to explore how intrinsically small-scale biotic processes can influence the form of entire landscapes, and to determine whether these processes create a distinctive topography.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Dietrich, WE (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.		Perron, J. Taylor/D-8983-2012	Perron, J. Taylor/0000-0002-0404-8701				Ahnert F., 1967, LEVOLUTION VERSANTS, P23; AMUNDSON R, 2004, EOS S, V85; ANDERSON RS, 1986, GEOL SOC AM BULL, V97, P1270, DOI 10.1130/0016-7606(1986)97<1270:EPDTPE>2.0.CO;2; Anderson RS, 2002, GEOMORPHOLOGY, V46, P35, DOI 10.1016/S0169-555X(02)00053-3; Bagnold R., 1941, PHYS BLOWN SAND DESE; Baker V.R., 1982, THE CHANNELS OF MARS, DOI [10.1029/EO063i045p00862, DOI 10.1029/EO063I045P00862]; Baker VR, 2001, NATURE, V412, P228, DOI 10.1038/35084172; BEAUMONT C, 1992, THRUST TECTONICS, P1; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; Bhattacharya JP, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022747; Brasier M, 2004, ORIGINS LIFE EVOL B, V34, P257, DOI 10.1023/B:ORIG.0000009845.62244.d3; Byrne S, 2003, SCIENCE, V299, P1051, DOI 10.1126/science.1080148; Chyba CF, 2005, SCIENCE, V308, P962, DOI 10.1126/science.1113157; Collins DBG, 2004, J GEOPHYS RES-EARTH, V109, DOI 10.1029/2003JF000028; COX NJ, 1980, EARTH SURF PROC LAND, V5, P271, DOI 10.1002/esp.3760050305; Craddock RA, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001505; CULLING WEH, 1960, J GEOL, V68, P336, DOI 10.1086/626663; Densmore AL, 1998, J GEOPHYS RES-SOL EA, V103, P15203, DOI 10.1029/98JB00510; Dietrich W.E., 2003, GEOPHYS MONOGR SER, V135, P103; Edmond JM, 2003, EARTH PLANET SC LETT, V216, P125, DOI 10.1016/S0012-821X(03)00510-7; Ehrlich HL, 1998, EARTH-SCI REV, V45, P45, DOI 10.1016/S0012-8252(98)00034-8; Fleming R.W., 1975, Q J ENG GEOL HYDROGE, V8, P1, DOI [10.1144/GSL.QJEG.1975.008.01.01, DOI 10.1144/GSL.QJEG.1975.008.01.01]; Furbish DJ, 2001, WATER RESOUR RES, V37, P2607, DOI 10.1029/2001WR000239; Gabet EJ, 2003, ANNU REV EARTH PL SC, V31, P249, DOI 10.1146/annurev.earth.31.100901.141314; Gabet EJ, 2003, WATER RESOUR RES, V39, DOI 10.1029/2003WR002341; Head JW, 2005, NATURE, V434, P346, DOI 10.1038/nature03359; Heimsath AM, 1997, NATURE, V388, P358, DOI 10.1038/41056; Heimsath AM, 2005, GEOLOGY, V33, P949, DOI 10.1130/G21868.1; Heimsath AM, 2002, GEOLOGY, V30, P111, DOI 10.1130/0091-7613(2002)030<0111:CS>2.0.CO;2; Heimsath AM, 2001, EARTH SURF PROC LAND, V26, P531, DOI 10.1002/esp.209; Hildes DHD, 2004, QUATERNARY SCI REV, V23, P409, DOI 10.1016/j.quascirev.2003.06.005; Hilley GE, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2002JB002284; Howard AD, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2005JE002459; HOWARD AD, 1983, GEOL SOC AM BULL, V94, P739, DOI 10.1130/0016-7606(1983)94<739:CCIB>2.0.CO;2; HOWARD AD, 1994, J GEOPHYS RES-SOL EA, V99, P13971, DOI 10.1029/94JB00744; HOWARD AD, 1994, WATER RESOUR RES, V30, P2261, DOI 10.1029/94WR00757; Howard AD, 1999, INCISED RIVER CHANNELS: PROCESSES, FORMS, ENGINEERING, AND MANAGEMENT, P277; Irwin RP, 2005, GEOLOGY, V33, P489, DOI 10.1130/G21333.1; Istanbulluoglu E, 2005, J GEOPHYS RES-EARTH, V110, DOI 10.1029/2004JF000249; IVERSON RM, 1986, J GEOL, V94, P349, DOI 10.1086/629034; Iverson RM, 2005, J GEOPHYS RES-EARTH, V110, DOI 10.1029/2004JF000268; Kasting JF, 2003, ANNU REV ASTRON ASTR, V41, P429, DOI 10.1146/annurev.astro.41.071601.170049; KIRKBY M, 1995, GEOMORPHOLOGY, V13, P319, DOI 10.1016/0169-555X(95)00065-D; Kirkby M.J., 1971, SPECIAL PUBLICATION, V3, P5; Kleidon A, 2000, CLIMATIC CHANGE, V44, P471, DOI 10.1023/A:1005559518889; Kump LR, 2000, ANNU REV EARTH PL SC, V28, P611, DOI 10.1146/annurev.earth.28.1.611; Lancaster N, 1998, EARTH SURF PROC LAND, V23, P69, DOI 10.1002/(SICI)1096-9837(199801)23:1&lt;69::AID-ESP823&gt;3.0.CO;2-G; Leopold L.B., 1992, FLUVIAL PROCESSES GE; MacGregor KR, 2000, GEOLOGY, V28, P1031, DOI 10.1130/0091-7613(2000)28<1031:NSOGLP>2.0.CO;2; Malin MC, 2003, SCIENCE, V302, P1931, DOI 10.1126/science.1090544; MCEWAN IK, 1991, THESIS U ABERDEEN; MCEWEN A, 2003, 6 INT C MARS, P3217; Micheli ER, 2002, EARTH SURF PROC LAND, V27, P687, DOI 10.1002/esp.340; Moore JM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL019002; Murray AB, 2003, EARTH SURF PROC LAND, V28, P131, DOI 10.1002/esp.428; Newman DK, 2002, SCIENCE, V296, P1071, DOI 10.1126/science.1010716; Nimmo F, 1998, ANNU REV EARTH PL SC, V26, P23, DOI 10.1146/annurev.earth.26.1.23; Perron JT, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017603; Piqueux S, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002007; Richards MA, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000115; Riquelme R, 2003, TECTONOPHYSICS, V361, P255, DOI 10.1016/S0040-1951(02)00649-2; Rodriguez-Iturbe I., 1997, FRACTAL RIVER BASINS; Roering JJ, 1999, WATER RESOUR RES, V35, P853, DOI 10.1029/1998WR900090; Roering JJ, 2005, GEOLOGY, V33, P349, DOI 10.1130/G21260.1; Roering JJ, 2004, EARTH SURF PROC LAND, V29, P1597, DOI 10.1002/esp.1112; ROERING JJ, 2004, J GEOPHYS RES, V109, DOI DOI 10.1029/200OJF000034; SCHRAG DP, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI DOI 10.1029/2001GC00219; SCHUMM SA, 1985, ANNU REV EARTH PL SC, V13, P5, DOI 10.1146/annurev.ea.13.050185.000253; Seidl M.A., 1992, CATENA S, V23, P101, DOI DOI 10.1029/2007WR006219; Sklar LS, 2004, WATER RESOUR RES, V40, DOI 10.1029/2003WR002496; Sklar LS, 2001, GEOLOGY, V29, P1087, DOI 10.1130/0091-7613(2001)029<1087:SARSCO>2.0.CO;2; SMITH TR, 1972, WATER RESOUR RES, V8, P1506, DOI 10.1029/WR008i006p01506; Stock J, 2003, WATER RESOUR RES, V39, DOI 10.1029/2001WR001057; STOCK JD, 2003, THESIS U CALIFORNIA; Tian F, 2005, SCIENCE, V308, P1014, DOI 10.1126/science.1106983; Tomasko MG, 2005, NATURE, V438, P765, DOI 10.1038/nature04126; Toy T.J., 2002, SOIL EROSION PROCESS; Tucker GE, 1998, WATER RESOUR RES, V34, P2751, DOI 10.1029/98WR01474; Tucker GE, 1997, WATER RESOUR RES, V33, P2031, DOI 10.1029/97WR00409; TUCKER GE, 1994, J GEOPHYS RES-SOL EA, V99, P12229, DOI 10.1029/94JB00320; van der Beek P, 1998, BASIN RES, V10, P49, DOI 10.1046/j.1365-2117.1998.00056.x; Ward PD, 2000, SCIENCE, V289, P1740, DOI 10.1126/science.289.5485.1740; WERNER BT, 1990, J GEOL, V98, P1, DOI 10.1086/629371; Whipple KX, 2004, J GEOPHYS RES-EARTH, V109, DOI 10.1029/2003JF000019; Whipple KX, 2004, ANNU REV EARTH PL SC, V32, P151, DOI 10.1146/annurev.earth.32.101802.120356; Willett SD, 1999, J GEOPHYS RES-SOL EA, V104, P28957, DOI 10.1029/1999JB900248; WILLGOOSE G, 1991, WATER RESOUR RES, V27, P1671, DOI 10.1029/91WR00935; WILLGOOSE G, 1994, J GEOPHYS RES-SOL EA, V99, P13987, DOI 10.1029/94JB00123; Yoo K, 2005, GEOLOGY, V33, P917, DOI 10.1130/G21831.1	90	282	301	7	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					411	418		10.1038/nature04452	http://dx.doi.org/10.1038/nature04452			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437104				2022-12-28	WOS:000234859200034
J	Ferres-Marco, D; Gutierrez-Garcia, I; Vallejo, DM; Bolivar, J; Gutierrez-Avino, FJ; Dominguez, M				Ferres-Marco, D; Gutierrez-Garcia, I; Vallejo, DM; Bolivar, J; Gutierrez-Avino, FJ; Dominguez, M			Epigenetic silencers and Notch collaborate to promote malignant tumours by Rb silencing	NATURE			English	Article							DROSOPHILA EYE; METHYLTRANSFERASE ACTIVITY; PIPSQUEAK PROTEIN; LOLA ENCODES; BTB-DOMAIN; HISTONE H3; METHYLATION; CANCER; DNA; POLYCOMB	Cancer is both a genetic and an epigenetic disease. Inactivation of tumour-suppressor genes by epigenetic changes is frequently observed in human cancers, particularly as a result of the modifications of histones and DNA methylation. It is therefore important to understand how these damaging changes might come about. By studying tumorigenesis in the Drosophila eye, here we identify two Polycomb group epigenetic silencers, Pipsqueak and Lola, that participate in this process. When coupled with overexpression of Delta, deregulation of the expression of Pipsqueak and Lola induces the formation of metastatic tumours. This phenotype depends on the histone-modifying enzymes Rpd3 ( a histone deacetylase), Su(var)3-9 and E(z), as well as on the chromodomain protein Polycomb. Expression of the gene Retinoblastoma-family protein (Rbf) is downregulated in these tumours and, indeed, this downregulation is associated with DNA hypermethylation. Together, these results establish a mechanism that links the Notch - Delta pathway, epigenetic silencing pathways and cell-cycle control in the process of tumorigenesis.	CSIC, UMH, Inst Neurosci, Alicante, Spain; Univ Cadiz, Fac Ciencias, Dept Bioquim & Biol Mol, Puerto Real 11510, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; Universidad de Cadiz	Dominguez, M (corresponding author), CSIC, UMH, Inst Neurosci, Campus San Juan,Apartado 18, Alicante, Spain.	m.dominguez@umh.es	Dominguez, Maria/G-2171-2014; Martínez, Diana Marcela Vallejo/AAE-8516-2019; BOLIVAR, JORGE/G-4322-2015; Ferres-Marco, Maria/G-8364-2015; Martínez, Diana Marcela Vallejo/AAE-7604-2019	Dominguez, Maria/0000-0002-3329-7862; BOLIVAR, JORGE/0000-0002-2645-9528; Ferres-Marco, Maria/0000-0002-0596-4891; Martínez, Diana Marcela Vallejo/0000-0003-0447-4265; Gutierrez Avino, Francisco Jose/0000-0002-9428-0765				Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Bray S, 2005, DEV CELL, V8, P279, DOI 10.1016/j.devcel.2004.11.020; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Chao JL, 2004, DEVELOPMENT, V131, P3839, DOI 10.1242/dev.01258; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dominguez M, 2005, DEV DYNAM, V232, P673, DOI 10.1002/dvdy.20311; Dominguez M, 2004, NAT GENET, V36, P31, DOI 10.1038/ng1281; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Firth LC, 2005, DEV CELL, V8, P541, DOI 10.1016/j.devcel.2005.01.017; GINIGER E, 1994, DEVELOPMENT, V120, P1385; Goeke S, 2003, NAT NEUROSCI, V6, P917, DOI 10.1038/nn1105; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Horowitz H, 1996, DEVELOPMENT, V122, P1859; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Jabbari K, 2004, GENE, V333, P143, DOI 10.1016/j.gene.2004.02.043; Janody F, 2004, GENETICS, V166, P187, DOI 10.1534/genetics.166.1.187; Kunert N, 2003, DEVELOPMENT, V130, P5083, DOI 10.1242/dev.00716; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lehmann M, 1998, J BIOL CHEM, V273, P28504, DOI 10.1074/jbc.273.43.28504; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Madden K, 1999, DEV BIOL, V213, P301, DOI 10.1006/dbio.1999.9399; Marhold J, 2004, DEVELOPMENT, V131, P6033, DOI 10.1242/dev.01531; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nguyen CT, 2002, CANCER RES, V62, P6456; Ohsako T, 2003, GENE, V311, P59, DOI 10.1016/S0378-1119(03)00554-7; Reddy MN, 2003, ONCOGENE, V22, P6301, DOI 10.1038/sj.onc.1206650; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rorth P, 1998, DEVELOPMENT, V125, P1049; Salzberg A, 2004, BIOCHEM BIOPH RES CO, V322, P465, DOI 10.1016/j.bbrc.2004.07.134; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schwendemann A, 2002, P NATL ACAD SCI USA, V99, P12883, DOI 10.1073/pnas.202341499; SIEGEL V, 1993, DEVELOPMENT, V119, P1187; Siegmund T, 2002, DEV GENES EVOL, V212, P152, DOI 10.1007/s00427-002-0219-2; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tie F, 2001, DEVELOPMENT, V128, P275; Toba G, 1999, GENETICS, V151, P725; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Weber U, 1995, EMBO J, V14, P6247, DOI 10.1002/j.1460-2075.1995.tb00315.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woodhouse EC, 2004, CELL CYCLE, V3, P38	50	165	168	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					430	436		10.1038/nature04376	http://dx.doi.org/10.1038/nature04376			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437107				2022-12-28	WOS:000234859200037
J	Kimball, AM				Kimball, AM			The health of nations: happy birthday WTO	LANCET			English	Editorial Material									Univ Washington, Sch Publ Hlth & Community Med, APEC Emerging Infect Network, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kimball, AM (corresponding author), Univ Washington, Sch Publ Hlth & Community Med, APEC Emerging Infect Network, Seattle, WA 98195 USA.	akimball@u.washington.edu						*FOOD SAF SEC KANS, SPS NOT TOOL; KIMBALL AM, 1999, PLAGUES POLITICS, P59; KIMBALL AM, 2001, PLAGUES POWER POLITI, P59; KIMBALL AM, 2002, INT C EM INF DIS ATL; Kimball AM, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-3; Lee Kelley., 2003, HLTH IMPACTS GLOBALI; *WHO HLTH TRAD GRO, 2002, TRAD HLTH SERV GLOB; *WORLD TRAD ORG CO, 2005, 10 ANN REV IMPL OP T; *WTO, 1994, REL WTO PROV TEXT 99; WTO, WHAT IS WTO	10	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					188	190		10.1016/S0140-6736(05)67762-8	http://dx.doi.org/10.1016/S0140-6736(05)67762-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427473				2022-12-28	WOS:000234810600006
J	Buehler, MJ; Gao, HJ				Buehler, MJ; Gao, HJ			Dynamical fracture instabilities due to local hyperelasticity at crack tips	NATURE			English	Article							STRESS; PROPAGATION; SILICON	As the speed of a crack propagating through a brittle material increases, a dynamical instability leads to an increased roughening of the fracture surface. Cracks moving at low speeds create atomically flat mirror-like surfaces; at higher speeds, rougher, less reflective ('mist') and finally very rough, irregularly faceted ('hackle') surfaces(1-5) are formed. The behaviour is observed in many different brittle materials, but the underlying physical principles, though extensively debated, remain unresolved(1-4). Most existing theories of fracture(6-12) assume a linear elastic stress-strain law. However, the relation between stress and strain in real solids is strongly nonlinear due to large deformations near a moving crack tip, a phenomenon referred to as hyperelasticity(13-17). Here we use massively parallel large-scale atomistic simulations-employing a simple atomistic material model that allows a systematic transition from linear elastic to strongly nonlinear behaviour-to show that hyperelasticity plays a governing role in the onset of the instability. We report a generalized model that describes the onset of instability as a competition between different mechanisms controlled by the local stress field(6-8) and local energy flow(13,14) near the crack tip. Our results indicate that such instabilities are intrinsic to dynamical fracture and they help to explain a range of controversial experimental(1-5,18) and computational(19-26) results.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; Max Planck Inst Met Res, D-70569 Stuttgart, Germany	Massachusetts Institute of Technology (MIT); Max Planck Society	Buehler, MJ (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave,Room 1-272, Cambridge, MA 02139 USA.	mbuehler@MIT.EDU	Buehler, Markus J./C-4580-2008; Gao, Huajian/F-9360-2010	Buehler, Markus J./0000-0002-4173-9659; Gao, Huajian/0000-0002-8656-846X				Abraham FF, 2005, J MECH PHYS SOLIDS, V53, P1071, DOI 10.1016/j.jmps.2004.12.005; Abraham FF, 1997, J MECH PHYS SOLIDS, V45, P1595, DOI 10.1016/S0022-5096(96)00103-2; ABRAHAM FF, 1994, PHYS REV LETT, V73, P272, DOI 10.1103/PhysRevLett.73.272; Allen M. P., 1989, COMPUTER SIMULATION, DOI DOI 10.1093/OSO/9780198803195.001.0001; Boresi A. P., 2000, ELASTICITY ENG MECH; Broberg B. K., 1999, CRACKS FRACTURE; Buehler M., 2004, SPRINGER LECT NOTES, P143; Buehler MJ, 2003, NATURE, V426, P141, DOI 10.1038/nature02096; Cramer T, 2000, PHYS REV LETT, V85, P788, DOI 10.1103/PhysRevLett.85.788; ESHELBY JD, 1971, SCI PROG, V59, P161; Fineberg J, 1999, PHYS REP, V313, P1, DOI 10.1016/S0370-1573(98)00085-4; FINEBERG J, 1991, PHYS REV LETT, V67, P457, DOI 10.1103/PhysRevLett.67.457; Freund L.B., 1998, DYNAMIC FRACTURE MEC; FREUND LB, 1974, J MECH PHYS SOLIDS, V22, P137, DOI 10.1016/0022-5096(74)90021-0; GAO HJ, 1993, J MECH PHYS SOLIDS, V41, P457, DOI 10.1016/0022-5096(93)90044-G; Gao HJ, 1997, PHIL MAG LETT, V76, P307, DOI 10.1080/095008397178896; Gao HJ, 1996, J MECH PHYS SOLIDS, V44, P1453, DOI 10.1016/0022-5096(96)00038-5; Gumbsch P, 1997, PHYS REV B, V55, P3445, DOI 10.1103/PhysRevB.55.3445; Guo GF, 2003, J MECH PHYS SOLIDS, V51, P1971, DOI 10.1016/j.jmps.2003.09.028; Hauch JA, 1999, PHYS REV LETT, V82, P3823, DOI 10.1103/PhysRevLett.82.3823; Heizler SI, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.016126; MARDER M, 1995, J MECH PHYS SOLIDS, V43, P1, DOI 10.1016/0022-5096(94)00060-I; Petersan PJ, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.015504; Ravi-Chandar K, 1998, INT J FRACTURE, V90, P83, DOI 10.1023/A:1007432017290; Rountree CL, 2002, ANNU REV MATER RES, V32, P377, DOI 10.1146/annurev.matsci.32.111201.142017; Slepyan L.I., 2002, FDN ENGN MECH, DOI 10.1007/978-3-540-48010-5; Swadener JG, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.085503; van Duin ACT, 2003, J PHYS CHEM A, V107, P3803, DOI 10.1021/jp0276303; YOFFE EH, 1951, PHILOS MAG, V42, P739; Zhou M, 2003, P ROY SOC A-MATH PHY, V459, P2347, DOI 10.1098/rspa.2003.1127	30	220	226	9	132	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					307	310		10.1038/nature04408	http://dx.doi.org/10.1038/nature04408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421566				2022-12-28	WOS:000234682100038
J	Xu, N; Tsai, CL; Lee, JT				Xu, N; Tsai, CL; Lee, JT			Transient homologous chromosome pairing marks the onset of X inactivation	SCIENCE			English	Article							XIST GENE; TSIX; MICE; CHOICE; XITE	Mammalian X inactivation turns off one female X chromosome to enact dosage compensation between XX and XY individuals. X inactivation is known to be regulated in cis by Xite, Tsix, and Xist, but in principle the two Xs must also be regulated in trans to ensure mutually exclusive silencing. Here, we demonstrate that interchromosomal pairing mediates this communication. Pairing occurs transiently at the onset of X inactivation and is specific to the X-inactivation center. Deleting Xite and Tsix perturbs pairing and counting/choice, whereas their autosomal insertion induces de novo X-autosome pairing. Ectopic X-autosome interactions inhibit endogenous X-X pairing and block the initiation of X-chromosome inactivation. Thus, Tsix and Xite function both in cis and in trans. We propose that Tsix and Xite regulate counting and mutually exclusive choice through X-X pairing.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Dept Mol Biol,Dept Genet, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Lee, JT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Dept Mol Biol,Dept Genet, Boston, MA 02114 USA.	lee@molbio.mgh.harvard.edu						Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; Brown S W, 1992, Seizure, V1, P71, DOI 10.1016/1059-1311(92)90002-I; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Heard E, 2005, CURR OPIN GENET DEV, V15, P482, DOI 10.1016/j.gde.2005.08.009; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; Lee JT, 2000, CELL, V103, P17, DOI 10.1016/S0092-8674(00)00101-X; Lee JT, 2005, SCIENCE, V309, P768, DOI 10.1126/science.1113673; Lee JT, 1999, P NATL ACAD SCI USA, V96, P3836, DOI 10.1073/pnas.96.7.3836; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lee JT, 2002, NAT GENET, V32, P195, DOI 10.1038/ng939; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Marahrens Y, 1999, GENE DEV, V13, P2624, DOI 10.1101/gad.13.20.2624; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Morey C, 2004, EMBO J, V23, P594, DOI 10.1038/sj.emboj.7600071; Ogawa Y, 2003, MOL CELL, V11, P731, DOI 10.1016/S1097-2765(03)00063-7; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Sado T, 2001, DEVELOPMENT, V128, P1275; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	21	313	328	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1149	1152		10.1126/science.1122984	http://dx.doi.org/10.1126/science.1122984			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16424298				2022-12-28	WOS:000235688100048
J	Durrer, R				Durrer, R			Astronomy - Is the mystery of cosmic magnetic fields solved?	SCIENCE			English	Editorial Material									Univ Geneva, Dept Theoret Phys, CH-1211 Geneva, Switzerland	University of Geneva	Durrer, R (corresponding author), Univ Geneva, Dept Theoret Phys, CH-1211 Geneva, Switzerland.	ruth.durrer@physics.unige.ch	Durrer, Ruth/D-2068-2013	Durrer, Ruth/0000-0001-9833-2086				Betschart G, 2004, CLASSICAL QUANT GRAV, V21, P2115, DOI 10.1088/0264-9381/21/8/014; Caprini C, 2005, PHYS REV D, V72, DOI 10.1103/PhysRevD.72.088301; Caprini C, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.023517; Gopal R, 2005, MON NOT R ASTRON SOC, V363, P521, DOI 10.1111/j.1365-2966.2005.09442.x; Grasso D, 2001, PHYS REP, V348, P163, DOI 10.1016/S0370-1573(00)00110-1; Ichiki K, 2006, SCIENCE, V311, P827, DOI 10.1126/science.1120690; Matarrese S, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.043502; Takahashi K, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.121301; Widrow LM, 2002, REV MOD PHYS, V74, P775, DOI 10.1103/RevModPhys.74.775	9	4	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					787	788		10.1126/science.1122395	http://dx.doi.org/10.1126/science.1122395			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469908	Green Accepted			2022-12-28	WOS:000235374900028
J	Kaiser, R				Kaiser, R			Flowers and fungi use scents to mimic each other	SCIENCE			English	Editorial Material							FLORAL MIMICRY; PLANT	Some flowering plants mimic the scent and appearance of mushroom fruiting bodies. Fungi' may also mimic flowers. in addition, infection of plants by certain fungi can direct the plant to develop nonfunctional floral-like structures that nonetheless primarily serve the reproductive advantage of the fungus. These various mimicries may serve to attract insects that in turn spread fungal spores or plant pollen, thus facilitating sexual reproduction of the cryptic organism.	Gicaudan Schweiz AG, Fragrance Res, CH-8600 Dubendorf, Switzerland		Kaiser, R (corresponding author), Gicaudan Schweiz AG, Fragrance Res, Ueberlandstr 138, CH-8600 Dubendorf, Switzerland.	roman.kaiser@givaudan.com						CONNICK WJ, 1991, J AGR FOOD CHEM, V39, P185, DOI 10.1021/jf00001a037; ENDRESS PK, 1994, DIVERSITY EVOLUTIONA, P127; FUNGANTI C, 1993, BIOORG MED CHEM LETT, V3, P2777; GAUMANN E, 1959, BEITR KRYPTOGAMENFL, V12, P355; Kaiser R, 2004, CHEM BIODIVERS, V1, P13, DOI 10.1002/cbdv.200490005; KAISER R, 1993, SCENT ORCHIDS, P31; Naef A, 2002, NEW PHYTOL, V154, P717, DOI 10.1046/j.1469-8137.2002.00406.x; Neinhuis C., 1994, PALMENGARTEN, V58, P15; Pfunder M, 2000, AM J BOT, V87, P48, DOI 10.2307/2656684; Raguso RA, 1998, MOL ECOL, V7, P1127, DOI 10.1046/j.1365-294x.1998.00426.x; ROY BA, 1993, NATURE, V362, P56, DOI 10.1038/362056a0; Roy BA, 1997, OECOLOGIA, V109, P414, DOI 10.1007/s004420050101; VOGEL S, 1978, FLORA, V167, P329	13	63	68	3	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					806	807		10.1126/science.1119499	http://dx.doi.org/10.1126/science.1119499			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469916				2022-12-28	WOS:000235374900035
J	Yildiz, A				Yildiz, A			GE prizewinner - How molecular motors move	SCIENCE			English	Editorial Material							HAND-OVER-HAND; MYOSIN-V		Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA	University of California System; University of California San Francisco	Yildiz, A (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA.	yildiz@cmp.ucsf.edu	Yildiz, Ahmet/E-6167-2015	Yildiz, Ahmet/0000-0003-4792-174X				Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Kubitscheck U, 2000, BIOPHYS J, V78, P2170, DOI 10.1016/S0006-3495(00)76764-6; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; Yildiz A, 2004, J BIOL CHEM, V279, P37223, DOI 10.1074/jbc.C400252200; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	7	8	8	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					792	793		10.1126/science.1125068	http://dx.doi.org/10.1126/science.1125068			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469911				2022-12-28	WOS:000235374900031
J	Gillies, J; Sheehan, M				Gillies, J; Sheehan, M			Commentary: When should patients be held responsible for their lifestyle choices?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Selkirk Hlth Ctr, Selkirk TD7 4LQ, Scotland; Univ Keele, Ctr Profess Eth, Keele ST5 5BG, Staffs, England	Keele University	Gillies, J (corresponding author), Selkirk Hlth Ctr, Selkirk TD7 4LQ, Scotland.	john.gillies@selkirkhc.borders.scot.nhs.uk		Sheehan, Mark/0000-0002-7191-901X				Barendregt JJ, 1997, NEW ENGL J MED, V337, P1052, DOI 10.1056/NEJM199710093371506; BEAUCHAMP T, 2001, PRINCIPLES MED ETHIC, P247; McPherson S, 2006, BRIT MED J, V332, P276, DOI 10.1136/bmj.332.7536.276; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; Wilkinson Stephen, 1999, J Appl Philos, V16, P255, DOI 10.1111/1468-5930.00128	5	2	2	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					279	279		10.1136/bmj.332.7536.279	http://dx.doi.org/10.1136/bmj.332.7536.279			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455727	Green Published			2022-12-28	WOS:000235259000022
J	Grey, JE; Enoch, S; Harding, KG				Grey, JE; Enoch, S; Harding, KG			ABC of wound healing - Wound assessment	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wales Hosp, Cardiff & Vale NHS Trust, Cardiff, Wales; Cardiff Univ, Wound Healing Res Unit, Cardiff, Wales; Royal Coll Surgeons England, London WC2A 3PN, England	Cardiff University; Cardiff University; Royal College of Surgeons of England	Grey, JE (corresponding author), Univ Wales Hosp, Cardiff & Vale NHS Trust, Cardiff, Wales.	joseph.grey@cardiffandvale.wales.nhs.uk	Harding, Keith/J-5605-2013	Harding, Keith/0000-0003-0048-3279				Falanga V, 2000, TEXT ATLAS WOUND MAN; Izadi K, 2005, CLIN PLAST SURG, V32, P209, DOI 10.1016/j.cps.2004.11.011; LAZARUS GS, 1994, ARCH DERMATOL, V130, P489, DOI 10.1001/archderm.130.4.489	3	91	93	1	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					285	288		10.1136/bmj.332.7536.285	http://dx.doi.org/10.1136/bmj.332.7536.285			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455730	Green Published			2022-12-28	WOS:000235259000025
J	Shao, ZJ; Li, W; Ren, J; Liang, XF; Xu, L; Diao, BW; Li, MC; Lu, MJ; Ren, HY; Cui, ZG; Zhu, BQ; Dai, ZW; Zhang, L; Chen, X; Kan, B; Xu, JG				Shao, ZJ; Li, W; Ren, J; Liang, XF; Xu, L; Diao, BW; Li, MC; Lu, MJ; Ren, HY; Cui, ZG; Zhu, BQ; Dai, ZW; Zhang, L; Chen, X; Kan, B; Xu, JG			Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China	LANCET			English	Article							FIELD GEL-ELECTROPHORESIS; MENINGOCOCCAL DISEASE; SUBGROUP-III; GENOTYPES; VARIANTS; PATTERNS; PROTEIN	Background Outbreaks of a new serogroup C meningococcal disease emerged during 2003-04 (five outbreaks with 43 cases) and in 2004-05 (five outbreaks with 29 cases), all in Anhui province, China. We describe the molecular epidemiology and features of the causative bacterial strains. Methods We used pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST) to analyse the strains. Findings Of 34 strains of Neisseria meningitidis cultured during 2003-04 from Anhui province, 31 were group C meningococci, 28 of which were associated with three of five outbreaks; one from a patient and 27 from close contacts of eight patients. Of 30 strains isolated from Anhui province during 2004-05, 17 were identified as serogroup C meningococci, ten of which were associated with four of five outbreaks. In a nationwide survey, 542 strains were isolated during 2004-05; 58 were serogroup C meningococci interspersed among 11 other provinces where no serogroup C outbreak occurred. Of the 106 serogroup C strains analysed, 89 had identical PFGE patterns, designated AH1. Of 28 strains selected for MLST analyses, 25 were sequence type 4821 (ST-4821), which did not belong to any of the previously reported sequence types that can form a new hypervirulent lineage. Interpretation ST-4821 seems to be unique and caused the serogroup C meningitis outbreaks during the two seasons from 2003 to 2005 in Anhui province. The emergence of this sequence type has epidemiological importance that should be monitored for future spread in China and the rest of the world.	Chinese Ctr Dis Control & Prevent China CDC, Natl Inst Communicable Dis Control & Prevent, Beijing 102206, Peoples R China; Chinese Ctr Dis Control & Prevent China CDC, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China; Chinese Ctr Dis Control & Prevent China CDC, Natl Immunizat Program Ctr, Beijing 102206, Peoples R China; China Anhui Prov Ctr Dis Control & Prevent, Hefei, Anhui, Peoples R China	Chinese Center for Disease Control & Prevention; National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention	Xu, JG (corresponding author), Chinese Ctr Dis Control & Prevent China CDC, Natl Inst Communicable Dis Control & Prevent, POB 5, Beijing 102206, Peoples R China.	xujg@public.bta.net.cn			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHTMAN M, 1992, J INFECT DIS, V165, P53, DOI 10.1093/infdis/165.1.53; Achtman M, 1995, MENINGOCOCCAL DIS, P159; Feil EJ, 2004, J BACTERIOL, V186, P1518, DOI 10.1128/JB.186.5.1518-1530.2004; Gautom RK, 1997, J CLIN MICROBIOL, V35, P2977, DOI 10.1128/JCM.35.11.2977-2980.1997; HU XJ, 1991, NEISSERIAE 1990, P165; Hu XJ, 1991, J CHIN EPIDEMIOL, V12, P136; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jolley KA, 2001, BIOINFORMATICS, V17, P1230, DOI 10.1093/bioinformatics/17.12.1230; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; *NAT COMM CLIN LAB, 2003, M7A6 NAT COMM CLIN L; National Association of State Public Health Veterinarians Inc. (NASPHV), 2005, MMWR Recomm Rep, V54, P1; Popovic T, 2001, J CLIN MICROBIOL, V39, P75, DOI 10.1128/JCM.39.1.75-85.2001; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Sacchi CT, 1998, CLIN DIAGN LAB IMMUN, V5, P845, DOI 10.1128/CDLI.5.6.845-855.1998; Takahashi H, 2004, J MED MICROBIOL, V53, P657, DOI 10.1099/jmm.0.45541-0; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Urwin R, 2004, INFECT IMMUN, V72, P5955, DOI 10.1128/IAI.72.10.5955-5962.2004; WANG JF, 1992, INFECT IMMUN, V60, P5267, DOI 10.1128/IAI.60.12.5267-5282.1992; ZHU PX, 1995, J CLIN MICROBIOL, V33, P458, DOI 10.1128/JCM.33.2.458-462.1995; Zhu PX, 2001, P NATL ACAD SCI USA, V98, P5234, DOI 10.1073/pnas.061386098	21	81	122	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					419	423		10.1016/S0140-6736(06)68141-5	http://dx.doi.org/10.1016/S0140-6736(06)68141-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458767				2022-12-28	WOS:000235139400032
J	Gostin, LO				Gostin, LO			Medical countermeasures for pandemic influenza: Ethics and the law	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Ctr Law & Publ Hlth, Washington, DC USA; Johns Hopkins Univ, Baltimore, MD USA	Georgetown University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						[Anonymous], NATL STRATEGY PANDEM; ARRAS JD, IN PRESS YALE J BIOL; Barry J.M., 2005, THREAT PANDEMIC INFL; Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; Bell D, 2006, EMERG INFECT DIS, V12, P81; CHECK E, 2005, NATURE          0525, DOI DOI 10.1038/435404A; Danzon PM, 2005, HEALTH AFFAIR, V24, P706, DOI 10.1377/hlthaff.24.3.706; *G7 FIN MIN CTR GL, VACC DEV G7 PIL ADV; GARDNER EM, 2005, VACCINE         1014; *I MED COUNC, 2001, STAT VACC DEV; Institute of Medicine, 2005, SMALLP VACC PROGR PU; Institute of Medicine, 2004, IMM SAF REV VACC AUT; Mello MM, 2005, JAMA-J AM MED ASSOC, V294, P1817, DOI 10.1001/jama.294.14.1817; Moscona A, 2005, NEW ENGL J MED, V353, P2633, DOI 10.1056/NEJMp058291; Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740; Osterholm MT, 2005, FOREIGN AFF, V84, P24, DOI 10.2307/20034418; *PUBL ENG PIL PROJ, 2005, CIT VOIC PAND FLU CH; ROSENTHAL E, 2006, INT HERALD TRIB 0109; Stohr K, 2004, SCIENCE, V306, P2195, DOI 10.1126/science.1108165; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; US Department of Health and Human Services, 2006, HHS PAND INFL PLAN; World Health Organization, CUM NUMB CONF HUM CA; World Health Organization (WHO), 2004, WHO PUBL; World Health Organization (WHO), 2005, WHO GLOB INFL PREP P; World Trade Organization, AGR TRAD REL ASP INT; Zamiska Nicholas, 2005, WALL STREET J   1103	27	59	64	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					554	556		10.1001/jama.295.5.554	http://dx.doi.org/10.1001/jama.295.5.554			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	007SP	16449621				2022-12-28	WOS:000234990300023
J	McCarthy, M				McCarthy, M			Passage from India	LANCET			English	Editorial Material									Lancet, New York, NY 10010 USA		McCarthy, M (corresponding author), Lancet, 360 Park Ave S, New York, NY 10010 USA.	michael.mccarthy@lancet.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					345	345		10.1016/S0140-6736(06)68072-0	http://dx.doi.org/10.1016/S0140-6736(06)68072-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443042				2022-12-28	WOS:000235084600031
J	Prins, JB; van der Meer, JWM; Bleijenberg, G				Prins, JB; van der Meer, JWM; Bleijenberg, G			Chronic fatigue syndrome	LANCET			English	Review							COGNITIVE-BEHAVIOR-THERAPY; MONOZYGOTIC TWINS DISCORDANT; RANDOMIZED CONTROLLED-TRIAL; MEDICALLY UNEXPLAINED SYMPTOMS; LOW-DOSE HYDROCORTISONE; GRADED-EXERCISE; DOUBLE-BLIND; FOLLOW-UP; MYALGIC ENCEPHALOMYELITIS; OBJECTIVE MEASURES	During the past two decades, there has been heated debate about chronic fatigue syndrome (CFS) among researchers, practitioners, and patients. Few illnesses have been discussed so extensively. The existence of the disorder has been questioned, its underlying pathophysiology debated, and an effective treatment opposed; patients' organisations have participated in scientific discussions. in this review, we look back on several controversies over CFS with respect to its definition, diagnosis, pathophysiology, and treatment. We review issues of epidemiology and clinical manifestations, focusing on the scientific status of CFS. Modern neuroscience and genetics research offer interesting findings for new hypotheses on the aetiology and pathogenesis of the illness. We also discuss promising future issues, such as psychopathophysiology and mechanisms of improvement, and suggest multidisciplinary prospective studies of CFS and fatigue in the general population. These studies should pay particular attention to similarities to and differences from functional somatic syndromes and other fatiguing conditions.	Radboud Univ Nijmegen Med Ctr, Dept Med Psychol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Expert Ctr Chron Fatigue, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Prins, JB (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Med Psychol, 840 Dept Med Psychol,POB 9101, NL-6500 HB Nijmegen, Netherlands.	j.prins@mps.umcn.nl						Afari N, 2005, PSYCHIAT ANN, V35, P350; Afari N, 2003, AM J PSYCHIAT, V160, P221, DOI 10.1176/appi.ajp.160.2.221; Afari N, 2000, J PSYCHOSOM RES, V48, P547, DOI 10.1016/S0022-3999(00)00093-3; Ball N, 2004, J PSYCHOSOM RES, V56, P207, DOI 10.1016/S0022-3999(03)00598-1; Barsky AJ, 1999, ANN INTERN MED, V130, P910, DOI 10.7326/0003-4819-130-11-199906010-00016; Bazelmans E, 2005, PSYCHOTHER PSYCHOSOM, V74, P218, DOI 10.1159/000085145; Bazelmans E, 2001, PSYCHOL MED, V31, P107, DOI 10.1017/S0033291799003189; Becker PD., 2002, J CHRONIC FATIGUE SY, V10, P3, DOI [10.1300/j092v10n02_02, DOI 10.1300/J092V10N02_02]; BELL EJ, 1984, J HYG-CAMBRIDGE, V93, P197, DOI 10.1017/S0022172400064718; Bentall RP, 2002, BRIT J PSYCHIAT, V181, P248, DOI 10.1192/bjp.181.3.248; Blacker CVR, 2004, JAMA-J AM MED ASSOC, V292, P1195, DOI 10.1001/jama.292.10.1195; Bleijenberg G, 2004, J INTERN MED, V256, P268, DOI 10.1111/j.1365-2796.2004.01379.x; Bleijenberg Gijs, 2003, Health Qual Life Outcomes, V1, P52, DOI 10.1186/1477-7525-1-52; Blockmans D, 2003, AM J MED, V114, P736, DOI 10.1016/S0002-9343(03)00182-7; BONNER D, 1994, J NEUROL NEUROSUR PS, V57, P617, DOI 10.1136/jnnp.57.5.617; Brace MJ, 2000, J DEV BEHAV PEDIATR, V21, P332, DOI 10.1097/00004703-200010000-00003; Brouwers FM, 2002, QJM-INT J MED, V95, P677, DOI 10.1093/qjmed/95.10.677; Buchwald D, 2001, PSYCHOSOM MED, V63, P936, DOI 10.1097/00006842-200111000-00012; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; Buchwald DS, 2000, AM J MED, V109, P531, DOI 10.1016/S0002-9343(00)00560-X; Butler JA, 2001, PSYCHOL MED, V31, P97, DOI 10.1017/S0033291799003001; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; BYRNE E, 1988, MED J AUSTRALIA, V148, P80, DOI 10.5694/j.1326-5377.1988.tb104513.x; Cairns R, 2005, OCCUP MED-OXFORD, V55, P20, DOI 10.1093/occmed/kqi013; Capuron L, 2002, NEUROPSYCHOPHARMACOL, V26, P643, DOI 10.1016/S0893-133X(01)00407-9; Carruthers BM, 2003, J CHRONIC FATIGUE SY, V11, P7, DOI [DOI 10.1300/J092V11N01_02, 10.1300/J092v11n01_02]; Chalder T, 2003, BRIT MED J, V327, P654, DOI 10.1136/bmj.327.7416.654; Charney DS, 2004, AM J PSYCHIAT, V161, P195, DOI 10.1176/appi.ajp.161.2.195; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Clark C, 2002, LANCET, V359, P97, DOI 10.1016/S0140-6736(02)07336-1; Clarke JN, 2003, SOC SCI MED, V57, P1387, DOI 10.1016/S0277-9536(02)00515-4; Cleare AJ, 2004, TRENDS ENDOCRIN MET, V15, P55, DOI 10.1016/j.tem.2003.12.002; Cleare AJ, 1999, LANCET, V353, P455, DOI 10.1016/S0140-6736(98)04074-4; Cleare AJ, 2003, ENDOCR REV, V24, P236, DOI 10.1210/er.2002-0014; CLEARE AJ, 2003, END ABSTR, V5, pS35; DAVID A, 1993, LANCET, V342, P1247, DOI 10.1016/0140-6736(93)92234-K; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; de Lange FP, 2004, BRAIN, V127, P1948, DOI 10.1093/brain/awh225; De Meirleir K, 2000, AM J MED, V108, P99, DOI 10.1016/S0002-9343(99)00300-9; Deale A, 1997, AM J PSYCHIAT, V154, P408; Deale A, 2001, SOC SCI MED, V52, P1859, DOI 10.1016/S0277-9536(00)00302-6; Deale A, 2001, AM J PSYCHIAT, V158, P2038, DOI 10.1176/appi.ajp.158.12.2038; DELANGE FP, IN PRESS NEUROIMAGE; Edmonds M, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003200.PUB2; Eriksen HR, 2004, J PSYCHOSOM RES, V56, P445, DOI 10.1016/S0022-3999(03)00629-9; FRIEDBERG F, 1994, CLIN INFECT DIS, V18, pS105, DOI 10.1093/clinids/18.Supplement_1.S105; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; Gaab J, 2004, J PSYCHOSOM RES, V56, P419, DOI 10.1016/S0022-3999(03)00625-1; Gow JW, 2001, CLIN INFECT DIS, V33, P2080, DOI 10.1086/324357; Hatcher S, 2003, PSYCHOL MED, V33, P1185, DOI 10.1017/S0033291703008274; Heijmans MJWM, 1998, J PSYCHOSOM RES, V45, P39, DOI 10.1016/S0022-3999(97)00265-1; Hickie I, 1999, PSYCHOL MED, V29, P259, DOI 10.1017/S0033291798007934; Hickie I, 1999, PSYCHOL MED, V29, P269, DOI 10.1017/S0033291798007922; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOOGVELD S, 2001, GEDRAGSTHERAPIE, V34, P275; Hotopf M, 1997, J PSYCHOSOM RES, V43, P1, DOI 10.1016/S0022-3999(97)00115-3; Jason LA, 2005, NEUROPSYCHOL REV, V15, P29, DOI 10.1007/s11065-005-3588-2; Jason LA, 1999, ARCH INTERN MED, V159, P2129, DOI 10.1001/archinte.159.18.2129; Jones JF, 2004, J ADOLESCENT HEALTH, V35, P34, DOI [10.1016/j.jadohealth.2003.09.007, 10.1016/S1054-139X(03)00372-0]; Jordan KM, 1998, J ADOLESCENT HEALTH, V22, P4, DOI 10.1016/S1054-139X(97)00212-7; Joyce J, 1997, QJM-MON J ASSOC PHYS, V90, P223, DOI 10.1093/qjmed/90.3.223; Kelley KW, 2003, BRAIN BEHAV IMMUN, V17, pS112; Kennedy G, 2004, ANN EPIDEMIOL, V14, P95, DOI 10.1016/j.annepidem.2003.10.004; King C, 2005, BIOL PSYCHOL, V68, P87, DOI 10.1016/j.biopsycho.2004.03.015; Komaroff AL, 1996, AM J MED, V100, P56, DOI 10.1016/S0002-9343(96)90012-1; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; Lawrie SM, 1997, PSYCHOL MED, V27, P343, DOI 10.1017/S0033291796004357; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; LLOYD AR, 1993, AM J MED, V94, P197, DOI 10.1016/0002-9343(93)90183-P; LLOYD AR, 2003, HDB CHRONIC FATIGUE, P108; Lyall M, 2003, J PSYCHOSOM RES, V55, P79, DOI 10.1016/S0022-3999(02)00515-9; Mahurin RK, 2004, NEUROPSYCHOLOGY, V18, P232, DOI 10.1037/0894-4105.18.2.232; McCrone P, 2004, PSYCHOL MED, V34, P991, DOI 10.1017/S0033291704001928; McKenzie R, 1998, JAMA-J AM MED ASSOC, V280, P1061, DOI 10.1001/jama.280.12.1061; MELAMED BG, 2003, HDB CHRONIC FATIGUE, P192; Metzger FA, 2002, ANN BEHAV MED, V24, P106, DOI 10.1207/S15324796ABM2402_07; Michiels V, 2001, ACTA PSYCHIAT SCAND, V103, P84, DOI 10.1034/j.1600-0447.2001.00017.x; Moss-Morris R, 2005, J HEALTH PSYCHOL, V10, P245, DOI 10.1177/1359105305049774; MossMorris R, 1996, BRIT J HEALTH PSYCH, V1, P15, DOI 10.1111/j.2044-8287.1996.tb00488.x; Nijs J, 2004, MED HYPOTHESES, V62, P759, DOI 10.1016/j.mehy.2003.11.030; Nisenbaum Rosane, 2003, Health Qual Life Outcomes, V1, P49, DOI 10.1186/1477-7525-1-49; Okada T, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-14; Olson LG, 2003, PSYCHOSOMATICS, V44, P38, DOI 10.1176/appi.psy.44.1.38; Page LA, 2003, J ROY SOC MED, V96, P223, DOI 10.1258/jrsm.96.5.223; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; Powell P, 2004, BRIT J PSYCHIAT, V184, P142, DOI 10.1192/bjp.184.2.142; Powell P, 2001, BRIT MED J, V322, P1; POWELL R, 1990, J PSYCHOSOM RES, V34, P665, DOI 10.1016/0022-3999(90)90111-G; PRICE JR, 2000, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/; Prins J, 2005, BRIT J PSYCHIAT, V187, P184, DOI 10.1192/bjp.187.2.184; Prins J.B., 2000, J CHRONIC FATIGUE SY, V7, P3, DOI DOI 10.1300/J092V07N04_; Prins JB, 2004, PSYCHOTHER PSYCHOSOM, V73, P174, DOI 10.1159/000076455; Prins JB, 2002, LANCET, V359, P1699, DOI 10.1016/S0140-6736(02)08577-X; Prins JB, 2001, LANCET, V358, P240, DOI 10.1016/S0140-6736(01)05424-1; Prins JB, 2001, LANCET, V357, P841, DOI 10.1016/S0140-6736(00)04198-2; Reeves WC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-25; Reid S, 2000, BMJ-BRIT MED J, V320, P292, DOI 10.1136/bmj.320.7230.292; Reyes M, 2003, ARCH INTERN MED, V163, P1530, DOI 10.1001/archinte.163.13.1530; Sabath DE, 2002, J INFECT DIS, V185, P828, DOI 10.1086/339194; Salit IE, 1997, J PSYCHIATR RES, V31, P59, DOI 10.1016/S0022-3956(96)00050-7; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; Schmaling KB, 2000, PSYCHOSOM MED, V62, P444, DOI 10.1097/00006842-200005000-00018; Severens JL, 2004, QJM-INT J MED, V97, P153, DOI 10.1093/qjmed/hch029; Sharpe M, 2002, CLIN MED, V2, P501; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Shorter E., 1992, PARALYSIS FATIGUE HI; Smith J, 2005, J CLIN PATHOL, V58, P860, DOI 10.1136/jcp.2004.022681; Solomon L, 2004, ARCH INTERN MED, V164, P2241, DOI 10.1001/archinte.164.20.2241; Solomon Laura, 2003, Health Qual Life Outcomes, V1, P48, DOI 10.1186/1477-7525-1-48; Stanley I, 2002, BRIT J GEN PRACT, V52, P355; Stulemeijer M, 2005, BMJ-BRIT MED J, V330, P14, DOI 10.1136/bmj.38301.587106.63; SURAWY C, 1995, BEHAV RES THER, V33, P535, DOI 10.1016/0005-7967(94)00077-W; SWANINK CMA, 1995, J INTERN MED, V237, P499, DOI 10.1111/j.1365-2796.1995.tb00876.x; SWANINK CMA, 1995, CLIN INFECT DIS, V21, P708, DOI 10.1093/clinids/21.3.708-a; SWANINK CMA, 1995, CLIN INFECT DIS, V20, P1390, DOI 10.1093/clinids/20.5.1390; The GKH, 2003, NETH J MED, V61, P285; Theorell T, 1999, PSYCHOSOM MED, V61, P304, DOI 10.1097/00006842-199905000-00009; van der Greef J, 2004, CURR OPIN CHEM BIOL, V8, P559, DOI 10.1016/j.cbpa.2004.08.013; Van Houdenhove B, 2004, PSYCHOTHER PSYCHOSOM, V73, P267, DOI 10.1159/000078843; Vercoulen JHMM, 1998, J PSYCHOSOM RES, V45, P507, DOI 10.1016/S0022-3999(98)00023-3; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Viner R, 2004, BRIT MED J, V329, P941, DOI 10.1136/bmj.38258.507928.55; Vollmer-Conna U, 2001, PSYCHOL MED, V31, P761, DOI 10.1017/S0033291701003841; Wallman KE, 2004, MED J AUSTRALIA, V180, P444, DOI 10.5694/j.1326-5377.2004.tb06019.x; Watson NF, 2004, SLEEP, V27, P973, DOI 10.1093/sleep/27.5.973; Watson NF, 2003, SLEEP, V26, P324, DOI 10.1093/sleep/26.3.324; Wearden AJ, 1998, BRIT J PSYCHIAT, V172, P485, DOI 10.1192/bjp.172.6.485; Weatherley-Jones E, 2004, J PSYCHOSOM RES, V56, P189, DOI 10.1016/S0022-3999(03)00377-5; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2; Wessely S, 2004, BRIT J PSYCHIAT, V185, P95, DOI 10.1192/bjp.185.2.95; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; Wessely S, 1997, AM J PUBLIC HEALTH, V87, P1449, DOI 10.2105/AJPH.87.9.1449; Wessely S, 1998, CHRONIC FATIGUE ITS; White PD, 2004, BRIT MED J, V329, P928, DOI 10.1136/bmj.329.7472.928; White PD, 2001, LANCET, V358, P1946, DOI 10.1016/S0140-6736(01)06961-6; Whiting P, 2001, JAMA-J AM MED ASSOC, V286, P1360, DOI 10.1001/jama.286.11.1360; Wilson A, 2001, AUST NZ J PSYCHIAT, V35, P520, DOI 10.1046/j.1440-1614.2001.00888.x; *WORK GROUP CFS ME, REP CHIEF MED OFF IN; Zachrisson O, 2002, EUR J PAIN-LONDON, V6, P455, DOI 10.1016/S1090-3801(02)00044-7	143	393	408	2	102	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					346	355		10.1016/S0140-6736(06)68073-2	http://dx.doi.org/10.1016/S0140-6736(06)68073-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	009AX	16443043				2022-12-28	WOS:000235084600032
J	Wang, RF; Nisoli, C; Freitas, RS; Li, J; McConville, W; Cooley, BJ; Lund, MS; Samarth, N; Leighton, C; Crespi, VH; Schiffer, P				Wang, RF; Nisoli, C; Freitas, RS; Li, J; McConville, W; Cooley, BJ; Lund, MS; Samarth, N; Leighton, C; Crespi, VH; Schiffer, P			Artificial 'spin ice' in a geometrically frustrated lattice of nanoscale ferromagnetic islands	NATURE			English	Article							ELECTRON-BEAM LITHOGRAPHY; ARRAYS; FABRICATION; MAGNETS	Frustration, defined as a competition between interactions such that not all of them can be satisfied, is important in systems ranging from neural networks to structural glasses. Geometrical frustration, which arises from the topology of a well-ordered structure rather than from disorder, has recently become a topic of considerable interest(1). In particular, geometrical frustration among spins in magnetic materials can lead to exotic low-temperature states(2), including 'spin ice', in which the local moments mimic the frustration of hydrogen ion positions in frozen water(3-6). Here we report an artificial geometrically frustrated magnet based on an array of lithographically fabricated single-domain ferromagnetic islands. The islands are arranged such that the dipole interactions create a two-dimensional analogue to spin ice. Images of the magnetic moments of individual elements in this correlated system allow us to study the local accommodation of frustration. We see both ice-like short-range correlations and an absence of long-range correlations, behaviour which is strikingly similar to the low-temperature state of spin ice. These results demonstrate that artificial frustrated magnets can provide an uncharted arena in which the physics of frustration can be directly visualized.	Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Minnesota System; University of Minnesota Twin Cities	Schiffer, P (corresponding author), Penn State Univ, Dept Phys, University Pk, PA 16802 USA.	schiffer@phys.psu.edu	Li, Jie/L-5091-2013; Nisoli, Cristiano/O-5134-2019; Schiffer, Peter/F-3227-2011; wang, ruifang/D-3037-2016; Samarth, Nitin/AAV-2322-2020; Freitas, Rafael S/K-1034-2013; Li, Jie/D-9021-2014; Samarth, Nitin/C-4475-2014	Nisoli, Cristiano/0000-0003-0053-1023; wang, ruifang/0000-0002-8456-9776; Samarth, Nitin/0000-0003-2599-346X; Freitas, Rafael S/0000-0002-0225-6195; Samarth, Nitin/0000-0003-2599-346X; Schiffer, Peter/0000-0002-6430-6549; Crespi, Vincent/0000-0003-3846-3193				Bramwell ST, 2001, SCIENCE, V294, P1495, DOI 10.1126/science.1064761; Cowburn RP, 2000, SCIENCE, V287, P1466, DOI 10.1126/science.287.5457.1466; Cowburn RP, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.092409; Davidovic D, 1996, PHYS REV LETT, V76, P815, DOI 10.1103/PhysRevLett.76.815; Gardner JS, 1999, PHYS REV LETT, V82, P1012, DOI 10.1103/PhysRevLett.82.1012; Harris MJ, 1997, PHYS REV LETT, V79, P2554, DOI 10.1103/PhysRevLett.79.2554; Hilgenkamp H, 2003, NATURE, V422, P50, DOI 10.1038/nature01442; Imre A, 2003, SUPERLATTICE MICROST, V34, P513, DOI 10.1016/j.spmi.2004.03.051; Lin CK, 2004, J VAC SCI TECHNOL B, V22, P1723, DOI 10.1116/1.1767824; Martin JI, 2003, J MAGN MAGN MATER, V256, P449, DOI 10.1016/S0304-8853(02)00898-3; Melko RG, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.067203; Moessner R, 2001, CAN J PHYS, V79, P1283, DOI 10.1139/cjp-79-11/12-1283; *OOMMF, 2005, OOMMF PROJ ITL NIST; PAULING L, 1945, NATURE CHEM BOND, P301; Ramirez AP, 1999, NATURE, V399, P333, DOI 10.1038/20619; Ramirez AP., 2001, HDB MAGNETIC MAT, Vvol 13, P423, DOI DOI 10.1016/S1567-2719(01)13008-8; Ross CA, 2002, J APPL PHYS, V91, P6848, DOI 10.1063/1.1452247; Siddharthan R, 1999, PHYS REV LETT, V83, P1854, DOI 10.1103/PhysRevLett.83.1854; Snyder J, 2001, NATURE, V413, P48, DOI 10.1038/35092516; Snyder J, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.064414; Stamps RL, 1998, J MAGN MAGN MATER, V177, P813, DOI 10.1016/S0304-8853(97)00330-2; Tsui YK, 1999, PHYS REV LETT, V82, P3532, DOI 10.1103/PhysRevLett.82.3532; Yang XM, 2003, J VAC SCI TECHNOL B, V21, P3017, DOI 10.1116/1.1630331; Zhitomirsky ME, 2000, PHYS REV LETT, V85, P3269, DOI 10.1103/PhysRevLett.85.3269	25	653	655	6	213	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					303	306		10.1038/nature04447	http://dx.doi.org/10.1038/nature04447			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421565	Green Submitted			2022-12-28	WOS:000234682100037
J	McCulloch, P				McCulloch, P			Surgical professionalism in the 21st century	LANCET			English	Editorial Material							KNOWLEDGE MANAGEMENT; ADVERSE EVENTS; CARDIAC-SURGERY; SUPPORT-SYSTEM; SPECIALIZATION; MULTICENTER; INFORMATION; ASSESSMENTS; PERFORMANCE; SIMULATION		Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England	University of Oxford	McCulloch, P (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England.	peter.mcculloch@nds.ox.ac.uk		McCulloch, Peter/0000-0002-3210-8273				Ashkan K, 2003, ANN ROY COLL SURG, V85, P149, DOI 10.1308/003588403321661271; Beiles CB, 2004, ANZ J SURG, V74, P146, DOI 10.1046/j.1445-2197.2004.02913.x; Birkmeyer JD, 1998, SURGERY, V124, P917, DOI 10.1067/msy.1998.90268; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Datta V, 2002, AM J SURG, V184, P70, DOI 10.1016/S0002-9610(02)00891-7; de Leval MR, 2000, J THORAC CARDIOV SUR, V119, P661, DOI 10.1016/S0022-5223(00)70006-7; Fine LG, 2003, BRIT MED J, V326, P25, DOI 10.1136/bmj.326.7379.25; Fisher J, 2000, Air Med J, V19, P137, DOI 10.1016/S1067-991X(00)90006-3; Frize M, 1998, J AM MED INFORM ASSN, P553; Gawande AA, 1999, SURGERY, V126, P66, DOI 10.1067/msy.1999.98664; Gould S, 1997, BRIT J SURG, V84, P595, DOI 10.1002/bjs.1800840503; GREENES RA, 1989, COMPUT BIOMED RES, V22, P113, DOI 10.1016/0010-4809(89)90021-9; Healey AN, 2004, QUAL SAF HEALTH CARE, V13, pI33, DOI 10.1136/qshc.2004.009936; Helmreich RL, 1997, SCI AM, V276, P62, DOI 10.1038/scientificamerican0597-62; Kalogeropoulos DA, 2003, COMPUT METH PROG BIO, V72, P65, DOI 10.1016/S0169-2607(02)00118-9; Knab JH, 2001, ANESTH ANALG, V93, P712, DOI 10.1097/00000539-200109000-00035; Kneebone R, 2003, MED EDUC, V37, P267, DOI 10.1046/j.1365-2923.2003.01440.x; Mackay S, 2003, ANN SURG, V238, P291, DOI 10.1097/01.sla.0000080829.29028.c4; Marescaux J, 2001, NATURE, V413, P379, DOI 10.1038/35096636; Martin JA, 1997, BRIT J SURG, V84, P273, DOI 10.1046/j.1365-2168.1997.02502.x; MATHESON NW, 1995, J AM MED INFORM ASSN, V2, P73, DOI 10.1136/jamia.1995.95261908; McCulloch P, 2003, BMJ-BRIT MED J, V327, P1192, DOI 10.1136/bmj.327.7425.1192; OTA D, 1995, COMPUT BIOL MED, V25, P127, DOI 10.1016/0010-4825(94)00009-F; Purkayastha S, 2004, HOSP MED, V65, P153, DOI 10.12968/hosp.2004.65.3.12394; Rosen J, 2001, ST HEAL T, V81, P417; Smith JAE, 2003, BRIT J SURG, V90, P583, DOI 10.1002/bjs.4085; Torkington J, 2000, ANN ROY COLL SURG, V82, P88; Tu JV, 2001, J VASC SURG, V33, P447, DOI 10.1067/mva.2001.113487; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517	30	21	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					177	181		10.1016/S0140-6736(06)67966-X	http://dx.doi.org/10.1016/S0140-6736(06)67966-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413881				2022-12-28	WOS:000234655500032
J	Dodd, JM; Crowther, CA; Robinson, JS				Dodd, JM; Crowther, CA; Robinson, JS			Oral misoprostol for induction of labour at term: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROSTAGLANDIN E-2	Objective To compare oral misoprostol solution with vaginal prostaglandin gel (dinoprostone) for induction of tabour at term to determine whether misoprostol is superior. Design Randomised double blind placebo controlled trial. Setting Maternity departments in three hospitals in Australia. Population Pregnant women with a singleton cephalic presentation at >= 36+6 weeks' gestation, with an indication for prostaglandin induction of tabour. Interventions 20 mu g oral misoprostol solution at two hourly intervals and placebo vaginal gel or vaginal dinoprostone gel at six hourly intervals and placebo oral solution. Main outcome measures Vaginal birth within 24 hours; uterine hyperstimulation with associated changes in fetal heart rate; caesarean section (all); and caesarean section for fetal distress. Results 741 women were randomised, 365 to the misoprostol group and 376 to the vaginal dinoprostone group. There were no significant differences between the two treatment groups in the primary outcomes: vaginal birth not achieved in 24 hours (misoprostol 168/365 (46.0%) v dinoprostone 155/376 (41.2%); relative risk 1.12,95% confidence interval 0.95 to 1.32; P=0.134), caesarean section (83/365 (22.7%) v 100/376 (26.6%); 0.82, 0.64 to 1.06; P=0.127), caesarean section for fetal distress (32/365 (8.8%) v 35/376 (9.30/6); 0.91, 0.57 to 1.44; P=0.679), or uterine hyperstimulation with changes in fetal heart rate (3/365 (0.8%) v 6/376 (1.6%6); 0.55, 0.14 to 2.21; P=0.401). Although there were differences in the process of tabour induction, there were no significant differences in adverse maternal or neonatal outcomes. Conclusions This trial shows no evidence that oral misoprostol is superior to vaginal dinoprostone for, induction of tabour. However, it does not lead to poorer health outcomes for women or their infants, and oral treatment is preferred by women. Trial registration National Health and, Medical Research Council, Perinatal Trials, PT0361.	Univ Adelaide, Dept Obstet & Gynaecol, Womens & Childrens Hosp, Adelaide, SA 5006, Australia	University of Adelaide; Womens & Childrens Hospital Australia	Dodd, JM (corresponding author), Univ Adelaide, Dept Obstet & Gynaecol, Womens & Childrens Hosp, Adelaide, SA 5006, Australia.	jodie.dodd@adelaide.edu.au	Dodd, Jodie/Y-6849-2019	Dodd, Jodie/0000-0002-6363-4874				ALFIREVIC Z, 2005, COCHRANE DB SYST REV; CHALMERS I, 1989, EFFECTIVE CARE PREGN, P59; COLLINS PW, 1985, DIGEST DIS SCI, V30, pS114, DOI 10.1007/BF01309395; COLLINS PW, 1990, MED RES REV, V10, P149, DOI 10.1002/med.2610100202; CURTIS P, 1987, J REPROD MED, V32, P91; Dallenbach P, 2003, AM J OBSTET GYNECOL, V188, P162, DOI 10.1067/mob.2003.108; GARRIS RE, 1989, CLIN PHARMACY, V8, P627; Gherman RB, 2001, J REPROD MED, V46, P641; Hofmeyr GJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001063.pub2; Hofmeyr GJ, 2001, BRIT J OBSTET GYNAEC, V108, P952, DOI 10.1111/j.1471-0528.2001.00231.x; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; Laws P, 2004, AUSTR MOTHERS BABIES; NASSAR N, 2000, AUSTR MOTHERS BABIES; *RANZCOG, 2001, EV CLIN GUID NUM 8 U; *RANZCOG, 2001, CLIN GUID INTR FET S; *RCOG, 2001, EV BAS CLIN GUID NUM; Riskin-Mashiah S, 1999, OBSTET GYN CLIN N AM, V26, P243, DOI 10.1016/S0889-8545(05)70072-3; *ROYAL AUSTR NZ CO, 2001, CLIN GUID INTR FET S; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shetty A, 2004, BJOG-INT J OBSTET GY, V111, P436, DOI 10.1111/j.1471-0528.2004.00107.x; Tessier F., 1997, American Journal of Obstetrics and Gynecology, V176, pS111, DOI 10.1016/S0002-9378(97)80441-3; Weeks AD, 2005, BJOG-INT J OBSTET GY, V112, P269, DOI 10.1111/j.1471-0528.2004.00490.x	22	36	37	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					509	511		10.1136/bmj.38729.513819.63	http://dx.doi.org/10.1136/bmj.38729.513819.63			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16455695	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000236155800012
J	Loke, YK; Price, D; Derry, S; Aronson, JK				Loke, YK; Price, D; Derry, S; Aronson, JK			Case reports of suspected adverse drug reactions - systematic literature survey of follow-up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONGESTIVE-HEART-FAILURE; PROTON PUMP INHIBITORS; NEPHROTIC SYNDROME; INTERFERON-ALPHA; PATIENT; TRIMETHOPRIM; ACARBOSE; THERAPY; INFANT; RHABDOMYOLYSIS	Objective To determine whether anecdotal reports of suspected adverse drug reactions are valuable early warning signals. Design Systematic literature survey. Data sources We evaluated all case reports of adverse drug reactions published in 1997 ill five medical journals. Reports were excluded if the adverse reaction had previously been described in earlier publications and was already listed in the product information of the drug reference source (the British National Formulary (BNF) or the Medicines Compendium). We used the Web of Knowledge Citation Index and Medline for 2003 to identify follow-up studies. Main outcome measures Primary: the number of suspected adverse reactions subjected to formal validation studies and the findings of these studies. Secondary: the number of instances in which the warning front the case report was incorporated into the product information. Results We evaluated 63 suspected adverse reactions and found that most (52/63, 83%) had not yet been subjected to further detailed evaluation. Data from controlled studies that supported the postulated link between the drug and the adverse event were available in only three cases. Of the 48 agents listed in the drug reference sources, details of the suspected reaction were subsequently added to the Medicines Compendium. in 15 instances, and to the BNF in seven instances. In each case, only one reaction had been confirmed. Conclusions Published case reports of suspected adverse reactions are of limited value as suspicions are seldom subjected to confirmatory investigation. Furthermore, these alerts are not incorporated into drug reference sources in a systematic manner.	Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	University of East Anglia; Radcliffe Infirmary; University of Oxford	Loke, YK (corresponding author), Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.	y.loke@uea.ac.uk						Antonen J, 1999, J RHEUMATOL, V26, P2585; Armstrong SC, 1997, AM J PSYCHIAT, V154, P581; Aronson JK, 2003, BRIT MED J, V326, P1346, DOI 10.1136/bmj.326.7403.1346; Aronson JK, 2002, FUND CLIN PHARMACOL, V16, P49, DOI 10.1046/j.1472-8206.2002.00066.x; Aul C, 1997, AM J HEMATOL, V54, P91; Autret E, 1997, LANCET, V350, P339, DOI 10.1016/S0140-6736(05)63390-9; Bagger JP, 1997, LANCET, V349, P1671, DOI 10.1016/S0140-6736(05)62638-4; Berent I, 1997, AM J PSYCHIAT, V154, P130; Blake G, 1997, NEUROLOGY, V49, P1747, DOI 10.1212/WNL.49.6.1747-a; Bosch X, 1997, LANCET, V350, P1300, DOI 10.1016/S0140-6736(05)62478-6; Brankin E, 1997, BRIT MED J, V314, P869; Brau N, 1997, LANCET, V349, P924, DOI 10.1016/S0140-6736(05)62700-6; *BRIT MED ASS ROYA, 1996, BRIT NAT FORM; Carrascosa M, 1997, LANCET, V349, P698, DOI 10.1016/S0140-6736(05)60134-1; Chattergoon DS, 1997, NEUROLOGY, V49, P1442, DOI 10.1212/WNL.49.5.1442; Coutinho AK, 1997, AM J HEMATOL, V54, P85, DOI 10.1002/(SICI)1096-8652(199701)54:1<85::AID-AJH15>3.0.CO;2-9; *DAT COMM, 1996, ABPI MED COMP; Derry S, 2001, BMC Med Res Methodol, V1, P7, DOI 10.1186/1471-2288-1-7; Di Gianantonio E, 2001, TERATOLOGY, V64, P262, DOI 10.1002/tera.1072; Dobrolet NC, 2001, PEDIATR TRANSPLANT, V5, P125, DOI 10.1034/j.1399-3046.2001.00044.x; Ebeling TA, 1997, AM J PSYCHIAT, V154, P1473; Echizen H, 2000, DRUG METAB DISPOS, V28, P937; Eke T, 1997, BRIT MED J, V314, P1387; Eke T, 1997, BRIT MED J, V314, P180, DOI 10.1136/bmj.314.7075.180; Esfahani FE, 1997, NEUROLOGY, V49, P306, DOI 10.1212/WNL.49.1.306; Evans M, 1997, BRIT MED J, V314, P1869, DOI 10.1136/bmj.314.7098.1869; Fogelson DL, 1997, AM J PSYCHIAT, V154, P436; Gateley CA, 1997, BRIT MED J, V314, P481, DOI 10.1136/bmj.314.7079.481; Gentile S, 1999, DIABETES CARE, V22, P1217, DOI 10.2337/diacare.22.7.1217; Gentile S, 2001, DIABETES OBES METAB, V3, P33, DOI 10.1046/j.1463-1326.2001.00103.x; Gill DS, 1997, AM J PSYCHIAT, V154, P1318; Gilroy N, 1997, LANCET, V350, P112, DOI 10.1016/S0140-6736(05)61813-2; Giordano N, 1997, LANCET, V349, P1600, DOI 10.1016/S0140-6736(05)61628-5; Glasziou P, 2004, BMJ-BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39; Good MJ, 1997, AM J PSYCHIAT, V154, P1472; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; HIGUERA CD, 1997, LANCET, V350, P714; Hoffman JR, 1999, WESTERN J MED, V170, P253; Hubner C, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63139-X; Johnsson E, 1997, LANCET, V350, P1520, DOI 10.1016/S0140-6736(05)63942-6; Kanjolia A, 1997, AM J HEMATOL, V54, P345, DOI 10.1002/(SICI)1096-8652(199704)54:4<345::AID-AJH21>3.0.CO;2-9; Kelly WN, 2003, ANN PHARMACOTHER, V37, P1774, DOI 10.1345/aph.1D202; KOCHWESER J, 1977, EUR J CLIN PHARMACOL, V11, P75, DOI 10.1007/BF00562895; Lanctot KL, 1995, CLIN PHARMACOL THER, V58, P692, DOI 10.1016/0009-9236(95)90026-8; Larsen JT, 1997, LANCET, V349, P878, DOI 10.1016/S0140-6736(05)61783-7; Loke YK, 2004, BRIT MED J, V329, P7, DOI 10.1136/bmj.329.7456.7; Loke YK, 2004, BRIT J CLIN PHARMACO, V57, P616, DOI 10.1111/j.0306-5251.2003.02055.x; Lutz M, 2002, PHARMACOGENETICS, V12, P73, DOI 10.1097/00008571-200201000-00010; MACFADYEN RJ, 1991, BRIT HEART J, V66, P206, DOI 10.1136/hrt.66.3.206; Martin RM, 2000, BRIT J CLIN PHARMACO, V50, P366, DOI 10.1046/j.1365-2125.2000.00262.x; Martinez BM, 1997, BRIT MED J, V314, P349, DOI 10.1136/bmj.314.7077.349; Matsumura T, 1997, LANCET, V350, P336, DOI 10.1016/S0140-6736(05)63386-7; Maurtua MA, 1997, AM J HEMATOL, V55, P53; McBride SR, 1997, LANCET, V349, P101, DOI 10.1016/S0140-6736(05)60884-7; Meeuwisse EJM, 1997, BRIT MED J, V314, P481, DOI 10.1136/bmj.314.7079.481a; Meyboom RHB, 1997, DRUG SAFETY, V17, P374, DOI 10.2165/00002018-199717060-00004; Morice AH, 1997, LANCET, V350, P1105, DOI 10.1016/S0140-6736(05)70471-2; Munera Y, 1997, BRIT MED J, V314, P1593, DOI 10.1136/bmj.314.7094.1593; NAGEL AG, 1997, NEUROLOGY, V48, P1467; Niedermaier G, 1997, LANCET, V349, P1071, DOI 10.1016/S0140-6736(05)62294-5; Paar D, 1997, LANCET, V349, P326, DOI 10.1016/S0140-6736(05)62825-5; Panayiotopoulos CP, 1997, NEUROLOGY, V49, P1467, DOI 10.1212/WNL.49.5.1467; Ramachandran S, 1997, BRIT MED J, V314, P1593, DOI 10.1136/bmj.314.7094.1593a; Reinhold U, 1997, LANCET, V349, P540, DOI 10.1016/S0140-6736(97)80091-8; Santonastaso M, 1997, LANCET, V350, P266, DOI 10.1016/S0140-6736(05)62230-1; Schliefer K, 1997, LANCET, V350, P413, DOI 10.1016/S0140-6736(05)64137-2; Schonhofer PS, 1997, BMJ-BRIT MED J, V314, P1805, DOI 10.1136/bmj.314.7097.1805; Schreiber W, 1997, AM J PSYCHIAT, V154, P1170; Schrijvers D, 1997, LANCET, V349, P402, DOI 10.1016/S0140-6736(97)80023-2; Shelley WB, 1997, LANCET, V350, P1223, DOI 10.1016/S0140-6736(05)63454-X; Shirota T, 1997, AM J HEMATOL, V56, P272; Speight EL, 1997, BRIT MED J, V314, P1466, DOI 10.1136/bmj.314.7092.1466; Stricker BHC, 2004, BRIT MED J, V329, P44, DOI 10.1136/bmj.329.7456.44; Tamm M, 1997, LANCET, V350, P1822, DOI 10.1016/S0140-6736(05)63638-0; Tandan T, 1997, LANCET, V349, P1145, DOI 10.1016/S0140-6736(05)63021-8; Tarsy D, 1997, NEUROLOGY, V49, P1176, DOI 10.1212/WNL.49.4.1176; Tewari K, 1997, LANCET, V350, P183, DOI 10.1016/S0140-6736(97)24029-8; Tilelli JA, 1997, LANCET, V349, P853, DOI 10.1016/S0140-6736(05)61757-6; Vandenbroucke JP, 2001, ANN INTERN MED, V134, P330, DOI 10.7326/0003-4819-134-4-200102200-00017; VanGerpen JA, 1997, NEUROLOGY, V48, P537, DOI 10.1212/WNL.48.2.537-a; VENNING GR, 1982, BMJ-BRIT MED J, V284, P249, DOI 10.1136/bmj.284.6311.249; Viraben R, 1997, LANCET, V350, P1366, DOI 10.1016/S0140-6736(05)65136-7; Warnock JK, 1997, AM J PSYCHIAT, V154, P288; Watts BV, 1997, AM J PSYCHIAT, V154, P1624; Wen PY, 1997, NEUROLOGY, V49, P632, DOI 10.1212/WNL.49.2.632; Wiggam MI, 1997, LANCET, V350, P292, DOI 10.1016/S0140-6736(05)62260-X; Yeung WL, 1997, LANCET, V350, P1594, DOI 10.1016/S0140-6736(97)09514-7; Yokose N, 1997, AM J HEMATOL, V55, P166, DOI 10.1002/(SICI)1096-8652(199707)55:3<166::AID-AJH11>3.0.CO;2-B	88	57	63	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					335	338E		10.1136/bmj.38701.399942.63	http://dx.doi.org/10.1136/bmj.38701.399942.63			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16421149	Green Published, Bronze			2022-12-28	WOS:000235376400018
J	Collins, RN				Collins, RN			How the ER stays in shape	CELL			English	Editorial Material							MEMBRANE CURVATURE; COMPLEXES	Understanding the molecular mechanisms that control the architecture of organelles is an area of intense study. In this issue of Cell, Voeltz et al. (2006) report that two membrane proteins, Rtn4a/NogoA and DP1/Yop1p, are responsible for the generation of tubular morphology in the endoplasmic reticulum (ER). The unusual membrane topology of these proteins may directly contribute to ER curvature.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Collins, RN (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rnc8@cornell.edu						Geng JM, 2005, EUKARYOT CELL, V4, P1166, DOI 10.1128/EC.4.7.1166-1174.2005; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VOELTZ GK, 2006, CELL; Woolf CJ, 2003, NEURON, V38, P153, DOI 10.1016/S0896-6273(03)00233-2	9	7	8	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 10	2006	124	3					464	466		10.1016/j.cell.2006.01.017	http://dx.doi.org/10.1016/j.cell.2006.01.017			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469692	Bronze			2022-12-28	WOS:000235464000008
J	Wayland, B; Fu, XF				Wayland, B; Fu, XF			Chemistry - Building molecules with carbon monoxide reductive coupling	SCIENCE			English	Editorial Material							CO; COMPLEX		Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Pennsylvania	Wayland, B (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	wayland@sas.upenn.edu						EGGERDING D, 1976, J AM CHEM SOC, V98, P3641, DOI 10.1021/ja00428a043; EVANS WJ, 1985, J AM CHEM SOC, V107, P3728, DOI 10.1021/ja00298a060; Gmelin L., 1825, ANN PHYS CHEM, V80, P31; Kerr RA, 2005, SCIENCE, V310, P1106, DOI 10.1126/science.310.5751.1106; Liebig J., 1834, ANN CHEM PHARM, V11, P182, DOI DOI 10.1002/JLAC.18340110206; MOLOY KG, 1986, J AM CHEM SOC, V108, P56, DOI 10.1021/ja00261a010; PROTASIEWICZ JD, 1991, J AM CHEM SOC, V113, P6564, DOI 10.1021/ja00017a030; Rostrup-Nielsen JR, 2005, SCIENCE, V308, P1421, DOI 10.1126/science.1113354; Sabzyan H, 2003, J MOL STRUC-THEOCHEM, V626, P143, DOI 10.1016/S0166-1280(03)00029-0; Schleyer PV, 2000, J ORG CHEM, V65, P426, DOI 10.1021/jo991267n; SEITZ G, 1992, CHEM REV, V92, P1227, DOI 10.1021/cr00014a004; SILVESTRI G, 1978, ELECTROCHIM ACTA, V23, P413, DOI 10.1016/0013-4686(78)87039-X; Summerscales OT, 2006, SCIENCE, V311, P829, DOI 10.1126/science.1121784; WAYLAND BB, 1989, J CHEM SOC CHEM COMM, P662, DOI 10.1039/c39890000662; West R., 1980, OXOCARBONS; WOLCZANSKI PT, 1980, ACCOUNTS CHEM RES, V13, P121, DOI 10.1021/ar50148a004; Zhang XX, 1997, J AM CHEM SOC, V119, P7938, DOI 10.1021/ja962248n	17	36	37	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 10	2006	311	5762					790	791		10.1126/science.1123884	http://dx.doi.org/10.1126/science.1123884			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469910				2022-12-28	WOS:000235374900030
J	Xu, X; Clark, JM; Forster, CA; Norell, MA; Erickson, GM; Eberth, DA; Jia, CK; Zhao, Q				Xu, X; Clark, JM; Forster, CA; Norell, MA; Erickson, GM; Eberth, DA; Jia, CK; Zhao, Q			A basal tyrannosauroid dinosaur from the Late Jurassic of China	NATURE			English	Article							THEROPOD; ANATOMY	The tyrannosauroid fossil record is mainly restricted to Cretaceous sediments of Laurasia, although some very fragmentary Jurassic specimens have been referred to this group(1,2). Here we report a new basal tyrannosauroid, Guanlong wucaii gen. et sp. nov., from the lower Upper Jurassic of the Junggar Basin(3,4), northwestern China. G. wucaii is the oldest known tyrannosauroid and shows several unexpectedly primitive pelvic features(5,6). Nevertheless, the limbs of G. wucaii share several features with derived coelurosaurs(7-9), and it possesses features shared by other coelurosaurian clades(10). This unusual combination of character states provides an insight into the poorly known early radiation of the Coelurosauria. Notably, the presumed predatory Guanlong has a large, fragile and highly pneumatic cranial crest that is among the most elaborate known in any non-avian dinosaur and could be comparable to some classical exaggerated ornamental traits among vertebrates.	Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; Amer Museum Nat Hist, New York, NY 10024 USA; George Washington Univ, Dept Biol Sci, Washington, DC 20052 USA; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Royal Tyrrell Museum, Drumheller, AB T0J 0Y0, Canada	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; American Museum of Natural History (AMNH); George Washington University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University System of Florida; Florida State University	Xu, X (corresponding author), Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China.	xingxu@vip.sina.com						Andersson Malte, 1994; Brochu CA, 2003, J VERTEBR PALEONTOL, V22, P1, DOI [10.1080/02724634.2003.10010947, DOI 10.1080/02724634.2003.10010947, 10.2307/3889334, DOI 10.2307/3889334]; CHEN P, 1996, CONTINENTAL JURASSIC, P395; Chure DJ, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P283; Currie PJ, 1995, J VERTEBR PALEONTOL, V15, P576, DOI 10.1080/02724634.1995.10011250; Currie PJ, 2003, ACTA PALAEONTOL POL, V48, P191; Eberth DA, 2001, CAN J EARTH SCI, V38, P1627, DOI 10.1139/e01-067; Erickson GM, 2004, NATURE, V430, P772, DOI 10.1038/nature02699; Gauthier J.A., 1986, ORIGIN BIRDS EVOLUTI, V8, P1; Hinchliffe J.R., 1985, P141; Holtz TR, 2004, DINOSAURIA, 2ND EDITION, P71; Holtz TR, 2004, DINOSAURIA, 2ND EDITION, P111; Horner JR, 2000, ANNU REV EARTH PL SC, V28, P19, DOI 10.1146/annurev.earth.28.1.19; Hurum JH, 2003, ACTA PALAEONTOL POL, V48, P161; Hutt S, 2001, CRETACEOUS RES, V22, P227, DOI 10.1006/cres.2001.0252; Makovicky PJ, 2004, DINOSAURIA, 2ND EDITION, P184; Naish Darren, 2004, Historical Biology, V16, P57, DOI 10.1080/08912960410001674200; Norell MA, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P49; Osborn HF, 1916, B AM MUS NAT HIST, V35, P733; Rauhut O.W.M., 2003, SPECIAL PAPERS PALAE, V69; Rauhut OWM, 2003, PALAEONTOLOGY, V46, P903, DOI 10.1111/1475-4983.00325; Reid R.E.H., 1997, P403; Sampson SD, 1997, ZOOL J LINN SOC-LOND, V121, P293, DOI 10.1111/j.1096-3642.1997.tb00340.x; Sereno PC, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P69; VICKARYOUS MK, 1997, ENCY DINOSAURS, P488; Xu X, 1999, NATURE, V399, P350, DOI 10.1038/20670; Xu X, 2004, NATURE, V431, P680, DOI 10.1038/nature02855; Xu X., 2002, THESIS CHINESE ACAD	28	143	158	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					715	718		10.1038/nature04511	http://dx.doi.org/10.1038/nature04511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467836				2022-12-28	WOS:000235193100042
J	Howard, BV; Van Horn, L; Hsia, J; Manson, JE; Stefanick, ML; Wassertheil-Smoller, S; Kuller, LH; LaCroix, AZ; Langer, RD; Lasser, NL; Lewis, CE; Limacher, MC; Margolis, KL; Mysiw, J; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Schatz, IJ; Snetselaar, LG; Stevens, VJ; Tinker, LF; Trevisan, M; Vitolins, MZ; Anderson, GL; Assaf, AR; Bassford, T; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Granek, I; Greenland, P; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hubbell, FA; Johnson, KC; Kotchen, JM				Howard, BV; Van Horn, L; Hsia, J; Manson, JE; Stefanick, ML; Wassertheil-Smoller, S; Kuller, LH; LaCroix, AZ; Langer, RD; Lasser, NL; Lewis, CE; Limacher, MC; Margolis, KL; Mysiw, J; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Schatz, IJ; Snetselaar, LG; Stevens, VJ; Tinker, LF; Trevisan, M; Vitolins, MZ; Anderson, GL; Assaf, AR; Bassford, T; Beresford, SAA; Black, HR; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Granek, I; Greenland, P; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Hubbell, FA; Johnson, KC; Kotchen, JM			Low-fat dietary pattern and risk of cardiovascular disease - The Women's Health Initiative randomized controlled dietary modification trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASE-LINE CHARACTERISTICS; CORONARY-HEART-DISEASE; PREVENTION; INTERVENTION; METAANALYSIS; STROKE; CANCER	Context Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed. Objective To test the hypothesis that a dietary intervention, intended to be low in fat and high in vegetables, fruits, and grains to reduce cancer, would reduce CVD risk. Design, Setting, and Participants Randomized controlled trial of 48 835 postmenopausal women aged 50 to 79 years, of diverse backgrounds and ethnicities, who participated in the Women's Health Initiative Dietary Modification Trial. Women were randomly assigned to an intervention (19 541 [40%]) or comparison group (29 294 [60%]) in a free-living setting. Study enrollment occurred between 1993 and 1998 in 40 US clinical centers; mean follow-up in this analysis was 8.1 years. Intervention Intensive behavior modification in group and individual sessions designed to reduce total fat intake to 20% of calories and increase intakes of vegetables/fruits to 5 servings/d and grains to at least 6 servings/d. The comparison group received diet-related education materials. Main Outcome Measures Fatal and nonfatal coronary heart disease (CHD), fatal and nonfatal stroke, and CVD (composite of CHD and stroke). Results By year 6, mean fat intake decreased by 8.2% of energy intake in the intervention vs the comparison group, with small decreases in saturated (2.9%), monounsaturated (3.3%), and polyunsaturated (1.5%) fat; increases occurred in intakes of vegetables/fruits (1.1 servings/d) and grains (0.5 serving/d). Low-density lipoprotein cholesterol levels, diastolic blood pressure, and factor VIIc levels were significantly reduced by 3.55 mg/dL, 0.31 mm Hg, and 4.29%, respectively; levels of high-density lipoprotein cholesterol, triglycerides, glucose, and insulin did not significantly differ in the intervention vs comparison groups. The numbers who developed CHD, stroke, and CVD (annualized incidence rates) were 1000 (0.63%), 434 (0.28%), and 1357 (0.86%) in the intervention and 1549 (0.65%), 642 (0.27%), and 2088 (0.88%) in the comparison group. The diet had no significant effects on incidence of CHD (hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.90-1.06), stroke (HR, 1.02; 95% CI, 0.90-1.15), or CVD (HR, 0.98; 95% CI, 0.92-1.05). Excluding participants with baseline CVD (3.4%), the HRs (95% CIs) for CHD and stroke were 0.94 (0.86-1.02) and 1.02 (0.90-1.17), respectively. Trends toward greater reductions in CHD risk were observed in those with lower intakes of saturated fat or trans fat or higher intakes of vegetables/fruits. Conclusions Over a mean of 8.1 years, a dietary intervention that reduced total fat intake and increased intakes of vegetables, fruits, and grains did not significantly reduce the risk of CHD, stroke, or CVD in postmenopausal women and achieved only modest effects on CVD risk factors, suggesting that more focused diet and lifestyle interventions may be needed to improve risk factors and reduce CVD risk.	Howard Univ, MedStar Res Inst, Washington, DC 20059 USA; Northwestern Univ, Chicago, IL 60611 USA; George Washington Univ, Washington, DC USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Stanford Prevent Res Ctr, Stanford, CA USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Pittsburgh, Pittsburgh, PA USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Florida, Gainesville, FL USA; Univ Minnesota, Minneapolis, MN USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Univ Miami, Miami, FL 33152 USA; Emory Univ, Atlanta, GA 30322 USA; Univ Calif Davis, Davis, CA 95616 USA; NHLBI, Bethesda, MD 20892 USA; Univ Wisconsin, Madison, WI USA; Univ Hawaii, Honolulu, HI 96822 USA; Univ Iowa, Iowa City, IA USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Univ Buffalo, Buffalo, NY USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Brown Univ, Providence, RI 02912 USA; Univ Arizona, Tucson, AZ USA; Rush Univ, Med Ctr, Chicago, IL 60612 USA; Univ Nevada, Reno, NV 89557 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Kaiser Permanente, Div Res, Oakland, CA USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA; Univ Cincinnati, Cincinnati, OH USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Hutzel Hosp, Detroit, MI USA; Univ Calif Irvine, Irvine, CA USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Howard University; Northwestern University; George Washington University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Stanford University; Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fred Hutchinson Cancer Center; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alabama System; University of Alabama Birmingham; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; University of Massachusetts System; University of Massachusetts Worcester; University of Miami; Emory University; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Wisconsin System; University of Wisconsin Madison; University of Hawaii System; University of Iowa; Kaiser Permanente; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Wake Forest University; Wake Forest Baptist Medical Center; Brown University; University of Arizona; Rush University; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Texas System; University of Texas Health San Antonio; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Ohio; University of Cincinnati; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Baylor College of Medicine; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; University of California System; University of California Irvine; University of Tennessee System; University of Tennessee Health Science Center; Medical College of Wisconsin	Howard, BV (corresponding author), MedStar Res Inst, 6495 New Hampshire Ave,Suite 201, Hyattsville, MD 20783 USA.	barbara.v.howard@medstar.net	Greenland, Philip/ABD-5528-2021	Hays-Grudo, Jennifer/0000-0002-8107-1243; Perri, Michael/0000-0003-3651-1542; trevisan, maurizio/0000-0001-5479-0050; Margolis, Karen/0000-0003-1862-7402; Caan, Bette/0000-0002-5803-310X				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], [No title captured]; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Beresford SAA, 2006, JAMA-J AM MED ASSOC, V295, P643, DOI 10.1001/jama.295.6.643; Bowen D, 2002, J AM DIET ASSOC, V102, P1631, DOI 10.1016/S0002-8223(02)90347-0; Chanmugam P, 2003, J AM DIET ASSOC, V103, P867, DOI 10.1016/S0002-8223(03)00381-X; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; DAYTON S, 1969, CIRCULATION S2, V60, P111; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Franz MJ, 2002, DIABETES CARE, V25, P148, DOI 10.2337/diacare.25.1.148; Fung TT, 2004, STROKE, V35, P2014, DOI 10.1161/01.STR.0000135762.89154.92; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Hellerstein MK, 2002, CURR OPIN LIPIDOL, V13, P33, DOI 10.1097/00041433-200202000-00006; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P39, DOI 10.1001/jama.295.1.39; Jackson RD, 2003, ANN EPIDEMIOL, V13, pS98, DOI 10.1016/S1047-2797(03)00046-2; KEYS A, 1982, PROG BIOCHEM PHARM, V19, P1; Krauss RM, 2000, CIRCULATION, V102, P2284; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; Liu S, 2000, AM J CLIN NUTR, V72, P922; Liu SM, 1999, AM J CLIN NUTR, V70, P412; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Oh K, 2005, AM J EPIDEMIOL, V161, P672, DOI 10.1093/aje/kwi085; Ornish D, 1998, JAMA-J AM MED ASSOC, V280, P2001, DOI 10.1001/jama.280.23.2001; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Patterson RE, 2003, J AM DIET ASSOC, V103, P454, DOI 10.1053/jada.2003.50068; Pereira MA, 2003, J WOMEN HEALTH GEN-B, V12, P115, DOI 10.1089/154099903321576501; Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092; Tinker Lesley Fels, 1996, P510; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; Wang CY, 1999, BIOMETRICS, V55, P711, DOI 10.1111/j.0006-341X.1999.00711.x; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X	41	756	774	3	93	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					655	666		10.1001/jama.295.6.655	http://dx.doi.org/10.1001/jama.295.6.655			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467234	Bronze			2022-12-28	WOS:000235168200025
J	Rahman, M; Pressel, S; Davis, BR; Nwachuku, C; Wright, JT; Whelton, PK; Barzilay, J; Batuman, V; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Wiegmann, T				Rahman, M; Pressel, S; Davis, BR; Nwachuku, C; Wright, JT; Whelton, PK; Barzilay, J; Batuman, V; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Wiegmann, T		ALLHAT Collaborative Res Grp	Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Annual Clinical Meeting of the National-Kidney-Foundation	APR 02-06, 2003	DALLAS, TX	Natl Kidney Fdn			LIPID-LOWERING TREATMENT; CHRONIC KIDNEY-DISEASE; CONVERTING ENZYME-INHIBITORS; CHRONIC RENAL-DISEASE; SECONDARY END-POINTS; BLOOD-PRESSURE; PROGRESSION; INSUFFICIENCY; DESIGN; TRIAL	Background: Chronic kidney disease is common in older patients with hypertension. Objective: To compare rates of coronary heart disease (CHID) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHID; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR. 6.0%, respectively). A baseline GFR of less than 53 mL/min per 1.73 m(2) (compared with > 104 mL/min per 1.73 m(2)) was independently associated with a 32% higher risk for CHD. Amlodipine was similar to chlorthalidone in reducing CHID (16.0% vs. 15.2%, respectively; hazard ratio, 1.06 [95% Cl, 0.89 to 1.27]), stroke, and combined CVD (CHID, coronary revascularization, angina, stroke, heart failure, and peripheral arterial disease), but less effective in preventing heart failure. Lisinopril was similar to chlorthalidone in preventing CHID (15.1% vs. 15.2%, respectively; hazard ratio, 1.00 [Cl, 0.84 to 1.20]), but was less effective in reducing stroke, combined CVD events, and heart failure. Design: Post hoc subgroup analysis. Setting: Multicenter randomized, double-blind, controlled trial. Participants: Persons with hypertension who were 55 years of age or older with 1 or more risk factors for CHID and who were stratified into 3 baseline GFR groups: normal or increased ( >= 90 mL/min per 1.73 m(2); n = 8126 patients), mild reduction (60 to 89 mL/min per 1.73 m(2); n = 18 109 patients), and moderate or severe reduction (< 60 mL/min per 1.73 m(2); n = 5662 patients). Interventions: Random assignment to chlorthalidone, amlodipine, or lisinopril. Measurements: Rates of ESRD, CHID, stroke, and combined CVD (CHID, coronary revascularization, angina, stroke, heart failure, and peripheral arterial disease). Results: In participants with a moderate to severe reduction in GFR, 6-year rates were higher for CHID than for ESRD (15.4% vs. Limitations: Proteinuria data were not available, and combination therapies were not tested. Conclusions: Older high-risk patients with hypertension and reduced GFR are more likely to develop CHID than to develop ESRD. A low GFR independently predicts increased risk for CHID. Neither amlodipine nor lisinopril is superior to chlorthalidone in preventing CHID, stroke, or combined CVD, and chlorthalidone is superior to both for preventing heart failure, independent of level of renal function.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Coordinating Ctr Clin Trials, Houston, TX 77030 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; NHLBI, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA; Kaiser Permanente Georgia, Tucker, GA USA; Univ Minnesota, Minneapolis, MN USA; Pitman Internal Med Associates, Pitman, NJ USA; Univ Calif Irvine, Irvine, CA USA; Bronx Nephrol Hypertens PC, Bronx, NY USA; Lehigh Valley Hosp, Allentown, PA USA; Vet Adm Med Ctr, Dayton, OH USA; Univ Missouri, Kansas City, MO 64110 USA; Vet Adm Med Ctr, Kansas City, MO 64128 USA; Androscoggin Clin Associates, Lewiston, ME USA; King Drew Med Ctr, Los Angeles, CA 90059 USA; Vet Adm Med Ctr, Los Angeles, CA 91343 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Tulane University; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Irvine; Lehigh Valley Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Missouri System; University of Missouri Kansas City; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Davis, BR (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Coordinating Ctr Clin Trials, 1200 Herman Pressler St,Suite E801, Houston, TX 77030 USA.	barry.r.davis@uth.tmc.edu		Batuman, Vecihi/0000-0002-1800-9009	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC035130] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		*ALL HAT, 2003, HYPERTENSION, V42, P239; [Anonymous], 2004, AM J KIDNEY DIS, V43, pS1; Appel LJ, 2003, J AM SOC NEPHROL, V14, pS166, DOI 10.1097/01.ASN.0000070081.15137.C0; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Berl T, 2003, ANN INTERN MED, V138, P542, DOI 10.7326/0003-4819-138-7-200304010-00010; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2005, J AM SOC NEPHROL, V16, P180, DOI 10.1681/ASN.2004070539; Culleton BF, 1999, KIDNEY INT, V56, P2214, DOI 10.1046/j.1523-1755.1999.00773.x; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Davis CE, 1997, CONTROL CLIN TRIALS, V18, P557, DOI 10.1016/S0197-2456(96)00133-X; Feldman HI, 2003, J AM SOC NEPHROL, V14, pS148, DOI 10.1097/01.ASN.0000070149.78399.CE; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Jafar TH, 2001, KIDNEY INT, V60, P1131, DOI 10.1046/j.1523-1755.2001.0600031131.x; Jafar TH, 2002, ANN INTERN MED, V137, P298, DOI 10.7326/0003-4819-137-4-200208200-00026; Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Levey AS, 1998, AM J KIDNEY DIS, V32, pS5, DOI 10.1053/ajkd.1998.v32.pm9820463; Manjunath G, 2003, KIDNEY INT, V63, P1121, DOI 10.1046/j.1523-1755.2003.00838.x; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Muntner P, 2005, J AM SOC NEPHROL, V16, P529, DOI 10.1681/ASN.2004080656; Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745; ONeill RT, 1997, CONTROL CLIN TRIALS, V18, P550, DOI 10.1016/S0197-2456(97)00075-5; Rahman M, 2005, ARCH INTERN MED, V165, P936, DOI 10.1001/archinte.165.8.936; Rahman M, 2004, ARCH INTERN MED, V164, P969, DOI 10.1001/archinte.164.9.969; Sarnak MJ, 2005, ANN INTERN MED, V142, P342, DOI 10.7326/0003-4819-142-5-200503010-00009; Sarnak MJ, 2003, HYPERTENSION, V42, P1050, DOI 10.1161/01.HYP.0000102971.85504.7c; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Vlagopoulos PT, 2005, MED CLIN N AM, V89, P587, DOI 10.1016/j.mcna.2004.11.003; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421	33	185	196	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					172	180		10.7326/0003-4819-144-3-200602070-00005	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	008XS	16461961				2022-12-28	WOS:000235074800003
J	DeLong, EF; Preston, CM; Mincer, T; Rich, V; Hallam, SJ; Frigaard, NU; Martinez, A; Sullivan, MB; Edwards, R; Brito, BR; Chisholm, SW; Karl, DM				DeLong, EF; Preston, CM; Mincer, T; Rich, V; Hallam, SJ; Frigaard, NU; Martinez, A; Sullivan, MB; Edwards, R; Brito, BR; Chisholm, SW; Karl, DM			Community genomics among stratified microbial assemblages in the ocean's interior	SCIENCE			English	Article							PACIFIC SUBTROPICAL GYRE; IN-SITU HYBRIDIZATION; MESOPELAGIC ZONE; MARINE; PROCHLOROCOCCUS; METAGENOMICS; DIVERSITY; SEQUENCES; ARCHAEA; DEEP	Microbial life predominates in the ocean, yet little is known about its genomic variability, especially along the depth continuum. We report here genomic analyses of planktonic microbial communities in the North Pacific Subtropical Gyre, from the ocean's surface to near-sea floor depths. Sequence variation in microbial community genes reflected vertical zonation of taxonomic groups, functional gene repertoires, and metabolic potential. The distributional patterns of microbial genes suggested depth-variable community trends in carbon and energy metabolism, attachment and motility, gene mobility, and host-viral interactions. Comparative genomic analyses of stratified microbial communities have the potential to provide significant insight into higher-order community organization and dynamics.	MIT, Cambridge, MA 02139 USA; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95064 USA; San Diego State Univ, San Diego, CA 92182 USA; Univ Hawaii, Honolulu, HI 96822 USA	Massachusetts Institute of Technology (MIT); Monterey Bay Aquarium Research Institute; California State University System; San Diego State University; University of Hawaii System	DeLong, EF (corresponding author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	delong@mit.edu	Sullivan, Matthew B/H-3256-2011; Edwards, Robert/Q-1691-2019; Karl, David/AFP-3837-2022; Frigaard, Niels-Ulrik/H-1277-2011	Sullivan, Matthew B/0000-0003-4040-9831; Edwards, Robert/0000-0001-8383-8949; Frigaard, Niels-Ulrik/0000-0002-9389-8109; Chisholm, Sallie/0000-0003-1480-2445; Karl, David/0000-0002-6660-6721; Mincer, Tracy/0000-0002-4644-5609				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Azam F, 1998, SCIENCE, V280, P694, DOI 10.1126/science.280.5364.694; Barns SM, 1996, P NATL ACAD SCI USA, V93, P9188, DOI 10.1073/pnas.93.17.9188; Beja O, 2000, ENVIRON MICROBIOL, V2, P516, DOI 10.1046/j.1462-2920.2000.00133.x; Breitbart M, 2004, FEMS MICROBIOL LETT, V236, P249, DOI 10.1016/j.femsle.2004.05.042; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; DeLong EF, 2005, NATURE, V437, P336, DOI 10.1038/nature04157; DeLong EF, 1999, APPL ENVIRON MICROB, V65, P5554; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DELONG EF, 2005, NAT REV MICROBIOL; Edwards RA, 2005, NAT REV MICROBIOL, V3, P504, DOI 10.1038/nrmicro1163; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Filee J, 2005, P NATL ACAD SCI USA, V102, P12471, DOI 10.1073/pnas.0503404102; Forbes E., 1856, PHYS ATLAS NATURAL P; FRIGAARD NU, IN PRESS NATURE; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; Hallam SJ, 2004, SCIENCE, V305, P1457, DOI 10.1126/science.1100025; Handelsman J, 2004, MICROBIOL MOL BIOL R, V68, P669, DOI 10.1128/MMBR.68.4.669-685.2004; HOCHACHKA PW, 1984, BIOCH ADAPTATION, P450; JOHNSON Z, UNPUB; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Karl DM, 2001, DEEP-SEA RES PT II, V48, P1449, DOI 10.1016/S0967-0645(00)00149-1; Karl DM, 1996, DEEP-SEA RES PT II, V43, P129, DOI 10.1016/0967-0645(96)00005-7; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; Letelier RM, 2004, LIMNOL OCEANOGR, V49, P508, DOI 10.4319/lo.2004.49.2.0508; Lindell D, 2004, P NATL ACAD SCI USA, V101, P11013, DOI 10.1073/pnas.0401526101; Moon-van der Staay SY, 2001, NATURE, V409, P607, DOI 10.1038/35054541; Morris RM, 2004, APPL ENVIRON MICROB, V70, P2836, DOI 10.1128/AEM.70.5.2836-2842.2004; Overbeek R, 2005, NUCLEIC ACIDS RES, V33, P5691, DOI 10.1093/nar/gki866; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pernthaler A, 2002, APPL ENVIRON MICROB, V68, P661, DOI 10.1128/AEM.68.2.661-667.2002; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Rappe MS, 2003, ANNU REV MICROBIOL, V57, P369, DOI 10.1146/annurev.micro.57.030502.090759; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Sullivan MB, 2005, PLOS BIOL, V3, P790, DOI 10.1371/journal.pbio.0030144; Sullivan MB, 2003, NATURE, V424, P1047, DOI 10.1038/nature01929; SUZUKI MT, 2005, MICROB ECOL; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; WATERBURY JB, 1993, APPL ENVIRON MICROB, V59, P3393, DOI 10.1128/AEM.59.10.3393-3399.1993; Weinbauer MG, 2004, FEMS MICROBIOL REV, V28, P127, DOI 10.1016/j.femsre.2003.08.001; Weinbauer MG, 2003, LIMNOL OCEANOGR, V48, P1457, DOI 10.4319/lo.2003.48.4.1457; West NJ, 2001, MICROBIOL-SGM, V147, P1731, DOI 10.1099/00221287-147-7-1731; Woese CR, 2004, MICROBIOL MOL BIOL R, V68, P173, DOI 10.1128/MMBR.68.2.173-186.2004; YAYANOS AA, 1995, ANNU REV MICROBIOL, V49, P777, DOI 10.1146/annurev.mi.49.100195.004021	47	995	1033	7	304	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2006	311	5760					496	503		10.1126/science.1120250	http://dx.doi.org/10.1126/science.1120250			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439655				2022-12-28	WOS:000235071400039
J	Mostoslavsky, R; Chua, KF; Lombard, DB; Pang, WW; Fischer, MR; Gellon, L; Liu, PF; Mostoslavsky, G; Franco, S; Murphy, MM; Mills, KD; Patel, P; Hsu, JT; Hong, AL; Ford, E; Cheng, HL; Kennedy, C; Nunez, N; Bronson, R; Frendewey, D; Auerbach, W; Valenzuela, D; Karow, M; Hottiger, MO; Hursting, S; Barrett, JC; Guarente, L; Mulligan, R; Demple, B; Yancopoulos, GD; Alt, FW				Mostoslavsky, R; Chua, KF; Lombard, DB; Pang, WW; Fischer, MR; Gellon, L; Liu, PF; Mostoslavsky, G; Franco, S; Murphy, MM; Mills, KD; Patel, P; Hsu, JT; Hong, AL; Ford, E; Cheng, HL; Kennedy, C; Nunez, N; Bronson, R; Frendewey, D; Auerbach, W; Valenzuela, D; Karow, M; Hottiger, MO; Hursting, S; Barrett, JC; Guarente, L; Mulligan, R; Demple, B; Yancopoulos, GD; Alt, FW			Genomic instability and aging-like phenotype in the absence of mammalian SIRT6	CELL			English	Article							BASE-EXCISION-REPAIR; DNA-REPAIR; CALORIE RESTRICTION; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; ADP-RIBOSYLTRANSFERASE; PROTEIN DEACETYLASES; IONIZING-RADIATION; OXIDATIVE STRESS; B-CELLS	The Sir2 histone deacetylase functions as a chromatin silencer to regulate recombination, genomic stability, and aging in budding yeast. Seven mammalian Sir2 homologs have been identified (SIRT1-SIRT7), and it has been speculated that some may have similar functions to Sir2. Here, we demonstrate that SIRT6 is a nuclear, chromatin-associated protein that promotes resistance to DNA damage and suppresses genomic instability in mouse cells, in association with a role in base excision repair (BER). SIRT6-deficient mice are small and at 2-3 weeks of age develop abnormalities that include profound lymphopenia, loss of subcutaneous fat, lordokyphosis, and severe metabolic defects, eventually dying at about 4 weeks. We conclude that one function of SIRT6 is to promote normal DNA repair, and that SIRT6 loss leads to abnormalities in mice that overlap with aging-associated degenerative processes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,CB Inst Biomed Res, Boston, MA 02115 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; NCI, Canc Res Ctr, Bethesda, MD 20892 USA; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Regeneron; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Zurich	Alt, FW (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,CB Inst Biomed Res, Boston, MA 02115 USA.	alt@enders.tch.harvard.edu	Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270; Gellon, Lionel/0000-0003-4981-581X; Frendewey, David/0000-0003-2305-3490; Mostoslavsky, Gustavo/0000-0002-0784-2169; Lombard, David/0000-0002-4292-0185; Hsu, Joyce/0000-0002-1825-4733; Hong, Andrew/0000-0003-0374-1667	PHS HHS [K08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allman D, 2005, IMMUNOL REV, V205, P18, DOI 10.1111/j.0105-2896.2005.00269.x; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Beard BC, 2003, P NATL ACAD SCI USA, V100, P7465, DOI 10.1073/pnas.1330328100; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Cabelof DC, 2003, DNA REPAIR, V2, P295, DOI 10.1016/S1568-7864(02)00219-7; Cabelof DC, 2002, MUTAT RES-FUND MOL M, V500, P135, DOI 10.1016/S0027-5107(02)00003-9; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Dorshkind K, 2003, CLIN IMMUNOL, V109, P197, DOI 10.1016/S1521-6616(03)00181-5; Dutnall RN, 2001, CELL, V105, P161, DOI 10.1016/S0092-8674(01)00305-1; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Garcia-Salcedo JA, 2003, EMBO J, V22, P5851, DOI 10.1093/emboj/cdg553; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hasan S, 2002, MOL CELL, V10, P1213, DOI 10.1016/S1097-2765(02)00745-1; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Lombardi G, 2005, J Endocrinol Invest, V28, P99; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Mori K, 2000, BIOCHEM BIOPH RES CO, V278, P665, DOI 10.1006/bbrc.2000.3864; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005; Murai M, 2001, P NATL ACAD SCI USA, V98, P13379, DOI 10.1073/pnas.231329598; Nilsen H, 2002, EMBO J, V21, P5943, DOI 10.1093/emboj/cdf581; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Pifer J, 2003, MECH AGEING DEV, V124, P207, DOI 10.1016/S0047-6374(02)00141-0; RINE J, 1987, GENETICS, V116, P9; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stephan RP, 1997, J IMMUNOL, V158, P1598; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Taub DD, 2005, IMMUNOL REV, V205, P72, DOI 10.1111/j.0105-2896.2005.00275.x; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	76	1136	1195	6	106	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 27	2006	124	2					315	329		10.1016/j.cell.2005.11.044	http://dx.doi.org/10.1016/j.cell.2005.11.044			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439206	Bronze			2022-12-28	WOS:000235068500020
J	Smith, IE; Chua, S				Smith, IE; Chua, S			ABC of breast diseases - Medical treatment of early breast cancer. III. chemotherapy	BRITISH MEDICAL JOURNAL			English	Editorial Material							ADJUVANT CHEMOTHERAPY											Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306	4	5	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					161	162		10.1136/bmj.332.7534.161	http://dx.doi.org/10.1136/bmj.332.7534.161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424494	Green Published			2022-12-28	WOS:000234905800027
J	Fuyuno, I				Fuyuno, I			Hwang scandal hits Korean biotech hard	NATURE			English	News Item																			0	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					265	265		10.1038/439265a	http://dx.doi.org/10.1038/439265a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421542				2022-12-28	WOS:000234682100016
J	Huisman, J; Thi, NNP; Karl, DM; Sommeijer, B				Huisman, J; Thi, NNP; Karl, DM; Sommeijer, B			Reduced mixing generates oscillations and chaos in the oceanic deep chlorophyll maximum	NATURE			English	Article							CENTRAL NORTH PACIFIC; SINKING PHYTOPLANKTON; LIGHT; VARIABILITY; NITRATE; MODELS	Deep chlorophyll maxima (DCMs) are widespread in large parts of the world's oceans(1-7). These deep layers of high chlorophyll concentration reflect a compromise of phytoplankton growth exposed to two opposing resource gradients: light supplied from above and nutrients supplied from below. It is often argued that DCMs are stable features. Here we show, however, that reduced vertical mixing can generate oscillations and chaos in phytoplankton biomass and species composition of DCMs. These fluctuations are caused by a difference in the timescales of two processes: (1) rapid export of sinking plankton, withdrawing nutrients from the euphotic zone and (2) a slow upward flux of nutrients fuelling new phytoplankton production. Climate models predict that global warming will reduce vertical mixing in the oceans(8-11). Our model indicates that reduced mixing will generate more variability in DCMs, thereby enhancing variability in oceanic primary production and in carbon export into the ocean interior.	Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, NL-1018 WS Amsterdam, Netherlands; CWI, NL-1090 GB Amsterdam, Netherlands; Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA	University of Amsterdam; University of Hawaii System	Huisman, J (corresponding author), Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Nieuwe Achtergracht 127, NL-1018 WS Amsterdam, Netherlands.	jef.huisman@science.uva.nl	Huisman, Jef/A-1089-2013; Karl, David/AFP-3837-2022	Huisman, Jef/0000-0001-9598-3211; 				Bopp L, 2001, GLOBAL BIOGEOCHEM CY, V15, P81, DOI 10.1029/1999GB001256; CULLEN JJ, 1982, CAN J FISH AQUAT SCI, V39, P791, DOI 10.1139/f82-108; Fennel K, 2003, LIMNOL OCEANOGR, V48, P1521, DOI 10.4319/lo.2003.48.4.1521; Finnigan TD, 2002, J PHYS OCEANOGR, V32, P2988, DOI 10.1175/1520-0485(2002)032<2988:OOEDMN>2.0.CO;2; Hodges BA, 2004, DEEP-SEA RES PT I, V51, P999, DOI 10.1016/j.dsr.2004.02.009; Holm-Hansen O, 2004, POLAR BIOL, V27, P699, DOI 10.1007/s00300-004-0641-1; Huisman J, 2004, ECOLOGY, V85, P2960, DOI 10.1890/03-0763; Huisman J, 1999, NATURE, V402, P407, DOI 10.1038/46540; Huisman J, 2002, AM NAT, V159, P245, DOI 10.1086/338511; Huisman J, 2002, J SEA RES, V48, P83, DOI 10.1016/S1385-1101(02)00137-5; Karl DM, 1996, DEEP-SEA RES PT II, V43, P539, DOI 10.1016/0967-0645(96)00002-1; Klausmeier CA, 2001, LIMNOL OCEANOGR, V46, P1998, DOI 10.4319/lo.2001.46.8.1998; Letelier RM, 2004, LIMNOL OCEANOGR, V49, P508, DOI 10.4319/lo.2004.49.2.0508; LEWIS MR, 1986, SCIENCE, V234, P870, DOI 10.1126/science.234.4778.870; Longhurst, 2006, ECOLOGICAL GEOGRAPHY; Mann KH, 1996, DYNAMICS MARINE ECOS, P480, DOI 10.2307/2960585; OKUBO A, 2001, DIFFUSION ECOLOGICAL; RINALDI S, 1993, B MATH BIOL, V55, P15, DOI 10.1007/BF02460293; Sarmiento JL, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002134; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; Schmittner A, 2005, NATURE, V434, P628, DOI 10.1038/nature03476; Smyth WD, 2001, J PHYS OCEANOGR, V31, P1969, DOI 10.1175/1520-0485(2001)031<1969:TEOMIT>2.0.CO;2; Vandermeer J, 2001, CHAOS SOLITON FRACT, V12, P265, DOI 10.1016/S0960-0779(00)00111-9; Venrick EL, 1999, J PLANKTON RES, V21, P1029, DOI 10.1093/plankt/21.6.1029; VENRICK EL, 1993, LIMNOL OCEANOGR, V38, P1135, DOI 10.4319/lo.1993.38.6.1135; VENRICK EL, 1973, FISH B-NOAA, V71, P41	26	267	281	5	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					322	325		10.1038/nature04245	http://dx.doi.org/10.1038/nature04245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421570	Green Submitted			2022-12-28	WOS:000234682100042
J	Razem, FA; El-Kereamy, A; Abrams, SR; Hill, RD				Razem, FA; El-Kereamy, A; Abrams, SR; Hill, RD			RETRACTED: The RNA-binding protein FCA is an abscisic acid receptor (Retracted Article. See vol 456, pg 824, 2008)	NATURE			English	Article; Retracted Publication							SIGNAL-TRANSDUCTION; BIOLOGICAL-ACTIVITY; AUTONOMOUS PATHWAY; ARABIDOPSIS; MODULATION; AUXIN; VERNALIZATION; ENCODES; TIR1	The phytohormone abscisic acid (ABA) regulates various physiological processes in plants. The molecular mechanisms by which this is achieved are not fully understood. Genetic approaches have characterized several downstream components of ABA signalling, but a receptor for ABA has remained elusive. Although studies indicate that several ABA response genes encode RNA-binding or RNA-processing proteins, none has been found to be functional in binding ABA. Here we show that FCA, an RNA-binding protein involved in flowering, binds ABA with high affinity in an interaction that is stereospecific and follows receptor kinetics. The interaction between FCA and ABA has molecular effects on downstream events in the autonomous floral pathway and, consequently, on the ability of the plant to undergo transition to flowering. We further show that ABA binding exerts a direct control on the FCA-mediated processing of precursor messenger RNA. Our results indicate that FCA is an ABA receptor involved in RNA metabolism and in controlling flowering time.	Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	University of Manitoba; National Research Council Canada	Hill, RD (corresponding author), Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.	rob_hill@umanitoba.ca						Bastow R, 2004, NATURE, V427, P164, DOI 10.1038/nature02269; Cheng YL, 2004, CURR OPIN PLANT BIOL, V7, P20, DOI 10.1016/j.pbi.2003.11.005; De Smet I, 2003, PLANT J, V33, P543, DOI 10.1046/j.1365-313X.2003.01652.x; Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543; Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441; Finkelstein Ruth R, 2002, Arabidopsis Book, V1, pe0058, DOI 10.1199/tab.0058; GUSTA LV, 1992, CAN J BOT, V70, P1550, DOI 10.1139/b92-195; Hays DB, 1996, J PLANT GROWTH REGUL, V15, P5, DOI 10.1007/BF00213128; Henderson IR, 2004, DEVELOPMENT, V131, P3829, DOI 10.1242/dev.01294; HILL RD, 1995, PLANT PHYSIOL, V108, P573, DOI 10.1104/pp.108.2.573; Himmelbach A, 2003, CURR OPIN PLANT BIOL, V6, P470, DOI 10.1016/S1369-5266(03)00090-6; Hugouvieux V, 2001, CELL, V106, P477, DOI 10.1016/S0092-8674(01)00460-3; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542; Kuhn JM, 2003, CURR OPIN PLANT BIOL, V6, P463, DOI 10.1016/S1369-5266(03)00084-0; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Li JX, 2002, NATURE, V418, P793, DOI 10.1038/nature00936; Lu C, 2000, PLANT CELL, V12, P2351, DOI 10.1105/tpc.12.12.2351; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Macknight R, 2002, PLANT CELL, V14, P877, DOI 10.1105/tpc.010456; Markarov AM, 2002, RUSS J PLANT PHYSL+, V49, P465, DOI 10.1023/A:1016399606792; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Michaels SD, 2001, PLANT CELL, V13, P935, DOI 10.1105/tpc.13.4.935; Nyangulu JM, 2005, J AM CHEM SOC, V127, P1662, DOI 10.1021/ja0429059; Quesada V, 2003, EMBO J, V22, P3142, DOI 10.1093/emboj/cdg305; Razem FA, 2004, J BIOL CHEM, V279, P9922, DOI 10.1074/jbc.M311064200; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; Simpson GG, 2004, CURR OPIN PLANT BIOL, V7, P570, DOI 10.1016/j.pbi.2004.07.002; Simpson GG, 2003, CELL, V113, P777, DOI 10.1016/S0092-8674(03)00425-2; Su WR, 2002, J PLANT PHYSIOL, V159, P557, DOI 10.1078/0176-1617-00732; Sung S, 2005, ANNU REV PLANT BIOL, V56, P491, DOI 10.1146/annurev.arplant.56.032604.144307; Sutton F, 2000, PLANT PHYSIOL, V124, P223, DOI 10.1104/pp.124.1.223; Wijayanti L, 1997, J PLANT GROWTH REGUL, V16, P115, DOI 10.1007/PL00006977; Xiong LM, 2001, DEV CELL, V1, P771, DOI 10.1016/S1534-5807(01)00087-9	34	246	291	0	66	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					290	294		10.1038/nature04373	http://dx.doi.org/10.1038/nature04373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421562				2022-12-28	WOS:000234682100034
J	Tectonidis, M				Tectonidis, M			Crisis in Niger - Outpatient care for severe acute malnutrition	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Med Frontieres, Dept Med, Paris, France	Sanofi-Aventis; Sanofi France	Tectonidis, M (corresponding author), Med Frontieres, Dept Med, Paris, France.							Briend A, 1999, LANCET, V353, P1767, DOI 10.1016/S0140-6736(99)01078-8; Collins S, 2001, LANCET, V358, P498, DOI 10.1016/S0140-6736(01)05630-6	2	21	21	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					224	227		10.1056/NEJMp058240	http://dx.doi.org/10.1056/NEJMp058240			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421363				2022-12-28	WOS:000234661100002
J	Tielsch, JM; Khatry, SK; Stoltzfus, RJ; Katz, J; LeClerq, SC; Adhikari, R; Mullany, LC; Shresta, S; Black, RE				Tielsch, JM; Khatry, SK; Stoltzfus, RJ; Katz, J; LeClerq, SC; Adhikari, R; Mullany, LC; Shresta, S; Black, RE			Effect of routine prophylactic supplementation with iron and folic acid on preschool child mortality in southern Nepal: community-based, cluster-randomised, placebo-controlled trial	LANCET			English	Article							ZINC SUPPLEMENTATION; GROWTH; ANEMIA; DEFICIENCY; APPETITE; DIARRHEA; INFANTS	Introduction Iron deficiency is widespread in the developing world and is especially common in young children who live on the Indian subcontinent. Supplementation with iron and folic acid alleviates severe anaemia and enhances neurodevelopment in deficient populations, but little is known about the risks of mortality and morbidity associated with supplementation. Methods We did a community-based, cluster-randomised, double-masked, placebo-controlled, 2 X 2 factorial trial in children aged 1-36 months and residing in southern Nepal. We randomly assigned children daily oral supplementation to age 36 months with: iron (12.5 mg) and folic acid (50 mu g; n=8337), zinc alone (10 mg), iron, folic acid, and zinc (n=9230), or placebo (n=8683); children aged 1-11 months received half the dose. Our primary outcome measure was all-cause mortality, and our secondary outcome measures included cause-specific mortality and incidence and severity of diarrhoea, dysentery, and acute respiratory illness. Analyses were by intention to treat. This study is registered at clinicaltrials.gov, number NCT00109551. Findings The iron and folic acid-containing groups of the study were stopped early in November, 2003, on the recommendation of the data and safety monitoring board; mortality in these groups did not differ from placebo and there was low power to detect positive or negative effects by the time enrolment was completed. We continued to enrol children to the placebo and zinc alone groups. 25 490 children participated and analyses are based on 29 097.3 person-years of follow-up. There was no difference in mortality between the groups who took iron and folic acid without or with zinc when compared with placebo (HR 1.03, 95% CI 0.78-1.37, and 1.00, 0.74-1.34, respectively). There were no significant differences in the attack rates for diarrhoea, dysentery, or respiratory infections between groups, although all the relative risks except one indicated modest, non-significant protective effects. Interpretation Daily supplementation of young children in southern Nepal with iron and folic acid with or without zinc has no effect on their risk of death, but might protect against diarrhoea, dysentery, and acute respiratory illness.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Nepal Nutr Intervent Project Sarlahi, Kathmandu, Nepal; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Tribhuvan Univ, Inst Med, Kathmandu, Nepal	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Cornell University; Tribhuvan University; Institute of Medicine (IoM) - Nepal	Tielsch, JM (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	jtielsch@jhsph.edu		Katz, Joanne/0000-0002-5997-7823; Tielsch, James/0000-0002-1151-060X; Black, Robert/0000-0001-9926-7984	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044004, R01HD038753] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD038753, R01 HD038753-04, R01 HD044004-03, R01 HD044004, HD 38753] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baqui AH, 2003, J NUTR, V133, P4150, DOI 10.1093/jn/133.12.4150; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Black MM, 2004, AM J CLIN NUTR, V80, P903, DOI 10.1093/ajcn/80.4.903; Black RE, 2003, J NUTR, V133, p1485S, DOI 10.1093/jn/133.5.1485S; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Brabin BJ, 2001, J NUTR, V131, p636S, DOI 10.1093/jn/131.2.636S; Caulfi eld L. E., 2004, COMP QUANTIFICATION; Christian P, 2001, AM J CLIN NUTR, V73, P1045; Dreyfuss M. L., 1997, JNMA, Journal of the Nepal Medical Association, V35, P234; FISHMAN SM, 2004, COMP QUANTIFICATION; Gera T, 2002, BMJ-BRIT MED J, V325, P1142, DOI 10.1136/bmj.325.7373.1142; Jiang TN, 2005, J NUTR, V135, P1106, DOI 10.1093/jn/135.5.1106; LAWLESS JW, 1994, J NUTR, V124, P645, DOI 10.1093/jn/124.5.645; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Lind T, 2004, AM J CLIN NUTR, V80, P729; Lozoff B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e51; *MIN HLTH, 1998, NEP MICR STAT SURV 1; *MIN HLTH NEP, 2001, NEW ERA ORC MACR NEP; Oppenheimer SJ, 2001, J NUTR, V131, p616S, DOI 10.1093/jn/131.2.616S; Pollitt E, 2001, J NUTR, V131, p669S, DOI 10.1093/jn/131.2.669S; PRADHAN EK, 1999, NNIPS MONOGRAPH NUMB, V1; Rice AL, 2004, COMP QUANTIFICATION; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; Sazawal S, 2001, PEDIATRICS, V108, P1280, DOI 10.1542/peds.108.6.1280; Shankar A. H., 2001, Nutrition and health in developing countries, P177; Siegel E, 2004, THESIS J HOPKINS U; Stoltzfus R, 2001, BRIT MED J, V323, P1, DOI DOI 10.1136/BMJ.323.7326.1389; Stoltzfus R, 2004, COMP QUANTIFICATION; Stoltzfus RJ, 2004, J NUTR, V134, P348, DOI 10.1093/jn/134.2.348; Stoltzfus RJ, 1998, GUIDELINES USE IRON; *UN ADM COORD COMM, 2000, 4 UNACCSCN; Usha Ramakrishnan, 2001, Nutrition and health in developing countries, P365	33	159	159	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 14	2006	367	9505					144	152		10.1016/S0140-6736(06)67963-4	http://dx.doi.org/10.1016/S0140-6736(06)67963-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003BB	16413878	Green Accepted			2022-12-28	WOS:000234655500029
J	Deaconescu, AM; Chambers, AL; Smith, AJ; Nickels, BE; Hochschild, A; Savery, NJ; Darst, SA				Deaconescu, AM; Chambers, AL; Smith, AJ; Nickels, BE; Hochschild, A; Savery, NJ; Darst, SA			Structural basis for bacterial transcription-coupled DNA repair	CELL			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; ELONGATION COMPLEX; CATABOLITE REPRESSION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; MFD MUTANT; PROTEIN	Coupling of transcription and DNA repair in bacteria is mediated by transcription-repair coupling factor (TRCF, the product of the mfd gene), which removes transcription elongation complexes stalled at DNA lesions and recruits the nucleotide excision repair machinery to the site. Here we describe the 3.2 angstrom-resolution X-ray crystal structure of Escherichia coli TRCF. The structure consists of a compact arrangement of eight domains, including a translocation module similar to the SF2 ATPase RecG, and a region of structural similarity to UvrB. Biochemical and genetic experiments establish that another domain with structural similarity to the Tudor-like domain of the transcription elongation factor NusG plays a critical role in TRCF/RNA polymerase interactions. Comparison with the translocation module of RecG as well as other structural features indicate that TRCF function involves largescale conformational changes. These data, along with a structural model for the interaction of TRCF with the transcription elongation complex, provide mechanistic insights into TRCF function.	Rockefeller Univ, New York, NY 10021 USA; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1TN, England	Rockefeller University; University of Bristol; Harvard University; Harvard Medical School; University of Cambridge	Deaconescu, AM (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockefeller.edu	Nickels, Bryce/AAF-2549-2020	Savery, Nigel/0000-0002-0803-4075; Chambers, Anna/0000-0001-8133-6240; Nickels, Bryce/0000-0001-7449-8831; Deaconescu, Alexandra/0000-0002-2742-5493	Biotechnology and Biological Sciences Research Council [BB/C507053/1] Funding Source: Medline; NIGMS NIH HHS [GM073829, GM44025] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044025, R01GM073829] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; BOCKRATH RC, 1977, MOL GEN GENET, V156, P133, DOI 10.1007/BF00283485; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Chambers AL, 2003, NUCLEIC ACIDS RES, V31, P6409, DOI 10.1093/nar/gkg868; COWTAN K, 1994, ESF CCP4 NEWSLETTER, V31, P34; DEACONESCU A, 2005, IN PRESS ACTA CRYST; Dove Simon L, 2004, Methods Mol Biol, V261, P231; Durr H, 2005, CELL, V121, P363, DOI 10.1016/j.cell.2005.03.026; Epshtein V, 2003, EMBO J, V22, P4719, DOI 10.1093/emboj/cdg452; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; GEORGE DL, 1975, MUTAT RES, V28, P347, DOI 10.1016/0027-5107(75)90229-8; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gulick AM, 2002, ACTA CRYSTALLOGR D, V58, P306, DOI 10.1107/S0907444901018832; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LI J, 1992, J BIOL CHEM, V267, P6012; Mahdi AA, 2003, EMBO J, V22, P724, DOI 10.1093/emboj/cdg043; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7; ORREN DK, 1990, J BIOL CHEM, V265, P15796; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; Pasman Z, 2000, BIOCHEMISTRY-US, V39, P5573, DOI 10.1021/bi992658z; Ponting CP, 2002, NUCLEIC ACIDS RES, V30, P3643, DOI 10.1093/nar/gkf498; RAIN JC, 2001, NATURE, V20, P8847; Roberts J, 2004, CURR OPIN MICROBIOL, V7, P120, DOI 10.1016/j.mib.2004.02.014; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Smith AJ, 2005, NUCLEIC ACIDS RES, V33, P755, DOI 10.1093/nar/gki225; Steiner T, 2002, EMBO J, V21, P4641, DOI 10.1093/emboj/cdf455; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Toulokhonov I, 2003, MOL CELL, V12, P1125, DOI 10.1016/S1097-2765(03)00439-8; Trautinger BW, 2005, MOL CELL, V19, P247, DOI 10.1016/j.molcel.2005.06.004; Truglio JJ, 2004, EMBO J, V23, P2498, DOI 10.1038/sj.emboj.7600263; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Washburn RS, 2003, J MOL BIOL, V329, P655, DOI 10.1016/S0022-2836(03)00465-0; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; WITKIN EM, 1966, SCIENCE, V152, P1345, DOI 10.1126/science.152.3727.1345; Zalieckas JM, 1998, MOL MICROBIOL, V27, P1031, DOI 10.1046/j.1365-2958.1998.00751.x; Zeng XM, 2000, MICROBIOL-UK, V146, P2901, DOI 10.1099/00221287-146-11-2901	56	160	163	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					507	520		10.1016/j.cell.2005.11.045	http://dx.doi.org/10.1016/j.cell.2005.11.045			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469698	Bronze			2022-12-28	WOS:000235464000014
J	Schuster, M; Duringer, P; Ghienne, JF; Vignaud, P; Mackaye, HT; Likius, A; Brunet, M				Schuster, M; Duringer, P; Ghienne, JF; Vignaud, P; Mackaye, HT; Likius, A; Brunet, M			The age of the Sahara Desert	SCIENCE			English	Article							UPPER MIOCENE; HOMINID; DISCOVERY; CHAD		Univ Bretagne Occidentale, Inst Univ Europeen Mer, CNRS, UMR 6538, F-29280 Plouzane, France; Univ Strasbourg, Ecole & Observ Sci Terre, Ctr Geochim Surface, CNRS,UMR 7517, F-67084 Strasbourg, France; Univ Poitiers, CNRS, UMR 6046, Lab Geobiol Biochronol & Paleontol Humaine, F-86022 Poitiers, France; Univ NDjamena, Dept Paleontol, NDjamena, Chad	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Bretagne Occidentale; Institut Universitaire Europeen de la Mer (IUEM); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Schuster, M (corresponding author), Univ Bretagne Occidentale, Inst Univ Europeen Mer, CNRS, UMR 6538, Domaine Ocean,1 Pl Nicolas Copern, F-29280 Plouzane, France.	schuster@univ-brest.fr	Lund, Laura/H-7335-2012	Ghienne, JF/0000-0002-9448-5285; Schuster, Mathieu/0000-0002-4412-8685				Brunet M, 1998, CR ACAD SCI II A, V326, P153, DOI 10.1016/S1251-8050(97)87460-5; Brunet M, 2005, NATURE, V434, P752, DOI 10.1038/nature03392; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Brunet M, 2000, J VERTEBR PALEONTOL, V20, P205, DOI 10.1671/0272-4634(2000)020[0205:CDOAVF]2.0.CO;2; CALLOT Y, 1988, B SOC GEOL FR, V4, P1073; Kocurek G., 1999, EOLIAN ENV SEDIMENTS, P239; Lancaster N, 2002, GEOLOGY, V30, P991, DOI 10.1130/0091-7613(2002)030<0991:LPAHDA>2.0.CO;2; Maley J., 2004, EVOLUTION VEGETATION, P179; RUDDIMAN WF, 1989, P ODP SCI RES, V108, P241; Schuster M, 2000, CR ACAD SCI II A, V331, P15, DOI 10.1016/S1251-8050(00)01377-X; Swezey C, 1999, SCIENCE, V286, P243; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880	12	206	217	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					821	821		10.1126/science.1120161	http://dx.doi.org/10.1126/science.1120161			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469920				2022-12-28	WOS:000235374900039
J	Markel, H				Markel, H			The stethoscope and the art of listening	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA.							BISHOP PJ, 1980, J ROY SOC MED, V73, P448, DOI 10.1177/014107688007300611; Duffin Jacalyn, 1998, SEE BETTER EYE LIFE; LAENNEC RTH, 1821, TREATISE DIS CHEST, P284; NULAND SB, 1995, DOCTORS BIOGRAPHY ME, P200; SIGERIST HE, 1933, GREAT DOCTORS BIOGRA, P283	5	28	31	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					551	553		10.1056/NEJMp048251	http://dx.doi.org/10.1056/NEJMp048251			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467541				2022-12-28	WOS:000235177500003
J	Sands, JM; Bichet, DG				Sands, JM; Bichet, DG			Nephrogenic diabetes insipidus	ANNALS OF INTERNAL MEDICINE			English	Review							WATER CHANNEL EXPRESSION; INDUCED DOWN-REGULATION; WILD-TYPE AQUAPORIN-2; AGE-RELATED POLYURIA; RAT-KIDNEY MEDULLA; KIDD BLOOD-GROUP; UREA TRANSPORTERS; COUNTERCURRENT MULTIPLICATION; DIFFERENTIAL-DIAGNOSIS; CLINICAL PRESENTATION		Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA; Univ Montreal, Montreal, PQ H3C 3J7, Canada	Emory University; Universite de Montreal	Sands, JM (corresponding author), Emory Univ, Sch Med, Div Renal, 1639 Pierce Dr,NE,WMB Room 338, Atlanta, GA 30322 USA.	jeff.sands@emory.edu		BICHET, DANIEL-G/0000-0003-2856-6850	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063657, P01DK061521, R01DK041707] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41707, R01 DK063657, R01-DK63657, P01-DK61521, R01 DK041707] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amlal H, 2000, AM J PHYSIOL-RENAL, V279, pF655, DOI 10.1152/ajprenal.2000.279.4.F655; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bagnasco SM, 2003, AM J PHYSIOL-RENAL, V284, pF3, DOI 10.1152/ajprenal.00260.2002; BATLLE DC, 1985, NEW ENGL J MED, V312, P408, DOI 10.1056/NEJM198502143120705; Bichet DG, 2004, NEW ENGL J MED, V350, P1281, DOI 10.1056/NEJMp048026; Bichet DG, 2002, J AM SOC NEPHROL, V13, p40A; BOTON R, 1987, AM J KIDNEY DIS, V10, P329, DOI 10.1016/S0272-6386(87)80098-7; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Catudioc-Vallero J, 1998, ADV EXP MED BIOL, V449, P183; CHRISTENSEN S, 1985, J CLIN INVEST, V75, P1869, DOI 10.1172/JCI111901; COGAN E, 1987, AM J PHYSIOL, V252, pF1080, DOI 10.1152/ajprenal.1987.252.6.F1080; Combet S, 2003, AM J PHYSIOL-RENAL, V284, pF199, DOI 10.1152/ajprenal.00167.2002; Combet S, 2001, AM J PHYSIOL-RENAL, V281, pF1123, DOI 10.1152/ajprenal.0139.2001; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Earm JH, 1998, J AM SOC NEPHROL, V9, P2181; Edwards A, 1998, AM J PHYSIOL-HEART C, V274, pH1202, DOI 10.1152/ajpheart.1998.274.4.H1202; EDWARDS A, 1997, AM J PHYSIOL, V272, P14; FORSSMAN H, 1942, NORD MED, V16, P3211; Frokiaer J, 1997, AM J PHYSIOL-RENAL, V273, pF213, DOI 10.1152/ajprenal.1997.273.2.F213; FUJIWARA TM, 1995, ANNU REV MED, V46, P331; GALLUCCI E, 1971, ARCH INT PHYS BIOCH, V79, P881, DOI 10.3109/13813457109104847; GOLDBERG H, 1988, AM J PHYSIOL, V255, pF995, DOI 10.1152/ajprenal.1988.255.5.F995; Hoekstra JA, 1996, AM J MED GENET, V61, P81; Jeck N, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e5; Jung JY, 2003, AM J PHYSIOL-RENAL, V285, pF1210, DOI 10.1152/ajprenal.00111.2003; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Klein JD, 2002, KIDNEY INT, V61, P995, DOI 10.1046/j.1523-1755.2002.00210.x; Knoers NVAM, 2001, PEDIATR NEPHROL, V16, P1146, DOI 10.1007/s004670100051; KOKKO JP, 1972, KIDNEY INT, V2, P214, DOI 10.1038/ki.1972.97; Kuwahara M, 2001, AM J HUM GENET, V69, P738, DOI 10.1086/323643; Li CL, 2004, AM J PHYSIOL-RENAL, V286, pF1154, DOI 10.1152/ajprenal.00453.2003; Lucien N, 2002, J BIOL CHEM, V277, P34101, DOI 10.1074/jbc.M205073200; Lucien N, 1998, J BIOL CHEM, V273, P12973, DOI 10.1074/jbc.273.21.12973; Marples D, 1996, J CLIN INVEST, V97, P1960, DOI 10.1172/JCI118628; MARPLES D, 1995, J CLIN INVEST, V95, P1838, DOI 10.1172/JCI117863; Marr N, 2002, HUM MOL GENET, V11, P779, DOI 10.1093/hmg/11.7.779; McIlraith CH, 1892, LANCET 140, P767, DOI [10.1016/S0140-6736(01)87712-6, DOI 10.1016/S0140-6736(01)87712-6, 10.1016/s0140-6736(01)87712-6]; Michimata M, 2003, KIDNEY INT, V64, P933, DOI 10.1046/j.1523-1755.2003.00182.x; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Nielsen J, 2003, AM J PHYSIOL-RENAL, V285, pF1198, DOI 10.1152/ajprenal.00118.2003; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; OKUSA MD, 1994, AM J MED, V97, P383, DOI 10.1016/0002-9343(94)90308-5; Olives B, 1996, FEBS LETT, V386, P156, DOI 10.1016/0014-5793(96)00425-5; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; ONEILL PA, 1992, MED LAB SCI, V49, P291; Pallone TL, 2003, AM J PHYSIOL-REG I, V284, pR1153, DOI 10.1152/ajpregu.00657.2002; Peters M, 2002, AM J MED, V112, P183, DOI 10.1016/S0002-9343(01)01086-5; Preisser L, 2000, AM J PHYSIOL-RENAL, V279, pF144, DOI 10.1152/ajprenal.2000.279.1.F144; Ranade K, 2001, HUM MOL GENET, V10, P2157, DOI 10.1093/hmg/10.19.2157; Reinalter SC, 2002, KIDNEY INT, V62, P253, DOI 10.1046/j.1523-1755.2002.00435.x; ROWE JW, 1976, NEPHRON, V17, P270, DOI 10.1159/000180731; Sands J.M., 2000, KIDNEY PHYSL PATHOPH, V3, P1175; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; Sands JM, 2003, ANNU REV PHYSIOL, V65, P543, DOI 10.1146/annurev.physiol.65.092101.142638; Sands JM, 2003, J MEMBRANE BIOL, V191, P149, DOI 10.1007/s00232-002-1053-1; Sands JM, 1998, AM J PHYSIOL-RENAL, V274, pF978, DOI 10.1152/ajprenal.1998.274.5.F978; Sands JM, 1996, J CLIN INVEST, V97, P2807, DOI 10.1172/JCI118736; Sands JM, 2002, J AM SOC NEPHROL, V13, P2795, DOI 10.1097/01.ASN.0000035084.94743.7C; SANDS JM, 1987, J CLIN INVEST, V79, P138, DOI 10.1172/JCI112774; SANDS JM, 1987, AM J PHYSIOL, V253, pF823, DOI 10.1152/ajprenal.1987.253.5.F823; Schlingmann KP, 2004, NEW ENGL J MED, V350, P1314, DOI 10.1056/NEJMoa032843; Sidoux-Walter F, 2000, BLOOD, V96, P1566, DOI 10.1182/blood.V96.4.1566.h8001566_1566_1573; SPORN IN, 1962, NEW ENGL J MED, V267, P130, DOI 10.1056/NEJM196207192670304; STEPHENSON JL, 1972, KIDNEY INT, V2, P85, DOI 10.1038/ki.1972.75; Swenson KL, 1997, AM J PHYSIOL-REG I, V273, pR35, DOI 10.1152/ajpregu.1997.273.1.R35; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; TAN TTM, 2003, AM J PHYSIOL-REG I, V285, pR1355; Timmer RT, 1999, J AM SOC NEPHROL, V10, P666; van Lieburg AF, 1999, J AM SOC NEPHROL, V10, P1958; van Os CH, 1998, P ASSOC AM PHYSICIAN, V110, P395; WARING AJ, 1945, AM J DIS CHILD, V69, P323; Wieth JO, 1974, COMP BIOCH PHYSL TRA, P317; WILLIAMS RH, 1947, ANN INTERN MED, V27, P84, DOI 10.7326/0003-4819-27-1-84; ZERBE RL, 1981, NEW ENGL J MED, V305, P1539, DOI 10.1056/NEJM198112243052601	76	91	95	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					186	194		10.7326/0003-4819-144-3-200602070-00007	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008XS	16461963				2022-12-28	WOS:000235074800005
J	Haber, P				Haber, P			Commentary: Challenge for doctors and policy makers	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Prince Alfred Hosp, Dept Drug & Alcohol Serv, Camperdown, NSW 2050, Australia	University of Sydney	Haber, P (corresponding author), Royal Prince Alfred Hosp, Dept Drug & Alcohol Serv, Camperdown, NSW 2050, Australia.	phaber@mail.usyd.edu.au						FULLARD M, 2005, GUT, V54, pA131; Greenfield SF, 1998, ARCH GEN PSYCHIAT, V55, P259, DOI 10.1001/archpsyc.55.3.259; Haber PS, 2003, J GASTROEN HEPATOL, V18, P1332, DOI 10.1046/j.1440-1746.2003.03217.x; Mato JM, 1999, J HEPATOL, V30, P1081, DOI 10.1016/S0168-8278(99)80263-3; McPherson S, 2006, BRIT MED J, V332, P276, DOI 10.1136/bmj.332.7536.276; Moriarty KJ, 2006, J EPIDEMIOL COMMUN H, V60, P94	6	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					277	278		10.1136/bmj.332.7536.277-a	http://dx.doi.org/10.1136/bmj.332.7536.277-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455724	Green Published			2022-12-28	WOS:000235259000020
J	Nascimento-Carvalho, CM; Moreno-Carvalho, OA				Nascimento-Carvalho, CM; Moreno-Carvalho, OA			Changing the diagnostic framework of meningococcal disease	LANCET			English	Editorial Material							CARE; CHILDREN		Univ Fed Bahia, Fac Med, Dept Paediat, Salvador, BA, Brazil; Jose Silveira Fdn, Salvador, BA, Brazil	Universidade Federal da Bahia	Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Fac Med, Dept Paediat, Salvador, BA, Brazil.	nascimentocarvalho@hotmail.com						APICELLA MA, 2000, MANDELL DOUGLAS BENN, P2228; Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; BROWNER WS, 1988, DESIGNING CLIN RES, P87; Granier S, 1998, BRIT J GEN PRACT, V48, P1167; Ninis N, 2005, BRIT MED J, V330, P1475, DOI 10.1136/bmj.330.7506.1475; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4; VICTORA CG, 1992, SOC SCI MED, V34, P899, DOI 10.1016/0277-9536(92)90258-R	9	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					371	372		10.1016/S0140-6736(06)67934-8	http://dx.doi.org/10.1016/S0140-6736(06)67934-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458743				2022-12-28	WOS:000235139400004
J	Schmidt, L				Schmidt, L			Psychosocial burden of infertility and assisted reproduction	LANCET			English	Editorial Material							FERTILITY TREATMENT; SATISFACTION; COUPLES		Univ Copenhagen, Inst Publ Hlth, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Schmidt, L (corresponding author), Univ Copenhagen, Inst Publ Hlth, DK-2200 Copenhagen N, Denmark.	L.Schmidt@pubhealth.ku.dk		Schmidt, Lone/0000-0002-9518-1734				Boivin J, 2003, SOC SCI MED, V57, P2325, DOI 10.1016/S0277-9536(03)00138-2; Daniluk JC, 2001, J COUNS DEV, V79, P439, DOI 10.1002/j.1556-6676.2001.tb01991.x; de Liz TM, 2005, HUM REPROD, V20, P1324, DOI 10.1093/humrep/deh743; Greil AL, 1997, SOC SCI MED, V45, P1679, DOI 10.1016/S0277-9536(97)00102-0; Jordan C, 1999, J BEHAV MED, V22, P341, DOI 10.1023/A:1018774019232; Schmidt L, 2005, HUM REPROD, V20, P3248, DOI 10.1093/humrep/dei193; Schmidt L, 2003, HUM REPROD, V18, P2638, DOI 10.1093/humrep/deg505; Slade P, 1997, HUM REPROD, V12, P183, DOI 10.1093/humrep/12.1.183; Souter VL, 1998, HUM REPROD, V13, P1831, DOI 10.1093/humrep/13.7.1831; Sundby JS, 1992, J WOMENS HEALTH, V1, P209; Sydsjo G, 2005, HUM REPROD, V20, P1952, DOI 10.1093/humrep/deh882; Verhaak CM, 2005, HUM REPROD, V20, P2253, DOI 10.1093/humrep/dei015	12	80	80	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					379	380		10.1016/S0140-6736(06)68117-8	http://dx.doi.org/10.1016/S0140-6736(06)68117-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	009UR	16458748				2022-12-28	WOS:000235139400009
J	Wright, AA; Katz, IT				Wright, AA; Katz, IT			Home testing for HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Wright, AA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.		Davey Smith, George/A-7407-2013; Wright, Alexi/T-5793-2019	Davey Smith, George/0000-0002-1407-8314; Katz, Ingrid/0000-0002-3014-238X				BRANSON B, 2005, FDA BLOOD PROD ADV C; Branson BM, 1998, JAMA-J AM MED ASSOC, V280, P1699, DOI 10.1001/jama.280.19.1699; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Spielberg F, 2005, FDA BLOOD PROD ADV C	4	68	70	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					437	440		10.1056/NEJMp058302	http://dx.doi.org/10.1056/NEJMp058302			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	008DC	16452553				2022-12-28	WOS:000235019400001
J	Kendall, MJ; Mehta, DK				Kendall, MJ; Mehta, DK			Sick children deserve a better deal	LANCET			English	Editorial Material									Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Royal Pharmaceut Soc Great Britain, London, England	University of Birmingham	Kendall, MJ (corresponding author), Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	m.j.kendall@bham.ac.uk						Caldwell PHY, 2004, LANCET, V364, P803, DOI 10.1016/S0140-6736(04)16942-0; Choonara I, 2002, DRUG SAFETY, V25, P1, DOI 10.2165/00002018-200225010-00001; COPE L, 1996, A HEY BOOK CHILDRENS; *EUR MED AG, 2004, MED CHILDR EUR PAED; HEY E, 2003, NEONATAL FORMULARY; *PAED FORM COMM, 2005, BNF CHILDR; TOMLIN S, 2005, PAEDIAT FORMULARY	7	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					281	283		10.1016/S0140-6736(06)68048-3	http://dx.doi.org/10.1016/S0140-6736(06)68048-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443023				2022-12-28	WOS:000235084600007
J	Sekiguchi, JM; Ferguson, DO				Sekiguchi, JM; Ferguson, DO			DNA double-strand break repair: A relentless hunt uncovers new prey	CELL			English	Editorial Material							V(D)J RECOMBINATION; INSTABILITY; MUTATIONS	A major pathway for repair of DNA double-strand breaks is nonhomologous end-joining (NHEJ). In this issue of Cell, Buck et al. (2006a) and Ahnesorg et al. (2006) report the discovery of a new NHEJ factor called Cernunnos-XLF. Both groups report that this protein is mutated in a rare inherited human syndrome characterized by severe immunodeficiency, developmental delay, and hypersensitivity to agents that cause DNA double-strand breaks.	Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ferguson, DO (corresponding author), Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Internal Med, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	daviferg@umich.edu		Sekiguchi, JoAnn/0000-0002-7178-4258				AHNESORG P, 2006, CELL; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; BUCK D, 2006, CELL; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; O'Driscoll M, 2004, DNA REPAIR, V3, P1227, DOI 10.1016/j.dnarep.2004.03.025; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x	10	49	49	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					260	262		10.1016/j.cell.2006.01.010	http://dx.doi.org/10.1016/j.cell.2006.01.010			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439201	Bronze			2022-12-28	WOS:000235068500014
J	Bomback, A				Bomback, A			Becoming a physician - The physical exam and the sense of smell	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ N Carolina Hosp, Chapel Hill, NC 27514 USA	University North Carolina Hospital	Bomback, A (corresponding author), Univ N Carolina Hosp, Chapel Hill, NC 27514 USA.		Bomback, Andrew/A-8063-2009						0	7	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					327	329		10.1056/NEJMp048244	http://dx.doi.org/10.1056/NEJMp048244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436763				2022-12-28	WOS:000234854000003
J	Flack, JC; Girvan, M; de Waal, FBM; Krakauer, DC				Flack, JC; Girvan, M; de Waal, FBM; Krakauer, DC			Policing stabilizes construction of social niches in primates	NATURE			English	Article							RECIPROCITY; CENTRALITY; ROBUSTNESS; MECHANISMS; EVOLUTION	All organisms interact with their environment, and in doing so shape it, modifying resource availability. Termed niche construction, this process has been studied primarily at the ecological level with an emphasis on the consequences of construction across generations(1). We focus on the behavioural process of construction within a single generation, identifying the role a robustness mechanism(2) - conflict management - has in promoting interactions that build social resource networks or social niches. Using 'knockout' experiments on a large, captive group of pigtailed macaques ( Macaca nemestrina), we show that a policing function, performed infrequently by a small subset of individuals(3), significantly contributes to maintaining stable resource networks in the face of chronic perturbations that arise through conflict. When policing is absent, social niches destabilize, with group members building smaller, less diverse, and less integrated grooming, play, proximity and contact-sitting networks. Instability is quantified in terms of reduced mean degree, increased clustering, reduced reach, and increased assortativity. Policing not only controls conflict(3-5), we find it significantly influences the structure of networks that constitute essential social resources in gregarious primate societies. The structure of such networks plays a critical role in infant survivorship(6), emergence and spread of cooperative behaviour(7), social learning and cultural traditions(8).	Santa Fe Inst, Santa Fe, NM 87501 USA; Emory Univ, Yerkes Natl Primate Res Ctr, Living Links Ctr, Atlanta, GA 30322 USA; Emory Univ, Neurosci & Anim Behav Program, Atlanta, GA 30322 USA	The Santa Fe Institute; Emory University; Emory University	Flack, JC (corresponding author), Santa Fe Inst, Santa Fe, NM 87501 USA.	jflack@santafe.edu	Girvan, Michelle/E-3982-2016	Girvan, Michelle/0000-0003-0299-0784; Girvan, Michelle/0000-0001-7519-2842				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; ALTMANN J, 1974, BEHAVIOUR, V49, P227, DOI 10.1163/156853974X00534; Boehm C., 1981, PRIMATE BEHAV SOCIOB, P161; CALDECOTT JO, 1986, CONTRIBUTIONS PRIMAT; de Waal F. B. M., 1977, Zeitschrift Tierpsychol, V44, P225; De Waal FBM, 2000, ANIM BEHAV, V60, P253, DOI 10.1006/anbe.2000.1471; de Waal FBM, 2000, SCIENCE, V289, P586, DOI 10.1126/science.289.5479.586; DEWAAL FBM, 1988, ETHOL SOCIOBIOL, V9, P101, DOI 10.1016/0162-3095(88)90016-7; DEWAAL FBM, 1985, AM J PRIMATOL, V9, P73, DOI 10.1002/ajp.1350090202; Flack J.C., 2004, MACAQUE SOC, P157; Flack JC, 2005, P ROY SOC B-BIOL SCI, V272, P1091, DOI 10.1098/rspb.2004.3019; Flack JC, 2005, AM NAT, V165, pE126, DOI 10.1086/429277; Frank SA, 2003, EVOLUTION, V57, P693; FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543; HUTCHINSON GE, 1957, COLD SPRING HARB SYM, V22, P415, DOI 10.1101/SQB.1957.022.01.039; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; KEPPEL G, 1991, DESIGN ANAL RESEARCH, P329; KRAKAUER DC, 2003, ENCY HUMAN GENOME, V2, P892; Lusseau D, 2004, P ROY SOC B-BIOL SCI, V271, pS477, DOI 10.1098/rsbl.2004.0225; Newman MEJ, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.026126; NOE R, 1995, TRENDS ECOL EVOL, V10, P336, DOI 10.1016/S0169-5347(00)89123-5; Odling-Smee FJ, 2003, NICHE CONSTRUCTION N; Silk JB, 2003, SCIENCE, V302, P1231, DOI 10.1126/science.1088580; Thierry Bernard, 2000, P106; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; WASSERMAN S, 1994, SOCIAL NETWORK ANAL, P107; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; WATTS DJ, 1999, SMALL WORLDS DYNAMIC, P199; Whiten A, 2005, NATURE, V437, P737, DOI 10.1038/nature04047	29	426	440	1	182	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					426	429		10.1038/nature04326	http://dx.doi.org/10.1038/nature04326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437106				2022-12-28	WOS:000234859200036
J	Suarez, JI; Tarr, RW; Selman, WR				Suarez, JI; Tarr, RW; Selman, WR			Current concepts: Aneurysmal subarachnoid hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RUPTURED INTRACRANIAL ANEURYSMS; DELAYED CEREBRAL-ISCHEMIA; HEALTH-CARE PROFESSIONALS; RISK-FACTORS; ENDOVASCULAR TREATMENT; COMPUTED-TOMOGRAPHY; CT; VASOSPASM; DIAGNOSIS; COILING		Case Western Reserve Univ, Univ Hosp Cleveland, Dept Neurol, Neurosci Crit Care & Cerebrovasc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Dept Radiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Dept Neurosurg, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Suarez, JI (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Dept Neurol, Neurosci Crit Care & Cerebrovasc Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA.	jose.suarez@uhhs.com						ADAMS HP, 1991, ANN NEUROL, V29, P461, DOI 10.1002/ana.410290502; ADAMS HP, 1987, NEUROLOGY, V37, P1586, DOI 10.1212/WNL.37.10.1586; American Heart Association, 2005, HEART DIS STROKE STA; Amin-Hanjani S, 2004, NEUROSURGERY, V54, P326, DOI 10.1227/01.NEU.0000103488.94855.4F; Bambakidis NC, 2004, CUR CLIN NEUROL, P365; Bardach NS, 2004, CIRCULATION, V109, P2207, DOI 10.1161/01.CIR.0000126433.12527.E6; Britz GW, 2005, LANCET, V366, P783, DOI 10.1016/S0140-6736(05)67190-5; BRODERICK JP, 1992, NEW ENGL J MED, V326, P733, DOI 10.1056/NEJM199203123261103; Broderick JP, 2003, STROKE, V34, P1375, DOI 10.1161/01.STR.0000074572.91827.F4; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; DRAKE CG, 1988, J NEUROSURG, V68, P985; Edlow JA, 2000, NEW ENGL J MED, V342, P29, DOI 10.1056/NEJM200001063420106; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008; Hackett ML, 2000, NEUROLOGY, V55, P658, DOI 10.1212/WNL.55.5.658; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; Hoeffner EG, 2004, RADIOLOGY, V231, P632, DOI 10.1148/radiol.2313021488; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Jayaraman MV, 2004, RADIOLOGY, V230, P510, DOI 10.1148/radiol.2302021465; Johnston SC, 2002, STROKE, V33, P2536, DOI 10.1161/01.STR.0000034708.66191.7D; Johnston SC, 1998, NEUROLOGY, V50, P1413, DOI 10.1212/WNL.50.5.1413; Kowalski RG, 2004, JAMA-J AM MED ASSOC, V291, P866, DOI 10.1001/jama.291.7.866; Latchaw RE, 1997, NEUROIMAG CLIN N AM, V7, P693; LEBLANC R, 1987, J NEUROSURG, V66, P35, DOI 10.3171/jns.1987.66.1.0035; LINDSAY KW, 1983, J NEUROSURG, V58, P57, DOI 10.3171/jns.1983.58.1.0057; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; Lozier AP, 2002, STROKE, V33, P2509, DOI 10.1161/01.STR.0000031928.71695.A9; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Mayer SA, 2002, NEUROLOGY, V59, P1750, DOI 10.1212/01.WNL.0000035748.91128.C2; McCarron MO, 2004, J NEUROL NEUROSUR PS, V75, P491, DOI 10.1136/jnnp.2003.016816; Mees SMD, 2003, NEUROLOGY, V61, P1132, DOI 10.1212/01.WNL.0000090466.68866.02; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Polmear A, 2003, CEPHALALGIA, V23, P935, DOI 10.1046/j.1468-2982.2003.00596.x; Qureshi AI, 2004, LANCET, V363, P804, DOI 10.1016/S0140-6736(04)15697-3; Qureshi AI, 2001, NEUROSURGERY, V49, P607, DOI 10.1097/00006123-200109000-00014; RINKEL GJ, 2005, COCHRANE DB SYST REV, V1; Roos YB, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001245, DOI 10.1002/14651858.CD001245]; Roos YBWEM, 2002, STROKE, V33, P1595, DOI 10.1161/01.STR.0000016401.49688.2F; Sames TA, 1996, ACAD EMERG MED, V3, P16, DOI 10.1111/j.1553-2712.1996.tb03296.x; SCHIEVINK WI, 1994, STROKE, V25, P889, DOI 10.1161/01.STR.25.4.889; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Suarez JI, 2004, J NEUROSURG, V100, P585, DOI 10.3171/jns.2004.100.4.0585; Suarez JI, 2002, CRIT CARE MED, V30, P1348, DOI 10.1097/00003246-200206000-00035; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Teunissen LL, 1996, STROKE, V27, P544, DOI 10.1161/01.STR.27.3.544; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; van der Jagt M, 1999, NEUROLOGY, V52, P34, DOI 10.1212/WNL.52.1.34; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; VANGIJN J, 1985, J NEUROSURG, V63, P355, DOI 10.3171/jns.1985.63.3.0355; White PM, 2003, LANCET, V362, P90, DOI 10.1016/S0140-6736(03)13891-3; Whitfield PC, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001697, DOI 10.1002/14651858.CD001697]; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3	58	572	604	2	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					387	396		10.1056/NEJMra052732	http://dx.doi.org/10.1056/NEJMra052732			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436770				2022-12-28	WOS:000234854000010
J	Vedral, V				Vedral, V			A better than perfect match	NATURE			English	Editorial Material									Univ Leeds, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Vedral, V (corresponding author), Univ Leeds, Leeds LS2 9JT, W Yorkshire, England.		Vedral, Vlatko/L-3270-2016; vedral, vlatko/P-1712-2014	Vedral, Vlatko/0000-0002-8588-2940; 				BORN M, 1964, NATURAL PHILOS CAUSE; Brooks M, 2004, NEW SCI, V181, P32; Taylor J., 2001, HIDDEN UNITY NATURES	3	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2006	439	7075					397	397		10.1038/439397a	http://dx.doi.org/10.1038/439397a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437094	Bronze			2022-12-28	WOS:000234859200023
J	Brennan, TA; Rothman, DJ; Blank, L; Blumenthal, D; Chimonas, SC; Cohen, JJ; Goldman, J; Kassirer, JP; Kimball, H; Naughton, J; Smelser, N				Brennan, TA; Rothman, DJ; Blank, L; Blumenthal, D; Chimonas, SC; Cohen, JJ; Goldman, J; Kassirer, JP; Kimball, H; Naughton, J; Smelser, N			Health industry practices that create conflicts of interest - A policy proposal for academic medical centers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACEUTICAL-INDUSTRY; PHYSICIAN CHARTER; DRUG COMPANIES; REPRESENTATIVES; PROFESSIONALISM; MILLENNIUM; GIFTS	Conflicts of interest between physicians' commitment to patient care and the desire of pharmaceutical companies and their representatives to sell their products pose challenges to the principles of medical professionalism. These conflicts occur when physicians have motives or are in situations for which reasonable observers could conclude that the moral requirements of the physician's roles are or will be compromised. Although physician groups, the manufacturers, and the federal government have instituted self-regulation of marketing, research in the psychology and social science of gift receipt and giving indicates that current controls will not satisfactorily protect the interests of patients. More stringent regulation is necessary, including the elimination or modification of common practices related to small gifts, pharmaceutical samples, continuing medical education, funds for physician travel, speakers bureaus, ghostwriting, and consulting and research contracts. We propose a policy under which academic medical centers would take the lead in eliminating the conflicts of interest that still characterize the relationship between physicians and the health care industry.	Harvard Univ, Sch Med, Boston, MA USA; Columbia Univ, Coll Phys & Surg, Inst Med Profess, New York, NY USA; Assoc Amer Med Coll, Washington, DC USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Univ Washington, Sch Med, Seattle, WA USA; Alliance Med Grp, San Francisco, CA USA; Univ Calif San Francisco, Sch Med, San Francisco, CA USA; Univ Calif Berkeley, Berkeley, CA 94720 USA	Harvard University; Harvard Medical School; Columbia University; Association of American Medical Colleges; Tufts University; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Brennan, TA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	tabrennan@partners.org		Chimonas, Susan/0000-0002-7742-5950				Angell M., 2004, TRUTH DRUG CO; Avorn J, 2004, POWERFUL MED BENEFIT; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Blank L, 2003, ANN INTERN MED, V138, P839, DOI 10.7326/0003-4819-138-10-200305200-00012; Blumenthal D, 2004, NEW ENGL J MED, V351, P1885, DOI 10.1056/NEJMhpr042734; Bowman M A, 1988, J Contin Educ Health Prof, V8, P13, DOI 10.1002/chp.4750080104; BROTZMAN GL, 1992, J FAM PRACTICE, V34, P54; Cain DM, 2005, J LEGAL STUD, V34, P1, DOI 10.1086/426699; Chimonas S, 2005, HEALTH AFFAIR, V24, P949, DOI 10.1377/hlthaff.24.4.949; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; CIALDINI RB, 1993, INFLUENCE SCI PRACTI, P21; CLEARY J D, 1992, Journal of Pharmacy Technology, V8, P27; Dana J, 2003, JAMA-J AM MED ASSOC, V290, P252, DOI 10.1001/jama.290.2.252; Erde E.L., 1996, CONFLICTS INTEREST C, P12; Gibson E, 2002, CAN MED ASSOC J, V166, P448; Kassirer J.P., 2004, TAKE MED COMPLICITY; Kassirer JP, 2004, WASH POST, pB3, DOI DOI 10.1016/S0735-1097(03)00232-8; KERBER R, 2004, BOSTON GLOBE    0310, pC1; Lipton Shira, 2004, Account Res, V11, P83, DOI 10.1080/03050620490512241; LURIE N, 1990, J GEN INTERN MED, V5, P240, DOI 10.1007/BF02600542; MATTHEWS AW, 2004, WALL STREET J   1101, pA1; McCormick BB, 2001, JAMA-J AM MED ASSOC, V286, P1994, DOI 10.1001/jama.286.16.1994; *NAT I HLTH CR MAN, 2000, PRESCR DRUGS MASS ME; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; PEAY MY, 1988, SOC SCI MED, V26, P1183, DOI 10.1016/0277-9536(88)90149-9; *PHRMA, 2003, PHRMA C C SPRING 200; Sandberg WS, 1997, ACAD MED, V72, P916, DOI 10.1097/00001888-199710000-00018; Schafer A, 2004, J MED ETHICS, V30, P8, DOI 10.1136/jme.2003.005702; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Studdert DM, 2004, NEW ENGL J MED, V351, P1891, DOI 10.1056/NEJMlim042229; SUROWIECKI J, 2002, NEW YORKER, P54; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	32	505	513	0	64	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2006	295	4					429	433		10.1001/jama.295.4.429	http://dx.doi.org/10.1001/jama.295.4.429			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005QJ	16434633				2022-12-28	WOS:000234838600023
J	Oh-Park, M; Dove, C; Sheskier, S; Sheehan, P				Oh-Park, M; Dove, C; Sheskier, S; Sheehan, P			Charcot neuroarthropathy in the era of HAART	LANCET			English	Editorial Material									Montefiore Med Ctr, Albert Einstein Coll Med, Dept Rehabil Med, Bronx, NY 10467 USA; Hosp Joint Dis & Med Ctr, Diabet Foot & Ankle Ctr, New York, NY 10003 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; NYU Langone Medical Center; Hospital for Joint Disease NYULMC	Oh-Park, M (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Rehabil Med, Bronx, NY 10467 USA.	mohpark@pol.net						Armstrong DG, 1997, DIABETIC MED, V14, P357, DOI 10.1002/(SICI)1096-9136(199705)14:5<357::AID-DIA341>3.3.CO;2-#; Keswani SC, 2002, AIDS, V16, P2105, DOI 10.1097/00002030-200211080-00002; Nolan D, 2004, ANTIVIR THER, V9, P849; Sutliff RL, 2002, AM J PHYSIOL-HEART C, V283, pH2363, DOI 10.1152/ajpheart.00151.2002	4	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					274	274		10.1016/S0140-6736(06)68039-2	http://dx.doi.org/10.1016/S0140-6736(06)68039-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427498				2022-12-28	WOS:000234810600034
J	Goll, MG; Kirpekar, F; Maggert, KA; Yoder, JA; Hsieh, CL; Zhang, XY; Golic, KG; Jacobsen, SE; Bestor, TH				Goll, MG; Kirpekar, F; Maggert, KA; Yoder, JA; Hsieh, CL; Zhang, XY; Golic, KG; Jacobsen, SE; Bestor, TH			Methylation of tRNA(AsP) by the DNA methyltransferase homolog Dnmt2	SCIENCE			English	Article							TRANSFER-RNA; CYTOSINE METHYLTRANSFERASES; NUCLEOTIDE-SEQUENCE; FISSION YEAST; MECHANISM; SUBSTRATE; BINDING; LIVER	The sequence and the structure of DNA methyltransferase-2 (Dnmt2) bear close affinities to authentic DNA cytosine methyltransferases. A combined genetic and biochemical approach revealed that human DNMT2 did not methylate DNA but instead methylated a small RNA; mass spectrometry showed that this RNA is aspartic acid transfer RNA (tRNA(Asp)) and that DNMT2 specifically methylated cytosine 38 in the anticodon loop. The function of DNMT2 is highly conserved, and human DNMT2 protein restored methylation in vitro to tRNA(Asp) from Dnmt2-deficient strains of mouse, Arabidopsis thaliana, and Drosophila melanogaster in a manner that was dependent on preexisting patterns of modified nucleosides. indirect sequence recognition is also a feature of eukaryotic DNA methyltransferases, which may have arisen from a Dnmt2-like RNA methyltransferase.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; Univ So Calif, Dept Urol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Columbia University; University of Southern Denmark; Texas A&M University System; Texas A&M University College Station; University of North Carolina; North Carolina State University; University of Southern California; University of Southern California; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Utah System of Higher Education; University of Utah	Bestor, TH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.	THB12@Columbia.edu	Yoder, Jeffrey A./I-5329-2019	Yoder, Jeffrey A./0000-0002-6083-1311; Maggert, Keith/0000-0002-9291-9481; Kirpekar, Finn/0000-0003-1901-2266				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Foster PG, 2003, STRUCTURE, V11, P1609, DOI 10.1016/j.str.2003.10.014; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; GOLL MG, UNPUB; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; HAUMONT E, 1984, BIOCHIMIE, V66, P579, DOI 10.1016/0300-9084(84)90154-8; JOHNSON GD, 1985, ARCH BIOCHEM BIOPHYS, V236, P448, DOI 10.1016/0003-9861(85)90647-2; King MY, 2002, BIOCHEMISTRY-US, V41, P11218, DOI 10.1021/bi026055q; KUCHINO Y, 1981, J BIOL CHEM, V256, P9059; Lee TT, 2005, CELL, V120, P599, DOI 10.1016/j.cell.2004.12.037; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MANGROO D, 1995, J BACTERIOL, V177, P2858, DOI 10.1128/jb.177.10.2858-2862.1995; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Taniguchi H, 1998, NUCLEIC ACIDS RES, V26, P1481, DOI 10.1093/nar/26.6.1481; WILKINSON CRM, 1995, NUCLEIC ACIDS RES, V23, P203, DOI 10.1093/nar/23.2.203; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	22	721	773	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					395	398		10.1126/science.1120976	http://dx.doi.org/10.1126/science.1120976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424344				2022-12-28	WOS:000234938500049
J	Winkowski, DE; Knudsen, EI				Winkowski, DE; Knudsen, EI			Top-down gain control of the auditory space map by gaze control circuitry in the barn owl	NATURE			English	Article							FRONTAL EYE FIELD; ATTENTIONAL MODULATION; OPTIC TECTUM; MICROSTIMULATION; MONKEY; NEURONS; ARCHISTRIATUM; INACTIVATION; MEMORY	High-level circuits in the brain that control the direction of gaze are intimately linked with the control of visual spatial attention(1-5). Immediately before an animal directs its gaze towards a stimulus, both psychophysical sensitivity to that visual stimulus and the responsiveness of high-order neurons in the cerebral cortex that represent the stimulus increase dramatically(3,6,7). Equivalent effects on behavioural sensitivity and neuronal responsiveness to visual stimuli result from focal electrical microstimulation of gaze control centres in monkeys(8-11). Whether the gaze control system modulates neuronal responsiveness in sensory modalities other than vision is unknown. Here we show that electrical microstimulation applied to gaze control circuitry in the forebrain of barn owls regulates the gain of midbrain auditory responses in an attention-like manner. When the forebrain circuit was activated, midbrain responses to auditory stimuli at the location encoded by the forebrain site were enhanced and spatial selectivity was sharpened. The same stimulation suppressed responses to auditory stimuli represented at other locations in the midbrain map. Such space-specific, top-down regulation of auditory responses by gaze control circuitry in the barn owl suggests that the central nervous system uses a common strategy for dynamically regulating sensory gain that applies across modalities, brain areas and classes of vertebrate species. This approach provides a path for discovering mechanisms that underlie top-down gain control in the central nervous system.	Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Winkowski, DE (corresponding author), Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA.	dwinkows@stanford.edu			NIDCD NIH HHS [F32 DC006569-01A2, F32 DC006569-02, F32 DC006569, R01 DC000155, R01 DC000155-28] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000155, F32DC006569] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; Cavanaugh J, 2004, J NEUROSCI, V24, P11236, DOI 10.1523/JNEUROSCI.3724-04.2004; COHEN YE, 1995, J NEUROSCI, V15, P5152; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; Dias EC, 1999, J NEUROPHYSIOL, V81, P2191, DOI 10.1152/jn.1999.81.5.2191; FISCHER B, 1981, EXP BRAIN RES, V44, P129; Harper NS, 2004, NATURE, V430, P682, DOI 10.1038/nature02768; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1230; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P799, DOI 10.1152/jn.1989.61.4.799; HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794; KNUDSEN EI, 1995, J NEUROSCI, V15, P5139; Knudsen EI, 1996, NATURE, V383, P428, DOI 10.1038/383428a0; KNUDSEN EI, 1982, J NEUROSCI, V2, P1177; Knudsen EI, 1996, EXP BRAIN RES, V108, P23; McAdams CJ, 1999, J NEUROSCI, V19, P431, DOI 10.1523/JNEUROSCI.19-01-00431.1999; Miller GL, 1999, J NEUROSCI, V19, P2326; Moore T, 2004, J NEUROPHYSIOL, V91, P152, DOI 10.1152/jn.00741.2002; Moore T, 2003, NEURON, V40, P671, DOI 10.1016/S0896-6273(03)00716-5; Moore T, 1998, P NATL ACAD SCI USA, V95, P8981, DOI 10.1073/pnas.95.15.8981; Moore T, 2003, NATURE, V421, P370, DOI 10.1038/nature01341; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; Muller JR, 2005, P NATL ACAD SCI USA, V102, P524, DOI 10.1073/pnas.0408311101; OLSEN JF, 1989, J NEUROSCI, V9, P2591; Reynolds JH, 2004, ANNU REV NEUROSCI, V27, P611, DOI 10.1146/annurev.neuro.26.041002.131039; RIZZOLATTI G, 1987, NEUROPSYCHOLOGIA, V25, P31, DOI 10.1016/0028-3932(87)90041-8; Rorden C, 1999, NEUROPSYCHOLOGIA, V37, P357, DOI 10.1016/S0028-3932(98)00072-4; SHEPHERD M, 1986, Q J EXP PSYCHOL-A, V38, P475, DOI 10.1080/14640748608401609; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; STANTON GB, 1988, J COMP NEUROL, V271, P493, DOI 10.1002/cne.902710403; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0	30	79	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					336	339		10.1038/nature04411	http://dx.doi.org/10.1038/nature04411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421572	Green Accepted			2022-12-28	WOS:000234682100045
J	Napolitano, C; Priori, SG; Schwartz, PJ; Bloise, R; Ronchetti, E; Nastoli, J; Bottelli, G; Cerrone, M; Leonardi, S				Napolitano, C; Priori, SG; Schwartz, PJ; Bloise, R; Ronchetti, E; Nastoli, J; Bottelli, G; Cerrone, M; Leonardi, S			Genetic testing in the long QT syndrome - Development and validation of an efficient approach to genotyping in clinical practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPOUND MUTATIONS; CHANNEL; ARRHYTHMIA; DISEASE; EVENTS; DEATH; RISK	Context In long QT syndrome (LQTS), disease severity and response to therapy vary according to the genetic loci. There exists a critical need to devise strategies to expedite genetic analysis. Objective To perform genetic screening inpatients with LQTS to determine the yield of genetic testing, as well as the type and the prevalence of mutations. Design, Patients, and Setting We investigated whether the detection of a set of frequently mutated codons in the KCNQ1, KCNH2, and SCN5A genes may translate in a novel strategy for rapid efficient genetic testing of 430 consecutive patients referred to our center between June 1996 and June 2004. The entire coding regions of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 were screened by denaturing high-performance liquid chromatography and DNA sequencing. The frequency and the type of mutations were defined to identify a set of recurring mutations. A separate cohort of 75 consecutive probands was used as a validation group to quantify prospectively the prevalence of the recurring mutations identified in the primary LQTS population. Main Outcome Measures Development of a novel approach to LQTS genotyping. Results We identified 235 different mutations, 138 of which were novel, in 310 (72%) of 430 probands (49% KCNQ1, 39% KCNH2, 10% SCN5A, 1.7% KCNE1, and 0.7% KCNE2). Fifty-eight percent of probands carried nonprivate mutations in 64 codons of KCNQ1, KCNH2, and SCN5A genes. A similar occurrence of mutations at these codons (52%) was confirmed in the prospective cohort of 75 probands and in previously published LQTS cohorts. Conclusions We have developed an approach to improve the efficiency of genetic screening for LQTS. This novel method may facilitate wider access to genotyping resulting in better risk stratification and treatment of LQTS patients.	Univ Pavia, Maugeri Fdn, I-27100 Pavia, Italy; Univ Pavia, Dept Cardiol, I-27100 Pavia, Italy; IRCCS Policlin S Matteo, Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; University of Pavia; IRCCS Fondazione San Matteo	Priori, SG (corresponding author), Univ Pavia, Maugeri Fdn, Via Ferrata 8, I-27100 Pavia, Italy.	spriori@fsm.it	Priori, Silvia G/ABH-6894-2020; napolitano, carlo/ABI-4608-2020; Leonardi, Sergio/AAK-1490-2020; Leonardi, Sergio/K-4334-2018; Napolitano, Carlo/K-4760-2016; Schwartz, Peter J/J-4267-2016; bloise, raffaella/AAC-2922-2020; Priori, Silvia G G/A-6116-2014	Priori, Silvia G/0000-0001-6877-0288; napolitano, carlo/0000-0002-7643-4628; Leonardi, Sergio/0000-0002-4800-6132; Leonardi, Sergio/0000-0002-4800-6132; Napolitano, Carlo/0000-0002-7643-4628; Schwartz, Peter J/0000-0003-0367-1048; bloise, raffaella/0000-0003-3485-9596; Priori, Silvia G G/0000-0001-6877-0288; Cerrone, Marina/0000-0002-6122-9939; ronchetti, elena/0000-0002-9185-7848; Nastoli, janni/0000-0002-5888-5951	NHLBI NIH HHS [HL68880] Funding Source: Medline; Telethon [GGP04066, GP0227Y01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonarakis SE, 1998, HUM MUTAT, V11, P1; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Moss AJ, 2002, CIRCULATION, V105, P794, DOI 10.1161/hc0702.105124; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Priori SG, 2004, JAMA-J AM MED ASSOC, V292, P1341, DOI 10.1001/jama.292.11.1341; Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147; Priori SG, 1998, CIRCULATION, V97, P2420, DOI 10.1161/01.CIR.97.24.2420; PRIORI SG, 2003, CARDIAC ELECTROPHYSI, P462; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; Schwartz PJ, 2001, CIRCULATION, V103, P89; Schwartz PJ, 2003, J CARDIOVASC ELECTR, V14, P1120, DOI 10.1046/j.1540-8167.2003.03339.x; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Tester DJ, 2005, HEART RHYTHM, V2, P507, DOI 10.1016/j.hrthm.2005.01.020; WARD O C, 1964, J Ir Med Assoc, V54, P103; Westenskow P, 2004, CIRCULATION, V109, P1834, DOI 10.1161/01.CIR.0000125524.34234.13; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C; Zareba W, 2003, J CARDIOVASC ELECTR, V14, P1149, DOI 10.1046/j.1540-8167.2003.03177.x	21	329	344	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					2975	2980		10.1001/jama.294.23.2975	http://dx.doi.org/10.1001/jama.294.23.2975			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414944	Bronze			2022-12-28	WOS:000234087700023
J	Nieto, P; Pijper, E; Barredo, D; Laurent, G; Olsen, RA; Baerends, EJ; Kroes, GJ; Farias, D				Nieto, P; Pijper, E; Barredo, D; Laurent, G; Olsen, RA; Baerends, EJ; Kroes, GJ; Farias, D			Reactive and nonreactive scattering of H-2 from a metal surface is electronically adiabatic	SCIENCE			English	Article							DISSOCIATIVE CHEMISORPTION; QUANTUM-THEORY; ROTATIONAL-EXCITATION; APPROXIMATION; ENERGY; MOLECULES; PT(111); ADSORPTION; EXCHANGE; DYNAMICS	The Born-Oppenheimer approximation of uncoupled electronic and nuclear motion is a standard tool of the computational chemist. However, its validity for molecule-metal surface reactions, which are important to heterogeneous catalysis, has been questioned because of the possibility of electron-hole pair excitations. We have performed experiments and calculations on the scattering of molecular hydrogen from a catalytically relevant metal surface, obtaining absolute probabilities for changes in the molecule's velocity parallel to the representative Pt(111) surface. The comparison for in-plane and out-of-plane scattering and results for dissociative chemisorption in the same system show that for hydrogen-metal systems, reaction and diffractive scattering can be accurately described using the Born-Oppenheimer approximation.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Free Univ Amsterdam, NL-1081 HV Amsterdam, Netherlands; Univ Autonoma Madrid, Dept Fis Mat Condensada C3, E-28049 Madrid, Spain; Univ Autonoma Madrid, Inst Nicolas Cabrera, E-28049 Madrid, Spain	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Autonomous University of Madrid; Autonomous University of Madrid	Kroes, GJ (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, POB 9502, NL-2300 RA Leiden, Netherlands.	g.j.kroes@chem.leidenuniv.nl	Farias, Daniel/L-2435-2013; Barredo, Daniel/D-3561-2015; Nieto, Pablo/E-7711-2013; Baerends, Evert Jan/F-7206-2011	Farias, Daniel/0000-0002-8537-8074; Barredo, Daniel/0000-0001-5307-1927; Nieto, Pablo/0000-0003-4789-9538; Baerends, Evert Jan/0000-0002-3045-4906				Alexander MH, 2002, SCIENCE, V296, P715, DOI 10.1126/science.1070472; Althorpe SC, 2002, NATURE, V416, P67, DOI 10.1038/416067a; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Born M, 1927, ANN PHYS-BERLIN, V84, P0457; Busnengo HF, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127601; Chorkendorff I., 2003, CONCEPTS MODERN CATA; Cizek M, 1998, J PHYS B-AT MOL OPT, V31, P2571, DOI 10.1088/0953-4075/31/11/018; COWIN JP, 1983, J CHEM PHYS, V79, P3537, DOI 10.1063/1.446208; DARLING GR, 1994, SURF SCI, V304, pL461, DOI 10.1016/0039-6028(94)91328-5; Darling GR, 1995, REP PROG PHYS, V58, P1595, DOI 10.1088/0034-4885/58/12/001; Farias D, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.246104; Farias D, 1998, REP PROG PHYS, V61, P1575, DOI 10.1088/0034-4885/61/12/001; Gergen B, 2001, SCIENCE, V294, P2521, DOI 10.1126/science.1066134; Gruning M, 2004, J PHYS CHEM A, V108, P4459, DOI 10.1021/jp031227u; Hammer B, 1999, PHYS REV B, V59, P7413, DOI 10.1103/PhysRevB.59.7413; Harich SA, 2002, NATURE, V419, P281, DOI 10.1038/nature01068; Huang Y, 2000, PHYS REV LETT, V84, P2985, DOI 10.1103/PhysRevLett.84.2985; Huang YH, 2000, SCIENCE, V290, P111, DOI 10.1126/science.290.5489.111; Kohguchi H, 2001, SCIENCE, V294, P832, DOI 10.1126/science.1063774; Kroes GJ, 2002, ACCOUNTS CHEM RES, V35, P193, DOI 10.1021/ar010104u; LUNTZ AC, 1990, J CHEM PHYS, V93, P5240, DOI 10.1063/1.459669; Luntz AC, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2000249; NORSKOV JK, 1981, J VAC SCI TECHNOL, V18, P420, DOI 10.1116/1.570802; Olsen RA, 2002, J CHEM PHYS, V116, P3841, DOI 10.1063/1.1446852; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; Pijper E, 2002, J CHEM PHYS, V117, P5885, DOI 10.1063/1.1501121; Truhlar DG, 1996, J PHYS CHEM-US, V100, P12771, DOI 10.1021/jp953748q; Vincent JK, 2004, SURF SCI, V573, P433, DOI 10.1016/j.susc.2004.10.010; Watts E, 1999, J CHEM PHYS, V111, P9791, DOI 10.1063/1.480315; White JD, 2005, NATURE, V433, P503, DOI 10.1038/nature03213	32	165	166	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	2006	312	5770					86	89		10.1126/science.1123057	http://dx.doi.org/10.1126/science.1123057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	029SJ	16469880				2022-12-28	WOS:000236584400035
J	Batty, GD; Der, G; Macintyre, S; Deary, L				Batty, GD; Der, G; Macintyre, S; Deary, L			Does IQ explain socioeconomic inequalities in health? Evidence from a population based cohort study in the west of Scotland	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MENTAL SURVEY 1932; COGNITIVE FUNCTION; CHILDHOOD IQ; SOCIAL-CLASS; EARLY-LIFE; INTELLIGENCE; MORTALITY; RISK; ASSOCIATION; POSITION	Objective To test the hypothesis that IQ is a fundamental cause of socioeconomic inequalities in health. Design Cross sectional and prospective cohort study, in which indicators of IQ were assessed by written test and socioeconomic position by self report. Setting West of Scotland. Participants 1347 people (739 women) aged 56 in 1987. Main outcome measures Total mortality and coronary heart disease mortality (ascertained between 1987 and 2004); respiratory function, self reported minor psychiatric morbidity, long term illness, and self perceived health (all assessed in 1988). Results In sex adjusted analyses, indices of socioeconomic position (childhood and current social class, education, income, and area deprivation) were significantly associated with each health outcome. Thus the greatest risk of ill health and mortality was evident in the most socioeconomically disadvantaged groups, as expected. After adjustment for IQ a marked attenuation in risk occurred for poor mental health (range of attenuation in risk ratio across the five socioeconomic indicators: 15-58%), long term illness (25-53%), poor self perceived health (41-56% respiratory function (44-66%), coronary heart disease mortality (31-111% and total mortality (45-131%). Despite the clear reduction in the magnitude of these effects after controlling for IQ in half of the associations examined the risk of I'll health in socioeconomically disadvantaged people was still at least twice that of advantaged people. Statistical significance was lost for only 5/25 separate socioeconomic health gradients that showed significant relations in sex adjusted analyses. Conclusions Scores from the IQ test used here did not completely explain the socioeconomic gradients in health. However, controlling for IQ did lead to a marked reduction in the magnitude of these gradients. Further exploration of the currently scant information about IQ socioeconomic position, and health is needed.	Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of Edinburgh	Batty, GD (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	david-b@msoc.mrc.gla.ac.uk	Macintyre, Sally/P-6246-2014; Deary, Ian J/C-6297-2009; Batty, GD/Y-4401-2018	Deary, Ian J/0000-0002-1733-263X; Batty, GD/0000-0003-1822-5753; Der, Geoff/0000-0002-8677-073X	Medical Research Council [MC_U130059821] Funding Source: Medline; Wellcome Trust [071954/Z/03/Z] Funding Source: Medline; MRC [MC_U130059821] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Acheson D., 1998, INDEPENDENT INQUIRY; ACHESON D, 1909, INDEPENDENT INQUIRY; Awad N, 2004, J CLIN EXP NEUROPSYC, V26, P1044, DOI 10.1080/13803390490514875; Batty GD, 2005, PAEDIATR PERINAT EP, V19, P452, DOI 10.1111/j.1365-3016.2005.00671.x; Batty GD, 2005, BRIT J PSYCHIAT, V187, P180, DOI 10.1192/bjp.187.2.180; Batty GD, 2004, BMJ-BRIT MED J, V329, P585, DOI 10.1136/bmj.329.7466.585; Black D, 1980, INEQUALITIES HLTH RE; Bosma H, 1999, BRIT MED J, V319, P1469, DOI 10.1136/bmj.319.7223.1469; CARSTAINS A, 1991, DEPRIVATION HLTH SCO; CARSTAIRS A, 1991, DEPRIVATION HLTH SCO; Chief Medical Officer, 2005, HLTH SCOTL 2004; COX DR, 1972, J R STAT SOC B, V34, P187; Deary IJ, 2005, PSYCHOL SCI, V16, P64, DOI 10.1111/j.0956-7976.2005.00781.x; Deary IJ, 2001, INTELLIGENCE, V29, P389, DOI 10.1016/S0160-2896(01)00062-9; Department of Health, 2004, CHOOS HLTH MAK HLTH; Der G., 1998, COMP W SCOTLAND 20 0; FORD G, 1994, SOC SCI MED, V39, P1037, DOI 10.1016/0277-9536(94)90375-1; GOLDBERG D, 2004, DETECTION PSYCHIAT I; Gordon D, 1999, INEQUALITIES HLTH; Gottfredson LS, 2004, J PERS SOC PSYCHOL, V86, P174, DOI 10.1037/0022-3514.86.1.174; Hart CL, 2003, PSYCHOSOM MED, V65, P877, DOI 10.1097/01.PSY.0000088584.82822.86; Heim A., 1970, MANUAL AH4 GROUP TES; KELMAN HR, 1994, AM J PUBLIC HEALTH, V84, P1255, DOI 10.2105/AJPH.84.8.1255; MACINTYRE S, 1989, READINGS NEW PUBLIC; Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1; Mackintosh Nicholas J., 2011, IQ HUMAN INTELLIGENC; Manolio TA, 2003, CURR HYPERTENS REP, V5, P255, DOI 10.1007/s11906-003-0029-6; Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3; MARMOT MG, 1984, LANCET, V1, P1003; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; *OFF POP CENS SURV, 1990, GEN HOUS SURV 1988; Office of Population Censuses and Surveys, 1980, CLASS OCC 1980; Osler M, 2003, J EPIDEMIOL COMMUN H, V57, P681, DOI 10.1136/jech.57.9.681; OTOOLE BI, 1992, PERS INDIV DIFFER, V13, P699, DOI 10.1016/0191-8869(92)90241-G; Pavlik VN, 2003, AM J EPIDEMIOL, V157, P327, DOI 10.1093/aje/kwf209; Rabbitt P, 2001, NEUROPSYCHOLOGIA, V39, P532, DOI 10.1016/S0028-3932(00)00099-3; *SAS I, 1999, SAS STATA US GUID VE; Singh-Manoux A, 2005, AM J EPIDEMIOL, V161, P831, DOI 10.1093/aje/kwi109; Taylor MD, 2003, J EPIDEMIOL COMMUN H, V57, P464, DOI 10.1136/jech.57.6.464; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; WEST P, 1994, SCOT MED J, V39, P101, DOI 10.1177/003693309403900403; Whalley LJ, 2001, BRIT MED J, V322, P819, DOI 10.1136/bmj.322.7290.819; Wilkinson RG, 2003, SOCIAL DETERMINANTS	44	116	118	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					580	583		10.1136/bmj.38723.660637.AE	http://dx.doi.org/10.1136/bmj.38723.660637.AE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	026CN	16452104	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000236314400016
J	Lund, T; Labriola, M; Christensen, KB; Bultmann, U; Villadsen, E				Lund, T; Labriola, M; Christensen, KB; Bultmann, U; Villadsen, E			Physical work environment risk factors for long term sickness absence: prospective findings among a cohort of 5357 employees in Denmark	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SELF-REPORTED AFFECT; METHOD VARIANCE; ASSOCIATIONS; PERCEPTIONS; DISABILITY; ARTIFACT; SYMPTOMS; INCREASE; SWEDEN; LEAVE	Objectives To examine the effects of physical work environment on long term sickness absence and to investigate interaction between physical and psychosocial risk factors. Design and setting Prospective cohort Study of long term sickness absence among employees in Denmark. Participants 5357 employees interviewed in 2000 about their physical work environment and various covariates were followed for 18 months in a national sickness absence register. Outcome measurements Cox regression analysis vas performed to assess risk estimates for physical risk factors in the work environment and onset of long term sickness absence, defined as receiving sickness absence compensation for eight consecutive weeks or more. Results 348 participants (6.9%) developed long term sickness absence during follow-up. Of these, 194 (55.7%) were women and 154 (44.3%) were men. For both female and male employees, risk of onset of long term sickness absence was increased by extreme bending or twisting of the neck or back, working mainly standing or squatting, lifting or carrying loads, and pushing or pulling loads. Significant interactions were found for three combinations of physical and psychosocial work environment risk factors among female employees (P < 0.05). Conclusion Uncomfortable working positions, lifting or carrying loads, and pushing or pulling loads increased the risk of onset of long term sickness absence. The study shows a potential for reducing long term sickness absence through modifying work postures straining the neck and back, reducing the risk of work done standing or walking, and reducing the risk associated with handling loads. Dealing with psychosocial stressors simultaneously may improve physical intervention efforts further for female employees.	Natl Inst Occupat Hlth, DK-2100 Copenhagen, Denmark		Lund, T (corresponding author), Natl Inst Occupat Hlth, Lerso Pk Alle 105, DK-2100 Copenhagen, Denmark.	tl@ami.dk	Christensen, Karl Bang/I-2650-2019	Christensen, Karl Bang/0000-0003-4518-5187; Bultmann, Ute/0000-0001-9589-9220				Alexanderson K, 2004, SCAND J PUBLIC HEALT, V32, P256, DOI 10.1080/14034950410021925; Alexanderson K, 2004, SCAND J PUBLIC HEALT, V32, P321, DOI 10.1080/14034940410019253; Allebeck P, 2004, SCAND J PUBLIC HEALT, V32, P49, DOI 10.1080/14034950410021853; Blank N, 1995, SCAND J SOC MED, V23, P265, DOI 10.1177/140349489502300408; Boedeker W, 2001, J OCCUP ENVIRON MED, V43, P1081; Burr H, 2003, SCAND J WORK ENV HEA, V29, P270, DOI 10.5271/sjweh.731; Devereux JJ, 2002, OCCUP ENVIRON MED, V59, P269, DOI 10.1136/oem.59.4.269; Henderson M, 2005, BMJ-BRIT MED J, V330, P802, DOI 10.1136/bmj.330.7495.802; Hoogendoorn WE, 2002, OCCUP ENVIRON MED, V59, P323, DOI 10.1136/oem.59.5.323; HOUTMAN ILD, 1994, SCAND J WORK ENV HEA, V20, P139, DOI 10.5271/sjweh.1419; Krause N, 2001, AM J IND MED, V40, P464, DOI 10.1002/ajim.1116; KRAUSE N, 2004, PSYCHOL WORKPLACE SA; Lund T, 2005, J OCCUP ENVIRON MED, V47, P1141, DOI 10.1097/01.jom.0000174301.80318.f2; Lund T, 2003, AM J IND MED, V44, P492, DOI 10.1002/ajim.10298; SPECTOR PE, 1987, J APPL PSYCHOL, V72, P438, DOI 10.1037/0021-9010.72.3.438; Trinkoff AM, 2001, J OCCUP ENVIRON MED, V43, P355, DOI 10.1097/00043764-200104000-00012; Vaananen A, 2003, SOC SCI MED, V57, P807, DOI 10.1016/S0277-9536(02)00450-1; Vahtera T, 2000, J EPIDEMIOL COMMUN H, V54, P484, DOI 10.1136/jech.54.7.484; Voss M, 2001, OCCUP ENVIRON MED, V58, P178, DOI 10.1136/oem.58.3.178; WILLIAMS LJ, 1989, J APPL PSYCHOL, V74, P462, DOI 10.1037/0021-9010.74.3.462	20	177	181	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	2006	332	7539					449	451		10.1136/bmj.38731.622975.3A	http://dx.doi.org/10.1136/bmj.38731.622975.3A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	018VM	16446280	Bronze, Green Published			2022-12-28	WOS:000235792900014
J	Griffiths, S; Sharp, R; Foote, TN; Bertin, I; Wanous, M; Reader, S; Colas, I; Moore, G				Griffiths, S; Sharp, R; Foote, TN; Bertin, I; Wanous, M; Reader, S; Colas, I; Moore, G			Molecular characterization of Ph1 as a major chromosome pairing locus in polyploid wheat	NATURE			English	Article							TRITICUM-AESTIVUM; HEXAPLOID WHEAT; GENETIC CONTROL; COMMON WHEAT; BAC LIBRARY; CONSTRUCTION; TURGIDUM; HOMOLOG; GENOMES	The foundation of western civilization owes much to the high fertility of bread wheat, which results from the stability of its polyploid genome. Despite possessing multiple sets of related chromosomes, hexaploid ( bread) and tetraploid ( pasta) wheat both behave as diploids at meiosis. Correct pairing of homologous chromosomes is controlled by the Ph1 locus(1). In wheat hybrids, Ph1 prevents pairing between related chromosomes(2). Lack of Ph1 activity in diploid relatives of wheat suggests that Ph1 arose on polyploidization(3). Absence of phenotypic variation, apart from dosage effects, and the failure of ethylmethane sulphonate treatment to yield mutants, indicates that Ph1 has a complex structure(4,5). Here we have localized Ph1 to a 2.5-megabase interstitial region of wheat chromosome 5B containing a structure consisting of a segment of subtelomeric heterochromatin that inserted into a cluster of cdc2-related genes after polyploidization. The correlation of the presence of this structure with Ph1 activity in related species, and the involvement of heterochromatin with Ph1 (ref. 6) and cdc2 genes with meiosis, makes the structure a good candidate for the Ph1 locus.	Augustana Coll, Sioux Falls, SD 57197 USA; John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Moore, G (corresponding author), John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England.	graham.moore@bbsrc.ac.uk	Colas, Isabelle/AAG-1908-2021	Colas, Isabelle/0000-0001-6980-9906				Allouis S, 2003, CEREAL RES COMMUN, V31, P331; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bass HW, 2000, J CELL SCI, V113, P1033; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; Cenci A, 2003, THEOR APPL GENET, V107, P931, DOI 10.1007/s00122-003-1331-z; CHAPMAN V, 1970, NATURE, V226, P376, DOI 10.1038/226376a0; DOVER GA, 1972, NATURE, V240, P159, DOI 10.1038/240159a0; Dunford RP, 2005, THEOR APPL GENET, V110, P925, DOI 10.1007/s00122-004-1912-5; Endo TR, 1996, J HERED, V87, P295, DOI 10.1093/oxfordjournals.jhered.a023003; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Foote T, 1997, GENETICS, V147, P801; Foote Trade N., 2004, Functional & Integrative Genomics, V4, P26, DOI 10.1007/s10142-003-0101-y; Giorgi B., 1978, Mutation Breeding Newsletter, P4; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; KURATA N, 1994, BIO-TECHNOL, V12, P276, DOI 10.1038/nbt0394-276; Martinez M, 2001, THEOR APPL GENET, V102, P751, DOI 10.1007/s001220051706; Martinez-Perez E, 2001, NATURE, V411, P204, DOI 10.1038/35075597; MOORE G, 1993, BIO-TECHNOL, V11, P584, DOI 10.1038/nbt0593-584; Paterson AH, 2004, P NATL ACAD SCI USA, V101, P9903, DOI 10.1073/pnas.0307901101; Prieto P, 2004, NAT CELL BIOL, V6, P906, DOI 10.1038/ncb1168; Rao P. S., 1968, WHEAT INFORM SERV, V26, P6; RILEY R, 1959, NATURE, V183, P1244, DOI 10.1038/1831244a0; RILEY R, 1958, NATURE, V182, P713, DOI 10.1038/182713a0; Roberts MA, 1999, GENETICS, V153, P1909; Sasaki T, 2005, PLANT CELL PHYSIOL, V46, P3, DOI 10.1093/pcp/pci503; Schlueter SD, 2003, NUCLEIC ACIDS RES, V31, P3597, DOI 10.1093/nar/gkg533; SEARS ER, 1977, CAN J GENET CYTOL, V19, P585, DOI 10.1139/g77-063; WALL AM, 1971, GENET RES, V18, P329, DOI 10.1017/S0016672300012726	29	333	368	1	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					749	752		10.1038/nature04434	http://dx.doi.org/10.1038/nature04434			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467840				2022-12-28	WOS:000235193100050
J	England, H; Weinberg, PS; Estes, NAM				England, H; Weinberg, PS; Estes, NAM			The automated external defibrillator - Clinical benefits and legal liability	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PUBLIC-ACCESS DEFIBRILLATION; HEART-ASSOCIATION REPORT; SUDDEN CARDIAC-ARREST; COST-EFFECTIVENESS; SURVIVAL; DEPLOYMENT; MORTALITY; PROVIDERS; SCHOOLS		Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Estes, NAM (corresponding author), Tufts Univ New England Med Ctr, POB 197,750 Washington St, Boston, MA 02111 USA.	nestes@tufts-nemc.org						American Heart Association, AED PROGR Q A; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; Balady GJ, 2002, CIRCULATION, V105, P1147, DOI 10.1161/hc0902.105998; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Capucci A, 2002, CIRCULATION, V106, P1065, DOI 10.1161/01.CIR.0000028148.62305.69; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P123; Cobb LA, 2002, JAMA-J AM MED ASSOC, V288, P3008, DOI 10.1001/jama.288.23.3008; Cram P, 2003, J GEN INTERN MED, V18, P745, DOI 10.1046/j.1525-1497.2003.21139.x; *DEP HLTH HUM SERV, GUID PUBL ACC DEF PR; England H, 2005, AM J CARDIOL, V95, P1484, DOI 10.1016/j.amjcard.2005.02.020; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; *HARTF, HARTF LOSS CONTR TIP; Hazinski MF, 2004, CIRCULATION, V109, P278, DOI 10.1161/01.CIR.0000109486.45545.AD; Helmandollar B T, 2001, Nephrol Nurs J, V28, P571; Jermyn B D, 2000, Prehosp Emerg Care, V4, P43, DOI 10.1080/10903120090941632; Lazar R A, 1997, JEMS, V22, pS21; LAZAR RA, 2002, JEMS S6, V27; Mancini M E, 1998, Am J Crit Care, V7, P314; Marenco JP, 2001, JAMA-J AM MED ASSOC, V285, P1193, DOI 10.1001/jama.285.9.1193; Myerburg RJ, 2003, J INTERV CARD ELECTR, V9, P189, DOI 10.1023/A:1026284407435; Myerburg RJ, 2002, CIRCULATION, V106, P1058, DOI 10.1161/01.CIR.0000028147.92190.A7; *NAT C STAT LEG, HLTH CAR PROGR STAT; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Nichol G, 2003, CIRCULATION, V108, P697, DOI 10.1161/01.CIR.0000084545.65645.28; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; Nichol G, 1998, CIRCULATION, V97, P1315, DOI 10.1161/01.CIR.97.13.1315; *OCC SAF HLTH ADM, 2001, OSHA PUBL, V3174; *OCC SAF HLTH ADM, 2003, OSHA PUBL, V3185; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; *US FDA, AUT EXT DEF AEDS PUB; *US FOOD DRUG ADM, ADV PAT OTC DEF PAT; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; WATTS DD, 1995, ANN EMERG MED, V26, P635, DOI 10.1016/S0196-0644(95)70017-X; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; 2003, FED REG, V68, P60342	41	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					687	690		10.1001/jama.295.6.687	http://dx.doi.org/10.1001/jama.295.6.687			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467238				2022-12-28	WOS:000235168200029
J	Peters, JL; Sutton, AJ; Jones, DR; Abrams, KR; Rushton, L				Peters, JL; Sutton, AJ; Jones, DR; Abrams, KR; Rushton, L			Comparison of two methods to detect publication bias in meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STATISTICAL TESTS; HETEROGENEITY; FILL; TRIM	Context Egger's regression test is often used to help detect publication bias in meta-analyses. However, the performance of this test and the usual funnel plot have been challenged particularly when the summary estimate is the natural log of the odds ratio (lnOR). Objective To compare the performance of Egger's regression test with a regression test based on sample size (a modification of Macaskill's test) with lnOR as the summary estimate. Design Simulation of meta-analyses under a number of scenarios in the presence and absence of publication bias and between-study heterogeneity. Main Outcome Measures Type I error rates (the proportion of false-positive results) for each regression test and their power to detect publication bias when it is present (the proportion of true-positive results). Results Type I error rates for Egger's regression test are higher than those for the alternative regression test. The alternative regression test has the appropriate type I error rates regardless of the size of the underlying OR, the number of primary studies in the meta-analysis, and the level of between-study heterogeneity. The alternative regression test has comparable power to Egger's regression test to detect publication bias under conditions of low between-study heterogeneity. Conclusion Because of appropriate type I error rates and reduction in the correlation between the lnOR and its variance, the alternative regression test can be used in place of Egger's regression test when the summary estimates are lnORs.	Univ Leicester, Dept Hlth Sci, Ctr Biostat & Genet Epidemiol, Leicester LE1 6TP, Leics, England; MRC, Inst Environm & Hlth, Leicester, Leics, England	University of Leicester; University of Leicester	Peters, JL (corresponding author), Univ Leicester, Dept Hlth Sci, Ctr Biostat & Genet Epidemiol, 22-28 Princess Rd W, Leicester LE1 6TP, Leics, England.	jlp9@leicester.ac.uk	Abrams, Keith/AAA-2557-2020	Sutton, Alexander/0000-0002-8934-9940; Abrams, Keith/0000-0002-7557-1567				[Anonymous], 2004, STAT STAT SOFTW REL; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Borenstein M., 1999, COMPREHENSIVE META A; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Engels EA, 2000, STAT MED, V19, P1707, DOI 10.1002/1097-0258(20000715)19:13<1707::AID-SIM491>3.0.CO;2-P; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Hedges LV, 1996, J EDUC BEHAV STAT, V21, P299, DOI 10.2307/1165338; Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; IRWIG L, 1991, JAMA-J AM MED ASSOC, V266, P1678, DOI 10.1001/jama.266.12.1678; Irwig L, 1998, BRIT MED J, V316, P470; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; PETERS JL, 2004, 0402 U LEIC DEP HLTH; PETES JL, 2005, PERFORMANCE TESTS AD; Rosenberg M.S., 1999, Q REV BIOL, V73, P126, DOI [10.1086/420179, DOI 10.1086/420179]; Schwarzer G, 2002, STAT MED, V21, P2465, DOI 10.1002/sim.1224; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; Slavin Robert E., 1986, EDUC RESEARCHER, V15, P5, DOI [10.3102/0013189X015009005, DOI 10.3102/0013189X015009005]; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Sutton AJAK, 2000, METHODS METAANALYSIS; Villar J, 2001, STAT MED, V20, P3635, DOI 10.1002/sim.1096; STATSDIRECT STAT SOF	26	1404	1434	7	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					676	680		10.1001/jama.295.6.676	http://dx.doi.org/10.1001/jama.295.6.676			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467236	Bronze			2022-12-28	WOS:000235168200027
J	Huff, JHK; Usmani, OS				Huff, JHK; Usmani, OS			Intra-cavity right ventricular metastasis	LANCET			English	Editorial Material									St Thomas Hosp, Dept Resp Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Huff, JHK (corresponding author), St Thomas Hosp, Dept Resp Med, London SE1 7EH, England.	jiminio@doctors.org.uk							0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					424	424		10.1016/S0140-6736(06)68142-7	http://dx.doi.org/10.1016/S0140-6736(06)68142-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458768				2022-12-28	WOS:000235139400033
J	Austin, DW; Allen, MS; McCollum, JM; Dar, RD; Wilgus, JR; Sayler, GS; Samatova, NF; Cox, CD; Simpson, ML				Austin, DW; Allen, MS; McCollum, JM; Dar, RD; Wilgus, JR; Sayler, GS; Samatova, NF; Cox, CD; Simpson, ML			Gene network shaping of inherent noise spectra	NATURE			English	Article							EXACT STOCHASTIC SIMULATION; TRANSCRIPTIONAL REGULATION; ESCHERICHIA-COLI; SINGLE-CELL; EXPRESSION	Recent work demonstrates that stochastic fluctuations in molecular populations have consequences for gene regulation(1-10). Previous experiments focused on noise sources or noise propagation through gene networks by measuring noise magnitudes. However, in theoretical analysis, we showed that noise frequency content is determined by the underlying gene circuits, leading to a mapping between gene circuit structure and the noise frequency range(11,12). An intriguing prediction from our previous studies was that negative autoregulation shifts noise to higher frequencies where it is more easily filtered out by gene networks(11) - a property that may contribute to the prevalence of autoregulation motifs ( for example, found in the regulation of similar to 40% of Escherichia coli genes). Here we measure noise frequency content in growing cultures of E. coli, and verify the link between gene circuit structure and noise spectra by demonstrating the negative autoregulation-mediated spectral shift. We further demonstrate that noise spectral measurements provide mechanistic insights into gene regulation, as perturbations of gene circuit parameters are discernible in the measured noise frequency ranges. These results suggest that noise spectral measurements could facilitate the discovery of novel regulatory relationships.	Oak Ridge Natl Lab, Mol Scale Engn & Nanoscale Technol Grp, Oak Ridge, TN 37831 USA; Oak Ridge Natl Lab, Div Math & Comp Sci, Oak Ridge, TN 37831 USA; Univ Tennessee, Knoxville, TN 37996 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	Simpson, ML (corresponding author), Oak Ridge Natl Lab, Mol Scale Engn & Nanoscale Technol Grp, Bethel Valley Rd, Oak Ridge, TN 37831 USA.	simpsonML1@ornl.gov	Cox, Chris D/A-9451-2013; Simpson, Michael/A-8410-2011	Cox, Chris D/0000-0001-9818-5477; Simpson, Michael/0000-0002-3933-3457; Allen, Michael/0000-0003-2293-8078; Dar, Roy/0000-0002-6006-4888				Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Arkin A, 1998, GENETICS, V149, P1633; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; BENDAT JS, 2000, DATA ANAL MEASUREMEN; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Cox Chris D., 2003, OMICS A Journal of Integrative Biology, V7, P317, DOI 10.1089/153623103322452422; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Gibson MA, 2000, J PHYS CHEM A, V104, P1876, DOI 10.1021/jp993732q; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Simpson ML, 2004, J THEOR BIOL, V229, P383, DOI 10.1016/j.jtbi.2004.04.017; Simpson ML, 2003, P NATL ACAD SCI USA, V100, P4551, DOI 10.1073/pnas.0736140100; Swain PS, 2002, P NATL ACAD SCI USA, V99, P12795, DOI 10.1073/pnas.162041399; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523	25	215	219	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					608	611		10.1038/nature04194	http://dx.doi.org/10.1038/nature04194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452980				2022-12-28	WOS:000235033900045
J	Heller, RC; Marians, KJ				Heller, RC; Marians, KJ			Replication fork reactivation downstream of a blocked nascent leading strand	NATURE			English	Article							ESCHERICHIA-COLI; DNA-REPLICATION; ULTRAVIOLET-LIGHT; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; MAMMALIAN-CELLS; HELICASE; PROTEIN; PRIA; MECHANISM	Unrepaired lesions in the DNA template pose a threat to accurate replication. Several pathways exist in Escherichia coli to reactivate a blocked replication fork. The process of recombination-dependent restart of broken forks is well understood, but the consequence of replication through strand-specific lesions is less well known. Here we show that replication can be restarted and leading-strand synthesis re-initiated downstream of an unrepaired block to leading-strand progression, even when the 3'-OH of the nascent leading strand is unavailable. We demonstrate that the loading by a replication restart system of a single hexamer of the replication fork helicase, DnaB, on the lagging-strand template is sufficient to coordinate priming by the DnaG primase of both the leading and lagging strands. These observations provide a mechanism for damage bypass during fork reactivation, demonstrate how daughter-strand gaps are generated opposite leading-strand lesions during the replication of ultraviolet-light-irradiated DNA, and help to explain the remarkable speed at which even a heavily damaged DNA template is replicated.	Cornell Univ, Weill Grad Sch Med Sci, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Marians, KJ (corresponding author), Cornell Univ, Weill Grad Sch Med Sci, Program Mol Biol, New York, NY 10021 USA.	kmarians@sloankettering.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIDGES BA, 1974, J BACTERIOL, V117, P1077, DOI 10.1128/JB.117.3.1077-1081.1974; BRIDGES BA, 1968, PROC R SOC SER B-BIO, V171, P213, DOI 10.1098/rspb.1968.0065; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; Galletto R, 2003, J MOL BIOL, V329, P441, DOI 10.1016/S0022-2836(03)00435-2; GANESAN AK, 1974, J MOL BIOL, V87, P103, DOI 10.1016/0022-2836(74)90563-4; Grompone G, 2004, MOL MICROBIOL, V52, P551, DOI 10.1111/j.1365-2958.2004.03997.x; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; Heller RC, 2005, MOL CELL, V17, P733, DOI 10.1016/j.molcel.2005.01.019; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; IYER VN, 1971, BIOCHIM BIOPHYS ACTA, V228, P117, DOI 10.1016/0005-2787(71)90551-X; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; McInerney P, 2004, J BIOL CHEM, V279, P21543, DOI 10.1074/jbc.M401649200; MENEGHINI R, 1976, BIOCHIM BIOPHYS ACTA, V425, P419, DOI 10.1016/0005-2787(76)90006-X; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Mitkova AV, 2003, J BIOL CHEM, V278, P52253, DOI 10.1074/jbc.M308956200; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; OGAWA T, 1980, ANNU REV BIOCHEM, V49, P421, DOI 10.1146/annurev.bi.49.070180.002225; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 2000, GENETICS, V155, P487; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Smith KC, 2004, BIOESSAYS, V26, P1322, DOI 10.1002/bies.20109; SWART JR, 1993, J BIOL CHEM, V268, P12970; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WITKIN EM, 1969, ANNU REV MICROBIOL, V23, P487, DOI 10.1146/annurev.mi.23.100169.002415; WU CA, 1992, J BIOL CHEM, V267, P4030; Xu LW, 2000, J BIOL CHEM, V275, P8196, DOI 10.1074/jbc.275.11.8196; Xu LW, 2003, MOL CELL, V11, P817, DOI 10.1016/S1097-2765(03)00061-3	34	249	251	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					557	562		10.1038/nature04329	http://dx.doi.org/10.1038/nature04329			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452972				2022-12-28	WOS:000235033900033
J	Wolfberg, AJ				Wolfberg, AJ			Volunteering overseas - Lessons from surgical brigades	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Dupuis CC, 2004, PLAST RECONSTR SURG, V113, P433, DOI 10.1097/01.PRS.0000097680.73556.A3; Fisher QA, 2001, ANESTHESIOLOGY, V95, P1315, DOI 10.1097/00000542-200112000-00007	2	68	69	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					443	445		10.1056/NEJMp058220	http://dx.doi.org/10.1056/NEJMp058220			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452555				2022-12-28	WOS:000235019400003
J	Blair, PS; Sidebotham, P; Berry, PJ; Evans, M; Fleming, PJ				Blair, PS; Sidebotham, P; Berry, PJ; Evans, M; Fleming, PJ			Major epidemiological changes in sudden infant death syndrome: a 20-year population-based study in the UK	LANCET			English	Article							SLEEP; RISK; ENVIRONMENT; POSITION; SCOTLAND; SIDS	Background Results of case-control studies in the past 5 years suggest that the epidemiology of sudden infant death syndrome (SIDS) has changed since the 1991 UK Back to Sleep campaign. The campaign's advice that parents put babies on their back to sleep led to a fall in death rates. We used a longitudinal dataset to assess these potential changes. Methods Population-based data from home visits have been collected for 369 consecutive unexpected infant deaths (300 SIDS and 69 explained deaths) in Avon over 20 years (1984-2003). Data obtained between 1993 and 1996 from 1300 controls with a chosen "reference" sleep before interview have been used for comparison. Findings Over the past 20 years, the proportion of children who died from SIDS while co-sleeping with their parents, has risen from 12% to 50% (p<0.0001), but the actual number of SIDS deaths in the parental bed has halved (p=0.01). The proportion seems to have increased partly because the Back to Sleep campaign led to fewer deaths in infants sleeping alone-rather than because of a rise in deaths of infants who bed-shared, and partly because of an increase in the number of deaths in infants sleeping with their parents on a sofa. The proportion of deaths in families from deprived socioeconomic backgrounds has risen from 47% to 74% (p=0.003), the prevalence of maternal smoking during pregnancy from 57% to 86% (p=0.0004), and the proportion of pre-term infants from 12% to 34% (p=0.0001). Although many SIDS infants come from large families, first-born infants are now the largest group. The age of infants who bed-share is significantly smaller than that before the campaign, and fewer are breastfed. Interpretation Factors that contribute to SIDS have changed in their importance over the past 20 years. Although the reasons for the rise in deaths when a parent sleeps with their infant on a sofa are still unclear, we strongly recommend that parents avoid this sleeping environment. Most SIDS deaths now occur in deprived families. To better understand contributory factors and plan preventive measures we need control data from similarly deprived families, and particularly, infant sleep environments.	Univ Bristol, Inst Child Life & Hlth, Dept Clin Sci, Bristol BS2 8AE, Avon, England; Univ Bristol, Dept Pathol & Microbiol, Bristol BS2 8AE, Avon, England; Univ Warwick, Dept Child Hlth, Coventry CV4 7AL, W Midlands, England; St Michaels Hosp, Dept Paediat Pathol, Bristol, Avon, England	University of Bristol; University of Bristol; University of Warwick	Fleming, PJ (corresponding author), Univ Bristol, Inst Child Life & Hlth, Dept Clin Sci, UBHT Educ Bldg, Bristol BS2 8AE, Avon, England.	peter.fleming@bris.ac.uk	Sidebotham, Peter D/E-3011-2010; Blair, Peter S/C-1213-2009; Fleming, Peter/O-3231-2019; Fleming, Peter J/A-9081-2010	Sidebotham, Peter D/0000-0003-4891-6926; Fleming, Peter/0000-0003-2521-5764; Fleming, Peter J/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087				Blair P, 2002, CHILD CARE HLTH DEV, V28, P49, DOI 10.1046/j.1365-2214.2002.00014.x; Blair PS, 2004, ARCH DIS CHILD, V89, P1106, DOI 10.1136/adc.2003.038067; Blair PS, 1999, BRIT MED J, V319, P1457, DOI 10.1136/bmj.319.7223.1457; Boyd P., 2003, J HEALTH SERV RES PO, V8, P24, DOI [10.1258/135581903766468846, DOI 10.1258/135581903766468846]; Carpenter RG, 2004, LANCET, V363, P185, DOI 10.1016/S0140-6736(03)15323-8; Daltveit AK, 1997, ARCH DIS CHILD, V77, P23, DOI 10.1136/adc.77.1.23; Fleming P., 2000, SUDDEN UNEXPECTED DE; Fleming Peter J, 2003, Semin Neonatol, V8, P159, DOI 10.1016/S1084-2756(02)00222-1; Fleming PJ, 2004, BMJ-BRIT MED J, V328, P331, DOI 10.1136/bmj.328.7435.331; Fleming PJ, 2003, PAEDIATR PERINAT EP, V17, P272, DOI 10.1046/j.1365-3016.2003.00465.x; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; GILBERT RE, 1992, ARCH DIS CHILD, V67, P272; Goldwater PN, 2003, ARCH DIS CHILD, V88, P1095, DOI 10.1136/adc.88.12.1095; Hauck FR, 2003, PEDIATRICS, V111, P1207; Kennedy H, 2004, SUDDEN UNEXPECTED DE; LEACH CEA, 1999, PEDIATRICS, P104; Limerick SR, 2004, J CLIN PATHOL, V57, P309, DOI 10.1136/jcp.2003.013052; Livesey A, 2005, BRIT MED J, V330, P227, DOI 10.1136/bmj.38323.652523.F7; McGarvey C, 2003, ARCH DIS CHILD, V88, P1058, DOI 10.1136/adc.88.12.1058; *OFF DEP PRIM MIN, 2000 IND LOC DEPR LO; *OFF NAT STAT STAT, HLTH STAT Q WINT 200, P70; Rose M, 1998, PAEDIATR PERINAT EP, V12, P217, DOI 10.1046/j.1365-3016.1998.00089.x; Tappin D, 2004, LANCET, V363, P994, DOI 10.1016/S0140-6736(04)15806-6; Tappin D, 2002, BMJ-BRIT MED J, V325, P1007, DOI 10.1136/bmj.325.7371.1007; WARDPLATT MP, 2005, BMJ-BRIT MED J, V330, P206; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282	27	216	221	0	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					314	319		10.1016/S0140-6736(06)67968-3	http://dx.doi.org/10.1016/S0140-6736(06)67968-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443038				2022-12-28	WOS:000235084600027
J	Moe, OW				Moe, OW			Kidney stones: pathophysiology and medical management	LANCET			English	Review							URIC-ACID NEPHROLITHIASIS; CALCIUM-SENSING RECEPTOR; FAMILIAL IDIOPATHIC HYPERCALCIURIA; STATES VETERAN POPULATION; VERTEBRAL BONE-DENSITY; RENAL-CALCULI; ABSORPTIVE HYPERCALCIURIA; POTASSIUM CITRATE; URINARY CALCIUM; UNITED-STATES	The formation of stones in the urinary tract stems from a wide range of underlying disorders. That clinicians look for the underlying causes for nephrolithiasis is imperative to direct management. There are many advances in genetics, pathophysiology, diagnostic imaging, medical treatment, medical prevention, and surgical intervention of 14 nephrolithiasis. Here, I provide a brief general background and focus mainly on pathophysiology and medical treatment of kidney stones. Although important advances have been made in understanding nephrolithiasis from single gene defects, the understanding of polygenetic causes of kidney stones is still largely elusive. A substantial proportion of data that resulted in new methods of treatment and prevention, which can be empirical or definitive, has focused on urinary luminal chemical composition of the precipitating solutes. Manipulation of inhibitors and epithelial factors is important and needs further investigation. Advances in the management of nephrolithiasis depend on combined efforts of clinicians and scientists to understand the pathophysiology.	Univ Texas, SW Med Ctr, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA.	orson.moe@utsouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048482, P01DK020543] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK-20543, R01-DK48482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate N, 2004, KIDNEY INT, V65, P386, DOI 10.1111/j.1523-1755.2004.00386.x; Alpern RJ, 1997, AM J KIDNEY DIS, V29, P291, DOI 10.1016/S0272-6386(97)90045-7; Amanzadeh J, 2003, KIDNEY INT, V64, P2142, DOI 10.1046/j.1523-1755.2003.00309.x; Asplin JR, 2002, ENDOCRIN METAB CLIN, V31, P927, DOI 10.1016/S0889-8529(02)00030-0; Auge BK, 2002, ENDOCRIN METAB CLIN, V31, P1065, DOI 10.1016/S0889-8529(02)00033-6; Bagley Demetrius H, 2002, Curr Opin Urol, V12, P277, DOI 10.1097/00042307-200207000-00003; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; BICHLER KH, 1985, MONATSSCHR KINDERH, V133, P256; Bilezikian JP, 2005, J INTERN MED, V257, P6, DOI 10.1111/j.1365-2796.2004.01422.x; Borghi L, 1996, J UROLOGY, V155, P839, DOI 10.1016/S0022-5347(01)66321-3; Borghi L, 2002, NEW ENGL J MED, V346, P77, DOI 10.1056/NEJMoa010369; BORGHI L, 1993, J CARDIOVASC PHARM, V22, pS78; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; Breuning M H, 2003, Ned Tijdschr Geneeskd, V147, P245; BRINKLEY LJ, 1990, J UROLOGY, V144, P94, DOI 10.1016/S0022-5347(17)39377-1; Busby JE, 2004, UROL CLIN N AM, V31, P89, DOI 10.1016/S0094-0143(03)00097-1; Cailhier JF, 2001, J UROLOGY, V166, P1484, DOI 10.1016/S0022-5347(05)65816-8; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Cirillo M, 1997, MINER ELECTROL METAB, V23, P265; COE FI, 1991, SEMIN NEPHROL, V11, P98; COE FL, 1977, ANN INTERN MED, V87, P404, DOI 10.7326/0003-4819-87-4-404; COE FL, 1979, NEW ENGL J MED, V300, P337, DOI 10.1056/NEJM197902153000703; COE FL, 1974, NEW ENGL J MED, V291, P1344; COE FL, 2004, BRENNER RECTORS KIDN, P1819; Curhan GC, 2004, ARCH INTERN MED, V164, P885, DOI 10.1001/archinte.164.8.885; Curhan GC, 1998, ANN INTERN MED, V128, P534, DOI 10.7326/0003-4819-128-7-199804010-00003; Curhan GC, 1997, J AM SOC NEPHROL, V8, P1568; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; Danpure CJ, 2005, AM J NEPHROL, V25, P303, DOI 10.1159/000086362; Daudon M, 2005, NEPHROL DIAL TRANSPL, V20, P468, DOI 10.1093/ndt/gfh594; DAUDON M, 1995, UROL RES, V23, P319, DOI 10.1007/BF00300021; Daudon M, 1995, Adv Nephrol Necker Hosp, V24, P167; DELAVEGA LP, NEPHROLITHIASIS META; DENT CE, 1951, Q J MED, V20, P205; Deveci S, 2004, UROLOGY, V64, P237, DOI 10.1016/j.urology.2004.03.029; Ekeruo WO, 2004, J UROLOGY, V172, P159, DOI 10.1097/01.ju.0000128574.50588.97; ENOMOTO A, 2002, NATURE, V742, P1; ETTINGER B, 1988, J UROLOGY, V139, P679, DOI 10.1016/S0022-5347(17)42599-7; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; Ettinger B, 1997, J UROLOGY, V158, P2069, DOI 10.1016/S0022-5347(01)68155-2; Evan AP, 2003, J CLIN INVEST, V111, P607, DOI 10.1172/JCI200317038; Favazza T, 2004, J SPINAL CORD MED, V27, P252, DOI 10.1080/10790268.2004.11753756; Gambaro G, 2004, AM J KIDNEY DIS, V44, P963, DOI 10.1053/j.ajkd.2004.06.030; Gettman MT, 1999, J ENDOUROL, V13, P653, DOI 10.1089/end.1999.13.653; Gianfrancesco F, 2003, AM J HUM GENET, V72, P1479, DOI 10.1086/375628; Gillen DL, 2005, KIDNEY INT, V67, P685, DOI 10.1111/j.1523-1755.2005.67128.x; GROVER PK, 1990, CLIN SCI, V79, P9, DOI 10.1042/cs0790009; Hamm LL, 2002, ENDOCRIN METAB CLIN, V31, P885, DOI 10.1016/S0889-8529(02)00031-2; HARBAR JA, 1986, J UROLOGY, V136, P146, DOI 10.1016/S0022-5347(17)44760-4; Harrington M, 2003, NUTR REV, V61, P179, DOI 10.1301/nr.2003.may.179-183; Harvey J A, 1990, J Lithotr Stone Dis, V2, P124; Heller HJ, 2002, J UROLOGY, V168, P1923, DOI 10.1016/S0022-5347(05)64264-4; Heneghan JP, 2003, RADIOLOGY, V229, P575, DOI 10.1148/radiol.2292021261; HERRING LC, 1962, J UROLOGY, V88, P545, DOI 10.1016/S0022-5347(17)64842-0; Holmes RP, 2001, KIDNEY INT, V59, P270, DOI 10.1046/j.1523-1755.2001.00488.x; Hoppe B, 2003, FRONT BIOSCI-LANDMRK, V8, pE437, DOI 10.2741/1135; Iwai N, 2004, KIDNEY INT, V66, P935, DOI 10.1111/j.1523-1755.2004.00839.x; JAEGER P, 1985, AM J NEPHROL, V5, P40, DOI 10.1159/000166901; Jeha S, 2005, CONTRIB NEPHROL, V147, P69, DOI 10.1159/000082545; JOHNSON CM, 1979, KIDNEY INT, V16, P624, DOI 10.1038/ki.1979.173; Kim SC, 2005, J UROLOGY, V173, P117, DOI 10.1097/01.ju.0000147270.68481.ce; Kim SC, 2003, CURR OPIN UROL, V13, P235, DOI 10.1097/00042307-200305000-00012; Kissen B, 1941, P SOC EXP BIOL MED, V46, P216; Knoll T, 2005, PEDIATR NEPHROL, V20, P19, DOI 10.1007/s00467-004-1663-1; Kok DJ, 2002, ENDOCRIN METAB CLIN, V31, P855, DOI 10.1016/S0889-8529(02)00037-3; Kuo RL, 2003, KIDNEY INT, V64, P2150, DOI 10.1046/j.1523-1755.2003.00316.x; LAERUM E, 1984, ACTA MED SCAND, V215, P383; Lemann J, 2003, AM J PHYSIOL-RENAL, V285, pF811, DOI 10.1152/ajprenal.00115.2003; Lemann J, 1999, NEPHRON, V81, P18; Lerolle N, 2001, NEPHROL DIAL TRANSPL, V16, P2317, DOI 10.1093/ndt/16.12.2317; Maalouf NM, 2004, KIDNEY INT, V65, P1422, DOI 10.1111/j.1523-1755.2004.00522.x; MALLUCHE HH, 1980, J CLIN ENDOCR METAB, V50, P654, DOI 10.1210/jcem-50-4-654; MANDEL NS, 1989, J UROLOGY, V142, P1513, DOI 10.1016/S0022-5347(17)39144-9; MANDEL NS, 1989, J UROLOGY, V142, P1516, DOI 10.1016/S0022-5347(17)39145-0; MARSHALL V, 1975, BRIT J UROL, V47, P117, DOI 10.1111/j.1464-410X.1975.tb03930.x; Martins MC, 1996, BRIT J UROL, V78, P176, DOI 10.1046/j.1464-410X.1996.00633.x; MEHES K, 1980, EUR J PEDIATR, V133, P239, DOI 10.1007/BF00496083; MILLINER DS, 1994, NEW ENGL J MED, V331, P1553, DOI 10.1056/NEJM199412083312304; Moe OW, 2005, CURR OPIN NEPHROL HY, V14, P368, DOI 10.1097/01.mnh.0000172724.29628.73; Moe OW, 2005, J AM SOC NEPHROL, V16, P729, DOI 10.1681/ASN.2004100888; Moe OW, 2002, ENDOCRIN METAB CLIN, V31, P895, DOI 10.1016/S0889-8529(02)00032-4; NICAR MJ, 1984, J UROLOGY, V131, P430, DOI 10.1016/S0022-5347(17)50438-3; Nyhan WL, 2005, CONTRIB NEPHROL, V147, P22, DOI 10.1159/000082539; Odvina CV, 2003, KIDNEY INT, V63, P240, DOI 10.1046/j.1523-1755.2003.00719.x; Ombra MN, 2001, AM J HUM GENET, V68, P1119, DOI 10.1086/320105; PACIFICI R, 1990, J CLIN ENDOCR METAB, V71, P138, DOI 10.1210/jcem-71-1-138; PAK CYC, 1994, MINER ELECTROL METAB, V20, P371; Pak CYC, 2004, KIDNEY INT, V66, P2032, DOI 10.1111/j.1523-1755.2004.00975.x; Pak CYC, 2003, AM J MED, V115, P26, DOI 10.1016/S0002-9343(03)00201-8; PAK CYC, 1986, J UROLOGY, V136, P1003, DOI 10.1016/S0022-5347(17)45188-3; Pak CYC, 2003, UROLOGY, V61, P523, DOI 10.1016/S0090-4295(02)02421-4; Pak CYC, 2003, J UROLOGY, V169, P465, DOI 10.1016/S0022-5347(05)63934-1; PAK CYC, 1991, AM J KIDNEY DIS, V17, P420, DOI 10.1016/S0272-6386(12)80635-4; PAK CYC, 1975, NEW ENGL J MED, V292, P497, DOI 10.1056/NEJM197503062921002; Pak CYC, 1998, LANCET, V351, P1797, DOI 10.1016/S0140-6736(98)01295-1; PAK CYC, 1981, J UROLOGY, V126, P717, DOI 10.1016/S0022-5347(17)54715-1; Pak CYC, 2002, UROLOGY, V60, P789, DOI 10.1016/S0090-4295(02)01908-8; PAK CYC, 1977, J CLIN INVEST, V59, P426, DOI 10.1172/JCI108656; Pak CYC, 2001, KIDNEY INT, V60, P757, DOI 10.1046/j.1523-1755.2001.060002757.x; PAK CYC, 1986, KIDNEY INT, V30, P422, DOI 10.1038/ki.1986.201; Palacin M, 2001, MOL MEMBR BIOL, V18, P21, DOI 10.1080/713816110; Pearle MS, 1999, J ENDOUROL, V13, P679, DOI 10.1089/end.1999.13.679; Peris P, 2002, SEMIN ARTHRITIS RHEU, V32, P64, DOI 10.1053/sarh.2002.33725; Petrucci M, 2000, KIDNEY INT, V58, P38, DOI 10.1046/j.1523-1755.2000.00138.x; PHILLIPS MJ, 1967, LANCET, V1, P1354; PIETSCHMANN F, 1992, J BONE MINER RES, V7, P1383; PREMINGER GM, 1985, J UROLOGY, V134, P20, DOI 10.1016/S0022-5347(17)46963-1; Randall A, 1937, ANN SURG, V105, P1009, DOI 10.1097/00000658-193706000-00014; Reddy ST, 2002, AM J KIDNEY DIS, V40, P265, DOI 10.1053/ajkd.2002.34504; Reed BY, 2002, J CLIN ENDOCR METAB, V87, P1476, DOI 10.1210/jc.87.4.1476; Reed BY, 1999, J CLIN ENDOCR METAB, V84, P3907, DOI 10.1210/jc.84.11.3907; Reich JD, 1997, UROLOGY, V50, P858, DOI 10.1016/S0090-4295(97)00410-X; ROBERTSON WG, 1979, CLIN SCI, V57, P285, DOI 10.1042/cs0570285; ROSE GA, 1975, UROL RES, V3, P61; ROUS SN, 1977, J UROLOGY, V118, P902, DOI 10.1016/S0022-5347(17)58242-7; SAKHAEE K, 1993, J UROLOGY, V150, P310, DOI 10.1016/S0022-5347(17)35468-X; Sakhaee K, 2002, KIDNEY INT, V62, P971, DOI 10.1046/j.1523-1755.2002.00508.x; Scott P, 1998, J AM SOC NEPHROL, V9, P425; Scott P, 1999, J AM SOC NEPHROL, V10, P1007; Scriver CR, 2001, J INHERIT METAB DIS, V24, P93, DOI 10.1023/A:1010351630856; Shattock, 1905, T PATHOL SOC LOND, V6, P275; Smith RC, 1996, AM J ROENTGENOL, V166, P97, DOI 10.2214/ajr.166.1.8571915; SOUCIE JM, 1994, KIDNEY INT, V46, P893, DOI 10.1038/ki.1994.347; Stamatelou KK, 2003, KIDNEY INT, V63, P1817, DOI 10.1046/j.1523-1755.2003.00917.x; Stoller ML, 2004, J UROLOGY, V171, P1920, DOI 10.1097/01.ju.0000120291.90839.49; STRAUSS AL, 1982, AM J MED, V72, P17, DOI 10.1016/0002-9343(82)90566-6; SUTHERLAND JW, 1985, MINER ELECTROL METAB, V11, P267; Taylor EN, 2004, J AM SOC NEPHROL, V15, P3225, DOI 10.1097/01.ASN.0000146012.44570.20; Teichman JMH, 2004, NEW ENGL J MED, V350, P684, DOI 10.1056/NEJMcp030813; Timio F, 2003, BLOOD PRESSURE, V12, P122, DOI 10.1080/08037050310001084; Trinchieri A, 1999, J UROLOGY, V162, P27, DOI 10.1097/00005392-199907000-00007; Vezzoli G, 2002, J AM SOC NEPHROL, V13, P2517, DOI 10.1097/01.ASN.0000030077.72157.D2; Von Unruh GE, 2004, J AM SOC NEPHROL, V15, P1567, DOI 10.1097/01.ASN.0000127864.26968.7F; Webster KE, 2000, HUM GENET, V107, P176, DOI 10.1007/s004390000351; YU TF, 1978, POSTGRAD MED, V63, P164; Zerwekh JE, 1998, J BONE MINER RES, V13, P1594, DOI 10.1359/jbmr.1998.13.10.1594; Zerwekh JE, 2002, ENDOCRIN METAB CLIN, V31, P869, DOI 10.1016/S0889-8529(02)00028-2; ZERWEKH JE, 1980, METABOLISM, V29, P13, DOI 10.1016/0026-0495(80)90091-8	138	570	621	5	116	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					333	344		10.1016/S0140-6736(06)68071-9	http://dx.doi.org/10.1016/S0140-6736(06)68071-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443041				2022-12-28	WOS:000235084600030
J	Tattevin, P; Souala, F; Revest, M; Taussig, D; Michelet, C				Tattevin, P; Souala, F; Revest, M; Taussig, D; Michelet, C			Confusion, memory disorders, and ophthalmoparesis in a patient with AIDS	LANCET			English	Editorial Material							WERNICKES ENCEPHALOPATHY		Pontchaillou Univ Med Ctr, Dept Infect Dis, F-35033 Rennes, France; Pontchaillou Univ Med Ctr, Dept Neurol, F-35033 Rennes, France	CHU Rennes; CHU Rennes	Tattevin, P (corresponding author), Pontchaillou Univ Med Ctr, Dept Infect Dis, Rue Guilloux, F-35033 Rennes, France.	pierre.tattevin@chu-rennes.fr	Revest, Matthieu/L-9533-2015; Tattevin, Pierre/L-7046-2015					Alcaide ML, 2003, INT J STD AIDS, V14, P712, DOI 10.1258/095646203322387992; Kaineg B, 2005, NEW ENGL J MED, V352, pE18, DOI 10.1056/NEJMicm040862; NADEL AM, 1976, JAMA-J AM MED ASSOC, V235, P2403, DOI 10.1001/jama.235.22.2403; Ogershok PR, 2002, AM J MED SCI, V323, P107, DOI 10.1097/00000441-200202000-00010; VORTMEYER AO, 1992, J NEUROL NEUROSUR PS, V55, P826, DOI 10.1136/jnnp.55.9.826	5	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					368	368		10.1016/S0140-6736(06)68075-6	http://dx.doi.org/10.1016/S0140-6736(06)68075-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	009AX	16443045				2022-12-28	WOS:000235084600034
J	Garcia-Diaz, M; Bebenek, K; Krahn, JM; Pedersen, LC; Kunkel, TA				Garcia-Diaz, M; Bebenek, K; Krahn, JM; Pedersen, LC; Kunkel, TA			Structural analysis of strand misalignment during DNA synthesis by a human DNA polymerase	CELL			English	Article							BASE EXCISION-REPAIR; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; CRYSTAL-STRUCTURE; REPLICATION FIDELITY; MISMATCH REPAIR; ERROR-PRONE; POL LAMBDA; FAMILY; MECHANISM	Insertions and deletions in coding sequences can alter the reading frame of genes and have profound biological consequences. In 1966, Streisinger proposed that these mutations result from strand slippage, which in repetitive sequences generates misaligned intermediates stabilized by correct base pairing that support polymerization. We report here crystal structures of human DNA polymerase lambda, which frequently generates deletion mutations, bound to such intermediates. Each contains an extra-helical template nucleotide upstream of the active site. Surprisingly, the extra nucleotide, even when combined with an adjacent mismatch, does not perturb polymerase active site geometry, which is indistinguishable from that for correctly aligned strands. These structures reveal how pol lambda can polymerize on substrates with minimal homology during repair of double-strand breaks and represent strand-slippage intermediates consistent with Streisinger's classical hypothesis. They are thus relevant to the origin of single-base deletions, a class of mutations that can confer strong biological phenotypes.	NIEHS, Struct Biol Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Genet Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Struct Biol Lab, NIH, DHHS, POB 12233, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019; Pedersen, Lars/C-6173-2019	Kunkel, Thomas A./0000-0002-9900-1788; Pedersen, Lars/0000-0002-4488-4077	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, Z01ES065070] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; BEBENEK K, 2004, VOL ADV PROTEIN CHEM, V69; Braithwaite EK, 2005, J BIOL CHEM, V280, P18469, DOI 10.1074/jbc.M411864200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Daley JM, 2005, J BIOL CHEM, V280, P29030, DOI 10.1074/jbc.M505277200; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Duval A, 2002, CANCER RES, V62, P2447; Efrati E, 1997, J BIOL CHEM, V272, P2559; Estabrook RA, 2004, J BIOL CHEM, V279, P31419, DOI 10.1074/jbc.M402950200; Fan W, 2004, BIOCHEM BIOPH RES CO, V323, P1328, DOI 10.1016/j.bbrc.2004.09.002; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Garcia-Diaz M, 2005, NAT STRUCT MOL BIOL, V12, P97, DOI 10.1038/nsmb876; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; Henderson IR, 1999, MOL MICROBIOL, V33, P919, DOI 10.1046/j.1365-2958.1999.01555.x; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Shcherbakova PV, 2003, J BIOL CHEM, V278, P43770, DOI 10.1074/jbc.M306893200; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tippin B, 2004, J BIOL CHEM, V279, P45360, DOI 10.1074/jbc.M408600200; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; van der Woude MW, 2004, CLIN MICROBIOL REV, V17, P581, DOI 10.1128/CMR.17.3.581-611.2004; Wells R.D., 1998, GENETIC INSTABILITIE; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; WOODSON SA, 1988, BIOCHEMISTRY-US, V27, P3130, DOI 10.1021/bi00409a004	60	82	82	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 27	2006	124	2					331	342		10.1016/j.cell.2005.10.039	http://dx.doi.org/10.1016/j.cell.2005.10.039			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439207	Bronze			2022-12-28	WOS:000235068500021
J	Palanichamy, MG; Agrawal, S; Yao, YG; Kong, QP; Sun, C; Khan, F; Chaudhuri, TK; Zhang, YP				Palanichamy, MG; Agrawal, S; Yao, YG; Kong, QP; Sun, C; Khan, F; Chaudhuri, TK; Zhang, YP			Comment on "Reconstructing the origin of Andaman islanders	SCIENCE			English	Editorial Material									Yunnan Univ, Lab Conservat & Utilizat Bioresource, Kunming 650091, Peoples R China; Chinese Acad Sci, Lab Cellular & Mol Evolut & Mol Biol Domest Anim, Kunming Inst Zool, Kunming 650223, Peoples R China; Sanjay Gandhi Inst Med Sci, Dept Med Genet, Lucknow 226014, Uttar Pradesh, India; N Bengal Univ, Dept Zool, Siliguri, W Bengal, India	Yunnan University; Chinese Academy of Sciences; Kunming Institute of Zoology; Sanjay Gandhi Postgraduate Institute of Medical Sciences; University of North Bengal	Zhang, YP (corresponding author), Yunnan Univ, Lab Conservat & Utilizat Bioresource, Kunming 650091, Peoples R China.	zhangyp1@263.net.cn	Sun, Chang/I-6326-2012; Yao, Yong-Gang/AAH-2303-2021	Yao, Yong-Gang/0000-0002-2955-0693				Endicott P, 2003, AM J HUM GENET, V72, P178, DOI 10.1086/345487; Palanichamy MG, 2004, AM J HUM GENET, V75, P966, DOI 10.1086/425871; PALANICHAMY MG, UNPUB; Thangaraj K, 2005, SCIENCE, V308, P996, DOI 10.1126/science.1109987; Thangaraj K, 2003, CURR BIOL, V13, P86, DOI 10.1016/S0960-9822(02)01336-2	5	20	20	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2006	311	5760								10.1126/science.1120176	http://dx.doi.org/10.1126/science.1120176			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439647				2022-12-28	WOS:000235071400027
J	Schroter, S; Tite, L; Hutchings, A; Black, N				Schroter, S; Tite, L; Hutchings, A; Black, N			Differences in review quality and recommendations for publication between peer reviewers suggested by authors or by editors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	5th International Congress on Peer Review and Biomedical Publication	SEP 16-18, 2005	Chicago, IL				RANDOMIZED-TRIAL	Context Many journals give authors who submit papers the opportunity to suggest reviewers. Use of these reviewers varies by journal and little is known about the quality of the reviews they produce. Objective To compare author- and editor-suggested reviewers to investigate differences in review quality and recommendations for publication. Design, Setting, and Participants Observational study of original research papers sent for external review at 10 biomedical journals. Editors were instructed to make decisions about their choice of reviewers in their usual manner. Journal administrators then requested additional reviews from the author's list of suggestions according to a strict protocol. Main Outcome Measure Review quality using the Review Quality Instrument and the proportion of reviewers recommending acceptance (including minor revision), revision, or rejection. Results There were 788 reviews for 329 manuscripts. Review quality (mean difference in Review Quality Instrument score, -0.05; P=.27) did not differ significantly between author- and editor-suggested reviewers. The author-suggested reviewers were more likely to recommend acceptance (odds ratio, 1.64; 95% confidence interval, 1.02-2.66) or revise (odds ratio, 2.66; 95% confidence interval, 1.43-4.97). This difference was larger in the open reviews of BMJ than among the blinded reviews of other journals for acceptance (P=.02). Where author- and editor-suggested reviewers differed in their recommendations, the final editorial decision to accept or reject a study was evenly balanced (50.9% of decisions consistent with the preferences of the author-suggested reviewers). Conclusions Author- and editor-suggested reviewers did not differ in the quality of their reviews, but author-suggested reviewers tended to make more favorable recommendations for publication. Editors can be confident that reviewers suggested by authors will complete adequate reviews of manuscripts, but should be cautious about relying on their recommendations for publication.	BMJ Editorial Off, BMA House, London WC1H 9JR, England; London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Schroter, S (corresponding author), BMJ Editorial Off, BMA House, Tavistock Sq, London WC1H 9JR, England.	sschroter@bmj.com	Schroter, Sara/G-3427-2012	Schroter, Sara/0000-0002-8791-8564; Hutchings, Andrew/0000-0003-0215-9923				Black N, 1998, JAMA-J AM MED ASSOC, V280, P231, DOI 10.1001/jama.280.3.231; Earnshaw JJ, 2000, ANN ROY COLL SURG, V82, P133; EVANS AT, 1993, J GEN INTERN MED, V8, P422, DOI 10.1007/BF02599618; KASSIRER JP, 1994, JAMA-J AM MED ASSOC, V272, P96, DOI 10.1001/jama.272.2.96; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Rennie D, 1999, PEER REV HLTH SCI; Schroter S, 2004, BRIT MED J, V328, P673, DOI 10.1136/bmj.38023.700775.AE; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; van Rooyen S, 1999, J CLIN EPIDEMIOL, V52, P625, DOI 10.1016/S0895-4356(99)00047-5; van Rooyen S, 1999, BRIT MED J, V318, P23; WAGER E, 2005, 5 INT C PEER REV BIO	11	82	89	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2006	295	3					314	317		10.1001/jama.295.3.314	http://dx.doi.org/10.1001/jama.295.3.314			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003LU	16418467	Green Accepted, Bronze			2022-12-28	WOS:000234684500025
J	Dial, S; Delaney, JAC; Barkun, AN; Suissa, S				Dial, S; Delaney, JAC; Barkun, AN; Suissa, S			Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTON PUMP INHIBITORS; GENERAL-PRACTICE; DIARRHEA; OMEPRAZOLE; INFECTION; COLITIS; COLONIZATION; COHORT; EPIDEMIOLOGY; INFORMATION	Context Recent reports suggest an increasing occurrence and severity of Clostridium difficile-associated disease. We assessed whether the use of gastric acid-suppressive agents is associated with an increased risk in the community. Objective To determine whether the use of gastric acid-suppressive agents increases the risk of C difficile-associated disease in a community population. Design, Setting, and Patients We conducted 2 population-based case-control studies using the United Kingdom General Practice Research Database (GPRD). In the first study we identified all 1672 cases of C difficile recorded between 1994 and 2004 among all patients registered for at least 2 years in each practice. Each case was matched to 10 controls on calendar time and the general practice. In the second study, a subset of these cases defined as community-acquired, that is, not hospitalized in the prior year, were matched on practice and age with controls also not hospitalized in the prior year. Main Outcome Measures The incidence of C difficile and risk associated with gastric acid-suppressive agent use. Results The incidence of C difficile in patients diagnosed by their general practitioners in the General Practice Research Database increased from less than 1 case per 100 000 in 1994 to 22 per 100 000 in 2004. The adjusted rate ratio of C difficile-associated disease with current use of proton pump inhibitors was 2.9 (95% confidence interval [CI], 2.4-3.4) and with H-2-receptor antagonists the rate ratio was 2.0 (95% Cl, 1.6-2.7). An elevated rate was also found with the use of nonsteroidal anti-inflammatory drugs (rate ratio, 1.3; 95% Cl, 1.2-1.5). Conclusions The use of acid-suppressive therapy, particularly proton pump inhibitors, is associated with an increased risk of community-acquired C difficile. The unexpected increase in risk with nonsteroidal anti-inflammatory drug use should be investigated further.	McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Crit Care & Resp & Clin Res, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Dial, S (corresponding author), 3650 St Urbain,Room K1 14, Montreal, PQ H2X 2P4, Canada.	sandra.dial@mcgill.ca	Delaney, Joseph A/J-8204-2019	Delaney, Joseph A/0000-0003-1771-1776				Agastya G, 2000, IMMUNOPHARM IMMUNOT, V22, P357, DOI 10.3109/08923970009016425; Al-Tureihi Farrah Ibrahim J, 2005, J Am Med Dir Assoc, V6, P105, DOI 10.1016/j.jamda.2005.01.003; [Anonymous], 2000, PHARMACOEPIDEM DR S; Barbut F, 2005, J MED MICROBIOL, V54, P181, DOI 10.1099/jmm.0.45804-0; Barrett S, 2004, J HOSP INFECT, V56, P83, DOI 10.1016/j.jhin.2003.12.001; Beaugerie L, 2003, ALIMENT PHARM THER, V17, P905, DOI 10.1046/j.1365-2036.2003.01531.x; Bignardi GE, 1998, J HOSP INFECT, V40, P1, DOI 10.1016/S0195-6701(98)90019-6; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; Cunney RJ, 1998, NEPHROL DIAL TRANSPL, V13, P2842, DOI 10.1093/ndt/13.11.2842; Cunningham R, 2003, J HOSP INFECT, V54, P243, DOI 10.1016/S0195-6701(03)00088-4; Dial S, 2004, CAN MED ASSOC J, V171, P33, DOI 10.1503/cmaj.1040876; FALSEN E, 1980, J CLIN MICROBIOL, V12, P297, DOI 10.1128/JCM.12.3.297-300.1980; GENTRIC A, 1992, LANCET, V340, P126, DOI 10.1016/0140-6736(92)90459-G; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; Geric B, 2004, J MED MICROBIOL, V53, P887, DOI 10.1099/jmm.0.45610-0; HIRSCHHORN LR, 1994, J INFECT DIS, V169, P127, DOI 10.1093/infdis/169.1.127; *HLTH PROT AG, REP CLOSTR DIFF IS F; *IMS HLTH NAT SAL, 2004 YEAR END US PRE; Itskowitz MS, 2003, ADV STUD MED, V3, P571; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; Johnson S, 1998, CLIN INFECT DIS, V26, P1027, DOI 10.1086/520276; Karlstrom O, 1998, CLIN INFECT DIS, V26, P141, DOI 10.1086/516277; Klingensmith ME, 1999, SURGERY, V126, P272, DOI 10.1016/S0039-6060(99)70165-0; Kyne L, 1998, J INFECTION, V36, P287, DOI 10.1016/S0163-4453(98)94207-4; Laheij RJF, 2004, JAMA-J AM MED ASSOC, V292, P1955, DOI 10.1001/jama.292.16.1955; Lawrenson R, 1999, J PUBLIC HEALTH MED, V21, P299, DOI 10.1093/pubmed/21.3.299; *MCDONALD LC, 2004, INF DIS SOC AM 42 AN; McEllistrem MC, 2005, CLIN INFECT DIS, V40, P265, DOI 10.1086/427113; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; Meyer AM, 2004, J CLIN GASTROENTEROL, V38, P772, DOI 10.1097/01.mcg.0000139057.05297.d6; MOSKOVITZ M, 1981, ARCH INTERN MED, V141, P663, DOI 10.1001/archinte.141.5.663; Muto CA, 2005, INFECT CONT HOSP EP, V26, P273, DOI 10.1086/502539; Mylonaki M, 2004, EUR J GASTROEN HEPAT, V16, P775, DOI 10.1097/01.meg.0000131040.38607.09; Noren T, 2004, J CLIN MICROBIOL, V42, P3635, DOI [10.1128/JCM.42.8.3635-3643.2004, 10.1128/jcm.42.8.3635-3643.2004]; Pepin J, 2005, CAN MED ASSOC J, V173, P1037, DOI 10.1503/cmaj.050978; Pepin J, 2004, CAN MED ASSOC J, V171, P466, DOI 10.1503/cmaj.1041104; Pepin J, 2005, CLIN INFECT DIS, V41, P1254, DOI 10.1086/496986; Price AB, 2003, BRIT J CLIN PHARMACO, V56, P477, DOI 10.1046/j.1365-2125.2003.01980.x; RILEY TV, 1986, J HYG-CAMBRIDGE, V96, P13, DOI 10.1017/S0022172400062483; ROBERT A, 1985, PROSTAG OTH LIPID M, V29, P961, DOI 10.1016/0090-6980(85)90221-7; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; Romero-Gomez M, 1998, J CLIN GASTROENTEROL, V26, P228, DOI 10.1097/00004836-199804000-00018; RUWART MJ, 1983, ADV PROSTAG THROMB L, V12, P93; Safdar N, 2002, ANN INTERN MED, V136, P834, DOI 10.7326/0003-4819-136-11-200206040-00013; Shah S, 2000, QJM-MON J ASSOC PHYS, V93, P175, DOI 10.1093/qjmed/93.3.175; SIMOR AE, 1993, CLIN INFECT DIS, V17, P672, DOI 10.1093/clinids/17.4.672; Spigaglia P, 2004, J MED MICROBIOL, V53, P1129, DOI 10.1099/jmm.0.45682-0; Thorens J, 1996, GUT, V39, P54, DOI 10.1136/gut.39.1.54; VIAL T, 1991, DRUG SAFETY, V6, P94, DOI 10.2165/00002018-199106020-00002; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Warny M, 2005, LANCET, V366, P1079, DOI 10.1016/S0140-6736(05)67420-X; Weightman NC, 2004, J HOSP INFECT, V56, P1, DOI 10.1016/j.jhin.2003.09.006; West BC, 1998, CLIN INFECT DIS, V26, P1234, DOI 10.1086/598353; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046; WILCOX M, 2001, 41 INT C ANT AG CHEM; Wilcox MH, 2003, BEST PRACT RES CL GA, V17, P475, DOI 10.1016/S1521-6918(03)00017-9; Williams C, 2001, BEST PRACT RES CL GA, V15, P511, DOI 10.1053/bega.2001.0191; WILSON KH, 1985, J INFECT DIS, V151, P355, DOI 10.1093/infdis/151.2.355; Wilton LV, 2003, DRUG SAFETY, V26, P121, DOI 10.2165/00002018-200326020-00005; Yoshida N, 2000, ALIMENT PHARM THERAP, V14, P74, DOI 10.1046/j.1365-2036.2000.014s1074.x; Zedtwitz-Liebenstein K, 2002, CRIT CARE MED, V30, P1118, DOI 10.1097/00003246-200205000-00026	63	695	722	3	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					2989	2995		10.1001/jama.294.23.2989	http://dx.doi.org/10.1001/jama.294.23.2989			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414946	Bronze			2022-12-28	WOS:000234087700025
J	Shekhawat, G; Tark, SH; Dravid, VP				Shekhawat, G; Tark, SH; Dravid, VP			MOSFET-embedded microcantilevers for measuring deflection in biomolecular sensors	SCIENCE			English	Article							THERMAL BIMORPH ACTUATOR; CANTILEVERS; BIOSENSOR; PROBE; ARRAY	A promising approach for detecting biomolecules follows their binding to immobilized probe molecules on microfabricated cantilevers; binding causes surface stresses that bend the cantilever. We measured this deflection, which is on the order of tens of nanometers, by embedding a metal-oxide semiconductor field-effect transistor (MOSFET) into the base of the cantilever and recording decreases in drain current with deflections as small as 5 nanometers. The gate region of the MOSFET responds to surface stresses and thus is embedded in silicon nitride so as to avoid direct contact with the sample solution. This approach, which offers low noise, high sensitivity, and direct readout, was used to detect specific binding events with biotin and antibodies.	Northwestern Univ, Int Inst Nanotechnol, Evanston, IL 60208 USA; Northwestern Univ, NUANCE Ctr, Evanston, IL 60208 USA; Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Shekhawat, G (corresponding author), Northwestern Univ, Int Inst Nanotechnol, Evanston, IL 60208 USA.	g-shekhawat@northwestern.edu; v-dravid@northwestern.edu	Dravid, Vinayak/B-6688-2009					Akiyama T, 2002, REV SCI INSTRUM, V73, P2643, DOI 10.1063/1.1488148; Akiyama T, 2000, J VAC SCI TECHNOL B, V18, P2669, DOI 10.1116/1.1327299; Baselt DR, 1997, P IEEE, V85, P672, DOI 10.1109/5.573755; Baselt DR, 1996, J VAC SCI TECHNOL B, V14, P789, DOI 10.1116/1.588714; Bashir R, 2000, J MICROMECH MICROENG, V10, P483, DOI 10.1088/0960-1317/10/4/301; Blaum A, 2001, ICMTS 2001: PROCEEDINGS OF THE 2001 INTERNATIONAL CONFERENCE ON MICROELECTRONIC TEST STRUCTURES, P125, DOI 10.1109/ICMTS.2001.928650; Boisen A, 2000, ULTRAMICROSCOPY, V82, P11, DOI 10.1016/S0304-3991(99)00148-5; Britton CL, 2000, ULTRAMICROSCOPY, V82, P17, DOI 10.1016/S0304-3991(99)00155-2; Dessard V, 2002, IEEE T ELECTRON DEV, V49, P1289, DOI 10.1109/TED.2002.1013288; Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316; HAMADA A, 1991, IEEE T ELECTRON DEV, V38, P895, DOI 10.1109/16.75220; Jaeger RC, 2000, IEEE J SOLID-ST CIRC, V35, P85, DOI 10.1109/4.818923; Jensenius H, 2000, APPL PHYS LETT, V76, P2615, DOI 10.1063/1.126426; Lange D, 2003, SENSOR ACTUAT A-PHYS, V103, P150, DOI 10.1016/S0924-4247(02)00307-2; Lavrik NV, 2004, REV SCI INSTRUM, V75, P2229, DOI 10.1063/1.1763252; Liu C., 2005, FDN MEMS; Marie R, 2002, ULTRAMICROSCOPY, V91, P29, DOI 10.1016/S0304-3991(02)00079-7; Minne SC, 1995, APPL PHYS LETT, V67, P3918, DOI 10.1063/1.115317; Minne SC, 1998, APPL PHYS LETT, V72, P2340, DOI 10.1063/1.121353; Raiteri R, 2001, SENSOR ACTUAT B-CHEM, V79, P115, DOI 10.1016/S0925-4005(01)00856-5; Rasmussen PA, 2003, ULTRAMICROSCOPY, V97, P371, DOI 10.1016/S0304-3991(03)00063-9; Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856; Wu GH, 2001, P NATL ACAD SCI USA, V98, P1560, DOI 10.1073/pnas.031362498; Yee YJ, 2000, J MICROMECH MICROENG, V10, P350, DOI 10.1088/0960-1317/10/3/308; Yue M, 2004, J MICROELECTROMECH S, V13, P290, DOI 10.1109/JMEMS.2003.823216	25	223	226	2	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	2006	311	5767					1592	1595		10.1126/science.1122588	http://dx.doi.org/10.1126/science.1122588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BK	16456038				2022-12-28	WOS:000236029500041
J	Aschwanden, C				Aschwanden, C			Professionalizing the postdoctoral experience	CELL			English	Editorial Material								The first postdoctoral association was launched in the United States 13 years ago. Although postdoctoral associations have made tremendous progress toward improving the lives of postdoctoral fellows, their job is not finished yet.											0	6	7	1	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 10	2006	124	3					445	447		10.1016/j.cell.2006.01.025	http://dx.doi.org/10.1016/j.cell.2006.01.025			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469686	Bronze			2022-12-28	WOS:000235464000001
J	Goff, SA; Klee, HJ				Goff, SA; Klee, HJ			Plant volatile compounds: Sensory cues for health and nutritional value?	SCIENCE			English	Review							HEME OXYGENASE-1; TASTE RECEPTORS; MAMMALIAN SWEET; BETA-CAROTENE; FLAVOR; PREFERENCES; BITTER; TOMATO; MACRONUTRIENTS; ANTIOXIDANT	Plants produce many volatile metabolites. A small subset of these compounds is sensed by animals and humans, and the volatile profiles are defining elements of the distinct flavors of individual foods. Flavor volatiles are derived from an array of nutrients, including amino acids, fatty acids, and carotenoids. In tomato, almost all of the important flavor-related volatiles are derived from essential nutrients. The predominance of volatiles derived from essential nutrients and health-promoting compounds suggests that these volatiles provide important information about the nutritional makeup of foods. Evidence supporting a relation between volatile perception and nutrient or health value will be reviewed.	Syngenta Biotechnol Inc, Syngenta Fellows Grp, Res Triangle Pk, NC 27709 USA; Univ Florida, Plant Mol & Cellular Biol Program, Inst Food & Agr Sci, Gainesville, FL 32611 USA	Syngenta; State University System of Florida; University of Florida	Goff, SA (corresponding author), Syngenta Biotechnol Inc, Syngenta Fellows Grp, 3054 Cornwallis Rd, Res Triangle Pk, NC 27709 USA.	stephen.goff@syngenta.com	Klee, Harry/A-7912-2008					ADETUMBI MA, 1983, MED HYPOTHESES, V12, P227, DOI 10.1016/0306-9877(83)90040-3; Aharoni A, 2004, PLANT CELL, V16, P3110, DOI 10.1105/tpc.104.023895; Ankri S, 1999, MICROBES INFECT, V1, P125, DOI 10.1016/S1286-4579(99)80003-3; [Anonymous], SOURCE BOOK FLAVORS; Bernays EA, 2005, NATURE, V436, P476, DOI 10.1038/436476a; Billing J, 1998, Q REV BIOL, V73, P3, DOI 10.1086/420058; Blake A. A., 2004, Flavor perception, P172; Brown K, 2002, SCIENCE, V296, P2327, DOI 10.1126/science.296.5577.2327; BUTTERY RG, 1993, ACS SYM SER, V525, P23; BUTTERY RG, 1988, J AGR FOOD CHEM, V36, P1247, DOI 10.1021/jf00084a030; Chen GP, 2004, PLANT PHYSIOL, V136, P2641, DOI 10.1104/pp.104.041608; Dyer J, 2005, BIOCHEM SOC T, V33, P302, DOI 10.1042/BST0330302; Early DM, 1998, J ANIM SCI, V76, P728; FURNESS JB, 1999, AM J PHYSIOL-GASTR L, V277, pG922, DOI DOI 10.1002/9780470910016.CH1; GARCIA J, 1955, SCIENCE, V122, P157; Gilbertson TA, 1997, AM J PHYSIOL-CELL PH, V272, pC1203, DOI 10.1152/ajpcell.1997.272.4.C1203; Giugliano D, 2000, NUTR METAB CARDIOVAS, V10, P38; Hill-Kapturczak N, 2001, AM J PHYSIOL-RENAL, V281, pF851, DOI 10.1152/ajprenal.0140.2001; Hofer D, 1999, NEWS PHYSIOL SCI, V14, P18; Hudson R, 1999, SCHWEIZ MED WSCHR, V129, P176; JENNINGS WG, 1967, CHEM PHYSL FLAVOURS; Lecanuet JP, 1996, EUR J OBSTET GYN R B, V68, P1, DOI 10.1016/0301-2115(96)02509-2; Lee KP, 2003, J INSECT PHYSIOL, V49, P1161, DOI 10.1016/j.jinsphys.2003.08.013; Lewinsohn E, 2005, J AGR FOOD CHEM, V53, P3142, DOI 10.1021/jf047927t; Mayntz D, 2005, SCIENCE, V307, P111, DOI 10.1126/science.1105493; Mennella JA, 2002, EARLY HUM DEV, V68, P71, DOI 10.1016/S0378-3782(02)00008-7; Mennella JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.6.e88; Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X; Mueller KL, 2005, NATURE, V434, P225, DOI 10.1038/nature03352; Myers KP, 2005, PHYSIOL BEHAV, V84, P407, DOI 10.1016/j.physbeh.2005.01.001; Myers KP, 2003, PHYSIOL BEHAV, V78, P173, DOI 10.1016/S0031-9384(02)00890-9; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; NIJSSEN L, 1997, VOLATILE COMPOUND S1, V7; Pichersky E, 2006, SCIENCE, V311, P808, DOI 10.1126/science.1118510; Pryor WA, 2000, NUTR REV, V58, P39; Rao AVR, 2000, J AM COLL NUTR, V19, P563, DOI 10.1080/07315724.2000.10718953; Raubenheimer D, 2003, J EXP BIOL, V206, P1669, DOI 10.1242/jeb.00336; Rawson N. E., 2004, Flavor perception, P57, DOI 10.1002/9780470995716.ch3; REINECCIUS G, 1991, CRIT REV FOOD SCI, V29, P381, DOI 10.1080/10408399109527534; Rouquier S, 2000, P NATL ACAD SCI USA, V97, P2870, DOI 10.1073/pnas.040580197; ROZIN P, 1990, NUTR REV, V48, P106, DOI 10.1111/j.1753-4887.1990.tb02912.x; Schaal B, 2000, CHEM SENSES, V25, P729, DOI 10.1093/chemse/25.6.729; Sclafani A, 2004, PHYSIOL BEHAV, V81, P773, DOI 10.1016/j.physbeh.2004.04.031; Sclafani A, 2001, APPETITE, V36, P79, DOI 10.1006/appe.2000.0370; Scott K, 2004, CURR OPIN NEUROBIOL, V14, P423, DOI 10.1016/j.conb.2004.06.003; Shadkchan Y, 2004, J ANTIMICROB CHEMOTH, V53, P832, DOI 10.1093/jac/dkh174; Sinha R, 2003, J Postgrad Med, V49, P222; Taylor A. J., 2004, Flavor perception, P1, DOI 10.1002/9780470995716.ch1; TIEMAN D, IN PRESS J EXP BOT; Titus CH, 2000, J ANIM SCI, V78, P1443; TRESSL R, 1973, J AGR FOOD CHEM, V21, P560, DOI 10.1021/jf60188a031; Vainio H, 2000, TOXICOL LETT, V112, P513, DOI 10.1016/S0378-4274(99)00208-8; Valero M, 2003, INT J FOOD MICROBIOL, V85, P73, DOI 10.1016/S0168-1605(02)00484-1; Villalba JJ, 2005, J CHEM ECOL, V31, P123, DOI 10.1007/s10886-005-0979-z; Villalba JJ, 2002, J ANIM SCI, V80, P2099; Villalba JJ, 2002, J ANIM SCI, V80, P1846; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Yiin YM, 2005, PHYSIOL BEHAV, V84, P217, DOI 10.1016/j.physbeh.2004.11.008; Zhang Y, 2005, NATURE, V438, P179, DOI 10.1038/nature04216; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	60	446	482	12	198	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					815	819		10.1126/science.1112614	http://dx.doi.org/10.1126/science.1112614			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469919				2022-12-28	WOS:000235374900038
J	Zhu, P; Baek, SH; Bourk, EM; Ohgi, KA; Garcia-Bassets, I; Sanjo, H; Akira, S; Kotol, PF; Glass, CK; Rosenfeld, MG; Rose, DW				Zhu, P; Baek, SH; Bourk, EM; Ohgi, KA; Garcia-Bassets, I; Sanjo, H; Akira, S; Kotol, PF; Glass, CK; Rosenfeld, MG; Rose, DW			Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway	CELL			English	Article							BREAST-CANCER CELLS; N-COR; ESTROGEN-RECEPTOR; HISTONE DEACETYLASE; PROSTATE-CANCER; COREPRESSOR COMPLEX; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; REGULATED TRANSCRIPTION; MOLECULAR DETERMINANTS	Defining the precise molecular strategies that coordinate patterns of transcriptional responses to specific signals is central for understanding normal development and homeostasis as well as the pathogenesis of hormone-dependent cancers. Here we report specific prostate cancer cell/macrophage interactions that mediate a switch in function of selective androgen receptor antagonists/modulators (SARMs) from repression to activation in vivo. This is based on an evolutionarily conserved receptor N-terminal L/HX7LL motif, selectively present in sex steroid receptors, that causes recruitment of TAB2 as a component of an N-CoR corepressor complex. TAB2 acts as a sensor for inflammatory signals by serving as a molecular beacon for recruitment of MEKK1, which in turn mediates dismissal of the N-CoR/HDAC complex and permits derepression of androgen and estrogen receptor target genes. Surprisingly, this conserved sensor strategy may have arisen to mediate reversal of sex steroid-dependent repression of a limited cohort of target genes in response to inflammatory signals, linking inflammatory and nuclear receptor ligand responses to essential reproductive functions.	Univ Calif San Diego, Sch Med, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, Mol Pathol Grad Program, La Jolla, CA 92093 USA; Seoul Natl Univ, Res Ctr Funct Cellulom, Dept Biol Sci, Seoul 151742, South Korea; Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Seoul National University (SNU); Osaka University	Zhu, P (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu; dwrose@ucsd.edu	Sroka, Isis C/A-2949-2009; Akira, Shizuo/C-3134-2009; Glass, Christopher/AAI-3933-2021; Garcia-Bassets, Ivan/F-5075-2010	Glass, Christopher/0000-0003-4344-3592; Garcia-Bassets, Ivan/0000-0002-6941-9585				Alen P, 1999, MOL CELL BIOL, V19, P6085; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chung TDK, 1999, PROSTATE, V38, P199; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cohen PE, 1999, J LEUKOCYTE BIOL, V66, P765, DOI 10.1002/jlb.66.5.765; Condon JC, 2004, P NATL ACAD SCI USA, V101, P4978, DOI 10.1073/pnas.0401124101; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; DelosSantos MJ, 1996, BIOL REPROD, V54, P563, DOI 10.1095/biolreprod54.3.563; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Glass CK, 2000, GENE DEV, V14, P121; Gouon-Evans V, 2000, DEVELOPMENT, V127, P2269; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guenther MG, 2000, GENE DEV, V14, P1048; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jepsen K, 2002, J CELL SCI, V115, P689; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kusumegi T, 2004, J BIOCHEM MOL TOXIC, V18, P1, DOI 10.1002/jbt.20004; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Leek RD, 1996, CANCER RES, V56, P4625; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Monroe DG, 2000, MOL CELL BIOL, V20, P4626, DOI 10.1128/MCB.20.13.4626-4634.2000; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PANA BC, 2001, P NATL ACAD SCI USA, V98, P1047; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shimura S, 2000, CANCER RES, V60, P5857; Smith WL, 1997, ACAD RADIOL, V4, P657, DOI 10.1016/S1076-6332(05)80273-9; Suzuki M, 2003, J BIOL CHEM, V278, P22644, DOI 10.1074/jbc.M212399200; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	65	218	221	1	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					615	629		10.1016/j.cell.2005.12.032	http://dx.doi.org/10.1016/j.cell.2005.12.032			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469706	Bronze			2022-12-28	WOS:000235464000022
J	Makris, NC; Ratilal, P; Symonds, DT; Jagannathan, S; Lee, S; Nero, RW				Makris, NC; Ratilal, P; Symonds, DT; Jagannathan, S; Lee, S; Nero, RW			Fish population and behavior revealed by instantaneous continental shelf-scale imaging	SCIENCE			English	Article							REVERBERATION; ENVIRONMENT; SCATTERING; MIGRATION	Until now, continental shelf environments have been monitored with highly localized line-transect methods from slow-moving research vessels. These methods significantly undersample fish populations in time and space, leaving an incomplete and ambiguous record of abundance and behavior. We show that fish populations in continental shelf environments can be instantaneously imaged over thousands of square kilometers and continuously monitored by a remote sensing technique in which the ocean acts as an acoustic waveguide. The technique has revealed the instantaneous horizontal structural characteristics and volatile short-term behavior of very large fish shoals, containing tens of millions of fish and stretching for many kilometers.	MIT, Ctr Ocean Sci & Engn, Dept Mech Engn, Cambridge, MA 02139 USA; Northeastern Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA; USN, Res Lab, Stennis Space Ctr, MS 39529 USA	Massachusetts Institute of Technology (MIT); Northeastern University; United States Department of Defense; United States Navy; Naval Research Laboratory	Makris, NC (corresponding author), MIT, Ctr Ocean Sci & Engn, Dept Mech Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	makris@mit.edu		Lee, Sunwoong/0000-0002-0485-0585				ANDRESON VC, 1967, J ACOUST SOC AM, V41, P6; Balls R., 1948, Journal du Conseil Copenhague, V15, P193; BARHAM EG, 1966, SCIENCE, V151, P1399, DOI 10.1126/science.151.3716.1399; Croft DP, 2003, FISH FISH, V4, P138, DOI 10.1046/j.1467-2979.2003.00113.x; Farmer DM, 1999, J ACOUST SOC AM, V106, P2481, DOI 10.1121/1.428082; FreuEn P., 1999, DYNAMICS PELAGIC FIS; Gerlotto F, 1999, CAN J FISH AQUAT SCI, V56, P6, DOI 10.1139/cjfas-56-1-6; Goodman J. W., 2000, STAT OPTICS, V1; Huse I, 1996, ICES J MAR SCI, V53, P863, DOI 10.1006/jmsc.1996.9999; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; LEGGETT WC, 1977, ANNU REV ECOL SYST, V8, P285, DOI 10.1146/annurev.es.08.110177.001441; Mackinson S, 1997, FISH RES, V31, P11, DOI 10.1016/S0165-7836(97)00020-9; MacLennan D.N., 1992, SPRINGER SCI BUS MED; MAKRIS NC, 1995, J ACOUST SOC AM, V97, P3547, DOI 10.1121/1.412440; Makris NC, 1996, J ACOUST SOC AM, V100, P769, DOI 10.1121/1.416239; Makris NC, 2001, J ACOUST SOC AM, V109, P909, DOI 10.1121/1.1339826; Medwin H., 1998, FUNDAMENTALS ACOUSTI; Misund OA, 1998, ICES J MAR SCI, V55, P58, DOI 10.1006/jmsc.1997.0228; Misund OA, 1997, REV FISH BIOL FISHER, V7, P1, DOI 10.1023/A:1018476523423; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; PITCHER TJ, 1997, DEV SUSTAINING WORLD, P143; Pitcher TJ., 1993, Behaviour of teleost fishes, P363, DOI 10.1007/978-94-011-1578-0_12; POTTS GW, 1970, J ZOOL, V161, P223; Ratilal P, 2005, J ACOUST SOC AM, V117, P1977, DOI 10.1121/1.1799252; RATILAL P, 2002, THESIS MIT CAMBRIDGE; ROSE GA, 1993, NATURE, V366, P458, DOI 10.1038/366458a0; Shaw E, 1970, DEV EVOLUTION BEHAVI, P452; Siebert W., 1986, CIRCUITS SIGNALS SYS; Sund O, 1935, NATURE, V135, P953, DOI 10.1038/135953a0	29	157	171	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					660	663		10.1126/science.1121756	http://dx.doi.org/10.1126/science.1121756			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456080				2022-12-28	WOS:000235257400048
J	Wills, M				Wills, M			Chemistry - Better asymmetric reactions	SCIENCE			English	Editorial Material									Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England	University of Warwick	Wills, M (corresponding author), Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.	m.wills@warwick.ac.uk	Wills, Martin/ABH-8311-2020	Wills, Martin/0000-0002-1646-2379				Bell S, 2006, SCIENCE, V311, P642, DOI 10.1126/science.1121977; COREY EJ, 1990, NOBEL LECT      1208; Cui XH, 2005, CHEM REV, V105, P3272, DOI 10.1021/cr0500131; Drury W. J., 2004, ANGEW CHEM, V116, P72; Drury WJ, 2004, ANGEW CHEM INT EDIT, V43, P70, DOI 10.1002/anie.200352755; 2001, NOB PRIZ CHEM 2001	6	9	9	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	2006	311	5761					619	620		10.1126/science.1123178	http://dx.doi.org/10.1126/science.1123178			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456069				2022-12-28	WOS:000235257400034
J	Bertoldi, F; Altenhoff, W; Weiss, A; Menten, KM; Thum, C				Bertoldi, F; Altenhoff, W; Weiss, A; Menten, KM; Thum, C			The trans-neptunian object UB313 is larger than Pluto	NATURE			English	Article								The most distant known object in the Solar System, 2003 UB313 ( 97 AU from the Sun), was recently discovered near its aphelion(1). Its high eccentricity and inclination to the ecliptic plane, along with its perihelion near the orbit of Neptune, identify it as a member of the 'scattered disk'. This disk of bodies probably originates in the Kuiper belt objects, which orbit near the ecliptic plane in circular orbits between 30 and 50 AU, and may include Pluto as a member. The optical brightness of 2003 UB313, if adjusted to Pluto's distance, is greater than that of Pluto, which suggested that it might be larger than Pluto(2). The actual size, however, could not be determined from the optical measurements because the surface reflectivity ( albedo) was unknown. Here we report observations of the thermal emission of 2003 UB313 at a wavelength of 1.2 mm, which in combination with the measured optical brightness leads to a diameter of 3,000 +/- 300 +/- 100 km. Here the first error reflects measurement uncertainties, while the second derives from the unknown object orientation. This makes 2003 UB313 the largest known trans-neptunian object, even larger than Pluto ( 2,300 km)(3). The albedo is 0.60 +/- 0.10 +/- 0.05, which is strikingly similar to that of Pluto, suggesting that the methane seen in the optical spectrum(2) causes a highly reflective icy surface.	Univ Bonn, Argelander Inst Astron, D-53121 Bonn, Germany; Max Planck Inst Radioastron, D-53121 Bonn, Germany; Inst Radio Astron Millimetr, F-38406 St Martin Dheres, France	University of Bonn; Max Planck Society	Bertoldi, F (corresponding author), Univ Bonn, Argelander Inst Astron, Hugel 71, D-53121 Bonn, Germany.	bertoldi@astro.uni-bonn.de						Altenhoff WJ, 2004, ASTRON ASTROPHYS, V415, P771, DOI 10.1051/0004-6361:20035603; Bowell E., 1989, ASTEROIDS, VII, P549; BROWN ME, 2005, ORGASTROPH0508633; BROWN ME, 2005, ORGASTROPH0510029; BROWN ME, 2005, 8577 IAU; RABINOWITZ D, 2005, ORGASTROPH0509401; REINSCH K, 1994, ICARUS, V108, P209, DOI 10.1006/icar.1994.1055; Sheppard SS, 2002, ASTRON J, V124, P1757, DOI 10.1086/341954; TEDESCO EF, 1989, ASTEROIDS, V2, P1090; THOLEN DJ, 1994, ICARUS, V108, P200, DOI 10.1006/icar.1994.1054; YOUNG EF, 1993, ICARUS, V102, P134, DOI 10.1006/icar.1993.1038; [No title captured]; JPL HORIZONS ON LINE	13	36	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2006	439	7076					563	564		10.1038/nature04494	http://dx.doi.org/10.1038/nature04494			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452973				2022-12-28	WOS:000235033900034
J	Haffner, ME				Haffner, ME			Focus on research - Adopting orphan drugs - Two dozen years of treating rare diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US FDA, Off Orphan Prod Dev, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Haffner, ME (corresponding author), US FDA, Off Orphan Prod Dev, Rockville, MD 20857 USA.							Anand Geeta, 2005, Wall St J (East Ed), pA10	1	110	116	2	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					445	447		10.1056/NEJMp058317	http://dx.doi.org/10.1056/NEJMp058317			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452556				2022-12-28	WOS:000235019400004
J	Baker, R				Baker, R			Professional regulation - Developing standards, criteria and thresholds to assess fitness to practise	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material								Do we need explicit, clear guidance on the professional behaviour of doctors or should guidance be largely implicit to account for the context and circumstances of clinical practice? In the aftermath of the Shipman case, doctors need to answer this question.	Univ Leicester, Leicester Gen Hosp, Dept Hlth Sci, Leicester LE5 4PW, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester	Baker, R (corresponding author), Univ Leicester, Leicester Gen Hosp, Dept Hlth Sci, Leicester LE5 4PW, Leics, England.	rb14@le.ac.uk		Baker, Richard/0000-0002-9215-0086				Allen I., 2000, HANDLING COMPLAINTS; General Medical Council, 2001, GOOD MED PRACT; MCINTOSH A, 1999, MAKING USE GUIDELINE, P63; Murphy E., 1998, HEALTH TECHNOL ASSES, V2, pI, DOI [DOI 10.3310/HTA2030, 10.3310/hta2030]; *NAT I CLIN EXC, 2004, GUID DEV PROC OV STA; *NAT I HLTH CLIN E, CIT COUNC; Raine R, 2004, LANCET, V364, P429, DOI 10.1016/S0140-6736(04)16766-4; ROSEN R, 2004, BEING DOCTOR REDEFIN; *ROYAL COLL GEN PR, 2002, GOOD MED PRACT GEN; *WORLD MED ASS, 2004, HELS DECL; *WORLD MED ASS, 1994, INT COD MED ETH	11	23	23	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2006	332	7535					230	232		10.1136/bmj.332.7535.230	http://dx.doi.org/10.1136/bmj.332.7535.230			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16439405	Green Submitted, Green Published			2022-12-28	WOS:000235086900024
J	Fu, KI; Fujimori, T				Fu, KI; Fujimori, T			Bleeding angiodysplasia in the duodenum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dokkyo Univ, Sch Med, Tochigi 3210293, Japan	Dokkyo Medical University	Fu, KI (corresponding author), Dokkyo Univ, Sch Med, Tochigi 3210293, Japan.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					283	283		10.1056/NEJMicm050195	http://dx.doi.org/10.1056/NEJMicm050195			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421369				2022-12-28	WOS:000234661100008
J	Herrling, P				Herrling, P			Experiments in social responsibility	NATURE			English	Editorial Material									Novartis Int, Corp Res, CH-4002 Basel, Switzerland	Novartis	Herrling, P (corresponding author), Novartis Int, Corp Res, CH-4002 Basel, Switzerland.								0	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 19	2006	439	7074					267	268		10.1038/439267a	http://dx.doi.org/10.1038/439267a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421547	Bronze			2022-12-28	WOS:000234682100021
J	Berwick, DM; Calkins, DR; McCannon, CJ; Hackbarth, AD				Berwick, DM; Calkins, DR; McCannon, CJ; Hackbarth, AD			The 100 000 Lives Campaign - Setting a goal and a deadline for improving health care quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAL EMERGENCY TEAM; REDUCE		Inst Healthcare Improvement, Cambridge, MA 02138 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 20 Univ Rd,7th Floor, Cambridge, MA 02138 USA.	dberwick@ihi.org	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				Adams K., 2003, PRIORITY AREAS NATL; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; Bellomo R, 2003, MED J AUSTRALIA, V179, P283, DOI 10.5694/j.1326-5377.2003.tb05548.x; Buist MD, 2002, BRIT MED J, V324, P387, DOI 10.1136/bmj.324.7334.387; Centers for Medicare and Medicaid Services, 2005, HOSP QUAL IN OV; DeVita MA, 2004, QUAL SAF HEALTH CARE, V13, P251, DOI 10.1136/qshc.2003.006585; Hillman K, 2005, LANCET, V365, P2091; Institute of Medicine, 2001, CROSSING QUALITY CHA; *JOINT COMM ACCR H, 2005, HOSP NAT PAT SAF GOA; Kohn KT, 1999, ERR IS HUMAN BUILDIN; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; National Quality Forum, 2003, SAF PRACT BETT HEALT; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Rozich J., 2001, J CLIN OUTCOMES MANA, V8, P27; Sandroni C, 2004, RESUSCITATION, V62, P291, DOI 10.1016/j.resuscitation.2004.03.020; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WACHTER RM, 2001, AHRQ PUBLICATION	21	465	480	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	2006	295	3					324	327		10.1001/jama.295.3.324	http://dx.doi.org/10.1001/jama.295.3.324			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003LU	16418469				2022-12-28	WOS:000234684500027
J	Johnson, JR; Kuskowski, MA; Wilt, TJ				Johnson, JR; Kuskowski, MA; Wilt, TJ			Systematic review: Antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Review							NOSOCOMIAL INFECTIONS; HYDROGEL; MULTICENTER; BENEFITS; EFFICACY; REDUCE; LATEX; COST; RISK	Background: The efficacy of antimicrobial urinary catheters in hospitalized patients is poorly defined. Purpose: To assess currently marketed antimicrobial urinary catheters for preventing catheter-associated urinary tract infection (UTI). Data Sources: Electronic databases, conference proceedings, bibliographies, trialists, and catheter manufacturers (search dates, 1966 to June 2005). Study Selection: Randomized and quasi-randomized trials of nitrofurazone-coated or silver alloy-coated antimicrobial urinary catheter use for less than 30 days; no language restriction. Data Extraction: Study design, study sample, inclusion and exclusion criteria, allocation, blinding, UTI definition, ascertainment methods, and proportion developing symptomatic UTI (primary end point) or bacteriuria (secondary end point) were extracted by using a structured data collection instrument. Data Synthesis: Twelve qualifying trials (13 392 total participants or catheters) were identified. They compared nitrofurazone-coated silicone (n = 3) or silver-coated latex (n = 9) catheters with silicone or latex catheters. No study addressed symptomatic UTI. All trials suggested protection against bacteriuria with test catheter use. However, effect size varied considerably and postrandomization exclusions were very common. Effect size was greatest in trials of nitrofurazone-coated catheters (all post-1995) and in pre-1995 silver alloy-coated catheter trials and was smallest in post-1995 silver alloy-coated catheter trials. Control group bacteriuria rate, control catheter type (latex vs. silicone), and patient sample (urology vs. other) also predicted effect size. Few studies addressed secondary bloodstream infection, mortality, costs, or microbial resistance. Short-term adverse effects were minimal. Limitations: The study was limited by the number, size, and quality of studies and by lack of the following: intention-to-treat analyses, data on clinical end points, and trials comparing nifrofurazone-coated with silver alloy-coated catheters. Conclusions: According to fair-quality evidence, antimicrobial urinary catheters can prevent bacteriuria in hospitalized patients during short-term catheterization, depending on antimicrobial coating and several other variables. Older data probably lack current relevance. Cost implications and effect on infectious complications remain undefined.	Vet Affairs Med Ctr, Minneapolis, MN 55417 USA; Univ Minnesota, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Johnson, JR (corresponding author), Vet Affairs Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA.	johns007@umn.edu						Al-Habdan I, 2003, INT SURG, V88, P152; Brosnahan J., 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD004013.PUB2; BRYAN CS, 1984, J UROLOGY, V132, P494, DOI 10.1016/S0022-5347(17)49707-2; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; BURT B, 2004, AM J INFECT CONTROL, V32, pE78; Cornia PB, 2003, AM J MED, V114, P404, DOI 10.1016/S0002-9343(02)01568-1; Eykyn SR, 1998, BRIT J UROL, V82, P79; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GROSS PA, 1983, AM J MED, V75, P658, DOI 10.1016/0002-9343(83)90453-9; Hartling L, 2005, ANN INTERN MED, V142, P1100, DOI 10.7326/0003-4819-142-12_Part_2-200506211-00010; Hepner DL, 2003, ANESTH ANALG, V96, P1219, DOI 10.1213/01.ANE.0000050768.04953.16; JOHNSON JR, 1993, ANTIMICROB AGENTS CH, V37, P2033, DOI 10.1128/AAC.37.9.2033; Karchmer TB, 2000, ARCH INTERN MED, V160, P3294, DOI 10.1001/archinte.160.21.3294; KRIEGER JN, 1983, J INFECT DIS, V148, P57, DOI 10.1093/infdis/148.1.57; Lai KK, 2002, AM J INFECT CONTROL, V30, P221, DOI 10.1067/mic.2002.120128; Laupland KB, 2005, CRIT CARE, V9, pR60, DOI 10.1186/cc3023; Lee SJ, 2004, INT J ANTIMICROB AG, V24, pS65, DOI 10.1016/j.ijantimicag.2004.02.013; LIEDBERG H, 1990, BRIT J UROL, V65, P379, DOI 10.1111/j.1464-410X.1990.tb14760.x; Liedberg H., 1993, Journal of Urology, V149, p405A; LIEDBERG H, 1990, EUR UROL, V17, P236; LUNDEBERG T, 1986, LANCET, V2, P1031; Maki DG, 2001, EMERG INFECT DIS, V7, P342, DOI 10.3201/eid0702.010240; Maki DG, 1998, INFECT CONT HOSP EP, V19, P682; MAKI DG, 1997, INFECT CONT HOSP E S, V18, P50; Newton T, 2002, INFECT CONT HOSP EP, V23, P217, DOI 10.1086/502038; PLATT R, 1982, NEW ENGL J MED, V307, P637, DOI 10.1056/NEJM198209093071101; Plowman R, 2001, J HOSP INFECT, V48, P33, DOI 10.1053/jhin.2001.0938; Rupp ME, 2004, AM J INFECT CONTROL, V32, P445, DOI 10.1016/j.ajic.2004.05.002; Saint S, 2000, ARCH INTERN MED, V160, P2670, DOI 10.1001/archinte.160.17.2670; Saint S, 2003, INFECT DIS CLIN N AM, V17, P411, DOI 10.1016/S0891-5520(03)00011-4; Saint S, 2002, ANN INTERN MED, V137, P125, DOI 10.7326/0003-4819-137-2-200207160-00012; Saint S, 1998, AM J MED, V105, P236, DOI 10.1016/S0002-9343(98)00240-X; Saint S, 1999, ARCH INTERN MED, V159, P800, DOI 10.1001/archinte.159.8.800; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SRINIVASAN A, 2005, IN PRESS INFECT CONT; Tambyah PA, 2002, INFECT CONT HOSP EP, V23, P27, DOI 10.1086/501964; Tambyah PA, 2000, ARCH INTERN MED, V160, P678, DOI 10.1001/archinte.160.5.678; Taylor James S, 2004, Dermatol Ther, V17, P289, DOI 10.1111/j.1396-0296.2004.04024.x; Thibon P, 2000, J HOSP INFECT, V45, P117, DOI 10.1053/jhin.1999.0715; Trinkaus D, 2004, AM J INFECT CONTROL, V32, pE105; Turjanmaa K, 2002, CURR OPIN ALLERGY CL, V2, P407, DOI 10.1097/00130832-200210000-00007; Verleyen P, 1999, EUR UROL, V36, P240, DOI 10.1159/000068005; WARREN J, 2001, NOSOCOMIAL HLTH CARE, P151; WARREN JW, 1991, MED CLIN N AM, V75, P481, DOI 10.1016/S0025-7125(16)30465-5	44	200	212	1	55	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					116	126		10.7326/0003-4819-144-2-200601170-00009	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	004AX	16418411				2022-12-28	WOS:000234725500008
J	Sun, QH; Wang, AX; Jin, XM; Natanzon, A; Duquaine, D; Brook, RD; Aguinaldo, JGS; Fayad, ZA; Fuster, V; Lippmann, M; Chen, LC; Rajagopalan, S				Sun, QH; Wang, AX; Jin, XM; Natanzon, A; Duquaine, D; Brook, RD; Aguinaldo, JGS; Fayad, ZA; Fuster, V; Lippmann, M; Chen, LC; Rajagopalan, S			Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIESEL EXHAUST PARTICLES; IN-VIVO; PEROXYNITRITE FORMATION; RADICAL GENERATION; AMBIENT PARTICLES; MORTALITY; HEART; LUNG; HEALTH; OZONE	Context Recent studies have suggested a link between inhaled particulate matter exposure in urban areas and susceptibility to cardiovascular events; however, the precise mechanisms remain to be determined. Objective To test the hypothesis that subchronic exposure to environmentally relevant particulate matter, even at low concentrations, potentiates atherosclerosis and alters vasomotor tone in a susceptible disease model. Design, Setting, and Participants Between July 21, 2004, and January 12, 2005, 28 apolipoprotein E-/- (apoE(-/-)) mice were, based on randomized assignments, fed with normal chow or high-fat chow and exposed to concentrated ambient particles of less than 2.5 mu m (PM2.5) or filtered air (FA) in Tuxedo, NY, for 6 hours per day, 5 days per week for a total of 6 months. Main Outcome Measures Composite atherosclerotic plaque in the thoracic and abdominal aorta and vasomotor tone changes. Results In the high-fat chow group, the mean (SD) composite plaque area of PM2.5 vs FA was 41.5% (9.8%) vs 26.2% (8.6%), respectively (P<.001); and in the normal chow group, the composite plaque area was 19.2% (13.1 %) vs 13.2% (8.1%), respectively (P=.15). Lipid content in the aortic arch measured by oil red-O staining revealed a 1.5-fold increase in mice fed the high-fat chow and exposed to PM2.5 vs FA (30.0 (8.2] vs 20.0 [7.0]; 95% confidence interval [CI], 1.21-1.83; P=.02). Vasoconstrictor responses to phenylephrine and serotonin challenge in the thoracic aorta of mice fed high-fat chow and exposed to PM2.5 were exaggerated compared with exposure to FA (mean [SE], 134.2% [5.2 %) vs 100.9% [2.9%], for phenylephrine, and 156.0% [5.6%] vs 125.1% [7.5%], for serotonin; both P=.03); relaxation to the endothelium-dependent agonist acetylcholine was attenuated (mean [SE] of half-maximal dose for dilation, 8.9 [0.2] X 10(-8) vs 4.3 [0.1] X 10(-8), respectively; P=.04). Mice fed high-fat chow and exposed to PM2.5 demonstrated marked increases in macrophage infiltration, expression of the inducible isoform of nitric oxide synthase, increased generation of reactive oxygen species, and greater immunostaining for the protein nitration product 3-nitrotyrosine (all P<.001). Conclusion In an apoE(-/-) mouse model, long-term exposure to low concentration of PM2.5 altered vasomotor tone, induced vascular inflammation, and potentiated atherosclerosis.	Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, New York, NY 10029 USA; NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY USA; NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Icahn School of Medicine at Mount Sinai; New York University; New York University; University of Michigan System; University of Michigan	Rajagopalan, S (corresponding author), Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, 1 Gustave L Levy Pl,Box 1030, New York, NY 10029 USA.		Cjem, Lung-Chi/H-5030-2012; Fayad, Zahi/Z-3272-2019; Fuster, Valentin/H-4319-2015	Fayad, Zahi/0000-0002-3439-7347; Fuster, Valentin/0000-0002-9043-9986; Chen, Lung Chi/0000-0003-1154-2107	NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260, R01ES013406] Funding Source: NIH RePORTER; NCI NIH HHS [1 R24 CA095823-01] Funding Source: Medline; NIEHS NIH HHS [ES00260, R01ES013406-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bai YS, 2001, FREE RADICAL BIO MED, V30, P555, DOI 10.1016/S0891-5849(00)00499-8; Bouthillier L, 1998, AM J PATHOL, V153, P1873, DOI 10.1016/S0002-9440(10)65701-X; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; Chen LC, 2005, INHAL TOXICOL, V17, P217, DOI 10.1080/08958370590912815; Choudhury RP, 2002, ATHEROSCLEROSIS, V162, P315, DOI 10.1016/S0021-9150(01)00730-4; Dellinger B, 2001, CHEM RES TOXICOL, V14, P1371, DOI 10.1021/tx010050x; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dvonch JT, 2004, INHAL TOXICOL, V16, P473, DOI 10.1080/08958370490439678; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749, DOI 10.1289/ehp.02110749; Han JY, 2001, FREE RADICAL BIO MED, V30, P516, DOI 10.1016/S0891-5849(00)00501-3; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Kwon HJ, 2001, EPIDEMIOLOGY, V12, P413, DOI 10.1097/00001648-200107000-00011; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Nemmar A, 2003, CIRCULATION, V107, P1202, DOI 10.1161/01.CIR.0000053568.13058.67; Nemmar A, 2002, AM J RESP CRIT CARE, V166, P998, DOI 10.1164/rccm.200110-026OC; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; Pope C. Arden III, 2000, Environmental Health Perspectives, V108, P713, DOI 10.2307/3454408; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Prahalad AK, 1999, TOXICOL APPL PHARM, V158, P81, DOI 10.1006/taap.1999.8701; Quay JL, 1998, AM J RESP CELL MOL, V19, P98, DOI 10.1165/ajrcmb.19.1.3132; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rossi G, 1999, ARCH ENVIRON HEALTH, V54, P158, DOI 10.1080/00039899909602254; Shukla A, 2000, AM J RESP CELL MOL, V23, P182, DOI 10.1165/ajrcmb.23.2.4035; SIOUTAS C, 1995, ENVIRON HEALTH PERSP, V103, P172, DOI 10.2307/3432274; Suwa T, 2002, J AM COLL CARDIOL, V39, P935, DOI 10.1016/S0735-1097(02)01715-1; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213, DOI 10.1164/ajrccm.161.4.9904084; Trogan E, 2004, ARTERIOSCL THROM VAS, V24, P1714, DOI 10.1161/01.ATV.0000139313.69015.1c; US EPA, NAT AMB AIR QUAL STA; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826, DOI 10.1164/ajrccm.164.5.2010160	33	592	623	4	111	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	2005	294	23					3003	3010		10.1001/jama.294.23.3003	http://dx.doi.org/10.1001/jama.294.23.3003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	995GB	16414948	Bronze			2022-12-28	WOS:000234087700027
J	Kaptchuk, TJ; Stason, WB; Davis, RB; Legedza, ATR; Schnyer, RN; Kerr, CE; Stone, DA; Nam, BH; Kirsch, I; Goldman, RH				Kaptchuk, TJ; Stason, WB; Davis, RB; Legedza, ATR; Schnyer, RN; Kerr, CE; Stone, DA; Nam, BH; Kirsch, I; Goldman, RH			Sham device versus inert pill: randomised controlled trial of two placebo treatments	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LONGITUDINAL DATA-ANALYSIS; SIDE; ACUPUNCTURE; NEEDLE; CONSENT	Objective To investigate whether a sham device (a validated sham acupuncture needle) has a greater placebo effect than all inert pill in patients with persistent arm pain. Design A single blind randomised controlled trial created from the two week placebo run-in periods for two nested trials that compared acupuncture and amitriptyline with their respective placebo controls. Comparison of participants who remained oil placebo continued beyond the run-in period to the end of the Study. Setting Academic medical centre. Participants 270 adults with arm pain due to repetitive use that had lasted at least three months despite treatment and who scored ! 3 oil a 10 point pain scale. Interventions Acupuncture with sham device twice a week for six weeks or placebo pill once a day for eight weeks. Main outcome measures Arm pain measured oil a 10 point pain scale. Secondary Outcomes were symptoms measured by the Levine symptom severity scale, function measured by Pransky's upper extremity function scale, and grip strength. Results Pain decreased during the two week placebo run-in period in both the sham device and placebo pill groups, but changes were not different between the groups (- 0.14, 95% confidence interval - 0.52 to 0.25, P = 0.49). Changes in severity scores for arm symptoms and grip strength were similar between groups, but arm function improved more in the placebo pill group (2.0, 0.06 to 3.92, P = 0.04). Longitudinal regression analyses that followed participants throughout the treatment period showed significantly greater downward slopes per week oil the 10 point arm pain scale in the sham device group than in the placebo pill group (- 0.33 (- 0.40 to - 0.26) v - 0.15 (- 0.2 t to 0.09), P = 0.0001) and oil the symptom severity scale (- 0.07 (- 0.09 to - 0.05) v - 0.05 (- 0.06 to - 0.03), P 0.02). Differences were not significant, however, oil the function scale or for g-rip strength. Reported adverse effects were different in the two groups. Conclusions The sham device had greater effects than the placebo pill on self reported pain and severity of symptoms over the entire course of treatment but not during the two week placebo run ill. Placebo effects seem to be malleable and depend oil the behaviours embedded in medical rituals.	Harvard Univ, Sch Med, Osher Inst, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; City Coll Greece, SE European Res Ctr, Thessaloniki 54624, Greece; Univ Plymouth, Plymouth PL4 8AA, Devon, England; Harvard Univ, Sch Med, Cambridge Hosp, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Plymouth; Harvard University; Cambridge Health Alliance; Cambridge Hospital	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Osher Inst, Boston, MA 02215 USA.	ted_kaptchuk@hms.harvard.edu	Kirsch, Irving/P-9316-2019; Kerr, Catherine E/D-3299-2009		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000402] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; COOPER WD, 1983, BRIT J CLIN PRACT, V37, P99; *DEP HHS, EL UND MECH PLAC EFF; ENGREN T, 1971, EXPT PSYCHOL; Goldberger JJ, 1997, AM HEART J, V134, P119, DOI 10.1016/S0002-8703(97)70115-7; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4; Kleinman A., 2002, SCI PLACEBO INTERDIS, P1; Kong J, 2006, J NEUROSCI, V26, P381, DOI 10.1523/JNEUROSCI.3556-05.2006; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LEVINE DW, 1993, J BONE JOINT SURG AM, V75A, P1585, DOI 10.2106/00004623-199311000-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Miller FG, 2004, JAMA-J AM MED ASSOC, V291, P599, DOI 10.1001/jama.291.5.599; MYERS ED, 1984, BRIT J CLIN PHARMACO, V17, P21, DOI 10.1111/j.1365-2125.1984.tb04993.x; MYERS MG, 1987, CLIN PHARMACOL THER, V42, P250, DOI 10.1038/clpt.1987.142; OConnor AM, 1996, J CLIN EPIDEMIOL, V49, P1271, DOI 10.1016/S0895-4356(96)00177-1; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Pransky G, 1997, J OCCUP ENVIRON MED, V39, P1195, DOI 10.1097/00043764-199712000-00014; REITER B, 1999, ORTHOPAEDIC PHYS EXA; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; TENNER E, 1996, WHY THINGS BIT BACK; Vase L, 2002, PAIN, V99, P443, DOI 10.1016/S0304-3959(02)00205-1; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; White P, 2003, PAIN, V106, P401, DOI 10.1016/j.pain.2003.08.013; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	27	356	365	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	2006	332	7538					391	394		10.1136/bmj.38726.603310.55	http://dx.doi.org/10.1136/bmj.38726.603310.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	017HZ	16452103	Bronze, Green Published			2022-12-28	WOS:000235686000016
J	Bhattacharyya, RP; Remenyi, A; Good, MC; Bashor, CJ; Falick, AM; Lim, WA				Bhattacharyya, RP; Remenyi, A; Good, MC; Bashor, CJ; Falick, AM; Lim, WA			The Ste5 scaffold allosterically modulates signaling output of the yeast mating pathway	SCIENCE			English	Article							PHEROMONE RESPONSE PATHWAY; MAP KINASE CASCADE; PROTEIN-PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; FEEDBACK PHOSPHORYLATION; CATALYTIC SUBUNIT; DOCKING MOTIF; ACTIVATION; REGULATORS; FUS3	Scaffold proteins organize signaling proteins into pathways and are often viewed as passive assembly platforms. We found that the Ste5 scaffold has a more active role in the yeast mating pathway: A fragment of Ste5 allosterically activated autophosphorylation of the mitogen-activated protein kinase Fus3. The resulting form of Fus3 is partially active-it is phosphorylated on only one of two key residues in the activation loop. Unexpectedly, at a systems level, autoactivated Fus3 appears to have a negative regulatory rote, promoting Ste5 phosphorylation and a decrease in pathway transcriptional output. Thus, scaffolds not only direct basic pathway connectivity but can precisely tune quantitative pathway input-output properties.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biol Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Mass Spectrometry Lab, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 600 16th St, San Francisco, CA 94143 USA.	lim@cmp.ucsf.edu	Good, Matthew C/GLS-0964-2022; Remenyi, Attila/N-1345-2016; Bhattacharyya, Roby/AAF-7670-2019	Bhattacharyya, Roby/0000-0001-6955-5088; Good, Matthew/0000-0002-6367-1034; Remenyi, Attila/0000-0002-8345-1311				Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Batkin M, 2000, BIOCHEMISTRY-US, V39, P5366, DOI 10.1021/bi000153z; BHATTACHARYYA RP, UNPUB; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; CHOI KY, 1994, CELL, V78, P499; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Elion EA, 2001, J CELL SCI, V114, P3967; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; FERRELL JE, 2000, SCI STKE, pPE1; Flotho A, 2004, J BIOL CHEM, V279, P47391, DOI 10.1074/jbc.M405681200; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Hao N, 2003, J BIOL CHEM, V278, P46506, DOI 10.1074/jbc.M308432200; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Inouye C, 1997, GENETICS, V147, P479; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Metodiev MV, 2002, SCIENCE, V296, P1483, DOI 10.1126/science.1070540; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINTEN JA, 1994, GENETICS, V138, P609; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Remenyi A, 2005, MOL CELL, V20, P951, DOI 10.1016/j.molcel.2005.10.030; Remenyi A, 2004, NAT STRUCT MOL BIOL, V11, P812, DOI 10.1038/nsmb820; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Schwartz MA, 2004, ANNU REV GENET, V38, P725, DOI 10.1146/annurev.genet.39.073003.112634; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; van Drogen F, 2000, CURR BIOL, V10, P630, DOI 10.1016/S0960-9822(00)00511-X; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	38	216	222	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					822	826		10.1126/science.1120941	http://dx.doi.org/10.1126/science.1120941			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16424299				2022-12-28	WOS:000235374900040
J	Zhang, KZ; Shen, XH; Wu, J; Sakaki, K; Saunders, T; Rutkowski, DT; Back, SH; Kaufman, RJ				Zhang, KZ; Shen, XH; Wu, J; Sakaki, K; Saunders, T; Rutkowski, DT; Back, SH; Kaufman, RJ			Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response	CELL			English	Article							C-REACTIVE PROTEIN; ELEMENT-BINDING PROTEINS; CREB/ATF-FAMILY; SITE-1 PROTEASE; CHOLESTEROL; PROTEOLYSIS; SREBP; ATF6; ATHEROSCLEROSIS; IDENTIFICATION	Regulated intramembrane proteolysis (RIP) of endoplasmic reticulum (ER) membrane-anchored transcription factors is known to maintain sterol homeostasis and to mediate the unfolded protein response (UPR). Here, we identified CREBH as a RIP-regulated liver-specific transcription factor that is cleaved upon ER stress and required to activate expression of acute phase response (APR) genes. Proinflammatory cytokines increase expression of ER membrane-anchored CREBH. In response to ER stress, CREBH is cleaved by site-1 and site-2 proteases to liberate an amino-terminal fragment that transits to the nucleus to activate transcription of the genes encoding serum amyloid P-component (SAP) and C-reactive protein (CRP). Proinflammatory cytokines and lipopolysaccharide activate the UPR and induce cleavage of CREBH in the liver in vivo. Together, our studies delineate a molecular mechanism for activation of an ER-localized transcription factor, CREBH, and reveal an unprecedented link by which ER stress initiates an acute inflammatory response.	Univ Michigan, Ctr Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Transgen Anim Model Core, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zhang, KZ (corresponding author), Univ Michigan, Ctr Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu		Saunders, Thom/0000-0003-2015-101X; Zhang, Kezhong/0000-0002-6062-235X; Rutkowski, Thomas/0000-0001-6586-4449	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042394, R37DK042394] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52173, R01 HL052173] Funding Source: Medline; NIDDK NIH HHS [DK42394, R01 DK042394] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Chin KT, 2005, NUCLEIC ACIDS RES, V33, P1859, DOI 10.1093/nar/gki332; Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Feramisco JD, 2005, P NATL ACAD SCI USA, V102, P3242, DOI 10.1073/pnas.0500206102; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Khovidhunkit W, 2000, J INFECT DIS, V181, pS462, DOI 10.1086/315611; Kondo S, 2005, NAT CELL BIOL, V7, P186, DOI 10.1038/ncb1213; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Miao HZ, 2004, BLOOD, V103, P3412, DOI 10.1182/blood-2003-10-3591; Nadanaka S, 2004, MOL BIOL CELL, V15, P2537, DOI 10.1091/mbc.E03-09-0693; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Ochrietor JD, 2000, CYTOKINE, V12, P888, DOI 10.1006/cyto.2000.0668; Omori Y, 2001, NUCLEIC ACIDS RES, V29, P2154, DOI 10.1093/nar/29.10.2154; Paul A, 2004, CIRCULATION, V109, P647, DOI 10.1161/01.CIR.0000114526.50618.24; Raggo C, 2002, MOL CELL BIOL, V22, P5639, DOI 10.1128/MCB.22.16.5639-5649.2002; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sattar N, 2004, CIRCULATION, V110, P2687, DOI 10.1161/01.CIR.0000145660.60487.94; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Wang Y, 2000, J BIOL CHEM, V275, P27013; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoo JY, 2003, P NATL ACAD SCI USA, V100, P1157, DOI 10.1073/pnas.0336385100; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	42	606	654	1	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					587	599		10.1016/j.cell.2005.11.040	http://dx.doi.org/10.1016/j.cell.2005.11.040			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469704	Bronze			2022-12-28	WOS:000235464000020
J	Kassem, S; Friedman, G				Kassem, S; Friedman, G			Subacute urinary retention	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hadassah Med Ctr, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center	Kassem, S (corresponding author), Hadassah Med Ctr, Kiryat Haddasah, IL-91120 Jerusalem, Israel.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					E5	E5		10.1056/NEJMicm041052	http://dx.doi.org/10.1056/NEJMicm041052			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467538				2022-12-28	WOS:000235177500012
J	Ghouri, N; Atcha, M; Sheikh, A				Ghouri, N; Atcha, M; Sheikh, A			Public health - Influence of Islam on smoking among Muslims	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Edinburgh, Gen Practice Sect, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Gen Practice Sect, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Ghouri, Noushima/0000-0002-8202-3913				Ahmad K, 2005, EUR J CARDIOV PREV R, V12, P203, DOI 10.1097/00149831-200506000-00003; *BBC NEWS ONL, BOLL LINK AS SMOK; Bush J, 2003, BRIT MED J, V326, P962, DOI 10.1136/bmj.326.7396.962; *CENTR INT AG, WORLD FACTB 2005; *DEP HLTH, 2005, HLTH SURV ENGL 2004; DOI AR, 1984, ISLAMIC LAW, V2, P84; Gatrad AR, 2001, ARCH DIS CHILD, V84, P72, DOI 10.1136/adc.84.1.72; *GLOBALINK, TOB CONTR COUNTR PRO; Hameed Abdul, 2002, J Ayub Med Coll Abbottabad, V14, P23; *ISL ONL, IS RUL SMOK STILL CO; *ISLAMICWEB, MUSL POP; JIBALY M, 1996, SMOKING SOCIAL POSIO; Kawachi I, 2005, BRIT MED J, V330, P265, DOI 10.1136/bmj.330.7486.265; *NHS HLTH DEV AG, FIN COST SMOK; Radwan Ghada N., 2003, Journal of the Egyptian Society of Parasitology, V33, P1087; Reynolds C, 1999, TOB CONTROL, V8, P89, DOI 10.1136/tc.8.1.89; RSIPLERCHAIM V, 1993, ISLAMIC MED ETHICS 2, P119; WHITE M, 2002, STUDY EXPLORE FEASIB; WHO, FRAM CONV TOB CONTR; *WHO E MED REG OFF, 2003, ISL RUL SMOK	20	87	88	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					291	294		10.1136/bmj.332.7536.291	http://dx.doi.org/10.1136/bmj.332.7536.291			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	011HN	16455732	Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000235259000026
J	Biondi-Zoccai, GGL; Lotrionte, M; Abbate, A; Testa, L; Remigi, E; Burzotta, F; Valgimigli, M; Romagnoli, E; Crea, F; Agostoni, P				Biondi-Zoccai, GGL; Lotrionte, M; Abbate, A; Testa, L; Remigi, E; Burzotta, F; Valgimigli, M; Romagnoli, E; Crea, F; Agostoni, P			Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RADIOCONTRAST-INDUCED NEPHROPATHY; RANDOMIZED CONTROLLED-TRIALS; N-ACETYLCYSTEINE; SYSTEMATIC REVIEWS; CLINICAL-TRIALS; DISEASE; PROPHYLAXIS; IMPACT; RISK	Objective To appraise multiple systematic reviews on the same clinical topic, focusing on predictors and correlates of quality of reporting of meta-analysis (QUOROM) scores. Design Case study. Setting Reviews providing at least individual quantitative estimates on role of acetylcysteine in the prevention of contrast associated nephropathy Data sources PubMed, the database of abstracts of reviews of effects, and the Cochrane database of systematic reviews (updated March 2005). Main outcome measures Funding, compliance with the QUOROM checklist, scores on the Oxman and Guyatt quality index, and authors' recommendations. Results 10 systematic reviews, published August 2003 to March 2005, were included. Nine pooled events despite heterogeneity and five recommended routine use of acetylcysteine, whereas the remaining studies called for further research. Compliance with the 18 items on the QUOROM checklist was relatively high (median 16, range 11 to 17), although shorter manuscripts had significantly lower scores (R = 0.73; P = 0.016). Reviewers who reported previous not for profit funding were more likely to score higher on the Oxman and Guyatt quality index. No association was found between QUOROM and Oxman and Guyatt scores (R = - 0.06; P = 0.86), mainly because of greater emphasis of the Oxman and Guyatt scores on the appraisal of bias in selection and validity assessment (inadequate in five reviews). Conclusions Multiple systematic reviews on the same clinical topic varied in quality of reporting and recommendations. Longer manuscripts and previous not for profit funding were associated with higher quality.	Policlin San Donato, Haemodynam & Cardiovasc Radiol Serv, I-20097 San Donato Milanese, Italy; Univ Milan, Inst Med Stat & Biometr, Milan, Italy; Univ Cattolica Sacro Cuore, Inst Cardiol, I-00168 Rome, Italy; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA; Univ KwaZulu Natal, Sch Engn, Durban, South Africa; Erasmus Univ, Med Ctr, Ctr Thorax, Rotterdam, Netherlands; Catholic Univ Hosp, Dept Cardiol, Campobasso, Italy; AZ Middelheim Hosp, Antwerp, Belgium	IRCCS Policlinico San Donato; University of Milan; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Virginia Commonwealth University; University of Kwazulu Natal; Erasmus University Rotterdam; Erasmus MC	Biondi-Zoccai, GGL (corresponding author), Policlin San Donato, Haemodynam & Cardiovasc Radiol Serv, Via Morandi 30, I-20097 San Donato Milanese, Italy.	gbiondizoccai@gmail.com	Romagnoli, Enrico/M-7725-2017; Trani, Carlo/K-3265-2018; Valgimigli, Marco/AAE-9103-2019; Biondi-Zoccai, Giuseppe/C-9670-2012; Abbate, Antonio/G-8805-2016; Testa, Luca/J-8226-2018; Burzotta, Francesco/K-1004-2018; Abbate, Antonio/E-3405-2014; Abbate, Antonio/C-2388-2008	Romagnoli, Enrico/0000-0003-1611-7708; Trani, Carlo/0000-0002-6569-9401; Valgimigli, Marco/0000-0002-4353-7110; Biondi-Zoccai, Giuseppe/0000-0001-6103-8510; Abbate, Antonio/0000-0002-1930-785X; Burzotta, Francesco/0000-0002-6569-9401; testa, luca/0000-0003-4687-3686				Agostoni P, 2005, EUR HEART J, V26, P881, DOI 10.1093/eurheartj/ehi116; Alonso A, 2004, AM J KIDNEY DIS, V43, P1, DOI 10.1053/j.ajkd.2003.09.009; ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; Bagshaw SM, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-38; Biondi-Zoccai GGL, 2005, AM HEART J, V149, P504, DOI 10.1016/j.ahj.2004.10.026; Biondi-Zoccai Giuseppe G, 2003, Ital Heart J, V4, P819; Birck R, 2003, LANCET, V362, P598, DOI 10.1016/S0140-6736(03)14189-X; Brigham-Grette J, 2001, QUATERNARY SCI REV, V20, P1, DOI 10.1016/S0277-3791(00)00136-0; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CLAKE M, COCHRANE REV HDB; CLARKE M, COCHRANE REV HDB 4 2; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Duong MH, 2005, CATHETER CARDIO INTE, V64, P471, DOI 10.1002/ccd.20342; Egger M, 2001, SYSTEMATIC REV HLTH; EGGER M, 2001, SYSTEMATIC REVISES H; Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; Goldenberg I, 2004, EUR HEART J, V25, P212, DOI 10.1016/j.ehj.2003.11.011; Guru V, 2004, CLIN NEPHROL, V62, P77; Hill RA, 2004, EUR HEART J, V25, P902, DOI 10.1016/j.ehj.2004.03.023; Hopayian K, 2001, BRIT MED J, V323, P681, DOI 10.1136/bmj.323.7314.681; Isenbarger DW, 2003, AM J CARDIOL, V92, P1454, DOI 10.1016/j.amjcard.2003.08.059; Jadad AR, 1997, CAN MED ASSOC J, V156, P1411; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Katerndahl DA, 1999, AM J EPIDEMIOL, V149, P429, DOI 10.1093/oxfordjournals.aje.a009830; Kshirsagar AV, 2004, J AM SOC NEPHROL, V15, P761, DOI 10.1097/01.ASN.0000116241.47678.49; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; LESNIAK W, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004755.PUB2.2004; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Linde K, 2003, J ROY SOC MED, V96, P17, DOI 10.1258/jrsm.96.1.17; McGinn TG, 2002, USERS GUIDE MED LIT, P461; Misra D, 2004, CLIN CARDIOL, V27, P607, DOI 10.1002/clc.4960271106; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nallamothu BK, 2004, AM J MED, V117, P938, DOI 10.1016/j.amjmed.2004.06.046; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Pannu N, 2004, KIDNEY INT, V65, P1366, DOI 10.1111/j.1523-1755.2004.00516.x; Patsopoulos NA, 2005, JAMA-J AM MED ASSOC, V293, P2362, DOI 10.1001/jama.293.19.2362; Sharp SJ, 1996, BRIT MED J, V313, P735; Shojania K G, 2001, Eff Clin Pract, V4, P157; Swingler GH, 2003, BRIT MED J, V327, P1083, DOI 10.1136/bmj.327.7423.1083; Testa L, 2005, EUR HEART J, V26, P2000, DOI 10.1093/eurheartj/ehi306	43	116	117	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2006	332	7535					202	206		10.1136/bmj.38693.516782.7C	http://dx.doi.org/10.1136/bmj.38693.516782.7C			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16415336	Green Published			2022-12-28	WOS:000235086900016
J	Li, XT; Lonard, DM; Jung, SY; Malovannaya, A; Feng, G; Qin, J; Tsai, SY; Tsai, MJ; O'Malley, BW				Li, XT; Lonard, DM; Jung, SY; Malovannaya, A; Feng, G; Qin, J; Tsai, SY; Tsai, MJ; O'Malley, BW			The SRC-3/AIB1 coactivator is degraded 14 in a ubiquitin- and ATP-independent manner by the REG gamma proteasome	CELL			English	Article							ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; STEROID-RECEPTOR; NUCLEAR RECEPTORS; GENE-EXPRESSION; ACTIVATOR PA28; MICE LACKING; AIB1; GROWTH; IDENTIFICATION	Steroid receptor coactivator-3 (SRC-3/AIB1) is an oncogene frequently amplified and overexpressed in breast cancers. Here we report that SRC-3 interacts with REG gamma, a proteasome activator known to stimulate the trypsin-like activity of the 20S proteasome. RNAi knockdown and gain-of-function experiments suggest that REG gamma promotes SRC-3 protein degradation. Cellular levels of REG gamma expression affect estrogen-receptor target-gene expression and cell growth as a result of its ability to promote degradation of the SRC-3 protein. In vitro proteasome proteolysis assays using purified REGy, SRC-3, and the 20S proteasome reinforce these conclusions and demonstrate that REG gamma promotes the degradation of SRC-3 in a ubiquitin- and ATP-independent manner. This work demonstrates the first example of a physiologically relevant endogenous cellular target for the REG gamma-proteasome complex. It also highlights the fact that an alternative mode of proteasome-mediated protein degradation, independent of the 19S proteasome regulatory cap, targets the SRC-3 protein for degradation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Chongqing Univ Med Sci, Affiliated Hosp 1, Chongqing 400016, Peoples R China	Baylor College of Medicine; Chongqing Medical University	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	berto@bcm.tmc.edu	Qin, Jun/A-1148-2010	Jung, Sung Yun/0000-0003-1521-7977	NIDDK NIH HHS [DK063802-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK063802] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abba MC, 2004, BREAST CANCER RES, V6, pR499, DOI 10.1186/bcr899; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Barton LF, 2004, J IMMUNOL, V172, P3948, DOI 10.4049/jimmunol.172.6.3948; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Bouras T, 2001, CANCER RES, V61, P903; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; JUGN SY, 2005, J MOL ENDOCRINOL, V19, P2451; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Li J, 2001, EMBO J, V20, P3359, DOI 10.1093/emboj/20.13.3359; Li J, 2001, BIOCHIMIE, V83, P373, DOI 10.1016/S0300-9084(01)01236-6; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lonard DM, 2004, MOL CELL BIOL, V24, P14, DOI 10.1128/MCB.24.1.14-24.2004; MA CP, 1992, J BIOL CHEM, V267, P10515; Masson P, 2001, J BIOL CHEM, V276, P1383, DOI 10.1074/jbc.M007379200; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moriishi K, 2003, J VIROL, V77, P10237, DOI 10.1128/JVI.77.19.10237-10249.2003; Murata S, 1999, J BIOL CHEM, V274, P38211, DOI 10.1074/jbc.274.53.38211; Murphy LC, 2000, CANCER RES, V60, P6266; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; ONATE SA, 1995, SCIENCE, V270, P1354; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Rechsteiner M, 2005, TRENDS CELL BIOL, V15, P27, DOI 10.1016/j.tcb.2004.11.003; Saffarian S, 2004, SCIENCE, V306, P108, DOI 10.1126/science.1099179; Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Wojcik C, 1998, EUR J CELL BIOL, V77, P151, DOI 10.1016/S0171-9335(98)80083-6; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan F, 2003, MOL ENDOCRINOL, V17, P1315, DOI 10.1210/me.2002-0209; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003	44	210	229	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					381	392		10.1016/j.cell.2005.11.037	http://dx.doi.org/10.1016/j.cell.2005.11.037			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439211	Bronze			2022-12-28	WOS:000235068500025
J	Bertelli, AAE				Bertelli, AAE			Stockpiling of raw material for oseltamivir is not justified	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Univ Milan, Dept Human Morphol, I-20133 Milan, Italy	University of Milan	Bertelli, AAE (corresponding author), Univ Milan, Dept Human Morphol, Via Mangiagalli 31, I-20133 Milan, Italy.	studiojli@usa.net						Barak V, 2001, EUR CYTOKINE NETW, V12, P290; Bertelli AAE, 2002, ANN NY ACAD SCI, V957, P295, DOI 10.1111/j.1749-6632.2002.tb02929.x; Madur G, 2006, BRIT MED J, V332, P5	3	3	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 21	2006	332	7534					178	178		10.1136/bmj.332.7534.178	http://dx.doi.org/10.1136/bmj.332.7534.178			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424506	Green Published			2022-12-28	WOS:000234905800035
J	Heald, R				Heald, R			Serving up a plate of chromosomes	SCIENCE			English	Editorial Material							CENP-E; KINETOCHORES; ALIGNMENT; SPINDLE		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Heald, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	bheald@calmail.berkeley.edu		Heald, Rebecca/0000-0001-6671-6528				Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Kapoor TM, 2006, SCIENCE, V311, P388, DOI 10.1126/science.1122142; Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040; MASTRONARDE DN, 1993, J CELL BIOL, V123, P1475, DOI 10.1083/jcb.123.6.1475; MURRAY AW, 1994, CURR BIOL, V4, P38, DOI 10.1016/S0960-9822(00)00007-5; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5	7	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2006	311	5759					343	344		10.1126/science.1123525	http://dx.doi.org/10.1126/science.1123525			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424328				2022-12-28	WOS:000234938500031
J	Yoong, JKC				Yoong, JKC			Heavy-metal meals of mercury	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Singapore Gen Hosp, Outram 169608, Singapore	Singapore General Hospital	Yoong, JKC (corresponding author), Singapore Gen Hosp, Outram 169608, Singapore.								0	4	5	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					E3	E3		10.1056/NEJMicm050190	http://dx.doi.org/10.1056/NEJMicm050190			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421361				2022-12-28	WOS:000234661100009
J	Ellermeier, CD; Hobbs, EC; Gonzalez-Pastor, JE; Losick, R				Ellermeier, CD; Hobbs, EC; Gonzalez-Pastor, JE; Losick, R			A three-protein signaling pathway governing immunity to a bacterial cannibalism toxin	CELL			English	Article							GLOBAL REPRESSOR MLC; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE-EXPRESSION; TRANSCRIPTION FACTOR; SPO0A REGULON; DNA-BINDING; SPORULATION; MEMBRANE; PROTEIN	We describe a three-protein signal-transduction pathway that governs immunity to a protein toxin involved in cannibalism by the spore-forming bacterium Baciflus subtilis. Cells of B. subtilis enter the pathway to sporulate under conditions of nutrient limitation but delay becoming committed to spore formation by killing nonsporulating siblings and feeding on the dead cells. Killing is mediated by the exported toxic protein SdpC. We report that extracellular SdpC induces the synthesis of an immunity protein, SdpI, that protects toxin-producing cells from being killed. SdpI, a polytopic membrane protein, is encoded by a two-gene operon under sporulation control that contains the gene for an autorepressor, SdpR. The autorepressor binds to and blocks the promoter for the operon. Evidence indicates that SdpI is also a signal-transduction protein that responds to the SdpC toxin by sequestering the SdpR autorepressor at the membrane. Sequestration relieves repression and stimulates synthesis of immunity protein.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Ellermeier, CD (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.	losick@mcb.harvard.edu	González-Pastor, José/I-2118-2015	González-Pastor, José/0000-0002-7615-7042; Ellermeier, Craig/0000-0002-8953-5081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohm A, 2004, CURR OPIN MICROBIOL, V7, P151, DOI 10.1016/j.mib.2004.02.009; Britton RA, 2002, J BACTERIOL, V184, P4881, DOI 10.1128/JB.184.17.4881-4890.2002; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Busenlehner LS, 2003, FEMS MICROBIOL REV, V27, P131, DOI 10.1016/S0168-6445(03)00054-8; CHUNG JD, 1994, J BACTERIOL, V176, P1977, DOI 10.1128/jb.176.7.1977-1984.1994; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; Dworkin J, 2005, CELL, V121, P401, DOI 10.1016/j.cell.2005.02.032; EICHENBERGER P, 2004, PLOS BIOL, V10, P1371; Fujita M, 2005, J BACTERIOL, V187, P1357, DOI 10.1128/JB.187.4.1357-1368.2005; Fujita M, 2002, MOL MICROBIOL, V43, P27, DOI 10.1046/j.1365-2958.2002.02732.x; Gonzalez-Pastor JE, 2003, SCIENCE, V301, P510, DOI 10.1126/science.1086462; GueroutFleury AM, 1996, GENE, V180, P57, DOI 10.1016/S0378-1119(96)00404-0; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; HAHN DR, 1988, MOL GEN GENET, V213, P125, DOI 10.1007/BF00333408; Harwood C.R., 1990, MOL BIOL METHODS BAC; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; Lehane MJ, 1997, P NATL ACAD SCI USA, V94, P11502, DOI 10.1073/pnas.94.21.11502; Miller JH, 1972, EXPT MOL BIOL; Molle V, 2003, MOL MICROBIOL, V50, P1683, DOI 10.1046/j.1365-2958.2003.03818.x; MuroPastor AM, 1997, J BACTERIOL, V179, P2788, DOI 10.1128/jb.179.8.2788-2791.1997; Parker GF, 1996, MICROBIOL-UK, V142, P3445, DOI 10.1099/13500872-142-12-3445; Steil L, 2003, J BACTERIOL, V185, P6358, DOI 10.1128/JB.185.21.6358-6370.2003; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tanaka Y, 2004, MOL MICROBIOL, V53, P941, DOI 10.1111/j.1365-2958.2004.04179.x; Veening JW, 2005, MOL MICROBIOL, V56, P1481, DOI 10.1111/j.1365-2958.2005.04659.x; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WILSON GA, 1968, J BACTERIOL, V95, P1439, DOI 10.1128/JB.95.4.1439-1449.1968; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1	31	135	146	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					549	559		10.1016/j.cell.2005.11.041	http://dx.doi.org/10.1016/j.cell.2005.11.041			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469701	Bronze			2022-12-28	WOS:000235464000017
J	Chambers, CD; Hernandez-Diaz, S; Van Marter, LJ; Werler, MM; Louik, C; Jones, KL; Mitchell, AA				Chambers, CD; Hernandez-Diaz, S; Van Marter, LJ; Werler, MM; Louik, C; Jones, KL; Mitchell, AA			Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL WITHDRAWAL SYNDROME; NITRIC-OXIDE; PREGNANT-WOMEN; EXPOSURE; FLUOXETINE; PAROXETINE; ANTIDEPRESSANTS; DEPRESSION; OUTCOMES; DEFECTS	BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) is associated with substantial infant mortality and morbidity. A previous cohort study suggested a possible association between maternal use of the selective serotonin-reuptake inhibitor (SSRI) fluoxetine late in the third trimester of pregnancy and the risk of PPHN in the infant. We performed a case-control study to assess whether PPHN is associated with exposure to SSRIs during late pregnancy. METHODS: Between 1998 and 2003, we enrolled 377 women whose infants had PPHN and 836 matched control women and their infants. Maternal interviews were conducted by nurses, who were blinded to the study hypothesis, regarding medication use in pregnancy and potential confounders, including demographic variables and health history. RESULTS: Fourteen infants with PPHN had been exposed to an SSRI after the completion of the 20th week of gestation, as compared with six control infants (adjusted odds ratio, 6.1; 95 percent confidence interval, 2.2 to 16.8). In contrast, neither the use of SSRIs before the 20th week of gestation nor the use of non-SSRI antidepressant drugs at any time during pregnancy was associated with an increased risk of PPHN. CONCLUSIONS: These data support an association between the maternal use of SSRIs in late pregnancy and PPHN in the offspring; further study of this association is warranted. These findings should be taken into account in decisions as to whether to continue the use of SSRIs during pregnancy.	Univ Calif San Diego, Med Ctr, Dept Pediat, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; Boston Univ, Sch Publ Hlth, Slone Epidemiol Ctr, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Chambers, CD (corresponding author), Univ Calif San Diego, Med Ctr, Dept Pediat, 200 W Arbor Dr,Mail Code 8446, San Diego, CA 92103 USA.	chchambers@ucsd.edu		Louik, Carol/0000-0001-5429-5084; Chambers, Christina D/0000-0003-4675-7722; Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814	NHLBI NIH HHS [HL50763] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abman SH, 1999, PEDIATR PULM, P201; Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; Bearer C, 1997, ENVIRON HEALTH PERSP, V105, P202; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Costei AM, 2002, ARCH PEDIAT ADOL MED, V156, P1129, DOI 10.1001/archpedi.156.11.1129; Dakshinamurti S, 2005, PEDIATR PULM, V39, P492, DOI 10.1002/ppul.20201; Eddahibi S, 2002, J LAB CLIN MED, V139, P194, DOI 10.1067/mlc.2002.122181; Farrow KN, 2005, SEMIN PERINATOL, V29, P8, DOI 10.1053/j.semperi.2005.02.003; Finkel MS, 1996, PSYCHOPHARMACOL BULL, V32, P653; Fricker J, 1996, LANCET, V347, P1397, DOI 10.1016/S0140-6736(96)91029-6; HAGEMAN JR, 1984, AM J DIS CHILD, V138, P592, DOI 10.1001/archpedi.1984.02140440076021; Hasler G, 2004, PSYCHOL MED, V34, P1047, DOI 10.1017/S0033291703001697; Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176; JOHN E, 1988, AUST PAEDIATR J, V24, P357; Kallen B, 2004, ARCH PEDIAT ADOL MED, V158, P312, DOI 10.1001/archpedi.158.4.312; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Laine K, 2004, THER DRUG MONIT, V26, P685, DOI 10.1097/00007691-200412000-00016; LEMBERGER L, 1985, J CLIN PSYCHIAT, V46, P14; MCMAHON TJ, 1993, J APPL PHYSIOL, V75, P93, DOI 10.1152/jappl.1993.75.1.93; MITCHELL AA, 1981, JAMA-J AM MED ASSOC, V245, P2311; MITCHELL AA, 1986, AM J EPIDEMIOL, V123, P670, DOI 10.1093/oxfordjournals.aje.a114286; MORSESKOLKO EL, 2005, JAMA-J AM MED ASSOC, V293, P2372; Moses-Kolko Eydie L, 2004, J Am Med Womens Assoc (1972), V59, P181; Nordeng H, 2001, ACTA PAEDIATR, V90, P288, DOI 10.1080/080352501300067596; REECE EA, 1987, OBSTET GYNECOL, V70, P696; Runo JR, 2003, LANCET, V361, P1533, DOI 10.1016/S0140-6736(03)13167-4; Sanz EJ, 2005, LANCET, V365, P482, DOI 10.1016/S0140-6736(05)17865-9; Suhara T, 1998, LANCET, V351, P332, DOI 10.1016/S0140-6736(97)07336-4; VanMarter LJ, 1996, PEDIATRICS, V97, P658; Walsh-Sukys MC, 2000, PEDIATRICS, V105, P14, DOI 10.1542/peds.105.1.14; Wisner KL, 1999, JAMA-J AM MED ASSOC, V282, P1264, DOI 10.1001/jama.282.13.1264; Yaron I, 1999, ARTHRITIS RHEUM, V42, P2561, DOI 10.1002/1529-0131(199912)42:12<2561::AID-ANR8>3.0.CO;2-U; Zeskind PS, 2004, PEDIATRICS, V113, P368, DOI 10.1542/peds.113.2.368	34	556	570	0	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					579	587		10.1056/NEJMoa052744	http://dx.doi.org/10.1056/NEJMoa052744			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467545				2022-12-28	WOS:000235177500007
J	Agrawal, A; Whorwell, PJ				Agrawal, A; Whorwell, PJ			BMJ learning - Irritable bowel syndrome: diagnosis and management	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOOD INTOLERANCE; PREVALENCE; EFFICACY; DIARRHEA; WOMEN		Wythenshawe Hosp, Educ & Res Ctr, Manchester M23 9LT, Lancs, England; Wythenshawe Hosp, Dept Med & Gastroenterol, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Whorwell, PJ (corresponding author), Wythenshawe Hosp, Educ & Res Ctr, Manchester M23 9LT, Lancs, England.	Peter.whorwell@smuht.nwest.nhs.uk		Whorwell, Peter/0000-0002-5220-8474				Bennett EJ, 1998, GUT, V43, P256, DOI 10.1136/gut.43.2.256; Chey WD, 2004, AM J GASTROENTEROL, V99, P2195, DOI 10.1111/j.1572-0241.2004.30509.x; Clouse RE, 2005, GUT, V54, P1332, DOI 10.1136/gut.2004.048884; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; Drossman DA, 2002, GASTROENTEROLOGY, V123, P2108, DOI 10.1053/gast.2002.37095; Evans BW, 2004, COCHRANE DB SYST REV, pCD003960, DOI DOI 10.1002/14651858.CD003960.PUB2; FRANCIS CY, 1994, LANCET, V344, P39, DOI 10.1016/S0140-6736(94)91055-3; GUTHRIE E, 1987, BRIT MED J, V295, P577, DOI 10.1136/bmj.295.6598.577; JONES VA, 1982, LANCET, V2, P1115; Lackner JA, 2004, J CONSULT CLIN PSYCH, V72, P1100, DOI 10.1037/0022-006X.72.6.1100; Locke GR, 2000, AM J GASTROENTEROL, V95, P157, DOI 10.1111/j.1572-0241.2000.01678.x; Longstreth GF, 2004, GASTROENTEROLOGY, V126, P1665, DOI 10.1053/j.gastro.2004.02.020; Maxwell PR, 2002, AM J GASTROENTEROL, V97, P104; Miller V, 2004, CLIN GASTROENTEROL H, V2, P1064, DOI 10.1016/S1542-3565(04)00545-2; O'Mahony L, 2005, GASTROENTEROLOGY, V128, P541, DOI 10.1053/j.gastro.2004.11.050; Shanahan F, 2005, AM J GASTROENTEROL, V100, P1558, DOI 10.1111/j.1572-0241.2005.50009.x; Spiegel BMR, 2004, GASTROENTEROLOGY, V126, P1721, DOI 10.1053/j.gastro.2004.03.012; Spiller R, 2005, GASTROENTEROLOGY, V128, P783, DOI 10.1053/j.gastro.2005.01.018; Tan G, 2005, AM J CLIN HYPN, V47, P161, DOI 10.1080/00029157.2005.10401481; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37; Wilson S, 2004, BRIT J GEN PRACT, V54, P495; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044	22	60	61	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2006	332	7536					280	283		10.1136/bmj.332.7536.280	http://dx.doi.org/10.1136/bmj.332.7536.280			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455728	Green Published			2022-12-28	WOS:000235259000023
J	Gregson, S; Garnett, GP; Nyamukapa, CA; Hallett, TB; Lewis, JJC; Mason, PR; Chandiwana, SK; Anderson, RM				Gregson, S; Garnett, GP; Nyamukapa, CA; Hallett, TB; Lewis, JJC; Mason, PR; Chandiwana, SK; Anderson, RM			HIV decline associated with behavior change in Eastern Zimbabwe	SCIENCE			English	Article							SUB-SAHARAN AFRICA; SEXUAL-BEHAVIOR; RISK BEHAVIOR; POPULATION; TRANSMISSION; PREVALENCE; SURVEILLANCE; INFECTION; MORTALITY; DYNAMICS	Few sub-Saharan African countries have witnessed declines in HIV prevalence, and only Uganda has compelling evidence for a decline founded on sexual behavior change. We report a decline in HIV prevalence in eastern Zimbabwe between 1998 and 2003 associated with sexual behavior change in four distinct socioeconomic strata. HIV prevalence fell most steeply at young ages-by 23 and 49%, respectively, among men aged 17 to 29 years and women aged 15 to 24 years-and in more educated groups. Sexually experienced men and women reported reductions in casual sex of 49 and 22%, respectively, whereas recent cohorts reported delayed sexual debut. Selective AIDS-induced mortality contributed to the decline in HIV prevalence.	Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London SW7 2AZ, England; Biomed Res & Training Inst, Harare, Zimbabwe; Univ Witwatersrand, Fac Hlth Sci Res & Postgrad Studies, Johannesburg, South Africa	Imperial College London; Biomedical Research Training Institute; University of Witwatersrand	Gregson, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London SW7 2AZ, England.	Sajgregson@aol.com	Garnett, Geoffrey P/A-9312-2008; Lewis, James/F-6333-2013	Lewis, James/0000-0002-8603-2761; Nyamukapa, Constance/0000-0001-6779-4069; Gregson, Simon/0000-0003-2707-0714; Anderson, Roy/0000-0002-9528-3175; Hallett, Timothy/0000-0002-9681-0424	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; Asamoah-Odei E, 2004, LANCET, V364, P35, DOI 10.1016/S0140-6736(04)16587-2; AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; Boily MC, 2002, AIDS, V16, P2101, DOI 10.1097/00002030-200210180-00025; Catania JA, 1999, J SEX RES, V36, P25, DOI 10.1080/00224499909551964; Decosas J, 2002, SEX TRANSM INFECT, V78, pI40, DOI 10.1136/sti.78.suppl_1.i40; Fylkesnes K, 1998, AIDS, V12, P1227, DOI 10.1097/00002030-199810000-00015; GARNETT GP, 1994, IMA J MATH APPL MED, V11, P161; Gisselquist D, 2002, INT J STD AIDS, V13, P657, DOI 10.1258/095646202760326390; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Gregson S, 2004, SEX TRANSM INFECT, V80, P36, DOI 10.1136/sti.2004.012088; Gregson S., 2001, Journal of International Development, V13, P467, DOI 10.1002/jid.798; Gregson S, 2002, AIDS, V16, P643, DOI 10.1097/00002030-200203080-00017; Gregson S, 2000, AIDS, V14, pS85; Kilian AHD, 1999, AIDS, V13, P391, DOI 10.1097/00002030-199902250-00012; Lopman BA, 2005, PLOS MED, V2, P142, DOI 10.1371/journal.pmed.0020037; MAHOMVA A, IN PRESS SEX TRANSM; Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MUNDANDI C, IN PRESS TROP MED IN; Mwaluko G, 2003, AIDS, V17, P2645, DOI 10.1097/00002030-200312050-00012; Parkhurst JO, 2002, LANCET, V360, P78, DOI 10.1016/S0140-6736(02)09340-6; Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166; UNAIDS, 1999, TRENDS HIV INC PREV; WAWER MJ, 2005, 12 ANN RETR C BOST U; World Bank, 2002, REP BUILD I MARK; *ZIMB MIN HLTH CHI, 2003, ZIMB NAT HIV AIDS ES	27	253	256	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					664	666		10.1126/science.1121054	http://dx.doi.org/10.1126/science.1121054			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456081				2022-12-28	WOS:000235257400049
J	Kim, DHD; Yu, VL				Kim, DHD; Yu, VL			A medical mystery - Concentric calcification	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Vet Affairs Med Ctr, Pittsburgh, PA 15240 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kim, DHD (corresponding author), Vet Affairs Med Ctr, Pittsburgh, PA 15240 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					508	508		10.1056/NEJMicm040259	http://dx.doi.org/10.1056/NEJMicm040259			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452562				2022-12-28	WOS:000235019400010
J	Wain-Hobson, S				Wain-Hobson, S			The third Bond	NATURE			English	Editorial Material									Inst Pasteur, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Wain-Hobson, S (corresponding author), Inst Pasteur, Paris, France.							DONOHUE J, 1956, P NATL ACAD SCI USA, V42, P60, DOI 10.1073/pnas.42.2.60; PAULING L, 1956, ARCH BIOCHEM BIOPHYS, V65, P164, DOI 10.1016/0003-9861(56)90185-0	2	7	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2006	439	7076					539	539		10.1038/439539a	http://dx.doi.org/10.1038/439539a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452962	Bronze			2022-12-28	WOS:000235033900024
J	He, FJ; Nowson, CA; MacGregor, GA				He, FJ; Nowson, CA; MacGregor, GA			Fruit and vegetable consumption and stroke: meta-analysis of cohort studies	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; MALE SMOKERS; RISK; POTASSIUM; SUPPLEMENTATION; MORTALITY; HOMOCYSTEINE	Background Increased consumption of fruit and vegetables has been shown to be associated with a reduced risk of stroke in most epidemiological studies, although the extent of the association is uncertain. We quantitatively assessed the relation between fruit and vegetable intake and incidence of stroke in a meta-analysis of cohort studies. Methods We searched MEDLINE, EMBASE, the Cochrane Library, and bibliographies of retrieved articles. Studies were included if they reported relative risks and corresponding 95% CIs of stroke with respect to frequency of fruit and vegetable intake. Findings Eight studies, consisting of nine independent cohorts, met the inclusion criteria. These groups included 257 551 individuals (4917 stroke events) with an average follow-up of 13 years. Compared with individuals who had less than three servings of fruit and vegetables per day, the pooled relative risk of stroke was 0.89 (95% CI 0.83-0.97) for those with three to five servings per day, and 0.74 (0.69-0.79) for those with more than five servings per day. Subgroup analyses showed that fruit and vegetables had a significant protective effect on both ischaemic and haemorrhagic stroke. Interpretation Increased fruit and vegetable intake in the range commonly consumed is associated with a reduced risk of stroke. Our results provide strong support for the recommendations to consume more than five servings of fruit and vegetables per day, which is likely to cause a major reduction in strokes.	St Georges Univ London, Blood Pressure Unit, London SW17 0RE, England; Deakin Univ, Ctr Phys Activ & Nutr Res, Sch Exercise & Nutr Sci, Geelong, Vic 3217, Australia	St Georges University London; Deakin University	He, FJ (corresponding author), St Georges Univ London, Blood Pressure Unit, London SW17 0RE, England.	fhe@sgul.ac.uk	He, Feng/HHS-6457-2022	He, Feng/0000-0002-1996-0744; He, Feng/0000-0003-2807-4119; Nowson, Caryl/0000-0001-6586-7965				APPEL LJ, 1997, NEW ENGL J MED, V336, P117; Bazzano LA, 2002, AM J CLIN NUTR, V76, P93; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; He FJ, 2005, HYPERTENSION, V45, P571, DOI 10.1161/01.HYP.0000158264.36590.19; He FJ, 2001, BMJ-BRIT MED J, V323, P497, DOI 10.1136/bmj.323.7311.497; He J, 1999, CLIN EXP HYPERTENS, V21, P785, DOI 10.3109/10641969909061008; Hirvonen T, 2000, STROKE, V31, P2301, DOI 10.1161/01.STR.31.10.2301; Ishimitsu T, 1995, J VASC RES, V32, P406, DOI 10.1159/000159116; John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6; Johnsen SP, 2003, AM J CLIN NUTR, V78, P57, DOI 10.1093/ajcn/78.1.57; Joint WHO/FAO Expert Consultation, DIET NUTR PREV CHRON; Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Law MR, 1998, EUR J CLIN NUTR, V52, P549, DOI 10.1038/sj.ejcn.1600603; Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230; Leppala JM, 1999, EUR J EPIDEMIOL, V15, P155, DOI 10.1023/A:1007504310431; MACGREGOR GA, 1982, LANCET, V2, P567; Ness AR, 1999, J CARDIOVASC RISK, V6, P229; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; Sauvaget C, 2003, STROKE, V34, P2355, DOI 10.1161/01.STR.0000089293.29739.97; Steffen LM, 2003, AM J CLIN NUTR, V78, P383, DOI 10.1093/ajcn/78.3.383; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; *USDA US DEP HHS, DIET GUID AM; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Young DB, 1999, SEMIN NEPHROL, V19, P477; 1994, REPORT CARDIOVASCULA	31	715	738	2	73	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					320	326		10.1016/S0140-6736(06)68069-0	http://dx.doi.org/10.1016/S0140-6736(06)68069-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443039				2022-12-28	WOS:000235084600028
J	Jefferson, T; Demicheli, V; Rivetti, D; Jones, M; Di Pietrantonj, C; Rivetti, A				Jefferson, T; Demicheli, V; Rivetti, D; Jones, M; Di Pietrantonj, C; Rivetti, A			Antivirals for influenza in healthy adults: systematic review	LANCET			English	Article							NEURAMINIDASE INHIBITOR ZANAMIVIR; RANDOMIZED CONTROLLED-TRIAL; HONG-KONG INFLUENZA; CONTROLLED FIELD TRIAL; B VIRUS-INFECTIONS; A H5N1 INFECTION; AMANTADINE HYDROCHLORIDE; DOUBLE-BLIND; RIMANTADINE HYDROCHLORIDE; OSELTAMIVIR TREATMENT	Background Use of antivirals is recommended for the control of seasonal and pandemic influenza. Our aim was to review the evidence of efficacy, effectiveness, and safety of registered antivirals against naturally occurring influenza in healthy adults. Methods We searched various Databases to October, 2005, and contacted manufacturers and corresponding authors. We included randomised controlled trials comparing prophylactic (n=27) or treatment (n=27) efficacy against symptomatic or asymptomatic influenza. We did a meta-analysis and expressed prophylactic efficacy as a proportion (1-relative risk [RR]). For treatment trials, because of inconsistent and non-standardised reporting, we expressed continuous outcomes either as means or as hazard ratios. Findings We included 51 reports of 52 randomised controlled trials. Amantadine prevented 61% (95% Cl 35-76) of influenza A cases and 25% (13-36) of cases of influenza-like illness, but caused nausea (OR 2.56, 1.37-4.79), insomnia and hallucinations (2.54,1.50-4.31), and withdrawals because of adverse events (2.54,1.60-4.06). There was no effect on symptomatic cases (RR 0.85, 0.40-1.80). In treatment, amantadine significantly shortened duration of fever compared with placebo (by 0.99 days, - 1.26 to - 0.71), but had no effect on nasal shedding of influenza A viruses (0 - 93, 0.71-1.21). The fewer data for rimantadine showed comparable effects. in prophylaxis, compared with placebo, neuraminidase inhibitors have no effect against influenza-like illness (1.28, 0.45-3.66 for oral oseltamivir 75 mg daily, 1.51, 0.77-2.95 for inhaled zanamivir 10 mg daily). Higher doses appear to make no difference. The efficacy of oral oseltamivir 75 mg daily against symptomatic influenza is 61% (15-82), or 73% (33-89) at 150 mg daily. Inhaled zanamivir 10 mg daily is 62% efficacious (15-83). Neither neuraminidase inhibitor appeared effective against asymptomatic influenza. Oseltamivir induces nausea (OR 1 - 79, 1.10-2.93), especially at higher prophylactic doses (2.29, 1.34-.3.92). Oseltamivir in a post-exposure prophylaxis role has a protective efficacy of 58.5% (15.6-79.6) for households and from 68% (34.9-84.2) to 89% (67-97) in contacts of index cases. in influenza cases, compared with placebo the hazard ratios for time to alleviation of symptoms were 1.33, 1.29-1.37 for zanamivir; 1.30, 1.13-1.50 for oseltamivir provided medication was started within 48 h of symptom onset. Viral nasal titres were significantly diminished by both drugs (weighted mean difference -0.62, -0.82 to -0.41). Oseltamivir at 150 mg daily was effective in preventing lower respiratory tract complications in influenza cases (OR 0.32, 0.18-0.57). We could find no credible data on the effects of oseltamivir on avian influenza. Interpretation The use of amantadine and rimantadine should be discouraged. Because of their low effectiveness, neuraminidase inhibitors should not be used in seasonal influenza control and should only be used in a serious epidemic or pandemic alongside other public-health measures.	Cochrane Vaccines Field, I-15100 Alessandria, Italy; Univ Queensland, Queensland Clin Trials Ctr, St Lucia, Qld 4067, Australia	University of Queensland	Jefferson, T (corresponding author), Cochrane Vaccines Field, ASL 20, I-15100 Alessandria, Italy.	Toj1@aol.com	Di Pietrantonj, Carlo/AAK-1340-2020; Jones, Mark/I-2720-2016	Di Pietrantonj, Carlo/0000-0002-7302-5714; Jones, Mark/0000-0001-6858-9710				Aoki FY, 2000, PHARMACOECONOMICS, V17, P187, DOI 10.2165/00019053-200017020-00007; AOKI FY, 1998, TXB INFLUENZA, P457; Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; Boivin G, 2000, J INFECT DIS, V181, P1471, DOI 10.1086/315392; BRADY MT, 1990, ANTIMICROB AGENTS CH, V34, P1633, DOI 10.1128/AAC.34.9.1633; Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; Burls A, 2002, Health Technol Assess, V6, P1; CALLMANDER E, 1968, J CLIN PHARMACOL N D, V8, P186, DOI 10.1002/j.1552-4604.1968.tb00269.x; Cooper NJ, 2003, BRIT MED J, V326, P1235, DOI 10.1136/bmj.326.7401.1235; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; DEEKS JJ, 2004, COCHRANE REV HDB 4 2; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; *EUR MED AG, 2005, SUMM REP REV INFL AN; GALBRAIT.AW, 1971, LANCET, V2, P113; Hayden FG, 2004, J INFECT DIS, V189, P440, DOI 10.1086/381128; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; HAYDEN FG, 1980, J INFECT DIS, V141, P535, DOI 10.1093/infdis/141.5.535; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; HAYDEN FG, 1986, ANTIMICROB AGENTS CH, V29, P339, DOI 10.1128/AAC.29.2.339; HAYDEN FG, 1981, ANTIMICROB AGENTS CH, V19, P226, DOI 10.1128/AAC.19.2.226; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HORNICK RB, 1969, B WORLD HEALTH ORGAN, V41, P671; Hurlburt RT, 1994, COMPREHENDING BEHAV; Ito S, 2000, Nihon Kokyuki Gakkai Zasshi, V38, P897; JEFFERSON T, 1999, COCHRANE DB SYST REV, V2, P1265; Jefferson T, 2004, COCHRANE DB SYST REV, V3; Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667; Kaiser L, 2000, CLIN INFECT DIS, V30, P587, DOI 10.1086/313696; KANTOR RJ, 1980, MIL MED, V145, P312; Kashiwagi S, 2000, Kansenshogaku Zasshi, V74, P1062; Kashiwagi S, 2000, Kansenshogaku Zasshi, V74, P1044; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; KITAMOTO O, 1971, Japanese Journal of Tuberculosis and Chest Diseases, V17, P1; KITAMOTO O, 1968, Japanese Journal of Tuberculosis and Chest Diseases, V15, P17; KNIGHT V, 1970, Infection and Immunity, V1, P200; Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X; Li LY, 2003, CHINESE MED J-PEKING, V116, P44; Makela MJ, 2000, J INFECTION, V40, P42, DOI 10.1053/jinf.1999.0602; MATE J, 1970, ACTA MICROBIOL HUNG, V17, P285; Matsumoto K, 1999, ANTIVIR THER, V4, P61; MILLET VM, 1982, ANTIMICROB AGENTS CH, V21, P1; MONTO AS, 1979, JAMA-J AM MED ASSOC, V241, P1003, DOI 10.1001/jama.241.10.1003; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; MULDOON RL, 1976, AM REV RESPIR DIS, V113, P487; NAFTA I, 1970, B WORLD HEALTH ORGAN, V42, P423; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; OKERBLOM N, 1970, BMJ-BRIT MED J, V3, P676, DOI 10.1136/bmj.3.5724.676; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PAYLER DK, 1984, LANCET, V1, P502; PECKINPA.RO, 1970, ANN NY ACAD SCI, V173, P62, DOI 10.1111/j.1749-6632.1970.tb53390.x; PETTERSSON RF, 1980, J INFECT DIS, V142, P377, DOI 10.1093/infdis/142.3.377; Plesnik V, 1977, Cesk Epidemiol Mikrobiol Imunol, V26, P216; Puhakka T, 2003, SCAND J INFECT DIS, V35, P52, DOI 10.1080/0036554021000026981; QUARLES JM, 1981, ANTIVIR RES, V1, P149, DOI 10.1016/0166-3542(81)90003-6; RABINOVICH S, 1969, AM J MED SCI, V257, P328, DOI 10.1097/00000441-196905000-00005; REUMAN PD, 1989, ANTIVIR RES, V11, P27, DOI 10.1016/0166-3542(89)90018-1; Schapira M, 1971, J R Coll Gen Pract, V21, P695; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; SMORODINTSEV AA, 1970, B WORLD HEALTH ORGAN, V42, P865; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Turner David, 2003, HEALTH TECHNOL ASSES, V7, P1, DOI DOI 10.3310/HTA7350; Tweed SA, 2004, EMERG INFECT DIS, V10, P2196, DOI 10.3201/eid1012.040961; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; WARD P, 2005, J ANTIMICROB CHEM S1, V55, pI15; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; WENDEL HA, 1966, CLIN PHARMACOL THER, V7, P38; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102; World Health Organization, GLOB AG INFL SURV CO; YOUNKIN SW, 1983, ANTIMICROB AGENTS CH, V23, P577, DOI 10.1128/AAC.23.4.577; YUEN KY, 2005, HONG KONG MED J, V3, P189	71	188	226	1	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	2006	367	9507					303	313		10.1016/S0140-6736(06)67970-1	http://dx.doi.org/10.1016/S0140-6736(06)67970-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443037				2022-12-28	WOS:000235084600026
J	Andersson, E; Tryggvason, U; Deng, QL; Friling, S; Alekseenko, Z; Robert, B; Perlmann, T; Ericson, J				Andersson, E; Tryggvason, U; Deng, QL; Friling, S; Alekseenko, Z; Robert, B; Perlmann, T; Ericson, J			Identification of intrinsic determinants of midbrain dopamine neurons	CELL			English	Article							EMBRYONIC STEM-CELLS; DEVELOPING SPINAL-CORD; CENTRAL-NERVOUS-SYSTEM; VENTRAL NEURAL-TUBE; HOMEOBOX GENE; FLOOR PLATE; SUBSTANTIA-NIGRA; VERTEBRATE CNS; MOTOR-NEURON; ROOF PLATE	The prospect of using cell replacement therapies has raised the key issue of whether elucidation of developmental pathways can facilitate the generation of therapeutically important cell types from stem cells. Here we show that the homeodomain proteins Lmx1 a and Msx1 function as determinants of midbrain dopamine neurons, cells that degenerate in patients with Parkinson's disease. Lmx1 a is sufficient and required to trigger dopamine cell differentiation. An early activity of Lmx1 a is to induce the expression of Msx1, which complements Lmx1a by inducing the proneural protein Ngn2 and neuronal differentiation. Importantly, expression of Lmx1 a in embryonic stem cells results in a robust generation of dopamine neurons with a "correct" midbrain identity. These data establish that Lmx1 a and Msx1 are critical intrinsic dopamine-neuron determinants in vivo and suggest that they may be essential tools in cell replacement strategies in Parkinson's disease.	Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden; Inst Pasteur, CNRS, F-75724 Paris 15, France	Karolinska Institutet; Ludwig Institute for Cancer Research; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Perlmann, T (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.	thomas.perlmann@licr.ki.se; johan.ericson@cmb.ki.se	Marklund, Ulrika/I-8814-2012; Deng, Qiaolin/AAD-6905-2020	Marklund, Ulrika/0000-0003-1426-1271; andersson, elisabet/0000-0003-3095-465X; Alekseenko, Zhanna/0000-0002-6560-9699; Ericson, Johan/0000-0002-8019-7127; Deng, Qiaolin/0000-0001-5934-7816				Arendt D, 1999, DEVELOPMENT, V126, P2309; Asbreuk CHJ, 2002, MOL CELL NEUROSCI, V21, P410, DOI 10.1006/mcne.2002.1182; Bach A, 2003, DEVELOPMENT, V130, P4025, DOI 10.1242/dev.00609; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Chizhikov VV, 2004, DEVELOPMENT, V131, P2693, DOI 10.1242/dev.01139; Chizhikov VV, 2004, J NEUROSCI, V24, P5694, DOI 10.1523/JNEUROSCI.0758-04.2004; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; Dhawan R R, 1997, Mol Vis, V3, P7; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Epstein DJ, 1999, DEVELOPMENT, V126, P281; Failli V, 2002, MECH DEVELOP, V118, P225, DOI 10.1016/S0925-4773(02)00254-X; GONZALEZ A, 1991, J COMP NEUROL, V303, P457, DOI 10.1002/cne.903030311; Houzelstein D, 1997, MECH DEVELOP, V65, P123, DOI 10.1016/S0925-4773(97)00065-8; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; Hynes M, 1999, CURR OPIN NEUROBIOL, V9, P26, DOI 10.1016/S0959-4388(99)80004-X; HYNES M, 1995, NEURON, V15, P95; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lee SK, 2004, DEVELOPMENT, V131, P3295, DOI 10.1242/dev.01179; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; Martinez S, 2001, INT J DEV BIOL, V45, P367; Millonig JH, 2000, NATURE, V403, P764, DOI 10.1038/35001573; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Novitch BG, 2003, NEURON, V40, P81, DOI 10.1016/j.neuron.2003.08.006; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Nunes I, 2003, P NATL ACAD SCI USA, V100, P4245, DOI 10.1073/pnas.0230529100; O'Hara FP, 2005, DEVELOPMENT, V132, P3163, DOI 10.1242/dev.01898; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Pierani A, 2001, NEURON, V29, P367, DOI 10.1016/S0896-6273(01)00212-4; Placzek M, 2005, NAT REV NEUROSCI, V6, P230, DOI 10.1038/nrn1628; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; Simone HH, 1998, EUR J NEUROSCI, V10, P389; Smidt MP, 2000, NAT NEUROSCI, V3, P337, DOI 10.1038/73902; Smidt MP, 2004, CELL TISSUE RES, V318, P35, DOI 10.1007/s00441-004-0943-1; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; Vallstedt A, 2001, NEURON, V31, P743, DOI 10.1016/S0896-6273(01)00412-3; van den Munckhof P, 2003, DEVELOPMENT, V130, P2535, DOI 10.1242/dev.00464; Wallen A, 2003, ANN NY ACAD SCI, V991, P48; Wang WD, 1996, MECH DEVELOP, V58, P203, DOI 10.1016/S0925-4773(96)00562-X; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wilkinson DG., 1992, SITU HYBRIDIZATION P, P75; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhao SL, 2004, EUR J NEUROSCI, V19, P1133, DOI 10.1111/j.1460-9568.2004.03206.x; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	57	446	458	2	35	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 27	2006	124	2					393	405		10.1016/j.cell.2005.10.037	http://dx.doi.org/10.1016/j.cell.2005.10.037			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439212	Bronze			2022-12-28	WOS:000235068500026
J	Katayama, Y; Battista, M; Kao, WM; Hidalgo, A; Peired, AJ; Thomas, SA; Frenette, PS				Katayama, Y; Battista, M; Kao, WM; Hidalgo, A; Peired, AJ; Thomas, SA; Frenette, PS			Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow	CELL			English	Article							COLONY-STIMULATING FACTOR; PROGENITOR CELLS; G-CSF; FACTOR-I; BLOOD STEM; MOBILIZATION; EXPRESSION; INNERVATION; SELECTIN; GALACTOCEREBROSIDE	Hematopoietic stem and progenitor cells (HSPC), attracted by the chemokine CXCL12, reside in specific niches in the bone marrow (BM). HSPC migration out of the BM is a critical process that underlies modern clinical stem cell transplantation. Here we demonstrate that enforced HSPC egress from BM niches depends critically on the nervous system. UDP-galactose ceramide galactosyltransferase-deficient (Cgt(-/-)) mice exhibit aberrant nerve conduction and display virtually no HSPC egress from BM following granulocyte colony-stimulating factor (G-CSF) or fucoidan administration. Adrenergic tone, osteoblast function, and bone CXCL12 are dysregulated in Cgt(-/-) mice. Pharmacological or genetic ablation of adrenergic neurotransmission indicates that norepinephrine (NE) signaling controls G-CSF-induced osteoblast suppression, bone CXCL12 downregulation, and HSPC mobilization. Further, administration of a beta(2) adrenergic agonist enhances mobilization in both control and NE-deficient mice. Thus, these results indicate that the sympathetic nervous system regulates the attraction of stem cells to their niche.	Mt Sinai Sch Med, Immunobiol Ctr, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Black Stem Family Cell Inst, Dept Med, New York, NY 10029 USA; Okayama Univ Hosp, Dept Hematol Oncol & Resp Med, Okayama 7008558, Japan; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Okayama University; Icahn School of Medicine at Mount Sinai; University of Pennsylvania	Frenette, PS (corresponding author), Mt Sinai Sch Med, Immunobiol Ctr, Dept Med, New York, NY 10029 USA.	paul.frenette@mssm.edu	Frenette, Paul S/J-8272-2012; Peired, Anna Julie/J-9952-2019; Hidalgo, Andrés/L-5643-2014	Frenette, Paul S/0000-0003-0862-9922; Peired, Anna Julie/0000-0001-9732-1369; Hidalgo, Andrés/0000-0001-5513-555X	NHLBI NIH HHS [HL69438] Funding Source: Medline; NIDDK NIH HHS [DK56638, T32 DK07792] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abkowitz JL, 2003, BLOOD, V102, P1249, DOI 10.1182/blood-2003-01-0318; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CALVO W, 1968, AM J ANAT, V123, P315, DOI 10.1002/aja.1001230206; Chien KR, 2005, CELL, V120, P533, DOI 10.1016/j.cell.2005.02.006; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; Delezay O, 1997, AIDS, V11, P1311, DOI 10.1097/00002030-199711000-00004; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Fedyk ER, 2001, J IMMUNOL, V166, P5749, DOI 10.4049/jimmunol.166.9.5749; Frenette PS, 2000, BLOOD, V96, P2460, DOI 10.1182/blood.V96.7.2460.h8002460_2460_2468; Froberg MK, 1999, TRANSFUSION, V39, P410, DOI 10.1046/j.1537-2995.1999.39499235675.x; HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hidalgo A, 2004, BLOOD, V104, P993, DOI 10.1182/blood-2003-10-3702; Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02-0820fje; HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059; IVERSEN PO, 1994, ACTA PHYSIOL SCAND, V150, P373, DOI 10.1111/j.1748-1716.1994.tb09701.x; Katayama Y, 2003, BLOOD, V102, P2060, DOI 10.1182/blood-2003-04-1212; Katayama Y, 2003, IMMUNITY, V18, P789, DOI 10.1016/S1074-7613(03)00150-X; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KORBLING M, 1995, BLOOD, V86, P2842; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Levesque JP, 2004, BLOOD, V104, P65, DOI 10.1182/blood-2003-05-1589; Levesque JP, 2002, EXP HEMATOL, V30, P440, DOI 10.1016/S0301-472X(02)00788-9; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031; LIVNAT S, 1985, J NEUROIMMUNOL, V10, P5, DOI 10.1016/0165-5728(85)90031-1; Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378-1119(03)00841-2; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; Papayannopoulou T, 2004, BLOOD, V103, P1580, DOI 10.1182/blood-2003-05-1595; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; RING PA, 1961, J BONE JOINT SURG BR, V43, P121, DOI 10.1302/0301-620X.43B1.121; Rix M, 1999, DIABETES CARE, V22, P827, DOI 10.2337/diacare.22.5.827; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood-2004-01-0272; Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756-3282(99)00215-X; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880; Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109; Sweeney EA, 2000, P NATL ACAD SCI USA, V97, P6544, DOI 10.1073/pnas.97.12.6544; Takamatsu Y, 1998, BLOOD, V92, P3465, DOI 10.1182/blood.V92.9.3465.421k35_3465_3473; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; Ueda Y, 2004, J EXP MED, V199, P47, DOI 10.1084/jem.20031104; Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood-2003-11-4011; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Wright N, 2003, BLOOD, V102, P1978, DOI 10.1182/blood-2002-10-3190; YAMAZAKI K, 1990, AM J ANAT, V187, P261, DOI 10.1002/aja.1001870306; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	63	959	1011	1	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					407	421		10.1016/j.cell.2005.10.041	http://dx.doi.org/10.1016/j.cell.2005.10.041			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439213	Bronze			2022-12-28	WOS:000235068500027
J	Mangano, DT; Tudor, IC; Dietzel, C				Mangano, DT; Tudor, IC; Dietzel, C		Multicenter Study Perioperative Is; Ischemia Res Educ Fdn	The risk associated with aprotinin in cardiac surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DOSE APROTININ; HYPOTHERMIC CIRCULATORY ARREST; PLACEBO-CONTROLLED TRIAL; BYPASS GRAFT-SURGERY; RENAL-FUNCTION; DOUBLE-BLIND; INTRAVASCULAR COAGULATION; CARDIOPULMONARY BYPASS; PROTEASE INHIBITOR; ENDOTHELIAL-CELLS	BACKGROUND The majority of patients undergoing surgical treatment for ST-elevation myocardial infarction receive antifibrinolytic therapy to limit blood loss. This approach appears counterintuitive to the accepted medical treatment of the same condition - namely, fibrinolysis to limit thrombosis. Despite this concern, no independent, large-scale safety assessment has been undertaken. METHODS In this observational study involving 4374 patients undergoing revascularization, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 patients) with regard to serious outcomes by propensity and multivariable methods. (Although aprotinin is a serine protease inhibitor, here we use the term antifibrinolytic therapy to include all three agents.) RESULTS In propensity-adjusted, multivariable logistic regression (C-index, 0.72), use of aprotinin was associated with a doubling in the risk of renal failure requiring dialysis among patients undergoing complex coronary-artery surgery (odds ratio, 2.59; 95 percent confidence interval, 1.36 to 4.95) or primary surgery (odds ratio, 2.34; 95 percent confidence interval, 1.27 to 4.31). Similarly, use of aprotinin in the latter group was associated with a 55 percent increase in the risk of myocardial infarction or heart failure (P<0.001) and a 181 percent increase in the risk of stroke or encephalopathy (P=0.001). Neither aminocaproic acid nor tranexamic acid was associated with an increased risk of renal, cardiac, or cerebral events. Adjustment according to propensity score for the use of any one of the three agents as compared with no agent yielded nearly identical findings. All the agents reduced blood loss. CONCLUSIONS The association between aprotinin and serious end-organ damage indicates that continued use is not prudent. In contrast, the less expensive generic medications aminocaproic acid and tranexamic acid are safe alternatives.	Ischemia Res & Educ Fdn, Editorial Off, San Bruno, CA 94066 USA		Mangano, DT (corresponding author), Ischemia Res & Educ Fdn, Editorial Off, 1111 Bayhill Dr,Ste 480, San Bruno, CA 94066 USA.	dtb@iref.org						Alderman EL, 1998, J THORAC CARDIOV SUR, V116, P716, DOI 10.1016/S0022-5223(98)00431-0; Alvarez JM, 1999, J CARDIOTHOR VASC AN, V13, P623, DOI 10.1016/S1053-0770(99)90019-8; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; BELLER FK, 1967, THROMB DIATH HAEMOST, V17, P427, DOI 10.1055/s-0038-1654168; BIDSTRUP BP, 1993, J THORAC CARDIOV SUR, V105, P147, DOI 10.1016/S0022-5223(19)33859-0; BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COSGROVE DM, 1992, ANN THORAC SURG, V54, P1031, DOI 10.1016/0003-4975(92)90066-D; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DAmbra MN, 1996, J THORAC CARDIOV SUR, V112, P1081, DOI 10.1016/S0022-5223(96)70110-1; DAVIS H, 1976, IN VITRO CELL DEV B, V12, P192; Eagle Kim A, 2004, Circulation, V110, pe340; FAUST RJ, 2002, QUESTIONS ANSWERS TR, P16; FEINDT PR, 1995, ANN THORAC SURG, V60, P1076, DOI 10.1016/0003-4975(95)00525-P; FISCHER JH, 1983, LANGENBECK ARCH CHIR, V360, P241, DOI 10.1007/BF01257428; FREMES SE, 1994, ANN THORAC SURG, V58, P1580, DOI 10.1016/0003-4975(94)91636-5; HAVEL M, 1994, J THORAC CARDIOV SUR, V107, P807; HAVEL MP, 1992, J THORAC CARDIOV SUR, V104, P654; Hill GE, 1997, ANN THORAC SURG, V63, P74; Kramer H J, 1984, Contrib Nephrol, V42, P233; KRAMER HJ, 1979, CLIN SCI, V56, P547, DOI 10.1042/cs0560547; LEMMER JH, 1994, J THORAC CARDIOV SUR, V107, P543, DOI 10.1016/S0022-5223(94)70101-6; LEVY JH, 1995, CIRCULATION, V92, P2236, DOI 10.1161/01.CIR.92.8.2236; MAIER M, 1985, HYPERTENSION, V7, P32, DOI 10.1161/01.HYP.7.1.32; Mangano DT, 2002, NEW ENGL J MED, V347, P1309, DOI 10.1056/NEJMoa020798; NAKAGAWA M, 1990, AM J PHYSIOL, V258, pF643, DOI 10.1152/ajprenal.1990.258.3.F643; Penkoske PA, 1995, ANN THORAC SURG, V60, pS529, DOI 10.1016/0003-4975(95)00877-2; PFLUGER H, 1983, UROL INT, V38, P150, DOI 10.1159/000280880; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; SAFFITZ JE, 1993, AM J CARDIOL, V72, P1080, DOI 10.1016/0002-9149(93)90867-C; SAMAMA CM, 1994, THROMB HAEMOSTASIS, V71, P663; Schweizer A, 2000, BRIT J ANAESTH, V84, P16, DOI 10.1093/oxfordjournals.bja.a013374; Sedrakyan A, 2004, J THORAC CARDIOV SUR, V128, P442, DOI 10.1016/j.jtcvs.2004.03.041; SETO S, 1983, HYPERTENSION, V5, P893, DOI 10.1161/01.HYP.5.6.893; Stover EP, 2000, J CARDIOTHOR VASC AN, V14, P171; SUNDT TM, 1993, ANN THORAC SURG, V55, P1418, DOI 10.1016/0003-4975(93)91082-X; Ulker S, 2002, CARDIOVASC RES, V55, P830, DOI 10.1016/S0008-6363(02)00489-3; Umbrain V, 1994, J Cardiothorac Vasc Anesth, V8, P198, DOI 10.1016/1053-0770(94)90062-0; VANOEVEREN W, 1990, J THORAC CARDIOV SUR, V99, P788; Vio CP, 1998, BIOL CHEM, V379, P1271, DOI 10.1515/bchm.1998.379.10.1271	40	780	830	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					353	365		10.1056/NEJMoa051379	http://dx.doi.org/10.1056/NEJMoa051379			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436767				2022-12-28	WOS:000234854000007
J	Goldblatt, P				Goldblatt, P			Commentary: Evidence will help achieve consensus	BRITISH MEDICAL JOURNAL			English	Editorial Material									Off Natl Stat, London SW1V 2QQ, England		Goldblatt, P (corresponding author), Off Natl Stat, London SW1V 2QQ, England.	Peter.Goldblatt@ons.gsi.gov.uk						Department of Health, 2003, CONF NHS COD PRACT; Iversen A, 2006, BRIT MED J, V332, P165, DOI 10.1136/bmj.332.7534.165	2	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					169	169		10.1136/bmj.332.7534.169	http://dx.doi.org/10.1136/bmj.332.7534.169			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424498	Green Published			2022-12-28	WOS:000234905800029
J	Gallant, JE; DeJesus, E; Arribas, JR; Pozniak, AL; Gazzard, B; Campo, RE; Lu, B; McColl, D; Chuck, S; Enejosa, J; Toole, JJ; Cheng, AK				Gallant, JE; DeJesus, E; Arribas, JR; Pozniak, AL; Gazzard, B; Campo, RE; Lu, B; McColl, D; Chuck, S; Enejosa, J; Toole, JJ; Cheng, AK		Study 934 Grp	Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; VIRUS-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; FANCONI-SYNDROME; SERUM CREATININE; DRUG-RESISTANCE; RENAL-FAILURE; ABACAVIR; ADULTS; ABNORMALITIES	BACKGROUND: Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere. METHODS: We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz once daily (tenofovir-emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz once daily (zidovudine-lamivudine group). The primary end point was the proportion of patients without baseline resistance to efavirenz in whom the HIV RNA level was less than 400 copies per milliliter at week 48 of the study. RESULTS: Through week 48, significantly more patients in the tenofovir-emtricitabine group reached and maintained the primary end point of less than 400 copies of HIV RNA per milliliter than did those in the zidovudine-lamivudine group (84 percent vs. 73 percent, respectively; 95 percent confidence interval for the difference, 4 to 19 percent; P=0.002). This difference excludes the inferiority of the tenofovir DF, emtricitabine, and efavirenz regimen, indicating a significantly greater response with this regimen. Significant differences were also seen in the proportion of patients with HIV RNA levels of less than 50 copies per milliliter (80 percent in the tenofovir-emtricitabine group vs. 70 percent in the zidovudine-lamivudine group; 95 percent confidence interval for the difference, 2 to 17 percent; P=0.02) and in increases in CD4 cell counts (190 vs. 158 cells per cubic millimeter, respectively; 95 percent confidence interval for the difference, 9 to 55; P=0.002). More patients in the zidovudine-lamivudine group than in the tenofovir-emtricitabine group had adverse events resulting in discontinuation of the study drugs (9 percent vs. 4 percent, respectively; P=0.02). In none of the patients did the K65R mutation develop. CONCLUSIONS: Through week 48, the combination of tenofovir DF and emtricitabine plus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA; Orlando Immunol Ctr, Orlando, FL USA; Hosp La Paz, Madrid, Spain; Chelsea & Westminster Hosp, London, England; Univ Miami, Miami, FL 33152 USA; Gilead Sci Inc, Foster City, CA 94404 USA	Johns Hopkins University; Orlando Immunology Center; Hospital Universitario La Paz; Imperial College London; University of Miami; Gilead Sciences	Gallant, JE (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Rm 443, Baltimore, MD 21287 USA.	jgallant@jhmi.edu	Arribas, Jose/A-1595-2015	Arribas, Jose/0000-0002-7410-9450				Bogner JR, 2001, J ACQ IMMUN DEF SYND, V27, P237, DOI 10.1097/00126334-200107010-00004; CASSETTI I, 2005, 3 IAS INT AIDS SOC C; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Creput C, 2003, AIDS, V17, P935, DOI 10.1097/00002030-200304110-00026; DeJesus E, 2004, CLIN INFECT DIS, V39, P1038, DOI 10.1086/424009; *DEP HLTH HUM SERV, 2005, PAN CLIN PRACT TREAT; Dube MP, 2005, AIDS, V19, P1807, DOI 10.1097/01.aids.0000183629.20041.bb; Gallant JE, 2005, CLIN INFECT DIS, V40, P1194, DOI 10.1086/428840; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Heath KV, 2002, J ACQ IMMUN DEF SYND, V30, P440, DOI [10.1097/00042560-200208010-00010, 10.1097/01.QAI.0000021701.48448.20]; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Karras A, 2003, CLIN INFECT DIS, V36, P1070, DOI 10.1086/368314; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; McComsey GA, 2004, CLIN INFECT DIS, V38, P263, DOI 10.1086/380790; MILLER MD, 2002, 6 INT C DRUG THER HI; MOYLE G, 2005, 12 C RETR OPP INF BO; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *REG COMPL CTR, 1992, DIV AIDS DAIDS TABL; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Rollot F, 2003, CLIN INFECT DIS, V37, pE174, DOI 10.1086/379829; Saint-Marc T, 2000, AIDS, V14, P37, DOI 10.1097/00002030-200001070-00005; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; US Department of Health and Human Services Food and Drug Administration, 2002, GUID IND ANT DRUGS U; Verhelst D, 2002, AM J KIDNEY DIS, V40, P1331, DOI 10.1053/ajkd.2002.36924	27	711	735	3	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					251	260		10.1056/NEJMoa051871	http://dx.doi.org/10.1056/NEJMoa051871			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421366				2022-12-28	WOS:000234661100005
J	Raper, SCB; Braithwaite, RJ				Raper, SCB; Braithwaite, RJ			Low sea level rise projections from mountain glaciers and icecaps under global warming	NATURE			English	Article							CLIMATE-CHANGE	The mean sea level has been projected to rise in the 21st century as a result of global warming(1). Such projections of sea level change depend on estimated future greenhouse emissions and on differing models, but model-average results from a mid-range scenario (A1B) suggests a 0.387-m rise by 2100 (refs 1, 2). The largest contributions to sea level rise are estimated to come from thermal expansion (0.288 m) and the melting of mountain glaciers and icecaps (0.106 m), with smaller inputs from Greenland (0.024 m) and Antarctica (20.074 m)(1). Here we apply a melt model(3) and a geometric volume model(4) to our lower estimate of ice volume(5-7) and assess the contribution of glaciers to sea level rise, excluding those in Greenland and Antarctica. We provide the first separate assessment of melt contributions from mountain glaciers and icecaps, as well as an improved treatment of volume shrinkage. We find that icecaps melt more slowly than mountain glaciers, whose area declines rapidly in the 21st century, making glaciers a limiting source for ice melt. Using two climate models, we project sea level rise due to melting of mountain glaciers and icecaps to be 0.046 and 0.051 m by 2100, about half that of previous projections(1,8).	Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany; Univ Manchester, Sch Environm & Dev, Manchester M13 9PL, Lancs, England	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; University of Manchester	Raper, SCB (corresponding author), Manchester Metropolitan Univ, Dalton Res Inst, CATE, Manchester M1 5GD, Lancs, England.	s.raper@mmu.ac.uk	Braithwaite, Roger James/AGW-0328-2022	Braithwaite, Roger/0000-0002-0387-7591				[Anonymous], 2000, SPECIAL REPORT EMISS; Arendt AA, 2002, SCIENCE, V297, P382, DOI 10.1126/science.1072497; Braithwaite RJ, 2002, PHYS CHEM EARTH, V27, P1445, DOI 10.1016/S1474-7065(02)00089-X; Braithwaite RJ., 2002, Z GLETSCHERKD GLAZIA, V38, P35; Church JA, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P639; COGLEY JG, 2003, 20031 GGHYDRO TRENT; Dyurgerov MB, 2000, P NATL ACAD SCI USA, V97, P1406, DOI 10.1073/pnas.97.4.1406; Dyurgerov MB, 1997, ARCTIC ALPINE RES, V29, P379, DOI 10.2307/1551986; *GEOPH FLUID DYN L, 2005, GFDL CM2 MOD; *GLOBE, 1997, NAT GEOD SURV DAT SE; KOTLYAKOV VM, 1997, WORLD ATLAS SNOW ICE, P1; Meehl GA, 2005, SCIENCE, V307, P1769, DOI 10.1126/science.1106663; MEIER F, 2005, GEOPHYS RES LETT, V32, DOI DOI 10.1029/2005GL023319; MEIER MF, 1996, GLACIERS ICE SHEETS, P89; New M, 1999, J CLIMATE, V12, P829, DOI 10.1175/1520-0442(1999)012<0829:RTCSTC>2.0.CO;2; *NSIDC, 1999, WORLD GLAC INV; Oerlemans J., 1993, ICE CLIMATE SYSTEM, V12, P101; Paterson W.S.B., 1994, PHYS GLACIERS, P480; Raper SCB, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021981; Raper SCB, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023460; Raper SCB, 2000, J GLACIOL, V46, P357, DOI 10.3189/172756500781833034; Rignot E, 2003, SCIENCE, V302, P434, DOI 10.1126/science.1087393; Van de Wal RSW, 2001, CLIM DYNAM, V18, P359, DOI 10.1007/s003820100184	23	203	222	6	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					311	313		10.1038/nature04448	http://dx.doi.org/10.1038/nature04448			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421567				2022-12-28	WOS:000234682100039
J	Perez-Moreno, M; Davis, MA; Wong, E; Pasolli, HA; Reynolds, AB; Fuchs, E				Perez-Moreno, M; Davis, MA; Wong, E; Pasolli, HA; Reynolds, AB; Fuchs, E			p120-Catenin mediates inflammatory responses in the skin	CELL			English	Article							NF-KAPPA-B; E-CADHERIN FUNCTION; RHO-FAMILY GTPASES; P120 CATENIN; CELL-ADHESION; BETA-CATENIN; EPIDERMAL MORPHOGENESIS; JUXTAMEMBRANE REGION; ADHERENS JUNCTION; ALPHA-CATENIN	Although p120-catenin regulates adherens junction (AJ) stability in cultured cells, genetic studies in lower eukaryotes have not revealed a role for this protein in vivo. Using conditional targeting in mice, we show that p120 null neonatal epidermis exhibits reduced intercellular AJ components but no overt disruption in barrier function or intercellular adhesion. As the mice age, however, they display epidermal hyperplasia and chronic inflammation, typified by hair degeneration and loss of body fat. Using skin engraftments and anti-inflammatory drugs, we show that these features are not attributable to reductions in junctional cadherins and catenins, but rather NFkB activation. Both in vivo and in vitro, p120 null epidermal cells activate nuclear NFkB, triggering a cascade of proinflammatory NFkB targets. Although the underlying mechanism is likely complex, we show that p120 affects NFkB activation and immune homeostasis in part through regulation of Rho GTPases. These findings provide important new insights into p120 function.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Rockefeller University; Vanderbilt University	Perez-Moreno, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA.	al.reynolds@vanderbilt.edu; fuchslb@rockefeller.edu	Perez-Moreno, Mirna/I-3687-2015; Fuchs, Elaine/G-1565-2016	Perez-Moreno, Mirna/0000-0002-0170-6406; Pasolli, Hilda Amalia/0000-0003-3899-3530; Davis, Michael/0000-0002-5406-4128	NATIONAL CANCER INSTITUTE [R29CA055724, P50CA095103, R01CA055724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883, R37AR027883] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA95103, P50 CA095103, CA55724, R01 CA055724] Funding Source: Medline; NIAMS NIH HHS [R01 AR027883-29, R01 AR027883, R37 AR027883] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Ciesiolka M, 2004, J CELL SCI, V117, P4325, DOI 10.1242/jcs.01298; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fang X, 2004, J CELL BIOL, V165, P87, DOI 10.1083/jcb.200307109; Franz CM, 2004, J BIOL CHEM, V279, P6588, DOI 10.1074/jbc.M312812200; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Grosheva I, 2001, J CELL SCI, V114, P695; Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Magie Craig R., 2002, Development (Cambridge), V129, P3771; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Mariner DJ, 2000, J CELL SCI, V113, P1481; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Paulson AF, 2000, J BIOL CHEM, V275, P30124, DOI 10.1074/jbc.M003048200; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pettitt J, 2003, J CELL BIOL, V162, P15, DOI 10.1083/jcb.200212136; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Werner S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Zhang JY, 2005, J CELL BIOL, V168, P561, DOI 10.1083/jcb.200411060	50	217	223	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					631	644		10.1016/j.cell.2005.11.043	http://dx.doi.org/10.1016/j.cell.2005.11.043			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469707	Bronze, Green Accepted			2022-12-28	WOS:000235464000023
J	Bonner, JA; Harari, PM; Giralt, J; Azarnia, N; Shin, DM; Cohen, RB; Jones, CU; Sur, R; Raben, D; Jassem, J; Ove, R; Kies, MS; Baselga, J; Youssoufian, H; Amellal, N; Rowinsky, EK; Ang, KK				Bonner, JA; Harari, PM; Giralt, J; Azarnia, N; Shin, DM; Cohen, RB; Jones, CU; Sur, R; Raben, D; Jassem, J; Ove, R; Kies, MS; Baselga, J; Youssoufian, H; Amellal, N; Rowinsky, EK; Ang, KK			Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; LOCALLY ADVANCED HEAD; PHASE-II MULTICENTER; RADIATION-THERAPY; ANTIBODY CETUXIMAB; CONCOMITANT RADIOCHEMOTHERAPY; ACCELERATED RADIOTHERAPY; RANDOMIZED-TRIAL; FRENCH HEAD; STAGE-III	BACKGROUND: We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck. METHODS: Patients with locoregionally advanced head and neck cancer were randomly assigned to treatment with high-dose radiotherapy alone (213 patients) or high-dose radiotherapy plus weekly cetuximab (211 patients) at an initial dose of 400 mg per square meter of body-surface area, followed by 250 mg per square meter weekly for the duration of radiotherapy. The primary end point was the duration of control of locoregional disease; secondary end points were overall survival, progression-free survival, the response rate, and safety. RESULTS: The median duration of locoregional control was 24.4 months among patients treated with cetuximab plus radiotherapy and 14.9 months among those given radiotherapy alone (hazard ratio for locoregional progression or death, 0.68; P=0.005). With a median follow-up of 54.0 months, the median duration of overall survival was 49.0 months among patients treated with combined therapy and 29.3 months among those treated with radiotherapy alone (hazard ratio for death, 0.74; P=0.03). Radiotherapy plus cetuximab significantly prolonged progression-free survival (hazard ratio for disease progression or death, 0.70; P=0.006). With the exception of acneiform rash and infusion reactions, the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups. CONCLUSIONS: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck.	ImClone Syst, Somerville, NJ 08876 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Wisconsin, Dept Human Oncol, Madison, WI USA; Vall dHebron Univ Hosp, Serv Radiat Oncol, Barcelona, Spain; Vall dHebron Univ Hosp, Serv Oncol, Barcelona, Spain; Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA; Univ Virginia, Dept Med, Charlottesville, VA USA; Radiol Associates Sacramento, Sacramento, CA USA; Univ Witwatersrand, Dept Radiat Oncol, Johannesburg, South Africa; Univ Colorado, Dept Radiat Oncol, Aurora, CO USA; Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland; Merck, Darmstadt, Germany	Eli Lilly; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Virginia; Radiological Associates of Sacramento; University of Witwatersrand; University of Colorado System; University of Colorado Anschutz Medical Campus; Fahrenheit Universities; Medical University Gdansk; Merck & Company; Merck & Company Germany	Rowinsky, EK (corresponding author), ImClone Syst, 33 ImClone Dr, Somerville, NJ 08876 USA.	eric.rowinsky@imclone.com	Ray, Dana M/C-3470-2013; de Sagredo, Jordi Giralt López/J-1873-2018; Shin, Dong Moon/G-9649-2013	de Sagredo, Jordi Giralt López/0000-0002-1840-5159; Shin, Dong Moon/0000-0002-8245-4174	NCI NIH HHS [CA06294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA006294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Ang KK, 2004, INT J RADIAT ONCOL, V58, P959, DOI 10.1016/j.ijrobp.2003.07.010; Ang KK, 2002, CANCER RES, V62, P7350; Argiris A, 2002, CURR OPIN ONCOL, V14, P323, DOI 10.1097/00001622-200205000-00012; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; BONNER JA, 1994, INT J RADIAT ONCOL, V29, P243, DOI 10.1016/0360-3016(94)90269-0; Bonner JA, 2000, J CLIN ONCOL, V18, p47S; Bourhis J, 2004, SEMIN ONCOL, V31, P822, DOI 10.1053/j.seminoncol.2004.09.002; Bourhis J., 2002, International Journal of Radiation Oncology Biology Physics, V54, P71, DOI 10.1016/S0360-3016(02)03180-2; Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; BRYCE DP, 1971, LARYNGOSCOPE, V81, P1481, DOI 10.1288/00005537-197109000-00012; BRYCE DP, 1963, ANN OTO RHINOL LARYN, V72, P416, DOI 10.1177/000348946307200211; Calais G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/jnci/91.24.2081; Cohen EEW, 2004, J CLIN ONCOL, V22, P1743, DOI 10.1200/JCO.2004.06.147; DASSONVILLE O, 1993, J CLIN ONCOL, V11, P1873, DOI 10.1200/JCO.1993.11.10.1873; Denis F, 2004, J CLIN ONCOL, V22, P69, DOI 10.1200/JCO.2004.08.021; Eriksen JG, 2004, INT J RADIAT ONCOL, V58, P561, DOI 10.1016/j.ijrobp.2003.09.043; Fleming ID, 1998, AJCC CANC STAGING MA; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Garden AS, 2004, CANCER, V100, P1171, DOI 10.1002/cncr.20069; Garden AS, 2001, P AN M AM SOC CLIN, V20, p223a; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Gupta AK, 2002, CLIN CANCER RES, V8, P885; HARARI PA, 2004, 0234 RTOG AM COLL RA; Harari PM, 2004, CURR PROB CANCER, V28, P7, DOI 10.1016/j.currproblcancer.2003.10.002; Harari PM, 2001, INT J RADIAT ONCOL, V49, P427, DOI 10.1016/S0360-3016(00)01488-7; Herbst RS, 2005, J CLIN ONCOL, V23, P5578, DOI 10.1200/JCO.2005.07.120; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Huang SM, 1999, CANCER RES, V59, P1935; Hynes N., 2005, NAT REV CANCER, V5, P580; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; KRAMER S, 1987, HEAD NECK SURG, V10, P19, DOI 10.1002/hed.2890100105; Lewin F, 1997, RADIOTHER ONCOL, V43, P23, DOI 10.1016/S0167-8140(97)01922-1; Liang K, 2003, INT J RADIAT ONCOL, V57, P246, DOI 10.1016/S0360-3016(03)00511-X; Maguire PD, 2004, INT J RADIAT ONCOL, V58, P698, DOI 10.1016/S0360-3016(03)01576-1; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Milas L, 2000, CLIN CANCER RES, V6, P701; Mittal BB, 2003, INT J RADIAT ONCOL, V57, P1219, DOI 10.1016/S0360-3016(03)01454-8; MUNRO AJ, 1995, BRIT J CANCER, V71, P83, DOI 10.1038/bjc.1995.17; Nguyen NP, 2004, ANN ONCOL, V15, P383, DOI 10.1093/annonc/mdh101; PAJAK TF, 1991, INT J RADIAT ONCOL, V20, P13, DOI 10.1016/0360-3016(91)90132-N; PARSONS JT, 1988, INT J RADIAT ONCOL, V14, P649, DOI 10.1016/0360-3016(88)90085-5; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Pignon JP, 2004, ANTI-CANCER DRUG, V15, P331, DOI 10.1097/00001813-200404000-00004; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; Saleh MN, 1999, CANCER BIOTHER RADIO, V14, P451, DOI 10.1089/cbr.1999.14.451; Staar S, 2001, INT J RADIAT ONCOL, V50, P1161, DOI 10.1016/S0360-3016(01)01544-9; Stell, 1992, Semin Radiat Oncol, V2, P195, DOI 10.1016/1053-4296(92)90008-9; TRIGO J, 2004, P AN M AM SOC CLIN, V23, P487; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Wendt TG, 1998, J CLIN ONCOL, V16, P1318, DOI 10.1200/JCO.1998.16.4.1318	52	3684	3860	2	203	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					567	578		10.1056/NEJMoa053422	http://dx.doi.org/10.1056/NEJMoa053422			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467544				2022-12-28	WOS:000235177500006
J	Brumfiel, G; Marris, E				Brumfiel, G; Marris, E			Physics wins the US budget race	NATURE			English	News Item																		Brumfiel G, 2006, NATURE, V439, P517, DOI 10.1038/439517a; 2006, NATURE, V439, P509	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					644	645		10.1038/439644a	http://dx.doi.org/10.1038/439644a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467806	Bronze			2022-12-28	WOS:000235193100011
J	Charo, IF; Ransohoff, RM				Charo, IF; Ransohoff, RM			Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MONOCYTE CHEMOATTRACTANT PROTEIN-1; LYMPHOID ORGAN DEVELOPMENT; LOW-DENSITY-LIPOPROTEIN; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; T-CELLS; SCAVENGER RECEPTOR; LESION FORMATION; CXC CHEMOKINES; FIRM ADHESION		Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94158 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Neuroinflammat Res Ctr, Cleveland, OH USA; Cleveland Clin Fdn, Mellen Ctr MS Treatment & Res, Cleveland, OH USA; Cleveland Clin Fdn, Cleveland Clin Lerner Coll Med, Cleveland, OH USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	Charo, IF (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, 1650 Owens St, San Francisco, CA 94158 USA.	icharo@gladstone.ucsf.edu; ransohr@ccf.org						Bacon K, 2002, J INTERF CYTOK RES, V22, P1067; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bikfalvi A, 2004, SEMIN THROMB HEMOST, V30, P379, DOI 10.1055/s-2004-831051; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; Calzascia T, 2005, IMMUNITY, V22, P175, DOI 10.1016/j.immuni.2004.12.008; Campbell DJ, 2003, IMMUNOL REV, V195, P58, DOI 10.1034/j.1600-065X.2003.00067.x; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Charo I F, 1999, Chem Immunol, V72, P30, DOI 10.1159/000058724; Charo IF, 2003, MICROCIRCULATION, V10, P259, DOI 10.1038/sj.mn.7800191; Chaudhuri A, 2003, NEW ENGL J MED, V348, P1598; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Cyster JG, 1999, CURR TOP MICROBIOL, V246, P87; Cyster JG, 2003, IMMUNOL REV, V195, P5, DOI 10.1034/j.1600-065X.2003.00075.x; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Daly C, 2003, MICROCIRCULATION, V10, P247, DOI 10.1038/sj.mn.7800190; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Devalaraja RM, 2000, J INVEST DERMATOL, V115, P234, DOI 10.1046/j.1523-1747.2000.00034.x; Feldmann Marc, 2004, Novartis Found Symp, V256, P53; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gonzalez P, 2001, GENES IMMUN, V2, P191, DOI 10.1038/sj.gene.6363760; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gu L, 1999, Chem Immunol, V72, P7, DOI 10.1159/000058723; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kivisakk P, 2002, CLIN EXP IMMUNOL, V129, P510, DOI 10.1046/j.1365-2249.2002.01947.x; Kivisakk P, 2004, ANN NEUROL, V55, P627, DOI 10.1002/ana.20049; Kivisakk P, 2003, P NATL ACAD SCI USA, V100, P8389, DOI 10.1073/pnas.1433000100; Kuziel WA, 2003, ATHEROSCLEROSIS, V167, P25, DOI 10.1016/S0021-9150(02)00382-9; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Lew EA, 2003, NEW ENGL J MED, V348, P1599; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mahad D, 2006, BRAIN, V129, P212, DOI 10.1093/brain/awh655; Mahad DJ, 2004, J NEUROPATH EXP NEUR, V63, P262, DOI 10.1093/jnen/63.3.262; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Martins-Green M., 1997, Cytokine and Growth Factor Reviews, V8, P221, DOI 10.1016/S1359-6101(97)00016-6; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; Muller G, 2003, IMMUNOL REV, V196, P265; Muller G, 2003, IMMUNOL REV, V195, P117, DOI 10.1034/j.1600-065X.2003.00073.x; Murphy PM, 2000, PHARMACOL REV, V52, P145; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Pan Y, 1997, NATURE, V389, P100, DOI 10.1038/38048; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796; Seibert C, 2004, CURR PHARM DESIGN, V10, P2041, DOI 10.2174/1381612043384312; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Sozzani S, 2000, J CLIN IMMUNOL, V20, P151, DOI 10.1023/A:1006659211340; Strieter RM, 2004, SEMIN CANCER BIOL, V14, P195, DOI 10.1016/j.semcancer.2003.10.006; Szalai C, 2001, ATHEROSCLEROSIS, V158, P233, DOI 10.1016/S0021-9150(01)00423-3; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Trebst C, 2001, ARCH NEUROL-CHICAGO, V58, P1975, DOI 10.1001/archneur.58.12.1975; Trebst C, 2001, AM J PATHOL, V159, P1701, DOI 10.1016/S0002-9440(10)63017-9; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Valdes AM, 2002, ARTERIOSCL THROM VAS, V22, P1924, DOI 10.1161/01.ATV.0000038486.48400.E7; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; WEISBERG SP, IN PRESS J CLIN INVE; Wuttge DM, 2004, ARTERIOSCL THROM VAS, V24, P750, DOI 10.1161/01.ATV.0000124102.11472.36; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	87	1855	1985	2	214	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					610	621		10.1056/NEJMra052723	http://dx.doi.org/10.1056/NEJMra052723			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467548				2022-12-28	WOS:000235177500010
J	Wiese, JG; Holman, RL				Wiese, JG; Holman, RL			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; Cogent Healthcare, Nashville, TN USA	Tulane University	Wiese, JG (corresponding author), Tulane Univ, Sch Med, Dept Med, SL-12,1430 Tulane Ave, New Orleans, LA 70112 USA.							Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					195	200		10.7326/0003-4819-144-3-200602070-00008	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008XS	16461964				2022-12-28	WOS:000235074800006
J	Lucassen, A; Parker, M; Wheeler, R				Lucassen, A; Parker, M; Wheeler, R			Ethics - Implications of data protection legislation for family history	BRITISH MEDICAL JOURNAL			English	Editorial Material							CANCER; CONFIDENTIALITY		Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England; Univ Oxford, Ethox Ctr, Oxford OX3 7LF, England; Southampton Univ NHS Trust, Southampton SO16 5YA, Hants, England	University of Oxford; University of Southampton	Lucassen, A (corresponding author), Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England.	a.m.lucassen@soton.ac.uk	Lucassen, Anneke/D-7764-2017	Lucassen, Anneke/0000-0003-3324-4338				Botkin JR, 1998, JAMA-J AM MED ASSOC, V279, P1808, DOI 10.1001/jama.279.22.1808; Council of Europa, 1997, CONV PROT HUM RIGHTS; Department of Health, 2003, CONF NHS COD PRACT; Douglas FS, 1999, J MED GENET, V36, P309; ECKSTEIN S, 2003, MANUAL RES ETHICS CO; Illman J, 2002, J NATL CANCER I, V94, P1269; *JOINT COMM MED GE, IN PRESS CONS CONF; Kerr B, 1998, EUR J SURG ONCOL, V24, P275, DOI 10.1016/S0748-7983(98)80005-X; LAURANCE J, 2005, INDEPENDENT     0510; Lucassen A, 2004, EUR J HUM GENET, V12, P93, DOI 10.1038/sj.ejhg.5201118; Newson AJ, 2005, EUR J HUM GENET, V13, P401, DOI 10.1038/sj.ejhg.5201360; Parker M, 2004, BRIT MED J, V329, P165, DOI 10.1136/bmj.329.7458.165	12	7	7	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					299	301		10.1136/bmj.332.7536.299	http://dx.doi.org/10.1136/bmj.332.7536.299			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455735	Green Published			2022-12-28	WOS:000235259000029
J	Suzuki, Y; Nijhout, HF				Suzuki, Y; Nijhout, HF			Evolution of a polyphenism by genetic accommodation	SCIENCE			English	Article							THRESHOLD EVOLUTION; TOBACCO HORNWORM; LEPIDOPTERA; TEMPERATURE; MECHANISMS; ECOLOGY	Polyphenisms are adaptations in which a genome is associated with discrete alternative phenotypes in different environments. Little is known about the mechanism by which polyphenisms originate. We show that a mutation in the juvenile hormone-regulatory pathway in Manduca sexta enables heat stress to reveal a hidden reaction norm of larval coloration. Selection for increased color change in response to heat stress resulted in the evolution of a larval color polyphenism and a corresponding change in hormonal titers through genetic accommodation. Evidently, mechanisms that regulate developmental hormones can mask genetic variation and act as evolutionary capacitors, facilitating the origin of novel adaptive phenotypes.	Duke Univ, Dept Biol, Durham, NC 27708 USA	Duke University	Suzuki, Y (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.	ys16@duke.edu		Suzuki, Yuichiro/0000-0002-0957-3564				Abouheif E, 2002, SCIENCE, V297, P249, DOI 10.1126/science.1071468; Bergman A, 2003, NATURE, V424, P549, DOI 10.1038/nature01765; BRADSHAW A. D., 1965, ADVANCE GENET, V13, P115, DOI 10.1016/S0065-2660(08)60048-6; CASEY TM, 1976, ECOLOGY, V57, P485, DOI 10.2307/1936433; Emlen DJ, 1996, EVOLUTION, V50, P1219, DOI [10.1111/j.1558-5646.1996.tb02362.x, 10.2307/2410662]; FAIN MJ, 1975, BIOL BULL-US, V149, P506, DOI 10.2307/1540383; Gibson G, 2004, NAT REV GENET, V5, P681, DOI 10.1038/nrg1426; HIRUMA K, 1993, INT J INSECT MORPHOL, V22, P103, DOI 10.1016/0020-7322(93)90003-J; HUDSON A, 1966, CAN J ZOOLOG, V44, P541, DOI 10.1139/z66-058; Kitching IJ, 2002, ZOOL J LINN SOC-LOND, V135, P471, DOI 10.1046/j.1096-3642.2002.00021.x; Moczek AP, 2003, EVOL DEV, V5, P259, DOI 10.1046/j.1525-142X.2003.03033.x; Moczek AP, 2003, BEHAV ECOL, V14, P841, DOI 10.1093/beheco/arg062; Moczek AP, 2002, EVOL DEV, V4, P252, DOI 10.1046/j.1525-142X.2002.02014.x; MORAN NA, 1992, AM NAT, V139, P971, DOI 10.1086/285369; Nijhout H.F., 1994, INSECT HORMONES; Petersen C, 2000, PHYSIOL ENTOMOL, V25, P35, DOI 10.1046/j.1365-3032.2000.00163.x; Rendel J. M, 1967, CANALIZATION GENE CO; ROFF DA, 1994, GENETICS, V136, P395; ROUNTREE DB, 1995, J INSECT PHYSIOL, V41, P1141, DOI 10.1016/0022-1910(95)00051-U; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SAFRANEK L, 1975, J INSECT PHYSIOL, V21, P1931, DOI 10.1016/0022-1910(75)90225-5; Schlichting CD, 1998, PHENOTYPIC EVOLUTION; SHAPIRO A.M., 1976, EVOL BIOL, V9, P259, DOI DOI 10.1007/978-1-4615-6950-3_6; Tomkins JL, 2004, NATURE, V431, P1099, DOI 10.1038/nature02918; West-Eberhard Mary Jane, 2003, pi	25	279	290	1	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					650	652		10.1126/science.1118888	http://dx.doi.org/10.1126/science.1118888			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456077				2022-12-28	WOS:000235257400045
J	Marchis, F; Hestroffer, D; Descamps, P; Berthier, J; Bouchez, AH; Campbell, RD; Chin, JCY; van Dam, MA; Hartman, SK; Johansson, EM; Lafon, RE; Le Mignant, D; de Pater, I; Stomski, PJ; Summers, DM; Vachier, F; Wizinovich, PL; Wong, MH				Marchis, F; Hestroffer, D; Descamps, P; Berthier, J; Bouchez, AH; Campbell, RD; Chin, JCY; van Dam, MA; Hartman, SK; Johansson, EM; Lafon, RE; Le Mignant, D; de Pater, I; Stomski, PJ; Summers, DM; Vachier, F; Wizinovich, PL; Wong, MH			A low density of 0.8 g cm(-3) for the Trojan binary asteroid 617 Patroclus	NATURE			English	Article							DISCOVERY	The Trojan population consists of two swarms of asteroids following the same orbit as Jupiter and located at the L4 and L5 stable Lagrange points of the Jupiter - Sun system ( leading and following Jupiter by 60 degrees). The asteroid 617 Patroclus is the only known binary Trojan(1). The orbit of this double system was hitherto unknown. Here we report that the components, separated by 680 km, move around the system's centre of mass, describing a roughly circular orbit. Using this orbital information, combined with thermal measurements to estimate the size of the components, we derive a very low density of 0.8(-0.1)(+0.2) g cm(-3). The components of 617 Patroclus are therefore very porous or composed mostly of water ice, suggesting that they could have been formed in the outer part of the Solar System(2).	Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Observ Paris, CNRS, UMR 8028, Inst Mecan Celeste & Calculs Ephemerides, F-75014 Paris, France; WM Keck Observ, Kamuela, HI 96743 USA	University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite	Marchis, F (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	fmarchis@berkeley.edu	van Dam, Marcos A./A-5548-2017; Marchis, Franck/H-3971-2012; van Dam, Marcos/AAW-7258-2021	van Dam, Marcos A./0000-0002-9499-9729; van Dam, Marcos/0000-0002-9499-9729; LE MIGNANT, David/0000-0002-5339-5515				Anderson JD, 2005, SCIENCE, V308, P1291, DOI 10.1126/science.1110422; Angeli CA, 1999, PLANET SPACE SCI, V47, P699, DOI 10.1016/S0032-0633(98)00122-6; Astakhov SA, 2005, MON NOT R ASTRON SOC, V360, P401, DOI 10.1111/j.1365-2966.2005.09072.x; BERTHIER J, 2001, B AM ASTRON SOC, V33; Bouchez AH, 2004, P SOC PHOTO-OPT INS, V5490, P321, DOI 10.1117/12.552503; Britt D. T., 2002, ASTEROIDS 3, VIII, P485; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; Descamps P, 2005, CELEST MECH DYN ASTR, V92, P381, DOI 10.1007/s10569-005-2629-8; DESCAMPS P, 2005, IAU S, V229; EMERY JP, 2005, AM ASTRON SOC DIV PL, V37; Fernandez YR, 2003, ASTRON J, V126, P1563, DOI 10.1086/377015; Gladman B, 1996, ICARUS, V122, P166, DOI 10.1006/icar.1996.0117; HESTROFFER D, 2005, IAU S, V229; Marchis F, 2004, PROC SPIE, V5490, P338, DOI 10.1117/12.550624; Marchis F, 2005, NATURE, V436, P822, DOI 10.1038/nature04018; MARCHIS F, 2005, IAU S, V229; MARCHIS F, IN PRESS ICARUS; MARCHIS F, 2004, AM ASTRON SOC DIV PL, V36; Merline W.J., 2001, IAU CIRC, V7703, P2; Merline W.J., 2002, ASTEROIDS, VIII, P289; Merline WJ, 1999, NATURE, V401, P565, DOI 10.1038/44089; Michalowski T, 2004, ASTRON ASTROPHYS, V423, P1159, DOI 10.1051/0004-6361:20040449; Morbidelli A, 2005, NATURE, V435, P462, DOI 10.1038/nature03540; PRAVEC P, 2004, AM ASTRON SOC DIV PL, V36; ROTH KC, 2001, B AM ASTRON SOC, V33; Tohline JE, 2002, ANNU REV ASTRON ASTR, V40, P349, DOI 10.1146/annurev.astro.40.060401.093810; Veillet C, 2002, NATURE, V416, P711, DOI 10.1038/416711a; WALSH KJ, 2005, AM ASTRON SOC DIV PL, V37; WEIDENSHILLING SJ, 2001, LUNAR PLANET SCI, V32, P1890	30	96	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					565	567		10.1038/nature04350	http://dx.doi.org/10.1038/nature04350			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452974	Green Submitted			2022-12-28	WOS:000235033900035
J	Roeffaers, MBJ; Sels, BF; Uji-i, H; De Schryver, FC; Jacobs, PA; De Vos, DE; Hofkens, J				Roeffaers, MBJ; Sels, BF; Uji-i, H; De Schryver, FC; Jacobs, PA; De Vos, DE; Hofkens, J			Spatially resolved observation of crystal-face-dependent catalysis by single turnover counting	NATURE			English	Article							ANIONIC CLAYS; HYDROTALCITES; EXCHANGE	Catalytic processes on surfaces have long been studied by probing model reactions on single-crystal metal surfaces under high vacuum conditions. Yet the vast majority of industrial heterogeneous catalysis occurs at ambient or elevated pressures using complex materials with crystal faces, edges and defects differing in their catalytic activity. Clearly, if new or improved catalysts are to be rationally designed, we require quantitative correlations between surface features and catalytic activity - ideally obtained under realistic reaction conditions(1-3). Transmission electron microscopy(4-6) and scanning tunnelling microscopy(7,8) have allowed in situ characterization of catalyst surfaces with atomic resolution, but are limited by the need for low-pressure conditions and conductive surfaces, respectively. Sum frequency generation spectroscopy can identify vibrations of adsorbed reactants and products in both gaseous and condensed phases(9), but so far lacks sensitivity down to the single molecule level. Here we adapt real-time monitoring of the chemical transformation of individual organic molecules by fluorescence microscopy(10-12) to monitor reactions catalysed by crystals of a layered double hydroxide immersed in reagent solution. By using a wide field microscope, we are able to map the spatial distribution of catalytic activity over the entire crystal by counting single turnover events. We find that ester hydrolysis proceeds on the lateral {10 (1) over bar0} crystal faces, while transesterification occurs on the entire outer crystal surface. Because the method operates at ambient temperature and pressure and in a condensed phase, it can be applied to the growing number of liquid-phase industrial organic transformations to localize catalytic activity on and in inorganic solids. An exciting opportunity is the use of probe molecules with different size and functionality, which should provide insight into shape-selective or structure-sensitive catalysis(13-15) and thus help with the rational design of new or more productive heterogeneous catalysts.	Katholieke Univ Leuven, Microbial Syst, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Mol Syst, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Div Mol & Nano Mat, B-3001 Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven	De Vos, DE (corresponding author), Katholieke Univ Leuven, Microbial Syst, Kasteelpk Arenberg 23, B-3001 Louvain, Belgium.	dirk.devos@biw.kuleuven.be; johan.hofkens@chem.kuleuven.be	Roeffaers, Maarten/D-9328-2011; Hofkens, Johan/AAP-9255-2020; Roeffaers, Maarten/AAB-8874-2020; Hofkens, Johan/AAL-4204-2020; Uji-i, Hiroshi/AAK-5275-2020; Hofkens, Johan/D-4284-2017	Roeffaers, Maarten/0000-0001-6582-6514; Uji-i, Hiroshi/0000-0002-0463-9659; Hofkens, Johan/0000-0002-9101-0567				Abello S, 2005, CHEM-EUR J, V11, P728, DOI 10.1002/chem.200400409; BERNASEK SL, 1973, PHYS REV LETT, V30, P1202, DOI 10.1103/PhysRevLett.30.1202; BOUDART M, 1966, J CATAL, V6, P92, DOI 10.1016/0021-9517(66)90113-8; CAI H, 1994, SCIENCE, V266, P1551, DOI 10.1126/science.266.5190.1551; Cavani F, 1991, CATAL TODAY, V11, P173, DOI 10.1016/0920-5861(91)80068-K; CORMA A, 1995, CHEM REV, V95, P559, DOI 10.1021/cr00035a006; Corma A, 1998, J CATAL, V173, P315, DOI 10.1006/jcat.1997.1930; Dellwig T, 2000, PHYS REV LETT, V85, P776, DOI 10.1103/PhysRevLett.85.776; ENGEL DJ, 1993, Patent No. 5350879; ERTL G, 2000, HDB HETEROGENEOUS CA; Flomenbom O, 2005, P NATL ACAD SCI USA, V102, P2368, DOI 10.1073/pnas.0409039102; Fogg AM, 2002, CHEM MATER, V14, P232, DOI 10.1021/cm0105099; Hansen PL, 2002, SCIENCE, V295, P2053, DOI 10.1126/science.1069325; Hansen TW, 2001, SCIENCE, V294, P1508, DOI 10.1126/science.1064399; Hell SW, 2003, NAT BIOTECHNOL, V21, P1347, DOI 10.1038/nbt895; Hellriegel C, 2005, NEW J PHYS, V7, DOI 10.1088/1367-2630/7/1/023; Helveg S, 2004, NATURE, V427, P426, DOI 10.1038/nature02278; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Martens JA, 2001, CATAL TODAY, V65, P111, DOI 10.1016/S0920-5861(00)00577-0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Roelofs JCAA, 2001, J CATAL, V203, P184, DOI 10.1006/jcat.2001.3295; Sels B, 1999, NATURE, V400, P855, DOI 10.1038/23674; Sels BF, 2001, CATAL REV, V43, P443, DOI 10.1081/CR-120001809; SERNA CJ, 1982, CLAY CLAY MINER, V30, P180, DOI 10.1346/CCMN.1982.0300303; Thomas J. M., 1996, PRINCIPLES PRACTICE; Thomas JM, 1996, FARADAY DISCUSS, V105, P1, DOI 10.1039/fd9960500001; Velonia K, 2005, ANGEW CHEM INT EDIT, V44, P560, DOI 10.1002/anie.200460625; Watanabe Y, 1998, MICROPOR MESOPOR MAT, V22, P399, DOI 10.1016/S1387-1811(98)00099-7; Wolff J, 2001, SCIENCE, V294, P134, DOI 10.1126/science.1063597; Zambelli T, 1997, NATURE, V390, P495, DOI 10.1038/37329	30	365	371	5	283	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					572	575		10.1038/nature04502	http://dx.doi.org/10.1038/nature04502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452976	Green Published			2022-12-28	WOS:000235033900037
J	Zhou, PB				Zhou, PB			REG gamma: A shortcut to destruction	CELL			English	Editorial Material							PROTEASOME; DEGRADATION; CLEAVAGE; PROTEIN	Destruction of intact cellular proteins is largely orchestrated by ATP-dependent ubiquitination and subsequent degradation by the 26S proteasome. The REG-20S proteasome, however, only degrades short peptides. In this issue of Cell, Li et al. (2006) challenge this notion by revealing that the proteasomal activator REG gamma directs degradation of the steroid receptor coactivator SRC-3 by the 20S proteasome in an ATP- and ubiquitin-independent manner.	Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Cornell University	Zhou, PB (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10021 USA.	pez2001@med.cornell.edu						Abba MC, 2004, BREAST CANCER RES, V6, pR499, DOI 10.1186/bcr899; Baugh JM, 2004, MOL CELL, V16, P575, DOI 10.1016/j.molcel.2004.10.017; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; LI X, 2006, CELL; Liao L, 2002, J STEROID BIOCHEM, V83, P3, DOI 10.1016/S0960-0760(02)00254-6; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Moriishi K, 2003, J VIROL, V77, P10237, DOI 10.1128/JVI.77.19.10237-10249.2003; Murata S, 1999, J BIOL CHEM, V274, P38211, DOI 10.1074/jbc.274.53.38211; Rechsteiner M, 2005, TRENDS CELL BIOL, V15, P27, DOI 10.1016/j.tcb.2004.11.003; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830	11	16	18	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					256	257		10.1016/j.cell.2006.01.003	http://dx.doi.org/10.1016/j.cell.2006.01.003			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439199	Bronze			2022-12-28	WOS:000235068500012
J	Schapiro, RH; Maher, MM; Misdraji, J; Bounds, BC; Harris, NL; Daskalakis, D				Schapiro, RH; Maher, MM; Misdraji, J; Bounds, BC; Harris, NL; Daskalakis, D			A woman with jaundice and a pancreatic mass - Mycobacterium tuberculosis infection of the pancreas and peripancreatic lymph nodes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OBSTRUCTIVE-JAUNDICE; RARE CAUSE; IMMUNOCOMPETENT PATIENTS; DIAGNOSIS; SECONDARY; INVOLVEMENT; EXPERIENCE; MANAGEMENT		Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Schapiro, RH (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.		Misdraji, Joseph/AGX-4779-2022; Misdraji, Joseph/AAD-4588-2019					Abe H, 1997, AM J GASTROENTEROL, V92, P526; Alam I, 1997, DIGEST DIS SCI, V42, P1295, DOI 10.1023/A:1018874612166; Auerbach O, 1944, AM J PATHOL, V20, P121; Brugge WR, 2004, NEW ENGL J MED, V351, P1218, DOI 10.1056/NEJMra031623; Brugge WR, 2004, GASTROINTEST ENDOSC, V59, P698, DOI 10.1016/S0016-5107(04)00175-0; Chaudhary A, 2002, DIGEST SURG, V19, P389, DOI 10.1159/000065832; CROWSON MC, 1984, BRIT J SURG, V71, P239, DOI 10.1002/bjs.1800710328; Das K, 2003, SURGERY, V134, P496, DOI 10.1067/S0039-6060(03)00149-1; Demir K, 2001, J GASTROEN HEPATOL, V16, P1071, DOI 10.1046/j.1440-1746.2001.02467.x; Elizondo ME, 2001, SURGERY, V129, P114, DOI 10.1067/msy.2001.104364; FAN ST, 1986, BRIT J SURG, V73, P373, DOI 10.1002/bjs.1800730517; Fernandez-del Castillo CF, 2003, NEW ENGL J MED, V349, P893, DOI 10.1056/NEJMcpc030022; Franco-Paredes C, 2002, AM J MED SCI, V323, P54, DOI 10.1097/00000441-200201000-00010; Govil H, 2002, DIAGN CYTOPATHOL, V26, P273, DOI 10.1002/dc.10098; Ibrahim E M, 1987, Trop Gastroenterol, V8, P167; Jazet Ingrid M., 2004, Eur J Intern Med, V15, P259, DOI 10.1016/j.ejim.2004.04.004; Kim KP, 2004, AM J GASTROENTEROL, V99, P1605, DOI 10.1111/j.1572-0241.2004.30336.x; Kumar Rakesh, 2003, Trop Gastroenterol, V24, P76; Liu QD, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-1; *MA GEN HOSP, 2003, NEW ENGL J MED, V349, P1954; *MA GEN HOSP, 2004, NEW ENGL J MED, V350, P1131; *MA GEN HOSP, 1951, NEW ENGL J MED, V244, P643; MARTIN KR, 1992, AM J GASTROENTEROL, V87, P1194; Obama K, 2003, SURG TODAY, V33, P229, DOI 10.1007/s005950300051; Ozden I, 2001, J Hepatobiliary Pancreat Surg, V8, P279, DOI 10.1007/s005340170029; Panzuto F, 2003, DIGEST LIVER DIS, V35, P283, DOI 10.1016/S1590-8658(03)00066-5; Paraf A, 1966, Rev Med Chir Mal Foie, V41, P101; Peyre CG, 2004, AM SURGEON, V70, P620; Poon RTP, 2001, HEPATO-GASTROENTEROL, V48, P1585; Pramesh C S, 2002, Trop Gastroenterol, V23, P142; Probst A, 2004, GASTROINTEST ENDOSC, V60, P145, DOI 10.1016/S0016-5107(04)01535-4; Redha S, 2001, Med J Malaysia, V56, P95; SARTIN JS, 1991, MAYO CLIN PROC, V66, P914, DOI 10.1016/S0025-6196(12)61578-X; Schneider A, 2002, PANCREATOLOGY, V2, P69, DOI 10.1159/000049451; Shan YS, 2000, PANCREAS, V21, P100, DOI 10.1097/00006676-200007000-00059; Woodfield JC, 2004, ANZ J SURG, V74, P368, DOI 10.1111/j.1445-1433.2004.02996.x; Xia F, 2003, WORLD J GASTROENTERO, V9, P1361, DOI 10.3748/wjg.v9.i6.1361	37	6	7	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					398	406		10.1056/NEJMcpc059037	http://dx.doi.org/10.1056/NEJMcpc059037			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436772				2022-12-28	WOS:000234854000013
J	Wadman, M				Wadman, M			The right combination	NATURE			English	Editorial Material																			0	12	12	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 26	2006	439	7075					390	391		10.1038/439390a	http://dx.doi.org/10.1038/439390a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437083				2022-12-28	WOS:000234859200015
J	Watts, G				Watts, G			Science commentary: Cannabis confusions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												geoff@scileg.freeserve.co.uk						ALTHA M, TYPES CANNABIS AVAIL; Fergusson DM, 2006, BRIT MED J, V332, P172, DOI 10.1136/bmj.332.7534.172; Shao Hong, 1996, Journal of the International Hemp Association, V3, P55; SMALL E, 1975, AM LAW SPECIES PROBL; 2005, NEW SCI         0917, P12	5	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 21	2006	332	7534					175	176		10.1136/bmj.332.7534.175	http://dx.doi.org/10.1136/bmj.332.7534.175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	006OC	16424501	Green Published			2022-12-28	WOS:000234905800032
J	Donaldson, SH; Bennett, WD; Zeman, KL; Knowles, MR; Tarran, R; Boucher, RC				Donaldson, SH; Bennett, WD; Zeman, KL; Knowles, MR; Tarran, R; Boucher, RC			Mucus clearance and lung function in cystic fibrosis with hypertonic saline	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUCOCILIARY CLEARANCE; AMILORIDE; DISEASE; AIRWAYS; SPUTUM	BACKGROUND: Abnormal homeostasis of the volume of airway surface liquid in patients with cystic fibrosis is thought to produce defects in mucus clearance and airway defense. Through osmotic forces, hypertonic saline may increase the volume of airway surface liquid, restore mucus clearance, and improve lung function. METHODS: A total of 24 patients with cystic fibrosis were randomly assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times daily with or without pretreatment with amiloride. Mucus clearance and lung function were measured during 14-day baseline and treatment periods. RESULTS: Long-term inhalation of hypertonic saline without pretreatment with amiloride (i.e., with placebo pretreatment) resulted in a sustained (greater/equal 8 hours) increase in 1-hour rates of mucus clearance, as compared with those with amiloride pretreatment (14.0+/-2.0 vs. 7.0+/-1.5 percent, respectively; P=0.02) and increased 24-hour rates of mucus clearance over baseline. Furthermore, inhalation of hypertonic saline with placebo improved the forced expiratory volume in one second (FEV(sub 1)) between the baseline period and the treatment period (mean difference, 6.62 percent; 95 percent confidence interval, 1.6 to 11.7; P=0.02), whereas hypertonic saline with amiloride did not improve FEV(sub 1) (mean difference, 2.9 percent; 95 percent confidence interval, -2.2 to 8.0; P=0.23). Forced vital capacity (FVC), the forced expiratory flow between 25 and 75 percent of FVC (FEF(sub 25-75)), and respiratory symptoms also significantly improved in patients treated with hypertonic saline and placebo, whereas the residual volume as a proportion of total lung capacity (RV:TLC) did not change in either group. A comparison of the changes in lung function in the two groups showed no significant difference. In vitro data suggested that sustained hydration of airway surfaces was responsible for the sustained improvement in mucus clearance, whereas inhibition of osmotically driven water transport by amiloride accounted for the observed loss of clinical benefit. CONCLUSIONS: In patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained acceleration of mucus clearance and improved lung function. This treatment may protect the lung from insults that reduce mucus clearance and produce lung disease.	Univ N Carolina, Chapel Hill Cyst Fibrosis Res & Treatment Ctr, Chapel Hill, NC USA; Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill	Donaldson, SH (corresponding author), Univ N Carolina, Chapel Hill Res & Treatment Ctr, 6019 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	scott_donaldson@med.unc.edu	Donaldson, Scott H./ABG-5157-2021	Donaldson, Scott H./0000-0003-4802-0388	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060280, K08HL068617, P01HL034322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [5-P01-HL34322, P50-HL060280, 1K08 HL68617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexis NE, 2001, AM J RESP CRIT CARE, V164, P1964, DOI 10.1164/ajrccm.164.10.2104051; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Ballmann Manfred, 2002, J Cyst Fibros, V1, P35, DOI 10.1016/S1569-1993(01)00009-1; CAMNER P, 1973, AM REV RESPIR DIS, V108, P131; Elkins MR, 2006, NEW ENGL J MED, V354, P229, DOI 10.1056/NEJMoa043900; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MORTENSEN J, 1993, CHEST, V103, P805, DOI 10.1378/chest.103.3.805; NARVARTE J, 1980, J GEN PHYSIOL, V76, P69, DOI 10.1085/jgp.76.1.69; Quittner AL, 2000, J PEDIATR PSYCHOL, V25, P403, DOI 10.1093/jpepsy/25.6.403; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; Sood N, 2003, AM J RESP CRIT CARE, V167, P158, DOI 10.1164/rccm.200204-293OC; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138	21	500	533	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					241	250		10.1056/NEJMoa043891	http://dx.doi.org/10.1056/NEJMoa043891			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421365	Bronze, Green Published			2022-12-28	WOS:000234661100004
J	Enwonwu, CO				Enwonwu, CO			Noma - The ulcer of extreme poverty	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Maryland, Sch Dent, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Nigerian Natl Inst Med Res, Lagos, Nigeria	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Enwonwu, CO (corresponding author), Univ Maryland, Sch Dent, Baltimore, MD 21201 USA.							Enwonwu CO, 2005, TROP MED INT HEALTH, V10, P65, DOI 10.1111/j.1365-3156.2004.01351.x; Enwonwu CO, 2000, CRIT REV ORAL BIOL M, V11, P159, DOI 10.1177/10454411000110020201; Fieger A, 2003, TROP MED INT HEALTH, V8, P402, DOI 10.1046/j.1365-3156.2003.01036.x; Marck KW, 2003, PLAST RECONSTR SURG, V111, P1702, DOI 10.1097/01.PRS.0000055445.84307.3C	4	35	36	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2006	354	3					221	224		10.1056/NEJMp058193	http://dx.doi.org/10.1056/NEJMp058193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	003DF	16421362				2022-12-28	WOS:000234661100001
J	Leape, LL; Fromson, JA				Leape, LL; Fromson, JA			Problem doctors: Is there a system-level solution?	ANNALS OF INTERNAL MEDICINE			English	Article							IMPAIRED PHYSICIANS; ALCOHOL; COMORBIDITY; PREVALENCE; BEHAVIOR; SUICIDE; PATIENT; ABUSE	Physician performance failures are not rare and pose substantial threats to patient welfare and safety. Few hospitals respond to such failures promptly or effectively. Failure to ensure the quality and safety of the performance of colleagues is a breach of medicine's fiduciary responsibility to the public. A major reason for this deficiency is the hospitals' lack of formal systems to monitor physician performance and to identify and correct shortcomings. To develop and implement these systems, hospitals need better performance measures and substantial expansion of external programs for assessment and remediation. This is a task well beyond the capacities of individual hospitals; a national effort is required. The authors call on the Federation of State Medical Boards, the American Board of Medical Specialties, and the Joint Commission on Accreditation of Healthcare Organizations (organizations that already bear a fiduciary responsibility for ensuring safe, competent care) to collaborate on developing better methods for measuring performance and to expand programs for helping practitioners who are deficient.	Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02215 USA.	leape@hsph.harvard.edu	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				*AM BOARD MED SPEC, 2004, STAT MAINT CERT PROG; BARNARD A, 2002, BOSTON GLOBE    0520, pA1; Benzer D G, 1995, Wis Med J, V94, P455; BLONDELL RD, 1993, PRIMARY CARE, V20, P209; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; CLARE AW, 1990, ALCOHOL ALCOHOLISM, V25, P277, DOI 10.1093/oxfordjournals.alcalc.a045001; *COLL PHYS SURG AL, 2004, PHYS ACH REV; *DEP VET AFF, 2004, DRUG FREE WORKPL PRO; Diaz A L, 1991, West J Nurs Res, V13, P97, DOI 10.1177/019394599101300107; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; *FED STAT MED BOAR, 2005, IPE OV; *FED STAT MED BOAR, 2003, SUMM 2002 BOARD ACT; *FED STAT MED BOAR, 2000, REP SPEC COMM PROF C; Fromson J, 2004, ADDRESSING CLIN PERF; Hickson GB, 2002, JAMA-J AM MED ASSOC, V287, P2951, DOI 10.1001/jama.287.22.2951; HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333; Kaufman A.S., 2006, ASSESSING ADOLESCENT, V3rd; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Linney B J, 1997, Physician Exec, V23, P55; Lipner RS, 2002, ACAD MED, V77, pS64, DOI 10.1097/00001888-200210001-00021; MCAULIFFE WE, 1991, AM J PUBLIC HEALTH, V81, P177, DOI 10.2105/AJPH.81.2.177; *MED BOARD CAL, 2005, MED BOARDS DIV PROGR; Neff KE, 2000, ENHANCING PHYS PERFO, P45; Papadakis MA, 2004, ACAD MED, V79, P244, DOI 10.1097/00001888-200403000-00011; Powell DH, 1994, PROFILES COGNITIVE A; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rosenstein AH, 2005, AM J NURS, V105, P54, DOI 10.1097/00000446-200501000-00025; Samkoff J S, 1990, Pa Med, V93, P40; Schernhammer E, 2005, NEW ENGL J MED, V352, P2473, DOI 10.1056/NEJMp058014; Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295; Sharpe V.A., 1998, MED HARM HIST CONCEP; Skipper GE, 1997, J ADDICT DIS, V16, P67, DOI 10.1300/J069v16n03_07; TALBOTT GD, 1980, POSTGRAD MED, V68, P56, DOI 10.1080/00325481.1980.11715621; TRUNKEY DD, 2007, J AM COLL SURGEONS, V192, P385; Watkins JP, 2000, J SUBST ABUSE TREAT, V19, P51, DOI 10.1016/S0740-5472(99)00099-9; 2005, NBME POST LICENSURE	37	175	176	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					107	115		10.7326/0003-4819-144-2-200601170-00008	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	004AX	16418410				2022-12-28	WOS:000234725500007
J	Kirichok, Y; Navarro, B; Clapham, DE				Kirichok, Y; Navarro, B; Clapham, DE			Whole-cell patch-clamp measurements of spermatozoa reveal an alkaline-activated Ca2+ channel	NATURE			English	Article							ION CHANNELS; MOUSE SPERM; CALCIUM-CHANNELS; MOTILITY; PH; DEPOLARIZATION; FERTILIZATION; PERMEATION; PHYSIOLOGY; CATSPER1	In mammals, sperm cells become motile during ejaculation and swim up the female reproductive tract. Before fertilization and to overcome various barriers, their motility must be hyperactivated, a motion that is characterized by vigorous asymmetric tail beating(1). Hyperactivation requires an increase in calcium in the flagella, a process that probably involves plasmalemmal ion channels(2-8). Numerous attempts in the past two decades to understand sperm cell channels have been frustrated by the difficulty of measuring spermatozoan transmembrane ion currents(2,3,9 - 16). Here, by using a simple approach to patch-clamp spermatozoa and to characterize whole-spermatozoan currents, we describe a constitutively active flagellar calcium channel that is strongly potentiated by intracellular alkalinization. This current is not present in spermatozoa lacking the sperm-specific putative ion channel protein, CatSper1. This plasma membrane protein of the six transmembrane-spanning ion channel superfamily is specifically localized to the principal piece of the sperm tail and is required for sperm cell hyperactivation and male fertility(4,5). Our results identify CatSper1 as a component of the key flagellar calcium channel, and suggest that intracellular alkalinization potentiates CatSper current to increase intraflagellar calcium and induce sperm hyperactivation.	Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst,Dept Cardiol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Clapham, DE (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst,Dept Cardiol, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019; Oka, Yoshitaka/C-9670-2010	Clapham, David/0000-0002-4459-9428; Oka, Yoshitaka/0000-0002-3482-3051				BABCOCK DF, 1992, P NATL ACAD SCI USA, V89, P6001, DOI 10.1073/pnas.89.13.6001; BABCOCK DF, 1983, J BIOL CHEM, V258, P6380; Carlson AE, 2005, J BIOL CHEM, V280, P32238, DOI 10.1074/jbc.M501430200; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; Cooper TG, 2005, HUM REPROD, V20, P9, DOI 10.1093/humrep/deh555; Darszon A, 2005, INT REV CYTOL, V243, P79, DOI 10.1016/S0074-7696(05)43002-8; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; ESPINOSA F, 1995, FEBS LETT, V372, P119, DOI 10.1016/0014-5793(95)00962-9; Espinosa F, 1998, FEBS LETT, V426, P47, DOI 10.1016/S0014-5793(98)00305-6; Florman HM, 1998, BIOL REPROD, V59, P12, DOI 10.1095/biolreprod59.1.12; Fraire-Zamora JJ, 2004, AM J PHYSIOL-CELL PH, V287, pC1688, DOI 10.1152/ajpcell.00141.2004; Gonzalez-Martinez MT, 2003, J BIOL CHEM, V278, P36304, DOI 10.1074/jbc.M304479200; Gorelik J, 2002, BIOPHYS J, V83, P3296, DOI 10.1016/S0006-3495(02)75330-7; Gu Y, 2004, DEV BIOL, V274, P308, DOI 10.1016/j.ydbio.2004.06.025; GUERRERO A, 1987, FEBS LETT, V220, P295, DOI 10.1016/0014-5793(87)80833-5; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Ho HC, 2002, DEV BIOL, V250, P208, DOI 10.1006/dbio.2002.0797; Ho HC, 2001, REPRODUCTION, V122, P519, DOI 10.1530/rep.0.1220519; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Lobley Anna, 2003, Reprod Biol Endocrinol, V1, P53, DOI 10.1186/1477-7827-1-53; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Sanchez D, 2001, FEBS LETT, V503, P111, DOI 10.1016/S0014-5793(01)02713-2; Santi CM, 1998, J GEN PHYSIOL, V112, P33, DOI 10.1085/jgp.112.1.33; Sather WA, 2003, ANNU REV PHYSIOL, V65, P133, DOI 10.1146/annurev.physiol.65.092101.142345; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Zeng Y, 1996, DEV BIOL, V173, P510, DOI 10.1006/dbio.1996.0044	28	321	345	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					737	740		10.1038/nature04417	http://dx.doi.org/10.1038/nature04417			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467839				2022-12-28	WOS:000235193100047
J	Mulch, A; Chamberlain, CP				Mulch, A; Chamberlain, CP			Earth science - The rise and growth of Tibet	NATURE			English	Editorial Material							SOUTHERN TIBET; PALEOALTIMETRY; PLATEAU; CLIMATE; PALEOELEVATION; HIMALAYA; MIOCENE; OROGEN; UPLIFT		Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA	Stanford University	Mulch, A (corresponding author), Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA.	mulch@pangea.stanford.edu	Mulch, Andreas/A-1324-2013					Beaumont C, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002809; Currie BS, 2005, GEOLOGY, V33, P181, DOI 10.1130/G21170.1; DANSGAARD W, 1964, TELLUS, V16, P436; Garzione CN, 2000, EARTH PLANET SC LETT, V183, P215, DOI 10.1016/S0012-821X(00)00252-1; Graham SA, 2005, AM J SCI, V305, P101, DOI 10.2475/ajs.305.2.101; McElwain JC, 2004, GEOLOGY, V32, P1017, DOI 10.1130/G20915.1; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; MOLNAR P, 1990, NATURE, V346, P29, DOI 10.1038/346029a0; Mulch A, 2004, GEOLOGY, V32, P525, DOI 10.1130/G20394.1; Rowley DB, 2006, NATURE, V439, P677, DOI 10.1038/nature04506; Rowley DB, 2001, EARTH PLANET SC LETT, V188, P253, DOI 10.1016/S0012-821X(01)00324-7; Spicer RA, 2003, NATURE, V421, P622, DOI 10.1038/nature01356; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978	13	143	172	5	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 9	2006	439	7077					670	671		10.1038/439670a	http://dx.doi.org/10.1038/439670a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	010KH	16467826				2022-12-28	WOS:000235193100030
J	Beresford, SAA; Johnson, KC; Ritenbaugh, C; Lasser, NL; Snetselaar, LG; Black, HR; Anderson, GL; Assaf, AR; Bassford, T; Bowen, D; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Harrigan, RC; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Kotchen, JM; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lewis, CE; Manson, JE; Margolis, KL; Mossavar-Rahmani, Y; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Stefanick, ML; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Whitlock, E				Beresford, SAA; Johnson, KC; Ritenbaugh, C; Lasser, NL; Snetselaar, LG; Black, HR; Anderson, GL; Assaf, AR; Bassford, T; Bowen, D; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Harrigan, RC; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Kotchen, JM; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lewis, CE; Manson, JE; Margolis, KL; Mossavar-Rahmani, Y; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Robbins, J; Rossouw, JE; Sarto, GE; Stefanick, ML; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Whitlock, E			Low-fat dietary pattern and risk of colorectal cancer - The Women's Health Initiative randomized controlled dietary modification trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-FIBER DIET; MEAT CONSUMPTION; COLON-CANCER; BETA-CAROTENE; RECURRENCE; VEGETABLES; INTERVENTION; PREVENTION; DISEASE; FRUIT	Context Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial. Objective To evaluate the effects of a low-fat eating pattern on risk of colorectal cancer in postmenopausal women. Design, Setting, and Participants The Women's Health Initiative Dietary Modification Trial, a randomized controlled trial conducted in 48 835 postmenopausal women aged 50 to 79 years recruited between 1993 and 1998 from 40 clinical centers throughout the United States. Interventions Participants were randomly assigned to the dietary modification intervention (n = 19 541; 40%) or the comparison group (n = 29 294; 60%). The intensive behavioral modification program aimed to motivate and support reductions in dietary fat, to increase consumption of vegetables and fruits, and to increase grain servings by using group sessions, self-monitoring techniques, and other tailored and targeted strategies. Women in the comparison group continued their usual eating pattern. Main Outcome Measure Invasive colorectal cancer incidence. Results A total of 480 incident cases of invasive colorectal cancer occurred during a mean follow-up of 8.1 (SD, 1.7) years. Intervention group participants significantly reduced their percentage of energy from fat by 10.7% more than did the comparison group at 1 year, and this difference between groups was mostly maintained (8.1% at year 6). Statistically significant increases in vegetable, fruit, and grain servings were also made. Despite these dietary changes, there was no evidence that the intervention reduced the risk of invasive colorectal cancer during the follow-up period. There were 201 women with invasive colorectal cancer (0.13% per year) in the intervention group and 279 (0.12% per year) in the comparison group (hazard ratio, 1.08; 95% confidence interval, 0.90-1.29). Secondary analyses suggested potential interactions with baseline aspirin use and combined estrogen-progestin use status (P=.01 for each). Colorectal examination rates, although not protocol defined, were comparable between the intervention and comparison groups. Similar results were seen in analyses adjusting for adherence to the intervention. Conclusion In this study, a low-fat dietary pattern intervention did not reduce the risk of colorectal cancer in postmenopausal women during 8.1 years of follow-up.	Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; Univ Arizona, Tucson, AZ USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Univ Iowa, Iowa City, IA USA; Rush Univ, Med Ctr, Chicago, IL 60612 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Brown Univ, Providence, RI 02912 USA; Univ Nevada, Reno, NV 89557 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Kaiser Permanente, Div Res, Oakland, CA USA; Harbor UCLA Res & Educ Inst, Torrance, CA USA; Univ Cincinnati, Cincinnati, OH USA; Univ Hawaii, Honolulu, HI 96822 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ N Carolina, Chapel Hill, NC USA; Wayne State Univ, Sch Med, Hutzel Hosp, Detroit, MI USA; Howard Univ, MedStar Res Inst, Washington, DC 20059 USA; George Washington Univ, Washington, DC USA; Univ Calif Irvine, Irvine, CA USA; Ohio State Univ, Columbus, OH 43210 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ Pittsburgh, Pittsburgh, PA USA; SUNY Stony Brook, Stony Brook, NY 11794 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Alabama Birmingham, Birmingham, AL USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; Univ Minnesota, Minneapolis, MN USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; Univ Miami, Miami, FL 33152 USA; Univ Florida, Gainesville, FL USA; Emory Univ, Atlanta, GA 30322 USA; Univ Calif Davis, Sacramento, CA 95817 USA; NHLBI, Bethesda, MD 20892 USA; Univ Wisconsin, Madison, WI USA; Stanford Prevent Res Ctr, Stanford, CA USA; Northwestern Univ, Chicago, IL 60611 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Univ Buffalo, Buffalo, NY USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA	University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; University of Arizona; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Iowa; Rush University; Fred Hutchinson Cancer Center; Brown University; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Texas System; University of Texas Health San Antonio; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Ohio; University of Cincinnati; University of Hawaii System; Baylor College of Medicine; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University; Howard University; George Washington University; University of California System; University of California Irvine; University System of Ohio; Ohio State University; Medical College of Wisconsin; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; University of Miami; State University System of Florida; University of Florida; Emory University; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Wisconsin System; University of Wisconsin Madison; Stanford University; Northwestern University; Wake Forest University; Wake Forest Baptist Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Kaiser Permanente	Beresford, SAA (corresponding author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA.	beresfrd@u.washington.edu	Wactawski-Wende, Jean/AGH-5457-2022	Wactawski-Wende, Jean/0000-0003-3096-9595; Ritenbaugh, Cheryl/0000-0002-3307-2727; Caan, Bette/0000-0002-5803-310X; Margolis, Karen/0000-0003-1862-7402; Bowen, Deborah/0000-0002-5177-8520; Hays-Grudo, Jennifer/0000-0002-8107-1243; Perri, Michael/0000-0003-3651-1542; Mossavar-Rahmani, Yasmin/0000-0002-9214-6124				Albanes D, 2000, CANCER CAUSE CONTROL, V11, P197, DOI 10.1023/A:1008936214087; Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; [Anonymous], [No title captured]; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Bowen D, 2002, J AM DIET ASSOC, V102, P1631, DOI 10.1016/S0002-8223(02)90347-0; BURKITT DP, 1969, LANCET, V2, P1229, DOI 10.1016/S0140-6736(69)90757-0; Carroll K K, 1975, Prog Biochem Pharmacol, V10, P308; Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172; Chin BCH, 2004, NUTR CANCER, V49, P49, DOI 10.1207/s15327914nc4901_7; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Gifford KD, 2002, AM J MED, V113, P89, DOI 10.1016/S0002-9343(01)00996-2; Giovannucci E, 2003, J WOMEN HEALTH GEN-B, V12, P173, DOI 10.1089/154099903321576574; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; Harnack L, 2002, AM J CLIN NUTR, V76, P889, DOI 10.1093/ajcn/76.4.889; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Heini AF, 1997, AM J MED, V102, P259, DOI 10.1016/S0002-9343(96)00456-1; Hofstad B, 1998, DIGESTION, V59, P148, DOI 10.1159/000007480; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655; Howe GR, 1997, CANCER CAUSE CONTROL, V8, P215, DOI 10.1023/A:1018476414781; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; INSULL W, 1990, ARCH INTERN MED, V150, P421, DOI 10.1001/archinte.150.2.421; Kim MK, 2005, INT J CANCER, V115, P790, DOI 10.1002/ijc.20943; Lanza E, 2001, AM J CLIN NUTR, V74, P387; Larsson SC, 2005, INT J CANCER, V113, P829, DOI 10.1002/ijc.20658; Law M, 2000, AM J CLIN NUTR, V72, p1291S, DOI 10.1093/ajcn/72.5.1291s; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; Mathew A, 2004, EUR J CANCER PREV, V13, P159, DOI 10.1097/01.cej.0000130022.23806.7b; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; MCMICHAEL AJ, 1988, CANCER RES, V48, P751; Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Patterson RE, 2004, J AM DIET ASSOC, V104, P654, DOI 10.1016/j.jada.2004.01.014; Peters U, 2003, LANCET, V361, P1491, DOI 10.1016/S0140-6736(03)13173-X; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Ries L., 2005, SEER CANC STAT REV 1; Ritenbaugh C, 2003, ANN EPIDEMIOL, V13, pS87, DOI 10.1016/S1047-2797(03)00044-9; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Smith-Warner SA, 2002, AM J EPIDEMIOL, V155, P1104, DOI 10.1093/aje/155.12.1104; STEINMETZ KA, 1993, INT J CANCER, V53, P711, DOI 10.1002/ijc.2910530502; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; THOMAS DB, 1987, CANCER RES, V47, P5771; Tinker Lesley Fels, 1996, P510; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; US Department of Health and Human Services and US Department of Agriculture, 2005, DIET GUID AM; Winawer Sidney J., 1999, American Journal of Medicine, V106, p3S, DOI 10.1016/S0002-9343(98)00338-6; Wu XC, 2004, CANCER EPIDEM BIOMAR, V13, P1215; Yang QH, 1997, AM J EPIDEMIOL, V146, P713	56	282	288	1	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	2006	295	6					643	654		10.1001/jama.295.6.643	http://dx.doi.org/10.1001/jama.295.6.643			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010DX	16467233				2022-12-28	WOS:000235168200024
J	Le Gal, G; Righini, M; Roy, PM; Sanchez, O; Aujesky, D; Bounameaux, H; Perrier, A				Le Gal, G; Righini, M; Roy, PM; Sanchez, O; Aujesky, D; Bounameaux, H; Perrier, A			Prediction of pulmonary embolism in the emergency department: The revised Geneva score	ANNALS OF INTERNAL MEDICINE			English	Article							SIMPLE CLINICAL-MODEL; D-DIMER; DIAGNOSTIC STRATEGIES; COMPUTED-TOMOGRAPHY; PROBABILITY; RULES; MANAGEMENT; THROMBOSIS	Background: Diagnosis of pulmonary embolism requires clinical probability assessment. Implicit assessment is accurate but is not standardized, and current prediction rules have shortcomings. Objective: To construct a simple score based entirely on clinical variables and independent from physicians' implicit judgment. Design: Derivation and external validation of the score in 2 independent management studies on pulmonary embolism diagnosis. Setting: Emergency departments of 3 university hospitals in Europe. Patients: Consecutive patients admitted for clinically suspected pulmonary embolism. Measurements: Collected data included demographic characteristics, risk factors, and clinical signs and symptoms suggestive of venous thromboembolism. The variables statistically significantly associated with pulmonary embolism in univariate analysis were included in a multivariate logistic regression model. Points were assigned according to the regression coefficients. The score was then externally validated in an independent cohort. Results: The score comprised 8 variables (points): age older than 65 years (1 point), previous deep venous thrombosis or pulmonary embolism (3 points), surgery or fracture within 1 month (2 points), active malignant condition (2 points), unilateral lower limb pain (3 points), hemoptysis (2 points), heart rate of 75 to 94 beats/min (3 points) or 95 beats/min or more (5 points), and pain on lower-limb deep venous palpation and unilateral edema (4 points). In the validation set, the prevalence of pulmonary embolism was 8% in the low-probability category (0 to 3 points), 28% in the intermediate-probability category (4 to 10 points), and 74% in the high probability category (>= 11 points). Limitations: Interobserver agreement for the score items was not studied. Conclusions: The proposed score is entirely standardized and is based on clinical variables. It has sustained internal and external validation and should now be tested for clinical usefulness in an outcome study.	Brest Univ Hosp, Brest, France; Univ Hosp Geneva, Geneva, Switzerland; Angers Univ Hosp, Angers, France; Hop Europeen Georges Pompidou, Paris, France; CHU Vaudois, CH-1011 Lausanne, Switzerland	CHU Brest; University of Geneva; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Le Gal, G (corresponding author), CHU Cavale Blanche, Dept Med Interne & Pneumol, EA 3878, F-29609 Brest, France.	gregoire.legal@chu-brest.fr	Roy, Pierre-Marie/AAA-7737-2022; LE GAL, Gregoire/K-1077-2012; Perrier, Arnaud/M-2263-2014; Righini, Marc/AAX-8731-2020	LE GAL, Gregoire/0000-0002-9253-248X; SANCHEZ, Olivier/0000-0003-1633-8391				Campbell IA, 2003, THORAX, V58, P470; Chagnon I, 2002, AM J MED, V113, P269, DOI 10.1016/S0002-9343(02)01212-3; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Kelly J, 2003, CHEST, V124, P1116, DOI 10.1378/chest.124.3.1116; Kruip MJHA, 2003, ANN INTERN MED, V138, P941, DOI 10.7326/0003-4819-138-12-200306170-00005; MCNEIL BJ, 1983, RADIOLOGY, V149, P75, DOI 10.1148/radiology.149.1.6611955; Musset D, 2002, LANCET, V360, P1914, DOI 10.1016/S0140-6736(02)11914-3; Perrier A, 2005, NEW ENGL J MED, V352, P1760, DOI 10.1056/NEJMoa042905; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; Perrier A, 2004, AM J MED, V116, P291, DOI 10.1016/j.amjmed.2003.09.041; Perrier A, 2003, AM J RESP CRIT CARE, V167, P39, DOI 10.1164/rccm.2106128; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; Perrier A, 2001, THROMB HAEMOSTASIS, V86, P475; Stein PD, 2004, ANN INTERN MED, V140, P589, DOI 10.7326/0003-4819-140-8-200404200-00005; Torbicki A, 2000, EUR HEART J, V21, P1301; Wasson JH, 1996, JAMA-J AM MED ASSOC, V275, P641, DOI 10.1001/jama.275.8.641; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010; Wells PS, 2000, THROMB HAEMOSTASIS, V83, P416; Wicki J, 2001, ARCH INTERN MED, V161, P92, DOI 10.1001/archinte.161.1.92; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539; 1990, JAMA, V263, P2753	24	662	680	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					165	171		10.7326/0003-4819-144-3-200602070-00004	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008XS	16461960				2022-12-28	WOS:000235074800002
J	Baron, MK; Boeckers, TM; Vaida, B; Faham, S; Gingery, M; Sawaya, MR; Salyer, D; Gundelfinger, ED; Bowie, JU				Baron, MK; Boeckers, TM; Vaida, B; Faham, S; Gingery, M; Sawaya, MR; Salyer, D; Gundelfinger, ED; Bowie, JU			An architectural framework that may lie at the core of the postsynaptic density	SCIENCE			English	Article							RECEPTOR SAM DOMAIN; ACTIN CYTOSKELETON; MASS-SPECTROMETRY; DENDRITIC SPINES; PROTEINS; FAMILY; ZINC; PLASTICITY; SPECIATION; NEURONS	The postsynaptic density (PSD) is a complex assembly of proteins associated with the postsynaptic membrane that organizes neurotransmitter receptors, signaling pathways, and regulatory elements within a cytosketetat matrix. Here we show that the sterile alpha motif domain of rat Shank3/ProSAP2, a master scaffolding protein located deep within the PSD, can form large sheets composed of helical fibers stacked side by side. Zn2+, which is found in high concentrations in the PSD, binds tightly to Shank3 and may regulate assembly. Sheets of the Shank protein could form a platform for the construction of the PSD complex.	Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Univ Calif Los Angeles US Dept Energy Inst Genom, Los Angeles, CA 90095 USA; Univ Ulm, Inst Anat & Cell Biol, Ulm, Germany; Leibniz Inst Neurobiol, D-39008 Magdeburg, Germany	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Ulm University; Leibniz Institut fur Neurobiologie (LIN)	Bowie, JU (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, 611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu			NATIONAL CANCER INSTITUTE [R01CA081000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063919, R01GM075922] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081000] Funding Source: Medline; NIGMS NIH HHS [R01 GM075922, R01 GM075922-04, R01 GM063919-07, R01 GM063919, R01 GM063919-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Behlke J, 2001, EUR BIOPHYS J BIOPHY, V30, P411, DOI 10.1007/s002490100164; Boeckers TM, 2005, J NEUROCHEM, V92, P519, DOI 10.1111/j.1471-4159.2004.02910.x; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Bresler T, 2004, J NEUROSCI, V24, P1507, DOI 10.1523/JNEUROSCI.3819-03.2004; Carlisle HJ, 2005, TRENDS NEUROSCI, V28, P182, DOI 10.1016/j.tins.2005.01.008; Caruso JA, 2003, ECOTOX ENVIRON SAFE, V56, P148, DOI 10.1016/S0147-6513(03)00058-7; Chang CJ, 2004, CHEM BIOL, V11, P203, DOI 10.1016/j.chembiol.2004.01.017; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Ehlers MD, 2002, TRENDS NEUROSCI, V25, P64, DOI 10.1016/S0166-2236(02)02061-1; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Jan HH, 2002, J NEUROCHEM, V83, P525, DOI 10.1046/j.1471-4159.2002.01093.x; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Li Y, 2001, J NEUROPHYSIOL, V86, P2597, DOI 10.1152/jn.2001.86.5.2597; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; MATUS AI, 1978, PROC R SOC SER B-BIO, V203, P135, DOI 10.1098/rspb.1978.0097; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Qualmann B, 2004, J NEUROSCI, V24, P2481, DOI 10.1523/JNEUROSCI.5479-03.2004; Roussignol G, 2005, J NEUROSCI, V25, P3560, DOI 10.1523/JNEUROSCI.4354-04.2005; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Valtschanoff JG, 2001, J NEUROSCI, V21, P1211; Vanhaecke F, 2002, ANAL BIOANAL CHEM, V374, P188, DOI 10.1007/s00216-002-1338-3; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Wouterlood FG, 2003, J NEUROSCI METH, V128, P129, DOI 10.1016/S0165-0270(03)00171-7; Zuber B, 2005, P NATL ACAD SCI USA, V102, P19192, DOI 10.1073/pnas.0509527102	33	218	222	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					531	535		10.1126/science.1118995	http://dx.doi.org/10.1126/science.1118995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439662				2022-12-28	WOS:000235071400048
J	Barrett, BJ; Parfrey, PS				Barrett, BJ; Parfrey, PS			Preventing nephropathy induced by contrast medium	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; ACUTE-RENAL-FAILURE; N-ACETYLCYSTEINE; RADIOCONTRAST NEPHROPATHY; CARDIAC-CATHETERIZATION; RANDOMIZED-TRIAL; SERUM CREATININE; RISK-FACTORS; NEPHROTOXICITY; HYDRATION		Mem Univ Newfoundland, Div Nephrol, St John, NF, Canada	Memorial University Newfoundland	Barrett, BJ (corresponding author), Hlth Sci Ctr, Patient Res Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.	bbarrett@mun.ca						Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; *AM COLL RAD, MAN CONTR MED VERS 5; Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; Bader BD, 2004, CLIN NEPHROL, V62, P1, DOI 10.5414/cnp62001; Bagshaw SM, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-38; Bagshaw SM, 2005, ARCH INTERN MED, V165, P1087, DOI 10.1001/archinte.165.10.1087; BARRETT BJ, 1993, RADIOLOGY, V188, P171, DOI 10.1148/radiology.188.1.8511292; Bartholomew BA, 2004, AM J CARDIOL, V93, P1515, DOI 10.1016/j.amjcard.2004.03.008; Carraro M, 1998, EUR RADIOL, V8, P144, DOI 10.1007/s003300050356; Chalmers N, 1999, BRIT J RADIOL, V72, P701, DOI 10.1259/bjr.72.859.10624328; CIGARROA RG, 1989, AM J MED, V86, P649, DOI 10.1016/0002-9343(89)90437-3; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dangas G, 2005, AM J CARDIOL, V95, P13, DOI 10.1016/j.amjcard.2004.08.056; Davidson CJ, 2000, CIRCULATION, V101, P2172, DOI 10.1161/01.CIR.101.18.2172; Fishbane S, 2004, J AM SOC NEPHROL, V15, P251, DOI 10.1097/01.ASN.0000107562.68920.92; Freeman RV, 2002, AM J CARDIOL, V90, P1068, DOI 10.1016/S0002-9149(02)02771-6; Gruberg L, 2000, J AM COLL CARDIOL, V36, P1542, DOI 10.1016/S0735-1097(00)00917-7; Guitterez Noel V, 2002, J Interv Cardiol, V15, P349; Gupta R K, 1999, Indian Heart J, V51, P521; Heyman SN, 1999, INVEST RADIOL, V34, P685, DOI 10.1097/00004424-199911000-00004; KATHOLI RE, 1995, RADIOLOGY, V195, P17, DOI 10.1148/radiology.195.1.7892462; Katholi RE, 1998, AM J KIDNEY DIS, V32, P64, DOI 10.1053/ajkd.1998.v32.pm9669426; KHOURY Z, 1995, PHARMACOTHERAPY, V15, P59; Kshirsagar AV, 2004, J AM SOC NEPHROL, V15, P761, DOI 10.1097/01.ASN.0000116241.47678.49; Kurnik BRC, 1998, AM J KIDNEY DIS, V31, P674, DOI 10.1053/ajkd.1998.v31.pm9531185; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Marenzi G, 2004, J AM COLL CARDIOL, V44, P1780, DOI 10.1016/j.jacc.2004.07.043; Marenzi G, 2003, NEW ENGL J MED, V349, P1333, DOI 10.1056/NEJMoa023204; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068; Merten GJ, 2004, JAMA-J AM MED ASSOC, V291, P2328, DOI 10.1001/jama.291.19.2328; MESSANA JM, 1990, RENAL FAILURE, V12, P75, DOI 10.3109/08860229009087121; Mueller C, 2002, ARCH INTERN MED, V162, P329, DOI 10.1001/archinte.162.3.329; Nallamothu BK, 2004, AM J MED, V117, P938, DOI 10.1016/j.amjmed.2004.06.046; Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766; Pannu N, 2004, KIDNEY INT, V65, P1366, DOI 10.1111/j.1523-1755.2004.00516.x; RICH MW, 1990, ARCH INTERN MED, V150, P1237, DOI 10.1001/archinte.150.6.1237; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; Sketch M H Jr, 2001, Am J Ther, V8, P155, DOI 10.1097/00045391-200105000-00004; Solomon R, 1998, KIDNEY INT, V53, P230, DOI 10.1038/sj.ki.4495510; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Spargias K, 2004, CIRCULATION, V110, P2837, DOI 10.1161/01.CIR.0000146396.19081.73; SPARGIAS K, 2005, CIRCULATION, V111, P379; Stevens NA, 1999, J AM COLL CARDIOL, V33, P403; Stone GW, 2003, JAMA-J AM MED ASSOC, V290, P2284, DOI 10.1001/jama.290.17.2284; Taylor AJ, 1998, CHEST, V114, P1570, DOI 10.1378/chest.114.6.1570; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Thomsen HS, 2005, EUR RADIOL, V15, P749, DOI 10.1007/s00330-004-2591-y; Thomsen HS, 2003, AM J ROENTGENOL, V181, P1463, DOI 10.2214/ajr.181.6.1811463; Trivedi HS, 2003, NEPHRON CLIN PRACT, V93, pC29, DOI 10.1159/000066641; Wang A, 2000, KIDNEY INT, V57, P1675, DOI 10.1046/j.1523-1755.2000.00012.x; WEINSTEIN JM, 1992, NEPHRON, V62, P413, DOI 10.1159/000187090; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32	54	430	461	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					379	386		10.1056/NEJMcp050801	http://dx.doi.org/10.1056/NEJMcp050801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436769				2022-12-28	WOS:000234854000009
J	Lubin, D; Vogelmann, AM				Lubin, D; Vogelmann, AM			A climatologically significant aerosol longwave indirect effect in the Arctic	NATURE			English	Article							PART II; CLOUD PROPERTIES; SEA-ICE; CLIMATE-CHANGE; SURFACE; POLLUTION; ALBEDO	The warming of Arctic climate and decreases in sea ice thickness and extent(1,2) observed over recent decades are believed to result from increased direct greenhouse gas forcing, changes in atmospheric dynamics having anthropogenic origin(3-5), and important positive reinforcements including ice - albedo and cloud - radiation feedbacks(6). The importance of cloud - radiation interactions is being investigated through advanced instrumentation deployed in the high Arctic since 1997 (refs 7, 8). These studies have established that clouds, via the dominance of longwave radiation, exert a net warming on the Arctic climate system throughout most of the year, except briefly during the summer(9). The Arctic region also experiences significant periodic influxes of anthropogenic aerosols, which originate from the industrial regions in lower latitudes(10). Here we use multisensor radiometric data(7,8) to show that enhanced aerosol concentrations alter the microphysical properties of Arctic clouds, in a process known as the 'first indirect' effect(11,12). Under frequently occurring cloud types we find that this leads to an increase of an average 3.4 watts per square metre in the surface longwave fluxes. This is comparable to a warming effect from established greenhouse gases and implies that the observed longwave enhancement is climatologically significant.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Brookhaven Natl Lab, Upton, NY 11973 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; United States Department of Energy (DOE); Brookhaven National Laboratory	Lubin, D (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	dlubin@ucsd.edu	Vogelmann, Andrew M/M-8779-2014	Vogelmann, Andrew M/0000-0003-1918-5423				BARRIE LA, 1986, ATMOS ENVIRON, V20, P643, DOI 10.1016/0004-6981(86)90180-0; Cavalieri DJ, 1997, SCIENCE, V278, P1104, DOI 10.1126/science.278.5340.1104; Clothiaux EE, 2000, J APPL METEOROL, V39, P645, DOI 10.1175/1520-0450(2000)039<0645:ODOCHA>2.0.CO;2; Delene DJ, 2002, J ATMOS SCI, V59, P1135, DOI 10.1175/1520-0469(2002)059<1135:VOAOPA>2.0.CO;2; Garrett TJ, 2002, J ATMOS SCI, V59, P769, DOI 10.1175/1520-0469(2002)059<0769:AEOCEA>2.0.CO;2; Guo G, 2005, IEEE GEOSCI REMOTE S, V2, P132, DOI 10.1109/LGRS.2005.844734; Jiang HL, 2001, J GEOPHYS RES-ATMOS, V106, P15113, DOI 10.1029/2000JD900303; Johannessen OM, 2004, TELLUS A, V56, P328, DOI 10.1111/j.1600-0870.2004.00060.x; Knuteson RO, 2004, J ATMOS OCEAN TECH, V21, P1777, DOI 10.1175/JTECH-1663.1; LEONTYEVA E, 1994, J CLIMATE, V7, P566, DOI 10.1175/1520-0442(1994)007<0566:EOCOTF>2.0.CO;2; Mahesh A, 2001, J APPL METEOROL, V40, P1279, DOI 10.1175/1520-0450(2001)040<1279:GBIRSO>2.0.CO;2; Moritz RE, 2002, SCIENCE, V297, P1497, DOI 10.1126/science.1076522; Morrison H, 2005, J ATMOS SCI, V62, P1678, DOI 10.1175/JAS3447.1; Payne RE, 1999, J ATMOS OCEAN TECH, V16, P739, DOI 10.1175/1520-0426(1999)016<0739:ANLACA>2.0.CO;2; Penner JE, 2004, NATURE, V427, P231, DOI 10.1038/nature02234; Rigor IG, 2002, J CLIMATE, V15, P2648, DOI 10.1175/1520-0442(2002)015<2648:ROSITT>2.0.CO;2; Shupe MD, 2004, J CLIMATE, V17, P616, DOI 10.1175/1520-0442(2004)017<0616:CRFOTA>2.0.CO;2; Stamnes K, 1999, J CLIMATE, V12, P46, DOI 10.1175/1520-0442-12.1.46; Thompson DWJ, 2000, J CLIMATE, V13, P1000, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Turner DD, 2005, J APPL METEOROL, V44, P427, DOI 10.1175/JAM2208.1; TWOMEY S, 1977, J ATMOS SCI, V34, P1149, DOI 10.1175/1520-0469(1977)034<1149:TIOPOT>2.0.CO;2; Uttal T, 2002, B AM METEOROL SOC, V83, P255, DOI 10.1175/1520-0477(2002)083<0255:SHBOTA>2.3.CO;2	22	136	136	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					453	456		10.1038/nature04449	http://dx.doi.org/10.1038/nature04449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437112				2022-12-28	WOS:000234859200042
J	Vaglio, A; Salvarani, C; Buzio, C				Vaglio, A; Salvarani, C; Buzio, C			Retroperitoneal fibrosis	LANCET			English	Review							ABDOMINAL AORTIC-ANEURYSM; POSITRON-EMISSION-TOMOGRAPHY; PRIMARY BILIARY-CIRRHOSIS; ERDHEIM-CHESTER-DISEASE; IDIOPATHIC RETROPERITONEAL; CHRONIC PERIAORTITIS; MULTIFOCAL FIBROSCLEROSIS; SCLEROSING PANCREATITIS; PERIANEURYSMAL FIBROSIS; WEGENERS-GRANULOMATOSIS	Retroperitoneal fibrosis encompasses a range of diseases characterised by the presence of a fibro-inflammatory tissue, which usually surrounds the abdominal aorta and the iliac arteries and extends into the retroperitoneum to envelop neighbouring structures-eg, ureters. Retroperitoneal fibrosis is generally idiopathic, but can also be secondary to the use of certain drugs, malignant diseases, infections, and surgery. Idiopathic disease was thought to result from a local inflammatory reaction to antigens in the atherosclerotic plaques of the abdominal aorta, but clinicolaboratory findings-namely, the presence of constitutional symptoms and the high concentrations of acute-phase reactants-and the frequent association of the disease with autoimmune diseases that involve other organs suggest that it might be a manifestation of a systemic autoimmune or inflammatory disease. Steroids are normally used to treat idiopathic retroperitoneal fibrosis, although other options g, immunosuppressants, tamoxifen-are available. The outlook is usually good, but, if not appropriately diagnosed or treated, the disease can cause severe complications, such as end-stage renal failure. Here, we review the different aspects of retroperitoneal fibrosis, focusing on idiopathic retroperitoneal fibrosis and on the differential diagnosis associated with the secondary forms.	Univ Parma, Dept Clin Med Nephrol & Hlth Sci, I-43100 Parma, Italy; Arcispedale S Maria Nuova, Rheumatol Serv, Reggio Emilia, Italy	University of Parma; IRCCS Arcispedale S. Maria Nuova	Vaglio, A (corresponding author), Univ Parma, Dept Clin Med Nephrol & Hlth Sci, Via Gramsci 14, I-43100 Parma, Italy.	augusto.vaglio@virgilio.it	Salvarani, Carlo/K-2431-2018; Vaglio, Augusto/AHE-8117-2022	Vaglio, Augusto/0000-0002-3814-9172; Salvarani, Carlo/0000-0001-5426-5133				Agarwal P, 2004, MOVEMENT DISORD, V19, P699, DOI 10.1002/mds.20200; AHMAD S, 1983, AM HEART J, V105, P1037, DOI 10.1016/0002-8703(83)90412-X; Al-Musawi D, 1998, BRIT J UROL, V82, P442; Albarran J., 1905, ASS FR UROL, V9, P511; Armigliato M, 2002, THYROID, V12, P829, DOI 10.1089/105072502760339415; ARRIVE L, 1989, RADIOLOGY, V172, P139, DOI 10.1148/radiology.172.1.2740497; BAKER LRI, 1987, BRIT J UROL, V60, P497, DOI 10.1111/j.1464-410X.1987.tb05028.x; Bonati L, 2003, WORLD J SURG, V27, P539, DOI 10.1007/s00268-003-6706-4; Bourouma R, 1997, NEPHROL DIAL TRANSPL, V12, P2407, DOI 10.1093/ndt/12.11.2407; Chander Subhash, 2002, Mol Imaging Biol, V4, P363, DOI 10.1016/S1536-1632(02)00021-5; Chizzolini C, 2002, ARTHRITIS RHEUM-US, V46, P1602, DOI 10.1002/art.10361; COFFIN CM, 1995, AM J SURG PATHOL, V19, P859, DOI 10.1097/00000478-199508000-00001; CORDONE RP, 1988, DIS COLON RECTUM, V31, P563, DOI 10.1007/BF02553733; Dehner LP, 1998, SEMIN DIAGN PATHOL, V15, P161; Demko TM, 1997, J AM SOC NEPHROL, V8, P684; DOI M, 1994, AM J OPHTHALMOL, V117, P358, DOI 10.1016/S0002-9394(14)73146-0; Drieskens O, 2002, CLIN NUCL MED, V27, P413, DOI 10.1097/00003072-200206000-00005; DUFFY PG, 1984, J UROLOGY, V131, P746, DOI 10.1016/S0022-5347(17)50607-2; Duvic C, 2004, NEPHROL DIAL TRANSPL, V19, P2397, DOI 10.1093/ndt/gfh050; FINAN BF, 1981, J UROLOGY, V126, P533, DOI 10.1016/S0022-5347(17)54612-1; Fugita OE, 2002, J ENDOUROL, V16, P571, DOI 10.1089/089277902320913251; Garcia JF, 1998, HISTOPATHOLOGY, V33, P459, DOI 10.1046/j.1365-2559.1998.00531.x; Gilkeson GS, 1996, RHEUM DIS CLIN N AM, V22, P23, DOI 10.1016/S0889-857X(05)70260-X; GLYNN TP, 1989, RADIOLOGY, V170, P726, DOI 10.1148/radiology.170.3.2916026; GRAHAM JR, 1966, NEW ENGL J MED, V274, P359, DOI 10.1056/NEJM196602172740701; Grotz W, 1998, LANCET, V352, P1195, DOI 10.1016/S0140-6736(05)60533-8; Hamano H, 2002, LANCET, V359, P1403, DOI 10.1016/S0140-6736(02)08359-9; HARREBY M, 1994, SCAND J UROL NEPHROL, V28, P237, DOI 10.3109/00365599409181272; HAUTEKEETE ML, 1990, J INTERN MED, V228, P533, DOI 10.1111/j.1365-2796.1990.tb00274.x; HELLSTROM HR, 1966, AM J MED, V40, P184, DOI 10.1016/0002-9343(66)90098-2; HOEKSTRA HJ, 1988, J SURG ONCOL, V37, P104, DOI 10.1002/jso.2930370208; Hofbauer LC, 1996, J RHEUMATOL, V23, P554; HUGHES D, 1993, AM J SURG PATHOL, V17, P482, DOI 10.1097/00000478-199305000-00007; Izzedine H, 2002, AM J MED, V113, P164, DOI 10.1016/S0002-9343(02)01170-1; Jendro MC, 2004, CLIN RHEUMATOL, V23, P52, DOI 10.1007/s10067-003-0801-7; Jois RN, 2004, RHEUMATOLOGY, V43, P1441, DOI 10.1093/rheumatology/keh326; Kardar AH, 2002, J UROLOGY, V168, P550, DOI 10.1016/S0022-5347(05)64677-0; Kikkawa Akira, 2004, World J Surg Oncol, V2, P33; Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106; KOEP L, 1977, SURGERY, V81, P250; Kottra JJ, 1996, RADIOL CLIN N AM, V34, P1259; Kunkler RB, 1998, BRIT J UROL, V82, P147; LeBlanc CMA, 2002, ARTHRIT RHEUM-ARTHR, V47, P210, DOI 10.1002/art.10267; LINDELL OI, 1987, J UROLOGY, V138, P727, DOI 10.1016/S0022-5347(17)43353-2; LOFFELD RJLF, 1993, LANCET, V341, P382, DOI 10.1016/0140-6736(93)90195-M; Marcolongo R, 2004, AM J MED, V116, P194, DOI 10.1016/j.amjmed.2003.08.033; MARTINEZ FDLI, 1992, J RHEUMATOL, V19, P1147; MARTORANA D, IN PRESS ARTHRITIS R; Marzano A, 2001, ANN RHEUM DIS, V60, P427, DOI 10.1136/ard.60.4.427; Milam MR, 2004, OBSTET GYNECOL, V104, P1134, DOI 10.1097/01.AOG.0000144118.90772.a1; Miller OF, 2003, J PEDIATR SURG, V38, P1685, DOI 10.1016/S0022-3468(03)00590-6; Mitchinson M J, 1971, Br J Urol, V43, P44; MITCHINSON MJ, 1984, HISTOPATHOLOGY, V8, P589, DOI 10.1111/j.1365-2559.1984.tb02371.x; MITCHINSON MJ, 1972, J CLIN PATHOL, V25, P287, DOI 10.1136/jcp.25.4.287; MITCHINSON MJ, 1970, J CLIN PATHOL, V23, P681, DOI 10.1136/jcp.23.8.681; MITCHINSON MJ, 1982, ATHEROSCLEROSIS, V45, P11, DOI 10.1016/0021-9150(82)90167-8; Modlin IM, 2004, AM J GASTROENTEROL, V99, P2466, DOI 10.1111/j.1572-0241.2004.40507.x; Moroni G, 1999, NEPHROL DIAL TRANSPL, V14, P1303, DOI 10.1093/ndt/14.5.1303; MOUL JW, 1992, J UROLOGY, V147, P124, DOI 10.1016/S0022-5347(17)37155-0; Nitecki SS, 1996, J VASC SURG, V23, P860, DOI 10.1016/S0741-5214(96)70249-5; OIKARINEN AI, 1988, BIOCHEM PHARMACOL, V37, P1451, DOI 10.1016/0006-2952(88)90006-8; Okada H, 1999, NEPHROL DIAL TRANSPL, V14, P1300, DOI 10.1093/ndt/14.5.1300; ORMOND JK, 1948, J UROLOGY, V59, P1072, DOI 10.1016/S0022-5347(17)69482-5; Oshiro H, 2005, AM J MED, V118, P782, DOI 10.1016/j.amjmed.2005.02.004; PARUMS DV, 1986, ATHEROSCLEROSIS, V61, P117, DOI 10.1016/0021-9150(86)90070-5; PARUMS DV, 1990, ARCH PATHOL LAB MED, V114, P383; PARUMS DV, 1991, BRIT J UROL, V67, P564, DOI 10.1111/j.1464-410X.1991.tb15216.x; PARUMS DV, 1990, HISTOPATHOLOGY, V16, P423; Petras RE, 2004, STERNBERGS DIAGNOSTI, P1475; Pfitzenmeyer P, 1996, EUR RESPIR J, V9, P1013, DOI 10.1183/09031936.96.09051013; Rabbani F, 2003, UROLOGY, V62, P1092, DOI 10.1016/S0090-4295(03)00770-2; RAMSHAW AL, 1994, J CLIN PATHOL, V47, P721, DOI 10.1136/jcp.47.8.721; Rehring TF, 2001, ANN VASC SURG, V15, P591, DOI 10.1007/s10016-001-0019-6; Ronda N, 2002, ARTHRITIS RHEUM-US, V46, P1595, DOI 10.1002/art.10362; Sakalihasan N, 2005, LANCET, V365, P1577, DOI 10.1016/S0140-6736(05)66459-8; SALDINO RM, 1972, J UROLOGY, V107, P582, DOI 10.1016/S0022-5347(17)61083-8; Salvarani C, 2005, ARTHRIT RHEUM-ARTHR, V53, P298, DOI 10.1002/art.21074; Salvarani C, 2002, NEW ENGL J MED, V347, P261, DOI 10.1056/NEJMra011913; Sasaki S, 1997, JPN CIRC J, V61, P231, DOI 10.1253/jcj.61.231; SCAVALLI AS, 1995, CLIN RHEUMATOL, V14, P481, DOI 10.1007/BF02207688; Schirmer M, 2003, EXP GERONTOL, V38, P463, DOI 10.1016/S0531-5565(02)00267-X; Serratrice J, 2000, J RHEUMATOL, V27, P1550; Seth A, 2001, J UROLOGY, V166, P622, DOI 10.1016/S0022-5347(05)66007-7; Shikuwa S, 2000, J GASTROENTEROL, V35, P646, DOI 10.1007/s005350070067; Tambyraja AL, 2004, J VASC SURG, V39, P400, DOI 10.1016/j.jvs.2003.07.029; Tang KH, 2002, EUR J GASTROEN HEPAT, V14, P783, DOI 10.1097/00042737-200207000-00013; TERMAATEN JC, 1993, NEPHRON, V63, P358, DOI 10.1159/000187226; THOMAS MH, 1973, BRIT J CANCER, V28, P453, DOI 10.1038/bjc.1973.171; Tsai TC, 1996, PEDIATR NEPHROL, V10, P208; Uibu T, 2004, LANCET, V363, P1422, DOI 10.1016/S0140-6736(04)16100-X; Vaglio A, 2002, J INTERN MED, V251, P268, DOI 10.1046/j.1365-2796.2002.00948.x; Vaglio A, 2003, AM J MED, V114, P454, DOI 10.1016/S0002-9343(03)00056-1; Vaglio A, 2005, ARTHRIT RHEUM-ARTHR, V53, P122, DOI 10.1002/art.20914; Vaglio A, 2005, CLIN EXP RHEUMATOL, V23, P231; Vaglio A, 2005, CURR OPIN RHEUMATOL, V17, P34, DOI 10.1097/01.bor.0000145517.83972.40; VAGLIO A, 2004, AUTOIMMUN REV S2, V3, P54; Vivas I, 2000, BRIT J RADIOL, V73, P214, DOI 10.1259/bjr.73.866.10884739; von Fritschen U, 1999, J VASC SURG, V30, P1090, DOI 10.1016/S0741-5214(99)70048-0; Warnatz K, 2005, ANN RHEUM DIS, V64, P828, DOI 10.1136/ard.2004.029793; WATERS VV, 1989, J UROLOGY, V141, P936, DOI 10.1016/S0022-5347(17)41059-7; WILSON MC, 1980, GUT, V21, P808, DOI 10.1136/gut.21.9.808; Wu Jamie, 2002, Cancer Control, V9, P432; Yamada H, 1998, INTERNAL MED, V37, P592, DOI 10.2169/internalmedicine.37.592	103	469	513	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	2006	367	9506					241	251		10.1016/S0140-6736(06)68035-5	http://dx.doi.org/10.1016/S0140-6736(06)68035-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427494				2022-12-28	WOS:000234810600030
J	Chandonia, JM; Brenner, SE				Chandonia, JM; Brenner, SE			The impact of structural genomics: Expectations and outcomes	SCIENCE			English	Review							PROTEIN-STRUCTURE; RIBOSOMAL-SUBUNIT; CRYSTAL-STRUCTURE; TARGET SELECTION; DATABASE; BIOLOGY; RESOLUTION; SCOP	Structural genomics (SG) projects aim to expand our structural knowledge of biological macromolecules while lowering the average costs of structure determination. We quantitatively analyzed the novelty, cost, and impact of structures solved by SG centers, and we contrast these results with traditional structural biology. The first structure identified in a protein family enables inference of the fold and of ancient relationships to other proteins; in the year ending 31 January 2005, about half of such structures were solved at a SG center rather than in a traditional laboratory. Furthermore, the cost of solving a structure at the most efficient SG center in the United States has dropped to one-quarter of the estimated cost of solving a structure by traditional methods. However, the efficiency of the top structural biology laboratories-even though they work on very challenging structures-is comparable to that of SG centers; moreover, traditional structural biology papers are cited significantly more often, suggesting greater current impact.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Brenner, SE (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Struct Genom Ctr, Phys Biosci Div, Berkeley, CA 94720 USA.	brenner@compbio.berkeley.edu	Brenner, Steven E/A-8729-2008	Brenner, Steven E/0000-0001-7559-6185; Chandonia, John-Marc/0000-0002-5153-9079	NHGRI NIH HHS [1-K22-HG00056] Funding Source: Medline; NIGMS NIH HHS [1-P50-GM62412, 1-R01-GM073109] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073109, P50GM062412] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Augustin MA, 2001, NAT STRUCT BIOL, V8, P57, DOI 10.1038/83060; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brenner SE, 2000, PROTEIN SCI, V9, P197; Brenner SE, 2000, NAT STRUCT BIOL, V7, P967, DOI 10.1038/80747; Brenner SE, 2001, NAT REV GENET, V2, P801, DOI 10.1038/35093574; Brenner SE, 1996, METHOD ENZYMOL, V266, P635; Chandonia JM, 2005, PROTEINS, V58, P166, DOI 10.1002/prot.20298; CHANDONIA JM, 2005, P 27 INT C IEEE ENG; Chen L, 2004, BIOINFORMATICS, V20, P2860, DOI 10.1093/bioinformatics/bth300; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Harrison SC, 2004, NAT STRUCT MOL BIOL, V11, P12, DOI 10.1038/nsmb0104-12; HUBER R, 1989, EMBO J, V8, P2125, DOI 10.1002/j.1460-2075.1989.tb08337.x; Lattman E, 2004, PROTEINS, V54, P611, DOI 10.1002/prot.20000; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Service R, 2005, SCIENCE, V307, P1554, DOI 10.1126/science.307.5715.1554; Smaglik P, 2000, NATURE, V403, P691, DOI 10.1038/35001729; STEITZ T, COMMUNICATION; Stevens RC, 2004, NAT STRUCT MOL BIOL, V11, P293, DOI 10.1038/nsmb0404-293; Todd AE, 2005, J MOL BIOL, V348, P1235, DOI 10.1016/j.jmb.2005.03.037; VANDERWAERDEN BL, 1969, MATH STAT, V156; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wlodawer A, 2005, NAT STRUCT MOL BIOL, V12, P634, DOI 10.1038/nsmb0805-634a	29	271	291	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 20	2006	311	5759					347	351		10.1126/science.1121018	http://dx.doi.org/10.1126/science.1121018			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424331	Green Submitted			2022-12-28	WOS:000234938500034
J	Noble, SIR; Nelson, A; Turner, C; Finlay, IG				Noble, SIR; Nelson, A; Turner, C; Finlay, IG			Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VENOUS THROMBOEMBOLISM; CANCER-PATIENTS	Objective To find out what inpatients with advanced cancer who are receiving palliative care think about the effect of thromboprophylaxis on overall quality of life. Design Qualitative study using audiotaping of semistructured interviews. Setting Regional cancer centre in Wales. Participants 28 inpatients with advanced metastatic cancer receiving palliative care and low molecular weight heparin. Main outcome measures Recurring themes on the effect of thromboprophylaxis on overall quality of life. Results Major emerging themes showed that patients knew about the risks of venous thromboembolism and die purpose of treatment with heparin. Media coverage had raised awareness about venous thromboembolism, and many had previous experience of thromboprophylaxis. All found low molecular weight heparin an acceptable intervention, and many said that it improved their quality of life by giving them a feeling of safety and reassurance. Antiembolic stockings were considered uncomfortable and had a negative impact on quality of life. Patients were concerned that because they had advanced disease they might not be eligible for thromboprophylaxis. Conclusion Low molecular weight heparin is acceptable to inpatients With advanced cancer receiving palliative care and has a positive impact on overall quality of life. Antiembolic stockings are an unacceptable intervention in this patient group. Guidelines on thromboprophylaxis are urgently needed for palliative care inpatient units and hospices.	Cardiff Univ, Cardiff CF10 3XQ, S Glam, Wales; Holme Tower Marie Curie Ctr, Penarth, S Glam, Wales; Velindre Hosp, Cardiff, S Glam, Wales	Cardiff University; Velindre Hospital	Noble, SIR (corresponding author), Gwent Hosp, Newport NP20 2UB, Gwent, Wales.	simon.noble@velindre-tr.wales.nhs.uk	Nelson, Annmarie/B-4893-2009; Nelson, Annmarie/AAD-2193-2020	Nelson, Annmarie/0000-0002-6075-8425; Nelson, Annmarie/0000-0002-6075-8425; Noble, Simon/0000-0001-5425-2383				AMBRUS JL, 1975, J MED, V6, P61; BICK RL, 1978, SEMIN THROMB HEMOST, V5, P1; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; *HOSP DIR, 2004, DIR HOSP CAR SERV UK; *HOUS COMM HLTH CO, 2004, 2 HOUS COMM HLTH COM; Johnson MJ, 1999, CLIN ONCOL-UK, V11, P105, DOI 10.1053/clon.1999.9023; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MISHLER E, 1984, DISCOURSE MED DIELEC; Noble SIR, 2005, PALLIATIVE MED, V19, P197, DOI 10.1191/0269216305pm1008oa; NOBLE SIR, IN PRESS J PAIN SYMP; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; SHEN VS, 1980, SOUTHERN MED J, V73, P841, DOI 10.1097/00007611-198007000-00005; SHEN VS, 1980, SOUTH MED J, V73, P811; SPROUL E. E., 1938, AMER JOUR CANCER, V34, P566	14	77	79	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	2006	332	7541					577	580		10.1136/bmj.38733.616065.802	http://dx.doi.org/10.1136/bmj.38733.616065.802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	026CN	16459340	Green Published, Bronze			2022-12-28	WOS:000236314400015
J	Kennedy, M; Droser, M; Mayer, LM; Pevear, D; Mrofka, D				Kennedy, M; Droser, M; Mayer, LM; Pevear, D; Mrofka, D			Late Precambrian oxygenation; Inception of the clay mineral factory	SCIENCE			English	Article							ORGANIC-MATTER PRESERVATION; EVOLUTION; LAND; CARBON; SEDIMENTS; CHEMISTRY; BIOLOGY; LIFE; RISE	An enigmatic stepwise increase in oxygen in the late Precambrian is widely considered a prerequisite for the expansion of animal life. Accumulation of oxygen requires organic matter burial in sediments, which is largely controlled by the sheltering or preservational effects of detrital clay minerals in modern marine continental margin depocenters. Here, we show mineralogical and geochemical evidence for an increase in clay mineral deposition in the Neoproterozoic that immediately predated the first metazoans. Today most clay minerals originate in biologically active soils, so initial expansion of a primitive land biota would greatly enhance production of pedogenic clay minerals ( the "clay mineral factory''), leading to increased marine burial of organic carbon via mineral surface preservation.	Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA; Univ Maine, Darling Marine Ctr, Walpole, ME 04573 USA	University of California System; University of California Riverside; University of Maine System; University of Maine Orono	Kennedy, M (corresponding author), Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA.	martink@mail.ucr.edu	Mayer, Lawrence M./A-1337-2009	Kennedy, Martin/0000-0002-1330-6864				[Anonymous], 1971, EVOLUTION SEDIMENTAR, DOI DOI 10.4319/LO.1972.17.1.0165; Banfield JF, 1999, P NATL ACAD SCI USA, V96, P3404, DOI 10.1073/pnas.96.7.3404; Brennan ST, 2004, GEOLOGY, V32, P473, DOI 10.1130/g20251.1; Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; CAMPBELL SE, 1979, ORIGINS LIFE EVOL B, V9, P335, DOI 10.1007/BF00926826; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; Chamley H., 1989, CLAY SEDIMENTOLOGY; CLOUD P, 1976, Paleobiology, V2, P351; COX R, 1995, GEOCHIM COSMOCHIM AC, V59, P2919, DOI 10.1016/0016-7037(95)00185-9; DERRY LA, 1992, GEOCHIM COSMOCHIM AC, V56, P1317, DOI 10.1016/0016-7037(92)90064-P; Dott RH, 2003, J GEOL, V111, P387, DOI 10.1086/375286; FranceLanord C, 1997, NATURE, V390, P65, DOI 10.1038/36324; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; HEDGES JI, 1995, MAR CHEM, V49, P81, DOI 10.1016/0304-4203(95)00008-F; HORODYSKI RJ, 1994, SCIENCE, V263, P494, DOI 10.1126/science.263.5146.494; Kah LC, 2004, NATURE, V431, P834, DOI 10.1038/nature02974; KEIL RG, 1994, GEOCHIM COSMOCHIM AC, V58, P879, DOI 10.1016/0016-7037(94)90512-6; KEIL RG, 1994, NATURE, V370, P549, DOI 10.1038/370549a0; Kennedy MJ, 2002, SCIENCE, V295, P657, DOI 10.1126/science.1066611; KNOLL AH, 2003, LIFE YOUNG PLANET, P247; KNOLL AH, 1999, SCIENCE, V284, P2129, DOI DOI 10.1126/SCIENCE.284.5423.2129; Lynch FL, 1997, CLAY CLAY MINER, V45, P618, DOI 10.1346/CCMN.1997.0450502; MARAIS DJD, 1992, NATURE, V359, P605, DOI 10.1038/359605a0; Mayer LM, 2004, GEOCHIM COSMOCHIM AC, V68, P3863, DOI 10.1016/j.gca.2004.03.019; MAYER LM, 1994, GEOCHIM COSMOCHIM AC, V58, P1271, DOI 10.1016/0016-7037(94)90381-6; Neaman A, 2005, AM J SCI, V305, P147, DOI 10.2475/ajs.305.2.147; Prave AR, 2002, GEOLOGY, V30, P811, DOI 10.1130/0091-7613(2002)030<0811:LOLITP>2.0.CO;2; Preiss W.V., 1987, GEOLOGICAL SURVEY S, V53, P438; Ransom B, 1998, GEOCHIM COSMOCHIM AC, V62, P1329, DOI 10.1016/S0016-7037(98)00050-7; Raven JA, 2001, J EXP BOT, V52, P381, DOI 10.1093/jexbot/52.suppl_1.381; Retallack G.J., 2001, SOILS INTRO PALEOPED, V2nd, DOI [10.1002/9780470698716, DOI 10.1002/9780470698716]; RONOV AB, 1964, GEOCHEM INT, P713; RUNNEGAR B, 1982, ALCHERINGA, V6, P223, DOI 10.1080/03115518208565415; Schultz L.G., 1964, 391C US GEOL SURV, V391, P1; Shields G, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000266; Weaver C. E., 1989, CLAYS MUDS SHALES, P819; Yuan XL, 2005, SCIENCE, V308, P1017, DOI 10.1126/science.1111347	37	197	212	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1446	1449		10.1126/science.1118929	http://dx.doi.org/10.1126/science.1118929			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16456036				2022-12-28	WOS:000236029400044
J	Sunshine, JM; A'Hearn, MF; Groussin, O; Li, JY; Belton, MJS; Delamere, WA; Kissel, J; Klaasen, KP; McFadden, LA; Meech, KJ; Melosh, HJ; Schultz, PH; Thomas, PC; Veverka, J; Yeomans, DK; Busko, IC; Desnoyer, M; Farnham, TL; Feaga, LM; Hampton, DL; Lindler, DJ; Lisse, CM; Wellnitz, DD				Sunshine, JM; A'Hearn, MF; Groussin, O; Li, JY; Belton, MJS; Delamere, WA; Kissel, J; Klaasen, KP; McFadden, LA; Meech, KJ; Melosh, HJ; Schultz, PH; Thomas, PC; Veverka, J; Yeomans, DK; Busko, IC; Desnoyer, M; Farnham, TL; Feaga, LM; Hampton, DL; Lindler, DJ; Lisse, CM; Wellnitz, DD			Exposed water ice deposits on the surface of comet 9P/Tempel 1	SCIENCE			English	Article							SATURNS MOON PHOEBE; INFRARED-SPECTROSCOPY; DEEP IMPACT; NUCLEUS; GRAINS	We report the direct detection of solid water ice deposits exposed on the surface of comet 9P/Tempel 1, as observed by the Deep Impact mission. Three anomalously colored areas are shown to include water ice on the basis of their near-infrared spectra, which include diagnostic water ice absorptions at wavelengths of 1.5 and 2.0 micrometers. These absorptions are well modeled as a mixture of nearby non-ice regions and 3 to 6% water ice particles 10 to 50 micrometers in diameter. These particle sizes are larger than those ejected during the impact experiment, which suggests that the surface deposits are loose aggregates. The total area of exposed water ice is substantially less than that required to support the observed ambient outgassing from the comet, which likely has additional source regions below the surface.	Sci Applicat Int Corp, Chantilly, VA 20151 USA; Univ Maryland, College Pk, MD 20742 USA; Belton Space Explorat Initiat, Tucson, AZ 85716 USA; Delamere Support Serv, Boulder, CO 80301 USA; Max Planck Inst Solar Syst Res, D-37191 Katlenburg Lindau, Germany; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Hawaii, Honolulu, HI 96822 USA; Univ Arizona, Tucson, AZ 85721 USA; Brown Univ, Providence, RI USA; Cornell Univ, Ithaca, NY 14853 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Ball Aerosp & Technol Corp, Boulder, CO 80301 USA; Sigma Sci, Greenbelt, MD 20771 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA	Science Applications International Corporation (SAIC); University System of Maryland; University of Maryland College Park; Max Planck Society; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hawaii System; University of Arizona; Brown University; Cornell University; Space Telescope Science Institute; Ball Aerospace & Technologies; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Sunshine, JM (corresponding author), Sci Applicat Int Corp, Chantilly, VA 20151 USA.	sunshinej@saic.com	Wellnitz, Dennis/B-4080-2012; Lisse, Carey M/B-7772-2016; Meech, Karen/CAH-1412-2022; McFadden, Lucy-Ann/I-4902-2013	Lisse, Carey M/0000-0002-9548-1526; McFadden, Lucy-Ann/0000-0002-0537-9975; Sunshine, Jessica/0000-0002-9413-8785; Meech, Karen/0000-0002-2058-5670; Feaga, Lori/0000-0002-4230-6759; Li, Jian-Yang/0000-0003-3841-9977				A'Hearn MF, 2005, SCIENCE, V310, P258, DOI 10.1126/science.1118923; Abell PA, 2005, ICARUS, V179, P174, DOI 10.1016/j.icarus.2005.06.012; AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; Barucci M. A., 2002, ASTEROIDS, P273; Barucci MA, 2004, SPACE SCI S, P647; Brown RH, 2004, SPACE SCI REV, V115, P111, DOI 10.1007/s11214-004-1453-x; CAMPINS H, 2003, B AM ASTRON SOC, V35, P10111; CLARK RN, 1981, J GEOPHYS RES, V86, P3087, DOI 10.1029/JB086iB04p03087; Clark RN, 2005, NATURE, V435, P66, DOI 10.1038/nature03558; COWAN JJ, 1979, MOON PLANETS, V21, P155, DOI 10.1007/BF00897085; Davies JK, 1997, ICARUS, V127, P238, DOI 10.1006/icar.1996.5673; DELAHODDE C, 2002, ASTEORIDS COMETS MET; Duncan MJ, 1997, SCIENCE, V276, P1670, DOI 10.1126/science.276.5319.1670; FANALE FP, 1984, ICARUS, V60, P476, DOI 10.1016/0019-1035(84)90157-X; Greenberg J., 1982, COMETS, P131; Hampton DL, 2005, SPACE SCI REV, V117, P43, DOI 10.1007/s11214-005-3390-8; HANNER MS, 1981, ICARUS, V47, P342, DOI 10.1016/0019-1035(81)90182-2; HAPKE BW, 1993, REFLECTANCE EMITTANC; Kawakita H, 2004, ASTROPHYS J, V601, pL191, DOI 10.1086/382073; Licandro J, 2002, EARTH MOON PLANETS, V90, P495, DOI 10.1023/A:1021567324530; Licandro J, 2003, ASTRON ASTROPHYS, V398, pL45, DOI 10.1051/0004-6361:20030009; Lisse CM, 2005, SPACE SCI REV, V117, P161, DOI 10.1007/s11214-005-3384-6; Nelson RM, 2004, ICARUS, V167, P1, DOI 10.1016/j.icarus.2003.10.008; Owen TC, 1999, ICARUS, V139, P379, DOI 10.1006/icar.1999.6116; Schleicher DG, 2006, ASTRON J, V131, P1130, DOI 10.1086/499301; Soderblom LA, 2004, ICARUS, V167, P100, DOI 10.1016/j.icarus.2003.08.019; Sugita S, 2005, SCIENCE, V310, P274, DOI 10.1126/science.1119091; Sunshine JM, 2005, SPACE SCI REV, V117, P269, DOI 10.1007/s11214-005-3388-2; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206	30	184	186	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	2006	311	5766					1453	1455		10.1126/science.1123632	http://dx.doi.org/10.1126/science.1123632			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	022BJ	16456037				2022-12-28	WOS:000236029400046
J	Angers, RC; Browning, SR; Seward, TS; Sigurdson, CJ; Miller, MW; Hoover, EA; Telling, GC				Angers, RC; Browning, SR; Seward, TS; Sigurdson, CJ; Miller, MW; Hoover, EA; Telling, GC			Prions in skeletal muscles of deer with chronic wasting disease	SCIENCE			English	Article							SPONGIFORM ENCEPHALOPATHY; MULE DEER; SCRAPIE; PROTEIN		Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; Colorado Div Wildlife, Wildlife Res Ctr, Ft Collins, CO 80526 USA	University of Kentucky; University of Kentucky; University of Kentucky; Colorado State University	Telling, GC (corresponding author), Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA.	gtell2@uky.edu	Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040334] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-25491] Funding Source: Medline; NINDS NIH HHS [2RO1 NS040334-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andreoletti O, 2004, NAT MED, V10, P591, DOI 10.1038/nm1055; Bosque PJ, 2002, P NATL ACAD SCI USA, V99, P3812, DOI 10.1073/pnas.052707499; Browning SR, 2004, J VIROL, V78, P13345, DOI 10.1128/JVI.78.23.13345-13350.2004; Buschmann A, 2005, J INFECT DIS, V192, P934, DOI 10.1086/431602; Hamir AN, 2004, VET PATHOL, V41, P78, DOI 10.1354/vp.41-1-78; Prinz M, 2003, AM J PATHOL, V162, P1103, DOI 10.1016/S0002-9440(10)63907-7; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; Spraker TR, 2002, VET PATHOL, V39, P110, DOI 10.1354/vp.39-1-110	8	153	160	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	2006	311	5764					1117	1117		10.1126/science.1122864	http://dx.doi.org/10.1126/science.1122864			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	017IU	16439622				2022-12-28	WOS:000235688100038
J	Chang, LF; Kamata, H; Solinas, G; Luo, JL; Maeda, S; Venuprasad, K; Liu, YC; Karin, M				Chang, LF; Kamata, H; Solinas, G; Luo, JL; Maeda, S; Venuprasad, K; Liu, YC; Karin, M			The E3 ubiquitin ligase itch couples JNK activation to TNF alpha-induced cell death by inducing c-FLIPL turnover	CELL			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; RECEPTOR-INDUCED APOPTOSIS; UP-REGULATION; CASPASE-8 ACTIVATION; MEDIATED APOPTOSIS; SIGNALING COMPLEX; JUN KINASE; PHOSPHORYLATION; PROTEIN	The proinflammatory cytokine tumor necrosis factor (TNF) alpha signals both cell survival and death. The biological outcome of TNF alpha treatment is determined by the balance between NF-kappa B and Jun kinase(JNK) signaling; NF-kappa B promotes survival, whereas JNK enhances cell death. Critically, identity of a JNK substrate that promotes TNF alpha-induced apoptosis has been outstanding. Here we show that TNF alpha-mediated JNK activation accelerates turnover of the NF-kappa B-induced antiapoptotic protein c-FLIP, an inhibitor of caspase-8. This is not due to direct c-FLIP phosphorylation but depends on JNK-mediated phosphorylation and activation of the E3 ubiquitin ligase Itch, which specifically ubiquitinates c-FLIP and induces its proteasomal degradation. JNK1 or Itch deficiency or treatment with a JNK in hi bitor renders mice resistant in three distinct models of TNFa-induced acute liver failure, and cells from these mice do not display inducible c-FLIPL ubiquitination and degradation. Thus, JNK antagonizes NF-kappa B during TNF alpha signaling by promoting the proteasomal elimination of c-FLIPL.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	University of California System; University of California San Diego; City of Hope; Beckman Research Institute of City of Hope; La Jolla Institute for Immunology	Chang, LF (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Kamata, Hideaki/N-3907-2017; Solinas, Giovanni/R-4777-2019; Solinas, Giovanni/P-6596-2017	Solinas, Giovanni/0000-0002-0140-2621; Solinas, Giovanni/0000-0002-0140-2621; LIU, YUN-CAI/0000-0002-0996-7109; poojary, venuprasd/0000-0001-8986-9092				Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Bai YL, 2004, MOL CELL, V15, P825, DOI 10.1016/j.molcel.2004.07.021; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Ciechanover A, 2004, BBA-MOL CELL RES, V1695, P3, DOI 10.1016/j.bbamcr.2004.09.018; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; DECKER K, 1974, REV PHYSIOL BIOCH P, V71, P77, DOI 10.1007/BFb0027661; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Park KS, 2002, EUR J IMMUNOGENET, V29, P7, DOI 10.1046/j.0960-7420.2001.00260.x; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; THORNE M, 2001, NATURE REV IMMUNOL, V1, P50; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	42	570	595	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					601	613		10.1016/j.cell.2006.01.021	http://dx.doi.org/10.1016/j.cell.2006.01.021			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469705	Bronze			2022-12-28	WOS:000235464000021
J	Stragier, P				Stragier, P			To kill but not be killed: A delicate balance	CELL			English	Editorial Material							BACILLUS-SUBTILIS; SPORULATION; THRESHOLD; BACTERIA; GENES; SPO0A	Before launching a missile, it is necessary to design an efficient safety net for self-protection. In this issue of Cell, Ellermeier et al. (2006) describe the mechanism underlying a biological safety net for the soil bacterium Bacillus subtilis. This bacterium protects itself from a toxic protein it secretes by upregulating an immunity protein, which it does by sequestering a transcriptional repressor at the plasma membrane.	CNRS, UPR 9073, Inst Biol Physicochim, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS)	Stragier, P (corresponding author), CNRS, UPR 9073, Inst Biol Physicochim, F-75005 Paris, France.	stragier@ibpc.fr		STRAGIER, Patrick/0000-0003-0849-3025				Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; Bohm A, 2004, CURR OPIN MICROBIOL, V7, P151, DOI 10.1016/j.mib.2004.02.009; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CHUNG JD, 1994, J BACTERIOL, V176, P1977, DOI 10.1128/jb.176.7.1977-1984.1994; ELLERMEIER CD, 2006, CELL; Fujita M, 2005, GENE DEV, V19, P2236, DOI 10.1101/gad.1335705; Fujita M, 2005, J BACTERIOL, V187, P1357, DOI 10.1128/JB.187.4.1357-1368.2005; Gonzalez-Pastor JE, 2003, SCIENCE, V301, P510, DOI 10.1126/science.1086462; Lin D, 2001, J APPL MICROBIOL, V91, P1044, DOI 10.1046/j.1365-2672.2001.01475.x; Turner MS, 2000, J BACTERIOL, V182, P5202, DOI 10.1128/JB.182.18.5202-5210.2000	10	12	12	1	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 10	2006	124	3					461	463		10.1016/j.cell.2006.01.018	http://dx.doi.org/10.1016/j.cell.2006.01.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469691	Bronze			2022-12-28	WOS:000235464000007
J	Merx, MW; Weber, C				Merx, MW; Weber, C			Statins: a preventive strike against sepsis in patients with cardiovascular disease?	LANCET			English	Editorial Material							MANAGEMENT; THERAPY		Rhein Westfal TH Aachen, Univ Klinikum, Med Klin, D-52057 Aachen, Germany; Rhein Westfal TH Aachen, Univ Klinikum, Inst Kardiovask Mol Biol, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Merx, MW (corresponding author), Rhein Westfal TH Aachen, Univ Klinikum, Med Klin, D-52057 Aachen, Germany.	mmerx@ukaachen.de	Weber, Christian/AAW-2153-2020	Weber, Christian/0000-0003-4610-8714				Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1; Briel M, 2005, CURR OPIN LIPIDOL, V16, P601; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Enserink M, 2005, SCIENCE, V309, P1976; Erkkila L, 2005, ANTIMICROB AGENTS CH, V49, P3959, DOI 10.1128/AAC.49.9.3959-3962.2005; Hackam DG, 2006, LANCET, V367, P413, DOI 10.1016/S0140-6736(06)68041-0; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901; Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334; Merx MW, 2005, CIRCULATION, V112, P117, DOI 10.1161/CIRCULATIONAHA.104.502195; PEDERSEN TR, 1994, LANCET, V344, P1383; Ray KK, 2005, J AM COLL CARDIOL, V46, P1425, DOI 10.1016/j.jacc.2005.05.086; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545	16	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					372	373		10.1016/S0140-6736(06)68042-2	http://dx.doi.org/10.1016/S0140-6736(06)68042-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458744				2022-12-28	WOS:000235139400005
J	Richardson, E				Richardson, E			Self-monitoring of oral anticoagulation	LANCET			English	Editorial Material																			0	1	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 4	2006	367	9508					412	412		10.1016/S0140-6736(06)68140-3	http://dx.doi.org/10.1016/S0140-6736(06)68140-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458765				2022-12-28	WOS:000235139400030
J	Etienne, RS; Latimer, AM; Silander, JA; Cowling, RM				Etienne, RS; Latimer, AM; Silander, JA; Cowling, RM			Comment on "Neutral ecological theory reveals isolation and rapid speciation in a biodiversity hot spot"	SCIENCE			English	Editorial Material							SAMPLING THEORY; CAPE FLORA; ALLELES	Latimer et at. (Reports, 9 September 2005, p. 1722) used an approximate likelihood function to estimate parameters of Hubbell's neutral model of biodiversity. Reanalysis with the exact likelihood not only yields different estimates but also shows that two similar likelihood maxima for very different parameter combinations can occur. This reveals a limitation of using species abundance data to gain insight into speciation and dispersal.	Univ Groningen, Community & Conservat Ecol Grp, NL-9750 AA Haren, Netherlands; Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA; Nelson Mandela Metropolitan Univ, Dept Bot, Terr Ecol Res Unit, ZA-6031 Port Elizabeth, South Africa	University of Groningen; University of Connecticut; Nelson Mandela University	Etienne, RS (corresponding author), Univ Groningen, Community & Conservat Ecol Grp, Box 14, NL-9750 AA Haren, Netherlands.	r.s.etienne@rug.nl	Cowling, Richard/AFU-6261-2022; Etienne, Rampal S./F-5835-2012	Etienne, Rampal S./0000-0003-2142-7612; Latimer, Andrew/0000-0001-8098-0448				Etienne RS, 2005, ECOL LETT, V8, P1147, DOI 10.1111/j.1461-0248.2005.00817.x; Etienne RS, 2005, ECOL LETT, V8, P493, DOI 10.1111/j.1461-0248.2005.00745.x; Etienne RS, 2005, ECOL LETT, V8, P253, DOI 10.1111/j.1461-0248.2004.00717.x; Etienne RS, 2004, ECOL LETT, V7, P170, DOI 10.1111/j.1461-0248.2004.00572.x; EWENS WJ, 1972, THEOR POPUL BIOL, V3, P87, DOI 10.1016/0040-5809(72)90035-4; Hubbell Stephen P., 2001, V32, pi; Latimer AM, 2005, SCIENCE, V309, P1722, DOI 10.1126/science.1115576; Linder HP, 2004, PHILOS T R SOC B, V359, P1623, DOI 10.1098/rstb.2004.1534; Richardson JE, 2001, NATURE, V412, P181, DOI 10.1038/35084067; SLINGSBY P, 1985, S AFR J BOT, V51, P30, DOI 10.1016/S0254-6299(16)31698-2	10	36	38	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					610B	+		10.1126/science.1121914	http://dx.doi.org/10.1126/science.1121914			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456064				2022-12-28	WOS:000235257400027
J	Tsao, DY; Freiwald, WA; Tootell, RBH; Livingstone, MS				Tsao, DY; Freiwald, WA; Tootell, RBH; Livingstone, MS			A cortical region consisting entirely of face-selective cells	SCIENCE			English	Article							TEMPORAL CORTEX; INFEROTEMPORAL CORTEX; NEURONS; MONKEY; PERCEPTION; MACAQUE; ORGANIZATION; OBJECTS; AREAS; REPRESENTATIONS	Face perception is a skill crucial to primates. In both humans and macaque monkeys, functional magnetic resonance imaging (fMRI) reveals a system of cortical regions that show increased blood flow when the subject views images of faces, compared with images of objects. However, the stimulus selectivity of single neurons within these fMRI-identified regions has not been studied. We used fMRI to identify and target the largest face-selective region in two macaques for single-unit recording. Almost all (97%) of the visually responsive neurons in this region were strongly face selective, indicating that a dedicated cortical area exists to support face processing in the macaque.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Univ Bremen, Ctr Adv Imaging, Brain Res Inst, D-28334 Bremen, Germany; Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Bremen; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Tsao, DY (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	doris@nmr.mgh.harvard.edu	Tudusciuc, Oana/C-1339-2011	Livingstone, Margaret/0000-0002-1950-0123	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR014075] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013135, R01EY016187, R01EY013025] Funding Source: NIH RePORTER; NCRR NIH HHS [P41:RR14075] Funding Source: Medline; NEI NIH HHS [R01 EY016187, R01 EY016187-01A2, EY13025, EY13135] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYLIS GC, 1987, J NEUROSCI, V7, P330; BAYLIS GC, 1985, BRAIN RES, V342, P91, DOI 10.1016/0006-8993(85)91356-3; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Eifuku S, 2004, J NEUROPHYSIOL, V91, P358, DOI 10.1152/jn.00198.2003; Gauthier I, 2000, NAT NEUROSCI, V3, P191, DOI 10.1038/72140; Gross C. G., 1973, HDB SENSORY PHYSIOLO, P451; HARRIES MH, 1991, J COGNITIVE NEUROSCI, V3, P9, DOI 10.1162/jocn.1991.3.1.9; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Liu J, 2002, NAT NEUROSCI, V5, P910, DOI 10.1038/nn909; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 2003, CURR OPIN NEUROBIOL, V13, P630, DOI 10.1016/j.conb.2003.09.017; Mukamel R, 2005, SCIENCE, V309, P951, DOI 10.1126/science.1110913; PERRETT DI, 1985, PROC R SOC SER B-BIO, V223, P293, DOI 10.1098/rspb.1985.0003; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; Pinsk MA, 2005, P NATL ACAD SCI USA, V102, P6996, DOI 10.1073/pnas.0502605102; ROLLS ET, 1992, PHILOS T R SOC B, V335, P11, DOI 10.1098/rstb.1992.0002; ROSCH E, 1978, COGN PSYCHOL, V8; Sugase Y, 1999, NATURE, V400, P869, DOI 10.1038/23703; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; Tsao DY, 2003, NAT NEUROSCI, V6, P989, DOI 10.1038/nn1111; Vanduffel W, 2001, NEURON, V32, P565, DOI 10.1016/S0896-6273(01)00502-5; Wang G, 1998, NEUROSCI RES, V32, P33, DOI 10.1016/S0168-0102(98)00062-5; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; Yovel G, 2004, NEURON, V44, P889, DOI 10.1016/S0896-6273(04)00728-7	28	731	745	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					670	674		10.1126/science.1119983	http://dx.doi.org/10.1126/science.1119983			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456083	Green Accepted			2022-12-28	WOS:000235257400051
J	Kemp, AIS; Hawkesworth, CJ; Paterson, BA; Kinny, PD				Kemp, AIS; Hawkesworth, CJ; Paterson, BA; Kinny, PD			Episodic growth of the Gondwana supercontinent from hafnium and oxygen isotopes in zircon	NATURE			English	Article							U-PB ZIRCON; DETRITAL ZIRCONS; CONTINENTAL-CRUST; LU-HF; MANTLE; EVOLUTION; ROCKS; AGES; AUSTRALIA/; CHONDRITES	It is thought that continental crust existed as early as 150 million years after planetary accretion(1), but assessing the rates and processes of subsequent crustal growth requires linking the apparently contradictory information from the igneous and sedimentary rock records. For example, the striking global peaks in juvenile igneous activity 2.7, 1.9 and 1.2 Gyr ago imply rapid crustal generation in response to the emplacement of mantle 'super-plumes', rather than by the continuous process of subduction(2-4). Yet uncertainties persist over whether these age peaks are artefacts of selective preservation(5), and over how to reconcile episodic crust formation with the smooth crustal evolution curves inferred from neodymium isotope variations of sedimentary rocks(6,7). Detrital zircons encapsulate a more representative record of igneous events than the exposed geology(1,8,9) and their hafnium isotope ratios reflect the time since the source of the parental magmas separated from the mantle. These 'model' ages are only meaningful if the host magma lacked a mixed or sedimentary source component(10), but the latter can be diagnosed by oxygen isotopes, which are strongly fractionated by rock-hydrosphere interactions. Here we report the first study that integrates hafnium and oxygen isotopes, all measured in situ on the same, precisely dated detrital zircon grains. The data reveal that crust generation in part of Gondwana was limited to major pulses at 1.9 and 3.3 Gyr ago, and that the zircons crystallized during repeated reworking of crust formed at these times. The implication is that the mechanisms of crust formation differed from those of crustal differentiation in ancient orogenic belts.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Curtin Univ Technol, Dept Appl Geol, Tecton Special Res Ctr, Perth, WA 6845, Australia	University of Bristol; Curtin University	Kemp, AIS (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg, Bristol BS8 1RJ, Avon, England.	tony.kemp@geo.sc.niigata-u.ac.jp	Facility, Edinburgh Ion Microprobe/AAD-8512-2020; Kinny, Peter/AAB-8474-2019; Kemp, Anthony/H-5179-2014	Facility, Edinburgh Ion Microprobe/0000-0001-6248-6657; Kinny, Peter/0000-0001-8296-2155; Kemp, Anthony/0000-0003-1642-0360				Albarede F, 1998, TECTONOPHYSICS, V296, P1, DOI 10.1016/S0040-1951(98)00133-4; ALLEGRE CJ, 1984, EARTH PLANET SC LETT, V67, P19, DOI 10.1016/0012-821X(84)90035-9; ARNDT NT, 1987, GEOLOGY, V15, P893, DOI 10.1130/0091-7613(1987)15<893:UAAOCA>2.0.CO;2; BlichertToft J, 1997, EARTH PLANET SC LETT, V148, P243, DOI 10.1016/S0012-821X(97)00040-X; Cavosie AJ, 2005, EARTH PLANET SC LETT, V235, P663, DOI 10.1016/j.epsl.2005.04.028; Chauvel C, 2001, EARTH PLANET SC LETT, V190, P137, DOI 10.1016/S0012-821X(01)00379-X; Clemens JD, 2003, EARTH-SCI REV, V61, P1, DOI 10.1016/S0012-8252(02)00107-1; Condie KC, 1998, EARTH PLANET SC LETT, V163, P97, DOI 10.1016/S0012-821X(98)00178-2; Eiler JM, 2001, REV MINERAL GEOCHEM, V43, P319, DOI 10.2138/gsrmg.43.1.319; GOODMAN AL, 1991, PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON HIGH SPIN PHYSICS AND GAMMA-SOFT NUCLEI, P1; Griffin WL, 2004, PRECAMBRIAN RES, V131, P231, DOI 10.1016/j.precamres.2003.12.011; GURNIS M, 1986, GEOLOGY, V14, P396, DOI 10.1130/0091-7613(1986)14<396:AECGAF>2.0.CO;2; HARRIS NBW, 1984, NATURE, V309, P773, DOI 10.1038/309773a0; Ireland TR, 1998, GEOLOGY, V26, P243, DOI 10.1130/0091-7613(1998)026<0243:DOTEPP>2.3.CO;2; Keay S, 1999, CONTRIB MINERAL PETR, V137, P323, DOI 10.1007/s004100050553; Knudsen TL, 2001, CONTRIB MINERAL PETR, V141, P83, DOI 10.1007/s004100000220; Maas R, 2001, J PETROL, V42, P1429, DOI 10.1093/petrology/42.8.1429; ONEIL JR, 1977, J GEOL SOC LONDON, V133, P559, DOI DOI 10.1144/GSJGS.133.6.0559; ONIONS RK, 1983, EARTH PLANET SC LETT, V63, P229, DOI 10.1016/0012-821X(83)90039-0; PATCHETT PJ, 1989, J GEOL, V97, P685, DOI 10.1086/629352; Patchett PJ, 2004, EARTH PLANET SC LETT, V222, P29, DOI 10.1016/j.epsl.2004.02.030; Peck WH, 2003, AM MINERAL, V88, P1003, DOI 10.2138/am-2003-0708; Scherer E, 2001, SCIENCE, V293, P683, DOI 10.1126/science.1061372; Shirey SB, 2003, LITHOS, V71, P243, DOI 10.1016/j.lithos.2003.07.007; STEIN M, 1994, NATURE, V372, P63, DOI 10.1038/372063a0; Tamura Y, 2002, J PETROL, V43, P1029, DOI 10.1093/petrology/43.6.1029; Valley JW, 2003, REV MINERAL GEOCHEM, V53, P343, DOI 10.2113/0530343; Valley JW, 2005, CONTRIB MINERAL PETR, V150, P561, DOI 10.1007/s00410-005-0025-8; Vervoort JD, 1999, GEOCHIM COSMOCHIM AC, V63, P533, DOI 10.1016/S0016-7037(98)00274-9; Vogel TA, 2004, EARTH PLANET SC LETT, V226, P149, DOI 10.1016/j.epsl.2004.07.013; Wilde SA, 2001, NATURE, V409, P175, DOI 10.1038/35051550; Williams IS, 2001, AUST J EARTH SCI, V48, P557, DOI 10.1046/j.1440-0952.2001.00883.x	32	569	596	5	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2006	439	7076					580	583		10.1038/nature04505	http://dx.doi.org/10.1038/nature04505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452978				2022-12-28	WOS:000235033900039
J	Emery, P				Emery, P			Treatment of rheumatoid arthritis	BRITISH MEDICAL JOURNAL			English	Review							CYCLIC CITRULLINATED PEPTIDE; RANDOMIZED CONTROLLED-TRIAL; INFLAMMATORY ARTHRITIS; FUSION PROTEIN; DOUBLE-BLIND; METHOTREXATE; INFLIXIMAB; ETANERCEPT; COMBINATION; REMISSION		Leeds Teaching Hosp NHS Trust, Acad Unit Musculoskeletal Dis, Chapel Allerton Hosp, Leeds LS7 4SA, W Yorkshire, England	Chapel Allerton Hospital; University of Leeds	Emery, P (corresponding author), Leeds Teaching Hosp NHS Trust, Acad Unit Musculoskeletal Dis, Chapel Allerton Hosp, Leeds LS7 4SA, W Yorkshire, England.	p.emery@leeds.ac.uk	emery, paul/B-3560-2013					BREEDVELD FC, IN PRESS ARTHRITIS R; Brown AK, 2005, ARTHRITIS RHEUM-US, V52, pS722; Buch MH, 2005, ARTHRITIS RHEUM-US, V52, P42, DOI 10.1002/art.20711; Conaghan PG, 2002, ARTHRITIS RHEUM, V46, P1971, DOI 10.1002/art.10274; Conaghan PG, 2002, ARTHRITIS RHEUM, V46, P1973; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Emery P, 1997, J RHEUMATOL, V24, P1436; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Furst DE, 2004, ANN RHEUM DIS, V63, P2, DOI 10.1136/ard.2004.029272; Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI [10.1002/art.21405, 10.1002/art.23364]; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; Grigor C, 2004, LANCET, V364, P263, DOI 10.1016/S0140-6736(04)16676-2; KELLY WN, 1989, TXB RHEUMATOLOGY; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kroot EJJA, 2000, ARTHRITIS RHEUM, V43, P1831, DOI 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; McGonagle D, 1998, LANCET, V352, P1137, DOI 10.1016/S0140-6736(97)12004-9; *NAT I HLTH CLIN E, NICE GUID US TNF BLO; Quinn MA, 2005, ARTHRITIS RHEUM-US, V52, P27, DOI 10.1002/art.20712; Quinn MA, 2003, CLIN EXP RHEUMATOL, V21, pS154; Rantapaa-Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223; van der Bijl AE, 2005, ARTHRITIS RHEUM-US, V52, pS346; Visser H, 2002, ARTHRITIS RHEUM, V46, P357, DOI 10.1002/art.10117; Wakefield RJ, 2000, ARTHRITIS RHEUM-US, V43, P2762, DOI 10.1002/1529-0131(200012)43:12<2762::AID-ANR16>3.0.CO;2-#; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401	27	86	96	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					152	155		10.1136/bmj.332.7534.152	http://dx.doi.org/10.1136/bmj.332.7534.152			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424492	Green Published			2022-12-28	WOS:000234905800025
J	Cohen, AT; Davidson, BL; Gallus, AS; Lassen, MR; Prins, MH; Tomkowski, W; Turpie, AGG; Egberts, JFM; Lensing, AWA				Cohen, AT; Davidson, BL; Gallus, AS; Lassen, MR; Prins, MH; Tomkowski, W; Turpie, AGG; Egberts, JFM; Lensing, AWA		ARTEMIS Investigators	Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEEP-VEIN THROMBOSIS; FATAL PULMONARY-EMBOLISM; THROMBOPROPHYLAXIS; METAANALYSIS; ENOXAPARIN; SURGERY; HEPARIN	Objective To determine the efficacy and safety of the anticoagulant fordaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism. Design Double blind randomised placebo controlled trial. Setting 15 centres in eight countries. Participants 849 medical patients aged 60 or more admitted to hospital for congestive heart failure, acute respiratory illness in the presence of chronic lung disease, or acute infectious or inflammatory disease and expected to remain in bed for at least four days. Interventions 2.5 mg fondaparinux or placebo subcutaneously once daily for six to 14 clays. Outcome measure The primary efficacy Outcome was venous thromboembolism detected by routine bilateral venography along with symptomatic venous thromboembolism LIP to clay 15. Secondary outcomes were bleeding and death. Patients were followed up at one month. Results 425 patients in the fondaparinux group and 414 patients in the placebo group were evaluable for safety analysis (10 were not treated). 644 patients (75.9%) were available for the primary efficacy analysis. Venous thromboembolism was detected ill 5.6% (18/321) of patients treated with fondaparinux and 10.5% (34/323) of patients given placebo, a relative risk reduction of 46.7% (95% confidence interval 7.7% to 69.30%). Symptomatic venous thromboembolism Occurred in five patients in the placebo group and none in the fondaparinux group (P = 0.029). Major bleeding occurred in one patient (0.2%) in each group. At the end of follow-up, 14 Patients in the fondaparinux group (3.3%) and 25 in die placebo group (6.0%) had died. Conclusion Fondaparinux is effective in the prevention of asymptomatic mid symptomatic venous thromboembolic events in older acute medical patients. The frequency of major bleeding was similar for both fondaparinux and placebo treated patients.	Guys Kings & St Thomas Sch Med, Dept Surg, London SE5 9PJ, England; Univ Washington, Sch Med, Seattle, WA USA; Swedish Med Ctr, Seattle, WA USA; Flinders Med Ctr, Dept Haematol, Adelaide, SA, Australia; Dept Clin Res, Spine Clin, Horsholm, Denmark; Acad Hosp Maastricht, Dept Clin Epidemiol & Technol Assessment, Maastricht, Netherlands; Natl TB & Lung Dis Res Inst, Warsaw, Poland; Hamilton Hlth Sci, Dept Med, Hamilton, ON, Canada; NV Organon, Clin Dev, NL-5340 BH Oss, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, NL-1105 AZ Amsterdam, Netherlands	University of London; King's College London; University of Washington; University of Washington Seattle; Swedish Medical Center; Flinders Medical Centre; Maastricht University; Maastricht University Medical Centre (MUMC); McMaster University; Merck & Company; University of Amsterdam; Academic Medical Center Amsterdam	Cohen, AT (corresponding author), Guys Kings & St Thomas Sch Med, Dept Surg, London SE5 9PJ, England.	alexander.cohen@kcl.ac.uk		Gallus, Alexander/0000-0001-7347-9989				Ageno W, 2002, HAEMATOLOGICA, V87, P746; Alikhan R, 2001, BLOOD, V98, p271A; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Baglin TP, 1997, J CLIN PATHOL, V50, P609, DOI 10.1136/jcp.50.7.609; Buller HR, 2003, NEW ENGL J MED, V349, P1695; Cohen A. T., 2000, Seminars in Hematology, V37, P19, DOI 10.1016/S0037-1963(00)90096-9; Cohen AT, 1996, HAEMOSTASIS, V26, P65; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Hampton KK, 2003, INT J CLIN PRACT, V57, P424; HEIR JA, 2002, ARCH INTERN MED, V162, P1245; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; Mismetti P, 2000, THROMB HAEMOSTASIS, V83, P14; Mismetti P, 2002, HAEMATOLOGICA, V87, P673; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; Turpie AGG, 2002, ARCH INTERN MED, V162, P1833, DOI 10.1001/archinte.162.16.1833; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407	20	602	631	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					325	327		10.1136/bmj.38733.466748.7C	http://dx.doi.org/10.1136/bmj.38733.466748.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16439370	Green Published, Bronze			2022-12-28	WOS:000235376400014
J	Bourgoin, M; Ouellette, NT; Xu, HT; Berg, J; Bodenschatz, E				Bourgoin, M; Ouellette, NT; Xu, HT; Berg, J; Bodenschatz, E			The role of pair dispersion in turbulent flow	SCIENCE			English	Article							PARTICLE ACCELERATIONS; RELATIVE DIFFUSION; DECAY	Mixing and transport in turbulent flows - which have strong local concentration fluctuations - essential in many natural and industrial systems including reactions in chemical mixers, combustion in engines and burners, droplet formation in warm clouds, and biological odor detection and chemotaxis. Local concentration fluctuations, in turn, are intimately tied to the problem of the separation of pairs of fluid elements. We have measured this separation rate in an intensely turbulent laboratory flow and have found, in quantitative agreement with the seminal predictions of Batchelor, that the initial separation of the pair plays an important rote in the subsequent spreading of the fluid elements. These results have surprising consequences for the decay of concentration fluctuations and have applications to biological and chemical systems.	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; CNRS, Unite Mixte Rech 5519, Lab Ecoulements Geophys & Ind, F-38041 Grenoble, France; Max Planck Inst Dynam & Self Org, Gottingen, Germany; Riso Natl Lab, DK-4000 Roskilde, Denmark	Cornell University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Max Planck Society; Technical University of Denmark	Bodenschatz, E (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.	eberhard.bodenschatz@ds.mpg.de	Berg, Jacob/B-5816-2016; Xu, Haitao/C-9857-2010; Ouellette, Nicholas/D-8541-2011	Berg, Jacob/0000-0003-2126-6476; Xu, Haitao/0000-0002-2863-7658; Ouellette, Nicholas/0000-0002-5172-0361; Bodenschatz, Eberhard/0000-0002-2901-0144; Bourgoin, Mickael/0000-0001-9442-7694				BATCHELOR GK, 1950, Q J ROY METEOR SOC, V76, P133, DOI 10.1002/qj.49707632804; Berloff PS, 2002, J PHYS OCEANOGR, V32, P764, DOI 10.1175/1520-0485(2002)032<0764:MTIOGP>2.0.CO;2; Biferale L, 2005, PHYS FLUIDS, V17, DOI [10.1063/1.2130751, 10.1063/1.1846771]; Boffetta G, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.094501; Edouard S, 1996, NATURE, V384, P444, DOI 10.1038/384444a0; Huber M, 2001, J ATMOS SCI, V58, P2377, DOI 10.1175/1520-0469(2001)058<2377:ACOTDI>2.0.CO;2; Jorgensen JB, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1863259; Kolmogoroff A, 1941, CR ACAD SCI URSS, V30, P301, DOI 10.1098/rspa.1991.0075; Kurien S, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.056302; La Porta A, 2001, NATURE, V409, P1017, DOI 10.1038/35059027; Moore P, 2004, J MARINE SYST, V49, P55, DOI 10.1016/j.jmarsys.2003.05.005; NELKIN M, 1981, PHYS FLUIDS, V24, P1754, DOI 10.1063/1.863597; Nicolleau F, 2004, PHYS FLUIDS, V16, P2309, DOI 10.1063/1.1736673; Obukhov A., 1941, DOKL AKAD NAUK SSSR, V5, P453; Ott S, 2000, J FLUID MECH, V422, P207, DOI 10.1017/S0022112000001658; Ouellette NT, 2006, EXP FLUIDS, V40, P301, DOI 10.1007/s00348-005-0068-7; Richardson LF, 1926, P R SOC LOND A-CONTA, V110, P709, DOI 10.1098/rspa.1926.0043; Sawford B, 2001, ANNU REV FLUID MECH, V33, P289, DOI 10.1146/annurev.fluid.33.1.289; Shraiman BI, 2000, NATURE, V405, P639, DOI 10.1038/35015000; SREENIVASAN KR, 1995, PHYS FLUIDS, V7, P2778, DOI 10.1063/1.868656; Thomson DJ, 2005, J FLUID MECH, V526, P277, DOI 10.1017/S0022112004002915; Virant M, 1997, MEAS SCI TECHNOL, V8, P1539, DOI 10.1088/0957-0233/8/12/017; Voth GA, 2002, J FLUID MECH, V469, P121, DOI 10.1017/S0022112002001842; WARHAFT Z, 1978, J FLUID MECH, V88, P659, DOI 10.1017/S0022112078002335; Wolf MC, 2004, J CHEM ECOL, V30, P501, DOI 10.1023/B:JOEC.0000018625.83906.95; YEUNG PK, 1994, PHYS FLUIDS, V6, P3416, DOI 10.1063/1.868399; Yeung PK, 2004, J FLUID MECH, V503, P93, DOI 10.1017/S0022112003007584; Yeung PK, 2002, ANNU REV FLUID MECH, V34, P115, DOI 10.1146/annurev.fluid.34.082101.170725	29	154	154	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	2006	311	5762					835	838		10.1126/science.1121726	http://dx.doi.org/10.1126/science.1121726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	012XT	16469922	Green Submitted			2022-12-28	WOS:000235374900044
J	Brosens, JJ; Lam, EWF; Parker, MG				Brosens, JJ; Lam, EWF; Parker, MG			Inflammation and sex steroid receptors: A motif for change	CELL			English	Editorial Material							N-COR; COACTIVATOR; COREPRESSOR; PROTEIN; BETA	Homeostasis in reproductive tissues requires integration of hormonal and inflammatory signals. In this issue of Cell, Zhu et al. (2006) discover that proinflammatory signals switch repressed steroid hormone receptors into transcriptional activators by targeting TAB2, an adaptor protein that tethers corepressors. These findings have implications for the treatment of endocrine-resistant cancers.	Univ London Imperial Coll Sci & Technol, Inst Reprod & Dev Biol, London W12 0NN, England; Univ London Imperial Coll Sci & Technol, Dept Oncol, London W12 0NN, England	Imperial College London; Imperial College London	Brosens, JJ (corresponding author), Univ London Imperial Coll Sci & Technol, Inst Reprod & Dev Biol, Hammersmith Campus, London W12 0NN, England.	m.parker@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Brosens, Jan/0000-0003-0116-9329				Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Chen B, 2005, INT J ONCOL, V27, P327; JABBOUR HN, 2005, ENDOCR REV; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; McDermott RS, 2002, EUR CYTOKINE NETW, V13, P121; Mendelson CR, 2005, J STEROID BIOCHEM, V93, P113, DOI 10.1016/j.jsbmb.2004.12.027; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Wu RJ, 2004, HUM REPROD UPDATE, V10, P119, DOI 10.1093/humupd/dmh011; ZHU P, 2006, CELL	10	4	4	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					466	468		10.1016/j.cell.2006.01.023	http://dx.doi.org/10.1016/j.cell.2006.01.023			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469693	Bronze			2022-12-28	WOS:000235464000009
J	Gehring, M; Huh, JH; Hsieh, TF; Penterman, J; Choi, Y; Harada, JJ; Goldberg, RB; Fischer, RL				Gehring, M; Huh, JH; Hsieh, TF; Penterman, J; Choi, Y; Harada, JJ; Goldberg, RB; Fischer, RL			DEMETER DNA glycosylase establishes MEDEA polycomb gene self-imprinting by allele-specific demethylation	CELL			English	Article							REPRESSIVE HISTONE METHYLATION; SEED DEVELOPMENT; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; METHYLTRANSFERASE ACTIVITY; ENDOSPERM DEVELOPMENT; PROTEIN; FERTILIZATION; EXPRESSION; COMPLEX	MEDEA (MEA) is an Arabidopsis Polycomb group gene that is imprinted in the endosperm. The maternal allele is expressed and the paternal allele is silent. MEA is controlled by DEMETER (DME), a DNA glycosylase required to activate MEA expression, and METHYLTRANSFERASE I (MET1), which maintains CG methylation at the MEA locus. Here we show that DME is responsible for endosperm maternal-allele-specific hypomethylation at the MEA gene. DME can excise 5-methylcytosine in vitro and when expressed in E coli. Abasic sites opposite 5-methylcytosine inhibit DME activity and might prevent DME from generating double-stranded DNA breaks. Unexpectedly, paternal-allele silencing is not controlled by DNA methylation. Rather, Polycomb group proteins that are expressed from the maternal genome, including MEA, control paternal MEA silencing. Thus, DME establishes MEA imprinting by removing 5-methylcytosine to activate the maternal allele. MEA imprinting is subsequently maintained in the endosperm by maternal MEA silencing the paternal allele.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Berkeley; University of California System; University of California Davis; University of California System; University of California Los Angeles	Gehring, M (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	rfischer@berkeley.edu		Hsieh, Tzung-Fu/0000-0001-7584-3721	NIGMS NIH HHS [R01 GM069415, GM069415] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069415] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bastow R, 2004, NATURE, V427, P164, DOI 10.1038/nature02269; Bender J, 2004, ANNU REV PLANT BIOL, V55, P41, DOI 10.1146/annurev.arplant.55.031903.141641; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao XF, 2002, P NATL ACAD SCI USA, V99, P16491, DOI 10.1073/pnas.162371599; Choi Y, 2004, P NATL ACAD SCI USA, V101, P7481, DOI 10.1073/pnas.0402328101; Choi YH, 2002, CELL, V110, P33, DOI 10.1016/S0092-8674(02)00807-3; Constancia M, 2004, NATURE, V432, P53, DOI 10.1038/432053a; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; David-Cordonnier MH, 2001, BIOCHEMISTRY-US, V40, P11811, DOI 10.1021/bi0112356; Delaval K, 2004, CURR OPIN GENET DEV, V14, P188, DOI 10.1016/j.gde.2004.01.005; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Gehring M, 2004, PLANT CELL, V16, pS203, DOI 10.1105/tpc.017988; Gong ZH, 2002, CELL, V111, P803, DOI 10.1016/S0092-8674(02)01133-9; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; Hanai R, 1998, INT J RADIAT BIOL, V73, P475, DOI 10.1080/095530098142013; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kapitonov VV, 2001, P NATL ACAD SCI USA, V98, P8714, DOI 10.1073/pnas.151269298; Kinoshita T, 1999, PLANT CELL, V11, P1945, DOI 10.1105/tpc.11.10.1945; Kinoshita T, 2004, SCIENCE, V303, P521, DOI 10.1126/science.1089835; Kiyosue T, 1999, P NATL ACAD SCI USA, V96, P4186, DOI 10.1073/pnas.96.7.4186; Kohler C, 2005, NAT GENET, V37, P28, DOI 10.1038/ng1495; Kohler C, 2003, EMBO J, V22, P4804, DOI 10.1093/emboj/cdg444; Kohler C, 2003, GENE DEV, V17, P1540, DOI 10.1101/gad.257403; Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Luo M, 1999, P NATL ACAD SCI USA, V96, P296, DOI 10.1073/pnas.96.1.296; Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Norman DPG, 2003, BIOCHEMISTRY-US, V42, P1564, DOI 10.1021/bi026823d; O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108; Ohad N, 1999, PLANT CELL, V11, P407, DOI 10.1105/tpc.11.3.407; PALMER BR, 1994, GENE, V143, P1, DOI 10.1016/0378-1119(94)90597-5; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; Sung SB, 2004, NATURE, V427, P159, DOI 10.1038/nature02195; Umlauf D, 2004, NAT GENET, V36, P1296, DOI 10.1038/ng1467; Vielle-Calzada JP, 1999, GENE DEV, V13, P2971, DOI 10.1101/gad.13.22.2971; Weinfeld M, 2001, RADIAT RES, V156, P584, DOI 10.1667/0033-7587(2001)156[0584:ROBERE]2.0.CO;2; Xiao WY, 2003, DEV CELL, V5, P891, DOI 10.1016/S1534-5807(03)00361-7	43	503	538	3	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					495	506		10.1016/j.cell.2005.12.034	http://dx.doi.org/10.1016/j.cell.2005.12.034			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469697	Bronze, Green Accepted			2022-12-28	WOS:000235464000013
J	Lynch, JA; Brent, AE; Leaf, DS; Pultz, MA; Desplan, C				Lynch, JA; Brent, AE; Leaf, DS; Pultz, MA; Desplan, C			Localized maternal orthodenticle patterns anterior and posterior in the long germ wasp Nasonia	NATURE			English	Article							SEGMENTATION GENE HUNCHBACK; DROSOPHILA EMBRYOS; BEETLE TRIBOLIUM; EXPRESSION; VITRIPENNIS; PROTEINS; GRADIENT; AXIS	The Bicoid (Bcd) gradient in Drosophila has long been a model for the action of a morphogen in establishing embryonic polarity(1). However, it is now clear that bcd is a unique feature of higher Diptera(2,3). An evolutionarily ancient gene, orthodenticle (otd), has a bcd-like role in the beetle Tribolium(4). Unlike the Bcd gradient, which arises by diffusion of protein from an anteriorly localized messenger RNA(1,5), the Tribolium Otd gradient forms by translational repression of otd mRNA by a posteriorly localized factor. These differences in gradient formation are correlated with differences in modes of embryonic patterning. Drosophila uses long germ embryogenesis, where the embryo derives from the entire anterior - posterior axis, and all segments are patterned at the blastoderm stage, before gastrulation. In contrast, Tribolium undergoes short germ embryogenesis: the embryo arises from cells in the posterior of the egg, and only anterior segments are patterned at the blastoderm stage, with the remaining segments arising after gastrulation from a growth zone. Here we describe the role of otd in the long germband embryo of the wasp Nasonia vitripennis. We show that Nasonia otd maternal mRNA is localized at both poles of the embryo, and resulting protein gradients pattern both poles. Thus, localized Nasonia otd has two major roles that allow long germ development. It activates anterior targets at the anterior of the egg in a manner reminiscent of the Bcd gradient, and it is required for pre-gastrulation expression of posterior gap genes.	NYU Biol, Ctr Dev Genet, New York, NY 10003 USA; Western Washington Univ, Bellingham, WA 98225 USA	New York University; Western Washington University	Desplan, C (corresponding author), NYU Biol, Ctr Dev Genet, 100 Washington Sq E, New York, NY 10003 USA.	cd38@nyu.edu		Desplan, Claude/0000-0002-6914-1413				BENDER M, 1988, DEV GENET, V9, P715, DOI 10.1002/dvg.1020090604; Bucher G, 2002, CURR BIOL, V12, pR85, DOI 10.1016/S0960-9822(02)00666-8; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; Dearden P, 1999, CURR BIOL, V9, pR591, DOI 10.1016/S0960-9822(99)80381-9; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; Goltsev Y, 2004, DEV BIOL, V275, P435, DOI 10.1016/j.ydbio.2004.08.021; KRAFT R, 1994, P NATL ACAD SCI USA, V91, P6634, DOI 10.1073/pnas.91.14.6634; LaRosee A, 1997, EMBO J, V16, P4403, DOI 10.1093/emboj/16.14.4403; Li YB, 1996, DEV GENES EVOL, V206, P35, DOI 10.1007/s004270050028; MARGOLIS JS, 1995, DEVELOPMENT, V121, P3067; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Pultz MA, 1999, DEVELOPMENT, V126, P701; Pultz MA, 2005, DEVELOPMENT, V132, P3705, DOI 10.1242/dev.01939; Pultz MA, 2000, GENETICS, V154, P1213; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Schroder R, 2003, NATURE, V422, P621, DOI 10.1038/nature01536; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; Stauber M, 2002, P NATL ACAD SCI USA, V99, P274, DOI 10.1073/pnas.012292899; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, CELL, V59, P553; van der Zee M, 2005, CURR BIOL, V15, P624, DOI 10.1016/j.cub.2005.02.057; Wimmer EA, 2000, SCIENCE, V287, P2476, DOI 10.1126/science.287.5462.2476; Wolff C, 1995, DEVELOPMENT, V121, P4227	27	137	141	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					728	732		10.1038/nature04445	http://dx.doi.org/10.1038/nature04445			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467838				2022-12-28	WOS:000235193100045
J	Hackam, DG; Mamdani, M; Li, P; Redelmeier, DA				Hackam, DG; Mamdani, M; Li, P; Redelmeier, DA			Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis	LANCET			English	Article							HEALTH-CARE PROFESSIONALS; ENDOTHELIAL-CELLS; IMPROVES SURVIVAL; ELDERLY-PATIENTS; CODING ACCURACY; INSULIN THERAPY; UNITED-STATES; MURINE MODEL; SIMVASTATIN; EPIDEMIOLOGY	Background Atherosclerosis and sepsis share several pathophysiological similarities, including immune dysregulation, increased thrombogenesis, and systemic inflammation. The relation between statins and risk of sepsis in patients with atherosclerosis is unknown. Methods We did a population-based cohort analysis through linked administrative databases in Ontario, Canada, with accrual from 1997 to 2002. We identified 141487 patients older than 65 years who had been hospitalised for an acute coronary syndrome, ischaemic stroke, or revascularisation, who survived for at least 3 months after discharge. 46 662 (33%) were prescribed a statin within 90 days of discharge, 94 825 (67%) were not. Propensity-based matching, which accounted for each individual's likelihood of receiving a statin, yielded a cohort of 69 168 patients, of whom half (34 584) received a statin and half (34 584) did not. Findings Incidence of sepsis was lower in patients receiving statins than in controls (71.2 vs 88.0 events per 10 000 person-years; hazard ratio [HR] 0.81; 95% CI 0.72-0.91). Adjustment for demographic characteristics, sepsis risk factors, comorbidities, and health-care use gave similar results (HR 0.81; 95% CI 0.72-0.90). The protective association between statins and sepsis persisted in high-risk subgroups, including patients with diabetes mellitus, chronic renal failure, or a history of infections. Significant reductions in severe sepsis (HR 0.83; 95% CI 0.70-0.97) and fatal sepsis (0.75; 0.61-0.93) were also observed. No benefit was noted with non-statin lipid-lowering agents (0.95; 0.75-1.22). Implications Use of stating in patients with atherosclerosis is associated with a reduced risk of subsequent sepsis. Randomised trials of statins for prevention of sepsis are warranted.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Div Clin Pharmacol & Toxicol, Toronto, ON M4N 3M5, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada; Univ Toronto, Clin Epidemiol & Hlth Care Res Program, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Fac Med, Toronto, ON, Canada; Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Hospital for Sick Children (SickKids); Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Redelmeier, DA (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Gen Internal Med, G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	clar@ices.on.ca	Hackam, Dan G/A-1143-2009					Al-Omran M, 2003, J VASC SURG, V38, P279, DOI 10.1016/S0741-5214(03)00274-X; Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Ando H, 2000, J PHARMACOL EXP THER, V294, P1043; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087; Austin PC, 2002, AM HEART J, V144, P290, DOI 10.1067/mhj.2002.123839; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Chan B., 1999, SUPPLY PHYS SERVICES; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Durant R, 2004, SHOCK, V22, P34, DOI 10.1097/01.shk.0000129197.46212.7e; Eaton S, 2002, AM J RESP CRIT CARE, V165, pA471; Ely EW, 2003, CRIT CARE MED, V31, P12, DOI 10.1097/00003246-200301000-00002; Fodor JG, 2000, CAN MED ASSOC J, V162, P1441; Giusti-Paiva A, 2004, SHOCK, V21, P271, DOI 10.1097/10.shk.0000115756.74059.ce; Halcox JPJ, 2004, CIRCULATION, V109, P42, DOI 10.1161/01.CIR.0000129500.29229.92; Humphries KH, 2000, J CLIN EPIDEMIOL, V53, P343, DOI 10.1016/S0895-4356(99)00188-2; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kothe H, 2000, CIRCULATION, V101, P1760, DOI 10.1161/01.CIR.101.15.1760; Landmesser U, 2005, CIRCULATION, V111, P2356, DOI 10.1161/01.CIR.0000164260.82417.3F; LATIES AM, 1991, AM J CARDIOL, V67, P447, DOI 10.1016/0002-9149(91)90002-3; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Levy AR, 1999, CAN J CARDIOL, V15, P1277; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mayo N E, 1994, Health Rep, V6, P62; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; Merx MW, 2005, CIRCULATION, V112, P117, DOI 10.1161/CIRCULATIONAHA.104.502195; Merx MW, 2004, CIRCULATION, V109, P2560, DOI 10.1161/01.CIR.0000129774.09737.5B; Naylor CD, 1999, CARDIOVASCULAR HLTH; Ollendorf DA, 2002, VALUE HEALTH, V5, P79, DOI 10.1046/j.1524-4733.2002.52013.x; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Pleiner J, 2004, CIRCULATION, V110, P3349, DOI 10.1161/01.CIR.0000147774.90396.ED; Pruefer D, 2002, CIRCULATION, V106, P2104, DOI 10.1161/01.CIR.0000034048.38910.91; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Sakabe K, 2004, AM J CARDIOL, V94, P497, DOI 10.1016/j.amjcard.2004.04.067; Schlienger RG, 2001, ARCH INTERN MED, V161, P2021, DOI 10.1001/archinte.161.16.2021; Shi JM, 2003, BLOOD COAGUL FIBRIN, V14, P575, DOI 10.1097/00001721-200309000-00010; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Song JL, 2003, MED MYCOL, V41, P417, DOI 10.1080/1369378031000137233; Steiner S, 2005, CIRCULATION, V111, P1841, DOI 10.1161/01.CIR.0000158665.27783.0C; Sundararajan V, 2005, CRIT CARE MED, V33, P71, DOI 10.1097/01.CCM.0000150027.98160.80; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991	49	222	238	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					413	418		10.1016/S0140-6736(06)68041-0	http://dx.doi.org/10.1016/S0140-6736(06)68041-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458766				2022-12-28	WOS:000235139400031
J	Rees, CJ				Rees, CJ			Commentary: Patient's experience - A bond with the support of Colin Rees	BRITISH MEDICAL JOURNAL			English	Editorial Material									S Tyneside Healthcare NHS Fdn Trust, Dept Gastroenterol, S Shields NE34 0PL, England		Rees, CJ (corresponding author), S Tyneside Healthcare NHS Fdn Trust, Dept Gastroenterol, S Shields NE34 0PL, England.	Colin.rees@sthct.nhs.uk						McPherson S, 2006, BRIT MED J, V332, P276, DOI 10.1136/bmj.332.7536.276	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 4	2006	332	7536					277	277		10.1136/bmj.332.7536.277	http://dx.doi.org/10.1136/bmj.332.7536.277			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	011HN	16455725	Green Published			2022-12-28	WOS:000235259000019
J	Salmon, DA; Teret, SP; MacIntyre, CR; Salisbury, D; Burgess, MA; Halsey, NA				Salmon, DA; Teret, SP; MacIntyre, CR; Salisbury, D; Burgess, MA; Halsey, NA			Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future	LANCET			English	Article							IMMUNIZATION; REQUIREMENTS; COVERAGE; HEALTH; LAW	Compulsory vaccination has contributed to the success of immunisation programmes in the USA and Australia, yet the benefits from compulsory vaccination are not universally recognised. Some people-experts and the public alike-believe that the benefits of compulsory vaccination are outweighed by the associated ethical problems. A review of vaccination legislation in the UK, Australia, and the USA raises four main points. First, compulsory vaccination may be effective in preventing disease outbreaks, reaching and sustaining high immunisation coverage rates, and expediting the introduction of new vaccines. Second, to be effective, compulsory programmes must have a reliable supply of safe and effective vaccines and most people must be willing to be vaccinated. Third, allowance of exemptions to compulsory vaccination may limit public backlash. Finally, compulsory vaccination may increase the burden on governments to ensure the safety of vaccines. Nevertheless, although compulsory immunisation can be very effective, it might not be acceptable in some countries where high coverage has been achieved through other approaches or efforts, such as in Sweden, Norway, Denmark, the Netherlands, and the UK. These factors should be considered when compulsory vaccinations are being introduced or immunisation laws refined. Lessons learned from compulsory vaccination could be useful to other public-health programmes.	Univ Florida, Coll Med, Dept Epidemiol & Hlth Policy Res, Gainesville, FL 32608 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Law & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Dept Hlth, Communicable Dis & Immunisat Team, London SE1 6TE, England	State University System of Florida; University of Florida; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Sydney; University of Sydney	Salmon, DA (corresponding author), Univ Florida, Coll Med, Dept Epidemiol & Hlth Policy Res, 1329 SW 16th St,Room 5239,POB 100177, Gainesville, FL 32608 USA.	das@ehpr.ufl.edu	MacIntyre, Chandini Raina/D-4182-2011	salmon, daniel/0000-0002-1035-4422; MacIntyre, C Raina/0000-0002-3060-0555				[Anonymous], 1999, JAMA, V281, P1482; *AUSTR DEP HLTH AG, 7 POINT PLAN; Baldwin P., 2005, CONTAGION STATE EURO; Briss PA, 2000, AM J PREV MED, V18, P97, DOI 10.1016/S0749-3797(99)00118-X; British Medical Association Board of Science and Education, 2003, CHILDH IMM GUID HEAL; CDC, 1978, MMWR MORB MORTAL WKL, V27, P303; CDC, 1999, MMWR MORB MORTAL WKL, V48, P243; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P502; Centers for Disease Control (CDC), 1981, MMWR Morb Mortal Wkly Rep, V30, P593; *DEP HLTH HUM SERV, 1999, VACC SAF ACT PLAN; Dunn PM, 1998, BRIT MED J, V317, P1144; Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0; Feikin DR, 2000, JAMA-J AM MED ASSOC, V284, P3145, DOI 10.1001/jama.284.24.3145; FOWINKLE EW, 1981, PUBLIC HEALTH REP, V96, P61; Gerber MA, 2001, PEDIATRICS, V107, P612, DOI 10.1542/peds.107.5.e84; Hinman AR, 2000, AM J PREV MED, V18, P92; Hull BP, 2003, AUST NZ J PUBL HEAL, V27, P533, DOI 10.1111/j.1467-842X.2003.tb00829.x; *I VACC SAF, VACC EX; Lawrence GL, 2004, VACCINE, V22, P2345, DOI 10.1016/j.vaccine.2003.10.038; MIDDAUGH JP, 1978, JAMA-J AM MED ASSOC, V239, P2128, DOI 10.1001/jama.239.20.2128; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; *MMR EXP GROUP, REP MMR EXP GROUP; ORENSTEIN WA, 1978, J INFECT DIS, V137, P847, DOI 10.1093/infdis/137.6.847; Orenstein WA, 1999, VACCINE, V17, pS19, DOI 10.1016/S0264-410X(99)00290-X; ORENSTEIN WA, 1992, IMMUNISATION OLD NEW, P58; Peter G, 2003, JAMA-J AM MED ASSOC, V290, P3122; Rota JS, 2001, AM J PUBLIC HEALTH, V91, P645, DOI 10.2105/AJPH.91.4.645; ROWLAND R, 2002, CHILDHOOD VACCINES S; *ROYAL COMM VACC, 1896, FIN REP; Salisbury DM, 2004, PAHO SCI P, P310; SALISBURY DM, 1999, VACCINES, P1033; Salmon DA, 2005, AM J PUBLIC HEALTH, V95, P778, DOI 10.2105/AJPH.2004.046193; Salmon DA, 2005, AM J PUBLIC HEALTH, V95, P436, DOI 10.2105/AJPH.2004.046201; Salmon DA, 2001, PUBLIC HEALTH REP, V116, P289, DOI 10.1016/S0033-3549(04)50050-X; Salmon DA, 1999, JAMA-J AM MED ASSOC, V282, P47, DOI 10.1001/jama.282.1.47; Stratton K, 2001, IMMUNIZATION SAFETY; THOMAS EG, 1980, MED HIST, V24, P1; *WHO, 2003, WKLY EPIDEMIOL REC, V4, P17; WILLIAMSON S, 1984, ARCH DIS CHILD, V59, P1195, DOI 10.1136/adc.59.12.1195; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430; Yarwood J, 2005, VACCINE, V23, P5670, DOI 10.1016/j.vaccine.2004.11.081; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2; 1896, BMJ, V2, P1396	43	150	150	1	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2006	367	9508					436	442		10.1016/S0140-6736(06)68144-0	http://dx.doi.org/10.1016/S0140-6736(06)68144-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009UR	16458770				2022-12-28	WOS:000235139400035
J	Cho, MK; McGee, G; Magnus, D				Cho, MK; McGee, G; Magnus, D			Research conduct - Lessons of the stem cell scandal	SCIENCE			English	Editorial Material									Stanford Ctr Biomed Eth, Dept Pediat, Palo Alto, CA 94304 USA; Albany Med Coll, Alden March Bioeth Inst, Albany, NY 12208 USA	Stanford University; Albany Medical College	Cho, MK (corresponding author), Stanford Ctr Biomed Eth, Dept Pediat, Palo Alto, CA 94304 USA.	micho@stanford.edu; dmagnus@stanford.edu						Brown S, 1998, SCI ENG ETHICS, V4, P487; *I MED NAT RES COU, 2002, INT SCI RES; *INT COMM MED J ED, 2005, UN REQ MAN SUBM BIOM; KIM TG, 2005, KOREA TIMES     0203; KIM TG, 2005, KOREA TIMES     0624; Lipton P, 1998, STUD HIST PHILOS SCI, V29A, P1, DOI 10.1016/S0039-3681(97)00022-8; Magnus D, 2005, SCIENCE, V308, P1747, DOI 10.1126/science.1114454; MIN JK, 2005, OHMY NEWS       1230; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; RYU J, 2005, KOREA TIMES     1218; *SEOUL NAT U INV C, 2005, INT REP PROF H WOOSU; SHAPIN S, 1984, SOC STUD SCI, V14, P481, DOI 10.1177/030631284014004001; Shapin S, 1989, LEVIATHAN AIR PUMP H; SHAPIN S, 1994, SOCIAL HIST TRUTH CA; *US DEP HHS OFF HU, 2004, GUID RES INV COD PRI; Weiss Rick, 2005, Washington Post, pA21; Weiss Rick, 2005, Washington Post, pA2; White C, 2005, BMJ-BRIT MED J, V331, P281, DOI 10.1136/bmj.331.7511.281; 2005, DONG LLBO       1125	19	31	33	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					614	615		10.1126/science.1124948	http://dx.doi.org/10.1126/science.1124948			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	011GY	16456065				2022-12-28	WOS:000235257400030
J	Arnon, SS; Schechter, R; Maslanka, SE; Jewell, NP; Hatheway, CL				Arnon, SS; Schechter, R; Maslanka, SE; Jewell, NP; Hatheway, CL			Human botulism immune globulin for the treatment of infant botulism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLOSTRIDIUM-DIFFICILE COLITIS; ANTITOXIN; TOXIN; MANAGEMENT; CALIFORNIA; DEATH	BACKGROUND: We created the orphan drug Human Botulism Immune Globulin Intravenous (Human) (BIG-IV), which neutralizes botulinum toxin, and evaluated its safety and efficacy in treating infant botulism, the intestinal-toxemia form of human botulism. METHODS: We performed a five-year, randomized, double-blind, placebo-controlled trial statewide, in California, of BIG-IV in 122 infants with suspected (and subsequently laboratory-confirmed) infant botulism (75 caused by type A Clostridium botulinum toxin, and 47 by type B toxin); treatment was given within three days after hospital admission. We subsequently performed a 6-year nationwide, open-label study of 382 laboratory-confirmed cases of infant botulism treated within 18 days after hospital admission. RESULTS: As compared with the control group in the randomized trial, infants treated with BIG-IV had a reduction in the mean length of the hospital stay, the primary efficacy outcome measure, from 5.7 weeks to 2.6 weeks (P<0.001). BIG-IV treatment also reduced the mean duration of intensive care by 3.2 weeks (P<0.001), the mean duration of mechanical ventilation by 2.6 weeks (P=0.01), the mean duration of tube or intravenous feeding by 6.4 weeks (P<0.001), and the mean hospital charges per patient by $88,600 (in 2004 U.S. dollars; P<0.001). There were no serious adverse events attributable to BIG-IV. In the open-label study, infants treated with BIG-IV within seven days of admission had a mean length of hospital stay of 2.2 weeks, and early treatment with BIG-IV shortened the mean length of stay significantly more than did later treatment. CONCLUSIONS: Prompt treatment of infant botulism type A or type B with BIG-IV was safe and effective in shortening the length and cost of the hospital stay and the severity of illness.	Calif Dept Hlth Serv, Infant Botulism Treatment & Prevent Program, Richmond, CA 94804 USA; Ctr Dis Control & Prevent, Natl Botulism Surveillance & Reference Lab, Atlanta, GA USA; Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA	California Department of Health Care Services; Centers for Disease Control & Prevention - USA; University of California System; University of California Berkeley	Arnon, SS (corresponding author), Calif Dept Hlth Serv, Infant Botulism Treatment & Prevent Program, 850 Marina Bay Pkwy,Rm E-361, Richmond, CA 94804 USA.	sarnon@dhs.ca.gov						[Anonymous], 2004, TXB PEDIAT INFECT DI; ARNON SS, 1982, J PEDIATR-US, V100, P568, DOI 10.1016/S0022-3476(82)80754-3; ARNON SS, 1977, JAMA-J AM MED ASSOC, V237, P1946, DOI 10.1001/jama.237.18.1946; ARNON SS, 1979, J PEDIATR-US, V94, P331, DOI 10.1016/S0022-3476(79)80863-X; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; Barash JR, 2005, J CLIN MICROBIOL, V43, P4280, DOI 10.1128/JCM.43.8.4280-4282.2005; Barash JR, 2004, J CLIN MICROBIOL, V42, P1713, DOI 10.1128/JCM.42.4.1713-1715.2004; BLACK RE, 1980, AM J MED, V69, P567, DOI 10.1016/0002-9343(80)90469-6; Centers for Disease Control and Prevention, 1998, HDB EPID CLIN LAB WO; Chang GY, 2003, EUR NEUROL, V49, P151, DOI 10.1159/000069073; CONOVER W. J, 1980, PRACTICAL NONPARAMET; COOPER MS, 1964, BOTULISM, P147; Department of Health and Human Services, 2005, FED REGISTER, V70, P13294; Fenicia L, 2002, EUR J CLIN MICROBIOL, V21, P736, DOI 10.1007/s10096-002-0816-z; GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982; HATHEWAY CH, 1984, J INFECT DIS, V150, P407, DOI 10.1093/infdis/150.3.407; JOHNSON RO, 1979, AM J DIS CHILD, V133, P586, DOI 10.1001/archpedi.1979.02130060026004; LONG SS, 1985, PEDIATRICS, V75, P935; Nevas M, 2005, J CLIN MICROBIOL, V43, P511, DOI 10.1128/JCM.43.1.511-513.2005; Nowakowski A, 2002, P NATL ACAD SCI USA, V99, P11346, DOI 10.1073/pnas.172229899; Schechter R, 1999, CLIN INFECT DIS, V29, P367, DOI 10.1086/520217; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHREINER MS, 1991, PEDIATRICS, V87, P159; Simpson LL, 2004, ANNU REV PHARMACOL, V44, P167, DOI 10.1146/annurev.pharmtox.44.101802.121554; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; WILCKE BW, 1980, J INFECT DIS, V141, P419, DOI 10.1093/infdis/141.4.419; 1994, MMWR MORB MORTAL WKL, V43, P505	27	244	254	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2006	354	5					462	471		10.1056/NEJMoa051926	http://dx.doi.org/10.1056/NEJMoa051926			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008DC	16452558				2022-12-28	WOS:000235019400006
J	Ruiz-Morales, JC; Canales-Vazquez, J; Savaniu, C; Marrero-Lopez, D; Zhou, WZ; Irvine, JTS				Ruiz-Morales, JC; Canales-Vazquez, J; Savaniu, C; Marrero-Lopez, D; Zhou, WZ; Irvine, JTS			Disruption of extended defects in solid oxide fuel cell anodes for methane oxidation	NATURE			English	Article							SOFC ANODES; TEMPERATURE; HYDROCARBONS; OPERATION; GAS	Point defects largely govern the electrochemical properties of oxides: at low defect concentrations, conductivity increases with concentration; however, at higher concentrations, defect - defect interactions start to dominate(1,2). Thus, in searching for electrochemically active materials for fuel cell anodes, high defect concentration is generally avoided. Here we describe an oxide anode formed from lanthanum-substituted strontium titanate (La-SrTiO3) in which we control the oxygen stoichiometry in order to break down the extended defect intergrowth regions and create phases with considerable disordered oxygen defects. We substitute Ti in these phases with Ga and Mn to induce redox activity and allow more flexible coordination. The material demonstrates impressive fuel cell performance using wet hydrogen at 950 degrees C. It is also important for fuel cell technology to achieve efficient electrode operation with different hydrocarbon fuels(3,4), although such fuels are more demanding than pure hydrogen. The best anode materials to date-Ni-YSZ ( yttria-stabilized zirconia) cermets(5) - suffer some disadvantages related to low tolerance to sulphur(6), carbon build-up when using hydrocarbon fuels(7) ( though device modifications and lower temperature operation can avoid this(8,9)) and volume instability on redox cycling. Our anode material is very active for methane oxidation at high temperatures, with open circuit voltages in excess of 1.2 V. The materials design concept that we use here could lead to devices that enable more-efficient energy extraction from fossil fuels and carbon-neutral fuels.	Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	Irvine, JTS (corresponding author), Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland.	jtsi@st-and.ac.uk	Zhou, Wuzong/AAA-8268-2019; Marrero-López, David/A-2850-2010; Ruiz-Morales, Juan Carlos/F-6918-2010; Zhou, Wuzong/GPS-4743-2022; Irvine, John TS/F-1283-2011; Canales-Vázquez, Jesús/K-7513-2012	Marrero-López, David/0000-0003-0632-6442; Ruiz-Morales, Juan Carlos/0000-0003-0174-3685; Zhou, Wuzong/0000-0001-9752-7076; Canales-Vázquez, Jesús/0000-0003-4089-2034; Irvine, John/0000-0002-8394-3359				Atkinson A, 2004, NAT MATER, V3, P17, DOI 10.1038/nmat1040; Canales-Vazquez J, 2005, J ELECTROCHEM SOC, V152, pA1458, DOI 10.1149/1.1921747; Canales-Vazquez J, 2005, ADV FUNCT MATER, V15, P1000, DOI 10.1002/adfm.200400362; Canales-Vazquez J, 2003, SOLID STATE IONICS, V159, P159, DOI 10.1016/S0167-2738(03)00002-X; Holtappels P, 2001, J ELECTROCHEM SOC, V148, pA923, DOI 10.1149/1.1383774; Irvine J. T. S., 2000, P 4 EUR SOFC FOR LUZ, P471; Irvine JTS, 2000, SOLID STATE IONICS, V136, P879, DOI 10.1016/S0167-2738(00)00568-3; KILNER JA, 1982, J ELECTROCHEM SOC, V129, pC143; Lin YB, 2005, SOLID STATE IONICS, V176, P1827, DOI 10.1016/j.ssi.2005.05.008; Liu JA, 2003, SOLID STATE IONICS, V158, P11, DOI 10.1016/S0167-2738(02)00769-5; Marina O. A., 2002, P 5 EUR SOL OX FUEL, P481; Marina OA, 2002, SOLID STATE IONICS, V149, P21, DOI 10.1016/S0167-2738(02)00140-6; Matsuzaki Y, 2000, SOLID STATE IONICS, V132, P261, DOI 10.1016/S0167-2738(00)00653-6; McIntosh S, 2003, ELECTROCHEM SOLID ST, V6, pA240, DOI 10.1149/1.1613231; Mukundan R, 2004, ELECTROCHEM SOLID ST, V7, pA5, DOI 10.1149/1.1627452; Murray EP, 1999, NATURE, V400, P649, DOI 10.1038/23220; OVALLE A, UNPUB SOLID STATE IO; Park SD, 2000, NATURE, V404, P265, DOI 10.1038/35005040; POEPPELMEIER KR, 1982, J SOLID STATE CHEM, V44, P89, DOI 10.1016/0022-4596(82)90404-2; Primdahl S, 2001, J ELECTROCHEM SOC, V148, pA74, DOI 10.1149/1.1344519; Singhal S.C., 2004, HIGH TEMPERATURE SOL; Tao SW, 2003, NAT MATER, V2, P320, DOI 10.1038/nmat871; Zhu WZ, 2003, MAT SCI ENG A-STRUCT, V362, P228, DOI 10.1016/S0921-5093(03)00620-8	23	345	357	9	326	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					568	571		10.1038/nature04438	http://dx.doi.org/10.1038/nature04438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452975				2022-12-28	WOS:000235033900036
J	Heller, DA; Jeng, ES; Yeung, TK; Martinez, BM; Moll, AE; Gastala, JB; Strano, MS				Heller, DA; Jeng, ES; Yeung, TK; Martinez, BM; Moll, AE; Gastala, JB; Strano, MS			Optical detection of DNA conformational polymorphism on single-walled carbon nanotubes	SCIENCE			English	Article							B-DNA; SPECTROSCOPY; TRANSITION; SENSORS	The transition of DNA secondary structure from an analogous B to Z conformation modulates the dielectric environment of the single-waited carbon nanotube (SWNT) around which it is adsorbed. The SWNT band-gap fluorescence undergoes a red shift when an encapsulating 30-nucleotide oligomer is exposed to counter ions that screen the charged backbone. The transition is thermodynamically identical for DNA on and off the nanotube, except that the propagation length of the former is shorter by five-sixths. The magnitude of the energy shift is described by using an effective medium model and the DNA geometry on the nanotube sidewall. We demonstrate the detection of the B-Z change in whole blood, tissue, and from within living mammalian cells.	Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Strano, MS (corresponding author), Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.	strano@uiuc.edu	Heller, Daniel A/A-4283-2008	Heller, Daniel A/0000-0002-6866-0000; Gastala, Joseph/0000-0001-8792-5302				Abascal JLF, 2004, MOL PHYS, V102, P2141, DOI 10.1080/00268970412331292704; Barone PW, 2005, NAT MATER, V4, P86, DOI 10.1038/nmat1276; DICKERSON RE, 1982, SCIENCE, V216, P475, DOI 10.1126/science.7071593; DUGUID J, 1993, BIOPHYS J, V65, P1916, DOI 10.1016/S0006-3495(93)81263-3; Geballe R., 1958, AM J PHYS, V26, P287, DOI 10.1119/1.1996131; Hartschuh A, 2005, CHEMPHYSCHEM, V6, P577, DOI 10.1002/cphc.200400408; Heller DA, 2005, ADV MATER, V17, P2793, DOI 10.1002/adma.200500477; JOVIN TM, 1987, ANNU REV PHYS CHEM, V38, P521, DOI 10.1146/annurev.pc.38.100187.002513; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Perebeinos V, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.257402; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; POHL FM, 1982, COLD SPRING HARB SYM, V47, P113; Popov VN, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.035436; Rich A, 1996, J BIOL CHEM, V271, P11595, DOI 10.1074/jbc.271.20.11595; Rohlfing M, 2000, PHYS REV B, V62, P4927, DOI 10.1103/PhysRevB.62.4927; Rothenburg S, 2005, P NATL ACAD SCI USA, V102, P1602, DOI 10.1073/pnas.0408714102; Saito R, 1998, PHYS PROPERTIES CARB; TUNG CS, 1984, NUCLEIC ACIDS RES, V12, P3343, DOI 10.1093/nar/12.7.3343; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; Zheng M, 2003, SCIENCE, V302, P1545, DOI 10.1126/science.1091911; ZIMMERMAN SB, 1982, ANNU REV BIOCHEM, V51, P395, DOI 10.1146/annurev.bi.51.070182.002143	21	405	428	2	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 27	2006	311	5760					508	511		10.1126/science.1120792	http://dx.doi.org/10.1126/science.1120792			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439657				2022-12-28	WOS:000235071400042
J	Neff, MW; Rine, J				Neff, MW; Rine, J			A fetching model organism	CELL			English	Editorial Material							EVOLUTION; PREFERENCE	The creation of the domestic dog and its many breeds has been an ongoing experiment in the rapid evolution of form and function. Now, advances in genomics have made Canis familiaris genetically tractable and poised to offer insights into evolution, development, and behavior.	Univ Calif Davis, Ctr Vet Genet, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Berkeley	Neff, MW (corresponding author), Univ Calif Davis, Ctr Vet Genet, Davis, CA 95616 USA.	mwneff@ucdavis.edu; jrine@berkeley.edu						BEADLE GW, 1980, SCI AM, V242, P112, DOI 10.1038/scientificamerican0180-112; Bearhop S, 2005, SCIENCE, V310, P502, DOI 10.1126/science.1115661; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; Colosimo PF, 2005, SCIENCE, V307, P1928, DOI 10.1126/science.1107239; Lim MM, 2004, NATURE, V429, P754, DOI 10.1038/nature02539; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Morris D., 2001, DOGS DICT DOG BREEDS; Pletcher MT, 2004, PLOS BIOL, V2, P2159, DOI 10.1371/journal.pbio.0020393; Schemske DW, 1999, P NATL ACAD SCI USA, V96, P11910, DOI 10.1073/pnas.96.21.11910; Sutter NB, 2004, GENOME RES, V14, P2388, DOI 10.1101/gr.3147604	10	44	46	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					229	231		10.1016/j.cell.2006.01.008	http://dx.doi.org/10.1016/j.cell.2006.01.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439192	Bronze			2022-12-28	WOS:000235068500005
J	Reppert, SM				Reppert, SM			A colorful model of the circadian clock	CELL			English	Editorial Material							SUN COMPASS; MONARCH; LIGHT	The migration of the colorful monarch butterfly provides biologists with a unique model system with which to study the cellular and molecular mechanisms underlying a sophisticated circadian clock. The monarch circadian clock is involved in the induction of the migratory state and navigation over long distances, using the sun as a compass.	Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Reppert, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, 362 Plantat St, Worcester, MA 01605 USA.	steven.reppert@umassmed.edu						Brower LP, 1996, J EXP BIOL, V199, P93; Froy O, 2003, SCIENCE, V300, P1303, DOI 10.1126/science.1084874; Goehring L, 2002, ECOL ENTOMOL, V27, P674, DOI 10.1046/j.1365-2311.2002.00454.x; Herman WS, 2001, P ROY SOC B-BIOL SCI, V268, P2509, DOI 10.1098/rspb.2001.1765; Labhart T, 2002, CURR OPIN NEUROBIOL, V12, P707, DOI 10.1016/S0959-4388(02)00384-7; Mouritsen H, 2002, P NATL ACAD SCI USA, V99, P10162, DOI 10.1073/pnas.152137299; Perez SM, 1997, NATURE, V387, P29, DOI 10.1038/387029a0; Reppert SM, 2004, CURR BIOL, V14, P155, DOI 10.1016/j.cub.2003.12.034; Ritz T, 2002, NEURON, V34, P503, DOI 10.1016/S0896-6273(02)00707-9; Sauman I, 2005, NEURON, V46, P457, DOI 10.1016/j.neuron.2005.03.014; Stalleicken J, 2006, J COMP PHYSIOL A, V192, P321, DOI 10.1007/s00359-005-0073-6; Stalleicken J, 2005, J EXP BIOL, V208, P2399, DOI 10.1242/jeb.01613; Stanewsky R, 2003, J NEUROBIOL, V54, P111, DOI 10.1002/neu.10164; Urquhart FA., 1960, MONARCH BUTTERFLY; Zhu HS, 2005, CURR BIOL, V15, pR953, DOI 10.1016/j.cub.2005.11.030	15	52	55	2	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					233	236		10.1016/j.cell.2006.01.009	http://dx.doi.org/10.1016/j.cell.2006.01.009			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439193	Bronze			2022-12-28	WOS:000235068500006
J	McMullan, DM; Cohen, GA				McMullan, DM; Cohen, GA			Images in clinical medicine: Radiographic evidence linking tobacco use and lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	McMullan, DM (corresponding author), Univ Washington, Seattle, WA 98195 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					397	397		10.1056/NEJMicm041134	http://dx.doi.org/10.1056/NEJMicm041134			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	005VY	16436771				2022-12-28	WOS:000234854000011
J	Horton, R				Horton, R			Expression of concern: non-steroidal anti-inflammatory drugs and the risk of oral cancer	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							FOUCHE G, 2006, GUARDIAN        0116, P19; KAREN M, 2006, CANC RES ADMITS FAKI; Sudbo J, 2005, LANCET, V366, P1359, DOI 10.1016/S0140-6736(05)67488-0	3	13	13	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 21	2006	367	9506					196	196		10.1016/S0140-6736(06)68014-8	http://dx.doi.org/10.1016/S0140-6736(06)68014-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005GM	16427477				2022-12-28	WOS:000234810600010
J	Larson, EB; Wang, L; Bowen, JD; McCormick, WC; Teri, L; Crane, P; Kukull, W				Larson, EB; Wang, L; Bowen, JD; McCormick, WC; Teri, L; Crane, P; Kukull, W			Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-ACTIVITY; ALZHEIMERS-DISEASE; COGNITIVE PERFORMANCE; APOLIPOPROTEIN-E; AEROBIC FITNESS; HEALTH; PEOPLE; ADULTS; WOMEN; IMPAIRMENT	Background: Alzheimer disease and other dementing disorders are major sources of morbidity and mortality in aging societies. Proven strategies to delay onset or reduce risk for dementing disorders would be greatly beneficial. Objective: To determine whether regular exercise is associated with a reduced risk for dementia and Alzheimer disease. Design: Prospective cohort study. Setting: Group Health Cooperative, Seattle, Washington. Participants: 1740 persons older than age 65 years without cognitive impairment who scored above the 25th percentile on the Cognitive Ability Screening Instrument (CASI) in the Adult Changes in Thought study and who were followed biennially to identify incident dementia. Measurements: Baseline measurements, including exercise frequency, cognitive function, physical function, depression, health conditions, lifestyle characteristics, and other potential risk factors for dementia (for example, apolipoprotein E EURO4); biennial assessment for dementia. Results: During a mean follow-up of 6.2 years (SD, 2.0), 158 participants developed dementia (107 developed Alzheimer disease). The incidence rate of dementia was 13.0 per 1000 person-years for participants who exercised 3 or more times per week compared with 19.7 per 1000 person-years for those who exercised fewer than 3 times per week. The age- and sex-adjusted hazard ratio of dementia was 0.62 (95% Cl, 0.44 to 0.86; P = 0.004). The interaction between exercise and performance-based physical function was statistically significant (P = 0.013). The risk reduction associated with exercise was greater in those with lower performance levels. Similar results were observed in analyses restricted to participants with incident Alzheimer disease. Limitations: Exercise was measured by self-reported frequency. The study population had a relatively high proportion of regular exercisers at baseline. Conclusion: These results suggest that regular exercise is associated with a delay in onset of dementia and Alzheimer disease, further supporting its value for elderly persons.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA; VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA	Group Health Cooperative; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Larson, EB (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	larson.e@ghc.org		Crane, Paul/0000-0003-4278-7465; Kukull, Walter/0000-0001-8761-9014	NIA NIH HHS [AG06781] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG006781] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Barnes DE, 2003, J AM GERIATR SOC, V51, P459, DOI 10.1046/j.1532-5415.2003.51153.x; Berg AO, 2002, ANN INTERN MED, V137, P205, DOI 10.7326/0003-4819-137-3-200208060-00014; Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x; Brown DW, 2004, MED SCI SPORT EXER, V36, P890, DOI 10.1249/01.MSS.0000126778.77049.76; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; COX DR, 1972, J R STAT SOC B, V34, P187; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; Ewbank DC, 1999, AM J PUBLIC HEALTH, V89, P90, DOI 10.2105/AJPH.89.1.90; Ganguli M, 1999, J AM GERIATR SOC, V47, P842, DOI 10.1111/j.1532-5415.1999.tb03842.x; Gomez-Pinilla F, 1998, NEUROSCIENCE, V85, P53, DOI 10.1016/S0306-4522(97)00576-9; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HAWKINS HL, 1992, PSYCHOL AGING, V7, P643, DOI 10.1037/0882-7974.7.4.643; HILL RD, 1993, J GERONTOL, V48, pP12, DOI 10.1093/geronj/48.1.P12; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Larson EB, 2004, ALZ DIS ASSOC DIS, V18, P54, DOI 10.1097/01.wad.0000126615.70030.70; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; LINN RT, 1995, ARCH NEUROL-CHICAGO, V52, P485, DOI 10.1001/archneur.1995.00540290075020; MADDEN DJ, 1989, PSYCHOL AGING, V4, P307, DOI 10.1037/0882-7974.4.3.307; MCCORMICK WC, 1994, J AM GERIATR SOC, V42, P517, DOI 10.1111/j.1532-5415.1994.tb04974.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOUL JL, 1995, J AGING PHYS ACTIV, V3, P135, DOI 10.1123/japa.3.2.135; Okumiya K, 1996, J AM GERIATR SOC, V44, P569, DOI 10.1111/j.1532-5415.1996.tb01444.x; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PHELAN EA, 2004, J AM GERIATR SOC, V54, P1559; Podewils LJ, 2005, AM J EPIDEMIOL, V161, P639, DOI 10.1093/aje/kwi092; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROGERS RL, 1990, J AM GERIATR SOC, V38, P123, DOI 10.1111/j.1532-5415.1990.tb03472.x; SHAY KA, 1992, PSYCHOL AGING, V7, P15, DOI 10.1037/0882-7974.7.1.15; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Teng EL, 1994, INT PSYCHOGERIATR, V6, P62, DOI DOI 10.1017/S1041610294001602; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; Teri L, 1998, J REHABIL RES DEV, V35, P411; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Wang L, 2002, J AM GERIATR SOC, V50, P1525, DOI 10.1046/j.1532-5415.2002.50408.x; Wang L, 2004, J AM GERIATR SOC, V52, P2045, DOI 10.1111/j.1532-5415.2004.52568.x; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; Williams P, 1997, AUST NZ J PUBL HEAL, V21, P45, DOI 10.1111/j.1467-842X.1997.tb01653.x; Yaffe K, 2001, ARCH INTERN MED, V161, P1703, DOI 10.1001/archinte.161.14.1703	44	891	937	5	262	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2006	144	2					73	81		10.7326/0003-4819-144-2-200601170-00004	http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	004AX	16418406				2022-12-28	WOS:000234725500003
J	Savolainen, V; Anstett, MC; Lexer, C; Hutton, I; Clarkson, JJ; Norup, MV; Powell, MP; Springate, D; Salamin, N; Baker, WJ				Savolainen, V; Anstett, MC; Lexer, C; Hutton, I; Clarkson, JJ; Norup, MV; Powell, MP; Springate, D; Salamin, N; Baker, WJ			Sympatric speciation in palms on an oceanic island	NATURE			English	Article							LORD-HOWE ISLAND; PACIFIC-OCEAN; DIVERGENCE; EVOLUTION; ORIGIN; SELECTION; ANIMALS	The origin of species diversity has challenged biologists for over two centuries. Allopatric speciation, the divergence of species resulting from geographical isolation, is well documented(1). However, sympatric speciation, divergence without geographical isolation, is highly controversial(2). Claims of sympatric speciation must demonstrate species sympatry, sister relationships, reproductive isolation, and that an earlier allopatric phase is highly unlikely(1). Here we provide clear support for sympatric speciation in a case study of two species of palm ( Arecaceae) on an oceanic island. A large dated phylogenetic tree shows that the two species of Howea, endemic to the remote Lord Howe Island, are sister taxa and diverged from each other well after the island was formed 6.9 million years ago(3). During fieldwork, we found a substantial disjunction in flowering time that is correlated with soil preference. In addition, a genome scan(4,5) indicates that few genetic loci are more divergent between the two species than expected under neutrality, a finding consistent with models of sympatric speciation involving disruptive/ divergent selection(2). This case study of sympatric speciation in plants provides an opportunity for refining theoretical models on the origin of species, and new impetus for exploring putative plant and animal examples on oceanic islands.	Royal Bot Gardens, Richmond TW9 3DS, Surrey, England; Ctr Evolutionary & Funct Ecol, UMR 5175, F-34293 Montpellier 5, France; Aarhus Univ, Dept Systemat Bot, DK-8000 Aarhus C, Denmark; Univ Lausanne, Dept Ecol & Evolut, CH-1015 Lausanne, Switzerland	Royal Botanic Gardens, Kew; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; Aarhus University; University of Lausanne	Savolainen, V (corresponding author), Royal Bot Gardens, Richmond TW9 3DS, Surrey, England.	v.savolainen@kew.org	Anstett, Marie Charlotte/N-7977-2017; Lexer, Christian/N-3702-2013; Baker, William/B-1244-2011	Baker, William/0000-0001-6727-1831; Anstett, Marie Charlotte/0000-0001-7786-0357; Salamin, Nicolas/0000-0002-3963-4954; Savolainen, Vincent/0000-0001-5350-9984; Lexer, Christian/0000-0002-7221-7482				BAILEY LH, 1939, GENTES HERBARIUM, V4, P189; Beaumont MA, 2005, TRENDS ECOL EVOL, V20, P435, DOI 10.1016/j.tree.2005.05.017; Beaumont MA, 1996, P ROY SOC B-BIOL SCI, V263, P1619, DOI 10.1098/rspb.1996.0237; Berry EW, 1905, TORREYA, V5; Brooke BP, 2003, QUATERNARY SCI REV, V22, P859, DOI 10.1016/S0277-3791(02)00253-6; BURRETT C, 1991, Australian Systematic Botany, V4, P13, DOI 10.1071/SB9910013; BUSH GL, 1994, TRENDS ECOL EVOL, V9, P285, DOI 10.1016/0169-5347(94)90031-0; Coyne J.A., 2004, SPECIATION; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Doebeli M, 2005, EVOLUTION, V59, P691; DRANSFIELD J, IN PRESS KEW B; Filchak KE, 2000, NATURE, V407, P739, DOI 10.1038/35037578; Gavrilets S, 2003, EVOLUTION, V57, P2197; Higashi M, 1999, NATURE, V402, P523, DOI 10.1038/990087; Kishino H, 2001, MOL BIOL EVOL, V18, P352, DOI 10.1093/oxfordjournals.molbev.a003811; Kondrashov AS, 1999, NATURE, V400, P351, DOI 10.1038/22514; Luikart G, 2003, NAT REV GENET, V4, P981, DOI 10.1038/nrg1226; MCDOUGALL I, 1981, J GEOL SOC AUST, V28, P155, DOI 10.1080/00167618108729154; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; Oliver WRB., 1917, T P NZ I, V49, P94; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Pickard J, 1983, CUNNINGHAMIA, V1, P133; Sanderson MJ, 1997, MOL BIOL EVOL, V14, P1218, DOI 10.1093/oxfordjournals.molbev.a025731; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; Sorenson MD, 2003, NATURE, V424, P928, DOI 10.1038/nature01863; Swofford DL, 2001, PAUP 4 0 PHYLOGENETI; Tregenza T, 1999, NATURE, V400, P311, DOI 10.1038/22419; Turelli M, 2001, TRENDS ECOL EVOL, V16, P330, DOI 10.1016/S0169-5347(01)02177-2; Vaughan RE, 1937, J ECOL, V25, P289, DOI 10.2307/2256197; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7	30	452	469	3	343	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 11	2006	441	7090					210	213		10.1038/nature04566	http://dx.doi.org/10.1038/nature04566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	040YP	16467788				2022-12-28	WOS:000237418800044
J	Hepworth, SJ; Schoemaker, MJ; Muir, KR; Swerdlow, AJ; van Tongeren, MJA; McKinney, PA				Hepworth, SJ; Schoemaker, MJ; Muir, KR; Swerdlow, AJ; van Tongeren, MJA; McKinney, PA			Mobile phone use and risk of glioma in adults: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CELLULAR-TELEPHONE USE; BRAIN-TUMOR RISK; EXPOSURE; CANCER; AREAS; HEAD	Objective To investigate the risk of glioma in adults ill relation to mobile phone use. Design Population based case-control Study With collection of personal interview data. Setting Five areas of the United Kingdom. Participants 966 people aged 18 to 69 years diagnosed with it glioma from 1 December 2000 to 29 February 2004 and 1716 controls randomly selected from general practitioner lists. Main outcome measures Odds ratios for risk of glioma in relation to mobile phone use. Results The overall odds ratio for regular phone use was 0.94 (95% confidence interval 0.78 to 1.13). There was no relation for risk of glioma and time since first use, lifetime years Of use, and cumulative number of calls and hours of use. A significant excess risk for reported Phone use ipsilateral to the tumour (1.24, 1.02 to 1.52) was paralleled by a significant reduction in risk (0.75, 0.61 to 0.93) for contralateral use. Conclusions Use of a mobile phone, either in the short or medium term, is not associated with an increased risk of glioma This is consistent with most but not all published studies. The complementary positive and negative risks associated with ipsilateral and contralateral use of the phone in relation to the side of the tumour might be due to recall bias.	LIGHT, Ctr Biostat & Epidemiol, Leeds LS2 9LN, W Yorkshire, England; Inst Canc Res, Epidemiol Sect, Sutton SM2 5NG, Surrey, England; Queens Med Ctr, Sch Community Hlth Sci, Div Epidemiol & Publ Hlth, Nottingham NG7 2UH, England; Univ Manchester, Div Epidemiol & Hlth Sci, Ctr Environm & Occupat Hlth, Manchester M13 9PL, Lancs, England	University of Leeds; University of London; Institute of Cancer Research - UK; University of Nottingham; University of Manchester	McKinney, PA (corresponding author), LIGHT, Ctr Biostat & Epidemiol, Leeds LS2 9LN, W Yorkshire, England.	p.a.mckinney@leeds.ac.uk		Schoemaker, Minouk/0000-0001-8403-2234; van Tongeren, Martie/0000-0002-1205-1898; Swerdlow, Anthony/0000-0001-5550-4159; Fleming, Sarah/0000-0002-7655-4806				Advisory Group on Non-Ionising Radiation (AGNIR), 2003, DOC NRPB, V14, P1; Ahlbom A, 2004, ENVIRON HEALTH PERSP, V112, P1741, DOI 10.1289/ehp.7306; AMINEN A, 2002, EPIDEMIOLOGY, V13, P356; Auvinen A, 2002, EPIDEMIOLOGY, V13, P356, DOI 10.1097/00001648-200205000-00018; Boice JD, 2002, EPIDEMIOLOGIC STUDIE; Cardis E, 1999, RADIAT PROT DOSIM, V83, P179, DOI 10.1093/oxfordjournals.rpd.a032657; Christensen HC, 2005, NEUROLOGY, V64, P1189, DOI 10.1212/01.WNL.0000156351.72313.D3; DIJNBYLOW P, 1999, RAD PROT DISOMETRY, V83, P139; Dimbylow PJ, 1999, RADIAT PROT DOSIM, V83, P139, DOI 10.1093/oxfordjournals.rpd.a032648; Habash Riadh W Y, 2003, Crit Rev Biomed Eng, V31, P197, DOI 10.1615/CritRevBiomedEng.v31.i3.20; Hardell L, 2005, OCCUP ENVIRON MED, V62, P390, DOI 10.1136/oem.2004.017434; Hardell L, 2003, INT J ONCOL, V22, P399; Inskip PD, 2001, NEW ENGL J MED, V344, P79, DOI 10.1056/NEJM200101113440201; Johansen C, 2001, JNCI-J NATL CANCER I, V93, P203, DOI 10.1093/jnci/93.3.203; KLEIHAES P, 1997, PATHOLOGY GENETICS T; KLEIHUES P, 1997, PATHOLOGY GENETICS H; Kleihues P., 1997, PATHOLOGY GENETICS T; Law GR, 2002, BRIT J CANCER, V86, P350, DOI 10.1038/sj/bjc/6600092; Lonn S, 2005, AM J EPIDEMIOL, V161, P526, DOI 10.1093/aje/kwi091; Lonn S, 2004, EPIDEMIOLOGY, V15, P653, DOI 10.1097/01.ede.0000142519.00772.bf; Lonn S, 2004, OCCUP ENVIRON MED, V61, P769, DOI 10.1136/oem.2003.012567; LONN S, 1952, AM J EPIDEMIOL, V161, P526; Muscat JE, 2000, JAMA-J AM MED ASSOC, V284, P3001, DOI 10.1001/jama.284.23.3001; *OFF POP CENS SURV, 1992, GEN PRACT MORB STAT; Parslow RC, 2003, RADIAT PROT DOSIM, V106, P233, DOI 10.1093/oxfordjournals.rpd.a006354; Rothman KJ, 2000, LANCET, V356, P1837, DOI 10.1016/S0140-6736(00)03244-X; SIENKIEWICZ ZJ, 2005, SUMMARY RECENT REPOR; SIENKIEWICZ ZJ, 2005, NRPBW65; Townsend PP., 1988, HLTH DEPRIVATION INE; World Health Organization, 2000, INT CLASS DIS ONC	30	114	125	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 15	2006	332	7546					883	886		10.1136/bmj.38720.687975.55	http://dx.doi.org/10.1136/bmj.38720.687975.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	037FK	16428250	Green Published, Bronze			2022-12-28	WOS:000237132100018
J	Chandola, T; Brunner, E; Marmot, M				Chandola, T; Brunner, E; Marmot, M			Chronic stress at work and the metabolic syndrome: prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; BLOOD-PRESSURE; CORONARY RISK; ASSOCIATION; LINK; REWARD	Objectives To investigate the association between stress at work and the metabolic syndrome. Design Prospective cohort study investigating the association between work stress and the metabolic syndrome. Participants 10 308 men and women, aged 35-55, employed in 20 London civil service departments at baseline (the Whitehall 11 study); follow-up was an average of 14 years. Main outcome measures Work stress based on the iso-strain model, measured on four occasions (1985-99). Biological measures of the metabolic syndrome, based on the National Cholesterol Education Program definition, measured in 1999. Results A dose-response relation was found between exposure to work stressors over 14 years and risk of the metabolic syndrome, independent of other relevant risk factors. Employees with chronic work stress (three or more exposures) were more than twice as likely to have the syndrome than those without work stress (odds ratio adjusted for age and employment grade 2.25, 95% confidence interval 1.31 to 3.85). Conclusions Stress at work is an important risk factor for the metabolic syndrome. The study provides evidence for the biological plausibility of the link between psychosocial stressors from everyday life and heart disease.	UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Chandola, T (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	t.chandola@ucl.ac.uk	Marmot, M G/Y-3920-2019; Chandola, Tarani/I-3192-2013; Brunner, Eric/H-2114-2011	Marmot, M G/0000-0002-2431-6419; Chandola, Tarani/0000-0002-1864-3413; Brunner, Eric/0000-0002-0595-4474	AHRQ HHS [HS06516] Funding Source: Medline; Medical Research Council [G19/35, G0100222, G8802774] Funding Source: Medline; NHLBI NIH HHS [HL36310] Funding Source: Medline; NIA NIH HHS [AG13196] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196, R37AG013196] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2006, SOCIAL DETERMINANTS; BJORNTORP P, 1991, J INTERN MED, V230, P195; Brunner EJ, 2002, CIRCULATION, V106, P2659, DOI 10.1161/01.CIR.0000038364.26310.BD; Brunner EJ, 1997, DIABETOLOGIA, V40, P1341, DOI 10.1007/s001250050830; Chandola T, 2005, OCCUP ENVIRON MED, V62, P223, DOI 10.1136/oem.2004.016675; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Hemingway H, 2005, CIRCULATION, V111, P3071, DOI 10.1161/CIRCULATIONAHA.104.497347; Karasek R., 1990, HLTH WORK STRESS PRO; Kuper Hannah, 2002, Semin Vasc Med, V2, P267, DOI 10.1055/s-2002-35401; LANDSBERGIS PA, 1994, SCAND J WORK ENV HEA, V20, P349, DOI 10.5271/sjweh.1386; Liao DP, 1998, CIRCULATION, V97, P828; Marmot M, 2005, INT J EPIDEMIOL, V34, P251, DOI 10.1093/ije/dyh372; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; Peter R, 1998, J EPIDEMIOL COMMUN H, V52, P540, DOI 10.1136/jech.52.9.540; Phillips DIW, 1998, J CLIN ENDOCR METAB, V83, P757, DOI 10.1210/jc.83.3.757; Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; Siegrist J, 1997, J INTERN MED, V242, P149, DOI 10.1046/j.1365-2796.1997.00167.x; Singh JP, 2000, AM J CARDIOL, V86, P309, DOI 10.1016/S0002-9149(00)00920-6; Steptoe A, 2004, OBES RES, V12, pA76; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; Vrijkotte TGM, 1999, PSYCHOSOM MED, V61, P796, DOI 10.1097/00006842-199911000-00012	25	658	688	1	79	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2006	332	7540					521	524A		10.1136/bmj.38693.435301.80	http://dx.doi.org/10.1136/bmj.38693.435301.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	023WB	16428252	Green Published, Bronze			2022-12-28	WOS:000236155800016
J	Lee, CF; Gong, Y; Brok, J; Boxall, EH; Gluud, C				Lee, CF; Gong, Y; Brok, J; Boxall, EH; Gluud, C			Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systemic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LONG-TERM EFFICACY; RANDOMIZED DOUBLE-BLIND; EVENT-REPORTING-SYSTEM; VIRUS CARRIER STATE; RISK NEONATES BORN; PERINATAL TRANSMISSION; IMMUNE GLOBULIN; ACTIVE IMMUNIZATION; PROTECTIVE EFFICACY; FINAL REPORT	Objective To evaluate the effects of hepatitis B vaccine and immunoglobulin in newborn infants of mothers positive for hepatitis B surface antigen. Design Systematic review and meta-analysis of randomised clinical trials. Data sources Electronic databases and hand searches. Review methods Randomised clinical trials were assessed for methodological quality. Meta-analysis was undertaken on three outcomes: the relative risks of hepatitis B occurrence, antibody levels to hepatitis B surface antigen, and adverse events. Results 29 randomised clinical trials were identified, five of which were considered high quality. Only three trials reported inclusion of mothers negative for hepatitis B e antigen. Compared with placebo or no intervention vaccination reduced the occurrence of hepatitis B (relative risk 0.28, 95% confidence interval 0.20 to 0.40; four trials). No significant difference in hepatitis B occurrence was found between recombinant vaccine and plasma derived vaccine (1.00, 0.71 to 1.42; four trials) and between high dose versus low dose vaccine (plasma derived vaccine 0.97, 0.55 to 1.68, three trials; recombinant vaccine 0.78, 0.31 to.1.94, one trial). Compared with placebo or no intervention, hepatitis B immunoglobulin or the combination of: plasma derived vaccine and hepatitis B immunoglobulin reduced hepatitis B occurrence (immunoglobulin 0.50, 0.41 to 0.60, one trial; vaccine and immunoglobulin 0.08, 0.03 to 0.17, three trials). Compared with vaccine alone, vaccine plus hepatitis B immunoglobulin reduced hepatitis B Occurrence (0.54, 0.41 to 0.73; 10 trials). Hepatitis B vaccine and hepatitis B immunoglobulin seem safe, but few trials reported on adverse events. Conclusion Hepatitis B vaccine, hepatitis B immunoglobulin, and vaccine plus immunoglobulin prevent hepatitis B Occurrence in newborn infants of mothers positive for hepatitis B surface antigen.	Univ Copenhagen Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit,Cochrane Hepatobiliary Grp, DK-2100 Copenhagen, Denmark; Tri Serv Gen Hosp, Dept Pharm Practice, Taipei, Taiwan; Heart England NHS Trust, Publ Hlth Lab, Hlth Protect Agcy, Birmingham, W Midlands, England	Rigshospitalet; University of Copenhagen; Tri-Service General Hospital; Health Protection Agency; Heart of England NHS Foundation Trust	Gong, Y (corresponding author), Univ Copenhagen Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit,Cochrane Hepatobiliary Grp, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	ygong@ctu.rh.dk	Gluud, Christian/HGB-3191-2022; Gluud, Christian/AAY-1027-2021; Gong, Yan/HDM-2351-2022	Gluud, Christian/0000-0002-8861-0799; 				Aggarwal R, 2004, BMJ-BRIT MED J, V329, P1080, DOI 10.1136/bmj.329.7474.1080; AKHTER S, 1992, Indian Journal of Pediatrics, V59, P411, DOI 10.1007/BF02751551; Alderson P, 2004, COCHRANE LIB; ALSNIELSEN B, 2004, P 12 COCHR C OTT CAN; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Assad S, 1999, VACCINE, V18, P57, DOI 10.1016/S0264-410X(99)00179-6; ASSATEERAWATT A, 1993, ASIAN PAC J ALLERGY, V11, P85; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185; BEASLEY RP, 1983, DEV BIOL STAND, V54, P363; BEASLEY RP, 1984, SEMIN LIVER DIS, V4, P113, DOI 10.1055/s-2008-1040651; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P33; Chen W, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000100.pub3; Da Villa G, 1999, VACCINE, V17, P1734, DOI 10.1016/S0264-410X(98)00414-9; DAVID MS, 1996, IMMUNISATION INFECT; Deeks J J, 2003, Health Technol Assess, V7, piii; DUSHEIKO G, 1998, OXFORD TXB CLIN HEPA, P376; DuVernoy TS, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.4.e52; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Etminan M, 2004, DRUG SAFETY, V27, P757, DOI 10.2165/00002018-200427110-00001; FARMER K, 1987, NEW ZEAL MED J, V100, P412; Fisher MA, 2001, ANN EPIDEMIOL, V11, P13, DOI 10.1016/S1047-2797(00)00078-8; Funk ML, 2002, J VIRAL HEPATITIS, V9, P52, DOI 10.1046/j.1365-2893.2002.00304.x; GARCIA EG, 1992, REV CUBA MED TROP, V44, P149; GOUDEAU A, 1983, DEV BIOL STAND, V54, P399; GROSHEIDE PM, 1993, AM J DIS CHILD, V147, P1316, DOI 10.1001/archpedi.1993.02160360058019; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HALL AJ, 1993, T ROY SOC TROP MED H, V87, P333, DOI 10.1016/0035-9203(93)90154-I; HALLIDAY ML, 1992, INT J EPIDEMIOL, V21, P564, DOI 10.1093/ije/21.3.564; Harris A, 2001, AUST NZ J PUBL HEAL, V25, P222, DOI 10.1111/j.1467-842X.2001.tb00566.x; Hayashi K, 1996, CONTROL CLIN TRIALS, V17, P99, DOI 10.1016/S0197-2456(96)80001-8; Heijtink RA, 2002, J MED VIROL, V66, P304, DOI 10.1002/jmv.2146; Hieu NT, 2002, VACCINE, V20, P1803, DOI 10.1016/S0264-410X(01)00518-7; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; International Conference on Harmonisation Expert Working Group, 1997, 1997 CFR ICH GUID; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ip H M, 1989, Acta Paediatr Jpn, V31, P654; IP HMH, 1989, LANCET, V1, P406; Kang P, 1995, Zhonghua Hu Li Za Zhi, V30, P390; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kojouharova M, 2001, INFECTION, V29, P342, DOI 10.1007/s15010-001-1150-6; KUKHLOVICH PA, 1996, ZH MIKROBIOL EPIDEMI, P55; KURU U, 1995, TURKISH J PEDIATR, V37, P93; Lee C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004790; LEE CY, 1991, PEDIATR INFECT DIS J, V10, P299, DOI 10.1097/00006454-199104000-00007; LEE PI, 1995, J PEDIATR-US, V126, P716, DOI 10.1016/S0022-3476(95)70398-5; Lee PI, 1995, VACCINE, V13, P1685, DOI 10.1016/0264-410X(95)00108-D; Lee W.J., 1999, Protistology, V1, P10; Lewis E, 2001, PEDIATR INFECT DIS J, V20, P1049, DOI 10.1097/00006454-200111000-00009; Li XM, 2003, WORLD J GASTROENTERO, V9, P1501, DOI 10.3748/wjg.v9.i7.1501; Liu L H, 1987, Zhonghua Liu Xing Bing Xue Za Zhi, V8, P325; Liu Z G, 1995, Zhonghua Liu Xing Bing Xue Za Zhi, V16, P81; LO KJ, 1985, HEPATO-GASTROENTEROL, V32, P65; Lolekha S, 2002, VACCINE, V20, P3739, DOI 10.1016/S0264-410X(02)00358-4; MacGregor IR, 2004, VOX SANG, V87, P3, DOI 10.1111/j.1741-6892.2004.00443.x; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; NAIR PV, 1984, GASTROENTEROLOGY, V87, P293; NAYAK NC, 1987, J MED VIROL, V21, P137, DOI 10.1002/jmv.1890210205; Niu MT, 1999, ARCH PEDIAT ADOL MED, V153, P1279, DOI 10.1001/archpedi.153.12.1279; Niu MT, 1996, PEDIATR INFECT DIS J, V15, P771, DOI 10.1097/00006454-199609000-00007; OKADA K, 1976, NEW ENGL J MED, V294, P746, DOI 10.1056/NEJM197604012941402; OON CJ, 1986, J INFECTION, V13, P255, DOI 10.1016/S0163-4453(86)91223-5; PIAZZA M, 1985, LANCET, V1, P949; PONGPIPAT D, 1986, ASIAN PAC J ALLERGY, V4, P33; PONGPIPAT D, 1988, ASIAN PAC J ALLERGY, V6, P107; PONGPIPAT D, 1989, ASIAN PAC J ALLERGY, V7, P37; POOVORAWAN Y, 1992, PEDIATR INFECT DIS J, V11, P816, DOI 10.1097/00006454-199210000-00002; Poovorawan Y, 1997, ARCH DIS CHILD-FETAL, V77, pF47, DOI 10.1136/fn.77.1.F47; Schroth R J, 2004, Cochrane Database Syst Rev, pCD003775, DOI 10.1002/14651858.CD003775.pub2; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEHGAL A, 1992, ACTA VIROL, V36, P359; SEHGAL A, 1992, J TROP PEDIATRICS, V38, P247, DOI 10.1093/tropej/38.5.247; Sriprakash I, 1997, TROP DOCT, V27, P176, DOI 10.1177/004947559702700323; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; THEPPISAI U, 1990, INT J GYNECOL OBSTET, V32, P353, DOI 10.1016/0020-7292(90)90113-Y; THEPPISAI U, 1987, Journal of the Medical Association of Thailand, V70, P459; TORMANS G, 1993, SOC SCI MED, V37, P173, DOI 10.1016/0277-9536(93)90453-B; WONG VCW, 1984, LANCET, V1, P921; XU ZY, 1995, J INFECT DIS, V171, P54, DOI 10.1093/infdis/171.1.54; XU ZY, 1985, CHINESE MED J-PEKING, V98, P623; XU ZY, 1985, PEDIATRICS, V76, P713; Yang YJ, 2003, PEDIATR INFECT DIS J, V22, P584, DOI 10.1097/00006454-200307000-00003; Yao JL, 1996, GUT, V38, pS37, DOI 10.1136/gut.38.Suppl_2.S37; YEOH EK, 1986, J INFECTION, V13, P15, DOI 10.1016/S0163-4453(86)92608-3; ZHU Q-Y, 1987, Australian and New Zealand Journal of Medicine, V17, P498; ZHU QR, 1994, CHINESE MED J-PEKING, V107, P915; Zhu QR, 1997, CHINESE MED J-PEKING, V110, P145	95	262	283	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2006	332	7537					328	332		10.1136/bmj.38719.435833.7C	http://dx.doi.org/10.1136/bmj.38719.435833.7C			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	012YI	16443611	Green Published, Bronze			2022-12-28	WOS:000235376400015
J	Lees, KR; Zivin, JA; Ashwood, T; Davalos, A; Davis, SM; Diener, H; Grotta, J; Lyden, P; Shuaib, A; Hardemark, H; Wasiewski, WW				Lees, KR; Zivin, JA; Ashwood, T; Davalos, A; Davis, SM; Diener, H; Grotta, J; Lyden, P; Shuaib, A; Hardemark, H; Wasiewski, WW		Trial Investigators	NXY-059 for acute ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OXIDE GENERIC NXY-059; SPIN TRAP AGENT; CEREBRAL-ISCHEMIA; NITRONE; MODEL; TOLERABILITY; COMBINATION; DISABILITY; TRANSIENT	BACKGROUND: NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 1722 patients with acute ischemic stroke who were randomly assigned to receive a 72-hour infusion of placebo or intravenous NXY-059 within 6 hours after the onset of the stroke. The primary outcome was disability at 90 days, as measured according to scores on the modified Rankin scale for disability (range, 0 to 5, with 0 indicating no residual symptoms and 5 indicating bedbound, requiring constant care). RESULTS: Among the 1699 subjects included in the efficacy analysis, NXY-059 significantly improved the overall distribution of scores on the modified Rankin scale, as compared with placebo (P=0.038 by the Cochran-Mantel-Haenszel test). The common odds ratio for improvement across all categories of the scale was 1.20 (95 percent confidence interval, 1.01 to 1.42). Mortality and rates of serious and nonserious adverse events were each similar in the two groups. NXY-059 did not improve neurologic functioning as measured according to the National Institutes of Health Stroke Scale (NIHSS): the difference between the two groups in the change from baseline scores was 0.1 point (95 percent confidence interval, -1.4 to 1.1; P=0.86). Likewise, no improvement was observed according to the Barthel index (P=0.14). In a post hoc analysis of patients who also received alteplase, NXY-059 was associated with a lower incidence of any hemorrhagic transformation (P=0.001) and symptomatic intracranial hemorrhage (P=0.036). CONCLUSIONS: The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke.	Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Gardiner Inst, Univ Dept Med & Therapeut,Cerebrovasc Clin, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, 44 Church St, Glasgow G11 6NT, Lanark, Scotland.	k.r.lees@clinmed.gla.ac.uk	Vanhooren, Geert/H-4433-2011; Witte, Otto/P-4127-2018; Deuschl, Gunther/A-7986-2010; Grotta, James/AAH-7423-2021; bladin, chris/B-9136-2013; Davis, Stephen M/L-5260-2013; Hamann, Gerhard F./J-6300-2014	Vanhooren, Geert/0000-0001-6818-9346; Witte, Otto/0000-0003-2101-4105; Deuschl, Gunther/0000-0002-4176-9196; Davis, Stephen M/0000-0003-0962-2300; Moulin, thierry/0000-0002-6639-8117; Dippel, Diederik/0000-0002-9234-3515; Cunha, Luis/0000-0002-0828-3485; Brozman, Miroslav/0000-0002-2680-538X; Andersen, Grethe/0000-0001-6807-2500; Gommans, John/0000-0003-3750-765X				Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chi GYH, 1998, DRUG INF J, V32, p1347S, DOI 10.1177/00928615980320S131; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; *CPMP, 2001, CPMPEWP56098; Dehouck MP, 2002, BRAIN RES, V955, P229, DOI 10.1016/S0006-8993(02)03469-8; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; GREEN AR, IN PRESS BRAIN RES; Hacke W, 2004, LANCET, V363, P768; Johnson SC, 2005, NEUROLOGY, V64, P654; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Lapchak PA, 2002, STROKE, V33, P1411, DOI 10.1161/01.STR.0000015346.00054.8B; Lapchak PA, 2002, STROKE, V33, P1665, DOI 10.1161/01.STR.0000017145.22806.AA; Lees KR, 2004, LANCET, V363, P439, DOI 10.1016/S0140-6736(04)15490-1; Lees KR, 2003, STROKE, V34, P482, DOI 10.1161/01.STR.0000053032.14223.81; Lees KR, 2001, CEREBROVASC DIS, V11, P20, DOI 10.1159/000047607; Lees KR, 2001, STROKE, V32, P675, DOI 10.1161/01.STR.32.3.675; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Mackay J, 2004, ATLAS HEART DIS STRO; MAHONEY F I, 1965, Md State Med J, V14, P61; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marshall JWB, 2003, STROKE, V34, P2228, DOI 10.1161/01.STR.0000087790.79851.A8; Marshall JWB, 2001, STROKE, V32, P190, DOI 10.1161/01.STR.32.1.190; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Saver JL, 2004, ARCH NEUROL-CHICAGO, V61, P1066, DOI 10.1001/archneur.61.7.1066; SAVER JL, 2004, ARCH NEUROL-CHICAGO, V61, P1599; Stokes ME, 2000, CATEGORICAL DATA ANA; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Weimar C, 2002, STROKE, V33, P2053, DOI 10.1161/01.STR.0000022808.21776.BF; Weir CJ, 2004, STROKE, V35, P2111, DOI 10.1161/01.STR.0000136556.34438.b3	34	491	534	0	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					588	600		10.1056/NEJMoa052980	http://dx.doi.org/10.1056/NEJMoa052980			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467546				2022-12-28	WOS:000235177500008
J	Zhang, PP; Tevaarwerk, E; Park, BN; Savage, DE; Celler, GK; Knezevic, I; Evans, PG; Eriksson, MA; Lagally, MG				Zhang, PP; Tevaarwerk, E; Park, BN; Savage, DE; Celler, GK; Knezevic, I; Evans, PG; Eriksson, MA; Lagally, MG			Electronic transport in nanometre-scale silicon-on-insulator membranes	NATURE			English	Article							CONDUCTION; SCATTERING; SI(001)	The widely used 'silicon-on-insulator' (SOI) system consists of a layer of single-crystalline silicon supported on a silicon dioxide substrate. When this silicon layer ( the template layer) is very thin, the assumption that an effectively infinite number of atoms contributes to its physical properties no longer applies, and new electronic, mechanical and thermodynamic phenomena arise(1-4), distinct from those of bulk silicon. The development of unusual electronic properties with decreasing layer thickness is particularly important for silicon microelectronic devices, in which (001)-oriented SOI is often used(5-7). Here we show - using scanning tunnelling microscopy, electronic transport measurements, and theory - that electronic conduction in thin SOI( 001) is determined not by bulk dopants but by the interaction of surface or interface electronic energy levels with the 'bulk' band structure of the thin silicon template layer. This interaction enables high-mobility carrier conduction in nanometre-scale SOI; conduction in even the thinnest membranes or layers of Si( 001) is therefore possible, independent of any considerations of bulk doping, provided that the proper surface or interface states are available to enable the thermal excitation of 'bulk' carriers in the silicon layer.	Univ Wisconsin, Madison, WI 53706 USA; Soitec USA, Peabody, MA 01960 USA	University of Wisconsin System; University of Wisconsin Madison	Lagally, MG (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	lagally@engr.wisc.edu	Evans, Paul G/A-9260-2009; Celler, George/G-3346-2014; Zhang, Pengpeng/N-9952-2014	Evans, Paul G/0000-0003-0421-6792; Celler, George/0000-0001-7871-0684; Savage, Donald/0000-0001-8515-4196				Celler GK, 2003, J APPL PHYS, V93, P4955, DOI 10.1063/1.1558223; Chen DX, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.205432; Chen DX, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165336; Cristoloveanu S., 1995, ELECT CHARACTERIZATI, V2nd; FONTES E, 1993, PHYS REV LETT, V70, P2790, DOI 10.1103/PhysRevLett.70.2790; Hamers RJ, 2000, ACCOUNTS CHEM RES, V33, P617, DOI 10.1021/ar970281o; Heike S, 1998, PHYS REV LETT, V81, P890, DOI 10.1103/PhysRevLett.81.890; HOLLINGER G, 1983, J VAC SCI TECHNOL A, V1, P640, DOI 10.1116/1.572199; HOVEL H, 2003, P ELECTROCHEM SOC, P75; KIM YA, 1999, ISSCC DIG TECH PAPER, V1, P432; Legrand B, 2000, APPL PHYS LETT, V76, P3271, DOI 10.1063/1.126603; Lin KC, 1998, APPL PHYS LETT, V72, P2313, DOI 10.1063/1.121346; Liu F, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.136101; Liu W, 2004, APPL PHYS LETT, V84, P3819, DOI 10.1063/1.1741039; LU ZH, 1995, NATURE, V378, P258, DOI 10.1038/378258a0; MCWHORTER PJ, 1986, APPL PHYS LETT, V48, P133, DOI 10.1063/1.96974; MEURIS M, 1995, SOLID STATE TECHNOL, V38, P109; NORTHRUP JE, 1993, PHYS REV B, V47, P10032, DOI 10.1103/PhysRevB.47.10032; Petersen CL, 2000, APPL PHYS LETT, V77, P3782, DOI 10.1063/1.1329871; Schroder D.K., 1998, SEMICONDUCTOR MAT DE; Seino K, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.245309; STROSCIO JA, 1985, PHYS REV LETT, V54, P1573, DOI 10.1103/PhysRevLett.54.1573; Sutter P, 2004, APPL PHYS LETT, V85, P3148, DOI 10.1063/1.1806539; SWARTZENTRUBER BS, 1993, PHYS REV B, V47, P13432, DOI 10.1103/PhysRevB.47.13432; Tanikawa T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.016801; TROMP RM, 1985, PHYS REV LETT, V55, P1303, DOI 10.1103/PhysRevLett.55.1303; YAN RH, 1992, IEEE T ELECTRON DEV, V39, P1704, DOI 10.1109/16.141237; Yoo K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.115424	28	157	187	0	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	2006	439	7077					703	706		10.1038/nature04501	http://dx.doi.org/10.1038/nature04501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	010KH	16467833				2022-12-28	WOS:000235193100039
J	Merkel, S; Kubo, A; Miyagi, L; Speziale, S; Duffy, TS; Mao, HK; Wenk, HR				Merkel, S; Kubo, A; Miyagi, L; Speziale, S; Duffy, TS; Mao, HK; Wenk, HR			Plastic deformation of MgGeO3 post-perovskite at lower mantle pressures	SCIENCE			English	Article							EARTHS D''-LAYER; SEISMIC ANISOTROPY; MGSIO3; PHASE; BOUNDARY; BASE; TEMPERATURE; POLYMORPHS; ELASTICITY; STABILITY	Polycrystalline MgGeO3 post-perovskite was plastically deformed in the diamond anvil cell between 104 and 130 gigapascals confining pressure and ambient temperature. In contrast with phenomenological considerations suggesting (010) as a slip plane, lattice planes near (100) became aligned perpendicular to the compression direction, suggesting that slip on (100) or (110) dominated plastic deformation. With the assumption that silicate post-perovskite behaves similarly at tower mantle conditions, a numerical model of seismic anisotropy in the D '' region implies a maximum contribution of post-perovskite to shear wave splitting of 3.7% with an oblique polarization.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA	University of California System; University of California Berkeley; Princeton University; Carnegie Institution for Science	Merkel, S (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	smerkel@berkeley.edu	Duffy, Thomas S/C-9140-2017; Merkel, Sébastien/E-5501-2011	Duffy, Thomas S/0000-0002-5357-1259; Merkel, Sébastien/0000-0003-2767-581X				Caracas R, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023164; Dupas-Bruzek C, 1998, PHYS CHEM MINER, V25, P501, DOI 10.1007/s002690050142; Garnero EJ, 2004, SCIENCE, V306, P259, DOI 10.1126/science.1103411; Hernlund JW, 2005, NATURE, V434, P882, DOI 10.1038/nature03472; Hirose K, 2005, AM MINERAL, V90, P262, DOI 10.2138/am.2005.1702; Iitaka T, 2004, NATURE, V430, P442, DOI 10.1038/nature02702; Kendall JM, 1998, GEODYNAMICS, V28, P97; Lawlis JD, 2001, PHYS CHEM MINER, V28, P557, DOI 10.1007/s002690100186; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; Mao WL, 2004, P NATL ACAD SCI USA, V101, P15867, DOI 10.1073/pnas.0407135101; McNamara AK, 2002, NATURE, V416, P310, DOI 10.1038/416310a; Merkel S, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000920; Moore MM, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002546; Murakami M, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021956; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Oganov AR, 2005, NATURE, V438, P1142, DOI 10.1038/nature04439; Oganov AR, 2004, NATURE, V430, P445, DOI 10.1038/nature02701; Panning M, 2004, SCIENCE, V303, P351, DOI 10.1126/science.1091524; ROSS NL, 1988, AM MINERAL, V73, P1355; Shim SH, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019639; Sidorin I, 1999, SCIENCE, V286, P1326, DOI 10.1126/science.286.5443.1326; Stackhouse S, 2005, EARTH PLANET SC LETT, V230, P1, DOI 10.1016/j.epsl.2004.11.021; Tsuchiya T, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020278; Wenk HR, 2004, EARTH PLANET SC LETT, V226, P507, DOI 10.1016/j.epsl.2004.07.033; WENK HR, 1998, TEXTURE ANISOTROPY, P560; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; Wookey J, 2005, GEOPHYS J INT, V161, P829, DOI 10.1111/j.1365-246X.2005.02623.x; Wysession ME, 1998, GEODYNAMICS, V28, P273	28	118	119	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					644	646		10.1126/science.1121808	http://dx.doi.org/10.1126/science.1121808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456075				2022-12-28	WOS:000235257400043
J	Blann, AD; Lip, GYH				Blann, AD; Lip, GYH			Venous thromboembolism	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HORMONE REPLACEMENT THERAPY; INITIAL TREATMENT; MANAGEMENT; DIAGNOSIS; RISK; FONDAPARINUX; CANCER; CONTRACEPTIVES; THROMBOSIS; ENOXAPARIN		City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Blann, AD (corresponding author), City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England.	a.blann@bham.ac.uk						Anderson AF, 2003, CIRCULATION S1, V107, P9, DOI [10.1161/01.CIR.0000078469.07362.E6, DOI 10.1161/01.CIR.0000078469.07362.E6]; Bertina RM, 2003, PATHOPHYSIOL HAEMO T, V33, P395, DOI 10.1159/000083835; Buller HR, 2005, J THROMB HAEMOST, V3, P1554, DOI 10.1111/j.1538-7836.2005.01414.x; Buller HR, 2004, ANN INTERN MED, V140, P867, DOI 10.7326/0003-4819-140-11-200406010-00007; Buller HR, 2003, NEW ENGL J MED, V349, P1695; Crowther MA, 2003, ANN INTERN MED, V138, P128, DOI 10.7326/0003-4819-138-2-200301210-00014; Garcia D, 2005, BRIT J HAEMATOL, V131, P301, DOI 10.1111/j.1365-2141.2005.05752.x; Gomes MPV, 2004, ARCH INTERN MED, V164, P1965, DOI 10.1001/archinte.164.18.1965; Gordois A, 2003, J THROMB HAEMOST, V1, P2167, DOI 10.1046/j.1538-7836.2003.00396.x; Haemostasis and Thrombosis Task Force, 1998, BRIT J HAEMATOL, V101, P374; Hansson PO, 1999, ARCH INTERN MED, V159, P1886, DOI 10.1001/archinte.159.16.1886; Hirsh J, 2004, CHEST, V126, p172S, DOI 10.1378/chest.126.3_suppl.172S; Ho WK, 2005, MED J AUSTRALIA, V182, P476, DOI 10.5694/j.1326-5377.2005.tb06791.x; Lee AYY, 2005, BRIT J HAEMATOL, V128, P291, DOI 10.1111/j.1365-2141.2004.05292.x; Lee CH, 2005, MED J AUSTRALIA, V182, P569, DOI 10.5694/j.1326-5377.2005.tb06816.x; Lip GYH, 2002, LANCET ONCOL, V3, P27, DOI 10.1016/S1470-2045(01)00619-2; Mismetti P, 2004, J THROMB HAEMOST, V2, P1058, DOI 10.1111/j.1538-7836.2004.00757.x; Ost D, 2005, JAMA-J AM MED ASSOC, V294, P706, DOI 10.1001/jama.294.6.706; Petralia GA, 2005, NAT CLIN PRACT ONCOL, V2, P356, DOI 10.1038/ncponc0225; Petrauskiene V, 2005, DIABETOLOGIA, V48, P1017, DOI 10.1007/s00125-005-1715-5; STEIN PD, 1991, CHEST, V100, P598, DOI 10.1378/chest.100.3.598; Turpie AGG, 2002, ARCH INTERN MED, V162, P1833, DOI 10.1001/archinte.162.16.1833; TURPIE AGG, 2003, ABC ANTITHROMBOTIC T; Weitz JI, 2005, J THROMB HAEMOST, V3, P1843, DOI 10.1111/j.1538-7836.2005.01374.x; White RH, 2005, ARCH INTERN MED, V165, P1782, DOI 10.1001/archinte.165.15.1782; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66; Wolozinsky Mia, 2005, Am J Cardiovasc Drugs, V5, P409, DOI 10.2165/00129784-200505060-00008; Wong PSC, 1999, POSTGRAD MED J, V75, P737, DOI 10.1136/pgmj.75.890.737; Wu O, 2005, THROMB HAEMOSTASIS, V94, P17, DOI 10.1160/TH04-11-0759	29	97	110	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2006	332	7535					215	219		10.1136/bmj.332.7535.215	http://dx.doi.org/10.1136/bmj.332.7535.215			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009BU	16439400	Green Published			2022-12-28	WOS:000235086900020
J	van Wouwe, JP; HiraSing, RA				van Wouwe, JP; HiraSing, RA			Prevention of sudden unexpected infant death	LANCET			English	Editorial Material							RISK		TNO, Netherlands Org Appl Sci Res, NL-2301 CE Leiden, Netherlands; VU Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands	Netherlands Organization Applied Science Research; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	van Wouwe, JP (corresponding author), TNO, Netherlands Org Appl Sci Res, NL-2301 CE Leiden, Netherlands.	Jp.vanwouwe@pg.tno.nl	Van Wouwe, Jacobus P/D-5549-2018	Van Wouwe, Jacobus P/0000-0001-9273-6258				Abramson H, 1944, J PEDIATR-US, V25, P404, DOI 10.1016/S0022-3476(44)80005-1; Blair PS, 2006, LANCET, V367, P314, DOI 10.1016/S0140-6736(06)67968-3; de Jonge G A, 2005, Ned Tijdschr Geneeskd, V149, P1273; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Flodmark CE, 2004, INT J OBESITY, V28, P1189, DOI 10.1038/sj.ijo.0802787; Gilbert R, 2005, INT J EPIDEMIOL, V34, P874, DOI 10.1093/ije/dyi088; Hirasing RA, 1997, CHILD HLTH NETHERLAN; Kattwinkel J, 2005, PEDIATRICS, V116, P1245, DOI 10.1542/peds.2005-1499; KRAMER MS, 2001, OPTIMAL DURATION EXC; Olds DL, 2004, PEDIATRICS, V114, P1560, DOI 10.1542/peds.2004-0961	10	6	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					277	278		10.1016/S0140-6736(06)67969-5	http://dx.doi.org/10.1016/S0140-6736(06)67969-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443020				2022-12-28	WOS:000235084600004
J	Condeelis, J; Pollard, JW				Condeelis, J; Pollard, JW			Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis	CELL			English	Review							MAMMARY-TUMORS; CANCER; PROGRESSION; INFLAMMATION; MOTILITY	Macrophages within the tumor microenvironment facilitate angiogenesis and extracellular-matrix breakdown and remodeling and promote tumor cell motility. Recent studies reveal that direct communication between macrophages and tumor cells leads to invasion and egress of tumor cells into the blood vessels (intravasation). Thus, macrophages are at the center of the invasion microenvironment and are an important drug target for cancer therapy.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Analyt Imaging Facil, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Ctr Study Reprod Biol & Womens Hlth, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Condeelis, J (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 MOrris Pk Ave, Bronx, NY 10461 USA.	condeeli@aecom.yu.edu; pollard@aecom.yu.edu	Peng, Chunwei/F-6788-2010		NCI NIH HHS [CA 94173, R01 CA094173, CA 100324, P30 CA 13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA100324, P30CA013330, R01CA094173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Condeelis J, 2005, ANNU REV CELL DEV BI, V21, P695, DOI 10.1146/annurev.cellbio.21.122303.120306; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin EY, 2002, J MAMMARY GLAND BIOL, V7, P147, DOI 10.1023/A:1020399802795; Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Oberg A, 2002, INT J COLORECTAL DIS, V17, P25; Oosterling SJ, 2005, J PATHOL, V207, P147, DOI 10.1002/path.1830; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; YAMAGUCHI H, 2006, IN PRESS EUR J CELL	19	1957	2059	10	301	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 27	2006	124	2					263	266		10.1016/j.cell.2006.01.007	http://dx.doi.org/10.1016/j.cell.2006.01.007			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439202	Bronze			2022-12-28	WOS:000235068500015
J	Enache, DI; Edwards, JK; Landon, P; Solsona-Espriu, B; Carley, AF; Herzing, AA; Watanabe, M; Kiely, CJ; Knight, DW; Hutchings, GJ				Enache, DI; Edwards, JK; Landon, P; Solsona-Espriu, B; Carley, AF; Herzing, AA; Watanabe, M; Kiely, CJ; Knight, DW; Hutchings, GJ			Solvent-free oxidation of primary alcohols to aldehydes using Au-Pd/TiO2 catalysts	SCIENCE			English	Article							LIQUID-PHASE OXIDATION; HYDROGEN-PEROXIDE; SELECTIVE OXIDATION; GOLD; H-2; GLYCEROL; KETONES; CARBON; PD	The oxidation of alcohols to aldehydes with O-2 in place of stoichiometric oxygen donors is a crucial process for the synthesis of fine chemicals. However, the catalysts that have been identified so far are relatively inactive with primary alkyl alcohols. We showed that Au/Pd-TiO2 catalysts give very high turnover frequencies (up to 270,000 turnovers per hour) for the oxidation of alcohols, including primary alkyl alcohols. The addition of Au to Pd nanocrystals improved the overall selectivity and, using scanning transmission electron microscopy combined with x-ray photoelectron spectroscopy, we showed that the Au-Pd nanocrystals were made up of a Au-rich core with a Pd-rich shell, indicating that the Au electronically influences the catalytic properties of Pd.	Cardiff Univ, Sch Chem, Cardiff CF10 3AT, Wales; Lehigh Univ, Ctr Adv Mat & Nanotechnol, Bethlehem, PA 18015 USA	Cardiff University; Lehigh University	Hutchings, GJ (corresponding author), Cardiff Univ, Sch Chem, Main Bldg,Pk Pl, Cardiff CF10 3AT, Wales.	hutch@cf.ac.uk	Espriu, Benjamin Solsona/H-2201-2015; Herzing, Andrew/D-6239-2012; Edwards, Jennifer/F-4518-2011; Carley, Albert/A-7372-2010; Kiely, Christopher/B-1959-2008	Espriu, Benjamin Solsona/0000-0001-7235-2038; Kiely, Christopher/0000-0001-5412-0970; Enache, Dan/0000-0002-9291-8198	Engineering and Physical Sciences Research Council [GR/R54590/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Abad A, 2005, ANGEW CHEM INT EDIT, V44, P4066, DOI 10.1002/anie.200500382; [Anonymous], 1984, CHROMIUM OXIDANTS OR, DOI DOI 10.1007/978-3-642-69362-5; Beller M., 2004, TRANSITION METALS OR; Biella S, 2003, CHEM COMMUN, P378, DOI 10.1039/b210506c; Bonnet N, 1998, J MICROSC-OXFORD, V190, P2, DOI 10.1046/j.1365-2818.1998.3250876.x; Carrettin S, 2002, CHEM COMMUN, P696, DOI 10.1039/b201112n; Chen MS, 2005, SCIENCE, V310, P291, DOI 10.1126/science.1115800; Edwards JK, 2005, J CATAL, V236, P69, DOI 10.1016/j.jcat.2005.09.015; Edwards JK, 2005, J MATER CHEM, V15, P4595, DOI 10.1039/b509542e; GRIFFITH WP, 1991, STUD SURF SCI CATAL, V66, P395; Hudlicky M., 1990, OXIDATIONS ORGANIC C; Landon P, 2003, PHYS CHEM CHEM PHYS, V5, P1917, DOI 10.1039/b211338b; Landon P, 2002, CHEM COMMUN, P2058, DOI 10.1039/b205248m; LEE DG, 1970, J ORG CHEM, V35, P3589, DOI 10.1021/jo00835a101; Marko IE, 1996, SCIENCE, V274, P2044, DOI 10.1126/science.274.5295.2044; MENGER FM, 1981, TETRAHEDRON LETT, V22, P1655, DOI 10.1016/S0040-4039(01)90402-2; Mori K, 2004, J AM CHEM SOC, V126, P10657, DOI 10.1021/ja0488683; NEUMANN R, 1995, APPL CATAL A-GEN, V122, P85, DOI 10.1016/0926-860X(94)00206-1; Okazaki K, 2005, APPL CATAL A-GEN, V291, P45, DOI 10.1016/j.apcata.2005.02.047; Pagliaro M, 2005, CHEM SOC REV, V34, P837, DOI 10.1039/b507094p; Pillai UR, 2003, APPL CATAL A-GEN, V245, P103, DOI 10.1016/S0926-860X(02)00617-8; Porta F, 2002, J CATAL, V211, P464, DOI 10.1006/jcat.2002.3745; Porta F, 2004, J CATAL, V224, P397, DOI 10.1016/j.jcat.2004.03.009; Prati L, 1998, J CATAL, V176, P552, DOI 10.1006/jcat.1998.2078; Schultz MJ, 2005, J AM CHEM SOC, V127, P8499, DOI 10.1021/ja050949r; Sheldon R A., 1981, METAL CATALYZED OXID; ten Brink GJ, 2000, SCIENCE, V287, P1636; Vazylyev M, 2005, TOP CATAL, V34, P93, DOI 10.1007/s11244-005-3793-5	28	1846	1881	22	1446	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					362	365		10.1126/science.1120560	http://dx.doi.org/10.1126/science.1120560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	007AE	16424335				2022-12-28	WOS:000234938500039
J	Collier, J				Collier, J			Big pharma and the UK Government	LANCET			English	Editorial Material									St Georges Univ London, London SW17 0RE, England	St Georges University London	Collier, J (corresponding author), St Georges Univ London, London SW17 0RE, England.	collier@sghms.ac.uk						*GOV RESP HLTH COM, 2005, GOV RESP HLTH COMM R; *HOUS COMM HLTH CO, 2005, 4 HOUS COMM HLTH COM	2	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 14	2006	367	9505					97	98		10.1016/S0140-6736(06)67943-9	http://dx.doi.org/10.1016/S0140-6736(06)67943-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	003BB	16413862				2022-12-28	WOS:000234655500010
J	Voeltz, GK; Prinz, WA; Shibata, Y; Rist, JM; Rapoport, TA				Voeltz, GK; Prinz, WA; Shibata, Y; Rist, JM; Rapoport, TA			A class of membrane proteins shaping the tubular endoplasmic reticulum	CELL			English	Article							NOGO-A; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; NEURITE OUTGROWTH; POLYPOSIS LOCUS; GENE FAMILY; INTERACTS; YEAST; IDENTIFICATION; LOCALIZATION	How is the characteristic shape of a membrane bound organelle achieved? We have used an in vitro system to address the mechanism by which the tubular network of the endoplasmic reticulum (ER) is generated and maintained. Based on the inhibitory effect of sulfhydryl reagents and antibodies, network formation in vitro requires the integral membrane protein Rtn4a/NogoA, a member of the ubiquitous reticulon family. Both in yeast and mammalian cells, the reticulons are largely restricted to the tubular ER and are excluded from the continuous sheets of the nuclear envelope and peripheral ER. Upon overexpression, the reticulons form tubular membrane structures. The reticulons interact with DP1/Yop1p, a conserved integral membrane protein that also localizes to the tubular ER. These proteins share an unusual hairpin topology in the membrane. The simultaneous absence of the reticulons and Yop1p in S. cerevisiae results in disrupted tubular ER. We propose that these "morphogenic" proteins partition into and stabilize highly curved ER membrane tubules.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Voeltz, GK (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 240 Longwood Ave, Boston, MA 02115 USA.	tom_rapoport@hms.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052586] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM052586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Calero M, 2001, J BIOL CHEM, V276, P12100, DOI 10.1074/jbc.M008439200; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chou T, 2001, BIOPHYS J, V80, P1075, DOI 10.1016/S0006-3495(01)76086-9; Dodd DA, 2005, J BIOL CHEM, V280, P12494, DOI 10.1074/jbc.M411827200; Dreier L, 2000, J CELL BIOL, V148, P883, DOI 10.1083/jcb.148.5.883; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; Farsad K, 2003, CURR OPIN CELL BIOL, V15, P372, DOI 10.1016/S0955-0674(03)00073-5; Geng JM, 2005, EUKARYOT CELL, V4, P1166, DOI 10.1128/EC.4.7.1166-1174.2005; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Heidtman M, 2005, MOL BIOL CELL, V16, P1673, DOI 10.1091/mbc.E04-10-0873; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; Iwahashi J, 2003, Cell Mol Biol (Noisy-le-grand), V49 Online Pub, pOL467; Iwahashi J, 2002, BIOCHEM BIOPH RES CO, V293, P698, DOI 10.1016/S0006-291X(02)00282-6; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Le Gall S, 2004, MOL BIOL CELL, V15, P447, DOI 10.1091/mbc.E03-05-0325; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Oertle T, 2003, FASEB J, V17, P1238, DOI 10.1096/fj.02-1166hyp; Oertle T, 2003, J NEUROSCI, V23, P5393; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Qi B, 2003, J CELL PHYSIOL, V196, P312, DOI 10.1002/jcp.10297; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; STELNER P, 2004, J NEUROCHEM, V89, P569; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656	37	808	821	2	60	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	2006	124	3					573	586		10.1016/j.cell.2005.11.047	http://dx.doi.org/10.1016/j.cell.2005.11.047			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014FG	16469703	Bronze			2022-12-28	WOS:000235464000019
J	Jauhar, S				Jauhar, S			Becoming a physician - The demise of the physical exam	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DIAGNOSING PNEUMONIA; AUSCULTATORY SKILLS; INTERNAL-MEDICINE; FAMILY-PRACTICE; PATIENT		Long Isl Jewish Med Ctr, Heart Failure Program, New Hyde Pk, NY 11042 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Northwell Health; Yeshiva University; Albert Einstein College of Medicine	Jauhar, S (corresponding author), Long Isl Jewish Med Ctr, Heart Failure Program, New Hyde Pk, NY 11042 USA.							Mangione S, 1999, AM J RESP CRIT CARE, V159, P1119, DOI 10.1164/ajrccm.159.4.9806083; Mangione S, 1998, JAMA-J AM MED ASSOC, V279, P1444; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; Metlay JP, 1997, JAMA-J AM MED ASSOC, V278, P1440, DOI 10.1001/jama.278.17.1440; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; Wipf JE, 1999, ARCH INTERN MED, V159, P1082, DOI 10.1001/archinte.159.10.1082	6	84	86	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2006	354	6					548	551		10.1056/NEJMp068013	http://dx.doi.org/10.1056/NEJMp068013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	010HF	16467540				2022-12-28	WOS:000235177500002
J	Sloand, EM; Scheinberg, P; Maciejewski, J; Young, NS				Sloand, EM; Scheinberg, P; Maciejewski, J; Young, NS			Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab)	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; BONE-MARROW; ANTIERYTHROPOIETIN ANTIBODIES; THYMOCYTE GLOBULIN; THYMOMA; THERAPY; ERYTHROPOIESIS; PLASMAPHERESIS; CYCLOPHOSPHAMIDE; CYTOTOXICITY	Background: Pure red-cell aplasia (PRCA) is a rare hematologic disease characterized by anemia, reticulocytopenia, and absence of bone marrow erythroid precursors. Most patients respond to some form of immunosuppressive treatment, but few prospective clinical trials have been performed. Objective: To examine the efficacy of a humanized monoclonal antibody to the interleukin-2 receptor (daclizumab) for treating PRCA. Design: Pilot study. Setting: Federal government research hospital. Patients: 15 patients with idiopathic PRCA. Intervention: Daclizumab, 1 mg/kg of body weight, every 2 weeks for a total of 5 infusions. Pure red-cell aplasia was defined as transfusion-dependent anemia with a reticulocyte count of 60 x 10(9) cells/L or less and bone marrow showing absent or diminished erythroid precursors. Measurements: Response to therapy was assessed by transfusion independence, increments in reticulocyte count, and nontransfused hemoglobin. Results: Daclizumab had little toxicity. Of the 15 patients, 6 patients (40%) responded to treatment. All responders became transfusion-independent and achieved normal or near-normal hemoglobin values and normal reticulocyte counts. Limitations: The study was unblinded, and the number of patients was too small to assess drug safety reliably. Conclusions: Daclizumab seems safe. Its efficacy in this pilot protocol suggests that expanded study in PRCA and other bone marrow failure syndromes is warranted.	NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sloand, EM (corresponding author), NHLBI, Hematol Branch, NIH, 9000 Rockville Pike,Bldg 10 CRC 4E5230, Bethesda, MD 20892 USA.	sloande@nih.gov	Scheinberg, Phillip/H-5251-2012	Scheinberg, Phillip/0000-0002-9047-4538				ABKOWITZ JL, 1986, AM J HEMATOL, V23, P363, DOI 10.1002/ajh.2830230408; ALMONDHIRY H, 1971, BLOOD-J HEMATOL, V38, P576, DOI 10.1182/blood.V38.5.576.576; Auner HW, 2002, BRIT J HAEMATOL, V116, P727, DOI 10.1046/j.1365-2141.2002.3317_3.x; Batlle M, 2002, BRIT J HAEMATOL, V118, P1192, DOI 10.1046/j.1365-2141.2002.36892.x; Bennett CL, 2005, BLOOD, V106, P3343, DOI 10.1182/blood-2005-02-0508; Brown KE, 1996, STEM CELLS, V14, P151, DOI 10.1002/stem.140151; Carswell CI, 2001, BIODRUGS, V15, P745, DOI 10.2165/00063030-200115110-00005; Charles RJ, 1996, BLOOD, V87, P4831, DOI 10.1182/blood.V87.11.4831.bloodjournal87114831; CLARK DA, 1984, BLOOD, V63, P277; Cobcroft R, 2001, BRIT J HAEMATOL, V113, P260, DOI 10.1046/j.1365-2141.2001.02693.x; DESEVILLA E, 1975, CANCER, V36, P1154, DOI 10.1002/1097-0142(197509)36:3<1154::AID-CNCR2820360349>3.0.CO;2-9; Fisch P, 2000, BRIT J HAEMATOL, V111, P1010, DOI 10.1046/j.1365-2141.2000.02429.x; FREUND LG, 1985, SCAND J HAEMATOL, V35, P315; Gershon SK, 2002, NEW ENGL J MED, V346, P1584; Go RS, 2001, BLOOD, V98, P483, DOI 10.1182/blood.V98.2.483; HIRST E, 1967, MEDICINE, V46, P225, DOI 10.1097/00005792-196705000-00001; HOFFMAN R, 1978, BLOOD, V52, P255; JACOBS EM, 1959, CANCER, V12, P47, DOI 10.1002/1097-0142(195901/02)12:1<47::AID-CNCR2820120110>3.0.CO;2-Q; KRANTZ SB, 1976, MED CLIN N AM, V60, P945, DOI 10.1016/S0025-7125(16)31841-7; KRANTZ SB, 1973, J CLIN INVEST, V52, P324, DOI 10.1172/JCI107188; Lacy MQ, 1996, BLOOD, V87, P3000, DOI 10.1182/blood.V87.7.3000.bloodjournal8773000; Maciejewski JP, 2003, BLOOD, V102, P3584, DOI 10.1182/blood-2003-04-1032; MANGAN KF, 1982, CLIN RES, V30, pA323; MANGAN KF, 1986, AM J HEMATOL, V23, P167, DOI 10.1002/ajh.2830230211; MARMONT A, 1984, BRIT J HAEMATOL, V56, P680, DOI 10.1111/j.1365-2141.1984.tb02193.x; MARMONT AM, 1991, SEMIN HEMATOL, V28, P285; Masuda M, 2000, AM J HEMATOL, V63, P102, DOI 10.1002/(SICI)1096-8652(200002)63:2<102::AID-AJH9>3.0.CO;2-P; MEANS RT, 1991, BLOOD, V78, P2564; MEANS RT, 1991, BRIT J HAEMATOL, V78, P114, DOI 10.1111/j.1365-2141.1991.tb04392.x; MESSNER HA, 1981, NEW ENGL J MED, V304, P1334, DOI 10.1056/NEJM198105283042205; Mori KL, 2003, BRIT J HAEMATOL, V123, P147, DOI 10.1046/j.1365-2141.2003.04553.x; Murakawa Tomohiro, 2002, Asian Cardiovasc Thorac Ann, V10, P150; Rossert J, 2004, J AM SOC NEPHROL, V15, P398, DOI 10.1097/01.ASN.0000107561.59698.42; Yamada O, 1997, BRIT J HAEMATOL, V97, P392, DOI 10.1046/j.1365-2141.1997.282672.x; YOUNG N, 2006, WILLIAMS HEMATOLOGY, P437; Young N S, 1983, J Clin Apher, V1, P95, DOI 10.1002/jca.2920010206; Young Neal S., 2000, Hematology Am Soc Hematol Educ Program, P18	37	10	10	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2006	144	3					181	185		10.7326/0003-4819-144-3-200602070-00006	http://dx.doi.org/10.7326/0003-4819-144-3-200602070-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008XS	16461962				2022-12-28	WOS:000235074800004
J	Kanwisher, N				Kanwisher, N			Neuroscience - What's in a face?	SCIENCE			English	Editorial Material									MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Kanwisher, N (corresponding author), MIT, 79 Amherst St, Cambridge, MA 02139 USA.	ngk@mit.edu						Baker C. R., UNPUB; COSMIDES L, 1994, COGNITION, V50, P41, DOI 10.1016/0010-0277(94)90020-5; DOWNING PE, IN PRESS CEREB CORTE; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; KANWISHER N, IN PRESS PHILOS T B; Saxe R, 2005, NEUROPSYCHOLOGIA, V43, P1391, DOI 10.1016/j.neuropsychologia.2005.02.013; TANAKA JW, 1993, Q J EXP PSYCHOL-A, V46, P225, DOI 10.1080/14640749308401045; Tsao DY, 2006, SCIENCE, V311, P670, DOI 10.1126/science.1119983	8	40	42	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	2006	311	5761					617	618		10.1126/science.1123983	http://dx.doi.org/10.1126/science.1123983			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	011GY	16456067				2022-12-28	WOS:000235257400032
J	Liu, G; Seiler, H; Wen, A; Zars, T; Ito, K; Wolf, R; Heisenberg, M; Liu, L				Liu, G; Seiler, H; Wen, A; Zars, T; Ito, K; Wolf, R; Heisenberg, M; Liu, L			Distinct memory traces for two visual features in the Drosophila brain	NATURE			English	Article							ADENYLYL-CYCLASE; FLIGHT SIMULATOR; CENTRAL COMPLEX; PATTERN RECOGNITION; LOCOMOTOR BEHAVIOR; OLFACTORY MEMORY; MUSHROOM BODIES; YAW TORQUE; MELANOGASTER; ORIENTATION	The fly Drosophila melanogaster can discriminate and remember visual landmarks. It analyses selected parts of its visual environment according to a small number of pattern parameters such as size, colour or contour orientation, and stores particular parameter values. Like humans, flies recognize patterns independently of the retinal position during acquisition of the pattern ( translation invariance). Here we show that the central-most part of the fly brain, the fan-shaped body, contains parts of a network mediating visual pattern recognition. We have identified short-term memory traces of two pattern parameters - elevation in the panorama and contour orientation. These can be localized to two groups of neurons extending branches as parallel, horizontal strata in the fan-shaped body. The central location of this memory store is well suited to mediate translational invariance.	Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China; Theodor Boveri Inst Biowissensch, Lehrstuhl Genet & Neurobiol, D-97074 Wurzburg, Germany; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of Missouri System; University of Missouri Columbia; University of Tokyo	Liu, L (corresponding author), Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, 15 Datun Rd, Beijing 100101, Peoples R China.	heisenberg@biozentrum.uni-wuerzburg.de; liuli@sun5.ibp.ac.cn		Zars, Troy/0000-0003-4114-9322				Abrams TW, 1998, LEARN MEMORY, V4, P496, DOI 10.1101/lm.4.6.496; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brembs B, 2000, LEARN MEMORY, V7, P104, DOI 10.1101/lm.7.2.104; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; DILL M, 1995, LEARN MEMORY, V2, P152, DOI 10.1101/lm.2.3-4.152; DILL M, 1995, PHILOS T ROY SOC B, V349, P143, DOI 10.1098/rstb.1995.0100; DILL M, 1993, NATURE, V365, P751, DOI 10.1038/365751a0; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; DUDAI Y, 1988, J COMP PHYSIOL A, V162, P101, DOI 10.1007/BF01342707; Ernst R, 1999, VISION RES, V39, P3920, DOI 10.1016/S0042-6989(99)00114-5; EYDING D, 1993, THESIS BAYERISCHE JU; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; Gerber B, 2004, CURR OPIN NEUROBIOL, V14, P737, DOI 10.1016/j.conb.2004.10.014; HANESCH U, 1989, CELL TISSUE RES, V257, P343, DOI 10.1007/BF00261838; HEISENBERG M, 1988, J COMP PHYSIOL A, V163, P373, DOI 10.1007/BF00604013; HEISENBERG M, 1979, J COMP PHYSIOL, V130, P113, DOI 10.1007/BF00611046; HEISENBERG M, 1994, CENTR BRAIN FUNCTION; Homberg U, 2004, NATURWISSENSCHAFTEN, V91, P199, DOI 10.1007/s00114-004-0525-9; Keller A, 2002, J NEUROBIOL, V50, P221, DOI 10.1002/neu.10029; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; PROKOP A, 1994, DEV BIOL, V161, P321, DOI 10.1006/dbio.1994.1034; Renger JJ, 2000, J NEUROSCI, V20, P3980; Schwaerzel M, 2002, NEURON, V35, P951, DOI 10.1016/S0896-6273(02)00832-2; STRAUSS R, 1993, J NEUROSCI, V13, P1852, DOI 10.1523/jneurosci.13-05-01852.1993; Strauss R, 2002, CURR OPIN NEUROBIOL, V12, P633, DOI 10.1016/S0959-4388(02)00385-9; STRAUSS R, 2002, THESIS BAYERISCHE JU; Tang SM, 2004, SCIENCE, V305, P1020, DOI 10.1126/science.1099839; Vitzthum H, 2002, J NEUROSCI, V22, P1114, DOI 10.1523/JNEUROSCI.22-03-01114.2002; WEIDTMANN N, 1993, THESIS BAYERISCHE JU; Wolf R, 1998, LEARN MEMORY, V5, P166; WOLF R, 1991, J COMP PHYSIOL A, V169, P699; Xia SZ, 1997, LEARN MEMORY, V4, P205, DOI 10.1101/lm.4.2.205; Zars T., 2000, Science (Washington D C), V288, P672, DOI 10.1126/science.288.5466.672; Zars T, 2000, LEARN MEMORY, V7, P18, DOI 10.1101/lm.7.1.18	37	314	330	5	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	2006	439	7076					551	556		10.1038/nature04381	http://dx.doi.org/10.1038/nature04381			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16452971				2022-12-28	WOS:000235033900032
J	Cohen, LS; Altshuler, LL; Harlow, BL; Nonacs, R; Newport, DJ; Viguera, AC; Suri, R; Burt, VK; Hendrick, V; Reminick, AM; Loughead, A; Vitonis, AF; Stowe, ZN				Cohen, LS; Altshuler, LL; Harlow, BL; Nonacs, R; Newport, DJ; Viguera, AC; Suri, R; Burt, VK; Hendrick, V; Reminick, AM; Loughead, A; Vitonis, AF; Stowe, ZN			Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEROTONIN REUPTAKE INHIBITORS; FOLLOW-UP; RECURRENCE; FLUOXETINE; SYMPTOMS; EXPOSURE; PREDICTORS; GUIDELINES; DISORDER; OUTCOMES	Context Pregnancy has historically been described as a time of emotional well-being, providing "protection" against psychiatric disorder. However, systematic delineation of risk of relapse in women who maintain or discontinue pharmacological treatment during pregnancy is necessary. Objective To describe risk of relapse in pregnant women who discontinued antidepressant medication proximate to conception compared with those who maintained treatment with these medications. Design, Setting, and Patients A prospective naturalistic investigation using longitudinal psychiatric assessments on a monthly basis across pregnancy; a survival analysis was conducted to determine time to relapse of depression during pregnancy. A total of 201 pregnant women were enrolled between March 1999 and April 2003 from 3 centers with specific expertise in the treatment of psychiatric illness during pregnancy. The cohort of women was recruited from (1) within the hospital clinics, (2) self-referral via advertisements and community outreach detailing the study, and (3) direct referrals from the community. Participants were considered eligible if they (1) had a history of major depression prior to pregnancy, (2) were less than 16 weeks' gestation, (3) were euthymic for at least 3 months prior to their last menstrual period, and (4) were currently or recently (<12 weeks prior to last menstrual period) receiving antidepressant treatment. Of the 201 participants, 13 miscarried, 5 electively terminated their pregnancy, 12 were lost to follow-up prior to completion of pregnancy, and 8 chose to discontinue participation in the study. Main Outcome Measure Relapse of major depression defined as fulfilling Structured Clinical Interview for DSM-IV [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition] Diagnosis (SCID) criteria. Results Among the 201 women in the sample, 86 (43%) experienced a relapse of major depression during pregnancy. Among the 82 women who maintained their medication throughout their pregnancy, 21 (26%) relapsed compared with 44 (68%) of the 65 women who discontinued medication. Women who discontinued medication relapsed significantly more frequently over the course of their pregnancy compared with women who maintained their medication (hazard ratio, 5.0; 95% confidence interval, 2.8-9.1; P<.001). Conclusions Pregnancy is not "protective" with respect to risk of relapse of major depression. Women with histories of depression who are euthymic in the context of ongoing antidepressant therapy should be aware of the association of depressive relapse during pregnancy with antidepressant discontinuation.	Harvard Univ, Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Clin Res Program, Sch Med,Dept Psychiat, Boston, MA 02114 USA; Univ Calif Los Angeles, Sch Med, Womens Mood Disorders Res Program, Los Angeles, CA 90024 USA; Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Emory Univ, Sch Med, Womens Mental Hlth Program, Atlanta, GA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Brigham & Women's Hospital; Emory University	Cohen, LS (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Clin Res Program, Sch Med,Dept Psychiat, WACC 812,15 Parkman St, Boston, MA 02114 USA.	lcohen2@partners.org	Newport, D. Jeffrey/AAN-5036-2020; Newport, Donald Jeffrey/H-9846-2013; Viguera, Adele/AGP-7361-2022	Newport, D. Jeffrey/0000-0003-1695-9710; Harlow, Bernard/0000-0002-6735-8862	NIMH NIH HHS [MH 56492-04, MH 56555-01A2, MH 56420-05] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056555, R01MH056492, R01MH056420] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Addis A, 2000, PSYCHOL MED, V30, P89, DOI 10.1017/S0033291799001270; Altshuler LL, 1996, AM J PSYCHIAT, V153, P592; Casper RC, 2003, J PEDIATR-US, V142, P402, DOI 10.1067/mpd.2003.139; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; Cohen L S, 2004, Arch Womens Ment Health, V7, P217, DOI 10.1007/s00737-004-0059-3; Cohen LS, 2004, CNS SPECTRUMS, V9, P209, DOI 10.1017/S1092852900009007; Cohen LS, 2004, PSYCHOTHER PSYCHOSOM, V73, P255, DOI 10.1159/000077745; Cohen LS, 1998, J CLIN PSYCHIAT, V59, P18; COX DR, 1972, J R STAT SOC B, V34, P187; Einarson TR, 2005, PHARMACOEPIDEM DR S, V14, P823, DOI 10.1002/pds.1084; Ericson A, 1999, EUR J CLIN PHARMACOL, V55, P503, DOI 10.1007/s002280050664; Evans J, 2001, BRIT MED J, V323, P257, DOI 10.1136/bmj.323.7307.257; First M.B., 2016, STRUCTURED CLIN INTE; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; Hallberg P, 2005, J CLIN PSYCHOPHARM, V25, P59, DOI 10.1097/01.jcp.0000150228.61501.e4; Henry AL, 2004, CLIN OBSTET GYNECOL, V47, P535, DOI 10.1097/01.grf.0000135341.48747.f9; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; KUPFER DJ, 1992, ARCH GEN PSYCHIAT, V49, P769; Laine K, 2003, ARCH GEN PSYCHIAT, V60, P720, DOI 10.1001/archpsyc.60.7.720; Lewinsohn PM, 2000, AM J PSYCHIAT, V157, P1584, DOI 10.1176/appi.ajp.157.10.1584; McGrath PJ, 2000, J CLIN PSYCHIAT, V61, P518, DOI 10.4088/JCP.v61n0710; Moses-Kolko EL, 2005, JAMA-J AM MED ASSOC, V293, P2372, DOI 10.1001/jama.293.19.2372; Mueller TI, 1999, AM J PSYCHIAT, V156, P1000; Newport DJ, 2002, J CLIN PSYCHIAT, V63, P31; Nonacs R, 2003, PSYCHIAT CLIN N AM, V26, P547, DOI 10.1016/S0193-953X(03)00046-7; Oberlander TF, 2004, J CLIN PSYCHIAT, V65, P230; OHARA MW, 1991, J ABNORM PSYCHOL, V100, P63, DOI 10.1037/0021-843X.100.1.63; Orr ST, 2002, AM J EPIDEMIOL, V156, P797, DOI 10.1093/aje/kwf131; *SAS I INC, 1992, SAS STAT US GUID VER; STEER RA, 1992, J CLIN EPIDEMIOL, V45, P1093, DOI 10.1016/0895-4356(92)90149-H; SURI T, 2004, ARCH WOMEN MENT HLTH, V7, P193; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Wisner KL, 2000, AM J PSYCHIAT, V157, P1933, DOI 10.1176/appi.ajp.157.12.1933; Wisner KL, 1999, JAMA-J AM MED ASSOC, V282, P1264, DOI 10.1001/jama.282.13.1264; Zajiceck E., 1981, PREGNANCY PSYCHOL SO, P57; Zeskind PS, 2004, PEDIATRICS, V113, P368, DOI 10.1542/peds.113.2.368	37	630	646	3	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2006	295	5					499	507		10.1001/jama.295.5.499	http://dx.doi.org/10.1001/jama.295.5.499			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	007SP	16449615				2022-12-28	WOS:000234990300017
J	Parfitt, A				Parfitt, A			Resuscitation guidelines	LANCET			English	Editorial Material							HOSPITAL CARDIAC-ARREST		St Thomas Hosp, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust	Parfitt, A (corresponding author), St Thomas Hosp, London SE1 7EH, England.	Andy.Parfitt@gstt.nhs.uk						Baren JM, 2005, ACAD EMERG MED, V12, P1027, DOI 10.1197/j.aem.2005.06.014; Chamberlain D, 2005, RESUSCITATION, V67, P157, DOI 10.1016/j.resuscitation.2005.05.011; HANDLEY AJ, 2005, RESUSCITATION GUIDEL; Hess EP, 2005, RESUSCITATION, V66, P7, DOI 10.1016/j.resuscitation.2005.01.011; Kause J, 2004, RESUSCITATION, V62, P275, DOI 10.1016/j.resuscitation.2004.05.016; Kern KB, 2005, RESUSCITATION, V64, P261, DOI 10.1016/j.resuscitation.2004.08.009; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 28	2006	367	9507					283	284		10.1016/S0140-6736(06)68049-5	http://dx.doi.org/10.1016/S0140-6736(06)68049-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	009AX	16443024				2022-12-28	WOS:000235084600008
J	Deville, S; Saiz, E; Nalla, RK; Tomsia, AP				Deville, S; Saiz, E; Nalla, RK; Tomsia, AP			Freezing as a path to build complex composites	SCIENCE			English	Article							HYDROXYAPATITE SCAFFOLDS; COMPRESSIVE STRENGTH; POROUS CERAMICS; FABRICATION; DESIGN; FIBERS	Materials that are strong, ultralightweight, and tough are in demand for a range of applications, requiring architectures and components carefully designed from the micrometer down to the nanometer scale. Nacre, a structure found in many molluscan shells, and bone are frequently used as examples for how nature achieves this through hybrid organic-inorganic composites. Unfortunately, it has proven extremely difficult to transcribe nacre-like clever designs into synthetic materials, partly because their intricate structures need to be replicated at several length scales. We demonstrate how the physics of ice formation can be used to develop sophisticated porous and layered-hybrid materials, including artificial bone, ceramic-metal composites, and porous scaffolds for osseous tissue regeneration with strengths up to four times higher than those of materials currently used for implantation.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Deville, S (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.	sdeville@lbl.gov	Deville, Sylvain/H-5515-2019	Deville, Sylvain/0000-0002-3363-3184	NIDCR NIH HHS [5R01 DE015633] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015633] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Addadi L, 1997, NATURE, V389, P912, DOI 10.1038/40010; Aizenberg J, 2005, SCIENCE, V309, P275, DOI 10.1126/science.1112255; Almirall A, 2004, BIOMATERIALS, V25, P3671, DOI 10.1016/j.biomaterials.2003.10.066; An Y. H., 2000, MECH TESTING BONE BO, P41; BIGNON A, 2002, THESIS NATL I APPL S; Clegg WJ, 1999, SCIENCE, V286, P1097, DOI 10.1126/science.286.5442.1097; del Real RP, 2002, BIOMATERIALS, V23, P3673, DOI 10.1016/S0142-9612(02)00101-1; Fantner GE, 2005, NAT MATER, V4, P612, DOI 10.1038/nmat1428; Gay G, 2002, CRYST GROWTH DES, V2, P135, DOI 10.1021/cg0100383; Hench LL, 2002, SCIENCE, V295, P1014, DOI 10.1126/science.1067404; ISHIGURO H, 1994, CRYOBIOLOGY, V31, P483, DOI 10.1006/cryo.1994.1059; JACKSON AP, 1988, PROC R SOC SER B-BIO, V234, P415, DOI 10.1098/rspb.1988.0056; Karlsson JOM, 2002, SCIENCE, V296, P655; Kawata M, 2004, J MATER SCI-MATER M, V15, P817, DOI 10.1023/B:JMSM.0000032823.66093.aa; Liu DM, 1997, CERAM INT, V23, P135, DOI 10.1016/S0272-8842(96)00009-0; Mayer G, 2005, SCIENCE, V310, P1144, DOI 10.1126/science.1116994; Milosevski M, 1999, CERAM INT, V25, P693, DOI 10.1016/S0272-8842(99)00003-6; Ota Y, 1997, J AM CERAM SOC, V80, P225, DOI 10.1111/j.1151-2916.1997.tb02814.x; Ramay HR, 2003, BIOMATERIALS, V24, P3293, DOI 10.1016/S0142-9612(03)00171-6; Roy TD, 2003, J BIOMED MATER RES A, V66A, P283, DOI 10.1002/jbm.a.10582; Saiz E, 2000, ACTA MATER, V48, P4449, DOI 10.1016/S1359-6454(00)00231-7; Sanchez C, 2005, NAT MATER, V4, P277, DOI 10.1038/nmat1339; Sellinger A, 1998, NATURE, V394, P256, DOI 10.1038/28354; Smith BL, 1999, NATURE, V399, P761, DOI 10.1038/21607; Sofie SW, 2001, J AM CERAM SOC, V84, P1459; Song F, 2003, BIOMATERIALS, V24, P3623, DOI 10.1016/S0142-9612(03)00215-1; Sous M, 1998, BIOMATERIALS, V19, P2147, DOI 10.1016/S0142-9612(98)00118-5; Tang ZY, 2003, NAT MATER, V2, P413, DOI 10.1038/nmat906; Wang RZ, 2001, J MATER RES, V16, P2485, DOI 10.1557/JMR.2001.0340; Worster MG, 1997, J PHYS CHEM B, V101, P6132, DOI 10.1021/jp9632448	30	1458	1515	48	1270	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	2006	311	5760					515	518		10.1126/science.1120937	http://dx.doi.org/10.1126/science.1120937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008WM	16439659	Green Submitted			2022-12-28	WOS:000235071400044
J	Edgar, BA				Edgar, BA			From cell structure to transcription: Hippo forges a new path	CELL			English	Review							YES-ASSOCIATED PROTEIN; NF2 TUMOR-SUPPRESSOR; HUMAN HOMOLOG; PROLIFERATION CONTROL; PROMOTES APOPTOSIS; DROSOPHILA LATS; GENETIC MOSAICS; CYCLE EXIT; GROWTH; MERLIN	The control of cell number during animal development is a longstanding puzzle. Recent studies in the fruit fly Drosophila melanogaster have defined a new signaling pathway that restricts cell proliferation in differentiating epithelia. The cytoskeletal proteins Merlin and Expanded, which play a role in cell adhesion and structure, control the activation of the Hippo/Salvador kinase complex, which in turn activates the Warts/Mats kinase complex. Warts/Mats kinase phosphorylates and inhibits Yorkie, a transcriptional coactivator that positively regulates cell growth, survival, and proliferation. This conserved signaling pathway contains several tumor-suppressor genes and regulates the contact inhibition of proliferation in cultured cells.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center	Edgar, BA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA.	bedgar@fhcrc.org						Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; BOEDIGHEIMER M, 1993, MECH DEVELOP, V44, P83, DOI 10.1016/0925-4773(93)90058-6; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Firth LC, 2005, DEV CELL, V8, P541, DOI 10.1016/j.devcel.2005.01.017; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Golovnina K, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-69; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; He Y, 2005, MOL BIOL CELL, V16, P4139, DOI 10.1091/mbc.e05-01-0018; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kamikubo Y, 2003, J BIOL CHEM, V278, P17609, DOI 10.1074/jbc.M211974200; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; McCartney BM, 2000, DEVELOPMENT, V127, P1315; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Mikeladze-Dvali T, 2005, CELL, V122, P775, DOI 10.1016/j.cell.2005.07.026; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; TAKAHASHI Y, 2000, CLIN CANCER RES, V11, P1280; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817	46	271	286	5	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					267	273		10.1016/j.cell.2006.01.005	http://dx.doi.org/10.1016/j.cell.2006.01.005			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439203	Bronze			2022-12-28	WOS:000235068500016
J	Eldridge, AG; Loktev, AV; Hansen, DV; Verschuren, EW; Reimann, JDR; Jackson, PK				Eldridge, AG; Loktev, AV; Hansen, DV; Verschuren, EW; Reimann, JDR; Jackson, PK			The Evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor Emi1	CELL			English	Article							POLO-LIKE KINASE; CELL-CYCLE; CENTROSOME DUPLICATION; UBIQUITIN LIGASES; REQUIRES E2F; PROTEIN; PLK1; PHOSPHORYLATION; DESTRUCTION; IDENTIFICATION	The anaphase-promoting complex/cyclosome (APC/C) inhibitor Emi1 controls progression to S phase and mitosis by stabilizing key APC/C ubiquitination substrates, including cyclin A. Examining Emi1 binding proteins, we identified the Evi5 oncogene as a regulator of Emi1 accumulation. Evi5 antagonizes SCF beta TrCP-dependent Emi1 ubiquitination and destruction by binding to a site adjacent to Emi1's DSGxxS degron and blocking both degron phosphorylation by Polo-like kinases and subsequent beta TrCP binding. Thus, Evi5 functions as a stabilizing factor maintaining Emi1 levels in S/G2 phase. Evi5 protein accumulates in early G1 following Plk1 destruction and is degraded in a Plk1 - and ubiquitin-dependent manner in early mitosis. Ablation of Evi5 induces precocious degradation of Emi1 by the Plk/SCF beta TrCP pathway, causing premature APC/C activation; cyclin destruction; cell-cycle arrest; centrosome overduplication; and, finally, mitotic catastrophe. We propose that the balance of Evi5 and Pololike kinase activities determines the timely accumulation of Emi1 and cyclin, ensuring mitotic fidelity.	Stanford Univ, Sch Med, Dept Canc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Jackson, PK (corresponding author), Stanford Univ, Sch Med, Dept Canc Biol, 300 Pasteur Dr, Stanford, CA 94305 USA.	pjackson@stanford.edu		Jackson, Peter/0000-0002-1742-2539; Hansen, David/0000-0001-9679-7189	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060439, R01GM054811, R01GM073023] Funding Source: NIH RePORTER; NCI NIH HHS [CA09302] Funding Source: Medline; NIGMS NIH HHS [R01 GM73023, R01 GM060439, R01 GM54811] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ang X. L., 2004, SCI STKE, V242, ppe31; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Faitar SL, 2005, GENOMICS, V86, P594, DOI 10.1016/j.ygeno.2005.06.002; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Liao XB, 1997, ONCOGENE, V14, P1023, DOI 10.1038/sj.onc.1200929; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Wakefield JG, 2000, CURR BIOL, V10, P1367, DOI 10.1016/S0960-9822(00)00776-4; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030	31	81	85	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	2006	124	2					367	380		10.1016/j.cell.2005.10.038	http://dx.doi.org/10.1016/j.cell.2005.10.038			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	008VJ	16439210	Bronze			2022-12-28	WOS:000235068500024
J	Hegelich, BM; Albright, BJ; Cobble, J; Flippo, K; Letzring, S; Paffett, M; Ruhl, H; Schreiber, J; Schulze, RK; Fernandez, JC				Hegelich, BM; Albright, BJ; Cobble, J; Flippo, K; Letzring, S; Paffett, M; Ruhl, H; Schreiber, J; Schulze, RK; Fernandez, JC			Laser acceleration of quasi-monoenergetic MeV ion beams	NATURE			English	Article							FAST IGNITION; PLASMA; ELECTRONS; SURFACES; DRIVEN; CARBON	Acceleration of particles by intense laser - plasma interactions represents a rapidly evolving field of interest, as highlighted by the recent demonstration(1-4) of laser-driven relativistic beams of monoenergetic electrons. Ultrahigh-intensity lasers can produce accelerating fields of 10 TV m(-1) (1 TV = 10(12) V), surpassing those in conventional accelerators by six orders of magnitude. Laser-driven ions with energies of several MeV per nucleon have also been produced(5-9). Such ion beams exhibit unprecedented characteristics - short pulse lengths, high currents and low transverse emittance(10) - but their exponential energy spectra have almost 100% energy spread. This large energy spread, which is a consequence of the experimental conditions used to date, remains the biggest impediment to the wider use of this technology. Here we report the production of quasi-monoenergetic laser-driven C5+ ions with a vastly reduced energy spread of 17%. The ions have a mean energy of 3 MeV per nucleon (full-width at half-maximum, similar to 0.5 MeV per nucleon) and a longitudinal emittance of less than 2 x 10(-6) eV s for pulse durations shorter than 1 ps. Such laser-driven, high-current, quasi-monoenergetic ion sources may enable significant advances in the development of compact MeV ion accelerators(11), new diagnostics(12,13), medical physics(14), inertial confinement fusion and fast ignition(15-17).	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Univ Nevada, Reno, NV 89557 USA; Univ Munich, Munich, Germany; Max Planck Inst Quantum Opt, D-85748 Garching, Germany	United States Department of Energy (DOE); Los Alamos National Laboratory; Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Munich; Max Planck Society	Hegelich, BM (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	hegelich@lanl.gov	Fernandez, Juan Carlos/H-3268-2011; Flippo, Kirk A./GXZ-7022-2022; Flippo, Kirk A./C-6872-2009	Fernandez, Juan Carlos/0000-0002-1438-1815; Flippo, Kirk A./0000-0002-4752-5141; Albright, Brian/0000-0002-7789-6525; Schulze, Roland/0000-0002-6601-817X; Hegelich, Bjorn Manuel/0000-0003-4709-3112				Atzeni S., 2004, PHYS INERTIAL CONFIN; AUGST S, 1991, J OPT SOC AM B, V8, P858, DOI 10.1364/JOSAB.8.000858; Borghesi M, 2001, PLASMA PHYS CONTR F, V43, pA267, DOI 10.1088/0741-3335/43/12A/320; Cobble JA, 2002, J APPL PHYS, V92, P1775, DOI 10.1063/1.1494128; Cowan TE, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.204801; Esirkepov TZ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.175003; Faure J, 2004, NATURE, V431, P541, DOI 10.1038/nature02963; Geddes CGR, 2004, NATURE, V431, P538, DOI 10.1038/nature02900; GITOMER SJ, 1986, PHYS FLUIDS, V29, P2679, DOI 10.1063/1.865510; Habs D, 2001, PROG PART NUCL PHYS, V46, P375, DOI 10.1016/S0146-6410(01)00143-0; HAMILTON JC, 1980, SURF SCI, V91, P199, DOI 10.1016/0039-6028(80)90080-1; Hatchett SP, 2000, PHYS PLASMAS, V7, P2076, DOI 10.1063/1.874030; Hegelich BM, 2005, PHYS PLASMAS, V12, DOI 10.1063/1.1915350; Hegelich M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.085002; Hein J, 2004, APPL PHYS B-LASERS O, V79, P419, DOI 10.1007/s00340-004-1586-3; Katsouleas T, 2004, NATURE, V431, P515, DOI 10.1038/431515a; Kodama R, 2001, NATURE, V412, P798, DOI 10.1038/35090525; Ledingham KWD, 2004, J PHYS D APPL PHYS, V37, P2341, DOI 10.1088/0022-3727/37/16/019; Maksimchuk A, 2000, PHYS REV LETT, V84, P4108, DOI 10.1103/PhysRevLett.84.4108; Mangles SPD, 2004, NATURE, V431, P535, DOI 10.1038/nature02939; Mourou GA, 2002, SCI AM, V286, P80; Patel PK, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.125004; RAMSIER RD, 1995, J VAC SCI TECHNOL A, V13, P188, DOI 10.1116/1.579397; Roth M, 2002, PHYS REV SPEC TOP-AC, V5, DOI 10.1103/PhysRevSTAB.5.061301; Roth M, 2001, PHYS REV LETT, V86, P436, DOI 10.1103/PhysRevLett.86.436; RUSCH G, 1991, NUCL TRACKS RAD MEAS, V19, P261; Snavely RA, 2000, PHYS REV LETT, V85, P2945, DOI 10.1103/PhysRevLett.85.2945; Temporal M, 2002, PHYS PLASMAS, V9, P3098, DOI 10.1063/1.1482375; Thomson JJ, 1911, PHILOS MAG, V21, P225, DOI 10.1080/14786440208637024; Wilks SC, 2001, PHYS PLASMAS, V8, P542, DOI 10.1063/1.1333697	30	635	659	2	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	2006	439	7075					441	444		10.1038/nature04400	http://dx.doi.org/10.1038/nature04400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	005XH	16437109	Green Published			2022-12-28	WOS:000234859200039
J	McMonagle, MP				McMonagle, MP			Images in clinical medicine: The importance of early cervical-spine radiography	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Westmead Hosp, Sydney, NSW 2145, Australia	University of Sydney	McMonagle, MP (corresponding author), Westmead Hosp, Sydney, NSW 2145, Australia.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2006	354	4					E4	E4		10.1056/NEJMicm040733	http://dx.doi.org/10.1056/NEJMicm040733			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	005VY	16436760				2022-12-28	WOS:000234854000012
J	Robinson, GV				Robinson, GV			Pulmonary embolism in hospital practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; RISK-FACTORS; PREVENTION; THERAPY		Royal Berkshire & Battle Hosp, Dept Resp Med, Reading RG1 5AN, Berks, England		Robinson, GV (corresponding author), Royal Berkshire & Battle Hosp, Dept Resp Med, Reading RG1 5AN, Berks, England.	gracevrobinson@yahoo.co.uk						Anderson AF, 2003, CIRCULATION S1, V107, P9, DOI [10.1161/01.CIR.0000078469.07362.E6, DOI 10.1161/01.CIR.0000078469.07362.E6]; Aurangzeb M, 2004, CRIT CARE CLIN, V20, P643, DOI 10.1016/j.ccc.2004.06.002; BARRITT DW, 1960, LANCET, V1, P1309; Campbell IA, 2003, THORAX, V58, P470; Chunilal SD, 2003, JAMA-J AM MED ASSOC, V290, P2849, DOI 10.1001/jama.290.21.2849; FABIAN TC, 1990, CRIT CARE MED, V18, P42; Geerts WH, 2001, CHEST, V119, p132S, DOI 10.1378/chest.119.1_suppl.132S; Goldhaber SZ, 2004, LANCET, V363, P1295, DOI 10.1016/S0140-6736(04)16004-2; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; Greaves M, 2001, CLIN MED, V1, P432; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; Heit JA, 2001, MAYO CLIN PROC, V76, P1102, DOI 10.4065/76.11.1102; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; Hull RD, 2000, ARCH INTERN MED, V160, P229, DOI 10.1001/archinte.160.2.229; Kakkar VV, 1998, BAILLIERE CLIN HAEM, V11, P605, DOI 10.1016/S0950-3536(98)80085-1; Kearon C, 2004, J THROMB HAEMOST, V2, P743, DOI 10.1046/j.1538-7836.2004.00698.x; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Konstantinides S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMoa021274; Lapostolle F, 2001, NEW ENGL J MED, V345, P779, DOI 10.1056/NEJMoa010378; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; Linkins LA, 2003, ANN INTERN MED, V139, P893, DOI 10.7326/0003-4819-139-11-200312020-00007; McColl MD, 1997, THROMB HAEMOSTASIS, V78, P1183; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; PALMBERG S, 1979, GERONTOLOGY, V25, P103, DOI 10.1159/000212327; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; Piccioli A, 2003, J THROMB HAEMOST, V1, P2271, DOI 10.1046/j.1538-7836.2003.00505.x; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Seligsohn U, 2001, NEW ENGL J MED, V344, P1222, DOI 10.1056/NEJM200104193441607; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; Wahlander K, 2002, THROMB RES, V107, P93, DOI 10.1016/S0049-3848(02)00259-1; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010	34	12	13	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 21	2006	332	7534					156	160F		10.1136/bmj.332.7534.156	http://dx.doi.org/10.1136/bmj.332.7534.156			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16424493	Green Published			2022-12-28	WOS:000234905800026
J	D'Costa, VM; McGrann, KM; Hughes, DW; Wright, GD				D'Costa, VM; McGrann, KM; Hughes, DW; Wright, GD			Sampling the antibiotic resistome	SCIENCE			English	Article							GRAM-POSITIVE PATHOGENS; IN-VITRO ACTIVITIES; RESISTANCE GENES; STREPTOCOCCUS-PNEUMONIAE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; UNITED-STATES; DAPTOMYCIN; VANCOMYCIN; DETERMINANTS	Microbial resistance to antibiotics currently spans all known classes of natural and synthetic compounds. It has not only hindered our treatment of infections but also dramatically reshaped drug discovery, yet its origins have not been systematically studied. Soil-dwelling bacteria produce and encounter a myriad of antibiotics, evolving corresponding sensing and evading strategies. They are a reservoir of resistance determinants that can be mobilized into the microbial community. Study of this reservoir could provide an early warning system for future clinically relevant antibiotic resistance mechanisms.	McMaster Univ, Dept Biochem & Biomed Sci, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Wright, GD (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada.	wrightge@mcmaster.ca	Garcia-Armisen, Tamara/A-6173-2008; Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				ALBORN WE, 1991, ANTIMICROB AGENTS CH, V35, P2282, DOI 10.1128/AAC.35.11.2282; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Critchley IA, 2003, ANTIMICROB AGENTS CH, V47, P1689, DOI 10.1128/AAC.47.5.1689-1693.2003; CUNDLIFFE E, 1992, ANTIMICROB AGENTS CH, V36, P348, DOI 10.1128/AAC.36.2.348; Cundliffe E, 2001, ANTON LEEUW INT J G, V79, P229, DOI 10.1023/A:1012065300116; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DEBONO M, 1988, J ANTIBIOT, V41, P1093, DOI 10.7164/antibiotics.41.1093; Descheemaeker P, 2000, J ANTIMICROB CHEMOTH, V45, P167, DOI 10.1093/jac/45.2.167; Doern GV, 2001, ANTIMICROB AGENTS CH, V45, P1721, DOI 10.1128/AAC.45.6.1721-1729.2001; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Guardabassi L, 2004, APPL ENVIRON MICROB, V70, P984, DOI 10.1128/AEM.70.2.984-990.2004; Hong HJ, 2002, MOL MICROBIOL, V44, P1199, DOI 10.1046/j.1365-2958.2002.02960.x; Hubbard BK, 2003, ANGEW CHEM INT EDIT, V42, P730, DOI 10.1002/anie.200390202; Jung D, 2004, CHEM BIOL, V11, P949, DOI 10.1016/j.chembiol.2004.04.020; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Marshall CG, 1998, ANTIMICROB AGENTS CH, V42, P2215, DOI 10.1128/AAC.42.9.2215; Myllykallio H, 2003, TRENDS MICROBIOL, V11, P220, DOI 10.1016/S0966-842X(03)00101-X; NOGUCHI N, 1995, ANTIMICROB AGENTS CH, V39, P2359, DOI 10.1128/AAC.39.10.2359; PENG H, 1993, J BIOL CHEM, V268, P24481; Piddock LJV, 1999, DRUGS, V58, P11, DOI 10.2165/00003495-199958002-00003; Riesenfeld CS, 2004, ENVIRON MICROBIOL, V6, P981, DOI 10.1111/j.1462-2920.2004.00664.x; Snydman DR, 2000, ANTIMICROB AGENTS CH, V44, P3447, DOI 10.1128/AAC.44.12.3447-3450.2000; THOMPSON CJ, 1983, P NATL ACAD SCI-BIOL, V80, P5190, DOI 10.1073/pnas.80.17.5190; Tran JH, 2002, P NATL ACAD SCI USA, V99, P5638, DOI 10.1073/pnas.082092899; Walsh C., 2003, ANTIBIOTICS ACTIONS; Waters B, 1997, ANTIMICROB AGENTS CH, V41, P2766, DOI 10.1128/AAC.41.12.2766	26	998	1055	9	434	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					374	377		10.1126/science.1120800	http://dx.doi.org/10.1126/science.1120800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424339				2022-12-28	WOS:000234938500043
J	Xu, J; Hofhuis, H; Heidstra, R; Sauer, M; Friml, J; Scheres, B				Xu, J; Hofhuis, H; Heidstra, R; Sauer, M; Friml, J; Scheres, B			A molecular framework for plant regeneration	SCIENCE			English	Article							ARABIDOPSIS ROOT-MERISTEM; DEPENDENT AUXIN GRADIENTS; ASYMMETRIC CELL-DIVISION; GNOM ARF-GEF; EFFLUX; TRANSPORT; SCARECROW; EXPRESSION; PATTERNS; POLARITY	Plants and some animals have a profound capacity to regenerate organs from adult tissues. Molecular mechanisms for regeneration have, however, been largely unexplored. Here we investigate a local regeneration response in Arabidopsis roots. Laser-induced wounding disrupts the flow of auxin-a cell-fate-instructive plant hormone-in root tips, and we demonstrate that resulting cell-fate changes require the PLETHORA, SHORTROOT, and SCARECROW transcription factors. These transcription factors regulate the expression and polar position of PIN auxin efflux-facilitating membrane proteins to reconstitute auxin transport in renewed root tips. Thus, a regeneration mechanism using embryonic root stem-cell patterning factors first responds to and subsequently stabilizes a new hormone distribution.	Univ Utrecht, Dept Mol Genet, NL-3584 CH Utrecht, Netherlands; Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany	Utrecht University; Eberhard Karls University of Tubingen	Scheres, B (corresponding author), Univ Utrecht, Dept Mol Genet, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	b.scheres@bio.uu.nl	Friml, Jiri/D-9511-2012; Xu, Jian/I-2921-2012; Sauer, Michael/G-3424-2011; Sauer, Michael/F-6519-2014	Friml, Jiri/0000-0002-8302-7596; Xu, Jian/0000-0001-6194-6316; Sauer, Michael/0000-0002-4014-9825; hofhuis, hugo/0000-0001-7882-7380; Scheres, Ben/0000-0001-5400-9578				Aida M, 2004, CELL, V119, P109, DOI 10.1016/j.cell.2004.09.018; Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Fukaki H, 1998, PLANT J, V14, P425, DOI 10.1046/j.1365-313X.1998.00137.x; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Heidstra R, 2004, GENE DEV, V18, P1964, DOI 10.1101/gad.305504; Heisler MG, 2005, CURR BIOL, V15, P1899, DOI 10.1016/j.cub.2005.09.052; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; MITCHISON GJ, 1981, PHILOS T ROY SOC B, V295, P461, DOI 10.1098/rstb.1981.0154; Nakajima K, 2001, NATURE, V413, P307, DOI 10.1038/35095061; Reinhardt D, 2003, NATURE, V426, P255, DOI 10.1038/nature02081; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; Sabatini S, 2003, GENE DEV, V17, P354, DOI 10.1101/gad.252503; SACHS T, 1991, DEVELOPMENT S, V1, P83; SACHS T, 1981, ADV BOT RES, V9, P152; Sieberer T, 2000, CURR BIOL, V10, P1595, DOI 10.1016/S0960-9822(00)00861-7; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; Vieten A, 2005, DEVELOPMENT, V132, P4521, DOI 10.1242/dev.02027; Xu J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449	25	250	272	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	2006	311	5759					385	388		10.1126/science.1121790	http://dx.doi.org/10.1126/science.1121790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	007AE	16424342	Green Submitted			2022-12-28	WOS:000234938500046
J	Nielsen, SG; Rehkamper, M; Norman, MD; Halliday, AN; Harrison, D				Nielsen, SG; Rehkamper, M; Norman, MD; Halliday, AN; Harrison, D			Thallium isotopic evidence for ferromanganese sediments in the mantle source of Hawaiian basalts	NATURE			English	Article							TRACE-ELEMENTS; GEOCHEMISTRY; PLUMES; PB; SYSTEMATICS; ENRICHMENT; SEAWATER; PRECISE; SAMPLES; CRUSTS	Ocean island basalts are generally thought to be the surface expression of mantle plumes, but the nature of the components in the source regions of such mantle plumes is a subject of long-standing debate. The lavas erupted at Hawaii have attracted particular attention, as it has been proposed that coupled Os-186 and Os-187 anomalies reflect interaction with the Earth's metallic core(1,2). It has recently been suggested, however, that such variations could also result from addition of oceanic ferromanganese sediments to the mantle source of these lavas(3-5). Here we show that Hawaiian picrites with osmium isotope anomalies also exhibit pronounced thallium isotope variations, which are coupled with caesium/thallium ratios that extend to values much lower than commonly observed for mantle-derived rocks. This correlation cannot be created by admixing of core material, and is best explained by the addition of ferromanganese sediments into the Hawaii mantle source region. However, the lack of correlation between thallium and osmium isotopes and the high thallium/osmium ratios of ferromanganese sediments preclude a sedimentary origin for the osmium isotope anomalies, and leaves core-mantle interaction as a viable explanation for the osmium isotope variations of the Hawaiian picrites.	ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; Macquarie Univ, Dept Earth & Planetary Sci, GEMOC, N Ryde, NSW 2109, Australia; Univ London Imperial Coll Sci Technol & Med, Dept Earth Sci & Engn, London SW7 2AZ, England; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	Swiss Federal Institutes of Technology Domain; ETH Zurich; Macquarie University; Imperial College London; Australian National University; University of Oxford	Nielsen, SG (corresponding author), ETH, Dept Earth Sci, Sonneggstr 5, CH-8092 Zurich, Switzerland.	snielsen@els.mq.edu.au	GAU, geochemist/H-1985-2016; Nielsen, Sune/C-7345-2011; Nielsen, Sune/P-3983-2019	Nielsen, Sune/0000-0002-0458-3739; Rehkamper, Mark/0000-0002-0075-9872; Norman, Marc/0000-0002-1357-5415				Bach W, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000419; Baker JA, 2004, EARTH PLANET SC LETT, V220, P277, DOI 10.1016/S0012-821X(04)00059-7; Bennett VC, 1996, NATURE, V381, P221, DOI 10.1038/381221a0; BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; Blichert-Toft J, 1999, SCIENCE, V285, P879, DOI 10.1126/science.285.5429.879; Brandon AD, 1999, EARTH PLANET SC LETT, V174, P25, DOI 10.1016/S0012-821X(99)00251-4; Brandon AD, 2005, EARTH PLANET SC LETT, V232, P211, DOI 10.1016/j.epsl.2005.01.034; Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; Eggins SM, 1997, CHEM GEOL, V134, P311, DOI 10.1016/S0009-2541(96)00100-3; Gauthier PJ, 1998, J VOLCANOL GEOTH RES, V81, P311, DOI 10.1016/S0377-0273(98)00002-X; Halliday AN, 2004, NATURE, V427, P505, DOI 10.1038/nature02275; HEINRICHS H, 1980, GEOCHIM COSMOCHIM AC, V44, P1519, DOI 10.1016/0016-7037(80)90116-7; HOFMANN AW, 1983, Z NATURFORSCH A, V38, P256; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; Humayun M, 2004, SCIENCE, V306, P91, DOI 10.1126/science.1101050; Jochum KP, 1996, CHEM GEOL, V130, P289, DOI 10.1016/0009-2541(96)00014-9; Koschinsky A, 2000, MAR SCI SER, P239; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; Nielsen SG, 2004, CHEM GEOL, V204, P109, DOI 10.1016/j.chemgeo.2003.11.006; NIELSEN SG, 2004, EOS, V84; NIELSEN SG, 2004, EOS, V85, pF1251; Noll PD, 1996, GEOCHIM COSMOCHIM AC, V60, P587, DOI 10.1016/0016-7037(95)00405-X; Norman MD, 1999, EARTH PLANET SC LETT, V168, P27, DOI 10.1016/S0012-821X(99)00043-6; Norman MD, 2004, GEOCHIM COSMOCHIM AC, V68, P3761, DOI 10.1016/j.gca.2004.02.025; Ravizza G, 2001, EARTH PLANET SC LETT, V188, P369, DOI 10.1016/S0012-821X(01)00337-5; Rehkamper M, 2004, EARTH PLANET SC LETT, V219, P77, DOI 10.1016/S0012-821X(03)00703-9; Rehkamper M, 2002, EARTH PLANET SC LETT, V197, P65, DOI 10.1016/S0012-821X(02)00462-4; Schersten A, 2004, NATURE, V427, P234, DOI 10.1038/nature02221; Walker RJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4799, DOI 10.1016/S0016-7037(97)00270-6; WALKER RJ, 1995, SCIENCE, V269, P819, DOI 10.1126/science.269.5225.819; WASSON JT, 1988, PHILOS T R SOC A, V325, P535, DOI 10.1098/rsta.1988.0066	32	95	99	9	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					314	317		10.1038/nature04450	http://dx.doi.org/10.1038/nature04450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16421568				2022-12-28	WOS:000234682100040
